CA3085147A1 - Chromenopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors - Google Patents
Chromenopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors Download PDFInfo
- Publication number
- CA3085147A1 CA3085147A1 CA3085147A CA3085147A CA3085147A1 CA 3085147 A1 CA3085147 A1 CA 3085147A1 CA 3085147 A CA3085147 A CA 3085147A CA 3085147 A CA3085147 A CA 3085147A CA 3085147 A1 CA3085147 A1 CA 3085147A1
- Authority
- CA
- Canada
- Prior art keywords
- pyridin
- chromeno
- amino
- methy1
- oxopyrrolidin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000005213 chromenopyridines Chemical class 0.000 title description 2
- 229940043355 kinase inhibitor Drugs 0.000 title description 2
- 150000003907 phosphatidylinositol monophosphates Chemical class 0.000 title description 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 title description 2
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 27
- 208000027866 inflammatory disease Diseases 0.000 claims abstract description 19
- 208000015122 neurodegenerative disease Diseases 0.000 claims abstract description 17
- 230000004770 neurodegeneration Effects 0.000 claims abstract description 15
- 208000030159 metabolic disease Diseases 0.000 claims abstract description 7
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 claims description 320
- 150000001875 compounds Chemical class 0.000 claims description 313
- 125000001072 heteroaryl group Chemical group 0.000 claims description 214
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 210
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 160
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 136
- 125000000623 heterocyclic group Chemical group 0.000 claims description 131
- 229910052757 nitrogen Inorganic materials 0.000 claims description 113
- 125000003118 aryl group Chemical group 0.000 claims description 107
- 238000000034 method Methods 0.000 claims description 94
- -1 (S)-9-oxo-6a,7,8,9-tetrahydro-6H-pyrido[2,3-b]pyrrolo[1,2-d][1,4]oxazin-2-yl Chemical group 0.000 claims description 87
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 83
- 229910052736 halogen Inorganic materials 0.000 claims description 70
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 69
- 150000002367 halogens Chemical class 0.000 claims description 69
- 125000000217 alkyl group Chemical group 0.000 claims description 66
- 125000004429 atom Chemical group 0.000 claims description 51
- 150000003839 salts Chemical class 0.000 claims description 40
- 201000010099 disease Diseases 0.000 claims description 37
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 36
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 36
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 32
- 208000035475 disorder Diseases 0.000 claims description 32
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims description 30
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 30
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims description 28
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 27
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 27
- 239000000651 prodrug Substances 0.000 claims description 27
- 229940002612 prodrug Drugs 0.000 claims description 27
- 239000012453 solvate Substances 0.000 claims description 26
- 229910052799 carbon Inorganic materials 0.000 claims description 25
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims description 18
- 230000002401 inhibitory effect Effects 0.000 claims description 17
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 17
- YAMHXTCMCPHKLN-UHFFFAOYSA-N imidazolidin-2-one Chemical compound O=C1NCCN1 YAMHXTCMCPHKLN-UHFFFAOYSA-N 0.000 claims description 16
- 239000003814 drug Substances 0.000 claims description 15
- 201000011510 cancer Diseases 0.000 claims description 14
- 210000004027 cell Anatomy 0.000 claims description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims description 14
- 239000003937 drug carrier Substances 0.000 claims description 13
- 125000003342 alkenyl group Chemical group 0.000 claims description 11
- 206010012289 Dementia Diseases 0.000 claims description 10
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 claims description 10
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 claims description 9
- 230000002062 proliferating effect Effects 0.000 claims description 9
- 108090000623 proteins and genes Proteins 0.000 claims description 8
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 7
- 125000003545 alkoxy group Chemical group 0.000 claims description 7
- 125000000304 alkynyl group Chemical group 0.000 claims description 7
- NQQRXZOPZBKCNF-NSCUHMNNSA-N (e)-but-2-enamide Chemical compound C\C=C\C(N)=O NQQRXZOPZBKCNF-NSCUHMNNSA-N 0.000 claims description 6
- 208000027747 Kennedy disease Diseases 0.000 claims description 6
- 208000003954 Spinal Muscular Atrophies of Childhood Diseases 0.000 claims description 6
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 6
- 125000005605 benzo group Chemical group 0.000 claims description 6
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 6
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 6
- 125000006564 (C4-C8) cycloalkyl group Chemical group 0.000 claims description 5
- 208000012659 Joint disease Diseases 0.000 claims description 5
- 208000032839 leukemia Diseases 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 125000003003 spiro group Chemical group 0.000 claims description 5
- 201000009030 Carcinoma Diseases 0.000 claims description 4
- 208000017604 Hodgkin disease Diseases 0.000 claims description 4
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 4
- 206010022489 Insulin Resistance Diseases 0.000 claims description 4
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 4
- 208000033526 Proximal spinal muscular atrophy type 3 Diseases 0.000 claims description 4
- 201000004810 Vascular dementia Diseases 0.000 claims description 4
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims description 4
- 208000006269 X-Linked Bulbo-Spinal Atrophy Diseases 0.000 claims description 4
- 230000001154 acute effect Effects 0.000 claims description 4
- 208000009956 adenocarcinoma Diseases 0.000 claims description 4
- 206010002022 amyloidosis Diseases 0.000 claims description 4
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 4
- 239000004202 carbamide Substances 0.000 claims description 4
- 230000007850 degeneration Effects 0.000 claims description 4
- 208000014674 injury Diseases 0.000 claims description 4
- 201000004815 juvenile spinal muscular atrophy Diseases 0.000 claims description 4
- 230000002503 metabolic effect Effects 0.000 claims description 4
- VSEAAEQOQBMPQF-UHFFFAOYSA-N morpholin-3-one Chemical compound O=C1COCCN1 VSEAAEQOQBMPQF-UHFFFAOYSA-N 0.000 claims description 4
- 208000005264 motor neuron disease Diseases 0.000 claims description 4
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims description 4
- 208000002320 spinal muscular atrophy Diseases 0.000 claims description 4
- 230000008733 trauma Effects 0.000 claims description 4
- 208000032527 type III spinal muscular atrophy Diseases 0.000 claims description 4
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 3
- 201000001320 Atherosclerosis Diseases 0.000 claims description 3
- 230000004544 DNA amplification Effects 0.000 claims description 3
- 208000032928 Dyslipidaemia Diseases 0.000 claims description 3
- 208000017170 Lipid metabolism disease Diseases 0.000 claims description 3
- 208000001344 Macular Edema Diseases 0.000 claims description 3
- 206010025415 Macular oedema Diseases 0.000 claims description 3
- 208000017442 Retinal disease Diseases 0.000 claims description 3
- 206010038923 Retinopathy Diseases 0.000 claims description 3
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 3
- 230000006907 apoptotic process Effects 0.000 claims description 3
- 206010003119 arrhythmia Diseases 0.000 claims description 3
- 230000006793 arrhythmia Effects 0.000 claims description 3
- 230000025084 cell cycle arrest Effects 0.000 claims description 3
- 230000001684 chronic effect Effects 0.000 claims description 3
- 208000029078 coronary artery disease Diseases 0.000 claims description 3
- 208000006575 hypertriglyceridemia Diseases 0.000 claims description 3
- 230000001939 inductive effect Effects 0.000 claims description 3
- 238000001802 infusion Methods 0.000 claims description 3
- VFQXVTODMYMSMJ-UHFFFAOYSA-N isonicotinamide Chemical compound NC(=O)C1=CC=NC=C1 VFQXVTODMYMSMJ-UHFFFAOYSA-N 0.000 claims description 3
- 208000017169 kidney disease Diseases 0.000 claims description 3
- 201000010230 macular retinal edema Diseases 0.000 claims description 3
- 201000001119 neuropathy Diseases 0.000 claims description 3
- 230000007823 neuropathy Effects 0.000 claims description 3
- 125000004043 oxo group Chemical group O=* 0.000 claims description 3
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 3
- 210000004881 tumor cell Anatomy 0.000 claims description 3
- 206010000830 Acute leukaemia Diseases 0.000 claims description 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 2
- 206010000871 Acute monocytic leukaemia Diseases 0.000 claims description 2
- 206010000890 Acute myelomonocytic leukaemia Diseases 0.000 claims description 2
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 claims description 2
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 206010059245 Angiopathy Diseases 0.000 claims description 2
- 201000003076 Angiosarcoma Diseases 0.000 claims description 2
- 208000036487 Arthropathies Diseases 0.000 claims description 2
- 206010003571 Astrocytoma Diseases 0.000 claims description 2
- 206010003591 Ataxia Diseases 0.000 claims description 2
- 102000007371 Ataxin-3 Human genes 0.000 claims description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 2
- 208000023514 Barrett esophagus Diseases 0.000 claims description 2
- 206010004146 Basal cell carcinoma Diseases 0.000 claims description 2
- 206010004593 Bile duct cancer Diseases 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 201000006474 Brain Ischemia Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010006542 Bulbar palsy Diseases 0.000 claims description 2
- 208000029402 Bulbospinal muscular atrophy Diseases 0.000 claims description 2
- 206010068597 Bulbospinal muscular atrophy congenital Diseases 0.000 claims description 2
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 claims description 2
- 206010008120 Cerebral ischaemia Diseases 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 208000005243 Chondrosarcoma Diseases 0.000 claims description 2
- 201000009047 Chordoma Diseases 0.000 claims description 2
- 208000006332 Choriocarcinoma Diseases 0.000 claims description 2
- 208000033647 Classic progressive supranuclear palsy syndrome Diseases 0.000 claims description 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 208000009798 Craniopharyngioma Diseases 0.000 claims description 2
- 208000011231 Crohn disease Diseases 0.000 claims description 2
- 206010067889 Dementia with Lewy bodies Diseases 0.000 claims description 2
- 201000010374 Down Syndrome Diseases 0.000 claims description 2
- 201000009051 Embryonal Carcinoma Diseases 0.000 claims description 2
- 206010014967 Ependymoma Diseases 0.000 claims description 2
- 208000006168 Ewing Sarcoma Diseases 0.000 claims description 2
- 206010016207 Familial Mediterranean fever Diseases 0.000 claims description 2
- 201000008808 Fibrosarcoma Diseases 0.000 claims description 2
- 201000011240 Frontotemporal dementia Diseases 0.000 claims description 2
- 208000003736 Gerstmann-Straussler-Scheinker Disease Diseases 0.000 claims description 2
- 206010072075 Gerstmann-Straussler-Scheinker syndrome Diseases 0.000 claims description 2
- 208000032612 Glial tumor Diseases 0.000 claims description 2
- 206010018338 Glioma Diseases 0.000 claims description 2
- 206010018985 Haemorrhage intracranial Diseases 0.000 claims description 2
- 206010019196 Head injury Diseases 0.000 claims description 2
- 208000001258 Hemangiosarcoma Diseases 0.000 claims description 2
- 208000023105 Huntington disease Diseases 0.000 claims description 2
- 208000008574 Intracranial Hemorrhages Diseases 0.000 claims description 2
- 208000018142 Leiomyosarcoma Diseases 0.000 claims description 2
- 208000034800 Leukoencephalopathies Diseases 0.000 claims description 2
- 208000009829 Lewy Body Disease Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 208000002569 Machado-Joseph Disease Diseases 0.000 claims description 2
- 208000019090 Machado-Joseph disease type 3 Diseases 0.000 claims description 2
- 208000007054 Medullary Carcinoma Diseases 0.000 claims description 2
- 208000000172 Medulloblastoma Diseases 0.000 claims description 2
- 206010027406 Mesothelioma Diseases 0.000 claims description 2
- 208000035489 Monocytic Acute Leukemia Diseases 0.000 claims description 2
- 201000002795 Muckle-Wells syndrome Diseases 0.000 claims description 2
- 208000034578 Multiple myelomas Diseases 0.000 claims description 2
- 208000001089 Multiple system atrophy Diseases 0.000 claims description 2
- 208000033835 Myelomonocytic Acute Leukemia Diseases 0.000 claims description 2
- 206010029260 Neuroblastoma Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010033885 Paraparesis Diseases 0.000 claims description 2
- 208000018737 Parkinson disease Diseases 0.000 claims description 2
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims description 2
- 208000007641 Pinealoma Diseases 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 2
- 208000032319 Primary lateral sclerosis Diseases 0.000 claims description 2
- 102000029797 Prion Human genes 0.000 claims description 2
- 108091000054 Prion Proteins 0.000 claims description 2
- 208000024777 Prion disease Diseases 0.000 claims description 2
- 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 2
- 201000000582 Retinoblastoma Diseases 0.000 claims description 2
- 208000021811 Sandhoff disease Diseases 0.000 claims description 2
- 206010039491 Sarcoma Diseases 0.000 claims description 2
- 201000010208 Seminoma Diseases 0.000 claims description 2
- 208000009106 Shy-Drager Syndrome Diseases 0.000 claims description 2
- 208000002548 Spastic Paraparesis Diseases 0.000 claims description 2
- 208000036834 Spinocerebellar ataxia type 3 Diseases 0.000 claims description 2
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 claims description 2
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 claims description 2
- 208000032859 Synucleinopathies Diseases 0.000 claims description 2
- 208000022292 Tay-Sachs disease Diseases 0.000 claims description 2
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 2
- 206010057644 Testis cancer Diseases 0.000 claims description 2
- 208000000323 Tourette Syndrome Diseases 0.000 claims description 2
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 2
- 206010044688 Trisomy 21 Diseases 0.000 claims description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 2
- 206010046298 Upper motor neurone lesion Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 2
- 206010063661 Vascular encephalopathy Diseases 0.000 claims description 2
- 208000014070 Vestibular schwannoma Diseases 0.000 claims description 2
- 208000008383 Wilms tumor Diseases 0.000 claims description 2
- 208000004064 acoustic neuroma Diseases 0.000 claims description 2
- 208000017733 acquired polycythemia vera Diseases 0.000 claims description 2
- 208000011912 acute myelomonocytic leukemia M4 Diseases 0.000 claims description 2
- 201000007180 bile duct carcinoma Diseases 0.000 claims description 2
- 201000001531 bladder carcinoma Diseases 0.000 claims description 2
- 230000006931 brain damage Effects 0.000 claims description 2
- 231100000874 brain damage Toxicity 0.000 claims description 2
- 208000029028 brain injury Diseases 0.000 claims description 2
- 208000003362 bronchogenic carcinoma Diseases 0.000 claims description 2
- 230000000747 cardiac effect Effects 0.000 claims description 2
- 230000022131 cell cycle Effects 0.000 claims description 2
- 230000003833 cell viability Effects 0.000 claims description 2
- 230000002490 cerebral effect Effects 0.000 claims description 2
- 206010008118 cerebral infarction Diseases 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 230000008859 change Effects 0.000 claims description 2
- 208000024207 chronic leukemia Diseases 0.000 claims description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 2
- 230000001054 cortical effect Effects 0.000 claims description 2
- 208000022993 cryopyrin-associated periodic syndrome Diseases 0.000 claims description 2
- 208000002445 cystadenocarcinoma Diseases 0.000 claims description 2
- 230000003412 degenerative effect Effects 0.000 claims description 2
- 208000017004 dementia pugilistica Diseases 0.000 claims description 2
- 208000016097 disease of metabolism Diseases 0.000 claims description 2
- 230000003073 embolic effect Effects 0.000 claims description 2
- 230000002124 endocrine Effects 0.000 claims description 2
- 208000037828 epithelial carcinoma Diseases 0.000 claims description 2
- 201000006061 fatal familial insomnia Diseases 0.000 claims description 2
- 210000001652 frontal lobe Anatomy 0.000 claims description 2
- 238000001631 haemodialysis Methods 0.000 claims description 2
- 208000025750 heavy chain disease Diseases 0.000 claims description 2
- 201000002222 hemangioblastoma Diseases 0.000 claims description 2
- 230000000322 hemodialysis Effects 0.000 claims description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 2
- 208000008675 hereditary spastic paraplegia Diseases 0.000 claims description 2
- 208000009326 ileitis Diseases 0.000 claims description 2
- BEHYAANJUKYBTH-UHFFFAOYSA-N imidazo[1,2-a]pyridine-2-carboxamide Chemical compound C1=CC=CC2=NC(C(=O)N)=CN21 BEHYAANJUKYBTH-UHFFFAOYSA-N 0.000 claims description 2
- 230000036039 immunity Effects 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 238000007917 intracranial administration Methods 0.000 claims description 2
- 206010023497 kuru Diseases 0.000 claims description 2
- 201000010901 lateral sclerosis Diseases 0.000 claims description 2
- 230000003902 lesion Effects 0.000 claims description 2
- 206010024627 liposarcoma Diseases 0.000 claims description 2
- 201000005296 lung carcinoma Diseases 0.000 claims description 2
- 208000037829 lymphangioendotheliosarcoma Diseases 0.000 claims description 2
- 208000012804 lymphangiosarcoma Diseases 0.000 claims description 2
- 201000000564 macroglobulinemia Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 206010027191 meningioma Diseases 0.000 claims description 2
- 230000035772 mutation Effects 0.000 claims description 2
- 208000001611 myxosarcoma Diseases 0.000 claims description 2
- 208000007538 neurilemmoma Diseases 0.000 claims description 2
- 235000005152 nicotinamide Nutrition 0.000 claims description 2
- 239000011570 nicotinamide Substances 0.000 claims description 2
- 208000031237 olivopontocerebellar atrophy Diseases 0.000 claims description 2
- 201000008968 osteosarcoma Diseases 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 208000004019 papillary adenocarcinoma Diseases 0.000 claims description 2
- 201000010198 papillary carcinoma Diseases 0.000 claims description 2
- 210000001428 peripheral nervous system Anatomy 0.000 claims description 2
- IBBMAWULFFBRKK-UHFFFAOYSA-N picolinamide Chemical compound NC(=O)C1=CC=CC=N1 IBBMAWULFFBRKK-UHFFFAOYSA-N 0.000 claims description 2
- 208000024724 pineal body neoplasm Diseases 0.000 claims description 2
- 201000004123 pineal gland cancer Diseases 0.000 claims description 2
- 208000037244 polycythemia vera Diseases 0.000 claims description 2
- 208000001282 primary progressive aphasia Diseases 0.000 claims description 2
- 208000032207 progressive 1 supranuclear palsy Diseases 0.000 claims description 2
- 201000002241 progressive bulbar palsy Diseases 0.000 claims description 2
- 206010036807 progressive multifocal leukoencephalopathy Diseases 0.000 claims description 2
- 201000000196 pseudobulbar palsy Diseases 0.000 claims description 2
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims description 2
- 206010039667 schwannoma Diseases 0.000 claims description 2
- 201000008407 sebaceous adenocarcinoma Diseases 0.000 claims description 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 2
- 230000001148 spastic effect Effects 0.000 claims description 2
- 210000000278 spinal cord Anatomy 0.000 claims description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 2
- 208000003755 striatonigral degeneration Diseases 0.000 claims description 2
- 201000010965 sweat gland carcinoma Diseases 0.000 claims description 2
- 206010042863 synovial sarcoma Diseases 0.000 claims description 2
- 201000003120 testicular cancer Diseases 0.000 claims description 2
- 230000001732 thrombotic effect Effects 0.000 claims description 2
- 208000032471 type 1 spinal muscular atrophy Diseases 0.000 claims description 2
- 208000010570 urinary bladder carcinoma Diseases 0.000 claims description 2
- 206010046766 uterine cancer Diseases 0.000 claims description 2
- BCHZICNRHXRCHY-UHFFFAOYSA-N 2h-oxazine Chemical compound N1OC=CC=C1 BCHZICNRHXRCHY-UHFFFAOYSA-N 0.000 claims 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- UHJCPTUYASMZRC-UHFFFAOYSA-N 1,3-benzodioxole-4-carboxamide Chemical compound NC(=O)C1=CC=CC2=C1OCO2 UHJCPTUYASMZRC-UHFFFAOYSA-N 0.000 claims 1
- HUSYTLMIRXITQS-UHFFFAOYSA-N 1,3-benzodioxole-5-carboxamide Chemical compound NC(=O)C1=CC=C2OCOC2=C1 HUSYTLMIRXITQS-UHFFFAOYSA-N 0.000 claims 1
- VQLZLWZOJUVIJO-UHFFFAOYSA-N 1-[3-(2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-7-ylamino)-5H-chromeno[4,3-c]pyridin-8-yl]pyrrolidin-2-one Chemical compound O=C1CCCN1C1=CC=C2C(OCC3=CC(NC4=CN=C5OCCOC5=C4)=NC=C23)=C1 VQLZLWZOJUVIJO-UHFFFAOYSA-N 0.000 claims 1
- RGAVZSBHNLJXIV-UHFFFAOYSA-N 1-[3-[[5-[4-(3-methoxypropanoyl)piperazin-1-yl]pyridin-3-yl]amino]-5,5-dimethylchromeno[4,3-c]pyridin-8-yl]pyrrolidin-2-one Chemical compound COCCC(=O)N1CCN(CC1)C=1C=C(C=NC=1)NC1=CC2=C(C=N1)C=1C=CC(=CC=1OC2(C)C)N1C(CCC1)=O RGAVZSBHNLJXIV-UHFFFAOYSA-N 0.000 claims 1
- RXYMBSJGSAGIIT-UHFFFAOYSA-N 1-[3-[[5-[4-(3-methoxypropanoyl)piperazin-1-yl]pyridin-3-yl]amino]-5-methyl-5H-chromeno[4,3-c]pyridin-8-yl]pyrrolidin-2-one Chemical compound COCCC(=O)N1CCN(CC1)C1=CN=CC(NC2=NC=C3C(=C2)C(C)OC2=CC(=CC=C32)N2CCCC2=O)=C1 RXYMBSJGSAGIIT-UHFFFAOYSA-N 0.000 claims 1
- RPLQTUFYYXLLJW-UHFFFAOYSA-N 1-[3-[[5-[4-(3-methoxypropanoyl)piperazin-1-yl]pyridin-3-yl]amino]-5H-chromeno[4,3-c]pyridin-8-yl]pyrrolidin-2-one Chemical compound COCCC(=O)N1CCN(CC1)C1=CN=CC(NC2=NC=C3C(COC4=CC(=CC=C34)N3CCCC3=O)=C2)=C1 RPLQTUFYYXLLJW-UHFFFAOYSA-N 0.000 claims 1
- CDWFQXBPMZJOGD-UHFFFAOYSA-N 1-[9-fluoro-3-[[5-[4-(3-methoxypropanoyl)piperazin-1-yl]pyridin-3-yl]amino]-5,5-dimethylchromeno[4,3-c]pyridin-8-yl]pyrrolidin-2-one Chemical compound COCCC(=O)N1CCN(CC1)C1=CN=CC(NC2=NC=C3C4=CC(F)=C(C=C4OC(C)(C)C3=C2)N2CCCC2=O)=C1 CDWFQXBPMZJOGD-UHFFFAOYSA-N 0.000 claims 1
- JFQKDQKFEUAJEH-UHFFFAOYSA-N 1-[9-fluoro-3-[[5-[4-(3-methoxypropanoyl)piperazin-1-yl]pyridin-3-yl]amino]-5-methyl-5H-chromeno[4,3-c]pyridin-8-yl]pyrrolidin-2-one Chemical compound COCCC(=O)N1CCN(CC1)C1=CN=CC(NC2=NC=C3C(=C2)C(C)OC2=CC(N4CCCC4=O)=C(F)C=C32)=C1 JFQKDQKFEUAJEH-UHFFFAOYSA-N 0.000 claims 1
- UIQWOPVBYSJUQG-UHFFFAOYSA-N 1-[9-fluoro-3-[[5-[4-(3-methoxypropanoyl)piperazin-1-yl]pyridin-3-yl]amino]-5H-chromeno[4,3-c]pyridin-8-yl]pyrrolidin-2-one Chemical compound COCCC(=O)N1CCN(CC1)C1=CN=CC(NC2=NC=C3C(COC4=CC(N5CCCC5=O)=C(F)C=C34)=C2)=C1 UIQWOPVBYSJUQG-UHFFFAOYSA-N 0.000 claims 1
- DNSISZSEWVHGLH-UHFFFAOYSA-N butanamide Chemical compound CCCC(N)=O DNSISZSEWVHGLH-UHFFFAOYSA-N 0.000 claims 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims 1
- ZMBYQTGAXZOMOO-UHFFFAOYSA-N imidazo[1,2-a]pyridine-3-carboxamide Chemical compound C1=CC=CN2C(C(=O)N)=CN=C21 ZMBYQTGAXZOMOO-UHFFFAOYSA-N 0.000 claims 1
- NNPRQFFDCTZUDQ-UHFFFAOYSA-N imidazo[1,2-a]pyridine-5-carboxamide Chemical compound NC(=O)C1=CC=CC2=NC=CN12 NNPRQFFDCTZUDQ-UHFFFAOYSA-N 0.000 claims 1
- ZQLZNGUJOGWVCB-UHFFFAOYSA-N imidazo[1,2-a]pyridine-7-carboxamide Chemical compound C1=C(C(=O)N)C=CN2C=CN=C21 ZQLZNGUJOGWVCB-UHFFFAOYSA-N 0.000 claims 1
- 229960003966 nicotinamide Drugs 0.000 claims 1
- MIIMQKFGHJWRIJ-UHFFFAOYSA-N oxaborole-4-carboxamide Chemical compound O1B=CC(=C1)C(=O)N MIIMQKFGHJWRIJ-UHFFFAOYSA-N 0.000 claims 1
- FHPMSPHSCATFOI-UHFFFAOYSA-N oxaborole-5-carboxamide Chemical compound O1B=CC=C1C(=O)N FHPMSPHSCATFOI-UHFFFAOYSA-N 0.000 claims 1
- GXHAENUAJYZNOA-UHFFFAOYSA-N oxolane-2-carboxamide Chemical compound NC(=O)C1CCCO1 GXHAENUAJYZNOA-UHFFFAOYSA-N 0.000 claims 1
- IPEHBUMCGVEMRF-UHFFFAOYSA-N pyrazinecarboxamide Chemical compound NC(=O)C1=CN=CC=N1 IPEHBUMCGVEMRF-UHFFFAOYSA-N 0.000 claims 1
- FBPSKWNKTAQKFC-UHFFFAOYSA-N pyrazolo[1,5-a]pyridine-2-carboxamide Chemical compound C1=CC=CN2N=C(C(=O)N)C=C21 FBPSKWNKTAQKFC-UHFFFAOYSA-N 0.000 claims 1
- JVOGPCAZHXALIS-UHFFFAOYSA-N pyrazolo[1,5-a]pyridine-3-carboxamide Chemical compound C1=CC=CC2=C(C(=O)N)C=NN21 JVOGPCAZHXALIS-UHFFFAOYSA-N 0.000 claims 1
- GEBGCSXVYUDDPU-UHFFFAOYSA-N pyridazine-4-carboxamide Chemical compound NC(=O)C1=CC=NN=C1 GEBGCSXVYUDDPU-UHFFFAOYSA-N 0.000 claims 1
- 125000004548 quinolin-3-yl group Chemical group N1=CC(=CC2=CC=CC=C12)* 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 abstract description 10
- 239000000203 mixture Substances 0.000 description 304
- 239000011541 reaction mixture Substances 0.000 description 177
- 239000007787 solid Substances 0.000 description 176
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 156
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 153
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 149
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 144
- 239000000243 solution Substances 0.000 description 138
- YMWUJEATGCHHMB-UHFFFAOYSA-N dichloromethane Natural products ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 127
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 126
- 238000002360 preparation method Methods 0.000 description 125
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 87
- 239000000047 product Substances 0.000 description 86
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 79
- 229910000024 caesium carbonate Inorganic materials 0.000 description 75
- 239000000725 suspension Substances 0.000 description 68
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 65
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 64
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 61
- 239000007832 Na2SO4 Substances 0.000 description 59
- WDVGNXKCFBOKDF-UHFFFAOYSA-N dicyclohexyl-[3,6-dimethoxy-2-[2,4,6-tri(propan-2-yl)phenyl]phenyl]phosphane Chemical compound COC1=CC=C(OC)C(C=2C(=CC(=CC=2C(C)C)C(C)C)C(C)C)=C1P(C1CCCCC1)C1CCCCC1 WDVGNXKCFBOKDF-UHFFFAOYSA-N 0.000 description 59
- 229910052938 sodium sulfate Inorganic materials 0.000 description 59
- 235000011152 sodium sulphate Nutrition 0.000 description 59
- 238000002953 preparative HPLC Methods 0.000 description 57
- 238000005481 NMR spectroscopy Methods 0.000 description 52
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 52
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 52
- 239000000654 additive Substances 0.000 description 52
- 230000000996 additive effect Effects 0.000 description 51
- 239000012044 organic layer Substances 0.000 description 51
- 101150041968 CDC13 gene Proteins 0.000 description 50
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 47
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 46
- 239000000543 intermediate Substances 0.000 description 43
- 239000012267 brine Substances 0.000 description 42
- 235000002639 sodium chloride Nutrition 0.000 description 41
- 125000006163 5-membered heteroaryl group Chemical group 0.000 description 38
- 229940045348 brown mixture Drugs 0.000 description 38
- 239000012071 phase Substances 0.000 description 36
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 35
- 239000012299 nitrogen atmosphere Substances 0.000 description 34
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 32
- CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 32
- 239000000706 filtrate Substances 0.000 description 31
- 239000007858 starting material Substances 0.000 description 29
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 29
- 238000004809 thin layer chromatography Methods 0.000 description 29
- 101100063435 Caenorhabditis elegans din-1 gene Proteins 0.000 description 28
- 239000010410 layer Substances 0.000 description 28
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 28
- CUYKNJBYIJFRCU-UHFFFAOYSA-N 3-aminopyridine Chemical compound NC1=CC=CN=C1 CUYKNJBYIJFRCU-UHFFFAOYSA-N 0.000 description 27
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 24
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 24
- 230000002829 reductive effect Effects 0.000 description 24
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 23
- 125000001424 substituent group Chemical group 0.000 description 23
- 239000004698 Polyethylene Substances 0.000 description 21
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 20
- 229940022663 acetate Drugs 0.000 description 20
- 238000006243 chemical reaction Methods 0.000 description 20
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 18
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 18
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 18
- 238000003756 stirring Methods 0.000 description 18
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 16
- 239000012043 crude product Substances 0.000 description 15
- 239000000741 silica gel Substances 0.000 description 15
- 229910002027 silica gel Inorganic materials 0.000 description 15
- 239000002904 solvent Substances 0.000 description 15
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 14
- 125000004093 cyano group Chemical group *C#N 0.000 description 14
- 229910000027 potassium carbonate Inorganic materials 0.000 description 14
- AFDHVMQGXHHQRJ-UHFFFAOYSA-N 1-(4-bromo-3-fluorophenyl)pyrrolidin-2-one Chemical compound C1=C(Br)C(F)=CC(N2C(CCC2)=O)=C1 AFDHVMQGXHHQRJ-UHFFFAOYSA-N 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 13
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 13
- 235000015320 potassium carbonate Nutrition 0.000 description 13
- LFKDJXLFVYVEFG-UHFFFAOYSA-N tert-butyl carbamate Chemical compound CC(C)(C)OC(N)=O LFKDJXLFVYVEFG-UHFFFAOYSA-N 0.000 description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 12
- 229910052740 iodine Chemical group 0.000 description 12
- 238000001816 cooling Methods 0.000 description 11
- 125000005842 heteroatom Chemical group 0.000 description 11
- 239000002480 mineral oil Substances 0.000 description 11
- 235000010446 mineral oil Nutrition 0.000 description 11
- 229910000069 nitrogen hydride Inorganic materials 0.000 description 11
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 10
- 239000003921 oil Substances 0.000 description 10
- 235000019198 oils Nutrition 0.000 description 10
- 238000003786 synthesis reaction Methods 0.000 description 10
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 9
- 125000004432 carbon atom Chemical group C* 0.000 description 9
- 150000004677 hydrates Chemical class 0.000 description 9
- KVKFRMCSXWQSNT-UHFFFAOYSA-N n,n'-dimethylethane-1,2-diamine Chemical compound CNCCNC KVKFRMCSXWQSNT-UHFFFAOYSA-N 0.000 description 9
- 229920006395 saturated elastomer Polymers 0.000 description 9
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 8
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 8
- 208000035143 Bacterial infection Diseases 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- 241000400611 Eucalyptus deanei Species 0.000 description 8
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 8
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 8
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 8
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 8
- 239000012346 acetyl chloride Substances 0.000 description 8
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 8
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 8
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 7
- 150000002632 lipids Chemical class 0.000 description 7
- OELZFJUWWFRWLC-UHFFFAOYSA-N oxazine-1 Chemical compound C1=CC(N(CC)CC)=CC2=[O+]C3=CC(N(CC)CC)=CC=C3N=C21 OELZFJUWWFRWLC-UHFFFAOYSA-N 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- 229910052717 sulfur Inorganic materials 0.000 description 7
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 description 6
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 6
- 244000166102 Eucalyptus leucoxylon Species 0.000 description 6
- 235000004694 Eucalyptus leucoxylon Nutrition 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- 125000002947 alkylene group Chemical group 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 239000003085 diluting agent Substances 0.000 description 6
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical group C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- ZGVAWYBJGMOKBV-UHFFFAOYSA-N methyl 5-bromo-2-chloropyridine-4-carboxylate Chemical compound COC(=O)C1=CC(Cl)=NC=C1Br ZGVAWYBJGMOKBV-UHFFFAOYSA-N 0.000 description 6
- 235000017557 sodium bicarbonate Nutrition 0.000 description 6
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 6
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 6
- JFHXGYMTUCHPLK-UHFFFAOYSA-N 1-(3-chloro-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one Chemical compound ClC1=CC2=C(C=N1)C=1C=CC(=CC=1OC2)N1C(CCC1)=O JFHXGYMTUCHPLK-UHFFFAOYSA-N 0.000 description 5
- USJMODARXIIDOU-UHFFFAOYSA-N 1-(5-aminopyridin-3-yl)pyrrolidin-2-one Chemical compound NC1=CN=CC(N2C(CCC2)=O)=C1 USJMODARXIIDOU-UHFFFAOYSA-N 0.000 description 5
- OCODJNASCDFXSR-UHFFFAOYSA-N 1-bromo-2-fluoro-4-iodobenzene Chemical compound FC1=CC(I)=CC=C1Br OCODJNASCDFXSR-UHFFFAOYSA-N 0.000 description 5
- FFQNNPQQIUKLGV-UHFFFAOYSA-N 7-bromo-2,3-dihydro-1h-pyrido[2,3-b][1,4]oxazine Chemical compound O1CCNC2=CC(Br)=CN=C21 FFQNNPQQIUKLGV-UHFFFAOYSA-N 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- 108091000080 Phosphotransferase Proteins 0.000 description 5
- 208000036142 Viral infection Diseases 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 150000001412 amines Chemical class 0.000 description 5
- 150000002148 esters Chemical class 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- VTWIGHWINGQPKA-UHFFFAOYSA-N methyl 2-chloro-5-[2-fluoro-4-(2-oxopyrrolidin-1-yl)phenyl]pyridine-4-carboxylate Chemical compound ClC=1C=C(C(=O)OC)C(=CN=1)C1=C(C=C(C=C1)N1C(CCC1)=O)F VTWIGHWINGQPKA-UHFFFAOYSA-N 0.000 description 5
- 125000002950 monocyclic group Chemical group 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 229910052698 phosphorus Inorganic materials 0.000 description 5
- 102000020233 phosphotransferase Human genes 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 230000009385 viral infection Effects 0.000 description 5
- BKWRLCIYMAYFPA-UHFFFAOYSA-N (2-fluoro-4-methoxycarbonylphenyl)boronic acid Chemical compound COC(=O)C1=CC=C(B(O)O)C(F)=C1 BKWRLCIYMAYFPA-UHFFFAOYSA-N 0.000 description 4
- QTNIZGZNNIWTGC-UHFFFAOYSA-N 1,5-naphthyridin-3-amine Chemical compound C1=CC=NC2=CC(N)=CN=C21 QTNIZGZNNIWTGC-UHFFFAOYSA-N 0.000 description 4
- 102100027824 3'(2'),5'-bisphosphate nucleotidase 1 Human genes 0.000 description 4
- SOSPMXMEOFGPIM-UHFFFAOYSA-N 3,5-dibromopyridine Chemical compound BrC1=CN=CC(Br)=C1 SOSPMXMEOFGPIM-UHFFFAOYSA-N 0.000 description 4
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 4
- MAGFXBKNQAAQQA-UHFFFAOYSA-N 5-bromo-2-chloropyridine-4-carbaldehyde Chemical compound ClC1=CC(C=O)=C(Br)C=N1 MAGFXBKNQAAQQA-UHFFFAOYSA-N 0.000 description 4
- MDQXGHBCDCOOSM-UHFFFAOYSA-N 5-bromopyridin-3-amine Chemical compound NC1=CN=CC(Br)=C1 MDQXGHBCDCOOSM-UHFFFAOYSA-N 0.000 description 4
- ZRORIJXOWXYPMO-UHFFFAOYSA-N 5-fluoropyridin-3-amine Chemical compound NC1=CN=CC(F)=C1 ZRORIJXOWXYPMO-UHFFFAOYSA-N 0.000 description 4
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 4
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 4
- KTAJDKPPMKRHFD-UHFFFAOYSA-N Brc1cncc(c1)N1CCNC1=O Chemical compound Brc1cncc(c1)N1CCNC1=O KTAJDKPPMKRHFD-UHFFFAOYSA-N 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 206010027476 Metastases Diseases 0.000 description 4
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 4
- 208000001132 Osteoporosis Diseases 0.000 description 4
- UBXIJOJXUFYNRG-MPJQEMCDSA-N PIP[5'](17:0/20:4(5Z,8Z,11Z,14Z)) Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCC)COP(O)(=O)O[C@@H]1C(O)[C@H](O)C(O)C(OP(O)(O)=O)C1O UBXIJOJXUFYNRG-MPJQEMCDSA-N 0.000 description 4
- 102000014418 Phosphatidylinositol-4-phosphate 5-kinases Human genes 0.000 description 4
- 108050003469 Phosphatidylinositol-4-phosphate 5-kinases Proteins 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 4
- 206010003246 arthritis Diseases 0.000 description 4
- 208000022362 bacterial infectious disease Diseases 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- 239000004305 biphenyl Chemical group 0.000 description 4
- IPWKHHSGDUIRAH-UHFFFAOYSA-N bis(pinacolato)diboron Chemical compound O1C(C)(C)C(C)(C)OB1B1OC(C)(C)C(C)(C)O1 IPWKHHSGDUIRAH-UHFFFAOYSA-N 0.000 description 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 235000019253 formic acid Nutrition 0.000 description 4
- 208000026278 immune system disease Diseases 0.000 description 4
- 208000023589 ischemic disease Diseases 0.000 description 4
- NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 description 4
- 230000009401 metastasis Effects 0.000 description 4
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 4
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 4
- 125000004076 pyridyl group Chemical group 0.000 description 4
- 239000000377 silicon dioxide Substances 0.000 description 4
- 229910000029 sodium carbonate Inorganic materials 0.000 description 4
- 235000017550 sodium carbonate Nutrition 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- MHCVCKDNQYMGEX-UHFFFAOYSA-N 1,1'-biphenyl;phenoxybenzene Chemical group C1=CC=CC=C1C1=CC=CC=C1.C=1C=CC=CC=1OC1=CC=CC=C1 MHCVCKDNQYMGEX-UHFFFAOYSA-N 0.000 description 3
- IOOQKNSFQJZRNN-UHFFFAOYSA-N 1-(5-bromopyridin-3-yl)pyrrolidin-2-one Chemical compound BrC1=CN=CC(N2C(CCC2)=O)=C1 IOOQKNSFQJZRNN-UHFFFAOYSA-N 0.000 description 3
- VQSJAWPFQCXIOB-VODLGYORSA-N 2,3-dihydroxypropyl [(1r,2r,3s,4r,5r,6s)-2,3,6-trihydroxy-4,5-diphosphonooxycyclohexyl] hydrogen phosphate Chemical compound OCC(O)COP(O)(=O)O[C@@H]1[C@H](O)[C@H](O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H]1O VQSJAWPFQCXIOB-VODLGYORSA-N 0.000 description 3
- NIWFXRKHWKGFMT-UHFFFAOYSA-N 2-acetyloxy-2-methylpropanoic acid Chemical compound CC(=O)OC(C)(C)C(O)=O NIWFXRKHWKGFMT-UHFFFAOYSA-N 0.000 description 3
- WTLNOANVTIKPEE-UHFFFAOYSA-N 2-acetyloxypropanoic acid Chemical compound OC(=O)C(C)OC(C)=O WTLNOANVTIKPEE-UHFFFAOYSA-N 0.000 description 3
- WGTJHNVZSWQLNB-UHFFFAOYSA-N 4-(5-bromopyridin-3-yl)morpholin-3-one Chemical compound BrC=1C=C(C=NC=1)N1C(COCC1)=O WGTJHNVZSWQLNB-UHFFFAOYSA-N 0.000 description 3
- COIOXTGXIQKWBH-UHFFFAOYSA-N 4-(5-bromopyridin-3-yl)morpholine Chemical compound BrC1=CN=CC(N2CCOCC2)=C1 COIOXTGXIQKWBH-UHFFFAOYSA-N 0.000 description 3
- SQSHZRBCVHCKPX-UHFFFAOYSA-N 4-bromo-3-fluoro-n,n-dimethylbenzamide Chemical compound CN(C)C(=O)C1=CC=C(Br)C(F)=C1 SQSHZRBCVHCKPX-UHFFFAOYSA-N 0.000 description 3
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 3
- AWXJVLYODIKXPY-UHFFFAOYSA-N 5-bromo-n-cyclopropylpyridin-3-amine Chemical compound BrC1=CN=CC(NC2CC2)=C1 AWXJVLYODIKXPY-UHFFFAOYSA-N 0.000 description 3
- BDLZEBCBFTUAHD-UHFFFAOYSA-N 5-methylsulfanylquinoline Chemical compound C1=CC=C2C(SC)=CC=CC2=N1 BDLZEBCBFTUAHD-UHFFFAOYSA-N 0.000 description 3
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 3
- 208000020084 Bone disease Diseases 0.000 description 3
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 235000010290 biphenyl Nutrition 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 208000037765 diseases and disorders Diseases 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- YOMFVLRTMZWACQ-UHFFFAOYSA-N ethyltrimethylammonium Chemical compound CC[N+](C)(C)C YOMFVLRTMZWACQ-UHFFFAOYSA-N 0.000 description 3
- 239000012065 filter cake Substances 0.000 description 3
- 229910052731 fluorine Inorganic materials 0.000 description 3
- 125000001188 haloalkyl group Chemical group 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 3
- 125000001041 indolyl group Chemical group 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 3
- XMJHPCRAQCTCFT-UHFFFAOYSA-N methyl chloroformate Chemical compound COC(Cl)=O XMJHPCRAQCTCFT-UHFFFAOYSA-N 0.000 description 3
- YCFNLAOHTIOOJJ-UHFFFAOYSA-N methyl n-(5-bromopyridin-3-yl)carbamate Chemical compound COC(=O)NC1=CN=CC(Br)=C1 YCFNLAOHTIOOJJ-UHFFFAOYSA-N 0.000 description 3
- QUYRNQHUIOWPCS-UHFFFAOYSA-N n-(5-bromo-2-methoxypyridin-3-yl)acetamide Chemical compound COC1=NC=C(Br)C=C1NC(C)=O QUYRNQHUIOWPCS-UHFFFAOYSA-N 0.000 description 3
- 125000001624 naphthyl group Chemical group 0.000 description 3
- OHENQANLQNOMAO-UHFFFAOYSA-N oxaborole Chemical compound O1B=CC=C1 OHENQANLQNOMAO-UHFFFAOYSA-N 0.000 description 3
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 3
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 3
- 150000003905 phosphatidylinositols Chemical class 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 125000006239 protecting group Chemical group 0.000 description 3
- 239000001632 sodium acetate Substances 0.000 description 3
- 235000017281 sodium acetate Nutrition 0.000 description 3
- 239000012279 sodium borohydride Substances 0.000 description 3
- 229910000033 sodium borohydride Inorganic materials 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- BKNJNAHBUNZASC-UHFFFAOYSA-N tert-butyl N-[5-(2-oxopyrrolidin-1-yl)pyridin-3-yl]carbamate Chemical compound O=C1N(CCC1)C=1C=C(C=NC=1)NC(OC(C)(C)C)=O BKNJNAHBUNZASC-UHFFFAOYSA-N 0.000 description 3
- GSTMUJGINQFVNK-UHFFFAOYSA-N tert-butyl n-(1,5-naphthyridin-3-yl)carbamate Chemical compound C1=CC=NC2=CC(NC(=O)OC(C)(C)C)=CN=C21 GSTMUJGINQFVNK-UHFFFAOYSA-N 0.000 description 3
- BKYBFDYKYQPBIO-UHFFFAOYSA-N tert-butyl n-(5-fluoropyridin-3-yl)carbamate Chemical compound CC(C)(C)OC(=O)NC1=CN=CC(F)=C1 BKYBFDYKYQPBIO-UHFFFAOYSA-N 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- UGOMMVLRQDMAQQ-UHFFFAOYSA-N xphos Chemical group CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 UGOMMVLRQDMAQQ-UHFFFAOYSA-N 0.000 description 3
- VHLBPPIUDAUUFY-UHFFFAOYSA-N (1-carbonochloridoylcyclopropyl) acetate Chemical compound CC(=O)OC1(C(Cl)=O)CC1 VHLBPPIUDAUUFY-UHFFFAOYSA-N 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 2
- OFGOXDSEEYDXQV-UHFFFAOYSA-N (5-bromo-2-chloropyridin-4-yl)methanol Chemical compound OCC1=CC(Cl)=NC=C1Br OFGOXDSEEYDXQV-UHFFFAOYSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- SQOQDQCSZASEHW-UHFFFAOYSA-N 1-(3-amino-5-methyl-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one Chemical compound CC1OC2=CC(=CC=C2C2=CN=C(N)C=C12)N1CCCC1=O SQOQDQCSZASEHW-UHFFFAOYSA-N 0.000 description 2
- GOSRQASUGWCPJF-UHFFFAOYSA-N 1-[5-methyl-3-(pyrido[2,3-b]pyrazin-7-ylamino)-5H-chromeno[4,3-c]pyridin-8-yl]pyrrolidin-2-one Chemical compound CC1OC2=CC(=CC=C2C2=CN=C(NC3=CC4=NC=CN=C4N=C3)C=C12)N1CCCC1=O GOSRQASUGWCPJF-UHFFFAOYSA-N 0.000 description 2
- BRSHAGAFOJOQSS-UHFFFAOYSA-N 1-[5-methyl-3-[(5-methylpyridin-3-yl)amino]-5H-chromeno[4,3-c]pyridin-8-yl]pyrrolidin-2-one Chemical compound CC1OC2=CC(=CC=C2C2=CN=C(NC3=CC(C)=CN=C3)C=C12)N1CCCC1=O BRSHAGAFOJOQSS-UHFFFAOYSA-N 0.000 description 2
- UFGHKCAYOUCBDY-UHFFFAOYSA-N 1-acetyloxycyclopropane-1-carboxylic acid Chemical compound CC(=O)OC1(C(O)=O)CC1 UFGHKCAYOUCBDY-UHFFFAOYSA-N 0.000 description 2
- JQLQPQVNTADVBJ-UHFFFAOYSA-N 2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-7-amine Chemical compound O1CCOC2=CC(N)=CN=C21 JQLQPQVNTADVBJ-UHFFFAOYSA-N 0.000 description 2
- HBEDSQVIWPRPAY-UHFFFAOYSA-N 2,3-dihydrobenzofuran Chemical compound C1=CC=C2OCCC2=C1 HBEDSQVIWPRPAY-UHFFFAOYSA-N 0.000 description 2
- YNTJKQDWYXUTLZ-UHFFFAOYSA-N 2-(3-chlorophenoxy)propanoic acid Chemical compound OC(=O)C(C)OC1=CC=CC(Cl)=C1 YNTJKQDWYXUTLZ-UHFFFAOYSA-N 0.000 description 2
- DOZVGKLYBRUPRZ-UHFFFAOYSA-N 2-chloro-5-[2-fluoro-4-(2-oxopyrrolidin-1-yl)phenyl]pyridine-4-carbaldehyde Chemical compound ClC1=NC=C(C(=C1)C=O)C1=C(C=C(C=C1)N1C(CCC1)=O)F DOZVGKLYBRUPRZ-UHFFFAOYSA-N 0.000 description 2
- BWLBGMIXKSTLSX-UHFFFAOYSA-N 2-hydroxyisobutyric acid Chemical compound CC(C)(O)C(O)=O BWLBGMIXKSTLSX-UHFFFAOYSA-N 0.000 description 2
- NWZXAAOTMBDUQY-UHFFFAOYSA-N 3,4-dihydro-1,4-oxazin-2-one Chemical compound O=C1CNC=CO1 NWZXAAOTMBDUQY-UHFFFAOYSA-N 0.000 description 2
- IDUSJBBWEKNWAK-UHFFFAOYSA-N 3,4-dihydro-2h-1,2-benzothiazine Chemical compound C1=CC=C2SNCCC2=C1 IDUSJBBWEKNWAK-UHFFFAOYSA-N 0.000 description 2
- TYTMZBZGMNQNBH-UHFFFAOYSA-N 3-iodo-5-methylsulfonylquinoline Chemical compound IC=1C=NC2=CC=CC(=C2C=1)S(=O)(=O)C TYTMZBZGMNQNBH-UHFFFAOYSA-N 0.000 description 2
- YRPRNBZLQPBYDS-UHFFFAOYSA-N 5-bromo-2-chloropyridine-4-carboxylic acid Chemical compound OC(=O)C1=CC(Cl)=NC=C1Br YRPRNBZLQPBYDS-UHFFFAOYSA-N 0.000 description 2
- HJOOFLFWIISCAI-UHFFFAOYSA-N 5-bromo-2-methoxypyridin-3-amine Chemical compound COC1=NC=C(Br)C=C1N HJOOFLFWIISCAI-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- 239000012388 BrettPhos 3rd generation precatalyst Substances 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- UDHXJZHVNHGCEC-UHFFFAOYSA-N Chlorophacinone Chemical compound C1=CC(Cl)=CC=C1C(C=1C=CC=CC=1)C(=O)C1C(=O)C2=CC=CC=C2C1=O UDHXJZHVNHGCEC-UHFFFAOYSA-N 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
- 230000005526 G1 to G0 transition Effects 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 2
- UZIWPOURUBNWNY-UHFFFAOYSA-N NC1=NC=C2C(COC3=CC(=CC=C23)N2CCCC2=O)=C1 Chemical compound NC1=NC=C2C(COC3=CC(=CC=C23)N2CCCC2=O)=C1 UZIWPOURUBNWNY-UHFFFAOYSA-N 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 2
- 102000001253 Protein Kinase Human genes 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- 102000014384 Type C Phospholipases Human genes 0.000 description 2
- 108010079194 Type C Phospholipases Proteins 0.000 description 2
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 2
- 125000003282 alkyl amino group Chemical group 0.000 description 2
- 235000011114 ammonium hydroxide Nutrition 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical compound C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- GZUXJHMPEANEGY-UHFFFAOYSA-N bromomethane Chemical compound BrC GZUXJHMPEANEGY-UHFFFAOYSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000012230 colorless oil Substances 0.000 description 2
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- ZOOSILUVXHVRJE-UHFFFAOYSA-N cyclopropanecarbonyl chloride Chemical compound ClC(=O)C1CC1 ZOOSILUVXHVRJE-UHFFFAOYSA-N 0.000 description 2
- PFWWSGFPICCWGU-UHFFFAOYSA-N cyclopropanesulfonyl chloride Chemical compound ClS(=O)(=O)C1CC1 PFWWSGFPICCWGU-UHFFFAOYSA-N 0.000 description 2
- OZYHLCOUAISLLG-UHFFFAOYSA-N cyclopropyl acetate Chemical compound CC(=O)OC1CC1 OZYHLCOUAISLLG-UHFFFAOYSA-N 0.000 description 2
- NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 150000001982 diacylglycerols Chemical class 0.000 description 2
- 125000004663 dialkyl amino group Chemical group 0.000 description 2
- IYYZUPMFVPLQIF-UHFFFAOYSA-N dibenzothiophene Chemical compound C1=CC=C2C3=CC=CC=C3SC2=C1 IYYZUPMFVPLQIF-UHFFFAOYSA-N 0.000 description 2
- 125000005436 dihydrobenzothiophenyl group Chemical group S1C(CC2=C1C=CC=C2)* 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 238000000132 electrospray ionisation Methods 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- CCGKOQOJPYTBIH-UHFFFAOYSA-N ethenone Chemical compound C=C=O CCGKOQOJPYTBIH-UHFFFAOYSA-N 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 125000004613 furo[2,3-c]pyridinyl group Chemical group O1C(=CC=2C1=CN=CC2)* 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- 235000001727 glucose Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 239000011630 iodine Chemical group 0.000 description 2
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- CKJNUZNMWOVDFN-UHFFFAOYSA-N methanone Chemical compound O=[CH-] CKJNUZNMWOVDFN-UHFFFAOYSA-N 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 125000002757 morpholinyl group Chemical group 0.000 description 2
- 230000004899 motility Effects 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- LXNAVEXFUKBNMK-UHFFFAOYSA-N palladium(II) acetate Substances [Pd].CC(O)=O.CC(O)=O LXNAVEXFUKBNMK-UHFFFAOYSA-N 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 150000003906 phosphoinositides Chemical class 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
- VVWRJUBEIPHGQF-MDZDMXLPSA-N propan-2-yl (ne)-n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)\N=N\C(=O)OC(C)C VVWRJUBEIPHGQF-MDZDMXLPSA-N 0.000 description 2
- 108060006633 protein kinase Proteins 0.000 description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 2
- GHBFNMLVSPCDGN-UHFFFAOYSA-N rac-1-monooctanoylglycerol Chemical compound CCCCCCCC(=O)OCC(O)CO GHBFNMLVSPCDGN-UHFFFAOYSA-N 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 125000006413 ring segment Chemical group 0.000 description 2
- 229930195734 saturated hydrocarbon Natural products 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- UNMVKEILYZPXBL-UHFFFAOYSA-N tert-butyl N-[5-[methyl(methylsulfonyl)amino]pyridin-3-yl]carbamate Chemical compound CN(S(=O)(=O)C)C=1C=C(C=NC=1)NC(OC(C)(C)C)=O UNMVKEILYZPXBL-UHFFFAOYSA-N 0.000 description 2
- TZAOPISIPNHPQT-UHFFFAOYSA-N tert-butyl n-(2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-7-yl)carbamate Chemical compound O1CCOC2=CC(NC(=O)OC(C)(C)C)=CN=C21 TZAOPISIPNHPQT-UHFFFAOYSA-N 0.000 description 2
- CIHOLLKRGTVIJN-UHFFFAOYSA-N tert‐butyl hydroperoxide Chemical compound CC(C)(C)OO CIHOLLKRGTVIJN-UHFFFAOYSA-N 0.000 description 2
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical class [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 description 2
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 2
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 2
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 2
- VXUYXOFXAQZZMF-UHFFFAOYSA-N titanium(IV) isopropoxide Chemical compound CC(C)O[Ti](OC(C)C)(OC(C)C)OC(C)C VXUYXOFXAQZZMF-UHFFFAOYSA-N 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- 229940116362 tragacanth Drugs 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- BWHDROKFUHTORW-UHFFFAOYSA-N tritert-butylphosphane Chemical compound CC(C)(C)P(C(C)(C)C)C(C)(C)C BWHDROKFUHTORW-UHFFFAOYSA-N 0.000 description 2
- 239000002691 unilamellar liposome Substances 0.000 description 2
- 229930195735 unsaturated hydrocarbon Natural products 0.000 description 2
- UKSZBOKPHAQOMP-SVLSSHOZSA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 UKSZBOKPHAQOMP-SVLSSHOZSA-N 0.000 description 1
- XFQNWPYGEGCIMF-HCUGAJCMSA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].[Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 XFQNWPYGEGCIMF-HCUGAJCMSA-N 0.000 description 1
- HZDNNJABYXNPPV-UHFFFAOYSA-N (2-chloro-2-oxoethyl) acetate Chemical compound CC(=O)OCC(Cl)=O HZDNNJABYXNPPV-UHFFFAOYSA-N 0.000 description 1
- PAORVUMOXXAMPL-SECBINFHSA-N (2s)-3,3,3-trifluoro-2-methoxy-2-phenylpropanoyl chloride Chemical compound CO[C@](C(Cl)=O)(C(F)(F)F)C1=CC=CC=C1 PAORVUMOXXAMPL-SECBINFHSA-N 0.000 description 1
- KZEDPVFJLQLDIZ-UHFFFAOYSA-N (5-diphenylphosphanyl-9,9-dimethylxanthen-4-yl)-diphenylphosphane Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1.C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZEDPVFJLQLDIZ-UHFFFAOYSA-N 0.000 description 1
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 description 1
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 description 1
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 description 1
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 1
- FIARMZDBEGVMLV-UHFFFAOYSA-N 1,1,2,2,2-pentafluoroethanolate Chemical group [O-]C(F)(F)C(F)(F)F FIARMZDBEGVMLV-UHFFFAOYSA-N 0.000 description 1
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 1
- SILNNFMWIMZVEQ-UHFFFAOYSA-N 1,3-dihydrobenzimidazol-2-one Chemical compound C1=CC=C2NC(O)=NC2=C1 SILNNFMWIMZVEQ-UHFFFAOYSA-N 0.000 description 1
- UXWCQXCEIZRGDD-UHFFFAOYSA-N 1-(4-bromo-2,5-difluorophenyl)pyrrolidin-2-one Chemical compound Fc1cc(N2CCCC2=O)c(F)cc1Br UXWCQXCEIZRGDD-UHFFFAOYSA-N 0.000 description 1
- BLJJKMOBCWJANL-UHFFFAOYSA-N 1-(5-aminopyridin-3-yl)cyclopropane-1-carbonitrile Chemical compound NC1=CN=CC(=C1)C1(CC1)C#N BLJJKMOBCWJANL-UHFFFAOYSA-N 0.000 description 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- ORZQZUKDNULJBO-UHFFFAOYSA-N 1-[3-(2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-ylamino)-5-methyl-5H-chromeno[4,3-c]pyridin-8-yl]pyrrolidin-2-one Chemical compound CC1OC2=CC(=CC=C2C2=CN=C(NC3=CC4=C(OCCN4)N=C3)C=C12)N1CCCC1=O ORZQZUKDNULJBO-UHFFFAOYSA-N 0.000 description 1
- KOJACVFCSPXXII-UHFFFAOYSA-N 1-[3-(2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-7-ylamino)-5-methyl-5H-chromeno[4,3-c]pyridin-8-yl]pyrrolidin-2-one Chemical compound CC1OC2=CC(=CC=C2C2=CN=C(NC3=CN=C4OCCOC4=C3)C=C12)N1CCCC1=O KOJACVFCSPXXII-UHFFFAOYSA-N 0.000 description 1
- XETTWJDWRMPUQB-UHFFFAOYSA-N 1-[3-[(1-acetyl-2,3-dihydropyrido[2,3-b][1,4]oxazin-7-yl)amino]-5-methyl-5H-chromeno[4,3-c]pyridin-8-yl]pyrrolidin-2-one Chemical compound CC1OC2=CC(=CC=C2C2=CN=C(NC3=CC4=C(OCCN4C(C)=O)N=C3)C=C12)N1CCCC1=O XETTWJDWRMPUQB-UHFFFAOYSA-N 0.000 description 1
- BFKSHQMEOYQLSY-UHFFFAOYSA-N 1-[3-[[1-(1-hydroxycyclopropanecarbonyl)-2,3-dihydropyrido[2,3-b][1,4]oxazin-7-yl]amino]-5-methyl-5H-chromeno[4,3-c]pyridin-8-yl]pyrrolidin-2-one Chemical compound CC1OC2=CC(=CC=C2C2=CN=C(NC3=CC4=C(OCCN4C(=O)C4(O)CC4)N=C3)C=C12)N1CCCC1=O BFKSHQMEOYQLSY-UHFFFAOYSA-N 0.000 description 1
- ZKUVSASCTSRXMI-UHFFFAOYSA-N 1-[3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]pyrrolidin-2-one Chemical compound CC1(C)OB(OC1(C)C)c1ccc(cc1F)N1CCCC1=O ZKUVSASCTSRXMI-UHFFFAOYSA-N 0.000 description 1
- KKQFCJNKBVYBCD-UHFFFAOYSA-N 1-[4-[6-chloro-4-[1-(methylamino)ethyl]pyridin-3-yl]-3-fluorophenyl]pyrrolidin-2-one Chemical compound CNC(C)C1=C(C=NC(Cl)=C1)C1=C(F)C=C(C=C1)N1CCCC1=O KKQFCJNKBVYBCD-UHFFFAOYSA-N 0.000 description 1
- VFTBMZOPLMSSJH-UHFFFAOYSA-N 1-[5-methyl-3-([1,3]thiazolo[5,4-b]pyridin-6-ylamino)-5H-chromeno[4,3-c]pyridin-8-yl]pyrrolidin-2-one Chemical compound CC1OC2=CC(=CC=C2C2=CN=C(NC3=CN=C4SC=NC4=C3)C=C12)N1CCCC1=O VFTBMZOPLMSSJH-UHFFFAOYSA-N 0.000 description 1
- WDMSQJPSRZMOSY-UHFFFAOYSA-N 1-[5-methyl-3-(pyridin-3-ylamino)-5H-chromeno[4,3-c]pyridin-8-yl]pyrrolidin-2-one Chemical compound CC1OC=2C=C(C=CC=2C=2C=NC(=CC=21)NC=1C=CC=NC=1)N1C(CCC1)=O WDMSQJPSRZMOSY-UHFFFAOYSA-N 0.000 description 1
- HKTXCSIGYNEJDF-UHFFFAOYSA-N 1-[5-methyl-3-(pyrimidin-5-ylamino)-5H-chromeno[4,3-c]pyridin-8-yl]pyrrolidin-2-one Chemical compound CC1OC2=CC(=CC=C2C2=CN=C(NC3=CN=CN=C3)C=C12)N1CCCC1=O HKTXCSIGYNEJDF-UHFFFAOYSA-N 0.000 description 1
- PTTIOPPYPFBQOL-UHFFFAOYSA-N 1-[5-methyl-3-[(5-methylsulfonylpyridin-3-yl)amino]-5H-chromeno[4,3-c]pyridin-8-yl]pyrrolidin-2-one Chemical compound CC1OC2=CC(=CC=C2C2=CN=C(NC3=CC(=CN=C3)S(C)(=O)=O)C=C12)N1CCCC1=O PTTIOPPYPFBQOL-UHFFFAOYSA-N 0.000 description 1
- OTSLKPLRMJHPOM-UHFFFAOYSA-N 1-[5-methyl-3-[(5-methylsulfonylquinolin-3-yl)amino]-5H-chromeno[4,3-c]pyridin-8-yl]pyrrolidin-2-one Chemical compound CC1OC=2C=C(C=CC=2C=2C=NC(=CC=21)NC=1C=NC2=CC=CC(=C2C=1)S(=O)(=O)C)N1C(CCC1)=O OTSLKPLRMJHPOM-UHFFFAOYSA-N 0.000 description 1
- IOYVJBJIJSQVMY-UHFFFAOYSA-N 1-[5-methyl-3-[(5-morpholin-4-ylpyridin-3-yl)amino]-5H-chromeno[4,3-c]pyridin-8-yl]pyrrolidin-2-one Chemical compound CC1OC2=CC(=CC=C2C2=CN=C(NC3=CC(=CN=C3)N3CCOCC3)C=C12)N1CCCC1=O IOYVJBJIJSQVMY-UHFFFAOYSA-N 0.000 description 1
- BVOAAZSKTBWKIZ-UHFFFAOYSA-N 1-[5-methyl-3-[[5-(2-oxopyrrolidin-1-yl)pyridin-3-yl]amino]-5H-chromeno[4,3-c]pyridin-8-yl]pyrrolidin-2-one Chemical compound CC1OC2=CC(=CC=C2C2=CN=C(NC3=CC(=CN=C3)N3CCCC3=O)C=C12)N1CCCC1=O BVOAAZSKTBWKIZ-UHFFFAOYSA-N 0.000 description 1
- DOGSQPBKZOMWDT-UHFFFAOYSA-N 1-bromo-2,5-difluoro-4-iodobenzene Chemical compound FC1=CC(I)=C(F)C=C1Br DOGSQPBKZOMWDT-UHFFFAOYSA-N 0.000 description 1
- GQXURJDNDYACGE-UHFFFAOYSA-N 1-hydroxycyclopropane-1-carboxylic acid Chemical compound OC(=O)C1(O)CC1 GQXURJDNDYACGE-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 description 1
- CNWINRVXAYPOMW-FCNJXWMTSA-N 1-stearoyl-2-arachidonoyl-sn-glycero-3-phospho-1D-myo-inositol 4,5-biphosphate Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCC)COP(O)(=O)O[C@@H]1[C@H](O)[C@H](O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H]1O CNWINRVXAYPOMW-FCNJXWMTSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- AWBOSXFRPFZLOP-UHFFFAOYSA-N 2,1,3-benzoxadiazole Chemical compound C1=CC=CC2=NON=C21 AWBOSXFRPFZLOP-UHFFFAOYSA-N 0.000 description 1
- JVSFQJZRHXAUGT-UHFFFAOYSA-N 2,2-dimethylpropanoyl chloride Chemical compound CC(C)(C)C(Cl)=O JVSFQJZRHXAUGT-UHFFFAOYSA-N 0.000 description 1
- OIQOAYVCKAHSEJ-UHFFFAOYSA-N 2-[2,3-bis(2-hydroxyethoxy)propoxy]ethanol;hexadecanoic acid;octadecanoic acid Chemical compound OCCOCC(OCCO)COCCO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O OIQOAYVCKAHSEJ-UHFFFAOYSA-N 0.000 description 1
- DGMOBVGABMBZSB-UHFFFAOYSA-N 2-methylpropanoyl chloride Chemical compound CC(C)C(Cl)=O DGMOBVGABMBZSB-UHFFFAOYSA-N 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- YHWMFDLNZGIJSD-UHFFFAOYSA-N 2h-1,4-oxazine Chemical compound C1OC=CN=C1 YHWMFDLNZGIJSD-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- ALKYHXVLJMQRLQ-UHFFFAOYSA-N 3-Hydroxy-2-naphthoate Chemical compound C1=CC=C2C=C(O)C(C(=O)O)=CC2=C1 ALKYHXVLJMQRLQ-UHFFFAOYSA-N 0.000 description 1
- DQTDPFYKQAQVJU-UHFFFAOYSA-N 3-bromo-1,5-naphthyridine Chemical compound C1=CC=NC2=CC(Br)=CN=C21 DQTDPFYKQAQVJU-UHFFFAOYSA-N 0.000 description 1
- PTTQIUHVDDBART-UHFFFAOYSA-N 3-bromo-2-chloro-5-nitropyridine Chemical compound [O-][N+](=O)C1=CN=C(Cl)C(Br)=C1 PTTQIUHVDDBART-UHFFFAOYSA-N 0.000 description 1
- HNNNBQRRIHKFLI-UHFFFAOYSA-N 3-bromo-5-fluoropyridine Chemical compound FC1=CN=CC(Br)=C1 HNNNBQRRIHKFLI-UHFFFAOYSA-N 0.000 description 1
- CNAIMMQZMLBREW-UHFFFAOYSA-N 3-bromo-5-methylsulfonylpyridine Chemical compound CS(=O)(=O)C1=CN=CC(Br)=C1 CNAIMMQZMLBREW-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 1
- ALKYHXVLJMQRLQ-UHFFFAOYSA-M 3-carboxynaphthalen-2-olate Chemical compound C1=CC=C2C=C(C([O-])=O)C(O)=CC2=C1 ALKYHXVLJMQRLQ-UHFFFAOYSA-M 0.000 description 1
- NVTBASMQHFMANH-UHFFFAOYSA-N 4-(chloromethyl)-1,3-thiazole;hydron;chloride Chemical compound Cl.ClCC1=CSC=N1 NVTBASMQHFMANH-UHFFFAOYSA-N 0.000 description 1
- RMYOGXPGIDWJLU-UHFFFAOYSA-N 4-bromo-3-fluorobenzoic acid Chemical compound OC(=O)C1=CC=C(Br)C(F)=C1 RMYOGXPGIDWJLU-UHFFFAOYSA-N 0.000 description 1
- IQTHEAQKKVAXGV-UHFFFAOYSA-N 4-ditert-butylphosphanyl-n,n-dimethylaniline Chemical compound CN(C)C1=CC=C(P(C(C)(C)C)C(C)(C)C)C=C1 IQTHEAQKKVAXGV-UHFFFAOYSA-N 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- VERUFXOALATMPS-UHFFFAOYSA-N 5,5-diamino-2-(2-phenylethenyl)cyclohex-3-ene-1,1-disulfonic acid Chemical compound C1=CC(N)(N)CC(S(O)(=O)=O)(S(O)(=O)=O)C1C=CC1=CC=CC=C1 VERUFXOALATMPS-UHFFFAOYSA-N 0.000 description 1
- OIZXYMRCGYMFRS-UHFFFAOYSA-N 5-(difluoromethoxy)pyridin-3-amine Chemical compound NC1=CN=CC(OC(F)F)=C1 OIZXYMRCGYMFRS-UHFFFAOYSA-N 0.000 description 1
- NJFRBMFEAGFNDC-UHFFFAOYSA-N 5-(trifluoromethyl)pyridin-3-amine Chemical compound NC1=CN=CC(C(F)(F)F)=C1 NJFRBMFEAGFNDC-UHFFFAOYSA-N 0.000 description 1
- PEAOEIWYQVXZMB-UHFFFAOYSA-N 5-bromo-2-chloropyridine Chemical compound ClC1=CC=C(Br)C=N1 PEAOEIWYQVXZMB-UHFFFAOYSA-N 0.000 description 1
- CHODTZCXWXCALP-UHFFFAOYSA-N 5-bromoquinoline Chemical compound C1=CC=C2C(Br)=CC=CC2=N1 CHODTZCXWXCALP-UHFFFAOYSA-N 0.000 description 1
- JXUWZXFVCBODAN-UHFFFAOYSA-N 5-methylpyridin-3-amine Chemical compound CC1=CN=CC(N)=C1 JXUWZXFVCBODAN-UHFFFAOYSA-N 0.000 description 1
- WVVYYGCQBNTEDL-UHFFFAOYSA-N 5-methylsulfonyl-1H-quinolin-2-one Chemical compound CS(=O)(=O)C1=C2C=CC(NC2=CC=C1)=O WVVYYGCQBNTEDL-UHFFFAOYSA-N 0.000 description 1
- CANURNQSWVOMTL-UHFFFAOYSA-N 5-methylsulfonylquinoline Chemical compound C1=CC=C2C(S(=O)(=O)C)=CC=CC2=N1 CANURNQSWVOMTL-UHFFFAOYSA-N 0.000 description 1
- 125000004939 6-pyridyl group Chemical group N1=CC=CC=C1* 0.000 description 1
- JRLTTZUODKEYDH-UHFFFAOYSA-N 8-methylquinoline Chemical group C1=CN=C2C(C)=CC=CC2=C1 JRLTTZUODKEYDH-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- ZHGNHOOVYPHPNJ-UHFFFAOYSA-N Amigdalin Chemical compound FC(F)(F)C(=O)OCC1OC(OCC2OC(OC(C#N)C3=CC=CC=C3)C(OC(=O)C(F)(F)F)C(OC(=O)C(F)(F)F)C2OC(=O)C(F)(F)F)C(OC(=O)C(F)(F)F)C(OC(=O)C(F)(F)F)C1OC(=O)C(F)(F)F ZHGNHOOVYPHPNJ-UHFFFAOYSA-N 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- ANVUICNGPOHXRE-UHFFFAOYSA-N C1(=CC=CC=C1)P(C1=CC=CC=C1)[C-]1C=CC=C1.[CH-]1C=CC=C1.[Fe+2].Cl.Cl Chemical compound C1(=CC=CC=C1)P(C1=CC=CC=C1)[C-]1C=CC=C1.[CH-]1C=CC=C1.[Fe+2].Cl.Cl ANVUICNGPOHXRE-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 108010004103 Chylomicrons Proteins 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 241001480079 Corymbia calophylla Species 0.000 description 1
- HTJDQJBWANPRPF-UHFFFAOYSA-N Cyclopropylamine Chemical compound NC1CC1 HTJDQJBWANPRPF-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 208000031637 Erythroblastic Acute Leukemia Diseases 0.000 description 1
- 208000036566 Erythroleukaemia Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
- 239000007821 HATU Substances 0.000 description 1
- 102100034535 Histone H3.1 Human genes 0.000 description 1
- 101001067844 Homo sapiens Histone H3.1 Proteins 0.000 description 1
- 101001053708 Homo sapiens Inhibitor of growth protein 2 Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 229910013470 LiC1 Inorganic materials 0.000 description 1
- 235000006552 Liquidambar styraciflua Nutrition 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- ZKGNPQKYVKXMGJ-UHFFFAOYSA-N N,N-dimethylacetamide Chemical compound CN(C)C(C)=O.CN(C)C(C)=O ZKGNPQKYVKXMGJ-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- WSLBJQQQZZTFBA-MLUQOLBVSA-N PIP[4'](17:0/20:4(5Z,8Z,11Z,14Z)) Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCC)COP(O)(=O)OC1C(O)C(O)C(OP(O)(O)=O)[C@@H](O)C1O WSLBJQQQZZTFBA-MLUQOLBVSA-N 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 241001504519 Papio ursinus Species 0.000 description 1
- 229910021120 PdC12 Inorganic materials 0.000 description 1
- 102100036146 Phosphatidylinositol 5-phosphate 4-kinase type-2 alpha Human genes 0.000 description 1
- 101710197236 Phosphatidylinositol 5-phosphate 4-kinase type-2 alpha Proteins 0.000 description 1
- 229920000604 Polyethylene Glycol 200 Polymers 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 229920002253 Tannate Polymers 0.000 description 1
- 229910052770 Uranium Inorganic materials 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 208000021841 acute erythroid leukemia Diseases 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 125000005466 alkylenyl group Chemical group 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 229950003153 amsonate Drugs 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- OISFUZRUIGGTSD-LJTMIZJLSA-N azane;(2r,3r,4r,5s)-6-(methylamino)hexane-1,2,3,4,5-pentol Chemical compound N.CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO OISFUZRUIGGTSD-LJTMIZJLSA-N 0.000 description 1
- 125000002785 azepinyl group Chemical group 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- 235000012216 bentonite Nutrition 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000004619 benzopyranyl group Chemical group O1C(C=CC2=C1C=CC=C2)* 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 150000005347 biaryls Chemical class 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 1
- HJZVHUQSQGITAM-UHFFFAOYSA-N butanamide Chemical compound CC[CH]C(N)=O HJZVHUQSQGITAM-UHFFFAOYSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- LDVVMCZRFWMZSG-UHFFFAOYSA-N captan Chemical compound C1C=CCC2C(=O)N(SC(Cl)(Cl)Cl)C(=O)C21 LDVVMCZRFWMZSG-UHFFFAOYSA-N 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 238000004296 chiral HPLC Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- 229910000366 copper(II) sulfate Inorganic materials 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000006880 cross-coupling reaction Methods 0.000 description 1
- 125000002100 cyclohexa-1,3-dienyl group Chemical group [H]C1([*])C([H])=C([H])C([H])=C([H])C1([H])[H] 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- IVWFNMCAPPQZMP-UHFFFAOYSA-N cyclopenta-1,3-diene;ditert-butyl(cyclopenta-2,4-dien-1-yl)phosphane;iron(2+) Chemical compound [Fe+2].C=1C=C[CH-]C=1.CC(C)(C)P(C(C)(C)C)C1=CC=C[CH-]1 IVWFNMCAPPQZMP-UHFFFAOYSA-N 0.000 description 1
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- YMGUBTXCNDTFJI-UHFFFAOYSA-N cyclopropanecarboxylic acid Chemical compound OC(=O)C1CC1 YMGUBTXCNDTFJI-UHFFFAOYSA-N 0.000 description 1
- AUQDITHEDVOTCU-UHFFFAOYSA-N cyclopropyl cyanide Chemical compound N#CC1CC1 AUQDITHEDVOTCU-UHFFFAOYSA-N 0.000 description 1
- 230000003436 cytoskeletal effect Effects 0.000 description 1
- DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
- 125000005508 decahydronaphthalenyl group Chemical group 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- CPELXLSAUQHCOX-DYCDLGHISA-N deuterium bromide Chemical compound [2H]Br CPELXLSAUQHCOX-DYCDLGHISA-N 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000012973 diazabicyclooctane Substances 0.000 description 1
- 125000002576 diazepinyl group Chemical group N1N=C(C=CC=C1)* 0.000 description 1
- ACYGYJFTZSAZKR-UHFFFAOYSA-J dicalcium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Ca+2].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O ACYGYJFTZSAZKR-UHFFFAOYSA-J 0.000 description 1
- YNHIGQDRGKUECZ-UHFFFAOYSA-N dichloropalladium;triphenylphosphanium Chemical compound Cl[Pd]Cl.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-N 0.000 description 1
- LCSNDSFWVKMJCT-UHFFFAOYSA-N dicyclohexyl-(2-phenylphenyl)phosphane Chemical group C1CCCCC1P(C=1C(=CC=CC=1)C=1C=CC=CC=1)C1CCCCC1 LCSNDSFWVKMJCT-UHFFFAOYSA-N 0.000 description 1
- 229960004132 diethyl ether Drugs 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 125000000723 dihydrobenzofuranyl group Chemical group O1C(CC2=C1C=CC=C2)* 0.000 description 1
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
- SPCNPOWOBZQWJK-UHFFFAOYSA-N dimethoxy-(2-propan-2-ylsulfanylethylsulfanyl)-sulfanylidene-$l^{5}-phosphane Chemical compound COP(=S)(OC)SCCSC(C)C SPCNPOWOBZQWJK-UHFFFAOYSA-N 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
- SXZIXHOMFPUIRK-UHFFFAOYSA-N diphenylmethanimine Chemical compound C=1C=CC=CC=1C(=N)C1=CC=CC=C1 SXZIXHOMFPUIRK-UHFFFAOYSA-N 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- UZZWBUYVTBPQIV-UHFFFAOYSA-N dme dimethoxyethane Chemical compound COCCOC.COCCOC UZZWBUYVTBPQIV-UHFFFAOYSA-N 0.000 description 1
- CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 229940069417 doxy Drugs 0.000 description 1
- 229940009662 edetate Drugs 0.000 description 1
- 238000003821 enantio-separation Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229950000206 estolate Drugs 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 230000028023 exocytosis Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 229940013317 fish oils Drugs 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical compound [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 125000004615 furo[2,3-b]pyridinyl group Chemical group O1C(=CC=2C1=NC=CC2)* 0.000 description 1
- YRTCKZIKGWZNCU-UHFFFAOYSA-N furo[3,2-b]pyridine Chemical compound C1=CC=C2OC=CC2=N1 YRTCKZIKGWZNCU-UHFFFAOYSA-N 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960001731 gluceptate Drugs 0.000 description 1
- KWMLJOLKUYYJFJ-VFUOTHLCSA-N glucoheptonic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O KWMLJOLKUYYJFJ-VFUOTHLCSA-N 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 229940049906 glutamate Drugs 0.000 description 1
- RZRNAYUHWVFMIP-HXUWFJFHSA-N glycerol monolinoleate Natural products CCCCCCCCC=CCCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-HXUWFJFHSA-N 0.000 description 1
- 125000004438 haloalkoxy group Chemical group 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- QKGYJVXSKCDGOK-UHFFFAOYSA-N hexane;propan-2-ol Chemical compound CC(C)O.CCCCCC QKGYJVXSKCDGOK-UHFFFAOYSA-N 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000005980 hexynyl group Chemical group 0.000 description 1
- XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical compound C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 150000004001 inositols Polymers 0.000 description 1
- UEXQBEVWFZKHNB-UHFFFAOYSA-N intermediate 29 Natural products C1=CC(N)=CC=C1NC1=NC=CC=N1 UEXQBEVWFZKHNB-UHFFFAOYSA-N 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-O isopropylaminium Chemical compound CC(C)[NH3+] JJWLVOIRVHMVIS-UHFFFAOYSA-O 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 229940091250 magnesium supplement Drugs 0.000 description 1
- CCERQOYLJJULMD-UHFFFAOYSA-M magnesium;carbanide;chloride Chemical compound [CH3-].[Mg+2].[Cl-] CCERQOYLJJULMD-UHFFFAOYSA-M 0.000 description 1
- VFZXMEQGIIWBFJ-UHFFFAOYSA-M magnesium;cyclopropane;bromide Chemical compound [Mg+2].[Br-].C1C[CH-]1 VFZXMEQGIIWBFJ-UHFFFAOYSA-M 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- BCVXHSPFUWZLGQ-UHFFFAOYSA-N mecn acetonitrile Chemical compound CC#N.CC#N BCVXHSPFUWZLGQ-UHFFFAOYSA-N 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- MJJNJXWFJPDUJI-UHFFFAOYSA-N methyl 7-bromo-2,3-dihydropyrido[2,3-b][1,4]oxazine-1-carboxylate Chemical compound COC(=O)N1CCOC2=C1C=C(Br)C=N2 MJJNJXWFJPDUJI-UHFFFAOYSA-N 0.000 description 1
- 229940102396 methyl bromide Drugs 0.000 description 1
- LRMHVVPPGGOAJQ-UHFFFAOYSA-N methyl nitrate Chemical compound CO[N+]([O-])=O LRMHVVPPGGOAJQ-UHFFFAOYSA-N 0.000 description 1
- JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- IHOAJGDCQMBZDI-UHFFFAOYSA-N n-(5-bromo-2-methoxypyridin-3-yl)methanesulfonamide Chemical compound COC1=NC=C(Br)C=C1NS(C)(=O)=O IHOAJGDCQMBZDI-UHFFFAOYSA-N 0.000 description 1
- NGLXIPCYRBBBFC-UHFFFAOYSA-N n-(5-bromopyridin-3-yl)methanesulfonamide Chemical compound CS(=O)(=O)NC1=CN=CC(Br)=C1 NGLXIPCYRBBBFC-UHFFFAOYSA-N 0.000 description 1
- 125000004370 n-butenyl group Chemical group [H]\C([H])=C(/[H])C([H])([H])C([H])([H])* 0.000 description 1
- WOOWBQQQJXZGIE-UHFFFAOYSA-N n-ethyl-n-propan-2-ylpropan-2-amine Chemical compound CCN(C(C)C)C(C)C.CCN(C(C)C)C(C)C WOOWBQQQJXZGIE-UHFFFAOYSA-N 0.000 description 1
- XBXCNNQPRYLIDE-UHFFFAOYSA-M n-tert-butylcarbamate Chemical compound CC(C)(C)NC([O-])=O XBXCNNQPRYLIDE-UHFFFAOYSA-M 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- ODUCDPQEXGNKDN-UHFFFAOYSA-N nitroxyl Chemical compound O=N ODUCDPQEXGNKDN-UHFFFAOYSA-N 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 125000004365 octenyl group Chemical group C(=CCCCCCC)* 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- 229940012843 omega-3 fatty acid Drugs 0.000 description 1
- 239000006014 omega-3 oil Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 125000005968 oxazolinyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000003585 oxepinyl group Chemical group 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 125000004095 oxindolyl group Chemical group N1(C(CC2=CC=CC=C12)=O)* 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- MUJIDPITZJWBSW-UHFFFAOYSA-N palladium(2+) Chemical compound [Pd+2] MUJIDPITZJWBSW-UHFFFAOYSA-N 0.000 description 1
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940014662 pantothenate Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 125000004115 pentoxy group Chemical group [*]OC([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 125000005981 pentynyl group Chemical group 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 125000001828 phenalenyl group Chemical group C1(C=CC2=CC=CC3=CC=CC1=C23)* 0.000 description 1
- 125000001792 phenanthrenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C=CC12)* 0.000 description 1
- 150000008105 phosphatidylcholines Chemical class 0.000 description 1
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 1
- SIOXPEMLGUPBBT-UHFFFAOYSA-N picolinic acid Chemical compound OC(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-N 0.000 description 1
- 229940075930 picrate Drugs 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 229920001610 polycaprolactone Polymers 0.000 description 1
- 229920002721 polycyanoacrylate Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920006324 polyoxymethylene Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 235000011181 potassium carbonates Nutrition 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000004237 preparative chromatography Methods 0.000 description 1
- DRINJBFRTLBHNF-UHFFFAOYSA-N propane-2-sulfonyl chloride Chemical compound CC(C)S(Cl)(=O)=O DRINJBFRTLBHNF-UHFFFAOYSA-N 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical compound OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 description 1
- BGUWFUQJCDRPTL-UHFFFAOYSA-N pyridine-4-carbaldehyde Chemical compound O=CC1=CC=NC=C1 BGUWFUQJCDRPTL-UHFFFAOYSA-N 0.000 description 1
- QAHXHCJENQEPHB-UHFFFAOYSA-N pyrido[2,3-b]pyrazin-7-amine Chemical compound N1=CC=NC2=CC(N)=CN=C21 QAHXHCJENQEPHB-UHFFFAOYSA-N 0.000 description 1
- FVLAYJRLBLHIPV-UHFFFAOYSA-N pyrimidin-5-amine Chemical compound NC1=CN=CN=C1 FVLAYJRLBLHIPV-UHFFFAOYSA-N 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- MOODSJOROWROTO-UHFFFAOYSA-N salicylsulfuric acid Chemical compound OC(=O)C1=CC=CC=C1OS(O)(=O)=O MOODSJOROWROTO-UHFFFAOYSA-N 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000008299 semisolid dosage form Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- LBJQKYPPYSCCBH-UHFFFAOYSA-N spiro[3.3]heptane Chemical compound C1CCC21CCC2 LBJQKYPPYSCCBH-UHFFFAOYSA-N 0.000 description 1
- PHICBFWUYUCFKS-UHFFFAOYSA-N spiro[4.4]nonane Chemical compound C1CCCC21CCCC2 PHICBFWUYUCFKS-UHFFFAOYSA-N 0.000 description 1
- CTDQAGUNKPRERK-UHFFFAOYSA-N spirodecane Chemical compound C1CCCC21CCCCC2 CTDQAGUNKPRERK-UHFFFAOYSA-N 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- NVBFHJWHLNUMCV-UHFFFAOYSA-N sulfamide Chemical group NS(N)(=O)=O NVBFHJWHLNUMCV-UHFFFAOYSA-N 0.000 description 1
- 229940071103 sulfosalicylate Drugs 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 238000004808 supercritical fluid chromatography Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 229950002757 teoclate Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000002769 thiazolinyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- VJYJJHQEVLEOFL-UHFFFAOYSA-N thieno[3,2-b]thiophene Chemical compound S1C=CC2=C1C=CS2 VJYJJHQEVLEOFL-UHFFFAOYSA-N 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 125000004784 trichloromethoxy group Chemical group ClC(O*)(Cl)Cl 0.000 description 1
- 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 1
- 229940086542 triethylamine Drugs 0.000 description 1
- IMNIMPAHZVJRPE-UHFFFAOYSA-N triethylenediamine Chemical compound C1CN2CCN1CC2 IMNIMPAHZVJRPE-UHFFFAOYSA-N 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 229910000404 tripotassium phosphate Inorganic materials 0.000 description 1
- 235000019798 tripotassium phosphate Nutrition 0.000 description 1
- NHDIQVFFNDKAQU-UHFFFAOYSA-N tripropan-2-yl borate Chemical compound CC(C)OB(OC(C)C)OC(C)C NHDIQVFFNDKAQU-UHFFFAOYSA-N 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical class CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 229910052720 vanadium Inorganic materials 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000028973 vesicle-mediated transport Effects 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 229930195724 β-lactose Natural products 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/61—Halogen atoms or nitro radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D515/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
- C07F5/02—Boron compounds
- C07F5/04—Esters of boric acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
Abstract
The invention relates to inhibitors of PI5P4K inhibitors useful in the treatment of cancers, neurodegenerative diseases, inflammatory disorders, and metabolic diseases, having the Formula (I); where A1, A2, G, R1, R2, R3, R4, and W are described herein.
Description
CHROMENOPYRIDINE DERIVATIVES AS PHOSPHATIDYLINOSITOL
PHOSPHATE KINASE INHIBITORS
Cross-Reference To Related Applications [0001] This application claims the benefit of priority of U.S. Provisional Application No.
62/609,578, filed December 22, 2017, which the entire disclosure is incorporated herein by reference in its entirety.
Field of Invention
PHOSPHATE KINASE INHIBITORS
Cross-Reference To Related Applications [0001] This application claims the benefit of priority of U.S. Provisional Application No.
62/609,578, filed December 22, 2017, which the entire disclosure is incorporated herein by reference in its entirety.
Field of Invention
[0002] The present invention is directed to inhibitors of phosphatidylinosito1-5-phosphate-4-kinase (PI5P4K) useful in the treatment of diseases or disorders associated with PI5P4K
enzymes. In particular, the invention is concerned with compounds and compositions inhibiting PI5P4K, methods of treating diseases or disorders associated with PI5P4K, and methods of synthesis of these compounds.
Back2round of the Invention
enzymes. In particular, the invention is concerned with compounds and compositions inhibiting PI5P4K, methods of treating diseases or disorders associated with PI5P4K, and methods of synthesis of these compounds.
Back2round of the Invention
[0003] A minor but ubiquitous component of cells, phosphoinositol lipids are pivotal players in many intracellular signal transduction pathways. Phosphoinositol lipids are formed when phosphatidylinositol (PtdIns) is converted, by the catalytic action of lipid kinases, to polyphosphoinositides. As a prototypic example, the membrane associated phospholipid, phosphatidylinositol-4,5-bisphosphate (PtdIns(4,5)P2), is formed by two successive phosphorylations of PtdIns by the phosphotidylinositolphosphate kinases (PIP
kinases).
kinases).
[0004]
PtdIns(4,5)P2 is a substrate for phospholipase C (PLC) and is converted into the second messengers inosito1-1,4,5-trisphosphate and diacylglycerol (DAG).
Phosphoinositides are involved in regulating a broad spectrum of activities from cytoskeletal assembly and motility to vesicle trafficking and exocytosis to transduction of intracellular signals including stimulating the release of intracellular calcium stores (Hinchliffe et al., Biochem. Soc. Trans., 1999, 27, 657-661).
PtdIns(4,5)P2 is a substrate for phospholipase C (PLC) and is converted into the second messengers inosito1-1,4,5-trisphosphate and diacylglycerol (DAG).
Phosphoinositides are involved in regulating a broad spectrum of activities from cytoskeletal assembly and motility to vesicle trafficking and exocytosis to transduction of intracellular signals including stimulating the release of intracellular calcium stores (Hinchliffe et al., Biochem. Soc. Trans., 1999, 27, 657-661).
[0005] PIP
kinases comprise a unique and promiscuous family of enzymes that catalyze the production of polyphosphorylated inositol lipids from monophosphorylated phosphoinositides. Isolation and purification of several different PIP kinase enzymes able to catalyze phosphorylation of phosphatidylinositol 4-phosphate and produce PtdIns(4,5)P2 led to the further categorization of these enzymes, dubbed the phosphatidylinositol 4-phosphate 5-kinases (PIP5Ks), into two types having different activities. The PIP kinases have no homology to other lipid or protein kinases at the primary sequence level, and are distinguished from each other by their lack of immuno-crossreactivity and by the fact that type I
PIP5Ks are stimulated in vitro by phosphatidic acid, whereas the type II PIP5Ks are not.
Furthermore, the recent discovery that the type II PTP5Ks are able to phosphorylate multiple lipid substrates in vitro suggests that this family of kinases is potentially able to generate several distinct, often subcellularly compartmentalized, phosphoinositol products for regulation of a variety of physiologically important processes (Hinchliffe et al., Biochem. Soc. Trans., 1999, 27, 657-661).
kinases comprise a unique and promiscuous family of enzymes that catalyze the production of polyphosphorylated inositol lipids from monophosphorylated phosphoinositides. Isolation and purification of several different PIP kinase enzymes able to catalyze phosphorylation of phosphatidylinositol 4-phosphate and produce PtdIns(4,5)P2 led to the further categorization of these enzymes, dubbed the phosphatidylinositol 4-phosphate 5-kinases (PIP5Ks), into two types having different activities. The PIP kinases have no homology to other lipid or protein kinases at the primary sequence level, and are distinguished from each other by their lack of immuno-crossreactivity and by the fact that type I
PIP5Ks are stimulated in vitro by phosphatidic acid, whereas the type II PIP5Ks are not.
Furthermore, the recent discovery that the type II PTP5Ks are able to phosphorylate multiple lipid substrates in vitro suggests that this family of kinases is potentially able to generate several distinct, often subcellularly compartmentalized, phosphoinositol products for regulation of a variety of physiologically important processes (Hinchliffe et al., Biochem. Soc. Trans., 1999, 27, 657-661).
[0006] One particular species of PI, phosphatidylinositol 5-phosphate (PI5P), has been implicated in the regulation of the tumor suppressor ING2 and the oncogene AKT. The phosphatidylinositol 5-phosphate 4-kinase (PI5P4K) family (a, 13, y isoforms) catalyzes the conversion of PI5P to PI4, 5 P2. These enzymes therefore represent one means by which cells can regulate endogenous PI5P levels. Mice deficient for PI5P4K13 (PI5P4K(3¨/¨) have been shown to exhibit enhanced insulin sensitivity and activation of AKT in skeletal muscle.
[0007] The pharmacological modulation of PIP5KII-beta activity and/or expression is therefore believed to be an appropriate point of therapeutic intervention in pathological conditions in which cell differentiation, proliferation, and/or motility are compromised, such as cancer or inflammation, and in metabolic disorders.
[0008] Currently, there are no known therapeutic agents which effectively inhibit the synthesis of PIP5KII-beta. Inhibition of PI5P4K with small molecule inhibitors, therefore, has the potential to be a treatment for cancers and other disorders. For this reason, there remains a considerable need for novel and potent small molecule inhibitors and agents capable of effectively inhibiting PIP5KII-beta function.
Summary of the Invention
Summary of the Invention
[0009] A first aspect of the invention relates to compounds of Formula (I):
w R3 (I) and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, isomers, and tautomers, thereof, wherein:
Ring Al is 5- to 6-membered heteroaryl;
Ring A2 is heteroaryl optionally substituted with one or more R8;
W is ¨0¨, ¨NH¨, ¨N(C1-6 alkyl)¨, ¨N(C3-8 cycloalkyl)¨, ¨N(ary1)¨, or ¨
N(heteroary1)¨;
G is a bond, ¨0¨, ¨NH¨, or ¨N(C1-6 alkyl)¨;
Ri is ¨N(R5)C(0)R6, ¨C(0)N(R5)(R6), ¨S(0)2N(R5)(R6), ¨N(R5)S(0)2R6, or heteroaryl wherein the heteroaryl is optionally substituted with one or more R7;
R2 is ¨H, halogen, ¨OH, ¨NH2, ¨NO2, ¨CN, ¨COOH, ¨C(0)NH2, C1-6 alkyl, C1-6 alkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, heterocyclyl, aryl, or heteroaryl;
R3 and R4 are each independently ¨H, halogen, C1-6 alkyl, C1-6 alkoxy, or C3-6 cycloalkyl, wherein the alkyl, alkoxy, or cycloalkyl is optionally substituted with one or more halogen, ¨OH, and ¨NH2; or R3 and R4 when taken together with the atom to which they are attached form a cycloalkyl or heterocyclyl;
Rs and R6 are independently, at each occurrence, ¨H, C1-6 alkyl, C2-6 alkenyl, or C2-6 alkynyl, wherein the alkyl, alkenyl, or alkynyl is optionally substituted with one or more R7;
or Rs and R6 when taken together with the atom to which they are each attached form a heterocycle optionally substituted with one or more R7;
R7 is independently ¨H, halogen, ¨OH, ¨NH2, ¨NO2, ¨CN, C1-6 alkyl, C1-6 alkoxy, C3-8 cycloalkyl, heterocyclyl, aryl, or heteroaryl;
Rs is independently ¨N(R9)C(0)Rio, ¨N(R9)C(0)0Rio, ¨N(R9)C(0)N(R9)(Rio), ¨N(R9)C(0)N(R9)(Rii), ¨N(R9)S(0)2Rio, ¨N(R9)S(0)2N(R9)(Rio), ¨S(0)2Rio ¨N(R9)(Rio), ¨
0Rio, ¨CF3, ¨CHF2, ¨Rio, ¨N(R9)C(0)Rii, ¨N(R9)(Rii) or halogen; or two R8 with the atoms they are attached form a C4-8 cycloalkyl or heterocyclyl, wherein the heterocyclyl or cycloalkyl is optionally substituted with one or more Ri2;
each R9 or Rio is independently, at each occurrence, ¨H, C1-6 alkyl, C3-8 cycloalkyl, or heterocyclyl, wherein the alkyl, cycloalkyl, or heterocyclyl is optionally substituted with one or more R13; or R9 and Rio when taken together with the atom to which they are each attached form a heterocycle ring optionally substituted with one or more R14 each Rii is aryl, C3-8 cycloalkyl, heterocyclyl, or heteroaryl, wherein the aryl or heteroaryl group is optionally substituted with one or more Ris and the cycloalkyl or heterocyclyl is optionally substituted with one or more R19;
each Ri2 is independently C1-6 alkyl, C3-6 cycloalkyl, ¨0R2o, ¨C(0)R2o, ¨C(0)0R2o, ¨
S(0)2R2o, or oxo; or two Ri2 taken together can form a C3-8 cycloalkyl or heterocyclyl, wherein the cycloalkyl or heterocyclyl are optionally substituted with one or more R14;
R13 is ¨H, halogen, ¨CN, oxo, C1-6 alkyl, ¨0R2o, ¨C(0)2R2o, C3-8 cycloalkyl, heterocyclyl, heteroaryl, aryl, or ¨C(0)N(R22)(R22), wherein the alkyl, aryl, or heteroaryl, is optionally substituted with one or more Ris;
Ri4 is independently ¨C(0)0R2o; ¨C(0)R2o, ¨0R2o, oxo, C1-6 alkyl, heterocycle, cycloalkyl, or aryl, wherein the alkyl, heterocycle, cycloalkyl, or aryl is optionally substituted with one or more R16; or two R14 taken together can form a C3-6 cycloalkyl or heterocyclyl;
R15 is ¨H, C1-6 alkyl, C1-6 alkoxy, heteroaryl, aryl, ¨N(R22)(R22), ¨N(R22)C(0)0R22, or ¨N(R22)C(0)¨U¨N(R22)¨Z;
U is ¨(CH2)p¨, ¨(CH2)p¨Ar¨, ¨CH=CH(CH2)p¨, or heterocyclyl;
Z is ¨R22 or ¨C(0)¨U¨N(R22)(R22);
R16 is C3-8 cycloalkyl, heterocyclyl, heteroaryl, or aryl, wherein the heterocyclyl, cycloalkyl, heteroaryl or aryl is optionally substituted with one or more R17;
R17 is independently ¨0R22, ¨N(R22)(R22), or ¨N(R22)C(0)¨V¨N(R22)¨E;
V is ¨(CH2)n¨, ¨(CH2)n¨Ar¨, or ¨CH=CH(CH2)n¨;
E is ¨R22 or ¨C(0)¨V¨N(R22)(R22);
Ar is aryl;
Ri8 is halogen, C1-6 alkyl, C3-6 cycloalkyl, ¨0R2o, ¨N(R2o)(R21), ¨C(0)R20, oxo, ¨N(R22)C(0)0R22, ¨N(R22)C(0)¨Q¨N(R22)¨F, or ¨N(R22)¨Q¨N(R22)¨F;
Q is ¨CH=CH(CH2)m¨, ¨(CH2)m¨, ¨(CH20)m¨, ¨(CH2)m¨Ar¨, or ¨(CH2CH20)0¨
(CH2)m¨;
F is ¨H, C1-6 alkyl, aryl, heteroaryl, ¨C(0)¨Q¨R22, or ¨C(0)¨Q¨N(R22)(R22), wherein the alkyl, aryl, or heteroaryl is optionally substituted with one or more R22;
or two R18 when on adjacent atoms may be taken together with the atoms to which they are each attached to form a C3-8 cycloalkyl or heterocyclic group optionally substituted with ¨
0R21 or oxo;
R19 is independently ¨H, halogen, ¨OH, ¨NH2, oxo, ¨C(0)R2o, ¨0R22, C3-6 cycloalkyl, or C1-6 alkyl; or two R19 when on adjacent atoms may be taken together with the atoms to which they are each attached to form an aryl or heteroaryl group optionally substituted with one or more R22;
Rzo is ¨H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, heterocyclyl, aryl, or heteroaryl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, heteroaryl, or aryl is optionally substituted with one or more ¨H, halogen, ¨CN, ¨OH, C1-6 alkyl, C1-6 alkoxy, C3-8 cycloalkyl, heterocyclyl, heteroaryl, or aryl;
R21 is ¨H, C1-6 alkyl, or ¨C(0)R22;
each R22 is independently ¨H, C1-6 alkyl, C1-6 alkOXy, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, heterocyclyl, aryl, or heteroaryl;
each p is independently 1-4;
each n is independently 1-4;
each m is independently 1-4; and o is 1-3.
w R3 (I) and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, isomers, and tautomers, thereof, wherein:
Ring Al is 5- to 6-membered heteroaryl;
Ring A2 is heteroaryl optionally substituted with one or more R8;
W is ¨0¨, ¨NH¨, ¨N(C1-6 alkyl)¨, ¨N(C3-8 cycloalkyl)¨, ¨N(ary1)¨, or ¨
N(heteroary1)¨;
G is a bond, ¨0¨, ¨NH¨, or ¨N(C1-6 alkyl)¨;
Ri is ¨N(R5)C(0)R6, ¨C(0)N(R5)(R6), ¨S(0)2N(R5)(R6), ¨N(R5)S(0)2R6, or heteroaryl wherein the heteroaryl is optionally substituted with one or more R7;
R2 is ¨H, halogen, ¨OH, ¨NH2, ¨NO2, ¨CN, ¨COOH, ¨C(0)NH2, C1-6 alkyl, C1-6 alkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, heterocyclyl, aryl, or heteroaryl;
R3 and R4 are each independently ¨H, halogen, C1-6 alkyl, C1-6 alkoxy, or C3-6 cycloalkyl, wherein the alkyl, alkoxy, or cycloalkyl is optionally substituted with one or more halogen, ¨OH, and ¨NH2; or R3 and R4 when taken together with the atom to which they are attached form a cycloalkyl or heterocyclyl;
Rs and R6 are independently, at each occurrence, ¨H, C1-6 alkyl, C2-6 alkenyl, or C2-6 alkynyl, wherein the alkyl, alkenyl, or alkynyl is optionally substituted with one or more R7;
or Rs and R6 when taken together with the atom to which they are each attached form a heterocycle optionally substituted with one or more R7;
R7 is independently ¨H, halogen, ¨OH, ¨NH2, ¨NO2, ¨CN, C1-6 alkyl, C1-6 alkoxy, C3-8 cycloalkyl, heterocyclyl, aryl, or heteroaryl;
Rs is independently ¨N(R9)C(0)Rio, ¨N(R9)C(0)0Rio, ¨N(R9)C(0)N(R9)(Rio), ¨N(R9)C(0)N(R9)(Rii), ¨N(R9)S(0)2Rio, ¨N(R9)S(0)2N(R9)(Rio), ¨S(0)2Rio ¨N(R9)(Rio), ¨
0Rio, ¨CF3, ¨CHF2, ¨Rio, ¨N(R9)C(0)Rii, ¨N(R9)(Rii) or halogen; or two R8 with the atoms they are attached form a C4-8 cycloalkyl or heterocyclyl, wherein the heterocyclyl or cycloalkyl is optionally substituted with one or more Ri2;
each R9 or Rio is independently, at each occurrence, ¨H, C1-6 alkyl, C3-8 cycloalkyl, or heterocyclyl, wherein the alkyl, cycloalkyl, or heterocyclyl is optionally substituted with one or more R13; or R9 and Rio when taken together with the atom to which they are each attached form a heterocycle ring optionally substituted with one or more R14 each Rii is aryl, C3-8 cycloalkyl, heterocyclyl, or heteroaryl, wherein the aryl or heteroaryl group is optionally substituted with one or more Ris and the cycloalkyl or heterocyclyl is optionally substituted with one or more R19;
each Ri2 is independently C1-6 alkyl, C3-6 cycloalkyl, ¨0R2o, ¨C(0)R2o, ¨C(0)0R2o, ¨
S(0)2R2o, or oxo; or two Ri2 taken together can form a C3-8 cycloalkyl or heterocyclyl, wherein the cycloalkyl or heterocyclyl are optionally substituted with one or more R14;
R13 is ¨H, halogen, ¨CN, oxo, C1-6 alkyl, ¨0R2o, ¨C(0)2R2o, C3-8 cycloalkyl, heterocyclyl, heteroaryl, aryl, or ¨C(0)N(R22)(R22), wherein the alkyl, aryl, or heteroaryl, is optionally substituted with one or more Ris;
Ri4 is independently ¨C(0)0R2o; ¨C(0)R2o, ¨0R2o, oxo, C1-6 alkyl, heterocycle, cycloalkyl, or aryl, wherein the alkyl, heterocycle, cycloalkyl, or aryl is optionally substituted with one or more R16; or two R14 taken together can form a C3-6 cycloalkyl or heterocyclyl;
R15 is ¨H, C1-6 alkyl, C1-6 alkoxy, heteroaryl, aryl, ¨N(R22)(R22), ¨N(R22)C(0)0R22, or ¨N(R22)C(0)¨U¨N(R22)¨Z;
U is ¨(CH2)p¨, ¨(CH2)p¨Ar¨, ¨CH=CH(CH2)p¨, or heterocyclyl;
Z is ¨R22 or ¨C(0)¨U¨N(R22)(R22);
R16 is C3-8 cycloalkyl, heterocyclyl, heteroaryl, or aryl, wherein the heterocyclyl, cycloalkyl, heteroaryl or aryl is optionally substituted with one or more R17;
R17 is independently ¨0R22, ¨N(R22)(R22), or ¨N(R22)C(0)¨V¨N(R22)¨E;
V is ¨(CH2)n¨, ¨(CH2)n¨Ar¨, or ¨CH=CH(CH2)n¨;
E is ¨R22 or ¨C(0)¨V¨N(R22)(R22);
Ar is aryl;
Ri8 is halogen, C1-6 alkyl, C3-6 cycloalkyl, ¨0R2o, ¨N(R2o)(R21), ¨C(0)R20, oxo, ¨N(R22)C(0)0R22, ¨N(R22)C(0)¨Q¨N(R22)¨F, or ¨N(R22)¨Q¨N(R22)¨F;
Q is ¨CH=CH(CH2)m¨, ¨(CH2)m¨, ¨(CH20)m¨, ¨(CH2)m¨Ar¨, or ¨(CH2CH20)0¨
(CH2)m¨;
F is ¨H, C1-6 alkyl, aryl, heteroaryl, ¨C(0)¨Q¨R22, or ¨C(0)¨Q¨N(R22)(R22), wherein the alkyl, aryl, or heteroaryl is optionally substituted with one or more R22;
or two R18 when on adjacent atoms may be taken together with the atoms to which they are each attached to form a C3-8 cycloalkyl or heterocyclic group optionally substituted with ¨
0R21 or oxo;
R19 is independently ¨H, halogen, ¨OH, ¨NH2, oxo, ¨C(0)R2o, ¨0R22, C3-6 cycloalkyl, or C1-6 alkyl; or two R19 when on adjacent atoms may be taken together with the atoms to which they are each attached to form an aryl or heteroaryl group optionally substituted with one or more R22;
Rzo is ¨H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, heterocyclyl, aryl, or heteroaryl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, heteroaryl, or aryl is optionally substituted with one or more ¨H, halogen, ¨CN, ¨OH, C1-6 alkyl, C1-6 alkoxy, C3-8 cycloalkyl, heterocyclyl, heteroaryl, or aryl;
R21 is ¨H, C1-6 alkyl, or ¨C(0)R22;
each R22 is independently ¨H, C1-6 alkyl, C1-6 alkOXy, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, heterocyclyl, aryl, or heteroaryl;
each p is independently 1-4;
each n is independently 1-4;
each m is independently 1-4; and o is 1-3.
[0010] Another aspect of the invention relates to a method of treating a disease or disorder associated with modulation of PI5P4K. The method comprises administering to a patient in need of a treatment for diseases or disorders associated with modulation of PI5P4K an effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof
[0011] Another aspect of the invention is directed to a method of inhibiting PI5P4K. The method involves administering to a patient in need thereof an effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof
[0012] Another aspect of the invention relates to a method of treating cancer. The method comprises administering to a patient in need thereof an effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof
[0013] Another aspect of the invention relates to a method of treating a neurodegenerative disease. The method comprises administering to a patient in need thereof an effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof
[0014] Another aspect of the invention relates to a method of treating a viral infection or disease. The method comprises administering to a patient in need thereof an effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof
[0015] Another aspect of the invention relates to a method of treating an inflammatory disease or condition. The method comprises administering to a patient in need thereof an effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof
[0016] Another aspect of the invention relates to a method of inducing cell cycle arrest, apoptosis in tumor cells and/or enhanced tumor-specific T-cell immunity. The method comprises contacting the cells with an effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof
[0017] Another aspect of the invention is directed to pharmaceutical compositions comprising a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof and a pharmaceutically acceptable carrier. The pharmaceutical acceptable carrier may further include an excipient, diluent, or surfactant.
[0018] Another aspect of the present invention relates to a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for use in the manufacture of a medicament for treating a disease associated with inhibiting PI5P4K.
[0019] Another aspect of the present invention relates to the use of a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, in the treatment of a disease associated with inhibiting PI5P4K.
[0020] The present invention further provides methods of treating a disease or disorder associated with modulation of PI5P4K including, cancer and metastasis, neurodegenerative diseases, immunological disorders, diabetes, bone and joint diseases, osteoporosis, arthritis inflammatory disorders, cardiovascular diseases, ischemic diseases, viral infections and diseases, viral infectivity and/or latency, and bacterial infections and diseases, comprising administering to a patient suffering from at least one of said diseases or disorder a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof
[0021] The present invention provides inhibitors of PI5P4K that are therapeutic agents in the treatment of diseases such as cancer and metastasis, neurodegenerative diseases, immunological disorders, diabetes, bone and joint diseases, osteoporosis, arthritis inflammatory disorders, cardiovascular diseases, ischemic diseases, viral infections and diseases, viral infectivity and/or latency, and bacterial infections and diseases.
[0022] The present invention further provides compounds and compositions with an improved efficacy and safety profile relative to known PI5P4K inhibitors. The present disclosure also provides agents with novel mechanisms of action toward PI5P4K
enzymes in the treatment of various types of diseases including cancer and metastasis, neurodegenerative diseases, immunological disorders, diabetes, bone and joint diseases, osteoporosis, arthritis inflammatory disorders, cardiovascular diseases, ischemic diseases, viral infections and diseases, viral infectivity and/or latency, and bacterial infections and diseases. Ultimately the present invention provides the medical community with a novel pharmacological strategy for the treatment of diseases and disorders associated with PI5P4K enzymes.
Detailed Description of the Invention
enzymes in the treatment of various types of diseases including cancer and metastasis, neurodegenerative diseases, immunological disorders, diabetes, bone and joint diseases, osteoporosis, arthritis inflammatory disorders, cardiovascular diseases, ischemic diseases, viral infections and diseases, viral infectivity and/or latency, and bacterial infections and diseases. Ultimately the present invention provides the medical community with a novel pharmacological strategy for the treatment of diseases and disorders associated with PI5P4K enzymes.
Detailed Description of the Invention
[0023] The present invention relates to compounds and compositions that are capable of inhibiting the activity PI5P4K. The invention features methods of treating, preventing or ameliorating a disease or disorder in which PI5P4K plays a role by administering to a patient in need thereof a therapeutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof The methods of the present invention can be used in the treatment of a variety of PI5P4K
dependent diseases and disorders by inhibiting the activity of PI5P4K enzymes.
Inhibition of PI5P4K provides a novel approach to the treatment, prevention, or amelioration of diseases including, but not limited to, cancer and metastasis, neurodegenerative diseases, immunological disorders, osteoporosis, arthritis inflammatory disorders, cardiovascular diseases, ischemic diseases, viral infections and diseases, and bacterial infections and diseases.
dependent diseases and disorders by inhibiting the activity of PI5P4K enzymes.
Inhibition of PI5P4K provides a novel approach to the treatment, prevention, or amelioration of diseases including, but not limited to, cancer and metastasis, neurodegenerative diseases, immunological disorders, osteoporosis, arthritis inflammatory disorders, cardiovascular diseases, ischemic diseases, viral infections and diseases, and bacterial infections and diseases.
[0024] In a first aspect of the invention, the compounds of Formula (I) are described:
(I) and pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, and tautomers thereof, wherein Al, A2, G, R1, R2, R3, R4, and W are described herein above.
(I) and pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, and tautomers thereof, wherein Al, A2, G, R1, R2, R3, R4, and W are described herein above.
[0025] The details of the invention are set forth in the accompanying description below.
Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, illustrative methods and materials are now described. Other features, objects, and advantages of the invention will be apparent from the description and from the claims. In the specification and the appended claims, the singular forms also include the plural unless the context clearly dictates otherwise.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. All patents and publications cited in this specification are incorporated herein by reference in their entireties.
Definitions
Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, illustrative methods and materials are now described. Other features, objects, and advantages of the invention will be apparent from the description and from the claims. In the specification and the appended claims, the singular forms also include the plural unless the context clearly dictates otherwise.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. All patents and publications cited in this specification are incorporated herein by reference in their entireties.
Definitions
[0026] The articles "a" and "an" are used in this disclosure to refer to one or more than one (i.e., to at least one) of the grammatical object of the article. By way of example, "an element"
means one element or more than one element.
means one element or more than one element.
[0027] The term "and/or" is used in this disclosure to mean either "and" or "or" unless indicated otherwise.
[0028] The term "optionally substituted" is understood to mean that a given chemical moiety (e.g., an alkyl group) can (but is not required to) be bonded other substituents (e.g., heteroatoms). For instance, an alkyl group that is optionally substituted can be a fully saturated alkyl chain (i.e., a pure hydrocarbon). Alternatively, the same optionally substituted alkyl group can have substituents different from hydrogen. For instance, it can, at any point along the chain be bounded to a halogen atom, a hydroxyl group, or any other substituent described herein. Thus the term "optionally substituted" means that a given chemical moiety has the potential to contain other functional groups, but does not necessarily have any further functional groups. Suitable substituents used in the optional substitution of the described groups include, without limitation, halogen, oxo, -OH, -CN, -COOH, -CH2CN, -0-(C1-C6) alkyl, (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6)haloalkoxy, -0-(C2-C6) alkenyl, -0-(C2-C6) alkynyl, (C2-C6) alkenyl, (C2-C6) alkynyl, -OH, -0P(0)(OH)2, -0C(0)(C1-C6) alkyl, -C(0)(C1-C6) alkyl, -0C(0)0(C1-C6) alkyl, -NH2, -NH((C1-C6) alkyl), -N((C1-C6) alky1)2, -NHC(0)(C1-C6) alkyl, -C(0)NH(C1-C6) alkyl, -S(0)2(C1-C6) alkyl, -S(0)NH(C1-C6) alkyl, and S(0)N((C1-C6) alky02. The substituents can themselves be optionally substituted.
"Optionally substituted" as used herein also refers to substituted or unsubstituted whose meaning is described below.
"Optionally substituted" as used herein also refers to substituted or unsubstituted whose meaning is described below.
[0029] As used herein, the term "substituted" means that the specified group or moiety bears one or more suitable substituents wherein the substituents may connect to the specified group or moiety at one or more positions. For example, an aryl substituted with a cycloalkyl may indicate that the cycloalkyl connects to one atom of the aryl with a bond or by fusing with the aryl and sharing two or more common atoms.
[0030] As used herein, the term "unsubstituted" means that the specified group bears no substituents.
[0031] Unless otherwise specifically defined, the term "aryl" refers to cyclic, aromatic hydrocarbon groups that have 1 to 3 aromatic rings, including monocyclic or bicyclic groups such as phenyl, biphenyl or naphthyl. Where containing two aromatic rings (bicyclic, etc.), the aromatic rings of the aryl group may be joined at a single point (e.g., biphenyl), or fused (e.g., naphthyl). The aryl group may be optionally substituted by one or more substituents, e.g., 1 to substituents, at any point of attachment. Exemplary substituents include, but are not limited to,
[0032] -H, -halogen, -0-(C1-C6) alkyl, (C1-C6) alkyl, -0-(C2-C6) alkenyl, -0-(C2-C6) alkynyl,
[0033] (C2-C6) alkenyl, (C2-C6) alkynyl, -OH, -0P(0)(OH)2, -0C(0)(C1-C6) alkyl, -C(0)(C1-C6) alkyl,
[0034] -0C(0)0(C i-C6) alkyl, -NH2, NH((C1-C6) alkyl), N((C1-C6) alky1)2, -S(0)2-(C1-C6) alkyl,
[0035] -S(0)NH(C1-C6) alkyl, and -S(0)N((C1-C6) alky02. The substituents can themselves be optionally substituted. Furthermore when containing two fused rings the aryl groups herein defined may have an unsaturated or partially saturated ring fused with a fully saturated ring. Exemplary ring systems of these aryl groups include, but are not limited to, phenyl, biphenyl, naphthyl, anthracenyl, phenalenyl, phenanthrenyl, indanyl, indenyl, tetrahydronaphthalenyl, tetrahydrobenzoannulenyl, and the like.
[0036] Unless otherwise specifically defined, "heteroaryl" means a monovalent monocyclic or polycyclic aromatic radical of 5 to 24 ring atoms, containing one or more ring heteroatoms selected from N, 0, S, P, or B, the remaining ring atoms being C.
Heteroaryl as herein defined also means a bicyclic heteroaromatic group wherein the heteroatom is selected from N, 0, S, P, or B. Heteroaryl as herein defined also means a tricyclic heteroaromatic group containing one or more ring heteroatoms selected from N, 0, S, P, or B. The aromatic radical is optionally substituted independently with one or more substituents described herein.
Examples include, but are not limited to, furyl, thienyl, pyrrolyl, pyridyl, pyrazolyl, pyrimidinyl, imidazolyl, isoxazolyl, oxazolyl, oxadiazolyl, pyrazinyl, indolyl, thiophen-2-yl, quinolinyl, benzopyranyl, isothiazolyl, thiazolyl, thiadiazole, indazole, benzimidazolyl, thieno[3,2-b]thiophene, triazolyl, triazinyl, imidazo[1,2-b]pyrazolyl, furo[2,3-c]pyridinyl, imidazo[1,2-a]pyridinyl, indazolyl, pyrrolo[2,3-c]pyridinyl, pyrrolo[3,2-c]pyridinyl, py razol o [3,4-c] py ri dinyl, thi eno [3,2-c] py ri dinyl, thi eno [2,3-c] pyri dinyl, thi eno [2,3 -b]pyridinyl, benzothiazolyl, indolyl, indolinyl, indolinonyl, dihydrobenzothiophenyl, dihydrobenzofuranyl, benzofuran, chromanyl, thiochromanyl, tetrahydroquinolinyl, dihydrobenzothiazine, quinolinyl, isoquinolinyl, 1,6-naphthyridinyl, benzo[de]isoquinolinyl, pyrido[4,3-b][1,6]naphthyridinyl, thieno[2,3-b]pyrazinyl, quinazolinyl, tetrazolo[1,5-a]pyridinyl, [1,2,4]triazolo[4,3-a]pyridinyl, isoindolyl, pyrrolo[2,3-b]pyridinyl, pyrrolo[3,4-b]pyridinyl, pyrrolo[3,2-b]pyridinyl, imidazo[5,4-b]pyridinyl, pyrrolo[1,2-a]pyrimidinyl, tetrahydro py rrol o [1,2-a] py rimi dinyl, 3 ,4-dihy dro-2H-12\,2-pyrrol o [2,1 -b] py ri mi dine, dibenzo[b,d] thiophene, pyridin-2-one, furo[3,2-c]pyridinyl, furo[2,3-c]pyridinyl, 1H-pyrido[3,4-b][1,4] thiazinyl, benzoxazolyl, benzisoxazolyl, furo[2,3-b]pyridinyl, benzothiophenyl, 1,5-naphthyridinyl, furo[3,2-b]pyridine, [1,2,4]triazolo[1,5-a]pyridinyl, benzo [1,2,3]triazo1y1, imidazo[1,2-a]pyrimidinyl, [1,2,4]triazolo[4,3-b]pyridazinyl, benzo[c] [1,2,5]thiadiazolyl, benzo[c] [1,2,5] oxadiazole, 1,3-dihy dro-2H-benzo [d] imidazol-2-one, 3,4-dihy dro-2H-py razol o [1,5 -b]
[1,2] oxazinyl, 4,5,6,7-tetrahy dropyrazol o [1,5 -a]pyridinyl, thiazolo[5,4-d]thiazolyl, imidazo[2,1-b][1,3,4]thiadiazolyl, thieno[2,3-b]pyrrolyl, 3H-indolyl, and derivatives thereof Furthermore, when containing two or more fused rings, the heteroaryl groups defined herein may have one or more saturated or partially unsaturated ring fused with a fully unsaturated ring, e.g., a 5-membered heteroaromatic ring containing 1-3 heteroatoms selected from N, S, or 0, or a 6-membered heteroaromatic ring containing 1-3 nitrogens, wherein the saturated or partially unsaturated ring includes 0-4 heteroatoms selected from N, 0, S, P, or B, and is optionally substituted with one or more oxo. In heteroaryl ring systems containing more than two fused rings, a saturated or partially unsaturated ring may further be fused with a saturated or partially unsaturated ring described herein. Exemplary ring systems of these heteroaryl groups include, for example, indolinyl, indolinonyl, dihy drobenzothiophenyl, dihy drobenzofuran, chromanyl, thiochromanyl, tetrahy droquinolinyl, dihy drobenzothiazine, 3,4 -dihy dro-1H-isoquinolinyl, 2,3-dihydrobenzofuranyl, benzofuranonyl, indolinyl, oxindolyl, indolyl, 1,6-dihy dro-7H-py razolo [3,4 -c] py ridin-7-onyl , 7,8-dihy dro-6H-pyrido [3,2-b] py rrolizinyl, 8H-py rido [3,2 -b] py rrolizinyl, 1,5,6,7 -tetrahy drocy clopenta[b]pyrazolo [4,3-el py ridinyl, 7, 8-dihy dro-6H-py ri do [3 ,2 -b] py rrolizine, py razolo [1,5 -a] py rimi din-7(4H)-only , 3 ,4 -dihy dropy razino [1,2 -a] indo1-1(2H)-onyl, or benzo [Cl [1,2] oxaborol-1(3H)-olyl.
Heteroaryl as herein defined also means a bicyclic heteroaromatic group wherein the heteroatom is selected from N, 0, S, P, or B. Heteroaryl as herein defined also means a tricyclic heteroaromatic group containing one or more ring heteroatoms selected from N, 0, S, P, or B. The aromatic radical is optionally substituted independently with one or more substituents described herein.
Examples include, but are not limited to, furyl, thienyl, pyrrolyl, pyridyl, pyrazolyl, pyrimidinyl, imidazolyl, isoxazolyl, oxazolyl, oxadiazolyl, pyrazinyl, indolyl, thiophen-2-yl, quinolinyl, benzopyranyl, isothiazolyl, thiazolyl, thiadiazole, indazole, benzimidazolyl, thieno[3,2-b]thiophene, triazolyl, triazinyl, imidazo[1,2-b]pyrazolyl, furo[2,3-c]pyridinyl, imidazo[1,2-a]pyridinyl, indazolyl, pyrrolo[2,3-c]pyridinyl, pyrrolo[3,2-c]pyridinyl, py razol o [3,4-c] py ri dinyl, thi eno [3,2-c] py ri dinyl, thi eno [2,3-c] pyri dinyl, thi eno [2,3 -b]pyridinyl, benzothiazolyl, indolyl, indolinyl, indolinonyl, dihydrobenzothiophenyl, dihydrobenzofuranyl, benzofuran, chromanyl, thiochromanyl, tetrahydroquinolinyl, dihydrobenzothiazine, quinolinyl, isoquinolinyl, 1,6-naphthyridinyl, benzo[de]isoquinolinyl, pyrido[4,3-b][1,6]naphthyridinyl, thieno[2,3-b]pyrazinyl, quinazolinyl, tetrazolo[1,5-a]pyridinyl, [1,2,4]triazolo[4,3-a]pyridinyl, isoindolyl, pyrrolo[2,3-b]pyridinyl, pyrrolo[3,4-b]pyridinyl, pyrrolo[3,2-b]pyridinyl, imidazo[5,4-b]pyridinyl, pyrrolo[1,2-a]pyrimidinyl, tetrahydro py rrol o [1,2-a] py rimi dinyl, 3 ,4-dihy dro-2H-12\,2-pyrrol o [2,1 -b] py ri mi dine, dibenzo[b,d] thiophene, pyridin-2-one, furo[3,2-c]pyridinyl, furo[2,3-c]pyridinyl, 1H-pyrido[3,4-b][1,4] thiazinyl, benzoxazolyl, benzisoxazolyl, furo[2,3-b]pyridinyl, benzothiophenyl, 1,5-naphthyridinyl, furo[3,2-b]pyridine, [1,2,4]triazolo[1,5-a]pyridinyl, benzo [1,2,3]triazo1y1, imidazo[1,2-a]pyrimidinyl, [1,2,4]triazolo[4,3-b]pyridazinyl, benzo[c] [1,2,5]thiadiazolyl, benzo[c] [1,2,5] oxadiazole, 1,3-dihy dro-2H-benzo [d] imidazol-2-one, 3,4-dihy dro-2H-py razol o [1,5 -b]
[1,2] oxazinyl, 4,5,6,7-tetrahy dropyrazol o [1,5 -a]pyridinyl, thiazolo[5,4-d]thiazolyl, imidazo[2,1-b][1,3,4]thiadiazolyl, thieno[2,3-b]pyrrolyl, 3H-indolyl, and derivatives thereof Furthermore, when containing two or more fused rings, the heteroaryl groups defined herein may have one or more saturated or partially unsaturated ring fused with a fully unsaturated ring, e.g., a 5-membered heteroaromatic ring containing 1-3 heteroatoms selected from N, S, or 0, or a 6-membered heteroaromatic ring containing 1-3 nitrogens, wherein the saturated or partially unsaturated ring includes 0-4 heteroatoms selected from N, 0, S, P, or B, and is optionally substituted with one or more oxo. In heteroaryl ring systems containing more than two fused rings, a saturated or partially unsaturated ring may further be fused with a saturated or partially unsaturated ring described herein. Exemplary ring systems of these heteroaryl groups include, for example, indolinyl, indolinonyl, dihy drobenzothiophenyl, dihy drobenzofuran, chromanyl, thiochromanyl, tetrahy droquinolinyl, dihy drobenzothiazine, 3,4 -dihy dro-1H-isoquinolinyl, 2,3-dihydrobenzofuranyl, benzofuranonyl, indolinyl, oxindolyl, indolyl, 1,6-dihy dro-7H-py razolo [3,4 -c] py ridin-7-onyl , 7,8-dihy dro-6H-pyrido [3,2-b] py rrolizinyl, 8H-py rido [3,2 -b] py rrolizinyl, 1,5,6,7 -tetrahy drocy clopenta[b]pyrazolo [4,3-el py ridinyl, 7, 8-dihy dro-6H-py ri do [3 ,2 -b] py rrolizine, py razolo [1,5 -a] py rimi din-7(4H)-only , 3 ,4 -dihy dropy razino [1,2 -a] indo1-1(2H)-onyl, or benzo [Cl [1,2] oxaborol-1(3H)-olyl.
[0037] Halogen or "halo" refers to fluorine, chlorine, bromine, or iodine.
[0038] Alkyl refers to a straight or branched chain saturated hydrocarbon containing 1-12 carbon atoms. Examples of a (C1-C6) alkyl group include, but are not limited to, methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, isobutyl, sec-butyl, tert-butyl, isopentyl, neopentyl, and isohexyl.
[0039] "Alkoxy"
refers to a straight or branched chain saturated hydrocarbon containing 1-12 carbon atoms containing a terminal "0" in the chain, i.e., -0(alkyl).
Examples of alkoxy groups include without limitation, methoxy, ethoxy, propoxy, butoxy, t-butoxy, or pentoxy groups.
refers to a straight or branched chain saturated hydrocarbon containing 1-12 carbon atoms containing a terminal "0" in the chain, i.e., -0(alkyl).
Examples of alkoxy groups include without limitation, methoxy, ethoxy, propoxy, butoxy, t-butoxy, or pentoxy groups.
[0040]
"Alkenyl" refers to a straight or branched chain unsaturated hydrocarbon containing 2-12 carbon atoms. The "alkenyl" group contains at least one double bond in the chain. The double bond of an alkenyl group can be unconjugated or conjugated to another unsaturated group. Examples of alkenyl groups include ethenyl, propenyl, n-butenyl, iso-butenyl, pentenyl, or hexenyl. An alkenyl group can be unsubstituted or substituted. Alkenyl, as herein defined, may be straight or branched.
"Alkenyl" refers to a straight or branched chain unsaturated hydrocarbon containing 2-12 carbon atoms. The "alkenyl" group contains at least one double bond in the chain. The double bond of an alkenyl group can be unconjugated or conjugated to another unsaturated group. Examples of alkenyl groups include ethenyl, propenyl, n-butenyl, iso-butenyl, pentenyl, or hexenyl. An alkenyl group can be unsubstituted or substituted. Alkenyl, as herein defined, may be straight or branched.
[0041]
"Alkynyl" refers to a straight or branched chain unsaturated hydrocarbon containing 2-12 carbon atoms. The "alkynyl" group contains at least one triple bond in the chain.
Examples of alkenyl groups include ethynyl, propargyl, n-butynyl, iso-butynyl, pentynyl, or hexynyl. An alkynyl group can be unsubstituted or substituted.
"Alkynyl" refers to a straight or branched chain unsaturated hydrocarbon containing 2-12 carbon atoms. The "alkynyl" group contains at least one triple bond in the chain.
Examples of alkenyl groups include ethynyl, propargyl, n-butynyl, iso-butynyl, pentynyl, or hexynyl. An alkynyl group can be unsubstituted or substituted.
[0042] The term "alkylene" or "alkylenyl" refers to a divalent alkyl radical. Any of the above mentioned monovalent alkyl groups may be an alkylene by abstraction of a second hydrogen atom from the alkyl. As herein defined, alkylene may also be a C1-C6 alkylene. An alkylene may further be a C1-C4 alkylene. Typical alkylene groups include, but are not limited to, -CH2-, -CH(CH3)-, -C(CH3)2-, -CH2CH2-, -CH2CH(CH3)-, -CH2C(CH3)2-, -CH2CH2CH2-, -CH2CH2CH2CH2-, and the like.
[0043]
"Cycloalkyl" means monocyclic saturated carbon rings containing 3-18 carbon atoms. Examples of cycloalkyl groups include, without limitations, cyclopropyl, cyclobutyl, cy cl op entyl, cyclohexyl, cycloheptanyl, cyclooctanyl, norboranyl, norborenyl, bicyclo[2.2.21octanyl, or bicyclo[2.2.21octenyl.
"Cycloalkyl" means monocyclic saturated carbon rings containing 3-18 carbon atoms. Examples of cycloalkyl groups include, without limitations, cyclopropyl, cyclobutyl, cy cl op entyl, cyclohexyl, cycloheptanyl, cyclooctanyl, norboranyl, norborenyl, bicyclo[2.2.21octanyl, or bicyclo[2.2.21octenyl.
[0044]
"Cycloalkylalkyl" means monocyclic saturated carbon rings containing 3-24 carbon atoms further substituted with (C1-C6) alkyl groups. In general cycloalkylalkyl groups herein described display the following formula n where m is an integer from 1 to 6 and n is an integer from 1 to 16. The cycloalkyl ring or carbocycle may be optionally substituted by one or more substituents, e.g., 1 to 5 substituents, at any point of attachment.
The substituents can themselves be optionally substituted. Examples of cycloalkyl groups include, without limitations, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptanyl, cyclooctanyl, norboranyl, norborenyl, bicy clo [2. 2. 2] octanyl, bicy clo [2. 2. 2] octenyl, decahydronaphthalenyl, octahydro-1H-indenyl, cy cl op entenyl, cyclohexenyl, cy cl ohexa-1,4-di enyl, cyclohexa-1,3-dienyl, 1,2,3,4-tetrahydronaphthalenyl, octahy drop ental enyl, 3 a,4,5,6,7,7 a-hexahy dro-1H-indenyl, 1,2,3,3 a-tetrahy dropental enyl, bi cy cl o [3.1. 0] hexanyl, bicy clo [2.1. 0] pentanyl, spiro [3 . 31heptanyl, bicyclo [2. 2.11heptanyl, bicyclo[2.2.11hept-2-enyl, bicy clo [2. 2. 2] octanyl, 6-methylbicyclo[3.1.11heptanyl, 2,6,6-trimethylbicyclo[3.1.11heptanyl, and derivatives thereof
"Cycloalkylalkyl" means monocyclic saturated carbon rings containing 3-24 carbon atoms further substituted with (C1-C6) alkyl groups. In general cycloalkylalkyl groups herein described display the following formula n where m is an integer from 1 to 6 and n is an integer from 1 to 16. The cycloalkyl ring or carbocycle may be optionally substituted by one or more substituents, e.g., 1 to 5 substituents, at any point of attachment.
The substituents can themselves be optionally substituted. Examples of cycloalkyl groups include, without limitations, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptanyl, cyclooctanyl, norboranyl, norborenyl, bicy clo [2. 2. 2] octanyl, bicy clo [2. 2. 2] octenyl, decahydronaphthalenyl, octahydro-1H-indenyl, cy cl op entenyl, cyclohexenyl, cy cl ohexa-1,4-di enyl, cyclohexa-1,3-dienyl, 1,2,3,4-tetrahydronaphthalenyl, octahy drop ental enyl, 3 a,4,5,6,7,7 a-hexahy dro-1H-indenyl, 1,2,3,3 a-tetrahy dropental enyl, bi cy cl o [3.1. 0] hexanyl, bicy clo [2.1. 0] pentanyl, spiro [3 . 31heptanyl, bicyclo [2. 2.11heptanyl, bicyclo[2.2.11hept-2-enyl, bicy clo [2. 2. 2] octanyl, 6-methylbicyclo[3.1.11heptanyl, 2,6,6-trimethylbicyclo[3.1.11heptanyl, and derivatives thereof
[0045]
"Heterocycly1" or "heterocycloalkyl" monocyclic rings containing carbon and heteroatoms taken from containing one or more ring heteroatoms selected from N, 0, S, P, or B and wherein there is not delocalized it electrons (aromaticity) shared among the ring carbon or heteroatoms. The heterocycloalkyl ring structure may be substituted by one or more substituents. The substituents can themselves be optionally substituted.
Examples of heterocyclyl rings include, but are not limited to, oxetanyl, azetadinyl, tetrahydrofuranyl, tetrahydropyranyl, pyrrolidinyl, oxazolinyl, oxazolidinyl, thiazolinyl, thiazolidinyl, pyranyl, thiopyranyl, tetrahydropyranyl, dioxalinyl, piperidinyl, morpholinyl, thiomorpholinyl, thiomorpholinyl S-oxide, thiomorpholinyl S-dioxide, piperazinyl, azepinyl, oxepinyl, diazepinyl, tropanyl, oxazolidinonyl, and homotropanyl.
"Heterocycly1" or "heterocycloalkyl" monocyclic rings containing carbon and heteroatoms taken from containing one or more ring heteroatoms selected from N, 0, S, P, or B and wherein there is not delocalized it electrons (aromaticity) shared among the ring carbon or heteroatoms. The heterocycloalkyl ring structure may be substituted by one or more substituents. The substituents can themselves be optionally substituted.
Examples of heterocyclyl rings include, but are not limited to, oxetanyl, azetadinyl, tetrahydrofuranyl, tetrahydropyranyl, pyrrolidinyl, oxazolinyl, oxazolidinyl, thiazolinyl, thiazolidinyl, pyranyl, thiopyranyl, tetrahydropyranyl, dioxalinyl, piperidinyl, morpholinyl, thiomorpholinyl, thiomorpholinyl S-oxide, thiomorpholinyl S-dioxide, piperazinyl, azepinyl, oxepinyl, diazepinyl, tropanyl, oxazolidinonyl, and homotropanyl.
[0046] The term "hydroxyalkyl" means an alkyl group as defined above, where the alkyl group is substituted with one or more OH groups. Examples of hydroxyalkyl groups include HO-CH2-, HO-CH2-CH2- and CH3-CH(OH)-.
[0047] The term "haloalkyl" as used herein refers to an alkyl group, as defined herein, which is substituted one or more halogen. Examples of haloalkyl groups include, but are not limited to, trifluoromethyl, difluoromethyl, pentafluoroethyl, trichloromethyl, etc.
[0048] The term "haloalkoxy" as used herein refers to an alkoxy group, as defined herein, which is substituted one or more halogen. Examples of haloalkyl groups include, but are not limited to, trifluoromethoxy, difluoromethoxy, pentafluoroethoxy, trichloromethoxy, etc.
[0049] The term "cyano" as used herein means a substituent having a carbon atom joined to a nitrogen atom by a triple bond, i.e., CI\1.
[0050] The term "amine" as used herein refers to primary (R-NH2, R # H), secondary (R2-NH, R2 # H) and tertiary (R3-N, R # H) amines. A substituted amine is intended to mean an amine where at least one of the hydrogen atoms has been replaced by the substituent.
[0051] The term "amino" as used herein means a substituent containing at least one nitrogen atom. Specifically, -NH2, -NH(alkyl) or alkylamino, -N(alkyl)2 or dialkylamino, amide-, carbamide-, urea, and sulfamide substituents are included in the term "amino".
[0052] The term "dialkylamino" as used herein refers to an amino or -NH2 group where both of the hydrogens have been replaced with alkyl groups, as defined herein above, i.e., -N(alkyl)2. The alkyl groups on the amino group can be the same or different alkyl groups.
Example of alkylamino groups include, but are not limited to, dimethylamino (i.e., -N(CH3)2), diethylamino, dipropylamino, diiso-propylamino, di-n-butylamino, di-sec-butylamino, di-tert-butylamino, methyl(ethyl)amino, methyl(butylamino), etc.
Example of alkylamino groups include, but are not limited to, dimethylamino (i.e., -N(CH3)2), diethylamino, dipropylamino, diiso-propylamino, di-n-butylamino, di-sec-butylamino, di-tert-butylamino, methyl(ethyl)amino, methyl(butylamino), etc.
[0053]
"Spirocycloalkyl" or "spirocycly1" means carbogenic bicyclic ring systems with both rings connected through a single atom. The ring can be different in size and nature, or identical in size and nature. Examples include spiropentane, spriohexane, spiroheptane, spirooctane, spirononane, or spirodecane. One or both of the rings in a spirocycle can be fused to another ring carbocyclic, heterocyclic, aromatic, or heteroaromatic ring.
One or more of the carbon atoms in the spirocycle can be substituted with a heteroatom (e.g., 0, N, S, or P). A
(C3-C12) spirocycloalkyl is a spirocycle containing between 3 and 12 carbon atoms. One or more of the carbon atoms can be substituted with a heteroatom.
"Spirocycloalkyl" or "spirocycly1" means carbogenic bicyclic ring systems with both rings connected through a single atom. The ring can be different in size and nature, or identical in size and nature. Examples include spiropentane, spriohexane, spiroheptane, spirooctane, spirononane, or spirodecane. One or both of the rings in a spirocycle can be fused to another ring carbocyclic, heterocyclic, aromatic, or heteroaromatic ring.
One or more of the carbon atoms in the spirocycle can be substituted with a heteroatom (e.g., 0, N, S, or P). A
(C3-C12) spirocycloalkyl is a spirocycle containing between 3 and 12 carbon atoms. One or more of the carbon atoms can be substituted with a heteroatom.
[0054] The term "spiroheterocycloalkyl" or "spiroheterocycly1" is understood to mean a spirocycle wherein at least one of the rings is a heterocycle (e.g., at least one of the rings is furanyl, morpholinyl, or piperadinyl).
[0055] The term "solvate" refers to a complex of variable stoichiometry formed by a solute and solvent. Such solvents for the purpose of the invention may not interfere with the biological activity of the solute. Examples of suitable solvents include, but are not limited to, water, Me0H, Et0H, and AcOH. Solvates wherein water is the solvent molecule are typically referred to as hydrates. Hydrates include compositions containing stoichiometric amounts of water, as well as compositions containing variable amounts of water.
[0056] The term "isomer" refers to compounds that have the same composition and molecular weight but differ in physical and/or chemical properties. The structural difference may be in constitution (geometric isomers) or in the ability to rotate the plane of polarized light (stereoisomers). With regard to stereoisomers, the compounds of Formula (I) may have one or more asymmetric carbon atom and may occur as racemates, racemic mixtures and as individual enantiomers or diastereomers.
[0057] The present invention also contemplates isotopically-labelled compounds of Formula I (e.g., those labeled with 2H and "C). Deuterated (i.e., 2H or D) and carbon-14 (i.e., 14C) isotopes are particularly preferred for their ease of preparation and detectability. Further, substitution with heavier isotopes such as deuterium may afford certain therapeutic advantages resulting from greater metabolic stability (e.g., increased in vivo half-life or reduced dosage requirements) and hence may be preferred in some circumstances. Isotopically labelled compounds of Formula I can generally be prepared by following procedures analogous to those disclosed in the Schemes and/or in the Examples herein below, by substituting an appropriate isotopically labelled reagent for a non-isotopically labelled reagent.
[0058] The disclosure also includes pharmaceutical compositions comprising an effective amount of a disclosed compound and a pharmaceutically acceptable carrier.
Representative "pharmaceutically acceptable salts" include, e.g., water-soluble and water-insoluble salts, such as the acetate, amsonate (4,4-diaminostilbene-2,2-disulfonate), benzenesulfonate, benzonate, bicarbonate, bisulfate, bitartrate, borate, bromide, butyrate, calcium, calcium edetate, camsylate, carbonate, chloride, citrate, clavulariate, dihydrochloride, edetate, edisylate, estolate, esylate, fumerate, fiunarate, gluceptate, gluconate, glutamate, glycollylarsanilate, hexafluorophosphate, hexylresorcinate, hydrabamine, hydrobromide, hydrochloride, hydroxynaphthoate, iodide, isothionate, lactate, lactobionate, laurate, magnesium, malate, maleate, mandelate, mesylate, methylbromide, methylnitrate, methylsulfate, mucate, napsylate, nitrate, N-methylglucamine ammonium salt, 3-hydroxy-2-naphthoate, oleate, oxalate, palmitate, pamoate (1,1-methene-bis-2-hydroxy-3-naphthoate, einbonate), pantothenate, phosphate/diphosphate, picrate, polygalacturonate, propionate, p-toluenesulfonate, salicylate, stearate, subacetate, succinate, sulfate, sulfosalicylate, suramate, tannate, tartrate, teoclate, tosylate, triethiodide, and valerate salts.
Representative "pharmaceutically acceptable salts" include, e.g., water-soluble and water-insoluble salts, such as the acetate, amsonate (4,4-diaminostilbene-2,2-disulfonate), benzenesulfonate, benzonate, bicarbonate, bisulfate, bitartrate, borate, bromide, butyrate, calcium, calcium edetate, camsylate, carbonate, chloride, citrate, clavulariate, dihydrochloride, edetate, edisylate, estolate, esylate, fumerate, fiunarate, gluceptate, gluconate, glutamate, glycollylarsanilate, hexafluorophosphate, hexylresorcinate, hydrabamine, hydrobromide, hydrochloride, hydroxynaphthoate, iodide, isothionate, lactate, lactobionate, laurate, magnesium, malate, maleate, mandelate, mesylate, methylbromide, methylnitrate, methylsulfate, mucate, napsylate, nitrate, N-methylglucamine ammonium salt, 3-hydroxy-2-naphthoate, oleate, oxalate, palmitate, pamoate (1,1-methene-bis-2-hydroxy-3-naphthoate, einbonate), pantothenate, phosphate/diphosphate, picrate, polygalacturonate, propionate, p-toluenesulfonate, salicylate, stearate, subacetate, succinate, sulfate, sulfosalicylate, suramate, tannate, tartrate, teoclate, tosylate, triethiodide, and valerate salts.
[0059] A
"patient" or "subject" is a mammal, e.g., a human, mouse, rat, guinea pig, dog, cat, horse, cow, pig, or non-human primate, such as a monkey, chimpanzee, baboon or rhesus.
"patient" or "subject" is a mammal, e.g., a human, mouse, rat, guinea pig, dog, cat, horse, cow, pig, or non-human primate, such as a monkey, chimpanzee, baboon or rhesus.
[0060] An "effective amount" when used in connection with a compound is an amount effective for treating or preventing a disease in a subject as described herein.
[0061] The term "carrier", as used in this disclosure, encompasses carriers, excipients, and diluents and means a material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material, involved in carrying or transporting a pharmaceutical agent from one organ, or portion of the body, to another organ, or portion of the body of a subject.
[0062] The term "treating" with regard to a subject, refers to improving at least one symptom of the subject's disorder. Treating includes curing, improving, or at least partially ameliorating the disorder.
[0063] The term "disorder" is used in this disclosure to mean, and is used interchangeably with, the terms disease, condition, or illness, unless otherwise indicated.
[0064] The term "administer", "administering", or "administration" as used in this disclosure refers to either directly administering a disclosed compound or pharmaceutically acceptable salt of the disclosed compound or a composition to a subject, or administering a prodrug derivative or analog of the compound or pharmaceutically acceptable salt of the compound or composition to the subject, which can form an equivalent amount of active compound within the subject's body.
[0065] The term "prodrug," as used in this disclosure, means a compound which is convertible in vivo by metabolic means (e.g., by hydrolysis) to a disclosed compound.
[0066] The present invention relates to compounds or pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, or tautomers thereof, capable of inhibiting PI5P4K, which are useful for the treatment of diseases and disorders associated with modulation of a PI5P4K enzyme. The invention further relates to compounds, or pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, or tautomers thereof, which are useful for inhibiting PI5P4K.
[0067] In one embodiment, the compounds of Formula (I) have the structure of Formula (Ia):
R6 yO
rc5 R4 R8 (Ia), wherein Yi is CH or N.
R6 yO
rc5 R4 R8 (Ia), wherein Yi is CH or N.
[0068] In another embodiment, the compounds of Formula (I) have the structure of Formula (Ib):
R6 ,N R4 G
I )- CO
R8 (Ib), wherein Yi is CH or N.
R6 ,N R4 G
I )- CO
R8 (Ib), wherein Yi is CH or N.
[0069] In another embodiment, the compounds of Formula (I) have the structure of Formula (Ic):
oõ?
R8 ,N W R3 )¨ co R8 (Ic), wherein Yi is CH or N.
oõ?
R8 ,N W R3 )¨ co R8 (Ic), wherein Yi is CH or N.
[0070] In another embodiment, the compounds of Formula (I) have the structure of Formula (Id):
R2 I Y1 e, R8 (Id), wherein Yi is CH or N.
R2 I Y1 e, R8 (Id), wherein Yi is CH or N.
[0071] In another embodiment, the compounds of Formula (I) have the structure of Formula (le):
R H R
R8 (le), wherein Yi is CH or N.
R H R
R8 (le), wherein Yi is CH or N.
[0072] In another embodiment, the compounds of Formula (I) have the structure of Formula (If):
wherein Yi is CH or N.
wherein Yi is CH or N.
[0073] In another embodiment, the compounds of Formula (I) have the structure of Formula (Ig):
R1 w R3 F., a, R2 G &¨(R ) c*d 8 P
(Ig) wherein Yi is CH or N.
R1 w R3 F., a, R2 G &¨(R ) c*d 8 P
(Ig) wherein Yi is CH or N.
[0074] In another embodiment, the compounds of Formula (I) have the structure of Formula (Ih):
R1 w R3 4110 g--(R8 R2 ) (Ih) wherein:
a, b, c, and d, are each independently C or N, wherein at least one of a, b, c, and d is N, and no more than two of a, b, c, and d, are N;
X3 and Y3 are each independently ¨0¨, -CH2-, or ¨N(R8)¨;
pis 1, 2, or 3.
R1 w R3 4110 g--(R8 R2 ) (Ih) wherein:
a, b, c, and d, are each independently C or N, wherein at least one of a, b, c, and d is N, and no more than two of a, b, c, and d, are N;
X3 and Y3 are each independently ¨0¨, -CH2-, or ¨N(R8)¨;
pis 1, 2, or 3.
[0075] In another embodiment, the compounds of Formula (I) have the structure of Formula (Ii):
* W i3R4 0 (Ii), wherein:
a, b, c, and d, are each independently C or N, wherein at least one of a, b, c, and d is N; and no more than two of a, b, c, d, and e, are N;
X4 and Zi are each independently ¨0¨, ¨N(R12)¨, or ¨C(R12)(R12)¨; and co is 1, 2, or 3.
* W i3R4 0 (Ii), wherein:
a, b, c, and d, are each independently C or N, wherein at least one of a, b, c, and d is N; and no more than two of a, b, c, d, and e, are N;
X4 and Zi are each independently ¨0¨, ¨N(R12)¨, or ¨C(R12)(R12)¨; and co is 1, 2, or 3.
[0076] In another embodiment, the compounds of Formula (I) have the structure of Formula (Ij):
e 0 d N
H (R18)2, wherein:
a, b, c, d, and e, are each independently C or N, wherein at least one of a, b, c, d, and e is N, and no more than two of a, b, c, d, and e, are N; and 2\, is 1, 2, or 3.
e 0 d N
H (R18)2, wherein:
a, b, c, d, and e, are each independently C or N, wherein at least one of a, b, c, d, and e is N, and no more than two of a, b, c, d, and e, are N; and 2\, is 1, 2, or 3.
[0077] In another embodiment, the compounds of Formula (I) have the structure of Formula (Ik):
R1 w R3 *a, e 0 dH (R19)), (Ik), wherein:
a, b, c, d, and e, are each independently C or N, wherein at least one of a, b, c, d, and e is N, and no more than two of a, b, c, d, and e, are N; and 2\, is 1, 2, or 3.
R1 w R3 *a, e 0 dH (R19)), (Ik), wherein:
a, b, c, d, and e, are each independently C or N, wherein at least one of a, b, c, d, and e is N, and no more than two of a, b, c, d, and e, are N; and 2\, is 1, 2, or 3.
[0078] In another embodiment, the compounds of Formula (I) have the structure of Formula (I1):
R1 w R3 ,,e G R2 R14 d N
CI:-41\14 (Ii) wherein:
a, b, c, d, and e, are each independently C or N, wherein at least one of a, b, c, d, and e is N, and no more than two of a, b, c, d, and e, are N;
Y4 is ¨0¨, ¨N(R14)¨, or ¨C(R14)(R14)¨; and (1:1 is 0, 1, or 2.
R1 w R3 ,,e G R2 R14 d N
CI:-41\14 (Ii) wherein:
a, b, c, d, and e, are each independently C or N, wherein at least one of a, b, c, d, and e is N, and no more than two of a, b, c, d, and e, are N;
Y4 is ¨0¨, ¨N(R14)¨, or ¨C(R14)(R14)¨; and (1:1 is 0, 1, or 2.
[0079] In another embodiment, the compounds of Formula (I) have the structure of Formula (Im):
* W i3R4 h*a, c d N
(Im), wherein:
a, b, c, d, and e, are each independently C or N, wherein at least one of a, b, c, d, and e is N, and no more than two of a, b, c, d, and e, are N.
* W i3R4 h*a, c d N
(Im), wherein:
a, b, c, d, and e, are each independently C or N, wherein at least one of a, b, c, d, and e is N, and no more than two of a, b, c, d, and e, are N.
[0080] In another embodiment, the compounds of Formula (I) have the structure of Formula (In):
R1 w R3 *a R2):1=G¨b 1 I
c N N Rig R9 R9 = (In), wherein:
a, b, c, d, and e, are each independently C or N, wherein at least one of a, b, c, d, and e is N, and no more than two of a, b, c, d, and e, are N.
R1 w R3 *a R2):1=G¨b 1 I
c N N Rig R9 R9 = (In), wherein:
a, b, c, d, and e, are each independently C or N, wherein at least one of a, b, c, d, and e is N, and no more than two of a, b, c, d, and e, are N.
[0081] In another embodiment, the compounds of Formula (I) have the structure of Formula (To):
,a, e 0 R2 Al G I II
dN
N(R22)C(0)-Q-N(R22)-F
(To), wherein:
a, b, c, d, and e, are each independently C or N, wherein at least one of a, b, c, d, and e is N, and no more than two of a, b, c, d, and e, are N.
,a, e 0 R2 Al G I II
dN
N(R22)C(0)-Q-N(R22)-F
(To), wherein:
a, b, c, d, and e, are each independently C or N, wherein at least one of a, b, c, d, and e is N, and no more than two of a, b, c, d, and e, are N.
[0082] In another embodiment, the compounds of Formula (I) have the structure of Formula (Ip):
a, b* e R2 Al G I II A
dN R10 R13 N(R22)C(0)-U-N(R22)-Z
(IP), wherein:
a, b, c, d, and e, are each independently C or N, wherein at least one of a, b, c, d, and e is N, and no more than two of a, b, c, d, and e, are N.
a, b* e R2 Al G I II A
dN R10 R13 N(R22)C(0)-U-N(R22)-Z
(IP), wherein:
a, b, c, d, and e, are each independently C or N, wherein at least one of a, b, c, d, and e is N, and no more than two of a, b, c, d, and e, are N.
[0083] In some embodiments of the compounds of Formula I, Ri is ¨N(R5)C(0)R6, ¨
C(0)N(R5)(R6), ¨S(0)2N(R5)(R6), -N(R5)S(0)2R6, or heteroaryl, wherein heteroaryl is optionally substituted with one or more R7. In another embodiment, Ri is ¨N(R5)C(0)R6, ¨
C(0)N(R5)(R6), ¨S(0)2N(R5)(R6), -N(R5)S(0)2R6, or heteroaryl. In another embodiment, Ri is ¨N(R5)C(0)R6, ¨C(0)N(R5)(R6), ¨S(0)2N(R5)(R6), or -N(R5)S(0)2R6. In another embodiment, Ri is ¨N(R5)C(0)R6, ¨C(0)N(R5)(R6), or ¨S(0)2N(R5)(R6). In another embodiment, Ri is ¨N(R5)C(0)R6 or ¨C(0)N(R5)(R6). In another embodiment, Ri is ¨
N(R5)C(0)R6. In another embodiment, Ri is ¨C(0)N(R5)(R6). In another embodiment, Ri is ¨S(0)2N(R5)(R6). In another embodiment, Ri is -N(R5)S(0)2R6. In another embodiment, Ri is heteroaryl. In another embodiment, Ri is heteroaryl optionally substituted with one or more R7.
C(0)N(R5)(R6), ¨S(0)2N(R5)(R6), -N(R5)S(0)2R6, or heteroaryl, wherein heteroaryl is optionally substituted with one or more R7. In another embodiment, Ri is ¨N(R5)C(0)R6, ¨
C(0)N(R5)(R6), ¨S(0)2N(R5)(R6), -N(R5)S(0)2R6, or heteroaryl. In another embodiment, Ri is ¨N(R5)C(0)R6, ¨C(0)N(R5)(R6), ¨S(0)2N(R5)(R6), or -N(R5)S(0)2R6. In another embodiment, Ri is ¨N(R5)C(0)R6, ¨C(0)N(R5)(R6), or ¨S(0)2N(R5)(R6). In another embodiment, Ri is ¨N(R5)C(0)R6 or ¨C(0)N(R5)(R6). In another embodiment, Ri is ¨
N(R5)C(0)R6. In another embodiment, Ri is ¨C(0)N(R5)(R6). In another embodiment, Ri is ¨S(0)2N(R5)(R6). In another embodiment, Ri is -N(R5)S(0)2R6. In another embodiment, Ri is heteroaryl. In another embodiment, Ri is heteroaryl optionally substituted with one or more R7.
[0084] In some embodiments of the compounds of Formula I, W is ¨0¨, ¨NH¨, ¨N(C1-6 alkyl)¨, ¨N(C3-8 cycloalkyl)¨, ¨N(ary1)¨, or ¨N(heteroary1)¨. In another embodiment, W is ¨
0-, -NH-, -N(C1-6 alkyl)-, -N(C3-8 cycloalkyl)-, or -N(ary1)-. In another embodiment, W is -0-, -NH-, -N(C1-6 alkyl)-, or -N(C3-8 cycloalkyl)-. In another embodiment, W
is -0-, -NH-, or -N(C1-6 alkyl)-. In another embodiment, W is -0- or -NH-. In another embodiment, W is -0-. In another embodiment, W is -NH-. In another embodiment, W is -0-.
In another embodiment, W is -N(C1-6 alkyl)-. In another embodiment, W is -N(C3-8 cycloalkyl)-. In another embodiment, W is -N(ary1)-. In another embodiment, W is -N(heteroary1)-.
0-, -NH-, -N(C1-6 alkyl)-, -N(C3-8 cycloalkyl)-, or -N(ary1)-. In another embodiment, W is -0-, -NH-, -N(C1-6 alkyl)-, or -N(C3-8 cycloalkyl)-. In another embodiment, W
is -0-, -NH-, or -N(C1-6 alkyl)-. In another embodiment, W is -0- or -NH-. In another embodiment, W is -0-. In another embodiment, W is -NH-. In another embodiment, W is -0-.
In another embodiment, W is -N(C1-6 alkyl)-. In another embodiment, W is -N(C3-8 cycloalkyl)-. In another embodiment, W is -N(ary1)-. In another embodiment, W is -N(heteroary1)-.
[0085] In some embodiments of the compounds of Formula I, R2 is H, halogen, -OH, -NH2, -NO2, -CN, -COOH, -C(0)NH2, C1-6 alkyl, C1-6 alkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, heterocyclyl, aryl, or heteroaryl. In another embodiment, R2 is H, halogen, -OH, -NH2, -NO2, -CN, -COOH, -C(0)NH2, C1-6 alkyl, C1-6 alkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, heterocyclyl, or aryl. In another embodiment, R2 is H, halogen, -OH, -NH2, -NO2, -CN, -COOH, -C(0)NH2, C1-6 alkyl, C1-6 alkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, or heterocyclyl. In another embodiment, R2 is H, halogen, -OH, -NH2, -NO2, -CN, -COOH, -C(0)NH2, C1-6 alkyl, C1-6 alkoxy, C2-6 alkenyl, C2-6 alkynyl, or C3-8 cycloalkyl.
In another embodiment, R2 is H, halogen, -OH, -NH2, -NO2, -CN, -COOH, -C(0)NH2, C1-6 alkyl, C1-6 alkoxy, C2-6 alkenyl, or C2-6 alkynyl. In another embodiment, R2 is H, halogen, -OH, -NH2, -NO2, -CN, -COOH, -C(0)NH2, C1-6 alkyl, C1-6 alkoxy, or C2-6 alkenyl. In another embodiment, R2 is H, halogen, -OH, -NH2, -NO2, -CN, -COOH, -C(0)NH2, alkyl, or C1-6 alkoxy. In another embodiment, R2 is H, halogen, -OH, -NH2, -NO2, -CN, -COOH, -C(0)NH2, or C1-6 alkyl. In another embodiment, R2 is H, halogen, -OH, -NH2, -NO2, -CN, -COOH, or C(0)NH2. In another embodiment, R2 is H, halogen, -OH, -NH2, -NO2, -CN, or -COOH. In another embodiment, R2 is H, halogen, -OH, -NH2, -NO2, or -CN.
In another embodiment, R2 is H, halogen, -OH, -NH2, or -NO2. In another embodiment, R2 is H, halogen, -OH, or -NH2. In another embodiment, R2 is H, halogen, or -OH.
In another embodiment, R2 is H or halogen. In another embodiment, R2 is H. In another embodiment, R2 is -OH. In another embodiment, R2 is -NH2. In another embodiment, R2 is halogen. In another embodiment, R2 is -NO2. In another embodiment, R2 is -CN. In another embodiment, R2 is -COOH. In another embodiment, R2 is -C(0)NH2. In another embodiment, R2 is C1-6 alkyl. In another embodiment, R2 is C1-6 alkoxy. In another embodiment, R2 is C2-6 alkenyl.
In another embodiment, R2 is C2-6 alkynyl. In another embodiment, R2 is C3-8 cycloalkyl. In another embodiment, R2 is heterocyclyl. In another embodiment, R2 is aryl. In another embodiment, R2 is heteroaryl.
In another embodiment, R2 is H, halogen, -OH, -NH2, -NO2, -CN, -COOH, -C(0)NH2, C1-6 alkyl, C1-6 alkoxy, C2-6 alkenyl, or C2-6 alkynyl. In another embodiment, R2 is H, halogen, -OH, -NH2, -NO2, -CN, -COOH, -C(0)NH2, C1-6 alkyl, C1-6 alkoxy, or C2-6 alkenyl. In another embodiment, R2 is H, halogen, -OH, -NH2, -NO2, -CN, -COOH, -C(0)NH2, alkyl, or C1-6 alkoxy. In another embodiment, R2 is H, halogen, -OH, -NH2, -NO2, -CN, -COOH, -C(0)NH2, or C1-6 alkyl. In another embodiment, R2 is H, halogen, -OH, -NH2, -NO2, -CN, -COOH, or C(0)NH2. In another embodiment, R2 is H, halogen, -OH, -NH2, -NO2, -CN, or -COOH. In another embodiment, R2 is H, halogen, -OH, -NH2, -NO2, or -CN.
In another embodiment, R2 is H, halogen, -OH, -NH2, or -NO2. In another embodiment, R2 is H, halogen, -OH, or -NH2. In another embodiment, R2 is H, halogen, or -OH.
In another embodiment, R2 is H or halogen. In another embodiment, R2 is H. In another embodiment, R2 is -OH. In another embodiment, R2 is -NH2. In another embodiment, R2 is halogen. In another embodiment, R2 is -NO2. In another embodiment, R2 is -CN. In another embodiment, R2 is -COOH. In another embodiment, R2 is -C(0)NH2. In another embodiment, R2 is C1-6 alkyl. In another embodiment, R2 is C1-6 alkoxy. In another embodiment, R2 is C2-6 alkenyl.
In another embodiment, R2 is C2-6 alkynyl. In another embodiment, R2 is C3-8 cycloalkyl. In another embodiment, R2 is heterocyclyl. In another embodiment, R2 is aryl. In another embodiment, R2 is heteroaryl.
[0086] In some embodiments of the compounds of Formula I, R3 is ¨H, halogen, C1-6 alkyl, C1-6 alkoxy, or C3-6 cycloalkyl. In another embodiment, R3 is ¨H, halogen, or C1-6 alkyl. In another embodiment, R3 is ¨H or halogen. In another embodiment, R3 is ¨H. In another embodiment, R3 is halogen. In another embodiment, R3 is C1-6 alkyl. In another embodiment, R3 is C1-6 alkoxy. In another embodiment, R3 is C3-6 cycloalkyl. In another embodiment, R3 is C1-6 alkyl optionally substituted with one or more halogen, ¨OH, and ¨NH2. In another embodiment, R3 is C3-6 cycloalkyl optionally substituted with one or more halogen, ¨OH, and ¨NH2. In another embodiment, R3 is C1_6 alkoxy optionally substituted with one or more halogen, ¨OH, and ¨NH2.
[0087] In some embodiments of the compounds of Formula I, R4 is ¨H, halogen, C1-6 alkyl, C1-6 alkoxy, or C3-6 cycloalkyl. In another embodiment, R4 is ¨H, halogen, or C1-6 alkyl. In another embodiment, R4 is ¨H or halogen. In another embodiment, R4 is ¨H. In another embodiment, R4 is halogen. In another embodiment, R4 is C1-6 alkyl. In another embodiment, R4 is C1-6 alkoxy. In another embodiment, R4 is C3-6 cycloalkyl. In another embodiment, R4 is C1-6 alkyl optionally substituted with one or more halogen, ¨OH, and ¨NH2. In another embodiment, R4 is C3-6 cycloalkyl optionally substituted with one or more halogen, ¨OH, and ¨NH2. In another embodiment, R4 is C1_6 alkoxy optionally substituted with one or more halogen, ¨OH, and ¨NH2.
[0088] In other embodiments of the compounds of Formula I, R3 and R4 when taken together with the atom to which they are attached form a C3-8 cycloalkyl or heterocyclyl. In another embodiment, R3 and R4 when taken together with the atom to which they are attached form a C3-8 cycloalkyl. In another embodiment, R3 and R4 when taken together with the atom to which they are attached form a heterocyclyl.
[0089] In some embodiments, Ring A2 is heteroaryl. In yet another embodiment, Ring A2 is heteroaryl optionally substituted with one or more Rs. In yet other embodiments, Ring Al is a 5- or 6-membered heteroaryl. In other embodiments, Ring Al is a 5-membered heteroaryl.
In other embodiments, Ring Al is a 6-membered heteroaryl.
In other embodiments, Ring Al is a 6-membered heteroaryl.
[0090] In some embodiments of the compounds of Formula I, Rs is, at each occurrence, ¨
H, C1-6 alkyl, C2-6 alkenyl, or C2-6 alkynyl. In another embodiment, Rs is, ¨H, C1-6 alkyl, or C2-6 alkenyl. In another embodiment, Rs is ¨H or C1-6 alkyl. In another embodiment, Rs is ¨H. In another embodiment, Rs is C1-6 alkyl. In another embodiment, Rs is C2-6 alkenyl. In another embodiment, Rs is C2-6 alkynyl. In another embodiment, Rs is C1-6 alkyl optionally substituted with one or more R7. In another embodiment, R5 is C2-6 alkenyl optionally substituted with one or more R7. In another embodiment, Rs is C2-6 alkynyl optionally substituted with one or more R7.
H, C1-6 alkyl, C2-6 alkenyl, or C2-6 alkynyl. In another embodiment, Rs is, ¨H, C1-6 alkyl, or C2-6 alkenyl. In another embodiment, Rs is ¨H or C1-6 alkyl. In another embodiment, Rs is ¨H. In another embodiment, Rs is C1-6 alkyl. In another embodiment, Rs is C2-6 alkenyl. In another embodiment, Rs is C2-6 alkynyl. In another embodiment, Rs is C1-6 alkyl optionally substituted with one or more R7. In another embodiment, R5 is C2-6 alkenyl optionally substituted with one or more R7. In another embodiment, Rs is C2-6 alkynyl optionally substituted with one or more R7.
[0091] In some embodiments of the compounds of Formula I, R6 is, at each occurrence, -H, C1-6 alkyl, C2-6 alkenyl, or C2-6 alkynyl. In another embodiment, R6 is, ¨H, C1-6 alkyl, or C2-6 alkenyl. In another embodiment, R6 is ¨H or C1-6 alkyl. In another embodiment, R6 is ¨H. In another embodiment, R6 is C1-6 alkyl. In another embodiment, R6 is C2-6 alkenyl. In another embodiment, R6 is C2-6 alkynyl. In another embodiment, R6 is C1-6 alkyl optionally substituted with one or more R7. In another embodiment, R6 is C2-6 alkenyl optionally substituted with one or more R7. In another embodiment, R6 is C2-6 alkynyl optionally substituted with one or more R7.
[0092] In other embodiments of the compounds of Formula I, Rs and R6 when taken together with the atom to which they are each attached form a heterocycle. In other embodiments of the compounds of Formula I, R5 and R6 when taken together with the atom to which they are each attached form a heterocycle optionally substituted with one or more R7.
[0093] In other embodiments of the compounds of Formula I, R7 is H, halogen, ¨OH, ¨
NH2, ¨NO2, ¨CN, C1-6 alkyl, C1-6 alkoxy, C3-8 cycloalkyl, heterocyclyl, aryl, or heteroaryl. In some embodiments, R7 is H. In some embodiments, R7 is halogen. In some embodiments, R7 is ¨OH. In some embodiments, R7 is ¨NH2. In some embodiments, R7 is ¨NO2. In some embodiments, R7 is ¨CN. In some embodiments, R7 is C1-6 alkyl. In some embodiments, R7 is C1-6 alkoxy. In some embodiments, R7 is C3-8 cycloalkyl. In some embodiments, R7 is heterocyclyl. In some embodiments, R7 is C3-8 cycloalkyl. In some embodiments, R7 aryl. In some embodiments, R7 is heteroaryl.
NH2, ¨NO2, ¨CN, C1-6 alkyl, C1-6 alkoxy, C3-8 cycloalkyl, heterocyclyl, aryl, or heteroaryl. In some embodiments, R7 is H. In some embodiments, R7 is halogen. In some embodiments, R7 is ¨OH. In some embodiments, R7 is ¨NH2. In some embodiments, R7 is ¨NO2. In some embodiments, R7 is ¨CN. In some embodiments, R7 is C1-6 alkyl. In some embodiments, R7 is C1-6 alkoxy. In some embodiments, R7 is C3-8 cycloalkyl. In some embodiments, R7 is heterocyclyl. In some embodiments, R7 is C3-8 cycloalkyl. In some embodiments, R7 aryl. In some embodiments, R7 is heteroaryl.
[0094] In other embodiments of the compounds of Formula I, Rs is¨N(R9)C(0)Rio, ¨
N(R9)C(0)0Rio, ¨N(R9)C(0)N(R9)(Rio), ¨N(R9)C(0)N(R9)(Ri 1), ¨N(R9)S(0)2Rio, ¨
N(R9)S(0)2N(R9)(Rio), ¨S (0)2Rio, ¨N(R9)(Rio), ¨OR io, ¨CF 3, ¨CHF2, ¨Rio, ¨N(R9)C(0)R 1, ¨N(R9)(Rii) or halogen. In another embodiment, Rs is¨N(R9)C(0)Rio. In another embodiment, Rs is ¨N(R9)C(0)0Rio. In another embodiment, Rs is¨N(R9)C(0)N(R9)(Rio). In another embodiment, Rs is ¨N(R9)C(0)N(R9)(Rii). In another embodiment, Rs is ¨
N(R9)S(0)2Rio. In another embodiment, Rs is ¨N(R9)S(0)2N(R9)(Rio). In another embodiment, Rs is ¨S(0)2Rio. In another embodiment, Rs is ¨N(R9)(Rio). In another embodiment, Rs is ¨0Rio. In another embodiment, Rs is ¨CF3. In another embodiment, Rs is ¨CHF2. In another embodiment, R8 is ¨Rio. In another embodiment, R8 is ¨N(R9)C(0)Rii. In another embodiment, R8 is ¨N(R9)(R11). In another embodiment, R8 is halogen.
N(R9)C(0)0Rio, ¨N(R9)C(0)N(R9)(Rio), ¨N(R9)C(0)N(R9)(Ri 1), ¨N(R9)S(0)2Rio, ¨
N(R9)S(0)2N(R9)(Rio), ¨S (0)2Rio, ¨N(R9)(Rio), ¨OR io, ¨CF 3, ¨CHF2, ¨Rio, ¨N(R9)C(0)R 1, ¨N(R9)(Rii) or halogen. In another embodiment, Rs is¨N(R9)C(0)Rio. In another embodiment, Rs is ¨N(R9)C(0)0Rio. In another embodiment, Rs is¨N(R9)C(0)N(R9)(Rio). In another embodiment, Rs is ¨N(R9)C(0)N(R9)(Rii). In another embodiment, Rs is ¨
N(R9)S(0)2Rio. In another embodiment, Rs is ¨N(R9)S(0)2N(R9)(Rio). In another embodiment, Rs is ¨S(0)2Rio. In another embodiment, Rs is ¨N(R9)(Rio). In another embodiment, Rs is ¨0Rio. In another embodiment, Rs is ¨CF3. In another embodiment, Rs is ¨CHF2. In another embodiment, R8 is ¨Rio. In another embodiment, R8 is ¨N(R9)C(0)Rii. In another embodiment, R8 is ¨N(R9)(R11). In another embodiment, R8 is halogen.
[0095] In other embodiments of the compounds of Formula I, two R8 with the atoms they are attached form a C4-8 cycloalkyl or heterocyclyl. In some embodiments, two R8 with the atoms they are attached form a C4-8 cycloalkyl. In some embodiments, two R8 with the atoms they are attached form a heterocyclyl. In some embodiments, two R8 with the atoms they are attached form a C4-8 cycloalkyl optionally substituted with one or more R12.
In some embodiments, two R8 with the atoms they are attached form a heterocyclyl optionally substituted with one or more R12.
In some embodiments, two R8 with the atoms they are attached form a heterocyclyl optionally substituted with one or more R12.
[0096] In some embodiments of the compounds of Formula I, R9 is ¨H, C1-6 alkyl, C3-8 cycloalkyl, or heterocyclyl. In another embodiment, R9 is ¨H. In another embodiment, R9 is C1-6 alkyl. In another embodiment, R9 is C3-8 cycloalkyl. In another embodiment, R9 is heterocyclyl. In another embodiment, R9 is C1-6 alkyl optionally substituted with one or more R13. In another embodiment, R9 is C3-8 cycloalkyl optionally substituted with one or more R13.
In another embodiment, R9 is heterocyclyl optionally substituted with one or more R13.
In another embodiment, R9 is heterocyclyl optionally substituted with one or more R13.
[0097] In some embodiments of the compounds of Formula I, Rio is ¨H, C1-6 alkyl, C3-8 cycloalkyl, or heterocyclyl. In another embodiment, Rio is ¨H. In another embodiment, Rio is C1-6 alkyl. In another embodiment, Rio is C3-8 cycloalkyl. In another embodiment, Rio is heterocyclyl. In another embodiment, Rio is C1-6 alkyl optionally substituted with one or more R13. In another embodiment, Rio is C3-8 cycloalkyl optionally substituted with one or more R13.
In another embodiment, Rio is heterocyclyl optionally substituted with one or more R13.
In another embodiment, Rio is heterocyclyl optionally substituted with one or more R13.
[0098] In other embodiments of the compounds of Formula I, R9 and Rio when taken together with the atom to which they are each attached form a heterocycle ring. In another mebodiment, R9 and Rio when taken together with the atom to which they are each attached form a heterocycle ring optionally substituted with one or more R14.
[0099] In other embodiments of the compounds of Formula I, Rii is aryl, C3-8 cycloalkyl, heterocyclyl, or heteroaryl. In another embodiment, Rii is aryl. In another embodiment, Rii is heteroaryl. In another embodiment, Rii is C3-8 cycloalkyl. In another embodiment, Rii is heterocyclyl. In another embodiment, Rii is aryl optionally substituted with one or more R18.
In another embodiment, Rii is heteroaryl optionally substituted with one or more R18. In another embodiment, Rii is C3-8 cycloalkyl optionally substituted with one or more R19. In another embodiment, Rii is heterocyclyl optionally substituted with one or more R19.
In another embodiment, Rii is heteroaryl optionally substituted with one or more R18. In another embodiment, Rii is C3-8 cycloalkyl optionally substituted with one or more R19. In another embodiment, Rii is heterocyclyl optionally substituted with one or more R19.
[0100] In other embodiments of the compounds of Formula I, each R12 is C1-6 alkyl, C3-6 cycloalkyl, ¨0R2o, ¨C(0)R2o, ¨C(0)0R20, ¨S(0)2R2o, or oxo. In another embodiment, R12 is C1-6 alkyl. In another embodiment, R12 is C3-6 cycloalkyl. In another embodiment, R12 is ¨
OR2o. In another embodiment, R12 is ¨C(0)R2o. In another embodiment, R12 is ¨C(0)0R2o.
In another embodiment, R12 is ¨S(0)2R2o. In another embodiment, R12 is oxo. In other embodiments of the compounds of Formula I, two R12 on the same carbon are taken together to form a C3-6 cycloalkyl.
OR2o. In another embodiment, R12 is ¨C(0)R2o. In another embodiment, R12 is ¨C(0)0R2o.
In another embodiment, R12 is ¨S(0)2R2o. In another embodiment, R12 is oxo. In other embodiments of the compounds of Formula I, two R12 on the same carbon are taken together to form a C3-6 cycloalkyl.
[0101] In some embodiments of the compounds of Formula I, R13 is H, halogen, ¨CN, Cl-6 alkyl, ¨0R20, ¨C(0)2R2o, C3-8 cycloalkyl, heterocyclyl, heteroaryl, aryl, or ¨C(0)N(R22)(R22).
In another embodiment, R13 is H. In another embodiment, R13 is halogen. In another embodiment, R13 is ¨CN. In another embodiment, R13 is ¨0R20. In another embodiment, R13 is ¨C(0)2R2o. In another embodiment, R13 is ¨C(0)N(R22)(R22). In another embodiment, R13 is aryl. In another embodiment, R13 is heterocyclyl. In another embodiment, R13 is C1-6 alkyl.
In another embodiment, R13 is C3-8 cycloalkyl. In another embodiment, R13 is aryl optionally substituted with one or more R15. In another embodiment, R13 is heterocyclyl ptionally substituted with one or more R15. In another embodiment, R13 is C1-6 alkyl ptionally substituted with one or more R15. In another embodiment, R13 is C3-8 cycloalkyl ptionally substituted with one or more R15.
In another embodiment, R13 is H. In another embodiment, R13 is halogen. In another embodiment, R13 is ¨CN. In another embodiment, R13 is ¨0R20. In another embodiment, R13 is ¨C(0)2R2o. In another embodiment, R13 is ¨C(0)N(R22)(R22). In another embodiment, R13 is aryl. In another embodiment, R13 is heterocyclyl. In another embodiment, R13 is C1-6 alkyl.
In another embodiment, R13 is C3-8 cycloalkyl. In another embodiment, R13 is aryl optionally substituted with one or more R15. In another embodiment, R13 is heterocyclyl ptionally substituted with one or more R15. In another embodiment, R13 is C1-6 alkyl ptionally substituted with one or more R15. In another embodiment, R13 is C3-8 cycloalkyl ptionally substituted with one or more R15.
[0102] In some embodiments of the compounds of Formula I, R14 is independently ¨
C(0)0R20, ¨C(0)R2o, oxo, C1-6 alkyl, heterocycle, C3-6 cycloalkyl, or aryl. In another embodiment, R14 is¨C(0)0R20. In another embodiment, R14 is oxo. In another embodiment, R14 is C1-6 alkyl. In another embodiment, R14 is heterocycle. In another embodiment, R14 is C3-6 cycloalkyl. In another embodiment, R14 is C3-6 aryl. In another embodiment, R14 is C1-6 alkyl optionally substituted with one or more R16. In another embodiment, R14 is heterocycle optionally substituted with one or more R16. In another embodiment, R14 is C3-6 cycloalkyl optionally substituted with one or more R16. In another embodiment, R14 is C3-6 aryl optionally substituted with one or more R16.
C(0)0R20, ¨C(0)R2o, oxo, C1-6 alkyl, heterocycle, C3-6 cycloalkyl, or aryl. In another embodiment, R14 is¨C(0)0R20. In another embodiment, R14 is oxo. In another embodiment, R14 is C1-6 alkyl. In another embodiment, R14 is heterocycle. In another embodiment, R14 is C3-6 cycloalkyl. In another embodiment, R14 is C3-6 aryl. In another embodiment, R14 is C1-6 alkyl optionally substituted with one or more R16. In another embodiment, R14 is heterocycle optionally substituted with one or more R16. In another embodiment, R14 is C3-6 cycloalkyl optionally substituted with one or more R16. In another embodiment, R14 is C3-6 aryl optionally substituted with one or more R16.
[0103] In some embodiments of the compounds of Formula I, Ri5 is H, C1-6 alkyl, C1-6 alkoxy, heteroaryl, aryl, ¨N(R22)(R22), ¨N(R22)C(0)0R22, or ¨N(R22)C(0)¨U¨N(R22)¨Z. In one embodiment, Ri5 is H. In one embodiment, Ri5 is C1-6 alkyl. In one embodiment, Ri5 is C1-6 alkoxy. In one embodiment, Ri5 is heteroaryl. In one embodiment, Ri5 is aryl. In one embodiment, R15 is ¨N(R22)(R22). In one embodiment, R15 is ¨N(R.22)C(0)0R22.
In one embodiment, R15 is ¨N(R22)C(0)¨U¨N(R22)¨Z.
In one embodiment, R15 is ¨N(R22)C(0)¨U¨N(R22)¨Z.
[0104] In other embodiments of the compounds of Formula I, U is ¨(CH2)p¨, ¨(CH2)p¨Ar¨
,¨CH=CH(CH2)p¨, or heterocyclyl. In another embodiment, U is ¨(CH2)p¨. In another embodiment, U is ¨(CH2)p¨Ar¨. In another embodiment, U is ¨CH=CH(CH2)p¨. In another embodiment, U is heterocyclyl.
,¨CH=CH(CH2)p¨, or heterocyclyl. In another embodiment, U is ¨(CH2)p¨. In another embodiment, U is ¨(CH2)p¨Ar¨. In another embodiment, U is ¨CH=CH(CH2)p¨. In another embodiment, U is heterocyclyl.
[0105] In some embodiments of the compounds of Formula I, Z is ¨R22 or N(R22)(R22). In other embodiments, Z is ¨R22. In other embodiments, Z is ¨C(0)¨U¨
N(R22)(R22).
N(R22)(R22).
[0106] In some embodiments of the compounds of Formula I, R16 is C3-8 cycloalkyl, heterocyclyl, heteroaryl, or aryl. In another embodiment, R16 is C3-8 cycloalkyl. In another embodiment, R16 is heterocyclyl. In another embodiment, R16 is heteroaryl. In another embodiment, R16 is aryl optionally substituted with one or more R17. In another embodiment, R16 is C3-8 cycloalkyl optionally substituted with one or more R17. In another embodiment, R16 is heterocyclyl optionally substituted with one or more R17. In another embodiment, R16 is heteroaryl optionally substituted with one or more R17. In another embodiment, R16 is aryl optionally substituted with one or more R17.
[0107] In some embodiments of the compounds of Formula I, R17 is independently ¨0R22, ¨N(R22)(R22), or ¨N(R22)C(0)¨V¨N(R22)¨E. In one embodiment, R17 is ¨0R22. In one embodiment, R17 is¨N(R22)(R22). In one embodiment, R17 is ¨N(R22)C(0)¨V¨N(R22)¨E.
[0108] In other embodiments of the compounds of Formula I, V is ¨(CH2)n¨, ¨(CH2)n¨Ar¨
, or ¨CH=CH(CH2)n¨. In one embodiment, R17 is ¨(CH2)n¨. In one embodiment, R17 is ¨
(CH2)n¨Ar¨. In one embodiment, R17 is ¨CH=CH(CH2)n¨. In one embodiment, Ar is aryl.
, or ¨CH=CH(CH2)n¨. In one embodiment, R17 is ¨(CH2)n¨. In one embodiment, R17 is ¨
(CH2)n¨Ar¨. In one embodiment, R17 is ¨CH=CH(CH2)n¨. In one embodiment, Ar is aryl.
[0109] In some embodiments of the compounds of Formula I, E is ¨R22 or N(R22)(R22). In one embodiment, E is ¨R22. In one embodiment, E is ¨C(0)¨V¨N(R22)(R22).
1 10] In some embodiments of the compounds of Formula I, R18 is halogen, C1-6 alkyl, C3-6 cycloalkyl, ¨0R2o, ¨N(R2o)(R21), ¨C(0)R2o, oxo, ¨N(R22)C(0)0R22, ¨N(R22)C(0)¨Q¨
N(R22)¨F, or ¨N(R22)¨Q¨N(R22)¨F. In another embodiment, R18 is halogen. In another embodiment, R18 is C1-6 alkyl. In another embodiment, R18 is C3-6 cycloalkyl.
In another embodiment, R18 is ¨0R20. In another embodiment, R18 is ¨N(R20)(R21). In another embodiment, R18 is ¨C(0)R20. In another embodiment, R18 is oxo. In another embodiment, R18 is ¨N(R22)C(0)0R22. In another embodiment, R18 is ¨N(R22)C(0)¨Q¨N(R22)¨F.
In another embodiment, R18 is¨N(R22)¨Q¨N(R22)¨F.
[0111] In some embodiments of the compounds of Formula I, two R18 when on adjacent atoms may be taken together with the atoms to which they are each attached to form a heterocyclic group. In another embodiment, two R18 when on adjacent atoms may be taken together with the atoms to which they are each attached to form a heterocyclic group optionally substituted with ¨0R21 or oxo.
[0112] In other embodiments of the compounds of Formula I, Q is ¨CH=CH(CH2)m¨, ¨
(CH2)m¨, ¨(CH20)m¨, ¨(CH2)m¨Ar¨, or ¨(CH2CH20)0¨(CH2)m¨. In another embodiment, Q is ¨CH=CH(CH2)m¨. In another embodiment, Q is ¨(CH2)m¨. In another embodiment, Q
is ¨
(CH2CH20)0¨CH2CH2¨. In another embodiment, Q is ¨(CH20)m¨. In another embodiment, Q
is ¨(CH2)m¨Ar¨. Yet in another embodiment, Q is ¨(CH2CH20)0¨(CH2)m.
[0113] In other embodiments of the compounds of Formula I, F is H, C1-6 alkyl, aryl, heteroaryl, ¨C(0)¨Q¨R22, or ¨C(0)¨Q¨N(R22)(R22). In another embodiment, F is H. In another embodiment, F is C1-6 alkyl. In another embodiment, F is ¨C(0)¨Q¨N(R22)(R22). In another embodiment, F is aryl. In another embodiment, F is heteroaryl. In another embodiment, F is ¨C(0)¨Q¨R22.
[0114] In other embodiments of the compounds of Formula I, F is H, C1-6 alkyl, aryl, heteroaryl, wherein the alkyl, aryl, or heteroaryl is optionally substituted with one or more R22.
In another embodiment, F is H. In another embodiment, F is C1-6 alkyl, wherein the alkyl is optionally substituted with one or more R22. In another embodiment, F is ¨C(0)¨Q¨
N(R22)(R22). In another embodiment, F is aryl, wherein the aryl is optionally substituted with one or more R22. In another embodiment, F is heteroaryl, wherein the heteroaryl is optionally substituted with one or more R22. In another embodiment, F is ¨C(0)¨Q¨R22 [0115] In some embodiments of the compounds of Formula I, R19 is ¨H, halogen, ¨OH, ¨
NH2, oxo, ¨C(0)R2o, ¨0R22, C3-6 cycloalkyl, or C1-6 alkyl. In one embodiment, R19 is ¨H. In one embodiment, R19 is halogen. In one embodiment, R19 is ¨OH. In one embodiment, R19 is ¨NH2. In one embodiment, R19 is oxo. In one embodiment, R19 is ¨C(0)R20. In one embodiment, R19 is ¨0R22. In one embodiment, R19 is C3-6 cycloalkyl. In one embodiment, R19 is C1-6 alkyl.
[0116] In some embodiments of the compounds of Formula I, two R19 when on adjacent atoms may be taken together with the atoms to which they are each attached to form an aryl group. In one embodiment, two R19 when on adjacent atoms may be taken together with the atoms to which they are each attached to form an aryl group optionally substituted with one or more R22.
[0117] In some embodiments of the compounds of Formula I, Rzo is ¨H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, heterocyclyl, aryl, or heteroaryl. In another embodiment, Rzo is ¨H. In another embodiment, Rzo is C1-6 alkyl. In another embodiment, Rzo is C2-6 alkenyl.
In another embodiment, Rzo is C2-6 alkynyl. In another embodiment, Rzo is C3-8 cycloalkyl. In another embodiment, Rzo is heterocyclyl. In another embodiment, Rzo is aryl.
In another embodiment, Rzo is heteroaryl. In another embodiment, Rzo is C1-6 alkyl optionally substituted with one or more H, halogen, ¨CN, ¨OH, C1-6 alkyl, C1-6 alkoxy, C3-8 cycloalkyl, heterocyclyl, heteroaryl, or aryl. In another embodiment, Rzo is C2-6 alkenyl optionally substituted with one or more H, halogen, ¨CN, ¨OH, C1-6 alkyl, C1-6 alkoxy, C3-8 cycloalkyl, heterocyclyl, heteroaryl, or aryl. In another embodiment, Rzo is C2-6 alkynyl optionally substituted with one or more H, halogen, ¨CN, ¨OH, C1-6 alkyl, C1-6 alkoxy, C3-8 cycloalkyl, heterocyclyl, heteroaryl, or aryl. In another embodiment, Rzo is C3-8 cycloalkyl optionally substituted with one or more H, halogen, ¨CN, ¨OH, C1-6 alkyl, C1-6 alkoxy, C3-8 cycloalkyl, heterocyclyl, heteroaryl, or aryl. In another embodiment, Rzo is heterocyclyl optionally substituted with one or more H, halogen, ¨CN, ¨OH, C1-6 alkyl, C1-6 alkoxy, C3-8 cycloalkyl, heterocyclyl, heteroaryl, or aryl. In another embodiment, Rzo is aryl. In another embodiment, Rzo is heteroaryl optionally substituted with one or more H, halogen, ¨CN, ¨OH, C1-6 alkyl, C1-6 alkoxy, C3-8 cycloalkyl, heterocyclyl, heteroaryl, or aryl.
[0118] In other embodiments of the compounds of Formula I, R21 is ¨H, C1-6 alkyl, or ¨
C(0)R22. In one embodiment, R21 is ¨H. In one embodiment, R21 is C1-6 alkyl.
In one embodiment, R21 is ¨C(0)R22.
[0119] In other embodiment of the compounds of Formula I, R22 is ¨H, C1-6 alkyl, C1-6 alkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, heterocyclyl, aryl, or heteroaryl. In another embodiment, R22 is ¨H. In another embodiment, R22 is C1-6 alkyl. In another embodiment, R22 is C1-6 alkoxy. In another embodiment, R22 is C2-6 alkenyl. In another embodiment, R22 is C2-6 alkynyl. In another embodiment, R22 is C3-8 cycloalkyl. In another embodiment, R22 is heterocyclyl. In another embodiment, R22 is aryl. In another embodiment, R22 is heteroaryl.
[0120] In one embodiment, p is 1, 2, 3, or 4. In another embodiment p is 1, 2, or 3. In another embodiment p is 1 or 2. In another embodiment p is 1. In another embodiment p is 2.
In another embodiment p is 3. In another embodiment p is 4.
[0121] In one embodiment, n is 1, 2, 3, or 4. In another embodiment n is 1, 2, or 3. In another embodiment n is 1 or 2. In another embodiment n is 1. In another embodiment n is 2.
In another embodiment n is 3. In another embodiment n is 4.
[0122] In one embodiment, m is 1, 2, 3, or 4. In another embodiment m is 1, 2, or 3. In another embodiment m is 1 or 2. In another embodiment m is 1. In another embodiment m is 2. In another embodiment m is 3. In another embodiment m is 4.
[0123] In one embodiment, o is 1, 2, or 3. In another embodiment o is 1 or 2. In another embodiment o is 1. In another embodiment o is 2. In another embodiment o is 3.
[0124] In some embodiments of the compounds of Formula I, Ri is ¨N(R5)C(0)R6, W is ¨
0¨, R2 is H, R3 is C1-6 alkyl, R4 is ¨H, G is ¨NH¨, Ring Al is a 5-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more Rs [0125] In some embodiments of the compounds of Formula I, Ri is ¨N(R5)C(0)R6, W is ¨
0¨, R2 is H, R3 is C1-6 alkyl, R4 is ¨H, G is ¨NH¨, Ring Al is a 6-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more Rs [0126] In some embodiments of the compounds of Formula I, Ri is ¨N(R5)C(0)R6, W is ¨
NH¨, R2 is H, R3 is C1-6 alkyl, R4 is ¨H, G is ¨NH¨, Ring Al is a 5-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more Rs [0127] In some embodiments of the compounds of Formula I, Ri is ¨N(R5)C(0)R6, W is ¨
NH¨, R2 is H, R3 is C1-6 alkyl, R4 is ¨H, G is ¨NH¨, Ring Al is a 6-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more Rs [0128] In some embodiments of the compounds of Formula I, Ri is ¨N(R5)C(0)R6, W is ¨
N(C1-6 alkyl)¨, R2 is H, R3 is C1-6 alkyl, R4 is ¨H, G is ¨NH¨, Ring Al is a 5-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more Rs [0129] In some embodiments of the compounds of Formula I, Ri is ¨N(R5)C(0)R6, W is ¨
N(C1-6 alkyl)¨, R2 is H, R3 is C1-6 alkyl, R4 is ¨H, G is ¨NH¨, Ring Al is a 6-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more Rs [0130] In some embodiments of the compounds of Formula I, Ri is ¨N(R5)C(0)R6, W is ¨
N(C3-8 cycloalkyl)¨, R2 is H, R3 is C1-6 alkyl, R4 is ¨H, G is ¨NH¨, Ring Al is a 5-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more Rs [0131] In some embodiments of the compounds of Formula I, Ri is ¨N(R5)C(0)R6, W is ¨
N(C3-8 cycloalkyl)¨, R2 is H, R3 is C1-6 alkyl, R4 is ¨H, G is ¨NH¨, Ring Al is a 6-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more Rs [0132] In some embodiments of the compounds of Formula I, Ri is ¨N(R5)C(0)R6, W is ¨N(ary1)¨, R2 is H, R3 is C1-6 alkyl, R4 is ¨H, G is ¨NH¨, Ring Al is a 5-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more R8 [0133] In some embodiments of the compounds of Formula I, Ri is ¨N(R5)C(0)R6, W is ¨N(ary1)¨, R2 is H, R3 is C1-6 alkyl, R4 is ¨H, G is ¨NH¨, Ring Al is a 6-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more R8 [0134] In some embodiments of the compounds of Formula I, Ri is ¨N(R5)C(0)R6, W is ¨
N(heteroary1)¨, R2 is H, R3 is C1-6 alkyl, R4 is ¨H, G is ¨NH¨, Ring Al is a 5-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more Rs [0135] In some embodiments of the compounds of Formula I, Ri is ¨N(R5)C(0)R6, W is ¨
N(heteroary1)¨, R2 is H, R3 is C1-6 alkyl, R4 is ¨H, G is ¨NH¨, Ring Al is a 6-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more Rs [0136] In some embodiments of the compounds of Formula I, Ri is ¨C(0)N(R5)(R6), W is ¨0¨, R2 is H, R3 is C1-6 alkyl, R4 is ¨H, G is ¨NH¨, Ring Al is a 5-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more Rs [0137] In some embodiments of the compounds of Formula I, Ri is ¨C(0)N(R5)(R6), W is ¨0¨, R2 is H, R3 is C1-6 alkyl, R4 is ¨H, G is ¨NH¨, Ring Al is a 6-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more Rs [0138] In some embodiments of the compounds of Formula I, Ri is ¨S(0)2N(R5)(R6), W is ¨0¨, R2 is H, R3 is C1-6 alkyl, R4 is ¨H, G is ¨NH¨, Ring Al is a 5-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more Rs [0139] In some embodiments of the compounds of Formula I, Ri is ¨S(0)2N(R5)(R6), W is ¨0¨, R2 is H, R3 is C1-6 alkyl, R4 is ¨H, G is ¨NH¨, Ring Al is a 6-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more Rs [0140] In some embodiments of the compounds of Formula I, Ri is -N(R5)S(0)2R6, W is ¨
0¨, R2 is H, R3 is C1-6 alkyl, R4 is ¨H, G is ¨NH¨, Ring Al is a 5-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more Rs [0141] In some embodiments of the compounds of Formula I, Ri is -N(R5)S(0)2R6, W is ¨
0¨, R2 is H, R3 is C1-6 alkyl, R4 is ¨H, G is ¨NH¨, Ring Al is a 6-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more Rs [0142] In some embodiments of the compounds of Formula I, Ri is heteroaryl, W is ¨0¨, R2 is H, R3 is C1-6 alkyl, R4 is ¨H, G is ¨NH¨, Ring Al is a 5-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more Rs [0143] In some embodiments of the compounds of Formula I, Ri is heteroaryl wherein heteroaryl is optionally substituted with one or more R7, W is ¨0¨, R2 is H, R3 is C1-6 alkyl, R4 is ¨H, G is ¨NH¨, Ring Al is a 5-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more R8 [0144] In some embodiments of the compounds of Formula I, Ri is heteroaryl, W is ¨0¨, R2 is H, R3 is C1-6 alkyl, R4 is ¨H, G is ¨NH¨, Ring Al is a 6-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more Rs [0145] In some embodiments of the compounds of Formula I, Ri is heteroaryl wherein heteroaryl is optionally substituted with one or more R7, W is ¨0¨, R2 is H, R3 is C1-6 alkyl, R4 is ¨H, G is ¨NH¨, Ring Al is a 6-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more R8 [0146] In some embodiments of the compounds of Formula I, Ri is ¨N(R5)C(0)R6, W is ¨
0¨, R2 is H, R3 is C1-6 alkyl, R4 is ¨H, G is a bond, Ring Al is a 5-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more Rs [0147] In some embodiments of the compounds of Formula I, Ri is ¨N(R5)C(0)R6, W is ¨
0¨, R2 is H, R3 is C1-6 alkyl, R4 is ¨H, G is a bond, Ring Al is a 6-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more Rs [0148] In some embodiments of the compounds of Formula I, Ri is ¨N(R5)C(0)R6, W is ¨
NH¨, R2 is H, R3 is C1-6 alkyl, R4 is ¨H, G is a bond, Ring Al is a 5-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more Rs [0149] In some embodiments of the compounds of Formula I, Ri is ¨N(R5)C(0)R6, W is ¨
NH¨, R2 is H, R3 is C1-6 alkyl, R4 is ¨H, G is a bond, Ring Al is a 6-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more R8 [0150] In some embodiments of the compounds of Formula I, Ri is ¨N(R5)C(0)R6, W is ¨
N(C1-6 alkyl)¨, R2 is H, R3 is C1-6 alkyl, R4 is ¨H, G is a bond, Ring Al is a 5-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more Rs [0151] In some embodiments of the compounds of Formula I, Ri is ¨N(R5)C(0)R6, W is ¨
N(C1-6 alkyl)¨, R2 is H, R3 is C1-6 alkyl, R4 is ¨H, G is a bond, Ring Al is a 6-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more Rs [0152] In some embodiments of the compounds of Formula I, Ri is ¨N(R5)C(0)R6, W is ¨
N(C3-8 cycloalkyl)¨, R2 is H, R3 is C1-6 alkyl, R4 is ¨H, G is a bond, Ring Al is a 5-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more Rs [0153] In some embodiments of the compounds of Formula I, Ri is ¨N(R5)C(0)R6, W is ¨
N(C3-8 cycloalkyl)¨, R2 is H, R3 is C1-6 alkyl, R4 is ¨H, G is a bond, Ring Al is a 6-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more Rs [0154] In some embodiments of the compounds of Formula I, Ri is ¨N(R5)C(0)R6, W is ¨N(ary1)¨, R2 is H, R3 is C1-6 alkyl, R4 is ¨H, G is a bond, Ring Al is a 5-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more R8 [0155] In some embodiments of the compounds of Formula I, Ri is ¨N(R5)C(0)R6, W is ¨N(ary1)¨, R2 is H, R3 is C1-6 alkyl, R4 is ¨H, G is a bond, Ring Al is a 6-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more R8 [0156] In some embodiments of the compounds of Formula I, Ri is ¨N(R5)C(0)R6, W is ¨
N(heteroary1)¨, R2 is H, R3 is C1-6 alkyl, R4 is ¨H, G is a bond, Ring Al is a 5-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more Rs [0157] In some embodiments of the compounds of Formula I, Ri is ¨N(R5)C(0)R6, W is ¨
N(heteroary1)¨, R2 is H, R3 is C1-6 alkyl, R4 is ¨H, G is a bond, Ring Al is a 6-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more Rs [0158] In some embodiments of the compounds of Formula I, Ri is ¨C(0)N(R5)(R6), W is ¨0¨, R2 is H, R3 is C1-6 alkyl, R4 is ¨H, G is a bond, Ring Al is a 5-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more Rs [0159] In some embodiments of the compounds of Formula I, Ri is ¨C(0)N(R5)(R6), W is ¨0¨, R2 is H, R3 is C1-6 alkyl, R4 is ¨H, G is a bond, Ring Al is a 6-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more Rs [0160] In some embodiments of the compounds of Formula I, Ri is ¨S(0)2N(R5)(R6), W is ¨0¨, R2 is H, R3 is C1-6 alkyl, R4 is ¨H, G is a bond, Ring Al is a 5-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more Rs [0161] In some embodiments of the compounds of Formula I, Ri is ¨S(0)2N(R5)(R6), W is ¨0¨, R2 is H, R3 is C1-6 alkyl, R4 is ¨H, G is a bond, Ring Al is a 6-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more Rs [0162] In some embodiments of the compounds of Formula I, Ri is ¨N(R5)C(0)R6, W is ¨
0¨, R2 is H, R3 is C1-6 alkyl, R4 is ¨H, G is ¨0¨, Ring Al is a 5-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more Rs [0163] In some embodiments of the compounds of Formula I, Ri is ¨N(R5)C(0)R6, W is ¨
0¨, R2 is H, R3 is C1-6 alkyl, R4 is ¨H, G is ¨0¨, Ring Al is a 6-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more Rs [0164] In some embodiments of the compounds of Formula I, Ri is ¨N(R5)C(0)R6, W is ¨
N(heteroary1)¨, R2 is H, R3 is C1-6 alkyl, R4 is ¨H, G is ¨0¨, Ring Al is a 6-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more Rs [0165] In some embodiments of the compounds of Formula I, Ri is ¨C(0)N(R5)(R6), W is ¨0¨, R2 is H, R3 is C1-6 alkyl, R4 is ¨H, G is ¨0¨, Ring Al is a 5-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more Rs [0166] In some embodiments of the compounds of Formula I, Ri is ¨S(0)2N(R5)(R6), W is ¨0¨, R2 is H, R3 is C1-6 alkyl, R4 is ¨H, G is ¨0¨, Ring Al is a 5-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more Rs [0167] In some embodiments of the compounds of Formula I, Ri is ¨S(0)2N(R5)(R6), W is ¨0¨, R2 is H, R3 is C1-6 alkyl, R4 is ¨H, G is ¨0¨, Ring Al is a 6-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more Rs [0168] In some embodiments of the compounds of Formula I, Ri is ¨N(R5)C(0)R6, W is ¨
0¨, R2 is H, R3 is C1-6 alkyl, R4 is ¨H, G is ¨N(C1-6 alkyl)¨, Ring Al is a 5-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more Rs [0169] In some embodiments of the compounds of Formula I, Ri is ¨N(R5)C(0)R6, W is ¨
0¨, R2 is H, R3 is C1-6 alkyl, R4 is ¨H, G is ¨N(C1-6 alkyl)¨, Ring Al is a 6-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more Rs [0170] In some embodiments of the compounds of Formula I, Ri is ¨N(R5)C(0)R6, W is ¨
N(heteroary1)¨, R2 is H, R3 is C1-6 alkyl, R4 is ¨H, G is ¨N(C1-6 alkyl)¨, Ring Al is a 6-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more Rs [0171] In some embodiments of the compounds of Formula I, Ri is ¨C(0)N(R5)(R6), W is ¨0¨, R2 is H, R3 is C1-6 alkyl, R4 is ¨H, G is ¨N(C1-6 alkyl)¨, Ring Al is a 5-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more Rs [0172] In some embodiments of the compounds of Formula I, Ri is ¨S(0)2N(R5)(R6), W is ¨0¨, R2 is H, R3 is C1-6 alkyl, R4 is ¨H, G is ¨N(C1-6 alkyl)¨, Ring Al is a 5-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more Rs [0173] In some embodiments of the compounds of Formula I, Ri is ¨S(0)2N(R5)(R6), W is ¨0¨, R2 is H, R3 is C1-6 alkyl, R4 is ¨H, G is ¨N(C1-6 alkyl)¨, Ring Al is a 6-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more Rs [0174] In some embodiments of the compounds of Formula I, Ri is ¨N(R5)C(0)R6, W is ¨
0¨, R2 is H, R3 is C1-6 alkyl, R4 is ¨H, G is ¨NH¨, Ring Al is a 5-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more Rs, Rs is ¨N(R9)C(0)R11, RH is aryl or heteroaryl optionally substituted with one or more R18, R18 is ¨N(R22)C(0)¨Q¨N(R22)¨F, or ¨N(R22)¨Q¨N(R22)¨F.
[0175] In some embodiments of the compounds of Formula I, Ri is ¨N(R5)C(0)R6, W is ¨
0¨, R2 is H, R3 is C1-6 alkyl, R4 is ¨H, G is ¨NH¨, Ring Al is a 6-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more Rs, Rs is ¨N(R9)C(0)R11, RH is aryl or heteroaryl optionally substituted with one or more R18, R18 is ¨N(R22)C(0)¨Q¨N(R22)¨F, or ¨N(R22)¨Q¨N(R22)¨F.
[0176] In some embodiments of the compounds of Formula I, Ri is ¨C(0)N(R5)(R6), W is ¨0¨, R2 is H, R3 is C1-6 alkyl, R4 is ¨H, G is ¨NH¨, Ring Al is a 5-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more Rs,.Rs is ¨N(R9)C(0)Rii, Ru is aryl or heteroaryl optionally substituted with one or more R18, R18 is ¨N(R22)C(0)¨Q¨N(R22)¨F, or ¨N(R22)¨Q¨N(R22)¨F.
[0177] In some embodiments of the compounds of Formula I, Ri is ¨C(0)N(R5)(R6), W is ¨0¨, R2 is H, R3 is C1-6 alkyl, R4 is ¨H, G is ¨NH¨, Ring Al is a 6-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more Rs, Rs is ¨N(R9)C(0)R11, Rii is aryl or heteroaryl optionally substituted with one or more Ris, Ris is ¨N(R22)C(0)¨Q¨N(R22)¨F, or ¨N(R22)¨Q¨N(R22)¨F.
[0178] In some embodiments of the compounds of Formula I, Ri is ¨S(0)2N(R5)(R6), W is ¨0¨, R2 is H, R3 is C1-6 alkyl, R4 is ¨H, G is ¨NH¨, Ring Al is a 5-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more Rs, Rs is ¨N(R9)C(0)R11, Rii is aryl or heteroaryl optionally substituted with one or more Ris, Ris is ¨N(R22)C(0)¨Q¨N(R22)¨F, or ¨N(R22)¨Q¨N(R22)¨F.
[0179] In some embodiments of the compounds of Formula I, Ri is ¨S(0)2N(R5)(R6), W is ¨0¨, R2 is H, R3 is C1-6 alkyl, R4 is ¨H, G is ¨NH¨, Ring Al is a 6-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more Rs, Rs is ¨N(R9)C(0)Rii, Rii is aryl or heteroaryl optionally substituted with one or more Ris, Ris is ¨N(R22)C(0)¨Q¨N(R22)¨F, or ¨N(R22)¨Q¨N(R22)¨F.
[0180] In some embodiments of the compounds of Formula I, Ri is ¨N(R5)C(0)R6, W is ¨
0¨, R2 is H, R3 is C1-6 alkyl, R4 is ¨H, G is ¨NH¨, Ring Al is a 5-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more Rs, Rs is ¨N(R9)C(0)Rio, Rio is C1-6 alkyl, C3-8 cycloalkyl, or heterocyclyl optionally substituted with one or more R13, R13 is alkyl optionally substituted with one or more R15, Ris is N(R22)C(0)¨U¨N(R22)¨Z.
[0181] In some embodiments of the compounds of Formula I, Ri is ¨N(R5)C(0)R6, W is ¨
0¨, R2 is H, R3 is C1-6 alkyl, R4 is ¨H, G is ¨NH¨, Ring Al is a 6-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more Rs, Rs is ¨N(R9)C(0)Rio, Rio is C1-6 alkyl, C3-8 cycloalkyl, or heterocyclyl optionally substituted with one or more R13, R13 is alkyl optionally substituted with one or more R15, Ris is N(R22)C(0)¨U¨N(R22)¨Z.
[0182] In some embodiments of the compounds of Formula I, Ri is ¨C(0)N(R5)(R6), W is ¨0¨, R2 is H, R3 is C1-6 alkyl, R4 is ¨H, G is ¨NH¨, Ring Al is a 5-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more Rs, Rs is ¨N(R9)C(0)Rio, Rio is C1-6 alkyl, C3-8 cycloalkyl, or heterocyclyl optionally substituted with one or more R13, R13 is alkyl optionally substituted with one or more R15, Ris is N(R22)C(0)¨U¨N(R22)¨Z.
[0183] In some embodiments of the compounds of Formula I, Ri is ¨C(0)N(R5)(R6), W is ¨0¨, R2 is H, R3 is C1-6 alkyl, R4 is ¨H, G is ¨NH¨, Ring Al is a 6-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more Rs, Rs is ¨N(R9)C(0)Rio, Rio is C1-6 alkyl, C3-8 cycloalkyl, or heterocyclyl optionally substituted with one or more R13, R13 is alkyl optionally substituted with one or more R15, Ris is N(R22)C(0)¨U¨N(R22)¨Z.
[0184] In some embodiments of the compounds of Formula I, Ri is ¨S(0)2N(R5)(R6), W is ¨0¨, R2 is H, R3 is C1-6 alkyl, R4 is ¨H, G is ¨NH¨, Ring Al is a 5-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more Rs, Rs is ¨N(R9)C(0)Rio, Rio is C1-6 alkyl, C3-8 cycloalkyl, or heterocyclyl optionally substituted with one or more R13, R13 is alkyl optionally substituted with one or more R15, Ris is N(R22)C(0)¨U¨N(R22)¨Z.
[0185] In some embodiments of the compounds of Formula I, Ri is ¨S(0)2N(R5)(R6), W is ¨0¨, R2 is H, R3 is C1-6 alkyl, R4 is ¨H, G is ¨NH¨, Ring Al is a 6-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more Rs, Rs is ¨N(R9)C(0)Rio, Rio is C1-6 alkyl, C3-8 cycloalkyl, or heterocyclyl optionally substituted with one or more R13, R13 is alkyl optionally substituted with one or more R15, Ris is N(R22)C(0)¨U¨N(R22)¨Z.
[0186] In some embodiments of the compounds of Formula I, Ri is ¨N(R5)C(0)R6, W is ¨
0¨, R2 is H, R3 is C1-6 alkyl, R4 is ¨H, G is ¨NH¨, Ring Al is a 5-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more Rs, Rs is ¨N(R9)C(0)Rio, R9 and Rio are taken together with the atom to which they are each attached form a heterocycle ring optionally substituted with one or more R14, R14 is C1-6 alkyl, heterocycle, C3-6 cycloalkyl, or aryl optionally substituted with one or more R16, R16 is C3-8 cycloalkyl, heterocyclyl, heteroaryl, or aryl optionally substituted with one or more R17, R17 is ¨N(R22)C(0)¨V¨N(R22)¨E.
[0187] In some embodiments of the compounds of Formula I, Ri is ¨N(R5)C(0)R6, W is ¨
0¨, R2 is H, R3 is C1-6 alkyl, R4 is ¨H, G is ¨NH¨, Ring Al is a 6-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more Rs, Rs is ¨N(R9)C(0)Rio, R9 and Rio are taken together with the atom to which they are each attached form a heterocycle ring optionally substituted with one or more R14, R14 is C1-6 alkyl, heterocycle, C3-6 cycloalkyl, or aryl optionally substituted with one or more R16, R16 is C3-8 cycloalkyl, heterocyclyl, heteroaryl, or aryl optionally substituted with one or more R17, R17 is ¨N(R22)C(0)¨V¨N(R22)¨E.
[0188] In some embodiments of the compounds of Formula I, Ri is ¨C(0)N(R5)(R6), W is ¨0¨, R2 is H, R3 is C1-6 alkyl, R4 is ¨H, G is ¨NH¨, Ring Al is a 5-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more Rs, Rs is ¨N(R9)C(0)Rio, R9 and Rio are taken together with the atom to which they are each attached form a heterocycle ring optionally substituted with one or more R14, R14 is C1-6 alkyl, heterocycle, C3-6 cycloalkyl, or aryl optionally substituted with one or more R16, R16 is C3-8 cycloalkyl, heterocyclyl, heteroaryl, or aryl optionally substituted with one or more R17, R17 is ¨N(R22)C(0)¨V¨N(R22)¨E.
[0189] In some embodiments of the compounds of Formula I, Ri is ¨C(0)N(R5)(R6), W is ¨0¨, R2 is H, R3 is C1-6 alkyl, R4 is ¨H, G is ¨NH¨, Ring Al is a 6-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more Rs, Rs is ¨N(R9)C(0)R10, R9 and Rio are taken together with the atom to which they are each attached form a heterocycle ring optionally substituted with one or more R14, R14 is C1-6 alkyl, heterocycle, C3-6 cycloalkyl, or aryl optionally substituted with one or more R16, R16 is C3-8 cycloalkyl, heterocyclyl, heteroaryl, or aryl optionally substituted with one or more R17, R17 is ¨N(R22)C(0)¨V¨N(R22)¨E..
[0190] In some embodiments of the compounds of Formula I, Ri is ¨S(0)2N(R5)(R6), W is ¨0¨, R2 is H, R3 is C1-6 alkyl, R4 is ¨H, G is ¨NH¨, Ring Al is a 5-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more Rs, Rs is ¨N(R9)C(0)R10, R9 and Rio are taken together with the atom to which they are each attached form a heterocycle ring optionally substituted with one or more R14, R14 is C1-6 alkyl, heterocycle, C3-6 cycloalkyl, or aryl optionally substituted with one or more R16, R16 is C3-8 cycloalkyl, heterocyclyl, heteroaryl, or aryl optionally substituted with one or more R17, R17 is ¨N(R22)C(0)¨V¨N(R22)¨E.
[0191] In some embodiments of the compounds of Formula I, Ri is ¨S(0)2N(R5)(R6), W is ¨0¨, R2 is H, R3 is C1-6 alkyl, R4 is ¨H, G is ¨NH¨, Ring Al is a 6-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more Rs, Rs is ¨N(R9)C(0)R10, R9 and Rio are taken together with the atom to which they are each attached form a heterocycle ring optionally substituted with one or more R14, R14 is C1-6 alkyl, heterocycle, C3-6 cycloalkyl, or aryl optionally substituted with one or more R16, R16 is C3-8 cycloalkyl, heterocyclyl, heteroaryl, or aryl optionally substituted with one or more R17, R17 is ¨N(R22)C(0)¨V¨N(R22)¨E.
[0192] In some embodiments of the compounds of Formula I, Ri is ¨N(R5)C(0)R6, W is ¨
0¨, R2 is H, R3 and R4 are taken together with the atom to which they are attached form a C3-8 cycloalkyl or heterocyclyl, G is ¨NH¨, Ring Al is a 6-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more R8 [0193] In some embodiments of the compounds of Formula I, Ri is ¨N(R5)C(0)R6, W is ¨
NH¨, R2 is H, R3 and R4 when taken together with the atom to which they are attached form a C3-8 cycloalkyl or heterocyclyl, G is ¨NH¨, Ring Al is a 5-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more R8 [0194] In some embodiments of the compounds of Formula I, Ri is ¨C(0)N(R5)(R6), W is ¨0¨, R2 is H, R3 and R4 when taken together with the atom to which they are attached form a C3-8 cycloalkyl or heterocyclyl, G is ¨NH¨, Ring Al is a 5-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more R8 [0195] In some embodiments of the compounds of Formula I, Ri is ¨C(0)N(R5)(R6), W is ¨0¨, R2 is H, R3 and R4 when taken together with the atom to which they are attached form a C3-8 cycloalkyl or heterocyclyl, G is ¨NH¨, Ring Al is a 6-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more R8 [0196] In some embodiments of the compounds of Formula I, Ri is ¨S(0)2N(R5)(R6), W is ¨0¨, R2 is H, R3 and R4 when taken together with the atom to which they are attached form a C3-8 cycloalkyl or heterocyclyl, G is ¨NH¨, Ring Al is a 5-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more Rs [0197] In some embodiments of the compounds of Formula I, Ri is ¨S(0)2N(R5)(R6), W is ¨0¨, R2 is H, R3 and R4 when taken together with the atom to which they are attached form a C3-8 cycloalkyl or heterocyclyl, G is ¨NH¨, Ring Al is a 6-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more R8 [0198] Non-limiting illustrative compounds of the present disclosure include:
N,N,5-trimethy1-3-((5 -(2- oxopy rrolidin- 1 -yl)pyridin-3 -yl)amino)-5H-chromeno [4,3-c] py ri dine-8 - carboxami de ;
N,N,5 -trimethy1-3 -(pyri din-3 -ylamino)-5 H-chromeno [4,3 -c] py ri dine- 8-carb oxami de ;
1-(3 -(( 1 - acety1-2,3 -dihy dro- 1 H-pyri do [2,3 -b] [1,4] oxazin-7-y0amino)-5-methyl-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one;
- cy clopropyl-N,N-dimethy1-3-((5 -(2- oxopy rrolidin- 1 -yl)pyridin-3 -yl)amino)-5H-chromeno [4,3 - c] py ri dine- 8 -carb oxami de ;
1-(3 -((5 -(difluoromethoxy )py ri din-3 -yl)amino)-5 -methy1-5 H- chromeno [4,3 -c] pyri din-8 -yl)pyrrolidin-2-one;
N,N,5 -trimethy1-3 -(((S )-9-oxo-6a,7, 8, 9-tetrahy dro-6H-py rido [2,3 -b]
pyrrolo [1,2-d] [1,4] oxazin-2-yl)amino)-5 H- chromeno [4,3 -c] py ri dine- 8- carb oxami de ;
(6aS)-2-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)-6,6a,7,8-tetrahydro-9H-pyrido[2,3-blpyrrolo[1,2-d][1,41oxazin-9-one;
5-cyclopropyl-N,N-dimethy1-3-4(S)-9-oxo-6a,7,8,9-tetrahydro-6H-pyrido[2,3-blpyrrolo[1,2-d][1,4]oxazin-2-yl)amino)-5H-chromeno[4,3-clpyridine-8-carboxamide;
1-(5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-y0cyclopropane-1-carbonitrile;
5-cyclopropyl-N,N-dimethy1-3-(pyridin-3-ylamino)-5H-chromeno[4,3-clpyridine-8-carboxamide;
1-(5-methy1-3-(pyridin-3-ylamino)-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one;
1-methy1-3-(5-((5-methyl-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y1)amino)pyridin-3-y1)imidazolidin-2-one;
N,N,5,6-tetramethy1-3-(pyridin-3-ylamino)-5,6-dihydrobenzo[c][2,6]naphthyridine-8-carboxamide;
N-methyl-N-(5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-y1)amino)pyridin-3-y1)methanesulfonamide;
1-(5-methy1-3-((1-(methylsulfony1)-2,3-dihydro-1H-pyrido[2,3-b][1,4loxazin-7-y0amino)-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one;
1-(3-((5-fluoropyridin-3-y0amino)-5-methyl-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one;
1-(3-41-(cyclopropylsulfony1)-2,3-dihydro-1H-pyrido[2,3-b][1,4loxazin-7-y0amino)-5-methyl-5H-chromeno[4,3-c]pyridin-8-y1)pyrrolidin-2-one;
(S)-2-(((R)-5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)-6,6a,7,8-tetrahydro-9H-pyrido[2,3-blpyrrolo[1,2-d][1,41oxazin-9-one;
(S)-2-(((S)-5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)-6,6a,7,8-tetrahydro-9H-pyrido[2,3-blpyrrolo[1,2-d][1,41oxazin-9-one;
1-(5-methy1-3-((5-(2-oxopyrrolidin-1-yOpyridin-3-y0amino)-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one;
1-(5-methy1-3-(pyrido[2,3-b]pyrazin-7-ylamino)-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one;
1-(3-((1,5-naphthyridin-3-y0amino)-5-methyl-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one;
1-(5-methy1-3-(pyrimidin-5-ylamino)-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one ;
N-cyclopropyl-N-(5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-y1)methanesulfonamide;
1-(5-methy1-3-((1-(methylsulfony1)-1H-pyrrolo[3,2-blpyridin-6-y0amino)-5H-chromeno[4,3-clpyridin-8-y1)pyrrolidin-2-one;
1-(5-methy1-3-41-pivaloy1-2,3-dihydro-1H-pyrido[2,3-b][1,41oxazin-7-y0amino)-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one;
1-(5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-y0imidazolidin-2-one;
1-(3-((2,3-dihydro-[1,4]dioxino[2,3-blpyridin-7-y0amino)-5-methyl-5H-chromeno[4,3-c]pyridin-8-y1)pyrrolidin-2-one;
1-(5-methy1-3-(thiazolo[5,4-blpyridin-6-ylamino)-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one;
1-(3-((1-(cyclopropanecarbony1)-2,3-dihydro-1H-pyrido[2,3-b][1,41oxazin-7-y0amino)-5-methyl-5H-chromeno[4,3-c]pyridin-8-y1)pyrrolidin-2-one;
3-((1-(cyclopropylsulfony1)-2,3-dihydro-1H-pyrido[2,3-b][1,41oxazin-7-y0amino)-N,N,5-trimethyl-5H-chromeno[4,3-c]pyridine-8-carboxamide;
N,N,5-trimethy1-3-41-pivaloy1-2,3-dihydro-1H-pyrido[2,3-b][1,41oxazin-7-y0amino)-5H-chromeno[4,3-c]pyridine-8-carboxamide;
3-((1-(cyclopropanecarbony1)-2,3-dihydro-1H-pyrido[2,3-b][1,41oxazin-7-y0amino)-N,N,5-trimethyl-5H-chromeno[4,3-c]pyridine-8-carboxamide;
3-((1-acety1-2,3-dihydro-1H-pyrido[2,3-b][1,41oxazin-7-y0amino)-N,N,5-trimethyl-5H-chromeno[4,3-c]pyridine-8-carboxamide;
N,N,5-trimethy1-3-((1-(methylsulfony1)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-yl)amino)-5H-chromeno[4,3-c]pyridine-8-carboxamide;
1-(5-methy1-3-((5-(trifluoromethyl)pyridin-3-yl)amino)-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one;
N-(2-methoxy-5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-y0acetamide;
N-(2-methoxy-5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-y1)methanesulfonamide;
1-(3-41-isobutyry1-2,3-dihydro-1H-pyrido[2,3-b][1,41oxazin-7-y0amino)-5-methyl-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one;
(S)-2-((5,5-dimethy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-y0amino)-6,6a,7,8-tetrahydro-9H-pyrido[2,3-blpyrrolo[1,2-d][1,4]oxazin-9-one;
N-(2-methoxy-5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c1pyridin-3-y0amino)pyridin-3-y1)-N-methylmethanesulfonamide;
1-(5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-y0amino)pyridin-3-y1)-3-(thiazol-4-ylmethypimidazolidin-2-one;
methyl 7-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-y1)amino)-2,3-dihydro-1H-pyrido[2,3-b][1,41oxazine-1-carboxylate;
1-(5-methy1-3-((5-(methylsulfonyl)pyridin-3-yl)amino)-5H-chromeno[4,3-c]pyridin-8-y1)pyrrolidin-2-one;
1-(3-((1-(2-hydroxyacety1)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)amino)-5-methy1-5H-chromeno[4,3-c]pyridin-8-y1)pyrrolidin-2-one;
methyl 7-((8-(dimethylcarbamoy1)-5-methy1-5H-chromeno[4,3-c]pyridin-3-yl)amino)-2,3-dihydro-1H-pyrido[2,3-b][1,41oxazine-1-carboxylate;
N-(2-methoxy-5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-y1)-N-methylacetamide;
1-(5,6-dimethy1-3-(pyridin-3-ylamino)-5,6-dihydrobenzo[c][2,61naphthyridin-8-yl)pyrrolidin-2-one;
1-(9-fluoro-5-methy1-3-(pyridin-3-ylamino)-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one;
(6aS)-2-((5,6-dimethy1-8-(2-oxopyrrolidin-1-y1)-5,6-dihydrobenzo[c][2,61naphthyridin-3-y1)amino)-6,6a,7,8-tetrahydro-9H-pyrido[2,3-b]pyrrolo[1,2-d][1,41oxazin-9-one;
methyl 7-((8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazine-1-carboxylate;
(S)-2-((8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)-6,6a,7,8-tetrahydro-9H-pyrido[2,3-b]pyrrolo[1,2-d][1,4]oxazin-9-one;
1-(5-methy1-3-((5-morpholinopyridin-3-y0amino)-5H-chromeno[4,3-c]pyridin-8-yOpyrrolidin-2-one;
1-(3-((1-(2-hydroxy-2-methylpropanoy1)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-yl)amino)-5-methy1-5H-chromeno[4,3-c]pyridin-8-y1)pyrrolidin-2-one;
1-(3-((1-(cyclopropanecarbony1)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)amino)-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one;
1-(3-((1-(methylsulfony1)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)amino)-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one;
(S)-2-((8-(2-oxopyrrolidin-1-yl)spiro[chromeno[4,3-clpyridine-5,3'-oxetan]-3-y0amino)-6,6a,7,8-tetrahydro-9H-pyrido[2,3-blpyrrolo[1,2-d][1,41oxazin-9-one;
(S)-2-((8-(2-oxopyrrolidin-1-yl)spiro[chromeno[4,3-clpyridine-5,11-cyclobutan1-3-y0amino)-6,6a,7,8-tetrahydro-9H-pyrido[2,3-blpyrrolo[1,2-d][1,4]oxazin-9-one;
7-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y1)amino)-1H-pyrido[2,3-b1[1,41oxazin-2(3H)-one;
1-(3-((2,3-dihydro-1H-pyrido[2,3-b][1,41oxazin-7-y0amino)-5-methyl-5H-chromeno[4,3-c]pyridin-8-y1)pyrrolidin-2-one;
1-(5-methy1-3-((5-methylpyridin-3-y0amino)-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one;
(6aS)-2-((9-fluoro-5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-y1)amino)-6,6a,7,8-tetrahydro-9H-pyrido[2,3-blpyrrolo[1,2-d][1,4]oxazin-9-one;
1-(3-((2,3-dihydro-[1,41dioxino[2,3-blpyridin-7-y0amino)-5,6-dimethyl-5,6-dihydrobenzo[c][2,61naphthyridin-8-yOpyrrolidin-2-one;
1-(3-41-(cyclopropylsulfony1)-2,3-dihydro-1H-pyrido[2,3-b][1,41oxazin-7-y0amino)-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one;
1-(3-41-(isopropylsulfony1)-2,3-dihydro-1H-pyrido[2,3-b][1,41oxazin-7-y0amino)-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one;
4-(5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-yOmorpholin-3-one;
1-(3-((1-(1-hydroxycyclopropane-1-carbony1)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)amino)-5-methyl-5H-chromeno[4,3-c]pyridin-8-y1)pyrrolidin-2-one;
1-(3-((1-(2-hydroxypropanoy1)-2,3-dihydro-1H-pyrido[2,3-b][1,41oxazin-7-y0amino)-5-methyl-5H-chromeno[4,3-c]pyridin-8-y1)pyrrolidin-2-one;
1-(3-((1-(isopropylsulfony1)-2,3-dihydro-1H-pyrido[2,3-b][1,41oxazin-7-y0amino)-5-methyl-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one;
(S)-2-((9-fluoro-5,5-dimethy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)-6,6a,7,8-tetrahydro-9H-pyrido[2,3-b]pyrrolo[1,2-d][1,4]oxazin-9-one;
N-(5-((5-methy1-8-(2-oxopyrrolidin-l-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-y0acetamide;
1-benzy1-3-(5-45-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-yOurea;
3-amino-N-(5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-yObenzamide;
1-(5-methy1-3-(pyridazin-4-ylamino)-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one;
1-(5-methy1-3-(pyridazin-3-ylamino)-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one;
1-(5-((9-fluoro-5,5-dimethy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-y1)imidazolidin-2-one;
1-methy1-3-(5-((5-methyl-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-yOurea;
N-(5-((5-methy1-8-(2-oxopyrrolidin-l-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-y1)-3-phenylpropanamide;
N-(5-((5-methy1-8-(2-oxopyrrolidin-l-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-y1)-2-phenylacetamide;
(1S,2S)-N-(5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-y1)-2-phenylcyclopropane-1-carboxamide;
N-(5-((5-methy1-8-(2-oxopyrrolidin-l-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-yOpicolinamide;
N-(5-((5-methy1-8-(2-oxopyrrolidin-l-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-yOnicotinamide;
N-(5-((5-methy1-8-(2-oxopyrrolidin-l-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-yOisonicotinamide;
4-fluoro-N-(5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-y1)amino)pyridin-3-y1)benzamide;
3-fluoro-N-(5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-y1)amino)pyridin-3-y1)benzamide;
3-methoxy-N-(5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-yObenzamide;
4-methoxy-N-(5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-yObenzamide;
1-(5-methy1-3-45-(pyridin-2-ylamino)pyridin-3-y0amino)-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one;
1-(5-methy1-3-45-(pyridazin-3-ylamino)pyridin-3-y0amino)-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one;
N-(5-((5-methy1-8-(2-oxopyrrolidin-l-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-y1)-3-phenylbutanamide;
2-methyl-N-(5-((5 -methyl- 8-(2-oxopyrroli din- 1 -y1)-5H-chromeno [4,3-c] py ri din-3 -yl)amino)pyridin-3 -y1)-3-phenylpropanami de;
N-(5-((5 -methyl- 8-(2-oxopy rroli din- 1 -y 0-5H-chromeno [4,3-c] pyri din-3-y Damino)py ridin-3 -y Otetrahy drofuran-2-carboxami de;
N-(5-((5 -methyl- 8-(2-oxopy rroli din- 1 -y1)-5H-chromeno [4,3-c] pyri din-3-yl)amino)py ridin-3 -yl)benzo[d] [1,3] dioxole-5 -carboxami de;
N-(5-((5 -methyl- 8-(2-oxopy rroli din- 1 -y1)-5H-chromeno [4,3-c] pyri din-3-yl)amino)py ridin-3 -yl)benzo[d] [1,3] dioxole-4-carboxami de;
1-(5 -methyl-3 -((5-(methylsulfonyl)quinolin-3 -yl)amino)-5H-chromeno [4,3-c]
py ri din- 8 -yl)pyrrolidin-2-one;
methyl 7-((9-fluoro-5-methyl- 8-(2-oxopy rroli din- 1 -y1)-5H-chromeno [4,3-c] py ri din-3-yl)amino)-2,3-dihy dro- 1H-pyri do [2,3-b] [1,4] oxazine- 1 -carboxylate;
N-(5-((5 -methyl- 8-(2-oxopy rroli din- 1 -y1)-5H-chromeno [4,3-c] pyri din-3-yl)amino)py ridin-3 -y1)-2-oxopyrroli dine-3-carboxami de;
N-(5-((5 -methyl- 8-(2-oxopy rroli din- 1 -y 0-5H-chromeno [4,3-c] pyri din-3-y Damino)py ridin-3 -y 0-2,3-dihy dro- 1H-indene-2-carboxami de;
N-(5-((5 -methyl- 8-(2-oxopy rroli din- 1 -y1)-5H-chromeno [4,3-c] pyri din-3-yl)amino)py ridin-3 -yl)pyrazolo [1,5-al py ri dine-2-carboxami de;
N-(5-((5 -methyl- 8-(2-oxopy rroli din- 1 -y 0-5H-chromeno [4,3-c] pyri din-3-y Damino)py ridin-3 -y 0-2,3-dihy drob enzofuran-2-carb oxami de;
methyl (5-45 -methyl- 8-(2-oxopyrroli din- 1 -y1)-5H-chromeno [4,3-c] py ri din-3-yl)amino)py ri din-3 -yl)carbamate;
4-((5-((5 -methy1-8 -(2-oxopy rroli din- 1 -y1)-5H-chromeno [4,3 -c] py ri din-3 -yl)amino)py ri din-3 -y0amino)-4-oxobutanoic acid;
N-(5-((5 -methyl- 8-(2-oxopy rroli din- 1 -y 0-5H-chromeno [4,3-c] pyri din-3-y Damino)py ridin-3 -y1)-1H-indole-6-carboxamide;
N-(5-((5 -methyl- 8-(2-oxopy rroli din- 1 -y 0-5H-chromeno [4,3-c] pyri din-3-y Damino)py ridin-3 -y1)-1H-indole-4-carboxamide;
N-(5-((5 -methyl- 8-(2-oxopy rroli din- 1 -y1)-5H-chromeno [4,3-c] pyri din-3-yl)amino)py ridin-3 -y1)-1H-benzo [d]imidazole-7-carboxamide;
N-(5-((5 -methyl- 8-(2-oxopy rroli din- 1 -y1)-5H-chromeno [4,3-c] pyri din-3-yl)amino)py ridin-3 -yl)imidazo [1,2-a] pyridine-2-carboxamide;
N-(5-((5 -methyl- 8-(2-oxopy rroli din- 1 -y 0-5H-chromeno [4,3-c] pyri din-3-y Damino)py ridin-3 -y1)-1H-indole-2-carboxamide;
2-(imidazo[1,2-a1pyridin-3-y1)-N-(5-45-methyl-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-y1)acetamide;
1-(5-((9-fluoro-5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-y1)imidazolidin-2-one;
4-formamido-3-hydroxy-N-(5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-yObenzamide;
N-(5-((5-methy1-8-(2-oxopyrrolidin-l-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-yOpyridazine-4-carboxamide;
6-amino-N-(5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-yOpyrazine-2-carboxamide;
2-hydroxy-N-(5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y1)amino)pyridin-3-y1)-3-phenylpropanamide;
N-(5-((5-methy1-8-(2-oxopyrrolidin-l-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-y0imidazo[1,2-alpyridine-3-carboxamide;
N-(5-((5-methy1-8-(2-oxopyrrolidin-l-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-yOpyrazolo[1,5-a]pyridine-3-carboxamide;
1-(3-((2,3-dihydro-[1,4]dioxino[2,3-blpyridin-7-y0amino)-5,5-dimethyl-5H-chromeno[4,3-c]pyridin-8-y1)pyrrolidin-2-one;
1-(3-((2,3-dihydro-[1,4]dioxino[2,3-blpyridin-7-y0amino)-9-fluoro-5-methyl-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one;
1-(3-((2,3-dihydro-[1,41dioxino[2,3-blpyridin-7-y0amino)-9-fluoro-5,5-dimethyl-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one;
2-hydroxy-N-(5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y1)amino)pyridin-3-y1)acetamide;
N-(5-((5-methy1-8-(2-oxopyrrolidin-l-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-yObenzo[d]oxazole-6-carboxamide;
1-hydroxy-N-(5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y1)amino)pyridin-3-y1)-1,3-dihydrobenzo[c][1,21oxaborole-5-carboxamide;
N-(5-((5-methy1-8-(2-oxopyrrolidin-l-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridazin-3-y0acetamide;
N-(5-((5-methy1-8-(2-oxopyrrolidin-l-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-y0imidazo[1,2-alpyridine-7-carboxamide;
1-(3-((2,3-dihydro-[1,41dioxino[2,3-blpyridin-7-y0amino)-5H-chromeno[4,3-clpyridin-8-y1)pyrrolidin-2-one;
1-(5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-y1)-3-(pyridin-2-yOurea;
1-hydroxy-N-(5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y1)amino)pyridin-3-y1)-1,3-dihydrobenzo[c][1,21oxaborole-6-carboxamide;
N-(5-((5-methy1-8-(2-oxopyrrolidin-l-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-y0imidazo[1,2-alpyridine-5-carboxamide;
1-(3-((2,3-dihydro-[1,41dioxino[2,3-blpyridin-7-y0amino)-9-fluoro-5H-chromeno[4,3-clpyridin-8-y1)pyrrolidin-2-one;
1-(5-methy1-4-(pyridin-4-y1)-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one;
1-(3-45-(4-(3-methoxypropanoyDpiperazin-1-y1)pyridin-3-y1)amino)-5H-chromeno[4,3-c]pyridin-8-y1)pyrrolidin-2-one;
1-(3-45-(4-(3-methoxypropanoyDpiperazin-1-yOpyridin-3-y0amino)-5-methyl-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one;
1-(3-45-(4-(3-methoxypropanoyDpiperazin-1-yOpyridin-3-y0amino)-5,5-dimethyl-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one;
(E)-4-(dimethylamino)-N-(3-(3-((5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-yl)amino)pyridin-3-yl)amino)-3-oxopropyl)phenyl)but-2-enamide;
2-amino-N-(5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-y1)isonicotinamide;
1-(9-fluoro-3-45-(4-(3-methoxypropanoyDpiperazin-1-yOpyridin-3-y0amino)-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one;
1-(9-fluoro-3-45-(4-(3-methoxypropanoyDpiperazin-1-yOpyridin-3-y0amino)-5-methyl-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one;
1-(9-fluoro-3-45-(4-(3-methoxypropanoyDpiperazin-1-yOpyridin-3-y0amino)-5,5-dimethyl-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one;
1-(5-((8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-y1)imidazolidin-2-one;
(E)-4-(4-(dimethylamino)but-2-enamido)-N-(5-((5-methy1-8-(2-oxopyrrolidin-l-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-yObenzamide;
(6aS)-8,8-dimethy1-2-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y1)amino)-6,6a,7,8-tetrahydro-9H-pyrido[2,3-blpyrrolo[1,2-d][1,4]oxazin-9-one;
(6aS)-2-((9-fluoro-5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-yOamino)-8,8-dimethy1-6,6a,7,8-tetrahydro-9H-pyrido[2,3-blpyrrolo[1,2-d][1,41oxazin-9-one;
1-hydroxy-N-(5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y1)amino)pyridin-3-y1)-1,3-dihydrobenzo[c][1,21oxaborole-4-carboxamide;
(6aR)-2-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)-6,6a,7,8-tetrahydro-9H-pyrido[2,3-blpyrrolo[1,2-d][1,41oxazin-9-one;
(6aS)-2-((9-fluoro-5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-y0amino)-8-methyl-6,6a,7,8-tetrahydro-9H-pyrido[2,3-blpyrrolo[1,2-d][1,4loxazin-9-one;
(6aR)-2-((9-fluoro-5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c1pyridin-y0amino)-6,6a,7,8-tetrahydro-9H-pyrido[2,3-blpyrrolo[1,2-d][1,41oxazin-9-one;
(R)-2-((8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)-6,6a,7,8-tetrahydro-9H-pyrido[2,3-blpyrrolo[1,2-d][1,41oxazin-9-one;
(R)-2-((5,5-dimethy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)-6,6a,7,8-tetrahydro-9H-pyrido[2,3-blpyrrolo[1,2-d][1,41oxazin-9-one;
(R)-2-((9-fluoro-5,5-dimethy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y1)amino)-6,6a,7,8-tetrahydro-9H-pyrido[2,3-blpyrrolo[1,2-d][1,4]oxazin-9-one;
(6aS)-8-methy1-2-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-yl)amino)-6,6a,7,8-tetrahydro-9H-pyrido[2,3-b]pyrrolo[1,2-d][1,4]oxazin-9-one;
4-(dimethylamino)-N-(3-(3-((5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-y1)amino)pyridin-3-y1)amino)-3-oxopropyl)phenyl)butanamide;
(E)-4-(dimethylamino)-N-(2-((3-((3-(5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-y1)-2-oxoimidazolidin-1-y1)methyl)phenyl)amino)-2-oxoethyl)but-2-enamide;
(6a'S)-2'-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-y1)amino)-6a',7'-dihydro-6'H,9'H-spiro[cyclopropane-1,8'-pyrido[2,3-blpyrrolo[1,2-d][1,4loxazinl-91-one;
(S)-2'-((5-(3-fluoro-4-(2-oxopyrrolidin-1-yl)phenyl)pyridin-2-yl)amino)-6a',7'-dihydro-6'H,9'H-spiro[cyclopropane-1,81-pyrido[2,3-blpyrrolo[1,2-d][1,4loxazinl-91-one;
(6a'S)-2'-((9-fluoro-5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-y0amino)-6a',7'-dihydro-6'H,91H-spiro[cyclopropane-1,8'-pyrido[2,3-blpyrrolo[1,2-d][1,4loxazinl-9'-one;
(E)-N-(5-((5,5-dimethy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-y1)-4-(4-(dimethylamino)but-2-enamido)benzamide;
(E)-N-(3-(3-((5-((5,5-dimethy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-y0amino)-3-oxopropyl)phenyl)-4-(dimethylamino)but-2-enamide;
(E)-4-(4-(dimethylamino)but-2-enamido)-N-(5 -((8-(2-oxopyrrolidin- 1 -y1)-5H-chromeno [4,3 -c] pyridin-3-y0amino)pyridin-3-yObenzamide;
1 -(5 -((9-fluoro-8-(2-oxopyrrolidin- 1 -y1)-5H-chromeno [4,3-clpyridin-3-y0amino)pyridin-3-y0imidazolidin-2-one;
1-(5 -((5,5 -dimethy1-8-(2-oxopyrrolidin-1 -y1)-5H-chromeno [4,3 -c] pyridin-3 -yl)amino)pyridin-3 -yl)imidazolidin-2-one;
(6aS)-2-((9-fluoro-5 -methyl-8-(2-oxopyrrolidin- 1 -y1)-5H-chromeno [4,3 -c]
pyridin-3-yl)amino)-8-hy droxy -6,6a,7, 8-tetrahy dro-9H-pyrido [2,3-blpyrrolo [1,2-d]
[1,41 oxazin-9-one;
(E)-4-(dimethylamino)-N-(2-((4-((3-(5 -((5-methyl-8-(2-oxopyrrolidin- 1 -y1)-chromeno [4,3-clpyridin-3-y0amino)pyridin-3-y1)-2-oxoimidazolidin- 1 -yl)methyl)phenyl)amino)-2-oxoethyl)but-2-enamide;
1 -(4-(pyridin-4-y1)-5H-chromeno [4,3-clpyridin-8-yOpyrrolidin-2-one;
1 -(5 -methy1-4-(pyridin-4-ylamino)-5H-chromeno [4,3 -c] pyridin-8-yOpyrrolidin-2-one;
(S)-2-((9-fluoro-5,5-dimethy1-8-(2-oxopyrrolidin-l-y1)-5H-chromeno [3,4-dlpyrimi din-3-yOamino)-6,6a,7,8-tetrahy dro-9H-pyrido [2,3 -b] pyrrolo [ 1,2-d] [1,4] oxazin-9-one;
(S)-2-((5,5-dimethy1-8-(2-oxopyrrolidin- 1 -y1)-5H-chromeno [3,4-d] pyrimidin-3-y0amino)-6,6a,7,8-tetrahy dro-9H-pyrido [2,3-b] pyrrolo [ 1,2-d] [1,4] oxazin-9-one;
(3 aR)-8-((5-methyl-8-(2-oxopyrrolidin- 1 -y1)-5H-chromeno [4,3 -c] pyridin-3 -yl)amino)-3 a,4-dihy dro-1H,3H-oxazolo [3,4-d] pyrido[2,3-b] [1,4] oxazin-1-one;
N-(5-((9-fluoro-5,5-dimethy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno [4,3-c]
pyridin-3-yl)amino)-2-methoxy pyridin-3-yl)acetamide;
N-(5-((5,5-dimethy1-8-(2-oxopyrrolidin- 1 -y1)-5H-chromeno [4,3 -c] pyridin-3-y0amino)-2-methoxy pyridin-3 -y0acetamide;
1 -(5 -methy1-3 -((5-(5 -methyl- 1, 1 -dioxido- 1,2,5-thiadiazolidin-2-yOpyridin-3-y0amino)-5H-chromeno [4,3-clpyridin-8-yOpyrrolidin-2-one;
(6aS, 8R)-2-((9-fluoro-5 -methyl-8-(2-oxopyrrolidin- 1 -y1)-5H-chromeno [4,3 -c] pyridin-3-yl)amino)-8-hy droxy -8-methy1-6,6a,7,8-tetrahy dro-9H-pyrido [2,3-blpyrrolo [1,2-d] [1,4] oxazin-9-one;
(6aS,8R)-8-hy droxy -8-methy1-2-((5 -methyl-8-(2-oxopyrrolidin- 1 -y1)-5H-chromeno [4,3-c] pyridin-3-yl)amino)-6,6a,7, 8-tetrahy dro-9H-pyrido [2,3-blpyrrolo [1,2-d]
[1,4] oxazin-9-one;
1 -(5,5 -dimethy1-3-((5 -(5 -methyl- 1, 1 -dioxido-1,2,5 -thiadiazolidin-2-yOpyridin-3-y0amino)-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one;
N-(5-((5-methy1-8-(2-oxopyrrolidin-l-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-y1)-1H-benzo[dlimidazole-4-carboxamide;
(3aR)-8-((9-fluoro-5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-y0amino)-3a,4-dihydro-1H,3H-oxazolo[3,4-dlpyrido[2,3-bl[1,410xazin-1-one;
4-(4-(dimethylamino)butanamido)-N-(5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-yObenzamide;
1-(5-methy1-3-4(S)-2-methy1-1,1-dioxido-2,3,3a,4-tetrahydropyrido[2,3-b][1,2,5]thiadiazolo[2,3-d][1,4loxazin-8-y0amino)-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one;
(S)-1-(5,5-dimethy1-3-((2-methy1-1,1-dioxido-2,3,3a,4-tetrahydropyrido[2,3-bl[1,2,5]thiadiazolo[2,3-d][1,4loxazin-8-y0amino)-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one;
(6aS)-8-hydroxy-2-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)-6,6a,7,8-tetrahydro-9H-pyrido[2,3-blpyrrolo[1,2-d][1,41oxazin-9-one;
1-(5-methy1-3-(oxazolo[4,5-blpyridin-6-ylamino)-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one;
1-(5,5-dimethy1-3-((1-methyl-2,3-dihydro-1H-pyrido[2,3-b][1,4loxazin-7-y0amino)-5H-chromeno[3,4-dlpyrimidin-8-yOpyrrolidin-2-one;
(S)-2-45,5-dimethy1-8-(4-methylisoxazol-3-y1)-5H-chromeno[4,3-c]pyridin-3-y0amino)-6,6a,7,8-tetrahydro-9H-pyrido[2,3-blpyrrolo[1,2-d][1,4]oxazin-9-one;
(S)-2-((5,5-dimethy1-8-(4-methy1-4H-1,2,4-triazol-3-y1)-5H-chromeno[3,4-dlpyrimidin-3-y0amino)-6,6a,7,8-tetrahydro-9H-pyrido[2,3-blpyrrolo[1,2-d][1,4]oxazin-9-one;
(S)-2-((5,5-dimethy1-8-(4-methy1-4H-1,2,4-triazol-3-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)-6,6a,7,8-tetrahydro-9H-pyrido[2,3-blpyrrolo[1,2-d][1,41oxazin-9-one;
N-(5-((5,5-dimethy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y1)amino)pyridin-3-y1)-4-(2-(2-(2-(2-((2-(2,6-dioxopiperidin-3-y1)-1,3-dioxoisoindolin-4-y1)amino)ethoxy)ethoxy)ethoxy)acetamido)benzamide; and N-(5-((5,5-dimethy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y1)amino)pyridin-3-y1)-4-(4-(2-((2-(2,6-dioxopiperidin-3-y1)-1,3-dioxoisoindolin-4-y1)oxy)acetamido)butanamido)benzamide.
[0199] It should be understood that all isomeric forms are included within the present invention, including mixtures thereof If the compound contains a double bond, the substituent may be in the E or Z configuration. If the compound contains a disubstituted cycloalkyl, the cycloalkyl substituent may have a cis- or trans configuration. All tautomeric forms are also intended to be included.
[0200]
Compounds of the invention, and pharmaceutically acceptable salts, hydrates, solvates, stereoisomers and prodrugs thereof may exist in their tautomeric form (for example, as an amide or imino ether). All such tautomeric forms are contemplated herein as part of the present invention.
[0201] The compounds of the invention may contain asymmetric or chiral centers, and, therefore, exist in different stereoisomeric forms. It is intended that all stereoisomeric forms of the compounds of the invention as well as mixtures thereof, including racemic mixtures, form part of the present invention. In addition, the present invention embraces all geometric and positional isomers. For example, if a compound of the invention incorporates a double bond or a fused ring, both the cis- and trans-forms, as well as mixtures, are embraced within the scope of the invention, each compound herein disclosed includes all the enantiomers that conform to the general structure of the compound. The compounds may be in a racemic or enantiomerically pure form, or any other form in terms of stereochemistry. The assay results may reflect the data collected for the racemic form, the enantiomerically pure form, or any other form in terms of stereo chemi stry [0202]
Diastereomeric mixtures can be separated into their individual diastereomers on the basis of their physical chemical differences by methods well known to those skilled in the art, such as, for example, by chromatography and/or fractional crystallization.
Enantiomers can be separated by converting the enantiomeric mixture into a diastereomeric mixture by reaction with an appropriate optically active compound (e.g., chiral auxiliary such as a chiral alcohol or Mosher's acid chloride), separating the diastereomers and converting (e.g., hydrolyzing) the individual diastereomers to the corresponding pure enantiomers. Also, some of the compounds of the invention may be atropisomers (e.g., substituted biaryls) and are considered as part of this invention. Enantiomers can also be separated by use of a chiral HPLC
column.
[0203] It is also possible that the compounds of the invention may exist in different tautomeric forms, and all such forms are embraced within the scope of the invention. Also, for example, all keto-enol and imine-enamine forms of the compounds are included in the invention.
[0204] All stereoisomers (for example, geometric isomers, optical isomers and the like) of the present compounds (including those of the salts, solvates, esters and prodrugs of the compounds as well as the salts, solvates and esters of the prodrugs), such as those which may exist due to asymmetric carbons on various substituents, including enantiomeric forms (which may exist even in the absence of asymmetric carbons), rotameric forms, atropisomers, and diastereomeric forms, are contemplated within the scope of this invention, as are positional isomers (such as, for example, 4-pyridyl and 3-pyridy1). (For example, if a compound of Formula (I)incorporates a double bond or a fused ring, both the cis- and trans-forms, as well as mixtures, are embraced within the scope of the invention. Also, for example, all keto-enol and imine-enamine forms of the compounds are included in the invention.) Individual stereoisomers of the compounds of the invention may, for example, be substantially free of other isomers, or may be admixed, for example, as racemates or with all other, or other selected, stereoisomers. The chiral centers of the present invention can have the S or R
configuration as defined by the IUPAC 1974 Recommendations. The use of the terms "salt", "solvate", "ester,"
"prodrug" and the like, is intended to equally apply to the salt, solvate, ester and prodrug of enantiomers, stereoisomers, rotamers, tautomers, positional isomers, racemates or prodrugs of the inventive compounds.
[0205] The compounds of Formula I may form salts which are also within the scope of this invention. Reference to a compound of the Formula herein is understood to include reference to salts thereof, unless otherwise indicated.
[0206] The present invention relates to compounds which are modulators of PI5P4K. In one embodiment, the compounds of the present invention are inhibitors of PI5P4K.
[0207] The invention is directed to compounds as described herein and pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, or tautomers thereof, and pharmaceutical compositions comprising one or more compounds as described herein, or pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, or tautomers thereof Method of Synthesizing the Compounds [0208] The compounds of the present invention may be made by a variety of methods, including standard chemistry. Suitable synthetic routes are depicted in the Schemes given below.
[0209] The compounds of Formula (I) may be prepared by methods known in the art of organic synthesis as set forth in part by the following synthetic schemes. In the schemes described below, it is well understood that protecting groups for sensitive or reactive groups are employed where necessary in accordance with general principles or chemistry. Protecting groups are manipulated according to standard methods of organic synthesis (T.
W. Greene and P. G. M. Wuts, "Protective Groups in Organic Synthesis", Third edition, Wiley, New York 1999). These groups are removed at a convenient stage of the compound synthesis using methods that are readily apparent to those skilled in the art. The selection processes, as well as the reaction conditions and order of those skilled in the art will recognize if a stereocenter exists in the compounds of Formula (I). Accordingly, the present invention includes both possible stereoisomers (unless specified in the synthesis) and includes not only racemic compounds but the individual enantiomers and/or diastereomers as well. When a compound is desired as a single enantiomer or diastereomer, it may be obtained by stereospecific synthesis or by resolution of the final product or any convenient intermediate.
Resolution of the final product, an intermediate, or a starting material may be affected by any suitable method known in the art. See, for example, "Stereochemistry of Organic Compounds" by E. L.
Eliel, S. H.
Wilen, and L. N. Mander (Wiley-lnterscience, 1994).
[0210] The compounds described herein may be made from commercially available starting materials or synthesized using known organic, inorganic, and/or enzymatic processes.
Preparation of compounds [0211] The compounds of the present invention can be prepared in a number of ways well known to those skilled in the art of organic synthesis. By way of example, compounds of the present invention can be synthesized using the methods described below, together with synthetic methods known in the art of synthetic organic chemistry, or variations thereon as appreciated by those skilled in the art. Preferred methods include but are not limited to those methods described below. Compounds of the present invention can be synthesized by following the steps outlined in General Scheme 1 which comprise different sequences of assembling intermediates or compounds (II). Starting materials are either commercially available or made by known procedures in the reported literature or as illustrated below.
[0212] A
compound of formula (I) may be obtained (Scheme 1) by starting from, for example, a compound of formula (II), wherein LG represents a leaving group including but not limited to, halogen (e.g., chlorine, bromine or iodine), or an alkyl-, aryl-or haloalkyl-sulfonate (such as triflate), and reacting said compound (II) with a compound of formula A2-G, wherein A2-G is defined below and represents a cyclic amine either as free base or a salt (such as HC1, TFA or acetic acid), optionally under the influence of a transition metal catalyst as described in for example Metal-Catalyzed Cross-Coupling Reactions, 2, Completely Revised and Enlarged Edition by A. de Meij ere and F. Diederich, Wiley VCH, 2004.
Scheme 1 *
* W W R4 __________________________________ 1/10' LG
(II) (I) [0213] The reaction may be carried out by coupling of a compound of formula (II), with an appropriate amine of formula A. The reaction may also be carried out using a suitable metal catalyst including, but not limited to, a palladium catalyst, e.g., di-tert-butylphosphinoferrocene palladium (II) dichloride, tetrakis(triphenylphosphine)palladium (0), palladium (II) diphenylphosphinoferrocene dichloride, palladium(II) acetate or bis(dibenzylideneacetone) palladium (0). Optionally a suitable ligand for example triphenylphosphine, tri-tert-butylphosphine or 2-(dicyclohexylphosphino)biphenyl or 2-dicyclohexylphosphino-2',4',6'-triisopropylbiphenyl is employed. Suitable base, including an (e.g., triethyl amine), an alkali metal or alkaline earth metal carbonate or hydroxide, or phosphate base, (e.g., potassium carbonate, sodium carbonate, cesium carbonate, sodium hydroxide, or potassium phosphate), may be used in the reaction. Said reaction may be performed at a temperature range between +20 C and +160 C, in suitable solvents, including, but not limited to, toluene, tetrahydrofuran, 2-methyl-tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, acetonitrile, water, ethanol, /V,N-dimethylacetamide or /V,N-dimethylformamide, or mixtures thereof If enantiomerically pure or enriched compound (II) is used in this reaction, an enantiomerically pure or enantiomerically enriched compound (I) is obtained.
Compounds of formula (II) and A are commercially available compounds, or are known in the literature, or they are prepared by standard processes known in the art. A
compound of formula (I), (II) or A may be separated into its enantiomers by standard processes known in the art by for example chromatography on a chiral stationary phase.
Methods of Using the Disclosed Compounds [0214] Another aspect of the invention relates to a method of treating a disease or disorder associated with modulation of PI5P4K. The method comprises administering to a patient in need of a treatment for diseases or disorders associated with modulation of PI5P4K an effective amount the compositions and compounds of Formula (I).
[0215] In another aspect, the present invention is directed to a method of inhibiting PI5P4K. The method involves administering to a patient in need thereof an effective amount of a compound of Formula (I).
[0216] Another aspect of the present invention relates to a method of treating, preventing, inhibiting or eliminating a disease or disorder in a patient associated with the inhibition of PI5P4K, the method comprising administering to a patient in need thereof an effective amount of a compound of Formula (I). In one embodiment, the disease may be, but not limited to, cancer or cell proliferative disorder, a metabloic disorder, neurodegenerative disease, and an inflammatory disease.
[0217] The present invention also relates to the use of an inhibitor of PI5P4K for the preparation of a medicament used in the treatment, prevention, inhibition or elimination of a disease or condition mediated by PI5P4K, wherein the medicament comprises a compound of Formula (I).
[0218] In another aspect, the present invention relates to a method for the manufacture of a medicament for treating, preventing, inhibiting, or eliminating a disease or condition mediated by PI5P4K, wherein the medicament comprises a compound of Formula (I).
[0219] Another aspect of the present invention relates to a compound of Formula (I) for use in the manufacture of a medicament for treating a disease associated with inhibiting PI5P4K.
[0220] In another aspect, the present invention relates to the use of a compound of Formula (I) in the treatment of a disease associated with inhibiting PI5P4K.
[0221] Another aspect of the invention relates to a method of treating cancer. The method comprises administering to a patient in need thereof an effective amount of a compound of Formula (I).
[0222] In another aspect of the invention, the method relates to treating a cell proliferative disease. The method comprises administering to a patient in need thereof an effective amount of a compound of Formula (I).
[0223] In yet another aspect, the present invention relates to a method of treating a neurodegenerative disease. The method comprises administering to a patient in need thereof an effective amount of a compound of Formula (I).
[0224] In another aspect, the present invention relates to a method of treating an inflammatory disease or condition. The method comprises administering to a patient in need thereof an effective amount of a compound of Formula (I).
[0225] Another aspect of the invention relates to a method of inducing cell cycle arrest, apoptosis in tumor cells, and/or enhanced tumor-specific T cell immunity. The method comprises contacting the cells with an effective amount of a compound of Formula (I).
[0226] In one embodiment, the present invention relates to the use of an inhibitor of PI5P4K for the preparation of a medicament used in treatment, prevention, inhibition or elimination of a disease or disorder associated with cancer or cell proliferative disorder, a metabloic disorder, neurodegenerative disease, and an inflammatory disease.
[0227] In another embodiment, the present invention relates to a compound of Formula (I) or a pharmaceutical composition comprising a compound of the present invention and a pharmaceutically acceptable carrier used for the treatment of cancers or cell proliferatives disorders including, but not limited to, leukemias (e.g., acute leukemia, acute lymphocytic leukemia, acute myelocytic leukemia, acute myeloblastic leukemia, acute promyelocytic leukemia, acute myelomonocytic leukemia, acute monocytic leukemia, acute erythroleukemia, chronic leukemia, chronic myelocytic leukemia, chronic lymphocytic leukemia), polycythemia vera, lymphoma (Hodgkin's disease, non-Hodgkin's disease), Waldenstrom's macroglobulinemia, heavy chain disease, and solid tumors such as sarcomas and carcinomas (e. g. , fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilm's tumor, cervical cancer, uterine cancer, testicular cancer, lung carcinoma, small cell lung carcinoma, bladder carcinoma, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodenroglioma, schwannoma, meningioma, melanoma, neuroblastoma, and retinoblastoma).
[0228] In another embodiment, the present invention relates to a compound of Formula (I) or a pharmaceutical composition comprising a compound of the present invention and a pharmaceutically acceptable carrier used for the treatment of neurodegenerative diseases including, but not limited to, brain trauma, spinal cord trauma, trauma to the peripheral nervous system, Alzheimer's disease, Pick's disease, diffuse Lewy body disease, progressive supranuclear palsy (Steel-Richardson syndrome), multisystem degeneration (Shy-Drager syndrome), motor neuron diseases including amyotrophic lateral sclerosis, degenerative ataxias, cortical basal degeneration, ALS-Parkinson's-Dementia complex of Guam, subacute sclerosing panencephalitis, Huntington's disease, Parkinson's disease, synucleinopathies, primary progressive aphasia, striatonigral degeneration, Machado-Joseph disease/spinocerebellar ataxia type 3 and olivopontocerebellar degenerations, Gilles De La Tourette's disease, bulbar and pseudobulbar palsy, spinal and spinobulbar muscular atrophy (Kennedy's disease), primary lateral sclerosis, familial spastic paraplegia, Werdnig-Hoffman disease, Kugelberg-Welander disease, Tay-Sach's disease, Sandhoff disease, familial spastic disease, Wohlfart-Kugelberg-Welander disease, spastic paraparesis, progressive multifocal leukoencephalopathy, and prion diseases (including Creutzfeldt-Jakob, Gerstmann-Straussler-Scheinker disease, Kuru and fatal familial insomnia, age-related dementia, vascular dementia, diffuse white matter disease (Binswanger's disease), dementia of endocrine or metabolic origin, dementia of head trauma and diffuse brain damage, dementia pugilistica or frontal lobe dementia, neurodegenerative disorders resulting from cerebral ischemia or infaction including embolic occlusion and thrombotic occlusion as well as intracranial hemorrhage of any type, intracranial and intravertebral lesions, hereditary cerebral angiopathy, normeuropathic hereditary amyloid, Down's syndrome, macroglobulinemia, secondary familial Mediterranean fever, Muckle-Wells syndrome, multiple myeloma, pancreatic- and cardiac-related amyloidosis, chronic hemodialysis arthropathy, and Finnish and Iowa amyloidosis.
[0229] In another embodiment, the present invention relates to a compound of Formula (I) or a pharmaceutical composition comprising a compound of the present invention and a pharmaceutically acceptable carrier used for the treatment of inflammatory disease. In some embodiments, the inflammatory disease is associated with a metabolic disorder.
In some embodiments the treated inflammation is associated with, but not limited to, Type II diabetes, insulin resistance cardiovascular disease, arrhythmia, atherosclerosis, coronary artery disease, hypertriglyceridemia, dyslipidemia, retinopathy, nephropathy, neuropathy, obesity, and macular edema.
[0230] In yet another embodiment, the present invention relates to a compound of Formula (I) or a pharmaceutical composition comprising a compound of the present invention and a pharmaceutically acceptable carrier used for the treatment of a metabolic disease including, but not limited, Type II diabetes, insulin resistance cardiovascular disease, arrhythmia, atherosclerosis, coronary artery disease, hypertriglyceridemia, dyslipidemia, retinopathy, nephropathy, neuropathy, obesity, and macular edema.
[0231] In another embodiment, the present invention relates to a compound of Formula (I) or a pharmaceutical composition comprising a compound of the present invention and a pharmaceutically acceptable carrier used for the treatment of inflammatory disease associated with inflammatory disease. In some embodiments the treated inflammation is associated with, but not limited to, ileitis, ulcerative colitis, Barrett's syndrome, or Crohn's disease.
[0232] In some embodiments, the patient is selected for treatment based on gene amplification and/or elevated tumor expression of PI5P4K. In other embodiments, the patient is selected for treatment based on gene amplification and/or elevated tumor expression of PI5P4Ka gene, PI5P4K13 gene, or PI5P4Ky gene. In other embodiments, the patient is selected for the treatment based on tumor expression of p53 mutations.
[0233] In some embodiments, administration of a compound of Formula (I) or a pharmaceutical composition comprising a compound of the present invention and a pharmaceutically acceptable carrier induces a change in the cell cycle or cell viability.
[0234] Another aspect of the invention is directed to pharmaceutical compositions comprising a compound of Formula (I) and a pharmaceutically acceptable carrier. The pharmaceutical acceptable carrier may further include an excipient, diluent, or surfactant.
[0235] In one embodiment, are provided methods of treating a disease or disorder associated with modulation of PI5P4K including, cancer or cell proliferative disorder, a metabloic disorder, neurodegenerative disease, and an inflammatory disease, comprising administering to a patient suffering from at least one of said diseases or disorder a compound of Formula (I).
[0236] One therapeutic use of the compounds or compositions of the present invention which inhibit PI5P4K is to provide treatment to patients or subjects suffering from c cancer or cell proliferative disorder, a metabloic disorder, neurodegenerative disease, and an inflammatory disease.
[0237] The disclosed compounds of the invention can be administered in effective amounts to treat or prevent a disorder and/or prevent the development thereof in subjects.
[0238]
Administration of the disclosed compounds can be accomplished via any mode of administration for therapeutic agents. These modes include systemic or local administration such as oral, nasal, parenteral, transdermal, subcutaneous, vaginal, buccal, rectal or topical administration modes.
[0239]
Depending on the intended mode of administration, the disclosed compositions can be in solid, semi-solid or liquid dosage form, such as, for example, injectables, tablets, suppositories, pills, time-release capsules, elixirs, tinctures, emulsions, syrups, powders, liquids, suspensions, or the like, sometimes in unit dosages and consistent with conventional pharmaceutical practices. Likewise, they can also be administered in intravenous (both bolus and infusion), intraperitoneal, subcutaneous or intramuscular form, and all using forms well known to those skilled in the pharmaceutical arts.
[0240]
Illustrative pharmaceutical compositions are tablets and gelatin capsules comprising a Compound of the Invention and a pharmaceutically acceptable carrier, such as a) a diluent, e.g., purified water, triglyceride oils, such as hydrogenated or partially hydrogenated vegetable oil, or mixtures thereof, corn oil, olive oil, sunflower oil, safflower oil, fish oils, such as EPA or DHA, or their esters or triglycerides or mixtures thereof, omega-3 fatty acids or derivatives thereof, lactose, dextrose, sucrose, mannitol, sorbitol, cellulose, sodium, saccharin, glucose and/or glycine; b) a lubricant, e.g., silica, talcum, stearic acid, its magnesium or calcium salt, sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride and/or polyethylene glycol; for tablets also; c) a binder, e.g., magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, magnesium carbonate, natural sugars such as glucose or beta-lactose, corn sweeteners, natural and synthetic gums such as acacia, tragacanth or sodium alginate, waxes and/or polyvinylpyrrolidone, if desired; d) a disintegrant, e.g., starches, agar, methyl cellulose, bentonite, xanthan gum, algic acid or its sodium salt, or effervescent mixtures; e) absorbent, colorant, flavorant and sweetener; f) an emulsifier or dispersing agent, such as Tween 80, Labrasol, HPMC, DOSS, caproyl 909, labrafac, labrafil, peceol, transcutol, capmul MCM, capmul PG-12, captex 355, gelucire, vitamin E TGPS or other acceptable emulsifier;
and/or g) an agent that enhances absorption of the compound such as cyclodextrin, hydroxypropyl-cyclodextrin, PEG400, PEG200.
[0241] Liquid, particularly injectable, compositions can, for example, be prepared by dissolution, dispersion, etc. For example, the disclosed compound is dissolved in or mixed with a pharmaceutically acceptable solvent such as, for example, water, saline, aqueous dextrose, glycerol, ethanol, and the like, to thereby form an injectable isotonic solution or suspension.
Proteins such as albumin, chylomicron particles, or serum proteins can be used to solubilize the disclosed compounds.
[0242] The disclosed compounds can be also formulated as a suppository that can be prepared from fatty emulsions or suspensions; using polyalkylene glycols such as propylene glycol, as the carrier.
[0243] The disclosed compounds can also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles. Liposomes can be formed from a variety of phospholipids, containing cholesterol, stearylamine or phosphatidylcholines. In some embodiments, a film of lipid components is hydrated with an aqueous solution of drug to a form lipid layer encapsulating the drug, as described in U.S. Pat. No. 5,262,564 which is hereby incorporated by reference in its entirety.
[0244]
Disclosed compounds can also be delivered by the use of monoclonal antibodies as individual carriers to which the disclosed compounds are coupled. The disclosed compounds can also be coupled with soluble polymers as targetable drug carriers. Such polymers can include polyvinylpyrrolidone, pyran copolymer, polyhydroxypropylmethacrylamide-phenol, polyhydroxyethylaspanamidephenol, or poly ethyleneoxidepolylysine substituted with palmitoyl residues. Furthermore, the Disclosed compounds can be coupled to a class of biodegradable polymers useful in achieving controlled release of a drug, for example, polylactic acid, polyepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates and cross-linked or amphipathic block copolymers of hydrogels. In one embodiment, disclosed compounds are not covalently bound to a polymer, e.g., a polycarboxylic acid polymer, or a polyacrylate.
[0245] Parental injectable administration is generally used for subcutaneous, intramuscular or intravenous injections and infusions. Injectables can be prepared in conventional forms, either as liquid solutions or suspensions or solid forms suitable for dissolving in liquid prior to injection.
[0246] Another aspect of the invention is directed to pharmaceutical compositions comprising a compound of Formula (I) and a pharmaceutically acceptable carrier. The pharmaceutical acceptable carrier may further include an excipient, diluent, or surfactant.
[0247]
Compositions can be prepared according to conventional mixing, granulating or coating methods, respectively, and the present pharmaceutical compositions can contain from about 0.1% to about 99%, from about 5% to about 90%, or from about 1% to about 20% of the disclosed compound by weight or volume.
[0248] The dosage regimen utilizing the disclosed compound is selected in accordance with a variety of factors including type, species, age, weight, sex and medical condition of the patient; the severity of the condition to be treated; the route of administration; the renal or hepatic function of the patient; and the particular disclosed compound employed. A physician or veterinarian of ordinary skill in the art can readily determine and prescribe the effective amount of the drug required to prevent, counter or arrest the progress of the condition.
[0249]
Effective dosage amounts of the disclosed compounds, when used for the indicated effects, range from about 0.5 mg to about 5000 mg of the disclosed compound as needed to treat the condition. Compositions for in vivo or in vitro use can contain about 0.5, 5, 20, 50, 75, 100, 150, 250, 500, 750, 1000, 1250, 2500, 3500, or 5000 mg of the disclosed compound, or, in a range of from one amount to another amount in the list of doses. In one embodiment, the compositions are in the form of a tablet that can be scored.
EXAMPLES
[0250] The disclosure is further illustrated by the following examples and synthesis schemes, which are not to be construed as limiting this disclosure in scope or spirit to the specific procedures herein described. It is to be understood that the examples are provided to illustrate certain embodiments and that no limitation to the scope of the disclosure is intended thereby. It is to be further understood that resort may be had to various other embodiments, modifications, and equivalents thereof which may suggest themselves to those skilled in the art without departing from the spirit of the present disclosure and/or scope of the appended claims.
Analytical Methods, Materials, and Instrumentation [0251] Unless otherwise noted, reagents and solvents were used as received from commercial suppliers. All solvents used were of analytical grade and commercially available anhydrous solvents were routinely used for reactions. Starting materials were available from commercial sources, or prepared according to literature procedures. Room temperature refers to +20-25 C. Solvent mixture compositions are given as volume percentages or volume ratios.
[0252]
Microwave heating was performed in a Biotage Initiator microwave cavity producing continuous irradiation at 2.45 GHz. It is understood that microwaves may be used for the heating of reaction mixtures.
[0253] Straight phase chromatography was manually performed on Merck Silica gel 60 (0.040-0.063 mm), or automatically using an ISCO Combiflash0 Companion TM
system using SiliaSepTTM normal-phase flash columns using the solvent system indicated.
[0254] NMR
spectra were recorded on a 400 MHz (or higher field) NMR spectrometer fitted with a probe of suitable configuration. Spectra were recorded at ambient temperature unless otherwise stated. Chemical shifts are given in ppm down- and upfield from TMS (0.00 ppm). The following reference signals were used: the residual solvent signal of DMSO-d6 6 2.5, CDC13 6 7.26 or Methanol-d4 6 3.31. Resonance multiplicities are denoted s, d, t, q, m and br for singlet, doublet, triplet, quartet, multiplet and broad, respectively.
[0255] High pressure liquid chromatography (HPLC) was performed on a reverse phase column. A linear gradient was applied using for example mobile phase A
(aqueous 0.1% NH3 or aqueous 0.1% acetic acid or aqueous 0.1% formic acid) and B (acetonitrile or methanol).
Mass spectrometer (MS) analyses were performed in positive ion mode using electrospray ionization (ES+).
[0256]
Preparative chromatography was run on a Gilson-PREP GX271 or GX281 with Trilution lc as software on a reverse phase column. A linear gradient was applied using for example mobile phase A (aqueous 0.1% NH3 or aqueous 0.1% acetic acid or aqueous 0.1%
formic acid) and B (acetonitrile or methanol).
[0257]
Preparative chiral chromatography for separation of enantiomers was run on a Thar SFC using supercritical fluid chromatography on a chiral stationary phase. A
linear gradient was applied using mobile phase A (carbon dioxide) and B (acetonitrile or methanol or ethanol or 2-propanol or any mixtures thereof). Additives (such as diethyl amine or isopropyl amine or ammonia or formic acid or TFA) may be used.
Abbreviations used in the following examples and elsewhere herein are:
atm atmosphere br broad Amphos (4-(N,N-Dimethylamino)phenyl)di-tert-butyl phosphine anh. anhydrous aq. aqueous BINAP ( )-2,2'-Bis(diphenylphosphino)-1,1'-binaphthalene BrettPhos 2-(dicyclohexylphosphino)3,6-dimethoxy-2',4',6'-triisopropy1-1,1'-biphenyl BrettPhos Pd G3 [(2-Di-cyclohexylphosphino-3,6-dimethoxy-2',4',6'-triisopropy1-1,1'-bipheny1)-2-(2'-amino-1,1' biphenyOlpalladium(II) methanesulfonate BuLi butyl lithium DCM dichloromethane DIAD diisopropyl azodiformate DIPEA N,N-diisopropylethylamine DMAc N,N-dimethyl acetamide DMAP N,N-dimethylpyridin-4-amine DME 1,2-Dimethoxyethane DMEDA N,N'-Dimethylethylenediamine DMF N,N-dimethyl formamide DMSO dimethyl sulfoxide EDCI.HC1 1-(3-Dimethylaminopropy1)-3-ethylcarbodiimide Hydrochloride Et0Ac ethyl acetate Et0H ethanol hour(s) HBTU 3-[Bis(dimethylamino)methyliumy11-3H-benzotriazol-1-oxide hexafluorophosphate HPLC high pressure (or performance) liquid chromatography KOtBu potassium tert-butoxide LCMS liquid chromatography mass spectrometry LHMDS Lithium bis(trimethylsilyl)amide MeCN acetonitrile 2-MeTHF 2-methyl tetrahydrofuran Me0H methanol n-BuLi butyl lithium NaOtBu sodium tert-butoxide PEPPSI-iPr [1,3-Bis(2,6-Diisopropylphenyl)imidazol-2-ylidene1(3-chloropyridyl)palladium(II) dichloride PdC12(Amphos) Bis(di-tert-buty1(4-dimethylaminophenyl)phosphine)dichloropalladium(II) Pd2(dba)3 Tris(dibenzylideneacetone)dipalladium(0) Pd(OAc)2 palladium(II) acetate PdC12(dppf) [1,11-Bis(diphenylphosphino)ferroceneldichloropalladium(II) quant. Quantitative rac racemic mixture rt room temperature Rt retention time sat. saturated TBAB tetrabutylammonium bromide TFA trifluoroacetic acid THF tetrahydrofuran XantPhos 4,5-Bis(diphenylphosphino)-9,9-dimethylxanthene XPhos 2-Dicyclohexylphosphino-2',4',6'-triisopropylbiphenyl ESI electrospray ionization HATU [bis(dimethylamino)methylene1-1H-1,2,3-triazolo[4,5-blpyridinium 3-oxide hexafluorophosphate m multiplet MeMgC1 methylmagnesium chloride MI-lz megahertz min minutes MS molecular sieves MsC1 methanesulfonyl chloride MW microwave NMR nuclear magnetic resonance ppm parts per million TLC thin layer chromatography Example 1: Intermediate 1-- Methyl 4-(6-chloro-4-formy1-3-pyridy1)-3-fluoro-benzoate C H3 el N CI
[0258] (2-Fluoro-4-methoxycarbonyl-phenyl)boronic acid (220 mg, 1.11 mmol), 5-bromo-2-chloro-pyridine-4-carbaldehyde (230 mg, 1.04 mmol), PdC12(PPh3)2 (37 mg, 0.05 mmol) and K2CO3 (360 mg, 2.61 mmol) were taken up in MeCN (5 ml) and water (1 ml) and the resulting mixture was stirred at 70 C for 1 h. When cooled to rt the mixture was concentrated and the resulting residue was diluted with water (3 ml) and extracted with Et0Ac (2 x 5 m1).
The combined organics were purified on a silica gel column eluted with 0-50%
Et0Ac in heptane to give the product as a gum (210 mg, 69%). MS ES+ m/z 294 [M+141+.
Example 2: Intermediate 2-- Methyl 4-16-chloro-4-(1-hydroxyethyl)-3-pyridy1]-3-fluo ro-b enzo ate F
N CI
[0259] 3M
MeMgC1 in THF (286 1, 0.86) was added dropwise to a solution of methyl 4-(6-chloro-4-formy1-3-pyridy1)-3-fluoro-benzoate (210 mg, 0.72 mmol) in THF (5 ml) at 0 C
under a nitrogen atmosphere and the resulting mixture was stirred at 0 C for 1 h. Sat. aq.
NH4C1 (2 ml) was added followed by water (2 ml) and Et0Ac (5 m1). The organic layer was separated and the aqueous layer extracted with Et0Ac (2 x 5 m1). The combined organics were washed with brine, dried over Na2SO4, filtered and concentrated to give the product as a gum (205 mg, 93%). MS ES+ m/z 310 [M+1-11+.
Example 3: Intermediate 3-- 3-Chloro-N,N,5-trimethy1-5H-chromeno[4,3-c]pyridine-8-carboxamide N CI
[0260] NaH (60%
in mineral oil, 51 mg, 1.32 mmol) was added to a solution of methyl 446-chloro-4-(1-hydroxyethyl)-3-pyridy11-3-fluoro-benzoate (205 mg, 0.66 mmol) in THF (5 ml) at 0 C under a nitrogen atmosphere. The mixture was stirred at 0 C for 30 min and then at rt overnight. More NaH (60% in mineral oil, 51 mg, 1.32 mmol) was added and the mixture was stirred at 40 C for 3.5 h, followed by 50 C for 4 h. The resulting mixture was cooled to rt. Water (3 ml) and Et0Ac (4 ml) were added to the mixture. The aqueous layer was separated and the organic layer extracted with 1M aq. NaOH (1 m1). The aqueous layers were combined and pH adjusted to ¨3 using 2M aq. HC1. The formed precipitate was collected, washed with water and dried to give the product as a solid (3-chloro-5-methy1-5H-chromeno[4,3-clpyridine-8-carboxylic acid). The solid was taken up in SOC12 (2 ml, 27.4 mmol). A drop of DMF was added to the resulting solution and the resulting mixture was stirred at 70 C
for 1 h. When cooled to rt the mixture was concentrated and the resulting residue was taken up in DCM (5 ml) and added slowly to 40% aq. dimethylamine (3 ml, 23.9 mmol) at rt. The resulting mixture was stirred at rt for 1 h and the organic layer separated. The aqueous layer was extracted with DCM (2 x 3 ml) and the combined organics were washed with sat. aq. NaHCO3, dried over Na2SO4, filtered, concentrated and purified on a silica gel column eluted with 0-100% Et0Ac in heptane to give the product as an oil (75 mg, 38%). MS ES+ m/z 303 [M+1-11+.
Example 4: Intermediate 4-- 1-(5-Amino-3-pyridyl)pyrrolidin-2-one N, I
[0261] 5-Bromopyridin-3-amine (10 g, 57.8 mmol), pyrrolidin-2-one (9 ml, 63.2 mmol), K2CO3 (15 g, 115.6 mmol), Cul (1.1 g, 5.78 mmol) and DMEDA (1.3 ml, 8.42 mmol) were taken up in 1,4-dioxane (100 ml) and the resulting mixture was refluxed overnight. After cooling to rt, Et0Ac was added and the mixture filtered through celite. The filtrate was concentrated and purified on a silica gel column to give the product as a solid (6 g, 59%). MS
ES+ m/z 178 [M+I-11+.
Example 5: Intermediate 5 -- (5S)-5-1(3-bromo-5-nitro-2-pyridyl)oxymethyl]pyrrolidin-2-one HN
[0262] 3-Bromo-2-chloro-5-nitro-pyridine (1 g, 4.21 mmol), (5 S)-5 -(hy droxymethyl)pyrrolidin-2-one (500 mg, 4.34 mmol) and K2CO3 (700 mg, 5.06 mmol) were taken up in MeCN (10 ml) and the resulting mixture was stirred at 70 C
overnight. More (55)-5-(hydroxymethyl)pyrrolidin-2-one (130 mg, 1.13 mmol) and K2CO3 (300 mg, 2.17 mmol) were added and stirring continued at 70 C for 5 h. After cooling to rt, the mixture was diluted with water (10 ml) and Et0Ac (10 ml) and the organic layer separated. The remaining aqueous layer was further extracted with Et0Ac (2 x 10 ml) and the combined organics were washed with brine, dried over Na2SO4, filtered and concentrated to give the product as a solid (1.13 g, 85%). MS ES+ m/z 316 [M+I-11+.
Example 6: Intermediate 6 -- (6S)-12-nitro-8-oxa-2,10-diazatricyclo17.4Ø02,61trideca-1(9),10,12-trien-3-one I
[0263] (5 S)-5-[(3-bromo-5 -nitro-2-py ri dy Doxy methyl] pyrroli din-2-one (1.13 g, 3.57 mmol), Cul (75 mg, 0.39 mmol), N,N'-dimethylethylenediamine (85 [11, 0.8 mmol) and K2CO3 (0.99 g, 7.15 mmol) were taken up in Et0Ac (20 ml) and the resulting mixture was stirred at 70 C for 2 h. More CuI (75 mg, 0.39 mmol) and N,N'-dimethylethylenediamine (85 [11, 0.8 mmol) were added and the mixture was refluxed for 2 h. Cs2CO3 (2 g, 6.14 mmol) and 1,4-dioxane (20 ml) were added and stirring continued at 100 C overnight. When cooled to rt the mixture was filtered through celite and rinsed with Et0Ac (2 x 5 m1). The filtrate was washed with half-saturated brine (20 ml), dried over Na2SO4, filtered and concentrated to give the product as a solid (720 mg, 86%). MS ES+ m/z 236 [M+1-11+.
Example 7: Intermediate 7 -- (68)-12-amino-8-oxa-2,10-diazatricyclo[7.4Ø02,6]trideca-1(9),10,12-trien-3-one I
[0264] (6S )-12-nitro-8-oxa-2,10-diazatricy clo [7. 4Ø 02,61trideca-1 (9),10,12-trien-3 -one (357 mg, 1.52 mmol), Fe (509 mg, 9.11 mmol) and ammonium chloride (244 mg, 4.55 mmol) were taken up in Et0H/H20 (4:1, 12.5 ml) and the resulting mixture was refluxed for 1.5 h. After cooling to rt the mixture was filtered through celite, rinsed with Me0H and the filtrate was concentrated. The resulting residue was suspended in water and pH
was adjusted to about ¨7 by careful addition of a sat. aq. NaHCO3. The mixture was extracted with Et0Ac and the combined organics were dried over Na2SO4, filtered and concentrated to give the product as a solid (212 mg, 68%). MS ES+ m/z 206 [M+1-11+.
Example 8: Intermediate 8 -- Methyl 4-[6-chloro-4-Icyclopropyl(hydroxy)methyl]-pyridy1]-3-fluoro-benzoate HO
N CI
[0265] The title compound was prepared as described in Intermediate 2, replacing MeMgC1 for bromo(cyclopropyl)magnesium, to give the product as a solid (1.2 g, 99%).
MS ES+ m/z 336 [M+H]+.
Example 9: Intermediate 9 -- 3-Chloro-5-cyclopropy1-5H-chromeno[4,3-c]pyridine-carboxylic acid HO
N CI
[0266] NaH (60%
in mineral oil, 429 mg, 10.7 mmol) was added to a solution of methyl 4-[6-chloro-44cyclopropyl(hydroxy)methy11-3-pyridy11-3-fluoro-benzoate (1.2 g, 3.57 mmol) in THF (15 ml) at 0 C under a nitrogen atmosphere. The mixture was stirred at 50 C for 4 h.
When cooled to rt, water (10 ml) and Et0Ac (20 ml) were added, the aqueous layer was separated and the organic layer extracted with 1M aq. NaOH (10 m1). The aqueous layers were combined and pH adjusted to about ¨3 using 2M aq. HC1. The formed precipitate was collected, washed with water and dried to give the product as a solid (900 mg, 84%). MS
ES+ m/z 302 [M+H]+.
Example 10: Intermediate 10 -- 3-Chloro-5-cyclopropyl-N,N-dimethy1-5H-chromeno [4,3-c] pyridine-8-carboxamide HqC 0 N CI
[0267] 3-Chloro-5-cyclopropy1-5H-chromeno [4,3-clpyridine-8-carboxylic acid (900 mg, 2.66 mmol), N-methylmethanamine HC1 (326 mg, 3.99 mmol), HBTU (1.11 g, 2.93 mmol) and TEA (1.11 ml, 7.98 mmol) were dissolved in DMF and the mixture was stirred at rt overnight. Water and Et0Ac were added, the organic layer separated and the aqueous layer extracted with Et0Ac. The combined organics were concentrated and purified on silica gel column, eluted with 50% Et0Ac in heptane, to give the product as a solid (600 mg, 69%). MS
ES+ m/z 329 [M+Hr.
Example 11: Intermediate 11 -- 4-(6-Chloro-4-formy1-3-pyridy1)-3-fluoro-N,N-dimethyl-benzamide H3CõN 0 N CI
[0268] The title compound was prepared as described in Intermediate 1, replacing (2-Fluoro-4-methoxycarbonyl-phenyl)boronic acid for [4-(dimethylcarbamoy1)-2-fluoro-phenyllboronic acid, to give the product as a gum (1.2 g, quant). MS ES+ m/z 307 [M+I-11+.
Example 12: Intermediate 12 -- 4-16-Chloro-4-(1-hydroxyethyl)-3-pyridy1]-3-fluoro-N,N-dimethyl-benzamide H3C,N sHO C H3 N CI
[0269] The title compound was prepared as described in Intermediate 2, starting from 4-(6-chloro-4-formy1-3-pyridy1)-3-fluoro-N,N-dimethyl-benzamide, to give the product as a gum (1.19 g, 94%). MS ES+ m/z 323 [M+F11+.
Example 13: Intermediate 13 -- 4-(4-Acety1-6-chloro-3-pyridy1)-3-fluoro-N,N-dimethyl-benzamide N CI
[0270] Dess-Martin periodinane (2 g, 4.72 mmol) was added to a solution of 4-[6-chloro-4-(1-hydroxyethyl)-3-pyridy11-3-fluoro-N,N-dimethyl-benzamide (1.10 g, 3.41 mmol) in DCM (15 ml) at rt and the resulting mixture was stirred at rt for 1 h. Sat.
aq. Na2S203 (10 ml) and sat. aq. NaHCO3 (20 ml) were added, the mixture was stirred at rt for 30 min and then filtered. The filter cake was washed with DCM (2 x 3 ml) and discarded. The organic layer was separated and the aqueous layer extracted with DCM (2 x 10 m1). The combined organics were washed with sat. aq. NaHCO3 (15 ml), dried over Na2SO4, filtered, concentrated and purified on a silica gel column eluted with 0-100% Et0Ac in heptane to give the product as a solid (828 mg, 76%). MS ES+ m/z 321 [M-411+.
Example 14: Intermediate 14 -- 3-Chloro-N,N,5,6-tetramethy1-5H-benzo[c][2,6]naphthyridine-8-carboxamide 0 C Fiq I
HqC N C H3 N CI
[0271] 4-(4-Acetyl-6-chloro-3-pyridy1)-3-fluoro-N,N-dimethyl-benzamide (300 mg, 0.94 mmol) was taken up in 2-methyltetrahydrofuran (5 ml) and titanium(IV) isopropoxide (560 IA, 1.87 mmol) was added. After 15 min at rt 40% MeNH2 in Me0H (600 IA, 5.34 mmol) was added and the resulting mixture was stirred at rt over weekend. Me0H (3 ml) was added and the mixture cooled to 0 C. NaBH4 (177 mg, 4.68 mmol) was added portion-wise and after 10 min the cooling bath was removed and the mixture stirred at rt for 3 h. Water (10 ml), sat. aq.
NH4C1 (5 ml) and Et0Ac (5 ml) were added and the mixture stirred at rt for 30 min. The organic layer was separated and the aqueous layer extracted with Et0Ac (3 x 5 m1). The combined organics were washed with brine, dried over Na2SO4, filtered, concentrated and purified on a silica gel column eluted with 0-100% Et0Ac in heptane to give the product as a gum (130 mg, 44%). MS ES+ m/z 316 [M+Hr.
Example 15: Intermediate 15 -- 12-Fluoro-4-(2-oxopyrrolidin-1-yl)phenyl]boronic acid ' F OH
[0272] n-BuLi (2.5M in hexanes, 5.20 ml, 13 mmol) was added dropwise over 10 min to a solution of 1-(4-bromo-3-fluoro-phenyl)pyrrolidin-2-one (3 g, 11.6 mmol) and triisopropyl borate (3.5 ml, 15.2 mmol) in THF (20 ml) at -78 C and the resulting mixture was stirred for 3 h. More n-BuLi (2.5M in hexanes, 5.20 ml, 13 mmol) was added dropwise over 5 min and the resulting mixture was stirred for 1.5 h. Water (10 ml) was added and the mixture allowed to reach rt. Diethylether (20 ml) was added and the aqueous layer separated.
The organic layer was extracted with 1M aq. NaOH (10 ml) and the aqueous layers were combined.
The pH was adjusted to about ¨1 using conc. HC1 and the mixture was extracted with Et0Ac (3 x 10 m1).
The combined organics were dried over Na2SO4, filtered and concentrated to give the product as a solid (1.45 g, 43%), which was used in the next step. MS ES+ m/z 224 [M+Hl+.
Example 16: Intermediate 16 -- 2-Chloro-5-12-fluoro-4-(2-oxopyrrolidin-1-yl)phenyl]pyridine-4-carbaldehyde N CI
[0273] The title compound was prepared as described in Intermediate 1, replacing (2-fluoro-4-methoxycarbonyl-phenyl)boronic acid for [2-fluoro-4-(2-oxopyrrolidin-yOphenyllboronic acid, to give the product as a gum (475 mg, 25%). MS ES+ m/z 319 [M+Hl+.
Example 17: Intermediate 17 -- 1-14-16-Chloro-4-(1-hydroxyethy1)-3-pyridy1]-3-fluoro-phenyl] pyrrolidin-2-one F I
N CI
[0274] The title compound was prepared as described in Intermediate 2, starting from 2-chl oro-5 - [2-fluoro-4-(2-oxopy rroli din-1 -y Opheny py ridine-4-carb al dehy de, to give the product as a gum (460 mg, 92%). MS ES+ m/z 335 [M+1-1[+.
Example 18: Intermediate 18 -- 1-(3-Chloro-5-methyl-5H-chromeno[4,3-c]pyridin-yl)pyrrolidin-2-one I
N CI
[0275] The title compound was prepared as described in Intermediate 9, starting from 1-[4- [6-chl oro-4-(1-hy droxy ethyl)-3-pyridyll -3-fluoro-pheny py rroli din-2-one, stirring the mixture at rt for 2 h and purification on a silica gel column eluted with 0-80% Et0Ac in heptane, to give the product as a solid (300 mg, 71%). MS ES+ m/z 315 [M+1-1[+.
Example 19: Intermediate 19 --1-(5-Amino-3-pyridyl)cyclopropanecarbonitrile cIAN
I I
[0276] rac-BINAP (73 mg, 0.12 mmol) and Pd2(dba)3 (53 mg, 0.06 mmol) were taken up in 1,4-dioxane (2 ml) and stirred at 50 C for 15 min. NaOtBu (224 mg, 2.33 mmol), dipheny lmethani mine (235 1, 1.40 mmol) and 1 -(5 -bromo-3-pyridy0cyclopropanecarbonitrile (260 mg, 1.17 mmol) were added together with 1,4-dioxane (3 ml) and the resulting mixture was stirred at 100 C for 1.5 h. When cooled to rt Et0H (5 ml) was followed by hydroxylamine HC1 (162 mg, 2.33 mmol) and sodium acetate (287 mg, 3.50 mmol) and the resulting mixture was stirred at rt overnight. The mixture was heated at 70 C
for 1 h. More Hydroxylamine chloride (162 mg, 2.33 mmol) and sodium acetate (287 mg, 3.50 mmol) were added and stirring continued at 70 C for 2 h. When cooled to rt the mixture was concentrated and the resulting residue was taken up in half-saturated NaHCO3 (10 ml) and Et0Ac (10 m1). The organic layer was separated and the aqueous layer extracted with Et0Ac (2 x 10 m1). The combined organics were washed with brine, dried over Na2SO4, filtered, concentrated and purified on a silica gel column eluted with 0-50% (10% Me0H
in Et0Ac with NH3) in heptane to give the product as an oil (110 mg, 59%). MS ES+ m/z 160 [M+1-11+.
Example 20: Intermediate 20 -- 1-(7-Bromo-2,3-dihydropyrido[2,3-b][1,41oxazin-ypethanone Br N
[0277] 7-Bromo-2,3-dihydro-1H-pyrido[2,3-b][1,41oxazine (1 g, 4.65 mmol) and Et3N
(971 1,11, 6.98 mmol) were taken up in 2-MeTHF (5 ml) and cooled to 0 C.
Acetyl chloride (398 1,11, 5.58 mmol) was added and the resulting mixture was stirred at rt for 1 h. DCM (10 ml) was added followed by acetyl chloride (398 1, 5.58 mmol) and the mixture was stirred at rt for 1 h. Et0Ac (20 ml) and water (10 ml) were added and the organic layer separated. To the aqueous layer was added 2M aq. NaOH (5 ml) and Et0Ac (10 ml) and the organic layer separated. The combined organics were washed with sat. aq. NaHCO3, brine, dried over Na2SO4, filtered and concentrated. Recrystallization from 2-propanol gave the product as a white solid (875 mg, 73%). MS ES+ m/z 257 [M+H1+.
Example 21: Intermediate 21 -- tert-Butyl N-(1-acetyl-2,3-dihydropyrido[2,3-b] [1,4] oxazin-7-yl)carbamate H3C1 ii I
[0278] The title compound was prepared as described in Example 31, replacing pyridine-3-amine for tert-butyl carbamate and 3-chloro-N,N,5-trimethy1-5H-chromeno[4,3-clpyridine-8-carboxamide for 1-(7-bromo-2,3-dihydropyrido [2,3 -b] [1,4] oxazin-1 -ypethanone, to give the product as a solid (157 mg, 28%). MS ES+ m/z 294 [M+Hr.
Example 22: Intermediate 22 -- 1-(7-Amino-2,3-dihydropyrido[2,3-b][1,4]oxazin-yl)ethenone I
[0279] tert-Butyl N-(1-acety1-2,3 -dihy dropy ri do [2,3-b] [1,4] oxazin-7-yl)carbamate (157 mg, 0.54 mmol) was dissolved in DCM (3 mL). TFA (0.41 ml, 5.35 mmol) was added and the reaction was stirred at room temperature for 2 h. The mixture was concentrated and the resulting residue was dissolved in Et0Ac and washed with sat. aq. Na2CO3 and brine. The organic layer was dried over MgSO4, filtered and concentrated to give the product as a solid (106 mg, quant.). MS ES+ m/z 194 [M+H1+.
Example 23: Intermediate 23 -- 1-[4-(4-Acetyl-6-chloro-3-pyridy1)-3-fluoro-phenyl] pyrrolidin-2-one F I
N CI
[0280] The title compound was prepared as described in Intermediate 13, replacing 4-[6-chloro-4-(1-hy droxy ethyl)-3 -py ridyl] -3-fluoro-N,N-dimethyl-b enzami de for 1- [446-chloro-4-(1-hydroxy ethyl)-3-pyridy11-3-fluoro-phenyll pyrrolidin-2-one, to give the product as a solid (250 mg, 84%). MS ES+ m/z 333 [M+H1+.
Example 24: Intermediate 24 -- 1-[4-[6-Chloro-4-11-(methylamino)ethy1]-3-pyridyl]-3-flu oro-p henyl] pyrrolidin-2-one N CI
[0281] 1 44-(4-Acety1-6-chl oro-3 -py ri dy1)-3-fl uoro-phenyl] pyrroli din-2-one (250 mg, 0.75 mmol) was taken up in 2-MeTHF (5 ml) and titanium(IV) isopropoxide (500 [1.1, 1.68 mmol) was added. After 15 min at rt MeNH2 in THF (2M, 2.25 ml, 4.51 mmol) was added and the resulting mixture was stirred at rt overnight. Me0H (3 ml) was added and the mixture cooled to 0 C. NaBH4 (142 mg, 3.76 mmol) was added portion wise and after 10 min the cooling bath was removed and the mixture stirred at rt for 3 h. Water, sat.
aq. NH4C1 and Et0Ac were added and the mixture stirred at rt for 30 min. The organic layer was separated and the aqueous layer extracted with Et0Ac. The combined organics were washed with brine, dried over Na2SO4, filtered and concentrated to give the product as a solid (242 mg, 93%). MS ES+
m/z 348 [M+1-11+.
Example 25: Intermediate 25 -- 1-(3-Chloro-5,6-dimethy1-5H-benzo [c] [2,6] naphthyridin-8-yl)pyrrolid in-2-one I
N CI
[0282] The title compound was prepared as described in Intermediate 9, except starting from 1- [4- [6-chloro-4- [1 -(methylamino)ethyl] -3-py ri dyl] -3 -fluoro-phenyl] pyrroli din-2-one, quenching with Me0H and concentrating the mixture, to give the crude product as a solid (245 mg, quant.). MS ES+ m/z 328 [M+1-11+.
Example 26: Intermediate 26 -- 1-(4-Bromo-2,5-difluoro-phenyl)pyrrolidin-2-one ciN F
Br [0283] 1-Bromo-2,5-difluoro-4-iodo-benzene (5 g, 15.7 mmol), Cul (450 mg, 2.36 mmol) and CsF (5.4 g, 35.5 mmol) were taken up in Et0Ac (30 ml) and the resulting mixture was degassed with nitrogen for 10 min. Pyrrolidin-2-one (1.31 ml, 17.2 mmol) and N,N'-dimethylethylenediamine (0.5 ml, 4.7mmo1) were added and the resulting mixture was stirred at 50 C for 4 h. More CuI (450 mg, 2.36 mmol) and N,N'-dimethylethylenediamine (0.5 ml, 4.7 mmol) were added and stirring continued overnight. More CuI (450 mg, 2.36 mmol), N,N'-dimethylethylenediamine (0.5 ml, 4.7 mmol), CsF (2 g, 13.17 mmol), pyrrolidin-2-one (0.75 ml, 9.85 mmol) and Et0Ac (15 ml) were added and stirring continued at 80 C
overnight.
When cooled to rt the mixture was filtered, the filter cake washed with Et0Ac (2 x 10 ml) and the filtrate washed with 0.5M aq. HC1 (60 ml), 5% NH4OH (50 ml), brine, dried over Na2SO4, filtered, concentrated and purified on a silica gel column eluted with 0-75%
Et0Ac in heptane to give the product as a solid (2.13 g, 49%). MS ES+ m/z 276 [M+1-11+.
Example 27: Intermediate 27 -- 1-12,5-Difluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl] pyrrolidin-2-one c c H3 [0284] 1-(4-Bromo-2,5-difluoro-phenyl)pyrrolidin-2-one (2.10 g, 7.61 mmol), 4,4,5,5-tetramethy1-2-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-y1)-1,3,2-dioxaborolane (2.50 g, 9.84 mmol) and KOAc (2.24 g, 22.8 mmol) were taken up in toluene (10 ml) and degassed with nitrogen for 5 min. Pd(dppf)C12 (500 mg, 0.68 mmol) was added and the resulting mixture was stirred at 100 C overnight. When cooled to rt Et0Ac (10 ml) and water (10 ml) were added to the mixture and the mixture filtered through celite. The organic layer was separated and the aqueous layer extracted with Et0Ac (2 x 10 m1). The combined organics were washed with brine, stirred with Na2SO4 and active charcoal, filtered through a plug of silica and concentrated to give the product as a solid, which was used without further purification (2.9 g). MS ES+ m/z 324 [MA41+.
Example 28: Intermediate 28 -- 2-Chloro-5-[2,5-difluoro-4-(2-oxopyrrolidin-1-yl)phenyl]pyridine-4-carbaldehyde N CI
[0285] The title compound was prepared as described in Intermediate 1, replacing (2-Fluoro-4-methoxy carbonyl-phenyl)boronic acid for 1-[2,5-difluoro-4-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-yOphenyllpyrrolidin-2-one, using 1,4-dioxane instead of MeCN and stirring the mixture at 90 C for 1 h, to give the product as a solid (1.37 g, 64%). MS ES+ m/z 337 [M+H]+.
Example 29: Intermediate 29 -- 1-14-16-Chloro-4-(1-hydroxyethyl)-3-pyridy1]-2,5-difluoro-phenyl] pyrrolidin-2-one N CI
[0286] The title compound was prepared as described in Intermediate 2, starting from 2-chl oro-5 - [2,5-difluoro-4-(2-oxopyrroli din-1 -y Ophenyll py ri dine-4-carb al dehy de, to give the product as a gum (1.19 g, 94%). MS ES+ m/z 353 [M+1-11+.
Example 30: Intermediate 30 -- 1-(3-Chloro-9-fluoro-5-methy1-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one 0 cH3 N CI
[0287] The title compound was prepared as described in Intermediate 9, starting from 1-[4- [6-chl oro-4-(1-hy droxy ethyl)-3-pyridyll -2,5-difluoro-phenyl] py rroli din-2-one, stirring the mixture at rt for 2 h and purification on a silica gel column eluted with 0-80% Et0Ac in heptane, to give the product as a solid (685 mg, 54%). MS ES+ m/z 333 [M+1-11+.
Example 31: N,N,5-trimethy1-3-(pyridin-3-ylamino)-5H-chromeno [4,3-c] pyridine-carboxamide H 3C 1\1 0 C H3 /N
I
N
[0288] XantPhos (14 mg, 0.03 mmol) and Pd2(dba)3 (11 mg, 0.01 mmol) were taken up in 1,4-dioxane (2 ml) and stirred at 50 C for 20 min. A solution of 3-chloro-N,N,5-trimethy1-5H-chromeno[4,3-clpyridine-8-carboxamide (75 mg, 0.25 mmol) in 1,4-dioxane (2 ml) was added followed by pyridin-3-amine (30 mg, 0.32 mmol) and NaOtBu (64 mg, 0.66 mmol) and the resulting mixture was stirred at 100 C for 2 h. After cooling at rt, the mixture was diluted with Et0Ac (3 ml) and filtered. The filtrate was concentrated and the resulting residue was dissolved in Me0H, filtered and purified by preparative HPLC to give the product as a solid. NMR
(500 MHz, DMSO-d6) 6 ppm 1.55 (d, J=6.62 Hz, 3 H), 2.96 (br s, 6 H), 5.29 -5.36 (m, 1 H), 6.75 (s, 1 H), 6.96 (d, J=1.58 Hz, 1 H), 7.07 (dd, J=7.88, 1.58 Hz, 1 H), 7.29 - 7.36 (m, 1 H), 7.93 (d, J=8.20 Hz, 1 H), 8.13 (dd, J=4.73, 1.26 Hz, 1 H), 8.22 (ddd, J=8.35, 2.68, 1.58 Hz, 1 H), 8.73 (s, 1 H), 8.83 (s, 1 H), 9.50 (s, 1 H). MS ES+ m/z 361 [M+1-11+.
Example 32: N,N,5-trimethy1-3-05-(2-oxopyrrolidin-1-yl)pyridin-3-yl)amino)-5H-chromeno[4,3-c]pyridine-8-carboxamide H3C'N
CH3 el N, I
N
[0289] The title compound was prepared as described in accordance with the accordance with the procedures of Example 31, replacing pyridine-3-amine for 1-(5-amino-3-pyridyl)pyrrolidin-2-one and stirring at 100 C overnight, to give the product as a solid (6 mg, 4%). NMR (500 MHz, CHLOROFORM-d) 6 ppm 1.63 (d, J=6.62 Hz, 3 H), 2.21 -2.30 (m, 2 H), 2.63 -2.69 (m, 2 H), 3.04 - 3.09 (m, 3 H), 3.14 (br s, 3 H), 3.96 (t, J=7.09 Hz, 2 H), 5.20 (q, J=6.73 Hz, 1 H), 6.83 (s, 1 H), 7.05 (s, 1 H), 7.12 (d, J=7.83 Hz, 1 H), 7.73 (d, J=7.88 Hz, 1 H), 7.77 - 7.92 (m, 1 H), 8.41 (br s, 1 H), 8.54 - 8.61 (m, 2 H), 8.73 (s, 1 H). MS ES+ m/z 444 [M+H1+.
Example 33: N,N,5-trimethy1-3-0(S)-9-oxo-6a,7,8,9-tetrahydro-6H-pyrido[2,3-b]pyrrolo [1,2-d] [1,4] oxazin-2-yl)amino)-5H-chromeno[4,3-c] pyridine-8-carboxamide I
N N
[0290] The title compound was prepared as described in accordance with the procedures of Example 31, replacing pyridine-3-amine for (6S)-12-amino-8-oxa-2,10-diazatricyclo[7.4Ø0^{2,6}1trideca-1(9),10,12-trien-3-one and stirring at 100 C overnight, to give the product as a solid (6 mg, 3%). 1FINMR (500 MHz, METHANOL-d4) 6 ppm 1.60 (dd, 3 H), 1.75 - 1.84 (m, 1 H), 2.32 - 2.40 (m, 1 H), 2.52 (ddd, 1 H), 2.71 - 2.80 (m, 1 H), 3.07 (s, 3 H), 3.12 (s, 3 H), 3.92 - 4.00 (m, 1 H), 4.11 - 4.18 (m, 1 H), 4.65 (dd, 1 H), 5.20 (q, 1 H), 6.65 (s, 1 H), 7.01 (d, 1 H), 7.10 (dd, 1 H), 7.86 (d, 1 H), 8.29 (d, 1 H), 8.58 (s, 1 H), 9.12 (dd, 1 H). MS ES+ m/z 472 [M+H1+.
Example 34: 5-cyclopropyl-N,N-dimethy1-3-(pyridin-3-ylamino)-5H-chromeno[4,3-c]pyridine-8-carboxamide H 3C,.N 0 /N
I
N N
[0291] The title compound was prepared as described in accordance with the procedures of Example 31, replacing 3-chloro-N,N,5-trimethy1-5H-chromeno[4,3-clpyridine-8-carboxamide for 3-chloro-5-cyclopropyl-N,N-dimethy1-5H-chromeno[4,3-clpyridine-carboxamide and stirring at 100 C overnight, to give the product as a solid (15 mg, 6%). 11-1 NMR (500 MHz, METHANOL-d4) 6 ppm 0.50 - 0.62 (m, 2 H), 0.66 - 0.77 (m, 2 H), 1.26 -1.33 (m, 1 H), 3.05 (s, 3 H), 3.10 (s, 3 H), 4.33 (d, J=8.83 Hz, 1 H), 6.89 (s, 1 H), 7.02 (s, 1 H), 7.09 (d, J=7.69 Hz, 1 H), 7.24 - 7.40 (m, 1 H), 7.86 (d, J=7.88 Hz, 1 H), 8.09 (dd, J=4.73, 1.58 Hz, 1 H), 8.27 (ddd, J=8.43, 2.60, 1.26 Hz, 1 H), 8.63 (s, 1 H), 8.83 (d, J=2.21 Hz, 1 H). MS
ES+ m/z 387 [M+Hr.
Example 35: 5-cyclopropyl-N,N-dimethy1-3-05-(2-oxopyrrolidin-1-yl)pyridin-3-yl)amino)-5H-chromeno[4,3-c]pyridine-8-carboxamide H 3C'N
N
[0292] The title compound was prepared as described in accordance with the procedures of Example 31, replacing pyridine-3-amine for 1-(5-amino-3-pyridyl)pyrrolidin-2-one and 3-chl oro-N,N,5 -trimethy1-5H-chromeno [4,3 -c] pyri dine-8-carboxami de for .. 3 -Chl oro-5 -cyclopropyl-N,N-dimethy1-5H-chromeno[4,3-clpyridine-8-carboxamide, and stirring at 100 C overnight, to give the product as a solid (35 mg, 20%). 11-1 NMR (500 MHz, DMSO-d6) 6 ppm 0.50 - 0.60 (m, 2 H), 0.63 - 0.76 (m, 2 H), 1.23 - 1.32 (m, 1 H), 2.08 -2.17 (m, 2 H), 2.53 - 2.56 (m, 2 H), 2.94 - 3.03 (m, 6 H), 3.85 - 3.92 (m, 2 H), 4.46 - 4.52 (m, 1 H), 6.94 - 6.97 (m, 1 H), 6.99 (d, J=1.58 Hz, 1 H), 7.07 (dd, J=7.88, 1.58 Hz, 1 H), 7.96 (d, J=7.88 Hz, 1 H), 8.39 (d, J=2.21 Hz, 1 H), 8.59 (t, J=2.21 Hz, 1 H), 8.75 - 8.76 (m, 1 H), 8.77 -8.79 (m, 1 H), 9.61 (s, 1 H). MS ES+ m/z 470 [M+H1+.
Example 36: 5-cyclopropyl-N,N-dimethy1-3-0(S)-9-oxo-6a,7,8,9-tetrahydro-6H-pyrido[2,3-b]pyrrolo [1,2-d] [1,4] oxazin-2-yl)amino)-5H-chromeno[4,3-c]
pyridine-8-carboxamide Ff/C 0 1\1 I
N
[0293] The title compound was prepared as described in in accordance with the procedures of Example 31, replacing pyridine-3-amine for (6S)-12-amino-8-oxa-2,10-diazatricyclo[7.4Ø02,6]trideca-1(9),10,12-trien-3-one and 3-chloro-N,N,5-trimethy1-5H-chromeno [4,3-c] py ri dine-8-carb oxami de for 3-chl oro-5 -cy cl opropyl-N,N-dimethy1-5H-chromeno[4,3-clpyridine-8-carboxamide, and stirring at 100 C overnight, to give the product as a solid (6 mg, 4%). 11-1NMR (500 MHz, DMSO-d6) 6 ppm 0.55 (td, J=7.96, 4.89 Hz, 2 H), 0.62 - 0.71 (m, 2 H), 1.22 - 1.29 (m, 1 H), 1.67 - 1.75 (m, 1 H), 2.20 - 2.26 (m, 1 H), 2.39 (br d, J=1.58 Hz, 1 H), 2.65 -2.74 (m, 1 H), 2.97 (br s, 6 H), 3.91 (t, J=10.56 Hz, 1 H), 4.05 -4.11 (m, 1 H), 4.45 (dd, J=9.14, 2.21 Hz, 1 H), 4.59 (dd, J=10.88, 2.99 Hz, 1 H), 6.87 (s, 1 H), 6.98 (d, J=1.58 Hz, 1 H), 7.06 (dd, J=7.88, 1.89 Hz, 1 H), 7.93 (d, J=8.20 Hz, 1 H), 8.44 (s, 1 H), 8.68 (s, 1 H), 8.97 (dd, J=2.52, 1.58 Hz, 1 H), 9.40 (s, 1 H). MS ES+ m/z 498 [M+Hr.
Example 37: N,N,5,6-tetramethy1-3-(pyridin-3-ylamino)-5,6-dihydrobenzo[c][2,6]naphthyridine-8-carboxamide N
N
[0294]
Pd2(dba)3 (18 mg, 0.02 mmol) and BrettPhos (21 mg, 0.04 mmol) were taken up in 1,4-dioxane (1 ml) and stirred at 50 C for 15 min. A solution of 3-chloro-N,N,5,6-tetramethyl-5H-benzo[c][2,61naphthyridine-8-carboxamide (125 mg, 0.4 mmol) in 1,4-dioxane (3 ml), pyridin-3-amine (56 mg, 0.59 mmol) and Cs2CO3 (358 mg, 1.10 mmol) were added and the resulting mixture was stirred at 100 C overnight. After cooling to rt, Et0Ac (5 ml) and half-saturated brine (5 ml) were added to the mixture and the organic layer separated. The remaining aqueous layer was further extracted with Et0Ac (5 m1). The combined organics where washed with brine, dried over Na2SO4, filtered, concentrated and purified by preparative HPLC to give the product as a solid (48 mg, 33%). 11-1 NMR (500 MHz, DMSO-d6) 6 ppm 1.07 (d, J=6.62 Hz, 3 H), 2.92 (s, 3 H), 2.97 (br s, 6 H), 4.51 (q, J=6.52 Hz, 1 H), 6.65 (d, J=1.58 Hz, 1 H), 6.67 (s, 1 H), 6.78 (dd, J=7.57, 1.58 Hz, 1 H), 7.28 - 7.31 (m, 1 H), 7.82 (d, J=7.88 Hz, 1 H), 8.10 (dd, J=4.57, 1.42 Hz, 1 H), 8.21 (ddd, J=8.35, 2.68, 1.58 Hz, 1 H), 8.70 (s, 1 H), 8.80 -8.82 (m, 1 H), 9.36 (s, 1 H). MS ES+ m/z 374 [M+H1+.
Example 38: 1-(5-methyl-3-(pyridin-3-ylamino)-5H-chromeno [4,3-c] pyridin-8-yl)pyrrolidin-2-one 0 N, I
N
[0295] The title compound was prepared as described in accordance with the procedures of Example 31, replacing 3-chloro-N,N,5-trimethy1-5H-chromeno[4,3-clpyridine-8-carboxamide for 1-(3-chloro-5-methyl-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one, to give the product as a solid (12 mg, 10%). 11-1 NMR (500 MHz, DMSO-d6) 6 ppm 1.54 (d, J=6.62 Hz, 3 H), 2.03 - 2.10 (m, 2 H), 2.49 - 2.51 (m, 2 H, obscured by DMSO), 3.81 - 3.90 (m, 2 H), 5.25 - 5.31 (m, 1 H), 6.75 (s, 1 H), 7.28 - 7.34 (m, 2 H), 7.41 (d, J=2.21 Hz, 1 H), 7.88 (d, J=8.51 Hz, 1 H), 8.12 (dd, J=4.73, 1.58 Hz, 1 H), 8.23 (ddd, J=8.43, 2.60, 1.58 Hz, 1 H), 8.67 (s, 1 H), 8.83 (d, J=2.21 Hz, 1 H), 9.46 (s, 1 H). MS ES+ m/z 373 [M+H1+.
Example 39: 1-(5-45-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno [4,3-c] pyrid in-3-yl)amino)pyrid in-3-yl)cyclo p rop ane-1-carb nitrite N N
NI I
[0296] The title compound was prepared as described in accordance with the procedures of Example 31, replacing pyridine-3-amine for 1-(5-amino-3-pyridyl)cyclopropanecarbonitrile and 3 -chl oro-N,N,5 -trimethy1-5H-chromeno [4,3 -c] py ri dine-8-carb oxami de for 1-(3-chloro-5-methy1-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one, to give the product as a solid (15 mg, 7%). 11-1 NMR (500 MHz, DMSO-d6) 6 ppm 1.54 (d, J=6.62 Hz, 3 H), 1.69 -1.77 (m, 2 H), 1.89 - 1.97 (m, 2 H), 2.02 - 2.10 (m, 2 H), 2.52 - 2.64 (m, 2 H), 3.81 -3.91 (m, 2 H), 5.34 (q, J=6.62 Hz, 1 H), 6.85 (s, 1 H), 7.34 (dd, J=8.83, 2.21 Hz, 1 H), 7.41 (d, J=2.21 Hz, 1 H), 7.93 (d, J=8.83 Hz, 1 H), 8.22 (d, J=1.89 Hz, 1 H), 8.50 (t, J=1.89 Hz, 1 H), 8.77 (s, 1 H), 9.18 - 9.27 (m, 1 H), 10.30 (br s, 1 H). MS ES+ m/z 438 [M+Hr.
Example 40: (6aS)-2-05-methyl-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)-6,6a,7,8-tetrahydro-9H-pyrido [2,3-b] pyrrolo [1,2-d] [1,4] oxazin-9-one o I
N
[0297] The title compound was prepared as described in accordance with the procedures of Example 37, replacing pyridine-3-amine for (65)-12-amino-8-oxa-2,10-diazatricy clo [7.4Ø 02,6]trideca-1(9),10,12-trien-3-one and 3 -chloro-N,N,5-trimethy1-5H-chromeno [4,3-c] py ri dine-8-carb oxami de for 1-(3 -chl oro-5 -methyl-5H-chromeno [4,3 -clpyridin-8-yOpyrrolidin-2-one, and stirring at 100 C for 40 min, to give the product as a solid (113 mg, 39%). 11-1NMR (500 MHz, DMSO-d6) 6 ppm 1.53 (dd, J=6.62, 1.58 Hz, 3 H), 1.64 -1.78 (m, 1 H), 2.02 -2.11 (m, 2 H), 2.17 - 2.28 (m, 1 H), 2.37 - 2.50 (m, 2 H), 2.64 -2.72 (m, 1 H), 3.80- 3.93 (m, 3 H), 4.08 (tdd, J=9.62, 9.62, 6.94, 3.15 Hz, 1 H), 4.59 (dd, J=10.88, 2.99 Hz, 1 H), 5.25 (q, J=6.52 Hz, 1 H), 6.66 - 6.68 (m, 1 H), 7.24 - 7.39 (m, 1 H), 7.40 (d, J=2.21 Hz, 1 H), 7.87 (d, J=8.83 Hz, 1 H), 8.39 (dd, J=2.52, 1.26 Hz, 1 H), 8.60 (s, 1 H), 8.97 (dd, J=4.10, 2.52 Hz, 1 H), 9.29 (d, J=2.84 Hz, 1 H). MS ES+ nilz 484 [M+H1+.
Example 41: 1-(3-05-(difluoromethoxy)pyridin-3-yl)amino)-5-methyl-5H-chromeno[4,3-c] pyridin-8-yl)pyrrolidin-2-one 0 c H3 F
I
N NOLF
[0298] The title compound was prepared as described in accordance with the procedures of Example 31, replacing pyridine-3-amine for 5-(difluoromethoxy)pyridin-3-amine and 3-chloro-N,N,5-trimethy1-5H-chromeno[4,3-clpyridine-8-carboxamide for 1-(3-chloro-5-methy1-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one, to give the product as a solid (18 mg, 13%). NMR (500 MHz, DMSO-d6) 6 ppm 1.54 (d, J=6.62 Hz, 3 H), 2.02 - 2.09 (m, 2 H), 2.48 - 2.50 (m, 2 H, obscured by DMSO), 3.82 - 3.87 (m, 2 H), 5.29 (q, J=6.73 Hz, 1 H), 6.77 (s, 1 H), 7.30 (t, J=73.50 Hz, 1 H), 7.32 (dd, J=8.51, 2.21 Hz, 1 H), 7.41 (d, J=2.21 Hz, 1 H), 7.90 (d, J=8.51 Hz, 1 H), 8.00 (d, J=2.52 Hz, 1 H), 8.32 (t, J=2.36 Hz, 1 H), 8.62 (d, J=2.21 Hz, 1 H), 8.72 (s, 1 H), 9.72 (s, 1 H). MS ES+ nilz 439 [M+H1+.
Example 42: 1-(3-((1-acetyl-2,3-dihydro-1H-pyrido [2,3-b] [1,4] oxazin-7-yl)amino)-5-methyl-5H-chromeno[4,3-c] pyridin-8-yl)pyrrolidin-2-one N NN) [0299] The title compound was prepared as described in accordance with the procedure of Example 37, replacing pyridine-3-amine for 1-(7-amino-2,3-dihydropyrido[2,3-b]
[1,4loxazin-1-yl)ethenone and 3-chloro-N,N,5-trimethy1-5H-chromeno[4,3-clpyridine-8-carboxamide for 1-(3-chloro-5-methy1-5H-chromeno[4,3-clpyridin-8-yl)pyrrolidin-2-one, and stirring at 100 C for 40 min, to give the product as a solid (42 mg, 46%). 11-1NMR (500 MHz, DMSO-d6) 6 ppm 1.53 (d, J=6.62 Hz, 3 H), 2.00 - 2.13 (m, 2 H), 2.31 (s, 3 H), 2.48-2.50(m, 2 H, obscured by DMSO), 3.76 - 3.94 (m, 4 H), 4.32 - 4.40 (m, 2 H), 5.25 (q, J=6.62 Hz, 1 H), 6.66 (s, 1 H), 7.31 (dd, J=8.51, 2.21 Hz, 1 H), 7.39 (m, 1 H), 7.86 (d, J=8.83 Hz, 1 H), 8.27 (br s, 1 H), 8.60 (s, 1 H), 9.21 (s, 1 H). MS ES+ m/z 472 [M+Hl+.
Example 43: 1-(5,6-dimethy1-3-(pyridin-3-ylamino)-5,6-dihydrobenzo[c][2,6]naphthyridin-8-yl)pyrrolidin-2-one N
[0300] Pyridin-3-amine (121 mg, 1.29 mmol), 1-(3-chloro-5,6-dimethy1-5H-benzo[c][2,6lnaphthyridin-8-yOpyrrolidin-2-one (169 mg, 0.52 mmol) and Cs2CO3 (336 mg, 1.03 mmol) were taken up in DMF (2 ml) and the mixture was degassed with nitrogen for 5 min. BrettPhos Pd G3 (23 mg, 0.03 mmol) and BrettPhos (14 mg, 0.03 mmol) were added and the mixture was stirred at 120 C overnight. After cooling to rt, the mixture was filtered through celite and concentrated. The residue was dissolved in Et0Ac, washed with water, brine, concentrated and purified by preparative HPLC to give the product as a solid (7 mg, 3%). 11-1 NMR (500 MHz, CHLOROFORM-d) 6 ppm 1.17 (d, J=6.62 Hz, 2 H), 1.27 - 1.27 (m, 1 H), 2.19 (t, J=7.57 Hz, 2 H), 2.65 (t, J=8.04 Hz, 2 H), 3.01 (s, 3 H), 3.93 (t, J=7.09 Hz, 2 H), 4.33 (d, J=6.62 Hz, 1 H), 6.54 - 6.57 (m, 1 H), 6.58 (s, 1 H), 6.89 (dd, J=8.20, 2.21 Hz, 1 H), 7.33 (d, J=2.21 Hz, 1 H), 7.69 (d, J=8.51 Hz, 1 H), 7.90 - 7.97 (m, 1 H), 8.30 (dd, J=4.73, 1.26 Hz, 1 H), 8.61 (s, 1 H), 8.62 (s, 1 H). MS ES+ m/z 386 [M+1-11+.
Example 44: (6aS)-2-05,6-dimethy1-8-(2-oxopyrrolidin-1-y1)-5,6-dihydrobenzo [c] [2,6] naphthyridin-3-yl)amino)-6,6a,7,8-tetrahydro-9H-pyrido [2,3-b] pyrrolo [1,2-d] [1,4] oxazin-9-one I
N
[0301] The title compound was prepared as described in accordance with the procedure of Example 43, replacing pyridine-3-amine for (6S)-12-amino-8-oxa-2,10-diazatricyclo[7.4Ø02,61trideca-1(9),10,12-trien-3-one to give the product as a solid (23 mg, 14%). 1H NMR (500 MHz, DMSO-d6) 6 ppm 1.06 (dd, J=6.62, 2.84 Hz, 3 H), 1.63 -1.77 (m, 1 H), 2.02 -2.23 (m, 2 H), 2.19 -2.28 (m, 1 H), 2.39 (br d, J=16.39 Hz, 1 H), 2.62 - 2.73 (m, 1 H), 2.90 (s, 3 H), 3.82 - 4.01 (m, 3 H), 4.02 - 4.12 (m, 1 H), 4.45 (br d, J=6.62 Hz, 1 H), 4.58 (dd, J=10.72, 3.15 Hz, 1 H), 6.58 (s, 1 H), 6.98 (dd, J=8.51, 1.89 Hz, 1 H), 7.13 (d, J=1.89 Hz, 1 H), 7.76 (d, J=8.51 Hz, 1 H), 8.36 (dd, J=9.14, 2.52 Hz, 1 H), 8.57 (s, 1 H), 8.95 (dd, J=6.94, 2.52 Hz, 1 H), 9.12 (s, 1 H), 2H obscured by DMSO. MS ES+ m/z 497 [M+1-11+.
Example 45: 1-(3-((2,3-dihydro-11,41dioxino12,3-b] pyridin-7-yl)amino)-5,6-dimethyl-5,6-dihyd rob enzo [c] [2,6] naphthyridin-8-yl)pyrrolid in-2-one I
N
[0302] The title compound was prepared as described in in accordance with the procedure of Example 43, replacing pyridine-3-amine for 2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-7-amine to give the product as a solid (22 mg, 13%). 11-1NMR (500 MHz, DMSO-d6) 6 ppm 1.05 (d, J=6.62 Hz, 3 H), 2.04 - 2.10 (m, 2 H), 2.90 (s, 3 H), 3.87 (t, J=7.41 Hz, 2 H), 4.25 (dt, J=3.78, 2.21 Hz, 2 H), 4.35 (dt, J=3.78, 2.21 Hz, 2 H), 4.46 (d, J=6.62 Hz, 1 H), 6.56 (s, 1 H), 6.98 (dd, J=8.35, 2.05 Hz, 1 H), 7.13 (d, J=2.21 Hz, 1 H), 7.75 (d, J=8.51 Hz, 1 H), 7.82 (d, J=2.52 Hz, 1 H), 7.92 (d, J=2.52 Hz, 1 H), 8.60 (s, 1 H), 9.02 - 9.08 (m, 1 H) 2H obscured by DMSO. MS ES+ m/z 444 [M+Hl+.
Example 46: 1-(9-fluoro-5-methyl-3-(pyridin-3-ylamino)-5H-chromeno14,3-c]
pyrid in-8-yl)pyrrolidin-2-one I
N
[0303] The title compound was prepared as described in accordance with the procedures of Example 31, replacing 3-chloro-N,N,5-trimethy1-5H-chromeno[4,3-c1pyridine-8-carboxamide for 1-(3-chloro-9-fluoro-5-methy1-5H-chromeno[4,3-c1pyridin-8-yOpyrrolidin-2-one and NaOtBu for Cs2CO3, to give the product as a solid (12 mg, 10%). 11-1 NMR (500 MHz, DMSO-d6) 6 ppm 1.54 (d, J=6.62 Hz, 3 H), 2.07 - 2.15 (m, 2 H), 2.43 (t, J=8.04 Hz, 2 H), 3.74 - 3.80 (m, 2 H), 5.26 - 5.35 (m, 1 H), 6.74 (s, 1 H), 7.06 (d, J=6.62 Hz, 1 H), 7.28 -7.33 (m, 1 H), 7.86 (d, J=11.66 Hz, 1 H), 8.13 (dd, J=4.57, 1.42 Hz, 1 H), 8.21 (ddd, J=8.35, 2.68, 1.26 Hz, 1 H), 8.71 (s, 1 H), 8.82 (d, J=2.21 Hz, 1 H), 9.50 (s, 1 H).
MS ES+ m/z 391 [M+H]+.
Example 47: (6aS)-2-09-fluoro-5-methyl-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c] pyridin-3-yl)amino)-6,6a,7,8-tetrahydro-9H-pyrido [2,3-b] pyrrolo[1,2-d]
[1,4] oxazin-9-one 0 ,H3 I
N N
[0304] The title compound was prepared as described in accordance with the procedures of Example 43, replacing pyridine-3-amine for (6S)-12-amino-8-oxa-2,10-diazatricy clo [7.4. 0. 02,6]trideca-1(9),10,12-trien-3-one and 1-(3-chloro-5,6-dimethy1-5H-benzo [c] [2,6lnaphthy ri din-8-y Opy rroli din-2-one for 1-[9-fluoro-5-methyl-3 -(3 -pyridylamino)-5H-chromeno[4,3-clpyridin-8-yllpyrrolidin-2-one, and stirring for 1 h, to give the product as a solid (193 mg, 45%). 11-1NMR (500 MHz, DMSO-d6) 6 ppm 1.53 (dd, J=6.46, 1.42 Hz, 3 H), 1.69 - 1.74 (m, 1 H), 2.08 - 2.15 (m, 2 H), 2.20 - 2.26 (m, 1 H), 2.39 - 2.45 (m, 3 H), 2.66 -2.70 (m, 1 H), 3.75 - 3.80 (m, 2 H), 3.93 (d, J=10.72 Hz, 1 H), 4.05 -4.11 (m, 1 H), 4.59 (dd, J=10.72, 3.15 Hz, 1 H), 5.26 (q, J=6.83 Hz, 1 H), 6.68 (s, 1 H), 7.05 (d, J=6.94 Hz, 1 H), 7.86 (s, 1 H), 8.39 (dd, J=2.52, 1.26 Hz, 1 H), 8.65 (s, 1 H), 8.97 (dd, J=3.94, 2.68 Hz, 1 H), 9.38 (d, J=2.52 Hz, 1 H). MS ES+ m/z 502 [M+Hl+.
Example 48: N-methyl-N-(5-05-methyl-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-yl)methanesulfonamide I I
N NN
0=5=0 Step 1: Preparation of 1-(4-bromo-3-fluorophenyl)pyrrolidin-2-one IN F
Br [0305] 1-Bromo-2-fluoro-4-iodobenzene (40.0 g, 133 mmol), CsF (50.5 g, 332 mmol) and Cul (7.60 g, 39.8 mmol) were taken up in Et0Ac (300 mL) and the resulting mixture was degassed with nitrogen for 10 min. Pyrrolidin-2-one (13.6 g, 159 mmol) and N,N'-dimethylethylenediamine (5.3 mL, 80 mmol) were added and the resulting mixture was stirred at 50 C for 18 h. A purple solution was formed gradually. LCMS (Rt = 0.655 min; MS Calcd:
257.0; MS Found: 257.8 [M+H1+). When cooled to 20 C, the mixture was filtered, the filter cake washed with Et0Ac (100 ml), and the filtrate combined with the next time reaction, washed with HC1 (0.5 M, 100 mL), 5% NH31120 (100 mL), dried over Na2SO4, filtered and concentrated to give 1-(4-bromo-3-fluorophenyl)pyrrolidin-2-one (33.6 g, yield: 95%) as a pale yellow solid.
11-1NMR (400 MHz, CDC13) 6 2.10-2.24 (2H, m), 2.61 (2H, t, J= 8.0 Hz), 3.82 (2H, t, J=
7.2 Hz), 7.24-7.27 (1H, m), 7.48 (1H, dd, J = 8.0, 8.0 Hz), 7.65 (1H, dd, J=
8.0, 2.4 Hz).
Step 2: Preparation of 1-(3 -fluoro-4-(4,4,5,5-tetramethy1-1,3,2-di oxaborol an-2-yl)phenyl)pyrrolidin-2-one õ.11\1 F
[0306] A
mixture of 1-(4-bromo-3-fluorophenyl)pyrrolidin-2-one (12.0 g, 46.5 mmol), B2Pin2 (17.7 g, 69.7 mmol) and Pd(dppf)C12 (3.40 g, 4.65 mmol) in toluene (200 mL) was stirred at 100 C for 40 h under N2 atmosphere. A red solution turned to black gradually. LCMS
(Rt = 0.689 min; MS Calcd: 305.2; MS Found: 306.1 [M+H1+). The reaction mixture was cooled to 20 C and filtered through silica gel and washed with MTBE (800 mL).
The solvent was evaporated under reduced pressure to give 1-(3-fluoro-4-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-yOphenyOpyrrolidin-2-one(20.0 g, crude) as a black brown gum.
Step 3: Preparation of 2-chloro-5-(2-fluoro-4-(2-oxopyrrolidin-1-yl)phenyl)is oni cotinal dehy de I
N CI
[0307] 1-(3 -Fl uoro-4-(4,4,5 ,5 -tetramethyl-1,3 ,2-di oxab orol an-2-yl)phenyl)py rroli din-2-one (7.84 g, 35.6 mmol), 5-bromo-2-chloroisonicotinaldehyde (16.0 g, 37.3 mmol), Pd(PPh3)4 (1.64 g, 1.42 mmol) and K2CO3 (14.8 g, 106 mmol) were taken up in MeCN (160 mL) and H20 (40 mL) and the resulting mixture was stirred at 70 C for 2 h. A black solution was formed. LCMS (Rt = 0.649 min; MS Calcd: 319.1; MS Found: 341.8 [M+Nal+). When cooled to 20 C the mixture was diluted with half-saturated brine (50 mL) and Et0Ac (50 m1). The organic layer was separated and the aqueous layer extracted with Et0Ac (50 mL
x2). The combined organics were dried over Na2SO4, filtered through a plug of silica and concentrated to give 2-chl oro-5-(2-fluoro-4-(2-oxopy rroli din-l-yl)phenyl)i s oni cotinal dehy de (13.8 g, crude) as a black brown gum.
Step 4: Preparation of 1-(4-(6-chloro-4-(1-hydroxy ethy Opy ri din-3 -y1)-3-fluorophenyOpyrrolidin-2-one OH
I
N CI
[0308] MeMgBr (3 M in Et20, 30 mL) was added slowly to a solution of 2-chloro-5-(2-fluoro-4-(2-oxopyrrolidin-1-yl)phenyl)isonicotinaldehyde (11.3 g, 35.4 mmol) in THF (200 mL) at 0 C under N2 atmosphere to give a suspension. The resulting mixture was stirred at 0 C for 2 h. LCMS (Rt = 0.617 min; MS Calcd: 334.1; MS Found: 334.9 [M+Hl+).
Sat.
aq.NH4C1 (80 mL) was added followed by Et0Ac (80 mL). The organic layer was separated and the aqueous layer extracted with Et0Ac (100 mL x2). The combined organics were dried over Na2SO4, filtered and concentrated to give 1-(4-(6-chloro-4-(1-hydroxyethyl)pyridin-3-y1)-3-fluorophenyl)pyrrolidin-2-one (12.5 g, crude) as a black brown gum.
Step 5: Preparation of 1-(3 -chl oro-5 -methyl-5H-chromeno [4,3-cl py ri din-8-y Opy rroli din-2-one I
N CI
[0309] NaH
(2.82 g, 70.5 mmol, 60% in mineral oil) was added to a solution of 1-(4-(6-chloro-4-(1-hydroxyethyppyridin-3-y1)-3-fluorophenyOpyrrolidin-2-one (11.8 g, 35.3 mmol) in THF (150 mL) at 20 C and the resulting mixture was stirred at 20 C for 2 h. A black solution was formed. LCMS (Rt = 0.654 min; MS Calcd: 314.1; MS Found: 314.9 [M+H]+).
Sat. aq. NH4C1 (80 mL) was added and the mixture extracted with Et0Ac (80 mL
x3). The combined organic layer was dried over Na2SO4, filtered, concentrated. The residue was purified by Combi Flash (60% Et0Ac in pentane) to give 1-(3-chloro-5-methy1-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (1.22 g, 3.88 mmol, yield: 11% for four steps) as a yellow solid.
NMR (400 MHz, CDC13) 6 1.62 (3H, d, J= 6.8 Hz), 2.10-2.24 (2H, m), 2.63 (2H, t, J=
8.0 Hz), 3.87 (2H, t, J= 8.0 Hz), 5.19 (1H, q, J= 6.8 Hz), 7.10 (1H, s), 7.32 (1H, d, J= 2.0 Hz), 7.41 (1H, dd, J= 8.4, 2.0 Hz), 7.72 (1H, d, J= 8.8 Hz), 8.64 (1H, s).
Step 6:
Preparation of tert-butyl (5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-yl)carbamate N NHBoc [0310] A
mixture of Pd2(dba)3 (44 mg, 0.047 mmol) and XantPhos (55 mg, 0.095 mmol) in 1,4-dioxane (1 mL) was stirred at 50 C for 10 min. 1-(3-Chloro-5-methy1-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (300 mg, 0.953 mmol), BocNH2 (167 mg, 1.43 mmol) in 1,4-dioxane (10 mL) and Cs2CO3 (776 mg, 2.38 mmol) were added, and the resulting mixture was stirred at 100 C for 16 h. A black brown mixture was formed. LCMS
(Rt = 0.688 min; MS Calcd: 395.2; MS Found: 396.0 [M+H]+). The reaction mixture was diluted with DCM (20 mL), filtered and concentrated to give tert-butyl (5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-yOcarbamate (500 mg, crude) as a black brown gum.
Step 7: Preparation of 1-(3-amino-5 -methyl-5H-chromeno [4,3-c] py ri din-8-yl)pyrroli din-2-one I
[0311] To a stirred solution of tert-butyl (5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-yOcarbamate (370 mg, 0.935 mmol) in DCM (6 mL) was added HC1/Et0Ac (4 M, 61 mL) at 20 C. The yellow solution turned to suspension, the reaction mixture was stirred for 1 hour. TLC indicated the starting material was consumed completely, and one new spot with larger polarity was detected. The mixture was concentrated. The residue was purified by Combi Flash (1% Et3N in Et0Ac) to give 1-(3-amino-5-methy1-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (200 mg, yield: 55% for two steps) as a yellow solid.
Step 8: Preparation of N-(5 -bromopy ri din-3 -yl)methanes ulfonami de Br NH
0=S=0 [0312] A
solution of 5-bromopyridin-3-amine (500 mg, 2.89 mmol) and pyridine (4.3 mL, 54 mmol) was stirred in DCM (20 mL), then MsC1 (331 mg, 2.89 mmol) was added into the above solution at 0 C, which was stirred at 20 C for 16 h. A yellow solution was formed.
TLC showed the starting material was consumed completely. The solution was diluted with H20 (30 mL) and was extracted with DCM (15 mL x3). The organic layer was washed with brine (15 mL), dried over Na2SO4 to give N-(5-bromopyridin-3-yOmethanesulfonamide (700 mg, yield: 96%) as a yellow solid.
Step 9: Preparation of N-(5-bromopy ri din-3 -y1)-N-methy lmethanes ulfonami de r Br 0=S=0 [0313] A
solution of N-(5-bromopyridin-3-yl)methanesulfonamide (700 mg, 2.79 mmol) in DMF (8 mL) was treated with K2CO3 (771 mg, 5.58 mmol) and CH3I (594 mg, 4.18 mmol) at 20 C for 18 h. A black brown solution was formed. TLC showed the starting material was consumed completely. The reaction was concentrated under reduced pressure. The residue was purified by Combi Flash (40% Et0Ac in pentane) to give N-(5-bromopyridin-3-y1)-N-methylmethanesulfonamide (563 mg, yield: 76%) as a red solid. 11-1 NMR (400 MHz, CDC13) 6 2.91 (3H, s), 3.37 (3H, s), 7.92 (1H, t, J= 2.0 Hz), 8.57 (1H, d, J= 2.0 Hz), 8.59 (1H, d, J=
2.0 Hz).
Step 10: Preparation of tert-butyl (5-(N-methylmethylsulfonamido)pyridin-3-yOcarbamate I
BocHNN
0==0 [0314] A
mixture of Pd2(dba)3 (86 mg, 0.094 mmol) and XantPhos (109 mg, 0.189 mmol) in 1,4-dioxane (1 mL) was stirred at 50 C for 10 min. N-(5-bromopyridin-3-y1)-N-methylmethanesulfonamide (500 mg, 1.89 mmol), BocNH2 (331 mg, 2.83 mmol) in dioxane (15 mL) and Cs2CO3 (1.54 g, 4.71 mmol) were added and the resulting mixture was stirred at 100 C for 16 h. A black brown mixture was formed. TLC indicated the starting material was consumed completely. The reaction mixture was diluted with DCM (10 mL), filtered and concentrated. The residue was purified by Combi Flash (60% Et0Ac in pentane) to give tert-butyl (5-(N-methylmethylsulfonamido)pyridin-3-yl)carbamate (275 mg, yield:
48%) as a brown solid.
11-1NMR (400 MHz, CDC13) 6 1.53 (9H, s), 2.91 (3H, s), 3.36 (3H, s), 6.73 (1H, brs), 8.08 (1H, s), 8.33 (1H, d, J= 2.4 Hz), 8.36 (1H, d, J= 2.4 Hz).
Step 11: Preparation of N-(5-aminopy ridin-3 -y1)-N-methy lmethanesulfonami de I
0==0 [0315] To a stirred solution of tert-butyl (5-(N-methylmethylsulfonamido)pyridin-3-yl)carbamate (275 mg, 0.912 mmol) in DCM (5 mL) was added HC1/Et0Ac (4 M, 8 mL) at 20 C. The yellow solution turned to suspension, the reaction mixture was stirred for 1 hour. TLC
indicated the starting material was consumed completely, and one new spot with larger polarity was detected. The mixture was concentrated to give N-(5-aminopyridin-3-y1)-N-methylmethanesulfonamide (215 mg, yield: 99%) as a yellow solid.
NMR (400 MHz, DMSO-d6) 6 3.13 (3H, s), 3.29 (3H, s), 7.60 (1H, t, J= 2.4 Hz), 7.92 (1H, d, J= 2.0 Hz), 8.09 (1H, d, J= 2.0 Hz).
Step 12:
Preparation of N-methyl-N-(5-05-methyl-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-yl)methanesulfonamide , N
0=S=0 [0316] A
mixture of Pd2(dba)3 (7 mg, 0.008 mmol) and BrettPhos (8 mg, 0.002 mmol) in 1,4-dioxane (1 mL) was stirred at 50 C for 10 min. 1-(3-Chloro-5-methy1-5H-chromeno[4,3-clpyridin-8-yl)pyrrolidin-2-one (50 mg, 0.16 mmol), N-(5-aminopyridin-3-y1)-N-methylmethanesulfonamide (45 mg, 0.19 mmol) in dioxane (3 mL) and Cs2CO3 (155 mg, 0.476 mmol) were added and the resulting mixture was stirred at 100 C for 16 h. A
black brown mixture was formed. LCMS (Rt = 0.595 min; MS Calcd: 479.2; MS Found: 480.0 [M+H1+).
The reaction mixture was diluted with DCM (10 mL), filtered and concentrated.
The residue was purified by prep-HPLC (0.05% NH31120 as an additive) and lyophilized to give N-methyl-N-(5-((5 -methy1-8-(2-oxopy rroli din-1 -y 0-5H-chromeno [4,3-c] pyri din-3-y Damino)py ridin-3 -yOmethanesulfonamide (22.8 mg, yield: 30%) as a white solid.
LC-MS (Shimadzu LCMS 2010, mobile phase: C) 10mM NH4HCO3 in Water; D) MECN.
Gradient: 1% D increase to 5% D within 0.6 min; 5% DB increase to 100% D
within 3.4 min;
then back to 1% D within 0.3 min. Flow rate 0.8 mL/min) purity is 100%, Rt =
2.640 min; MS
Calcd.: 479.2, MS Found: 480.3 [M+141+.
11-1NMR (400 MHz, DMSO-d6) 6 1.53 (3H, d, J= 6.0 Hz), 2.02-2.09 (2H, m), 2.64 (2H, overlap with DMSO), 3.04 (3H, s), 3.29 (3H, s), 3.84 (2H, t, J= 6.8 Hz), 5.28 (1H, q, J= 6.4 Hz), 6.75 (1H, s), 7.32 (1H, dd, J= 8.4, 2.0 Hz), 7.40 (1H, s), 7.89 (1H, d, J= 8.4 Hz), 8.19 (1H, s), 8.29 (1H, s), 8.70 (1H, s), 8.75 (1H, s), 9.61 (1H, brs).
Example 49: 1-(5-methyl-3-01-(methylsulfony1)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)amino)-5H-chromeno[4,3-c]pyridin-8-y1)pyrrolidin-2-one I , N
0=S=0 Step 1: Preparation of 7-bromo-1-(methylsulfony1)-2,3-dihydro-1H-pyrido[2,3-b]
[1,4] oxazine Br N
0=SI =0 [0317] To a solution of 7-bromo-2,3-dihydro-1H-pyrido[2,3-b1[1,4loxazine (300 mg, 1.40 mmol) in DCM (5 mL) was added pyridine (221 mg, 2.80 mmol) and MsC1 (321 mg, 2.80 mmol) at 15 C, the mixture was stirred at 15 C for 16 h. A red solution was formed. Crude LCMS showed the purity of the product (Rt = 0.757 min; MS Calcd: 292.0; MS
Found: 292.7 [M+1-11+). The mixture was added sat.NH31120 (10 mL), extracted with DCM (10 mL x3), and dried over Na2SO4, the residue was purified by Combi Flash (DCM) to give 7-bromo-1-(methylsulfony1)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazine(350 mg, yield: 85%) as a white solid.
11-1NMR (400 MHz, CDC13) 6 1.55 (3H, s), 3.90 (2H, t, J= 4.4 Hz), 4.45 (2H, t, J= 4.4 Hz), 8.08 (1H, d, J= 2.0 Hz), 8.19(1H, d, J= 2.0 Hz).
Step 2:
Preparation of tert-butyl (1 -(methylsulfony1)-2,3-dihy dro-1H-py ri do [2,3 -b] [1,4] oxazin-7-yl)carbamate j BocHNN
0==0 [0318] A
mixture of Pd2(dba)3 (55 mg, 0.060 mmol) and XantPhos (69 mg, 0.12 mmol) in 1,4-dioxane (1 mL) was stirred at 50 C for 10 min. 7-Bromo-1-(methylsulfony1)-2,3-dihydro-1H-pyrido[2,3-b] [1,4loxazine (350 mg, 1.19 mmol), BocNH2 (210 mg, 1.79 mmol) in dioxane (10 mL) and Cs2CO3 (973 mg, 2.98 mmol) were added, and the resulting mixture was stirred at 100 C for 16 h. A black brown mixture was formed. LCMS (Rt = 0.596 min; MS
Calcd:
329.1; MS Found: 330.1 [M+H1+). The reaction mixture was diluted with DCM (20 mL), filtered and concentrated. The residue was purified by Combi Flash (60% Et0Ac in pentane) to give tert-butyl (1-(methylsulfony1)-2,3 -dihy dro-1H-pyri do [2,3-b] [1,4] oxazin-7-yl)carbamate (270 mg, yield: 69%) as a yellow gum.
11-1 NMR (400 MHz, CDC13) 6 1.51 (9H, s), 3.02 (3H, s), 3.88 (2H, t, J= 8.4 Hz), 4.41 (2H, t, J= 8.0 Hz), 6.42 (1H, brs), 8.01 (1H, s), 8.16 (1H, s).
Step 3: Preparation of 1-(methylsulfony1)-2,3-dihy dro-1H-py ri do [2,3 -b]
[1,4] oxazin-7-amine 0=S=0 [0319] To a stirred solution of tert-butyl (1-(methylsulfony1)-2,3-dihydro-1H-pyrido[2,3-b1[1,41oxazin-7-yl)carbamate (270 mg, 0.820 mmol) in DCM (4 mL) was added HC1/Et0Ac (4 M, 10 mL) at 20 C. The red solution turned to suspension, then the reaction mixture was stirred for 1 h. TLC indicated the starting material was consumed completely, and one major new spot with larger polarity was detected. The mixture was concentrated to give 1-(methylsulfony1)-2,3-dihydro-1H-pyrido[2,3-b][1,41oxazin-7-amine (240 mg, yield: 97%) as an off-white solid.
11-1 NMR (400 MHz, DMSO-d6) 6 3.25 (3H, s), 3.84 (2H, t, J= 4.4 Hz), 4.32 (2H, brs), 4.43 (2H, t, J= 4.4 Hz), 7.96 (1H, d, J= 2.0 Hz), 8.03 (1H, d, J= 2.0 Hz).
Step 4: Preparation of 1-(5-methy1-3-01-(methylsulfony1)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-y1)amino)-5H-chromeno[4,3-c]pyridin-8-y1)pyrrolidin-2-one I , N
0=S=0 [0320] A
mixture of Pd2(dba)3 (7 mg, 0.008 mmol) and BrettPhos (8 mg, 0.002 mmol) in 1,4-dioxane (1 mL) was stirred at 50 C for 10 min. 1-(3-Chloro-5-methy1-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one (50 mg, 0.16 mmol), 1-(methylsulfony1)-2,3-dihydro-1H-pyrido[2,3-b1[1,410xazin-7-amine (84 mg, 0.28 mmol) in dioxane (3 mL) and Cs2CO3 (155 mg, 0.476 mmol) were added and the resulting mixture was stirred at 100 C for 16 h. A black brown mixture was formed. LCMS (Rt = 0.587 min; MS Calcd: 507.2; MS Found:
508.3 [M+1-11+). The reaction mixture was diluted with DCM (10 mL), filtered and concentrated. The residue was purified by prep-HPLC (normal phase, Hexane-IPA (50-100% B)) and lyophilized to give impure product (25 mg) as a yellow solid, then purified by prep-HPLC
(0.05% NH31120 as an additive) and lyophilized to give 1-(5-methy1-3-((1-(methylsulfony1)-2,3-dihydro-1H-pyrido [2,3 -b] [1,4] oxazin-7-y0amino)-5H-chromeno [4,3-c] pyridin-8-yOpyrrolidin-2-one (18.1 mg, yield: 22%) as a white solid.
[0321] LC-MS
(Shimadzu LCMS 2010, Mobile phase: from 90% [water + 0.04% TFA]
and 10% [MeCN +0.02% TFA] to 20% [water + 0.04% TFA] and 80% [MeCN + 0.02%
TFA]
in 1.35 min, then under this condition for 0.9 min, finally changed to 90%
[water + 0.04%
TFA] and 10% [MeCN + 0.02% TFA] and under this condition for 0.75 min. ) purity is 96.38%, Rt = 2.190 min; MS Calcd.: 507.2, MS Found: 508.1 [M+Hr.
11-1NMR (400 MHz, D20+CDC13) 6 1.58 (3H, d, J= 6.8 Hz), 2.12-2.21 (2H, m), 2.63 (2H, t, J= 8.0 Hz), 3.06 (3H, s), 3.84 (2H, t, J = 6.0 Hz), 3.91 (2H, t, J = 4.8 Hz), 4.45 (2H, t, J = 4.4 Hz), 5.13 (1H, q, J= 6.4 Hz), 6.52 (1H, s), 7.28 (1H, overlap with CDC13), 7.37 (1H, dd, J =
8.0, 2.0 Hz), 7.66 (1H, d, J = 7.6 Hz), 8.07 (1H, d, J = 2.0 Hz), 8.27 (1H, d, J = 2.0 Hz), 8.50 (1H, s).
Example 50: 1-(3-((5-fluoropyridin-3-yl)amino)-5-methyl-5H-chromeno14,3-c]
pyridin-8-yl)pyrrolidin-2-one Step 1: Preparation of tert-butyl (5-fluoropyridin-3-yl)carbamate BocHN
r-[0322] A
mixture of Pd2(dba)3 (78 mg, 0.085 mmol) and XantPhos (99 mg, 0.17 mmol) in 1,4-dioxane (1 mL) was stirred at 50 C for 10 min. 3-Bromo-5-fluoropyridine (300 mg, 1.70 mmol), BocNH2 (300 mg, 2.56 mmol) in dioxane (10 mL) and Cs2CO3 (1.39 g, 4.26 mmol) were added and the resulting mixture was stirred at 100 C for 16 h. A black brown mixture was formed. LCMS (Rt = 0.619 min; MS Calcd: 212.1; MS Found: 213.0 [M+Hl+).
The reaction mixture was diluted with DCM (10 mL), filtered and concentrated. The residue was purified by Combi Flash (17% Et0Ac in pentane) to give tert-butyl (5-fluoropyridin-3-yl)carbamate (360 mg, yield: 99%) as a yellow solid.
11-1NMR (400 MHz, CDC13) 6 1.53 (9H, s), 6.65 (1H, brs), 7.85 (1H, d, J= 9.2 Hz), 8.14 (1H, d, J= 2.0 Hz), 8.15-8.16 (1H, m).
Step 2: Preparation of 5-fluoropyridin-3-amine [0323] To a stirred solution of tert-butyl (5-fluoropyridin-3-yl)carbamate (350 mg, 1.65 mmol) in DCM (4 mL) was added HC1/Et0Ac (4 M, 15 mL) at 20 C. The yellow solution turned to suspension. Then the reaction mixture was stirred for 1 hour. TLC
indicated the starting material was consumed completely, and one new spot with larger polarity was detected.
The mixture was concentrated to give 5-fluoropyridin-3-amine (245 mg, yield:
100%) as a yellow solid.
11-1NMR (400 MHz, DMSO-d6) 6 7.27 (2H, t, J= 11.2 Hz), 7.33 (1H, dt, J= 10.8, 2.0 Hz), 7.93 (1H, d, J= 2.0 Hz), 8.07-8.11 (1H, m).
Step 3:
Preparation of 1-(3 -((5-fluoropyri din-3 -yl)amino)-5 -methyl-5H-chromeno [4,3-c] py ri din-8-yl)py rroli din-2-one N NF
[0324] A
mixture of Pd2(dba)3 (7 mg, 0.008 mmol) and BrettPhos (8 mg, 0.002 mmol) in 1,4-dioxane (1 mL) was stirred at 50 C for 10 min. 1-(3-Chloro-5-methy1-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (50 mg, 0.16 mmol), 5-fluoropyridin-3-amine (28 mg, 0.19 mmol) in dioxane (3 mL) and Cs2CO3 (155 mg, 0.476 mmol) were added and the resulting mixture was stirred at 100 C for 16 h. A black brown mixture was formed. LCMS
(Rt = 0.639 min; MS Calcd: 390.2; MS Found: 391.1 [M+Hl+). The reaction mixture was diluted with DCM (10 mL), filtered and concentrated. The residue was purified by prep-HPLC
(0.05%
NH31120 as an additive) and lyophilized to give impure product (20 mg) as an off-white solid.
The impure product was purified by prep-HPLC (0.05% NH31120 as an additive) and lyophilized to give 1-(3 -((5-fluoropy ri din-3 -yl)amino)-5-methyl-5H-chromeno [4,3 -c] py ri din-8-yl)pyrrolidin-2-one (7.3 mg, yield: 12%) as a white solid.
[0325] LC-MS
(Shimadzu LCMS 2010, mobile phase: from 100% [water + 0.05%
NH3+120] and 0% [MeCN] to 5% [water + 0.05% NH31-120] and 95% [MeCN] in 5.8 min, then under this condition for 1.1 min, finally changed to 100% [water + 0.05%
NH31-120] and 0% [MeCN] and under this condition for 0.09 min.) purity is 99.62%, Rt = 3.234 min; MS
Calcd.: 390.2, MS Found: 391.2 [M+Hl+.
11-1NMR (400 MHz, DMSO-d6) 6 1.52 (3H, d, J= 6.4 Hz), 2.00-2.06 (2H, m), 2.48 (2H, overlap with DMSO), 3.82 (2H, t, J= 7.2 Hz), 5.27 (1H, q, J= 6.8 Hz), 6.78 (1H, s), 7.30 (1H, dd, J= 8.4, 2.4 Hz), 7.39 (1H, d, J= 2.0 Hz), 7.87 (1H, d, J= 8.4 Hz), 8.04 (1H, d, J=
2.8 Hz), 8.39 (1H, dt, J= 12.4, 2.0 Hz), 8.53 (1H, t, J= 2.0 Hz), 8.70 (1H, s), 9.92 (1H, brs).
Example 51: N-cycl op ro pyl-N-(5-05-methyl-8-(2-oxo pyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-yl)methanesulfonamide I I
N NNI\
0==0 Step 1: Preparation of 5-bromo-N-cyclopropylpyridin-3-amine BrNA
[0326] To a mixture of 3,5-dibromopyridine (2.01 g, 8.48 mmol), cyclopropanamine (969 mg, 17.0 mmol), Cu (54 mg, 0.85 mmol) in H20 (3 mL) were added and the resulting mixture was stirred at 100 C for 42 h. A black brown mixture was formed. LCMS (Rt =
0.453 min;
MS Calcd: 214.0; MS Found: 214.8 [M+H]+). The reaction mixture was diluted with DCM (20 mL), and was extracted with DCM (10 mL x3), dried over Na2SO4 and concentrated. The residue was purified by Combi Flash (45% Et0Ac in pentane) to give 5-bromo-N-cyclopropylpyridin-3-amine (220 mg, yield: 12%) as a yellow solid.
Step 2: Preparation of N-(5 -bromopy ri din-3 -y1)-N-cy cl opropy lmethanesulfonami de I
BrNA
0==0 solution of 5-bromo-N-cyclopropylpyridin-3-amine (220 mg, 1.03 mmol) and pyridine (2 mL) was stirred in DCM (5 mL), then MsC1 (142 mg, 1.24 mmol) was added into the above solution at 0 C, which was stirred at 20 C for 16 h. A red solution was formed.
LCMS (Rt = 0.591 min; MS Calcd: 292.0; MS Found: 292.7 [M+H1+). The solution was diluted with H20 (20 mL) and was extracted with DCM (10 mL x3). The organic layer was dried over Na2SO4, and concentrated. The residue was purified by Combi Flash (50% Et0Ac in pentane) to give N-(5-bromopyridin-3-y1)-N-cyclopropylmethanesulfonamide (160 mg, yield: 53%) as a yellow solid.
11-1NMR (400 MHz, CDC13) 6 0.77-0.82 (2H, m), 0.94-1.02 (2H, m), 2.92-2.97 (1H, m), 2.98 (3H, s), 7.87 (1H, t, J= 2.0 Hz), 8.52-8.61 (2H, m).
Step 3: Preparation of tert-butyl (5 -(N-cy cl opropy lmethylsulfonami do)py ri din-3 -yl)carb amate BocHNI
0==0 [0328] A
mixture of Pd2(dba)3 (25 mg, 0.027 mmol) and XantPhos (32 mg, 0.055 mmol) in 1,4-dioxane (1 mL) was stirred at 50 C for 10 min. N-(5-bromopyridin-3-y1)-N-cyclopropylmethanesulfonamide (160 mg, 0.550 mmol), BocNH2 (97 mg, 0.824 mmol) in dioxane (6 mL) and Cs2CO3 (448 mg, 1.37 mmol) were added, and the resulting mixture was stirred at 100 C for 16 h. A black brown mixture was formed. LCMS (Rt = 0.586 min; MS
Calcd: 327.1; MS Found: 327.9 [M+H1+). The reaction mixture was diluted with DCM (15 mL), filtered and concentrated. The residue was purified by Combi Flash (90%
Et0Ac in pentane) to give tert-butyl (5-(N-cyclopropylmethylsulfonamido)pyridin-3-yOcarbamate (179 mg, yield: 99%) as a yellow solid.
Step 4: Preparation of N-(5 -aminopy ri din-3-y1)-N-cy cl opropy lmethanesulfonami de 0==0 [0329] To a stirred solution of tert-butyl (5-(N-cyclopropylmethylsulfonamido)pyridin-3-yOcarbamate (179 mg, 0.547 mmol) in DCM (3 mL) was added HC1/Et0Ac (4 M, 7 mL) at 20 C. The yellow solution turned to suspension, the reaction mixture was stirred for 1 hour. TLC
indicated the starting material was consumed completely, and one new spot with larger polarity was detected. The mixture was concentrated to give N-(5-aminopyridin-3-y1)-N-cyclopropylmethanesulfonamide (124 mg, yield: 100%) as a yellow solid.
11-1NMR (400 MHz, DMSO-d6) 6 0.64-0.72 (2H, m), 0.85-0.93 (2H, m), 3.19 (3H, s), 3.20-3.24 (1H, m), 7.56 (1H, t, J= 2.0 Hz), 7.92 (1H, d, J= 2.0 Hz), 8.07 (1H, d, J= 2.0 Hz).
Step 5:
Preparation of N-cy cl opropyl-N-(5 -((5-methyl-8-(2-oxopy rroli din-1 -y1)-5H-chromeno [4,3-c] py ri din-3-y0amino)pyri din-3 -y Omethanesulfonami de I I
N NNI\
0==0 [0330] A
mixture of Pd2(dba)3 (7 mg, 0.008 mmol) and BrettPhos (8 mg, 0.002 mmol) in 1,4-dioxane (1 mL) was stirred at 50 C for 10 min. 1-(3-Chloro-5-methy1-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (50 mg, 0.16 mmol), N-(5-aminopyridin-3-y1)-N-cyclopropylmethanesulfonamide (50 mg, 0.19 mmol) in dioxane (3 mL) and Cs2CO3 (155 mg, 0.476 mmol) were added and the resulting mixture was stirred at 100 C for 16 h. A black brown mixture was formed. LCMS (Rt = 0.616 min; MS Calcd: 505.2; MS Found:
506.1 [M+H1+). The reaction mixture was diluted with DCM (10 mL), filtered and concentrated. The residue was purified by prep-HPLC (0.05% NH31120 as an additive) and lyophilized to give N-cy cl opropyl-N-(5 -((5-methyl-8-(2-oxopy rrol i din-1 -y1)-5H-chromeno [4,3-c] py ri din-3 -yOamino)pyridin-3-yOmethanesulfonamide (10.2 mg, yield: 13%) as a white solid.
[0331] LC-MS
(Shimadzu LCMS 2010, mobile phase: C) 10mM NH4HCO3 in Water; D) MECN. Gradient: 1% D increase to 5% D within 0.6 min; 5% DB increase to 100% D
within 3.4 min; then back to 1% D within 0.3 min. Flow rate 0.8 mL/min) purity is 100%, Rt = 2.766 min; MS Calcd.: 505.2, MS Found: 506.3 [M+1-11+.
11-1NMR (400 MHz, CDC13) 6 0.81-0.86 (2H, m), 0.94-0.99 (2H, m), 1.61 (3H, d, J= 6.8 Hz), 2.14-2.21 (2H, m), 2.63 (2H, t, J= 8.4 Hz), 2.95-3.00 (1H, m), 3.01 (3H, s), 3.87 (2H, t, J= 7.2 Hz), 5.15 (1H, q, J= 6.4 Hz), 6.65 (1H, s), 6.70 (1H, brs), 7.27 (1H, s), 7.40 (1H, dd, J= 8.4, 2.0 Hz), 7.68 (1H, d, J= 8.4 Hz), 8.08 (1H, d, J= 2.0 Hz), 8.26 (1H, d, J= 2.0 Hz), 8.52 (1H, d, J= 2.4 Hz), 8.56 (1H, s).
Example 52: 1-(3-01-(cyclopropylsulfony1)-2,3-dihydro-1H-pyrido12,3-b]11,41oxazin-7-yl)amino)-5-methyl-5H-chromeno14,3-c]pyridin-8-y1)pyrrolidin-2-one N N N
0==0 Step 1:
Preparation of 7-bromo-1-(cyclopropylsulfony1)-2,3-dihydro-1H-pyrido[2,3-b] [1,41oxazine Br N
0==0 [0332] To a solution of 7-bromo-2,3-dihydro-1H-pyrido[2,3-b][1,41oxazine (300 mg, 1.40 mmol) in pyridine (10 mL) was added cyclopropanesulfonyl chloride (787 mg, 5.60 mmol) under nitrogen. The resulting mixture was stirred for 40 h at 20 C. The orange solution was formed. LCMS showed the starting material was not consumed. Additional cyclopropanesulfonyl chloride (787 mg, 5.60 mmol) was added, and stirred for 60 h at 50 C.
The solution turned to black. LCMS showed the starting material was consumed nearly, and the purity of desired product (Rt = 0.625 min; MS Calcd: 320.0; MS Found:
320.8 [M+H1+).
Pyridine was removed under reduced pressure. The residue was purified by Combi Flash (50 % Et0Ac in pentane) to give 7-bromo-1-(cyclopropylsulfony1)-2,3-dihydro-1H-pyrido[2,3-b][1,41oxazine (343 mg, yield: 77%) as a yellow solid.
11-1NMR (400 MHz, CDC13) 6 1.00-1.13 (2H, m), 1.21-1.31 (2H, m), 2.40-2.52 (1H, m), 3.87 (2H, t, J = 4.4 Hz), 4.48 (2H, t, J = 4.8 Hz), 8.07 (1H, d, J = 2.0 Hz), 8.22 (1H, d, J = 2.4 Hz).
Step 2:
Preparation of tert-butyl (1-(cy cl opropylsulfony1)-2,3 -dihy dro-1H-py ri do [2,3 -b] [1,4] oxazin-7-yl)carbamate f BocHNN
0=S=0 [0333] A
mixture of Pd2(dba)3 (49 mg, 0.053 mmol) and XantPhos (62 mg, 0.11 mmol) in 1,4-dioxane (1 mL) was stirred at 50 C for 10 min. 7-Bromo-1-(cyclopropylsulfony1)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazine (340 mg, 1.07 mmol), BocNH2 (187 mg, 1.60 mmol) in dioxane (12 mL) and Cs2CO3 (868 mg, 2.66 mmol) were added and the resulting mixture was stirred at 100 C for 16 h. A black brown mixture was formed. LCMS (Rt = 0.639 min; MS
Calcd: 355.1; MS Found: 356.1 [M+H]+). The reaction mixture was diluted with DCM (10 mL), filtered and concentrated. The residue was purified by Combi Flash (55%
Et0Ac in pentane) to give tert-butyl (1-(cyclopropylsulfony1)-2,3-dihydro-1H-pyrido[2,3-b][1,4loxazin-7-yOcarbamate (375 mg, yield: 99%) as a yellow solid.
11-1NMR (400 MHz, CDC13) 6 1.00-1.09 (2H, m), 1.25-1.30 (2H, m), 1.51 (9H, s), 2.44-2.54 (1H, m), 3.87 (2H, t, J= 4.4 Hz), 4.45 (2H, t, J= 4.4 Hz), 6.57 (1H, brs), 8.03 (1H, d, J = 2.0 Hz), 8.18 (1H, d, J = 2.4 Hz).
Step 3: Preparation of 1 -(cy cl opropylsulfony1)-2,3 -dihy dro-1H-py ri do [2,3-b] [1,4] oxazin-7-amine ) 0==0 [0334] To a stirred solution of tert-butyl (1-(cyclopropylsulfony1)-2,3-dihydro-1H-pyrido[2,3-b][1,4loxazin-7-yOcarbamate (375 mg, 1.06 mmol) in DCM (6 mL) was added HC1/Et0Ac (4 M, 8 mL) at 20 C. The yellow solution turned to suspension. Then the reaction mixture was stirred for 1 hour. TLC indicated the starting material was consumed completely, and one new spot with larger polarity was detected. The mixture was concentrated to afford 1-(cy cl opropylsulfony1)-2,3-dihy dro-1H-py ri do [2,3-b] [1,4] oxazin-7-amine (305 mg, yield:
99%) as a yellow solid.
NMR (400 MHz, DMSO-d6) 6 0.94-1.12 (4H, m), 2.89-3.02 (1H, m), 3.82-3.94 (2H, m), 4.42-4.52 (2H, m), 8.04 (1H, s), 8.07 (1H, s).
Step 4:
Preparation of 1-(3-((1 -(cy cl opropylsulfony1)-2,3-dihy dro-1H-py ri do [2,3 -b] [1,4] oxazin-7-y 1)amino)-5 -methyl-5H-chromeno [4,3-c] py ridin-8-yl)py rroli din-2-one I
N N N
0==0 [0335] A
mixture of Pd2(dba)3 (7 mg, 0.008 mmol) and BrettPhos (8 mg, 0.002 mmol) in 1,4-dioxane (1 mL) was stirred at 50 C for 10 min. 1-(3-Chloro-5-methy1-5H-chromeno[4,3-clpyridin-8-yl)pyrrolidin-2-one (50 mg, 0.16 mmol), 1-(cyclopropylsulfony1)-2,3-dihydro-1H-pyrido[2,3-b][1,41oxazin-7-amine (56 mg, 0.19 mmol) in dioxane (3 mL) and Cs2CO3 (155 mg, 0.476 mmol) were added and the resulting mixture was stirred at 100 C for 16 h. A black brown mixture was formed. LCMS (Rt = 0.604 min; MS Calcd: 533.2; MS Found:
534.1 [M+Hl+). The reaction mixture was diluted with DCM (10 mL), filtered and concentrated. The residue was purified by prep-HPLC (0.05% NH3.H20 as an additive) and lyophilized to give 1-(3-((1-(cyclopropylsulfony1)-2,3-dihydro-1H-pyrido[2,3-b] [1,4] oxazin-7-yl)amino)-5-methy1-5H-chromeno[4,3-c]pyridin-8-y1)pyrrolidin-2-one (19.4 mg, yield: 23%) as a white solid.
[0336] LC-MS
(Shimadzu LCMS 2010, mobile phase: C) 10mM NH4HCO3 in Water; D) MECN. Gradient: 1% D increase to 5% D within 0.6 min; 5% DB increase to 100% D
within 3.4 min; then back to 1% D within 0.3 min. Flow rate 0.8 mL/min) purity is 99.54%, Rt = 2.786 min; MS Calcd.: 533.2, MS Found: 534.3 [M+141+.
NMR (400 MHz, DMSO-d6) 6 1.02-1.08 (4H, m), 1.51 (3H, d, J= 6.8 Hz), 2.00-2.09 (2H, m), 2.49 (2H, overlap with DMSO), 2.85-2.93 (1H, m), 3.80-3.86 (4H, m), 4.39 (2H, t, J=
4.4 Hz), 5.23 (1H, q, J= 6.4 Hz), 6.64 (1H, s), 7.30 (1H, dd, J= 8.8, 2.0 Hz), 7.38 (1H, d, J=
2.0 Hz), 7.86 (1H, d, J= 8.8 Hz), 8.33 (1H, d, J= 2.4 Hz), 8.38 (1H, d, J= 2.4 Hz), 8.59 (1H, s), 9.30 (1H, brs).
Example 53: 1-methyl-3-(5-05-methyl-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-yl)imidazolidin-2-one c I I
N
0 \
Step 1: Preparation of 1-(5-bromopyridin-3-y1)-3-methylimidazolidin-2-one 0 \
[0337] To a solution of 1-(5-bromopyridin-3-yl)imidazolidin-2-one (500 mg, 2.07 mmol) in THF (10 mL) was added NaH (99 mg, 2.5 mmol, 60% in mineral oil) portion-wise at 0 C, the reaction was warmed to 15 C and stirred for 0.5 hour. Mel (382 mg, 2.69 mmol) was added and the mixture was stirred at 15 C for another 16 h. A red suspension was formed. Crude LCMS showed the purity of the product (Rt = 0.681 min; MS Calcd: 255.0; MS
Found: 255.8 [M+H1+). The reaction was diluted with H20 (10 mL), extracted with Et0Ac (10 mL x3), dried over Na2SO4 and concentrated to give a crude product which was purified by Combi Flash (60% Et0Ac in pentane) to give 1-(5-bromopyridin-3-y1)-3-methylimidazolidin-2-one (310 mg, yield: 58%) as a light yellow solid.
11-1NMR (400 MHz, CDC13) 6 2.92 (3H, s), 3.53 - 3.57 (2H, m), 3.81 - 3.85 (2H, m), 8.33 (1H, d, J = 2.0 Hz), 8.43 (1H, t, J = 2.0 Hz), 8.52 (1H, d, J = 2.0 Hz).
Step 2: Preparation of tert-butyl (5-(3-methy1-2-oxoimidazolidin-1-y1)pyridin-3-y1)carbamate BocHNN
\
[0338] A
mixture of Pd2(dba)3 (55 mg, 0.060 mmol) and XantPhos (70 mg, 0.12 mmol) in 1,4-dioxane (1 mL) was stirred at 50 C for 10 min. 1-(5-Bromopyridin-3-y1)-3-methylimidazolidin-2-one (310 mg, 1.21 mmol), BocNH2 (212 mg, 1.82 mmol) in dioxane (10 mL) and Cs2CO3 (986 mg, 3.03 mmol) were added and the resulting mixture was stirred at 100 C for 16 h. A black brown mixture was formed. LCMS (Rt = 0.530 min; MS Calcd:
292.2;
MS Found: 293.1 [M+H1+). The reaction mixture was diluted with DCM (20 mL), filtered and concentrated. The residue was purified by Combi Flash (Et0Ac) to give tert-butyl (5-(3-methy1-2-oxoimidazolidin-1-yl)pyridin-3-yl)carbamate (300 mg, yield: 85%) as a white solid.
11-1NMR (400 MHz, CDC13) 6 1.52 (9H, s), 2.91 (3H, s), 3.51 (2H, t, J= 8.4 Hz), 3.84 (2H, t, J= 8.4 Hz), 6.60 (1H, brs), 8.26 (1H, s), 8.28 (1H, s), 8.45 (1H, s).
Step 3: Preparation of 1-(5-aminopyridin-3-y1)-3-methylimidazolidin-2-one H NN
0 \
[0339] To a stirred solution of tert-butyl (5-(3-methy1-2-oxoimidazolidin-1-yl)pyridin-3-yl)carbamate (300 mg, 1.03 mmol) in DCM (4 mL) was added HC1/Et0Ac (4 M, 10 mL) at 20 C. The yellow solution turned to suspension, the reaction mixture was stirred for 1 hour. TLC
indicated the starting material was consumed completely, and one new spot with larger polarity was detected. The mixture was concentrated to give 1-(5-aminopyridin-3-y1)-3-methylimidazolidin-2-one (234 mg, yield: 100%) as an off-white solid.
11-1NMR (400 MHz, DMSO-d6) 6 2.79 (3H, s), 3.51 (2H, t, J= 8.4 Hz), 3.80 (2H, t, J= 8.8 Hz), 6.53 (2H, brs), 7.62 (1H, s), 7.66 (1H, s), 8.34 (1H, s).
Step 4: Preparation of 1-methy1-3-(5-((5-methyl-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-y1)imidazolidin-2-one I
N N
0 \
[0340] A
mixture of Pd2(dba)3 (7 mg, 0.008 mmol) and BrettPhos (8 mg, 0.002 mmol) in 1,4-dioxane (1 mL) was stirred at 50 C for 10 min. 1-(3-Chloro-5-methy1-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (50 mg, 0.16 mmol), 1-(5-aminopyridin-3-y1)-3-methylimidazolidin-2-one (72 mg, 0.32 mmol) in dioxane (3 mL) and Cs2CO3 (155 mg, 0.476 mmol) were added and the resulting mixture was stirred at 100 C for 16 h. A
black brown mixture was formed. LCMS (Rt = 0.591 min; MS Calcd: 470.2; MS Found: 471.3 [M+H1+).
1 10] In some embodiments of the compounds of Formula I, R18 is halogen, C1-6 alkyl, C3-6 cycloalkyl, ¨0R2o, ¨N(R2o)(R21), ¨C(0)R2o, oxo, ¨N(R22)C(0)0R22, ¨N(R22)C(0)¨Q¨
N(R22)¨F, or ¨N(R22)¨Q¨N(R22)¨F. In another embodiment, R18 is halogen. In another embodiment, R18 is C1-6 alkyl. In another embodiment, R18 is C3-6 cycloalkyl.
In another embodiment, R18 is ¨0R20. In another embodiment, R18 is ¨N(R20)(R21). In another embodiment, R18 is ¨C(0)R20. In another embodiment, R18 is oxo. In another embodiment, R18 is ¨N(R22)C(0)0R22. In another embodiment, R18 is ¨N(R22)C(0)¨Q¨N(R22)¨F.
In another embodiment, R18 is¨N(R22)¨Q¨N(R22)¨F.
[0111] In some embodiments of the compounds of Formula I, two R18 when on adjacent atoms may be taken together with the atoms to which they are each attached to form a heterocyclic group. In another embodiment, two R18 when on adjacent atoms may be taken together with the atoms to which they are each attached to form a heterocyclic group optionally substituted with ¨0R21 or oxo.
[0112] In other embodiments of the compounds of Formula I, Q is ¨CH=CH(CH2)m¨, ¨
(CH2)m¨, ¨(CH20)m¨, ¨(CH2)m¨Ar¨, or ¨(CH2CH20)0¨(CH2)m¨. In another embodiment, Q is ¨CH=CH(CH2)m¨. In another embodiment, Q is ¨(CH2)m¨. In another embodiment, Q
is ¨
(CH2CH20)0¨CH2CH2¨. In another embodiment, Q is ¨(CH20)m¨. In another embodiment, Q
is ¨(CH2)m¨Ar¨. Yet in another embodiment, Q is ¨(CH2CH20)0¨(CH2)m.
[0113] In other embodiments of the compounds of Formula I, F is H, C1-6 alkyl, aryl, heteroaryl, ¨C(0)¨Q¨R22, or ¨C(0)¨Q¨N(R22)(R22). In another embodiment, F is H. In another embodiment, F is C1-6 alkyl. In another embodiment, F is ¨C(0)¨Q¨N(R22)(R22). In another embodiment, F is aryl. In another embodiment, F is heteroaryl. In another embodiment, F is ¨C(0)¨Q¨R22.
[0114] In other embodiments of the compounds of Formula I, F is H, C1-6 alkyl, aryl, heteroaryl, wherein the alkyl, aryl, or heteroaryl is optionally substituted with one or more R22.
In another embodiment, F is H. In another embodiment, F is C1-6 alkyl, wherein the alkyl is optionally substituted with one or more R22. In another embodiment, F is ¨C(0)¨Q¨
N(R22)(R22). In another embodiment, F is aryl, wherein the aryl is optionally substituted with one or more R22. In another embodiment, F is heteroaryl, wherein the heteroaryl is optionally substituted with one or more R22. In another embodiment, F is ¨C(0)¨Q¨R22 [0115] In some embodiments of the compounds of Formula I, R19 is ¨H, halogen, ¨OH, ¨
NH2, oxo, ¨C(0)R2o, ¨0R22, C3-6 cycloalkyl, or C1-6 alkyl. In one embodiment, R19 is ¨H. In one embodiment, R19 is halogen. In one embodiment, R19 is ¨OH. In one embodiment, R19 is ¨NH2. In one embodiment, R19 is oxo. In one embodiment, R19 is ¨C(0)R20. In one embodiment, R19 is ¨0R22. In one embodiment, R19 is C3-6 cycloalkyl. In one embodiment, R19 is C1-6 alkyl.
[0116] In some embodiments of the compounds of Formula I, two R19 when on adjacent atoms may be taken together with the atoms to which they are each attached to form an aryl group. In one embodiment, two R19 when on adjacent atoms may be taken together with the atoms to which they are each attached to form an aryl group optionally substituted with one or more R22.
[0117] In some embodiments of the compounds of Formula I, Rzo is ¨H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, heterocyclyl, aryl, or heteroaryl. In another embodiment, Rzo is ¨H. In another embodiment, Rzo is C1-6 alkyl. In another embodiment, Rzo is C2-6 alkenyl.
In another embodiment, Rzo is C2-6 alkynyl. In another embodiment, Rzo is C3-8 cycloalkyl. In another embodiment, Rzo is heterocyclyl. In another embodiment, Rzo is aryl.
In another embodiment, Rzo is heteroaryl. In another embodiment, Rzo is C1-6 alkyl optionally substituted with one or more H, halogen, ¨CN, ¨OH, C1-6 alkyl, C1-6 alkoxy, C3-8 cycloalkyl, heterocyclyl, heteroaryl, or aryl. In another embodiment, Rzo is C2-6 alkenyl optionally substituted with one or more H, halogen, ¨CN, ¨OH, C1-6 alkyl, C1-6 alkoxy, C3-8 cycloalkyl, heterocyclyl, heteroaryl, or aryl. In another embodiment, Rzo is C2-6 alkynyl optionally substituted with one or more H, halogen, ¨CN, ¨OH, C1-6 alkyl, C1-6 alkoxy, C3-8 cycloalkyl, heterocyclyl, heteroaryl, or aryl. In another embodiment, Rzo is C3-8 cycloalkyl optionally substituted with one or more H, halogen, ¨CN, ¨OH, C1-6 alkyl, C1-6 alkoxy, C3-8 cycloalkyl, heterocyclyl, heteroaryl, or aryl. In another embodiment, Rzo is heterocyclyl optionally substituted with one or more H, halogen, ¨CN, ¨OH, C1-6 alkyl, C1-6 alkoxy, C3-8 cycloalkyl, heterocyclyl, heteroaryl, or aryl. In another embodiment, Rzo is aryl. In another embodiment, Rzo is heteroaryl optionally substituted with one or more H, halogen, ¨CN, ¨OH, C1-6 alkyl, C1-6 alkoxy, C3-8 cycloalkyl, heterocyclyl, heteroaryl, or aryl.
[0118] In other embodiments of the compounds of Formula I, R21 is ¨H, C1-6 alkyl, or ¨
C(0)R22. In one embodiment, R21 is ¨H. In one embodiment, R21 is C1-6 alkyl.
In one embodiment, R21 is ¨C(0)R22.
[0119] In other embodiment of the compounds of Formula I, R22 is ¨H, C1-6 alkyl, C1-6 alkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, heterocyclyl, aryl, or heteroaryl. In another embodiment, R22 is ¨H. In another embodiment, R22 is C1-6 alkyl. In another embodiment, R22 is C1-6 alkoxy. In another embodiment, R22 is C2-6 alkenyl. In another embodiment, R22 is C2-6 alkynyl. In another embodiment, R22 is C3-8 cycloalkyl. In another embodiment, R22 is heterocyclyl. In another embodiment, R22 is aryl. In another embodiment, R22 is heteroaryl.
[0120] In one embodiment, p is 1, 2, 3, or 4. In another embodiment p is 1, 2, or 3. In another embodiment p is 1 or 2. In another embodiment p is 1. In another embodiment p is 2.
In another embodiment p is 3. In another embodiment p is 4.
[0121] In one embodiment, n is 1, 2, 3, or 4. In another embodiment n is 1, 2, or 3. In another embodiment n is 1 or 2. In another embodiment n is 1. In another embodiment n is 2.
In another embodiment n is 3. In another embodiment n is 4.
[0122] In one embodiment, m is 1, 2, 3, or 4. In another embodiment m is 1, 2, or 3. In another embodiment m is 1 or 2. In another embodiment m is 1. In another embodiment m is 2. In another embodiment m is 3. In another embodiment m is 4.
[0123] In one embodiment, o is 1, 2, or 3. In another embodiment o is 1 or 2. In another embodiment o is 1. In another embodiment o is 2. In another embodiment o is 3.
[0124] In some embodiments of the compounds of Formula I, Ri is ¨N(R5)C(0)R6, W is ¨
0¨, R2 is H, R3 is C1-6 alkyl, R4 is ¨H, G is ¨NH¨, Ring Al is a 5-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more Rs [0125] In some embodiments of the compounds of Formula I, Ri is ¨N(R5)C(0)R6, W is ¨
0¨, R2 is H, R3 is C1-6 alkyl, R4 is ¨H, G is ¨NH¨, Ring Al is a 6-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more Rs [0126] In some embodiments of the compounds of Formula I, Ri is ¨N(R5)C(0)R6, W is ¨
NH¨, R2 is H, R3 is C1-6 alkyl, R4 is ¨H, G is ¨NH¨, Ring Al is a 5-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more Rs [0127] In some embodiments of the compounds of Formula I, Ri is ¨N(R5)C(0)R6, W is ¨
NH¨, R2 is H, R3 is C1-6 alkyl, R4 is ¨H, G is ¨NH¨, Ring Al is a 6-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more Rs [0128] In some embodiments of the compounds of Formula I, Ri is ¨N(R5)C(0)R6, W is ¨
N(C1-6 alkyl)¨, R2 is H, R3 is C1-6 alkyl, R4 is ¨H, G is ¨NH¨, Ring Al is a 5-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more Rs [0129] In some embodiments of the compounds of Formula I, Ri is ¨N(R5)C(0)R6, W is ¨
N(C1-6 alkyl)¨, R2 is H, R3 is C1-6 alkyl, R4 is ¨H, G is ¨NH¨, Ring Al is a 6-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more Rs [0130] In some embodiments of the compounds of Formula I, Ri is ¨N(R5)C(0)R6, W is ¨
N(C3-8 cycloalkyl)¨, R2 is H, R3 is C1-6 alkyl, R4 is ¨H, G is ¨NH¨, Ring Al is a 5-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more Rs [0131] In some embodiments of the compounds of Formula I, Ri is ¨N(R5)C(0)R6, W is ¨
N(C3-8 cycloalkyl)¨, R2 is H, R3 is C1-6 alkyl, R4 is ¨H, G is ¨NH¨, Ring Al is a 6-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more Rs [0132] In some embodiments of the compounds of Formula I, Ri is ¨N(R5)C(0)R6, W is ¨N(ary1)¨, R2 is H, R3 is C1-6 alkyl, R4 is ¨H, G is ¨NH¨, Ring Al is a 5-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more R8 [0133] In some embodiments of the compounds of Formula I, Ri is ¨N(R5)C(0)R6, W is ¨N(ary1)¨, R2 is H, R3 is C1-6 alkyl, R4 is ¨H, G is ¨NH¨, Ring Al is a 6-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more R8 [0134] In some embodiments of the compounds of Formula I, Ri is ¨N(R5)C(0)R6, W is ¨
N(heteroary1)¨, R2 is H, R3 is C1-6 alkyl, R4 is ¨H, G is ¨NH¨, Ring Al is a 5-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more Rs [0135] In some embodiments of the compounds of Formula I, Ri is ¨N(R5)C(0)R6, W is ¨
N(heteroary1)¨, R2 is H, R3 is C1-6 alkyl, R4 is ¨H, G is ¨NH¨, Ring Al is a 6-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more Rs [0136] In some embodiments of the compounds of Formula I, Ri is ¨C(0)N(R5)(R6), W is ¨0¨, R2 is H, R3 is C1-6 alkyl, R4 is ¨H, G is ¨NH¨, Ring Al is a 5-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more Rs [0137] In some embodiments of the compounds of Formula I, Ri is ¨C(0)N(R5)(R6), W is ¨0¨, R2 is H, R3 is C1-6 alkyl, R4 is ¨H, G is ¨NH¨, Ring Al is a 6-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more Rs [0138] In some embodiments of the compounds of Formula I, Ri is ¨S(0)2N(R5)(R6), W is ¨0¨, R2 is H, R3 is C1-6 alkyl, R4 is ¨H, G is ¨NH¨, Ring Al is a 5-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more Rs [0139] In some embodiments of the compounds of Formula I, Ri is ¨S(0)2N(R5)(R6), W is ¨0¨, R2 is H, R3 is C1-6 alkyl, R4 is ¨H, G is ¨NH¨, Ring Al is a 6-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more Rs [0140] In some embodiments of the compounds of Formula I, Ri is -N(R5)S(0)2R6, W is ¨
0¨, R2 is H, R3 is C1-6 alkyl, R4 is ¨H, G is ¨NH¨, Ring Al is a 5-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more Rs [0141] In some embodiments of the compounds of Formula I, Ri is -N(R5)S(0)2R6, W is ¨
0¨, R2 is H, R3 is C1-6 alkyl, R4 is ¨H, G is ¨NH¨, Ring Al is a 6-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more Rs [0142] In some embodiments of the compounds of Formula I, Ri is heteroaryl, W is ¨0¨, R2 is H, R3 is C1-6 alkyl, R4 is ¨H, G is ¨NH¨, Ring Al is a 5-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more Rs [0143] In some embodiments of the compounds of Formula I, Ri is heteroaryl wherein heteroaryl is optionally substituted with one or more R7, W is ¨0¨, R2 is H, R3 is C1-6 alkyl, R4 is ¨H, G is ¨NH¨, Ring Al is a 5-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more R8 [0144] In some embodiments of the compounds of Formula I, Ri is heteroaryl, W is ¨0¨, R2 is H, R3 is C1-6 alkyl, R4 is ¨H, G is ¨NH¨, Ring Al is a 6-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more Rs [0145] In some embodiments of the compounds of Formula I, Ri is heteroaryl wherein heteroaryl is optionally substituted with one or more R7, W is ¨0¨, R2 is H, R3 is C1-6 alkyl, R4 is ¨H, G is ¨NH¨, Ring Al is a 6-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more R8 [0146] In some embodiments of the compounds of Formula I, Ri is ¨N(R5)C(0)R6, W is ¨
0¨, R2 is H, R3 is C1-6 alkyl, R4 is ¨H, G is a bond, Ring Al is a 5-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more Rs [0147] In some embodiments of the compounds of Formula I, Ri is ¨N(R5)C(0)R6, W is ¨
0¨, R2 is H, R3 is C1-6 alkyl, R4 is ¨H, G is a bond, Ring Al is a 6-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more Rs [0148] In some embodiments of the compounds of Formula I, Ri is ¨N(R5)C(0)R6, W is ¨
NH¨, R2 is H, R3 is C1-6 alkyl, R4 is ¨H, G is a bond, Ring Al is a 5-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more Rs [0149] In some embodiments of the compounds of Formula I, Ri is ¨N(R5)C(0)R6, W is ¨
NH¨, R2 is H, R3 is C1-6 alkyl, R4 is ¨H, G is a bond, Ring Al is a 6-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more R8 [0150] In some embodiments of the compounds of Formula I, Ri is ¨N(R5)C(0)R6, W is ¨
N(C1-6 alkyl)¨, R2 is H, R3 is C1-6 alkyl, R4 is ¨H, G is a bond, Ring Al is a 5-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more Rs [0151] In some embodiments of the compounds of Formula I, Ri is ¨N(R5)C(0)R6, W is ¨
N(C1-6 alkyl)¨, R2 is H, R3 is C1-6 alkyl, R4 is ¨H, G is a bond, Ring Al is a 6-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more Rs [0152] In some embodiments of the compounds of Formula I, Ri is ¨N(R5)C(0)R6, W is ¨
N(C3-8 cycloalkyl)¨, R2 is H, R3 is C1-6 alkyl, R4 is ¨H, G is a bond, Ring Al is a 5-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more Rs [0153] In some embodiments of the compounds of Formula I, Ri is ¨N(R5)C(0)R6, W is ¨
N(C3-8 cycloalkyl)¨, R2 is H, R3 is C1-6 alkyl, R4 is ¨H, G is a bond, Ring Al is a 6-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more Rs [0154] In some embodiments of the compounds of Formula I, Ri is ¨N(R5)C(0)R6, W is ¨N(ary1)¨, R2 is H, R3 is C1-6 alkyl, R4 is ¨H, G is a bond, Ring Al is a 5-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more R8 [0155] In some embodiments of the compounds of Formula I, Ri is ¨N(R5)C(0)R6, W is ¨N(ary1)¨, R2 is H, R3 is C1-6 alkyl, R4 is ¨H, G is a bond, Ring Al is a 6-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more R8 [0156] In some embodiments of the compounds of Formula I, Ri is ¨N(R5)C(0)R6, W is ¨
N(heteroary1)¨, R2 is H, R3 is C1-6 alkyl, R4 is ¨H, G is a bond, Ring Al is a 5-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more Rs [0157] In some embodiments of the compounds of Formula I, Ri is ¨N(R5)C(0)R6, W is ¨
N(heteroary1)¨, R2 is H, R3 is C1-6 alkyl, R4 is ¨H, G is a bond, Ring Al is a 6-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more Rs [0158] In some embodiments of the compounds of Formula I, Ri is ¨C(0)N(R5)(R6), W is ¨0¨, R2 is H, R3 is C1-6 alkyl, R4 is ¨H, G is a bond, Ring Al is a 5-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more Rs [0159] In some embodiments of the compounds of Formula I, Ri is ¨C(0)N(R5)(R6), W is ¨0¨, R2 is H, R3 is C1-6 alkyl, R4 is ¨H, G is a bond, Ring Al is a 6-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more Rs [0160] In some embodiments of the compounds of Formula I, Ri is ¨S(0)2N(R5)(R6), W is ¨0¨, R2 is H, R3 is C1-6 alkyl, R4 is ¨H, G is a bond, Ring Al is a 5-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more Rs [0161] In some embodiments of the compounds of Formula I, Ri is ¨S(0)2N(R5)(R6), W is ¨0¨, R2 is H, R3 is C1-6 alkyl, R4 is ¨H, G is a bond, Ring Al is a 6-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more Rs [0162] In some embodiments of the compounds of Formula I, Ri is ¨N(R5)C(0)R6, W is ¨
0¨, R2 is H, R3 is C1-6 alkyl, R4 is ¨H, G is ¨0¨, Ring Al is a 5-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more Rs [0163] In some embodiments of the compounds of Formula I, Ri is ¨N(R5)C(0)R6, W is ¨
0¨, R2 is H, R3 is C1-6 alkyl, R4 is ¨H, G is ¨0¨, Ring Al is a 6-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more Rs [0164] In some embodiments of the compounds of Formula I, Ri is ¨N(R5)C(0)R6, W is ¨
N(heteroary1)¨, R2 is H, R3 is C1-6 alkyl, R4 is ¨H, G is ¨0¨, Ring Al is a 6-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more Rs [0165] In some embodiments of the compounds of Formula I, Ri is ¨C(0)N(R5)(R6), W is ¨0¨, R2 is H, R3 is C1-6 alkyl, R4 is ¨H, G is ¨0¨, Ring Al is a 5-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more Rs [0166] In some embodiments of the compounds of Formula I, Ri is ¨S(0)2N(R5)(R6), W is ¨0¨, R2 is H, R3 is C1-6 alkyl, R4 is ¨H, G is ¨0¨, Ring Al is a 5-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more Rs [0167] In some embodiments of the compounds of Formula I, Ri is ¨S(0)2N(R5)(R6), W is ¨0¨, R2 is H, R3 is C1-6 alkyl, R4 is ¨H, G is ¨0¨, Ring Al is a 6-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more Rs [0168] In some embodiments of the compounds of Formula I, Ri is ¨N(R5)C(0)R6, W is ¨
0¨, R2 is H, R3 is C1-6 alkyl, R4 is ¨H, G is ¨N(C1-6 alkyl)¨, Ring Al is a 5-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more Rs [0169] In some embodiments of the compounds of Formula I, Ri is ¨N(R5)C(0)R6, W is ¨
0¨, R2 is H, R3 is C1-6 alkyl, R4 is ¨H, G is ¨N(C1-6 alkyl)¨, Ring Al is a 6-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more Rs [0170] In some embodiments of the compounds of Formula I, Ri is ¨N(R5)C(0)R6, W is ¨
N(heteroary1)¨, R2 is H, R3 is C1-6 alkyl, R4 is ¨H, G is ¨N(C1-6 alkyl)¨, Ring Al is a 6-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more Rs [0171] In some embodiments of the compounds of Formula I, Ri is ¨C(0)N(R5)(R6), W is ¨0¨, R2 is H, R3 is C1-6 alkyl, R4 is ¨H, G is ¨N(C1-6 alkyl)¨, Ring Al is a 5-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more Rs [0172] In some embodiments of the compounds of Formula I, Ri is ¨S(0)2N(R5)(R6), W is ¨0¨, R2 is H, R3 is C1-6 alkyl, R4 is ¨H, G is ¨N(C1-6 alkyl)¨, Ring Al is a 5-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more Rs [0173] In some embodiments of the compounds of Formula I, Ri is ¨S(0)2N(R5)(R6), W is ¨0¨, R2 is H, R3 is C1-6 alkyl, R4 is ¨H, G is ¨N(C1-6 alkyl)¨, Ring Al is a 6-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more Rs [0174] In some embodiments of the compounds of Formula I, Ri is ¨N(R5)C(0)R6, W is ¨
0¨, R2 is H, R3 is C1-6 alkyl, R4 is ¨H, G is ¨NH¨, Ring Al is a 5-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more Rs, Rs is ¨N(R9)C(0)R11, RH is aryl or heteroaryl optionally substituted with one or more R18, R18 is ¨N(R22)C(0)¨Q¨N(R22)¨F, or ¨N(R22)¨Q¨N(R22)¨F.
[0175] In some embodiments of the compounds of Formula I, Ri is ¨N(R5)C(0)R6, W is ¨
0¨, R2 is H, R3 is C1-6 alkyl, R4 is ¨H, G is ¨NH¨, Ring Al is a 6-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more Rs, Rs is ¨N(R9)C(0)R11, RH is aryl or heteroaryl optionally substituted with one or more R18, R18 is ¨N(R22)C(0)¨Q¨N(R22)¨F, or ¨N(R22)¨Q¨N(R22)¨F.
[0176] In some embodiments of the compounds of Formula I, Ri is ¨C(0)N(R5)(R6), W is ¨0¨, R2 is H, R3 is C1-6 alkyl, R4 is ¨H, G is ¨NH¨, Ring Al is a 5-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more Rs,.Rs is ¨N(R9)C(0)Rii, Ru is aryl or heteroaryl optionally substituted with one or more R18, R18 is ¨N(R22)C(0)¨Q¨N(R22)¨F, or ¨N(R22)¨Q¨N(R22)¨F.
[0177] In some embodiments of the compounds of Formula I, Ri is ¨C(0)N(R5)(R6), W is ¨0¨, R2 is H, R3 is C1-6 alkyl, R4 is ¨H, G is ¨NH¨, Ring Al is a 6-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more Rs, Rs is ¨N(R9)C(0)R11, Rii is aryl or heteroaryl optionally substituted with one or more Ris, Ris is ¨N(R22)C(0)¨Q¨N(R22)¨F, or ¨N(R22)¨Q¨N(R22)¨F.
[0178] In some embodiments of the compounds of Formula I, Ri is ¨S(0)2N(R5)(R6), W is ¨0¨, R2 is H, R3 is C1-6 alkyl, R4 is ¨H, G is ¨NH¨, Ring Al is a 5-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more Rs, Rs is ¨N(R9)C(0)R11, Rii is aryl or heteroaryl optionally substituted with one or more Ris, Ris is ¨N(R22)C(0)¨Q¨N(R22)¨F, or ¨N(R22)¨Q¨N(R22)¨F.
[0179] In some embodiments of the compounds of Formula I, Ri is ¨S(0)2N(R5)(R6), W is ¨0¨, R2 is H, R3 is C1-6 alkyl, R4 is ¨H, G is ¨NH¨, Ring Al is a 6-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more Rs, Rs is ¨N(R9)C(0)Rii, Rii is aryl or heteroaryl optionally substituted with one or more Ris, Ris is ¨N(R22)C(0)¨Q¨N(R22)¨F, or ¨N(R22)¨Q¨N(R22)¨F.
[0180] In some embodiments of the compounds of Formula I, Ri is ¨N(R5)C(0)R6, W is ¨
0¨, R2 is H, R3 is C1-6 alkyl, R4 is ¨H, G is ¨NH¨, Ring Al is a 5-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more Rs, Rs is ¨N(R9)C(0)Rio, Rio is C1-6 alkyl, C3-8 cycloalkyl, or heterocyclyl optionally substituted with one or more R13, R13 is alkyl optionally substituted with one or more R15, Ris is N(R22)C(0)¨U¨N(R22)¨Z.
[0181] In some embodiments of the compounds of Formula I, Ri is ¨N(R5)C(0)R6, W is ¨
0¨, R2 is H, R3 is C1-6 alkyl, R4 is ¨H, G is ¨NH¨, Ring Al is a 6-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more Rs, Rs is ¨N(R9)C(0)Rio, Rio is C1-6 alkyl, C3-8 cycloalkyl, or heterocyclyl optionally substituted with one or more R13, R13 is alkyl optionally substituted with one or more R15, Ris is N(R22)C(0)¨U¨N(R22)¨Z.
[0182] In some embodiments of the compounds of Formula I, Ri is ¨C(0)N(R5)(R6), W is ¨0¨, R2 is H, R3 is C1-6 alkyl, R4 is ¨H, G is ¨NH¨, Ring Al is a 5-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more Rs, Rs is ¨N(R9)C(0)Rio, Rio is C1-6 alkyl, C3-8 cycloalkyl, or heterocyclyl optionally substituted with one or more R13, R13 is alkyl optionally substituted with one or more R15, Ris is N(R22)C(0)¨U¨N(R22)¨Z.
[0183] In some embodiments of the compounds of Formula I, Ri is ¨C(0)N(R5)(R6), W is ¨0¨, R2 is H, R3 is C1-6 alkyl, R4 is ¨H, G is ¨NH¨, Ring Al is a 6-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more Rs, Rs is ¨N(R9)C(0)Rio, Rio is C1-6 alkyl, C3-8 cycloalkyl, or heterocyclyl optionally substituted with one or more R13, R13 is alkyl optionally substituted with one or more R15, Ris is N(R22)C(0)¨U¨N(R22)¨Z.
[0184] In some embodiments of the compounds of Formula I, Ri is ¨S(0)2N(R5)(R6), W is ¨0¨, R2 is H, R3 is C1-6 alkyl, R4 is ¨H, G is ¨NH¨, Ring Al is a 5-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more Rs, Rs is ¨N(R9)C(0)Rio, Rio is C1-6 alkyl, C3-8 cycloalkyl, or heterocyclyl optionally substituted with one or more R13, R13 is alkyl optionally substituted with one or more R15, Ris is N(R22)C(0)¨U¨N(R22)¨Z.
[0185] In some embodiments of the compounds of Formula I, Ri is ¨S(0)2N(R5)(R6), W is ¨0¨, R2 is H, R3 is C1-6 alkyl, R4 is ¨H, G is ¨NH¨, Ring Al is a 6-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more Rs, Rs is ¨N(R9)C(0)Rio, Rio is C1-6 alkyl, C3-8 cycloalkyl, or heterocyclyl optionally substituted with one or more R13, R13 is alkyl optionally substituted with one or more R15, Ris is N(R22)C(0)¨U¨N(R22)¨Z.
[0186] In some embodiments of the compounds of Formula I, Ri is ¨N(R5)C(0)R6, W is ¨
0¨, R2 is H, R3 is C1-6 alkyl, R4 is ¨H, G is ¨NH¨, Ring Al is a 5-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more Rs, Rs is ¨N(R9)C(0)Rio, R9 and Rio are taken together with the atom to which they are each attached form a heterocycle ring optionally substituted with one or more R14, R14 is C1-6 alkyl, heterocycle, C3-6 cycloalkyl, or aryl optionally substituted with one or more R16, R16 is C3-8 cycloalkyl, heterocyclyl, heteroaryl, or aryl optionally substituted with one or more R17, R17 is ¨N(R22)C(0)¨V¨N(R22)¨E.
[0187] In some embodiments of the compounds of Formula I, Ri is ¨N(R5)C(0)R6, W is ¨
0¨, R2 is H, R3 is C1-6 alkyl, R4 is ¨H, G is ¨NH¨, Ring Al is a 6-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more Rs, Rs is ¨N(R9)C(0)Rio, R9 and Rio are taken together with the atom to which they are each attached form a heterocycle ring optionally substituted with one or more R14, R14 is C1-6 alkyl, heterocycle, C3-6 cycloalkyl, or aryl optionally substituted with one or more R16, R16 is C3-8 cycloalkyl, heterocyclyl, heteroaryl, or aryl optionally substituted with one or more R17, R17 is ¨N(R22)C(0)¨V¨N(R22)¨E.
[0188] In some embodiments of the compounds of Formula I, Ri is ¨C(0)N(R5)(R6), W is ¨0¨, R2 is H, R3 is C1-6 alkyl, R4 is ¨H, G is ¨NH¨, Ring Al is a 5-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more Rs, Rs is ¨N(R9)C(0)Rio, R9 and Rio are taken together with the atom to which they are each attached form a heterocycle ring optionally substituted with one or more R14, R14 is C1-6 alkyl, heterocycle, C3-6 cycloalkyl, or aryl optionally substituted with one or more R16, R16 is C3-8 cycloalkyl, heterocyclyl, heteroaryl, or aryl optionally substituted with one or more R17, R17 is ¨N(R22)C(0)¨V¨N(R22)¨E.
[0189] In some embodiments of the compounds of Formula I, Ri is ¨C(0)N(R5)(R6), W is ¨0¨, R2 is H, R3 is C1-6 alkyl, R4 is ¨H, G is ¨NH¨, Ring Al is a 6-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more Rs, Rs is ¨N(R9)C(0)R10, R9 and Rio are taken together with the atom to which they are each attached form a heterocycle ring optionally substituted with one or more R14, R14 is C1-6 alkyl, heterocycle, C3-6 cycloalkyl, or aryl optionally substituted with one or more R16, R16 is C3-8 cycloalkyl, heterocyclyl, heteroaryl, or aryl optionally substituted with one or more R17, R17 is ¨N(R22)C(0)¨V¨N(R22)¨E..
[0190] In some embodiments of the compounds of Formula I, Ri is ¨S(0)2N(R5)(R6), W is ¨0¨, R2 is H, R3 is C1-6 alkyl, R4 is ¨H, G is ¨NH¨, Ring Al is a 5-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more Rs, Rs is ¨N(R9)C(0)R10, R9 and Rio are taken together with the atom to which they are each attached form a heterocycle ring optionally substituted with one or more R14, R14 is C1-6 alkyl, heterocycle, C3-6 cycloalkyl, or aryl optionally substituted with one or more R16, R16 is C3-8 cycloalkyl, heterocyclyl, heteroaryl, or aryl optionally substituted with one or more R17, R17 is ¨N(R22)C(0)¨V¨N(R22)¨E.
[0191] In some embodiments of the compounds of Formula I, Ri is ¨S(0)2N(R5)(R6), W is ¨0¨, R2 is H, R3 is C1-6 alkyl, R4 is ¨H, G is ¨NH¨, Ring Al is a 6-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more Rs, Rs is ¨N(R9)C(0)R10, R9 and Rio are taken together with the atom to which they are each attached form a heterocycle ring optionally substituted with one or more R14, R14 is C1-6 alkyl, heterocycle, C3-6 cycloalkyl, or aryl optionally substituted with one or more R16, R16 is C3-8 cycloalkyl, heterocyclyl, heteroaryl, or aryl optionally substituted with one or more R17, R17 is ¨N(R22)C(0)¨V¨N(R22)¨E.
[0192] In some embodiments of the compounds of Formula I, Ri is ¨N(R5)C(0)R6, W is ¨
0¨, R2 is H, R3 and R4 are taken together with the atom to which they are attached form a C3-8 cycloalkyl or heterocyclyl, G is ¨NH¨, Ring Al is a 6-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more R8 [0193] In some embodiments of the compounds of Formula I, Ri is ¨N(R5)C(0)R6, W is ¨
NH¨, R2 is H, R3 and R4 when taken together with the atom to which they are attached form a C3-8 cycloalkyl or heterocyclyl, G is ¨NH¨, Ring Al is a 5-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more R8 [0194] In some embodiments of the compounds of Formula I, Ri is ¨C(0)N(R5)(R6), W is ¨0¨, R2 is H, R3 and R4 when taken together with the atom to which they are attached form a C3-8 cycloalkyl or heterocyclyl, G is ¨NH¨, Ring Al is a 5-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more R8 [0195] In some embodiments of the compounds of Formula I, Ri is ¨C(0)N(R5)(R6), W is ¨0¨, R2 is H, R3 and R4 when taken together with the atom to which they are attached form a C3-8 cycloalkyl or heterocyclyl, G is ¨NH¨, Ring Al is a 6-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more R8 [0196] In some embodiments of the compounds of Formula I, Ri is ¨S(0)2N(R5)(R6), W is ¨0¨, R2 is H, R3 and R4 when taken together with the atom to which they are attached form a C3-8 cycloalkyl or heterocyclyl, G is ¨NH¨, Ring Al is a 5-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more Rs [0197] In some embodiments of the compounds of Formula I, Ri is ¨S(0)2N(R5)(R6), W is ¨0¨, R2 is H, R3 and R4 when taken together with the atom to which they are attached form a C3-8 cycloalkyl or heterocyclyl, G is ¨NH¨, Ring Al is a 6-membered heteroaryl, Ring A2 is heteroaryl optionally substituted with one or more R8 [0198] Non-limiting illustrative compounds of the present disclosure include:
N,N,5-trimethy1-3-((5 -(2- oxopy rrolidin- 1 -yl)pyridin-3 -yl)amino)-5H-chromeno [4,3-c] py ri dine-8 - carboxami de ;
N,N,5 -trimethy1-3 -(pyri din-3 -ylamino)-5 H-chromeno [4,3 -c] py ri dine- 8-carb oxami de ;
1-(3 -(( 1 - acety1-2,3 -dihy dro- 1 H-pyri do [2,3 -b] [1,4] oxazin-7-y0amino)-5-methyl-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one;
- cy clopropyl-N,N-dimethy1-3-((5 -(2- oxopy rrolidin- 1 -yl)pyridin-3 -yl)amino)-5H-chromeno [4,3 - c] py ri dine- 8 -carb oxami de ;
1-(3 -((5 -(difluoromethoxy )py ri din-3 -yl)amino)-5 -methy1-5 H- chromeno [4,3 -c] pyri din-8 -yl)pyrrolidin-2-one;
N,N,5 -trimethy1-3 -(((S )-9-oxo-6a,7, 8, 9-tetrahy dro-6H-py rido [2,3 -b]
pyrrolo [1,2-d] [1,4] oxazin-2-yl)amino)-5 H- chromeno [4,3 -c] py ri dine- 8- carb oxami de ;
(6aS)-2-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)-6,6a,7,8-tetrahydro-9H-pyrido[2,3-blpyrrolo[1,2-d][1,41oxazin-9-one;
5-cyclopropyl-N,N-dimethy1-3-4(S)-9-oxo-6a,7,8,9-tetrahydro-6H-pyrido[2,3-blpyrrolo[1,2-d][1,4]oxazin-2-yl)amino)-5H-chromeno[4,3-clpyridine-8-carboxamide;
1-(5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-y0cyclopropane-1-carbonitrile;
5-cyclopropyl-N,N-dimethy1-3-(pyridin-3-ylamino)-5H-chromeno[4,3-clpyridine-8-carboxamide;
1-(5-methy1-3-(pyridin-3-ylamino)-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one;
1-methy1-3-(5-((5-methyl-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y1)amino)pyridin-3-y1)imidazolidin-2-one;
N,N,5,6-tetramethy1-3-(pyridin-3-ylamino)-5,6-dihydrobenzo[c][2,6]naphthyridine-8-carboxamide;
N-methyl-N-(5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-y1)amino)pyridin-3-y1)methanesulfonamide;
1-(5-methy1-3-((1-(methylsulfony1)-2,3-dihydro-1H-pyrido[2,3-b][1,4loxazin-7-y0amino)-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one;
1-(3-((5-fluoropyridin-3-y0amino)-5-methyl-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one;
1-(3-41-(cyclopropylsulfony1)-2,3-dihydro-1H-pyrido[2,3-b][1,4loxazin-7-y0amino)-5-methyl-5H-chromeno[4,3-c]pyridin-8-y1)pyrrolidin-2-one;
(S)-2-(((R)-5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)-6,6a,7,8-tetrahydro-9H-pyrido[2,3-blpyrrolo[1,2-d][1,41oxazin-9-one;
(S)-2-(((S)-5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)-6,6a,7,8-tetrahydro-9H-pyrido[2,3-blpyrrolo[1,2-d][1,41oxazin-9-one;
1-(5-methy1-3-((5-(2-oxopyrrolidin-1-yOpyridin-3-y0amino)-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one;
1-(5-methy1-3-(pyrido[2,3-b]pyrazin-7-ylamino)-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one;
1-(3-((1,5-naphthyridin-3-y0amino)-5-methyl-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one;
1-(5-methy1-3-(pyrimidin-5-ylamino)-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one ;
N-cyclopropyl-N-(5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-y1)methanesulfonamide;
1-(5-methy1-3-((1-(methylsulfony1)-1H-pyrrolo[3,2-blpyridin-6-y0amino)-5H-chromeno[4,3-clpyridin-8-y1)pyrrolidin-2-one;
1-(5-methy1-3-41-pivaloy1-2,3-dihydro-1H-pyrido[2,3-b][1,41oxazin-7-y0amino)-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one;
1-(5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-y0imidazolidin-2-one;
1-(3-((2,3-dihydro-[1,4]dioxino[2,3-blpyridin-7-y0amino)-5-methyl-5H-chromeno[4,3-c]pyridin-8-y1)pyrrolidin-2-one;
1-(5-methy1-3-(thiazolo[5,4-blpyridin-6-ylamino)-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one;
1-(3-((1-(cyclopropanecarbony1)-2,3-dihydro-1H-pyrido[2,3-b][1,41oxazin-7-y0amino)-5-methyl-5H-chromeno[4,3-c]pyridin-8-y1)pyrrolidin-2-one;
3-((1-(cyclopropylsulfony1)-2,3-dihydro-1H-pyrido[2,3-b][1,41oxazin-7-y0amino)-N,N,5-trimethyl-5H-chromeno[4,3-c]pyridine-8-carboxamide;
N,N,5-trimethy1-3-41-pivaloy1-2,3-dihydro-1H-pyrido[2,3-b][1,41oxazin-7-y0amino)-5H-chromeno[4,3-c]pyridine-8-carboxamide;
3-((1-(cyclopropanecarbony1)-2,3-dihydro-1H-pyrido[2,3-b][1,41oxazin-7-y0amino)-N,N,5-trimethyl-5H-chromeno[4,3-c]pyridine-8-carboxamide;
3-((1-acety1-2,3-dihydro-1H-pyrido[2,3-b][1,41oxazin-7-y0amino)-N,N,5-trimethyl-5H-chromeno[4,3-c]pyridine-8-carboxamide;
N,N,5-trimethy1-3-((1-(methylsulfony1)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-yl)amino)-5H-chromeno[4,3-c]pyridine-8-carboxamide;
1-(5-methy1-3-((5-(trifluoromethyl)pyridin-3-yl)amino)-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one;
N-(2-methoxy-5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-y0acetamide;
N-(2-methoxy-5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-y1)methanesulfonamide;
1-(3-41-isobutyry1-2,3-dihydro-1H-pyrido[2,3-b][1,41oxazin-7-y0amino)-5-methyl-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one;
(S)-2-((5,5-dimethy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-y0amino)-6,6a,7,8-tetrahydro-9H-pyrido[2,3-blpyrrolo[1,2-d][1,4]oxazin-9-one;
N-(2-methoxy-5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c1pyridin-3-y0amino)pyridin-3-y1)-N-methylmethanesulfonamide;
1-(5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-y0amino)pyridin-3-y1)-3-(thiazol-4-ylmethypimidazolidin-2-one;
methyl 7-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-y1)amino)-2,3-dihydro-1H-pyrido[2,3-b][1,41oxazine-1-carboxylate;
1-(5-methy1-3-((5-(methylsulfonyl)pyridin-3-yl)amino)-5H-chromeno[4,3-c]pyridin-8-y1)pyrrolidin-2-one;
1-(3-((1-(2-hydroxyacety1)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)amino)-5-methy1-5H-chromeno[4,3-c]pyridin-8-y1)pyrrolidin-2-one;
methyl 7-((8-(dimethylcarbamoy1)-5-methy1-5H-chromeno[4,3-c]pyridin-3-yl)amino)-2,3-dihydro-1H-pyrido[2,3-b][1,41oxazine-1-carboxylate;
N-(2-methoxy-5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-y1)-N-methylacetamide;
1-(5,6-dimethy1-3-(pyridin-3-ylamino)-5,6-dihydrobenzo[c][2,61naphthyridin-8-yl)pyrrolidin-2-one;
1-(9-fluoro-5-methy1-3-(pyridin-3-ylamino)-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one;
(6aS)-2-((5,6-dimethy1-8-(2-oxopyrrolidin-1-y1)-5,6-dihydrobenzo[c][2,61naphthyridin-3-y1)amino)-6,6a,7,8-tetrahydro-9H-pyrido[2,3-b]pyrrolo[1,2-d][1,41oxazin-9-one;
methyl 7-((8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazine-1-carboxylate;
(S)-2-((8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)-6,6a,7,8-tetrahydro-9H-pyrido[2,3-b]pyrrolo[1,2-d][1,4]oxazin-9-one;
1-(5-methy1-3-((5-morpholinopyridin-3-y0amino)-5H-chromeno[4,3-c]pyridin-8-yOpyrrolidin-2-one;
1-(3-((1-(2-hydroxy-2-methylpropanoy1)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-yl)amino)-5-methy1-5H-chromeno[4,3-c]pyridin-8-y1)pyrrolidin-2-one;
1-(3-((1-(cyclopropanecarbony1)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)amino)-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one;
1-(3-((1-(methylsulfony1)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)amino)-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one;
(S)-2-((8-(2-oxopyrrolidin-1-yl)spiro[chromeno[4,3-clpyridine-5,3'-oxetan]-3-y0amino)-6,6a,7,8-tetrahydro-9H-pyrido[2,3-blpyrrolo[1,2-d][1,41oxazin-9-one;
(S)-2-((8-(2-oxopyrrolidin-1-yl)spiro[chromeno[4,3-clpyridine-5,11-cyclobutan1-3-y0amino)-6,6a,7,8-tetrahydro-9H-pyrido[2,3-blpyrrolo[1,2-d][1,4]oxazin-9-one;
7-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y1)amino)-1H-pyrido[2,3-b1[1,41oxazin-2(3H)-one;
1-(3-((2,3-dihydro-1H-pyrido[2,3-b][1,41oxazin-7-y0amino)-5-methyl-5H-chromeno[4,3-c]pyridin-8-y1)pyrrolidin-2-one;
1-(5-methy1-3-((5-methylpyridin-3-y0amino)-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one;
(6aS)-2-((9-fluoro-5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-y1)amino)-6,6a,7,8-tetrahydro-9H-pyrido[2,3-blpyrrolo[1,2-d][1,4]oxazin-9-one;
1-(3-((2,3-dihydro-[1,41dioxino[2,3-blpyridin-7-y0amino)-5,6-dimethyl-5,6-dihydrobenzo[c][2,61naphthyridin-8-yOpyrrolidin-2-one;
1-(3-41-(cyclopropylsulfony1)-2,3-dihydro-1H-pyrido[2,3-b][1,41oxazin-7-y0amino)-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one;
1-(3-41-(isopropylsulfony1)-2,3-dihydro-1H-pyrido[2,3-b][1,41oxazin-7-y0amino)-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one;
4-(5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-yOmorpholin-3-one;
1-(3-((1-(1-hydroxycyclopropane-1-carbony1)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)amino)-5-methyl-5H-chromeno[4,3-c]pyridin-8-y1)pyrrolidin-2-one;
1-(3-((1-(2-hydroxypropanoy1)-2,3-dihydro-1H-pyrido[2,3-b][1,41oxazin-7-y0amino)-5-methyl-5H-chromeno[4,3-c]pyridin-8-y1)pyrrolidin-2-one;
1-(3-((1-(isopropylsulfony1)-2,3-dihydro-1H-pyrido[2,3-b][1,41oxazin-7-y0amino)-5-methyl-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one;
(S)-2-((9-fluoro-5,5-dimethy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)-6,6a,7,8-tetrahydro-9H-pyrido[2,3-b]pyrrolo[1,2-d][1,4]oxazin-9-one;
N-(5-((5-methy1-8-(2-oxopyrrolidin-l-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-y0acetamide;
1-benzy1-3-(5-45-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-yOurea;
3-amino-N-(5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-yObenzamide;
1-(5-methy1-3-(pyridazin-4-ylamino)-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one;
1-(5-methy1-3-(pyridazin-3-ylamino)-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one;
1-(5-((9-fluoro-5,5-dimethy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-y1)imidazolidin-2-one;
1-methy1-3-(5-((5-methyl-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-yOurea;
N-(5-((5-methy1-8-(2-oxopyrrolidin-l-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-y1)-3-phenylpropanamide;
N-(5-((5-methy1-8-(2-oxopyrrolidin-l-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-y1)-2-phenylacetamide;
(1S,2S)-N-(5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-y1)-2-phenylcyclopropane-1-carboxamide;
N-(5-((5-methy1-8-(2-oxopyrrolidin-l-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-yOpicolinamide;
N-(5-((5-methy1-8-(2-oxopyrrolidin-l-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-yOnicotinamide;
N-(5-((5-methy1-8-(2-oxopyrrolidin-l-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-yOisonicotinamide;
4-fluoro-N-(5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-y1)amino)pyridin-3-y1)benzamide;
3-fluoro-N-(5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-y1)amino)pyridin-3-y1)benzamide;
3-methoxy-N-(5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-yObenzamide;
4-methoxy-N-(5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-yObenzamide;
1-(5-methy1-3-45-(pyridin-2-ylamino)pyridin-3-y0amino)-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one;
1-(5-methy1-3-45-(pyridazin-3-ylamino)pyridin-3-y0amino)-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one;
N-(5-((5-methy1-8-(2-oxopyrrolidin-l-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-y1)-3-phenylbutanamide;
2-methyl-N-(5-((5 -methyl- 8-(2-oxopyrroli din- 1 -y1)-5H-chromeno [4,3-c] py ri din-3 -yl)amino)pyridin-3 -y1)-3-phenylpropanami de;
N-(5-((5 -methyl- 8-(2-oxopy rroli din- 1 -y 0-5H-chromeno [4,3-c] pyri din-3-y Damino)py ridin-3 -y Otetrahy drofuran-2-carboxami de;
N-(5-((5 -methyl- 8-(2-oxopy rroli din- 1 -y1)-5H-chromeno [4,3-c] pyri din-3-yl)amino)py ridin-3 -yl)benzo[d] [1,3] dioxole-5 -carboxami de;
N-(5-((5 -methyl- 8-(2-oxopy rroli din- 1 -y1)-5H-chromeno [4,3-c] pyri din-3-yl)amino)py ridin-3 -yl)benzo[d] [1,3] dioxole-4-carboxami de;
1-(5 -methyl-3 -((5-(methylsulfonyl)quinolin-3 -yl)amino)-5H-chromeno [4,3-c]
py ri din- 8 -yl)pyrrolidin-2-one;
methyl 7-((9-fluoro-5-methyl- 8-(2-oxopy rroli din- 1 -y1)-5H-chromeno [4,3-c] py ri din-3-yl)amino)-2,3-dihy dro- 1H-pyri do [2,3-b] [1,4] oxazine- 1 -carboxylate;
N-(5-((5 -methyl- 8-(2-oxopy rroli din- 1 -y1)-5H-chromeno [4,3-c] pyri din-3-yl)amino)py ridin-3 -y1)-2-oxopyrroli dine-3-carboxami de;
N-(5-((5 -methyl- 8-(2-oxopy rroli din- 1 -y 0-5H-chromeno [4,3-c] pyri din-3-y Damino)py ridin-3 -y 0-2,3-dihy dro- 1H-indene-2-carboxami de;
N-(5-((5 -methyl- 8-(2-oxopy rroli din- 1 -y1)-5H-chromeno [4,3-c] pyri din-3-yl)amino)py ridin-3 -yl)pyrazolo [1,5-al py ri dine-2-carboxami de;
N-(5-((5 -methyl- 8-(2-oxopy rroli din- 1 -y 0-5H-chromeno [4,3-c] pyri din-3-y Damino)py ridin-3 -y 0-2,3-dihy drob enzofuran-2-carb oxami de;
methyl (5-45 -methyl- 8-(2-oxopyrroli din- 1 -y1)-5H-chromeno [4,3-c] py ri din-3-yl)amino)py ri din-3 -yl)carbamate;
4-((5-((5 -methy1-8 -(2-oxopy rroli din- 1 -y1)-5H-chromeno [4,3 -c] py ri din-3 -yl)amino)py ri din-3 -y0amino)-4-oxobutanoic acid;
N-(5-((5 -methyl- 8-(2-oxopy rroli din- 1 -y 0-5H-chromeno [4,3-c] pyri din-3-y Damino)py ridin-3 -y1)-1H-indole-6-carboxamide;
N-(5-((5 -methyl- 8-(2-oxopy rroli din- 1 -y 0-5H-chromeno [4,3-c] pyri din-3-y Damino)py ridin-3 -y1)-1H-indole-4-carboxamide;
N-(5-((5 -methyl- 8-(2-oxopy rroli din- 1 -y1)-5H-chromeno [4,3-c] pyri din-3-yl)amino)py ridin-3 -y1)-1H-benzo [d]imidazole-7-carboxamide;
N-(5-((5 -methyl- 8-(2-oxopy rroli din- 1 -y1)-5H-chromeno [4,3-c] pyri din-3-yl)amino)py ridin-3 -yl)imidazo [1,2-a] pyridine-2-carboxamide;
N-(5-((5 -methyl- 8-(2-oxopy rroli din- 1 -y 0-5H-chromeno [4,3-c] pyri din-3-y Damino)py ridin-3 -y1)-1H-indole-2-carboxamide;
2-(imidazo[1,2-a1pyridin-3-y1)-N-(5-45-methyl-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-y1)acetamide;
1-(5-((9-fluoro-5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-y1)imidazolidin-2-one;
4-formamido-3-hydroxy-N-(5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-yObenzamide;
N-(5-((5-methy1-8-(2-oxopyrrolidin-l-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-yOpyridazine-4-carboxamide;
6-amino-N-(5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-yOpyrazine-2-carboxamide;
2-hydroxy-N-(5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y1)amino)pyridin-3-y1)-3-phenylpropanamide;
N-(5-((5-methy1-8-(2-oxopyrrolidin-l-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-y0imidazo[1,2-alpyridine-3-carboxamide;
N-(5-((5-methy1-8-(2-oxopyrrolidin-l-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-yOpyrazolo[1,5-a]pyridine-3-carboxamide;
1-(3-((2,3-dihydro-[1,4]dioxino[2,3-blpyridin-7-y0amino)-5,5-dimethyl-5H-chromeno[4,3-c]pyridin-8-y1)pyrrolidin-2-one;
1-(3-((2,3-dihydro-[1,4]dioxino[2,3-blpyridin-7-y0amino)-9-fluoro-5-methyl-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one;
1-(3-((2,3-dihydro-[1,41dioxino[2,3-blpyridin-7-y0amino)-9-fluoro-5,5-dimethyl-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one;
2-hydroxy-N-(5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y1)amino)pyridin-3-y1)acetamide;
N-(5-((5-methy1-8-(2-oxopyrrolidin-l-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-yObenzo[d]oxazole-6-carboxamide;
1-hydroxy-N-(5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y1)amino)pyridin-3-y1)-1,3-dihydrobenzo[c][1,21oxaborole-5-carboxamide;
N-(5-((5-methy1-8-(2-oxopyrrolidin-l-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridazin-3-y0acetamide;
N-(5-((5-methy1-8-(2-oxopyrrolidin-l-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-y0imidazo[1,2-alpyridine-7-carboxamide;
1-(3-((2,3-dihydro-[1,41dioxino[2,3-blpyridin-7-y0amino)-5H-chromeno[4,3-clpyridin-8-y1)pyrrolidin-2-one;
1-(5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-y1)-3-(pyridin-2-yOurea;
1-hydroxy-N-(5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y1)amino)pyridin-3-y1)-1,3-dihydrobenzo[c][1,21oxaborole-6-carboxamide;
N-(5-((5-methy1-8-(2-oxopyrrolidin-l-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-y0imidazo[1,2-alpyridine-5-carboxamide;
1-(3-((2,3-dihydro-[1,41dioxino[2,3-blpyridin-7-y0amino)-9-fluoro-5H-chromeno[4,3-clpyridin-8-y1)pyrrolidin-2-one;
1-(5-methy1-4-(pyridin-4-y1)-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one;
1-(3-45-(4-(3-methoxypropanoyDpiperazin-1-y1)pyridin-3-y1)amino)-5H-chromeno[4,3-c]pyridin-8-y1)pyrrolidin-2-one;
1-(3-45-(4-(3-methoxypropanoyDpiperazin-1-yOpyridin-3-y0amino)-5-methyl-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one;
1-(3-45-(4-(3-methoxypropanoyDpiperazin-1-yOpyridin-3-y0amino)-5,5-dimethyl-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one;
(E)-4-(dimethylamino)-N-(3-(3-((5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-yl)amino)pyridin-3-yl)amino)-3-oxopropyl)phenyl)but-2-enamide;
2-amino-N-(5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-y1)isonicotinamide;
1-(9-fluoro-3-45-(4-(3-methoxypropanoyDpiperazin-1-yOpyridin-3-y0amino)-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one;
1-(9-fluoro-3-45-(4-(3-methoxypropanoyDpiperazin-1-yOpyridin-3-y0amino)-5-methyl-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one;
1-(9-fluoro-3-45-(4-(3-methoxypropanoyDpiperazin-1-yOpyridin-3-y0amino)-5,5-dimethyl-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one;
1-(5-((8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-y1)imidazolidin-2-one;
(E)-4-(4-(dimethylamino)but-2-enamido)-N-(5-((5-methy1-8-(2-oxopyrrolidin-l-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-yObenzamide;
(6aS)-8,8-dimethy1-2-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y1)amino)-6,6a,7,8-tetrahydro-9H-pyrido[2,3-blpyrrolo[1,2-d][1,4]oxazin-9-one;
(6aS)-2-((9-fluoro-5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-yOamino)-8,8-dimethy1-6,6a,7,8-tetrahydro-9H-pyrido[2,3-blpyrrolo[1,2-d][1,41oxazin-9-one;
1-hydroxy-N-(5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y1)amino)pyridin-3-y1)-1,3-dihydrobenzo[c][1,21oxaborole-4-carboxamide;
(6aR)-2-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)-6,6a,7,8-tetrahydro-9H-pyrido[2,3-blpyrrolo[1,2-d][1,41oxazin-9-one;
(6aS)-2-((9-fluoro-5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-y0amino)-8-methyl-6,6a,7,8-tetrahydro-9H-pyrido[2,3-blpyrrolo[1,2-d][1,4loxazin-9-one;
(6aR)-2-((9-fluoro-5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c1pyridin-y0amino)-6,6a,7,8-tetrahydro-9H-pyrido[2,3-blpyrrolo[1,2-d][1,41oxazin-9-one;
(R)-2-((8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)-6,6a,7,8-tetrahydro-9H-pyrido[2,3-blpyrrolo[1,2-d][1,41oxazin-9-one;
(R)-2-((5,5-dimethy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)-6,6a,7,8-tetrahydro-9H-pyrido[2,3-blpyrrolo[1,2-d][1,41oxazin-9-one;
(R)-2-((9-fluoro-5,5-dimethy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y1)amino)-6,6a,7,8-tetrahydro-9H-pyrido[2,3-blpyrrolo[1,2-d][1,4]oxazin-9-one;
(6aS)-8-methy1-2-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-yl)amino)-6,6a,7,8-tetrahydro-9H-pyrido[2,3-b]pyrrolo[1,2-d][1,4]oxazin-9-one;
4-(dimethylamino)-N-(3-(3-((5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-y1)amino)pyridin-3-y1)amino)-3-oxopropyl)phenyl)butanamide;
(E)-4-(dimethylamino)-N-(2-((3-((3-(5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-y1)-2-oxoimidazolidin-1-y1)methyl)phenyl)amino)-2-oxoethyl)but-2-enamide;
(6a'S)-2'-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-y1)amino)-6a',7'-dihydro-6'H,9'H-spiro[cyclopropane-1,8'-pyrido[2,3-blpyrrolo[1,2-d][1,4loxazinl-91-one;
(S)-2'-((5-(3-fluoro-4-(2-oxopyrrolidin-1-yl)phenyl)pyridin-2-yl)amino)-6a',7'-dihydro-6'H,9'H-spiro[cyclopropane-1,81-pyrido[2,3-blpyrrolo[1,2-d][1,4loxazinl-91-one;
(6a'S)-2'-((9-fluoro-5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-y0amino)-6a',7'-dihydro-6'H,91H-spiro[cyclopropane-1,8'-pyrido[2,3-blpyrrolo[1,2-d][1,4loxazinl-9'-one;
(E)-N-(5-((5,5-dimethy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-y1)-4-(4-(dimethylamino)but-2-enamido)benzamide;
(E)-N-(3-(3-((5-((5,5-dimethy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-y0amino)-3-oxopropyl)phenyl)-4-(dimethylamino)but-2-enamide;
(E)-4-(4-(dimethylamino)but-2-enamido)-N-(5 -((8-(2-oxopyrrolidin- 1 -y1)-5H-chromeno [4,3 -c] pyridin-3-y0amino)pyridin-3-yObenzamide;
1 -(5 -((9-fluoro-8-(2-oxopyrrolidin- 1 -y1)-5H-chromeno [4,3-clpyridin-3-y0amino)pyridin-3-y0imidazolidin-2-one;
1-(5 -((5,5 -dimethy1-8-(2-oxopyrrolidin-1 -y1)-5H-chromeno [4,3 -c] pyridin-3 -yl)amino)pyridin-3 -yl)imidazolidin-2-one;
(6aS)-2-((9-fluoro-5 -methyl-8-(2-oxopyrrolidin- 1 -y1)-5H-chromeno [4,3 -c]
pyridin-3-yl)amino)-8-hy droxy -6,6a,7, 8-tetrahy dro-9H-pyrido [2,3-blpyrrolo [1,2-d]
[1,41 oxazin-9-one;
(E)-4-(dimethylamino)-N-(2-((4-((3-(5 -((5-methyl-8-(2-oxopyrrolidin- 1 -y1)-chromeno [4,3-clpyridin-3-y0amino)pyridin-3-y1)-2-oxoimidazolidin- 1 -yl)methyl)phenyl)amino)-2-oxoethyl)but-2-enamide;
1 -(4-(pyridin-4-y1)-5H-chromeno [4,3-clpyridin-8-yOpyrrolidin-2-one;
1 -(5 -methy1-4-(pyridin-4-ylamino)-5H-chromeno [4,3 -c] pyridin-8-yOpyrrolidin-2-one;
(S)-2-((9-fluoro-5,5-dimethy1-8-(2-oxopyrrolidin-l-y1)-5H-chromeno [3,4-dlpyrimi din-3-yOamino)-6,6a,7,8-tetrahy dro-9H-pyrido [2,3 -b] pyrrolo [ 1,2-d] [1,4] oxazin-9-one;
(S)-2-((5,5-dimethy1-8-(2-oxopyrrolidin- 1 -y1)-5H-chromeno [3,4-d] pyrimidin-3-y0amino)-6,6a,7,8-tetrahy dro-9H-pyrido [2,3-b] pyrrolo [ 1,2-d] [1,4] oxazin-9-one;
(3 aR)-8-((5-methyl-8-(2-oxopyrrolidin- 1 -y1)-5H-chromeno [4,3 -c] pyridin-3 -yl)amino)-3 a,4-dihy dro-1H,3H-oxazolo [3,4-d] pyrido[2,3-b] [1,4] oxazin-1-one;
N-(5-((9-fluoro-5,5-dimethy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno [4,3-c]
pyridin-3-yl)amino)-2-methoxy pyridin-3-yl)acetamide;
N-(5-((5,5-dimethy1-8-(2-oxopyrrolidin- 1 -y1)-5H-chromeno [4,3 -c] pyridin-3-y0amino)-2-methoxy pyridin-3 -y0acetamide;
1 -(5 -methy1-3 -((5-(5 -methyl- 1, 1 -dioxido- 1,2,5-thiadiazolidin-2-yOpyridin-3-y0amino)-5H-chromeno [4,3-clpyridin-8-yOpyrrolidin-2-one;
(6aS, 8R)-2-((9-fluoro-5 -methyl-8-(2-oxopyrrolidin- 1 -y1)-5H-chromeno [4,3 -c] pyridin-3-yl)amino)-8-hy droxy -8-methy1-6,6a,7,8-tetrahy dro-9H-pyrido [2,3-blpyrrolo [1,2-d] [1,4] oxazin-9-one;
(6aS,8R)-8-hy droxy -8-methy1-2-((5 -methyl-8-(2-oxopyrrolidin- 1 -y1)-5H-chromeno [4,3-c] pyridin-3-yl)amino)-6,6a,7, 8-tetrahy dro-9H-pyrido [2,3-blpyrrolo [1,2-d]
[1,4] oxazin-9-one;
1 -(5,5 -dimethy1-3-((5 -(5 -methyl- 1, 1 -dioxido-1,2,5 -thiadiazolidin-2-yOpyridin-3-y0amino)-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one;
N-(5-((5-methy1-8-(2-oxopyrrolidin-l-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-y1)-1H-benzo[dlimidazole-4-carboxamide;
(3aR)-8-((9-fluoro-5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-y0amino)-3a,4-dihydro-1H,3H-oxazolo[3,4-dlpyrido[2,3-bl[1,410xazin-1-one;
4-(4-(dimethylamino)butanamido)-N-(5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-yObenzamide;
1-(5-methy1-3-4(S)-2-methy1-1,1-dioxido-2,3,3a,4-tetrahydropyrido[2,3-b][1,2,5]thiadiazolo[2,3-d][1,4loxazin-8-y0amino)-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one;
(S)-1-(5,5-dimethy1-3-((2-methy1-1,1-dioxido-2,3,3a,4-tetrahydropyrido[2,3-bl[1,2,5]thiadiazolo[2,3-d][1,4loxazin-8-y0amino)-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one;
(6aS)-8-hydroxy-2-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)-6,6a,7,8-tetrahydro-9H-pyrido[2,3-blpyrrolo[1,2-d][1,41oxazin-9-one;
1-(5-methy1-3-(oxazolo[4,5-blpyridin-6-ylamino)-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one;
1-(5,5-dimethy1-3-((1-methyl-2,3-dihydro-1H-pyrido[2,3-b][1,4loxazin-7-y0amino)-5H-chromeno[3,4-dlpyrimidin-8-yOpyrrolidin-2-one;
(S)-2-45,5-dimethy1-8-(4-methylisoxazol-3-y1)-5H-chromeno[4,3-c]pyridin-3-y0amino)-6,6a,7,8-tetrahydro-9H-pyrido[2,3-blpyrrolo[1,2-d][1,4]oxazin-9-one;
(S)-2-((5,5-dimethy1-8-(4-methy1-4H-1,2,4-triazol-3-y1)-5H-chromeno[3,4-dlpyrimidin-3-y0amino)-6,6a,7,8-tetrahydro-9H-pyrido[2,3-blpyrrolo[1,2-d][1,4]oxazin-9-one;
(S)-2-((5,5-dimethy1-8-(4-methy1-4H-1,2,4-triazol-3-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)-6,6a,7,8-tetrahydro-9H-pyrido[2,3-blpyrrolo[1,2-d][1,41oxazin-9-one;
N-(5-((5,5-dimethy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y1)amino)pyridin-3-y1)-4-(2-(2-(2-(2-((2-(2,6-dioxopiperidin-3-y1)-1,3-dioxoisoindolin-4-y1)amino)ethoxy)ethoxy)ethoxy)acetamido)benzamide; and N-(5-((5,5-dimethy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y1)amino)pyridin-3-y1)-4-(4-(2-((2-(2,6-dioxopiperidin-3-y1)-1,3-dioxoisoindolin-4-y1)oxy)acetamido)butanamido)benzamide.
[0199] It should be understood that all isomeric forms are included within the present invention, including mixtures thereof If the compound contains a double bond, the substituent may be in the E or Z configuration. If the compound contains a disubstituted cycloalkyl, the cycloalkyl substituent may have a cis- or trans configuration. All tautomeric forms are also intended to be included.
[0200]
Compounds of the invention, and pharmaceutically acceptable salts, hydrates, solvates, stereoisomers and prodrugs thereof may exist in their tautomeric form (for example, as an amide or imino ether). All such tautomeric forms are contemplated herein as part of the present invention.
[0201] The compounds of the invention may contain asymmetric or chiral centers, and, therefore, exist in different stereoisomeric forms. It is intended that all stereoisomeric forms of the compounds of the invention as well as mixtures thereof, including racemic mixtures, form part of the present invention. In addition, the present invention embraces all geometric and positional isomers. For example, if a compound of the invention incorporates a double bond or a fused ring, both the cis- and trans-forms, as well as mixtures, are embraced within the scope of the invention, each compound herein disclosed includes all the enantiomers that conform to the general structure of the compound. The compounds may be in a racemic or enantiomerically pure form, or any other form in terms of stereochemistry. The assay results may reflect the data collected for the racemic form, the enantiomerically pure form, or any other form in terms of stereo chemi stry [0202]
Diastereomeric mixtures can be separated into their individual diastereomers on the basis of their physical chemical differences by methods well known to those skilled in the art, such as, for example, by chromatography and/or fractional crystallization.
Enantiomers can be separated by converting the enantiomeric mixture into a diastereomeric mixture by reaction with an appropriate optically active compound (e.g., chiral auxiliary such as a chiral alcohol or Mosher's acid chloride), separating the diastereomers and converting (e.g., hydrolyzing) the individual diastereomers to the corresponding pure enantiomers. Also, some of the compounds of the invention may be atropisomers (e.g., substituted biaryls) and are considered as part of this invention. Enantiomers can also be separated by use of a chiral HPLC
column.
[0203] It is also possible that the compounds of the invention may exist in different tautomeric forms, and all such forms are embraced within the scope of the invention. Also, for example, all keto-enol and imine-enamine forms of the compounds are included in the invention.
[0204] All stereoisomers (for example, geometric isomers, optical isomers and the like) of the present compounds (including those of the salts, solvates, esters and prodrugs of the compounds as well as the salts, solvates and esters of the prodrugs), such as those which may exist due to asymmetric carbons on various substituents, including enantiomeric forms (which may exist even in the absence of asymmetric carbons), rotameric forms, atropisomers, and diastereomeric forms, are contemplated within the scope of this invention, as are positional isomers (such as, for example, 4-pyridyl and 3-pyridy1). (For example, if a compound of Formula (I)incorporates a double bond or a fused ring, both the cis- and trans-forms, as well as mixtures, are embraced within the scope of the invention. Also, for example, all keto-enol and imine-enamine forms of the compounds are included in the invention.) Individual stereoisomers of the compounds of the invention may, for example, be substantially free of other isomers, or may be admixed, for example, as racemates or with all other, or other selected, stereoisomers. The chiral centers of the present invention can have the S or R
configuration as defined by the IUPAC 1974 Recommendations. The use of the terms "salt", "solvate", "ester,"
"prodrug" and the like, is intended to equally apply to the salt, solvate, ester and prodrug of enantiomers, stereoisomers, rotamers, tautomers, positional isomers, racemates or prodrugs of the inventive compounds.
[0205] The compounds of Formula I may form salts which are also within the scope of this invention. Reference to a compound of the Formula herein is understood to include reference to salts thereof, unless otherwise indicated.
[0206] The present invention relates to compounds which are modulators of PI5P4K. In one embodiment, the compounds of the present invention are inhibitors of PI5P4K.
[0207] The invention is directed to compounds as described herein and pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, or tautomers thereof, and pharmaceutical compositions comprising one or more compounds as described herein, or pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, or tautomers thereof Method of Synthesizing the Compounds [0208] The compounds of the present invention may be made by a variety of methods, including standard chemistry. Suitable synthetic routes are depicted in the Schemes given below.
[0209] The compounds of Formula (I) may be prepared by methods known in the art of organic synthesis as set forth in part by the following synthetic schemes. In the schemes described below, it is well understood that protecting groups for sensitive or reactive groups are employed where necessary in accordance with general principles or chemistry. Protecting groups are manipulated according to standard methods of organic synthesis (T.
W. Greene and P. G. M. Wuts, "Protective Groups in Organic Synthesis", Third edition, Wiley, New York 1999). These groups are removed at a convenient stage of the compound synthesis using methods that are readily apparent to those skilled in the art. The selection processes, as well as the reaction conditions and order of those skilled in the art will recognize if a stereocenter exists in the compounds of Formula (I). Accordingly, the present invention includes both possible stereoisomers (unless specified in the synthesis) and includes not only racemic compounds but the individual enantiomers and/or diastereomers as well. When a compound is desired as a single enantiomer or diastereomer, it may be obtained by stereospecific synthesis or by resolution of the final product or any convenient intermediate.
Resolution of the final product, an intermediate, or a starting material may be affected by any suitable method known in the art. See, for example, "Stereochemistry of Organic Compounds" by E. L.
Eliel, S. H.
Wilen, and L. N. Mander (Wiley-lnterscience, 1994).
[0210] The compounds described herein may be made from commercially available starting materials or synthesized using known organic, inorganic, and/or enzymatic processes.
Preparation of compounds [0211] The compounds of the present invention can be prepared in a number of ways well known to those skilled in the art of organic synthesis. By way of example, compounds of the present invention can be synthesized using the methods described below, together with synthetic methods known in the art of synthetic organic chemistry, or variations thereon as appreciated by those skilled in the art. Preferred methods include but are not limited to those methods described below. Compounds of the present invention can be synthesized by following the steps outlined in General Scheme 1 which comprise different sequences of assembling intermediates or compounds (II). Starting materials are either commercially available or made by known procedures in the reported literature or as illustrated below.
[0212] A
compound of formula (I) may be obtained (Scheme 1) by starting from, for example, a compound of formula (II), wherein LG represents a leaving group including but not limited to, halogen (e.g., chlorine, bromine or iodine), or an alkyl-, aryl-or haloalkyl-sulfonate (such as triflate), and reacting said compound (II) with a compound of formula A2-G, wherein A2-G is defined below and represents a cyclic amine either as free base or a salt (such as HC1, TFA or acetic acid), optionally under the influence of a transition metal catalyst as described in for example Metal-Catalyzed Cross-Coupling Reactions, 2, Completely Revised and Enlarged Edition by A. de Meij ere and F. Diederich, Wiley VCH, 2004.
Scheme 1 *
* W W R4 __________________________________ 1/10' LG
(II) (I) [0213] The reaction may be carried out by coupling of a compound of formula (II), with an appropriate amine of formula A. The reaction may also be carried out using a suitable metal catalyst including, but not limited to, a palladium catalyst, e.g., di-tert-butylphosphinoferrocene palladium (II) dichloride, tetrakis(triphenylphosphine)palladium (0), palladium (II) diphenylphosphinoferrocene dichloride, palladium(II) acetate or bis(dibenzylideneacetone) palladium (0). Optionally a suitable ligand for example triphenylphosphine, tri-tert-butylphosphine or 2-(dicyclohexylphosphino)biphenyl or 2-dicyclohexylphosphino-2',4',6'-triisopropylbiphenyl is employed. Suitable base, including an (e.g., triethyl amine), an alkali metal or alkaline earth metal carbonate or hydroxide, or phosphate base, (e.g., potassium carbonate, sodium carbonate, cesium carbonate, sodium hydroxide, or potassium phosphate), may be used in the reaction. Said reaction may be performed at a temperature range between +20 C and +160 C, in suitable solvents, including, but not limited to, toluene, tetrahydrofuran, 2-methyl-tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, acetonitrile, water, ethanol, /V,N-dimethylacetamide or /V,N-dimethylformamide, or mixtures thereof If enantiomerically pure or enriched compound (II) is used in this reaction, an enantiomerically pure or enantiomerically enriched compound (I) is obtained.
Compounds of formula (II) and A are commercially available compounds, or are known in the literature, or they are prepared by standard processes known in the art. A
compound of formula (I), (II) or A may be separated into its enantiomers by standard processes known in the art by for example chromatography on a chiral stationary phase.
Methods of Using the Disclosed Compounds [0214] Another aspect of the invention relates to a method of treating a disease or disorder associated with modulation of PI5P4K. The method comprises administering to a patient in need of a treatment for diseases or disorders associated with modulation of PI5P4K an effective amount the compositions and compounds of Formula (I).
[0215] In another aspect, the present invention is directed to a method of inhibiting PI5P4K. The method involves administering to a patient in need thereof an effective amount of a compound of Formula (I).
[0216] Another aspect of the present invention relates to a method of treating, preventing, inhibiting or eliminating a disease or disorder in a patient associated with the inhibition of PI5P4K, the method comprising administering to a patient in need thereof an effective amount of a compound of Formula (I). In one embodiment, the disease may be, but not limited to, cancer or cell proliferative disorder, a metabloic disorder, neurodegenerative disease, and an inflammatory disease.
[0217] The present invention also relates to the use of an inhibitor of PI5P4K for the preparation of a medicament used in the treatment, prevention, inhibition or elimination of a disease or condition mediated by PI5P4K, wherein the medicament comprises a compound of Formula (I).
[0218] In another aspect, the present invention relates to a method for the manufacture of a medicament for treating, preventing, inhibiting, or eliminating a disease or condition mediated by PI5P4K, wherein the medicament comprises a compound of Formula (I).
[0219] Another aspect of the present invention relates to a compound of Formula (I) for use in the manufacture of a medicament for treating a disease associated with inhibiting PI5P4K.
[0220] In another aspect, the present invention relates to the use of a compound of Formula (I) in the treatment of a disease associated with inhibiting PI5P4K.
[0221] Another aspect of the invention relates to a method of treating cancer. The method comprises administering to a patient in need thereof an effective amount of a compound of Formula (I).
[0222] In another aspect of the invention, the method relates to treating a cell proliferative disease. The method comprises administering to a patient in need thereof an effective amount of a compound of Formula (I).
[0223] In yet another aspect, the present invention relates to a method of treating a neurodegenerative disease. The method comprises administering to a patient in need thereof an effective amount of a compound of Formula (I).
[0224] In another aspect, the present invention relates to a method of treating an inflammatory disease or condition. The method comprises administering to a patient in need thereof an effective amount of a compound of Formula (I).
[0225] Another aspect of the invention relates to a method of inducing cell cycle arrest, apoptosis in tumor cells, and/or enhanced tumor-specific T cell immunity. The method comprises contacting the cells with an effective amount of a compound of Formula (I).
[0226] In one embodiment, the present invention relates to the use of an inhibitor of PI5P4K for the preparation of a medicament used in treatment, prevention, inhibition or elimination of a disease or disorder associated with cancer or cell proliferative disorder, a metabloic disorder, neurodegenerative disease, and an inflammatory disease.
[0227] In another embodiment, the present invention relates to a compound of Formula (I) or a pharmaceutical composition comprising a compound of the present invention and a pharmaceutically acceptable carrier used for the treatment of cancers or cell proliferatives disorders including, but not limited to, leukemias (e.g., acute leukemia, acute lymphocytic leukemia, acute myelocytic leukemia, acute myeloblastic leukemia, acute promyelocytic leukemia, acute myelomonocytic leukemia, acute monocytic leukemia, acute erythroleukemia, chronic leukemia, chronic myelocytic leukemia, chronic lymphocytic leukemia), polycythemia vera, lymphoma (Hodgkin's disease, non-Hodgkin's disease), Waldenstrom's macroglobulinemia, heavy chain disease, and solid tumors such as sarcomas and carcinomas (e. g. , fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilm's tumor, cervical cancer, uterine cancer, testicular cancer, lung carcinoma, small cell lung carcinoma, bladder carcinoma, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodenroglioma, schwannoma, meningioma, melanoma, neuroblastoma, and retinoblastoma).
[0228] In another embodiment, the present invention relates to a compound of Formula (I) or a pharmaceutical composition comprising a compound of the present invention and a pharmaceutically acceptable carrier used for the treatment of neurodegenerative diseases including, but not limited to, brain trauma, spinal cord trauma, trauma to the peripheral nervous system, Alzheimer's disease, Pick's disease, diffuse Lewy body disease, progressive supranuclear palsy (Steel-Richardson syndrome), multisystem degeneration (Shy-Drager syndrome), motor neuron diseases including amyotrophic lateral sclerosis, degenerative ataxias, cortical basal degeneration, ALS-Parkinson's-Dementia complex of Guam, subacute sclerosing panencephalitis, Huntington's disease, Parkinson's disease, synucleinopathies, primary progressive aphasia, striatonigral degeneration, Machado-Joseph disease/spinocerebellar ataxia type 3 and olivopontocerebellar degenerations, Gilles De La Tourette's disease, bulbar and pseudobulbar palsy, spinal and spinobulbar muscular atrophy (Kennedy's disease), primary lateral sclerosis, familial spastic paraplegia, Werdnig-Hoffman disease, Kugelberg-Welander disease, Tay-Sach's disease, Sandhoff disease, familial spastic disease, Wohlfart-Kugelberg-Welander disease, spastic paraparesis, progressive multifocal leukoencephalopathy, and prion diseases (including Creutzfeldt-Jakob, Gerstmann-Straussler-Scheinker disease, Kuru and fatal familial insomnia, age-related dementia, vascular dementia, diffuse white matter disease (Binswanger's disease), dementia of endocrine or metabolic origin, dementia of head trauma and diffuse brain damage, dementia pugilistica or frontal lobe dementia, neurodegenerative disorders resulting from cerebral ischemia or infaction including embolic occlusion and thrombotic occlusion as well as intracranial hemorrhage of any type, intracranial and intravertebral lesions, hereditary cerebral angiopathy, normeuropathic hereditary amyloid, Down's syndrome, macroglobulinemia, secondary familial Mediterranean fever, Muckle-Wells syndrome, multiple myeloma, pancreatic- and cardiac-related amyloidosis, chronic hemodialysis arthropathy, and Finnish and Iowa amyloidosis.
[0229] In another embodiment, the present invention relates to a compound of Formula (I) or a pharmaceutical composition comprising a compound of the present invention and a pharmaceutically acceptable carrier used for the treatment of inflammatory disease. In some embodiments, the inflammatory disease is associated with a metabolic disorder.
In some embodiments the treated inflammation is associated with, but not limited to, Type II diabetes, insulin resistance cardiovascular disease, arrhythmia, atherosclerosis, coronary artery disease, hypertriglyceridemia, dyslipidemia, retinopathy, nephropathy, neuropathy, obesity, and macular edema.
[0230] In yet another embodiment, the present invention relates to a compound of Formula (I) or a pharmaceutical composition comprising a compound of the present invention and a pharmaceutically acceptable carrier used for the treatment of a metabolic disease including, but not limited, Type II diabetes, insulin resistance cardiovascular disease, arrhythmia, atherosclerosis, coronary artery disease, hypertriglyceridemia, dyslipidemia, retinopathy, nephropathy, neuropathy, obesity, and macular edema.
[0231] In another embodiment, the present invention relates to a compound of Formula (I) or a pharmaceutical composition comprising a compound of the present invention and a pharmaceutically acceptable carrier used for the treatment of inflammatory disease associated with inflammatory disease. In some embodiments the treated inflammation is associated with, but not limited to, ileitis, ulcerative colitis, Barrett's syndrome, or Crohn's disease.
[0232] In some embodiments, the patient is selected for treatment based on gene amplification and/or elevated tumor expression of PI5P4K. In other embodiments, the patient is selected for treatment based on gene amplification and/or elevated tumor expression of PI5P4Ka gene, PI5P4K13 gene, or PI5P4Ky gene. In other embodiments, the patient is selected for the treatment based on tumor expression of p53 mutations.
[0233] In some embodiments, administration of a compound of Formula (I) or a pharmaceutical composition comprising a compound of the present invention and a pharmaceutically acceptable carrier induces a change in the cell cycle or cell viability.
[0234] Another aspect of the invention is directed to pharmaceutical compositions comprising a compound of Formula (I) and a pharmaceutically acceptable carrier. The pharmaceutical acceptable carrier may further include an excipient, diluent, or surfactant.
[0235] In one embodiment, are provided methods of treating a disease or disorder associated with modulation of PI5P4K including, cancer or cell proliferative disorder, a metabloic disorder, neurodegenerative disease, and an inflammatory disease, comprising administering to a patient suffering from at least one of said diseases or disorder a compound of Formula (I).
[0236] One therapeutic use of the compounds or compositions of the present invention which inhibit PI5P4K is to provide treatment to patients or subjects suffering from c cancer or cell proliferative disorder, a metabloic disorder, neurodegenerative disease, and an inflammatory disease.
[0237] The disclosed compounds of the invention can be administered in effective amounts to treat or prevent a disorder and/or prevent the development thereof in subjects.
[0238]
Administration of the disclosed compounds can be accomplished via any mode of administration for therapeutic agents. These modes include systemic or local administration such as oral, nasal, parenteral, transdermal, subcutaneous, vaginal, buccal, rectal or topical administration modes.
[0239]
Depending on the intended mode of administration, the disclosed compositions can be in solid, semi-solid or liquid dosage form, such as, for example, injectables, tablets, suppositories, pills, time-release capsules, elixirs, tinctures, emulsions, syrups, powders, liquids, suspensions, or the like, sometimes in unit dosages and consistent with conventional pharmaceutical practices. Likewise, they can also be administered in intravenous (both bolus and infusion), intraperitoneal, subcutaneous or intramuscular form, and all using forms well known to those skilled in the pharmaceutical arts.
[0240]
Illustrative pharmaceutical compositions are tablets and gelatin capsules comprising a Compound of the Invention and a pharmaceutically acceptable carrier, such as a) a diluent, e.g., purified water, triglyceride oils, such as hydrogenated or partially hydrogenated vegetable oil, or mixtures thereof, corn oil, olive oil, sunflower oil, safflower oil, fish oils, such as EPA or DHA, or their esters or triglycerides or mixtures thereof, omega-3 fatty acids or derivatives thereof, lactose, dextrose, sucrose, mannitol, sorbitol, cellulose, sodium, saccharin, glucose and/or glycine; b) a lubricant, e.g., silica, talcum, stearic acid, its magnesium or calcium salt, sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride and/or polyethylene glycol; for tablets also; c) a binder, e.g., magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, magnesium carbonate, natural sugars such as glucose or beta-lactose, corn sweeteners, natural and synthetic gums such as acacia, tragacanth or sodium alginate, waxes and/or polyvinylpyrrolidone, if desired; d) a disintegrant, e.g., starches, agar, methyl cellulose, bentonite, xanthan gum, algic acid or its sodium salt, or effervescent mixtures; e) absorbent, colorant, flavorant and sweetener; f) an emulsifier or dispersing agent, such as Tween 80, Labrasol, HPMC, DOSS, caproyl 909, labrafac, labrafil, peceol, transcutol, capmul MCM, capmul PG-12, captex 355, gelucire, vitamin E TGPS or other acceptable emulsifier;
and/or g) an agent that enhances absorption of the compound such as cyclodextrin, hydroxypropyl-cyclodextrin, PEG400, PEG200.
[0241] Liquid, particularly injectable, compositions can, for example, be prepared by dissolution, dispersion, etc. For example, the disclosed compound is dissolved in or mixed with a pharmaceutically acceptable solvent such as, for example, water, saline, aqueous dextrose, glycerol, ethanol, and the like, to thereby form an injectable isotonic solution or suspension.
Proteins such as albumin, chylomicron particles, or serum proteins can be used to solubilize the disclosed compounds.
[0242] The disclosed compounds can be also formulated as a suppository that can be prepared from fatty emulsions or suspensions; using polyalkylene glycols such as propylene glycol, as the carrier.
[0243] The disclosed compounds can also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles. Liposomes can be formed from a variety of phospholipids, containing cholesterol, stearylamine or phosphatidylcholines. In some embodiments, a film of lipid components is hydrated with an aqueous solution of drug to a form lipid layer encapsulating the drug, as described in U.S. Pat. No. 5,262,564 which is hereby incorporated by reference in its entirety.
[0244]
Disclosed compounds can also be delivered by the use of monoclonal antibodies as individual carriers to which the disclosed compounds are coupled. The disclosed compounds can also be coupled with soluble polymers as targetable drug carriers. Such polymers can include polyvinylpyrrolidone, pyran copolymer, polyhydroxypropylmethacrylamide-phenol, polyhydroxyethylaspanamidephenol, or poly ethyleneoxidepolylysine substituted with palmitoyl residues. Furthermore, the Disclosed compounds can be coupled to a class of biodegradable polymers useful in achieving controlled release of a drug, for example, polylactic acid, polyepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates and cross-linked or amphipathic block copolymers of hydrogels. In one embodiment, disclosed compounds are not covalently bound to a polymer, e.g., a polycarboxylic acid polymer, or a polyacrylate.
[0245] Parental injectable administration is generally used for subcutaneous, intramuscular or intravenous injections and infusions. Injectables can be prepared in conventional forms, either as liquid solutions or suspensions or solid forms suitable for dissolving in liquid prior to injection.
[0246] Another aspect of the invention is directed to pharmaceutical compositions comprising a compound of Formula (I) and a pharmaceutically acceptable carrier. The pharmaceutical acceptable carrier may further include an excipient, diluent, or surfactant.
[0247]
Compositions can be prepared according to conventional mixing, granulating or coating methods, respectively, and the present pharmaceutical compositions can contain from about 0.1% to about 99%, from about 5% to about 90%, or from about 1% to about 20% of the disclosed compound by weight or volume.
[0248] The dosage regimen utilizing the disclosed compound is selected in accordance with a variety of factors including type, species, age, weight, sex and medical condition of the patient; the severity of the condition to be treated; the route of administration; the renal or hepatic function of the patient; and the particular disclosed compound employed. A physician or veterinarian of ordinary skill in the art can readily determine and prescribe the effective amount of the drug required to prevent, counter or arrest the progress of the condition.
[0249]
Effective dosage amounts of the disclosed compounds, when used for the indicated effects, range from about 0.5 mg to about 5000 mg of the disclosed compound as needed to treat the condition. Compositions for in vivo or in vitro use can contain about 0.5, 5, 20, 50, 75, 100, 150, 250, 500, 750, 1000, 1250, 2500, 3500, or 5000 mg of the disclosed compound, or, in a range of from one amount to another amount in the list of doses. In one embodiment, the compositions are in the form of a tablet that can be scored.
EXAMPLES
[0250] The disclosure is further illustrated by the following examples and synthesis schemes, which are not to be construed as limiting this disclosure in scope or spirit to the specific procedures herein described. It is to be understood that the examples are provided to illustrate certain embodiments and that no limitation to the scope of the disclosure is intended thereby. It is to be further understood that resort may be had to various other embodiments, modifications, and equivalents thereof which may suggest themselves to those skilled in the art without departing from the spirit of the present disclosure and/or scope of the appended claims.
Analytical Methods, Materials, and Instrumentation [0251] Unless otherwise noted, reagents and solvents were used as received from commercial suppliers. All solvents used were of analytical grade and commercially available anhydrous solvents were routinely used for reactions. Starting materials were available from commercial sources, or prepared according to literature procedures. Room temperature refers to +20-25 C. Solvent mixture compositions are given as volume percentages or volume ratios.
[0252]
Microwave heating was performed in a Biotage Initiator microwave cavity producing continuous irradiation at 2.45 GHz. It is understood that microwaves may be used for the heating of reaction mixtures.
[0253] Straight phase chromatography was manually performed on Merck Silica gel 60 (0.040-0.063 mm), or automatically using an ISCO Combiflash0 Companion TM
system using SiliaSepTTM normal-phase flash columns using the solvent system indicated.
[0254] NMR
spectra were recorded on a 400 MHz (or higher field) NMR spectrometer fitted with a probe of suitable configuration. Spectra were recorded at ambient temperature unless otherwise stated. Chemical shifts are given in ppm down- and upfield from TMS (0.00 ppm). The following reference signals were used: the residual solvent signal of DMSO-d6 6 2.5, CDC13 6 7.26 or Methanol-d4 6 3.31. Resonance multiplicities are denoted s, d, t, q, m and br for singlet, doublet, triplet, quartet, multiplet and broad, respectively.
[0255] High pressure liquid chromatography (HPLC) was performed on a reverse phase column. A linear gradient was applied using for example mobile phase A
(aqueous 0.1% NH3 or aqueous 0.1% acetic acid or aqueous 0.1% formic acid) and B (acetonitrile or methanol).
Mass spectrometer (MS) analyses were performed in positive ion mode using electrospray ionization (ES+).
[0256]
Preparative chromatography was run on a Gilson-PREP GX271 or GX281 with Trilution lc as software on a reverse phase column. A linear gradient was applied using for example mobile phase A (aqueous 0.1% NH3 or aqueous 0.1% acetic acid or aqueous 0.1%
formic acid) and B (acetonitrile or methanol).
[0257]
Preparative chiral chromatography for separation of enantiomers was run on a Thar SFC using supercritical fluid chromatography on a chiral stationary phase. A
linear gradient was applied using mobile phase A (carbon dioxide) and B (acetonitrile or methanol or ethanol or 2-propanol or any mixtures thereof). Additives (such as diethyl amine or isopropyl amine or ammonia or formic acid or TFA) may be used.
Abbreviations used in the following examples and elsewhere herein are:
atm atmosphere br broad Amphos (4-(N,N-Dimethylamino)phenyl)di-tert-butyl phosphine anh. anhydrous aq. aqueous BINAP ( )-2,2'-Bis(diphenylphosphino)-1,1'-binaphthalene BrettPhos 2-(dicyclohexylphosphino)3,6-dimethoxy-2',4',6'-triisopropy1-1,1'-biphenyl BrettPhos Pd G3 [(2-Di-cyclohexylphosphino-3,6-dimethoxy-2',4',6'-triisopropy1-1,1'-bipheny1)-2-(2'-amino-1,1' biphenyOlpalladium(II) methanesulfonate BuLi butyl lithium DCM dichloromethane DIAD diisopropyl azodiformate DIPEA N,N-diisopropylethylamine DMAc N,N-dimethyl acetamide DMAP N,N-dimethylpyridin-4-amine DME 1,2-Dimethoxyethane DMEDA N,N'-Dimethylethylenediamine DMF N,N-dimethyl formamide DMSO dimethyl sulfoxide EDCI.HC1 1-(3-Dimethylaminopropy1)-3-ethylcarbodiimide Hydrochloride Et0Ac ethyl acetate Et0H ethanol hour(s) HBTU 3-[Bis(dimethylamino)methyliumy11-3H-benzotriazol-1-oxide hexafluorophosphate HPLC high pressure (or performance) liquid chromatography KOtBu potassium tert-butoxide LCMS liquid chromatography mass spectrometry LHMDS Lithium bis(trimethylsilyl)amide MeCN acetonitrile 2-MeTHF 2-methyl tetrahydrofuran Me0H methanol n-BuLi butyl lithium NaOtBu sodium tert-butoxide PEPPSI-iPr [1,3-Bis(2,6-Diisopropylphenyl)imidazol-2-ylidene1(3-chloropyridyl)palladium(II) dichloride PdC12(Amphos) Bis(di-tert-buty1(4-dimethylaminophenyl)phosphine)dichloropalladium(II) Pd2(dba)3 Tris(dibenzylideneacetone)dipalladium(0) Pd(OAc)2 palladium(II) acetate PdC12(dppf) [1,11-Bis(diphenylphosphino)ferroceneldichloropalladium(II) quant. Quantitative rac racemic mixture rt room temperature Rt retention time sat. saturated TBAB tetrabutylammonium bromide TFA trifluoroacetic acid THF tetrahydrofuran XantPhos 4,5-Bis(diphenylphosphino)-9,9-dimethylxanthene XPhos 2-Dicyclohexylphosphino-2',4',6'-triisopropylbiphenyl ESI electrospray ionization HATU [bis(dimethylamino)methylene1-1H-1,2,3-triazolo[4,5-blpyridinium 3-oxide hexafluorophosphate m multiplet MeMgC1 methylmagnesium chloride MI-lz megahertz min minutes MS molecular sieves MsC1 methanesulfonyl chloride MW microwave NMR nuclear magnetic resonance ppm parts per million TLC thin layer chromatography Example 1: Intermediate 1-- Methyl 4-(6-chloro-4-formy1-3-pyridy1)-3-fluoro-benzoate C H3 el N CI
[0258] (2-Fluoro-4-methoxycarbonyl-phenyl)boronic acid (220 mg, 1.11 mmol), 5-bromo-2-chloro-pyridine-4-carbaldehyde (230 mg, 1.04 mmol), PdC12(PPh3)2 (37 mg, 0.05 mmol) and K2CO3 (360 mg, 2.61 mmol) were taken up in MeCN (5 ml) and water (1 ml) and the resulting mixture was stirred at 70 C for 1 h. When cooled to rt the mixture was concentrated and the resulting residue was diluted with water (3 ml) and extracted with Et0Ac (2 x 5 m1).
The combined organics were purified on a silica gel column eluted with 0-50%
Et0Ac in heptane to give the product as a gum (210 mg, 69%). MS ES+ m/z 294 [M+141+.
Example 2: Intermediate 2-- Methyl 4-16-chloro-4-(1-hydroxyethyl)-3-pyridy1]-3-fluo ro-b enzo ate F
N CI
[0259] 3M
MeMgC1 in THF (286 1, 0.86) was added dropwise to a solution of methyl 4-(6-chloro-4-formy1-3-pyridy1)-3-fluoro-benzoate (210 mg, 0.72 mmol) in THF (5 ml) at 0 C
under a nitrogen atmosphere and the resulting mixture was stirred at 0 C for 1 h. Sat. aq.
NH4C1 (2 ml) was added followed by water (2 ml) and Et0Ac (5 m1). The organic layer was separated and the aqueous layer extracted with Et0Ac (2 x 5 m1). The combined organics were washed with brine, dried over Na2SO4, filtered and concentrated to give the product as a gum (205 mg, 93%). MS ES+ m/z 310 [M+1-11+.
Example 3: Intermediate 3-- 3-Chloro-N,N,5-trimethy1-5H-chromeno[4,3-c]pyridine-8-carboxamide N CI
[0260] NaH (60%
in mineral oil, 51 mg, 1.32 mmol) was added to a solution of methyl 446-chloro-4-(1-hydroxyethyl)-3-pyridy11-3-fluoro-benzoate (205 mg, 0.66 mmol) in THF (5 ml) at 0 C under a nitrogen atmosphere. The mixture was stirred at 0 C for 30 min and then at rt overnight. More NaH (60% in mineral oil, 51 mg, 1.32 mmol) was added and the mixture was stirred at 40 C for 3.5 h, followed by 50 C for 4 h. The resulting mixture was cooled to rt. Water (3 ml) and Et0Ac (4 ml) were added to the mixture. The aqueous layer was separated and the organic layer extracted with 1M aq. NaOH (1 m1). The aqueous layers were combined and pH adjusted to ¨3 using 2M aq. HC1. The formed precipitate was collected, washed with water and dried to give the product as a solid (3-chloro-5-methy1-5H-chromeno[4,3-clpyridine-8-carboxylic acid). The solid was taken up in SOC12 (2 ml, 27.4 mmol). A drop of DMF was added to the resulting solution and the resulting mixture was stirred at 70 C
for 1 h. When cooled to rt the mixture was concentrated and the resulting residue was taken up in DCM (5 ml) and added slowly to 40% aq. dimethylamine (3 ml, 23.9 mmol) at rt. The resulting mixture was stirred at rt for 1 h and the organic layer separated. The aqueous layer was extracted with DCM (2 x 3 ml) and the combined organics were washed with sat. aq. NaHCO3, dried over Na2SO4, filtered, concentrated and purified on a silica gel column eluted with 0-100% Et0Ac in heptane to give the product as an oil (75 mg, 38%). MS ES+ m/z 303 [M+1-11+.
Example 4: Intermediate 4-- 1-(5-Amino-3-pyridyl)pyrrolidin-2-one N, I
[0261] 5-Bromopyridin-3-amine (10 g, 57.8 mmol), pyrrolidin-2-one (9 ml, 63.2 mmol), K2CO3 (15 g, 115.6 mmol), Cul (1.1 g, 5.78 mmol) and DMEDA (1.3 ml, 8.42 mmol) were taken up in 1,4-dioxane (100 ml) and the resulting mixture was refluxed overnight. After cooling to rt, Et0Ac was added and the mixture filtered through celite. The filtrate was concentrated and purified on a silica gel column to give the product as a solid (6 g, 59%). MS
ES+ m/z 178 [M+I-11+.
Example 5: Intermediate 5 -- (5S)-5-1(3-bromo-5-nitro-2-pyridyl)oxymethyl]pyrrolidin-2-one HN
[0262] 3-Bromo-2-chloro-5-nitro-pyridine (1 g, 4.21 mmol), (5 S)-5 -(hy droxymethyl)pyrrolidin-2-one (500 mg, 4.34 mmol) and K2CO3 (700 mg, 5.06 mmol) were taken up in MeCN (10 ml) and the resulting mixture was stirred at 70 C
overnight. More (55)-5-(hydroxymethyl)pyrrolidin-2-one (130 mg, 1.13 mmol) and K2CO3 (300 mg, 2.17 mmol) were added and stirring continued at 70 C for 5 h. After cooling to rt, the mixture was diluted with water (10 ml) and Et0Ac (10 ml) and the organic layer separated. The remaining aqueous layer was further extracted with Et0Ac (2 x 10 ml) and the combined organics were washed with brine, dried over Na2SO4, filtered and concentrated to give the product as a solid (1.13 g, 85%). MS ES+ m/z 316 [M+I-11+.
Example 6: Intermediate 6 -- (6S)-12-nitro-8-oxa-2,10-diazatricyclo17.4Ø02,61trideca-1(9),10,12-trien-3-one I
[0263] (5 S)-5-[(3-bromo-5 -nitro-2-py ri dy Doxy methyl] pyrroli din-2-one (1.13 g, 3.57 mmol), Cul (75 mg, 0.39 mmol), N,N'-dimethylethylenediamine (85 [11, 0.8 mmol) and K2CO3 (0.99 g, 7.15 mmol) were taken up in Et0Ac (20 ml) and the resulting mixture was stirred at 70 C for 2 h. More CuI (75 mg, 0.39 mmol) and N,N'-dimethylethylenediamine (85 [11, 0.8 mmol) were added and the mixture was refluxed for 2 h. Cs2CO3 (2 g, 6.14 mmol) and 1,4-dioxane (20 ml) were added and stirring continued at 100 C overnight. When cooled to rt the mixture was filtered through celite and rinsed with Et0Ac (2 x 5 m1). The filtrate was washed with half-saturated brine (20 ml), dried over Na2SO4, filtered and concentrated to give the product as a solid (720 mg, 86%). MS ES+ m/z 236 [M+1-11+.
Example 7: Intermediate 7 -- (68)-12-amino-8-oxa-2,10-diazatricyclo[7.4Ø02,6]trideca-1(9),10,12-trien-3-one I
[0264] (6S )-12-nitro-8-oxa-2,10-diazatricy clo [7. 4Ø 02,61trideca-1 (9),10,12-trien-3 -one (357 mg, 1.52 mmol), Fe (509 mg, 9.11 mmol) and ammonium chloride (244 mg, 4.55 mmol) were taken up in Et0H/H20 (4:1, 12.5 ml) and the resulting mixture was refluxed for 1.5 h. After cooling to rt the mixture was filtered through celite, rinsed with Me0H and the filtrate was concentrated. The resulting residue was suspended in water and pH
was adjusted to about ¨7 by careful addition of a sat. aq. NaHCO3. The mixture was extracted with Et0Ac and the combined organics were dried over Na2SO4, filtered and concentrated to give the product as a solid (212 mg, 68%). MS ES+ m/z 206 [M+1-11+.
Example 8: Intermediate 8 -- Methyl 4-[6-chloro-4-Icyclopropyl(hydroxy)methyl]-pyridy1]-3-fluoro-benzoate HO
N CI
[0265] The title compound was prepared as described in Intermediate 2, replacing MeMgC1 for bromo(cyclopropyl)magnesium, to give the product as a solid (1.2 g, 99%).
MS ES+ m/z 336 [M+H]+.
Example 9: Intermediate 9 -- 3-Chloro-5-cyclopropy1-5H-chromeno[4,3-c]pyridine-carboxylic acid HO
N CI
[0266] NaH (60%
in mineral oil, 429 mg, 10.7 mmol) was added to a solution of methyl 4-[6-chloro-44cyclopropyl(hydroxy)methy11-3-pyridy11-3-fluoro-benzoate (1.2 g, 3.57 mmol) in THF (15 ml) at 0 C under a nitrogen atmosphere. The mixture was stirred at 50 C for 4 h.
When cooled to rt, water (10 ml) and Et0Ac (20 ml) were added, the aqueous layer was separated and the organic layer extracted with 1M aq. NaOH (10 m1). The aqueous layers were combined and pH adjusted to about ¨3 using 2M aq. HC1. The formed precipitate was collected, washed with water and dried to give the product as a solid (900 mg, 84%). MS
ES+ m/z 302 [M+H]+.
Example 10: Intermediate 10 -- 3-Chloro-5-cyclopropyl-N,N-dimethy1-5H-chromeno [4,3-c] pyridine-8-carboxamide HqC 0 N CI
[0267] 3-Chloro-5-cyclopropy1-5H-chromeno [4,3-clpyridine-8-carboxylic acid (900 mg, 2.66 mmol), N-methylmethanamine HC1 (326 mg, 3.99 mmol), HBTU (1.11 g, 2.93 mmol) and TEA (1.11 ml, 7.98 mmol) were dissolved in DMF and the mixture was stirred at rt overnight. Water and Et0Ac were added, the organic layer separated and the aqueous layer extracted with Et0Ac. The combined organics were concentrated and purified on silica gel column, eluted with 50% Et0Ac in heptane, to give the product as a solid (600 mg, 69%). MS
ES+ m/z 329 [M+Hr.
Example 11: Intermediate 11 -- 4-(6-Chloro-4-formy1-3-pyridy1)-3-fluoro-N,N-dimethyl-benzamide H3CõN 0 N CI
[0268] The title compound was prepared as described in Intermediate 1, replacing (2-Fluoro-4-methoxycarbonyl-phenyl)boronic acid for [4-(dimethylcarbamoy1)-2-fluoro-phenyllboronic acid, to give the product as a gum (1.2 g, quant). MS ES+ m/z 307 [M+I-11+.
Example 12: Intermediate 12 -- 4-16-Chloro-4-(1-hydroxyethyl)-3-pyridy1]-3-fluoro-N,N-dimethyl-benzamide H3C,N sHO C H3 N CI
[0269] The title compound was prepared as described in Intermediate 2, starting from 4-(6-chloro-4-formy1-3-pyridy1)-3-fluoro-N,N-dimethyl-benzamide, to give the product as a gum (1.19 g, 94%). MS ES+ m/z 323 [M+F11+.
Example 13: Intermediate 13 -- 4-(4-Acety1-6-chloro-3-pyridy1)-3-fluoro-N,N-dimethyl-benzamide N CI
[0270] Dess-Martin periodinane (2 g, 4.72 mmol) was added to a solution of 4-[6-chloro-4-(1-hydroxyethyl)-3-pyridy11-3-fluoro-N,N-dimethyl-benzamide (1.10 g, 3.41 mmol) in DCM (15 ml) at rt and the resulting mixture was stirred at rt for 1 h. Sat.
aq. Na2S203 (10 ml) and sat. aq. NaHCO3 (20 ml) were added, the mixture was stirred at rt for 30 min and then filtered. The filter cake was washed with DCM (2 x 3 ml) and discarded. The organic layer was separated and the aqueous layer extracted with DCM (2 x 10 m1). The combined organics were washed with sat. aq. NaHCO3 (15 ml), dried over Na2SO4, filtered, concentrated and purified on a silica gel column eluted with 0-100% Et0Ac in heptane to give the product as a solid (828 mg, 76%). MS ES+ m/z 321 [M-411+.
Example 14: Intermediate 14 -- 3-Chloro-N,N,5,6-tetramethy1-5H-benzo[c][2,6]naphthyridine-8-carboxamide 0 C Fiq I
HqC N C H3 N CI
[0271] 4-(4-Acetyl-6-chloro-3-pyridy1)-3-fluoro-N,N-dimethyl-benzamide (300 mg, 0.94 mmol) was taken up in 2-methyltetrahydrofuran (5 ml) and titanium(IV) isopropoxide (560 IA, 1.87 mmol) was added. After 15 min at rt 40% MeNH2 in Me0H (600 IA, 5.34 mmol) was added and the resulting mixture was stirred at rt over weekend. Me0H (3 ml) was added and the mixture cooled to 0 C. NaBH4 (177 mg, 4.68 mmol) was added portion-wise and after 10 min the cooling bath was removed and the mixture stirred at rt for 3 h. Water (10 ml), sat. aq.
NH4C1 (5 ml) and Et0Ac (5 ml) were added and the mixture stirred at rt for 30 min. The organic layer was separated and the aqueous layer extracted with Et0Ac (3 x 5 m1). The combined organics were washed with brine, dried over Na2SO4, filtered, concentrated and purified on a silica gel column eluted with 0-100% Et0Ac in heptane to give the product as a gum (130 mg, 44%). MS ES+ m/z 316 [M+Hr.
Example 15: Intermediate 15 -- 12-Fluoro-4-(2-oxopyrrolidin-1-yl)phenyl]boronic acid ' F OH
[0272] n-BuLi (2.5M in hexanes, 5.20 ml, 13 mmol) was added dropwise over 10 min to a solution of 1-(4-bromo-3-fluoro-phenyl)pyrrolidin-2-one (3 g, 11.6 mmol) and triisopropyl borate (3.5 ml, 15.2 mmol) in THF (20 ml) at -78 C and the resulting mixture was stirred for 3 h. More n-BuLi (2.5M in hexanes, 5.20 ml, 13 mmol) was added dropwise over 5 min and the resulting mixture was stirred for 1.5 h. Water (10 ml) was added and the mixture allowed to reach rt. Diethylether (20 ml) was added and the aqueous layer separated.
The organic layer was extracted with 1M aq. NaOH (10 ml) and the aqueous layers were combined.
The pH was adjusted to about ¨1 using conc. HC1 and the mixture was extracted with Et0Ac (3 x 10 m1).
The combined organics were dried over Na2SO4, filtered and concentrated to give the product as a solid (1.45 g, 43%), which was used in the next step. MS ES+ m/z 224 [M+Hl+.
Example 16: Intermediate 16 -- 2-Chloro-5-12-fluoro-4-(2-oxopyrrolidin-1-yl)phenyl]pyridine-4-carbaldehyde N CI
[0273] The title compound was prepared as described in Intermediate 1, replacing (2-fluoro-4-methoxycarbonyl-phenyl)boronic acid for [2-fluoro-4-(2-oxopyrrolidin-yOphenyllboronic acid, to give the product as a gum (475 mg, 25%). MS ES+ m/z 319 [M+Hl+.
Example 17: Intermediate 17 -- 1-14-16-Chloro-4-(1-hydroxyethy1)-3-pyridy1]-3-fluoro-phenyl] pyrrolidin-2-one F I
N CI
[0274] The title compound was prepared as described in Intermediate 2, starting from 2-chl oro-5 - [2-fluoro-4-(2-oxopy rroli din-1 -y Opheny py ridine-4-carb al dehy de, to give the product as a gum (460 mg, 92%). MS ES+ m/z 335 [M+1-1[+.
Example 18: Intermediate 18 -- 1-(3-Chloro-5-methyl-5H-chromeno[4,3-c]pyridin-yl)pyrrolidin-2-one I
N CI
[0275] The title compound was prepared as described in Intermediate 9, starting from 1-[4- [6-chl oro-4-(1-hy droxy ethyl)-3-pyridyll -3-fluoro-pheny py rroli din-2-one, stirring the mixture at rt for 2 h and purification on a silica gel column eluted with 0-80% Et0Ac in heptane, to give the product as a solid (300 mg, 71%). MS ES+ m/z 315 [M+1-1[+.
Example 19: Intermediate 19 --1-(5-Amino-3-pyridyl)cyclopropanecarbonitrile cIAN
I I
[0276] rac-BINAP (73 mg, 0.12 mmol) and Pd2(dba)3 (53 mg, 0.06 mmol) were taken up in 1,4-dioxane (2 ml) and stirred at 50 C for 15 min. NaOtBu (224 mg, 2.33 mmol), dipheny lmethani mine (235 1, 1.40 mmol) and 1 -(5 -bromo-3-pyridy0cyclopropanecarbonitrile (260 mg, 1.17 mmol) were added together with 1,4-dioxane (3 ml) and the resulting mixture was stirred at 100 C for 1.5 h. When cooled to rt Et0H (5 ml) was followed by hydroxylamine HC1 (162 mg, 2.33 mmol) and sodium acetate (287 mg, 3.50 mmol) and the resulting mixture was stirred at rt overnight. The mixture was heated at 70 C
for 1 h. More Hydroxylamine chloride (162 mg, 2.33 mmol) and sodium acetate (287 mg, 3.50 mmol) were added and stirring continued at 70 C for 2 h. When cooled to rt the mixture was concentrated and the resulting residue was taken up in half-saturated NaHCO3 (10 ml) and Et0Ac (10 m1). The organic layer was separated and the aqueous layer extracted with Et0Ac (2 x 10 m1). The combined organics were washed with brine, dried over Na2SO4, filtered, concentrated and purified on a silica gel column eluted with 0-50% (10% Me0H
in Et0Ac with NH3) in heptane to give the product as an oil (110 mg, 59%). MS ES+ m/z 160 [M+1-11+.
Example 20: Intermediate 20 -- 1-(7-Bromo-2,3-dihydropyrido[2,3-b][1,41oxazin-ypethanone Br N
[0277] 7-Bromo-2,3-dihydro-1H-pyrido[2,3-b][1,41oxazine (1 g, 4.65 mmol) and Et3N
(971 1,11, 6.98 mmol) were taken up in 2-MeTHF (5 ml) and cooled to 0 C.
Acetyl chloride (398 1,11, 5.58 mmol) was added and the resulting mixture was stirred at rt for 1 h. DCM (10 ml) was added followed by acetyl chloride (398 1, 5.58 mmol) and the mixture was stirred at rt for 1 h. Et0Ac (20 ml) and water (10 ml) were added and the organic layer separated. To the aqueous layer was added 2M aq. NaOH (5 ml) and Et0Ac (10 ml) and the organic layer separated. The combined organics were washed with sat. aq. NaHCO3, brine, dried over Na2SO4, filtered and concentrated. Recrystallization from 2-propanol gave the product as a white solid (875 mg, 73%). MS ES+ m/z 257 [M+H1+.
Example 21: Intermediate 21 -- tert-Butyl N-(1-acetyl-2,3-dihydropyrido[2,3-b] [1,4] oxazin-7-yl)carbamate H3C1 ii I
[0278] The title compound was prepared as described in Example 31, replacing pyridine-3-amine for tert-butyl carbamate and 3-chloro-N,N,5-trimethy1-5H-chromeno[4,3-clpyridine-8-carboxamide for 1-(7-bromo-2,3-dihydropyrido [2,3 -b] [1,4] oxazin-1 -ypethanone, to give the product as a solid (157 mg, 28%). MS ES+ m/z 294 [M+Hr.
Example 22: Intermediate 22 -- 1-(7-Amino-2,3-dihydropyrido[2,3-b][1,4]oxazin-yl)ethenone I
[0279] tert-Butyl N-(1-acety1-2,3 -dihy dropy ri do [2,3-b] [1,4] oxazin-7-yl)carbamate (157 mg, 0.54 mmol) was dissolved in DCM (3 mL). TFA (0.41 ml, 5.35 mmol) was added and the reaction was stirred at room temperature for 2 h. The mixture was concentrated and the resulting residue was dissolved in Et0Ac and washed with sat. aq. Na2CO3 and brine. The organic layer was dried over MgSO4, filtered and concentrated to give the product as a solid (106 mg, quant.). MS ES+ m/z 194 [M+H1+.
Example 23: Intermediate 23 -- 1-[4-(4-Acetyl-6-chloro-3-pyridy1)-3-fluoro-phenyl] pyrrolidin-2-one F I
N CI
[0280] The title compound was prepared as described in Intermediate 13, replacing 4-[6-chloro-4-(1-hy droxy ethyl)-3 -py ridyl] -3-fluoro-N,N-dimethyl-b enzami de for 1- [446-chloro-4-(1-hydroxy ethyl)-3-pyridy11-3-fluoro-phenyll pyrrolidin-2-one, to give the product as a solid (250 mg, 84%). MS ES+ m/z 333 [M+H1+.
Example 24: Intermediate 24 -- 1-[4-[6-Chloro-4-11-(methylamino)ethy1]-3-pyridyl]-3-flu oro-p henyl] pyrrolidin-2-one N CI
[0281] 1 44-(4-Acety1-6-chl oro-3 -py ri dy1)-3-fl uoro-phenyl] pyrroli din-2-one (250 mg, 0.75 mmol) was taken up in 2-MeTHF (5 ml) and titanium(IV) isopropoxide (500 [1.1, 1.68 mmol) was added. After 15 min at rt MeNH2 in THF (2M, 2.25 ml, 4.51 mmol) was added and the resulting mixture was stirred at rt overnight. Me0H (3 ml) was added and the mixture cooled to 0 C. NaBH4 (142 mg, 3.76 mmol) was added portion wise and after 10 min the cooling bath was removed and the mixture stirred at rt for 3 h. Water, sat.
aq. NH4C1 and Et0Ac were added and the mixture stirred at rt for 30 min. The organic layer was separated and the aqueous layer extracted with Et0Ac. The combined organics were washed with brine, dried over Na2SO4, filtered and concentrated to give the product as a solid (242 mg, 93%). MS ES+
m/z 348 [M+1-11+.
Example 25: Intermediate 25 -- 1-(3-Chloro-5,6-dimethy1-5H-benzo [c] [2,6] naphthyridin-8-yl)pyrrolid in-2-one I
N CI
[0282] The title compound was prepared as described in Intermediate 9, except starting from 1- [4- [6-chloro-4- [1 -(methylamino)ethyl] -3-py ri dyl] -3 -fluoro-phenyl] pyrroli din-2-one, quenching with Me0H and concentrating the mixture, to give the crude product as a solid (245 mg, quant.). MS ES+ m/z 328 [M+1-11+.
Example 26: Intermediate 26 -- 1-(4-Bromo-2,5-difluoro-phenyl)pyrrolidin-2-one ciN F
Br [0283] 1-Bromo-2,5-difluoro-4-iodo-benzene (5 g, 15.7 mmol), Cul (450 mg, 2.36 mmol) and CsF (5.4 g, 35.5 mmol) were taken up in Et0Ac (30 ml) and the resulting mixture was degassed with nitrogen for 10 min. Pyrrolidin-2-one (1.31 ml, 17.2 mmol) and N,N'-dimethylethylenediamine (0.5 ml, 4.7mmo1) were added and the resulting mixture was stirred at 50 C for 4 h. More CuI (450 mg, 2.36 mmol) and N,N'-dimethylethylenediamine (0.5 ml, 4.7 mmol) were added and stirring continued overnight. More CuI (450 mg, 2.36 mmol), N,N'-dimethylethylenediamine (0.5 ml, 4.7 mmol), CsF (2 g, 13.17 mmol), pyrrolidin-2-one (0.75 ml, 9.85 mmol) and Et0Ac (15 ml) were added and stirring continued at 80 C
overnight.
When cooled to rt the mixture was filtered, the filter cake washed with Et0Ac (2 x 10 ml) and the filtrate washed with 0.5M aq. HC1 (60 ml), 5% NH4OH (50 ml), brine, dried over Na2SO4, filtered, concentrated and purified on a silica gel column eluted with 0-75%
Et0Ac in heptane to give the product as a solid (2.13 g, 49%). MS ES+ m/z 276 [M+1-11+.
Example 27: Intermediate 27 -- 1-12,5-Difluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl] pyrrolidin-2-one c c H3 [0284] 1-(4-Bromo-2,5-difluoro-phenyl)pyrrolidin-2-one (2.10 g, 7.61 mmol), 4,4,5,5-tetramethy1-2-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-y1)-1,3,2-dioxaborolane (2.50 g, 9.84 mmol) and KOAc (2.24 g, 22.8 mmol) were taken up in toluene (10 ml) and degassed with nitrogen for 5 min. Pd(dppf)C12 (500 mg, 0.68 mmol) was added and the resulting mixture was stirred at 100 C overnight. When cooled to rt Et0Ac (10 ml) and water (10 ml) were added to the mixture and the mixture filtered through celite. The organic layer was separated and the aqueous layer extracted with Et0Ac (2 x 10 m1). The combined organics were washed with brine, stirred with Na2SO4 and active charcoal, filtered through a plug of silica and concentrated to give the product as a solid, which was used without further purification (2.9 g). MS ES+ m/z 324 [MA41+.
Example 28: Intermediate 28 -- 2-Chloro-5-[2,5-difluoro-4-(2-oxopyrrolidin-1-yl)phenyl]pyridine-4-carbaldehyde N CI
[0285] The title compound was prepared as described in Intermediate 1, replacing (2-Fluoro-4-methoxy carbonyl-phenyl)boronic acid for 1-[2,5-difluoro-4-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-yOphenyllpyrrolidin-2-one, using 1,4-dioxane instead of MeCN and stirring the mixture at 90 C for 1 h, to give the product as a solid (1.37 g, 64%). MS ES+ m/z 337 [M+H]+.
Example 29: Intermediate 29 -- 1-14-16-Chloro-4-(1-hydroxyethyl)-3-pyridy1]-2,5-difluoro-phenyl] pyrrolidin-2-one N CI
[0286] The title compound was prepared as described in Intermediate 2, starting from 2-chl oro-5 - [2,5-difluoro-4-(2-oxopyrroli din-1 -y Ophenyll py ri dine-4-carb al dehy de, to give the product as a gum (1.19 g, 94%). MS ES+ m/z 353 [M+1-11+.
Example 30: Intermediate 30 -- 1-(3-Chloro-9-fluoro-5-methy1-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one 0 cH3 N CI
[0287] The title compound was prepared as described in Intermediate 9, starting from 1-[4- [6-chl oro-4-(1-hy droxy ethyl)-3-pyridyll -2,5-difluoro-phenyl] py rroli din-2-one, stirring the mixture at rt for 2 h and purification on a silica gel column eluted with 0-80% Et0Ac in heptane, to give the product as a solid (685 mg, 54%). MS ES+ m/z 333 [M+1-11+.
Example 31: N,N,5-trimethy1-3-(pyridin-3-ylamino)-5H-chromeno [4,3-c] pyridine-carboxamide H 3C 1\1 0 C H3 /N
I
N
[0288] XantPhos (14 mg, 0.03 mmol) and Pd2(dba)3 (11 mg, 0.01 mmol) were taken up in 1,4-dioxane (2 ml) and stirred at 50 C for 20 min. A solution of 3-chloro-N,N,5-trimethy1-5H-chromeno[4,3-clpyridine-8-carboxamide (75 mg, 0.25 mmol) in 1,4-dioxane (2 ml) was added followed by pyridin-3-amine (30 mg, 0.32 mmol) and NaOtBu (64 mg, 0.66 mmol) and the resulting mixture was stirred at 100 C for 2 h. After cooling at rt, the mixture was diluted with Et0Ac (3 ml) and filtered. The filtrate was concentrated and the resulting residue was dissolved in Me0H, filtered and purified by preparative HPLC to give the product as a solid. NMR
(500 MHz, DMSO-d6) 6 ppm 1.55 (d, J=6.62 Hz, 3 H), 2.96 (br s, 6 H), 5.29 -5.36 (m, 1 H), 6.75 (s, 1 H), 6.96 (d, J=1.58 Hz, 1 H), 7.07 (dd, J=7.88, 1.58 Hz, 1 H), 7.29 - 7.36 (m, 1 H), 7.93 (d, J=8.20 Hz, 1 H), 8.13 (dd, J=4.73, 1.26 Hz, 1 H), 8.22 (ddd, J=8.35, 2.68, 1.58 Hz, 1 H), 8.73 (s, 1 H), 8.83 (s, 1 H), 9.50 (s, 1 H). MS ES+ m/z 361 [M+1-11+.
Example 32: N,N,5-trimethy1-3-05-(2-oxopyrrolidin-1-yl)pyridin-3-yl)amino)-5H-chromeno[4,3-c]pyridine-8-carboxamide H3C'N
CH3 el N, I
N
[0289] The title compound was prepared as described in accordance with the accordance with the procedures of Example 31, replacing pyridine-3-amine for 1-(5-amino-3-pyridyl)pyrrolidin-2-one and stirring at 100 C overnight, to give the product as a solid (6 mg, 4%). NMR (500 MHz, CHLOROFORM-d) 6 ppm 1.63 (d, J=6.62 Hz, 3 H), 2.21 -2.30 (m, 2 H), 2.63 -2.69 (m, 2 H), 3.04 - 3.09 (m, 3 H), 3.14 (br s, 3 H), 3.96 (t, J=7.09 Hz, 2 H), 5.20 (q, J=6.73 Hz, 1 H), 6.83 (s, 1 H), 7.05 (s, 1 H), 7.12 (d, J=7.83 Hz, 1 H), 7.73 (d, J=7.88 Hz, 1 H), 7.77 - 7.92 (m, 1 H), 8.41 (br s, 1 H), 8.54 - 8.61 (m, 2 H), 8.73 (s, 1 H). MS ES+ m/z 444 [M+H1+.
Example 33: N,N,5-trimethy1-3-0(S)-9-oxo-6a,7,8,9-tetrahydro-6H-pyrido[2,3-b]pyrrolo [1,2-d] [1,4] oxazin-2-yl)amino)-5H-chromeno[4,3-c] pyridine-8-carboxamide I
N N
[0290] The title compound was prepared as described in accordance with the procedures of Example 31, replacing pyridine-3-amine for (6S)-12-amino-8-oxa-2,10-diazatricyclo[7.4Ø0^{2,6}1trideca-1(9),10,12-trien-3-one and stirring at 100 C overnight, to give the product as a solid (6 mg, 3%). 1FINMR (500 MHz, METHANOL-d4) 6 ppm 1.60 (dd, 3 H), 1.75 - 1.84 (m, 1 H), 2.32 - 2.40 (m, 1 H), 2.52 (ddd, 1 H), 2.71 - 2.80 (m, 1 H), 3.07 (s, 3 H), 3.12 (s, 3 H), 3.92 - 4.00 (m, 1 H), 4.11 - 4.18 (m, 1 H), 4.65 (dd, 1 H), 5.20 (q, 1 H), 6.65 (s, 1 H), 7.01 (d, 1 H), 7.10 (dd, 1 H), 7.86 (d, 1 H), 8.29 (d, 1 H), 8.58 (s, 1 H), 9.12 (dd, 1 H). MS ES+ m/z 472 [M+H1+.
Example 34: 5-cyclopropyl-N,N-dimethy1-3-(pyridin-3-ylamino)-5H-chromeno[4,3-c]pyridine-8-carboxamide H 3C,.N 0 /N
I
N N
[0291] The title compound was prepared as described in accordance with the procedures of Example 31, replacing 3-chloro-N,N,5-trimethy1-5H-chromeno[4,3-clpyridine-8-carboxamide for 3-chloro-5-cyclopropyl-N,N-dimethy1-5H-chromeno[4,3-clpyridine-carboxamide and stirring at 100 C overnight, to give the product as a solid (15 mg, 6%). 11-1 NMR (500 MHz, METHANOL-d4) 6 ppm 0.50 - 0.62 (m, 2 H), 0.66 - 0.77 (m, 2 H), 1.26 -1.33 (m, 1 H), 3.05 (s, 3 H), 3.10 (s, 3 H), 4.33 (d, J=8.83 Hz, 1 H), 6.89 (s, 1 H), 7.02 (s, 1 H), 7.09 (d, J=7.69 Hz, 1 H), 7.24 - 7.40 (m, 1 H), 7.86 (d, J=7.88 Hz, 1 H), 8.09 (dd, J=4.73, 1.58 Hz, 1 H), 8.27 (ddd, J=8.43, 2.60, 1.26 Hz, 1 H), 8.63 (s, 1 H), 8.83 (d, J=2.21 Hz, 1 H). MS
ES+ m/z 387 [M+Hr.
Example 35: 5-cyclopropyl-N,N-dimethy1-3-05-(2-oxopyrrolidin-1-yl)pyridin-3-yl)amino)-5H-chromeno[4,3-c]pyridine-8-carboxamide H 3C'N
N
[0292] The title compound was prepared as described in accordance with the procedures of Example 31, replacing pyridine-3-amine for 1-(5-amino-3-pyridyl)pyrrolidin-2-one and 3-chl oro-N,N,5 -trimethy1-5H-chromeno [4,3 -c] pyri dine-8-carboxami de for .. 3 -Chl oro-5 -cyclopropyl-N,N-dimethy1-5H-chromeno[4,3-clpyridine-8-carboxamide, and stirring at 100 C overnight, to give the product as a solid (35 mg, 20%). 11-1 NMR (500 MHz, DMSO-d6) 6 ppm 0.50 - 0.60 (m, 2 H), 0.63 - 0.76 (m, 2 H), 1.23 - 1.32 (m, 1 H), 2.08 -2.17 (m, 2 H), 2.53 - 2.56 (m, 2 H), 2.94 - 3.03 (m, 6 H), 3.85 - 3.92 (m, 2 H), 4.46 - 4.52 (m, 1 H), 6.94 - 6.97 (m, 1 H), 6.99 (d, J=1.58 Hz, 1 H), 7.07 (dd, J=7.88, 1.58 Hz, 1 H), 7.96 (d, J=7.88 Hz, 1 H), 8.39 (d, J=2.21 Hz, 1 H), 8.59 (t, J=2.21 Hz, 1 H), 8.75 - 8.76 (m, 1 H), 8.77 -8.79 (m, 1 H), 9.61 (s, 1 H). MS ES+ m/z 470 [M+H1+.
Example 36: 5-cyclopropyl-N,N-dimethy1-3-0(S)-9-oxo-6a,7,8,9-tetrahydro-6H-pyrido[2,3-b]pyrrolo [1,2-d] [1,4] oxazin-2-yl)amino)-5H-chromeno[4,3-c]
pyridine-8-carboxamide Ff/C 0 1\1 I
N
[0293] The title compound was prepared as described in in accordance with the procedures of Example 31, replacing pyridine-3-amine for (6S)-12-amino-8-oxa-2,10-diazatricyclo[7.4Ø02,6]trideca-1(9),10,12-trien-3-one and 3-chloro-N,N,5-trimethy1-5H-chromeno [4,3-c] py ri dine-8-carb oxami de for 3-chl oro-5 -cy cl opropyl-N,N-dimethy1-5H-chromeno[4,3-clpyridine-8-carboxamide, and stirring at 100 C overnight, to give the product as a solid (6 mg, 4%). 11-1NMR (500 MHz, DMSO-d6) 6 ppm 0.55 (td, J=7.96, 4.89 Hz, 2 H), 0.62 - 0.71 (m, 2 H), 1.22 - 1.29 (m, 1 H), 1.67 - 1.75 (m, 1 H), 2.20 - 2.26 (m, 1 H), 2.39 (br d, J=1.58 Hz, 1 H), 2.65 -2.74 (m, 1 H), 2.97 (br s, 6 H), 3.91 (t, J=10.56 Hz, 1 H), 4.05 -4.11 (m, 1 H), 4.45 (dd, J=9.14, 2.21 Hz, 1 H), 4.59 (dd, J=10.88, 2.99 Hz, 1 H), 6.87 (s, 1 H), 6.98 (d, J=1.58 Hz, 1 H), 7.06 (dd, J=7.88, 1.89 Hz, 1 H), 7.93 (d, J=8.20 Hz, 1 H), 8.44 (s, 1 H), 8.68 (s, 1 H), 8.97 (dd, J=2.52, 1.58 Hz, 1 H), 9.40 (s, 1 H). MS ES+ m/z 498 [M+Hr.
Example 37: N,N,5,6-tetramethy1-3-(pyridin-3-ylamino)-5,6-dihydrobenzo[c][2,6]naphthyridine-8-carboxamide N
N
[0294]
Pd2(dba)3 (18 mg, 0.02 mmol) and BrettPhos (21 mg, 0.04 mmol) were taken up in 1,4-dioxane (1 ml) and stirred at 50 C for 15 min. A solution of 3-chloro-N,N,5,6-tetramethyl-5H-benzo[c][2,61naphthyridine-8-carboxamide (125 mg, 0.4 mmol) in 1,4-dioxane (3 ml), pyridin-3-amine (56 mg, 0.59 mmol) and Cs2CO3 (358 mg, 1.10 mmol) were added and the resulting mixture was stirred at 100 C overnight. After cooling to rt, Et0Ac (5 ml) and half-saturated brine (5 ml) were added to the mixture and the organic layer separated. The remaining aqueous layer was further extracted with Et0Ac (5 m1). The combined organics where washed with brine, dried over Na2SO4, filtered, concentrated and purified by preparative HPLC to give the product as a solid (48 mg, 33%). 11-1 NMR (500 MHz, DMSO-d6) 6 ppm 1.07 (d, J=6.62 Hz, 3 H), 2.92 (s, 3 H), 2.97 (br s, 6 H), 4.51 (q, J=6.52 Hz, 1 H), 6.65 (d, J=1.58 Hz, 1 H), 6.67 (s, 1 H), 6.78 (dd, J=7.57, 1.58 Hz, 1 H), 7.28 - 7.31 (m, 1 H), 7.82 (d, J=7.88 Hz, 1 H), 8.10 (dd, J=4.57, 1.42 Hz, 1 H), 8.21 (ddd, J=8.35, 2.68, 1.58 Hz, 1 H), 8.70 (s, 1 H), 8.80 -8.82 (m, 1 H), 9.36 (s, 1 H). MS ES+ m/z 374 [M+H1+.
Example 38: 1-(5-methyl-3-(pyridin-3-ylamino)-5H-chromeno [4,3-c] pyridin-8-yl)pyrrolidin-2-one 0 N, I
N
[0295] The title compound was prepared as described in accordance with the procedures of Example 31, replacing 3-chloro-N,N,5-trimethy1-5H-chromeno[4,3-clpyridine-8-carboxamide for 1-(3-chloro-5-methyl-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one, to give the product as a solid (12 mg, 10%). 11-1 NMR (500 MHz, DMSO-d6) 6 ppm 1.54 (d, J=6.62 Hz, 3 H), 2.03 - 2.10 (m, 2 H), 2.49 - 2.51 (m, 2 H, obscured by DMSO), 3.81 - 3.90 (m, 2 H), 5.25 - 5.31 (m, 1 H), 6.75 (s, 1 H), 7.28 - 7.34 (m, 2 H), 7.41 (d, J=2.21 Hz, 1 H), 7.88 (d, J=8.51 Hz, 1 H), 8.12 (dd, J=4.73, 1.58 Hz, 1 H), 8.23 (ddd, J=8.43, 2.60, 1.58 Hz, 1 H), 8.67 (s, 1 H), 8.83 (d, J=2.21 Hz, 1 H), 9.46 (s, 1 H). MS ES+ m/z 373 [M+H1+.
Example 39: 1-(5-45-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno [4,3-c] pyrid in-3-yl)amino)pyrid in-3-yl)cyclo p rop ane-1-carb nitrite N N
NI I
[0296] The title compound was prepared as described in accordance with the procedures of Example 31, replacing pyridine-3-amine for 1-(5-amino-3-pyridyl)cyclopropanecarbonitrile and 3 -chl oro-N,N,5 -trimethy1-5H-chromeno [4,3 -c] py ri dine-8-carb oxami de for 1-(3-chloro-5-methy1-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one, to give the product as a solid (15 mg, 7%). 11-1 NMR (500 MHz, DMSO-d6) 6 ppm 1.54 (d, J=6.62 Hz, 3 H), 1.69 -1.77 (m, 2 H), 1.89 - 1.97 (m, 2 H), 2.02 - 2.10 (m, 2 H), 2.52 - 2.64 (m, 2 H), 3.81 -3.91 (m, 2 H), 5.34 (q, J=6.62 Hz, 1 H), 6.85 (s, 1 H), 7.34 (dd, J=8.83, 2.21 Hz, 1 H), 7.41 (d, J=2.21 Hz, 1 H), 7.93 (d, J=8.83 Hz, 1 H), 8.22 (d, J=1.89 Hz, 1 H), 8.50 (t, J=1.89 Hz, 1 H), 8.77 (s, 1 H), 9.18 - 9.27 (m, 1 H), 10.30 (br s, 1 H). MS ES+ m/z 438 [M+Hr.
Example 40: (6aS)-2-05-methyl-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)-6,6a,7,8-tetrahydro-9H-pyrido [2,3-b] pyrrolo [1,2-d] [1,4] oxazin-9-one o I
N
[0297] The title compound was prepared as described in accordance with the procedures of Example 37, replacing pyridine-3-amine for (65)-12-amino-8-oxa-2,10-diazatricy clo [7.4Ø 02,6]trideca-1(9),10,12-trien-3-one and 3 -chloro-N,N,5-trimethy1-5H-chromeno [4,3-c] py ri dine-8-carb oxami de for 1-(3 -chl oro-5 -methyl-5H-chromeno [4,3 -clpyridin-8-yOpyrrolidin-2-one, and stirring at 100 C for 40 min, to give the product as a solid (113 mg, 39%). 11-1NMR (500 MHz, DMSO-d6) 6 ppm 1.53 (dd, J=6.62, 1.58 Hz, 3 H), 1.64 -1.78 (m, 1 H), 2.02 -2.11 (m, 2 H), 2.17 - 2.28 (m, 1 H), 2.37 - 2.50 (m, 2 H), 2.64 -2.72 (m, 1 H), 3.80- 3.93 (m, 3 H), 4.08 (tdd, J=9.62, 9.62, 6.94, 3.15 Hz, 1 H), 4.59 (dd, J=10.88, 2.99 Hz, 1 H), 5.25 (q, J=6.52 Hz, 1 H), 6.66 - 6.68 (m, 1 H), 7.24 - 7.39 (m, 1 H), 7.40 (d, J=2.21 Hz, 1 H), 7.87 (d, J=8.83 Hz, 1 H), 8.39 (dd, J=2.52, 1.26 Hz, 1 H), 8.60 (s, 1 H), 8.97 (dd, J=4.10, 2.52 Hz, 1 H), 9.29 (d, J=2.84 Hz, 1 H). MS ES+ nilz 484 [M+H1+.
Example 41: 1-(3-05-(difluoromethoxy)pyridin-3-yl)amino)-5-methyl-5H-chromeno[4,3-c] pyridin-8-yl)pyrrolidin-2-one 0 c H3 F
I
N NOLF
[0298] The title compound was prepared as described in accordance with the procedures of Example 31, replacing pyridine-3-amine for 5-(difluoromethoxy)pyridin-3-amine and 3-chloro-N,N,5-trimethy1-5H-chromeno[4,3-clpyridine-8-carboxamide for 1-(3-chloro-5-methy1-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one, to give the product as a solid (18 mg, 13%). NMR (500 MHz, DMSO-d6) 6 ppm 1.54 (d, J=6.62 Hz, 3 H), 2.02 - 2.09 (m, 2 H), 2.48 - 2.50 (m, 2 H, obscured by DMSO), 3.82 - 3.87 (m, 2 H), 5.29 (q, J=6.73 Hz, 1 H), 6.77 (s, 1 H), 7.30 (t, J=73.50 Hz, 1 H), 7.32 (dd, J=8.51, 2.21 Hz, 1 H), 7.41 (d, J=2.21 Hz, 1 H), 7.90 (d, J=8.51 Hz, 1 H), 8.00 (d, J=2.52 Hz, 1 H), 8.32 (t, J=2.36 Hz, 1 H), 8.62 (d, J=2.21 Hz, 1 H), 8.72 (s, 1 H), 9.72 (s, 1 H). MS ES+ nilz 439 [M+H1+.
Example 42: 1-(3-((1-acetyl-2,3-dihydro-1H-pyrido [2,3-b] [1,4] oxazin-7-yl)amino)-5-methyl-5H-chromeno[4,3-c] pyridin-8-yl)pyrrolidin-2-one N NN) [0299] The title compound was prepared as described in accordance with the procedure of Example 37, replacing pyridine-3-amine for 1-(7-amino-2,3-dihydropyrido[2,3-b]
[1,4loxazin-1-yl)ethenone and 3-chloro-N,N,5-trimethy1-5H-chromeno[4,3-clpyridine-8-carboxamide for 1-(3-chloro-5-methy1-5H-chromeno[4,3-clpyridin-8-yl)pyrrolidin-2-one, and stirring at 100 C for 40 min, to give the product as a solid (42 mg, 46%). 11-1NMR (500 MHz, DMSO-d6) 6 ppm 1.53 (d, J=6.62 Hz, 3 H), 2.00 - 2.13 (m, 2 H), 2.31 (s, 3 H), 2.48-2.50(m, 2 H, obscured by DMSO), 3.76 - 3.94 (m, 4 H), 4.32 - 4.40 (m, 2 H), 5.25 (q, J=6.62 Hz, 1 H), 6.66 (s, 1 H), 7.31 (dd, J=8.51, 2.21 Hz, 1 H), 7.39 (m, 1 H), 7.86 (d, J=8.83 Hz, 1 H), 8.27 (br s, 1 H), 8.60 (s, 1 H), 9.21 (s, 1 H). MS ES+ m/z 472 [M+Hl+.
Example 43: 1-(5,6-dimethy1-3-(pyridin-3-ylamino)-5,6-dihydrobenzo[c][2,6]naphthyridin-8-yl)pyrrolidin-2-one N
[0300] Pyridin-3-amine (121 mg, 1.29 mmol), 1-(3-chloro-5,6-dimethy1-5H-benzo[c][2,6lnaphthyridin-8-yOpyrrolidin-2-one (169 mg, 0.52 mmol) and Cs2CO3 (336 mg, 1.03 mmol) were taken up in DMF (2 ml) and the mixture was degassed with nitrogen for 5 min. BrettPhos Pd G3 (23 mg, 0.03 mmol) and BrettPhos (14 mg, 0.03 mmol) were added and the mixture was stirred at 120 C overnight. After cooling to rt, the mixture was filtered through celite and concentrated. The residue was dissolved in Et0Ac, washed with water, brine, concentrated and purified by preparative HPLC to give the product as a solid (7 mg, 3%). 11-1 NMR (500 MHz, CHLOROFORM-d) 6 ppm 1.17 (d, J=6.62 Hz, 2 H), 1.27 - 1.27 (m, 1 H), 2.19 (t, J=7.57 Hz, 2 H), 2.65 (t, J=8.04 Hz, 2 H), 3.01 (s, 3 H), 3.93 (t, J=7.09 Hz, 2 H), 4.33 (d, J=6.62 Hz, 1 H), 6.54 - 6.57 (m, 1 H), 6.58 (s, 1 H), 6.89 (dd, J=8.20, 2.21 Hz, 1 H), 7.33 (d, J=2.21 Hz, 1 H), 7.69 (d, J=8.51 Hz, 1 H), 7.90 - 7.97 (m, 1 H), 8.30 (dd, J=4.73, 1.26 Hz, 1 H), 8.61 (s, 1 H), 8.62 (s, 1 H). MS ES+ m/z 386 [M+1-11+.
Example 44: (6aS)-2-05,6-dimethy1-8-(2-oxopyrrolidin-1-y1)-5,6-dihydrobenzo [c] [2,6] naphthyridin-3-yl)amino)-6,6a,7,8-tetrahydro-9H-pyrido [2,3-b] pyrrolo [1,2-d] [1,4] oxazin-9-one I
N
[0301] The title compound was prepared as described in accordance with the procedure of Example 43, replacing pyridine-3-amine for (6S)-12-amino-8-oxa-2,10-diazatricyclo[7.4Ø02,61trideca-1(9),10,12-trien-3-one to give the product as a solid (23 mg, 14%). 1H NMR (500 MHz, DMSO-d6) 6 ppm 1.06 (dd, J=6.62, 2.84 Hz, 3 H), 1.63 -1.77 (m, 1 H), 2.02 -2.23 (m, 2 H), 2.19 -2.28 (m, 1 H), 2.39 (br d, J=16.39 Hz, 1 H), 2.62 - 2.73 (m, 1 H), 2.90 (s, 3 H), 3.82 - 4.01 (m, 3 H), 4.02 - 4.12 (m, 1 H), 4.45 (br d, J=6.62 Hz, 1 H), 4.58 (dd, J=10.72, 3.15 Hz, 1 H), 6.58 (s, 1 H), 6.98 (dd, J=8.51, 1.89 Hz, 1 H), 7.13 (d, J=1.89 Hz, 1 H), 7.76 (d, J=8.51 Hz, 1 H), 8.36 (dd, J=9.14, 2.52 Hz, 1 H), 8.57 (s, 1 H), 8.95 (dd, J=6.94, 2.52 Hz, 1 H), 9.12 (s, 1 H), 2H obscured by DMSO. MS ES+ m/z 497 [M+1-11+.
Example 45: 1-(3-((2,3-dihydro-11,41dioxino12,3-b] pyridin-7-yl)amino)-5,6-dimethyl-5,6-dihyd rob enzo [c] [2,6] naphthyridin-8-yl)pyrrolid in-2-one I
N
[0302] The title compound was prepared as described in in accordance with the procedure of Example 43, replacing pyridine-3-amine for 2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-7-amine to give the product as a solid (22 mg, 13%). 11-1NMR (500 MHz, DMSO-d6) 6 ppm 1.05 (d, J=6.62 Hz, 3 H), 2.04 - 2.10 (m, 2 H), 2.90 (s, 3 H), 3.87 (t, J=7.41 Hz, 2 H), 4.25 (dt, J=3.78, 2.21 Hz, 2 H), 4.35 (dt, J=3.78, 2.21 Hz, 2 H), 4.46 (d, J=6.62 Hz, 1 H), 6.56 (s, 1 H), 6.98 (dd, J=8.35, 2.05 Hz, 1 H), 7.13 (d, J=2.21 Hz, 1 H), 7.75 (d, J=8.51 Hz, 1 H), 7.82 (d, J=2.52 Hz, 1 H), 7.92 (d, J=2.52 Hz, 1 H), 8.60 (s, 1 H), 9.02 - 9.08 (m, 1 H) 2H obscured by DMSO. MS ES+ m/z 444 [M+Hl+.
Example 46: 1-(9-fluoro-5-methyl-3-(pyridin-3-ylamino)-5H-chromeno14,3-c]
pyrid in-8-yl)pyrrolidin-2-one I
N
[0303] The title compound was prepared as described in accordance with the procedures of Example 31, replacing 3-chloro-N,N,5-trimethy1-5H-chromeno[4,3-c1pyridine-8-carboxamide for 1-(3-chloro-9-fluoro-5-methy1-5H-chromeno[4,3-c1pyridin-8-yOpyrrolidin-2-one and NaOtBu for Cs2CO3, to give the product as a solid (12 mg, 10%). 11-1 NMR (500 MHz, DMSO-d6) 6 ppm 1.54 (d, J=6.62 Hz, 3 H), 2.07 - 2.15 (m, 2 H), 2.43 (t, J=8.04 Hz, 2 H), 3.74 - 3.80 (m, 2 H), 5.26 - 5.35 (m, 1 H), 6.74 (s, 1 H), 7.06 (d, J=6.62 Hz, 1 H), 7.28 -7.33 (m, 1 H), 7.86 (d, J=11.66 Hz, 1 H), 8.13 (dd, J=4.57, 1.42 Hz, 1 H), 8.21 (ddd, J=8.35, 2.68, 1.26 Hz, 1 H), 8.71 (s, 1 H), 8.82 (d, J=2.21 Hz, 1 H), 9.50 (s, 1 H).
MS ES+ m/z 391 [M+H]+.
Example 47: (6aS)-2-09-fluoro-5-methyl-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c] pyridin-3-yl)amino)-6,6a,7,8-tetrahydro-9H-pyrido [2,3-b] pyrrolo[1,2-d]
[1,4] oxazin-9-one 0 ,H3 I
N N
[0304] The title compound was prepared as described in accordance with the procedures of Example 43, replacing pyridine-3-amine for (6S)-12-amino-8-oxa-2,10-diazatricy clo [7.4. 0. 02,6]trideca-1(9),10,12-trien-3-one and 1-(3-chloro-5,6-dimethy1-5H-benzo [c] [2,6lnaphthy ri din-8-y Opy rroli din-2-one for 1-[9-fluoro-5-methyl-3 -(3 -pyridylamino)-5H-chromeno[4,3-clpyridin-8-yllpyrrolidin-2-one, and stirring for 1 h, to give the product as a solid (193 mg, 45%). 11-1NMR (500 MHz, DMSO-d6) 6 ppm 1.53 (dd, J=6.46, 1.42 Hz, 3 H), 1.69 - 1.74 (m, 1 H), 2.08 - 2.15 (m, 2 H), 2.20 - 2.26 (m, 1 H), 2.39 - 2.45 (m, 3 H), 2.66 -2.70 (m, 1 H), 3.75 - 3.80 (m, 2 H), 3.93 (d, J=10.72 Hz, 1 H), 4.05 -4.11 (m, 1 H), 4.59 (dd, J=10.72, 3.15 Hz, 1 H), 5.26 (q, J=6.83 Hz, 1 H), 6.68 (s, 1 H), 7.05 (d, J=6.94 Hz, 1 H), 7.86 (s, 1 H), 8.39 (dd, J=2.52, 1.26 Hz, 1 H), 8.65 (s, 1 H), 8.97 (dd, J=3.94, 2.68 Hz, 1 H), 9.38 (d, J=2.52 Hz, 1 H). MS ES+ m/z 502 [M+Hl+.
Example 48: N-methyl-N-(5-05-methyl-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-yl)methanesulfonamide I I
N NN
0=5=0 Step 1: Preparation of 1-(4-bromo-3-fluorophenyl)pyrrolidin-2-one IN F
Br [0305] 1-Bromo-2-fluoro-4-iodobenzene (40.0 g, 133 mmol), CsF (50.5 g, 332 mmol) and Cul (7.60 g, 39.8 mmol) were taken up in Et0Ac (300 mL) and the resulting mixture was degassed with nitrogen for 10 min. Pyrrolidin-2-one (13.6 g, 159 mmol) and N,N'-dimethylethylenediamine (5.3 mL, 80 mmol) were added and the resulting mixture was stirred at 50 C for 18 h. A purple solution was formed gradually. LCMS (Rt = 0.655 min; MS Calcd:
257.0; MS Found: 257.8 [M+H1+). When cooled to 20 C, the mixture was filtered, the filter cake washed with Et0Ac (100 ml), and the filtrate combined with the next time reaction, washed with HC1 (0.5 M, 100 mL), 5% NH31120 (100 mL), dried over Na2SO4, filtered and concentrated to give 1-(4-bromo-3-fluorophenyl)pyrrolidin-2-one (33.6 g, yield: 95%) as a pale yellow solid.
11-1NMR (400 MHz, CDC13) 6 2.10-2.24 (2H, m), 2.61 (2H, t, J= 8.0 Hz), 3.82 (2H, t, J=
7.2 Hz), 7.24-7.27 (1H, m), 7.48 (1H, dd, J = 8.0, 8.0 Hz), 7.65 (1H, dd, J=
8.0, 2.4 Hz).
Step 2: Preparation of 1-(3 -fluoro-4-(4,4,5,5-tetramethy1-1,3,2-di oxaborol an-2-yl)phenyl)pyrrolidin-2-one õ.11\1 F
[0306] A
mixture of 1-(4-bromo-3-fluorophenyl)pyrrolidin-2-one (12.0 g, 46.5 mmol), B2Pin2 (17.7 g, 69.7 mmol) and Pd(dppf)C12 (3.40 g, 4.65 mmol) in toluene (200 mL) was stirred at 100 C for 40 h under N2 atmosphere. A red solution turned to black gradually. LCMS
(Rt = 0.689 min; MS Calcd: 305.2; MS Found: 306.1 [M+H1+). The reaction mixture was cooled to 20 C and filtered through silica gel and washed with MTBE (800 mL).
The solvent was evaporated under reduced pressure to give 1-(3-fluoro-4-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-yOphenyOpyrrolidin-2-one(20.0 g, crude) as a black brown gum.
Step 3: Preparation of 2-chloro-5-(2-fluoro-4-(2-oxopyrrolidin-1-yl)phenyl)is oni cotinal dehy de I
N CI
[0307] 1-(3 -Fl uoro-4-(4,4,5 ,5 -tetramethyl-1,3 ,2-di oxab orol an-2-yl)phenyl)py rroli din-2-one (7.84 g, 35.6 mmol), 5-bromo-2-chloroisonicotinaldehyde (16.0 g, 37.3 mmol), Pd(PPh3)4 (1.64 g, 1.42 mmol) and K2CO3 (14.8 g, 106 mmol) were taken up in MeCN (160 mL) and H20 (40 mL) and the resulting mixture was stirred at 70 C for 2 h. A black solution was formed. LCMS (Rt = 0.649 min; MS Calcd: 319.1; MS Found: 341.8 [M+Nal+). When cooled to 20 C the mixture was diluted with half-saturated brine (50 mL) and Et0Ac (50 m1). The organic layer was separated and the aqueous layer extracted with Et0Ac (50 mL
x2). The combined organics were dried over Na2SO4, filtered through a plug of silica and concentrated to give 2-chl oro-5-(2-fluoro-4-(2-oxopy rroli din-l-yl)phenyl)i s oni cotinal dehy de (13.8 g, crude) as a black brown gum.
Step 4: Preparation of 1-(4-(6-chloro-4-(1-hydroxy ethy Opy ri din-3 -y1)-3-fluorophenyOpyrrolidin-2-one OH
I
N CI
[0308] MeMgBr (3 M in Et20, 30 mL) was added slowly to a solution of 2-chloro-5-(2-fluoro-4-(2-oxopyrrolidin-1-yl)phenyl)isonicotinaldehyde (11.3 g, 35.4 mmol) in THF (200 mL) at 0 C under N2 atmosphere to give a suspension. The resulting mixture was stirred at 0 C for 2 h. LCMS (Rt = 0.617 min; MS Calcd: 334.1; MS Found: 334.9 [M+Hl+).
Sat.
aq.NH4C1 (80 mL) was added followed by Et0Ac (80 mL). The organic layer was separated and the aqueous layer extracted with Et0Ac (100 mL x2). The combined organics were dried over Na2SO4, filtered and concentrated to give 1-(4-(6-chloro-4-(1-hydroxyethyl)pyridin-3-y1)-3-fluorophenyl)pyrrolidin-2-one (12.5 g, crude) as a black brown gum.
Step 5: Preparation of 1-(3 -chl oro-5 -methyl-5H-chromeno [4,3-cl py ri din-8-y Opy rroli din-2-one I
N CI
[0309] NaH
(2.82 g, 70.5 mmol, 60% in mineral oil) was added to a solution of 1-(4-(6-chloro-4-(1-hydroxyethyppyridin-3-y1)-3-fluorophenyOpyrrolidin-2-one (11.8 g, 35.3 mmol) in THF (150 mL) at 20 C and the resulting mixture was stirred at 20 C for 2 h. A black solution was formed. LCMS (Rt = 0.654 min; MS Calcd: 314.1; MS Found: 314.9 [M+H]+).
Sat. aq. NH4C1 (80 mL) was added and the mixture extracted with Et0Ac (80 mL
x3). The combined organic layer was dried over Na2SO4, filtered, concentrated. The residue was purified by Combi Flash (60% Et0Ac in pentane) to give 1-(3-chloro-5-methy1-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (1.22 g, 3.88 mmol, yield: 11% for four steps) as a yellow solid.
NMR (400 MHz, CDC13) 6 1.62 (3H, d, J= 6.8 Hz), 2.10-2.24 (2H, m), 2.63 (2H, t, J=
8.0 Hz), 3.87 (2H, t, J= 8.0 Hz), 5.19 (1H, q, J= 6.8 Hz), 7.10 (1H, s), 7.32 (1H, d, J= 2.0 Hz), 7.41 (1H, dd, J= 8.4, 2.0 Hz), 7.72 (1H, d, J= 8.8 Hz), 8.64 (1H, s).
Step 6:
Preparation of tert-butyl (5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-yl)carbamate N NHBoc [0310] A
mixture of Pd2(dba)3 (44 mg, 0.047 mmol) and XantPhos (55 mg, 0.095 mmol) in 1,4-dioxane (1 mL) was stirred at 50 C for 10 min. 1-(3-Chloro-5-methy1-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (300 mg, 0.953 mmol), BocNH2 (167 mg, 1.43 mmol) in 1,4-dioxane (10 mL) and Cs2CO3 (776 mg, 2.38 mmol) were added, and the resulting mixture was stirred at 100 C for 16 h. A black brown mixture was formed. LCMS
(Rt = 0.688 min; MS Calcd: 395.2; MS Found: 396.0 [M+H]+). The reaction mixture was diluted with DCM (20 mL), filtered and concentrated to give tert-butyl (5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-yOcarbamate (500 mg, crude) as a black brown gum.
Step 7: Preparation of 1-(3-amino-5 -methyl-5H-chromeno [4,3-c] py ri din-8-yl)pyrroli din-2-one I
[0311] To a stirred solution of tert-butyl (5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-yOcarbamate (370 mg, 0.935 mmol) in DCM (6 mL) was added HC1/Et0Ac (4 M, 61 mL) at 20 C. The yellow solution turned to suspension, the reaction mixture was stirred for 1 hour. TLC indicated the starting material was consumed completely, and one new spot with larger polarity was detected. The mixture was concentrated. The residue was purified by Combi Flash (1% Et3N in Et0Ac) to give 1-(3-amino-5-methy1-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (200 mg, yield: 55% for two steps) as a yellow solid.
Step 8: Preparation of N-(5 -bromopy ri din-3 -yl)methanes ulfonami de Br NH
0=S=0 [0312] A
solution of 5-bromopyridin-3-amine (500 mg, 2.89 mmol) and pyridine (4.3 mL, 54 mmol) was stirred in DCM (20 mL), then MsC1 (331 mg, 2.89 mmol) was added into the above solution at 0 C, which was stirred at 20 C for 16 h. A yellow solution was formed.
TLC showed the starting material was consumed completely. The solution was diluted with H20 (30 mL) and was extracted with DCM (15 mL x3). The organic layer was washed with brine (15 mL), dried over Na2SO4 to give N-(5-bromopyridin-3-yOmethanesulfonamide (700 mg, yield: 96%) as a yellow solid.
Step 9: Preparation of N-(5-bromopy ri din-3 -y1)-N-methy lmethanes ulfonami de r Br 0=S=0 [0313] A
solution of N-(5-bromopyridin-3-yl)methanesulfonamide (700 mg, 2.79 mmol) in DMF (8 mL) was treated with K2CO3 (771 mg, 5.58 mmol) and CH3I (594 mg, 4.18 mmol) at 20 C for 18 h. A black brown solution was formed. TLC showed the starting material was consumed completely. The reaction was concentrated under reduced pressure. The residue was purified by Combi Flash (40% Et0Ac in pentane) to give N-(5-bromopyridin-3-y1)-N-methylmethanesulfonamide (563 mg, yield: 76%) as a red solid. 11-1 NMR (400 MHz, CDC13) 6 2.91 (3H, s), 3.37 (3H, s), 7.92 (1H, t, J= 2.0 Hz), 8.57 (1H, d, J= 2.0 Hz), 8.59 (1H, d, J=
2.0 Hz).
Step 10: Preparation of tert-butyl (5-(N-methylmethylsulfonamido)pyridin-3-yOcarbamate I
BocHNN
0==0 [0314] A
mixture of Pd2(dba)3 (86 mg, 0.094 mmol) and XantPhos (109 mg, 0.189 mmol) in 1,4-dioxane (1 mL) was stirred at 50 C for 10 min. N-(5-bromopyridin-3-y1)-N-methylmethanesulfonamide (500 mg, 1.89 mmol), BocNH2 (331 mg, 2.83 mmol) in dioxane (15 mL) and Cs2CO3 (1.54 g, 4.71 mmol) were added and the resulting mixture was stirred at 100 C for 16 h. A black brown mixture was formed. TLC indicated the starting material was consumed completely. The reaction mixture was diluted with DCM (10 mL), filtered and concentrated. The residue was purified by Combi Flash (60% Et0Ac in pentane) to give tert-butyl (5-(N-methylmethylsulfonamido)pyridin-3-yl)carbamate (275 mg, yield:
48%) as a brown solid.
11-1NMR (400 MHz, CDC13) 6 1.53 (9H, s), 2.91 (3H, s), 3.36 (3H, s), 6.73 (1H, brs), 8.08 (1H, s), 8.33 (1H, d, J= 2.4 Hz), 8.36 (1H, d, J= 2.4 Hz).
Step 11: Preparation of N-(5-aminopy ridin-3 -y1)-N-methy lmethanesulfonami de I
0==0 [0315] To a stirred solution of tert-butyl (5-(N-methylmethylsulfonamido)pyridin-3-yl)carbamate (275 mg, 0.912 mmol) in DCM (5 mL) was added HC1/Et0Ac (4 M, 8 mL) at 20 C. The yellow solution turned to suspension, the reaction mixture was stirred for 1 hour. TLC
indicated the starting material was consumed completely, and one new spot with larger polarity was detected. The mixture was concentrated to give N-(5-aminopyridin-3-y1)-N-methylmethanesulfonamide (215 mg, yield: 99%) as a yellow solid.
NMR (400 MHz, DMSO-d6) 6 3.13 (3H, s), 3.29 (3H, s), 7.60 (1H, t, J= 2.4 Hz), 7.92 (1H, d, J= 2.0 Hz), 8.09 (1H, d, J= 2.0 Hz).
Step 12:
Preparation of N-methyl-N-(5-05-methyl-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-yl)methanesulfonamide , N
0=S=0 [0316] A
mixture of Pd2(dba)3 (7 mg, 0.008 mmol) and BrettPhos (8 mg, 0.002 mmol) in 1,4-dioxane (1 mL) was stirred at 50 C for 10 min. 1-(3-Chloro-5-methy1-5H-chromeno[4,3-clpyridin-8-yl)pyrrolidin-2-one (50 mg, 0.16 mmol), N-(5-aminopyridin-3-y1)-N-methylmethanesulfonamide (45 mg, 0.19 mmol) in dioxane (3 mL) and Cs2CO3 (155 mg, 0.476 mmol) were added and the resulting mixture was stirred at 100 C for 16 h. A
black brown mixture was formed. LCMS (Rt = 0.595 min; MS Calcd: 479.2; MS Found: 480.0 [M+H1+).
The reaction mixture was diluted with DCM (10 mL), filtered and concentrated.
The residue was purified by prep-HPLC (0.05% NH31120 as an additive) and lyophilized to give N-methyl-N-(5-((5 -methy1-8-(2-oxopy rroli din-1 -y 0-5H-chromeno [4,3-c] pyri din-3-y Damino)py ridin-3 -yOmethanesulfonamide (22.8 mg, yield: 30%) as a white solid.
LC-MS (Shimadzu LCMS 2010, mobile phase: C) 10mM NH4HCO3 in Water; D) MECN.
Gradient: 1% D increase to 5% D within 0.6 min; 5% DB increase to 100% D
within 3.4 min;
then back to 1% D within 0.3 min. Flow rate 0.8 mL/min) purity is 100%, Rt =
2.640 min; MS
Calcd.: 479.2, MS Found: 480.3 [M+141+.
11-1NMR (400 MHz, DMSO-d6) 6 1.53 (3H, d, J= 6.0 Hz), 2.02-2.09 (2H, m), 2.64 (2H, overlap with DMSO), 3.04 (3H, s), 3.29 (3H, s), 3.84 (2H, t, J= 6.8 Hz), 5.28 (1H, q, J= 6.4 Hz), 6.75 (1H, s), 7.32 (1H, dd, J= 8.4, 2.0 Hz), 7.40 (1H, s), 7.89 (1H, d, J= 8.4 Hz), 8.19 (1H, s), 8.29 (1H, s), 8.70 (1H, s), 8.75 (1H, s), 9.61 (1H, brs).
Example 49: 1-(5-methyl-3-01-(methylsulfony1)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)amino)-5H-chromeno[4,3-c]pyridin-8-y1)pyrrolidin-2-one I , N
0=S=0 Step 1: Preparation of 7-bromo-1-(methylsulfony1)-2,3-dihydro-1H-pyrido[2,3-b]
[1,4] oxazine Br N
0=SI =0 [0317] To a solution of 7-bromo-2,3-dihydro-1H-pyrido[2,3-b1[1,4loxazine (300 mg, 1.40 mmol) in DCM (5 mL) was added pyridine (221 mg, 2.80 mmol) and MsC1 (321 mg, 2.80 mmol) at 15 C, the mixture was stirred at 15 C for 16 h. A red solution was formed. Crude LCMS showed the purity of the product (Rt = 0.757 min; MS Calcd: 292.0; MS
Found: 292.7 [M+1-11+). The mixture was added sat.NH31120 (10 mL), extracted with DCM (10 mL x3), and dried over Na2SO4, the residue was purified by Combi Flash (DCM) to give 7-bromo-1-(methylsulfony1)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazine(350 mg, yield: 85%) as a white solid.
11-1NMR (400 MHz, CDC13) 6 1.55 (3H, s), 3.90 (2H, t, J= 4.4 Hz), 4.45 (2H, t, J= 4.4 Hz), 8.08 (1H, d, J= 2.0 Hz), 8.19(1H, d, J= 2.0 Hz).
Step 2:
Preparation of tert-butyl (1 -(methylsulfony1)-2,3-dihy dro-1H-py ri do [2,3 -b] [1,4] oxazin-7-yl)carbamate j BocHNN
0==0 [0318] A
mixture of Pd2(dba)3 (55 mg, 0.060 mmol) and XantPhos (69 mg, 0.12 mmol) in 1,4-dioxane (1 mL) was stirred at 50 C for 10 min. 7-Bromo-1-(methylsulfony1)-2,3-dihydro-1H-pyrido[2,3-b] [1,4loxazine (350 mg, 1.19 mmol), BocNH2 (210 mg, 1.79 mmol) in dioxane (10 mL) and Cs2CO3 (973 mg, 2.98 mmol) were added, and the resulting mixture was stirred at 100 C for 16 h. A black brown mixture was formed. LCMS (Rt = 0.596 min; MS
Calcd:
329.1; MS Found: 330.1 [M+H1+). The reaction mixture was diluted with DCM (20 mL), filtered and concentrated. The residue was purified by Combi Flash (60% Et0Ac in pentane) to give tert-butyl (1-(methylsulfony1)-2,3 -dihy dro-1H-pyri do [2,3-b] [1,4] oxazin-7-yl)carbamate (270 mg, yield: 69%) as a yellow gum.
11-1 NMR (400 MHz, CDC13) 6 1.51 (9H, s), 3.02 (3H, s), 3.88 (2H, t, J= 8.4 Hz), 4.41 (2H, t, J= 8.0 Hz), 6.42 (1H, brs), 8.01 (1H, s), 8.16 (1H, s).
Step 3: Preparation of 1-(methylsulfony1)-2,3-dihy dro-1H-py ri do [2,3 -b]
[1,4] oxazin-7-amine 0=S=0 [0319] To a stirred solution of tert-butyl (1-(methylsulfony1)-2,3-dihydro-1H-pyrido[2,3-b1[1,41oxazin-7-yl)carbamate (270 mg, 0.820 mmol) in DCM (4 mL) was added HC1/Et0Ac (4 M, 10 mL) at 20 C. The red solution turned to suspension, then the reaction mixture was stirred for 1 h. TLC indicated the starting material was consumed completely, and one major new spot with larger polarity was detected. The mixture was concentrated to give 1-(methylsulfony1)-2,3-dihydro-1H-pyrido[2,3-b][1,41oxazin-7-amine (240 mg, yield: 97%) as an off-white solid.
11-1 NMR (400 MHz, DMSO-d6) 6 3.25 (3H, s), 3.84 (2H, t, J= 4.4 Hz), 4.32 (2H, brs), 4.43 (2H, t, J= 4.4 Hz), 7.96 (1H, d, J= 2.0 Hz), 8.03 (1H, d, J= 2.0 Hz).
Step 4: Preparation of 1-(5-methy1-3-01-(methylsulfony1)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-y1)amino)-5H-chromeno[4,3-c]pyridin-8-y1)pyrrolidin-2-one I , N
0=S=0 [0320] A
mixture of Pd2(dba)3 (7 mg, 0.008 mmol) and BrettPhos (8 mg, 0.002 mmol) in 1,4-dioxane (1 mL) was stirred at 50 C for 10 min. 1-(3-Chloro-5-methy1-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one (50 mg, 0.16 mmol), 1-(methylsulfony1)-2,3-dihydro-1H-pyrido[2,3-b1[1,410xazin-7-amine (84 mg, 0.28 mmol) in dioxane (3 mL) and Cs2CO3 (155 mg, 0.476 mmol) were added and the resulting mixture was stirred at 100 C for 16 h. A black brown mixture was formed. LCMS (Rt = 0.587 min; MS Calcd: 507.2; MS Found:
508.3 [M+1-11+). The reaction mixture was diluted with DCM (10 mL), filtered and concentrated. The residue was purified by prep-HPLC (normal phase, Hexane-IPA (50-100% B)) and lyophilized to give impure product (25 mg) as a yellow solid, then purified by prep-HPLC
(0.05% NH31120 as an additive) and lyophilized to give 1-(5-methy1-3-((1-(methylsulfony1)-2,3-dihydro-1H-pyrido [2,3 -b] [1,4] oxazin-7-y0amino)-5H-chromeno [4,3-c] pyridin-8-yOpyrrolidin-2-one (18.1 mg, yield: 22%) as a white solid.
[0321] LC-MS
(Shimadzu LCMS 2010, Mobile phase: from 90% [water + 0.04% TFA]
and 10% [MeCN +0.02% TFA] to 20% [water + 0.04% TFA] and 80% [MeCN + 0.02%
TFA]
in 1.35 min, then under this condition for 0.9 min, finally changed to 90%
[water + 0.04%
TFA] and 10% [MeCN + 0.02% TFA] and under this condition for 0.75 min. ) purity is 96.38%, Rt = 2.190 min; MS Calcd.: 507.2, MS Found: 508.1 [M+Hr.
11-1NMR (400 MHz, D20+CDC13) 6 1.58 (3H, d, J= 6.8 Hz), 2.12-2.21 (2H, m), 2.63 (2H, t, J= 8.0 Hz), 3.06 (3H, s), 3.84 (2H, t, J = 6.0 Hz), 3.91 (2H, t, J = 4.8 Hz), 4.45 (2H, t, J = 4.4 Hz), 5.13 (1H, q, J= 6.4 Hz), 6.52 (1H, s), 7.28 (1H, overlap with CDC13), 7.37 (1H, dd, J =
8.0, 2.0 Hz), 7.66 (1H, d, J = 7.6 Hz), 8.07 (1H, d, J = 2.0 Hz), 8.27 (1H, d, J = 2.0 Hz), 8.50 (1H, s).
Example 50: 1-(3-((5-fluoropyridin-3-yl)amino)-5-methyl-5H-chromeno14,3-c]
pyridin-8-yl)pyrrolidin-2-one Step 1: Preparation of tert-butyl (5-fluoropyridin-3-yl)carbamate BocHN
r-[0322] A
mixture of Pd2(dba)3 (78 mg, 0.085 mmol) and XantPhos (99 mg, 0.17 mmol) in 1,4-dioxane (1 mL) was stirred at 50 C for 10 min. 3-Bromo-5-fluoropyridine (300 mg, 1.70 mmol), BocNH2 (300 mg, 2.56 mmol) in dioxane (10 mL) and Cs2CO3 (1.39 g, 4.26 mmol) were added and the resulting mixture was stirred at 100 C for 16 h. A black brown mixture was formed. LCMS (Rt = 0.619 min; MS Calcd: 212.1; MS Found: 213.0 [M+Hl+).
The reaction mixture was diluted with DCM (10 mL), filtered and concentrated. The residue was purified by Combi Flash (17% Et0Ac in pentane) to give tert-butyl (5-fluoropyridin-3-yl)carbamate (360 mg, yield: 99%) as a yellow solid.
11-1NMR (400 MHz, CDC13) 6 1.53 (9H, s), 6.65 (1H, brs), 7.85 (1H, d, J= 9.2 Hz), 8.14 (1H, d, J= 2.0 Hz), 8.15-8.16 (1H, m).
Step 2: Preparation of 5-fluoropyridin-3-amine [0323] To a stirred solution of tert-butyl (5-fluoropyridin-3-yl)carbamate (350 mg, 1.65 mmol) in DCM (4 mL) was added HC1/Et0Ac (4 M, 15 mL) at 20 C. The yellow solution turned to suspension. Then the reaction mixture was stirred for 1 hour. TLC
indicated the starting material was consumed completely, and one new spot with larger polarity was detected.
The mixture was concentrated to give 5-fluoropyridin-3-amine (245 mg, yield:
100%) as a yellow solid.
11-1NMR (400 MHz, DMSO-d6) 6 7.27 (2H, t, J= 11.2 Hz), 7.33 (1H, dt, J= 10.8, 2.0 Hz), 7.93 (1H, d, J= 2.0 Hz), 8.07-8.11 (1H, m).
Step 3:
Preparation of 1-(3 -((5-fluoropyri din-3 -yl)amino)-5 -methyl-5H-chromeno [4,3-c] py ri din-8-yl)py rroli din-2-one N NF
[0324] A
mixture of Pd2(dba)3 (7 mg, 0.008 mmol) and BrettPhos (8 mg, 0.002 mmol) in 1,4-dioxane (1 mL) was stirred at 50 C for 10 min. 1-(3-Chloro-5-methy1-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (50 mg, 0.16 mmol), 5-fluoropyridin-3-amine (28 mg, 0.19 mmol) in dioxane (3 mL) and Cs2CO3 (155 mg, 0.476 mmol) were added and the resulting mixture was stirred at 100 C for 16 h. A black brown mixture was formed. LCMS
(Rt = 0.639 min; MS Calcd: 390.2; MS Found: 391.1 [M+Hl+). The reaction mixture was diluted with DCM (10 mL), filtered and concentrated. The residue was purified by prep-HPLC
(0.05%
NH31120 as an additive) and lyophilized to give impure product (20 mg) as an off-white solid.
The impure product was purified by prep-HPLC (0.05% NH31120 as an additive) and lyophilized to give 1-(3 -((5-fluoropy ri din-3 -yl)amino)-5-methyl-5H-chromeno [4,3 -c] py ri din-8-yl)pyrrolidin-2-one (7.3 mg, yield: 12%) as a white solid.
[0325] LC-MS
(Shimadzu LCMS 2010, mobile phase: from 100% [water + 0.05%
NH3+120] and 0% [MeCN] to 5% [water + 0.05% NH31-120] and 95% [MeCN] in 5.8 min, then under this condition for 1.1 min, finally changed to 100% [water + 0.05%
NH31-120] and 0% [MeCN] and under this condition for 0.09 min.) purity is 99.62%, Rt = 3.234 min; MS
Calcd.: 390.2, MS Found: 391.2 [M+Hl+.
11-1NMR (400 MHz, DMSO-d6) 6 1.52 (3H, d, J= 6.4 Hz), 2.00-2.06 (2H, m), 2.48 (2H, overlap with DMSO), 3.82 (2H, t, J= 7.2 Hz), 5.27 (1H, q, J= 6.8 Hz), 6.78 (1H, s), 7.30 (1H, dd, J= 8.4, 2.4 Hz), 7.39 (1H, d, J= 2.0 Hz), 7.87 (1H, d, J= 8.4 Hz), 8.04 (1H, d, J=
2.8 Hz), 8.39 (1H, dt, J= 12.4, 2.0 Hz), 8.53 (1H, t, J= 2.0 Hz), 8.70 (1H, s), 9.92 (1H, brs).
Example 51: N-cycl op ro pyl-N-(5-05-methyl-8-(2-oxo pyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-yl)methanesulfonamide I I
N NNI\
0==0 Step 1: Preparation of 5-bromo-N-cyclopropylpyridin-3-amine BrNA
[0326] To a mixture of 3,5-dibromopyridine (2.01 g, 8.48 mmol), cyclopropanamine (969 mg, 17.0 mmol), Cu (54 mg, 0.85 mmol) in H20 (3 mL) were added and the resulting mixture was stirred at 100 C for 42 h. A black brown mixture was formed. LCMS (Rt =
0.453 min;
MS Calcd: 214.0; MS Found: 214.8 [M+H]+). The reaction mixture was diluted with DCM (20 mL), and was extracted with DCM (10 mL x3), dried over Na2SO4 and concentrated. The residue was purified by Combi Flash (45% Et0Ac in pentane) to give 5-bromo-N-cyclopropylpyridin-3-amine (220 mg, yield: 12%) as a yellow solid.
Step 2: Preparation of N-(5 -bromopy ri din-3 -y1)-N-cy cl opropy lmethanesulfonami de I
BrNA
0==0 solution of 5-bromo-N-cyclopropylpyridin-3-amine (220 mg, 1.03 mmol) and pyridine (2 mL) was stirred in DCM (5 mL), then MsC1 (142 mg, 1.24 mmol) was added into the above solution at 0 C, which was stirred at 20 C for 16 h. A red solution was formed.
LCMS (Rt = 0.591 min; MS Calcd: 292.0; MS Found: 292.7 [M+H1+). The solution was diluted with H20 (20 mL) and was extracted with DCM (10 mL x3). The organic layer was dried over Na2SO4, and concentrated. The residue was purified by Combi Flash (50% Et0Ac in pentane) to give N-(5-bromopyridin-3-y1)-N-cyclopropylmethanesulfonamide (160 mg, yield: 53%) as a yellow solid.
11-1NMR (400 MHz, CDC13) 6 0.77-0.82 (2H, m), 0.94-1.02 (2H, m), 2.92-2.97 (1H, m), 2.98 (3H, s), 7.87 (1H, t, J= 2.0 Hz), 8.52-8.61 (2H, m).
Step 3: Preparation of tert-butyl (5 -(N-cy cl opropy lmethylsulfonami do)py ri din-3 -yl)carb amate BocHNI
0==0 [0328] A
mixture of Pd2(dba)3 (25 mg, 0.027 mmol) and XantPhos (32 mg, 0.055 mmol) in 1,4-dioxane (1 mL) was stirred at 50 C for 10 min. N-(5-bromopyridin-3-y1)-N-cyclopropylmethanesulfonamide (160 mg, 0.550 mmol), BocNH2 (97 mg, 0.824 mmol) in dioxane (6 mL) and Cs2CO3 (448 mg, 1.37 mmol) were added, and the resulting mixture was stirred at 100 C for 16 h. A black brown mixture was formed. LCMS (Rt = 0.586 min; MS
Calcd: 327.1; MS Found: 327.9 [M+H1+). The reaction mixture was diluted with DCM (15 mL), filtered and concentrated. The residue was purified by Combi Flash (90%
Et0Ac in pentane) to give tert-butyl (5-(N-cyclopropylmethylsulfonamido)pyridin-3-yOcarbamate (179 mg, yield: 99%) as a yellow solid.
Step 4: Preparation of N-(5 -aminopy ri din-3-y1)-N-cy cl opropy lmethanesulfonami de 0==0 [0329] To a stirred solution of tert-butyl (5-(N-cyclopropylmethylsulfonamido)pyridin-3-yOcarbamate (179 mg, 0.547 mmol) in DCM (3 mL) was added HC1/Et0Ac (4 M, 7 mL) at 20 C. The yellow solution turned to suspension, the reaction mixture was stirred for 1 hour. TLC
indicated the starting material was consumed completely, and one new spot with larger polarity was detected. The mixture was concentrated to give N-(5-aminopyridin-3-y1)-N-cyclopropylmethanesulfonamide (124 mg, yield: 100%) as a yellow solid.
11-1NMR (400 MHz, DMSO-d6) 6 0.64-0.72 (2H, m), 0.85-0.93 (2H, m), 3.19 (3H, s), 3.20-3.24 (1H, m), 7.56 (1H, t, J= 2.0 Hz), 7.92 (1H, d, J= 2.0 Hz), 8.07 (1H, d, J= 2.0 Hz).
Step 5:
Preparation of N-cy cl opropyl-N-(5 -((5-methyl-8-(2-oxopy rroli din-1 -y1)-5H-chromeno [4,3-c] py ri din-3-y0amino)pyri din-3 -y Omethanesulfonami de I I
N NNI\
0==0 [0330] A
mixture of Pd2(dba)3 (7 mg, 0.008 mmol) and BrettPhos (8 mg, 0.002 mmol) in 1,4-dioxane (1 mL) was stirred at 50 C for 10 min. 1-(3-Chloro-5-methy1-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (50 mg, 0.16 mmol), N-(5-aminopyridin-3-y1)-N-cyclopropylmethanesulfonamide (50 mg, 0.19 mmol) in dioxane (3 mL) and Cs2CO3 (155 mg, 0.476 mmol) were added and the resulting mixture was stirred at 100 C for 16 h. A black brown mixture was formed. LCMS (Rt = 0.616 min; MS Calcd: 505.2; MS Found:
506.1 [M+H1+). The reaction mixture was diluted with DCM (10 mL), filtered and concentrated. The residue was purified by prep-HPLC (0.05% NH31120 as an additive) and lyophilized to give N-cy cl opropyl-N-(5 -((5-methyl-8-(2-oxopy rrol i din-1 -y1)-5H-chromeno [4,3-c] py ri din-3 -yOamino)pyridin-3-yOmethanesulfonamide (10.2 mg, yield: 13%) as a white solid.
[0331] LC-MS
(Shimadzu LCMS 2010, mobile phase: C) 10mM NH4HCO3 in Water; D) MECN. Gradient: 1% D increase to 5% D within 0.6 min; 5% DB increase to 100% D
within 3.4 min; then back to 1% D within 0.3 min. Flow rate 0.8 mL/min) purity is 100%, Rt = 2.766 min; MS Calcd.: 505.2, MS Found: 506.3 [M+1-11+.
11-1NMR (400 MHz, CDC13) 6 0.81-0.86 (2H, m), 0.94-0.99 (2H, m), 1.61 (3H, d, J= 6.8 Hz), 2.14-2.21 (2H, m), 2.63 (2H, t, J= 8.4 Hz), 2.95-3.00 (1H, m), 3.01 (3H, s), 3.87 (2H, t, J= 7.2 Hz), 5.15 (1H, q, J= 6.4 Hz), 6.65 (1H, s), 6.70 (1H, brs), 7.27 (1H, s), 7.40 (1H, dd, J= 8.4, 2.0 Hz), 7.68 (1H, d, J= 8.4 Hz), 8.08 (1H, d, J= 2.0 Hz), 8.26 (1H, d, J= 2.0 Hz), 8.52 (1H, d, J= 2.4 Hz), 8.56 (1H, s).
Example 52: 1-(3-01-(cyclopropylsulfony1)-2,3-dihydro-1H-pyrido12,3-b]11,41oxazin-7-yl)amino)-5-methyl-5H-chromeno14,3-c]pyridin-8-y1)pyrrolidin-2-one N N N
0==0 Step 1:
Preparation of 7-bromo-1-(cyclopropylsulfony1)-2,3-dihydro-1H-pyrido[2,3-b] [1,41oxazine Br N
0==0 [0332] To a solution of 7-bromo-2,3-dihydro-1H-pyrido[2,3-b][1,41oxazine (300 mg, 1.40 mmol) in pyridine (10 mL) was added cyclopropanesulfonyl chloride (787 mg, 5.60 mmol) under nitrogen. The resulting mixture was stirred for 40 h at 20 C. The orange solution was formed. LCMS showed the starting material was not consumed. Additional cyclopropanesulfonyl chloride (787 mg, 5.60 mmol) was added, and stirred for 60 h at 50 C.
The solution turned to black. LCMS showed the starting material was consumed nearly, and the purity of desired product (Rt = 0.625 min; MS Calcd: 320.0; MS Found:
320.8 [M+H1+).
Pyridine was removed under reduced pressure. The residue was purified by Combi Flash (50 % Et0Ac in pentane) to give 7-bromo-1-(cyclopropylsulfony1)-2,3-dihydro-1H-pyrido[2,3-b][1,41oxazine (343 mg, yield: 77%) as a yellow solid.
11-1NMR (400 MHz, CDC13) 6 1.00-1.13 (2H, m), 1.21-1.31 (2H, m), 2.40-2.52 (1H, m), 3.87 (2H, t, J = 4.4 Hz), 4.48 (2H, t, J = 4.8 Hz), 8.07 (1H, d, J = 2.0 Hz), 8.22 (1H, d, J = 2.4 Hz).
Step 2:
Preparation of tert-butyl (1-(cy cl opropylsulfony1)-2,3 -dihy dro-1H-py ri do [2,3 -b] [1,4] oxazin-7-yl)carbamate f BocHNN
0=S=0 [0333] A
mixture of Pd2(dba)3 (49 mg, 0.053 mmol) and XantPhos (62 mg, 0.11 mmol) in 1,4-dioxane (1 mL) was stirred at 50 C for 10 min. 7-Bromo-1-(cyclopropylsulfony1)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazine (340 mg, 1.07 mmol), BocNH2 (187 mg, 1.60 mmol) in dioxane (12 mL) and Cs2CO3 (868 mg, 2.66 mmol) were added and the resulting mixture was stirred at 100 C for 16 h. A black brown mixture was formed. LCMS (Rt = 0.639 min; MS
Calcd: 355.1; MS Found: 356.1 [M+H]+). The reaction mixture was diluted with DCM (10 mL), filtered and concentrated. The residue was purified by Combi Flash (55%
Et0Ac in pentane) to give tert-butyl (1-(cyclopropylsulfony1)-2,3-dihydro-1H-pyrido[2,3-b][1,4loxazin-7-yOcarbamate (375 mg, yield: 99%) as a yellow solid.
11-1NMR (400 MHz, CDC13) 6 1.00-1.09 (2H, m), 1.25-1.30 (2H, m), 1.51 (9H, s), 2.44-2.54 (1H, m), 3.87 (2H, t, J= 4.4 Hz), 4.45 (2H, t, J= 4.4 Hz), 6.57 (1H, brs), 8.03 (1H, d, J = 2.0 Hz), 8.18 (1H, d, J = 2.4 Hz).
Step 3: Preparation of 1 -(cy cl opropylsulfony1)-2,3 -dihy dro-1H-py ri do [2,3-b] [1,4] oxazin-7-amine ) 0==0 [0334] To a stirred solution of tert-butyl (1-(cyclopropylsulfony1)-2,3-dihydro-1H-pyrido[2,3-b][1,4loxazin-7-yOcarbamate (375 mg, 1.06 mmol) in DCM (6 mL) was added HC1/Et0Ac (4 M, 8 mL) at 20 C. The yellow solution turned to suspension. Then the reaction mixture was stirred for 1 hour. TLC indicated the starting material was consumed completely, and one new spot with larger polarity was detected. The mixture was concentrated to afford 1-(cy cl opropylsulfony1)-2,3-dihy dro-1H-py ri do [2,3-b] [1,4] oxazin-7-amine (305 mg, yield:
99%) as a yellow solid.
NMR (400 MHz, DMSO-d6) 6 0.94-1.12 (4H, m), 2.89-3.02 (1H, m), 3.82-3.94 (2H, m), 4.42-4.52 (2H, m), 8.04 (1H, s), 8.07 (1H, s).
Step 4:
Preparation of 1-(3-((1 -(cy cl opropylsulfony1)-2,3-dihy dro-1H-py ri do [2,3 -b] [1,4] oxazin-7-y 1)amino)-5 -methyl-5H-chromeno [4,3-c] py ridin-8-yl)py rroli din-2-one I
N N N
0==0 [0335] A
mixture of Pd2(dba)3 (7 mg, 0.008 mmol) and BrettPhos (8 mg, 0.002 mmol) in 1,4-dioxane (1 mL) was stirred at 50 C for 10 min. 1-(3-Chloro-5-methy1-5H-chromeno[4,3-clpyridin-8-yl)pyrrolidin-2-one (50 mg, 0.16 mmol), 1-(cyclopropylsulfony1)-2,3-dihydro-1H-pyrido[2,3-b][1,41oxazin-7-amine (56 mg, 0.19 mmol) in dioxane (3 mL) and Cs2CO3 (155 mg, 0.476 mmol) were added and the resulting mixture was stirred at 100 C for 16 h. A black brown mixture was formed. LCMS (Rt = 0.604 min; MS Calcd: 533.2; MS Found:
534.1 [M+Hl+). The reaction mixture was diluted with DCM (10 mL), filtered and concentrated. The residue was purified by prep-HPLC (0.05% NH3.H20 as an additive) and lyophilized to give 1-(3-((1-(cyclopropylsulfony1)-2,3-dihydro-1H-pyrido[2,3-b] [1,4] oxazin-7-yl)amino)-5-methy1-5H-chromeno[4,3-c]pyridin-8-y1)pyrrolidin-2-one (19.4 mg, yield: 23%) as a white solid.
[0336] LC-MS
(Shimadzu LCMS 2010, mobile phase: C) 10mM NH4HCO3 in Water; D) MECN. Gradient: 1% D increase to 5% D within 0.6 min; 5% DB increase to 100% D
within 3.4 min; then back to 1% D within 0.3 min. Flow rate 0.8 mL/min) purity is 99.54%, Rt = 2.786 min; MS Calcd.: 533.2, MS Found: 534.3 [M+141+.
NMR (400 MHz, DMSO-d6) 6 1.02-1.08 (4H, m), 1.51 (3H, d, J= 6.8 Hz), 2.00-2.09 (2H, m), 2.49 (2H, overlap with DMSO), 2.85-2.93 (1H, m), 3.80-3.86 (4H, m), 4.39 (2H, t, J=
4.4 Hz), 5.23 (1H, q, J= 6.4 Hz), 6.64 (1H, s), 7.30 (1H, dd, J= 8.8, 2.0 Hz), 7.38 (1H, d, J=
2.0 Hz), 7.86 (1H, d, J= 8.8 Hz), 8.33 (1H, d, J= 2.4 Hz), 8.38 (1H, d, J= 2.4 Hz), 8.59 (1H, s), 9.30 (1H, brs).
Example 53: 1-methyl-3-(5-05-methyl-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-yl)imidazolidin-2-one c I I
N
0 \
Step 1: Preparation of 1-(5-bromopyridin-3-y1)-3-methylimidazolidin-2-one 0 \
[0337] To a solution of 1-(5-bromopyridin-3-yl)imidazolidin-2-one (500 mg, 2.07 mmol) in THF (10 mL) was added NaH (99 mg, 2.5 mmol, 60% in mineral oil) portion-wise at 0 C, the reaction was warmed to 15 C and stirred for 0.5 hour. Mel (382 mg, 2.69 mmol) was added and the mixture was stirred at 15 C for another 16 h. A red suspension was formed. Crude LCMS showed the purity of the product (Rt = 0.681 min; MS Calcd: 255.0; MS
Found: 255.8 [M+H1+). The reaction was diluted with H20 (10 mL), extracted with Et0Ac (10 mL x3), dried over Na2SO4 and concentrated to give a crude product which was purified by Combi Flash (60% Et0Ac in pentane) to give 1-(5-bromopyridin-3-y1)-3-methylimidazolidin-2-one (310 mg, yield: 58%) as a light yellow solid.
11-1NMR (400 MHz, CDC13) 6 2.92 (3H, s), 3.53 - 3.57 (2H, m), 3.81 - 3.85 (2H, m), 8.33 (1H, d, J = 2.0 Hz), 8.43 (1H, t, J = 2.0 Hz), 8.52 (1H, d, J = 2.0 Hz).
Step 2: Preparation of tert-butyl (5-(3-methy1-2-oxoimidazolidin-1-y1)pyridin-3-y1)carbamate BocHNN
\
[0338] A
mixture of Pd2(dba)3 (55 mg, 0.060 mmol) and XantPhos (70 mg, 0.12 mmol) in 1,4-dioxane (1 mL) was stirred at 50 C for 10 min. 1-(5-Bromopyridin-3-y1)-3-methylimidazolidin-2-one (310 mg, 1.21 mmol), BocNH2 (212 mg, 1.82 mmol) in dioxane (10 mL) and Cs2CO3 (986 mg, 3.03 mmol) were added and the resulting mixture was stirred at 100 C for 16 h. A black brown mixture was formed. LCMS (Rt = 0.530 min; MS Calcd:
292.2;
MS Found: 293.1 [M+H1+). The reaction mixture was diluted with DCM (20 mL), filtered and concentrated. The residue was purified by Combi Flash (Et0Ac) to give tert-butyl (5-(3-methy1-2-oxoimidazolidin-1-yl)pyridin-3-yl)carbamate (300 mg, yield: 85%) as a white solid.
11-1NMR (400 MHz, CDC13) 6 1.52 (9H, s), 2.91 (3H, s), 3.51 (2H, t, J= 8.4 Hz), 3.84 (2H, t, J= 8.4 Hz), 6.60 (1H, brs), 8.26 (1H, s), 8.28 (1H, s), 8.45 (1H, s).
Step 3: Preparation of 1-(5-aminopyridin-3-y1)-3-methylimidazolidin-2-one H NN
0 \
[0339] To a stirred solution of tert-butyl (5-(3-methy1-2-oxoimidazolidin-1-yl)pyridin-3-yl)carbamate (300 mg, 1.03 mmol) in DCM (4 mL) was added HC1/Et0Ac (4 M, 10 mL) at 20 C. The yellow solution turned to suspension, the reaction mixture was stirred for 1 hour. TLC
indicated the starting material was consumed completely, and one new spot with larger polarity was detected. The mixture was concentrated to give 1-(5-aminopyridin-3-y1)-3-methylimidazolidin-2-one (234 mg, yield: 100%) as an off-white solid.
11-1NMR (400 MHz, DMSO-d6) 6 2.79 (3H, s), 3.51 (2H, t, J= 8.4 Hz), 3.80 (2H, t, J= 8.8 Hz), 6.53 (2H, brs), 7.62 (1H, s), 7.66 (1H, s), 8.34 (1H, s).
Step 4: Preparation of 1-methy1-3-(5-((5-methyl-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-y1)imidazolidin-2-one I
N N
0 \
[0340] A
mixture of Pd2(dba)3 (7 mg, 0.008 mmol) and BrettPhos (8 mg, 0.002 mmol) in 1,4-dioxane (1 mL) was stirred at 50 C for 10 min. 1-(3-Chloro-5-methy1-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (50 mg, 0.16 mmol), 1-(5-aminopyridin-3-y1)-3-methylimidazolidin-2-one (72 mg, 0.32 mmol) in dioxane (3 mL) and Cs2CO3 (155 mg, 0.476 mmol) were added and the resulting mixture was stirred at 100 C for 16 h. A
black brown mixture was formed. LCMS (Rt = 0.591 min; MS Calcd: 470.2; MS Found: 471.3 [M+H1+).
110 The reaction mixture was diluted with DCM (10 mL), filtered and concentrated.
The residue was purified by prep-HPLC (0.05% NH31120 as an additive) and lyophilized to give 1-methyl-3-(5 -((5-methy1-8-(2-oxopy rroli din-1-y 0-5H-chromeno [4,3-c] py ri din-3-y0amino)py ri din-3 -yOimidazolidin-2-one (24.3 mg, yield: 33%) as an off-white solid.
[0341] LC-MS
(Shimadzu LCMS 2010, mobile phase: from 100% [water + 0.05%
NH3+1201 and 0% [MeCN] to 5% [water + 0.05% NH311201 and 95% [MeCN] in 5.8 min, then under this condition for 1.1 min, finally changed to 100% [water + 0.05%
NH31-1201 and 0% [MeCN] and under this condition for 0.09 min.) purity is 99.53%, Rt = 2.854 min; MS
Calcd.: 470.2, MS Found: 471.2 [M+Hl+.
11-1NMR (400 MHz, DMSO-d6) 6 1.53 (3H, d, J= 6.4 Hz), 2.02-2.09 (2H, m), 2.55 (2H, overlap with DMSO), 2.79 (3H, s), 3.49 (2H, t, J= 6.0 Hz), 3.78-3.87 (4H, m), 5.26 (1H, q, J
= 6.8 Hz), 6.75 (1H, s), 7.31 (1H, dd, J= 8.8, 2.0 Hz), 7.39 (1H, d, J= 2.0 Hz), 7.89 (1H, d, J
= 8.8 Hz), 8.29 (1H, d, J= 2.4 Hz), 8.47 (1H, t, J= 2.4 Hz), 8.59 (1H, d, J=
2.4 Hz), 8.66 (1H, s), 9.46 (1H, brs).
Example 54: 1-(5-methyl-3-((5-(2-oxopyrrolidin-1-yl)pyridin-3-yl)amino)-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one I I
N N N
Step 1: Preparation of 1-(5-bromopyridin-3-yl)pyrrolidin-2-one I
[0342] A
mixture of 3,5-dibromopyridine (2.00 g, 8.44 mmol), pyrrolidin-2-one (861 mg, 10.1 mmol), K2CO3 (4.08 g, 29.5 mmol), CuI (80 mg, 0.42 mmol), TMEA (49 mg, 0.42 mmol) in dioxane (30 mL) was stirred at 110 C for 20 h. A blue solution was formed gradually. Then added pyrrolidin-2-one (862 mg, 10.1 mmol), TMEA (49 mg, 0.42 mmol), CuI (80 mg, 0.42 mmol) and stirred at 110 C for 20 h. The previous mixture was added pyrrolidin-2-one (862 mg, 10.1 mmol), CuI (80 mg, 0.42 mmol), TMEA (49 mg, 0.42 mmol) and stirred at
The residue was purified by prep-HPLC (0.05% NH31120 as an additive) and lyophilized to give 1-methyl-3-(5 -((5-methy1-8-(2-oxopy rroli din-1-y 0-5H-chromeno [4,3-c] py ri din-3-y0amino)py ri din-3 -yOimidazolidin-2-one (24.3 mg, yield: 33%) as an off-white solid.
[0341] LC-MS
(Shimadzu LCMS 2010, mobile phase: from 100% [water + 0.05%
NH3+1201 and 0% [MeCN] to 5% [water + 0.05% NH311201 and 95% [MeCN] in 5.8 min, then under this condition for 1.1 min, finally changed to 100% [water + 0.05%
NH31-1201 and 0% [MeCN] and under this condition for 0.09 min.) purity is 99.53%, Rt = 2.854 min; MS
Calcd.: 470.2, MS Found: 471.2 [M+Hl+.
11-1NMR (400 MHz, DMSO-d6) 6 1.53 (3H, d, J= 6.4 Hz), 2.02-2.09 (2H, m), 2.55 (2H, overlap with DMSO), 2.79 (3H, s), 3.49 (2H, t, J= 6.0 Hz), 3.78-3.87 (4H, m), 5.26 (1H, q, J
= 6.8 Hz), 6.75 (1H, s), 7.31 (1H, dd, J= 8.8, 2.0 Hz), 7.39 (1H, d, J= 2.0 Hz), 7.89 (1H, d, J
= 8.8 Hz), 8.29 (1H, d, J= 2.4 Hz), 8.47 (1H, t, J= 2.4 Hz), 8.59 (1H, d, J=
2.4 Hz), 8.66 (1H, s), 9.46 (1H, brs).
Example 54: 1-(5-methyl-3-((5-(2-oxopyrrolidin-1-yl)pyridin-3-yl)amino)-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one I I
N N N
Step 1: Preparation of 1-(5-bromopyridin-3-yl)pyrrolidin-2-one I
[0342] A
mixture of 3,5-dibromopyridine (2.00 g, 8.44 mmol), pyrrolidin-2-one (861 mg, 10.1 mmol), K2CO3 (4.08 g, 29.5 mmol), CuI (80 mg, 0.42 mmol), TMEA (49 mg, 0.42 mmol) in dioxane (30 mL) was stirred at 110 C for 20 h. A blue solution was formed gradually. Then added pyrrolidin-2-one (862 mg, 10.1 mmol), TMEA (49 mg, 0.42 mmol), CuI (80 mg, 0.42 mmol) and stirred at 110 C for 20 h. The previous mixture was added pyrrolidin-2-one (862 mg, 10.1 mmol), CuI (80 mg, 0.42 mmol), TMEA (49 mg, 0.42 mmol) and stirred at
111 for 20 hour still. The addition procedure was repeated three times. LCMS (Rt =
0.542 min; MS
Calcd: 242.0; MS Found: 243.1 [M+H1+). The reaction mixture was diluted with Et0Ac (30 mL), filtered and concentrated. The residue was purified by Combi Flash (48%
Et0Ac in pentane) to give impure product (2.00 g) as red liquid, then the impure product was diluted with Et0Ac (50 mL), washed with NaOH (5% in water, 15 mL x3). The organic layer was dried over anhydrous sodium sulfate, and concentrated in vacuum to give 1-(5-bromopyridin-3-yl)pyrrolidin-2-one (400 mg, yield: 20%) as a yellow solid.
11-1NMR (400 MHz, CDC13) 6 2.20-2.26 (2H, m), 2.64 (2H, t, J= 7.6 Hz), 3.88 (2H, t, J=
6.8 Hz), 8.44 (1H, d, J= 2.0 Hz), 8.49 (1H, t, J= 2.0 Hz), 8.64 (1H, d, J=2.0 Hz).
Step 2: Preparation of tert-butyl (5-(2-oxopyrrolidin-1-yl)pyridin-3-yl)carbamate BocHN N
[0343] A
mixture of Pd2(dba)3 (57 mg, 0.062 mmol) and XantPhos (72 mg, 0.12 mmol) in 1,4-dioxane (1 mL) was stirred at 50 C for 10 min. 1-(5-Bromopyridin-3-yl)pyrrolidin-2-one (300 mg, 1.24 mmol), BocNH2 (218 mg, 1.87 mmol) in dioxane (12 mL) and Cs2CO3 (1.01 g, 3.11 mmol) were added and the resulting mixture was stirred at 100 C for 16 h. A black brown mixture was formed. LCMS (Rt = 0.530 min; MS Calcd: 277.1; MS Found: 277.9 [M+H1+).
The reaction mixture was diluted with DCM (20 mL), filtered and concentrated.
The residue was purified by Combi Flash (80% Et0Ac in pentane) to give tert-butyl (5-(2-oxopyrrolidin-1-yl)pyridin-3-yl)carbamate (231 mg, yield: 67%) as a white solid.
11-1NMR (400 MHz, CDC13) 6 1.52 (9H, s), 2.16-2.26 (2H, m), 2.62 (2H, t, J =
8.0 Hz), 3.90 (2H, t, J= 7.2 Hz), 6.59 (1H, brs), 8.36 (2H, s), 8.51 (1H, s).
Step 3: Preparation of 1-(5-aminopyridin-3-yl)pyrrolidin-2-one I
H2NI\JD
[0344] To a stirred solution of tert-butyl (5-(2-oxopyrrolidin-1-yl)pyridin-3-yl)carbamate (230 mg, 0.829 mmol) in DCM (6 mL) was added HC1/Et0Ac (4 M, 8 mL) at 20 C.
The red solution turned to suspension, the reaction mixture was stirred for 1 hour.
TLC indicated the starting material was consumed completely, and one new spot with larger polarity was detected.
0.542 min; MS
Calcd: 242.0; MS Found: 243.1 [M+H1+). The reaction mixture was diluted with Et0Ac (30 mL), filtered and concentrated. The residue was purified by Combi Flash (48%
Et0Ac in pentane) to give impure product (2.00 g) as red liquid, then the impure product was diluted with Et0Ac (50 mL), washed with NaOH (5% in water, 15 mL x3). The organic layer was dried over anhydrous sodium sulfate, and concentrated in vacuum to give 1-(5-bromopyridin-3-yl)pyrrolidin-2-one (400 mg, yield: 20%) as a yellow solid.
11-1NMR (400 MHz, CDC13) 6 2.20-2.26 (2H, m), 2.64 (2H, t, J= 7.6 Hz), 3.88 (2H, t, J=
6.8 Hz), 8.44 (1H, d, J= 2.0 Hz), 8.49 (1H, t, J= 2.0 Hz), 8.64 (1H, d, J=2.0 Hz).
Step 2: Preparation of tert-butyl (5-(2-oxopyrrolidin-1-yl)pyridin-3-yl)carbamate BocHN N
[0343] A
mixture of Pd2(dba)3 (57 mg, 0.062 mmol) and XantPhos (72 mg, 0.12 mmol) in 1,4-dioxane (1 mL) was stirred at 50 C for 10 min. 1-(5-Bromopyridin-3-yl)pyrrolidin-2-one (300 mg, 1.24 mmol), BocNH2 (218 mg, 1.87 mmol) in dioxane (12 mL) and Cs2CO3 (1.01 g, 3.11 mmol) were added and the resulting mixture was stirred at 100 C for 16 h. A black brown mixture was formed. LCMS (Rt = 0.530 min; MS Calcd: 277.1; MS Found: 277.9 [M+H1+).
The reaction mixture was diluted with DCM (20 mL), filtered and concentrated.
The residue was purified by Combi Flash (80% Et0Ac in pentane) to give tert-butyl (5-(2-oxopyrrolidin-1-yl)pyridin-3-yl)carbamate (231 mg, yield: 67%) as a white solid.
11-1NMR (400 MHz, CDC13) 6 1.52 (9H, s), 2.16-2.26 (2H, m), 2.62 (2H, t, J =
8.0 Hz), 3.90 (2H, t, J= 7.2 Hz), 6.59 (1H, brs), 8.36 (2H, s), 8.51 (1H, s).
Step 3: Preparation of 1-(5-aminopyridin-3-yl)pyrrolidin-2-one I
H2NI\JD
[0344] To a stirred solution of tert-butyl (5-(2-oxopyrrolidin-1-yl)pyridin-3-yl)carbamate (230 mg, 0.829 mmol) in DCM (6 mL) was added HC1/Et0Ac (4 M, 8 mL) at 20 C.
The red solution turned to suspension, the reaction mixture was stirred for 1 hour.
TLC indicated the starting material was consumed completely, and one new spot with larger polarity was detected.
112 The mixture was concentrated to give 1-(5-aminopyridin-3-yl)pyrrolidin-2-one (146 mg, yield:
99%) as a black brown solid. Used in the next step without further purification.
NMR (400 MHz, DMSO-d6) 6 2.06-2.13 (2H, m), 2.54 (2H, t, J= 7.2 Hz), 3.82 (2H, t, J=
6.4 Hz), 7.81 (1H, s), 7.88 (1H, s), 8.38 (1H, s).
Step 4: Preparation of 1-(5-methyl-3 -((5-(2-oxopy rroli din-1 -y Opy ri din-3 -y pamino)-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one I I
N N N
[0345] A
mixture of Pd2(dba)3 (7 mg, 0.008 mmol) and BrettPhos (8 mg, 0.002 mmol) in 1,4-dioxane (1 mL) was stirred at 50 C for 10 min. 1-(3-Chloro-5-methy1-5H-chromeno[4,3-clpyridin-8-yl)pyrrolidin-2-one (50 mg, 0.16 mmol), 1-(5-aminopyridin-3-yl)pyrrolidin-2-one (50 mg, 0.16 mmol) in dioxane (3 mL) and Cs2CO3 (155 mg, 0.476 mmol) were added and the resulting mixture was stirred at 100 C for 16 h. A black brown mixture was formed. LCMS
(Rt = 0.586 min; MS Calcd: 455.2; MS Found: 456.0 [M+H1+). The reaction mixture was diluted with DCM (10 mL), filtered and concentrated. The residue was purified by prep-HPLC
(0.05% NH31120 as an additive) and lyophilized to give 1-(5-methy1-3-45-(2-oxopyrrolidin-1-yOpyridin-3-y0amino)-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (12.3 mg, yield:
17%) as an off-white solid.
[0346] LC-MS
(Shimadzu LCMS 2010, mobile phase: C) 10mM NH4HCO3 in Water; D) MECN. Gradient: 1% D increase to 5% D within 0.6 min; 5% DB increase to 100% D
within 3.4 min; then back to 1% D within 0.3 min. Flow rate 0.8 mL/min) purity is 100%, Rt = 2.573 min; MS Calcd.: 455.2, MS Found: 456.3 [M+141+.
NMR (400 MHz, DMSO-d6) 6 1.53 (3H, d, J= 6.4 Hz), 2.01-2.16 (4H, m), 2.50 (4H, overlap with DMSO), 3.81-3.90 (4H, m), 5.27 (1H, q, J= 7.2 Hz), 6.76 (1H, s), 7.31 (1H, dd, J= 8.8, 1.6 Hz), 7.40 (1H, s), 7.88 (1H, d, J= 8.8 Hz), 8.35 (1H, s), 8.58 (1H, t, J= 2.4 Hz), 8.67 (1H, s), 8.71 (1H, d, J= 2.0 Hz), 9.46 (1H, brs).
Example 55: 1-(5-05-methyl-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-yl)amino)pyridin-3-yl)imidazolidin-2-one
99%) as a black brown solid. Used in the next step without further purification.
NMR (400 MHz, DMSO-d6) 6 2.06-2.13 (2H, m), 2.54 (2H, t, J= 7.2 Hz), 3.82 (2H, t, J=
6.4 Hz), 7.81 (1H, s), 7.88 (1H, s), 8.38 (1H, s).
Step 4: Preparation of 1-(5-methyl-3 -((5-(2-oxopy rroli din-1 -y Opy ri din-3 -y pamino)-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one I I
N N N
[0345] A
mixture of Pd2(dba)3 (7 mg, 0.008 mmol) and BrettPhos (8 mg, 0.002 mmol) in 1,4-dioxane (1 mL) was stirred at 50 C for 10 min. 1-(3-Chloro-5-methy1-5H-chromeno[4,3-clpyridin-8-yl)pyrrolidin-2-one (50 mg, 0.16 mmol), 1-(5-aminopyridin-3-yl)pyrrolidin-2-one (50 mg, 0.16 mmol) in dioxane (3 mL) and Cs2CO3 (155 mg, 0.476 mmol) were added and the resulting mixture was stirred at 100 C for 16 h. A black brown mixture was formed. LCMS
(Rt = 0.586 min; MS Calcd: 455.2; MS Found: 456.0 [M+H1+). The reaction mixture was diluted with DCM (10 mL), filtered and concentrated. The residue was purified by prep-HPLC
(0.05% NH31120 as an additive) and lyophilized to give 1-(5-methy1-3-45-(2-oxopyrrolidin-1-yOpyridin-3-y0amino)-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (12.3 mg, yield:
17%) as an off-white solid.
[0346] LC-MS
(Shimadzu LCMS 2010, mobile phase: C) 10mM NH4HCO3 in Water; D) MECN. Gradient: 1% D increase to 5% D within 0.6 min; 5% DB increase to 100% D
within 3.4 min; then back to 1% D within 0.3 min. Flow rate 0.8 mL/min) purity is 100%, Rt = 2.573 min; MS Calcd.: 455.2, MS Found: 456.3 [M+141+.
NMR (400 MHz, DMSO-d6) 6 1.53 (3H, d, J= 6.4 Hz), 2.01-2.16 (4H, m), 2.50 (4H, overlap with DMSO), 3.81-3.90 (4H, m), 5.27 (1H, q, J= 7.2 Hz), 6.76 (1H, s), 7.31 (1H, dd, J= 8.8, 1.6 Hz), 7.40 (1H, s), 7.88 (1H, d, J= 8.8 Hz), 8.35 (1H, s), 8.58 (1H, t, J= 2.4 Hz), 8.67 (1H, s), 8.71 (1H, d, J= 2.0 Hz), 9.46 (1H, brs).
Example 55: 1-(5-05-methyl-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-yl)amino)pyridin-3-yl)imidazolidin-2-one
113 I I
N
[0347] A
mixture of Pd2(dba)3 (16 mg, 0.017 mmol) and BrettPhos (18 mg, 0.034 mmol) was stirred at 50 C for 10 min. 1-(3-Amino-5-methy1-5H-chromeno[4,3-clpyridin-yOpyrrolidin-2-one (100 mg, 0.338 mmol), 1-(5-bromopyridin-3-yl)imidazolidin-2-one (245 mg, 1.02 mmol) in dioxane (5 mL) and Cs2CO3 (441 mg, 1.35 mmol) were added and the resulting mixture was stirred at 100 C for 18 h. A black brown mixture was formed. In a separate vial, a mixture of Pd2(dba)3 (16 mg, 0.017 mmol) and BrettPhos (18 mg, 0.034 mmol) was stirred at 50 C for 15 min and added to the previous reaction mixture together with additional Cs2CO3 (441 mg, 1.35 mmol). The resulting reaction mixture was stirred at 100 C
for 18 h. LCMS (Rt = 0.583 min; MS Calcd: 456.2; MS Found: 457.1 [M+H1+). The reaction mixture was diluted with DCM (15 mL), filtered and concentrated. The residue was purified by Combi Flash (10% DCM in Et0Ac), then the impure product (70 mg) was purified by prep-HPLC (0.05% NH31120 as an additive) and lyophilized to give 1-(5-((5-methy1-8-(2-oxopy rroli din-1-y 0-5H-chromeno [4,3 -c] py ri din-3-y0amino)py ri din-3-y Dimi dazoli din-2-one (8.0 mg, yield: 5%) as a white solid.
[0348] LC-MS
(Shimadzu LCMS 2010, mobile phase: C) 10mM NH4HCO3 in Water; D) MECN. Gradient: I% D increase to 5% D within 0.6 min; 5% DB increase to 100% D
within 3.4 min; then back to I% D within 0.3 min. Flow rate 0.8 mL/min) purity is 95.39%, Rt = 2.454 min; MS Calcd.: 456.2, MS Found: 457.3 [M+1-11+.
NMR (400 MHz, DMSO-d6) 6 1.53 (3H, d, J= 6.8 Hz), 2.02-2.10 (2H, m), 2.54 (2H, overlap with DMSO), 3.46 (2H, t, J= 8.0 Hz), 3.81-3.93 (4H, m), 5.27 (1H, q, J= 6.0 Hz), 6.76 (1H, s), 7.12 (1H, brs), 7.32 (1H, dd, J= 8.4, 2.0 Hz), 7.40 (1H, d, J=
2.0 Hz), 7.89 (1H, d, J= 8.8 Hz), 8.27 (1H, d, J= 2.0 Hz), 8.42 (1H, t, J= 2.0 Hz), 8.64 (1H, d, J= 2.0 Hz), 8.66 (1H, s), 9.43 (1H, brs).
Example 56: 1-(5-45-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno14,3-c]pyridin-y1)amino)pyridin-3-y1)-3-(thiazol-4-ylmethypimidazolidin-2-one
N
[0347] A
mixture of Pd2(dba)3 (16 mg, 0.017 mmol) and BrettPhos (18 mg, 0.034 mmol) was stirred at 50 C for 10 min. 1-(3-Amino-5-methy1-5H-chromeno[4,3-clpyridin-yOpyrrolidin-2-one (100 mg, 0.338 mmol), 1-(5-bromopyridin-3-yl)imidazolidin-2-one (245 mg, 1.02 mmol) in dioxane (5 mL) and Cs2CO3 (441 mg, 1.35 mmol) were added and the resulting mixture was stirred at 100 C for 18 h. A black brown mixture was formed. In a separate vial, a mixture of Pd2(dba)3 (16 mg, 0.017 mmol) and BrettPhos (18 mg, 0.034 mmol) was stirred at 50 C for 15 min and added to the previous reaction mixture together with additional Cs2CO3 (441 mg, 1.35 mmol). The resulting reaction mixture was stirred at 100 C
for 18 h. LCMS (Rt = 0.583 min; MS Calcd: 456.2; MS Found: 457.1 [M+H1+). The reaction mixture was diluted with DCM (15 mL), filtered and concentrated. The residue was purified by Combi Flash (10% DCM in Et0Ac), then the impure product (70 mg) was purified by prep-HPLC (0.05% NH31120 as an additive) and lyophilized to give 1-(5-((5-methy1-8-(2-oxopy rroli din-1-y 0-5H-chromeno [4,3 -c] py ri din-3-y0amino)py ri din-3-y Dimi dazoli din-2-one (8.0 mg, yield: 5%) as a white solid.
[0348] LC-MS
(Shimadzu LCMS 2010, mobile phase: C) 10mM NH4HCO3 in Water; D) MECN. Gradient: I% D increase to 5% D within 0.6 min; 5% DB increase to 100% D
within 3.4 min; then back to I% D within 0.3 min. Flow rate 0.8 mL/min) purity is 95.39%, Rt = 2.454 min; MS Calcd.: 456.2, MS Found: 457.3 [M+1-11+.
NMR (400 MHz, DMSO-d6) 6 1.53 (3H, d, J= 6.8 Hz), 2.02-2.10 (2H, m), 2.54 (2H, overlap with DMSO), 3.46 (2H, t, J= 8.0 Hz), 3.81-3.93 (4H, m), 5.27 (1H, q, J= 6.0 Hz), 6.76 (1H, s), 7.12 (1H, brs), 7.32 (1H, dd, J= 8.4, 2.0 Hz), 7.40 (1H, d, J=
2.0 Hz), 7.89 (1H, d, J= 8.8 Hz), 8.27 (1H, d, J= 2.0 Hz), 8.42 (1H, t, J= 2.0 Hz), 8.64 (1H, d, J= 2.0 Hz), 8.66 (1H, s), 9.43 (1H, brs).
Example 56: 1-(5-45-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno14,3-c]pyridin-y1)amino)pyridin-3-y1)-3-(thiazol-4-ylmethypimidazolidin-2-one
114 I I
o zN
Step 1: Preparation of 1-(5-bromopyridin-3-y1)-3-(thiazol-4-ylmethypimidazolidin-2-one L;1 Br o zNN
[0349] To a solution of 1-(5-bromopyridin-3-yl)imidazolidin-2-one (100 mg, 0.413 mmol) in DMF (2 mL) was added NaH (66 mg, 1.6 mmol, 60% in mineral oil) and then the mixture was stirred at 25 C for 30 min. To the mixture was added 4-(chloromethyl)thiazole hydrogen chloride (105 mg, 0.619 mmol) at 0 C and the mixture was stirred at 25 C for 3 h. A gray suspension was formed. LCMS showed 1-(5-bromopyridin-3-yl)imidazolidin-2-one was consumed completely and desired product (Rt = 0.560 min; MS Calcd: 338.0; MS
Found: 338.7 [M+H1+) was detected. The mixture was combined with another batch and the combined mixture was poured into sat. aq.NH4C1 (50 mL), extracted with Et0Ac (50 mL
x3). The combined organic layer was washed with brine (50 mL x6), dried over Na2SO4 and concentrated to dryness. The residue was purified by Combi Flash (eluenting with Et0Ac) to give 1-(5-bromopyridin-3-y1)-3-(thiazol-4-ylmethypimidazolidin-2-one (288 mg, yield: 93%) as a yellow gum.
11-1 NMR (400 MHz, CDC13) 6 3.60-3.70 (2H, m), 3.80-3.89 (m, 2 H), 4.67 (2H, s), 7.32 (1H, d, J= 2.0 Hz), 8.34 (1H, d, J= 2.0 Hz), 8.47 (1H, t, J= 2.0 Hz), 8.52 (1H, d, J=2.0 Hz), 8.81 (1H, s).
Step 2: Preparation of 1-(5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno [4,3-c] py ri din-3-y0amino)pyridin-3-y1)-3-(thiazol-4-ylmethypimidazolidin-2-one
o zN
Step 1: Preparation of 1-(5-bromopyridin-3-y1)-3-(thiazol-4-ylmethypimidazolidin-2-one L;1 Br o zNN
[0349] To a solution of 1-(5-bromopyridin-3-yl)imidazolidin-2-one (100 mg, 0.413 mmol) in DMF (2 mL) was added NaH (66 mg, 1.6 mmol, 60% in mineral oil) and then the mixture was stirred at 25 C for 30 min. To the mixture was added 4-(chloromethyl)thiazole hydrogen chloride (105 mg, 0.619 mmol) at 0 C and the mixture was stirred at 25 C for 3 h. A gray suspension was formed. LCMS showed 1-(5-bromopyridin-3-yl)imidazolidin-2-one was consumed completely and desired product (Rt = 0.560 min; MS Calcd: 338.0; MS
Found: 338.7 [M+H1+) was detected. The mixture was combined with another batch and the combined mixture was poured into sat. aq.NH4C1 (50 mL), extracted with Et0Ac (50 mL
x3). The combined organic layer was washed with brine (50 mL x6), dried over Na2SO4 and concentrated to dryness. The residue was purified by Combi Flash (eluenting with Et0Ac) to give 1-(5-bromopyridin-3-y1)-3-(thiazol-4-ylmethypimidazolidin-2-one (288 mg, yield: 93%) as a yellow gum.
11-1 NMR (400 MHz, CDC13) 6 3.60-3.70 (2H, m), 3.80-3.89 (m, 2 H), 4.67 (2H, s), 7.32 (1H, d, J= 2.0 Hz), 8.34 (1H, d, J= 2.0 Hz), 8.47 (1H, t, J= 2.0 Hz), 8.52 (1H, d, J=2.0 Hz), 8.81 (1H, s).
Step 2: Preparation of 1-(5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno [4,3-c] py ri din-3-y0amino)pyridin-3-y1)-3-(thiazol-4-ylmethypimidazolidin-2-one
115 I I
H
o N
/1\1 [0350] A
mixture of Pd2(dba)3 (16 mg, 0.017 mmol) and BrettPhos (18 mg, 0.034 mmol) was stirred at 50 C for 10 min. 1-(3-amino-5-methy1-5H-chromeno[4,3-clpyridin-y Opy rroli din-2-one (50 mg, 0.17 mmol), 1-(5 -bromopy ri din-3-y 0-3-(thi azol-4-ylmethypimidazolidin-2-one (69 mg, 0.20 mmol) in dioxane (4 mL) and Cs2CO3 (165 mg, 0.508 mmol) were added and the resulting mixture was stirred at 100 C for 16 h. A black brown mixture was formed. LCMS (Rt = 0.603 min; MS Calcd: 553.2; MS Found:
554.1 [M+H1+). The reaction mixture was diluted with DCM (10 mL), filtered and concentrated. The residue was purified by prep-HPLC (0.05% NH31120 as an additive) and lyophilized to give 1-(5 -((5-methy1-8-(2-oxopy rroli din-1-y 0-5H-chromeno [4,3-c] py ri din-3-y0amino)py ri din-3 -y1)-3-(thiazol-4-ylmethypimidazolidin-2-one (39.6 mg, yield: 42%) as a white solid.
[0351] LC-MS
(Shimadzu LCMS 2010, mobile phase: C) 10mM NH4HCO3 in Water; D) MECN. Gradient: 1% D increase to 5% D within 0.6 min; 5% DB increase to 100% D
within 3.4 min; then back to 1% D within 0.3 min. Flow rate 0.8 mL/min) purity is 100%, Rt = 2.610 min; MS Calcd.: 553.2, MS Found: 554.3 [M+141+.
11-1NMR (400 MHz, DMSO-d6) 6 1.53 (3H, d, J= 6.4 Hz), 2.01-2.10 (2H, m), 2.52 (2H, overlap with DMSO), 3.51 (2H, t, J= 7.6 Hz), 3.80-3.90 (4H, m), 4.56 (2H, s), 5.26 (1H, q, J
= 6.4 Hz), 6.75 (1H, s), 7.31 (1H, dd, J= 8.8, 2.0 Hz), 7.39 (1H, d, J= 2.0 Hz), 7.63 (1H, d, J
= 2.0 Hz), 7.88 (1H, d, J= 8.4 Hz), 8.31 (1H, d, J= 1.6 Hz), 8.49 (1H, t, J=
2.0 Hz), 8.59 (1H, d, J= 2.0 Hz), 8.66 (1H, s), 9.10 (1H, d, J= 1.6 Hz), 9.45 (1H, brs).
Example 57: 1-(5-methyl-3-01-(methylsulfony1)-1H-pyrrolo [3,2-b] pyridin-6-yl)amino)-5H-chromeno14,3-c]pyridin-8-yl)pyrrolidin-2-one - N
N N
H
o N
/1\1 [0350] A
mixture of Pd2(dba)3 (16 mg, 0.017 mmol) and BrettPhos (18 mg, 0.034 mmol) was stirred at 50 C for 10 min. 1-(3-amino-5-methy1-5H-chromeno[4,3-clpyridin-y Opy rroli din-2-one (50 mg, 0.17 mmol), 1-(5 -bromopy ri din-3-y 0-3-(thi azol-4-ylmethypimidazolidin-2-one (69 mg, 0.20 mmol) in dioxane (4 mL) and Cs2CO3 (165 mg, 0.508 mmol) were added and the resulting mixture was stirred at 100 C for 16 h. A black brown mixture was formed. LCMS (Rt = 0.603 min; MS Calcd: 553.2; MS Found:
554.1 [M+H1+). The reaction mixture was diluted with DCM (10 mL), filtered and concentrated. The residue was purified by prep-HPLC (0.05% NH31120 as an additive) and lyophilized to give 1-(5 -((5-methy1-8-(2-oxopy rroli din-1-y 0-5H-chromeno [4,3-c] py ri din-3-y0amino)py ri din-3 -y1)-3-(thiazol-4-ylmethypimidazolidin-2-one (39.6 mg, yield: 42%) as a white solid.
[0351] LC-MS
(Shimadzu LCMS 2010, mobile phase: C) 10mM NH4HCO3 in Water; D) MECN. Gradient: 1% D increase to 5% D within 0.6 min; 5% DB increase to 100% D
within 3.4 min; then back to 1% D within 0.3 min. Flow rate 0.8 mL/min) purity is 100%, Rt = 2.610 min; MS Calcd.: 553.2, MS Found: 554.3 [M+141+.
11-1NMR (400 MHz, DMSO-d6) 6 1.53 (3H, d, J= 6.4 Hz), 2.01-2.10 (2H, m), 2.52 (2H, overlap with DMSO), 3.51 (2H, t, J= 7.6 Hz), 3.80-3.90 (4H, m), 4.56 (2H, s), 5.26 (1H, q, J
= 6.4 Hz), 6.75 (1H, s), 7.31 (1H, dd, J= 8.8, 2.0 Hz), 7.39 (1H, d, J= 2.0 Hz), 7.63 (1H, d, J
= 2.0 Hz), 7.88 (1H, d, J= 8.4 Hz), 8.31 (1H, d, J= 1.6 Hz), 8.49 (1H, t, J=
2.0 Hz), 8.59 (1H, d, J= 2.0 Hz), 8.66 (1H, s), 9.10 (1H, d, J= 1.6 Hz), 9.45 (1H, brs).
Example 57: 1-(5-methyl-3-01-(methylsulfony1)-1H-pyrrolo [3,2-b] pyridin-6-yl)amino)-5H-chromeno14,3-c]pyridin-8-yl)pyrrolidin-2-one - N
N N
116 Step 1: Preparation of 6-bromo-1-(methylsulfony1)-1H-pyrrolo [3,2-b] pyridine N
Br [0352] A
solution of 6-bromo-1H-pyrrolo[3,2-blpyridine (700 mg, 3.55 mmol) and pyridine (5.3 mL, 66 mmol) was stirred in DCM (10 mL), then MsC1 (488 mg, 4.26 mmol) was added into the above solution at 0 C, which was stirred at 20 C for 16 h. A
yellow solution was formed. LCMS is 98% (Rt = 0.609 min; MS Calcd: 273.9; MS Found: 274.8 [M+Hl+).
The solution was diluted with H20 (20 mL) and was extracted with DCM (20 mL
x3). The organic layer was washed with brine (15 mL), dried over Na2SO4, and concentrated. The residue was purified by Combi Flash (50% Et0Ac in pentane) to give impure product (700 mg) as a white solid. Then the product was washed with PE:Et0Ac=3:1 (5 mL x3), the filtrate was concentrated to give 6-bromo-1-(methylsulfony1)-1H-pyrrolo[3,2-b]pyridine (200 mg, yield:
20%) as a white solid.
NMR (400 MHz, CDC13) 6 3.81 (3H, s), 6.92 (1H, d, J= 3.6 Hz), 7.67 (1H, d, J=
3.6 Hz), 8.38 (1H, d, J= 2.0 Hz), 8.67 (1H, d, J= 1.6 Hz).
Step 2: Preparation of 1-(5-methy1-3-((1-(methylsulfony1)-1H-pyrrolo[3,2-blpyridin-6-y0amino)-5H-chromeno [4,3-c] py ri din-8-y Opy rroli din-2-one I
N N
Ok [0353] A
mixture of Pd2(dba)3 (5 mg, 0.005 mmol) and BrettPhos (5 mg, 0.01 mmol) in 1,4-dioxane (1 mL) was stirred at 50 C for 10 min. 1-(3-Amino-5-methy1-5H-chromeno [4,3-clpyridin-8-yl)pyrrolidin-2-one (30 mg, 0.10 mmol), 6-bromo-1-(methylsulfony1)-pyrrolo[3,2-blpyridine (28 mg, 0.10 mmol) in dioxane (3 mL) and Cs2CO3 (99 mg, 0.30 mmol) were added and the resulting mixture was stirred at 100 C for 18 h. A black brown mixture was formed. LCMS showed the most of starting material was not consumed. In a separate vial, a mixture of Pd2(dba)3 (5 mg, 0.005 mmol) and BrettPhos (5 mg, 0.01 mmol) in 1,4-dioxane (1 mL) was stirred at 50 C for 15 min and added to the previous reaction mixture together with additional Cs2CO3 (99 mg, 0.30 mmol), 6-bromo-1-(methylsulfony1)-1H-pyrrolo[3,2-
Br [0352] A
solution of 6-bromo-1H-pyrrolo[3,2-blpyridine (700 mg, 3.55 mmol) and pyridine (5.3 mL, 66 mmol) was stirred in DCM (10 mL), then MsC1 (488 mg, 4.26 mmol) was added into the above solution at 0 C, which was stirred at 20 C for 16 h. A
yellow solution was formed. LCMS is 98% (Rt = 0.609 min; MS Calcd: 273.9; MS Found: 274.8 [M+Hl+).
The solution was diluted with H20 (20 mL) and was extracted with DCM (20 mL
x3). The organic layer was washed with brine (15 mL), dried over Na2SO4, and concentrated. The residue was purified by Combi Flash (50% Et0Ac in pentane) to give impure product (700 mg) as a white solid. Then the product was washed with PE:Et0Ac=3:1 (5 mL x3), the filtrate was concentrated to give 6-bromo-1-(methylsulfony1)-1H-pyrrolo[3,2-b]pyridine (200 mg, yield:
20%) as a white solid.
NMR (400 MHz, CDC13) 6 3.81 (3H, s), 6.92 (1H, d, J= 3.6 Hz), 7.67 (1H, d, J=
3.6 Hz), 8.38 (1H, d, J= 2.0 Hz), 8.67 (1H, d, J= 1.6 Hz).
Step 2: Preparation of 1-(5-methy1-3-((1-(methylsulfony1)-1H-pyrrolo[3,2-blpyridin-6-y0amino)-5H-chromeno [4,3-c] py ri din-8-y Opy rroli din-2-one I
N N
Ok [0353] A
mixture of Pd2(dba)3 (5 mg, 0.005 mmol) and BrettPhos (5 mg, 0.01 mmol) in 1,4-dioxane (1 mL) was stirred at 50 C for 10 min. 1-(3-Amino-5-methy1-5H-chromeno [4,3-clpyridin-8-yl)pyrrolidin-2-one (30 mg, 0.10 mmol), 6-bromo-1-(methylsulfony1)-pyrrolo[3,2-blpyridine (28 mg, 0.10 mmol) in dioxane (3 mL) and Cs2CO3 (99 mg, 0.30 mmol) were added and the resulting mixture was stirred at 100 C for 18 h. A black brown mixture was formed. LCMS showed the most of starting material was not consumed. In a separate vial, a mixture of Pd2(dba)3 (5 mg, 0.005 mmol) and BrettPhos (5 mg, 0.01 mmol) in 1,4-dioxane (1 mL) was stirred at 50 C for 15 min and added to the previous reaction mixture together with additional Cs2CO3 (99 mg, 0.30 mmol), 6-bromo-1-(methylsulfony1)-1H-pyrrolo[3,2-
117 b]pyridine (80 mg, 0.29 mmol). The resulting reaction mixture was stirred at 100 C for 18 h.
LCMS (Rt = 0.603 min; MS Calcd: 489.2; MS Found: 490.0 [M+Hl+). The reaction mixture was diluted with DCM (10 mL), filtered and concentrated. The residue was purified by Combi Flash (10% Me0H in Et0Ac), then the impure product (50 mg) was purified by prep-HPLC
(0.05% NH31120 as an additive) and lyophilized to give 1-(5-methy1-3-((1-(methylsulfony1)-1H-py rrol o [3,2-b] py ri din-6-y0amino)-5H-chromeno [4,3 -c] py ri din-8-yl)py rroli din-2-one (8.4 mg, yield: 17%) as a white solid.
[0354] LC-MS
(Shimadzu LCMS 2010, mobile phase: C) 10mM NH4HCO3 in Water; D) MeCN. Gradient: 1% D increase to 5% D within 0.6 min; 5% DB increase to 100% D
within 3.4 min; then back to 1% D within 0.3 min. Flow rate 0.8 mL/min) purity is 96.44%, Rt = 2.776 min; MS Calcd.: 489.2, MS Found: 490.2 [M+Hl+.
11-1NMR (400 MHz, DMSO-d6) 6 1.55 (3H, d, J= 6.4 Hz), 2.02-2.09 (2H, m), 2.57 (2H, overlap with DMSO), 3.47 (3H, s), 3.85 (2H, t, J= 8.0 Hz), 5.29 (1H, q, J= 6.4 Hz), 6.78 (1H, s), 6.89 (1H, d, J= 4.0 Hz), 7.32 (1H, dd, J= 8.8, 2.0 Hz), 7.41 (1H, d, J= 2.4 Hz), 7.73 (1H, d, J= 4.0 Hz), 7.94 (1H, d, J= 8.8 Hz), 8.69 (1H, s), 8.79 (1H, d, J= 2.4 Hz), 8.83 (1H, d, J= 2.0 Hz), 9.66 (1H, brs).
Example 58: 1-(3-((1-(1-hydroxycyclopropane-1-carbonyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)amino)-5-methyl-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one I
N
OX
Step 1: Preparation of 1 -acetoxy cy cl opropane-1 -carboxy c acid OH
oc0Ac [0355] 1-Hydroxycyclopropane-1-carboxylic acid (600 mg, 5.88 mmol) was slowly added acetyl chloride (923 mg, 11.8 mmol) at 0 C. Then the reaction mixture was warmed to 20 C, stirred at 20 C for 18 h under N2 atmosphere. A brown solution was formed gradually. Acetyl
LCMS (Rt = 0.603 min; MS Calcd: 489.2; MS Found: 490.0 [M+Hl+). The reaction mixture was diluted with DCM (10 mL), filtered and concentrated. The residue was purified by Combi Flash (10% Me0H in Et0Ac), then the impure product (50 mg) was purified by prep-HPLC
(0.05% NH31120 as an additive) and lyophilized to give 1-(5-methy1-3-((1-(methylsulfony1)-1H-py rrol o [3,2-b] py ri din-6-y0amino)-5H-chromeno [4,3 -c] py ri din-8-yl)py rroli din-2-one (8.4 mg, yield: 17%) as a white solid.
[0354] LC-MS
(Shimadzu LCMS 2010, mobile phase: C) 10mM NH4HCO3 in Water; D) MeCN. Gradient: 1% D increase to 5% D within 0.6 min; 5% DB increase to 100% D
within 3.4 min; then back to 1% D within 0.3 min. Flow rate 0.8 mL/min) purity is 96.44%, Rt = 2.776 min; MS Calcd.: 489.2, MS Found: 490.2 [M+Hl+.
11-1NMR (400 MHz, DMSO-d6) 6 1.55 (3H, d, J= 6.4 Hz), 2.02-2.09 (2H, m), 2.57 (2H, overlap with DMSO), 3.47 (3H, s), 3.85 (2H, t, J= 8.0 Hz), 5.29 (1H, q, J= 6.4 Hz), 6.78 (1H, s), 6.89 (1H, d, J= 4.0 Hz), 7.32 (1H, dd, J= 8.8, 2.0 Hz), 7.41 (1H, d, J= 2.4 Hz), 7.73 (1H, d, J= 4.0 Hz), 7.94 (1H, d, J= 8.8 Hz), 8.69 (1H, s), 8.79 (1H, d, J= 2.4 Hz), 8.83 (1H, d, J= 2.0 Hz), 9.66 (1H, brs).
Example 58: 1-(3-((1-(1-hydroxycyclopropane-1-carbonyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)amino)-5-methyl-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one I
N
OX
Step 1: Preparation of 1 -acetoxy cy cl opropane-1 -carboxy c acid OH
oc0Ac [0355] 1-Hydroxycyclopropane-1-carboxylic acid (600 mg, 5.88 mmol) was slowly added acetyl chloride (923 mg, 11.8 mmol) at 0 C. Then the reaction mixture was warmed to 20 C, stirred at 20 C for 18 h under N2 atmosphere. A brown solution was formed gradually. Acetyl
118 chloride was removed under reduced pressure to give 1-acetoxycyclopropane-1 -carboxylic acid (840 mg, yield: 99%) as a black brown solid.
1FINMR (400 MHz, DMSO-d6) 6 1.10-1.20 (2H, m), 1.30-1.40 (2H, m), 2.01 (3H, s), 13.11 (1H, brs).
Step 2:
Preparation of 1 -(7-bromo-2,3-dihy dro-1H-pyri do [2,3-b] [1,4] oxazine-1 -carbonyl)cy clopropyl acetate Br N
00Ac [0356] In a separate vial, to a solution of 1-acetoxycyclopropane-1-carboxylic acid (804 mg, 5.58 mmol) in DCM (5 mL) was added oxalyl chloride (885 mg, 6.98 mmol).
The yellow solution was stirred at 20 C for 0.5 hour. The mixture was concentrated to give crude 1-(chlorocarbonyl)cyclopropyl acetate as a yellow oil.
[0357] To a solution of 7-bromo-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazine (300 mg, 1.40 mmol) in DCM (5 mL) was added Et3N (706 mg, 6.98 mmol). The reaction mixture was cooled to 0 C and then dropwise added 1-(chlorocarbonyl)cyclopropyl acetate in DCM
(5 mL). The reaction mixture was then warmed to 20 C, stirred at 20 C for 16 h under N2 atmosphere. A
red solution was formed. LCMS (Rt = 0.588 min, MS Calcd.: 340.0; MS Found:
340.8 [M+Hl+). TLC showed the starting material was consumed completely. The reaction mixture was concentrated. The residue was purified by Combi Flash (78% DCM in PE (1%
Et3N as an additive)) to give 1-(7-bromo-2,3-dihy dro-1H-pyrido [2,3 -b] [1,4] oxazine-1 -carbonyl)cyclopropyl acetate (475 mg, yield: 99% for two steps) as a red gum.
Step 3: Preparation of 1-(7-((5 -methyl-8-(2-oxopy rrol i din-1 -y1)-5H-chromeno [4,3-c] py ri din-3-yl)amino)-2,3 -dihy dro-1H-pyri do [2,3 -b] [1,4] oxazine-1 -carbonyl)cy cl opropyl acetate c 0 N N N
0)c0Ac
1FINMR (400 MHz, DMSO-d6) 6 1.10-1.20 (2H, m), 1.30-1.40 (2H, m), 2.01 (3H, s), 13.11 (1H, brs).
Step 2:
Preparation of 1 -(7-bromo-2,3-dihy dro-1H-pyri do [2,3-b] [1,4] oxazine-1 -carbonyl)cy clopropyl acetate Br N
00Ac [0356] In a separate vial, to a solution of 1-acetoxycyclopropane-1-carboxylic acid (804 mg, 5.58 mmol) in DCM (5 mL) was added oxalyl chloride (885 mg, 6.98 mmol).
The yellow solution was stirred at 20 C for 0.5 hour. The mixture was concentrated to give crude 1-(chlorocarbonyl)cyclopropyl acetate as a yellow oil.
[0357] To a solution of 7-bromo-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazine (300 mg, 1.40 mmol) in DCM (5 mL) was added Et3N (706 mg, 6.98 mmol). The reaction mixture was cooled to 0 C and then dropwise added 1-(chlorocarbonyl)cyclopropyl acetate in DCM
(5 mL). The reaction mixture was then warmed to 20 C, stirred at 20 C for 16 h under N2 atmosphere. A
red solution was formed. LCMS (Rt = 0.588 min, MS Calcd.: 340.0; MS Found:
340.8 [M+Hl+). TLC showed the starting material was consumed completely. The reaction mixture was concentrated. The residue was purified by Combi Flash (78% DCM in PE (1%
Et3N as an additive)) to give 1-(7-bromo-2,3-dihy dro-1H-pyrido [2,3 -b] [1,4] oxazine-1 -carbonyl)cyclopropyl acetate (475 mg, yield: 99% for two steps) as a red gum.
Step 3: Preparation of 1-(7-((5 -methyl-8-(2-oxopy rrol i din-1 -y1)-5H-chromeno [4,3-c] py ri din-3-yl)amino)-2,3 -dihy dro-1H-pyri do [2,3 -b] [1,4] oxazine-1 -carbonyl)cy cl opropyl acetate c 0 N N N
0)c0Ac
119 mixture of Pd2(dba)3 (34 mg, 0.037 mmol) and BrettPhos (40 mg, 0.074 mmol) in 1,4-dioxane (1 mL) was stirred at 50 C for 10 min. Compound 7 (110 mg, 0.372 mmol), 1-(3-amino-5-methy1-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one2 (190 mg, 0.558 mmol) in 1,4-dioxane (7 mL) and Cs2CO3 (364 mg, 1.12 mmol) were added. The resulting mixture was stirred at 100 C for 6 h. A black brown mixture was formed. LCMS (Rt =
0.597 min; MS
Calcd: 555.2; MS Found: 556.1 [M+H]+). The reaction mixture was diluted with DCM (10 mL), filtered and concentrated. The residue was purified by prep-HPLC (normal phase, PE-Et0H) and concentrated to give 1-(7-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c] pyridin-3-y0amino)-2,3-dihy dro-1H-pyrido[2,3-b] [1,4] oxazine-1 -carbonyl)cy clopropyl acetate (50 mg, yield: 24%) as a yellow solid.
Step 4:
Preparation of 1-(3 -((1-(1 -hy droxy cy clopropane-1 -carbonyl)-2,3-dihy dro-py ri do [2,3 -b] [1,4] oxazin-7-yl)amino)-5-methyl-5H-chromeno [4,3 -c] py ri din-8-yl)py rroli din-2-one NN
H
103591 To a solution of 1-(7-45-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)-2,3-dihydro-1H-pyrido[2,3-b][1,4loxazine-1-carbonyl)cyclopropyl acetate (50 mg, 0.090 mmol) in 1,4-dioxane (3 mL) was added Me0H (1.1 mL, 27 mmol).
Then the yellow solution was added K2CO3 (37 mg, 0.27 mmol), stirred at 20 C
for 4 h. LCMS
(Rt = 0.563 min; MS Calcd: 513.2; MS Found: 514.1 [M+Hl+). The reaction mixture was filtered and concentrated. The residue was purified by prep-HPLC (0.05%
NH31120 as an additive) and lyophilized to give 1-(3-41-(1-hydroxycyclopropane-1-carbony1)-2,3-dihydro-1H-py ri do [2,3-b] [1,4] oxazin-7-yl)amino)-5-methyl-5H-chromeno [4,3 -c] py ri din-8-yl)pyrrolidin-2-one (7.0 mg, yield: 15%) as a white solid.
NMR (400 MHz, DMSO-d6) 6 0.85-0.95 (2H, m), 1.10-1.20 (2H, m), 1.52 (3H, d, J=
6.4 Hz), 2.01-2.09 (2H, m), 2.55 (2H, overlap with DMSO), 3.84 (2H, t, J= 7.2 Hz), 4.14 (2H, t, J= 4.0 Hz), 4.39 (2H, t, J= 4.0 Hz), 5.23 (1H, q, J= 6.4 Hz), 6.62 (1H, brs), 6.66 (1H, s), 7.30 (1H, dd, J= 8.8, 2.0 Hz), 7.38 (1H, d, J= 2.0 Hz), 7.86 (1H, d, J= 8.8 Hz), 8.24 (1H, d, J= 2.4 Hz), 8.59 (1H, s), 8.61 (1H, d, J= 2.4 Hz), 9.21 (1H, brs).
0.597 min; MS
Calcd: 555.2; MS Found: 556.1 [M+H]+). The reaction mixture was diluted with DCM (10 mL), filtered and concentrated. The residue was purified by prep-HPLC (normal phase, PE-Et0H) and concentrated to give 1-(7-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c] pyridin-3-y0amino)-2,3-dihy dro-1H-pyrido[2,3-b] [1,4] oxazine-1 -carbonyl)cy clopropyl acetate (50 mg, yield: 24%) as a yellow solid.
Step 4:
Preparation of 1-(3 -((1-(1 -hy droxy cy clopropane-1 -carbonyl)-2,3-dihy dro-py ri do [2,3 -b] [1,4] oxazin-7-yl)amino)-5-methyl-5H-chromeno [4,3 -c] py ri din-8-yl)py rroli din-2-one NN
H
103591 To a solution of 1-(7-45-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)-2,3-dihydro-1H-pyrido[2,3-b][1,4loxazine-1-carbonyl)cyclopropyl acetate (50 mg, 0.090 mmol) in 1,4-dioxane (3 mL) was added Me0H (1.1 mL, 27 mmol).
Then the yellow solution was added K2CO3 (37 mg, 0.27 mmol), stirred at 20 C
for 4 h. LCMS
(Rt = 0.563 min; MS Calcd: 513.2; MS Found: 514.1 [M+Hl+). The reaction mixture was filtered and concentrated. The residue was purified by prep-HPLC (0.05%
NH31120 as an additive) and lyophilized to give 1-(3-41-(1-hydroxycyclopropane-1-carbony1)-2,3-dihydro-1H-py ri do [2,3-b] [1,4] oxazin-7-yl)amino)-5-methyl-5H-chromeno [4,3 -c] py ri din-8-yl)pyrrolidin-2-one (7.0 mg, yield: 15%) as a white solid.
NMR (400 MHz, DMSO-d6) 6 0.85-0.95 (2H, m), 1.10-1.20 (2H, m), 1.52 (3H, d, J=
6.4 Hz), 2.01-2.09 (2H, m), 2.55 (2H, overlap with DMSO), 3.84 (2H, t, J= 7.2 Hz), 4.14 (2H, t, J= 4.0 Hz), 4.39 (2H, t, J= 4.0 Hz), 5.23 (1H, q, J= 6.4 Hz), 6.62 (1H, brs), 6.66 (1H, s), 7.30 (1H, dd, J= 8.8, 2.0 Hz), 7.38 (1H, d, J= 2.0 Hz), 7.86 (1H, d, J= 8.8 Hz), 8.24 (1H, d, J= 2.4 Hz), 8.59 (1H, s), 8.61 (1H, d, J= 2.4 Hz), 9.21 (1H, brs).
120 Example 59: 1-(3-01-(2-hydroxy-2-methylpropanoy1)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)amino)-5-methyl-5H-chromeno[4,3-c]pyridin-8-y1)pyrrolidin-2-one N
Step 1: Preparation of 2-acetoxy-2-methylpropanoic acid OH
Ac0 [0360] 2-Hydroxy-2-methylpropanoic acid (4.00 g, 38.4 mmol) was slowly added acetyl chloride (5.5 mL, 76.9 mmol) at 20 C. Then the reaction mixture was stirred at 20 C for 12 h under N2 atmosphere. A colorless solution was formed gradually. Acetyl chloride was removed under reduced pressure to afford 2-acetoxy-2-methylpropanoic acid (8 g, crude) as colorless oil.
11-1NMR (400 MHz, CDC13) 6 1.57 (6H, s), 2.06 (3H, s), 11.91 (1H, brs).
Step 2: Preparation of 1 -(7-bromo-2,3 -dihy dro-1H-py ri do [2,3-b] [1,4]
oxazin-l-y 1)-2-methyl-1-oxopropan-2-y1 acetate OAc Brn:N
[0361] To a solution of 2-acetoxy-2-methylpropanoic acid (1.09 g, 7.44 mmol) in DCM (6 mL), DMF (68 mg, 0.93 mmol) was added oxalyl chloride (0.814 mL, 9.30 mmol).
The reaction mixture was stirred at 10 C for 0.5 hour. A light yellow solution was formed. The mixture was concentrated to give crude 1-chloro-2-methyl-1-oxopropan-2-y1 acetate as a yellow oil. To a solution of 7-bromo-2,3-dihydro-1H-pyrido[2,3-b][1,4loxazine (100 mg, 0.465 mmol) in DCM (6 mL) was added Et3N (1.29 mL, 9.30 mmol). The reaction mixture was cooled to 0 C and then dropwise added to the crude product 1-chloro-2-methy1-1-oxopropan-2-y1 acetate in DCM (4 mL). The reaction mixture was then warmed to 10 C, stirred at 10 C for 12 h under N2 atmosphere. The colorless solution turned to an orange
Step 1: Preparation of 2-acetoxy-2-methylpropanoic acid OH
Ac0 [0360] 2-Hydroxy-2-methylpropanoic acid (4.00 g, 38.4 mmol) was slowly added acetyl chloride (5.5 mL, 76.9 mmol) at 20 C. Then the reaction mixture was stirred at 20 C for 12 h under N2 atmosphere. A colorless solution was formed gradually. Acetyl chloride was removed under reduced pressure to afford 2-acetoxy-2-methylpropanoic acid (8 g, crude) as colorless oil.
11-1NMR (400 MHz, CDC13) 6 1.57 (6H, s), 2.06 (3H, s), 11.91 (1H, brs).
Step 2: Preparation of 1 -(7-bromo-2,3 -dihy dro-1H-py ri do [2,3-b] [1,4]
oxazin-l-y 1)-2-methyl-1-oxopropan-2-y1 acetate OAc Brn:N
[0361] To a solution of 2-acetoxy-2-methylpropanoic acid (1.09 g, 7.44 mmol) in DCM (6 mL), DMF (68 mg, 0.93 mmol) was added oxalyl chloride (0.814 mL, 9.30 mmol).
The reaction mixture was stirred at 10 C for 0.5 hour. A light yellow solution was formed. The mixture was concentrated to give crude 1-chloro-2-methyl-1-oxopropan-2-y1 acetate as a yellow oil. To a solution of 7-bromo-2,3-dihydro-1H-pyrido[2,3-b][1,4loxazine (100 mg, 0.465 mmol) in DCM (6 mL) was added Et3N (1.29 mL, 9.30 mmol). The reaction mixture was cooled to 0 C and then dropwise added to the crude product 1-chloro-2-methy1-1-oxopropan-2-y1 acetate in DCM (4 mL). The reaction mixture was then warmed to 10 C, stirred at 10 C for 12 h under N2 atmosphere. The colorless solution turned to an orange
121 solution gradually. LCMS (Rt = 0.614 min; MS Calcd: 342.0; MS Found: 342.9 [M+Hl+). The reaction mixture was concentrated. The residue was purified by Combi Flash (1%
Et3N in DCM) to afford 1-(7-bromo-2,3-dihydro-1H-pyrido[2,3-b][1,41oxazin-1-y1)-2-methyl-1-oxopropan-2-y1 acetate (320 mg, yield: 50% over three steps) as yellow oil.
Step 3: Preparation of 2-methy1-1-(7-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c] pyridin-3-y0amino)-2,3 -dihy dro-IH-pyrido [2,3 -b] [1,4] oxazin-1-y1)-1 -oxopropan-2-y1 acetate I
N N N
ox0Ac [0362] A
mixture of Pd2(dba)3 (37 mg, 0.041 mmol) and BrettPhos (44 mg, 0.081 mmol) in 1,4-dioxane (1 mL) was stirred at 50 C for 10 min. 1-(3-amino-5-methy1-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (120 mg, 0.406 mmol), 1-(7-bromo-2,3-dihydro-1H-pyrido [2,3-b] [1,4] oxazin-l-y1)-2-methyl-l-oxopropan-2-y1 acetate (160 mg, 0.467 mmol) in 1,4-dioxane (7 mL) and Cs2CO3 (397 mg, 1.22 mmol) were added and the resulting mixture was stirred at 100 C for 6 h. A black brown mixture was formed. LCMS (Rt =
0.615 min; MS
Calcd: 557.2; MS Found: 558.0 [M+Hl+). The reaction mixture was diluted with DCM (20 mL), filtered and concentrated. The residue was purified by prep-HPLC (normal phase, Hexane-Et0H) and concentrated to give 2-methyl-I -(7-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno [4,3-c] py ridin-3 -y0amino)-2,3 -dihy dro-1H-py ri do [2,3-b]
[1,4] oxazin-1 -y1)-1-oxopropan-2-y1 acetate(90 mg, yield: 40%) as a yellow solid.
Step 4: Preparation of 1 -(3-((1 -(2-hy droxy -2-methy 1prop anoy1)-2,3-dihy dro-IH-py rido [2,3 -b] [1,4] oxazin-7-yl)amino)-5-methy1-5H-chromeno [4,3-c] py ridin-8-yl)py rroli din-2-one c 0 "
NN
HO
Et3N in DCM) to afford 1-(7-bromo-2,3-dihydro-1H-pyrido[2,3-b][1,41oxazin-1-y1)-2-methyl-1-oxopropan-2-y1 acetate (320 mg, yield: 50% over three steps) as yellow oil.
Step 3: Preparation of 2-methy1-1-(7-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c] pyridin-3-y0amino)-2,3 -dihy dro-IH-pyrido [2,3 -b] [1,4] oxazin-1-y1)-1 -oxopropan-2-y1 acetate I
N N N
ox0Ac [0362] A
mixture of Pd2(dba)3 (37 mg, 0.041 mmol) and BrettPhos (44 mg, 0.081 mmol) in 1,4-dioxane (1 mL) was stirred at 50 C for 10 min. 1-(3-amino-5-methy1-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (120 mg, 0.406 mmol), 1-(7-bromo-2,3-dihydro-1H-pyrido [2,3-b] [1,4] oxazin-l-y1)-2-methyl-l-oxopropan-2-y1 acetate (160 mg, 0.467 mmol) in 1,4-dioxane (7 mL) and Cs2CO3 (397 mg, 1.22 mmol) were added and the resulting mixture was stirred at 100 C for 6 h. A black brown mixture was formed. LCMS (Rt =
0.615 min; MS
Calcd: 557.2; MS Found: 558.0 [M+Hl+). The reaction mixture was diluted with DCM (20 mL), filtered and concentrated. The residue was purified by prep-HPLC (normal phase, Hexane-Et0H) and concentrated to give 2-methyl-I -(7-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno [4,3-c] py ridin-3 -y0amino)-2,3 -dihy dro-1H-py ri do [2,3-b]
[1,4] oxazin-1 -y1)-1-oxopropan-2-y1 acetate(90 mg, yield: 40%) as a yellow solid.
Step 4: Preparation of 1 -(3-((1 -(2-hy droxy -2-methy 1prop anoy1)-2,3-dihy dro-IH-py rido [2,3 -b] [1,4] oxazin-7-yl)amino)-5-methy1-5H-chromeno [4,3-c] py ridin-8-yl)py rroli din-2-one c 0 "
NN
HO
122 [0363] To a solution of 2-methyl- 1-(7-((5 -methyl-8-(2-oxopy rroli din-1 -y1)-5H-chromeno [4,3-c] py ri din-3 -yl)amino)-2,3 -dihy dro-1H-py ri do [2,3-b]
[1,4] oxazin-l-y1)-1 -oxopropan-2-y1 acetate (90 mg, 0.16 mmol) in dioxane (4 mL) was added Me0H
(1.3 mL, 32 mmol). Then the yellow solution was added K2CO3 (67 mg, 0.48 mmol), stirred at 20 C for 4 h. LCMS (Rt = 0.695 min; MS Calcd: 515.2; MS Found: 516.1 [M+H1+). The reaction mixture was filtered and concentrated. The residue was purified by prep-HPLC (0.05%
NH31-120 as an additive) and lyophilized to give 1-(3-41-(2-hydroxy-2-methylpropanoy1)-2,3-dihydro-1H-py ri do [2,3-b] [1,4] oxazin-7-yl)amino)-5-methyl-5H-chromeno [4,3 -c] py ri din-8-yl)py rroli din-2-one (20.6 mg, yield: 25%) as a white solid.
11-INMR (400 MHz, DMSO-d6) 6 1.42 (6H, s), 1.51 (3H, d, J= 6.4 Hz), 2.00-2.09 (2H, m), 2.53 (2H, overlap with DMSO), 3.83 (2H, t, J= 7.6 Hz), 4.30-4.40 (4H, m), 5.23 (1H, q, J=
6.4 Hz), 5.85 (1H, brs), 6.64 (1H, s), 7.29 (1H, dd, J= 8.8, 2.0 Hz), 7.38 (1H, d, J= 2.0 Hz), 7.85 (1H, d, J= 8.8 Hz), 8.33 (1H, d, J= 2.4 Hz), 8.44 (1H, d, J= 2.4 Hz), 8.58 (1H, s), 9.18 (1H, brs).
Example 60: 1-(3-01-(2-hydroxypropanoy1)-2,3-dihydro-1H-pyrido12,3-b]11,41oxazin-7-yl)amino)-5-methyl-5H-chromeno14,3-c]pyridin-8-y1)pyrrolidin-2-one I
NN
OHr0 Step 1: Preparation of 2-acetoxypropanoic acid Ac0).LOH
[0364] 2-hydroxypropanoic acid (4.00 g, 44.4 mmol) was slowly added acetyl chloride (6.34 mL, 88.8 mmol) at 20 C. Then the reaction mixture was stirred at 20 C
for 12 h under N2 atmosphere. A colorless solution was formed gradually. Acetyl chloride was removed under reduced pressure to afford 2-acetoxypropanoic acid (7 g, crude) as colorless oil.
11-INMR (400 MHz, CDC13) 6 1.53 (3H, d, J= 7.2 Hz), 2.10 (3H, s), 5.10 (1H, q, J= 7.2 Hz), 10.41 (1H, brs).
[1,4] oxazin-l-y1)-1 -oxopropan-2-y1 acetate (90 mg, 0.16 mmol) in dioxane (4 mL) was added Me0H
(1.3 mL, 32 mmol). Then the yellow solution was added K2CO3 (67 mg, 0.48 mmol), stirred at 20 C for 4 h. LCMS (Rt = 0.695 min; MS Calcd: 515.2; MS Found: 516.1 [M+H1+). The reaction mixture was filtered and concentrated. The residue was purified by prep-HPLC (0.05%
NH31-120 as an additive) and lyophilized to give 1-(3-41-(2-hydroxy-2-methylpropanoy1)-2,3-dihydro-1H-py ri do [2,3-b] [1,4] oxazin-7-yl)amino)-5-methyl-5H-chromeno [4,3 -c] py ri din-8-yl)py rroli din-2-one (20.6 mg, yield: 25%) as a white solid.
11-INMR (400 MHz, DMSO-d6) 6 1.42 (6H, s), 1.51 (3H, d, J= 6.4 Hz), 2.00-2.09 (2H, m), 2.53 (2H, overlap with DMSO), 3.83 (2H, t, J= 7.6 Hz), 4.30-4.40 (4H, m), 5.23 (1H, q, J=
6.4 Hz), 5.85 (1H, brs), 6.64 (1H, s), 7.29 (1H, dd, J= 8.8, 2.0 Hz), 7.38 (1H, d, J= 2.0 Hz), 7.85 (1H, d, J= 8.8 Hz), 8.33 (1H, d, J= 2.4 Hz), 8.44 (1H, d, J= 2.4 Hz), 8.58 (1H, s), 9.18 (1H, brs).
Example 60: 1-(3-01-(2-hydroxypropanoy1)-2,3-dihydro-1H-pyrido12,3-b]11,41oxazin-7-yl)amino)-5-methyl-5H-chromeno14,3-c]pyridin-8-y1)pyrrolidin-2-one I
NN
OHr0 Step 1: Preparation of 2-acetoxypropanoic acid Ac0).LOH
[0364] 2-hydroxypropanoic acid (4.00 g, 44.4 mmol) was slowly added acetyl chloride (6.34 mL, 88.8 mmol) at 20 C. Then the reaction mixture was stirred at 20 C
for 12 h under N2 atmosphere. A colorless solution was formed gradually. Acetyl chloride was removed under reduced pressure to afford 2-acetoxypropanoic acid (7 g, crude) as colorless oil.
11-INMR (400 MHz, CDC13) 6 1.53 (3H, d, J= 7.2 Hz), 2.10 (3H, s), 5.10 (1H, q, J= 7.2 Hz), 10.41 (1H, brs).
123 Step 2:
Preparation of 1-(7-bromo-2,3 -dihy dro-1H-py ri do [2,3 -b] [1,4] oxazin-1 -y1)-1-oxopropan-2-y1 acetate _N 0 Br o0Ac 103651 To a solution of 2-acetoxypropanoic acid (983 mg, 7.44 mmol) in DCM (6 mL), DMF (68 mg, 0.93 mmol) was added oxalyl chloride (0.814 mL, 9.30 mmol). The reaction mixture was stirred at 10 C for 0.5 hour. Alight yellow solution was formed.
The mixture was concentrated to give 1-chloro-1-oxopropan-2-y1 acetate as a yellow oil. To a solution of 7-bromo-2,3-dihydro-1H-pyrido[2,3-b][1,41oxazine (400 mg, 1.86 mmol) in DCM (10 mL) was added Et3N (1.29 mL, 9.30 mmol). The reaction mixture was cooled to 0 C and then dropwise added the crude product 1-chloro-1-oxopropan-2-y1 acetate in DCM (4 mL). The reaction mixture was then warmed to 10 C, stirred at 10 C for 12 h under N2 atmosphere.
The colorless solution turned to orange gradually. LCMS (Rt = 0.583 min; MS
Calcd: 330.0;
MS Found: 330.8 [M+Hl+). The reaction mixture was concentrated. The residue was purified by Combi Flash (1% Et3N in DCM) to afford 1-(7-bromo-2,3-dihydro-1H-pyrido[2,3-b][1,41oxazin-1-y1)-1-oxopropan-2-y1 acetate (500 mg, yield: 82% over three steps) as yellow oil.
Step 3: Preparation of 1-(7-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)-2,3 -dihy dro-1H-pyrido [2,3 -b] [1,41oxazin-1-y1)-1-oxopropan-2-y1 acetate N N N
o0Ac [0366] A
mixture of Pd2(dba)3 (37 mg, 0.040 mmol) and BrettPhos (43 mg, 0.81 mmol) in 1,4-dioxane (1 mL) was stirred at 50 C for 10 min. 1-(3-amino-5-methy1-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (120 mg, 0.406 mmol), 1-(7-bromo-2,3-dihydro-1H-pyrido[2,3-b][1,41oxazin-1-y1)-1-oxopropan-2-y1 acetate (160 mg, 0.487 mmol) in 1,4-dioxane (7 mL) and Cs2CO3 (397 mg, 1.22 mmol) were added and the resulting mixture was stirred at
Preparation of 1-(7-bromo-2,3 -dihy dro-1H-py ri do [2,3 -b] [1,4] oxazin-1 -y1)-1-oxopropan-2-y1 acetate _N 0 Br o0Ac 103651 To a solution of 2-acetoxypropanoic acid (983 mg, 7.44 mmol) in DCM (6 mL), DMF (68 mg, 0.93 mmol) was added oxalyl chloride (0.814 mL, 9.30 mmol). The reaction mixture was stirred at 10 C for 0.5 hour. Alight yellow solution was formed.
The mixture was concentrated to give 1-chloro-1-oxopropan-2-y1 acetate as a yellow oil. To a solution of 7-bromo-2,3-dihydro-1H-pyrido[2,3-b][1,41oxazine (400 mg, 1.86 mmol) in DCM (10 mL) was added Et3N (1.29 mL, 9.30 mmol). The reaction mixture was cooled to 0 C and then dropwise added the crude product 1-chloro-1-oxopropan-2-y1 acetate in DCM (4 mL). The reaction mixture was then warmed to 10 C, stirred at 10 C for 12 h under N2 atmosphere.
The colorless solution turned to orange gradually. LCMS (Rt = 0.583 min; MS
Calcd: 330.0;
MS Found: 330.8 [M+Hl+). The reaction mixture was concentrated. The residue was purified by Combi Flash (1% Et3N in DCM) to afford 1-(7-bromo-2,3-dihydro-1H-pyrido[2,3-b][1,41oxazin-1-y1)-1-oxopropan-2-y1 acetate (500 mg, yield: 82% over three steps) as yellow oil.
Step 3: Preparation of 1-(7-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)-2,3 -dihy dro-1H-pyrido [2,3 -b] [1,41oxazin-1-y1)-1-oxopropan-2-y1 acetate N N N
o0Ac [0366] A
mixture of Pd2(dba)3 (37 mg, 0.040 mmol) and BrettPhos (43 mg, 0.81 mmol) in 1,4-dioxane (1 mL) was stirred at 50 C for 10 min. 1-(3-amino-5-methy1-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (120 mg, 0.406 mmol), 1-(7-bromo-2,3-dihydro-1H-pyrido[2,3-b][1,41oxazin-1-y1)-1-oxopropan-2-y1 acetate (160 mg, 0.487 mmol) in 1,4-dioxane (7 mL) and Cs2CO3 (397 mg, 1.22 mmol) were added and the resulting mixture was stirred at
124 100 C for 6 h. A black brown mixture was formed. LCMS (Rt = 0.595 min; MS
Calcd: 543.2;
MS Found: 544.0 [M+Hr). The reaction mixture was diluted with DCM (20 mL), filtered and concentrated. The residue was purified by prep-HPLC (normal phase, Hexane-Et0H) and concentrated to give 1-(7-45-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-y1)amino)-2,3-dihydro-1H-pyrido[2,3-b] [1,4] oxazin-1 -y1)-1-oxoprop an-2-y' acetate (140 mg, yield: 63%) as a yellow solid.
Step 4:
Preparation of 1-(3-((1-(2-hydroxypropanoy1)-2,3-dihydro-1H-pyrido[2,3-b] [1,4] oxazin-7-y 1)amino)-5 -methyl-5H-chromeno [4,3-c] py ridin-8-yl)py rroli din-2-one I
NN
HO
[0367] To a solution of 1-(7-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)-2,3-dihydro-1H-pyrido[2,3-b] [1,4] oxazin-1-y1)-1 -oxopropan-2-y1 acetate (140 mg, 0.257 mmol) in dioxane (6 mL) was added Me0H (2.1 mL, 51 mmol). Then the yellow solution was added K2CO3 (107 mg, 0.772 mmol), stirred at 20 C for 3 h. LCMS
(Rt = 0.562 min; MS Calcd: 501.2; MS Found: 502.0 [M+H]+). The reaction mixture was filtered and concentrated. The residue was purified by prep-HPLC (0.05%
NH31120 as an additive) and lyophilized to give 1-(3-((1-(2-hydroxypropanoy1)-2,3-dihydro-1H-pyrido[2,3-b] [1,4] oxazin-7-y 1)amino)-5 -methyl-5H-chromeno [4,3-c] py ridin-8-yl)py rroli din-2-one (31.6 mg, yield: 24%) as a white solid.
11-INMR (400 MHz, DMSO-d6) 6 1.29 (3H, d, J = 6.4 Hz), 1.51 (3H, d, J = 6.4 Hz), 2.00-2.09 (2H, m), 2.53 (2H, overlap with DMSO), 3.83 (2H, t, J= 7.6 Hz), 3.87-4.08 (2H, m), 4.30-4.40 (2H, m), 4.62-4.68 (1H, m), 5.23 (1H, q, J= 6.4 Hz), 5.44 (1H, d, J=
7.2 Hz), 6.65 (1H, s), 7.29 (1H, dd, J= 8.8, 2.4 Hz), 7.38 (1H, d, J= 2.4 Hz), 7.85 (1H, d, J = 8.8 Hz), 8.28 (1H, d, J= 2.0 Hz), 8.58 (1H, s), 8.67 (1H, brs), 9.22 (1H, s).
Example 61: 1-(3-01-(2-hydroxyacety1)-2,3-dihydro-1H-pyrido12,3-b]11,41oxazin-yl)amino)-5-methyl-5H-chromeno14,3-c]pyridin-8-y1)pyrrolidin-2-one
Calcd: 543.2;
MS Found: 544.0 [M+Hr). The reaction mixture was diluted with DCM (20 mL), filtered and concentrated. The residue was purified by prep-HPLC (normal phase, Hexane-Et0H) and concentrated to give 1-(7-45-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-y1)amino)-2,3-dihydro-1H-pyrido[2,3-b] [1,4] oxazin-1 -y1)-1-oxoprop an-2-y' acetate (140 mg, yield: 63%) as a yellow solid.
Step 4:
Preparation of 1-(3-((1-(2-hydroxypropanoy1)-2,3-dihydro-1H-pyrido[2,3-b] [1,4] oxazin-7-y 1)amino)-5 -methyl-5H-chromeno [4,3-c] py ridin-8-yl)py rroli din-2-one I
NN
HO
[0367] To a solution of 1-(7-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)-2,3-dihydro-1H-pyrido[2,3-b] [1,4] oxazin-1-y1)-1 -oxopropan-2-y1 acetate (140 mg, 0.257 mmol) in dioxane (6 mL) was added Me0H (2.1 mL, 51 mmol). Then the yellow solution was added K2CO3 (107 mg, 0.772 mmol), stirred at 20 C for 3 h. LCMS
(Rt = 0.562 min; MS Calcd: 501.2; MS Found: 502.0 [M+H]+). The reaction mixture was filtered and concentrated. The residue was purified by prep-HPLC (0.05%
NH31120 as an additive) and lyophilized to give 1-(3-((1-(2-hydroxypropanoy1)-2,3-dihydro-1H-pyrido[2,3-b] [1,4] oxazin-7-y 1)amino)-5 -methyl-5H-chromeno [4,3-c] py ridin-8-yl)py rroli din-2-one (31.6 mg, yield: 24%) as a white solid.
11-INMR (400 MHz, DMSO-d6) 6 1.29 (3H, d, J = 6.4 Hz), 1.51 (3H, d, J = 6.4 Hz), 2.00-2.09 (2H, m), 2.53 (2H, overlap with DMSO), 3.83 (2H, t, J= 7.6 Hz), 3.87-4.08 (2H, m), 4.30-4.40 (2H, m), 4.62-4.68 (1H, m), 5.23 (1H, q, J= 6.4 Hz), 5.44 (1H, d, J=
7.2 Hz), 6.65 (1H, s), 7.29 (1H, dd, J= 8.8, 2.4 Hz), 7.38 (1H, d, J= 2.4 Hz), 7.85 (1H, d, J = 8.8 Hz), 8.28 (1H, d, J= 2.0 Hz), 8.58 (1H, s), 8.67 (1H, brs), 9.22 (1H, s).
Example 61: 1-(3-01-(2-hydroxyacety1)-2,3-dihydro-1H-pyrido12,3-b]11,41oxazin-yl)amino)-5-methyl-5H-chromeno14,3-c]pyridin-8-y1)pyrrolidin-2-one
125 c 0 I
NN
H
Step 1: Preparation of 2-(7-bromo-2,3 -dihy dro-1H-py ri do [2,3-b] [1,4]
oxazin-1 -y1)-2-oxoethyl acetate BrN
OCY
[0368] To a solution of 7-bromo-2,3-dihydro-1H-pyrido[2,3-b][1,41oxazine (537 mg, 2.50 mmol) in DCM (12 mL) was added pyridine (1.01 mL, 12.5 mmol). The reaction mixture was cooled to 0 C and then dropwise added 2-chloro-2-oxoethyl acetate in DCM (6 mL). The reaction mixture was then warmed to 20 C, stirred at 20 C for 12 h under N2 atmosphere. The colorless solution turned to yellow gradually. LCMS (Rt = 0.560 min; MS Calcd:
313.9; MS
Found: 314.8 [M+Hl+). The reaction mixture was concentrated. The residue was purified by Combi Flash (1% Et3N in DCM) to afford 2-(7-bromo-2,3-dihydro-1H-pyrido[2,3-b][1,41oxazin-1-y1)-2-oxoethyl acetate (630 mg, yield: 80%) as a yellow solid.
11-1NMR (400 MHz, CDC13) 2.21 (3H, s), 3.86 (2H, t, J = 4.4 Hz), 4.67 (2H, t, J = 4.8 Hz), 4.85 (2H, s), 8.08 (1H, d, J= 2.4 Hz), 8.55 (1H, brs).
Step 2: Preparation of 2-(7-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)-2,3 -dihy dro-1H-py ri do [2,3 -b] [1,4] oxazin-l-y1)-2-oxo ethyl acetate N N N
o0Ac [0369] A
mixture of Pd2(dba)3 (28 mg, 0.030 mmol) and BrettPhos (33 mg, 0.060 mmol) in 1,4-dioxane (1 mL) was stirred at 50 C for 10 min. 1-(3-amino-5-methy1-5H-chromeno[4,3-clpyridin-8-yl)pyrrolidin-2-one (90 mg, 0.30 mmol), 2-(7-bromo-2,3-dihydro-1H-pyrido[2,3-b][1,41oxazin-1-y1)-2-oxoethyl acetate (100 mg, 0.317 mmol) in dioxane (6 mL) and Cs2CO3
NN
H
Step 1: Preparation of 2-(7-bromo-2,3 -dihy dro-1H-py ri do [2,3-b] [1,4]
oxazin-1 -y1)-2-oxoethyl acetate BrN
OCY
[0368] To a solution of 7-bromo-2,3-dihydro-1H-pyrido[2,3-b][1,41oxazine (537 mg, 2.50 mmol) in DCM (12 mL) was added pyridine (1.01 mL, 12.5 mmol). The reaction mixture was cooled to 0 C and then dropwise added 2-chloro-2-oxoethyl acetate in DCM (6 mL). The reaction mixture was then warmed to 20 C, stirred at 20 C for 12 h under N2 atmosphere. The colorless solution turned to yellow gradually. LCMS (Rt = 0.560 min; MS Calcd:
313.9; MS
Found: 314.8 [M+Hl+). The reaction mixture was concentrated. The residue was purified by Combi Flash (1% Et3N in DCM) to afford 2-(7-bromo-2,3-dihydro-1H-pyrido[2,3-b][1,41oxazin-1-y1)-2-oxoethyl acetate (630 mg, yield: 80%) as a yellow solid.
11-1NMR (400 MHz, CDC13) 2.21 (3H, s), 3.86 (2H, t, J = 4.4 Hz), 4.67 (2H, t, J = 4.8 Hz), 4.85 (2H, s), 8.08 (1H, d, J= 2.4 Hz), 8.55 (1H, brs).
Step 2: Preparation of 2-(7-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)-2,3 -dihy dro-1H-py ri do [2,3 -b] [1,4] oxazin-l-y1)-2-oxo ethyl acetate N N N
o0Ac [0369] A
mixture of Pd2(dba)3 (28 mg, 0.030 mmol) and BrettPhos (33 mg, 0.060 mmol) in 1,4-dioxane (1 mL) was stirred at 50 C for 10 min. 1-(3-amino-5-methy1-5H-chromeno[4,3-clpyridin-8-yl)pyrrolidin-2-one (90 mg, 0.30 mmol), 2-(7-bromo-2,3-dihydro-1H-pyrido[2,3-b][1,41oxazin-1-y1)-2-oxoethyl acetate (100 mg, 0.317 mmol) in dioxane (6 mL) and Cs2CO3
126 (298 mg, 0.914 mmol) were added and the resulting mixture was stirred at 100 C for 16 h. A
black brown mixture was formed. LCMS (Rt = 0.555 min; MS Calcd: 529.2; MS
Found: 530.1 [M+Hl+). The reaction mixture was diluted with DCM (10 mL), filtered and concentrated. The residue was purified by prep-HPLC (normal phase, Hexane-Et0H) and lyophilized to give 2-(7-((5-methy1-8-(2-oxopy rroli din-1-y 0-5H-chromeno [4,3-c] py ridin-3 -y0amino)-2,3 -dihy dro-1H-pyrido[2,3-b][1,41oxazin-1-y1)-2-oxoethyl acetate (30 mg, yield: 19%) as a red solid.
Step 3: Preparation of 1-(3-((1 -(2-hy droxy acety1)-2,3 -dihy dro-1H-py rido [2,3 -b] [1,4] oxazin-7-y Damino)-5-methy1-5H-chromeno [4,3 -c] pyri din-8-y Opy rroli din-2-one gN 0 I
NN
H
[0370] To a solution of 2-(7-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c] pyridin-3-yl)amino)-2,3 -dihy dro-1H-pyrido [2,3 -b] [1,4] oxazin-1-y1)-2-oxoethyl acetate (30 mg, 0.056 mmol) in dioxane (2 mL) was added Me0H (363 mg, 11.3 mmol). Then the yellow solution was added K2CO3 (23 mg, 0.17 mmol), stirred at 20 C for 3 h. LCMS
(Rt = 0.552 min; MS Calcd: 487.2; MS Found: 488.0 [M+Hl+). The reaction mixture was filtered and concentrated. The residue was purified by prep-HPLC (0.05% NH31120 as an additive) and lyophilized to give 1-(3 -((1 -(2-hy droxy acety1)-2,3-dihy dro-1H-py ri do [2,3-b] [1,4] oxazin-7-yl)amino)-5-methy1-5H-chromeno[4,3-c]pyridin-8-y1)pyrrolidin-2-one (12.5 mg, yield: 45%) as a white solid.
NMR (400 MHz, DMSO-d6) 6 1.52 (3H, d, J= 6.4 Hz), 2.01-2.09 (2H, m), 2.55 (2H, overlap with DMSO), 3.80-3.86 (4H, m), 4.30-4.35 (4H, m), 5.08 (1H, t, J= 6.0 Hz), 5.23 (1H, q, J= 6.0 Hz), 6.66 (1H, s), 7.30 (1H, dd, J= 8.4, 2.0 Hz), 7.38 (1H, d, J= 1.6 Hz), 7.85 (1H, d, J= 8.4 Hz), 8.27 (1H, d, J= 2.4 Hz), 8.59 (1H, s), 8.80 (1H, brs), 9.24 (1H, s).
Example 62: 1-(3-((2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-7-yl)amino)-5-methyl-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one
black brown mixture was formed. LCMS (Rt = 0.555 min; MS Calcd: 529.2; MS
Found: 530.1 [M+Hl+). The reaction mixture was diluted with DCM (10 mL), filtered and concentrated. The residue was purified by prep-HPLC (normal phase, Hexane-Et0H) and lyophilized to give 2-(7-((5-methy1-8-(2-oxopy rroli din-1-y 0-5H-chromeno [4,3-c] py ridin-3 -y0amino)-2,3 -dihy dro-1H-pyrido[2,3-b][1,41oxazin-1-y1)-2-oxoethyl acetate (30 mg, yield: 19%) as a red solid.
Step 3: Preparation of 1-(3-((1 -(2-hy droxy acety1)-2,3 -dihy dro-1H-py rido [2,3 -b] [1,4] oxazin-7-y Damino)-5-methy1-5H-chromeno [4,3 -c] pyri din-8-y Opy rroli din-2-one gN 0 I
NN
H
[0370] To a solution of 2-(7-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c] pyridin-3-yl)amino)-2,3 -dihy dro-1H-pyrido [2,3 -b] [1,4] oxazin-1-y1)-2-oxoethyl acetate (30 mg, 0.056 mmol) in dioxane (2 mL) was added Me0H (363 mg, 11.3 mmol). Then the yellow solution was added K2CO3 (23 mg, 0.17 mmol), stirred at 20 C for 3 h. LCMS
(Rt = 0.552 min; MS Calcd: 487.2; MS Found: 488.0 [M+Hl+). The reaction mixture was filtered and concentrated. The residue was purified by prep-HPLC (0.05% NH31120 as an additive) and lyophilized to give 1-(3 -((1 -(2-hy droxy acety1)-2,3-dihy dro-1H-py ri do [2,3-b] [1,4] oxazin-7-yl)amino)-5-methy1-5H-chromeno[4,3-c]pyridin-8-y1)pyrrolidin-2-one (12.5 mg, yield: 45%) as a white solid.
NMR (400 MHz, DMSO-d6) 6 1.52 (3H, d, J= 6.4 Hz), 2.01-2.09 (2H, m), 2.55 (2H, overlap with DMSO), 3.80-3.86 (4H, m), 4.30-4.35 (4H, m), 5.08 (1H, t, J= 6.0 Hz), 5.23 (1H, q, J= 6.0 Hz), 6.66 (1H, s), 7.30 (1H, dd, J= 8.4, 2.0 Hz), 7.38 (1H, d, J= 1.6 Hz), 7.85 (1H, d, J= 8.4 Hz), 8.27 (1H, d, J= 2.4 Hz), 8.59 (1H, s), 8.80 (1H, brs), 9.24 (1H, s).
Example 62: 1-(3-((2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-7-yl)amino)-5-methyl-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one
127 I
NO
Step 1: Preparation of tert-butyl (2,3 -dihy dro- [1,4] di oxino [2,3 -b]
pyridin-7-yl)carbamate BocH N
mixture of 7-bromo-2,3-dihydro-[1,41dioxino[2,3-b1pyridine (500 mg, 2.31 mmol), BocNH2 (325 mg, 2.78 mmol), Pd2(dba)3 (106 mg, 0.116 mmol), XantPhos (201 mg, 0.347 mmol) and Cs2CO3 (1.13 g, 3.47 mmol) in anhydrous dioxane (5 mL) was degassed and purged with N2 for 3 times. Then the resulting reaction mixture was heated at 100 C for 16 h under N2 atmosphere. LCMS (Rt = 0.752 min; MS Calcd: 252.1; MS Found: 252.9 [M+Hl+). To the reaction mixture was added water (25 mL), then extracted with Et0Ac (25 mL x3). The combined organic layer was washed brine (25 mL), dried over anhydrous Na2SO4 and concentrated. The residue was purified by Combi Flash (20% to 50% DCM in Et0Ac) to give tert-butyl (2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-7-yl)carbamate (400 mg, yield: 69%) as a yellow solid.
11-1NMR (400 MHz, CDC13) (51.51 (9H, s), 4.21-4.24 (2H, m), 4.37-4.40 (2H, m), 6.44 (1H, brs), 7.55 (1H, s), 7.64 (1H, d, J= 2.4 Hz).
Step 2: Preparation of 2,3-dihy dro- [1,4] di oxino [2,3 -b] pyridin-7-amine 103721 To a solution of tert-butyl (2,3 -dihy dro- [1,4] dioxino [2,3-b] pyridin-7-yl)carbamate (400 mg, 1.59 mmol) in Et0Ac (5 mL) was added 4N HC1 gas inEt0Ac (20 mL) at 10-15 C.
Then the reaction mixture was stirred at 10-15 C for 2 h. The reaction mixture turned into cloudy from clear solution. LCMS indicated the starting material was consumed up. The reaction mixture was concentrated to give 2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-7-amine (290 mg, yield: 97%, HC1 salt) as a yellow solid.
11-1NMR (400 MHz, DMSO-d6) (54.29-4.32 (2H, m), 4.43-4.45 (2H, m), 7.37 (1H, d, J= 2.4 Hz), 7.80 (1H, d, J = 2.4 Hz).
NO
Step 1: Preparation of tert-butyl (2,3 -dihy dro- [1,4] di oxino [2,3 -b]
pyridin-7-yl)carbamate BocH N
mixture of 7-bromo-2,3-dihydro-[1,41dioxino[2,3-b1pyridine (500 mg, 2.31 mmol), BocNH2 (325 mg, 2.78 mmol), Pd2(dba)3 (106 mg, 0.116 mmol), XantPhos (201 mg, 0.347 mmol) and Cs2CO3 (1.13 g, 3.47 mmol) in anhydrous dioxane (5 mL) was degassed and purged with N2 for 3 times. Then the resulting reaction mixture was heated at 100 C for 16 h under N2 atmosphere. LCMS (Rt = 0.752 min; MS Calcd: 252.1; MS Found: 252.9 [M+Hl+). To the reaction mixture was added water (25 mL), then extracted with Et0Ac (25 mL x3). The combined organic layer was washed brine (25 mL), dried over anhydrous Na2SO4 and concentrated. The residue was purified by Combi Flash (20% to 50% DCM in Et0Ac) to give tert-butyl (2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-7-yl)carbamate (400 mg, yield: 69%) as a yellow solid.
11-1NMR (400 MHz, CDC13) (51.51 (9H, s), 4.21-4.24 (2H, m), 4.37-4.40 (2H, m), 6.44 (1H, brs), 7.55 (1H, s), 7.64 (1H, d, J= 2.4 Hz).
Step 2: Preparation of 2,3-dihy dro- [1,4] di oxino [2,3 -b] pyridin-7-amine 103721 To a solution of tert-butyl (2,3 -dihy dro- [1,4] dioxino [2,3-b] pyridin-7-yl)carbamate (400 mg, 1.59 mmol) in Et0Ac (5 mL) was added 4N HC1 gas inEt0Ac (20 mL) at 10-15 C.
Then the reaction mixture was stirred at 10-15 C for 2 h. The reaction mixture turned into cloudy from clear solution. LCMS indicated the starting material was consumed up. The reaction mixture was concentrated to give 2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-7-amine (290 mg, yield: 97%, HC1 salt) as a yellow solid.
11-1NMR (400 MHz, DMSO-d6) (54.29-4.32 (2H, m), 4.43-4.45 (2H, m), 7.37 (1H, d, J= 2.4 Hz), 7.80 (1H, d, J = 2.4 Hz).
128 Step 3: Preparation of 1 -(3-42,3-dihy dro- [1,4] di oxino [2,3 -b] py ri din-7-y0amino)-5-methyl-5H-chromeno[4,3-c]pyridin-8-yOpyrrolidin-2-one 0 LjL.L1 N 0 N
[0373] A
mixture of 1-(3 -chloro-5 -methyl-5H-chromeno [4,3-c] py ri din-8-yl)py rroli din-2-one (80 mg, 0.25 mmol), 2,3-dihydro-[1,41dioxino[2,3-b]pyridin-7-amine (72 mg, 0.38 mmol, HC1 salt), Pd2(dba)3 (12 mg, 0.013 mmol), BrettPhos (14 mg, 0.025 mmol) and Cs2CO3 (248 mg, 0.762 mmol) in anhydrous dioxane (3 mL) was degassed and purged with N2 for 3 times.
Then the resulting reaction mixture was heated at 100 C for 16 h under N2 atmosphere. The reaction mixture turned into yellow suspension from red. Crude LCMS (Rt =
0.693 min; MS
Calcd: 430.2; MS Found: 431.0 [M+H1+). To the reaction mixture was added water (25 mL), then extracted with Et0Ac/THF (25 mL x2, 1/1). The combined organic layer was washed with brine (25 mL), dried over anhydrous Na2SO4 and concentrated. The residue was purified by prep-HPLC (0.225% FA as an additive). Most of the MeCN was removed under reduced pressure and the remaining part was lyophilized to give 1-(3-42,3-dihydro-[1,41dioxino[2,3-b]pyridin-7-yl)amino)-5-methyl-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one (40.4 mg, yield: 37%) as a yellow solid.
[0374] LCMS was taken on a quadrupole Mass Spectrometer on Shimadzu LCMS 2010 (Shim-pack XR-ODS 3.0*30 mm 2.2 pm) operating in ES (+) ionization mode. Flow Rate: 0.8 mL/min, Acquire Time: 3 min, Wavelength: UV220, Oven Tem.: 50 C, Mobile phase: from 90% [water + 0.04% TFA] and 10% [MeCN +0.02 % TFA] to 20% [water + 0.04% TFA]
and 80% [MeCN + 0.02% TFA] in 1.35 min, then under this condition for 0.9 min, finally changed to 90% [water + 0.04% TFA] and 10% [MeCN + 0.02% TFA] and under this condition for 0.75 min. purity is 99.74%, Rt = 1.254 min; MS Calcd.: 430.2, MS Found: 431.0 [M+Hr.
11-1NMR (400 MHz, DMSO-d6) (51.52 (3H, d, J= 6.4 Hz), 2.01-2.10 (2H, m), 2.52-2.54 (2H, m), 3.75-3.86 (2H, m), 4.20-4.30 (2H, m), 4.35-4.40 (2H, m), 5.26 (1H, q, J=
6.4 Hz), 6.67 (1H, s), 7.31 (1H, dd, J= 8.5, 2.3 Hz), 7.40 (1H, d, J= 2.0 Hz), 7.82 (1H, d, J= 2.5 Hz), 7.86 (1H, d, J= 8.8 Hz), 7.94 (1H, d, J= 2.5 Hz), 8.61 (1H, s), 9.34 (1H, brs).
[0373] A
mixture of 1-(3 -chloro-5 -methyl-5H-chromeno [4,3-c] py ri din-8-yl)py rroli din-2-one (80 mg, 0.25 mmol), 2,3-dihydro-[1,41dioxino[2,3-b]pyridin-7-amine (72 mg, 0.38 mmol, HC1 salt), Pd2(dba)3 (12 mg, 0.013 mmol), BrettPhos (14 mg, 0.025 mmol) and Cs2CO3 (248 mg, 0.762 mmol) in anhydrous dioxane (3 mL) was degassed and purged with N2 for 3 times.
Then the resulting reaction mixture was heated at 100 C for 16 h under N2 atmosphere. The reaction mixture turned into yellow suspension from red. Crude LCMS (Rt =
0.693 min; MS
Calcd: 430.2; MS Found: 431.0 [M+H1+). To the reaction mixture was added water (25 mL), then extracted with Et0Ac/THF (25 mL x2, 1/1). The combined organic layer was washed with brine (25 mL), dried over anhydrous Na2SO4 and concentrated. The residue was purified by prep-HPLC (0.225% FA as an additive). Most of the MeCN was removed under reduced pressure and the remaining part was lyophilized to give 1-(3-42,3-dihydro-[1,41dioxino[2,3-b]pyridin-7-yl)amino)-5-methyl-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one (40.4 mg, yield: 37%) as a yellow solid.
[0374] LCMS was taken on a quadrupole Mass Spectrometer on Shimadzu LCMS 2010 (Shim-pack XR-ODS 3.0*30 mm 2.2 pm) operating in ES (+) ionization mode. Flow Rate: 0.8 mL/min, Acquire Time: 3 min, Wavelength: UV220, Oven Tem.: 50 C, Mobile phase: from 90% [water + 0.04% TFA] and 10% [MeCN +0.02 % TFA] to 20% [water + 0.04% TFA]
and 80% [MeCN + 0.02% TFA] in 1.35 min, then under this condition for 0.9 min, finally changed to 90% [water + 0.04% TFA] and 10% [MeCN + 0.02% TFA] and under this condition for 0.75 min. purity is 99.74%, Rt = 1.254 min; MS Calcd.: 430.2, MS Found: 431.0 [M+Hr.
11-1NMR (400 MHz, DMSO-d6) (51.52 (3H, d, J= 6.4 Hz), 2.01-2.10 (2H, m), 2.52-2.54 (2H, m), 3.75-3.86 (2H, m), 4.20-4.30 (2H, m), 4.35-4.40 (2H, m), 5.26 (1H, q, J=
6.4 Hz), 6.67 (1H, s), 7.31 (1H, dd, J= 8.5, 2.3 Hz), 7.40 (1H, d, J= 2.0 Hz), 7.82 (1H, d, J= 2.5 Hz), 7.86 (1H, d, J= 8.8 Hz), 7.94 (1H, d, J= 2.5 Hz), 8.61 (1H, s), 9.34 (1H, brs).
129 Example 63: 1-(5-methyl-3-(pyrido[2,3-b]pyrazin-7-ylamino)-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one gN 0 N N
Step 1: Preparation of tert-butyl pyrido[2,3-blpyrazin-7-ylcarbamate I
BocHNN
[0375] A
mixture of 7-bromopyrido[2,3-blpyrazine (500 mg, 2.38 mmol), BocNH2 (335 mg, 2.86 mmol), Pd2(dba)3 (109 mg, 0.119 mmol), XantPhos (207 mg, 0.357 mmol) and Cs2CO3 (1.16 g, 3.57 mmol) in anhydrous dioxane (10 mL) was degassed and purged with N2 for 3 times. Then the resulting reaction mixture was heated at 110 C for 16 h. A black suspension was formed. To the reaction mixture was added water (25 mL) and Et0Ac (25 mL), then filtered through a pad of celite and the solid was washed with Et0Ac (20 mL x3). The filtrate was separated and the aqueous layer was extracted with Et0Ac (25 mL
x2). The combined organic layer was washed with brine (25 mL), dried over anhydrous Na2SO4 and concentrated. The residue was purified by Combi Flash (35% to 70% Et0Ac in pentane) to give tert-butyl pyrido[2,3-blpyrazin-7-ylcarbamate (150 mg, yield: 26%) as a yellow solid.
11-1NMR (400 MHz, DMSO-d6) (51.54 (9H, s), 8.61 (1H, s), 8.95-9.00 (2H, m), 9.13 (1H, d, J= 2.8 Hz), 10.29 (1H, brs).
Step 2: Preparation of pyrido[2,3-blpyrazin-7-amine [0376] To a solution of tert-butyl pyrido[2,3-blpyrazin-7-ylcarbamate (150 mg, 0.609 mmol) in Et0Ac (2 mL) was added 4 N HC1 inEt0Ac (10 mL) from 10-15 C. Then the reaction mixture was stirred at 10-15 C for 1 hour. The reaction mixture turned into brown cloudy from yellow solution. Crude LCMS (Rt = 0.382 min; MS Calcd: 146.1; MS
Found: 147.0 [M+H1+). The reaction mixture was concentrated to give pyrido[2,3-blpyrazin-7-amine (100 mg, yield: 90%, HC1 salt) as a brown solid.
Step 1: Preparation of tert-butyl pyrido[2,3-blpyrazin-7-ylcarbamate I
BocHNN
[0375] A
mixture of 7-bromopyrido[2,3-blpyrazine (500 mg, 2.38 mmol), BocNH2 (335 mg, 2.86 mmol), Pd2(dba)3 (109 mg, 0.119 mmol), XantPhos (207 mg, 0.357 mmol) and Cs2CO3 (1.16 g, 3.57 mmol) in anhydrous dioxane (10 mL) was degassed and purged with N2 for 3 times. Then the resulting reaction mixture was heated at 110 C for 16 h. A black suspension was formed. To the reaction mixture was added water (25 mL) and Et0Ac (25 mL), then filtered through a pad of celite and the solid was washed with Et0Ac (20 mL x3). The filtrate was separated and the aqueous layer was extracted with Et0Ac (25 mL
x2). The combined organic layer was washed with brine (25 mL), dried over anhydrous Na2SO4 and concentrated. The residue was purified by Combi Flash (35% to 70% Et0Ac in pentane) to give tert-butyl pyrido[2,3-blpyrazin-7-ylcarbamate (150 mg, yield: 26%) as a yellow solid.
11-1NMR (400 MHz, DMSO-d6) (51.54 (9H, s), 8.61 (1H, s), 8.95-9.00 (2H, m), 9.13 (1H, d, J= 2.8 Hz), 10.29 (1H, brs).
Step 2: Preparation of pyrido[2,3-blpyrazin-7-amine [0376] To a solution of tert-butyl pyrido[2,3-blpyrazin-7-ylcarbamate (150 mg, 0.609 mmol) in Et0Ac (2 mL) was added 4 N HC1 inEt0Ac (10 mL) from 10-15 C. Then the reaction mixture was stirred at 10-15 C for 1 hour. The reaction mixture turned into brown cloudy from yellow solution. Crude LCMS (Rt = 0.382 min; MS Calcd: 146.1; MS
Found: 147.0 [M+H1+). The reaction mixture was concentrated to give pyrido[2,3-blpyrazin-7-amine (100 mg, yield: 90%, HC1 salt) as a brown solid.
130 11-1 NMR (400 MHz, DMSO-d6) (5 7.40 (1H, d, J= 2.8 Hz), 8.72 (1H, s), 8.78 (1H, d, J= 2.4 Hz), 8.83 (1H, s).
Step 3: Preparation of 1-(5 -methyl-3-(py ri do [2,3 -b] py razin-7-ylamino)-5H-chromeno [4,3 -c]pyridin-8-yl)pyrrolidin-2-one N N
[0377] A
mixture of 1-(3 -chloro-5 -methyl-5H-chromeno [4,3-c] py ri din-8-yl)py rroli din-2-one (80 mg, 0.25 mmol), pyrido[2,3-b]pyrazin-7-amine (70 mg, 0.38 mmol, HC1 salt), Pd2(dba)3 (12 mg, 0.013 mmol), BrettPhos (14 mg, 0.025 mmol) and Cs2CO3 (248 mg, 0.762 mmol) in anhydrous dioxane (2 mL) was degassed and purged with N2 for 3 times.
Then the reaction mixture was heated at 100 C for 16 h under N2 atmosphere. Crude LCMS
(Rt = 0.382 min; MS Calcd: 424.2; MS Found: 425.0 [M+H1+). The mixture was filtered through a pad of celite and the solid was washed with Me0H (5 mL x3). The filtrate was concentrated and the residue was purified by prep-HPLC (0.225% FA as an additive). Most of the MeCN
was removed under reduced pressure and the remaining part was lyophilized to give 1-(5-methyl-3 -(pyri do [2,3 -b] py razin-7-y lamino)-5H-chromeno [4,3-c] py ri din-8-yl)py rroli din-2-one (3.8 mg, yield: 3.5%) as a red solid.
[0378] LC-MS
(Agilent LCMS 1200-6140A, mobile phase: from 99% [water + 0.1% FA]
and 1% [MeCN + 0.1% FA] to 95% [water + 0.1% FA] and 5% [MeCN + 0.1% FA] in 0.6 min, then changed to 100% [MeCN + 0.1% FA] under this condition for 3.4 min, finally back to 99% [water + 0.1% FA] and 1% [MeCN + 0.1% FA] and under this condition for 0.5 min.) purity is 100%, Rt = 2.558 min; MS Calcd.: 424.2, MS Found: 425.3 [M+Hr.
11-1NMR (400 MHz, DMSO-d6) (5 1.58 (3H, d, J= 6.4 Hz), 2.05-2.10 (2H, m), 2.55-2.60 (2H, m), 3.80-3.90 (2H, m), 5.35 (1H, q, J= 6.4 Hz), 6.92 (1H, s), 7.35 (1H, d J=
8.4 Hz), 7.43 (1H, s), 7.95 (1H, d, J= 8.8 Hz), 8.60-8.90 (2H, m), 8.93 (1H, s), 9.15-9.25 (2H, m), 10.27 (1H, brs).
Example 64: 1-(3-((1,5-naphthyridin-3-yl)amino)-5-methyl-5H-chromeno14,3-c]
pyridin-8-yl)pyrrolidin-2-one
Step 3: Preparation of 1-(5 -methyl-3-(py ri do [2,3 -b] py razin-7-ylamino)-5H-chromeno [4,3 -c]pyridin-8-yl)pyrrolidin-2-one N N
[0377] A
mixture of 1-(3 -chloro-5 -methyl-5H-chromeno [4,3-c] py ri din-8-yl)py rroli din-2-one (80 mg, 0.25 mmol), pyrido[2,3-b]pyrazin-7-amine (70 mg, 0.38 mmol, HC1 salt), Pd2(dba)3 (12 mg, 0.013 mmol), BrettPhos (14 mg, 0.025 mmol) and Cs2CO3 (248 mg, 0.762 mmol) in anhydrous dioxane (2 mL) was degassed and purged with N2 for 3 times.
Then the reaction mixture was heated at 100 C for 16 h under N2 atmosphere. Crude LCMS
(Rt = 0.382 min; MS Calcd: 424.2; MS Found: 425.0 [M+H1+). The mixture was filtered through a pad of celite and the solid was washed with Me0H (5 mL x3). The filtrate was concentrated and the residue was purified by prep-HPLC (0.225% FA as an additive). Most of the MeCN
was removed under reduced pressure and the remaining part was lyophilized to give 1-(5-methyl-3 -(pyri do [2,3 -b] py razin-7-y lamino)-5H-chromeno [4,3-c] py ri din-8-yl)py rroli din-2-one (3.8 mg, yield: 3.5%) as a red solid.
[0378] LC-MS
(Agilent LCMS 1200-6140A, mobile phase: from 99% [water + 0.1% FA]
and 1% [MeCN + 0.1% FA] to 95% [water + 0.1% FA] and 5% [MeCN + 0.1% FA] in 0.6 min, then changed to 100% [MeCN + 0.1% FA] under this condition for 3.4 min, finally back to 99% [water + 0.1% FA] and 1% [MeCN + 0.1% FA] and under this condition for 0.5 min.) purity is 100%, Rt = 2.558 min; MS Calcd.: 424.2, MS Found: 425.3 [M+Hr.
11-1NMR (400 MHz, DMSO-d6) (5 1.58 (3H, d, J= 6.4 Hz), 2.05-2.10 (2H, m), 2.55-2.60 (2H, m), 3.80-3.90 (2H, m), 5.35 (1H, q, J= 6.4 Hz), 6.92 (1H, s), 7.35 (1H, d J=
8.4 Hz), 7.43 (1H, s), 7.95 (1H, d, J= 8.8 Hz), 8.60-8.90 (2H, m), 8.93 (1H, s), 9.15-9.25 (2H, m), 10.27 (1H, brs).
Example 64: 1-(3-((1,5-naphthyridin-3-yl)amino)-5-methyl-5H-chromeno14,3-c]
pyridin-8-yl)pyrrolidin-2-one
131 csIN 0 Step 1: Preparation of tert-butyl (1,5-naphthyridin-3-yl)carbamate I
BocHNNI"
mixture of 3-bromo-1,5-naphthyridine (300 mg, 1.44 mmol), BocNH2 (202 mg, 1.72 mmol), Pd2(dba)3 (66 mg, 0.072 mmol), XantPhos (125 mg, 0.215 mmol) and Cs2CO3 (701 mg, 2.15 mmol) in anhydrous dioxane (8 mL) was degassed and purged with N2 for 3 times. Then the resulting reaction mixture was heated at 110 C for 16 h. The reaction mixture turned into yellow suspension from red. The reaction mixture was cooled to room temperature, then diluted with water (25 mL) and extracted with Et0Ac (25 mL x3). The combined organic layer was filtered and the filtrate was washed with brine (25 mL), dried over anhydrous Na2SO4 and concentrated. The residue was purified by Combi Flash (25% to 60% Et0Ac in pentane to give tert-butyl (1,5-naphthyridin-3-yl)carbamate (253 mg, yield: 72%) as a yellow solid.
11-1NMR (400 MHz, CDC13) (51.57 (9H, s), 7.03 (1H, brs), 7.53 (1H, dd, J= 8.0, 4.0 Hz), 8.33 (1H, d, J= 8.4 Hz), 8.50 (1H, s), 8.90-9.00 (2H, m).
Step 2: Preparation of 1,5-naphthyridin-3-amine [0380] To a solution of tert-butyl (1,5-naphthyridin-3-yl)carbamate (253 mg, 1.03 mmol) in Et0Ac (5 mL) was added 4 N HC1 in Et0Ac (10 mL) at 10-15 C. Then the reaction mixture was stirred at 10-15 C for 2 h. The reaction mixture turned into cloudy from clear solution.
The mixture was concentrated to give 1,5-naphthyridin-3-amine (160 mg, yield:
85% yield, HC1 salt) as a yellow solid.
11-1NMR (400 MHz, DMSO-d6) (57.44 (1H, d, J= 2.4 Hz), 7.70 (1H, dd, J= 8.4, 6.0 Hz), 8.75-8.85 (2H, m), 8.90 (1H, d, J= 4.8 Hz).
Step 3: Preparation of 1-(3-((1,5-naphthyridin-3-yl)amino)-5-methy1-5H-chromeno [4,3-c]pyridin-8-yl)pyrrolidin-2-one
BocHNNI"
mixture of 3-bromo-1,5-naphthyridine (300 mg, 1.44 mmol), BocNH2 (202 mg, 1.72 mmol), Pd2(dba)3 (66 mg, 0.072 mmol), XantPhos (125 mg, 0.215 mmol) and Cs2CO3 (701 mg, 2.15 mmol) in anhydrous dioxane (8 mL) was degassed and purged with N2 for 3 times. Then the resulting reaction mixture was heated at 110 C for 16 h. The reaction mixture turned into yellow suspension from red. The reaction mixture was cooled to room temperature, then diluted with water (25 mL) and extracted with Et0Ac (25 mL x3). The combined organic layer was filtered and the filtrate was washed with brine (25 mL), dried over anhydrous Na2SO4 and concentrated. The residue was purified by Combi Flash (25% to 60% Et0Ac in pentane to give tert-butyl (1,5-naphthyridin-3-yl)carbamate (253 mg, yield: 72%) as a yellow solid.
11-1NMR (400 MHz, CDC13) (51.57 (9H, s), 7.03 (1H, brs), 7.53 (1H, dd, J= 8.0, 4.0 Hz), 8.33 (1H, d, J= 8.4 Hz), 8.50 (1H, s), 8.90-9.00 (2H, m).
Step 2: Preparation of 1,5-naphthyridin-3-amine [0380] To a solution of tert-butyl (1,5-naphthyridin-3-yl)carbamate (253 mg, 1.03 mmol) in Et0Ac (5 mL) was added 4 N HC1 in Et0Ac (10 mL) at 10-15 C. Then the reaction mixture was stirred at 10-15 C for 2 h. The reaction mixture turned into cloudy from clear solution.
The mixture was concentrated to give 1,5-naphthyridin-3-amine (160 mg, yield:
85% yield, HC1 salt) as a yellow solid.
11-1NMR (400 MHz, DMSO-d6) (57.44 (1H, d, J= 2.4 Hz), 7.70 (1H, dd, J= 8.4, 6.0 Hz), 8.75-8.85 (2H, m), 8.90 (1H, d, J= 4.8 Hz).
Step 3: Preparation of 1-(3-((1,5-naphthyridin-3-yl)amino)-5-methy1-5H-chromeno [4,3-c]pyridin-8-yl)pyrrolidin-2-one
132 csIN 0 I
[0381] A
mixture of 1-(3 -chloro-5 -methyl-5H-chromeno [4,3-c] py ri din-8-yl)py rroli din-2-one (80 mg, 0.25 mmol), 1,5-naphthyridin-3-amine (55 mg, 0.30 mmol, HC1 salt), Pd2(dba)3 (12 mg, 0.013 mmol), BrettPhos (14 mg, 0.025 mmol) and Cs2CO3 (248 mg, 0.762 mmol) in anhydrous dioxane (2 mL) was degassed and purged with N2 for 3 times. Then the resulting reaction mixture was stirred at 100 C for 16 h. The reaction mixture turned into yellow suspension from black. Crude LCMS (Rt = 0.733 min; MS Calcd: 423.2; MS Found:
424.1 [M+H]+). The reaction mixture was filtered and the solid was washed with Me0H
(5 mL x3).
The filtrate was concentrated and the residue was purified by prep-HPLC
(0.225% FA as an additive). Most of the MeCN was removed under reduced pressure and the remaining part was lyophilized to give 1-(3-((1,5-naphthyridin-3-y0amino)-5-methyl-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (6.6 mg, yield: 5.5%) as a red solid.
[0382] LC-MS
(Agilent LCMS 1200-6140A, mobile phase: from 99% [water + 0.1% FA]
and 1% [MeCN + 0.1% FA] to 95% [water + 0.1% FA] and 5% [MeCN + 0.1% FA] in 0.6 min, then changed to 100% [MeCN + 0.1% FA] under this condition for 3.4 min, finally back to 99% [water + 0.1% FA] and 1% [MeCN + 0.1% FA] and under this condition for 0.5 min.) purity is 100%, Rt = 2.371 min; MS Calcd.: 423.2, MS Found: 424.3 [M+Hr.
11-1 NMR (400 MHz, DMSO-d6) 5 1.58 (3H, d, J= 6.4 Hz), 2.00-2.15 (2H, m), 2.55-2.60 (2H, m), 3.80-3.95 (2H, m), 5.35 (1H, q, J= 6.4 Hz), 6.90 (1H, s), 7.36 (1H, ddJ=
8.4, 2.0 Hz), 7.44 (1H, d, J= 2.4 Hz), 7.61 (1H, dd, J= 8.4, 4.4 Hz), 7.96 (1H, d, J= 8.8 Hz), 8.38 (1H, d, J= 8.3 Hz), 8.83 (1H, s), 8.92 (1H, d, J= 2.8 Hz), 9.04 (1H, d, J= 2.8 Hz), 9.13 (1H, d, J=
2.3 Hz), 10.12 (1H, brs).
Example 65: 1-(5-methyl-3-(thiazolo[5,4-b]pyridin-6-ylamino)-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one çN 0 0 N s N
N N
[0381] A
mixture of 1-(3 -chloro-5 -methyl-5H-chromeno [4,3-c] py ri din-8-yl)py rroli din-2-one (80 mg, 0.25 mmol), 1,5-naphthyridin-3-amine (55 mg, 0.30 mmol, HC1 salt), Pd2(dba)3 (12 mg, 0.013 mmol), BrettPhos (14 mg, 0.025 mmol) and Cs2CO3 (248 mg, 0.762 mmol) in anhydrous dioxane (2 mL) was degassed and purged with N2 for 3 times. Then the resulting reaction mixture was stirred at 100 C for 16 h. The reaction mixture turned into yellow suspension from black. Crude LCMS (Rt = 0.733 min; MS Calcd: 423.2; MS Found:
424.1 [M+H]+). The reaction mixture was filtered and the solid was washed with Me0H
(5 mL x3).
The filtrate was concentrated and the residue was purified by prep-HPLC
(0.225% FA as an additive). Most of the MeCN was removed under reduced pressure and the remaining part was lyophilized to give 1-(3-((1,5-naphthyridin-3-y0amino)-5-methyl-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (6.6 mg, yield: 5.5%) as a red solid.
[0382] LC-MS
(Agilent LCMS 1200-6140A, mobile phase: from 99% [water + 0.1% FA]
and 1% [MeCN + 0.1% FA] to 95% [water + 0.1% FA] and 5% [MeCN + 0.1% FA] in 0.6 min, then changed to 100% [MeCN + 0.1% FA] under this condition for 3.4 min, finally back to 99% [water + 0.1% FA] and 1% [MeCN + 0.1% FA] and under this condition for 0.5 min.) purity is 100%, Rt = 2.371 min; MS Calcd.: 423.2, MS Found: 424.3 [M+Hr.
11-1 NMR (400 MHz, DMSO-d6) 5 1.58 (3H, d, J= 6.4 Hz), 2.00-2.15 (2H, m), 2.55-2.60 (2H, m), 3.80-3.95 (2H, m), 5.35 (1H, q, J= 6.4 Hz), 6.90 (1H, s), 7.36 (1H, ddJ=
8.4, 2.0 Hz), 7.44 (1H, d, J= 2.4 Hz), 7.61 (1H, dd, J= 8.4, 4.4 Hz), 7.96 (1H, d, J= 8.8 Hz), 8.38 (1H, d, J= 8.3 Hz), 8.83 (1H, s), 8.92 (1H, d, J= 2.8 Hz), 9.04 (1H, d, J= 2.8 Hz), 9.13 (1H, d, J=
2.3 Hz), 10.12 (1H, brs).
Example 65: 1-(5-methyl-3-(thiazolo[5,4-b]pyridin-6-ylamino)-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one çN 0 0 N s N
N N
133 [0383] A
mixture of 1-(3-amino-5-methy1-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (100 mg, 0.339 mmol), 6-bromothiazolo[5,4-blpyridine (109 mg, 0.508 mmol), Pd2(dba)3 (31 mg, 0.034 mmol), BrettPhos (36 mg, 0.068 mmol) and Cs2CO3 (221 mg, 0.677 mmol) in anhydrous dioxane (3 mL) was degassed and purged with N2 for 3 times. Then the resulting reaction mixture was heated at 100 C for 16 h under N2 atmosphere. The reaction mixture turned into yellow suspension from red. Crude LCMS (Rt = 0.750 min; MS Calcd:
429.1; MS
Found: 430.0 [M+Hl+). To the reaction mixture was added water (25 mL), then extracted with Et0Ac/THF (25 mL x3, 1/1). The combined organic layer was washed with brine (25 mL), dried over anhydrous Na2SO4 and concentrated. The residue was purified by prep-HPLC
(0.225% FA as an additive). Most of the MeCN was removed under reduced pressure and the remaining part was lyophilized to give the product, which was further triturated with MeCN (3 mL), then filtered and washed with MeCN (0.5 mL x2) and lyophilized to give 1-(5-methy1-3-(thiazolo [5,4-b] py ri din-6-ylamino)-5H-chromeno [4,3 -c] py ri din-8-yl)pyrroli din-2-one (14.2 mg, yield: 10%) as a yellow solid.
[0384] LCMS was taken on a quadrupole Mass Spectrometer on Shimadzu LCMS 2010 (Shim-pack XR-ODS 3.0*30 mm 2.2 um) operating in ES (+) ionization mode. Flow Rate: 0.8 mL/min, Acquire Time: 3 min, Wavelength: UV220, Oven Tem.: 50 C, Mobile phase: from 90% [water + 0.04% TFA] and 10% [MeCN +0.02 % TFA] to 20% [water + 0.04% TFA]
and 80% [MeCN + 0.02% TFA] in 1.35 min, then under this condition for 0.9 min, finally changed to 90% [water + 0.04% TFA] and 10% [MeCN + 0.02% TFA] and under this condition for 0.75 min. purity is 99.80%, Rt = 1.400 min; MS Calcd.: 429.1, MS Found: 430.0 [M+Hr.
11-1 NMR (400 MHz, DMSO-d6) 5 1.56 (3H, d, J= 6.4 Hz), 2.01-2.10 (2H, m), 2.52-2.54 (2H, m), 3.80-3.90 (2H, m), 5.31 (1H, q, J= 6.4 Hz), 6.79 (1H, s), 7.33 (1H, dd, J=
8.7, 2.1 Hz), 7.42 (1H, d, J = 2.0 Hz), 7.91 (1H, d, J= 8.8 Hz), 8.76 (1H, s), 8.79 (1H, d, J= 2.5 Hz), 9.14 (1H, d, J= 2.5 Hz), 9.50 (1H, s), 9.78 (1H, brs).
Example 66: N-(5-09-fluoro-5,5-dimethy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-y1)amino)-2-methoxypyridin-3-y1)acetamide gN 0 N N NH
mixture of 1-(3-amino-5-methy1-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (100 mg, 0.339 mmol), 6-bromothiazolo[5,4-blpyridine (109 mg, 0.508 mmol), Pd2(dba)3 (31 mg, 0.034 mmol), BrettPhos (36 mg, 0.068 mmol) and Cs2CO3 (221 mg, 0.677 mmol) in anhydrous dioxane (3 mL) was degassed and purged with N2 for 3 times. Then the resulting reaction mixture was heated at 100 C for 16 h under N2 atmosphere. The reaction mixture turned into yellow suspension from red. Crude LCMS (Rt = 0.750 min; MS Calcd:
429.1; MS
Found: 430.0 [M+Hl+). To the reaction mixture was added water (25 mL), then extracted with Et0Ac/THF (25 mL x3, 1/1). The combined organic layer was washed with brine (25 mL), dried over anhydrous Na2SO4 and concentrated. The residue was purified by prep-HPLC
(0.225% FA as an additive). Most of the MeCN was removed under reduced pressure and the remaining part was lyophilized to give the product, which was further triturated with MeCN (3 mL), then filtered and washed with MeCN (0.5 mL x2) and lyophilized to give 1-(5-methy1-3-(thiazolo [5,4-b] py ri din-6-ylamino)-5H-chromeno [4,3 -c] py ri din-8-yl)pyrroli din-2-one (14.2 mg, yield: 10%) as a yellow solid.
[0384] LCMS was taken on a quadrupole Mass Spectrometer on Shimadzu LCMS 2010 (Shim-pack XR-ODS 3.0*30 mm 2.2 um) operating in ES (+) ionization mode. Flow Rate: 0.8 mL/min, Acquire Time: 3 min, Wavelength: UV220, Oven Tem.: 50 C, Mobile phase: from 90% [water + 0.04% TFA] and 10% [MeCN +0.02 % TFA] to 20% [water + 0.04% TFA]
and 80% [MeCN + 0.02% TFA] in 1.35 min, then under this condition for 0.9 min, finally changed to 90% [water + 0.04% TFA] and 10% [MeCN + 0.02% TFA] and under this condition for 0.75 min. purity is 99.80%, Rt = 1.400 min; MS Calcd.: 429.1, MS Found: 430.0 [M+Hr.
11-1 NMR (400 MHz, DMSO-d6) 5 1.56 (3H, d, J= 6.4 Hz), 2.01-2.10 (2H, m), 2.52-2.54 (2H, m), 3.80-3.90 (2H, m), 5.31 (1H, q, J= 6.4 Hz), 6.79 (1H, s), 7.33 (1H, dd, J=
8.7, 2.1 Hz), 7.42 (1H, d, J = 2.0 Hz), 7.91 (1H, d, J= 8.8 Hz), 8.76 (1H, s), 8.79 (1H, d, J= 2.5 Hz), 9.14 (1H, d, J= 2.5 Hz), 9.50 (1H, s), 9.78 (1H, brs).
Example 66: N-(5-09-fluoro-5,5-dimethy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-y1)amino)-2-methoxypyridin-3-y1)acetamide gN 0 N N NH
134 [0385] A
mixture of Pd2(dba)3 (18 mg, 0.019 mmol) and Brettphos (21 mg, 0.038 mmol) in 1,4-dioxane (1 mL) was stirred at 50 C for 10 min. 1-(3-amino-9-fluoro-5,5-dimethy1-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (80 mg, 0.24 mmol), N-(5-bromo-2-methoxypyridin-3-yl)acetamide (59 mg, 0.24 mmol) in dioxane (4 mL) and Cs2CO3 (199 mg, 0.611 mmol) were added and the resulting mixture was stirred at 100 C for 15 hours. A black brown mixture was formed. LCMS showed that the purity of the desired product is 60% (Rt =
0.610 min; MS Calcd: 491.2; MS Found: 492.1 [M+Hl+). The reaction mixture was diluted with DCM (10 mL), filtered and concentrated. The residue was purified by prep-HPLC (0.05%
N}{31120 as an additive) and lyophilized to give N-(5-((9-fluoro-5,5-dimethy1-8-(2-oxopy rroli din-l-y1)-5H-chromeno [4,3 -c] py ridin-3 -yl)amino)-2-methoxy py ridin-3 -yl)acetamide (70.3 mg, yield: 59%) as a light yellow solid.
11-1NMR (400 MHz, DMSO-d6) 6 1.55 (6H, s), 2.06-2.13 (5H, m), 2.43 (2H, t, J=
7.6 Hz), 3.77 (2H, t, J= 7.2 Hz), 3.91 (3H, s), 6.73 (1H, s), 7.02 (1H, d, J= 6.8 Hz), 7.86 (1H, d, J=
12.0 Hz), 8.31 (1H, d, J= 2.4 Hz), 8.58 (1H, d, J= 2.0 Hz), 8.66 (1H, s), 9.26 (1H, brs), 9.36 (1H, brs).
Example 67: N,N,5-trimethy1-3-((1-piyaloy1-2,3-dihydro-1H-pyrido12,3-b]11,41oxazin-7-yl)amino)-5H-chromeno14,3-c]pyridine-8-carboxamide N N N
0<
Step 1: Preparation of 4-bromo-3-fluoro-N,N-dimethylbenzamide Br 103861 To a suspension of 4-bromo-3-fluorobenzoic acid (20.0 g, 91.3 mmol) in 50C12 (100 mL) was added DMF (0.5 mL) at 10-15 C. Then the reaction mixture was heated at 80 C for 2 h. The mixture turned into yellow solution from suspension. The reaction mixture was concentrated and the residue was diluted with anhydrous toluene (50 mL) and concentrated in
mixture of Pd2(dba)3 (18 mg, 0.019 mmol) and Brettphos (21 mg, 0.038 mmol) in 1,4-dioxane (1 mL) was stirred at 50 C for 10 min. 1-(3-amino-9-fluoro-5,5-dimethy1-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (80 mg, 0.24 mmol), N-(5-bromo-2-methoxypyridin-3-yl)acetamide (59 mg, 0.24 mmol) in dioxane (4 mL) and Cs2CO3 (199 mg, 0.611 mmol) were added and the resulting mixture was stirred at 100 C for 15 hours. A black brown mixture was formed. LCMS showed that the purity of the desired product is 60% (Rt =
0.610 min; MS Calcd: 491.2; MS Found: 492.1 [M+Hl+). The reaction mixture was diluted with DCM (10 mL), filtered and concentrated. The residue was purified by prep-HPLC (0.05%
N}{31120 as an additive) and lyophilized to give N-(5-((9-fluoro-5,5-dimethy1-8-(2-oxopy rroli din-l-y1)-5H-chromeno [4,3 -c] py ridin-3 -yl)amino)-2-methoxy py ridin-3 -yl)acetamide (70.3 mg, yield: 59%) as a light yellow solid.
11-1NMR (400 MHz, DMSO-d6) 6 1.55 (6H, s), 2.06-2.13 (5H, m), 2.43 (2H, t, J=
7.6 Hz), 3.77 (2H, t, J= 7.2 Hz), 3.91 (3H, s), 6.73 (1H, s), 7.02 (1H, d, J= 6.8 Hz), 7.86 (1H, d, J=
12.0 Hz), 8.31 (1H, d, J= 2.4 Hz), 8.58 (1H, d, J= 2.0 Hz), 8.66 (1H, s), 9.26 (1H, brs), 9.36 (1H, brs).
Example 67: N,N,5-trimethy1-3-((1-piyaloy1-2,3-dihydro-1H-pyrido12,3-b]11,41oxazin-7-yl)amino)-5H-chromeno14,3-c]pyridine-8-carboxamide N N N
0<
Step 1: Preparation of 4-bromo-3-fluoro-N,N-dimethylbenzamide Br 103861 To a suspension of 4-bromo-3-fluorobenzoic acid (20.0 g, 91.3 mmol) in 50C12 (100 mL) was added DMF (0.5 mL) at 10-15 C. Then the reaction mixture was heated at 80 C for 2 h. The mixture turned into yellow solution from suspension. The reaction mixture was concentrated and the residue was diluted with anhydrous toluene (50 mL) and concentrated in
135 turn for 3 times to remove most of S0C12. Then the residue was dissolved in anhydrous DCM
(50 mL) and added dropwise to a mixture of dimethylamine HC1 salt (14.9 g, 183 mmol) and Et3N (37.0 g, 365 mmol) in anhydrous DCM (150 mL) at 0 C. After the completion of the addition, the reaction mixture was stirred at 10-15 C for 2 h. A lot of precipitate was formed after stirring. To the reaction mixture was added water (100 mL), then extracted with DCM
(100 mL x3). The combined organic layer was washed with 1N aqueous HC1 (100 mL), 1N
aqueous NaOH (100 mL), brine (100 mL), dried over anhydrous Na2SO4 and concentrated to give 4-bromo-3-fluoro-N,N-dimethylbenzamide (22.3 g, yield: 99%) as a yellow solid.
11-1NMR (400 MHz, CDC13) 2.99 (3H, s), 3.10 (3H, s), 7.10 (1H, dd, J= 8.2, 1.3 Hz), 7.20 (1H, dd, J= 8.6, 1.9 Hz), 7.60 (1H, dd, J= 8.2, 6.9 Hz).
Step 2: Preparation of 3-fluoro-N,N-dimethy1-4-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-yl)benzamide N
IT
B
[0387] A
mixture of 4-bromo-3-fluoro-N,N-dimethylbenzamide (5.00 g, 20.3 mmol), B2Pin2 (7.74 g, 30.5 mmol), Pd(dppf)C12(1.49 g, 2.03 mmol) and KOAc (5.98 g, 61.0 mmol) in anhydrous dioxane (50 mL) was degassed and purged with N2 for 3 times. Then the reaction mixture was heated at 90 C for 16 h. The reaction mixture turned into black from red suspension. To the reaction mixture was added water (200 mL) and Et0Ac (200 mL), then filtered through a pad of celite. The filtrate was separated and aqueous layer was extracted with Et0Ac (100 mL x2). The combined organic layer was washed with brine (100 mL), dried over anhydrous Na2SO4 and concentrated. The residue was purified by Combi Flash (30% to 75%
Et0Ac in pentane) to give 3-fluoro-N,N-dimethy1-4-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-yl)benzamide (5.50 g, yield: 92%) as a yellow solid.
11-1NMR (400 MHz, CDC13) 61.35 (12H, s), 2.93 (3H, s), 3.08 (3H, s), 7.09 (1H, dd, J= 9.3, 1.3 Hz), 7.16 (1H, dd, J= 7.5, 1.3 Hz), 7.76 (1H, dd, J= 7.5, 6.0 Hz).
Step 3: Preparation of 1-(5-bromo-2-chloropyridin-4-ypethan-1-ol
(50 mL) and added dropwise to a mixture of dimethylamine HC1 salt (14.9 g, 183 mmol) and Et3N (37.0 g, 365 mmol) in anhydrous DCM (150 mL) at 0 C. After the completion of the addition, the reaction mixture was stirred at 10-15 C for 2 h. A lot of precipitate was formed after stirring. To the reaction mixture was added water (100 mL), then extracted with DCM
(100 mL x3). The combined organic layer was washed with 1N aqueous HC1 (100 mL), 1N
aqueous NaOH (100 mL), brine (100 mL), dried over anhydrous Na2SO4 and concentrated to give 4-bromo-3-fluoro-N,N-dimethylbenzamide (22.3 g, yield: 99%) as a yellow solid.
11-1NMR (400 MHz, CDC13) 2.99 (3H, s), 3.10 (3H, s), 7.10 (1H, dd, J= 8.2, 1.3 Hz), 7.20 (1H, dd, J= 8.6, 1.9 Hz), 7.60 (1H, dd, J= 8.2, 6.9 Hz).
Step 2: Preparation of 3-fluoro-N,N-dimethy1-4-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-yl)benzamide N
IT
B
[0387] A
mixture of 4-bromo-3-fluoro-N,N-dimethylbenzamide (5.00 g, 20.3 mmol), B2Pin2 (7.74 g, 30.5 mmol), Pd(dppf)C12(1.49 g, 2.03 mmol) and KOAc (5.98 g, 61.0 mmol) in anhydrous dioxane (50 mL) was degassed and purged with N2 for 3 times. Then the reaction mixture was heated at 90 C for 16 h. The reaction mixture turned into black from red suspension. To the reaction mixture was added water (200 mL) and Et0Ac (200 mL), then filtered through a pad of celite. The filtrate was separated and aqueous layer was extracted with Et0Ac (100 mL x2). The combined organic layer was washed with brine (100 mL), dried over anhydrous Na2SO4 and concentrated. The residue was purified by Combi Flash (30% to 75%
Et0Ac in pentane) to give 3-fluoro-N,N-dimethy1-4-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-yl)benzamide (5.50 g, yield: 92%) as a yellow solid.
11-1NMR (400 MHz, CDC13) 61.35 (12H, s), 2.93 (3H, s), 3.08 (3H, s), 7.09 (1H, dd, J= 9.3, 1.3 Hz), 7.16 (1H, dd, J= 7.5, 1.3 Hz), 7.76 (1H, dd, J= 7.5, 6.0 Hz).
Step 3: Preparation of 1-(5-bromo-2-chloropyridin-4-ypethan-1-ol
136 Br N CI
[0388] To a solution of 5-bromo-2-chloroisonicotinaldehyde (5.00 g, 22.7 mmol) in anhydrous THF (100 mL) was added MeMgBr (15.1 mL, 45.4 mmol, 3 M in Et20) dropwise at 0 C. After the completion of addition, the reaction mixture was stirred at 10-15 C for 2 h.
The reaction mixture turned into brown solution from yellow. The reaction mixture was quenched with saturated aqueous NH4C1 (200 mL) and extracted with Et0Ac (200 mL x2).
The combined organic layer was washed with brine (100 mL), dried over anhydrous Na2SO4 and concentrated to give 1-(5-bromo-2-chloropyridin-4-ypethan-1-ol (5.30 g, yield: 99%) as a yellow solid.
11-1NMR (400 MHz, CDC13) (51.47 (3H, d, J= 6.8 Hz), 2.90 (1H, d, J= 3.6 Hz), 5.05-5.15 (1H, m), 7.59 (1H, s), 8.35 (1H, s).
Step 4:
Preparation of 4-(6-chl oro-4-(1 -hy droxy ethyl)py ri din-3 -y1)-3-fluoro-N,N-dimethylbenzamide OH
I
N CI
[0389] A
mixture of 1-(5-bromo-2-chloropyridin-4-ypethan-1-ol (2.00 g, 8.46 mmol), 3-fluoro-N,N-dimethy1-4-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-yObenzamide (2.73 g, 9.30 mmol), Pd(dppf)C12 (619 mg, 0.846 mmol) and Na2CO3 (2.69 g, 25.37 mmol) in dioxane (50 mL) and H20 (10 mL) was degassed and purged with N2 for 3 times. Then the resulting reaction mixture was heated at 90 C for 16 h. The reaction mixture turned into black from red. LCMS (Rt = 0.726 min; MS Calcd: 322.1; MS Found: 322.8 [M+H1+). To the reaction mixture was added water (100 mL), then extracted with Et0Ac (100 mL x3). The combined organic layer was washed with brine (100 mL), dried over anhydrous Na2SO4 and concentrated. The residue was purified by Combi Flash (50% to 100% Et0Ac in pentane) to give 4-(6-chloro-4-(1-hydroxyethyl)pyridin-3-y1)-3-fluoro-N,N-dimethylbenzamide (1.44 g, yield: 53%) as yellow gum.
Step 5: Preparation of 3-chloro-N,N,5-trimethy1-5H-chromeno[4,3-clpyridine-8-carboxamide
[0388] To a solution of 5-bromo-2-chloroisonicotinaldehyde (5.00 g, 22.7 mmol) in anhydrous THF (100 mL) was added MeMgBr (15.1 mL, 45.4 mmol, 3 M in Et20) dropwise at 0 C. After the completion of addition, the reaction mixture was stirred at 10-15 C for 2 h.
The reaction mixture turned into brown solution from yellow. The reaction mixture was quenched with saturated aqueous NH4C1 (200 mL) and extracted with Et0Ac (200 mL x2).
The combined organic layer was washed with brine (100 mL), dried over anhydrous Na2SO4 and concentrated to give 1-(5-bromo-2-chloropyridin-4-ypethan-1-ol (5.30 g, yield: 99%) as a yellow solid.
11-1NMR (400 MHz, CDC13) (51.47 (3H, d, J= 6.8 Hz), 2.90 (1H, d, J= 3.6 Hz), 5.05-5.15 (1H, m), 7.59 (1H, s), 8.35 (1H, s).
Step 4:
Preparation of 4-(6-chl oro-4-(1 -hy droxy ethyl)py ri din-3 -y1)-3-fluoro-N,N-dimethylbenzamide OH
I
N CI
[0389] A
mixture of 1-(5-bromo-2-chloropyridin-4-ypethan-1-ol (2.00 g, 8.46 mmol), 3-fluoro-N,N-dimethy1-4-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-yObenzamide (2.73 g, 9.30 mmol), Pd(dppf)C12 (619 mg, 0.846 mmol) and Na2CO3 (2.69 g, 25.37 mmol) in dioxane (50 mL) and H20 (10 mL) was degassed and purged with N2 for 3 times. Then the resulting reaction mixture was heated at 90 C for 16 h. The reaction mixture turned into black from red. LCMS (Rt = 0.726 min; MS Calcd: 322.1; MS Found: 322.8 [M+H1+). To the reaction mixture was added water (100 mL), then extracted with Et0Ac (100 mL x3). The combined organic layer was washed with brine (100 mL), dried over anhydrous Na2SO4 and concentrated. The residue was purified by Combi Flash (50% to 100% Et0Ac in pentane) to give 4-(6-chloro-4-(1-hydroxyethyl)pyridin-3-y1)-3-fluoro-N,N-dimethylbenzamide (1.44 g, yield: 53%) as yellow gum.
Step 5: Preparation of 3-chloro-N,N,5-trimethy1-5H-chromeno[4,3-clpyridine-8-carboxamide
137 I
N CI
[0390] To a solution of 4-(6-chloro-4-(1-hydroxyethyl)pyridin-3-y1)-3-fluoro-N,N-dimethylbenzamide (1.44 g, 4.46 mmol) in anhydrous THF (60 mL) was added NaH
(357 mg, 8.92 mmol, 60% dispersion in mineral oil) at 10-15 C. Then the reaction mixture was stirred at 25 C for 3 h. The reaction mixture was turned into brown suspension from gray. Crude LCMS (Rt = 0.792 min; MS Calcd: 302.1; MS Found: 302.8 [M+Hl+). The reaction mixture was quenched with saturated aqueous NH4C1 (50 mL), then extracted with Et0Ac (100 mL
x2). The combined organic layer was washed with brine (50 mL), dried over anhydrous Na2SO4 and concentrated. The residue was purified by Combi Flash (50% to 100% Et0Ac in pentane) to give 3-chloro-N,N,5-trimethy1-5H-chromeno[4,3-clpyridine-8-carboxamide (1.00 g, yield:
74%) as a white solid.
11-1NMR (400 MHz, CDC13) (51.64 (3H, d, J= 6.8 Hz), 3.02 (3H, s), 3.12 (3H, s), 5.22 (1H, q, J= 6.8 Hz), 7.07 (1H, s), 7.10-7.15 (2H, m), 7.79 (1H, d, J= 8.0 Hz), 8.72 (1H, s).
Step 6:
Preparation of tert-butyl (8-(dimethylcarbamoy1)-5-methy1-5H-chromeno[4,3-c] py ri din-3-yl)carbamate I
N NHBoc [0391] A mixture of 3 -chl oro-N,N,5 -trimethy1-5H-chromeno [4,3 -c] py ri dine-8-carboxamide (800 mg, 2.64 mmol), BocNH2 (464 mg, 3.96 mmol), Pd2(dba)3 (121 mg, 0.132 mmol), XantPhos (153 mg, 0.264 mmol) and Cs2CO3 (1.72 g, 5.28 mmol) in anhydrous dioxane (25 mL) was degassed and purged with N2 for 3 times. Then the resulting reaction mixture was heated at 100 C for 16 h. The reaction mixture turned into yellow suspension from red. Crude LCMS (Rt = 0.817 min; MS Calcd: 383.1; MS Found: 383.9 [M+Hl+). The reaction mixture was diluted with water (50 mL) and then extracted with Et0Ac (50 mL
x3). The combined organic layer was washed with brine (50 mL), dried over anhydrous Na2SO4 and concentrated to give tert-butyl (8-(dimethylcarbamoy1)-5-methy1-5H-chromeno[4,3-clpyridin-
N CI
[0390] To a solution of 4-(6-chloro-4-(1-hydroxyethyl)pyridin-3-y1)-3-fluoro-N,N-dimethylbenzamide (1.44 g, 4.46 mmol) in anhydrous THF (60 mL) was added NaH
(357 mg, 8.92 mmol, 60% dispersion in mineral oil) at 10-15 C. Then the reaction mixture was stirred at 25 C for 3 h. The reaction mixture was turned into brown suspension from gray. Crude LCMS (Rt = 0.792 min; MS Calcd: 302.1; MS Found: 302.8 [M+Hl+). The reaction mixture was quenched with saturated aqueous NH4C1 (50 mL), then extracted with Et0Ac (100 mL
x2). The combined organic layer was washed with brine (50 mL), dried over anhydrous Na2SO4 and concentrated. The residue was purified by Combi Flash (50% to 100% Et0Ac in pentane) to give 3-chloro-N,N,5-trimethy1-5H-chromeno[4,3-clpyridine-8-carboxamide (1.00 g, yield:
74%) as a white solid.
11-1NMR (400 MHz, CDC13) (51.64 (3H, d, J= 6.8 Hz), 3.02 (3H, s), 3.12 (3H, s), 5.22 (1H, q, J= 6.8 Hz), 7.07 (1H, s), 7.10-7.15 (2H, m), 7.79 (1H, d, J= 8.0 Hz), 8.72 (1H, s).
Step 6:
Preparation of tert-butyl (8-(dimethylcarbamoy1)-5-methy1-5H-chromeno[4,3-c] py ri din-3-yl)carbamate I
N NHBoc [0391] A mixture of 3 -chl oro-N,N,5 -trimethy1-5H-chromeno [4,3 -c] py ri dine-8-carboxamide (800 mg, 2.64 mmol), BocNH2 (464 mg, 3.96 mmol), Pd2(dba)3 (121 mg, 0.132 mmol), XantPhos (153 mg, 0.264 mmol) and Cs2CO3 (1.72 g, 5.28 mmol) in anhydrous dioxane (25 mL) was degassed and purged with N2 for 3 times. Then the resulting reaction mixture was heated at 100 C for 16 h. The reaction mixture turned into yellow suspension from red. Crude LCMS (Rt = 0.817 min; MS Calcd: 383.1; MS Found: 383.9 [M+Hl+). The reaction mixture was diluted with water (50 mL) and then extracted with Et0Ac (50 mL
x3). The combined organic layer was washed with brine (50 mL), dried over anhydrous Na2SO4 and concentrated to give tert-butyl (8-(dimethylcarbamoy1)-5-methy1-5H-chromeno[4,3-clpyridin-
138 3-yl)carbamate (1.14 g, crude) as brown gum, which was directly used for the next step without further purification.
Step 7: Preparation of 3-amino-N,N,5-trimethy1-5H-chromeno [4,3-c] pyri dine-8-carboxamide [0392] To a solution of tert-butyl (8-(dimethylcarbamoy1)-5-methy1-5H-chromeno[4,3-clpyridin-3-yOcarbamate (1.14 g, crude) in anhydrous DCM (10 mL) was added TFA
(10 mL) at 10-15 C. Then the reaction mixture was stirred at 10-15 C for 2 h. The reaction mixture turned into yellow solution from brown. Crude LCMS (Rt = 0.627 min; MS Calcd:
283.1; MS
Found: 283.9 [M+Hl+). The reaction mixture was concentrated and the residue was basified with 1N aqueous NaOH to pH = 10, then extracted with DCM (50 mL x3). The combined organic layer was washed with brine (25 mL), dried over anhydrous Na2SO4 and concentrated. The residue was purified by Combi Flash (0 to 10% Me0H in Et0Ac) to give 3-amino-N,N,5-trimethy1-5H-chromeno[4,3-clpyridine-8-carboxamide (550 mg, yield:
65% for 2 steps) as a yellow solid.
11-1NMR (400 MHz, CDC13) (51.56 (3H, d, J= 6.8 Hz), 3.02 (3H, s), 3.10 (3H, s), 4.66 (2H, brs), 5.10 (1H, q, J= 6.8 Hz), 6.29 (1H, s), 7.01 (1H, s), 7.07 (1H, dd, J=
8.0, 1.6 Hz), 7.68 (1H, d, J= 8.0 Hz), 8.44 (1H, s).
Step 8: Preparation of N,N,5 -tri methy1-3-((1 -pival oy1-2,3-dihy dro-1H-py ri do [2,3-b] [1,4] oxazin-7-yl)amino)-5H-chromeno [4,3 -c] py ri dine-8-carb oxami de N N N
[0393] A mixture of 3-amino-N,N,5-trimethy1-5H-chromeno [4,3 -c] py ri dine-8-carboxamide (80 mg, 0.28 mmol), 1-(7-bromo-2,3-dihydro-1H-pyrido[2,3-b]
[1,4loxazin-1-y1)-2,2-dimethylpropan-1-one (127 mg, 0.424 mmol), Pd2(dba)3 (26 mg, 0.028 mmol), BrettPhos (30 mg, 0.056 mmol) and Cs2CO3 (184 mg, 0.565 mol) in anhydrous dioxane (3
Step 7: Preparation of 3-amino-N,N,5-trimethy1-5H-chromeno [4,3-c] pyri dine-8-carboxamide [0392] To a solution of tert-butyl (8-(dimethylcarbamoy1)-5-methy1-5H-chromeno[4,3-clpyridin-3-yOcarbamate (1.14 g, crude) in anhydrous DCM (10 mL) was added TFA
(10 mL) at 10-15 C. Then the reaction mixture was stirred at 10-15 C for 2 h. The reaction mixture turned into yellow solution from brown. Crude LCMS (Rt = 0.627 min; MS Calcd:
283.1; MS
Found: 283.9 [M+Hl+). The reaction mixture was concentrated and the residue was basified with 1N aqueous NaOH to pH = 10, then extracted with DCM (50 mL x3). The combined organic layer was washed with brine (25 mL), dried over anhydrous Na2SO4 and concentrated. The residue was purified by Combi Flash (0 to 10% Me0H in Et0Ac) to give 3-amino-N,N,5-trimethy1-5H-chromeno[4,3-clpyridine-8-carboxamide (550 mg, yield:
65% for 2 steps) as a yellow solid.
11-1NMR (400 MHz, CDC13) (51.56 (3H, d, J= 6.8 Hz), 3.02 (3H, s), 3.10 (3H, s), 4.66 (2H, brs), 5.10 (1H, q, J= 6.8 Hz), 6.29 (1H, s), 7.01 (1H, s), 7.07 (1H, dd, J=
8.0, 1.6 Hz), 7.68 (1H, d, J= 8.0 Hz), 8.44 (1H, s).
Step 8: Preparation of N,N,5 -tri methy1-3-((1 -pival oy1-2,3-dihy dro-1H-py ri do [2,3-b] [1,4] oxazin-7-yl)amino)-5H-chromeno [4,3 -c] py ri dine-8-carb oxami de N N N
[0393] A mixture of 3-amino-N,N,5-trimethy1-5H-chromeno [4,3 -c] py ri dine-8-carboxamide (80 mg, 0.28 mmol), 1-(7-bromo-2,3-dihydro-1H-pyrido[2,3-b]
[1,4loxazin-1-y1)-2,2-dimethylpropan-1-one (127 mg, 0.424 mmol), Pd2(dba)3 (26 mg, 0.028 mmol), BrettPhos (30 mg, 0.056 mmol) and Cs2CO3 (184 mg, 0.565 mol) in anhydrous dioxane (3
139 mL) was degassed and purged with N2 for 3 times. Then the resulting reaction mixture was heated at 100 C for 16 hr under N2 atmosphere. The reaction mixture turned into yellow suspension from red. Crude LCMS (Rt = 0.734 min; MS Calcd: 501.2; MS Found:
502.1 [M+Hl+). The reaction mixture was diluted with DCM (20 mL) then filtered through a pad of celite. The filtrate was concentrated and the residue purified by prep-HPLC
(0.05% NH3.H20 as an additive). Most of MeCN was removed under reduced pressure and the remaining part was lyophilized to give N,N,5 -trimethy1-3-((1 -pival oy1-2,3-dihy dro-1H-py ri do [2,3-b] [1,4]oxazin-7-y0amino)-5H-chromeno[4,3-clpyridine-8-carboxamide (46.4 mg, yield: 33%) as a yellow solid.
[0394] LCMS was taken on a quadrupole Mass Spectrometer on Shimadzu LCMS 2010 (Shim-pack XR-ODS 3.0*30 mm 2.2 pin) operating in ES (+) ionization mode. Flow Rate: 0.8 mL/min, Acquire Time: 3 min, Wavelength: UV220, Oven Tem.: 50 C, Mobile phase: from 90% [water + 0.04% TFA] and 10% [MeCN +0.02 % TFA] to 20% [water + 0.04% TFA]
and 80% [MeCN + 0.02% TFA] in 1.35 min, then under this condition for 0.9 min, finally changed to 90% [water + 0.04% TFA] and 10% [MeCN + 0.02% TFA] and under this condition for 0.75 min. the purity is 95.98%, Rt = 1.340 min; MS Calcd.: 501.2, MS Found:
502.1 [M+H1+.
11-1NMR (400 MHz, DMSO-d6) 5 1.33 (9H, s), 1.54 (3H, d, J= 6.4 Hz), 3.37 (6H, s), 3.95-4.05 (2H, m), 4.30-4.40 (2H, m), 5.27 (1H, q, J= 6.4 Hz), 6.67 (1H, s), 6.95 (1H, s), 7.06 (1H, d, J= 7.6 Hz), 7.92 (1H, dd, J= 8.0, 1.2 Hz), 8.30 (1H, d, J= 2.4 Hz), 8.37 (1H, s), 8.67 (1H, s), 9.27 (1H, brs).
Example 68: 3-01-(cyclopropanecarbony1)-2,3-dihydro-1H-pyrido12,3-b]11,41oxazin-7-yl)amino)-N,N,5-trimethyl-5H-chromeno14,3-c]pyridine-8-carboxamide I
N N N
[0395] A mixture of 3-amino-N,N,5 -trimethy1-5H-chromeno [4,3 -c] py ri dine-8-carboxamide (80 mg, 0.28 mmol), (7-bromo-2,3-dihydro-1H-pyrido[2,3-b][1,41oxazin-1-y1)(cyclopropyl)methanone (120 mg, 0.424 mmol), Pd2(dba)3 (26 mg, 0.028 mmol), BrettPhos (30 mg, 0.056 mmol) and Cs2CO3 (184 mg, 0.565 mol) in anhydrous dioxane (3 mL) was
502.1 [M+Hl+). The reaction mixture was diluted with DCM (20 mL) then filtered through a pad of celite. The filtrate was concentrated and the residue purified by prep-HPLC
(0.05% NH3.H20 as an additive). Most of MeCN was removed under reduced pressure and the remaining part was lyophilized to give N,N,5 -trimethy1-3-((1 -pival oy1-2,3-dihy dro-1H-py ri do [2,3-b] [1,4]oxazin-7-y0amino)-5H-chromeno[4,3-clpyridine-8-carboxamide (46.4 mg, yield: 33%) as a yellow solid.
[0394] LCMS was taken on a quadrupole Mass Spectrometer on Shimadzu LCMS 2010 (Shim-pack XR-ODS 3.0*30 mm 2.2 pin) operating in ES (+) ionization mode. Flow Rate: 0.8 mL/min, Acquire Time: 3 min, Wavelength: UV220, Oven Tem.: 50 C, Mobile phase: from 90% [water + 0.04% TFA] and 10% [MeCN +0.02 % TFA] to 20% [water + 0.04% TFA]
and 80% [MeCN + 0.02% TFA] in 1.35 min, then under this condition for 0.9 min, finally changed to 90% [water + 0.04% TFA] and 10% [MeCN + 0.02% TFA] and under this condition for 0.75 min. the purity is 95.98%, Rt = 1.340 min; MS Calcd.: 501.2, MS Found:
502.1 [M+H1+.
11-1NMR (400 MHz, DMSO-d6) 5 1.33 (9H, s), 1.54 (3H, d, J= 6.4 Hz), 3.37 (6H, s), 3.95-4.05 (2H, m), 4.30-4.40 (2H, m), 5.27 (1H, q, J= 6.4 Hz), 6.67 (1H, s), 6.95 (1H, s), 7.06 (1H, d, J= 7.6 Hz), 7.92 (1H, dd, J= 8.0, 1.2 Hz), 8.30 (1H, d, J= 2.4 Hz), 8.37 (1H, s), 8.67 (1H, s), 9.27 (1H, brs).
Example 68: 3-01-(cyclopropanecarbony1)-2,3-dihydro-1H-pyrido12,3-b]11,41oxazin-7-yl)amino)-N,N,5-trimethyl-5H-chromeno14,3-c]pyridine-8-carboxamide I
N N N
[0395] A mixture of 3-amino-N,N,5 -trimethy1-5H-chromeno [4,3 -c] py ri dine-8-carboxamide (80 mg, 0.28 mmol), (7-bromo-2,3-dihydro-1H-pyrido[2,3-b][1,41oxazin-1-y1)(cyclopropyl)methanone (120 mg, 0.424 mmol), Pd2(dba)3 (26 mg, 0.028 mmol), BrettPhos (30 mg, 0.056 mmol) and Cs2CO3 (184 mg, 0.565 mol) in anhydrous dioxane (3 mL) was
140 degassed and purged with N2 for 3 times. Then the resulting reaction mixture was heated at 100 C for 16 hr under N2 atmosphere. The reaction mixture turned into yellow suspension from red. Crude LCMS (Rt = 0.712 min; MS Calcd: 485.2; MS Found:
486.1 [M+Hl+). The reaction mixture was diluted with DCM (20 mL) then filtered through a pad of celite. The filtrate was concentrated and the residue purified by prep-HPLC
(0.05% NH3.H20 as an additive). The desired fraction was concentrated and the residue was triturated with MeCN (3 mL), then washed with MeCN (0.5 mL x2) and then lyophilized to give 3-(cy cloprop anecarb ony1)-2,3 -dihy dro-1H-py ri do [2,3 -b] [1,4] oxazin-7-y0amino)-N,N,5-trimethyl-5H-chromeno[4,3-clpyridine-8-carboxamide (22.9 mg, yield: 17%) as a white solid.
[0396] LCMS was taken on a quadrupole Mass Spectrometer on Shimadzu LCMS 2010 (Shim-pack XR-ODS 3.0*30 mm 2.2 pin) operating in ES (+) ionization mode. Flow Rate: 0.8 mL/min, Acquire Time: 3 min, Wavelength: UV220, Oven Tem.: 50 C, Mobile phase: from 90% [water + 0.04% TFA] and 10% [MeCN +0.02 % TFA] to 20% [water + 0.04% TFA]
and 80% [MeCN + 0.02% TFA] in 1.35 min, then under this condition for 0.9 min, finally changed to 90% [water + 0.04% TFA] and 10% [MeCN + 0.02% TFA] and under this condition for 0.75 min. purity is 99.74%, Rt = 1.254 min; MS Calcd.: 430.2, MS Found: 431.0 [M+H1+.
11-1NMR (400 MHz, DMSO-d6) 5 0.90-1.00 (4H, m), 1.53 (3H, d, J= 6.4 Hz), 2.15-2.30 (1H, m), 2.96 (6H, s), 3.95-4.00 (2H, m), 4.35-4.40 (2H, m), 5.29 (1H, q, J= 6.4 Hz), 6.67 (1H, s), 6.95 (1H, d, J= 1.6 Hz), 7.06 (1H, dd, J= 8.0, 1.6 Hz), 7.94 (1H, d, J= 8.0 Hz), 8.20 (1H, s), 8.60-8.65 (2H, m), 9.37 (1H, brs).
Example 69: methyl 7-08-(dimethylcarbamoy1)-5-methyl-5H-chromeno[4,3-c]pyridin-yl)amino)-2,3-dihydro-1H-pyrido [2,3-b] [1,4] oxazine-1-carboxylate NN
[0397] A mixture of 3-amino-N,N,5 -trimethy1-5H-chromeno [4,3 -c] py ri dine-8-carboxamide (80 mg, 0.28 mmol), methyl 7-bromo-2,3-dihydro-1H-pyrido[2,3-b][1,41oxazine-1-carboxylate(116 mg, 0.424 mmol), Pd2(dba)3 (26 mg, 0.028 mmol), BrettPhos (30 mg, 0.056 mmol) and Cs2CO3 (184 mg, 0.565 mol) in anhydrous dioxane (3 mL) was degassed and purged with N2 for 3 times. Then the resulting reaction mixture was
486.1 [M+Hl+). The reaction mixture was diluted with DCM (20 mL) then filtered through a pad of celite. The filtrate was concentrated and the residue purified by prep-HPLC
(0.05% NH3.H20 as an additive). The desired fraction was concentrated and the residue was triturated with MeCN (3 mL), then washed with MeCN (0.5 mL x2) and then lyophilized to give 3-(cy cloprop anecarb ony1)-2,3 -dihy dro-1H-py ri do [2,3 -b] [1,4] oxazin-7-y0amino)-N,N,5-trimethyl-5H-chromeno[4,3-clpyridine-8-carboxamide (22.9 mg, yield: 17%) as a white solid.
[0396] LCMS was taken on a quadrupole Mass Spectrometer on Shimadzu LCMS 2010 (Shim-pack XR-ODS 3.0*30 mm 2.2 pin) operating in ES (+) ionization mode. Flow Rate: 0.8 mL/min, Acquire Time: 3 min, Wavelength: UV220, Oven Tem.: 50 C, Mobile phase: from 90% [water + 0.04% TFA] and 10% [MeCN +0.02 % TFA] to 20% [water + 0.04% TFA]
and 80% [MeCN + 0.02% TFA] in 1.35 min, then under this condition for 0.9 min, finally changed to 90% [water + 0.04% TFA] and 10% [MeCN + 0.02% TFA] and under this condition for 0.75 min. purity is 99.74%, Rt = 1.254 min; MS Calcd.: 430.2, MS Found: 431.0 [M+H1+.
11-1NMR (400 MHz, DMSO-d6) 5 0.90-1.00 (4H, m), 1.53 (3H, d, J= 6.4 Hz), 2.15-2.30 (1H, m), 2.96 (6H, s), 3.95-4.00 (2H, m), 4.35-4.40 (2H, m), 5.29 (1H, q, J= 6.4 Hz), 6.67 (1H, s), 6.95 (1H, d, J= 1.6 Hz), 7.06 (1H, dd, J= 8.0, 1.6 Hz), 7.94 (1H, d, J= 8.0 Hz), 8.20 (1H, s), 8.60-8.65 (2H, m), 9.37 (1H, brs).
Example 69: methyl 7-08-(dimethylcarbamoy1)-5-methyl-5H-chromeno[4,3-c]pyridin-yl)amino)-2,3-dihydro-1H-pyrido [2,3-b] [1,4] oxazine-1-carboxylate NN
[0397] A mixture of 3-amino-N,N,5 -trimethy1-5H-chromeno [4,3 -c] py ri dine-8-carboxamide (80 mg, 0.28 mmol), methyl 7-bromo-2,3-dihydro-1H-pyrido[2,3-b][1,41oxazine-1-carboxylate(116 mg, 0.424 mmol), Pd2(dba)3 (26 mg, 0.028 mmol), BrettPhos (30 mg, 0.056 mmol) and Cs2CO3 (184 mg, 0.565 mol) in anhydrous dioxane (3 mL) was degassed and purged with N2 for 3 times. Then the resulting reaction mixture was
141 heated at 100 C for 16 h under N2 atmosphere. The reaction mixture turned into yellow suspension from red. Crude LCMS (Rt = 0.777 min; MS Calcd: 475.2; MS Found:
476.0 [M+Hl+). The reaction mixture was diluted with dioxane (5 mL) then filtered through a pad of celite and the solid was washed with dioxane (10 mL x3). The filtrate was concentrated and the residue purified by prep-HPLC (0.05% NH3.H20 as an additive). Most of MeCN
was removed under reduced pressure and the remaining part was lyophilized to give methyl 7-((8-(dimethylcarb amoy1)-5 -methyl-5H-chromeno [4,3-c] py ri din-3 -y0amino)-2,3 -dihy dro-1H-pyrido[2,3-b][1,4]oxazine-1-carboxylate (30.2 mg, yield: 22%) as a yellow solid.
[0398] LC-MS
(Agilent LCMS 1200-6140A, mobile phase: from 99% [water + 0.1% FA]
and 1% [MeCN + 0.1% FA] to 95% [water + 0.1% FA] and 5% [MeCN + 0.1% FA] in 0.6 min, then changed to 100% [MeCN + 0.1% FA] under this condition for 3.4 min, finally back to 99% [water + 0.1% FA] and 1% [MeCN + 0.1% FA] and under this condition for 0.5 min.) purity is 96.46%, Rt = 2.490 min; MS Calcd.: 475.2, MS Found: 476.3 [M+Hr.
11-1NMR (400 MHz, DMSO-d6) (51.54 (3H, d, J= 6.8 Hz), 2.96 (6H, s), 3.79 (3H, s), 3.85-3.90 (2H, m), 4.30-4.35 (2H, m), 5.31 (1H, q, J = 6.4 Hz), 6.68 (1H, s), 6.95 (1H, d, J= 1.6 Hz), 7.06 (1H, dd, J= 8.0, 1.2 Hz), 7.93 (1H, d, J = 8.0 Hz), 8.28 (1H, d, J =
2.8 Hz), 8.65-8.70 (2H, m), 9.33 (1H, brs).
Example 70: 3-((1-acetyl-2,3-dihydro-1H-pyrido[2,3-b][1,4]0xazin-7-yl)amino)-N,N,5-trimethyl-5H-chromeno[4,3-c]pyridine-8-carboxamide N -N
o\
Step 1: Preparation of 1 -(7-bromo-2,3 -dihy dro-1H-py ri do [2,3-b] [1,4]
oxazin-l-y 1)ethan-1 -one Br) No
476.0 [M+Hl+). The reaction mixture was diluted with dioxane (5 mL) then filtered through a pad of celite and the solid was washed with dioxane (10 mL x3). The filtrate was concentrated and the residue purified by prep-HPLC (0.05% NH3.H20 as an additive). Most of MeCN
was removed under reduced pressure and the remaining part was lyophilized to give methyl 7-((8-(dimethylcarb amoy1)-5 -methyl-5H-chromeno [4,3-c] py ri din-3 -y0amino)-2,3 -dihy dro-1H-pyrido[2,3-b][1,4]oxazine-1-carboxylate (30.2 mg, yield: 22%) as a yellow solid.
[0398] LC-MS
(Agilent LCMS 1200-6140A, mobile phase: from 99% [water + 0.1% FA]
and 1% [MeCN + 0.1% FA] to 95% [water + 0.1% FA] and 5% [MeCN + 0.1% FA] in 0.6 min, then changed to 100% [MeCN + 0.1% FA] under this condition for 3.4 min, finally back to 99% [water + 0.1% FA] and 1% [MeCN + 0.1% FA] and under this condition for 0.5 min.) purity is 96.46%, Rt = 2.490 min; MS Calcd.: 475.2, MS Found: 476.3 [M+Hr.
11-1NMR (400 MHz, DMSO-d6) (51.54 (3H, d, J= 6.8 Hz), 2.96 (6H, s), 3.79 (3H, s), 3.85-3.90 (2H, m), 4.30-4.35 (2H, m), 5.31 (1H, q, J = 6.4 Hz), 6.68 (1H, s), 6.95 (1H, d, J= 1.6 Hz), 7.06 (1H, dd, J= 8.0, 1.2 Hz), 7.93 (1H, d, J = 8.0 Hz), 8.28 (1H, d, J =
2.8 Hz), 8.65-8.70 (2H, m), 9.33 (1H, brs).
Example 70: 3-((1-acetyl-2,3-dihydro-1H-pyrido[2,3-b][1,4]0xazin-7-yl)amino)-N,N,5-trimethyl-5H-chromeno[4,3-c]pyridine-8-carboxamide N -N
o\
Step 1: Preparation of 1 -(7-bromo-2,3 -dihy dro-1H-py ri do [2,3-b] [1,4]
oxazin-l-y 1)ethan-1 -one Br) No
142 [0399] To a solution of 7-bromo-2,3-dihydro-1H-pyrido[2,3-b][1,41oxazine (260 mg, 1.21 mmol) and DMAP (30 mg, 0.24 mmol) in anhydrous pyridine (5 mL) was added acetyl chloride (380 mg, 4.84 mmol) dropwise at 10-15 C. Then the reaction mixture was stirred at 10-15 C for 2 h. The reaction mixture turned into brown solution from yellow.
Crude LCMS (Rt = 0.683 min; MS Calcd: 256.0; MS Found: 256.9 [M+Hl+). To the reaction mixture was added water (50 mL), then extracted with DCM (50 mL x2). The combined organic layer was washed with brine (50 mL), dried over anhydrous Na2SO4 and concentrated.
The residue was purified by Combi Flash (5% to 10% DCM in Et0Ac, 1% TEA as additive) to give 1-(7-bromo-2,3-dihy dro-1H-pyri do [2,3 -b] [1,4] oxazin-1 -yl)ethan-1 -one (240 mg, yield: 77%) as yellow gum.
11-1NMR (400 MHz, CDC13) 62.35 (3H, s), 3.90-4.00 (2H, m), 4.45-4.50 (2H, m), 8.11 (1H, s), 8.69 (1H, s).
Step 2: Preparation of 3-((1-acety1-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)amino)-N,N,5-trimethy1-5H-chromeno [4,3 -c] pyri dine-8-carb oxami de N N N
[0400] A mixture of 3-amino-N,N,5 -trimethy1-5H-chromeno [4,3 -c] py ri dine-8-carboxamide (80 mg, 0.28 mmol), 1-(7-bromo-2,3-dihydro-1H-pyrido[2,3-b][1,41oxazin-1-yl)ethan-1-one (109 mg, 0.424 mmol), Pd2(dba)3 (26 mg, 0.028 mmol), BrettPhos (30 mg, 0.056 mmol) and Cs2CO3(184 mg, 0.565 mol) in anhydrous dioxane (3 mL) was degassed and purged with N2 for 3 times. Then the resulting reaction mixture was heated at 100 C for 16 h under N2 atmosphere. The reaction mixture turned into yellow suspension from red. Crude LCMS (Rt = 0.679 min; MS Calcd: 459.2; MS Found: 460.1 [M+Hl+). The reaction mixture was diluted with DCM (20 mL) then filtered through a pad of celite. The filtrate was concentrated and the residue purified by prep-HPLC (0.05% NH3.H20 as an additive). Most of MeCN was removed under reduced pressure and the remaining part was lyophilized to give 3-((1-acetyl-2,3 -dihy dro-1H-pyri do [2,3 -b] [1,4] oxazin-7-y0amino)-N,N,5-trimethyl-5H-chromeno[4,3-clpyridine-8-carboxamide (51.8 mg, yield: 40%) as a yellow solid.
Crude LCMS (Rt = 0.683 min; MS Calcd: 256.0; MS Found: 256.9 [M+Hl+). To the reaction mixture was added water (50 mL), then extracted with DCM (50 mL x2). The combined organic layer was washed with brine (50 mL), dried over anhydrous Na2SO4 and concentrated.
The residue was purified by Combi Flash (5% to 10% DCM in Et0Ac, 1% TEA as additive) to give 1-(7-bromo-2,3-dihy dro-1H-pyri do [2,3 -b] [1,4] oxazin-1 -yl)ethan-1 -one (240 mg, yield: 77%) as yellow gum.
11-1NMR (400 MHz, CDC13) 62.35 (3H, s), 3.90-4.00 (2H, m), 4.45-4.50 (2H, m), 8.11 (1H, s), 8.69 (1H, s).
Step 2: Preparation of 3-((1-acety1-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)amino)-N,N,5-trimethy1-5H-chromeno [4,3 -c] pyri dine-8-carb oxami de N N N
[0400] A mixture of 3-amino-N,N,5 -trimethy1-5H-chromeno [4,3 -c] py ri dine-8-carboxamide (80 mg, 0.28 mmol), 1-(7-bromo-2,3-dihydro-1H-pyrido[2,3-b][1,41oxazin-1-yl)ethan-1-one (109 mg, 0.424 mmol), Pd2(dba)3 (26 mg, 0.028 mmol), BrettPhos (30 mg, 0.056 mmol) and Cs2CO3(184 mg, 0.565 mol) in anhydrous dioxane (3 mL) was degassed and purged with N2 for 3 times. Then the resulting reaction mixture was heated at 100 C for 16 h under N2 atmosphere. The reaction mixture turned into yellow suspension from red. Crude LCMS (Rt = 0.679 min; MS Calcd: 459.2; MS Found: 460.1 [M+Hl+). The reaction mixture was diluted with DCM (20 mL) then filtered through a pad of celite. The filtrate was concentrated and the residue purified by prep-HPLC (0.05% NH3.H20 as an additive). Most of MeCN was removed under reduced pressure and the remaining part was lyophilized to give 3-((1-acetyl-2,3 -dihy dro-1H-pyri do [2,3 -b] [1,4] oxazin-7-y0amino)-N,N,5-trimethyl-5H-chromeno[4,3-clpyridine-8-carboxamide (51.8 mg, yield: 40%) as a yellow solid.
143 [0401] LC-MS
(Agilent LCMS 1200-6140A, mobile phase: from 99% [water + 0.1% FA]
and 1% [MeCN + 0.1% FA] to 95% [water + 0.1% FA] and 5% [MeCN + 0.1% FA] in 0.6 min, then changed to 100% [MeCN + 0.1% FA] under this condition for 3.4 min, finally back to 99% [water + 0.1% FA] and 1% [MeCN + 0.1% FA] and under this condition for 0.5 min.) purity is 98.12%, Rt = 2.167 min; MS Calcd.: 459.2, MS Found: 460.4 [M+Hr 11-1 NMR (400 MHz, DMSO-d6) 1.53 (3H, d, J= 6.8 Hz), 2.28 (3H, s), 2.96 (6H, s), 3.85-3.90 (2H, m), 4.30-4.40 (2H, m), 5.31 (1H, q, J= 6.8 Hz), 6.67 (1H, s), 6.95 (1H, s), 7.06 (1H, dd, J= 8.0, 1.6 Hz), 7.92 (1H, d, J= 8.0 Hz), 8.29 (1H, s), 8.67 (1H, s), 8.80 (1H, s), 9.32 (1H, brs).
Example 71: N,N,5-trimethy1-3-01-(methylsulfony1)-2,3-dihydro-1H-pyrido[2,3-b][1,4]0xazin-7-y1)amino)-5H-chromeno[4,3-c]pyridine-8-carboxamide I
NN
0==0 [0402] A mixture of 3-amino-N,N,5 -trimethy1-5H-chromeno [4,3 -c] py ri dine-8-carboxamide (80 mg, 0.28 mmol), 7-bromo-1-(methylsulfony1)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazine (124 mg, 0.424 mmol), Pd2(dba)3 (26 mg, 0.028 mmol), BrettPhos (30 mg, 0.056 mmol) and Cs2CO3(184 mg, 0.565 mol) in anhydrous dioxane (3 mL) was degassed and purged with N2 for 3 times. Then the resulting reaction mixture was heated at 100 C for 16 h under N2 atmosphere. The reaction mixture turned into yellow suspension from red. Crude LCMS (Rt = 0.713 min; MS Calcd: 495.2; MS Found: 496.1 [M+H]+). To the reaction mixture was added water (25 mL), then extracted with Et0Ac (25 mL x2). The combined organic layer was washed with brine (25 mL), dried over anhydrous Na2SO4 and concentrated.
The residue was purified by prep-HPLC (0.225% formic acid as an additive). Most of MeCN
was removed under reduced pressure and the remaining part was lyophilized to give N,N,5-trimethy1-3-41-(methylsulfony 0-2,3-dihy dro-1H-py ri do [2,3 -b] [1,4] oxazin-7-yl)amino)-5H-chromeno [4,3-c]pyridine-8-carboxamide (24.1 mg, yield: 17%) as a white solid.
[0403] LCMS was taken on a quadrupole Mass Spectrometer on Shimadzu LCMS 2010 (Shim-pack XR-ODS 3.0*30 mm 2.2 um) operating in ES (+) ionization mode. Flow Rate: 0.8
(Agilent LCMS 1200-6140A, mobile phase: from 99% [water + 0.1% FA]
and 1% [MeCN + 0.1% FA] to 95% [water + 0.1% FA] and 5% [MeCN + 0.1% FA] in 0.6 min, then changed to 100% [MeCN + 0.1% FA] under this condition for 3.4 min, finally back to 99% [water + 0.1% FA] and 1% [MeCN + 0.1% FA] and under this condition for 0.5 min.) purity is 98.12%, Rt = 2.167 min; MS Calcd.: 459.2, MS Found: 460.4 [M+Hr 11-1 NMR (400 MHz, DMSO-d6) 1.53 (3H, d, J= 6.8 Hz), 2.28 (3H, s), 2.96 (6H, s), 3.85-3.90 (2H, m), 4.30-4.40 (2H, m), 5.31 (1H, q, J= 6.8 Hz), 6.67 (1H, s), 6.95 (1H, s), 7.06 (1H, dd, J= 8.0, 1.6 Hz), 7.92 (1H, d, J= 8.0 Hz), 8.29 (1H, s), 8.67 (1H, s), 8.80 (1H, s), 9.32 (1H, brs).
Example 71: N,N,5-trimethy1-3-01-(methylsulfony1)-2,3-dihydro-1H-pyrido[2,3-b][1,4]0xazin-7-y1)amino)-5H-chromeno[4,3-c]pyridine-8-carboxamide I
NN
0==0 [0402] A mixture of 3-amino-N,N,5 -trimethy1-5H-chromeno [4,3 -c] py ri dine-8-carboxamide (80 mg, 0.28 mmol), 7-bromo-1-(methylsulfony1)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazine (124 mg, 0.424 mmol), Pd2(dba)3 (26 mg, 0.028 mmol), BrettPhos (30 mg, 0.056 mmol) and Cs2CO3(184 mg, 0.565 mol) in anhydrous dioxane (3 mL) was degassed and purged with N2 for 3 times. Then the resulting reaction mixture was heated at 100 C for 16 h under N2 atmosphere. The reaction mixture turned into yellow suspension from red. Crude LCMS (Rt = 0.713 min; MS Calcd: 495.2; MS Found: 496.1 [M+H]+). To the reaction mixture was added water (25 mL), then extracted with Et0Ac (25 mL x2). The combined organic layer was washed with brine (25 mL), dried over anhydrous Na2SO4 and concentrated.
The residue was purified by prep-HPLC (0.225% formic acid as an additive). Most of MeCN
was removed under reduced pressure and the remaining part was lyophilized to give N,N,5-trimethy1-3-41-(methylsulfony 0-2,3-dihy dro-1H-py ri do [2,3 -b] [1,4] oxazin-7-yl)amino)-5H-chromeno [4,3-c]pyridine-8-carboxamide (24.1 mg, yield: 17%) as a white solid.
[0403] LCMS was taken on a quadrupole Mass Spectrometer on Shimadzu LCMS 2010 (Shim-pack XR-ODS 3.0*30 mm 2.2 um) operating in ES (+) ionization mode. Flow Rate: 0.8
144 mL/min, Acquire Time: 3 min, Wavelength: UV220, Oven Tem.: 50 C, Mobile phase: from 90% [water + 0.04% TFA] and 10% [MeCN +0.02 % TFA] to 20% [water + 0.04% TFA]
and 80% [MeCN + 0.02% TFA] in 1.35 min, then under this condition for 0.9 min, finally changed to 90% [water + 0.04% TFA] and 10% [MeCN + 0.02% TFA] and under this condition for 0.75 min. the purity is 95.71%, Rt = 1.245 min; MS Calcd.: 495.2, MS Found:
496.0 [M+Hr 11-1 NMR (400 MHz, DMSO-d6) (51.54 (3H, d, J= 6.4 Hz), 2.96 (6H, s), 3.22 (3H, s), 3.80-3.85 (2H, m), 4.35-4.40 (2H, m), 5.29 (1H, q, J = 6.4 Hz), 6.68 (1H, s), 6.96 (1H, d, J= 1.6 Hz), 7.06 (1H, dd, J= 8.0, 1.6 Hz), 7.93 (1H, d, J= 8.0 Hz), 8.30-8.40 (2H, m), 8.68 (1H, s), 9.40 (1H, brs).
Example 72: 3-01-(cyclopropylsulfony1)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-yl)amino)-N,N,5-trimethyl-5H-chromeno[4,3-c]pyridine-8-carboxamide N N N
0==0 [0404] A mixture of 3 -chl oro-N,N,5 -trimethy1-5H-chromeno [4,3 -c] py ri dine-8-carboxamide (80 mg, 0.26 mmol), 1-(cyclopropylsulfony1)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-amine (116 mg, 0.396 mmol, HC1 salt), Pd2(dba)3 (12 mg, 0.013 mmol), BrettPhos (14 mg, 0.026 mmol) and Cs2CO3 (258 mg, 0.793 mmol) in anhydrous dioxane (3 mL) was degassed and purged with N2 for 3 times. The resulting reaction mixture was heated at 100 C for 16 hour under N2 atmosphere. The reaction mixture turned into yellow suspension from red. Then Pd2(dba)3 (24 mg, 0.026 mmol), BrettPhos (28 mg, 0.052 mmol) and Cs2CO3 (172 mg, 0.529 mmol) were added to the reaction mixture under N2 atmosphere and the resulting reaction mixture was stirred at 100 C for 48 h. Crude LCMS (Rt =
0.719 min; MS
Calcd: 521.2; MS Found: 522.0 [M+H]+). To the reaction mixture was added water (25 mL) and extracted with Et0Ac/THF (25 mL x2, 1/1). The combined organic layer was washed with brine (25 mL), dried over anhydrous Na2SO4 and concentrated. The residue was purified by prep-HPLC (0.05% NH3.H20 as an additive). Most of MeCN was removed under reduced pressure and the remaining part was lyophilized to give 3-((1-(cyclopropylsulfony1)-2,3-
and 80% [MeCN + 0.02% TFA] in 1.35 min, then under this condition for 0.9 min, finally changed to 90% [water + 0.04% TFA] and 10% [MeCN + 0.02% TFA] and under this condition for 0.75 min. the purity is 95.71%, Rt = 1.245 min; MS Calcd.: 495.2, MS Found:
496.0 [M+Hr 11-1 NMR (400 MHz, DMSO-d6) (51.54 (3H, d, J= 6.4 Hz), 2.96 (6H, s), 3.22 (3H, s), 3.80-3.85 (2H, m), 4.35-4.40 (2H, m), 5.29 (1H, q, J = 6.4 Hz), 6.68 (1H, s), 6.96 (1H, d, J= 1.6 Hz), 7.06 (1H, dd, J= 8.0, 1.6 Hz), 7.93 (1H, d, J= 8.0 Hz), 8.30-8.40 (2H, m), 8.68 (1H, s), 9.40 (1H, brs).
Example 72: 3-01-(cyclopropylsulfony1)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-yl)amino)-N,N,5-trimethyl-5H-chromeno[4,3-c]pyridine-8-carboxamide N N N
0==0 [0404] A mixture of 3 -chl oro-N,N,5 -trimethy1-5H-chromeno [4,3 -c] py ri dine-8-carboxamide (80 mg, 0.26 mmol), 1-(cyclopropylsulfony1)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-amine (116 mg, 0.396 mmol, HC1 salt), Pd2(dba)3 (12 mg, 0.013 mmol), BrettPhos (14 mg, 0.026 mmol) and Cs2CO3 (258 mg, 0.793 mmol) in anhydrous dioxane (3 mL) was degassed and purged with N2 for 3 times. The resulting reaction mixture was heated at 100 C for 16 hour under N2 atmosphere. The reaction mixture turned into yellow suspension from red. Then Pd2(dba)3 (24 mg, 0.026 mmol), BrettPhos (28 mg, 0.052 mmol) and Cs2CO3 (172 mg, 0.529 mmol) were added to the reaction mixture under N2 atmosphere and the resulting reaction mixture was stirred at 100 C for 48 h. Crude LCMS (Rt =
0.719 min; MS
Calcd: 521.2; MS Found: 522.0 [M+H]+). To the reaction mixture was added water (25 mL) and extracted with Et0Ac/THF (25 mL x2, 1/1). The combined organic layer was washed with brine (25 mL), dried over anhydrous Na2SO4 and concentrated. The residue was purified by prep-HPLC (0.05% NH3.H20 as an additive). Most of MeCN was removed under reduced pressure and the remaining part was lyophilized to give 3-((1-(cyclopropylsulfony1)-2,3-
145 dihy dro-1H-py ri do [2,3-b] [1,4] oxazin-7-y0amino)-N,N,5 -trimethy1-5H-chromeno [4,3-clpyridine-8-carboxamide (18.9 mg, yield: 14%) as a yellow solid.
[0405] LCMS was taken on a quadrupole Mass Spectrometer on Shimadzu LCMS 2010 (Shim-pack XR-ODS 3.0*30 mm 2.2 pin) operating in ES (+) ionization mode. Flow Rate: 0.8 mL/min, Acquire Time: 3 min, Wavelength: UV220, Oven Tem.: 50 C, Mobile phase: from 90% [water + 0.04% TFA] and 10% [MeCN +0.02 % TFA] to 20% [water + 0.04% TFA]
and 80% [MeCN + 0.02% TFA] in 1.35 min, then under this condition for 0.9 min, finally changed to 90% [water + 0.04% TFA] and 10% [MeCN + 0.02% TFA] and under this condition for 0.75 min. purity is 96.25%, Rt = 1.307 min; MS Calcd.: 521.2, MS Found: 522.0 [M+H1+.
11-1NMR (400 MHz, DMSO-d6) (5 0.90-1.10 (4H, m), 1.54 (3H, d, J= 5.6 Hz), 2.85-3.05 (7H, m), 3.80-3.90 (2H, m), 4.35-4.45 (2H, m), 5.25-5.35 (1H, m), 6.68 (1H, s), 6.96 (1H, s), 7.06 (1H, d, J= 7.6 Hz), 7.94 (1H, d, J= 7.6 Hz), 8.35-8.40 (2H, m), 8.67 (1H, s), 9.41 (1H, brs).
Example 73: (S)-2-05,5-dimethy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-y1)amino)-6,6a,7,8-tetrahydro-9H-pyrido[2,3-b]pyrrolo[1,2-d][1,4]oxazin-9-one N N
Step 1: Preparation of methyl 5-bromo-2-chloroisonicotinate 0 OMe Br CI
[0406] To a suspension of 5-bromo-2-chloroisonicotinic acid (5.00 g, 21.2 mmol) in Me0H (50 mL) was added dropwise 50C12 (8.20 g, 69.0 mmol, 5 mL) at 0 C. The reaction was warmed to about 20 C and then refluxed (70 C) for 3 hrs. A slight yellow cloudy was formed. TLC (PE/Et0Ac=1:1, by UV) showed 5-bromo-2-chloroisonicotinic acid (Rf¨O) was consumed completely and a new spot (Rf-0.5) was formed. After cooling to 20 C, the solvent was concentrated in vacuum. The residue was diluted with Et0Ac (200 mL), washed with saturated aqueous NaHCO3 (100 mL x2), brine (100 mL), dried over anhydrous sodium sulfate
[0405] LCMS was taken on a quadrupole Mass Spectrometer on Shimadzu LCMS 2010 (Shim-pack XR-ODS 3.0*30 mm 2.2 pin) operating in ES (+) ionization mode. Flow Rate: 0.8 mL/min, Acquire Time: 3 min, Wavelength: UV220, Oven Tem.: 50 C, Mobile phase: from 90% [water + 0.04% TFA] and 10% [MeCN +0.02 % TFA] to 20% [water + 0.04% TFA]
and 80% [MeCN + 0.02% TFA] in 1.35 min, then under this condition for 0.9 min, finally changed to 90% [water + 0.04% TFA] and 10% [MeCN + 0.02% TFA] and under this condition for 0.75 min. purity is 96.25%, Rt = 1.307 min; MS Calcd.: 521.2, MS Found: 522.0 [M+H1+.
11-1NMR (400 MHz, DMSO-d6) (5 0.90-1.10 (4H, m), 1.54 (3H, d, J= 5.6 Hz), 2.85-3.05 (7H, m), 3.80-3.90 (2H, m), 4.35-4.45 (2H, m), 5.25-5.35 (1H, m), 6.68 (1H, s), 6.96 (1H, s), 7.06 (1H, d, J= 7.6 Hz), 7.94 (1H, d, J= 7.6 Hz), 8.35-8.40 (2H, m), 8.67 (1H, s), 9.41 (1H, brs).
Example 73: (S)-2-05,5-dimethy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-y1)amino)-6,6a,7,8-tetrahydro-9H-pyrido[2,3-b]pyrrolo[1,2-d][1,4]oxazin-9-one N N
Step 1: Preparation of methyl 5-bromo-2-chloroisonicotinate 0 OMe Br CI
[0406] To a suspension of 5-bromo-2-chloroisonicotinic acid (5.00 g, 21.2 mmol) in Me0H (50 mL) was added dropwise 50C12 (8.20 g, 69.0 mmol, 5 mL) at 0 C. The reaction was warmed to about 20 C and then refluxed (70 C) for 3 hrs. A slight yellow cloudy was formed. TLC (PE/Et0Ac=1:1, by UV) showed 5-bromo-2-chloroisonicotinic acid (Rf¨O) was consumed completely and a new spot (Rf-0.5) was formed. After cooling to 20 C, the solvent was concentrated in vacuum. The residue was diluted with Et0Ac (200 mL), washed with saturated aqueous NaHCO3 (100 mL x2), brine (100 mL), dried over anhydrous sodium sulfate
146 and filtered. The filtrate was concentrated in vacuum to afford methyl 5-bromo-chloroisonicotinate (5.00 g, yield: 94%) as yellow liquid.
11-1 NMR (400 MHz, DMSO-d6) 6 3.92 (s, 3H), 7.90 (s, 1H), 8.79 (s, 1H).
Step 2: Preparation of 1-(4-bromo-3-fluorophenyl)pyrrolidin-2-one VN F
Br [0407] 1-Bromo-2-fluoro-4-iodobenzene (90.0 g, 299 mmol), CsF (114 g, 748 mmol) and Cul (17.1 g, 89.7 mmol) were taken up in Et0Ac (1000 mL) and the resulting mixture was degassed with nitrogen for 10 min. Pyrrolidin-2-one(32.6 g, 383 mmol) and ethane-1,2-diamine (10.8 g, 179 mmol) were added and the resulting mixture was stirred at 50 C for 18 hrs. A blue suspension was formed. TLC (PE/Et0Ac=2:1, by UV) showed 1-bromo-2-fluoro-4-iodobenzene (Rf-0.9) was consumed completely and a main new spot (Rf-0.3) was formed.
The suspension was cooling to about 20 C and then worked up with batch of pyrrolidin-2-one.
The combined mixture was filtered and the cake was washed with Et0Ac (300 mL
x2). The combined filtrate was washed with 0.5 M aq. HC1 (1000 mL), 5% NH4OH (1000 mL), dried over Na2SO4, filtered and concentrated to dryness. The residue was triturated with MTBE/PE
(1:1, 200 mL) for 30 min and filtered. The solid was washed with MTBE/PE (1:1, 50 mL) and dried in vacuum to give 1-(4-bromo-3-fluorophenyl)pyrrolidin-2-one (66.0 g, yield: 43%) as an off-white solid.
11-1NMR (400 MHz, CDC13) 6 2.14-2.23 (2H, m), 2.63 (2H, t, J= 8.0 Hz), 3.83 (2H, t, J=
7.2 Hz), 7.25-7.29 (1H, m), 7.47-7.53 (1H, m), 7.65 (1H, dd, J= 11.2, 2.8 Hz) Step 3: Preparation of 1-(3-fluoro-4-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-yOphenyOpyrrolidin-2-one F
[0408] To a mixture of 1-(4-bromo-3-fluorophenyl)pyrrolidin-2-one (10.0 g, 38.8 mmol), B2Pin2 (14.8 g, 58.1 mmol) and KOAc (11.4 g, 116 mmol) in toluene (200 mL) was added
11-1 NMR (400 MHz, DMSO-d6) 6 3.92 (s, 3H), 7.90 (s, 1H), 8.79 (s, 1H).
Step 2: Preparation of 1-(4-bromo-3-fluorophenyl)pyrrolidin-2-one VN F
Br [0407] 1-Bromo-2-fluoro-4-iodobenzene (90.0 g, 299 mmol), CsF (114 g, 748 mmol) and Cul (17.1 g, 89.7 mmol) were taken up in Et0Ac (1000 mL) and the resulting mixture was degassed with nitrogen for 10 min. Pyrrolidin-2-one(32.6 g, 383 mmol) and ethane-1,2-diamine (10.8 g, 179 mmol) were added and the resulting mixture was stirred at 50 C for 18 hrs. A blue suspension was formed. TLC (PE/Et0Ac=2:1, by UV) showed 1-bromo-2-fluoro-4-iodobenzene (Rf-0.9) was consumed completely and a main new spot (Rf-0.3) was formed.
The suspension was cooling to about 20 C and then worked up with batch of pyrrolidin-2-one.
The combined mixture was filtered and the cake was washed with Et0Ac (300 mL
x2). The combined filtrate was washed with 0.5 M aq. HC1 (1000 mL), 5% NH4OH (1000 mL), dried over Na2SO4, filtered and concentrated to dryness. The residue was triturated with MTBE/PE
(1:1, 200 mL) for 30 min and filtered. The solid was washed with MTBE/PE (1:1, 50 mL) and dried in vacuum to give 1-(4-bromo-3-fluorophenyl)pyrrolidin-2-one (66.0 g, yield: 43%) as an off-white solid.
11-1NMR (400 MHz, CDC13) 6 2.14-2.23 (2H, m), 2.63 (2H, t, J= 8.0 Hz), 3.83 (2H, t, J=
7.2 Hz), 7.25-7.29 (1H, m), 7.47-7.53 (1H, m), 7.65 (1H, dd, J= 11.2, 2.8 Hz) Step 3: Preparation of 1-(3-fluoro-4-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-yOphenyOpyrrolidin-2-one F
[0408] To a mixture of 1-(4-bromo-3-fluorophenyl)pyrrolidin-2-one (10.0 g, 38.8 mmol), B2Pin2 (14.8 g, 58.1 mmol) and KOAc (11.4 g, 116 mmol) in toluene (200 mL) was added
147 Pd(dppf)C12 (2.84 g, 3.87 mmol) under N2 and then the mixture was stirred at 100 C for 40 hrs under N2 atmosphere. The red solution turned to black. LCMS showed about 11% of 1-(4-bromo-3-fluorophenyl)pyrrolidin-2-one (Rt = 0.650 min; MS Calcd: 257.0; MS
Found: 257.9 [M+H]+) was remained and desired product (50% purity; Rt = 0.698 min; MS
Calcd: 305.2;
MS Found: 305.7 [M+H]+) was detected. The mixture was stirred at 100 C for another 16 hrs.
LCMS showed about 3.99% of 1-(4-bromo-3-fluorophenyl)pyrrolidin-2-one (Rt =
0.654 min;
MS Calcd: 257.0; MS Found: 257.8 [M+H]+) was remained and desired product (47%
purity;
Rt = 0.702 min; MS Calcd: 305.2; MS Found: 305.9 [M+H]+) was detected. The mixture was stirred at 100 C for another 16 hrs. LCMS showed 1-(4-bromo-3-fluorophenyl)pyrrolidin-2-one was consumed completely and desired product (48% purity; Rt = 0.772 min;
MS Calcd:
305.2; MS Found: 223.9 [M-2,3-dimethylbutanen was detected. The reaction mixture was cooled to 20 C and filtered through silica gel and washed with MTBE (800 mL).
The solvent was evaporated under reduced pressure to afford the product 1-(3-fluoro-4-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-yOphenyOpyrrolidin-2-one (12.0 g, crude) as a black brown solid.
Step 4:
Preparation of methyl 2-chloro-5-(2-fluoro-4-(2-oxopyrrolidin-1-yl)phenyl)isonicotinate cil\1 0 OMe I
CI
[0409] To a suspension of methyl 5-bromo-2-chloroisonicotinate (1.00 g, 3.99 mmol), 1-(3 -fluoro-4-(4,4,5,5 -tetramethy1-1,3,2-di oxaborol an-2-yl)phenyl)py rroli din-2-one (1.58 g, 5.19 mmol, crude) and Pd(dppf)C12 (292 mg, 0.399 mmol) in dioxane (20 mL) was added K3PO4 (2.54 g, 12.0 mmol) under N2 atmosphere and then the resulting mixture was stirred at about 80 C for 16 hrs. A black solution was formed. LCMS showed methyl 5-bromo-2-chloroisonicotinate was consumed completely and desired MS (Rt = 0.818 min; MS
Calcd:
348.1; MS Found: 348.9 [M+H]+) was detected. TLC (PE/Et0Ac = 1:1, by UV) showed methyl 5-bromo-2-chloroisonicotinate (Rf-0.8) was consumed completely and a new spot (Rf-0.4) was formed. The mixture was poured into water (50 mL) and extracted with Et0Ac (50 mL
x4). The combined organic layer was washed with brine (100 mL), dried over Na2SO4 and concentrated to dryness. The residue was purified by combi flash (Et0Ac in pentane from 0%
Found: 257.9 [M+H]+) was remained and desired product (50% purity; Rt = 0.698 min; MS
Calcd: 305.2;
MS Found: 305.7 [M+H]+) was detected. The mixture was stirred at 100 C for another 16 hrs.
LCMS showed about 3.99% of 1-(4-bromo-3-fluorophenyl)pyrrolidin-2-one (Rt =
0.654 min;
MS Calcd: 257.0; MS Found: 257.8 [M+H]+) was remained and desired product (47%
purity;
Rt = 0.702 min; MS Calcd: 305.2; MS Found: 305.9 [M+H]+) was detected. The mixture was stirred at 100 C for another 16 hrs. LCMS showed 1-(4-bromo-3-fluorophenyl)pyrrolidin-2-one was consumed completely and desired product (48% purity; Rt = 0.772 min;
MS Calcd:
305.2; MS Found: 223.9 [M-2,3-dimethylbutanen was detected. The reaction mixture was cooled to 20 C and filtered through silica gel and washed with MTBE (800 mL).
The solvent was evaporated under reduced pressure to afford the product 1-(3-fluoro-4-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-yOphenyOpyrrolidin-2-one (12.0 g, crude) as a black brown solid.
Step 4:
Preparation of methyl 2-chloro-5-(2-fluoro-4-(2-oxopyrrolidin-1-yl)phenyl)isonicotinate cil\1 0 OMe I
CI
[0409] To a suspension of methyl 5-bromo-2-chloroisonicotinate (1.00 g, 3.99 mmol), 1-(3 -fluoro-4-(4,4,5,5 -tetramethy1-1,3,2-di oxaborol an-2-yl)phenyl)py rroli din-2-one (1.58 g, 5.19 mmol, crude) and Pd(dppf)C12 (292 mg, 0.399 mmol) in dioxane (20 mL) was added K3PO4 (2.54 g, 12.0 mmol) under N2 atmosphere and then the resulting mixture was stirred at about 80 C for 16 hrs. A black solution was formed. LCMS showed methyl 5-bromo-2-chloroisonicotinate was consumed completely and desired MS (Rt = 0.818 min; MS
Calcd:
348.1; MS Found: 348.9 [M+H]+) was detected. TLC (PE/Et0Ac = 1:1, by UV) showed methyl 5-bromo-2-chloroisonicotinate (Rf-0.8) was consumed completely and a new spot (Rf-0.4) was formed. The mixture was poured into water (50 mL) and extracted with Et0Ac (50 mL
x4). The combined organic layer was washed with brine (100 mL), dried over Na2SO4 and concentrated to dryness. The residue was purified by combi flash (Et0Ac in pentane from 0%
148 to 50%) to give methyl 2-chloro-5-(2-fluoro-4-(2-oxopyrrolidin-1-yl)phenyl)isonicotinate (560 mg, yield: 40%) as an off-white solid.
11-1 NMR (400 MHz, CDC13) 6 2.23 (2H, if, J= 8.0, 6.8 Hz), 2.68 (2H, t, J= 8.0 Hz), 3.82 (3H, s), 3.92 (2H, t, J= 6.8 Hz), 7.33 (1H, t, J= 8.4 Hz), 7.49 (1H, dd, J=
8.4, 2.0 Hz), 7.72 (1H, dd, J= 12.8 , 2.0 Hz), 7.83 (1H, s), 8.44 (1H, s).
Step 5:
Preparation of 1-(4-(6-chloro-4-(2-hydroxypropan-2-yOpyridin-3-y1)-3-fluorophenyOpyrrolidin-2-one OH
I
N CI
[0410] To a solution of methyl 2-chloro-5-(2-fluoro-4-(2-oxopyrrolidin-1-yl)phenyl)isonicotinate (550 mg, 1.58 mmol) in THF (10 mL) at -78 C was added MeMgBr (3 M in THF, 1.16 mL). After the addition, the reaction mixture was allowed to warm to 20 C
and stirred at 20 C for 1 hr. LCMS (ES7139-20-pla) showed about 22% methyl 2-chloro-5-(2-fluoro-4-(2-oxopyrrolidin-1-yl)phenyl)isonicotinate (Rt=0.676 min, min; MS
Calcd: 348.1;
MS Found: 348.8 [M+H1+) was remained and desired product (43% purity; Rt=0.627 min; MS
Calcd: 348.1; MS Found: 348.8 [M+Hr) was detected. TLC (PE/Et0Ac=1:1, by UV) showed about 10% of methyl 2-chloro-5-(2-fluoro-4-(2-oxopyrrolidin-1-yl)phenyl)isonicotinate (Rf-0.4) was remained and a new spot (Rf-0.3) was formed. The mixture was poured into sat. aq.NH4C1 (20 mL) and extracted with Et0Ac (20 mL x3). The combined organic layer was washed with brine (40 mL), dried over Na2SO4 and concentrated to dryness. The residue was purified by combi flash (Et0Ac in pentane from 10% to 50%) to give 1-(4-(6-chloro-4-(2-hydroxypropan-2-yl)pyridin-3-y1)-3-fluorophenyl)pyrrolidin-2-one (150 mg, yield: 27%) as a yellow solid.
11-1 NMR (400 MHz, CDC13) 6 1.44 (3H, s), 1.47 (3H, s), 1.71 (1H, s), 2.15-2.35 (2H, m), 2.69 (2H, t, J= 8.0 Hz), 3.92 (2 H, t, J= 7.2 Hz), 7.22 (1H, J= 8.4 Hz), 7.47 (1H, dd, J= 8.4 Hz, 2.0 Hz), 7.66 (1H, dd, J= 11.6 Hz, 2.0 Hz), 7.70 (1H, s), 8.07 (1H, s).
Step 6: Preparation of 1-(3-chloro-5,5-dimethy1-5H-chromeno[4,3-clpyridin-8-yl)pyrrolidin-2-one
11-1 NMR (400 MHz, CDC13) 6 2.23 (2H, if, J= 8.0, 6.8 Hz), 2.68 (2H, t, J= 8.0 Hz), 3.82 (3H, s), 3.92 (2H, t, J= 6.8 Hz), 7.33 (1H, t, J= 8.4 Hz), 7.49 (1H, dd, J=
8.4, 2.0 Hz), 7.72 (1H, dd, J= 12.8 , 2.0 Hz), 7.83 (1H, s), 8.44 (1H, s).
Step 5:
Preparation of 1-(4-(6-chloro-4-(2-hydroxypropan-2-yOpyridin-3-y1)-3-fluorophenyOpyrrolidin-2-one OH
I
N CI
[0410] To a solution of methyl 2-chloro-5-(2-fluoro-4-(2-oxopyrrolidin-1-yl)phenyl)isonicotinate (550 mg, 1.58 mmol) in THF (10 mL) at -78 C was added MeMgBr (3 M in THF, 1.16 mL). After the addition, the reaction mixture was allowed to warm to 20 C
and stirred at 20 C for 1 hr. LCMS (ES7139-20-pla) showed about 22% methyl 2-chloro-5-(2-fluoro-4-(2-oxopyrrolidin-1-yl)phenyl)isonicotinate (Rt=0.676 min, min; MS
Calcd: 348.1;
MS Found: 348.8 [M+H1+) was remained and desired product (43% purity; Rt=0.627 min; MS
Calcd: 348.1; MS Found: 348.8 [M+Hr) was detected. TLC (PE/Et0Ac=1:1, by UV) showed about 10% of methyl 2-chloro-5-(2-fluoro-4-(2-oxopyrrolidin-1-yl)phenyl)isonicotinate (Rf-0.4) was remained and a new spot (Rf-0.3) was formed. The mixture was poured into sat. aq.NH4C1 (20 mL) and extracted with Et0Ac (20 mL x3). The combined organic layer was washed with brine (40 mL), dried over Na2SO4 and concentrated to dryness. The residue was purified by combi flash (Et0Ac in pentane from 10% to 50%) to give 1-(4-(6-chloro-4-(2-hydroxypropan-2-yl)pyridin-3-y1)-3-fluorophenyl)pyrrolidin-2-one (150 mg, yield: 27%) as a yellow solid.
11-1 NMR (400 MHz, CDC13) 6 1.44 (3H, s), 1.47 (3H, s), 1.71 (1H, s), 2.15-2.35 (2H, m), 2.69 (2H, t, J= 8.0 Hz), 3.92 (2 H, t, J= 7.2 Hz), 7.22 (1H, J= 8.4 Hz), 7.47 (1H, dd, J= 8.4 Hz, 2.0 Hz), 7.66 (1H, dd, J= 11.6 Hz, 2.0 Hz), 7.70 (1H, s), 8.07 (1H, s).
Step 6: Preparation of 1-(3-chloro-5,5-dimethy1-5H-chromeno[4,3-clpyridin-8-yl)pyrrolidin-2-one
149 I
N CI
[0411] To a solution of 1 -(4-(6-chl oro-4-(2-hy droxy propan-2-yl)py ri din-3 -y1)-3-fluorophenyl)pyrrolidin-2-one (100 mg, 0.287 mmol) in THF (3 mL) was added NaH
(24 mg, 0.59 mmol, 60% in mineral oil) at about 25 C and then the mixture was stirred at 25 C for 2 h. A yellow suspension was formed. TLC (PE/Et0Ac=1:1, by UV) showed 1-(4-(6-chloro-4-(2-hy droxypropan-2-y Opy ri din-3-y1)-3 -fluoropheny Opy rroli din-2-one was consumed completely and a new spot was formed. Sat aq.NH4C1 (10 mL) was added and the mixture extracted with Et0Ac (10 mL x3). The combined organics were washed with brine (20 mL), dried over Na2SO4, filtered, concentrated to dryness. The residue was purified on a silica gel column eluted with 0-100% Et0Ac in pentane to give 1-(3-chloro-5,5-dimethy1-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one (110 mg, yield: 78%) as alight yellow solid.
11-1NMR (400 MHz, CDC13) 6 1.64 (6H, s), 2.15-2.30 (2H, m), 2.66 (2H, t, J=
8.0 Hz), 3.90 (2 H, t, J= 7.2 Hz), 7.17 (1H, s), 7.32 (1H, d, J= 2.4 Hz), 7.46 (1H, dd, J=
8.4 Hz, 2.0 Hz), 7.75 (1H, d, J= 8.8 Hz), 8.70 (1H, s).
Step 7:
Preparation of (S)-2-((5,5-dimethy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c] py ri din-3-yl)amino)-6,6a,7,8-tetrahy dro-9H-pyri do [2,3-b] pyrrol o [1,2-d] [1,4] oxazin-9-one H
N
[0412] To a suspension of 1-(3 -chl oro-5,5 -dimethy1-5H-chromeno [4,3 -c] py ri din-8-yl)pyrrolidin-2-one (50 mg, 0.15 mmol), (S)-2-amino-6,6a,7,8-tetrahydro-9H-pyrido[2,3-b]pyrrolo[1,2-d][1,41oxazin-9-one (47 mg, 0.23mmo1) and Cs2CO3 (149 mg, 0.456 mmol) in dioxane (1 mL) was added Pd2(dba)3 (14 mg, 0.015 mmol), BrettPhos (16 mg, 0.030 mmol) under N2 and then the mixture was stirred at 100 C for 16 hrs. A brown suspension was formed.
LCMS showed 1-(3-chloro-5,5-dimethy1-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one was consumed completely and 62% of desired product (Rt=0.585 min, MS Calcd:
497.2; MS
N CI
[0411] To a solution of 1 -(4-(6-chl oro-4-(2-hy droxy propan-2-yl)py ri din-3 -y1)-3-fluorophenyl)pyrrolidin-2-one (100 mg, 0.287 mmol) in THF (3 mL) was added NaH
(24 mg, 0.59 mmol, 60% in mineral oil) at about 25 C and then the mixture was stirred at 25 C for 2 h. A yellow suspension was formed. TLC (PE/Et0Ac=1:1, by UV) showed 1-(4-(6-chloro-4-(2-hy droxypropan-2-y Opy ri din-3-y1)-3 -fluoropheny Opy rroli din-2-one was consumed completely and a new spot was formed. Sat aq.NH4C1 (10 mL) was added and the mixture extracted with Et0Ac (10 mL x3). The combined organics were washed with brine (20 mL), dried over Na2SO4, filtered, concentrated to dryness. The residue was purified on a silica gel column eluted with 0-100% Et0Ac in pentane to give 1-(3-chloro-5,5-dimethy1-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one (110 mg, yield: 78%) as alight yellow solid.
11-1NMR (400 MHz, CDC13) 6 1.64 (6H, s), 2.15-2.30 (2H, m), 2.66 (2H, t, J=
8.0 Hz), 3.90 (2 H, t, J= 7.2 Hz), 7.17 (1H, s), 7.32 (1H, d, J= 2.4 Hz), 7.46 (1H, dd, J=
8.4 Hz, 2.0 Hz), 7.75 (1H, d, J= 8.8 Hz), 8.70 (1H, s).
Step 7:
Preparation of (S)-2-((5,5-dimethy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c] py ri din-3-yl)amino)-6,6a,7,8-tetrahy dro-9H-pyri do [2,3-b] pyrrol o [1,2-d] [1,4] oxazin-9-one H
N
[0412] To a suspension of 1-(3 -chl oro-5,5 -dimethy1-5H-chromeno [4,3 -c] py ri din-8-yl)pyrrolidin-2-one (50 mg, 0.15 mmol), (S)-2-amino-6,6a,7,8-tetrahydro-9H-pyrido[2,3-b]pyrrolo[1,2-d][1,41oxazin-9-one (47 mg, 0.23mmo1) and Cs2CO3 (149 mg, 0.456 mmol) in dioxane (1 mL) was added Pd2(dba)3 (14 mg, 0.015 mmol), BrettPhos (16 mg, 0.030 mmol) under N2 and then the mixture was stirred at 100 C for 16 hrs. A brown suspension was formed.
LCMS showed 1-(3-chloro-5,5-dimethy1-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one was consumed completely and 62% of desired product (Rt=0.585 min, MS Calcd:
497.2; MS
150 Found: 498.1 [M+H]+) was detected. The mixture was diluted with DCM/Me0H
(10:1, 10 mL) and filtered. The cake was washed with DCM/Me0H (10:1, 5 mL). The filtrate was concentrated to dryness. The residue was purified by prep-HPLC (0.225% FA as an additive) to give (S)-2-((5,5-dimethy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)-6,6a,7,8-tetrahy dro-9H-py ri do [2,3 -b] py rrol o [1,2-d] [1,4]
oxazin-9-one (42 mg, yield: 54%; 0.514 FA salt) as an off-white solid.
11-1NMR (400 MHz, DMSO-d6) 6 1.55 (6H, d, J= 2.4 Hz), 1.64-1.75 (1H, m), 2.00-2.10 (2H, m), 2.17-2.27 (1H, m), 2.33-2.35 (2H, m), 2.59-2.65 (1H, m), 2.67-2.73 (1H, m), 3.81-3.94 (3H, m), 4.03-4.11 (1H, m), 4.58 (1H, dd, J= 10.8 Hz, 3.2 Hz), 6.74 (1H, s), 7.29 (1H, dd, J
= 8.4 Hz, 2.0 Hz), 7.39 (1H, d, J= 2.0 Hz), 7.88 (1H, d, J= 8.8 Hz), 8.16 (0.5H, s), 8.38 (1H, d, J= 2.4 Hz), 8.62 (1H, s), 8.97 (1H, d, J= 2.4 Hz), 9.29 (1H, s).
Example 74: 1-(3-01-(cyclopropylsulfony1)-2,3-dihydro-1H-pyrido12,3-b]11,41oxazin-7-yl)amino)-5H-chromeno14,3-c]pyridin-8-y1)pyrrolidin-2-one N N N
0=
Step 1: Preparation of (5-bromo-2-chloropyridin-4-yl)methanol HO
Br NCI
[0413] To a solution of methyl methyl 5-bromo-2-chloroisonicotinate (13.0 g, 51.9 mmol) in THF (100 mL) was added NaBH4 (7.85 g, 208 mmol) and LiC1 (8.80 g, 208 mmol) at 0 C.
The reaction was warmed to about 25 C and stirred for 64 hrs. A white suspension was formed.
TLC (PE/Et0Ac=1:1, by UV) showed methyl 5-bromo-2-chloroisonicotinate was consumed completely and a new spot was formed. The mixture was poured into water (300 mL) and extracted with Et0Ac (200 mLx3). The combined organic layer was washed with brine (300 mLx2), dried over Na2SO4 and concentrated to dryness to give (5-bromo-2-chloropyridin-4-yl)methanol (10.7 g, 92% yield) as a white solid.
(10:1, 10 mL) and filtered. The cake was washed with DCM/Me0H (10:1, 5 mL). The filtrate was concentrated to dryness. The residue was purified by prep-HPLC (0.225% FA as an additive) to give (S)-2-((5,5-dimethy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)-6,6a,7,8-tetrahy dro-9H-py ri do [2,3 -b] py rrol o [1,2-d] [1,4]
oxazin-9-one (42 mg, yield: 54%; 0.514 FA salt) as an off-white solid.
11-1NMR (400 MHz, DMSO-d6) 6 1.55 (6H, d, J= 2.4 Hz), 1.64-1.75 (1H, m), 2.00-2.10 (2H, m), 2.17-2.27 (1H, m), 2.33-2.35 (2H, m), 2.59-2.65 (1H, m), 2.67-2.73 (1H, m), 3.81-3.94 (3H, m), 4.03-4.11 (1H, m), 4.58 (1H, dd, J= 10.8 Hz, 3.2 Hz), 6.74 (1H, s), 7.29 (1H, dd, J
= 8.4 Hz, 2.0 Hz), 7.39 (1H, d, J= 2.0 Hz), 7.88 (1H, d, J= 8.8 Hz), 8.16 (0.5H, s), 8.38 (1H, d, J= 2.4 Hz), 8.62 (1H, s), 8.97 (1H, d, J= 2.4 Hz), 9.29 (1H, s).
Example 74: 1-(3-01-(cyclopropylsulfony1)-2,3-dihydro-1H-pyrido12,3-b]11,41oxazin-7-yl)amino)-5H-chromeno14,3-c]pyridin-8-y1)pyrrolidin-2-one N N N
0=
Step 1: Preparation of (5-bromo-2-chloropyridin-4-yl)methanol HO
Br NCI
[0413] To a solution of methyl methyl 5-bromo-2-chloroisonicotinate (13.0 g, 51.9 mmol) in THF (100 mL) was added NaBH4 (7.85 g, 208 mmol) and LiC1 (8.80 g, 208 mmol) at 0 C.
The reaction was warmed to about 25 C and stirred for 64 hrs. A white suspension was formed.
TLC (PE/Et0Ac=1:1, by UV) showed methyl 5-bromo-2-chloroisonicotinate was consumed completely and a new spot was formed. The mixture was poured into water (300 mL) and extracted with Et0Ac (200 mLx3). The combined organic layer was washed with brine (300 mLx2), dried over Na2SO4 and concentrated to dryness to give (5-bromo-2-chloropyridin-4-yl)methanol (10.7 g, 92% yield) as a white solid.
151 11-1NMR (400 MHz, CDC13) 6 2.07 (1H, brs), 4.77 (2H, d, J= 4.8 Hz), 7.60 (1H, s), 8.44 (1H, s).
Step 2: Preparation of 1 -(4-(6-chl oro-4-(hy droxy methyl)py ri din-3 -y1)-3-fluorophenyl)pyrrolidin-2-one r_121 OH
I
N CI
[0414] A
mixture of (5-bromo-2-chloropyridin-4-yOmethanol (9.70 g, 43.6 mmol) and 1-(3 -fluoro-4-(4,4,5 ,5 -tetramethyl-1,3 ,2-di oxaborol an-2-yl)phenyl)pyrroli din-2-one (19.14 g, 45.8 mmol, ), Pd(dppf)C12.CH2C12 (3.56 g, 4.36 mmol) and Na2CO3 (13.9 g, 131 mmol) in dioxane (150 mL)/H20 (30 mL) was degassed and purged with N2 for 3 times. Then the resulting reaction mixture was heated at 90 C for 16 hrs. A black suspension was formed. TLC
(Et0Ac/PE=1:1, by UV) showed (5-bromo-2-chloropyridin-4-yOmethanol was consumed completely and one major new spot with larger polarity was detected. The mixture was combined with last batch and the combined mixture was poured into water (300 mL) and extracted with Et0Ac (300 mLx3). The organic layer was washed with brine (100 mL), dried over Na2SO4 and concentrated to dryness. The residue was purified by Combi Flash (eluenting with Et0Ac in pentane from 0% to 100%) to give 1-(4-(6-chloro-4-(hydroxymethyl)pyridin-3-y1)-3-fluorophenyl)pyrrolidin-2-one (4.5 g, 29%) as a gray solid.
1FINMR (400 MHz, CDC13) 6 1.87 (1H, t, J= 6.0 Hz), 2.17-2.28 (2H, m), 2.63-2.70 (2H, m), 3.85-3.95 (2H, m), 4.60 (2H, d, J = 6.0 Hz), 7.23 (1H, t, J= 8.4 Hz), 7.41-7.48 (1H, m), 7.66-7.74 (2H, m) 8.21 (1H, s) Step 3: Preparation of 1-(3-chloro-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one I
N CI
[0415] To a solution of 1 -(4-(6-chl oro-4-(hy droxy methyl)pyri din-3-y1)-3-fluorophenyl)pyrrolidin-2-one (4.50 g, 14.0 mmol) in THF (100 mL) was added NaH (1.68 g,
Step 2: Preparation of 1 -(4-(6-chl oro-4-(hy droxy methyl)py ri din-3 -y1)-3-fluorophenyl)pyrrolidin-2-one r_121 OH
I
N CI
[0414] A
mixture of (5-bromo-2-chloropyridin-4-yOmethanol (9.70 g, 43.6 mmol) and 1-(3 -fluoro-4-(4,4,5 ,5 -tetramethyl-1,3 ,2-di oxaborol an-2-yl)phenyl)pyrroli din-2-one (19.14 g, 45.8 mmol, ), Pd(dppf)C12.CH2C12 (3.56 g, 4.36 mmol) and Na2CO3 (13.9 g, 131 mmol) in dioxane (150 mL)/H20 (30 mL) was degassed and purged with N2 for 3 times. Then the resulting reaction mixture was heated at 90 C for 16 hrs. A black suspension was formed. TLC
(Et0Ac/PE=1:1, by UV) showed (5-bromo-2-chloropyridin-4-yOmethanol was consumed completely and one major new spot with larger polarity was detected. The mixture was combined with last batch and the combined mixture was poured into water (300 mL) and extracted with Et0Ac (300 mLx3). The organic layer was washed with brine (100 mL), dried over Na2SO4 and concentrated to dryness. The residue was purified by Combi Flash (eluenting with Et0Ac in pentane from 0% to 100%) to give 1-(4-(6-chloro-4-(hydroxymethyl)pyridin-3-y1)-3-fluorophenyl)pyrrolidin-2-one (4.5 g, 29%) as a gray solid.
1FINMR (400 MHz, CDC13) 6 1.87 (1H, t, J= 6.0 Hz), 2.17-2.28 (2H, m), 2.63-2.70 (2H, m), 3.85-3.95 (2H, m), 4.60 (2H, d, J = 6.0 Hz), 7.23 (1H, t, J= 8.4 Hz), 7.41-7.48 (1H, m), 7.66-7.74 (2H, m) 8.21 (1H, s) Step 3: Preparation of 1-(3-chloro-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one I
N CI
[0415] To a solution of 1 -(4-(6-chl oro-4-(hy droxy methyl)pyri din-3-y1)-3-fluorophenyl)pyrrolidin-2-one (4.50 g, 14.0 mmol) in THF (100 mL) was added NaH (1.68 g,
152 42.1 mmol, 60% in mineral oil) at about 25 C and then the mixture was stirred at 25 C for 2 hrs. A yellow suspension was formed. TLC (PE/Et0Ac=1:1, by UV) showed 1-(4-(6-chloro-4-(hydroxymethyl)pyridin-3-y1)-3-fluorophenyl)pyrrolidin-2-one was consumed completely and a new spot was formed. Sat. aq. NH4C1 (200 mL) was added and the mixture was extracted with Et0Ac (200 mLx3). The combined organics were washed with brine (300 mL), dried over Na2SO4, filtered, concentrated to dryness. The residue was purified on a silica gel column eluted with 0-10% Me0H in DCM to give 1-(3-chloro-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one (2.3 g, 55% yield) as a gray solid.
11-1NMR (400 MHz, CDC13) 6 2.15-2.26 (2H, m), 2.21 (2H, t, J= 8.0 Hz), 3.90 (2H, t, J= 7.2 Hz), 5.11 (2H, s), 7.15 (1H, s), 7.35-7.39 (1H, m), 7.45 (1H, dd, J = 8.8, 2.4 Hz ), 7.75 (1H, d, J = 8.4 Hz), 8.68 (s, 1 H).
Step 4:
Preparation of 1-(3-((1 -(cy cl opropylsulfony1)-2,3-dihy dro-1H-py ri do [2,3 -b] [1,4] oxazin-7-yl)amino)-5H-chromeno [4,3 -c] py ri din-8-yl)pyrroli din-2-one N N N
0=
[0416] To a suspension of 1-(3-chloro-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one (80 mg, 0.28 mmol), 1-(cyclopropylsulfony1)-2,3-dihydro-1H-pyrido[2,3-b][1,41oxazin-7-amine (109 mg, 0.341 mmol) and Cs2CO3 (278 mg, 0.853 mmol) in dioxane (5 mL) was added Pd2(dba)3 (26 mg, 28 limo') and BrettPhos (31 mg, 57 limo') under Nz. Then the mixture was stirred at 100 C for 16 hrs. A brown suspension was formed. LCMS showed 1-(3-chloro-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one was consumed completely and desired product (36% purity; Rt = 0.727 min; MS Calcd: 519.2; MS Found: 519.9 [M+H1+) was detected. TLC
(DCM/Me0H=10:1, by UV) showed 1-(3-chloro-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one was consumed completely and a new spot was formed. The mixture was diluted with DCM/Me0H (10:1, 30 mL) and filtered. The cake was washed with DCM/Me0H (10:1, mL). The filtrate was concentrated to dryness. The residue was purified by Combi Flash (Me0H in DCM from 0% to 10%) to give crude product, which was triturated with MeCN (7 mL) at 25 C for 2 hrs. The mixture was filtered and the cake was washed with MeCN (2 mL).
The solid was triturated with DMSO/H20 (2 mL/5 mL) at 20 C for 1 h and filtered. The cake
11-1NMR (400 MHz, CDC13) 6 2.15-2.26 (2H, m), 2.21 (2H, t, J= 8.0 Hz), 3.90 (2H, t, J= 7.2 Hz), 5.11 (2H, s), 7.15 (1H, s), 7.35-7.39 (1H, m), 7.45 (1H, dd, J = 8.8, 2.4 Hz ), 7.75 (1H, d, J = 8.4 Hz), 8.68 (s, 1 H).
Step 4:
Preparation of 1-(3-((1 -(cy cl opropylsulfony1)-2,3-dihy dro-1H-py ri do [2,3 -b] [1,4] oxazin-7-yl)amino)-5H-chromeno [4,3 -c] py ri din-8-yl)pyrroli din-2-one N N N
0=
[0416] To a suspension of 1-(3-chloro-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one (80 mg, 0.28 mmol), 1-(cyclopropylsulfony1)-2,3-dihydro-1H-pyrido[2,3-b][1,41oxazin-7-amine (109 mg, 0.341 mmol) and Cs2CO3 (278 mg, 0.853 mmol) in dioxane (5 mL) was added Pd2(dba)3 (26 mg, 28 limo') and BrettPhos (31 mg, 57 limo') under Nz. Then the mixture was stirred at 100 C for 16 hrs. A brown suspension was formed. LCMS showed 1-(3-chloro-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one was consumed completely and desired product (36% purity; Rt = 0.727 min; MS Calcd: 519.2; MS Found: 519.9 [M+H1+) was detected. TLC
(DCM/Me0H=10:1, by UV) showed 1-(3-chloro-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one was consumed completely and a new spot was formed. The mixture was diluted with DCM/Me0H (10:1, 30 mL) and filtered. The cake was washed with DCM/Me0H (10:1, mL). The filtrate was concentrated to dryness. The residue was purified by Combi Flash (Me0H in DCM from 0% to 10%) to give crude product, which was triturated with MeCN (7 mL) at 25 C for 2 hrs. The mixture was filtered and the cake was washed with MeCN (2 mL).
The solid was triturated with DMSO/H20 (2 mL/5 mL) at 20 C for 1 h and filtered. The cake
153 was washed with MeCN (2 mL) and dried in reduced pressure to give 1-(3-((1-(cy cl opropylsulfony1)-2,3-dihy dro-1H-py ri do [2,3-b] [1,4] oxazin-7-y0amino)-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (45.8 mg, 30% yield) as a yellow solid.
11-1NMR (400 MHz, DMSO-d6) 6 1.03-1.12 (4H, m), 2.02-2.15 (2H, m), 2.55 (2H, overlap with DMSO), 2.87-2.95 (1H, m), 3.81-3.88 (4H, m), 4.41 (2H, t, J= 4.4 Hz), 5.09 (2H, s), 6.85 (1H, s), 7.30-7.40 (2H, m), 7.87 (1H, d, J= 8.4 Hz), 8.37 (1H, d, J= 2.0 Hz), 8.41 (1H, d, J= 2.0 Hz), 8.59 (1H, s), 9.31 (1H, brs).
Example 75: (S)-2-08-(2-oxopyrrolidin-1-y1)-5H-chromeno14,3-c]pyridin-3-yl)amino)-6,6a,7,8-tetrahydro-9H-pyrido12,3-b]pyrrolo11,2-d]11,41oxazin-9-one c 0 I
[0417] To a suspension of 1-(3-chloro-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (80 mg, 0.27 mmol), (S)-2-amino-6,6a,7,8-tetrahydro-9H-pyrido[2,3-b]pyrrolo[1,2-d] [1,41oxazin-9-one (66 mg, 0.32 mmol) and Cs2CO3 (260 mg, 0.796 mmol) in dioxane (5 mL) was added Pd2(dba)3 (24 mg, 0.027 mmol), BrettPhos (29 mg, 0.053 mmol) under N2. Then the mixture was stirred at 100 C for 16 hrs. A brown suspension was formed. LCMS
showed 1-(3-chloro-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one was consumed completely and desired product (Rt = 0.676 min; MS Calcd: 469.2; MS Found: 470.0 [M+1-11+) was detected.
The mixture was diluted with DCM/Me0H (10:1, 10 mL) and filtered. The cake was washed with DCM/Me0H (10:1, 5 mL). The filtrate was concentrated to dryness. The residue was triturated with DMSO/MECN/Me0H (1:1:1, 5 mL) and filtered. The cake was washed with MECN (2 mL) and the solid was triturated with MECN (2 mL) for 16 hrs at 25 C.
The mixture was filtered and the cake was washed with MECN (1 mL) and dried in reduced pressure to give (S)-2-((8-(2-oxopy rroli din-l-y1)-5H-chromeno [4,3 -c] py ri din-3-yl)amino)-6,6a,7,8-tetrahydro-9H-pyrido[2,3-blpyrrolo[1,2-d][1,41oxazin-9-one (31 mg, 24% yield) as an off-white solid.
1-1-1NMR (400 MHz, DMSO-d6) 6 1.65-1.75 (1H, m), 2.00-2.11 (2H, m), 2.17-2.28 (1H, m), 2.35-2.48 (2H, m), 2.55 (2H, overlap with DMSO), 2.62-2.67 (1H, m), 3.80-3.94 (3H, m), 4.03-4.13 (1H, m), 4.58 (1H, dd, J= 10.8 Hz, 3.2 Hz), 5.09 (2H, s), 6.65 (1H, s), 7.33 (1H,
11-1NMR (400 MHz, DMSO-d6) 6 1.03-1.12 (4H, m), 2.02-2.15 (2H, m), 2.55 (2H, overlap with DMSO), 2.87-2.95 (1H, m), 3.81-3.88 (4H, m), 4.41 (2H, t, J= 4.4 Hz), 5.09 (2H, s), 6.85 (1H, s), 7.30-7.40 (2H, m), 7.87 (1H, d, J= 8.4 Hz), 8.37 (1H, d, J= 2.0 Hz), 8.41 (1H, d, J= 2.0 Hz), 8.59 (1H, s), 9.31 (1H, brs).
Example 75: (S)-2-08-(2-oxopyrrolidin-1-y1)-5H-chromeno14,3-c]pyridin-3-yl)amino)-6,6a,7,8-tetrahydro-9H-pyrido12,3-b]pyrrolo11,2-d]11,41oxazin-9-one c 0 I
[0417] To a suspension of 1-(3-chloro-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (80 mg, 0.27 mmol), (S)-2-amino-6,6a,7,8-tetrahydro-9H-pyrido[2,3-b]pyrrolo[1,2-d] [1,41oxazin-9-one (66 mg, 0.32 mmol) and Cs2CO3 (260 mg, 0.796 mmol) in dioxane (5 mL) was added Pd2(dba)3 (24 mg, 0.027 mmol), BrettPhos (29 mg, 0.053 mmol) under N2. Then the mixture was stirred at 100 C for 16 hrs. A brown suspension was formed. LCMS
showed 1-(3-chloro-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one was consumed completely and desired product (Rt = 0.676 min; MS Calcd: 469.2; MS Found: 470.0 [M+1-11+) was detected.
The mixture was diluted with DCM/Me0H (10:1, 10 mL) and filtered. The cake was washed with DCM/Me0H (10:1, 5 mL). The filtrate was concentrated to dryness. The residue was triturated with DMSO/MECN/Me0H (1:1:1, 5 mL) and filtered. The cake was washed with MECN (2 mL) and the solid was triturated with MECN (2 mL) for 16 hrs at 25 C.
The mixture was filtered and the cake was washed with MECN (1 mL) and dried in reduced pressure to give (S)-2-((8-(2-oxopy rroli din-l-y1)-5H-chromeno [4,3 -c] py ri din-3-yl)amino)-6,6a,7,8-tetrahydro-9H-pyrido[2,3-blpyrrolo[1,2-d][1,41oxazin-9-one (31 mg, 24% yield) as an off-white solid.
1-1-1NMR (400 MHz, DMSO-d6) 6 1.65-1.75 (1H, m), 2.00-2.11 (2H, m), 2.17-2.28 (1H, m), 2.35-2.48 (2H, m), 2.55 (2H, overlap with DMSO), 2.62-2.67 (1H, m), 3.80-3.94 (3H, m), 4.03-4.13 (1H, m), 4.58 (1H, dd, J= 10.8 Hz, 3.2 Hz), 5.09 (2H, s), 6.65 (1H, s), 7.33 (1H,
154 dd, J= 8.8 Hz, 2.4 Hz), 7.37 (1H, d, J= 2.4 Hz), 7.86 (1H, d, J= 8.4 Hz), 8.41 (1H, d, J=
2.8 Hz), 8.59 (1H, s), 8.96 (1H, d, J= 2.4 Hz), 9.29 (1H, brs).
Example 76: 1-(3-01-(cyclopropanecarbony1)-2,3-dihydro-1H-pyrido12,3-b]11,41oxazin-7-yl)amino)-5H-chromeno14,3-c]pyridin-8-y1)pyrrolidin-2-one I
NN
[0418] To a suspension of 1-(3-amino-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (80 mg, 0.28 mmol), (7-bromo-2,3 -dihy dro-1H-py rido [2,3 -b] [1,4] oxazin-l-y1)(cyclopropyOmethanone (97 mg, 0.34 mmol) and Cs2CO3 (278 mg, 0.853 mmol) in dioxane (5 mL) was added Pd2(dba)3 (26 mg, 0.028 mmol), BrettPhos (31 mg, 0.057 mmol) under N2 Then the mixture was stirred at 100 C for 16 hrs. A brown suspension was formed. LCMS
showed -(3 -amino-5H-chromeno [4,3 -c] py ri din-8-yl)pyrroli din-2-one was consumed completely and desired product (Rt = 0.707 min; MS Calcd: 469.2; MS Found:
484.0 [M+H]+) was detected. The mixture was diluted with DCM/Me0H (10:1, 10 mL) and filtered. The cake was washed with DCM/Me0H (10:1, 5 mL). The filtrate was concentrated to dryness. The residue was triturated with DMSO/MECN (1:1, 5 mL) and filtered. The cake was washed with MECN (2 mL) and the solid was triturated with MECN (2 mL) for 16 h at 25 C.
The mixture was filtered and the cake was washed with MECN (1 mL). The cake was triturated with MECN
(3 mL) at 25 C for 16 hrs. The mixture was filtered and the cake was washed with MECN (1 mL). The cake was lyophilized for 18 hrs to give 1-(3-41-(cyclopropanecarbony1)-2,3-dihydro-1H-py ri do [2,3-b] [1,4] oxazin-7-yl)amino)-5H-chromeno [4,3-c] py ri din-8-y Opy rroli din-2-one (31.6 mg, 23% yield) as a yellow solid.
11-1 NMR (400 MHz, DMSO-d6) 6 0.90-1.04 (4H, m), 2.01-2.11 (2H, m), 2.17-2.26 (1H, m), 2.55 (2H, overlap with DMSO), 3.84 (2H, t, J= 7.2 Hz), 3.94-4.03 (2H, m), 4.37 (2H, t, J=
4.0 Hz), 5.08 (2H, s), 6.64 (1H, s), 7.30-7.40 (2H, m), 7.86 (1H, d, J= 8.4 Hz), 8.20 (1H, s), 8.56 (1H, s), 8.62 (1H, d, J= 2.0 Hz), 9.27 (1H, s).
Example 77: methyl 7-08-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazine-1-carboxylate
2.8 Hz), 8.59 (1H, s), 8.96 (1H, d, J= 2.4 Hz), 9.29 (1H, brs).
Example 76: 1-(3-01-(cyclopropanecarbony1)-2,3-dihydro-1H-pyrido12,3-b]11,41oxazin-7-yl)amino)-5H-chromeno14,3-c]pyridin-8-y1)pyrrolidin-2-one I
NN
[0418] To a suspension of 1-(3-amino-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (80 mg, 0.28 mmol), (7-bromo-2,3 -dihy dro-1H-py rido [2,3 -b] [1,4] oxazin-l-y1)(cyclopropyOmethanone (97 mg, 0.34 mmol) and Cs2CO3 (278 mg, 0.853 mmol) in dioxane (5 mL) was added Pd2(dba)3 (26 mg, 0.028 mmol), BrettPhos (31 mg, 0.057 mmol) under N2 Then the mixture was stirred at 100 C for 16 hrs. A brown suspension was formed. LCMS
showed -(3 -amino-5H-chromeno [4,3 -c] py ri din-8-yl)pyrroli din-2-one was consumed completely and desired product (Rt = 0.707 min; MS Calcd: 469.2; MS Found:
484.0 [M+H]+) was detected. The mixture was diluted with DCM/Me0H (10:1, 10 mL) and filtered. The cake was washed with DCM/Me0H (10:1, 5 mL). The filtrate was concentrated to dryness. The residue was triturated with DMSO/MECN (1:1, 5 mL) and filtered. The cake was washed with MECN (2 mL) and the solid was triturated with MECN (2 mL) for 16 h at 25 C.
The mixture was filtered and the cake was washed with MECN (1 mL). The cake was triturated with MECN
(3 mL) at 25 C for 16 hrs. The mixture was filtered and the cake was washed with MECN (1 mL). The cake was lyophilized for 18 hrs to give 1-(3-41-(cyclopropanecarbony1)-2,3-dihydro-1H-py ri do [2,3-b] [1,4] oxazin-7-yl)amino)-5H-chromeno [4,3-c] py ri din-8-y Opy rroli din-2-one (31.6 mg, 23% yield) as a yellow solid.
11-1 NMR (400 MHz, DMSO-d6) 6 0.90-1.04 (4H, m), 2.01-2.11 (2H, m), 2.17-2.26 (1H, m), 2.55 (2H, overlap with DMSO), 3.84 (2H, t, J= 7.2 Hz), 3.94-4.03 (2H, m), 4.37 (2H, t, J=
4.0 Hz), 5.08 (2H, s), 6.64 (1H, s), 7.30-7.40 (2H, m), 7.86 (1H, d, J= 8.4 Hz), 8.20 (1H, s), 8.56 (1H, s), 8.62 (1H, d, J= 2.0 Hz), 9.27 (1H, s).
Example 77: methyl 7-08-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazine-1-carboxylate
155 N N N
[0419] To a suspension of 1-(3-amino-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one (80 mg, 0.28 mmol), methyl 7-bromo-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazine-1-carboxylate (93 mg, 0.34 mmol) and Cs2CO3 (278 mg, 0.853 mmol) in dioxane (5 mL) was added Pd2(dba)3 (26 mg, 0.028 mmol), BrettPhos (31 mg, 0.057 mmol) under Nz.
Then the mixture was stirred at 100 C for 16 hrs. A brown suspension was formed. LCMS
showed 1-(3-amino-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one was consumed completely and desired product (Rt = 0.696 min; MS Calcd: 473.2; MS Found: 474.0 [M+H]+) was detected.
The mixture was diluted with DCM/Me0H (10:1, 10 mL) and filtered. The cake was washed with DCM/Me0H (10:1, 5 mL). The filtrate was concentrated to dryness. The residue was triturated with DMSO/MECN (1:1, 5 mL) and filtered. The cake was washed with MECN (2 mL) and the solid was triturated with MECN (2 mL) for 16 h at 25 C. The mixture was filtered and the cake was washed with MECN (1 mL) and dried in reduced pressure to give methyl 7-((8-(2-oxopyrroli din-1 -y1)-5H-chromeno [4,3 -c] py ri din-3 -yl)amino)-2,3 -dihy dro-1H-pyrido[2,3-b] [1,4]oxazine-1-carboxylate (32.6 mg, 24% yield) as a yellow solid.
11-1NMR (400 MHz, DMSO-d6) 6 2.01-2.11 (2H, m), 2.55 (2H, overlap with DMSO), 3.79 (3H, s), 3.81-3.89 (4H, m), 4.32 (2H, t, J= 4.4 Hz), 5.09 (2H, s), 6.65 (1H, s), 7.33 (1H, dd, J
= 8.8 Hz, 2.4 Hz), 7.37 (1H, d, J= 2.4 Hz), 7.86 (1H, d, J= 8.8 Hz), 8.26 (1H, d, J= 2.4 Hz), 8.60 (1H, s), 8.64-8.69 (1H., m), 9.22 (1H, brs).
Example 78: 1-(3-01-(methylsulfony1)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)amino)-5H-chromeno[4,3-c]pyridin-8-y1)pyrrolidin-2-one N N N
0=L
[0419] To a suspension of 1-(3-amino-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one (80 mg, 0.28 mmol), methyl 7-bromo-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazine-1-carboxylate (93 mg, 0.34 mmol) and Cs2CO3 (278 mg, 0.853 mmol) in dioxane (5 mL) was added Pd2(dba)3 (26 mg, 0.028 mmol), BrettPhos (31 mg, 0.057 mmol) under Nz.
Then the mixture was stirred at 100 C for 16 hrs. A brown suspension was formed. LCMS
showed 1-(3-amino-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one was consumed completely and desired product (Rt = 0.696 min; MS Calcd: 473.2; MS Found: 474.0 [M+H]+) was detected.
The mixture was diluted with DCM/Me0H (10:1, 10 mL) and filtered. The cake was washed with DCM/Me0H (10:1, 5 mL). The filtrate was concentrated to dryness. The residue was triturated with DMSO/MECN (1:1, 5 mL) and filtered. The cake was washed with MECN (2 mL) and the solid was triturated with MECN (2 mL) for 16 h at 25 C. The mixture was filtered and the cake was washed with MECN (1 mL) and dried in reduced pressure to give methyl 7-((8-(2-oxopyrroli din-1 -y1)-5H-chromeno [4,3 -c] py ri din-3 -yl)amino)-2,3 -dihy dro-1H-pyrido[2,3-b] [1,4]oxazine-1-carboxylate (32.6 mg, 24% yield) as a yellow solid.
11-1NMR (400 MHz, DMSO-d6) 6 2.01-2.11 (2H, m), 2.55 (2H, overlap with DMSO), 3.79 (3H, s), 3.81-3.89 (4H, m), 4.32 (2H, t, J= 4.4 Hz), 5.09 (2H, s), 6.65 (1H, s), 7.33 (1H, dd, J
= 8.8 Hz, 2.4 Hz), 7.37 (1H, d, J= 2.4 Hz), 7.86 (1H, d, J= 8.8 Hz), 8.26 (1H, d, J= 2.4 Hz), 8.60 (1H, s), 8.64-8.69 (1H., m), 9.22 (1H, brs).
Example 78: 1-(3-01-(methylsulfony1)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)amino)-5H-chromeno[4,3-c]pyridin-8-y1)pyrrolidin-2-one N N N
0=L
156 [0420] To a suspension of 1-(3-amino-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (80 mg, 0.28 mmol), 7-bromo-1-(methylsulfony1)-2,3-dihydro-1H-pyrido[2,3-b][1,41oxazine (100 mg, 0.341 mmol) and Cs2CO3 (278 mg, 0.853 mmol) in dioxane (5 mL) was added Pd2(dba)3 (26 mg, 0.028 mmol), BrettPhos (31 mg, 0.057 mmol) under Nz. Then the mixture was stirred at 100 C for 16 hrs. A brown suspension was formed. LCMS showed 1-(3-amino-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one was consumed completely and desired product (Rt = 0.693 min; MS Calcd: 493.1; MS Found: 494.0 [M+Hl+) was detected. The mixture was diluted with DCM/Me0H (10:1, 10 mL) and filtered. The cake was washed with DCM/Me0H (10:1, 5 mL). The filtrate was concentrated to dryness. The residue purified by prep-HPLC (column: DuraShell 150*25mm*Sum; mobile phase: [water (0.05% ammonia hydroxide v/v)-MECN];B%: 30%-50%,10min) and lyophilized to give 143-41-(methylsulfony 0-2,3-dihy dro-1H-py ri do [2,3 -b] [1,4] oxazin-7-yl)amino)-5H-chromeno [4,3-clpyridin-8-yOpyrrolidin-2-one (46.6 mg, 32% yield) as a yellow solid.
11-1NMR (400 MHz, DMSO-d6) 6 2.00-2.10 (2H, m), 2.55 (2H, overlap with DMSO), 3.22 (3H, s), 3.81-3.89 (4H, m), 4.34-4.39 (2H, m), 5.09 (2H, s), 6.65 (1H, s), 7.33 (1H, dd, J=
8.4 Hz, 2.0 Hz), 7.37 (1H, d, J= 2.0 Hz), 7.86 (1H, d, J= 8.8 Hz), 8.36 (2H, s), 8.59 (1H, s), 9.29 (1H, brs).
Example 79: 1-(3-01-(isopropylsulfony1)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)amino)-5H-chromeno[4,3-c]pyridin-8-y1)pyrrolidin-2-one I
N N N
0=b,( 0 \
[0421] To a suspension of 1-(3-amino-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (80 mg, 0.28 mmol), 7-bromo-1 -(is opropylsulfony1)-2,3 -dihy dro-1H-pyrido [2,3-b][1,41oxazine (109 mg, 0.341 mmol) and Cs2CO3 (278 mg, 0.853 mmol) in dioxane (5 mL) was added Pd2(dba)3 (26 mg, 0.028 mmol), BrettPhos (31 mg, 0.057 mmol) under N2. Then the mixture was stirred at 100 C for 16 hrs. A brown suspension was formed. LCMS
showed 1-(3-amino-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one was consumed completely and desired product (Rt = 0.731 min; MS Calcd: 521.2; MS Found: 521.9 [M+Hl+) was detected.
TLC (D
CM/Me0H=10: 1, by UV) showed 1-(3 -amino-5H-chromeno [4,3 -clpy ridin-8-
11-1NMR (400 MHz, DMSO-d6) 6 2.00-2.10 (2H, m), 2.55 (2H, overlap with DMSO), 3.22 (3H, s), 3.81-3.89 (4H, m), 4.34-4.39 (2H, m), 5.09 (2H, s), 6.65 (1H, s), 7.33 (1H, dd, J=
8.4 Hz, 2.0 Hz), 7.37 (1H, d, J= 2.0 Hz), 7.86 (1H, d, J= 8.8 Hz), 8.36 (2H, s), 8.59 (1H, s), 9.29 (1H, brs).
Example 79: 1-(3-01-(isopropylsulfony1)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)amino)-5H-chromeno[4,3-c]pyridin-8-y1)pyrrolidin-2-one I
N N N
0=b,( 0 \
[0421] To a suspension of 1-(3-amino-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (80 mg, 0.28 mmol), 7-bromo-1 -(is opropylsulfony1)-2,3 -dihy dro-1H-pyrido [2,3-b][1,41oxazine (109 mg, 0.341 mmol) and Cs2CO3 (278 mg, 0.853 mmol) in dioxane (5 mL) was added Pd2(dba)3 (26 mg, 0.028 mmol), BrettPhos (31 mg, 0.057 mmol) under N2. Then the mixture was stirred at 100 C for 16 hrs. A brown suspension was formed. LCMS
showed 1-(3-amino-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one was consumed completely and desired product (Rt = 0.731 min; MS Calcd: 521.2; MS Found: 521.9 [M+Hl+) was detected.
TLC (D
CM/Me0H=10: 1, by UV) showed 1-(3 -amino-5H-chromeno [4,3 -clpy ridin-8-
157 yl)pyrrolidin-2-one was consumed completely and a new spot was formed. The mixture was diluted with DCM/Me0H (10:1, 10 mL) and filtered. The cake was washed with DCM/Me0H
(10:1, 5 mL). The filtrate was concentrated to dryness. The residue was purified by Combi Flash (Me0H in DCM from 0% to 10%) to give crude product, which was purified by prep-HPLC (column: DuraShell 150*25mm*Sum; mobile phase: [water (0.05% ammonia hydroxide v/v)-MECN]; B%: 25%-45%, 10min) and lyophilized to give 1-(3-((1-(isopropylsulfony1)-2,3-dihydro-1H-py ri do [2,3-b] [1,4] oxazin-7-yl)amino)-5H-chromeno [4,3 -c] py ridin-8-yl)pyrrolidin-2-one (41 mg, 28% yield) as a yellow solid.
11-1NMR (400 MHz, DMSO-d6) 6 1.35 (6H, d, J= 6.8 Hz), 2.00-2.13 (2H, m), 2.55 (2H, overlap with DMSO), 3.72-3.80 (1H, m), 3.80-3.89 (4H, m), 4.35 (2H, t, J= 4.0 Hz), 5.09 (2H, s), 6.65 (1H, s), 7.33 (1H, dd, J= 8.4 Hz, 2.0 Hz), 7.37 (1H, d, J= 2.0 Hz), 7.87 (1H, d, J= 8.8 Hz), 8.30 (2H, dd, J= 10.8 Hz, 2.4 Hz), 8.57 (1H, s), 9.29 (1H, brs).
Example 80: 1-(5-methyl-3-(pyrimidin-5-ylamino)-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one N N N
Step 1: Preparation of 5 -bromo-2-chloroisonicotinaldehy de (D
Br tNCI
[0422] To a solution of LDA (2 M in THF, 296 mL) in THF (500 mL) was added a solution of 5-bromo-2-chloropyridine (95.0 g, 493 mmol) in THF (200 mL) dropwise at -75 C over a period of 2.5 h under Nz. The reaction mixture was stirred at -75 C for 1 hour. DMF (49 mL, 641 mmol) was then added over a period of 1 hour and the reaction mixture was stirred for 1.5 h. A black solution was formed. TLC showed the starting material was consumed completely.
The reaction was quenched by the addition of acetic acid (50 wt% in THF, 100 mL) at -75 C
followed by warming to between ¨40 and ¨30 C over 2 h. The reaction was added H20 (300 mL) slowly and then extracted with Et0Ac (500 mL x3). The combined organic phase was dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by Combi
(10:1, 5 mL). The filtrate was concentrated to dryness. The residue was purified by Combi Flash (Me0H in DCM from 0% to 10%) to give crude product, which was purified by prep-HPLC (column: DuraShell 150*25mm*Sum; mobile phase: [water (0.05% ammonia hydroxide v/v)-MECN]; B%: 25%-45%, 10min) and lyophilized to give 1-(3-((1-(isopropylsulfony1)-2,3-dihydro-1H-py ri do [2,3-b] [1,4] oxazin-7-yl)amino)-5H-chromeno [4,3 -c] py ridin-8-yl)pyrrolidin-2-one (41 mg, 28% yield) as a yellow solid.
11-1NMR (400 MHz, DMSO-d6) 6 1.35 (6H, d, J= 6.8 Hz), 2.00-2.13 (2H, m), 2.55 (2H, overlap with DMSO), 3.72-3.80 (1H, m), 3.80-3.89 (4H, m), 4.35 (2H, t, J= 4.0 Hz), 5.09 (2H, s), 6.65 (1H, s), 7.33 (1H, dd, J= 8.4 Hz, 2.0 Hz), 7.37 (1H, d, J= 2.0 Hz), 7.87 (1H, d, J= 8.8 Hz), 8.30 (2H, dd, J= 10.8 Hz, 2.4 Hz), 8.57 (1H, s), 9.29 (1H, brs).
Example 80: 1-(5-methyl-3-(pyrimidin-5-ylamino)-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one N N N
Step 1: Preparation of 5 -bromo-2-chloroisonicotinaldehy de (D
Br tNCI
[0422] To a solution of LDA (2 M in THF, 296 mL) in THF (500 mL) was added a solution of 5-bromo-2-chloropyridine (95.0 g, 493 mmol) in THF (200 mL) dropwise at -75 C over a period of 2.5 h under Nz. The reaction mixture was stirred at -75 C for 1 hour. DMF (49 mL, 641 mmol) was then added over a period of 1 hour and the reaction mixture was stirred for 1.5 h. A black solution was formed. TLC showed the starting material was consumed completely.
The reaction was quenched by the addition of acetic acid (50 wt% in THF, 100 mL) at -75 C
followed by warming to between ¨40 and ¨30 C over 2 h. The reaction was added H20 (300 mL) slowly and then extracted with Et0Ac (500 mL x3). The combined organic phase was dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by Combi
158 Flash (5% Et0Ac in pentane) to give impure product (50 g) as a yellow solid.
The solid was washed with PE (50 mL x3) to give 5-bromo-2-chloroisonicotinaldehyde (30.0 g, yield: 28%) as an off-white solid.
11-1NMR (400 MHz, DMSO-d6) 6 7.81 (1H, s), 8.85 (1H, s), 10.10 (1H, s).
Step 2: Preparation of 1-(4-bromo-3-fluorophenyl)pyrrolidin-2-one F
Br [0423] 1-Bromo-2-fluoro-4-iodobenzene (90.0 g, 299 mmol), CsF (114 g, 748 mmol) and Cul (17.1 g, 89.7 mmol) were taken up in Et0Ac (1000 mL) and the resulting mixture was degassed with nitrogen for 10 min. Pyrrolidin-2-one (32.6 g, 383 mmol) and ethane-1,2-diamine (10.8 g, 179 mmol) were added and the resulting mixture was stirred at 50 C for 18 h. A blue suspension was formed. TLC showed 1-bromo-2-fluoro-4-iodobenzene was consumed completely. The suspension was cooling to about 20 C and then worked up with last batch reaction. The combined mixture was filtered and the cake was washed with Et0Ac (300 mL x2). The combined filtrate was washed with 0.5 M aq. HC1 (1000 mL), 5%
(1000 mL), dried over Na2SO4, filtered and concentrated to dryness. The residue was triturated with MTBE/PE (1:1, 200 mL) for 30 min and filtered. The solid was washed with MTBE/PE
(50 mL) and dried in vacuum to give 1-(4-bromo-3-fluorophenyl)pyrrolidin-2-one (66.0 g, yield: 43%) as an off-white solid.
11-1NMR (400 MHz, CDC13) 6 2.14-2.23 (2H, m), 2.63 (2H, t, J= 8.0 Hz), 3.83 (2H, t, J=
7.2 Hz), 7.25-7.29 (1H, m), 7.47-7.53 (1H, m), 7.65 (1H, dd, J= 11.2 Hz, 2.8 Hz) Step 3: Preparation of 1-(3 -fluoro-4-(4,4,5,5-tetramethy1-1,3,2-di oxaborol an-2-yOphenyOpyrrolidin-2-one F
,0 [0424] A
mixture of 1-(4-bromo-3-fluorophenyl)pyrrolidin-2-one (56.0 g, 217 mmol), B2Pin2 (66.1 g, 260 mmol), KOAc (63.9 g, 650 mmol) and Pd(dppf)C12 (7.94 g, 10.8 mmol) in
The solid was washed with PE (50 mL x3) to give 5-bromo-2-chloroisonicotinaldehyde (30.0 g, yield: 28%) as an off-white solid.
11-1NMR (400 MHz, DMSO-d6) 6 7.81 (1H, s), 8.85 (1H, s), 10.10 (1H, s).
Step 2: Preparation of 1-(4-bromo-3-fluorophenyl)pyrrolidin-2-one F
Br [0423] 1-Bromo-2-fluoro-4-iodobenzene (90.0 g, 299 mmol), CsF (114 g, 748 mmol) and Cul (17.1 g, 89.7 mmol) were taken up in Et0Ac (1000 mL) and the resulting mixture was degassed with nitrogen for 10 min. Pyrrolidin-2-one (32.6 g, 383 mmol) and ethane-1,2-diamine (10.8 g, 179 mmol) were added and the resulting mixture was stirred at 50 C for 18 h. A blue suspension was formed. TLC showed 1-bromo-2-fluoro-4-iodobenzene was consumed completely. The suspension was cooling to about 20 C and then worked up with last batch reaction. The combined mixture was filtered and the cake was washed with Et0Ac (300 mL x2). The combined filtrate was washed with 0.5 M aq. HC1 (1000 mL), 5%
(1000 mL), dried over Na2SO4, filtered and concentrated to dryness. The residue was triturated with MTBE/PE (1:1, 200 mL) for 30 min and filtered. The solid was washed with MTBE/PE
(50 mL) and dried in vacuum to give 1-(4-bromo-3-fluorophenyl)pyrrolidin-2-one (66.0 g, yield: 43%) as an off-white solid.
11-1NMR (400 MHz, CDC13) 6 2.14-2.23 (2H, m), 2.63 (2H, t, J= 8.0 Hz), 3.83 (2H, t, J=
7.2 Hz), 7.25-7.29 (1H, m), 7.47-7.53 (1H, m), 7.65 (1H, dd, J= 11.2 Hz, 2.8 Hz) Step 3: Preparation of 1-(3 -fluoro-4-(4,4,5,5-tetramethy1-1,3,2-di oxaborol an-2-yOphenyOpyrrolidin-2-one F
,0 [0424] A
mixture of 1-(4-bromo-3-fluorophenyl)pyrrolidin-2-one (56.0 g, 217 mmol), B2Pin2 (66.1 g, 260 mmol), KOAc (63.9 g, 650 mmol) and Pd(dppf)C12 (7.94 g, 10.8 mmol) in
159 toluene (800 mL) was stirred at 100 C for 55 h under N2 atmosphere. The red solution turned to black gradually. LCMS (Rt = 0.690 min; MS Calcd: 305.2; MS Found: 305.9 [M+H1+). The reaction mixture was cooled to 20 C and filtered through silica gel and washed with MTBE
(1.5 L). The solvent was evaporated under reduced pressure to give 1-(3-fluoro-4-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-yOphenyOpyrrolidin-2-one (75.0 g, crude) as a black brown gum.
Step 4: Preparation of 2-chloro-5-(2-fluoro-4-(2-oxopyrrolidin-1-yl)phenyl)is oni cotinal dehy de I
N CI
[0425] 5-Bromo-2-chloroisonicotinaldehy de (20.0 g, 90.7 mmol), 1-(3-fluoro-4-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-yOphenyOpyrrolidin-2-one (33.4 g, crude), Pd(PPh3)4 (3.15 g, 2.72 mmol) and K2CO3 (37.6 g, 272 mmol) were taken up in MeCN (400 mL) and H20 (100 mL) and the resulting mixture was stirred at 70 C for 2 h. A black solution was formed. LCMS
(Rt = 0.649 min; MS Calcd: 318.1; MS Found: 318.8 [M+H1+). When cooled to 20 C the mixture was diluted with half-saturated brine (120 mL) and Et0Ac (150 mL). The organic layer was separated, and the aqueous layer was extracted with Et0Ac (150 mL
x2). The combined organics were dried over Na2SO4, filtered through a plug of silica and concentrated.
The residue was combined with last batch, purified by Combi Flash (50% DCM in PE) to give 2-chloro-5-(2-fluoro-4-(2-oxopyrrolidin-1-yl)phenyl)isonicotinaldehy de (47.0 g, crude) as a yellow solid.
Step 5: Preparation of 1 -(4-(6-chl oro-4-(1 -hy droxy ethyl)py ri din-3 -y1)-3-fluorophenyl)pyrrolidin-2-one OH
I
N CI
(1.5 L). The solvent was evaporated under reduced pressure to give 1-(3-fluoro-4-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-yOphenyOpyrrolidin-2-one (75.0 g, crude) as a black brown gum.
Step 4: Preparation of 2-chloro-5-(2-fluoro-4-(2-oxopyrrolidin-1-yl)phenyl)is oni cotinal dehy de I
N CI
[0425] 5-Bromo-2-chloroisonicotinaldehy de (20.0 g, 90.7 mmol), 1-(3-fluoro-4-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-yOphenyOpyrrolidin-2-one (33.4 g, crude), Pd(PPh3)4 (3.15 g, 2.72 mmol) and K2CO3 (37.6 g, 272 mmol) were taken up in MeCN (400 mL) and H20 (100 mL) and the resulting mixture was stirred at 70 C for 2 h. A black solution was formed. LCMS
(Rt = 0.649 min; MS Calcd: 318.1; MS Found: 318.8 [M+H1+). When cooled to 20 C the mixture was diluted with half-saturated brine (120 mL) and Et0Ac (150 mL). The organic layer was separated, and the aqueous layer was extracted with Et0Ac (150 mL
x2). The combined organics were dried over Na2SO4, filtered through a plug of silica and concentrated.
The residue was combined with last batch, purified by Combi Flash (50% DCM in PE) to give 2-chloro-5-(2-fluoro-4-(2-oxopyrrolidin-1-yl)phenyl)isonicotinaldehy de (47.0 g, crude) as a yellow solid.
Step 5: Preparation of 1 -(4-(6-chl oro-4-(1 -hy droxy ethyl)py ri din-3 -y1)-3-fluorophenyl)pyrrolidin-2-one OH
I
N CI
160 [0426] MeMgBr (3 M in Et20, 47 mL) was added slowly to a solution of 2-chloro-5-(2-fluoro-4-(2-oxopyrrolidin-l-yl)phenyl)isonicotinaldehyde (30.0 g, crude) in THF (500 mL) at 0 C under a nitrogen atmosphere to give a black suspension. The resulting mixture was stirred at 0 C for 2 h. LCMS (Rt = 0.608 min; MS Calcd: 334.1; MS Found: 334.9 [M+Hl+). Sat.
aq.NH4C1 (200 mL) was added followed by Et0Ac (200 mL). The organic layer was separated and the aqueous layer was extracted with Et0Ac (180 mL x2). The combined organics were dried over Na2SO4, filtered and concentrated to give 1-(4-(6-chloro-4-(1-hydroxyethyl)pyridin-3-y1)-3-fluorophenyl)pyrrolidin-2-one (31.0 g, crude) as a black brown gum.
Step 6: Preparation of 1-(3 -chl oro-5 -methyl-5H-chromeno [4,3-c] py ri din-8-y Opy rroli din-2-one I
N CI
[0427] NaH
(4.78 g, 119 mmol, 60% in mineral oil) was added to a solution of 1-(4-(6-chloro-4-(1-hydroxyethyl)pyridin-3-y1)-3-fluorophenyl)pyrrolidin-2-one (20.0 g, crude) in THF (300 mL) at 20 C and the resulting mixture was stirred at 20 C for 16 h.
A black solution was formed. LCMS (Rt = 0.665 min; MS Calcd: 314.1; MS Found: 314.9 [M+H]+).
Sat.
aq.NH4C1 (80 mL) was added and the mixture extracted with Et0Ac (100 mL x3).
The combined organic layer was dried over Na2SO4, filtered, concentrated. The residue was purified by Combi Flash (88% Et0Ac in pentane) to give impure product (10.0 g), then purified by Combi Flash (8% Et0Ac in DCM) to give 1-(3-chloro-5-methy1-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (7.80 g, yield: 21% for four steps) as a yellow solid.
Step 7: Preparation of 1-(5-methyl-3-(pyrimi din-5 -ylamino)-5H-chromeno [4,3-c] py ri din-8-yl)pyrrolidin-2-one N NN
aq.NH4C1 (200 mL) was added followed by Et0Ac (200 mL). The organic layer was separated and the aqueous layer was extracted with Et0Ac (180 mL x2). The combined organics were dried over Na2SO4, filtered and concentrated to give 1-(4-(6-chloro-4-(1-hydroxyethyl)pyridin-3-y1)-3-fluorophenyl)pyrrolidin-2-one (31.0 g, crude) as a black brown gum.
Step 6: Preparation of 1-(3 -chl oro-5 -methyl-5H-chromeno [4,3-c] py ri din-8-y Opy rroli din-2-one I
N CI
[0427] NaH
(4.78 g, 119 mmol, 60% in mineral oil) was added to a solution of 1-(4-(6-chloro-4-(1-hydroxyethyl)pyridin-3-y1)-3-fluorophenyl)pyrrolidin-2-one (20.0 g, crude) in THF (300 mL) at 20 C and the resulting mixture was stirred at 20 C for 16 h.
A black solution was formed. LCMS (Rt = 0.665 min; MS Calcd: 314.1; MS Found: 314.9 [M+H]+).
Sat.
aq.NH4C1 (80 mL) was added and the mixture extracted with Et0Ac (100 mL x3).
The combined organic layer was dried over Na2SO4, filtered, concentrated. The residue was purified by Combi Flash (88% Et0Ac in pentane) to give impure product (10.0 g), then purified by Combi Flash (8% Et0Ac in DCM) to give 1-(3-chloro-5-methy1-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (7.80 g, yield: 21% for four steps) as a yellow solid.
Step 7: Preparation of 1-(5-methyl-3-(pyrimi din-5 -ylamino)-5H-chromeno [4,3-c] py ri din-8-yl)pyrrolidin-2-one N NN
161 [0428] A
mixture of Pd2(dba)3 (7 mg, 0.01 mmol) and BrettPhos (9 mg, 0.02 mmol) in 1,4-dioxane (1 mL) was stirred at 50 C for 10 min. 1-(3-chloro-5-methy1-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (50 mg, 0.16 mmol), pyrimidin-5-amine (18 mg, 0.19 mmol) in dioxane (3 mL) and Cs2CO3 (155 mg, 0.476 mmol) were added and the resulting mixture was stirred at 100 C for 16 h. A black brown mixture was formed. LCMS (Rt =
0.605 min;
MS Calcd: 373.2; MS Found: 373.9 [M+H1+). The reaction mixture was diluted with DCM (10 mL), filtered and concentrated. The residue was purified by prep-HPLC (0.05%
NH31120 as an additive) and lyophilized to give 1-(5-methy1-3-(pyrimidin-5-ylamino)-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (13.8 mg, yield: 23%) as a white solid.
11-1NMR (400 MHz, DMSO-d6) 6 1.55 (3H, d, J= 6.8 Hz), 2.02-2.09 (2H, m), 2.53 (2H, overlap with DMSO), 3.85 (2H, t, J= 7.6 Hz), 5.31 (1H, q, J= 6.8 Hz), 6.77 (1H, s), 7.33 (1H, dd, J= 8.8, 2.4 Hz), 7.42 (1H, d, J= 2.0 Hz), 7.91 (1H, d, J= 8.4 Hz), 8.72 (1H, s), 8.73 (1H, s), 9.16 (2H, s), 9.64 (1H, brs).
Example 81: 1-(5-methyl-3-05-(trifluoromethyppyridin-3-yl)amino)-5H-chromeno[4,3-c] pyridin-8-yl)pyrrolid in-2-one I QN
[0429] A
mixture of Pd2(dba)3 (11 mg, 0.012 mmol) and BrettPhos (13 mg, 0.025 mmol) in 1,4-dioxane (1 mL) was stirred at 50 C for 10 min. 1-(3-chloro-5-methy1-5H-chromeno[4,3-clpyridin-8-yl)pyrrolidin-2-one (80 mg, 0.25 mmol), 5-(trifluoromethyl)pyridin-3-amine (49 mg, 0.30 mmol) in dioxane (5 mL) and Cs2CO3 (248 mg, 0.762 mmol) were added and the resulting mixture was stirred at 100 C for 16 h. A black brown mixture was formed. LCMS
(Rt = 0.702 min; MS Calcd: 440.2; MS Found: 440.9 [M+H1+). The reaction mixture was diluted with DCM (10 mL), filtered and concentrated. The residue was purified by prep-HPLC
(0.05% N}{31120 as an additive) and lyophilized to give 1-(5-methy1-3-((5-(trifluoromethyl)py ri din-3 -yl)amino)-5H-chromeno [4,3-c] pyri din-8-y Opy rroli din-2-one (25.0 mg, yield: 22%) as a white solid.
1-1-1NMR (400 MHz, DMSO-d6) 6 1.53 (3H, d, J= 6.8 Hz), 2.00-2.09 (2H, m), 2.52 (2H, overlap with DMSO), 3.83 (2H, t, J= 7.6 Hz), 5.29 (1H, q, J= 6.8 Hz), 6.77 (1H, s), 7.30
mixture of Pd2(dba)3 (7 mg, 0.01 mmol) and BrettPhos (9 mg, 0.02 mmol) in 1,4-dioxane (1 mL) was stirred at 50 C for 10 min. 1-(3-chloro-5-methy1-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (50 mg, 0.16 mmol), pyrimidin-5-amine (18 mg, 0.19 mmol) in dioxane (3 mL) and Cs2CO3 (155 mg, 0.476 mmol) were added and the resulting mixture was stirred at 100 C for 16 h. A black brown mixture was formed. LCMS (Rt =
0.605 min;
MS Calcd: 373.2; MS Found: 373.9 [M+H1+). The reaction mixture was diluted with DCM (10 mL), filtered and concentrated. The residue was purified by prep-HPLC (0.05%
NH31120 as an additive) and lyophilized to give 1-(5-methy1-3-(pyrimidin-5-ylamino)-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (13.8 mg, yield: 23%) as a white solid.
11-1NMR (400 MHz, DMSO-d6) 6 1.55 (3H, d, J= 6.8 Hz), 2.02-2.09 (2H, m), 2.53 (2H, overlap with DMSO), 3.85 (2H, t, J= 7.6 Hz), 5.31 (1H, q, J= 6.8 Hz), 6.77 (1H, s), 7.33 (1H, dd, J= 8.8, 2.4 Hz), 7.42 (1H, d, J= 2.0 Hz), 7.91 (1H, d, J= 8.4 Hz), 8.72 (1H, s), 8.73 (1H, s), 9.16 (2H, s), 9.64 (1H, brs).
Example 81: 1-(5-methyl-3-05-(trifluoromethyppyridin-3-yl)amino)-5H-chromeno[4,3-c] pyridin-8-yl)pyrrolid in-2-one I QN
[0429] A
mixture of Pd2(dba)3 (11 mg, 0.012 mmol) and BrettPhos (13 mg, 0.025 mmol) in 1,4-dioxane (1 mL) was stirred at 50 C for 10 min. 1-(3-chloro-5-methy1-5H-chromeno[4,3-clpyridin-8-yl)pyrrolidin-2-one (80 mg, 0.25 mmol), 5-(trifluoromethyl)pyridin-3-amine (49 mg, 0.30 mmol) in dioxane (5 mL) and Cs2CO3 (248 mg, 0.762 mmol) were added and the resulting mixture was stirred at 100 C for 16 h. A black brown mixture was formed. LCMS
(Rt = 0.702 min; MS Calcd: 440.2; MS Found: 440.9 [M+H1+). The reaction mixture was diluted with DCM (10 mL), filtered and concentrated. The residue was purified by prep-HPLC
(0.05% N}{31120 as an additive) and lyophilized to give 1-(5-methy1-3-((5-(trifluoromethyl)py ri din-3 -yl)amino)-5H-chromeno [4,3-c] pyri din-8-y Opy rroli din-2-one (25.0 mg, yield: 22%) as a white solid.
1-1-1NMR (400 MHz, DMSO-d6) 6 1.53 (3H, d, J= 6.8 Hz), 2.00-2.09 (2H, m), 2.52 (2H, overlap with DMSO), 3.83 (2H, t, J= 7.6 Hz), 5.29 (1H, q, J= 6.8 Hz), 6.77 (1H, s), 7.30
162 (1H, dd, J= 8.4, 2.0 Hz), 7.39 (1H, d, J= 2.0 Hz), 7.91 (1H, d, J= 8.4 Hz), 8.42 (1H, s), 8.74 (1H, s), 9.79 (1H, t, J= 2.0 Hz), 8.94 (1H, d, J= 2.4 Hz), 9.85 (1H, brs).
Example 82: 1-(3-01-(cyclopropanecarbony1)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)amino)-5-methyl-5H-chromeno[4,3-c]pyridin-8-y1)pyrrolidin-2-one c 0 I I
N
Step 1:
Preparation of tert-butyl (5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c] py ri din-3-yl)carbamate I
N NHBoc [0430] A
mixture of Pd2(dba)3 (581 mg, 0.635 mmol) and XantPhos (735 mg, 1.27 mmol) in 1,4-dioxane (1 mL) was stirred at 50 C for 10 min. 1-(3-Chloro-5-methy1-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (4.00 g, 12.7 mmol), BocNH2 (1.94 g, 16.5 mmol) in dioxane (80 mL) and Cs2CO3 (10.3 g, 31.7 mmol) were added and the resulting mixture was stirred at 100 C for 16 h. A black brown mixture was formed. LCMS
(Rt = 0.680 min; MS Calcd: 395.2; MS Found: 396.1 [M+Hl+). The reaction mixture was diluted with DCM (30 mL), filtered and concentrated to give tert-butyl (5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-yOcarbamate(6.00 g, crude) as a black brown gum.
Used in the next step without further purification.
Step 2: Preparation of 1-(3-amino-5 -methyl-5H-chromeno [4,3-c] py ri din-8-yl)pyrroli din-2-one I
Example 82: 1-(3-01-(cyclopropanecarbony1)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)amino)-5-methyl-5H-chromeno[4,3-c]pyridin-8-y1)pyrrolidin-2-one c 0 I I
N
Step 1:
Preparation of tert-butyl (5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c] py ri din-3-yl)carbamate I
N NHBoc [0430] A
mixture of Pd2(dba)3 (581 mg, 0.635 mmol) and XantPhos (735 mg, 1.27 mmol) in 1,4-dioxane (1 mL) was stirred at 50 C for 10 min. 1-(3-Chloro-5-methy1-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (4.00 g, 12.7 mmol), BocNH2 (1.94 g, 16.5 mmol) in dioxane (80 mL) and Cs2CO3 (10.3 g, 31.7 mmol) were added and the resulting mixture was stirred at 100 C for 16 h. A black brown mixture was formed. LCMS
(Rt = 0.680 min; MS Calcd: 395.2; MS Found: 396.1 [M+Hl+). The reaction mixture was diluted with DCM (30 mL), filtered and concentrated to give tert-butyl (5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-yOcarbamate(6.00 g, crude) as a black brown gum.
Used in the next step without further purification.
Step 2: Preparation of 1-(3-amino-5 -methyl-5H-chromeno [4,3-c] py ri din-8-yl)pyrroli din-2-one I
163 [0431] To a stirred solution of tert-butyl (5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-yOcarbamate (5.01 g, crude) in DCM (40 mL) was added HC1/Et0Ac (4 M, 300 mL) at 20 C. The yellow solution turned to suspension, the reaction mixture was stirred for 20 h. LCMS (Rt = 0.522 min; MS Calcd: 295.1; MS Found:
295.8 [M+H]+). The mixture was concentrated. The residue was purified by Combi Flash (1% Et3N
in Et0Ac) to give 1-(3 -amino-5 -methyl-5H-chromeno [4,3 -c] py ri din-8-yl)pyrroli din-2-one (2.62 g, yield: 70% for two steps) as a yellow solid.
Step 3: Preparation of (7-bromo-2,3 -dihy dro-1H-pyri do [2,3-b] [1,4] oxazin-1 -yl)(cy clopropyOmethanone BrjN) Ovr [0432] In a separate vial, to a solution of cyclopropanecarboxylic acid (240 mg, 2.79 mmol) in DCM (2 mL), DMF (25 mg, 0.35 mmol) was added oxalyl chloride (0.3 mL, 3.5 mmol). The reaction mixture was stirred at 20 C for 0.5 hour. A light yellow solution was formed. The mixture was concentrated to give crude cyclopropanecarbonyl chloride as a yellow oil.
[0433] To a solution of 7-bromo-2,3-dihydro-1H-pyrido[2,3-b][1,4] oxazine in DCM (6 mL) was added Et3N (0.5 mL, 3.5 mmol). The reaction mixture was cooled to 0 C
and then added the resuting crude cyclopropanecarbonyl chloride in DCM (2 mL) dropwise. The reaction mixture was then warmed to 20 C, stirred at 20 C for 2 h under N2 atmosphere.
The colorless solution turned to yellow gradually. LCMS (Rt = 0.601 min; MS
Calcd: 282.0;
MS Found: 282.6 [M+H]+). The reaction mixture was concentrated together with the last batch.
The residue was purified by Combi Flash (1% Et3N in DCM) to afford (7-bromo-2,3-dihydro-1H-pyrido [2,3-b] [1,4] oxazin-1-y1)(cyclopropyOmethanone (240 mg, yield: 92%) as a yellow gum.
[0434] 1FINMR
(400 MHz, CDC13) 6 0.95-1.01 (2H, m), 1.17-1.23 (2H, m), 1.89-1.20 (1H, m), 4.02 (2H, t, J= 4.8 Hz), 4.46 (2H, t, J= 4.8 Hz), 8.06 (1H, d, J = 2.4 Hz), 8.20 (1H, brs).
Step 4:
Preparation of 1-(3-((1 -(cy cl opropanecarb ony1)-2,3-dihy dro-1H-pyri do [2,3-b] [1,4] oxazin-7-yl)amino)-5-methy1-5H-chromeno [4,3-c] py ridin-8-yl)py rrol i din-2-one
295.8 [M+H]+). The mixture was concentrated. The residue was purified by Combi Flash (1% Et3N
in Et0Ac) to give 1-(3 -amino-5 -methyl-5H-chromeno [4,3 -c] py ri din-8-yl)pyrroli din-2-one (2.62 g, yield: 70% for two steps) as a yellow solid.
Step 3: Preparation of (7-bromo-2,3 -dihy dro-1H-pyri do [2,3-b] [1,4] oxazin-1 -yl)(cy clopropyOmethanone BrjN) Ovr [0432] In a separate vial, to a solution of cyclopropanecarboxylic acid (240 mg, 2.79 mmol) in DCM (2 mL), DMF (25 mg, 0.35 mmol) was added oxalyl chloride (0.3 mL, 3.5 mmol). The reaction mixture was stirred at 20 C for 0.5 hour. A light yellow solution was formed. The mixture was concentrated to give crude cyclopropanecarbonyl chloride as a yellow oil.
[0433] To a solution of 7-bromo-2,3-dihydro-1H-pyrido[2,3-b][1,4] oxazine in DCM (6 mL) was added Et3N (0.5 mL, 3.5 mmol). The reaction mixture was cooled to 0 C
and then added the resuting crude cyclopropanecarbonyl chloride in DCM (2 mL) dropwise. The reaction mixture was then warmed to 20 C, stirred at 20 C for 2 h under N2 atmosphere.
The colorless solution turned to yellow gradually. LCMS (Rt = 0.601 min; MS
Calcd: 282.0;
MS Found: 282.6 [M+H]+). The reaction mixture was concentrated together with the last batch.
The residue was purified by Combi Flash (1% Et3N in DCM) to afford (7-bromo-2,3-dihydro-1H-pyrido [2,3-b] [1,4] oxazin-1-y1)(cyclopropyOmethanone (240 mg, yield: 92%) as a yellow gum.
[0434] 1FINMR
(400 MHz, CDC13) 6 0.95-1.01 (2H, m), 1.17-1.23 (2H, m), 1.89-1.20 (1H, m), 4.02 (2H, t, J= 4.8 Hz), 4.46 (2H, t, J= 4.8 Hz), 8.06 (1H, d, J = 2.4 Hz), 8.20 (1H, brs).
Step 4:
Preparation of 1-(3-((1 -(cy cl opropanecarb ony1)-2,3-dihy dro-1H-pyri do [2,3-b] [1,4] oxazin-7-yl)amino)-5-methy1-5H-chromeno [4,3-c] py ridin-8-yl)py rrol i din-2-one
164 c 0 I
NN
[0435] A
mixture of Pd2(dba)3 (16 mg, 0.017 mmol) and BrettPhos (18 mg, 0.034 mmol) in 1,4-dioxane (1 mL) was stirred at 50 C for 10 min. 1-(3-Amino-5-methy1-5H-chromeno [4,3-c] py ri din-8-y Opy rrol i din-2-one (50 mg, 0.17 mmol), (7-bromo-2,3-dihydro-1H-pyrido[2,3-b][1,410xazin-1-y1)(cyclopropyl)methanone (58 mg, 0.20 mmol) in dioxane (3 mL) and Cs2CO3 (165 mg, 0.508 mmol) were added and the resulting mixture was stirred at 100 C for 16 h. A black brown mixture was formed. LCMS (Rt = 0.598 min; MS
Calcd: 497.2;
MS Found: 498.0 [M+Hl+). The reaction mixture was diluted with DCM (10 mL), filtered and concentrated. The residue was purified by prep-HPLC (0.05% NH31-120 as an additive) and lyophilized to give 1-(3 -((1-(cy cloprop anecarbony1)-2,3 -dihy dro-1H-py ri do [2,3-b] [1,4] oxazin-7-y 1)amino)-5 -methyl-5H-chromeno [4,3-c] py ridin-8-yl)py rrol i din-2-one (20.2 mg, yield: 24%) as an off-white solid.
11-1NMR (400 MHz, DMSO-d6) 6 0.92-0.99 (4H, m), 1.52 (3H, d, J= 6.4 Hz), 2.03-2.09 (2H, m), 2.20-2.33 (1H, m), 2.54 (2H, overlap with DMSO), 3.84 (2H, t, J= 6.8 Hz), 3.96-4.00 (2H, m), 4.37 (2H, t, J= 4.4 Hz), 5.24 (1H, q, J= 6.4 Hz), 6.65 (1H, s), 7.30 (1H, dd, J= 8.4, 2.4 Hz), 7.39 (1H, d, J= 2.4 Hz), 7.87 (1H, d, J= 8.8 Hz), 8.20 (1H, s), 8.57 (1H, s), 8.62 (1H, d, J= 2.4 Hz), 9.28 (1H, brs).
Example 83: methyl 7-05-methyl-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazine-1-carboxylate N
Step 1: Preparation of methyl 7-bromo-2,3-dihy dro-1H-py ri do [2,3-b] [1,4]
oxazine-1 -carboxylate
NN
[0435] A
mixture of Pd2(dba)3 (16 mg, 0.017 mmol) and BrettPhos (18 mg, 0.034 mmol) in 1,4-dioxane (1 mL) was stirred at 50 C for 10 min. 1-(3-Amino-5-methy1-5H-chromeno [4,3-c] py ri din-8-y Opy rrol i din-2-one (50 mg, 0.17 mmol), (7-bromo-2,3-dihydro-1H-pyrido[2,3-b][1,410xazin-1-y1)(cyclopropyl)methanone (58 mg, 0.20 mmol) in dioxane (3 mL) and Cs2CO3 (165 mg, 0.508 mmol) were added and the resulting mixture was stirred at 100 C for 16 h. A black brown mixture was formed. LCMS (Rt = 0.598 min; MS
Calcd: 497.2;
MS Found: 498.0 [M+Hl+). The reaction mixture was diluted with DCM (10 mL), filtered and concentrated. The residue was purified by prep-HPLC (0.05% NH31-120 as an additive) and lyophilized to give 1-(3 -((1-(cy cloprop anecarbony1)-2,3 -dihy dro-1H-py ri do [2,3-b] [1,4] oxazin-7-y 1)amino)-5 -methyl-5H-chromeno [4,3-c] py ridin-8-yl)py rrol i din-2-one (20.2 mg, yield: 24%) as an off-white solid.
11-1NMR (400 MHz, DMSO-d6) 6 0.92-0.99 (4H, m), 1.52 (3H, d, J= 6.4 Hz), 2.03-2.09 (2H, m), 2.20-2.33 (1H, m), 2.54 (2H, overlap with DMSO), 3.84 (2H, t, J= 6.8 Hz), 3.96-4.00 (2H, m), 4.37 (2H, t, J= 4.4 Hz), 5.24 (1H, q, J= 6.4 Hz), 6.65 (1H, s), 7.30 (1H, dd, J= 8.4, 2.4 Hz), 7.39 (1H, d, J= 2.4 Hz), 7.87 (1H, d, J= 8.8 Hz), 8.20 (1H, s), 8.57 (1H, s), 8.62 (1H, d, J= 2.4 Hz), 9.28 (1H, brs).
Example 83: methyl 7-05-methyl-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazine-1-carboxylate N
Step 1: Preparation of methyl 7-bromo-2,3-dihy dro-1H-py ri do [2,3-b] [1,4]
oxazine-1 -carboxylate
165 ===.1 Br [0436] To a solution of 7-bromo-2,3-dihydro-1H-pyrido[2,3-b][1,41oxazine (1.00 g, 4.65 mmol) in pyridine (15 mL) was added methyl carbonochloridate (659 mg, 6.98 mmol) under nitrogen at 20 C. The resulting mixture was stirred for 16 h. An orange solution was formed.
LCMS showed 7-bromo-2,3-dihydro-1H-pyrido[2,3-b][1,41oxazine was not consumed.
Then dropwise added methyl carbonochloridate (659 mg, 6.98 mmol) and DMAP (113 mg, 0.930 mmol). The resulting mixture was stirred for 40 h at 20 C. LCMS showed 7-bromo-2,3-dihydro-1H-pyrido[2,3-b][1,41oxazine was not consumed still. The resulting mixture was stirred at 50 C for 20 h. LCMS (Rt = 0.602 min; MS Calcd: 274.0; MS Found:
274.8 [M+H1+).
The reaction mixture was concentrated. The residue was purified by Combi Flash (45% DCM
in PE (1% Et3N as an additive)) to give methyl 7-bromo-2,3-dihydro-1H-pyrido[2,3-b][1,41oxazine-1-carboxylate (785 mg, yield: 62%) as an off-white solid.
11-1NMR (400 MHz, CDC13) 6 3.86 (3H, s), 3.93 (2H, t, J = 5.6 Hz), 4.38 (2H, t, J = 4.8 Hz), 7.98 (1H, d, J= 2.4 Hz), 8.56 (1H, brs).
Step 2: Preparation of methyl 7-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)-2,3-dihydro-1H-pyrido[2,3-b] [1,4] oxazine-1 -carboxylate N -N
[0437] A
mixture of Pd2(dba)3 (16 mg, 0.017 mmol) and BrettPhos (18 mg, 0.034 mmol) in 1,4-dioxane (1 mL) was stirred at 50 C for 10 min. 1-(3-Amino-5-methy1-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (50 mg, 0.17 mmol), methyl 7-bromo-2,3-dihydro-1H-pyrido[2,3-b][1,41oxazine-1-carboxylate (46 mg, 0.17 mmol) in dioxane (3 mL) and Cs2CO3 (165 mg, 0.508 mmol) were added and the resulting mixture was stirred at 100 C
for 6 h. A black brown mixture was formed. LCMS (Rt = 0.583 min; MS Calcd:
487.2; MS
Found: 487.9 [M+H1+). The reaction mixture was diluted with DCM (10 mL), filtered and
LCMS showed 7-bromo-2,3-dihydro-1H-pyrido[2,3-b][1,41oxazine was not consumed.
Then dropwise added methyl carbonochloridate (659 mg, 6.98 mmol) and DMAP (113 mg, 0.930 mmol). The resulting mixture was stirred for 40 h at 20 C. LCMS showed 7-bromo-2,3-dihydro-1H-pyrido[2,3-b][1,41oxazine was not consumed still. The resulting mixture was stirred at 50 C for 20 h. LCMS (Rt = 0.602 min; MS Calcd: 274.0; MS Found:
274.8 [M+H1+).
The reaction mixture was concentrated. The residue was purified by Combi Flash (45% DCM
in PE (1% Et3N as an additive)) to give methyl 7-bromo-2,3-dihydro-1H-pyrido[2,3-b][1,41oxazine-1-carboxylate (785 mg, yield: 62%) as an off-white solid.
11-1NMR (400 MHz, CDC13) 6 3.86 (3H, s), 3.93 (2H, t, J = 5.6 Hz), 4.38 (2H, t, J = 4.8 Hz), 7.98 (1H, d, J= 2.4 Hz), 8.56 (1H, brs).
Step 2: Preparation of methyl 7-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)-2,3-dihydro-1H-pyrido[2,3-b] [1,4] oxazine-1 -carboxylate N -N
[0437] A
mixture of Pd2(dba)3 (16 mg, 0.017 mmol) and BrettPhos (18 mg, 0.034 mmol) in 1,4-dioxane (1 mL) was stirred at 50 C for 10 min. 1-(3-Amino-5-methy1-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (50 mg, 0.17 mmol), methyl 7-bromo-2,3-dihydro-1H-pyrido[2,3-b][1,41oxazine-1-carboxylate (46 mg, 0.17 mmol) in dioxane (3 mL) and Cs2CO3 (165 mg, 0.508 mmol) were added and the resulting mixture was stirred at 100 C
for 6 h. A black brown mixture was formed. LCMS (Rt = 0.583 min; MS Calcd:
487.2; MS
Found: 487.9 [M+H1+). The reaction mixture was diluted with DCM (10 mL), filtered and
166 concentrated. The residue was purified by prep-HPLC (0.05% NH31120 as an additive) and lyophilized to give methyl 7-((5 -methyl-8-(2-oxopyrrolidin-1-y1)-5H-chromeno [4,3 -c] pyridin-3-yl)amino)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazine-1-carboxylate (12.1 mg, yield: 15%) as a white solid.
11-1NMR (400 MHz, DMSO-d6) 6 1.52 (3H, d, J= 6.4 Hz), 2.02-2.09 (2H, m), 2.52 (2H, overlap with DMSO), 3.78 (3H, s), 3.81-3.88 (4H, m), 4.31 (2H, t, J= 4.0 Hz), 5.24 (1H, q, J
= 6.4 Hz), 6.66 (1H, s), 7.30 (1H, dd, J= 8.4, 2.0 Hz), 7.38 (1H, d, J= 2.4 Hz), 7.86 (1H, d, J
= 8.4 Hz), 8.25 (1H, d, J= 2.4 Hz), 8.60 (1H, s), 8.67 (1H, brs), 9.23 (1H, brs).
Example 84: 1-(3-((1-isobutyry1-2,3-dihydro-1H-pyrido12,3-b]11,41oxazin-7-yl)amino)-5-methyl-5H-chromeno14,3-c]pyridin-8-yl)pyrrolidin-2-one N N
CD
Step 1:
Preparation of 1-(7-bromo-2,3 -dihy dro-1H-py ri do [2,3 -b] [1,4] oxazin-1 -y1)-2-methylpropan-1-one BrjNo [0438] To a solution of 7-bromo-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazine (600 mg, 2.79 mmol) in DCM (5 mL) was added pyridine (1.1 mL). The reaction mixture was cooled to 0 C
and then added isobutyryl chloride (595 mg, 5.58 mmol) in DCM (2 mL) dropwise.
The reaction mixture was then warmed to 10 C, stirred at 10 C for 12 h under N2 atmosphere.
The colorless solution turned to an orange solution gradually. LCMS (Rt =
0.603 min; MS
Calcd: 286.0; MS Found: 286.7 [M+Hr). The residue was purified by Combi Flash (1% Et3N
in DCM) to give 1 -(7-bromo-2,3 -dihy dro-1H-py ri do [2,3-b] [1,4] oxazin-1 -y 0-2-methy 1prop an-1-one (700 mg, yield: 88%) as a white solid.
11-1NMR (400 MHz, DMSO-d6) 6 1.52 (3H, d, J= 6.4 Hz), 2.02-2.09 (2H, m), 2.52 (2H, overlap with DMSO), 3.78 (3H, s), 3.81-3.88 (4H, m), 4.31 (2H, t, J= 4.0 Hz), 5.24 (1H, q, J
= 6.4 Hz), 6.66 (1H, s), 7.30 (1H, dd, J= 8.4, 2.0 Hz), 7.38 (1H, d, J= 2.4 Hz), 7.86 (1H, d, J
= 8.4 Hz), 8.25 (1H, d, J= 2.4 Hz), 8.60 (1H, s), 8.67 (1H, brs), 9.23 (1H, brs).
Example 84: 1-(3-((1-isobutyry1-2,3-dihydro-1H-pyrido12,3-b]11,41oxazin-7-yl)amino)-5-methyl-5H-chromeno14,3-c]pyridin-8-yl)pyrrolidin-2-one N N
CD
Step 1:
Preparation of 1-(7-bromo-2,3 -dihy dro-1H-py ri do [2,3 -b] [1,4] oxazin-1 -y1)-2-methylpropan-1-one BrjNo [0438] To a solution of 7-bromo-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazine (600 mg, 2.79 mmol) in DCM (5 mL) was added pyridine (1.1 mL). The reaction mixture was cooled to 0 C
and then added isobutyryl chloride (595 mg, 5.58 mmol) in DCM (2 mL) dropwise.
The reaction mixture was then warmed to 10 C, stirred at 10 C for 12 h under N2 atmosphere.
The colorless solution turned to an orange solution gradually. LCMS (Rt =
0.603 min; MS
Calcd: 286.0; MS Found: 286.7 [M+Hr). The residue was purified by Combi Flash (1% Et3N
in DCM) to give 1 -(7-bromo-2,3 -dihy dro-1H-py ri do [2,3-b] [1,4] oxazin-1 -y 0-2-methy 1prop an-1-one (700 mg, yield: 88%) as a white solid.
167 NMR (400 MHz, CDC13) 1.21 (6H, d, J= 6.8 Hz), 2.94-2.97 (1H, m), 3.93 (2H, t, J= 4.4 Hz), 4.44 (2H, t, J= 4.8 Hz), 8.05 (1H, d, J= 2.0 Hz), 8.44 (1H, brs).
Step 2:
Preparation of 1 -(3 -((l-i s obuty ry1-2,3 -dihy dro-1H-py ri do [2,3-b]
[1,4] oxazin-7-yl)amino)-5 -methyl-5H-chromeno [4,3-c] py ri din-8-yl)pyrroli din-2-one XNJ
N N
[0439] A
mixture of Pd2(dba)3 (16 mg, 0.017 mmol) and BrettPhos (18 mg, 0.034 mmol) in 1,4-dioxane (1 mL) was stirred at 50 C for 10 min. 1-(3-Amino-5-methy1-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (50 mg, 0.17 mmol), 1-(7-bromo-2,3-dihydro-1H-pyrido[2,3-b][1,4]0xazin-1-y1)-2-methylpropan-1-one (58 mg, 0.20 mmol) in dioxane (4 mL) and Cs2CO3 (165 mg, 0.508 mmol) were added and the resulting mixture was stirred at 100 C for 16 h. A black brown mixture was formed. LCMS (Rt = 0.604 min; MS
Calcd: 499.2;
MS Found: 500.2 [M+Hl+). The reaction mixture was diluted with DCM (10 mL), filtered and concentrated. The residue was purified by prep-HPLC (0.225% FA as an additive) and lyophilized to give 1-(3-((1-isobutyry1-2,3-dihydro-1H-pyrido[2,3-b] [1,4]
oxazin-7-y0amino)-5-methy1-5H-chromeno [4,3-clpyridin-8-yOpyrrolidin-2-one (31.9 mg, yield: 38%) as a yellow solid.
NMR (400 MHz, DMSO-d6) 6 1.13 (6H, d, J= 6.4 Hz), 1.52 (3H, d, J= 6.4 Hz), 2.01-2.09 (2H, m), 2.57 (2H, overlap with DMSO), 3.10-3.30 (1H, m), 3.84 (2H, t, J=
7.2 Hz), 3.92 (2H, t, J= 4.4 Hz), 4.35 (2H, t, J= 4.4 Hz), 5.24 (1H, q, J= 6.0 Hz), 6.65 (1H, s), 7.30 (1H, dd, J= 8.8, 2.0 Hz), 7.38 (1H, d, J= 2.0 Hz), 7.86 (1H, d, J= 8.0 Hz), 8.26 (1H, s), 8.57 (2H, s), 9.24 (1H, brs).
Example 85: 1-(3-01-(isopropylsulfony1)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)amino)-5-methyl-5H-chromeno[4,3-c]pyridin-8-y1)pyrrolidin-2-one
Step 2:
Preparation of 1 -(3 -((l-i s obuty ry1-2,3 -dihy dro-1H-py ri do [2,3-b]
[1,4] oxazin-7-yl)amino)-5 -methyl-5H-chromeno [4,3-c] py ri din-8-yl)pyrroli din-2-one XNJ
N N
[0439] A
mixture of Pd2(dba)3 (16 mg, 0.017 mmol) and BrettPhos (18 mg, 0.034 mmol) in 1,4-dioxane (1 mL) was stirred at 50 C for 10 min. 1-(3-Amino-5-methy1-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (50 mg, 0.17 mmol), 1-(7-bromo-2,3-dihydro-1H-pyrido[2,3-b][1,4]0xazin-1-y1)-2-methylpropan-1-one (58 mg, 0.20 mmol) in dioxane (4 mL) and Cs2CO3 (165 mg, 0.508 mmol) were added and the resulting mixture was stirred at 100 C for 16 h. A black brown mixture was formed. LCMS (Rt = 0.604 min; MS
Calcd: 499.2;
MS Found: 500.2 [M+Hl+). The reaction mixture was diluted with DCM (10 mL), filtered and concentrated. The residue was purified by prep-HPLC (0.225% FA as an additive) and lyophilized to give 1-(3-((1-isobutyry1-2,3-dihydro-1H-pyrido[2,3-b] [1,4]
oxazin-7-y0amino)-5-methy1-5H-chromeno [4,3-clpyridin-8-yOpyrrolidin-2-one (31.9 mg, yield: 38%) as a yellow solid.
NMR (400 MHz, DMSO-d6) 6 1.13 (6H, d, J= 6.4 Hz), 1.52 (3H, d, J= 6.4 Hz), 2.01-2.09 (2H, m), 2.57 (2H, overlap with DMSO), 3.10-3.30 (1H, m), 3.84 (2H, t, J=
7.2 Hz), 3.92 (2H, t, J= 4.4 Hz), 4.35 (2H, t, J= 4.4 Hz), 5.24 (1H, q, J= 6.0 Hz), 6.65 (1H, s), 7.30 (1H, dd, J= 8.8, 2.0 Hz), 7.38 (1H, d, J= 2.0 Hz), 7.86 (1H, d, J= 8.0 Hz), 8.26 (1H, s), 8.57 (2H, s), 9.24 (1H, brs).
Example 85: 1-(3-01-(isopropylsulfony1)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)amino)-5-methyl-5H-chromeno[4,3-c]pyridin-8-y1)pyrrolidin-2-one
168 gN 0 NN
0=L( Step 1:
Preparation of 7-bromo-1 -(i s opropylsulfony1)-2,3-dihy dro-1H-py ri do [2,3 -b] [1,4] oxazine Br [0440] To a solution of 7-bromo-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazine (1.00 g, 4.65 mmol) in DMF (5 mL) was added NaH (558 mg, 14.0 mmol, 60% in mineral oil) at 0 C. The reaction mixture was heated to 50 C for 1 hour, and then cooled to 0 C. The reaction mixture was dropwise added propane-2-sulfonyl chloride (1.33 g, 9.30 mmol). The reaction mixture was warmed to 20 C, stirred at 20 C for 16 h under N2 atmosphere. A black mixture was formed. The reaction mixture was diluted with Et0Ac (80 mL). The organic layers were washed with H20 (25 mL x3), dried over Na2SO4, filtered and concentrated. The residue was combined with last batch, purified by Combi Flash (30% Et0Ac in pentane (1%
Et3N as an additive)) to give 7-bromo-1-(isopropylsulfony1)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazine (610 mg, yield: 34%) as a yellow gum.
11-1 NMR (400 MHz, CDC13) 6 1.44 (6H, d, J= 7.2 Hz), 3.37-3.48 (1H, m), 3.84 (2H, t, J =
4.4 Hz), 4.44 (2H, t, J = 4.4 Hz), 7.99 (1H, d, J= 2.0 Hz), 8.02 (1H, d, J=
2.4 Hz).
Step 2: Preparation of 1-(3-41-(isopropylsulfony1)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)amino)-5-methy1-5H-chromeno [4,3 -c] pyri din-8-yl)py rroli din-2-one NN
0=L(
0=L( Step 1:
Preparation of 7-bromo-1 -(i s opropylsulfony1)-2,3-dihy dro-1H-py ri do [2,3 -b] [1,4] oxazine Br [0440] To a solution of 7-bromo-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazine (1.00 g, 4.65 mmol) in DMF (5 mL) was added NaH (558 mg, 14.0 mmol, 60% in mineral oil) at 0 C. The reaction mixture was heated to 50 C for 1 hour, and then cooled to 0 C. The reaction mixture was dropwise added propane-2-sulfonyl chloride (1.33 g, 9.30 mmol). The reaction mixture was warmed to 20 C, stirred at 20 C for 16 h under N2 atmosphere. A black mixture was formed. The reaction mixture was diluted with Et0Ac (80 mL). The organic layers were washed with H20 (25 mL x3), dried over Na2SO4, filtered and concentrated. The residue was combined with last batch, purified by Combi Flash (30% Et0Ac in pentane (1%
Et3N as an additive)) to give 7-bromo-1-(isopropylsulfony1)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazine (610 mg, yield: 34%) as a yellow gum.
11-1 NMR (400 MHz, CDC13) 6 1.44 (6H, d, J= 7.2 Hz), 3.37-3.48 (1H, m), 3.84 (2H, t, J =
4.4 Hz), 4.44 (2H, t, J = 4.4 Hz), 7.99 (1H, d, J= 2.0 Hz), 8.02 (1H, d, J=
2.4 Hz).
Step 2: Preparation of 1-(3-41-(isopropylsulfony1)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)amino)-5-methy1-5H-chromeno [4,3 -c] pyri din-8-yl)py rroli din-2-one NN
0=L(
169 [0441] A
mixture of Pd2(dba)3 (16 mg, 0.017 mmol) and BrettPhos (18 mg, 0.034 mmol) in 1,4-dioxane (1 mL) was stirred at 50 C for 10 min. 1-(3-Amino-5-methy1-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (50 mg, 0.17 mmol), 7-bromo-(isopropylsulfony1)-2,3-dihydro-1H-pyrido[2,3-b][1,4loxazine (65 mg, 0.20 mmol) in dioxane (4 mL) and Cs2CO3 (165 mg, 0.508 mmol) were added and the resulting mixture was stirred at 100 C for 16 h. A black brown mixture was formed. LCMS (Rt = 0.614 min; MS
Calcd: 535.2;
MS Found: 536.1 [M+H]+). The reaction mixture was diluted with DCM (10 mL), filtered and concentrated. The residue was purified by prep-HPLC (0.05% NH31120 as an additive) and lyophilized to give 1-(3 -((1-(i s opropylsulfony1)-2,3-dihy dro-1H-pyri do [2,3-b] [1,4] oxazin-7-yl)amino)-5-methy1-5H-chromeno[4,3-c]pyridin-8-y1)pyrrolidin-2-one (42.8 mg, yield: 47%) as an off-white solid.
11-1NMR (400 MHz, DMSO-d6) 6 1.34 (6H, d, J= 6.8 Hz), 1.52 (3H, d, J= 6.4 Hz), 2.01-2.08 (2H, m), 2.56 (2H, overlap with DMSO), 3.71-3.78 (1H, m), 3.80-3.85 (4H, m), 4.34 (2H, t, J= 4.4 Hz), 5.23 (1H, q, J= 6.4 Hz), 6.65 (1H, s), 7.30 (1H, dd, J=
8.8, 2.0 Hz), 7.38 (1H, d, J= 2.0 Hz), 7.86 (1H, d, J= 8.4 Hz), 8.26 (1H, d, J= 2.0 Hz), 8.29 (1H, d, J= 2.0 Hz), 8.58 (1H, s), 9.28 (1H, brs).
Example 86: 1-(5-methyl-3-((1-pivaloy1-2,3-dihydro-1H-pyrido [2,3-b] [1,4]
oxazin-7-yl)amino)-5H-chromeno[4,3-c] pyridin-8-yl)pyrrolid in-2-one 4) N N N
OX
Step 1:
Preparation of 1 -(7-bromo-2,3 -dihy dro-1H-py ri do [2,3-b] [1,4] oxazin-1 -y1)-2,2-dimethy 1propan-1 -one 0) BrN
CD)<
[0442] To a solution of 7-bromo-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazine (500 mg, 2.33 mmol) in pyridine (15 mL) was added pivaloyl chloride (700 mg, 5.81 mmol) under nitrogen
mixture of Pd2(dba)3 (16 mg, 0.017 mmol) and BrettPhos (18 mg, 0.034 mmol) in 1,4-dioxane (1 mL) was stirred at 50 C for 10 min. 1-(3-Amino-5-methy1-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (50 mg, 0.17 mmol), 7-bromo-(isopropylsulfony1)-2,3-dihydro-1H-pyrido[2,3-b][1,4loxazine (65 mg, 0.20 mmol) in dioxane (4 mL) and Cs2CO3 (165 mg, 0.508 mmol) were added and the resulting mixture was stirred at 100 C for 16 h. A black brown mixture was formed. LCMS (Rt = 0.614 min; MS
Calcd: 535.2;
MS Found: 536.1 [M+H]+). The reaction mixture was diluted with DCM (10 mL), filtered and concentrated. The residue was purified by prep-HPLC (0.05% NH31120 as an additive) and lyophilized to give 1-(3 -((1-(i s opropylsulfony1)-2,3-dihy dro-1H-pyri do [2,3-b] [1,4] oxazin-7-yl)amino)-5-methy1-5H-chromeno[4,3-c]pyridin-8-y1)pyrrolidin-2-one (42.8 mg, yield: 47%) as an off-white solid.
11-1NMR (400 MHz, DMSO-d6) 6 1.34 (6H, d, J= 6.8 Hz), 1.52 (3H, d, J= 6.4 Hz), 2.01-2.08 (2H, m), 2.56 (2H, overlap with DMSO), 3.71-3.78 (1H, m), 3.80-3.85 (4H, m), 4.34 (2H, t, J= 4.4 Hz), 5.23 (1H, q, J= 6.4 Hz), 6.65 (1H, s), 7.30 (1H, dd, J=
8.8, 2.0 Hz), 7.38 (1H, d, J= 2.0 Hz), 7.86 (1H, d, J= 8.4 Hz), 8.26 (1H, d, J= 2.0 Hz), 8.29 (1H, d, J= 2.0 Hz), 8.58 (1H, s), 9.28 (1H, brs).
Example 86: 1-(5-methyl-3-((1-pivaloy1-2,3-dihydro-1H-pyrido [2,3-b] [1,4]
oxazin-7-yl)amino)-5H-chromeno[4,3-c] pyridin-8-yl)pyrrolid in-2-one 4) N N N
OX
Step 1:
Preparation of 1 -(7-bromo-2,3 -dihy dro-1H-py ri do [2,3-b] [1,4] oxazin-1 -y1)-2,2-dimethy 1propan-1 -one 0) BrN
CD)<
[0442] To a solution of 7-bromo-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazine (500 mg, 2.33 mmol) in pyridine (15 mL) was added pivaloyl chloride (700 mg, 5.81 mmol) under nitrogen
170 at 20 C. The resulting mixture was stirred at 50 C for 16 h. An orange solution was formed.
LCMS (Rt = 0.653 min; MS Calcd: 300.0; MS Found: 300.7 [M+Hl+). The reaction mixture was concentrated. The residue was combined with last batch, purified by Combi Flash (50%
DCM in PE (1% Et3N as an additive)) to give 1-(7-bromo-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-1-y1)-2,2-dimethylpropan-1-one (680 mg, yield: 89%) as a yellow solid.
Step 2: Preparation of 1-(5 -methyl-3 -((1-piv al oy1-2,3 -dihy dro-1H-py ri do [2,3-b] [1,4] oxazin-7-y Damino)-5H-chromeno [4,3-c] pyri din-8-y Opy rroli din-2-one gN 0 I
N N N
[0443] A
mixture of Pd2(dba)3 (16 mg, 0.017 mmol) and BrettPhos (18 mg, 0.034 mmol) in 1,4-dioxane (1 mL) was stirred at 50 C for 10 min. 1-(3-amino-5-methy1-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (50 mg, 0.17 mmol), 1-(7-bromo-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-1-y1)-2,2-dimethylpropan-l-one (49 mg, 0.16 mmol) in dioxane (4 mL) and Cs2CO3 (165 mg, 0.508 mmol) were added and the resulting mixture was stirred at 100 C for 18 h. A black brown mixture was formed. A mixture of Pd2(dba)3 (16 mg, 0.017 mmol) and BrettPhos (18 mg, 0.034 mmol) in 1,4-dioxane (1 mL) was stirred at 50 C for 15 min and added to the previous reaction mixture together with additional Cs2CO3 (165 mg, 0.508 mmol).
The resulting reaction mixture was stirred at 100 C for 18 h. LCMS (Rt =
0.605 min; MS
Calcd: 513.2; MS Found: 514.0 [M+H]+). The reaction mixture was diluted with DCM (10 mL), filtered and concentrated. The residue was purified by prep-HPLC (0.225%
FA as an additive) and lyophilized to give 1-(5-methy1-3-41-pivaloy1-2,3-dihydro-1H-pyrido[2,3-b] [1,4] oxazin-7-yl)amino)-5H-chromeno [4,3 -c] py ri din-8-yl)pyrroli din-2-one (16.0 mg, yield:
19%) as a yellow solid.
NMR (400 MHz, DMSO-d6) 6 1.32 (9H, s), 1.52 (3H, d, J= 6.4 Hz), 2.02-2.09 (2H, m), 2.53 (2H, overlap with DMSO), 3.83 (2H, t, J= 7.6 Hz), 4.02 (2H, t, J= 4.0 Hz), 4.35 (2H, t, J= 4.4 Hz), 5.23 (1H, q, J= 6.4 Hz), 6.64 (1H, s), 7.29 (1H, dd, J= 8.4, 2.4 Hz), 7.38 (1H, d, J= 2.0 Hz), 7.85 (1H, d, J= 8.8 Hz), 8.28 (1H, d, J= 2.4 Hz), 8.34 (1H, d, J=
2.4 Hz), 8.59 (1H, s), 9.17 (1H, brs).
LCMS (Rt = 0.653 min; MS Calcd: 300.0; MS Found: 300.7 [M+Hl+). The reaction mixture was concentrated. The residue was combined with last batch, purified by Combi Flash (50%
DCM in PE (1% Et3N as an additive)) to give 1-(7-bromo-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-1-y1)-2,2-dimethylpropan-1-one (680 mg, yield: 89%) as a yellow solid.
Step 2: Preparation of 1-(5 -methyl-3 -((1-piv al oy1-2,3 -dihy dro-1H-py ri do [2,3-b] [1,4] oxazin-7-y Damino)-5H-chromeno [4,3-c] pyri din-8-y Opy rroli din-2-one gN 0 I
N N N
[0443] A
mixture of Pd2(dba)3 (16 mg, 0.017 mmol) and BrettPhos (18 mg, 0.034 mmol) in 1,4-dioxane (1 mL) was stirred at 50 C for 10 min. 1-(3-amino-5-methy1-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (50 mg, 0.17 mmol), 1-(7-bromo-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-1-y1)-2,2-dimethylpropan-l-one (49 mg, 0.16 mmol) in dioxane (4 mL) and Cs2CO3 (165 mg, 0.508 mmol) were added and the resulting mixture was stirred at 100 C for 18 h. A black brown mixture was formed. A mixture of Pd2(dba)3 (16 mg, 0.017 mmol) and BrettPhos (18 mg, 0.034 mmol) in 1,4-dioxane (1 mL) was stirred at 50 C for 15 min and added to the previous reaction mixture together with additional Cs2CO3 (165 mg, 0.508 mmol).
The resulting reaction mixture was stirred at 100 C for 18 h. LCMS (Rt =
0.605 min; MS
Calcd: 513.2; MS Found: 514.0 [M+H]+). The reaction mixture was diluted with DCM (10 mL), filtered and concentrated. The residue was purified by prep-HPLC (0.225%
FA as an additive) and lyophilized to give 1-(5-methy1-3-41-pivaloy1-2,3-dihydro-1H-pyrido[2,3-b] [1,4] oxazin-7-yl)amino)-5H-chromeno [4,3 -c] py ri din-8-yl)pyrroli din-2-one (16.0 mg, yield:
19%) as a yellow solid.
NMR (400 MHz, DMSO-d6) 6 1.32 (9H, s), 1.52 (3H, d, J= 6.4 Hz), 2.02-2.09 (2H, m), 2.53 (2H, overlap with DMSO), 3.83 (2H, t, J= 7.6 Hz), 4.02 (2H, t, J= 4.0 Hz), 4.35 (2H, t, J= 4.4 Hz), 5.23 (1H, q, J= 6.4 Hz), 6.64 (1H, s), 7.29 (1H, dd, J= 8.4, 2.4 Hz), 7.38 (1H, d, J= 2.0 Hz), 7.85 (1H, d, J= 8.8 Hz), 8.28 (1H, d, J= 2.4 Hz), 8.34 (1H, d, J=
2.4 Hz), 8.59 (1H, s), 9.17 (1H, brs).
171 Example 87: N-(2-methoxy-5-05-methyl-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-y1)amino)pyridin-3-y1)acetamide c 0 1 1 )c NN
Step 1: Preparation of N-(5 -bromo-2-methoxy py ridin-3 -yl)acetamide BrN
[0444] To a solution of 5-bromo-2-methoxypyridin-3-amine (1.00 g, 4.90 mmol) in pyridine (15 mL) was added acetic anhydride (528 mg, 5.18 mmol) dropwise at 0 C. And the resulting mixture was stirred at 20 C for 12 h. A yellow solution was formed.
LCMS (Rt =
0.813 min; MS Calcd: 243.9; MS Found: 246.7 [M+H1+). The reaction mixture was concentrated under reduced pressure. The crude product was purified by combi flash (10%
Et0Ac in pentane (1% Et3N as an additive)) to give N-(5-bromo-2-methoxypyridin-yl)acetamide (1.05 g, yield: 87%) as a white solid.
11-1 NMR (400 MHz, CDC13) 6 2.23 (3H, s), 4.00 (3H, s), 7.60 (1H, brs), 7.89 (1H, d, J = 2.0 Hz), 8.78 (1H, d, J = 2.0 Hz).
Step 2:
Preparation of N-(2-methoxy-5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno [4,3-c] py ri din-3 -yl)amino)py ri din-3 -y0acetami de 1 1 )c NN
[0445] A
mixture of Pd2(dba)3 (25 mg, 0.027 mmol) and BrettPhos (29 mg, 0.054 mmol) in 1,4-dioxane (1 mL) was stirred at 50 C for 10 min. 1-(3-Amino-5-methy1-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (80 mg, 0.27 mmol), N-(5-bromo-2-methoxypyridin-3-yl)acetamide (79 mg, 0.32 mmol) in dioxane (5 mL) and Cs2CO3 (265 mg, 0.813 mmol) were added and the resulting mixture was stirred at 100 C for 16 h. A black
Step 1: Preparation of N-(5 -bromo-2-methoxy py ridin-3 -yl)acetamide BrN
[0444] To a solution of 5-bromo-2-methoxypyridin-3-amine (1.00 g, 4.90 mmol) in pyridine (15 mL) was added acetic anhydride (528 mg, 5.18 mmol) dropwise at 0 C. And the resulting mixture was stirred at 20 C for 12 h. A yellow solution was formed.
LCMS (Rt =
0.813 min; MS Calcd: 243.9; MS Found: 246.7 [M+H1+). The reaction mixture was concentrated under reduced pressure. The crude product was purified by combi flash (10%
Et0Ac in pentane (1% Et3N as an additive)) to give N-(5-bromo-2-methoxypyridin-yl)acetamide (1.05 g, yield: 87%) as a white solid.
11-1 NMR (400 MHz, CDC13) 6 2.23 (3H, s), 4.00 (3H, s), 7.60 (1H, brs), 7.89 (1H, d, J = 2.0 Hz), 8.78 (1H, d, J = 2.0 Hz).
Step 2:
Preparation of N-(2-methoxy-5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno [4,3-c] py ri din-3 -yl)amino)py ri din-3 -y0acetami de 1 1 )c NN
[0445] A
mixture of Pd2(dba)3 (25 mg, 0.027 mmol) and BrettPhos (29 mg, 0.054 mmol) in 1,4-dioxane (1 mL) was stirred at 50 C for 10 min. 1-(3-Amino-5-methy1-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (80 mg, 0.27 mmol), N-(5-bromo-2-methoxypyridin-3-yl)acetamide (79 mg, 0.32 mmol) in dioxane (5 mL) and Cs2CO3 (265 mg, 0.813 mmol) were added and the resulting mixture was stirred at 100 C for 16 h. A black
172 brown mixture was formed. LCMS (Rt = 0.586 min; MS Calcd: 459.2; MS Found:
460.0 [M+H1+).The reaction mixture was diluted with DCM (10 mL), filtered and concentrated. The residue was purified by prep-HPLC (0.05% NH31120 as an additive) and lyophilized to give N-(2-methoxy -5 -((5-methyl-8-(2-oxopy rroli din-l-y1)-5H-chromeno [4,3-c] py ri din-3 -yl)amino)pyridin-3-yOacetamide (50.2 mg, yield: 40%) as an off-white solid.
11-1NMR (400 MHz, DMSO-d6) 6 1.52 (3H, d, J= 6.4 Hz), 2.02-2.09 (2H, m), 2.12 (3H, s), 2.52 (2H, overlap with DMSO), 3.84 (2H, t, J= 8.0 Hz), 3.91 (3H, s), 5.23 (1H, q, J= 6.4 Hz), 6.66 (1H, s), 7.30 (1H, dd, J= 8.8, 2.0 Hz), 7.38 (1H, d, J= 2.0 Hz), 7.85 (1H, d, J= 8.8 Hz), 8.32 (1H, d, J= 2.4 Hz), 8.56-8.59 (2H, m), 9.16 (1H, brs), 9.35 (1H, brs).
Example 88: N-(2-methoxy-5-05-methyl-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-yl)methanesulfonamide N N N-S=0 H
Step 1: Preparation of N-(5 -bromo-2-methoxy pyridin-3-yl)methanesulfonamide f 9.0 BrN-SC
[0446] A
solution of 5-bromo-2-methoxypyridin-3-amine (1.00 g, 4.93 mmol) and pyridine (7.4 mL, 91 mmol) was stirred in DCM (25 mL), then MsC1 (564 mg, 4.93 mmol) was added into the above solution at 0 C, which was stirred at 20 C for 16 h. A brown solution was formed. LCMS (Rt = 0.582 min; MS Calcd: 280.0; MS Found: 280.7 [M+H1+). The solution was diluted with H20 (20 mL) and was extracted with DCM (15 mL x3). The organic layer was washed with brine (15 mL), dried over Na2SO4.The residue was purified by Combi Flash (20% Et0Ac in pentane) to give N-(5-bromo-2-methoxypyridin-3-yOmethanesulfonamide (1.06 g, yield: 77%) as an off-white solid.
11-1NMR (400 MHz, CDC13) 6 3.04 (3H, s), 3.99 (3H, s), 6.74 (1H, brs), 7.89 (1H, d, J= 2.0 Hz), 7.97 (1H, d, J= 2.0 Hz).
Step 2:
Preparation of N-(2-methoxy-5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno [4,3-c] py ri din-3-y0amino)py ri din-3 -y Omethanesulfonami de
460.0 [M+H1+).The reaction mixture was diluted with DCM (10 mL), filtered and concentrated. The residue was purified by prep-HPLC (0.05% NH31120 as an additive) and lyophilized to give N-(2-methoxy -5 -((5-methyl-8-(2-oxopy rroli din-l-y1)-5H-chromeno [4,3-c] py ri din-3 -yl)amino)pyridin-3-yOacetamide (50.2 mg, yield: 40%) as an off-white solid.
11-1NMR (400 MHz, DMSO-d6) 6 1.52 (3H, d, J= 6.4 Hz), 2.02-2.09 (2H, m), 2.12 (3H, s), 2.52 (2H, overlap with DMSO), 3.84 (2H, t, J= 8.0 Hz), 3.91 (3H, s), 5.23 (1H, q, J= 6.4 Hz), 6.66 (1H, s), 7.30 (1H, dd, J= 8.8, 2.0 Hz), 7.38 (1H, d, J= 2.0 Hz), 7.85 (1H, d, J= 8.8 Hz), 8.32 (1H, d, J= 2.4 Hz), 8.56-8.59 (2H, m), 9.16 (1H, brs), 9.35 (1H, brs).
Example 88: N-(2-methoxy-5-05-methyl-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-yl)methanesulfonamide N N N-S=0 H
Step 1: Preparation of N-(5 -bromo-2-methoxy pyridin-3-yl)methanesulfonamide f 9.0 BrN-SC
[0446] A
solution of 5-bromo-2-methoxypyridin-3-amine (1.00 g, 4.93 mmol) and pyridine (7.4 mL, 91 mmol) was stirred in DCM (25 mL), then MsC1 (564 mg, 4.93 mmol) was added into the above solution at 0 C, which was stirred at 20 C for 16 h. A brown solution was formed. LCMS (Rt = 0.582 min; MS Calcd: 280.0; MS Found: 280.7 [M+H1+). The solution was diluted with H20 (20 mL) and was extracted with DCM (15 mL x3). The organic layer was washed with brine (15 mL), dried over Na2SO4.The residue was purified by Combi Flash (20% Et0Ac in pentane) to give N-(5-bromo-2-methoxypyridin-3-yOmethanesulfonamide (1.06 g, yield: 77%) as an off-white solid.
11-1NMR (400 MHz, CDC13) 6 3.04 (3H, s), 3.99 (3H, s), 6.74 (1H, brs), 7.89 (1H, d, J= 2.0 Hz), 7.97 (1H, d, J= 2.0 Hz).
Step 2:
Preparation of N-(2-methoxy-5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno [4,3-c] py ri din-3-y0amino)py ri din-3 -y Omethanesulfonami de
173 N., N N N-S=C) H \
[0447] A
mixture of Pd2(dba)3 (25 mg, 0.027 mmol) and BrettPhos (29 mg, 0.054 mmol) in 1,4-dioxane (1 mL) was stirred at 50 C for 10 min. 1-(3-amino-5-methy1-5H-chromeno[4,3-clpyridin-8-yl)pyrrolidin-2-one (80 mg, 0.27 mmol), N-(5-bromo-2-methoxypyridin-3-yOmethanesulfonamide (91 mg, 0.32 mol) in dioxane (5 mL) and Cs2CO3 (265 mg, 0.813 mmol) were added and the resulting mixture was stirred at 100 C for 16 h. A
black brown mixture was formed. LCMS (Rt = 0.590 min; MS Calcd: 495.2; MS Found: 496.0 [M+H1+).
The reaction mixture was diluted with DCM (10 mL), filtered and concentrated.
The residue was purified by prep-HPLC (0.05% NH31120 as an additive) and lyophilized to give N-(2-methoxy-5 -((5-methyl-8-(2-oxopy rroli din-1 -y1)-5H-chromeno [4,3-c] py ri din-3 -yOamino)pyridin-3-yOmethanesulfonamide (22.0 mg, yield: 16%) as an off-white solid.
11-1 NMR (400 MHz, DMSO-d6) 6 1.52 (3H, d, J= 6.8 Hz), 2.02-2.09 (2H, m), 2.51 (2H, overlap with DMSO), 3.03 (3H, s), 3.83 (2H, t, J= 8.0 Hz), 3.88 (3H, s), 5.24 (1H, q, J= 6.8 Hz), 6.64 (1H, s), 7.30 (1H, dd, J= 8.4, 2.0 Hz), 7.38 (1H, d, J= 2.0 Hz), 7.86 (1H, d, J= 8.8 Hz), 7.98 (1H, d, J= 2.4 Hz), 8.33 (1H, d, J= 2.8 Hz), 8.50 (1H, s), 9.05 (1H, brs), 9.22 (1H, brs).
Example 89: N-(2-methoxy-5-05-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno 14,3-c]pyridin-3-yl)amino)pyridin-3-y1)-N-methylacetamide N N I
[0448] A
mixture of Pd2(dba)3 (16 mg, 0.017 mmol) and BrettPhos (18 mg, 0.034 mmol) in dioxane (3 mL) was stirred at 50 C for 15 minutes under N2. Then Cs2CO3 (165 mg, 0.51 mmol), 1-(3-amino-5-methy1-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (50 mg, 0.17 mmol) and N-(5-bromo-2-methoxypyridin-3-y1)-N-methylacetamide (44 mg, 0.17 mmol) was added. The resulting mixture was stirred at 100 C for 12 h under Nz. A black suspension was formed. LCMS the purity of the desired product (Rt = 716min; MS Calcd: 473.5;
MS Found:
[0447] A
mixture of Pd2(dba)3 (25 mg, 0.027 mmol) and BrettPhos (29 mg, 0.054 mmol) in 1,4-dioxane (1 mL) was stirred at 50 C for 10 min. 1-(3-amino-5-methy1-5H-chromeno[4,3-clpyridin-8-yl)pyrrolidin-2-one (80 mg, 0.27 mmol), N-(5-bromo-2-methoxypyridin-3-yOmethanesulfonamide (91 mg, 0.32 mol) in dioxane (5 mL) and Cs2CO3 (265 mg, 0.813 mmol) were added and the resulting mixture was stirred at 100 C for 16 h. A
black brown mixture was formed. LCMS (Rt = 0.590 min; MS Calcd: 495.2; MS Found: 496.0 [M+H1+).
The reaction mixture was diluted with DCM (10 mL), filtered and concentrated.
The residue was purified by prep-HPLC (0.05% NH31120 as an additive) and lyophilized to give N-(2-methoxy-5 -((5-methyl-8-(2-oxopy rroli din-1 -y1)-5H-chromeno [4,3-c] py ri din-3 -yOamino)pyridin-3-yOmethanesulfonamide (22.0 mg, yield: 16%) as an off-white solid.
11-1 NMR (400 MHz, DMSO-d6) 6 1.52 (3H, d, J= 6.8 Hz), 2.02-2.09 (2H, m), 2.51 (2H, overlap with DMSO), 3.03 (3H, s), 3.83 (2H, t, J= 8.0 Hz), 3.88 (3H, s), 5.24 (1H, q, J= 6.8 Hz), 6.64 (1H, s), 7.30 (1H, dd, J= 8.4, 2.0 Hz), 7.38 (1H, d, J= 2.0 Hz), 7.86 (1H, d, J= 8.8 Hz), 7.98 (1H, d, J= 2.4 Hz), 8.33 (1H, d, J= 2.8 Hz), 8.50 (1H, s), 9.05 (1H, brs), 9.22 (1H, brs).
Example 89: N-(2-methoxy-5-05-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno 14,3-c]pyridin-3-yl)amino)pyridin-3-y1)-N-methylacetamide N N I
[0448] A
mixture of Pd2(dba)3 (16 mg, 0.017 mmol) and BrettPhos (18 mg, 0.034 mmol) in dioxane (3 mL) was stirred at 50 C for 15 minutes under N2. Then Cs2CO3 (165 mg, 0.51 mmol), 1-(3-amino-5-methy1-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (50 mg, 0.17 mmol) and N-(5-bromo-2-methoxypyridin-3-y1)-N-methylacetamide (44 mg, 0.17 mmol) was added. The resulting mixture was stirred at 100 C for 12 h under Nz. A black suspension was formed. LCMS the purity of the desired product (Rt = 716min; MS Calcd: 473.5;
MS Found:
174 474.1 [M+H1+). The reaction mixture was filtered and then concentrated. The crude product was purified by prep-HPLC (normal Phase, Hexane-Et0H) and lyophilized to give N-(2-methoxy-5 -((5-methyl-8-(2-oxopy rroli din-1 -y1)-5H-chromeno [4,3-c] py ri din-3 -yOamino)pyridin-3-y1)-N-methylacetamide (12.0 mg, yield: 15%) as a white solid.
11-1NMR (400 MHz, DMSO-d6) 6 1.51 (3H, d, J= 6.8 Hz), 1.74 (3H, s), 2.03-2.09 (2H, m), 2.52 (2H, overlap with DMSO), 3.05 (3H, s), 3.83 (2H, t, J= 7.2 Hz), 3.89 (3H, s), 5.25 (1H, q, J= 6.4 Hz), 6.65 (1H, s), 7.30 (1H, dd, J= 2.0, 8.0 Hz), 7.39 (1H, d, J=
2.0 Hz), 7.85 (1H, d, J= 8.0 Hz), 8.18 (1H, d, J= 2.0 Hz), 8.39 (1H, s), 8.63 (1H, s), 9.30 (1H, brs).
Example 90: N-(2-methoxy-5-05-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno 14,3-c]pyridin-3-yl)amino)pyridin-3-y1)-N-methylmethanesulfonamide [0449] A
mixture of Pd2(dba)3 (16 mg, 0.017 mmol) and BrettPhos (18 mg, 0.034 mmol) in 1,4-dioxane (1 mL) was stirred at 50 C for 10 min. 1-(3-Amino-5-methy1-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (50 mg, 0.17 mmol), N-(5-bromo-2-methoxypyridin-3-y1)-N-methylmethanesulfonamide (60 mg, 0.20 mmol) in dioxane (4 mL) and Cs2CO3 (165 mg, 0.508 mmol) were added and the resulting mixture was stirred at 100 C
for 16 h. A black brown mixture was formed. LCMS (Rt = 0.603 min; MS Calcd:
509.2; MS
Found: 510.0 [M+H1+). The reaction mixture was diluted with DCM (10 mL), filtered and concentrated. The residue was purified by prep-HPLC (0.05% NH31120 as an additive) and lyophilized to impure product (50 mg), then purified by prep-HPLC (normal phase, Hexane-Et0H) and lyophilized to give N-(2-methoxy-5-45-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-y1)-N-methylmethanesulfonamide (25.6 mg, yield: 30%) as a white solid.
11-1NMR (400 MHz, DMSO-d6) 6 1.52 (3H, d, J= 6.0 Hz), 2.01-2.09 (2H, m), 2.55 (2H, overlap with DMSO), 3.05 (3H, s), 3.17 (3H, s), 3.84 (2H, t, J= 8.0 Hz), 3.91 (3H, s), 5.25 (1H, q, J= 6.4 Hz), 6.65 (1H, s), 7.30 (1H, dd, J= 8.4, 2.4 Hz), 7.39 (1H, d, J= 2.0 Hz), 7.86 (1H, d, J= 8.8 Hz), 8.13 (1H, d, J= 2.4 Hz), 8.43 (1H, d, J= 2.4 Hz), 8.64 (1H, s), 9.29 (1H, brs).
11-1NMR (400 MHz, DMSO-d6) 6 1.51 (3H, d, J= 6.8 Hz), 1.74 (3H, s), 2.03-2.09 (2H, m), 2.52 (2H, overlap with DMSO), 3.05 (3H, s), 3.83 (2H, t, J= 7.2 Hz), 3.89 (3H, s), 5.25 (1H, q, J= 6.4 Hz), 6.65 (1H, s), 7.30 (1H, dd, J= 2.0, 8.0 Hz), 7.39 (1H, d, J=
2.0 Hz), 7.85 (1H, d, J= 8.0 Hz), 8.18 (1H, d, J= 2.0 Hz), 8.39 (1H, s), 8.63 (1H, s), 9.30 (1H, brs).
Example 90: N-(2-methoxy-5-05-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno 14,3-c]pyridin-3-yl)amino)pyridin-3-y1)-N-methylmethanesulfonamide [0449] A
mixture of Pd2(dba)3 (16 mg, 0.017 mmol) and BrettPhos (18 mg, 0.034 mmol) in 1,4-dioxane (1 mL) was stirred at 50 C for 10 min. 1-(3-Amino-5-methy1-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (50 mg, 0.17 mmol), N-(5-bromo-2-methoxypyridin-3-y1)-N-methylmethanesulfonamide (60 mg, 0.20 mmol) in dioxane (4 mL) and Cs2CO3 (165 mg, 0.508 mmol) were added and the resulting mixture was stirred at 100 C
for 16 h. A black brown mixture was formed. LCMS (Rt = 0.603 min; MS Calcd:
509.2; MS
Found: 510.0 [M+H1+). The reaction mixture was diluted with DCM (10 mL), filtered and concentrated. The residue was purified by prep-HPLC (0.05% NH31120 as an additive) and lyophilized to impure product (50 mg), then purified by prep-HPLC (normal phase, Hexane-Et0H) and lyophilized to give N-(2-methoxy-5-45-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-y1)-N-methylmethanesulfonamide (25.6 mg, yield: 30%) as a white solid.
11-1NMR (400 MHz, DMSO-d6) 6 1.52 (3H, d, J= 6.0 Hz), 2.01-2.09 (2H, m), 2.55 (2H, overlap with DMSO), 3.05 (3H, s), 3.17 (3H, s), 3.84 (2H, t, J= 8.0 Hz), 3.91 (3H, s), 5.25 (1H, q, J= 6.4 Hz), 6.65 (1H, s), 7.30 (1H, dd, J= 8.4, 2.4 Hz), 7.39 (1H, d, J= 2.0 Hz), 7.86 (1H, d, J= 8.8 Hz), 8.13 (1H, d, J= 2.4 Hz), 8.43 (1H, d, J= 2.4 Hz), 8.64 (1H, s), 9.29 (1H, brs).
175 Example 91: 1-(5-methyl-3-((5-(methylsulfonyl)pyridin-3-yl)amino)-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one I
0" Nip [0450] A
mixture of Pd2(dba)3 (16 mg, 0.017 mmol) and BrettPhos (18 mg, 0.034 mmol) in 1,4-dioxane (1 mL) was stirred at 50 C for 10 min. 1-(3-Amino-5-methy1-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (50 mg, 0.17 mmol), 3-bromo-5-(methylsulfonyl)pyridine (48 mg, 0.20 mmol) in dioxane (3 mL) and Cs2CO3 (165 mg, 0.508 mmol) were added and the resulting mixture was stirred at 100 C for 16 h. A
black brown mixture was formed. LCMS (Rt = 0.615 min; MS Calcd: 450.1; MS Found: 451.0 [M+H1+).
The reaction mixture was diluted with DCM (10 mL), filtered and concentrated.
The residue was purified by prep-HPLC (0.05% NH31120 as an additive) and lyophilized to give 1-(5-methyl-3 -((5-(methylsulfony Opyri din-3-y Damino)-5H-chromeno [4,3-c] py ri din-8-yOpyrrolidin-2-one (9.0 mg, yield: 12%) as a white solid.
11-1 NMR (400 MHz, DMSO-d6) 6 1.55 (3H, d, J= 6.4 Hz), 2.02-2.09 (2H, m), 2.53 (2H, overlap with DMSO), 3.32 (3H, s), 3.85 (2H, t, J= 8.0 Hz), 5.32 (1H, q, J= 6.4 Hz), 6.80 (1H, s), 7.33 (1H, dd, J= 8.8, 2.4 Hz), 7.42 (1H, d, J= 2.4 Hz), 7.94 (1H, d, J= 8.8 Hz), 8.58 (1H, d, J= 2.0 Hz), 8.77 (1H, s), 8.88 (1H, t, J= 2.0 Hz), 9.03 (1H, d, J= 2.4 Hz), 9.95 (1H, brs).
Example 92: 1-(5-methyl-3-((5-(methylsulfonyl)quinolin-3-yl)amino)-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one N N
Step 1: Preparation of 5-(methylthio)quinoline
0" Nip [0450] A
mixture of Pd2(dba)3 (16 mg, 0.017 mmol) and BrettPhos (18 mg, 0.034 mmol) in 1,4-dioxane (1 mL) was stirred at 50 C for 10 min. 1-(3-Amino-5-methy1-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (50 mg, 0.17 mmol), 3-bromo-5-(methylsulfonyl)pyridine (48 mg, 0.20 mmol) in dioxane (3 mL) and Cs2CO3 (165 mg, 0.508 mmol) were added and the resulting mixture was stirred at 100 C for 16 h. A
black brown mixture was formed. LCMS (Rt = 0.615 min; MS Calcd: 450.1; MS Found: 451.0 [M+H1+).
The reaction mixture was diluted with DCM (10 mL), filtered and concentrated.
The residue was purified by prep-HPLC (0.05% NH31120 as an additive) and lyophilized to give 1-(5-methyl-3 -((5-(methylsulfony Opyri din-3-y Damino)-5H-chromeno [4,3-c] py ri din-8-yOpyrrolidin-2-one (9.0 mg, yield: 12%) as a white solid.
11-1 NMR (400 MHz, DMSO-d6) 6 1.55 (3H, d, J= 6.4 Hz), 2.02-2.09 (2H, m), 2.53 (2H, overlap with DMSO), 3.32 (3H, s), 3.85 (2H, t, J= 8.0 Hz), 5.32 (1H, q, J= 6.4 Hz), 6.80 (1H, s), 7.33 (1H, dd, J= 8.8, 2.4 Hz), 7.42 (1H, d, J= 2.4 Hz), 7.94 (1H, d, J= 8.8 Hz), 8.58 (1H, d, J= 2.0 Hz), 8.77 (1H, s), 8.88 (1H, t, J= 2.0 Hz), 9.03 (1H, d, J= 2.4 Hz), 9.95 (1H, brs).
Example 92: 1-(5-methyl-3-((5-(methylsulfonyl)quinolin-3-yl)amino)-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one N N
Step 1: Preparation of 5-(methylthio)quinoline
176 ON
[0451] To a mixture of 5-bromoquinoline(2.00 g, 9.61 mmol) in DMSO (10 mL) was added Cul (1.83 g, 9.61 mmol) and DABCO (2.16 g, 19.2 mmol). The mixture was degassed and purged with N2 for 3 times, and stirred at 130 C for 36 h. A brown suspension was formed.
The reaction was repeated to increase the amount of crude brown suspension.
The crude mixtures from were combined and filtered. The filtrate was diluted with H20 (60 mL), extracted with Et0Ac (50 mL x 3). The combined layer was washed with brine (30 mL), dried over Na2SO4 and concentrated. The residue was purified by Combi Flash (Et0Ac in pentane form 0 to 20%) to give 5-(methylthio)quinoline (900 mg, yield: 9%) as yellow oil.
Step 2: Preparation of 5-(methylsulfonyl)quinoline 0=S=0 [0452] To a mixture of 5-(methylthio)quinoline (900 mg, 1.68 mmol) in Me0H (10 mL) was added mCPBA (905 mg, 4.20 mmol, 80% purity) at 0 C. The mixture was stirred at 0 C
for 2 h to give a colorless solution. TLC (PE/Et0Ac = 1/1) showed that starting material was consumed and a more polar spot (Rf = 0.20) was formed. The mixture was added sat. Na2S203 (10 mL), extracted with Et0Ac (50 mL x3). The combined layer was washed with brine (50 mL), dried over Na2SO4 and concentrated, the residue was purified by Combi Flash (Et0Ac in pentane from 0 to 50%) to give 5-(methylsulfonyOquinolone (300 mg, yield: 48%) as a white solid.
11-INMR (400 MHz, CDC13) 6 3.21 (3H, s), 7.65 (1H, dd, J= 8.8, 4.0 Hz), 7.88 (1H, dd, J =
8.4, 7.2 Hz), 8.41 (1H, dd, J= 7.6, 1.6 Hz), 8.45 (1H, d, J= 9.2 Hz), 8.78 (1H, dd, J = 4.4, 1.6 Hz), 9.14(1H, d, J= 8.8 Hz).
Step 3: Preparation of 3-iodo-5-(methylsulfonyl)quinoline 0=S=0
[0451] To a mixture of 5-bromoquinoline(2.00 g, 9.61 mmol) in DMSO (10 mL) was added Cul (1.83 g, 9.61 mmol) and DABCO (2.16 g, 19.2 mmol). The mixture was degassed and purged with N2 for 3 times, and stirred at 130 C for 36 h. A brown suspension was formed.
The reaction was repeated to increase the amount of crude brown suspension.
The crude mixtures from were combined and filtered. The filtrate was diluted with H20 (60 mL), extracted with Et0Ac (50 mL x 3). The combined layer was washed with brine (30 mL), dried over Na2SO4 and concentrated. The residue was purified by Combi Flash (Et0Ac in pentane form 0 to 20%) to give 5-(methylthio)quinoline (900 mg, yield: 9%) as yellow oil.
Step 2: Preparation of 5-(methylsulfonyl)quinoline 0=S=0 [0452] To a mixture of 5-(methylthio)quinoline (900 mg, 1.68 mmol) in Me0H (10 mL) was added mCPBA (905 mg, 4.20 mmol, 80% purity) at 0 C. The mixture was stirred at 0 C
for 2 h to give a colorless solution. TLC (PE/Et0Ac = 1/1) showed that starting material was consumed and a more polar spot (Rf = 0.20) was formed. The mixture was added sat. Na2S203 (10 mL), extracted with Et0Ac (50 mL x3). The combined layer was washed with brine (50 mL), dried over Na2SO4 and concentrated, the residue was purified by Combi Flash (Et0Ac in pentane from 0 to 50%) to give 5-(methylsulfonyOquinolone (300 mg, yield: 48%) as a white solid.
11-INMR (400 MHz, CDC13) 6 3.21 (3H, s), 7.65 (1H, dd, J= 8.8, 4.0 Hz), 7.88 (1H, dd, J =
8.4, 7.2 Hz), 8.41 (1H, dd, J= 7.6, 1.6 Hz), 8.45 (1H, d, J= 9.2 Hz), 8.78 (1H, dd, J = 4.4, 1.6 Hz), 9.14(1H, d, J= 8.8 Hz).
Step 3: Preparation of 3-iodo-5-(methylsulfonyl)quinoline 0=S=0
177 [0453] To a solution of 5-(methylsulfonyl)quinolone (300 mg, 1.45 mmol) in MeCN (5 mL) was added 12 (440 mg, 1.74 mmol) and TBHP (1.49 g, 11.6 mmol, 70% purity in H20).
The mixture was stirred at 80 C for 24 h to give a brown solution. The mixture was added TBHP (298 mg, 2.32 mmol, 70% in H20) and stirred for another 24 h. The reaction mixture was added sat.Na2S203 (40 mL), extracted with Et0Ac (40 mL x3).The combined organic layer was washed with brine (20 mL), dried over Na2SO4 and concentrated. The residue was purified by Combi Flash (Et0Ac in pentane from 0 to 50%) to give 3-iodo-5-(methylsulfonyl)quinoline (180 mg, yield: 30%) as a white solid.
11-1 NMR (400 MHz, CDC13) 6 3.20 (3H, s), 7.88 (1H, dd, J= 8.8, 7.6 Hz), 8.41-8.36 (2H, m), 9.19 (1H, d, J= 2.0 Hz), 9.50 (1H, d, J= 1.2 Hz).
Step 4: Preparation of 1-(5-methy1-3-45-(methylsulfonyOquinolin-3-y0amino)-5H-chromeno [4,3 -c] py ri din-8-yl)pyrroli din-2-one gN 0 N N
[0454] To a suspension of 1-(3 -amino-5 -methyl-5H-chromeno [4,3 -c] pyridin-8-yl)pyrrolidin-2-one (100 mg, 0.338 mmol) and 3-iodo-5-(methylsulfonyOquinoline (124 mg, 0.372 mmol) in dioxane (2 mL) was added Pd2(dba)3 (31 mg, 0.033 mmol) BrettPhos (36 mg, 0.067 mmol) and Cs2CO3 (331 mg, 1.02 mmol), purged and degassed with N2 for 3 times. The mixture was stirred at 100 C for 16 h. A brown suspension was formed. LCMS
showed that starting material was consumed and the purity of desired product (Rt = 0.779 min; MS Calcd:
500.6; MS Found: 501.3 [M+H1+). The mixture was diluted with H20 (20 mL), extracted with DCM (20 mL x3). The combined layer was washed with brine (20 mL), dried over Na2SO4 and concentrated. The residue was purified by Combi Flash (Me0H in DCM from 0 to 5%) to give an orange solid. It was triturated with MeCN (5 mL x3), filtered and put in vacuum to give 1-(5 -methyl-3-45 -(methylsulfony Oquinolin-3-y0amino)-5H-chromeno [4,3-c] py ri din-8-yOpyrrolidin-2-one (82 mg, yield: 48%) as a yellow solid.
11-1NMR (400 MHz, DMSO-d6) 6 1.58 (3H, d, J= 6.4 Hz), 2.05-2.09 (2H, m), 2.51-2.53 (2H, m, overlapped with DMSO), 3.44 (3H, s), 3.86 (2H, t, J= 7.6 Hz), 5.34 (1H, q, J= 6.4 Hz), 6.90 (1H, s), 7.36 (1H, dd, J= 8.8, 2.4 Hz), 7.43 (1H, d, J= 2.4 Hz), 7.73 (1H, dd, J= 8.0,
The mixture was stirred at 80 C for 24 h to give a brown solution. The mixture was added TBHP (298 mg, 2.32 mmol, 70% in H20) and stirred for another 24 h. The reaction mixture was added sat.Na2S203 (40 mL), extracted with Et0Ac (40 mL x3).The combined organic layer was washed with brine (20 mL), dried over Na2SO4 and concentrated. The residue was purified by Combi Flash (Et0Ac in pentane from 0 to 50%) to give 3-iodo-5-(methylsulfonyl)quinoline (180 mg, yield: 30%) as a white solid.
11-1 NMR (400 MHz, CDC13) 6 3.20 (3H, s), 7.88 (1H, dd, J= 8.8, 7.6 Hz), 8.41-8.36 (2H, m), 9.19 (1H, d, J= 2.0 Hz), 9.50 (1H, d, J= 1.2 Hz).
Step 4: Preparation of 1-(5-methy1-3-45-(methylsulfonyOquinolin-3-y0amino)-5H-chromeno [4,3 -c] py ri din-8-yl)pyrroli din-2-one gN 0 N N
[0454] To a suspension of 1-(3 -amino-5 -methyl-5H-chromeno [4,3 -c] pyridin-8-yl)pyrrolidin-2-one (100 mg, 0.338 mmol) and 3-iodo-5-(methylsulfonyOquinoline (124 mg, 0.372 mmol) in dioxane (2 mL) was added Pd2(dba)3 (31 mg, 0.033 mmol) BrettPhos (36 mg, 0.067 mmol) and Cs2CO3 (331 mg, 1.02 mmol), purged and degassed with N2 for 3 times. The mixture was stirred at 100 C for 16 h. A brown suspension was formed. LCMS
showed that starting material was consumed and the purity of desired product (Rt = 0.779 min; MS Calcd:
500.6; MS Found: 501.3 [M+H1+). The mixture was diluted with H20 (20 mL), extracted with DCM (20 mL x3). The combined layer was washed with brine (20 mL), dried over Na2SO4 and concentrated. The residue was purified by Combi Flash (Me0H in DCM from 0 to 5%) to give an orange solid. It was triturated with MeCN (5 mL x3), filtered and put in vacuum to give 1-(5 -methyl-3-45 -(methylsulfony Oquinolin-3-y0amino)-5H-chromeno [4,3-c] py ri din-8-yOpyrrolidin-2-one (82 mg, yield: 48%) as a yellow solid.
11-1NMR (400 MHz, DMSO-d6) 6 1.58 (3H, d, J= 6.4 Hz), 2.05-2.09 (2H, m), 2.51-2.53 (2H, m, overlapped with DMSO), 3.44 (3H, s), 3.86 (2H, t, J= 7.6 Hz), 5.34 (1H, q, J= 6.4 Hz), 6.90 (1H, s), 7.36 (1H, dd, J= 8.8, 2.4 Hz), 7.43 (1H, d, J= 2.4 Hz), 7.73 (1H, dd, J= 8.0,
178 7.6 Hz), 7.96 (1H, d, J= 8.4 Hz), 8.22 (1H, dd, J= 3.6, 1.2 Hz), 8.26 (1H, d, J= 8.8 Hz), 8.76 (1H, s), 9.22 (1H, d, J= 2.4 Hz), 9.52 (1H, d, J= 2.8 Hz), 10.10 (1H, s) Example 93: 7-05-methyl-8-(2- oxo pyrrolid in-1-y1)-5H- chromeno14,3- c] pyridin-3-yl)amino)-1H-pyrido 12,3-b] [1,4] oxazin-2(3H)- one N N NO
Step 1: Preparation of 7-((5 -methyl-8-(2-oxopy rroli din-l-y1)-5H-chromeno [4,3-c] py ri din-3-yl)amino)-1 -((2-(trimethylsilyl)ethoxy)methyl)-1H-py ri do [2,3-b] [1,4]
oxazin-2(3H)-one -;-, I
N N
EM
[0455] A
mixture of Pd2(dba)3 (25 mg, 0.027 mmol) and BrettPhos (29 mg, 0.054 mmol) in 1,4-dioxane (1 mL) was stirred at 50 C for 10 min. 1-(3-amino-5-methy1-5H-chromeno[4,3-clpyridin-8-yl)pyrrolidin-2-one (80 mg, 0.27 mmol), 7-bromo-1-42-(trimethylsilypethoxy)methyl)-1H-pyrido[2,3-b][1,41oxazin-2(3H)-one (117 mg, 0.325 mmol) in dioxane (7 mL) and Cs2CO3 (176 mg, 0.542 mmol) were added and the resulting mixture was stirred at 100 C for 16 h. A black brown mixture was formed. LCMS (Rt =
0.718 min;
MS Calcd: 573.2; MS Found: 574.1 [M+H]+). The reaction mixture was diluted with dioxane (10 mL), filtered and concentrated. The residue was purified by Combi Flash (Et0Ac) to give 7-((5-methyl-8-(2-oxopy rroli din-l-y1)-5H-chromeno [4,3 -c] py ridin-3 -yl)amino)-1-42-(trimethylsilypethoxy)methyl)-1H-pyrido[2,3-b][1,4]oxazin-2(3H)-one (145 mg, yield: 93%) as a light yellow solid.
Step 2: Preparation of 7-45-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-yOamino)-1H-pyrido [2,3 -b] [1,4] oxazin-2(3H)-one
Step 1: Preparation of 7-((5 -methyl-8-(2-oxopy rroli din-l-y1)-5H-chromeno [4,3-c] py ri din-3-yl)amino)-1 -((2-(trimethylsilyl)ethoxy)methyl)-1H-py ri do [2,3-b] [1,4]
oxazin-2(3H)-one -;-, I
N N
EM
[0455] A
mixture of Pd2(dba)3 (25 mg, 0.027 mmol) and BrettPhos (29 mg, 0.054 mmol) in 1,4-dioxane (1 mL) was stirred at 50 C for 10 min. 1-(3-amino-5-methy1-5H-chromeno[4,3-clpyridin-8-yl)pyrrolidin-2-one (80 mg, 0.27 mmol), 7-bromo-1-42-(trimethylsilypethoxy)methyl)-1H-pyrido[2,3-b][1,41oxazin-2(3H)-one (117 mg, 0.325 mmol) in dioxane (7 mL) and Cs2CO3 (176 mg, 0.542 mmol) were added and the resulting mixture was stirred at 100 C for 16 h. A black brown mixture was formed. LCMS (Rt =
0.718 min;
MS Calcd: 573.2; MS Found: 574.1 [M+H]+). The reaction mixture was diluted with dioxane (10 mL), filtered and concentrated. The residue was purified by Combi Flash (Et0Ac) to give 7-((5-methyl-8-(2-oxopy rroli din-l-y1)-5H-chromeno [4,3 -c] py ridin-3 -yl)amino)-1-42-(trimethylsilypethoxy)methyl)-1H-pyrido[2,3-b][1,4]oxazin-2(3H)-one (145 mg, yield: 93%) as a light yellow solid.
Step 2: Preparation of 7-45-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-yOamino)-1H-pyrido [2,3 -b] [1,4] oxazin-2(3H)-one
179 0 Ny0 N N)CNO
[0456] To a solution of 7-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)-1-42-(trimethylsilypethoxy)methyl)-1H-pyrido[2,3-1301[1,410xazin-2(3H)-one (145 mg, 0.253 mmol) in DCM (5 mL) was added TFA (3.9 mL, 53 mmol) at 10 C, and it was stirred at 10 C for 1 hour. Then the mixture was concentrated under reduced pressure and the residue was diluted with Me0H (5 mL) and then ethylenediamine (576 mg, 5.05 mmol) was added at 10 C. The residue was stirred at 10 C for 16 h. The yellow solution turned to white suspension gradually. Crude LCMS showed that the purity of product was 92%
(Rt = 0.553 min, MS Calcd.: 443.2; MS Found: 443.9 [M+H1+). The mixture was concentrated under reduced pressure. The residue was purified by prep-HPLC (0.225% FA as an additive) and lyophilized to give 7-45-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)-1H-pyrido[2,3-b][1,41oxazin-2(3H)-one (11.5 mg, yield: 10%) as a red solid.
11-1 NMR (400 MHz, DMSO-d6) 6 1.52 (3H, d, J= 6.4 Hz), 2.02-2.09 (2H, m), 2.53 (2H, overlap with DMSO), 3.83 (2H, t, J= 8.0 Hz), 4.70 (2H, s), 5.24 (1H, q, J= 6.4 Hz), 6.66 (1H, s), 7.31 (1H, dd, J= 8.8, 2.4 Hz), 7.38 (1H, d, J= 2.0 Hz), 7.77 (1H, d, J= 2.4 Hz), 7.86 (1H, d, J= 8.4 Hz), 8.06 (1H, d, J= 2.0 Hz), 8.59 (1H, s), 9.32 (1H, brs), 10.86 (1H, brs).
Example 94: 1-(3-((2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)amino)-5-methyl-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one I
N N N
[0457] A
mixture of Pd2(dba)3 (28 mg, 0.030 mmol) and BrettPhos (33 mg, 0.061 mmol) in 1,4-dioxane (1 mL) was stirred at 50 C for 10 min. 1-(3-Amino-5-methy1-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (90 mg, 0.30 mmol), 2-(7-bromo-2,3-dihydro-1H-pyrido[2,3-b][1,41oxazin-1-y1)-2-oxoethyl acetate (100 mg, 0.317 mmol) in dioxane (5 mL) and Cs2CO3 (298 mg, 0.914 mmol) were added and the resulting mixture was stirred at 100 C for 16 h. A black brown mixture was formed. TLC indicated the most of starting
[0456] To a solution of 7-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)-1-42-(trimethylsilypethoxy)methyl)-1H-pyrido[2,3-1301[1,410xazin-2(3H)-one (145 mg, 0.253 mmol) in DCM (5 mL) was added TFA (3.9 mL, 53 mmol) at 10 C, and it was stirred at 10 C for 1 hour. Then the mixture was concentrated under reduced pressure and the residue was diluted with Me0H (5 mL) and then ethylenediamine (576 mg, 5.05 mmol) was added at 10 C. The residue was stirred at 10 C for 16 h. The yellow solution turned to white suspension gradually. Crude LCMS showed that the purity of product was 92%
(Rt = 0.553 min, MS Calcd.: 443.2; MS Found: 443.9 [M+H1+). The mixture was concentrated under reduced pressure. The residue was purified by prep-HPLC (0.225% FA as an additive) and lyophilized to give 7-45-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)-1H-pyrido[2,3-b][1,41oxazin-2(3H)-one (11.5 mg, yield: 10%) as a red solid.
11-1 NMR (400 MHz, DMSO-d6) 6 1.52 (3H, d, J= 6.4 Hz), 2.02-2.09 (2H, m), 2.53 (2H, overlap with DMSO), 3.83 (2H, t, J= 8.0 Hz), 4.70 (2H, s), 5.24 (1H, q, J= 6.4 Hz), 6.66 (1H, s), 7.31 (1H, dd, J= 8.8, 2.4 Hz), 7.38 (1H, d, J= 2.0 Hz), 7.77 (1H, d, J= 2.4 Hz), 7.86 (1H, d, J= 8.4 Hz), 8.06 (1H, d, J= 2.0 Hz), 8.59 (1H, s), 9.32 (1H, brs), 10.86 (1H, brs).
Example 94: 1-(3-((2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)amino)-5-methyl-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one I
N N N
[0457] A
mixture of Pd2(dba)3 (28 mg, 0.030 mmol) and BrettPhos (33 mg, 0.061 mmol) in 1,4-dioxane (1 mL) was stirred at 50 C for 10 min. 1-(3-Amino-5-methy1-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (90 mg, 0.30 mmol), 2-(7-bromo-2,3-dihydro-1H-pyrido[2,3-b][1,41oxazin-1-y1)-2-oxoethyl acetate (100 mg, 0.317 mmol) in dioxane (5 mL) and Cs2CO3 (298 mg, 0.914 mmol) were added and the resulting mixture was stirred at 100 C for 16 h. A black brown mixture was formed. TLC indicated the most of starting
180 material was consumed. The reaction mixture was diluted with DCM (10 mL), filtered and concentrated. The residue was purified by Combi Flash (1% Et3N in Et0Ac), then the impure product (50 mg) was purified by prep-HPLC (0.05% NH31120 as an additive) and lyophilized to give 1-(3 -((2,3 -dihy dro-1H-pyri do [2,3-b] [1,4] oxazin-7-yl)amino)-5-methy1-5H-chromeno[4,3-c1pyridin-8-yOpyrrolidin-2-one (5.9 mg, yield: 5%) as an off-white solid.
11-1NMR (400 MHz, DMSO-d6) 6 1.50 (3H, d, J= 5.6 Hz), 2.00-2.09 (2H, m), 2.58 (2H, overlap with DMSO), 3.25-3.29 (2H, m), 3.83 (2H, t, J= 6.0 Hz), 4.17-4.24 (2H, m), 5.21 (1H, q, J= 6.0 Hz), 6.09 (1H, s), 6.61 (1H, s), 7.30 (1H, d, J= 7.6 Hz), 7.36 (2H, d, J= 4.8 Hz), 7.59 (1H, s), 7.83 (1H, d, J= 8.4 Hz), 8.55 (1H, brs), 8.94 (1H, brs).
Example 95: 4-(5-05-methyl-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-yl)amino)pyridin-3-yl)morpholin-3-one c 0 o Step 1: Preparation of 4-(5-bromopyridin-3-yl)morpholin-3-one BrN
0() [0458] A
solution of Pd2(dba)3 (322 mg, 0.352 mmol) and XantPhos (204 mg, 0.352 mmol) in dioxane (10 mL) was stirred at 50 C for 5 min under Nz. Then 3,5-dibromopyridine (1.00 g, 4.20 mmol), morpholin-3-one (356 mg, 0.352 mmol) and Cs2CO3 (2.30 g, 7.00 mmol) was added to the solution. The resulting mixture was stirred at 100 C for 12 h under Nz. A black brown solid was formed. TLC (Et0Ac/PE = 2:1) showed starting material was consumed completely and the new point was formed at Rf = 0.28. The reaction mixture was filtered and the filtrate was concentrated. Amounts of crude product were increased using the same procedure. The combined amounts of crude were then purified by combi flash (with 6% Et0Ac in pentane) to give 4-(5-bromopyridin-3-yl)morpholin-3-one (510 mg, yield:
51%) as a yellow solid.
11-1NMR (400 MHz, DMSO-d6) 6 1.50 (3H, d, J= 5.6 Hz), 2.00-2.09 (2H, m), 2.58 (2H, overlap with DMSO), 3.25-3.29 (2H, m), 3.83 (2H, t, J= 6.0 Hz), 4.17-4.24 (2H, m), 5.21 (1H, q, J= 6.0 Hz), 6.09 (1H, s), 6.61 (1H, s), 7.30 (1H, d, J= 7.6 Hz), 7.36 (2H, d, J= 4.8 Hz), 7.59 (1H, s), 7.83 (1H, d, J= 8.4 Hz), 8.55 (1H, brs), 8.94 (1H, brs).
Example 95: 4-(5-05-methyl-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-yl)amino)pyridin-3-yl)morpholin-3-one c 0 o Step 1: Preparation of 4-(5-bromopyridin-3-yl)morpholin-3-one BrN
0() [0458] A
solution of Pd2(dba)3 (322 mg, 0.352 mmol) and XantPhos (204 mg, 0.352 mmol) in dioxane (10 mL) was stirred at 50 C for 5 min under Nz. Then 3,5-dibromopyridine (1.00 g, 4.20 mmol), morpholin-3-one (356 mg, 0.352 mmol) and Cs2CO3 (2.30 g, 7.00 mmol) was added to the solution. The resulting mixture was stirred at 100 C for 12 h under Nz. A black brown solid was formed. TLC (Et0Ac/PE = 2:1) showed starting material was consumed completely and the new point was formed at Rf = 0.28. The reaction mixture was filtered and the filtrate was concentrated. Amounts of crude product were increased using the same procedure. The combined amounts of crude were then purified by combi flash (with 6% Et0Ac in pentane) to give 4-(5-bromopyridin-3-yl)morpholin-3-one (510 mg, yield:
51%) as a yellow solid.
181 11-1 NMR (400 MHz, CDC13) 6 3.81 (2H, t, J= 5.2 Hz), 4.05 (2H, t, J= 5.2 Hz), 4.36 (2H, s), 7.97 (1H, d, J= 2.0 Hz), 8.57 (2H, dd, J= 4.0, 2.0 Hz).
Step 2: Preparation of 4-(5-((5 -methyl-8-(2-oxopy rroli din-1 -y 0-5H-chromeno [4,3 -c] py ri din-3-yl)amino)pyridin-3-yl)morpholin-3-one c 0 ,N
I
NN
o [0459] A
mixture of Pd2(dba)3 (22 mg, 0.024 mmol) and BrettPhos (25 mg, 0.047 mmol) in dioxane (3 mL) was stirred at 50 C for 5 min under N2. Then Cs2CO3 (232 mg, 0.711 mmol), 1-(3-amino-5-methyl-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (70 mg, 0.24 mmol) and 4-(5-bromopyridin-3-yl)morpholin-3-one (79 mg, 0.30 mmol) was added to the mixture.
The resulting mixture was stirred at 100 C for 18 h under Nz. A black suspension was formed.
LCMS showed starting material was consumed completely and the purity of the desired product (Rt = 0.567 min; MS Calcd: 471.2; MS Found: 472.2 [M+H1+). The reaction mixture was filtered and the filtrate was concentrated. The crude product was purified by prep-HPLC
(0.05% NH31120 as an additive) and lyophilized to give 4-(5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-yOmorpholin-3-one (27 mg, yield:
24%) as a yellow solid.
11-1 NMR (400 MHz, DMSO-d6) 6 1.53 (3H, d, J= 2.4 Hz), 2.01-2.08 (2H, m), 2.50 (2H, overlap with DMSO), 3.78 (2H, t, J= 5.2 Hz), 3.83 (2H, t, J= 7.6 Hz), 4.01 (2H, t, J= 5.2 Hz), 4.52 (2H, s), 5.27 (1H, q, J= 6.6 Hz), 6.75 (1H, s), 7.31 (1H, dd, J=
8.4, 2.0 Hz), 7.39 (1H, d, J= 2.0 Hz), 7.88 (1H, d, J= 8.8 Hz), 8.17 (1H, d, J= 2.0 Hz), 8.35 (1H, t, J= 2.0 Hz), 8.68 (2H, m), 9.58 (1H, brs).
Example 96: 1-(5-methyl-3-((5-morpholinopyridin-3-yl)amino)-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one I
NN
Step 2: Preparation of 4-(5-((5 -methyl-8-(2-oxopy rroli din-1 -y 0-5H-chromeno [4,3 -c] py ri din-3-yl)amino)pyridin-3-yl)morpholin-3-one c 0 ,N
I
NN
o [0459] A
mixture of Pd2(dba)3 (22 mg, 0.024 mmol) and BrettPhos (25 mg, 0.047 mmol) in dioxane (3 mL) was stirred at 50 C for 5 min under N2. Then Cs2CO3 (232 mg, 0.711 mmol), 1-(3-amino-5-methyl-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (70 mg, 0.24 mmol) and 4-(5-bromopyridin-3-yl)morpholin-3-one (79 mg, 0.30 mmol) was added to the mixture.
The resulting mixture was stirred at 100 C for 18 h under Nz. A black suspension was formed.
LCMS showed starting material was consumed completely and the purity of the desired product (Rt = 0.567 min; MS Calcd: 471.2; MS Found: 472.2 [M+H1+). The reaction mixture was filtered and the filtrate was concentrated. The crude product was purified by prep-HPLC
(0.05% NH31120 as an additive) and lyophilized to give 4-(5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-yOmorpholin-3-one (27 mg, yield:
24%) as a yellow solid.
11-1 NMR (400 MHz, DMSO-d6) 6 1.53 (3H, d, J= 2.4 Hz), 2.01-2.08 (2H, m), 2.50 (2H, overlap with DMSO), 3.78 (2H, t, J= 5.2 Hz), 3.83 (2H, t, J= 7.6 Hz), 4.01 (2H, t, J= 5.2 Hz), 4.52 (2H, s), 5.27 (1H, q, J= 6.6 Hz), 6.75 (1H, s), 7.31 (1H, dd, J=
8.4, 2.0 Hz), 7.39 (1H, d, J= 2.0 Hz), 7.88 (1H, d, J= 8.8 Hz), 8.17 (1H, d, J= 2.0 Hz), 8.35 (1H, t, J= 2.0 Hz), 8.68 (2H, m), 9.58 (1H, brs).
Example 96: 1-(5-methyl-3-((5-morpholinopyridin-3-yl)amino)-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one I
NN
182 Step 1: Preparation of 4-(5-bromopyridin-3-yl)morpholine r BrN
[0460] To a solution of 3,5-dibromopyridine (1.10 g, 4.60 mmol) in dioxane (2 mL) was added morpholine (200 mg, 2.30 mmol), Cs2CO3 (1.10 g, 3.20 mmol), XantPhos (39 mg, 0.068 mmol) and Pd2(dba)3 (62 mg, 0.068 mmol). The resulting mixture was degassed and purged with Nz for three times and then stirred at 90 C for 5 h under Nz. A yellow suspension was formed. TLC-Plate 1 (Et0Ac/PE = 1:1) showed starting material was consumed and new spots were formed at Rf = 0.22 and 0.82. LCMS showed the starting material was consumed nearly and the purity of the desired product (Rt = 0.439 min; MS Calcd: 242.0; MS
Found: 244.7 [M+H1+). H20 (15 mL) and DCM (20 mL) was added to the reaction mixture and then separated. The combined organic layer was washed with brine (10 mL) dried over anhydrous Na2SO4 and concentrated. The crude product was purified by combi flash (50%
Et0Ac in pentane) and concentrated to give 4-(5-bromopyridin-3-yl)morpholine (300 mg, yield: 38%) as a light yellow solid.
11-1NMR (400 MHz, CDC13) 6 3.21 (4H, t, J= 5.2 Hz), 3.87 (4H, t, J= 4.8 Hz), 7.30 (1H, t, J
= 2.0 Hz), 8.16(1H, d, J= 2.0 Hz), 8.21 (1H, d, J= 2.4 Hz).
Step 2: Preparation of 1-(5-methy1-3-((5-morpholinopyridin-3-yl)amino)-5H-chromeno[4,3-c] pyridin-8-yl)pyrrolidin-2-one I
N
[0461] To a mixture of Pd2(dba)3 (15 mg, 0.017 mmol) in dioxane (1 mL) was added BrettPhos (18 mg, 0.034 mmol). The resulting mixture was degassed and purged with N2 and then stirred at 50 C for 10 min. The reaction mixture was cooled to 20 C and 1-(3-amino-5-methy1-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one (50 mg, 0.17 mmol), 4-(5-bromopyridin-3-yl)morpholine (54 mg, 0.22 mmol) and Cs2CO3 (165 mg, 0.500 mmol) were added and then stirring at 100 C for 18 h under Nz. A black suspension was formed. LCMS
showed the starting material was consumed completely and the purity of the desired product
[0460] To a solution of 3,5-dibromopyridine (1.10 g, 4.60 mmol) in dioxane (2 mL) was added morpholine (200 mg, 2.30 mmol), Cs2CO3 (1.10 g, 3.20 mmol), XantPhos (39 mg, 0.068 mmol) and Pd2(dba)3 (62 mg, 0.068 mmol). The resulting mixture was degassed and purged with Nz for three times and then stirred at 90 C for 5 h under Nz. A yellow suspension was formed. TLC-Plate 1 (Et0Ac/PE = 1:1) showed starting material was consumed and new spots were formed at Rf = 0.22 and 0.82. LCMS showed the starting material was consumed nearly and the purity of the desired product (Rt = 0.439 min; MS Calcd: 242.0; MS
Found: 244.7 [M+H1+). H20 (15 mL) and DCM (20 mL) was added to the reaction mixture and then separated. The combined organic layer was washed with brine (10 mL) dried over anhydrous Na2SO4 and concentrated. The crude product was purified by combi flash (50%
Et0Ac in pentane) and concentrated to give 4-(5-bromopyridin-3-yl)morpholine (300 mg, yield: 38%) as a light yellow solid.
11-1NMR (400 MHz, CDC13) 6 3.21 (4H, t, J= 5.2 Hz), 3.87 (4H, t, J= 4.8 Hz), 7.30 (1H, t, J
= 2.0 Hz), 8.16(1H, d, J= 2.0 Hz), 8.21 (1H, d, J= 2.4 Hz).
Step 2: Preparation of 1-(5-methy1-3-((5-morpholinopyridin-3-yl)amino)-5H-chromeno[4,3-c] pyridin-8-yl)pyrrolidin-2-one I
N
[0461] To a mixture of Pd2(dba)3 (15 mg, 0.017 mmol) in dioxane (1 mL) was added BrettPhos (18 mg, 0.034 mmol). The resulting mixture was degassed and purged with N2 and then stirred at 50 C for 10 min. The reaction mixture was cooled to 20 C and 1-(3-amino-5-methy1-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one (50 mg, 0.17 mmol), 4-(5-bromopyridin-3-yl)morpholine (54 mg, 0.22 mmol) and Cs2CO3 (165 mg, 0.500 mmol) were added and then stirring at 100 C for 18 h under Nz. A black suspension was formed. LCMS
showed the starting material was consumed completely and the purity of the desired product
183 (Rt = 0.701 min; MS Calcd: 457.1; MS Found: 458.2 [M+H1+). The reaction mixture was filtered and the filtrate was concentrated. The crude product was purified by prep-HPLC
(0.05% NH31120 as an additive) and lyophilized to give 1-(5-methy1-3-((5-morpholinopyridin-3-y0amino)-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (27.7 mg, yield:
35%) as an off-white solid.
NMR (400 MHz, DMSO-d6) 6 1.52 (3H, d, J= 6.8 Hz), 2.01-2.09 (2H, m), 2.50 (2H, overlap with DMSO), 3.15 (4H, t, J= 4.8Hz), 3.77 (4H, t, J= 4.8 Hz), 3.83 (2H, t, J= 7.6 Hz), 5.26 (1H, q, J= 6.4 Hz), 6.72 (1H, s), 7.30 (1H, dd, J= 8.4, 2.4 Hz), 7.38 (1H, d, J= 2.4 Hz), 7.87 (3H, dd, J= 8.8 Hz, 2.0 Hz), 8.28 (1H, d, J= 2.0 Hz), 8.66 (1H, s), 9.32 (1H, brs).
Example 97: 1-(5-methyl-3-((5-methylpyridin-3-yl)amino)-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one [0462] A
mixture of Pd2(dba)3 (15 mg, 0.017 mmol) and BrettPhos (18 mg, 0.034 limo') in dioxane (2 mL) was degassed and purged with Nz for three times. The resulting mixture was stirred 50 C for 30 min. 1-(3-Chloro-5-methy1-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (53 mg, 0.17 mmol), 5-methylpyridin-3-amine (24 mg, 0.22 mmol) were added.
And then the resulting mixture was stirred at 100 C for 16 h under Nz. A black suspension was formed.
LCMS showed starting material was consumed completely and the purity of the desired product (Rt = 0.698 min; MS Calcd: 386.1; MS Found: 387.0 [M+H1+). The reaction mixture was filtered and the filtrate was concentrated. The crude product was purified by prep-HPLC
(0.05% NH31120 as an additive) and lyophilized to give 1-(5-methy1-3-((5-methylpyridin-3-yl)amino)-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (14.3 mg, yield: 22%) as a white solid.
NMR (400 MHz, DMSO-d6) 6 1.53 (3H, d, J= 6.8 Hz), 2.02-2.09 (2H, m), 2.28 (3H, s) 2.52 (2H, overlap with DMSO), 3.84 (2H, t, J= 7.6 Hz), 5.27 (1H, q, J= 6.5 Hz), 6.72 (1H, s), 7.31 (1H, dd, J= 8.4, 2.4 Hz), 7.40 (1H, d, J= 2.0 Hz), 7.87 (1H, d, J=
8.8 Hz), 7.95 (1H, d, J= 2.0 Hz), 8.08 (1H, d, J= 2.0 Hz), 8.60 (1H, d, J= 2.0 Hz), 8.68 (1H, s), 9.36 (1H, brs).
(0.05% NH31120 as an additive) and lyophilized to give 1-(5-methy1-3-((5-morpholinopyridin-3-y0amino)-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (27.7 mg, yield:
35%) as an off-white solid.
NMR (400 MHz, DMSO-d6) 6 1.52 (3H, d, J= 6.8 Hz), 2.01-2.09 (2H, m), 2.50 (2H, overlap with DMSO), 3.15 (4H, t, J= 4.8Hz), 3.77 (4H, t, J= 4.8 Hz), 3.83 (2H, t, J= 7.6 Hz), 5.26 (1H, q, J= 6.4 Hz), 6.72 (1H, s), 7.30 (1H, dd, J= 8.4, 2.4 Hz), 7.38 (1H, d, J= 2.4 Hz), 7.87 (3H, dd, J= 8.8 Hz, 2.0 Hz), 8.28 (1H, d, J= 2.0 Hz), 8.66 (1H, s), 9.32 (1H, brs).
Example 97: 1-(5-methyl-3-((5-methylpyridin-3-yl)amino)-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one [0462] A
mixture of Pd2(dba)3 (15 mg, 0.017 mmol) and BrettPhos (18 mg, 0.034 limo') in dioxane (2 mL) was degassed and purged with Nz for three times. The resulting mixture was stirred 50 C for 30 min. 1-(3-Chloro-5-methy1-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (53 mg, 0.17 mmol), 5-methylpyridin-3-amine (24 mg, 0.22 mmol) were added.
And then the resulting mixture was stirred at 100 C for 16 h under Nz. A black suspension was formed.
LCMS showed starting material was consumed completely and the purity of the desired product (Rt = 0.698 min; MS Calcd: 386.1; MS Found: 387.0 [M+H1+). The reaction mixture was filtered and the filtrate was concentrated. The crude product was purified by prep-HPLC
(0.05% NH31120 as an additive) and lyophilized to give 1-(5-methy1-3-((5-methylpyridin-3-yl)amino)-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (14.3 mg, yield: 22%) as a white solid.
NMR (400 MHz, DMSO-d6) 6 1.53 (3H, d, J= 6.8 Hz), 2.02-2.09 (2H, m), 2.28 (3H, s) 2.52 (2H, overlap with DMSO), 3.84 (2H, t, J= 7.6 Hz), 5.27 (1H, q, J= 6.5 Hz), 6.72 (1H, s), 7.31 (1H, dd, J= 8.4, 2.4 Hz), 7.40 (1H, d, J= 2.0 Hz), 7.87 (1H, d, J=
8.8 Hz), 7.95 (1H, d, J= 2.0 Hz), 8.08 (1H, d, J= 2.0 Hz), 8.60 (1H, d, J= 2.0 Hz), 8.68 (1H, s), 9.36 (1H, brs).
184 Example 98: methyl (5-05-methyl-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-yl)carbamate I
NNAO
Step 1: Preparation of methyl (5-bromopyridin-3-yl)carbamate I
BrN )(0 [0463] To a solution of 5-bromopyridin-3-amine (1.00 g, 5.78 mmol) and pyridine (1.4 mL) in DCM (10 mL) was added methyl chloroformate (1.36 g, 1 4.4 mmol). The resulting mixture was stirred at 24 C for 2 h. A yellow solution was formed. LCMS (Rt =
0.658 min;
MS Calcd: 230.0; MS Found: 230.7 [M+H1+). The reaction mixture was diluted with 10%
aqueous CuSO4 (60 mL), then separated and the aqueous layer was extracted with DCM (20 mL x3). The combined organic layer was concentrated and the crude product was triturated with MTBE (13 mL) to give methyl (5-bromopyridin-3-yl)carbamate (900 mg, yield: 67%) as a gray solid.
11-1 NMR (400 MHz, CDC13) (53.81 (3H, s), 6.93 (1H, s), 8.26 (1H, s), 8.40-8.75 (2H, m) Step 2: Preparation of methyl (5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c] py ri din-3-yl)amino)pyri din-3-yl)carb amate A
[0464] To a suspension of 1-(3 -amino-5 -methyl-5H-chromeno [4,3 -c] pyridin-8-yl)pyrrolidin-2-one (70 mg, 0.24 mmol), methyl (5-bromopyridin-3-yl)carbamate (66 mg, 0.28 mmol), BrettPhos (25 mg, 0.047 mmol) and Cs2CO3 (232 mg, 0.711 mmol) in anhydrous dioxane (3 mL) was added Pd2(dba)3 (22 mg, 0.024 mmol) under N2 atmosphere.
The resulting mixture was stirred at 90 C for 12 h under N2 atmosphere. A black brown suspension was
NNAO
Step 1: Preparation of methyl (5-bromopyridin-3-yl)carbamate I
BrN )(0 [0463] To a solution of 5-bromopyridin-3-amine (1.00 g, 5.78 mmol) and pyridine (1.4 mL) in DCM (10 mL) was added methyl chloroformate (1.36 g, 1 4.4 mmol). The resulting mixture was stirred at 24 C for 2 h. A yellow solution was formed. LCMS (Rt =
0.658 min;
MS Calcd: 230.0; MS Found: 230.7 [M+H1+). The reaction mixture was diluted with 10%
aqueous CuSO4 (60 mL), then separated and the aqueous layer was extracted with DCM (20 mL x3). The combined organic layer was concentrated and the crude product was triturated with MTBE (13 mL) to give methyl (5-bromopyridin-3-yl)carbamate (900 mg, yield: 67%) as a gray solid.
11-1 NMR (400 MHz, CDC13) (53.81 (3H, s), 6.93 (1H, s), 8.26 (1H, s), 8.40-8.75 (2H, m) Step 2: Preparation of methyl (5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c] py ri din-3-yl)amino)pyri din-3-yl)carb amate A
[0464] To a suspension of 1-(3 -amino-5 -methyl-5H-chromeno [4,3 -c] pyridin-8-yl)pyrrolidin-2-one (70 mg, 0.24 mmol), methyl (5-bromopyridin-3-yl)carbamate (66 mg, 0.28 mmol), BrettPhos (25 mg, 0.047 mmol) and Cs2CO3 (232 mg, 0.711 mmol) in anhydrous dioxane (3 mL) was added Pd2(dba)3 (22 mg, 0.024 mmol) under N2 atmosphere.
The resulting mixture was stirred at 90 C for 12 h under N2 atmosphere. A black brown suspension was
185 formed. LCMS (Rt = 0.589 min; MS Calcd: 445.1; MS Found: 446.0 [M+Hl+). The reaction mixture was concentrated and the crude product was purified by prep-HPLC
(0.225% FA as an additive) and lyophilized to give methyl (5-45-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-yOcarbamate (35.5 mg, yield: 32%) as a yellow solid.
NMR (400 MHz, DMSO-d6) 1.54 (3H, d, J= 6.8 Hz), 2.02-2.09 (2H, m), 2.5-2.53 (2H, overlapped with DMSO), 3.72 (3H, s), 3.84 (2H, t, J= 7.9 Hz), 5.29 (1H, q, J=
6.6 Hz), 6.77 (1H, s), 7.33 (1H, dd, J= 8.7, 2.1 Hz), 7.40 (1H, d, J= 2.0 Hz), 7.91 (1H, d, J = 8.8 Hz), 8.27 (1H, s), 8.42 (1H, s), 8.68 (1H, s), 8.78 (1H, s), 9.74 (1H, brs), 10.09 (1H, brs).
Example 99: 1-methyl-3-(5-05-methyl-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-yl)urea gN 0 I
N NN AN
H H
[0465] To a mixture of 1-(3-amino-5-methy1-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one (70 mg, 0.24 mmol), 1-(5-bromopyridin-3-y1)-3-methylurea (65 mg, 0.28 mmol), Cs2CO3 (232 mg, 0.711 mmol) in dioxane (3 mL) was added Pd2(dba)3 (22 mg, 0.024 mmol) and BrettPhos (25 mg, 0.047 mmol) under N2 atmosphere. The resulting mixture was stirred at 100 C for 12 h under N2 atmosphere. A red solution was formed. LCMS (Rt =
0.682 min; MS
Calcd: 444.1; MS Found: 445.1 [M+Hl+). The reaction mixture was filtered and the filtrated was concentrated. The residue was purified by prep-HPLC (0.225% FA as an additive) and lyophilized to give 1-methy1-3-(5-45-methyl-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-yOurea (8.7 mg, yield: 8%) as a yellow solid.
NMR (400 MHz, DMSO-d6) (5 1.55 (3H, d, J= 6.5 Hz), 2.03-2.10 (2H, m), 2.52-2.53 (2H, overlapped with DMSO), 2.69 (3H, d, J= 4.5 Hz), 3.85 (2H, t, J= 7.9 Hz), 5.31 (1H, q, J= 6.7 Hz), 6.48 (1H, d, J= 4.8 Hz), 6.81 (1H, s), 7.35 (1H, dd, J= 8.5, 2.3 Hz), 7.41 (1H, d, J= 2.0 Hz), 7.92 (1H, d, J= 8.8 Hz), 8.42 (1H, t, J= 2.0 Hz), 8.46 (1H, d, J=
1.8 Hz), 8.71 (1H, s), 8.87 (1H, d, J= 1.8 Hz), 9.38 (1H, brs), 10.00 (1H, brs).
Example 100: N-(5-05-methyl-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-yl)amino)pyridin-3-yl)acetamide
(0.225% FA as an additive) and lyophilized to give methyl (5-45-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-yOcarbamate (35.5 mg, yield: 32%) as a yellow solid.
NMR (400 MHz, DMSO-d6) 1.54 (3H, d, J= 6.8 Hz), 2.02-2.09 (2H, m), 2.5-2.53 (2H, overlapped with DMSO), 3.72 (3H, s), 3.84 (2H, t, J= 7.9 Hz), 5.29 (1H, q, J=
6.6 Hz), 6.77 (1H, s), 7.33 (1H, dd, J= 8.7, 2.1 Hz), 7.40 (1H, d, J= 2.0 Hz), 7.91 (1H, d, J = 8.8 Hz), 8.27 (1H, s), 8.42 (1H, s), 8.68 (1H, s), 8.78 (1H, s), 9.74 (1H, brs), 10.09 (1H, brs).
Example 99: 1-methyl-3-(5-05-methyl-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-yl)urea gN 0 I
N NN AN
H H
[0465] To a mixture of 1-(3-amino-5-methy1-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one (70 mg, 0.24 mmol), 1-(5-bromopyridin-3-y1)-3-methylurea (65 mg, 0.28 mmol), Cs2CO3 (232 mg, 0.711 mmol) in dioxane (3 mL) was added Pd2(dba)3 (22 mg, 0.024 mmol) and BrettPhos (25 mg, 0.047 mmol) under N2 atmosphere. The resulting mixture was stirred at 100 C for 12 h under N2 atmosphere. A red solution was formed. LCMS (Rt =
0.682 min; MS
Calcd: 444.1; MS Found: 445.1 [M+Hl+). The reaction mixture was filtered and the filtrated was concentrated. The residue was purified by prep-HPLC (0.225% FA as an additive) and lyophilized to give 1-methy1-3-(5-45-methyl-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-yOurea (8.7 mg, yield: 8%) as a yellow solid.
NMR (400 MHz, DMSO-d6) (5 1.55 (3H, d, J= 6.5 Hz), 2.03-2.10 (2H, m), 2.52-2.53 (2H, overlapped with DMSO), 2.69 (3H, d, J= 4.5 Hz), 3.85 (2H, t, J= 7.9 Hz), 5.31 (1H, q, J= 6.7 Hz), 6.48 (1H, d, J= 4.8 Hz), 6.81 (1H, s), 7.35 (1H, dd, J= 8.5, 2.3 Hz), 7.41 (1H, d, J= 2.0 Hz), 7.92 (1H, d, J= 8.8 Hz), 8.42 (1H, t, J= 2.0 Hz), 8.46 (1H, d, J=
1.8 Hz), 8.71 (1H, s), 8.87 (1H, d, J= 1.8 Hz), 9.38 (1H, brs), 10.00 (1H, brs).
Example 100: N-(5-05-methyl-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-yl)amino)pyridin-3-yl)acetamide
186 gN 0 I
N N
Step 1: Preparation of N-(5 -bromopy ri din-3 -yl)acetami de Br N
[0466] To a solution of 5-bromopyridin-3-amine (1.00 g, 5.78 mmol) in pyridine (10 mL) was added acetic anhydride (708 mg, 6.94 mmol) at N2 atmosphere. The resulting mixture was stirred at 25 C for 12 h. A yellow solution was formed. LCMS (Rt = 0.422 min;
MS Calcd:
214.0; MS Found: 214.7 [M+H1+). The reaction mixture was concentrated under reduced pressure. Water (20 mL) was added to the resulting mixture and then extracted with Et0Ac (20 mL x3). The combined organic layer was washed with saturated aqueous NaHCO3(50 mL x3), brine (20 mL), dried over anhydrous Na2SO4 and concentrated to give N-(5-bromopyridin-3-yl)acetamide (1.21 g, yield: 97%) as a yellow solid.
1FINMR (400MHz, CDC13) (5 2.21 (3H, s), 7.78 (1H, brs), 8.37-8.41 (1H, m), 8.42-8.47 (2H, m) Step 2: Preparation of N-(5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno [4,3-c] py ri din-3-yl)amino)pyridin-3-yl)acetamide I
N N
[0467] A
mixture of BrettPhos (25 mg, 0.047 mmol) and Pd2(dba)3 (22 mg, 0.024 mmol) in anhydrous dioxane (1 mL) was stirred at 50 C for 5 min under N2 atmosphere. Then 1-(3-amino-5-methy1-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one (70 mg, 0.24 mmol), N-(5-bromopyridin-3-yl)acetamide (61 mg, 0.28 mmol) and Cs2CO3 (232 mg, 0.711 mmol) were added under N2 atmosphere and the resulting mixture was stirred at 100 C for 12 h under N2 atmosphere. A black suspension was formed. LCMS (Rt = 0.721 min; MS Calcd:
429.1; MS
Found: 430.0 [M+H1+). The reaction mixture was filtered and the filtrate was concentrated.
N N
Step 1: Preparation of N-(5 -bromopy ri din-3 -yl)acetami de Br N
[0466] To a solution of 5-bromopyridin-3-amine (1.00 g, 5.78 mmol) in pyridine (10 mL) was added acetic anhydride (708 mg, 6.94 mmol) at N2 atmosphere. The resulting mixture was stirred at 25 C for 12 h. A yellow solution was formed. LCMS (Rt = 0.422 min;
MS Calcd:
214.0; MS Found: 214.7 [M+H1+). The reaction mixture was concentrated under reduced pressure. Water (20 mL) was added to the resulting mixture and then extracted with Et0Ac (20 mL x3). The combined organic layer was washed with saturated aqueous NaHCO3(50 mL x3), brine (20 mL), dried over anhydrous Na2SO4 and concentrated to give N-(5-bromopyridin-3-yl)acetamide (1.21 g, yield: 97%) as a yellow solid.
1FINMR (400MHz, CDC13) (5 2.21 (3H, s), 7.78 (1H, brs), 8.37-8.41 (1H, m), 8.42-8.47 (2H, m) Step 2: Preparation of N-(5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno [4,3-c] py ri din-3-yl)amino)pyridin-3-yl)acetamide I
N N
[0467] A
mixture of BrettPhos (25 mg, 0.047 mmol) and Pd2(dba)3 (22 mg, 0.024 mmol) in anhydrous dioxane (1 mL) was stirred at 50 C for 5 min under N2 atmosphere. Then 1-(3-amino-5-methy1-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one (70 mg, 0.24 mmol), N-(5-bromopyridin-3-yl)acetamide (61 mg, 0.28 mmol) and Cs2CO3 (232 mg, 0.711 mmol) were added under N2 atmosphere and the resulting mixture was stirred at 100 C for 12 h under N2 atmosphere. A black suspension was formed. LCMS (Rt = 0.721 min; MS Calcd:
429.1; MS
Found: 430.0 [M+H1+). The reaction mixture was filtered and the filtrate was concentrated.
187 The crude product was purified by prep-HPLC (0.225% FA as an additive) and lyophilized to give N-(5-((5 -methyl-8-(2-oxopy rroli din-l-y1)-5H-chromeno [4,3-c] py ri din-3 -yl)amino)pyridin-3-yl)acetamide (31.2 mg, yield: 31%) as a yellow solid.
11-1 NMR (400 MHz, DMSO-d6) 1.55 (3H, d, J= 6.3 Hz), 2.04-2.12 (2H, m), 2.13 (3H, s), 2.52-2.53 (2H, overlapped with DMSO), 3.84 (2H, t, J= 7.5 Hz), 5.31 (1H, q, J=
6.8 Hz), 6.80 (1H, s), 7.35 (1H, d, J= 8.7 Hz), 7.40 (1H, d, J= 2.0 Hz), 7.91 (1H, d, J= 8.5 Hz), 8.50 (1H, d, J= 1.8 Hz), 8.57 (1H, s), 8.70 (1H, s), 8.92 (1H, s), 9.94 (1H, brs), 10.51 (1H, brs).
Example 101: 2-hydroxy-N-(5-05-methyl-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-yl)acetamide N )-OH
Step 1: Preparation of 2-acetoxyacetic acid [0468] To a solution of 2-hydroxyacetic acid (500 mg, 6.57 mmol) in pyridine (2 mL) was added acetic anhydride (691 mg, 6.77 mmol) at 0 C. The resulting mixture was stirred at 25 C for 12 h. A yellow solution was formed. The reaction mixture was concentrated and the residue was diluted with saturated aqueous NaHCO3 (10 mL) and Et0Ac (20 mL) then separated. The aqueous layer was acidified with 1N aqueous HC1 to adjust pH =
6 and extracted with Et0Ac (30 mL x2), DCM (20 mL x2). The combined organic concentrated to give 2-acetoxyacetic acid (100 mg, crude) as a white solid, which was directly used for next step without purification.
11-1NMR (400 MHz, DMSO-d6) (5 1.98 (3H, s), 4.09 (2H, s) Step 2: Preparation of tert-butyl (5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-yl)amino)pyridin-3-yl)carbamate
11-1 NMR (400 MHz, DMSO-d6) 1.55 (3H, d, J= 6.3 Hz), 2.04-2.12 (2H, m), 2.13 (3H, s), 2.52-2.53 (2H, overlapped with DMSO), 3.84 (2H, t, J= 7.5 Hz), 5.31 (1H, q, J=
6.8 Hz), 6.80 (1H, s), 7.35 (1H, d, J= 8.7 Hz), 7.40 (1H, d, J= 2.0 Hz), 7.91 (1H, d, J= 8.5 Hz), 8.50 (1H, d, J= 1.8 Hz), 8.57 (1H, s), 8.70 (1H, s), 8.92 (1H, s), 9.94 (1H, brs), 10.51 (1H, brs).
Example 101: 2-hydroxy-N-(5-05-methyl-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-yl)acetamide N )-OH
Step 1: Preparation of 2-acetoxyacetic acid [0468] To a solution of 2-hydroxyacetic acid (500 mg, 6.57 mmol) in pyridine (2 mL) was added acetic anhydride (691 mg, 6.77 mmol) at 0 C. The resulting mixture was stirred at 25 C for 12 h. A yellow solution was formed. The reaction mixture was concentrated and the residue was diluted with saturated aqueous NaHCO3 (10 mL) and Et0Ac (20 mL) then separated. The aqueous layer was acidified with 1N aqueous HC1 to adjust pH =
6 and extracted with Et0Ac (30 mL x2), DCM (20 mL x2). The combined organic concentrated to give 2-acetoxyacetic acid (100 mg, crude) as a white solid, which was directly used for next step without purification.
11-1NMR (400 MHz, DMSO-d6) (5 1.98 (3H, s), 4.09 (2H, s) Step 2: Preparation of tert-butyl (5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-yl)amino)pyridin-3-yl)carbamate
188 N N NHBoc [0469] To a mixture of 1-(3-amino-5 -methyl-5H-chromeno [4,3 -c] pyri din-8-yl)py rroli din-2-one (1.60 g, 5.42 mmol), tert-butyl (5-bromopyridin-3-yl)carbamate (1.78 g, 6.50 mmol), Cs2CO3 (5.30 g, 16.3 mmol) and BrettPhos (582 mg, 1.08 mmol) in anhydrous dioxane (40 mL) was added Pd2(dba)3 (496 mg, 0.542 mmol) under N2 atmosphere. Then the resulting mixture was stirred at 90 C for 16 h under N2 atmosphere. A red suspension was formed.
LCMS (Rt = 0.753 min; MS Calcd: 487.2; MS Found: 488.3 [M+H1+). The reaction mixture was diluted with water (30 mL), THF (20 mL) and Et0Ac (50 mL) and separated.
The aqueous layer was extracted with THF/Et0Ac (30 mL x3, 1/2). The combined organic layer was washed with brine (50 mL), dried over anhydrous Na2SO4 and concentrated. The residue was purified by Combi Flash (3% Me0H in DCM) to give tert-butyl (5-45-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-yl)carbamate (1.90 g, yield: 68%) as a red solid.
11-1NMR (400 MHz, CDC13) (51.52 (9H, s), 1.58 (3H, d, J = 6.8 Hz), 2.11-2.20 (2H, m), 2.62 (2H, t, J= 8.2 Hz), 3.85 (2H, t, J= 7.8 Hz), 5.12 (1H, q, J = 6.5 Hz), 6.65 (1H, s), 6.85 (1H, s), 7.08 (1H, s), 7.25 (1H, d, J= 2.1 Hz) 7.33 (1H, dd, J= 8.7, 2.1 Hz), 7.64 (1H, d, J= 8.5 Hz), 8.13 (1H, d, J= 2.3 Hz), 8.30-8.32 (2H, m), 8.51 (1H, brs).
Step 3: Preparation of 1-(3-((5 -aminopy ri din-3 -yl)amino)-5-methyl-5H-chromeno [4,3-c] py ri din-8-yl)py rroli din-2-one c 0 N
[0470] To a suspension of tert-butyl (5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-yl)carbamate (1.90 g, 3.90 mmol) in Et0Ac (4 mL) was added HC1/Et0Ac (40 mL, 4 M in Et0Ac). The resulting mixture was stirred at 20 C for 12 h. A yellow suspension was formed. LCMS (Rt = 0.571 min; MS Calcd:
387.1; MS
Found: 388.1[M+H]+). The reaction mixture was concentrated to give 1-(3-((5-aminopyridin-
LCMS (Rt = 0.753 min; MS Calcd: 487.2; MS Found: 488.3 [M+H1+). The reaction mixture was diluted with water (30 mL), THF (20 mL) and Et0Ac (50 mL) and separated.
The aqueous layer was extracted with THF/Et0Ac (30 mL x3, 1/2). The combined organic layer was washed with brine (50 mL), dried over anhydrous Na2SO4 and concentrated. The residue was purified by Combi Flash (3% Me0H in DCM) to give tert-butyl (5-45-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-yl)carbamate (1.90 g, yield: 68%) as a red solid.
11-1NMR (400 MHz, CDC13) (51.52 (9H, s), 1.58 (3H, d, J = 6.8 Hz), 2.11-2.20 (2H, m), 2.62 (2H, t, J= 8.2 Hz), 3.85 (2H, t, J= 7.8 Hz), 5.12 (1H, q, J = 6.5 Hz), 6.65 (1H, s), 6.85 (1H, s), 7.08 (1H, s), 7.25 (1H, d, J= 2.1 Hz) 7.33 (1H, dd, J= 8.7, 2.1 Hz), 7.64 (1H, d, J= 8.5 Hz), 8.13 (1H, d, J= 2.3 Hz), 8.30-8.32 (2H, m), 8.51 (1H, brs).
Step 3: Preparation of 1-(3-((5 -aminopy ri din-3 -yl)amino)-5-methyl-5H-chromeno [4,3-c] py ri din-8-yl)py rroli din-2-one c 0 N
[0470] To a suspension of tert-butyl (5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-yl)carbamate (1.90 g, 3.90 mmol) in Et0Ac (4 mL) was added HC1/Et0Ac (40 mL, 4 M in Et0Ac). The resulting mixture was stirred at 20 C for 12 h. A yellow suspension was formed. LCMS (Rt = 0.571 min; MS Calcd:
387.1; MS
Found: 388.1[M+H]+). The reaction mixture was concentrated to give 1-(3-((5-aminopyridin-
189 3-yl)amino)-5-methyl-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (2.70 g, crude, HC1 salt) as a yellow solid, which was used for the next step directly.
11-1 NMR (400 MHz, DMSO-d6) 1.53 (3H, d, J= 6.8 Hz), 1.99-2.10 (2H, m), 2.51-2.53 (2H, overlapped with DMSO), 3.84 (2H, t, J= 7.8 Hz), 5.30 (1H, q, J= 6.7 Hz), 6.94 (1H, s), 7.33 (1H, dd, J= 8.5, 2.2 Hz), 7.40 (1H, d, J= 2.3 Hz), 7.61 (1H, s), 7.79 (1H, t, J= 2.1 Hz), 7.90 (1H, t, J= 8.5 Hz), 8.65 (1H, s), 8.71 (1H, s), 10.47 (1H, brs), 10.95 (1H, brs), 11.90 (1H, brs).
Step 4: Preparation of 2-((5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-y1)amino)-2-oxoethyl acetate N N)0y [0471] A
mixture of 1-(3-((5-aminopyridin-3-yl)amino)-5-methy1-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (60 mg, 0.14 mmol), 2-acetoxyacetic acid (33 mg, 0.28 mmol) and EDCITIC1 (54 mg, 0.28 mmol) in pyridine (3 mL) was stirred at 50 C for 2 h. A yellow solution was formed. LCMS (Rt = 0.692 min; MS Calcd: 487.2; MS Found: 488.3 [M+H]+).
The reaction mixture was diluted with water (5 mL) and Et0Ac (10 mL) then separated. The aqueous layer was extracted with Et0Ac (10 mL x4). The combined organic layer was dried over anhydrous Na2SO4 and concentrated under reduced pressure to give 2-((5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno [4,3 -c] pyridin-3-yl)amino)pyridin-3-yl)amino)-2-oxoethyl acetate (82 mg, crude) as yellow gum, which was directly used for next step without purification.
Step 5: Preparation of 2-hy droxy -N-(5-((5 -methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno [4,3-clpyridin-3-yl)amino)pyridin-3-yl)acetamide c\N 0 OH
N N
11-1 NMR (400 MHz, DMSO-d6) 1.53 (3H, d, J= 6.8 Hz), 1.99-2.10 (2H, m), 2.51-2.53 (2H, overlapped with DMSO), 3.84 (2H, t, J= 7.8 Hz), 5.30 (1H, q, J= 6.7 Hz), 6.94 (1H, s), 7.33 (1H, dd, J= 8.5, 2.2 Hz), 7.40 (1H, d, J= 2.3 Hz), 7.61 (1H, s), 7.79 (1H, t, J= 2.1 Hz), 7.90 (1H, t, J= 8.5 Hz), 8.65 (1H, s), 8.71 (1H, s), 10.47 (1H, brs), 10.95 (1H, brs), 11.90 (1H, brs).
Step 4: Preparation of 2-((5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-y1)amino)-2-oxoethyl acetate N N)0y [0471] A
mixture of 1-(3-((5-aminopyridin-3-yl)amino)-5-methy1-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (60 mg, 0.14 mmol), 2-acetoxyacetic acid (33 mg, 0.28 mmol) and EDCITIC1 (54 mg, 0.28 mmol) in pyridine (3 mL) was stirred at 50 C for 2 h. A yellow solution was formed. LCMS (Rt = 0.692 min; MS Calcd: 487.2; MS Found: 488.3 [M+H]+).
The reaction mixture was diluted with water (5 mL) and Et0Ac (10 mL) then separated. The aqueous layer was extracted with Et0Ac (10 mL x4). The combined organic layer was dried over anhydrous Na2SO4 and concentrated under reduced pressure to give 2-((5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno [4,3 -c] pyridin-3-yl)amino)pyridin-3-yl)amino)-2-oxoethyl acetate (82 mg, crude) as yellow gum, which was directly used for next step without purification.
Step 5: Preparation of 2-hy droxy -N-(5-((5 -methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno [4,3-clpyridin-3-yl)amino)pyridin-3-yl)acetamide c\N 0 OH
N N
190 [0472] To a solution of 2-((5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-yl)amino)-2-oxoethyl acetate (82 mg, 0.17 mmol) in THF/Me0H (6 mL, 2/1) was added 1N aqueous NaOH (2 mL) at 25 C. The resulting mixture was stirred at 25 C for 2 h. A yellow solution was formed. LCMS (Rt = 0.561 min; MS Calcd:
445.1; MS Found: 446.1 [M+H1+). The reaction mixture was diluted with Et0Ac (10 mL) and H20 (5 mL) then separated. The aqueous layer was extracted with Et0Ac (20 mL
x3). The combined organic layer was washed with brine (15 mL), dried over anhydrous Na2SO4 and concentrated. The residue was purified by prep-HPLC (0.225% FA as an additive) and lyophilized, then triturated with MeCN (0.5 mL) to give 2-hydroxy-N-(5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-y1)amino)pyridin-3-y1)acetamide (9.9 mg, yield: 13% for 3 steps) as a yellow solid.
11-INMR (400 MHz, DMSO-d6) 61.55 (3H, d, J= 6.5 Hz), 1.99-2.10 (2H, m), 2.50-2.52 (2H, m, overlapped with DMSO), 3.85 (2H, t, J= 8.0 Hz), 4.07 (2H, s), 5.31 (1H, q, J= 6.7 Hz), 6.80 (1H, s), 7.34 (1H, dd, J= 8.5, 2.3 Hz), 7.41 (1H, d, J= 2.3 Hz), 7.91 (1H, d, J= 8.5 Hz), 8.52 (1H, s), 8.67-8.71 (2H, m), 8.85 (1H, s), 9.77 (1H, brs), 10.14 (1H, brs).
Example 102: 1-(5-45-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno14,3-c]pyridin-yl)amino)pyridin-3-y1)-3-(pyridin-2-yOurea H H
Step 1: Preparation of 1-(5-bromopyridin-3-y1)-3-(pyridin-2-yl)urea BrN).LN
H H
[0473] A
solution of pyridine (0.7 mL) and triphosgene (2.57 g, 8.66 mmol) in DCM (6 mL) was stirred at 0 C for 20 minutes. A solution of 5-bromopyridin-3-amine (300 mg, 1.73 mmol) in DCM (6 mL) was added dropwise at 0 C. The resulting mixture was stirred at 25 C
for 1 hour. Then pyridin-2-amine (136 mg, 1.45 mmol) was added at 0 C. The resulting mixture was stirred at 25 C for 12 h. A light red suspension was formed. LCMS
showed the
445.1; MS Found: 446.1 [M+H1+). The reaction mixture was diluted with Et0Ac (10 mL) and H20 (5 mL) then separated. The aqueous layer was extracted with Et0Ac (20 mL
x3). The combined organic layer was washed with brine (15 mL), dried over anhydrous Na2SO4 and concentrated. The residue was purified by prep-HPLC (0.225% FA as an additive) and lyophilized, then triturated with MeCN (0.5 mL) to give 2-hydroxy-N-(5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-y1)amino)pyridin-3-y1)acetamide (9.9 mg, yield: 13% for 3 steps) as a yellow solid.
11-INMR (400 MHz, DMSO-d6) 61.55 (3H, d, J= 6.5 Hz), 1.99-2.10 (2H, m), 2.50-2.52 (2H, m, overlapped with DMSO), 3.85 (2H, t, J= 8.0 Hz), 4.07 (2H, s), 5.31 (1H, q, J= 6.7 Hz), 6.80 (1H, s), 7.34 (1H, dd, J= 8.5, 2.3 Hz), 7.41 (1H, d, J= 2.3 Hz), 7.91 (1H, d, J= 8.5 Hz), 8.52 (1H, s), 8.67-8.71 (2H, m), 8.85 (1H, s), 9.77 (1H, brs), 10.14 (1H, brs).
Example 102: 1-(5-45-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno14,3-c]pyridin-yl)amino)pyridin-3-y1)-3-(pyridin-2-yOurea H H
Step 1: Preparation of 1-(5-bromopyridin-3-y1)-3-(pyridin-2-yl)urea BrN).LN
H H
[0473] A
solution of pyridine (0.7 mL) and triphosgene (2.57 g, 8.66 mmol) in DCM (6 mL) was stirred at 0 C for 20 minutes. A solution of 5-bromopyridin-3-amine (300 mg, 1.73 mmol) in DCM (6 mL) was added dropwise at 0 C. The resulting mixture was stirred at 25 C
for 1 hour. Then pyridin-2-amine (136 mg, 1.45 mmol) was added at 0 C. The resulting mixture was stirred at 25 C for 12 h. A light red suspension was formed. LCMS
showed the
191 purity of desired product (Rt = 0.682 min; MS Calcd: 292.0; MS Found: 293.1 [M+Hl+). The reaction mixture was diluted with DCM (20 mL), H20 (10 mL) and separated. The aqueous layer was extracted with DCM (15 mL x2) and Et0Ac/THF (15 mL x2, 2/1). The combined organic layer was dried over anhydrous Na2SO4 and concentrated. The residue was purified by Combi Flash (3% Me0H in DCM) to give 1-(5-bromopyridin-3-y1)-3-(pyridin-2-yl)urea (100 mg, yield: 20%) as a white solid.
NMR (400 MHz, DMSO-d6) (57.05 (1H, t, J= 6.4 Hz), 7.45 (1H, d, J= 8.0 Hz), 7.78 (1H, t, J= 7.9 Hz), 8.31-8.39 (3H, m), 8.63 (1H, s), 9.70 (1H, brs), 10.98 (1H, brs).
Step 2: Preparation of 1-(5-((5 -methyl-8-(2-oxopyrroli din-1 -y1)-5H-chromeno [4,3-c] py ri din-3-yl)amino)py ri din-3-y1)-3 -(pyri din-2-yl)urea I I it N -N -H H H
[0474] To a suspension of 1-(3 -amino-5 -methyl-5H-chromeno[4,3 -c] pyridin-8-yl)pyrrolidin-2-one (60 mg, 0.20 mmol), 1-(5-bromopyridin-3-y1)-3-(pyridin-2-yl)urea (70 mg, 0.24 mol), BrettPhos (22 mg, 0.041 mmol) and Cs2CO3 (199 mg, 0.609 mmol) in anhydrous dioxane (10 mL) was added Pd2(dba)3 (18 mg, 0.020 mmol) under N2 atmosphere.
The resulting mixture was stirred at 90 C for 12 h under N2 atmosphere. A black brown suspension was formed. LCMS (Rt = 0.743 min; MS Calcd: 507.2; MS Found: 508.4 [M+Hl+).
The reaction mixture was filtered and the filtrate was concentrated. The residue was purified by prep-HPLC (0.225% FA as an additive) twice and lyophilized to give 1-(5-((5-methy1-8-(2-oxopy rroli din-1-y 0-5H-chromeno [4,3 -c] py ri din-3-y0amino)py ri din-3-y1)-3-(py ri din-2-yOurea (4.4 mg, yield: 4 %) as a white solid.
NMR (400 MHz, DMSO-d6) (5 1.55 (3H, d, J= 6.5 Hz), 2.03-2.10 (2H, m), 2.51-2.53 (2H, overlapped with DMSO), 3.85 (2H, t, J= 7.8 Hz), 5.29 (1H, q, J= 6.8 Hz), 6.77 (1H, s), 7.03-7.06 (1H, m), 7.33 (1H, dd, J= 8.5, 2.1 Hz), 7.41 (1H, d, J= 2.2 Hz), 7.54 (1H, d, J= 8.3 Hz), 7.58-7.80 (1H, m), 7.91 (1H, d, J= 8.7 Hz), 8.26 (1H, d, J= 2.2 Hz), 8.32 (1H, d, J= 4.3 Hz), 8.45 (1H, t, J= 2.1 Hz), 8.63 (1H, d, J= 2.2 Hz), 8.69 (1H, s), 9.20 (1H, brs), 9.52 (1H, brs), 10.57 (1H, brs).
Example 103: 1-benzy1-3-(5-05-methyl-8-(2-oxopyrrolidin-1-y1)-5H-chromeno 14,3-
NMR (400 MHz, DMSO-d6) (57.05 (1H, t, J= 6.4 Hz), 7.45 (1H, d, J= 8.0 Hz), 7.78 (1H, t, J= 7.9 Hz), 8.31-8.39 (3H, m), 8.63 (1H, s), 9.70 (1H, brs), 10.98 (1H, brs).
Step 2: Preparation of 1-(5-((5 -methyl-8-(2-oxopyrroli din-1 -y1)-5H-chromeno [4,3-c] py ri din-3-yl)amino)py ri din-3-y1)-3 -(pyri din-2-yl)urea I I it N -N -H H H
[0474] To a suspension of 1-(3 -amino-5 -methyl-5H-chromeno[4,3 -c] pyridin-8-yl)pyrrolidin-2-one (60 mg, 0.20 mmol), 1-(5-bromopyridin-3-y1)-3-(pyridin-2-yl)urea (70 mg, 0.24 mol), BrettPhos (22 mg, 0.041 mmol) and Cs2CO3 (199 mg, 0.609 mmol) in anhydrous dioxane (10 mL) was added Pd2(dba)3 (18 mg, 0.020 mmol) under N2 atmosphere.
The resulting mixture was stirred at 90 C for 12 h under N2 atmosphere. A black brown suspension was formed. LCMS (Rt = 0.743 min; MS Calcd: 507.2; MS Found: 508.4 [M+Hl+).
The reaction mixture was filtered and the filtrate was concentrated. The residue was purified by prep-HPLC (0.225% FA as an additive) twice and lyophilized to give 1-(5-((5-methy1-8-(2-oxopy rroli din-1-y 0-5H-chromeno [4,3 -c] py ri din-3-y0amino)py ri din-3-y1)-3-(py ri din-2-yOurea (4.4 mg, yield: 4 %) as a white solid.
NMR (400 MHz, DMSO-d6) (5 1.55 (3H, d, J= 6.5 Hz), 2.03-2.10 (2H, m), 2.51-2.53 (2H, overlapped with DMSO), 3.85 (2H, t, J= 7.8 Hz), 5.29 (1H, q, J= 6.8 Hz), 6.77 (1H, s), 7.03-7.06 (1H, m), 7.33 (1H, dd, J= 8.5, 2.1 Hz), 7.41 (1H, d, J= 2.2 Hz), 7.54 (1H, d, J= 8.3 Hz), 7.58-7.80 (1H, m), 7.91 (1H, d, J= 8.7 Hz), 8.26 (1H, d, J= 2.2 Hz), 8.32 (1H, d, J= 4.3 Hz), 8.45 (1H, t, J= 2.1 Hz), 8.63 (1H, d, J= 2.2 Hz), 8.69 (1H, s), 9.20 (1H, brs), 9.52 (1H, brs), 10.57 (1H, brs).
Example 103: 1-benzy1-3-(5-05-methyl-8-(2-oxopyrrolidin-1-y1)-5H-chromeno 14,3-
192 c] pyridin-3-yl)amino)pyridin-3-yl)urea N N A N
H H
Step 1: Preparation of 1-benzy1-3-(5-bromopyridin-3-yl)urea I
BrNAN
H H
[0475] To a mixture of 5-bromopyridin-3-amine (1.00 g, 5.80 mmol) and Et3N (1.6 mL) in DCM (10 mL) was added (isocyanatomethyObenzene (924 mg, 6.94 mmol) at 0 C.
The resulting mixture was stirred at 25 C for 12 h. A white suspension was formed. LCMS (Rt =
0.601 min; MS Calcd: 305.0; MS Found: 305.9 [M+H1+). The reaction mixture was concentrated and the crude product was purified by Combi Flash (5% Me0H in DCM) then triturated with DCM/PE (5 mL, 1/3) to give a mixture of 1-benzy1-3-(5-bromopyridin-3-yl)urea and side product 3-((3-benzylureido)methyl)benzene-1-ylium, which was used for next step without purification.
Step 2: Preparation of 1-benzy1-3 -(5 -((5-methyl-8-(2-oxopy rrolidin-1 -y1)-5H-chromeno [4,3 -c] py ri din-3-yl)amino)pyri din-3-yl)urea I I
N N N).( N
H H
[0476] A
mixture of 1-(3-amino-5-methy1-5H-chromeno [4,3-clpyridin-8-yOpyrrolidin-2-one (70 mg, 0.24 mmol), 1-benzy1-3-(5-bromopyridin-3-yl)urea (116 mg, crude), Cs2CO3 (232 mg, 0.711 mmol), BrettPhos (25 mg, 0.047 mmol) and Pd2(dba)3 (22 mg, 0.024 mol) in anhydrous dioxane (0.5 mL) were stirred at 100 C for 12 h under N2 atmosphere. A white suspension was formed. LCMS (Rt = 0.745 min; MS Calcd: 520.2; MS Found: 521.1 [M+141+).
The reaction mixture was filtered and the filtrate was concentrated. The crude product was
H H
Step 1: Preparation of 1-benzy1-3-(5-bromopyridin-3-yl)urea I
BrNAN
H H
[0475] To a mixture of 5-bromopyridin-3-amine (1.00 g, 5.80 mmol) and Et3N (1.6 mL) in DCM (10 mL) was added (isocyanatomethyObenzene (924 mg, 6.94 mmol) at 0 C.
The resulting mixture was stirred at 25 C for 12 h. A white suspension was formed. LCMS (Rt =
0.601 min; MS Calcd: 305.0; MS Found: 305.9 [M+H1+). The reaction mixture was concentrated and the crude product was purified by Combi Flash (5% Me0H in DCM) then triturated with DCM/PE (5 mL, 1/3) to give a mixture of 1-benzy1-3-(5-bromopyridin-3-yl)urea and side product 3-((3-benzylureido)methyl)benzene-1-ylium, which was used for next step without purification.
Step 2: Preparation of 1-benzy1-3 -(5 -((5-methyl-8-(2-oxopy rrolidin-1 -y1)-5H-chromeno [4,3 -c] py ri din-3-yl)amino)pyri din-3-yl)urea I I
N N N).( N
H H
[0476] A
mixture of 1-(3-amino-5-methy1-5H-chromeno [4,3-clpyridin-8-yOpyrrolidin-2-one (70 mg, 0.24 mmol), 1-benzy1-3-(5-bromopyridin-3-yl)urea (116 mg, crude), Cs2CO3 (232 mg, 0.711 mmol), BrettPhos (25 mg, 0.047 mmol) and Pd2(dba)3 (22 mg, 0.024 mol) in anhydrous dioxane (0.5 mL) were stirred at 100 C for 12 h under N2 atmosphere. A white suspension was formed. LCMS (Rt = 0.745 min; MS Calcd: 520.2; MS Found: 521.1 [M+141+).
The reaction mixture was filtered and the filtrate was concentrated. The crude product was
193 purified by prep-HPLC (0.225% FA as an additive) and lyophilized to give 1-benzy1-3-(5-45-methy1-8-(2-oxopy rroli din-1 -y 0-5H-chromeno [4,3 -c] py ri din-3-yl)amino)py ri din-3-yl)urea (12.9 mg, yield: 9%) as a white solid.
NMR (400 MHz, DMSO-d6) 1.53 (3H, d, J= 6.6 Hz), 2.01-2.09 (2H, m), 2.51-2.53 (2H, overlapped with DMSO), 3.85 (2H, t, J= 8.0 Hz), 4.32 (2H, d, J= 5.9 Hz), 5.27 (1H, q, J=
6.4 Hz), 6.79 (1H, s), 6.81 (1H, t, J= 5.9 Hz), 7.23-7.29 (1H, m), 7.30-7.36 (4H, m), 7.39 (1H, d, J= 2.2 Hz), 7.88 (1H, d, J= 8.7 Hz), 8.13 (1H, s), 8.23 (1H, s), 8.34 (1H, s), 8.58 (1H, s), 8.90 (1H, s), 9.52 (1H, brs), 10.57 (1H, brs).
Example 104: N-(5-05-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-yl)amino)pyridin-3-y1)-2-oxopyrrolidine-3-carboxamide N N
NH
[0477] A
solution of 1-(3-((5-aminopyridin-3-yl)amino)-5-methy1-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (60 mg, 0.14 mmol), 2-oxopyrrolidine-3-carboxylic acid (27 mg, 0.21 mmol) and EDCI HC1 (40 mg, 0.21 mmol) in pyridine (4 mL) was stirred at 50 C for 2 h under N2 atmosphere. A brown solution was formed. LCMS (Rt = 0.675 min; MS
Calcd:
498.2; MS Found: 499.3 [M+H1+). The reaction mixture was diluted with saturated aqueous NaHCO3 (5 mL) and DCM (15 mL) then separated. The aqueous layer was extracted with DCM (15 mL x3). The combined organic layer was concentrated and the residue was purified by prep-HPLC (0.225% FA as an additive) and lyophilized to give N-(5-((5-methy1-8-(2-oxopy rroli din-1-y 0-5H-chromeno [4,3 -c] py ri din-3-y0amino)py ri din-3-y 0-2-oxopyrroli dine-3-carboxamide (36.3 mg, yield: 49%) as a yellow solid.
NMR (400 MHz, DMSO-d6) (5 1.54 (3H, d, J= 6.5 Hz), 2.01-2.09 (2H, m), 2.25-2.28 (1H, m), 2.35-2.41 (1H, m), 2.51-2.53 (2H, overlap with DMSO), 3.20-3.36 (3H, m), 3.83 (2H, t, J
= 8.0 Hz), 5.27 (1H, q, J= 6.6 Hz), 6.75 (1H, s), 7.31 (1H, dd, J= 8.7, 1.9 Hz), 7.39 (1H, d, J
= 2.3 Hz), 7.89 (1H, d, J = 8.5 Hz), 7.97 (1H, s), 8.39 (1H, s), 8.58 (1H, t, J= 2.0 Hz), 8.63 (1H, s), 8.67 (1H, brs), 9.57 (1H, brs), 10.41 (1H, brs).
NMR (400 MHz, DMSO-d6) 1.53 (3H, d, J= 6.6 Hz), 2.01-2.09 (2H, m), 2.51-2.53 (2H, overlapped with DMSO), 3.85 (2H, t, J= 8.0 Hz), 4.32 (2H, d, J= 5.9 Hz), 5.27 (1H, q, J=
6.4 Hz), 6.79 (1H, s), 6.81 (1H, t, J= 5.9 Hz), 7.23-7.29 (1H, m), 7.30-7.36 (4H, m), 7.39 (1H, d, J= 2.2 Hz), 7.88 (1H, d, J= 8.7 Hz), 8.13 (1H, s), 8.23 (1H, s), 8.34 (1H, s), 8.58 (1H, s), 8.90 (1H, s), 9.52 (1H, brs), 10.57 (1H, brs).
Example 104: N-(5-05-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-yl)amino)pyridin-3-y1)-2-oxopyrrolidine-3-carboxamide N N
NH
[0477] A
solution of 1-(3-((5-aminopyridin-3-yl)amino)-5-methy1-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (60 mg, 0.14 mmol), 2-oxopyrrolidine-3-carboxylic acid (27 mg, 0.21 mmol) and EDCI HC1 (40 mg, 0.21 mmol) in pyridine (4 mL) was stirred at 50 C for 2 h under N2 atmosphere. A brown solution was formed. LCMS (Rt = 0.675 min; MS
Calcd:
498.2; MS Found: 499.3 [M+H1+). The reaction mixture was diluted with saturated aqueous NaHCO3 (5 mL) and DCM (15 mL) then separated. The aqueous layer was extracted with DCM (15 mL x3). The combined organic layer was concentrated and the residue was purified by prep-HPLC (0.225% FA as an additive) and lyophilized to give N-(5-((5-methy1-8-(2-oxopy rroli din-1-y 0-5H-chromeno [4,3 -c] py ri din-3-y0amino)py ri din-3-y 0-2-oxopyrroli dine-3-carboxamide (36.3 mg, yield: 49%) as a yellow solid.
NMR (400 MHz, DMSO-d6) (5 1.54 (3H, d, J= 6.5 Hz), 2.01-2.09 (2H, m), 2.25-2.28 (1H, m), 2.35-2.41 (1H, m), 2.51-2.53 (2H, overlap with DMSO), 3.20-3.36 (3H, m), 3.83 (2H, t, J
= 8.0 Hz), 5.27 (1H, q, J= 6.6 Hz), 6.75 (1H, s), 7.31 (1H, dd, J= 8.7, 1.9 Hz), 7.39 (1H, d, J
= 2.3 Hz), 7.89 (1H, d, J = 8.5 Hz), 7.97 (1H, s), 8.39 (1H, s), 8.58 (1H, t, J= 2.0 Hz), 8.63 (1H, s), 8.67 (1H, brs), 9.57 (1H, brs), 10.41 (1H, brs).
194 Example 105: 4-05-05-methyl-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-yl)amino)pyridin-3-yl)amino)-4-oxobutanoic acid I
NNrOH
Step 1: Preparation of tert-butyl 4-((5-bromopyridin-3-y0amino)-4-oxobutanoate )ro Br N
[0478] A
mixture of 5-bromopyridin-3-amine (300 mg, 1.73 mmol), mono-tert-butyl succinic acid (301 mg, 1.73 mmol) and EDCI.HC1 (365 mg, 1.90 mmol) in pyridine (5 mL) was heated at 50 C for 1 hour. An orange solution was formed. The mixture was concentrated and the residue was poured into water (20 mL) and stirred for 2 minutes. The aqueous layer was extracted with ethyl acetate (20 mL x3). The combined organic layer was washed with water (20 mL x2) and brine (20 mL), dried over anhydrous Na2SO4, filtered and concentrated. The residue was triturated with pentane/EtOAC (3 mL, 3/1) to give tert-butyl 4-((5-bromopyridin-3-y0amino)-4-oxobutanoate(470 mg, yield: 82%) as a yellow solid.
11-1 NMR (400 MHz DMSO-d6) (51.39 (9H, s), 2.52-2.55 (2H, m), 2.57-2.62 (2H, m), 8.30-8.40 (2H, m), 8.62-8.65 (1H, m), 10.41 (1H, brs) Step 2: Preparation of 4-((5 -((5-methyl-8-(2-oxopyrroli din-1 -y1)-5H-chromeno [4,3-c] py ri din-3-y0amino)pyridin-3-y0amino)-4-oxobutanoic acid I
N
[0479] A
mixture of 1-(3-amino-5-methy1-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (60 mg, 0.18 mmol, HC1 salt), tert-butyl 4-((5-bromopyridin-3-y0amino)-4-oxobutanoate (60 mg, 0.18 mmol), Pd2(dba)3 (17 mg, 0.018 mmol), BrettPhos (19 mg, 0.036 mmol), Cs2CO3 (118 mg, 0.362 mmol) in anhydrous dioxane (3 mL) was degassed and purged with N2 for 3
NNrOH
Step 1: Preparation of tert-butyl 4-((5-bromopyridin-3-y0amino)-4-oxobutanoate )ro Br N
[0478] A
mixture of 5-bromopyridin-3-amine (300 mg, 1.73 mmol), mono-tert-butyl succinic acid (301 mg, 1.73 mmol) and EDCI.HC1 (365 mg, 1.90 mmol) in pyridine (5 mL) was heated at 50 C for 1 hour. An orange solution was formed. The mixture was concentrated and the residue was poured into water (20 mL) and stirred for 2 minutes. The aqueous layer was extracted with ethyl acetate (20 mL x3). The combined organic layer was washed with water (20 mL x2) and brine (20 mL), dried over anhydrous Na2SO4, filtered and concentrated. The residue was triturated with pentane/EtOAC (3 mL, 3/1) to give tert-butyl 4-((5-bromopyridin-3-y0amino)-4-oxobutanoate(470 mg, yield: 82%) as a yellow solid.
11-1 NMR (400 MHz DMSO-d6) (51.39 (9H, s), 2.52-2.55 (2H, m), 2.57-2.62 (2H, m), 8.30-8.40 (2H, m), 8.62-8.65 (1H, m), 10.41 (1H, brs) Step 2: Preparation of 4-((5 -((5-methyl-8-(2-oxopyrroli din-1 -y1)-5H-chromeno [4,3-c] py ri din-3-y0amino)pyridin-3-y0amino)-4-oxobutanoic acid I
N
[0479] A
mixture of 1-(3-amino-5-methy1-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (60 mg, 0.18 mmol, HC1 salt), tert-butyl 4-((5-bromopyridin-3-y0amino)-4-oxobutanoate (60 mg, 0.18 mmol), Pd2(dba)3 (17 mg, 0.018 mmol), BrettPhos (19 mg, 0.036 mmol), Cs2CO3 (118 mg, 0.362 mmol) in anhydrous dioxane (3 mL) was degassed and purged with N2 for 3
195 times. Then the resulting reaction mixture was heated at 90 C for 20 h under N2 atmosphere.
The reaction mixture turned into yellow suspension from red suspension. LCMS
(Rt = 0.564 min; MS Calcd: 487.2; MS Found: 488.1 [M+Hl+). The reaction mixture was diluted with water (10 mL), adjusted pH = 6 by 0.1 N aqueous HC1 solution, and extracted with Et0Ac (20 mL x3). The combined organic layer was washed with water (20 mL x2), brine (20 mL
x2), dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by prep-HPLC (0.225% FA as an additive) and lyophilized to give 4-((5-((5-methy1-8-(2-oxopy rroli din-l-y1)-5H-chromeno [4,3 -c] py ri din-3-yl)amino)py ri din-3-yl)amino)-4-oxobutanoic acid (26.7 mg, yield: 30%) as a yellow solid.
11-1NMR (400 MHz DMSO-d6) 1.54 (3H, d, J= 6.5 Hz), 2.02-2.09 (2H, m), 2.52-2.54 (2H, m, ovelapped with the peak of DMSO), 2.56 (2H, t, J = 6.0 Hz), 2.60-2.65 (2H, m), 3.79-3.88 (2H, m), 5.27 (1H, q, J= 6.4 Hz), 6.76 (1H, s), 7.32 (1H, dd, J = 8.7, 2.1 Hz), 7.40 (1H, d, J
= 2.0 Hz), 7.89 (1H, d, J= 8.8 Hz), 8.38 (1H, s), 8.52-8.55 (1H, m), 8.65-8.70 (2H, m), 9.60 (1H, brs), 10.28 (1H, brs).
Example 106: 3-amino-N-(5-05-methyl-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-yl)benzamide rN 0 NH, N N N -H
Step 1: Preparation of tert-butyl (3-((5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-yOcarbamoyl)phenyl)carbamate I I N N N
NHBoc [0480] A
mixture of 1-(3-amino-5-methy1-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (60 mg, 0.20 mmol), tert-butyl (3-((5-bromopyridin-3-yl)carbamoyl)phenyl)carbamate (88 mg, 0.22 mmol), Pd2(dba)3 (19 mg, 0.020 mmol), BrettPhos (22 mg, 0.041 mmol), Cs2CO3 (132 mg, 0.406 mmol) in t-Amyl alcohol (3 mL) was degassed and purged with N2 for 3 times.
The reaction mixture turned into yellow suspension from red suspension. LCMS
(Rt = 0.564 min; MS Calcd: 487.2; MS Found: 488.1 [M+Hl+). The reaction mixture was diluted with water (10 mL), adjusted pH = 6 by 0.1 N aqueous HC1 solution, and extracted with Et0Ac (20 mL x3). The combined organic layer was washed with water (20 mL x2), brine (20 mL
x2), dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by prep-HPLC (0.225% FA as an additive) and lyophilized to give 4-((5-((5-methy1-8-(2-oxopy rroli din-l-y1)-5H-chromeno [4,3 -c] py ri din-3-yl)amino)py ri din-3-yl)amino)-4-oxobutanoic acid (26.7 mg, yield: 30%) as a yellow solid.
11-1NMR (400 MHz DMSO-d6) 1.54 (3H, d, J= 6.5 Hz), 2.02-2.09 (2H, m), 2.52-2.54 (2H, m, ovelapped with the peak of DMSO), 2.56 (2H, t, J = 6.0 Hz), 2.60-2.65 (2H, m), 3.79-3.88 (2H, m), 5.27 (1H, q, J= 6.4 Hz), 6.76 (1H, s), 7.32 (1H, dd, J = 8.7, 2.1 Hz), 7.40 (1H, d, J
= 2.0 Hz), 7.89 (1H, d, J= 8.8 Hz), 8.38 (1H, s), 8.52-8.55 (1H, m), 8.65-8.70 (2H, m), 9.60 (1H, brs), 10.28 (1H, brs).
Example 106: 3-amino-N-(5-05-methyl-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-yl)benzamide rN 0 NH, N N N -H
Step 1: Preparation of tert-butyl (3-((5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-yOcarbamoyl)phenyl)carbamate I I N N N
NHBoc [0480] A
mixture of 1-(3-amino-5-methy1-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (60 mg, 0.20 mmol), tert-butyl (3-((5-bromopyridin-3-yl)carbamoyl)phenyl)carbamate (88 mg, 0.22 mmol), Pd2(dba)3 (19 mg, 0.020 mmol), BrettPhos (22 mg, 0.041 mmol), Cs2CO3 (132 mg, 0.406 mmol) in t-Amyl alcohol (3 mL) was degassed and purged with N2 for 3 times.
196 Then the resulting reaction mixture was heated at 90 C for 16 h under N2 atmosphere. The reaction mixture turned into gray suspension from white suspension. LCMS (Rt =
0.788 min;
MS Calcd: 606.3; MS Found: 607.1 [M+H]+). The reaction mixture was diluted with water (20 mL) and extracted with Et0AdTHF (25 mL x2, 1/1). The combined organic layer was washed with water (30 mL x2), brine (30 mL x2), dried over anhydrous Na2SO4, filtered and concentrated to give tert-butyl (3-((5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-yl)carbamoyl)phenyl)carbamate (110 mg, crude) as a yellow solid. It was used for next step without further purification.
Step 2: Preparation of 3 -amino-N-(5 -((5-methyl-8-(2-oxopy rroli din-l-y1)-5H-chromeno [4,3 -c] pyridin-3-yl)amino)pyridin-3 -yl)benzamide gN 0 r 0 H
[0481] To a stirred solution of tert-butyl (3-((5-((5-methy1-8-(2-oxopyrrolidin-l-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-yl)carbamoyl)phenyl)carbamate (80 mg, crude) in DCM (2 mL) was added TFA (2 mL) dropwise at 25 C. The reaction mixture was stirred at 25 C for 3 h. A yellow solution was formed. LCMS (Rt = 0.690 min; MS Calcd:
506.2; MS
Found: 507.1 [M+H]+). The mixture was concentrated and the residue was basified with saturated Na2CO3 aqueous solution (10 mL) to pH = 10 and extracted with Et0Ac/THF (20 mL x3, 1/1). The combined organic layer was washed with water (20 mL x2), brine (20 mL
x2), dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by prep-HPLC (0.225% FA as an additive) and lyophilized to give 3-amino-N-(5-((5-methy1-8-(2-oxopy rroli din-l-y1)-5H-chromeno [4,3 -c] py ri din-3-yl)amino)py ri din-3-yl)b enzami de (25.9 mg, yield: 25% for two steps) as a yellow solid.
1FINMR (400 MHz DMSO-d6) 61.55 (3H, d, J= 6.8 Hz), 2.02-2.10 (2H, m), 2.52-2.54 (2H, m, overlapped with the peak of DMSO), 3.82-3.88 (2H, m), 5.29 (1H, q, J = 6.4 Hz), 6.77-6.81 (2H, m), 7.10-7.15 (2H, m), 7.18 (1H, t, J= 8.0 Hz), 7.33 (1H, dd, J=
8.5, 2.3 Hz), 7.41 (1H, d, J= 2.3 Hz), 7.89 (1H, d, J= 8.8 Hz), 8.49 (1H, s), 8.65-8.68 (1H, m), 8.69 (1H, s), 8.70-8.75 (1H, m), 9.55 (1H, brs), 10.31 (1H, brs). Note: two protons of aniline were not observed.
0.788 min;
MS Calcd: 606.3; MS Found: 607.1 [M+H]+). The reaction mixture was diluted with water (20 mL) and extracted with Et0AdTHF (25 mL x2, 1/1). The combined organic layer was washed with water (30 mL x2), brine (30 mL x2), dried over anhydrous Na2SO4, filtered and concentrated to give tert-butyl (3-((5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-yl)carbamoyl)phenyl)carbamate (110 mg, crude) as a yellow solid. It was used for next step without further purification.
Step 2: Preparation of 3 -amino-N-(5 -((5-methyl-8-(2-oxopy rroli din-l-y1)-5H-chromeno [4,3 -c] pyridin-3-yl)amino)pyridin-3 -yl)benzamide gN 0 r 0 H
[0481] To a stirred solution of tert-butyl (3-((5-((5-methy1-8-(2-oxopyrrolidin-l-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-yl)carbamoyl)phenyl)carbamate (80 mg, crude) in DCM (2 mL) was added TFA (2 mL) dropwise at 25 C. The reaction mixture was stirred at 25 C for 3 h. A yellow solution was formed. LCMS (Rt = 0.690 min; MS Calcd:
506.2; MS
Found: 507.1 [M+H]+). The mixture was concentrated and the residue was basified with saturated Na2CO3 aqueous solution (10 mL) to pH = 10 and extracted with Et0Ac/THF (20 mL x3, 1/1). The combined organic layer was washed with water (20 mL x2), brine (20 mL
x2), dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by prep-HPLC (0.225% FA as an additive) and lyophilized to give 3-amino-N-(5-((5-methy1-8-(2-oxopy rroli din-l-y1)-5H-chromeno [4,3 -c] py ri din-3-yl)amino)py ri din-3-yl)b enzami de (25.9 mg, yield: 25% for two steps) as a yellow solid.
1FINMR (400 MHz DMSO-d6) 61.55 (3H, d, J= 6.8 Hz), 2.02-2.10 (2H, m), 2.52-2.54 (2H, m, overlapped with the peak of DMSO), 3.82-3.88 (2H, m), 5.29 (1H, q, J = 6.4 Hz), 6.77-6.81 (2H, m), 7.10-7.15 (2H, m), 7.18 (1H, t, J= 8.0 Hz), 7.33 (1H, dd, J=
8.5, 2.3 Hz), 7.41 (1H, d, J= 2.3 Hz), 7.89 (1H, d, J= 8.8 Hz), 8.49 (1H, s), 8.65-8.68 (1H, m), 8.69 (1H, s), 8.70-8.75 (1H, m), 9.55 (1H, brs), 10.31 (1H, brs). Note: two protons of aniline were not observed.
197 Example 107: N-(5-05-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-yl)amino)pyridin-3-y1)-2-phenylacetamide I I
N NN
Step 1: Preparation N-(5-aminopyridin-3-y1)-2-phenylacetamide rNi 0 [0482] A
mixture of 2-phenylacetic acid (374 mg, 2.75 mmol), pyridine-3,5-diamine (300 mg, 2.75 mmol) and EDCI.HC1 (580 mg, 3.02 mmol) in pyridine (5 mL) was heated at 50 C
for 2 h. A black solution was formed. LCMS (Rt = 0.405 min; MS Calcd: 227.1;
MS Found:
227.9 [M+H]+). The mixture was concentrated and the residue was poured into water (20 mL) and stirred for 2 minutes. The aqueous layer was extracted with ethyl acetate (20 mL x3). The combined organic layer was washed with water (30 mL x2) and brine (30 mL), dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by Combi Flash (50%
to 100% Et0Ac in pentane) to give N-(5-aminopyridin-3-y1)-2-phenylacetamide (450 mg, yield: 61%) as a light yellow solid.
Step 2: Preparation of N-(5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno [4,3 -c] py ri din-3 -yl)amino)py ri din-3 -y1)-2-pheny lacetami de el I
[0483] A
mixture of 1-(3 -chloro-5 -methyl-5H-chromeno [4,3-c] py ri din-8-yl)py rroli din-2-one (60 mg, 0.19 mmol), N-(5-aminopyridin-3-y1)-2-phenylacetamide (61 mg, 0.23 mmol), Pd2(dba)3 (18 mg, 0.019 mmol), BrettPhos (21 mg, 0.038 mmol), Cs2CO3 (124 mg, 0.381 mmol) in anhydrous dioxane (3 mL) was degassed and purged with N2 for 3 times. Then the resulting reaction mixture was heated at 90 C for 16 h under N2 atmosphere. The reaction
N NN
Step 1: Preparation N-(5-aminopyridin-3-y1)-2-phenylacetamide rNi 0 [0482] A
mixture of 2-phenylacetic acid (374 mg, 2.75 mmol), pyridine-3,5-diamine (300 mg, 2.75 mmol) and EDCI.HC1 (580 mg, 3.02 mmol) in pyridine (5 mL) was heated at 50 C
for 2 h. A black solution was formed. LCMS (Rt = 0.405 min; MS Calcd: 227.1;
MS Found:
227.9 [M+H]+). The mixture was concentrated and the residue was poured into water (20 mL) and stirred for 2 minutes. The aqueous layer was extracted with ethyl acetate (20 mL x3). The combined organic layer was washed with water (30 mL x2) and brine (30 mL), dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by Combi Flash (50%
to 100% Et0Ac in pentane) to give N-(5-aminopyridin-3-y1)-2-phenylacetamide (450 mg, yield: 61%) as a light yellow solid.
Step 2: Preparation of N-(5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno [4,3 -c] py ri din-3 -yl)amino)py ri din-3 -y1)-2-pheny lacetami de el I
[0483] A
mixture of 1-(3 -chloro-5 -methyl-5H-chromeno [4,3-c] py ri din-8-yl)py rroli din-2-one (60 mg, 0.19 mmol), N-(5-aminopyridin-3-y1)-2-phenylacetamide (61 mg, 0.23 mmol), Pd2(dba)3 (18 mg, 0.019 mmol), BrettPhos (21 mg, 0.038 mmol), Cs2CO3 (124 mg, 0.381 mmol) in anhydrous dioxane (3 mL) was degassed and purged with N2 for 3 times. Then the resulting reaction mixture was heated at 90 C for 16 h under N2 atmosphere. The reaction
198 mixture turned into gray suspension from red suspension. LCMS (Rt = 0.800 min;
MS Calcd:
505.2; MS Found: 506.1 [M+Hl+). The mixture was diluted with water (20 mL) and extracted with Et0Ac (20 mL x2). The combined organic layer was washed with water (20 mL
x2), brine (20 mL x2), dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by prep-HPLC (0.225% FA as an additive) and lyophilized to give N-(5-((5-methy1-8-(2-oxopy rroli din-l-y1)-5H-chromeno [4,3 -c] py ri din-3-yl)amino)py ri din-3-y1)-2-phenylacetami de (7.4 mg, yield: 8%) as a yellow solid.
NMR (400 MHz DMSO-d6) 1.51-1.56 (3H, m), 2.02-2.10 (2H, m), 2.62-2.64 (2H, m, overlapped with the peak of DMSO), 3.68-3.72 (2H, m), 3.82-3.88 (2H, m), 5.24-5.32 (1H, m), 6.72-6.77 (1H, m), 7.22-7.41 (7H, m), 7.86-7.92 (1H, m), 8.38 (1H, s), 8.55 (1H, s), 8.60-8.68 (2H, m), 9.55 (1H, brs), 10.42 (1H, brs).
Example 108: N-(5-05-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-yl)amino)pyridin-3-y1)-1H-indole-6-carboxamide I I
N NN
Step 1: Preparation of N-(5-bromopyridin-3-y1)-1H-indole-6-carboxamide I
BrN
[0484] A
mixture of 1H-indole-6-carboxylic acid (307mg, 1.90 mmol), 5-bromopyridin-3-amine (300 mg, 1.73 mmol) and EDCI.HC1 (365 mg, 1.90 mmol) in pyridine (5 mL) was heated at 50 C for 1 hour. An orange solution was formed. LCMS (Rt = 0.733 min; MS Calcd:
315.0; MS Found: 315.9 [M+Hl+). The mixture was concentrated and the residue was poured into water (20 mL) and stirred for 2 minutes. The aqueous layer was extracted with ethyl acetate (20 mL x3). The combined organic layer was washed with water (20 mL
x2) and brine (20 mL), dried over anhydrous Na2SO4, filtered and concentrated. The residue was triturated with pentane/EtOAC (3 mL, 3/1) to give N-(5-bromopyridin-3-y1)-1H-indole-6-carboxamide (440 mg, yield: 80%) as a light yellow solid.
MS Calcd:
505.2; MS Found: 506.1 [M+Hl+). The mixture was diluted with water (20 mL) and extracted with Et0Ac (20 mL x2). The combined organic layer was washed with water (20 mL
x2), brine (20 mL x2), dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by prep-HPLC (0.225% FA as an additive) and lyophilized to give N-(5-((5-methy1-8-(2-oxopy rroli din-l-y1)-5H-chromeno [4,3 -c] py ri din-3-yl)amino)py ri din-3-y1)-2-phenylacetami de (7.4 mg, yield: 8%) as a yellow solid.
NMR (400 MHz DMSO-d6) 1.51-1.56 (3H, m), 2.02-2.10 (2H, m), 2.62-2.64 (2H, m, overlapped with the peak of DMSO), 3.68-3.72 (2H, m), 3.82-3.88 (2H, m), 5.24-5.32 (1H, m), 6.72-6.77 (1H, m), 7.22-7.41 (7H, m), 7.86-7.92 (1H, m), 8.38 (1H, s), 8.55 (1H, s), 8.60-8.68 (2H, m), 9.55 (1H, brs), 10.42 (1H, brs).
Example 108: N-(5-05-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-yl)amino)pyridin-3-y1)-1H-indole-6-carboxamide I I
N NN
Step 1: Preparation of N-(5-bromopyridin-3-y1)-1H-indole-6-carboxamide I
BrN
[0484] A
mixture of 1H-indole-6-carboxylic acid (307mg, 1.90 mmol), 5-bromopyridin-3-amine (300 mg, 1.73 mmol) and EDCI.HC1 (365 mg, 1.90 mmol) in pyridine (5 mL) was heated at 50 C for 1 hour. An orange solution was formed. LCMS (Rt = 0.733 min; MS Calcd:
315.0; MS Found: 315.9 [M+Hl+). The mixture was concentrated and the residue was poured into water (20 mL) and stirred for 2 minutes. The aqueous layer was extracted with ethyl acetate (20 mL x3). The combined organic layer was washed with water (20 mL
x2) and brine (20 mL), dried over anhydrous Na2SO4, filtered and concentrated. The residue was triturated with pentane/EtOAC (3 mL, 3/1) to give N-(5-bromopyridin-3-y1)-1H-indole-6-carboxamide (440 mg, yield: 80%) as a light yellow solid.
199 1-1-1NMR (400 MHz DMSO-d6) (56.55 (1H, t, J= 2.0 Hz), 7.60 (1H, t, J= 2.8 Hz), 7.68 (1H, s), 8.12 (1H, s), 8.43 (1H, d, J= 2.0 Hz), 8.49 (1H, s), 8.58 (1H, t, J= 2.1 Hz), 8.97 (1H, d, J
= 2.3 Hz), 10.55 (1H, brs), 11.55 (1H, brs).
Step 2: Preparation of N-(5-((5 -methyl-8-(2-oxopy rroli din-l-y1)-5H-chromeno [4,3 -c] py ri din-3-y0amino)pyridin-3-y1)-1H-indole-6-carboxamide N N N
[0485] A
mixture of 1-(3-amino-5-methy1-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (60 mg, 0.020 mmol), N-(5-bromopyridin-3-y1)-1H-indole-6-carboxamide (71 mg, 0.22 mmol), Pd2(dba)3 (19 mg, 0.020 mmol), BrettPhos (22 mg, 0.041 mmol), Cs2CO3 (132 mg, 0.406 mmol) in dioxane (3 mL) was degassed and purged with N2 for 3 times.
Then the resulting reaction mixture was heated at 90 C for 14 h under N2 atmosphere. The reaction mixture turned into yellow suspension from red suspension. LCMS (Rt = 0.733 min; MS Calcd:
530.2; MS Found: 531.3 [M+H1+). The mixture was diluted with water (20 mL) and extracted with Et0Ac/THF (20 mL x3, 1/1). The combined organic layer was washed with water (20 mL
x2), brine (20 mL x2), dried over anhydrous Na2SO4, filtered and concentrated.
The residue was purified by prep-HPLC (0.225% FA as an additive) and lyophilized to give N-(5-((5-methy1-8-(2-oxopy rroli din-1 -y 0-5H-chromeno [4,3 -c] py ri din-3-y0amino)py ri din-3 -y1)-1H-indole-6-carboxamide (7.37 mg, yield: 6.5%) as a yellow solid.
1-1-1NMR (400 MHz DMSO-d6) (5 1.56 (3H, d, J= 6.5 Hz), 2.02-2.10 (2H, m), 2.52-2.54 (2H, m, overlapped with the peak of DMSO), 3.82-3.88 (2H, m), 5.30 (1H, q, J= 6.5 Hz), 6.54-6.57 (1H, m), 6.80 (1H, s), 7.33 (1H, dd, J= 8.8, 2.3 Hz), 7.41 (1H, d, J= 2.3 Hz), 7.58 (1H, t, J= 2.8 Hz), 7.69 (2H, s), 7.90 (1H, d, J= 8.8 Hz), 8.12 (1H, d, J= 0.8 Hz), 8.57 (1H, s), 8.70 (1H, s), 8.73-8.77 (2H, m), 9.65 (1H, brs), 10.46 (1H, brs), 11.52 (1H, brs).
Example 109: N-(5-05-methyl-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-yl)amino)pyridin-3-yl)benzo[d]oxazole-6-carboxamide
= 2.3 Hz), 10.55 (1H, brs), 11.55 (1H, brs).
Step 2: Preparation of N-(5-((5 -methyl-8-(2-oxopy rroli din-l-y1)-5H-chromeno [4,3 -c] py ri din-3-y0amino)pyridin-3-y1)-1H-indole-6-carboxamide N N N
[0485] A
mixture of 1-(3-amino-5-methy1-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (60 mg, 0.020 mmol), N-(5-bromopyridin-3-y1)-1H-indole-6-carboxamide (71 mg, 0.22 mmol), Pd2(dba)3 (19 mg, 0.020 mmol), BrettPhos (22 mg, 0.041 mmol), Cs2CO3 (132 mg, 0.406 mmol) in dioxane (3 mL) was degassed and purged with N2 for 3 times.
Then the resulting reaction mixture was heated at 90 C for 14 h under N2 atmosphere. The reaction mixture turned into yellow suspension from red suspension. LCMS (Rt = 0.733 min; MS Calcd:
530.2; MS Found: 531.3 [M+H1+). The mixture was diluted with water (20 mL) and extracted with Et0Ac/THF (20 mL x3, 1/1). The combined organic layer was washed with water (20 mL
x2), brine (20 mL x2), dried over anhydrous Na2SO4, filtered and concentrated.
The residue was purified by prep-HPLC (0.225% FA as an additive) and lyophilized to give N-(5-((5-methy1-8-(2-oxopy rroli din-1 -y 0-5H-chromeno [4,3 -c] py ri din-3-y0amino)py ri din-3 -y1)-1H-indole-6-carboxamide (7.37 mg, yield: 6.5%) as a yellow solid.
1-1-1NMR (400 MHz DMSO-d6) (5 1.56 (3H, d, J= 6.5 Hz), 2.02-2.10 (2H, m), 2.52-2.54 (2H, m, overlapped with the peak of DMSO), 3.82-3.88 (2H, m), 5.30 (1H, q, J= 6.5 Hz), 6.54-6.57 (1H, m), 6.80 (1H, s), 7.33 (1H, dd, J= 8.8, 2.3 Hz), 7.41 (1H, d, J= 2.3 Hz), 7.58 (1H, t, J= 2.8 Hz), 7.69 (2H, s), 7.90 (1H, d, J= 8.8 Hz), 8.12 (1H, d, J= 0.8 Hz), 8.57 (1H, s), 8.70 (1H, s), 8.73-8.77 (2H, m), 9.65 (1H, brs), 10.46 (1H, brs), 11.52 (1H, brs).
Example 109: N-(5-05-methyl-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-yl)amino)pyridin-3-yl)benzo[d]oxazole-6-carboxamide
200 NN
Step]: 1st Batch [0486] A
mixture of 1-(3-((5 -aminopy ri din-3-yl)amino)-5 -methyl-5H-chromeno [4,3-clpyridin-8-yOpyrrolidin-2-one (60 mg, 0.14 mmol, HC1 salt), benzo[d]oxazole-6-carboxylic acid (28 mg, 0.17 mmol) and EDCI.HC1 (33 mg, 0.17 mmol) in pyridine (2 mL) was heated at 30 C for 4 h. A yellow solution was formed. LCMS (Rt = 0.713 min; MS Calcd:
532.2; MS
Found: 533.1 [M+H1+). The mixture was concentrated and the residue was poured into water (20 mL) and stirred for 2 minutes. The aqueous layer was extracted with ethyl acetate (20 mL
x3). The combined organic layer was washed with water (20 mL x2) and brine (20 mL), dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by prep-HPLC
(0.225% FA as an additive) and lyophilized to give side product 4-formamido-3-hydroxy-N-(5 -((5-methy1-8-(2-oxopy rroli din-1-y 0-5H-chromeno [4,3-c] py ridin-3 -y Damino)py ridin-3 -yObenzamide (109A) (15.9 mg, yield: 20%) as a yellow solid.
11-1NMR (400 MHz DMSO-d6) (51.56 (3H, d, J= 6.5 Hz), 2.02-2.10 (2H, m), 2.52-2.54 (2H, m, overlapped with the peak of DMSO), 3.84 (2H, t, J= 7.4 Hz), 5.29 (1H, q, J
= 6.5 Hz), 6.81 (1H, s), 7.32 (1H, dd, J= 8.5, 2.0 Hz), 7.40 (1H, d, J= 2.0 Hz), 7.48-7.53 (2H, m), 7.89 (1H, d, J= 8.5 Hz), 8.27 (1H, d, J= 8.5 Hz), 8.37 (1H, d, J = 1.3 Hz), 8.56-8.62 (1H, m), 8.70 (1H, s), 8.74 (1H, s), 8.84 (1H, s), 9.78 (1H, brs), 9.84 (1H, brs), 10.51 (2H, brs).
Step 2: 2nd Batch [0487] A
mixture of 1-(3-((5 -aminopy ri din-3-yl)amino)-5 -methyl-5H-chromeno [4,3-clpyridin-8-yOpyrrolidin-2-one (60 mg, 0.14 mmol, HC1 salt), benzo[d]oxazole-6-carboxylic acid (28 mg, 0.17 mmol) and EDCI.HC1 (33 mg, 0.17 mmol) in pyridine (2 mL) was heated at 30 C for 4 h. A yellow solution was formed. LCMS (Rt = 0.713 min; MS Calcd:
532.2; MS
Found: 533.1 [M+H1+). The mixture was concentrated and the residue was poured into water (20 mL) and stirred for 2 minutes. The aqueous layer was extracted with ethyl acetate (20 mL
x3).The combined organic layer was washed with water (20 mL x2) and brine (20 mL), dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by prep-HPLC
(0.05% NH3.H20 as an additive) and lyophilized to give N-(5-45-methy1-8-(2-oxopyrrolidin-
Step]: 1st Batch [0486] A
mixture of 1-(3-((5 -aminopy ri din-3-yl)amino)-5 -methyl-5H-chromeno [4,3-clpyridin-8-yOpyrrolidin-2-one (60 mg, 0.14 mmol, HC1 salt), benzo[d]oxazole-6-carboxylic acid (28 mg, 0.17 mmol) and EDCI.HC1 (33 mg, 0.17 mmol) in pyridine (2 mL) was heated at 30 C for 4 h. A yellow solution was formed. LCMS (Rt = 0.713 min; MS Calcd:
532.2; MS
Found: 533.1 [M+H1+). The mixture was concentrated and the residue was poured into water (20 mL) and stirred for 2 minutes. The aqueous layer was extracted with ethyl acetate (20 mL
x3). The combined organic layer was washed with water (20 mL x2) and brine (20 mL), dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by prep-HPLC
(0.225% FA as an additive) and lyophilized to give side product 4-formamido-3-hydroxy-N-(5 -((5-methy1-8-(2-oxopy rroli din-1-y 0-5H-chromeno [4,3-c] py ridin-3 -y Damino)py ridin-3 -yObenzamide (109A) (15.9 mg, yield: 20%) as a yellow solid.
11-1NMR (400 MHz DMSO-d6) (51.56 (3H, d, J= 6.5 Hz), 2.02-2.10 (2H, m), 2.52-2.54 (2H, m, overlapped with the peak of DMSO), 3.84 (2H, t, J= 7.4 Hz), 5.29 (1H, q, J
= 6.5 Hz), 6.81 (1H, s), 7.32 (1H, dd, J= 8.5, 2.0 Hz), 7.40 (1H, d, J= 2.0 Hz), 7.48-7.53 (2H, m), 7.89 (1H, d, J= 8.5 Hz), 8.27 (1H, d, J= 8.5 Hz), 8.37 (1H, d, J = 1.3 Hz), 8.56-8.62 (1H, m), 8.70 (1H, s), 8.74 (1H, s), 8.84 (1H, s), 9.78 (1H, brs), 9.84 (1H, brs), 10.51 (2H, brs).
Step 2: 2nd Batch [0487] A
mixture of 1-(3-((5 -aminopy ri din-3-yl)amino)-5 -methyl-5H-chromeno [4,3-clpyridin-8-yOpyrrolidin-2-one (60 mg, 0.14 mmol, HC1 salt), benzo[d]oxazole-6-carboxylic acid (28 mg, 0.17 mmol) and EDCI.HC1 (33 mg, 0.17 mmol) in pyridine (2 mL) was heated at 30 C for 4 h. A yellow solution was formed. LCMS (Rt = 0.713 min; MS Calcd:
532.2; MS
Found: 533.1 [M+H1+). The mixture was concentrated and the residue was poured into water (20 mL) and stirred for 2 minutes. The aqueous layer was extracted with ethyl acetate (20 mL
x3).The combined organic layer was washed with water (20 mL x2) and brine (20 mL), dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by prep-HPLC
(0.05% NH3.H20 as an additive) and lyophilized to give N-(5-45-methy1-8-(2-oxopyrrolidin-
201 1-y1)-5H-chromeno [4,3-c] pyridin-3 -yl)amino)pyridin-3-yl)benzo [d] oxazol e-6-carboxamide (21.7 mg, yield: 29%) as a gray solid.
11-1NMR (400 MHz DMSO-d6) 1.56 (3H, d, J= 6.5 Hz), 2.02-2.10 (2H, m), 2.52-2.54 (2H, m, overlapped with the peak of DMSO), 3.82-3.88 (2H, m), 5.29 (1H, q, J= 6.8 Hz), 6.79 (1H, s), 7.33 (1H, dd, J= 8.4, 2.1 Hz), 7.41 (1H, d, J= 2.3 Hz), 7.90 (1H, d, J= 8.8 Hz), 7.98 (1H, d, J= 8.3 Hz), 8.08 (1H, dd, J= 8.4, 1.6 Hz), 8.45 (1H, s), 8.52 (1H, d, J= 2.0 Hz), 8.65-8.73 (3H, m), 8.96 (1H, s), 9.54 (1H, brs), 10.55 (1H, brs).
Example 110: N-(5-05-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-yl)amino)pyridin-3-y1)-3-phenylpropanamide NN
1.1 Step 1: Preparation of N-(5-aminopyridin-3-y1)-3-phenylpropanamide [0488] A
mixture of 3-phenylpropanoic acid (413 mg, 2.75 mmol), pyridine-3,5-diamine (300 mg, 2.75 mmol) and EDCI.HC1 (580 mg, 3.03 mmol) in pyridine (5 mL) was heated at 50 C for 2 h. A black solution was formed. The mixture was concentrated and the residue was poured into water (20 mL) and stirred for 2 minutes. The aqueous layer was extracted with ethyl acetate (20 mL x3). The combined organic layer was washed with water (20 mL x2) and brine (20 mL x2), dried over anhydrous Na2SO4, filtered and concentrated.
The residue was purified by Combi Flash (50% to 100% Et0Ac in pentane) to give N-(5-aminopyridin-3-y1)-3-phenylpropanamide (400 mg, yield: 59%) as a light yellow solid.
11-1NMR (400 MHz DMSO-d6) (52.63 (2H, t, J= 7.7 Hz), 2.91 (2H, t, J= 7.7 Hz), 5.34 (2H, brs), 7.15-7.22 (1H, m), 7.23-7.32 (4H, m), 7.38 (1H, t, J= 2.3 Hz), 7.63 (1H, d, J= 2.5 Hz), 7.86 (1H, d, J= 2.0 Hz), 9.83 (1H, brs).
Step 2: Preparation of N-(5-((5 -methyl-8-(2-oxopy rroli din-l-y1)-5H-chromeno [4,3 -c] py ri din-3-yl)amino)pyridin-3-y1)-3-phenylpropanamide
11-1NMR (400 MHz DMSO-d6) 1.56 (3H, d, J= 6.5 Hz), 2.02-2.10 (2H, m), 2.52-2.54 (2H, m, overlapped with the peak of DMSO), 3.82-3.88 (2H, m), 5.29 (1H, q, J= 6.8 Hz), 6.79 (1H, s), 7.33 (1H, dd, J= 8.4, 2.1 Hz), 7.41 (1H, d, J= 2.3 Hz), 7.90 (1H, d, J= 8.8 Hz), 7.98 (1H, d, J= 8.3 Hz), 8.08 (1H, dd, J= 8.4, 1.6 Hz), 8.45 (1H, s), 8.52 (1H, d, J= 2.0 Hz), 8.65-8.73 (3H, m), 8.96 (1H, s), 9.54 (1H, brs), 10.55 (1H, brs).
Example 110: N-(5-05-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-yl)amino)pyridin-3-y1)-3-phenylpropanamide NN
1.1 Step 1: Preparation of N-(5-aminopyridin-3-y1)-3-phenylpropanamide [0488] A
mixture of 3-phenylpropanoic acid (413 mg, 2.75 mmol), pyridine-3,5-diamine (300 mg, 2.75 mmol) and EDCI.HC1 (580 mg, 3.03 mmol) in pyridine (5 mL) was heated at 50 C for 2 h. A black solution was formed. The mixture was concentrated and the residue was poured into water (20 mL) and stirred for 2 minutes. The aqueous layer was extracted with ethyl acetate (20 mL x3). The combined organic layer was washed with water (20 mL x2) and brine (20 mL x2), dried over anhydrous Na2SO4, filtered and concentrated.
The residue was purified by Combi Flash (50% to 100% Et0Ac in pentane) to give N-(5-aminopyridin-3-y1)-3-phenylpropanamide (400 mg, yield: 59%) as a light yellow solid.
11-1NMR (400 MHz DMSO-d6) (52.63 (2H, t, J= 7.7 Hz), 2.91 (2H, t, J= 7.7 Hz), 5.34 (2H, brs), 7.15-7.22 (1H, m), 7.23-7.32 (4H, m), 7.38 (1H, t, J= 2.3 Hz), 7.63 (1H, d, J= 2.5 Hz), 7.86 (1H, d, J= 2.0 Hz), 9.83 (1H, brs).
Step 2: Preparation of N-(5-((5 -methyl-8-(2-oxopy rroli din-l-y1)-5H-chromeno [4,3 -c] py ri din-3-yl)amino)pyridin-3-y1)-3-phenylpropanamide
202 I
NN
[0489] A
mixture of 1-(3 -chloro-5 -methyl-5H-chromeno [4,3-c] py ri din-8-yl)py rroli din-2-one (60 mg, 0.19 mmol), N-(5-aminopyridin-3-y1)-3-phenylpropanamide (61 mg, 0.23 mmol), Pd2(dba)3 (18 mg, 0.019 mmol), BrettPhos (21 mg, 0.038 mmol), Cs2CO3 (124 mg, 0.381 mmol) in dioxane (3 mL) was degassed and purged with N2 for 3 times.
Then the resulting reaction mixture was heated at 90 C for 16 h under N2 atmosphere. The reaction mixture turned into gray suspension from red suspension. LCMS (Rt = 0.750 min;
MS Calcd:
519.2; MS Found: 520.1 [M+Hl+). The mixture was diluted with water (20 mL) and extracted with Et0Ac (20 mL x2). The combined organic layer was washed with water (20 mL
x2), brine (20 mL x2), dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by prep-HPLC (0.225% FA as an additive) and lyophilized to give N-(5-((5-methy1-8-(2-oxopy rroli din-l-y1)-5H-chromeno [4,3 -c] py ri din-3-yl)amino)py ri din-3-y1)-3-phenylpropanamide (30.2 mg, yield: 30%) as a yellow solid.
11-1NMR (400 MHz DMSO-d6) 61.55 (3H, d, J= 6.5 Hz), 2.02-2.10 (2H, m), 2.52-2.54 (2H, m, overlapped with the peak of DMSO), 2.69 (2H, t, J= 7.7 Hz), 2.94 (2H, t, J=
7.7 Hz), 3.84 (2H, t, J= 7.5 Hz), 5.28 (1H, q, J= 6.4 Hz), 6.76 (1H, s), 7.17-7.23 (1H, m), 7.25-7.35 (5H, m),7.41 (1H, d, J= 1.8 Hz), 7.89 (1H, d, J= 8.5 Hz), 8.34 (1H, s), 8.48-8.53 (1H, m),8.63-8.70 (2H, m), 9.53 (1H, brs), 10.15 (1H, brs).
Example 111: (18,28)-N-(5-05-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-y1)-2-phenylcyclopropane-1-carboxamide I )1 Step 1: Preparation of (1S ,25)-N-(5-aminopyri din-3 -y 0-2-phenylcy cl opropane-1 -carboxamide
NN
[0489] A
mixture of 1-(3 -chloro-5 -methyl-5H-chromeno [4,3-c] py ri din-8-yl)py rroli din-2-one (60 mg, 0.19 mmol), N-(5-aminopyridin-3-y1)-3-phenylpropanamide (61 mg, 0.23 mmol), Pd2(dba)3 (18 mg, 0.019 mmol), BrettPhos (21 mg, 0.038 mmol), Cs2CO3 (124 mg, 0.381 mmol) in dioxane (3 mL) was degassed and purged with N2 for 3 times.
Then the resulting reaction mixture was heated at 90 C for 16 h under N2 atmosphere. The reaction mixture turned into gray suspension from red suspension. LCMS (Rt = 0.750 min;
MS Calcd:
519.2; MS Found: 520.1 [M+Hl+). The mixture was diluted with water (20 mL) and extracted with Et0Ac (20 mL x2). The combined organic layer was washed with water (20 mL
x2), brine (20 mL x2), dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by prep-HPLC (0.225% FA as an additive) and lyophilized to give N-(5-((5-methy1-8-(2-oxopy rroli din-l-y1)-5H-chromeno [4,3 -c] py ri din-3-yl)amino)py ri din-3-y1)-3-phenylpropanamide (30.2 mg, yield: 30%) as a yellow solid.
11-1NMR (400 MHz DMSO-d6) 61.55 (3H, d, J= 6.5 Hz), 2.02-2.10 (2H, m), 2.52-2.54 (2H, m, overlapped with the peak of DMSO), 2.69 (2H, t, J= 7.7 Hz), 2.94 (2H, t, J=
7.7 Hz), 3.84 (2H, t, J= 7.5 Hz), 5.28 (1H, q, J= 6.4 Hz), 6.76 (1H, s), 7.17-7.23 (1H, m), 7.25-7.35 (5H, m),7.41 (1H, d, J= 1.8 Hz), 7.89 (1H, d, J= 8.5 Hz), 8.34 (1H, s), 8.48-8.53 (1H, m),8.63-8.70 (2H, m), 9.53 (1H, brs), 10.15 (1H, brs).
Example 111: (18,28)-N-(5-05-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-y1)-2-phenylcyclopropane-1-carboxamide I )1 Step 1: Preparation of (1S ,25)-N-(5-aminopyri din-3 -y 0-2-phenylcy cl opropane-1 -carboxamide
203 o I )1 [0490] A
mixture of (1S,2S)-2-phenylcyclopropane-1 -carboxylic acid (360 mg, 2.22 mmol), pyridine-3,5-diamine (242 mg, 2.22 mmol) and EDCI.HC1 (468 mg, 2.44 mmol) in pyridine (5 mL) was heated at 50 C for 2 h. A black solution was formed. The mixture was concentrated and the residue was poured into water (20 mL) and stirred for 2 minutes. The aqueous layer was extracted with ethyl acetate (20 mL x3). The combined organic layer was washed with water (20 mL x2) and brine (20 mL), dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by Combi Flash (50% to 100% Et0Ac in pentane) to give (1S,2S)-N-(5-aminopyridin-3-y1)-2-phenylcyclopropane-1-carboxamide (390 mg, yield: 64%) as a light yellow solid.
1FINMR (400 MHz DMSO-d6) 5 1.34-1.40 (1H, m), 1.45-1.52 (1H, m), 2.05-2.11 (1H, m), 2.33-2.41 (1H, m), 5.33 (2H, brs), 7.15-7.23 (3H, m), 7.26-7.32 (2H, m), 7.34 (1H, t, J= 2.1 Hz), 7.62 (1H, d, J= 2.5 Hz), 7.89 (1H, d, J= 2.0 Hz), 10.14 (1H, brs).
Step 2: Preparation of (1 S,2S)-N-(5 -((5-methyl-8-(2-oxopy rroli din-1 -y1)-5H-chromeno [4,3-c] py ri din-3-yl)amino)pyri din-3-y1)-2-phenylcy cl oprop ane-1 -carboxami de 1 )L,, 104911 N ',"4 [0491] A
mixture of 1-(3 -chloro-5 -methyl-5H-chromeno [4,3-c] py ri din-8-yl)py rroli din-2-one (60 mg, 0.19 mmol), (1S,2S)-N-(5-aminopyridin-3-y1)-2-phenylcyclopropane-l-carboxamide (54 mg, 0.21 mmol), Pd2(dba)3 (18 mg, 0.019 mmol), BrettPhos (21 mg, 0.038 mmol), Cs2CO3 (124 mg, 0.381 mmol) in anhydrous dioxane (3 mL) was degassed and purged with N2 for 3 times. Then the resulting reaction mixture was heated at 90 C
for 16 h under N2 atmosphere. The reaction mixture turned into gray suspension from red suspension. LCMS (Rt = 0.659 min; MS Calcd: 531.2; MS Found: 532.0 [M+Hl+). The mixture was diluted with water (20 mL) and extracted with Et0Ac (20 mL x2). The combined organic layer was washed with water (20 mL x2), brine (20 mL x2), dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by prep-HPLC (0.225% FA as an additive) and
mixture of (1S,2S)-2-phenylcyclopropane-1 -carboxylic acid (360 mg, 2.22 mmol), pyridine-3,5-diamine (242 mg, 2.22 mmol) and EDCI.HC1 (468 mg, 2.44 mmol) in pyridine (5 mL) was heated at 50 C for 2 h. A black solution was formed. The mixture was concentrated and the residue was poured into water (20 mL) and stirred for 2 minutes. The aqueous layer was extracted with ethyl acetate (20 mL x3). The combined organic layer was washed with water (20 mL x2) and brine (20 mL), dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by Combi Flash (50% to 100% Et0Ac in pentane) to give (1S,2S)-N-(5-aminopyridin-3-y1)-2-phenylcyclopropane-1-carboxamide (390 mg, yield: 64%) as a light yellow solid.
1FINMR (400 MHz DMSO-d6) 5 1.34-1.40 (1H, m), 1.45-1.52 (1H, m), 2.05-2.11 (1H, m), 2.33-2.41 (1H, m), 5.33 (2H, brs), 7.15-7.23 (3H, m), 7.26-7.32 (2H, m), 7.34 (1H, t, J= 2.1 Hz), 7.62 (1H, d, J= 2.5 Hz), 7.89 (1H, d, J= 2.0 Hz), 10.14 (1H, brs).
Step 2: Preparation of (1 S,2S)-N-(5 -((5-methyl-8-(2-oxopy rroli din-1 -y1)-5H-chromeno [4,3-c] py ri din-3-yl)amino)pyri din-3-y1)-2-phenylcy cl oprop ane-1 -carboxami de 1 )L,, 104911 N ',"4 [0491] A
mixture of 1-(3 -chloro-5 -methyl-5H-chromeno [4,3-c] py ri din-8-yl)py rroli din-2-one (60 mg, 0.19 mmol), (1S,2S)-N-(5-aminopyridin-3-y1)-2-phenylcyclopropane-l-carboxamide (54 mg, 0.21 mmol), Pd2(dba)3 (18 mg, 0.019 mmol), BrettPhos (21 mg, 0.038 mmol), Cs2CO3 (124 mg, 0.381 mmol) in anhydrous dioxane (3 mL) was degassed and purged with N2 for 3 times. Then the resulting reaction mixture was heated at 90 C
for 16 h under N2 atmosphere. The reaction mixture turned into gray suspension from red suspension. LCMS (Rt = 0.659 min; MS Calcd: 531.2; MS Found: 532.0 [M+Hl+). The mixture was diluted with water (20 mL) and extracted with Et0Ac (20 mL x2). The combined organic layer was washed with water (20 mL x2), brine (20 mL x2), dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by prep-HPLC (0.225% FA as an additive) and
204 lyophilized to give (1S,2S)-N-(5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-y1)-2-phenylcyclopropane-1-carboxamide (21.3 mg, yield:
21%) as a yellow solid.
1FINMR (400 MHz DMSO-d6) 1.39-1.46 (1H, m), 1.52-1.58 (4H, m), 2.02-2.10 (2H, m), 2.11-2.17 (1H, m), 2.40-2.44 (1H, m), 2.52-2.54 (2H, m, overlapped with the peak of DMSO), 3.85 (2H, t, J= 7.7 Hz), 5.28 (1H, q, J= 6.3 Hz), 6.76 (1H, s), 7.19-7.25 (3H, m), 7.29-7.35 (3H, m), 7.41 (1H, d, J= 1.8 Hz), 7.89 (1H, d, J= 8.5 Hz), 8.39 (1H, s), 8.54 (1H, s), 8.63-8.68 (2H, m), 9.56 (1H, brs), 10.51 (1H, brs).
Example 112: N-(5-05-methyl-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-yl)amino)pyridin-3-yl)picolinamide I I ) N NN N
H
Step 1: Preparation of N-(5-aminopyridin-3-yl)picolinamide o I )N
[0492] A
mixture of picolinic acid (338 mg, 2.75 mmol), pyridine-3,5-diamine (300 mg, 2.75 mmol) and EDCI.HC1 (580 mg, 3.02 mmol) in pyridine (5 mL) was heated at 50 C for 2 h. A black solution was formed. LCMS (Rt = 0.329 min; MS Calcd: 214.1; MS
Found: 214.9 [M+H]+). The mixture was concentrated and the residue was poured into water (20 mL) and stirred for 2 minutes. The aqueous layer was extracted with ethyl acetate (20 mL x3). The combined organic layer was washed with water (20 mL x2) and brine (20 mL x2), dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by Combi Flash (50%
to 100% Et0Ac in pentane) to give N-(5-aminopyridin-3-yl)picolinamide (400 mg, yield:
61%) as alight yellow solid.
1FINMR (400 MHz DMSO-d6) (55.39 (2H, brs), 7.64 (1H, t, J= 2.3 Hz), 7.67-7.72 (2H, m), 8.08 (1H, td, J= 7.7, 1.5 Hz), 8.13-8.17 (2H, m), 8.73-8.76 (1H, m), 10.54 (1H, brs).
21%) as a yellow solid.
1FINMR (400 MHz DMSO-d6) 1.39-1.46 (1H, m), 1.52-1.58 (4H, m), 2.02-2.10 (2H, m), 2.11-2.17 (1H, m), 2.40-2.44 (1H, m), 2.52-2.54 (2H, m, overlapped with the peak of DMSO), 3.85 (2H, t, J= 7.7 Hz), 5.28 (1H, q, J= 6.3 Hz), 6.76 (1H, s), 7.19-7.25 (3H, m), 7.29-7.35 (3H, m), 7.41 (1H, d, J= 1.8 Hz), 7.89 (1H, d, J= 8.5 Hz), 8.39 (1H, s), 8.54 (1H, s), 8.63-8.68 (2H, m), 9.56 (1H, brs), 10.51 (1H, brs).
Example 112: N-(5-05-methyl-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-yl)amino)pyridin-3-yl)picolinamide I I ) N NN N
H
Step 1: Preparation of N-(5-aminopyridin-3-yl)picolinamide o I )N
[0492] A
mixture of picolinic acid (338 mg, 2.75 mmol), pyridine-3,5-diamine (300 mg, 2.75 mmol) and EDCI.HC1 (580 mg, 3.02 mmol) in pyridine (5 mL) was heated at 50 C for 2 h. A black solution was formed. LCMS (Rt = 0.329 min; MS Calcd: 214.1; MS
Found: 214.9 [M+H]+). The mixture was concentrated and the residue was poured into water (20 mL) and stirred for 2 minutes. The aqueous layer was extracted with ethyl acetate (20 mL x3). The combined organic layer was washed with water (20 mL x2) and brine (20 mL x2), dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by Combi Flash (50%
to 100% Et0Ac in pentane) to give N-(5-aminopyridin-3-yl)picolinamide (400 mg, yield:
61%) as alight yellow solid.
1FINMR (400 MHz DMSO-d6) (55.39 (2H, brs), 7.64 (1H, t, J= 2.3 Hz), 7.67-7.72 (2H, m), 8.08 (1H, td, J= 7.7, 1.5 Hz), 8.13-8.17 (2H, m), 8.73-8.76 (1H, m), 10.54 (1H, brs).
205 Step 2: Preparation of N-(5-((5 -methyl-8-(2-oxopy rroli din-l-y1)-5H-chromeno [4,3 -c] py ri din-3 -yl)amino)pyridin-3-yl)pi colinamide I ) NN N
H I
[0493] A
mixture of 1-(3 -chloro-5 -methyl-5H-chromeno [4,3-c] py ri din-8-yl)py rroli din-2-one (60 mg, 0.19 mmol), N-(5-aminopyridin-3-yl)picolinamide (50 mg, 0.21 mmol), Pd2(dba)3 (18 mg, 0.019 mmol), BrettPhos (21 mg, 0.038 mmol) and Cs2CO3 (124 mg, 0.381 mmol) in anhydrous dioxane (3 mL) was degassed and purged with N2 for 3 times.
Then the resulting reaction mixture was heated at 90 C for 30 h under N2 atmosphere. The reaction mixture turned into gray suspension from red suspension. LCMS (Rt = 0.717 min;
MS Calcd:
492.2; MS Found: 493.1 [M+H]+). The mixture was diluted with water (10 mL) and filtered and the solid was washed with water (10 mL) and Et0Ac (10 mL). The filtrate was concentrated and the residue was purified by prep-HPLC (0.225% FA as an additive) and lyophilized to give N-(5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-yl)picolinamide (7.7 mg, yield: 8%) as a yellow solid.
11-1 NMR (400 MHz DMSO-d6) (51.56 (3H, d, J= 6.5 Hz), 2.02-2.10 (2H, m), 2.52-2.54 (2H, m, overlapped with the peak of DMSO), 3.85 (2H, t, J= 7.5 Hz), 5.29 (1H, q, J=
6.8 Hz), 6.79 (1H, s), 7.33 (1H, dd, J= 8.7, 2.1 Hz), 7.41 (1H, d, J= 2.3 Hz), 7.72 (1H, dd, J= 6.7, 4.9 Hz), 7.90 (1H, d, J= 8.8 Hz), 8.11 (1H, td, J= 7.7, 1.5 Hz), 8.18-8.21 (1H, m), 8.61 (1H, s), 8.71 (1H, s), 8.74 (1H, s), 8.78 (1H, d, J= 4.8 Hz), 8.81-8.85 (1H, m), 9.59 (1H, brs), 10.87 (1H, brs).
Example 113: N-(5-05-methyl-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-yl)amino)pyridin-3-yl)nicotinamide c 0 I
NN)N
H
Step 1: Preparation of N-(5 -bromopy ridin-3 -yl)nicotinamide
H I
[0493] A
mixture of 1-(3 -chloro-5 -methyl-5H-chromeno [4,3-c] py ri din-8-yl)py rroli din-2-one (60 mg, 0.19 mmol), N-(5-aminopyridin-3-yl)picolinamide (50 mg, 0.21 mmol), Pd2(dba)3 (18 mg, 0.019 mmol), BrettPhos (21 mg, 0.038 mmol) and Cs2CO3 (124 mg, 0.381 mmol) in anhydrous dioxane (3 mL) was degassed and purged with N2 for 3 times.
Then the resulting reaction mixture was heated at 90 C for 30 h under N2 atmosphere. The reaction mixture turned into gray suspension from red suspension. LCMS (Rt = 0.717 min;
MS Calcd:
492.2; MS Found: 493.1 [M+H]+). The mixture was diluted with water (10 mL) and filtered and the solid was washed with water (10 mL) and Et0Ac (10 mL). The filtrate was concentrated and the residue was purified by prep-HPLC (0.225% FA as an additive) and lyophilized to give N-(5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-yl)picolinamide (7.7 mg, yield: 8%) as a yellow solid.
11-1 NMR (400 MHz DMSO-d6) (51.56 (3H, d, J= 6.5 Hz), 2.02-2.10 (2H, m), 2.52-2.54 (2H, m, overlapped with the peak of DMSO), 3.85 (2H, t, J= 7.5 Hz), 5.29 (1H, q, J=
6.8 Hz), 6.79 (1H, s), 7.33 (1H, dd, J= 8.7, 2.1 Hz), 7.41 (1H, d, J= 2.3 Hz), 7.72 (1H, dd, J= 6.7, 4.9 Hz), 7.90 (1H, d, J= 8.8 Hz), 8.11 (1H, td, J= 7.7, 1.5 Hz), 8.18-8.21 (1H, m), 8.61 (1H, s), 8.71 (1H, s), 8.74 (1H, s), 8.78 (1H, d, J= 4.8 Hz), 8.81-8.85 (1H, m), 9.59 (1H, brs), 10.87 (1H, brs).
Example 113: N-(5-05-methyl-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-yl)amino)pyridin-3-yl)nicotinamide c 0 I
NN)N
H
Step 1: Preparation of N-(5 -bromopy ridin-3 -yl)nicotinamide
206 Br N r N
HJJ
[0494] A
mixture of nicotinic acid (213 mg, 1.73 mmol), 5-bromopyridin-3-amine (300 mg, 1.73 mmol) and EDCI.HC1 (365 mg, 1.91 mmol) in pyridine (3 mL) was heated at 50 C
for 2 h. An orange solution was formed. The mixture was concentrated and the residue was poured into water (20 mL) and stirred for 2 minutes. The aqueous layer was extracted with ethyl acetate (20 mL x3). The combined organic layer was washed with water (20 mL x2) and brine (20 mL), dried over anhydrous Na2SO4, filtered and concentrated. The residue was triturated with pentane/EtOAC (3 mL, 3/1) to give N-(5-bromopyridin-3-yl)nicotinamide (400 mg, yield: 82%) as a yellow solid.
11-1 NMR (400 MHz DMSO-d6) (57.60 (1H, dd, J= 7.9, 4.9 Hz), 8.31 (1H, dt, J=
8.0, 1.9 Hz), 8.46 (1H, d, J= 2.0 Hz), 8.51 (1H, t, J= 2.1 Hz), 8.80 (1H, dd, J= 4.8, 1.5 Hz), 8.90 (1H, d, J= 2.3 Hz), 9.13 (1H, d, J= 1.8 Hz), 10.81 (1H, brs).
Step 2: Preparation of N-(5-((5 -methyl-8-(2-oxopy rroli din-l-y1)-5H-chromeno [4,3 -c] py ri din-3-y Damino)py ri din-3-y Oni cotinami de N N N N
H
[0495] A
mixture of 1-(3-amino-5-methy1-5H-chromeno [4,3-clpyridin-8-yOpyrrolidin-2-one (60 mg, 0.20 mmol), N-(5-bromopyridin-3-yl)nicotinamide (62 mg, 0.22 mmol), Pd2(dba)3 (19 mg, 0.020 mmol), BrettPhos (22 mg, 0.041 mmol) and Cs2CO3 (132 mg, 0.406 mmol) in anhydrous dioxane (3 mL) was degassed and purged with N2 for 3 times. Then the resulting reaction mixture was heated at 90 C for 16 h under N2 atmosphere. The reaction mixture turned into gray suspension from red suspension. LCMS (Rt = 0.682 min; MS
Calcd: 492.2;
MS Found: 493.1 [M+H1+). The mixture was diluted with water (10 mL) and extracted with Et0Ac/THF (20 mL x2, 1/1). The combined organic layer was washed with water (20 mL
x2), brine (20 mL x2), dried over anhydrous Na2SO4, filtered and concentrated.
The residue was purified by prep-HPLC (0.225% FA as an additive) and lyophilized to give N-(5-((5-
HJJ
[0494] A
mixture of nicotinic acid (213 mg, 1.73 mmol), 5-bromopyridin-3-amine (300 mg, 1.73 mmol) and EDCI.HC1 (365 mg, 1.91 mmol) in pyridine (3 mL) was heated at 50 C
for 2 h. An orange solution was formed. The mixture was concentrated and the residue was poured into water (20 mL) and stirred for 2 minutes. The aqueous layer was extracted with ethyl acetate (20 mL x3). The combined organic layer was washed with water (20 mL x2) and brine (20 mL), dried over anhydrous Na2SO4, filtered and concentrated. The residue was triturated with pentane/EtOAC (3 mL, 3/1) to give N-(5-bromopyridin-3-yl)nicotinamide (400 mg, yield: 82%) as a yellow solid.
11-1 NMR (400 MHz DMSO-d6) (57.60 (1H, dd, J= 7.9, 4.9 Hz), 8.31 (1H, dt, J=
8.0, 1.9 Hz), 8.46 (1H, d, J= 2.0 Hz), 8.51 (1H, t, J= 2.1 Hz), 8.80 (1H, dd, J= 4.8, 1.5 Hz), 8.90 (1H, d, J= 2.3 Hz), 9.13 (1H, d, J= 1.8 Hz), 10.81 (1H, brs).
Step 2: Preparation of N-(5-((5 -methyl-8-(2-oxopy rroli din-l-y1)-5H-chromeno [4,3 -c] py ri din-3-y Damino)py ri din-3-y Oni cotinami de N N N N
H
[0495] A
mixture of 1-(3-amino-5-methy1-5H-chromeno [4,3-clpyridin-8-yOpyrrolidin-2-one (60 mg, 0.20 mmol), N-(5-bromopyridin-3-yl)nicotinamide (62 mg, 0.22 mmol), Pd2(dba)3 (19 mg, 0.020 mmol), BrettPhos (22 mg, 0.041 mmol) and Cs2CO3 (132 mg, 0.406 mmol) in anhydrous dioxane (3 mL) was degassed and purged with N2 for 3 times. Then the resulting reaction mixture was heated at 90 C for 16 h under N2 atmosphere. The reaction mixture turned into gray suspension from red suspension. LCMS (Rt = 0.682 min; MS
Calcd: 492.2;
MS Found: 493.1 [M+H1+). The mixture was diluted with water (10 mL) and extracted with Et0Ac/THF (20 mL x2, 1/1). The combined organic layer was washed with water (20 mL
x2), brine (20 mL x2), dried over anhydrous Na2SO4, filtered and concentrated.
The residue was purified by prep-HPLC (0.225% FA as an additive) and lyophilized to give N-(5-((5-
207 methyl-8-(2-oxopy rroli din-1 -y 0-5H-chromeno [4,3 -c] py ri din-3-yl)amino)py ri din-3 -yl)nicotinamide (37.4 mg, yield: 36%) as a light yellow solid.
1FINMR (400 MHz DMSO-d6) 1.56 (3H, d, J= 6.5 Hz), 2.02-2.10 (2H, m), 2.52-2.56 (2H, m, overlapped with the peak of DMSO), 3.82-3.88 (2H, m), 5.29 (1H, q, J= 6.3 Hz), 6.79 (1H, s), 7.33 (1H, dd, J= 8.8, 2.3 Hz), 7.41 (1H, d, J= 2.3 Hz), 7.58-7.64 (1H, m), 7.90 (1H, d, J= 9.3 Hz), 8.34 (1H, d, J= 7.8 Hz), 8.53 (1H, s), 8.67-8.83 (4H,m), 9.15 (1H, s), 9.62 (1H, brs), 10.69 (1H, brs).
Example 114: N-(5-05-methyl-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-yl)amino)pyridin-3-yl)isonicotinamide I ).C) N N-H
Step 1: Preparation of N-(5 -bromopy ridin-3-yl)is onicotinamide I
BrNi H N
[0496] A
mixture of isonicotinic acid (213 mg, 1.73 mmol), 5-bromopyridin-3-amine (300 mg, 1.73 mmol) and EDCI.HC1 (365 mg, 1.90 mmol) in pyridine (3 mL) was heated at 50 C
for 2 h. An orange solution was formed. The mixture was concentrated and the residue was poured into water (20 mL) and stirred for 2 minutes. The aqueous layer was extracted with ethyl acetate (20 mL x3). The combined organic layer was washed with water (20 mL x2) and brine (20 mL), dried over anhydrous Na2SO4, filtered and concentrated. The residue was triturated with pentane/EtOAC (3 mL, 3/1) to give N-(5-bromopyridin-3-yl)isonicotinamide (300 mg, yield: 62%) as a yellow solid.
1FINMR (400 MHz DMSO-d6) (57.68-7.90 (2H, m), 8.48-8.53 (2H, m), 8.81-8.85 (2H, m), 8.91 (1H, d, J= 2.0 Hz), 10.87 (1H, brs).
Step 2: Preparation of N-(5-((5 -methyl-8-(2-oxopy rroli din-l-y1)-5H-chromeno [4,3 -c] py ri din-3 -yl)amino)pyridin-3-yl)isonicotinami de
1FINMR (400 MHz DMSO-d6) 1.56 (3H, d, J= 6.5 Hz), 2.02-2.10 (2H, m), 2.52-2.56 (2H, m, overlapped with the peak of DMSO), 3.82-3.88 (2H, m), 5.29 (1H, q, J= 6.3 Hz), 6.79 (1H, s), 7.33 (1H, dd, J= 8.8, 2.3 Hz), 7.41 (1H, d, J= 2.3 Hz), 7.58-7.64 (1H, m), 7.90 (1H, d, J= 9.3 Hz), 8.34 (1H, d, J= 7.8 Hz), 8.53 (1H, s), 8.67-8.83 (4H,m), 9.15 (1H, s), 9.62 (1H, brs), 10.69 (1H, brs).
Example 114: N-(5-05-methyl-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-yl)amino)pyridin-3-yl)isonicotinamide I ).C) N N-H
Step 1: Preparation of N-(5 -bromopy ridin-3-yl)is onicotinamide I
BrNi H N
[0496] A
mixture of isonicotinic acid (213 mg, 1.73 mmol), 5-bromopyridin-3-amine (300 mg, 1.73 mmol) and EDCI.HC1 (365 mg, 1.90 mmol) in pyridine (3 mL) was heated at 50 C
for 2 h. An orange solution was formed. The mixture was concentrated and the residue was poured into water (20 mL) and stirred for 2 minutes. The aqueous layer was extracted with ethyl acetate (20 mL x3). The combined organic layer was washed with water (20 mL x2) and brine (20 mL), dried over anhydrous Na2SO4, filtered and concentrated. The residue was triturated with pentane/EtOAC (3 mL, 3/1) to give N-(5-bromopyridin-3-yl)isonicotinamide (300 mg, yield: 62%) as a yellow solid.
1FINMR (400 MHz DMSO-d6) (57.68-7.90 (2H, m), 8.48-8.53 (2H, m), 8.81-8.85 (2H, m), 8.91 (1H, d, J= 2.0 Hz), 10.87 (1H, brs).
Step 2: Preparation of N-(5-((5 -methyl-8-(2-oxopy rroli din-l-y1)-5H-chromeno [4,3 -c] py ri din-3 -yl)amino)pyridin-3-yl)isonicotinami de
208 gN
H
mixture of 1-(3-amino-5-methy1-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (60 mg, 0.20 mmol), N-(5-bromopyridin-3-yl)isonicotinamide (62 mg, 0.22 mmol), Pd2(dba)3 (19 mg, 0.020 mmol), BrettPhos (22 mg, 0.041 mmol) and Cs2CO3 (132 mg, 0.406 mmol) in anhydrous dioxane (3 mL) was degassed and purged with N2 for 3 times. Then the resulting reaction mixture was heated at 90 C for 16 h under N2 atmosphere. The reaction mixture turned into gray suspension from red suspension. LCMS (Rt = 0.713 min;
MS Calcd:
492.2; MS Found: 493.1 [M+H1+). The mixture was diluted with water (20 mL) and extracted with Et0Ac/THF (20 mL x2, 1/1). The combined organic layer was washed with water (20 mL
x2), brine (20 mL x2), dried over anhydrous Na2SO4, filtered and concentrated.
The residue was purified by prep-HPLC (0.225% FA as an additive) and lyophilized to give N-(5-((5-methy1-8-(2-oxopy rroli din-1 -y 0-5H-chromeno [4,3 -c] py ri din-3-yl)amino)py ri din-3 -yl)isonicotinamide (15.3 mg, yield: 15%) as a yellow solid.
11-1NMR (400 MHz DMSO-d6) 61.55 (3H, d, J= 6.5 Hz), 2.00-2.10 (2H, m), 2.47-2.49 (2H, m, overlapped with the peak of DMSO), 3.79-3.88 (2H, m), 5.28 (1H, q, J = 6.5 Hz), 6.78 (1H, s), 7.31 (1H, dd, J= 8.7, 2.1 Hz), 7.40 (1H, d, J= 2.3 Hz), 7.86-7.92 (3H, m), 8.52 (1H, s), 8.67(1H, s), 8.72 (2H, d, J= 1.5 Hz), 8.82 (2H, d, J= 5.8 Hz), 9.60 (1H, brs), 10.73 (1H, brs).
Example 115: 2-amino-N-(5-05-methyl-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-yl)isonicotinamide I LXN Ytr H I N
Step 1: Preparation of 4-methoxybenzyl 2-(bis(4-methoxybenzyl)amino)isonicotinate
H
mixture of 1-(3-amino-5-methy1-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (60 mg, 0.20 mmol), N-(5-bromopyridin-3-yl)isonicotinamide (62 mg, 0.22 mmol), Pd2(dba)3 (19 mg, 0.020 mmol), BrettPhos (22 mg, 0.041 mmol) and Cs2CO3 (132 mg, 0.406 mmol) in anhydrous dioxane (3 mL) was degassed and purged with N2 for 3 times. Then the resulting reaction mixture was heated at 90 C for 16 h under N2 atmosphere. The reaction mixture turned into gray suspension from red suspension. LCMS (Rt = 0.713 min;
MS Calcd:
492.2; MS Found: 493.1 [M+H1+). The mixture was diluted with water (20 mL) and extracted with Et0Ac/THF (20 mL x2, 1/1). The combined organic layer was washed with water (20 mL
x2), brine (20 mL x2), dried over anhydrous Na2SO4, filtered and concentrated.
The residue was purified by prep-HPLC (0.225% FA as an additive) and lyophilized to give N-(5-((5-methy1-8-(2-oxopy rroli din-1 -y 0-5H-chromeno [4,3 -c] py ri din-3-yl)amino)py ri din-3 -yl)isonicotinamide (15.3 mg, yield: 15%) as a yellow solid.
11-1NMR (400 MHz DMSO-d6) 61.55 (3H, d, J= 6.5 Hz), 2.00-2.10 (2H, m), 2.47-2.49 (2H, m, overlapped with the peak of DMSO), 3.79-3.88 (2H, m), 5.28 (1H, q, J = 6.5 Hz), 6.78 (1H, s), 7.31 (1H, dd, J= 8.7, 2.1 Hz), 7.40 (1H, d, J= 2.3 Hz), 7.86-7.92 (3H, m), 8.52 (1H, s), 8.67(1H, s), 8.72 (2H, d, J= 1.5 Hz), 8.82 (2H, d, J= 5.8 Hz), 9.60 (1H, brs), 10.73 (1H, brs).
Example 115: 2-amino-N-(5-05-methyl-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-yl)isonicotinamide I LXN Ytr H I N
Step 1: Preparation of 4-methoxybenzyl 2-(bis(4-methoxybenzyl)amino)isonicotinate
209 PMB0), N'PMB
[0498] To a solution of ethyl 2-aminoisonicotinate (1.50 g, 9.03 mmol) in anhydrous DMF
(20 mL) was added NaH (1.44 g, 36.1 mmol, 60% dispersion in mineral oil) at 0 C. The reaction mixture was stirred at 0 C for 1 hour. Then PMB-Cl (4-methoxybenzochloride) (5.65 g, 36.1 mmol) was added dropwise to the reaction mixture at 0 C. The resulting reaction mixture was stirred at 25-30 C for 49 h. The reaction mixture was quenched with saturated aqueous NH4C1 (50 mL), then extracted with Et0Ac (50 mL x3). The combined organic layer was washed with water (50 mL x3), brine (50 mL), dried over anhydrous Na2SO4 and concentrated. The residue was purified by Combi Flash (10% to 30% Et0Ac in pentane) to give 4-methoxybenzyl 2-(bis(4-methoxybenzyl)amino)isonicotinate (160 mg, yield: 3.6%) as a white solid.
Step 2: Preparation of 2-(bis(4-methoxybenzyl)amino)isonicotinic acid HO), N'PMB
[0499] To a solution of 4-methoxybenzyl 2-(bis(4-methoxybenzyl)amino)isonicotinate (160 mg, 0.320 mmol) in THF (4 mL) and Me0H (2 mL) was added 2N aqueous NaOH
(4 mL) at 20-25 C. Then the reaction mixture was stirred at 20-25 C for 2 h.
The reaction mixture turned into yellow solution from cloudy. LCMS (Rt = 0.763 min; MS Calcd:
378.2; MS Found:
379.0 [M+H1+). The reaction mixture was acidified with 2N aqueous HC1 to pH =
6, then extracted with Et0Ac (25 mL x2). The combined organic layer was washed with brine (25 mL), dried over anhydrous Na2SO4 and concentrated. The residue was purified by prep-TLC
(DCM/Me0H, 10/1) to give 2-(bis(4-methoxybenzyl)amino)isonicotinic acid (70 mg, yield:
58%) as yellow gum.
11-1NMR (400 MHz, CDC13) (53.76 (6H, s), 4.69 (4H, s), 6.81 (4H, d, J = 8.4 Hz), 6.90-7.15 (6H, m), 8.26 (1H, s).
Step 3: Preparation of 2-(bis(4-methoxybenzyl)amino)-N-(5-((5-methy1-8-(2-oxopyrrolidin-1-y 0-5H-chromeno [4,3 -c] pyri din-3-yl)amino)py ridin-3 -yl)i s oni cotinami de
[0498] To a solution of ethyl 2-aminoisonicotinate (1.50 g, 9.03 mmol) in anhydrous DMF
(20 mL) was added NaH (1.44 g, 36.1 mmol, 60% dispersion in mineral oil) at 0 C. The reaction mixture was stirred at 0 C for 1 hour. Then PMB-Cl (4-methoxybenzochloride) (5.65 g, 36.1 mmol) was added dropwise to the reaction mixture at 0 C. The resulting reaction mixture was stirred at 25-30 C for 49 h. The reaction mixture was quenched with saturated aqueous NH4C1 (50 mL), then extracted with Et0Ac (50 mL x3). The combined organic layer was washed with water (50 mL x3), brine (50 mL), dried over anhydrous Na2SO4 and concentrated. The residue was purified by Combi Flash (10% to 30% Et0Ac in pentane) to give 4-methoxybenzyl 2-(bis(4-methoxybenzyl)amino)isonicotinate (160 mg, yield: 3.6%) as a white solid.
Step 2: Preparation of 2-(bis(4-methoxybenzyl)amino)isonicotinic acid HO), N'PMB
[0499] To a solution of 4-methoxybenzyl 2-(bis(4-methoxybenzyl)amino)isonicotinate (160 mg, 0.320 mmol) in THF (4 mL) and Me0H (2 mL) was added 2N aqueous NaOH
(4 mL) at 20-25 C. Then the reaction mixture was stirred at 20-25 C for 2 h.
The reaction mixture turned into yellow solution from cloudy. LCMS (Rt = 0.763 min; MS Calcd:
378.2; MS Found:
379.0 [M+H1+). The reaction mixture was acidified with 2N aqueous HC1 to pH =
6, then extracted with Et0Ac (25 mL x2). The combined organic layer was washed with brine (25 mL), dried over anhydrous Na2SO4 and concentrated. The residue was purified by prep-TLC
(DCM/Me0H, 10/1) to give 2-(bis(4-methoxybenzyl)amino)isonicotinic acid (70 mg, yield:
58%) as yellow gum.
11-1NMR (400 MHz, CDC13) (53.76 (6H, s), 4.69 (4H, s), 6.81 (4H, d, J = 8.4 Hz), 6.90-7.15 (6H, m), 8.26 (1H, s).
Step 3: Preparation of 2-(bis(4-methoxybenzyl)amino)-N-(5-((5-methy1-8-(2-oxopyrrolidin-1-y 0-5H-chromeno [4,3 -c] pyri din-3-yl)amino)py ridin-3 -yl)i s oni cotinami de
210 I I
N
H I
[0500] A
mixture of 1-(3-((5-aminopyridin-3-yl)amino)-5-methy1-5H-chromeno[4,3-c] py ri din-8-yl)py rroli din-2-one (80 mg, 0.17 mmol, HC1 salt), 2-(bi s (4-methoxybenzypamino)isonicotinic acid (70 mg, 0.18 mmol) and EDCI.HC1 (33 mg, 0.17 mmol) in pyridine (3 mL) was stirred at 50 C for 2 h. The reaction mixture turned into yellow solution from colorless. LCMS (Rt = 0.855 min; MS Calcd: 747.3; MS Found:
748.4 [M+H1+).
The reaction mixture was diluted with water (25 mL), then extracted with Et0Ac (25 mL x3).
The combined organic layer was washed with saturated aqueous NaHCO3 (25 mL), brine (25 mL), dried over anhydrous Na2SO4 and concentrated. The residue was purified by prep-TLC
(DCM/Me0H, 10/1) to give 2-(bis(4-methoxybenzypamino)-N-(5-45-methyl-8-(2-oxopyrrolidin-1-y1)-5H-chromeno [4,3-c] py ri din-3-yl)amino)py ri din-3-yl)i s oni cotinami de (70 mg, yield: 54%) as a yellow solid.
Step 4: Preparation of 2-amino-N-(5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno [4,3-c] py ri din-3-yl)amino)py ri din-3-yl)i s oni cotinami de I \ I N N N)-NH 2 H
[0501] A
mixture of 2-(bi s (4-methoxy b enzy Damino)-N-(5 -45-methy1-8-(2-oxopy rroli din-1-y1)-5H-chromeno [4,3-c] py ri din-3 -yl)amino)py ri din-3-yl)i s oni cotinami de (70 mg, 0.094 mmol) in TFA (3 mL) was stirred at 50 C for 2 h. The reaction mixture turned into red solution from yellow. LCMS (Rt = 0.688 min; MS Calcd: 507.2; MS Found: 508.3 [M+H1+).
The reaction mixture was concentrated and the residue was basified with 2N aqueous NaOH to pH
= 10, then extracted with Et0Ac/THF (25 mL x3, 1/1). The combined organic layer was washed with brine (25 mL), dried over anhydrous Na2SO4 and concentrated. The crude product was triturated with MeCN (5 mL), filtered, then washed with MeCN (2 mL x2) and dried under
N
H I
[0500] A
mixture of 1-(3-((5-aminopyridin-3-yl)amino)-5-methy1-5H-chromeno[4,3-c] py ri din-8-yl)py rroli din-2-one (80 mg, 0.17 mmol, HC1 salt), 2-(bi s (4-methoxybenzypamino)isonicotinic acid (70 mg, 0.18 mmol) and EDCI.HC1 (33 mg, 0.17 mmol) in pyridine (3 mL) was stirred at 50 C for 2 h. The reaction mixture turned into yellow solution from colorless. LCMS (Rt = 0.855 min; MS Calcd: 747.3; MS Found:
748.4 [M+H1+).
The reaction mixture was diluted with water (25 mL), then extracted with Et0Ac (25 mL x3).
The combined organic layer was washed with saturated aqueous NaHCO3 (25 mL), brine (25 mL), dried over anhydrous Na2SO4 and concentrated. The residue was purified by prep-TLC
(DCM/Me0H, 10/1) to give 2-(bis(4-methoxybenzypamino)-N-(5-45-methyl-8-(2-oxopyrrolidin-1-y1)-5H-chromeno [4,3-c] py ri din-3-yl)amino)py ri din-3-yl)i s oni cotinami de (70 mg, yield: 54%) as a yellow solid.
Step 4: Preparation of 2-amino-N-(5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno [4,3-c] py ri din-3-yl)amino)py ri din-3-yl)i s oni cotinami de I \ I N N N)-NH 2 H
[0501] A
mixture of 2-(bi s (4-methoxy b enzy Damino)-N-(5 -45-methy1-8-(2-oxopy rroli din-1-y1)-5H-chromeno [4,3-c] py ri din-3 -yl)amino)py ri din-3-yl)i s oni cotinami de (70 mg, 0.094 mmol) in TFA (3 mL) was stirred at 50 C for 2 h. The reaction mixture turned into red solution from yellow. LCMS (Rt = 0.688 min; MS Calcd: 507.2; MS Found: 508.3 [M+H1+).
The reaction mixture was concentrated and the residue was basified with 2N aqueous NaOH to pH
= 10, then extracted with Et0Ac/THF (25 mL x3, 1/1). The combined organic layer was washed with brine (25 mL), dried over anhydrous Na2SO4 and concentrated. The crude product was triturated with MeCN (5 mL), filtered, then washed with MeCN (2 mL x2) and dried under
211 vacuum to give 2-amino-N-(5-((5-methyl-8-(2-oxopy rrol idin-1 -y1)-5H-chromeno [4,3 -clpyridin-3-yl)amino)pyridin-3-yl)isonicotinamide (32.4 mg yield: 68%) as a yellow solid.
NMR (400 MHz, DMSO-d6) (51.55 (3H, d, J= 6.6 Hz), 2.02-2.11 (2H, m), 2.53-2.56 (2H, m), 3.85 (2H, t, J= 7.8 Hz), 5.29 (1H, q, J= 6.5 Hz), 6.24 (2H, brs), 6.78 (1H, s), 6.90 (1H, s), 6.96 (1H, dd, J= 5.3, 1.3 Hz), 7.33 (1H, dd, J= 8.6, 2.1 Hz), 7.41 (1H, d, J= 2.2 Hz), 7.89 (1H, d, J= 8.7 Hz), 8.08 (1H, d, J= 5.1 Hz), 8.46 (1H, d, J= 2.0 Hz), 8.63-8.71 (3H, m), 9.50 (1H, brs), 10.46 (1H, brs).
Example 116: 1-hydroxy-N-(5-05-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-y1)-1,3-dihydrobenzo[c][1,2]oxaborole-5-carboxamide I
NN
Step 1: Preparation of 3-(acetoxymethyl)-4-bromobenzoic acid HO OAc Br [0502] To a mixture of 4-bromo-3-(hydroxymethyl)benzoic acid (300 mg, 1.30 mmol) in pyridine (10 mL) was added acetic anhydride (132 mg, 1.30 mmol), the reaction mixture was stirred at 25 C for 2 h to give a yellow solution. LCMS showed the reaction was completed.
The mixture was concentrated under reduced pressure to remove pyridine and then diluted with water (10 mL). The pH of the mixture was adjusted to 2 with 2 N aqueous HC1 and then extracted with Et0Ac (20 mL x2). The combined extracts was washed with brine (25 mL x2), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to give 3-(acetoxymethyl)-4-bromobenzoic acid (300 mg, yield: 85%) as a white solid.
NMR (400 MHz, DMSO-d6) (52.11 (3H, s), 5.17 (2H, s), 7.76-7.85 (2H, m), 8.01 (1H, s), 13.28 (1H, brs).
Step 2: Preparation of 2-bromo-5-((5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-yOcarbamoyObenzyl acetate
NMR (400 MHz, DMSO-d6) (51.55 (3H, d, J= 6.6 Hz), 2.02-2.11 (2H, m), 2.53-2.56 (2H, m), 3.85 (2H, t, J= 7.8 Hz), 5.29 (1H, q, J= 6.5 Hz), 6.24 (2H, brs), 6.78 (1H, s), 6.90 (1H, s), 6.96 (1H, dd, J= 5.3, 1.3 Hz), 7.33 (1H, dd, J= 8.6, 2.1 Hz), 7.41 (1H, d, J= 2.2 Hz), 7.89 (1H, d, J= 8.7 Hz), 8.08 (1H, d, J= 5.1 Hz), 8.46 (1H, d, J= 2.0 Hz), 8.63-8.71 (3H, m), 9.50 (1H, brs), 10.46 (1H, brs).
Example 116: 1-hydroxy-N-(5-05-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-y1)-1,3-dihydrobenzo[c][1,2]oxaborole-5-carboxamide I
NN
Step 1: Preparation of 3-(acetoxymethyl)-4-bromobenzoic acid HO OAc Br [0502] To a mixture of 4-bromo-3-(hydroxymethyl)benzoic acid (300 mg, 1.30 mmol) in pyridine (10 mL) was added acetic anhydride (132 mg, 1.30 mmol), the reaction mixture was stirred at 25 C for 2 h to give a yellow solution. LCMS showed the reaction was completed.
The mixture was concentrated under reduced pressure to remove pyridine and then diluted with water (10 mL). The pH of the mixture was adjusted to 2 with 2 N aqueous HC1 and then extracted with Et0Ac (20 mL x2). The combined extracts was washed with brine (25 mL x2), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to give 3-(acetoxymethyl)-4-bromobenzoic acid (300 mg, yield: 85%) as a white solid.
NMR (400 MHz, DMSO-d6) (52.11 (3H, s), 5.17 (2H, s), 7.76-7.85 (2H, m), 8.01 (1H, s), 13.28 (1H, brs).
Step 2: Preparation of 2-bromo-5-((5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-yOcarbamoyObenzyl acetate
212 I
NN OAc Br [0503] To a mixture of 1-(3-((5-aminopyridin-3-y0amino)-5-methyl-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (100 mg, 0.217 mmol, 2HC1 salt) and 3-(acetoxymethyl)-4-bromobenzoic acid (119 mg, 0.434 mmol) in pyridine (5 mL) was added EDCI.HC1 (83 mg, 0.43 mmol), the reaction mixture was stirred at 50 C for 2 h to give a yellow solution. LCMS
(Rt = 0.763 min; MS Calcd: 643.1; MS Found: 644.1 [M+Hl+). The mixture was concentrated under reduced pressure and the crude product was washed with MeCN (10 mL x2) to give 2-bromo-5-((5 -((5-methyl-8-(2-oxopyrroli din-l-y1)-5H-chromeno [4,3 -c] py ri din-3 -yOamino)pyridin-3-yOcarbamoyObenzyl acetate (60 mg, yield: 43%) as a yellow solid.
NMR (400 MHz, DMSO-d6) (51.57 (3H, d, J= 6.8 Hz), 2.00-2.12 (2H, m), 2.15 (3H, s), 2.49-2.52 (2H, m), 3.86 (2H, t, J= 7.6 Hz), 5.22 (2H, s), 5.34 (1H, q, J= 6.4 Hz), 6.90 (1H, s), 7.36 (1H, dd, J= 8.4, 2.0 Hz), 7.42 (1H, d, J= 2.0 Hz), 7.88-7.99 (3H, m), 8.11 (1H, d, J
= 2.0 Hz), 8.74-8.79 (2H, m), 8.92 (1H, s), 9.13 (1H, s), 10.31 (1H, brs), 11.14 (1H, brs).
Step 3: Preparation of 5 -((5-((5-methyl-8-(2-oxopyrroli din-1 -y1)-5H-chromeno [4,3-c] py ri din-3-yl)amino)py ri din-3 -yl)carbamoy1)-2-(4,4,5,5 -tetramethy1-1,3,2-di oxaborol an-2-y Obenzyl acetate I
NN OAc The Pt batch [0504] To a mixture of 2-bromo-5-((5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-yOcarbamoyObenzyl acetate (60 mg, 0.093 mmol) in dioxane (8 mL) was added KOAc (27 mg, 0.28 mmol), B2Pin2 (36 mg, 0.14 mmol) and Pd(dppf)C12 (7 mg, 0.009 mmol) under N2 atmosphere, then the reaction mixture
NN OAc Br [0503] To a mixture of 1-(3-((5-aminopyridin-3-y0amino)-5-methyl-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (100 mg, 0.217 mmol, 2HC1 salt) and 3-(acetoxymethyl)-4-bromobenzoic acid (119 mg, 0.434 mmol) in pyridine (5 mL) was added EDCI.HC1 (83 mg, 0.43 mmol), the reaction mixture was stirred at 50 C for 2 h to give a yellow solution. LCMS
(Rt = 0.763 min; MS Calcd: 643.1; MS Found: 644.1 [M+Hl+). The mixture was concentrated under reduced pressure and the crude product was washed with MeCN (10 mL x2) to give 2-bromo-5-((5 -((5-methyl-8-(2-oxopyrroli din-l-y1)-5H-chromeno [4,3 -c] py ri din-3 -yOamino)pyridin-3-yOcarbamoyObenzyl acetate (60 mg, yield: 43%) as a yellow solid.
NMR (400 MHz, DMSO-d6) (51.57 (3H, d, J= 6.8 Hz), 2.00-2.12 (2H, m), 2.15 (3H, s), 2.49-2.52 (2H, m), 3.86 (2H, t, J= 7.6 Hz), 5.22 (2H, s), 5.34 (1H, q, J= 6.4 Hz), 6.90 (1H, s), 7.36 (1H, dd, J= 8.4, 2.0 Hz), 7.42 (1H, d, J= 2.0 Hz), 7.88-7.99 (3H, m), 8.11 (1H, d, J
= 2.0 Hz), 8.74-8.79 (2H, m), 8.92 (1H, s), 9.13 (1H, s), 10.31 (1H, brs), 11.14 (1H, brs).
Step 3: Preparation of 5 -((5-((5-methyl-8-(2-oxopyrroli din-1 -y1)-5H-chromeno [4,3-c] py ri din-3-yl)amino)py ri din-3 -yl)carbamoy1)-2-(4,4,5,5 -tetramethy1-1,3,2-di oxaborol an-2-y Obenzyl acetate I
NN OAc The Pt batch [0504] To a mixture of 2-bromo-5-((5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-yOcarbamoyObenzyl acetate (60 mg, 0.093 mmol) in dioxane (8 mL) was added KOAc (27 mg, 0.28 mmol), B2Pin2 (36 mg, 0.14 mmol) and Pd(dppf)C12 (7 mg, 0.009 mmol) under N2 atmosphere, then the reaction mixture
213 was stirred at 100 C under N2 atmosphere for 5 h to give a brown suspension.
LCMS (Rt = 0.844 min; MS Calcd: 689.3; MS Found: 690.4 [M+H]+). The mixture was diluted with water (15 mL) and then extracted with Et0Ac (20 mL x2). The combined extracts was washed with brine (30 mL x2), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to give 5-((5-((5 -methyl-8-(2-oxopy rroli din-1 -y1)-5H-chromeno [4,3-c] py ri din-3-yl)amino)py ri din-3 -yl)carb amoy1)-2-(4,4,5,5 -tetramethyl-1,3 ,2-di oxab orol an-2-y Obenzyl acetate (60 mg, crude) as a brown solid.
The 2nd batch [0505] To a mixture of 2-bromo-5 -((5-((5 -methyl-8-(2-oxopy rrolidin-1 -y1)-5H-chromeno [4,3-c] py ridin-3 -yl)amino)py ridin-3 -y Ocarbamoy enzyl acetate (120 mg, 0.187 mmol) in dioxane (10 mL) was added KOAc (55 mg, 0.56 mmol), B2Pin2 (71 mg, 0.28 mmol) and Pd(dppf)C12 (14 mg, 0.019 mmol) under N2 atmosphere, then the reaction mixture was stirred at 100 C under N2 atmosphere for 5 h to give a brown suspension.
LCMS (Rt = 0.852 min; MS Calcd: 689.3; MS Found: 690.4 [M+H]+). The mixture was diluted with water (10 mL) and then extracted with Et0Ac (20 mL x2). The combined extracts was washed with brine (25 mL x2), dried over anhydrous Na2SO4, filtered and concentrated. The residue was combined with the first batch and purified by Combi Flash (DCM/Me0H, 100/1 to 95/5) to give 5-((5-((5-methyl-8-(2-oxopy rroli din-l-y1)-5H-chromeno [4,3 -c] py ri din-3-yl)amino)py ri din-3 -yl)carbamoy1)-2-(4,4,5 ,5 -tetramethyl-1,3 ,2-di oxab orol an-2-y Obenzyl acetate (120 mg, average yield: 44%) as a brown solid.
Step 4: Preparation of 1 -hy droxy -N-(5 -((5-methyl-8-(2-oxopy rrol i din-1 -y1)-5H-chromeno [4,3-c] py ri din-3-y0amino)py ri din-3-y1)-1,3 -dihy drobenzo [c]
[1,2] oxaborole-5-carboxamide I
NN
OH
[0506] To a mixture of 5-((5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c] py ri din-3-yl)amino)py ri din-3 -yl)carb amoy1)-2-(4,4,5,5 -tetramethy1-1,3,2-di oxab orol an-2-
LCMS (Rt = 0.844 min; MS Calcd: 689.3; MS Found: 690.4 [M+H]+). The mixture was diluted with water (15 mL) and then extracted with Et0Ac (20 mL x2). The combined extracts was washed with brine (30 mL x2), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to give 5-((5-((5 -methyl-8-(2-oxopy rroli din-1 -y1)-5H-chromeno [4,3-c] py ri din-3-yl)amino)py ri din-3 -yl)carb amoy1)-2-(4,4,5,5 -tetramethyl-1,3 ,2-di oxab orol an-2-y Obenzyl acetate (60 mg, crude) as a brown solid.
The 2nd batch [0505] To a mixture of 2-bromo-5 -((5-((5 -methyl-8-(2-oxopy rrolidin-1 -y1)-5H-chromeno [4,3-c] py ridin-3 -yl)amino)py ridin-3 -y Ocarbamoy enzyl acetate (120 mg, 0.187 mmol) in dioxane (10 mL) was added KOAc (55 mg, 0.56 mmol), B2Pin2 (71 mg, 0.28 mmol) and Pd(dppf)C12 (14 mg, 0.019 mmol) under N2 atmosphere, then the reaction mixture was stirred at 100 C under N2 atmosphere for 5 h to give a brown suspension.
LCMS (Rt = 0.852 min; MS Calcd: 689.3; MS Found: 690.4 [M+H]+). The mixture was diluted with water (10 mL) and then extracted with Et0Ac (20 mL x2). The combined extracts was washed with brine (25 mL x2), dried over anhydrous Na2SO4, filtered and concentrated. The residue was combined with the first batch and purified by Combi Flash (DCM/Me0H, 100/1 to 95/5) to give 5-((5-((5-methyl-8-(2-oxopy rroli din-l-y1)-5H-chromeno [4,3 -c] py ri din-3-yl)amino)py ri din-3 -yl)carbamoy1)-2-(4,4,5 ,5 -tetramethyl-1,3 ,2-di oxab orol an-2-y Obenzyl acetate (120 mg, average yield: 44%) as a brown solid.
Step 4: Preparation of 1 -hy droxy -N-(5 -((5-methyl-8-(2-oxopy rrol i din-1 -y1)-5H-chromeno [4,3-c] py ri din-3-y0amino)py ri din-3-y1)-1,3 -dihy drobenzo [c]
[1,2] oxaborole-5-carboxamide I
NN
OH
[0506] To a mixture of 5-((5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c] py ri din-3-yl)amino)py ri din-3 -yl)carb amoy1)-2-(4,4,5,5 -tetramethy1-1,3,2-di oxab orol an-2-
214 yObenzyl acetate (120 mg, 0.174 mmol) in Me0H (8 mL) was added a solution of NaOH (14 mg, 0.35 mmol) in Me0H (2 mL), then the reaction mixture was stirred at 40 C
for 4 h to give a brown solution. LCMS (Rt = 0.714 min; MS Calcd: 547.2; MS Found: 548.0 [M+Hl+). The mixture was concentrated under reduced pressure. The residue was purified by prep-HPLC
(0.05% NH3.H20 as an additive) to give 1-hydroxy-N-(5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno [4,3-c] py ridin-3 -yl)amino)py ri din-3-y1)-1,3 -dihy drobenzo [c] [1,2] oxaborol e-5-carboxamide (12.0 mg, yield: 12%) as a yellow solid.
11-1 NMR (400 MHz, DMSO-d6) 61.55 (3H, d, J= 6.4 Hz), 2.00-2.09 (2H, m), 2.49-2.52 (2H, m), 3.84 (2H, t, J= 6.8 Hz), 5.10 (2H, s), 5.28 (1H, q, J= 6.4 Hz), 6.77 (1H, s), 7.32 (1H, dd, J= 8.8, 2.4 Hz), 7.40 (1H, d, J= 2.4 Hz), 7.84-7.90 (2H, m), 7.90-7.96 (1H, m), 8.00 (1H, s), 8.49 (1H, d, J= 1.6 Hz), 8.64-8.71 (3H, m), 9.39 (1H, brs), 9.50 (1H, brs), 10.50 (1H, brs).
Example 117: 1-hydroxy-N-(5-05-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-y1)-1,3-dihydrobenzo[c][1,2]oxaborole-6-carboxamide N NHNH =
Step 1: Preparation of 3-bromo-4-(hydroxymethyl)benzoic acid B
HO r OH
105071 To a mixture of 3-bromo-4-formylbenzoic acid (500 mg, 2.18 mmol) in anhydrous THF (15 mL) was added NaBH4 (83 mg, 2.18 mmol) in portions at 0 C, then warmed to 20 C and stirred for 3 h to give a black suspension. LCMS showed the reaction was completed.
The mixture was quenched with water (10 mL). The pH of the mixture was adjusted to 2 with 1N aqueous HC1, then extracted with Et0Ac (20 mL x2), the combined extracts was washed with brine (30 mL x2), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to give 3-bromo-4-(hydroxymethyl)benzoic acid (460 mg, yield: 91%) as a white solid.
for 4 h to give a brown solution. LCMS (Rt = 0.714 min; MS Calcd: 547.2; MS Found: 548.0 [M+Hl+). The mixture was concentrated under reduced pressure. The residue was purified by prep-HPLC
(0.05% NH3.H20 as an additive) to give 1-hydroxy-N-(5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno [4,3-c] py ridin-3 -yl)amino)py ri din-3-y1)-1,3 -dihy drobenzo [c] [1,2] oxaborol e-5-carboxamide (12.0 mg, yield: 12%) as a yellow solid.
11-1 NMR (400 MHz, DMSO-d6) 61.55 (3H, d, J= 6.4 Hz), 2.00-2.09 (2H, m), 2.49-2.52 (2H, m), 3.84 (2H, t, J= 6.8 Hz), 5.10 (2H, s), 5.28 (1H, q, J= 6.4 Hz), 6.77 (1H, s), 7.32 (1H, dd, J= 8.8, 2.4 Hz), 7.40 (1H, d, J= 2.4 Hz), 7.84-7.90 (2H, m), 7.90-7.96 (1H, m), 8.00 (1H, s), 8.49 (1H, d, J= 1.6 Hz), 8.64-8.71 (3H, m), 9.39 (1H, brs), 9.50 (1H, brs), 10.50 (1H, brs).
Example 117: 1-hydroxy-N-(5-05-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-y1)-1,3-dihydrobenzo[c][1,2]oxaborole-6-carboxamide N NHNH =
Step 1: Preparation of 3-bromo-4-(hydroxymethyl)benzoic acid B
HO r OH
105071 To a mixture of 3-bromo-4-formylbenzoic acid (500 mg, 2.18 mmol) in anhydrous THF (15 mL) was added NaBH4 (83 mg, 2.18 mmol) in portions at 0 C, then warmed to 20 C and stirred for 3 h to give a black suspension. LCMS showed the reaction was completed.
The mixture was quenched with water (10 mL). The pH of the mixture was adjusted to 2 with 1N aqueous HC1, then extracted with Et0Ac (20 mL x2), the combined extracts was washed with brine (30 mL x2), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to give 3-bromo-4-(hydroxymethyl)benzoic acid (460 mg, yield: 91%) as a white solid.
215 NMR (400 MHz, DMSO-d6) (54.56 (2H, d, J= 5.2 Hz), 5.63 (1H, brs), 7.67 (1H, d, J=
8.0 Hz), 7.97 (1H, dd, J= 8.0, 1.6 Hz), 8.04 (1H, d, J= 1.6 Hz), 13.19 (1H, brs).
Step 2: Preparation of 4-(acetoxymethyl)-3-bromobenzoic acid B
HO r OAc [0508] To a mixture of 3-bromo-4-(hydroxymethyl)benzoic acid (460 mg, 1.99 mmol) in pyridine (10 mL) was added acetic anhydride (203 mg, 1.99 mmol), the reaction mixture was stirred at 25 C for 2 h to give a pale yellow solution. LCMS showed the reaction was completed. The mixture was quenched with water (10 mL) and the pH was adjusted to 1 with 1N aqueous HC1. The mixture was extracted with Et0Ac (20 mL x2), the combined extracts was washed with brine (30 mL x 2), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to give 4-(acetoxymethyl)-3-bromobenzoic acid (500 mg, yield:
92%) as an off-white solid.
NMR (400 MHz, DMSO-d6) (52.14 (3H, s), 5.17 (2H, s), 7.61 (1H, d, J= 8.0 Hz), 7.95 (1H, dd, J= 8.0, 1.2 Hz), 8.11 (1H, d, J= 1.2 Hz), 13.38 (1H, brs).
Step 3: Preparation of 2-bromo-4-((5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-yOcarbamoyObenzyl acetate I Br N NHNH
OAc [0509] To a mixture of 1-(3-((5-aminopyridin-3-y0amino)-5-methyl-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (300 mg, 0.652 mmol, HC1 salt) and 4-(acetoxymethyl)-3-bromobenzoic acid (178 mg, 0.652 mmol) in pyridine (10 mL) was added EDCI.HC1 (250 mg, 1.30 mmol), the reaction mixture was stirred at 50 C for 3 h to give a yellow solution. LCMS
(Rt = 0.759 min; MS Calcd: 643.1; MS Found: 644.1 [M+H1+). The mixture was concentrated under reduced pressure to give a residue. The residue was washed with Me0H (20 mL x2) to give 2-bromo-4-((5-((5-methyl-8-(2-oxopy rroli din-l-y1)-5H-chromeno [4,3-c] py ri din-3-yOamino)pyridin-3-yOcarbamoyObenzyl acetate (280 mg, yield: 67%) as a yellow solid.
8.0 Hz), 7.97 (1H, dd, J= 8.0, 1.6 Hz), 8.04 (1H, d, J= 1.6 Hz), 13.19 (1H, brs).
Step 2: Preparation of 4-(acetoxymethyl)-3-bromobenzoic acid B
HO r OAc [0508] To a mixture of 3-bromo-4-(hydroxymethyl)benzoic acid (460 mg, 1.99 mmol) in pyridine (10 mL) was added acetic anhydride (203 mg, 1.99 mmol), the reaction mixture was stirred at 25 C for 2 h to give a pale yellow solution. LCMS showed the reaction was completed. The mixture was quenched with water (10 mL) and the pH was adjusted to 1 with 1N aqueous HC1. The mixture was extracted with Et0Ac (20 mL x2), the combined extracts was washed with brine (30 mL x 2), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to give 4-(acetoxymethyl)-3-bromobenzoic acid (500 mg, yield:
92%) as an off-white solid.
NMR (400 MHz, DMSO-d6) (52.14 (3H, s), 5.17 (2H, s), 7.61 (1H, d, J= 8.0 Hz), 7.95 (1H, dd, J= 8.0, 1.2 Hz), 8.11 (1H, d, J= 1.2 Hz), 13.38 (1H, brs).
Step 3: Preparation of 2-bromo-4-((5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-yOcarbamoyObenzyl acetate I Br N NHNH
OAc [0509] To a mixture of 1-(3-((5-aminopyridin-3-y0amino)-5-methyl-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (300 mg, 0.652 mmol, HC1 salt) and 4-(acetoxymethyl)-3-bromobenzoic acid (178 mg, 0.652 mmol) in pyridine (10 mL) was added EDCI.HC1 (250 mg, 1.30 mmol), the reaction mixture was stirred at 50 C for 3 h to give a yellow solution. LCMS
(Rt = 0.759 min; MS Calcd: 643.1; MS Found: 644.1 [M+H1+). The mixture was concentrated under reduced pressure to give a residue. The residue was washed with Me0H (20 mL x2) to give 2-bromo-4-((5-((5-methyl-8-(2-oxopy rroli din-l-y1)-5H-chromeno [4,3-c] py ri din-3-yOamino)pyridin-3-yOcarbamoyObenzyl acetate (280 mg, yield: 67%) as a yellow solid.
216 NMR (400 MHz, DMSO-d6) (51.57 (3H, d, J= 6.8 Hz), 2.00-2.14 (2H, m), 2.16 (3H, s), 2.50-2.53 (2H, m), 3.86 (2H, t, J= 8.0 Hz), 5.22 (2H, s), 5.34 (1H, q, J= 6.0 Hz), 6.89 (1H, s), 7.36 (1H, dd, J= 8.8, 2.4 Hz), 7.42 (1H, d, J= 2.0 Hz), 7.68 (1H, d, J=
8.4 Hz), 7.94 (1H, d, J= 8.8 Hz), 8.06 (1H, dd, J= 8.0, 1.6 Hz), 8.31 (1H, d, J= 2.0 Hz), 8.73-8.79 (2H, m), 8.92 (1H, d, J= 2.0 Hz), 9.11 (1H, d, J= 2.0 Hz), 10.28 (1H, brs), 11.08 (1H, brs).
Step 4: Preparation of 4-((5 -((5-methyl-8-(2-oxopyrroli din-1 -y1)-5H-chromeno [4,3-c] py ri din-3-yl)amino)py ri din-3 -yl)carbamoy1)-2-(4,4,5,5 -tetramethy1-1,3,2-di oxaborol an-2-y Obenzyl acetate OAc [0510] To a mixture of 2-bromo-4-((5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y1)amino)pyridin-3-y1)carbamoyl)benzyl acetate (200 mg, 0.311 mmol) in dioxane (8 mL) was added KOAc (92 mg, 0.93 mmol), B2Pin2 (119 mg, 0.467 mmol) and Pd(dppf)C12 (23 mg, 0.031 mmol) under N2 atmosphere, then the reaction mixture was stirred at 90 C under N2 atmosphere for 16 h to give a brown suspension.
LCMS (Rt = 0.811 min; MS Calcd: 689.3; MS Found: 690.1 [M+Hl+). The mixture was diluted with water (15 mL) and extracted with Et0Ac (20 mL x2). The combined extracts was washed with brine (30 mL x2), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by Combi Flash (DCM: Me0H = 100/1 to 95/5) to give 4-((5-((5 -methy1-8-(2-oxopy rroli din-1 -y1)-5H-chromeno [4,3-c] py ri din-3-y0amino)py ri din-3-yOcarbamoy1)-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yObenzyl acetate (120 mg, yield:
43%, purity: 77%) as a brown gum.
Step 5: Preparation of 1 -hy droxy -N-(5 -((5-methyl-8-(2-oxopy rrol i din-1 -y1)-5H-chromeno [4,3-c] py ri din-3-y0amino)py ri din-3-y1)-1,3 -dihy drobenzo [c]
[1,2] oxab orol e-6-carboxamide
8.4 Hz), 7.94 (1H, d, J= 8.8 Hz), 8.06 (1H, dd, J= 8.0, 1.6 Hz), 8.31 (1H, d, J= 2.0 Hz), 8.73-8.79 (2H, m), 8.92 (1H, d, J= 2.0 Hz), 9.11 (1H, d, J= 2.0 Hz), 10.28 (1H, brs), 11.08 (1H, brs).
Step 4: Preparation of 4-((5 -((5-methyl-8-(2-oxopyrroli din-1 -y1)-5H-chromeno [4,3-c] py ri din-3-yl)amino)py ri din-3 -yl)carbamoy1)-2-(4,4,5,5 -tetramethy1-1,3,2-di oxaborol an-2-y Obenzyl acetate OAc [0510] To a mixture of 2-bromo-4-((5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y1)amino)pyridin-3-y1)carbamoyl)benzyl acetate (200 mg, 0.311 mmol) in dioxane (8 mL) was added KOAc (92 mg, 0.93 mmol), B2Pin2 (119 mg, 0.467 mmol) and Pd(dppf)C12 (23 mg, 0.031 mmol) under N2 atmosphere, then the reaction mixture was stirred at 90 C under N2 atmosphere for 16 h to give a brown suspension.
LCMS (Rt = 0.811 min; MS Calcd: 689.3; MS Found: 690.1 [M+Hl+). The mixture was diluted with water (15 mL) and extracted with Et0Ac (20 mL x2). The combined extracts was washed with brine (30 mL x2), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by Combi Flash (DCM: Me0H = 100/1 to 95/5) to give 4-((5-((5 -methy1-8-(2-oxopy rroli din-1 -y1)-5H-chromeno [4,3-c] py ri din-3-y0amino)py ri din-3-yOcarbamoy1)-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yObenzyl acetate (120 mg, yield:
43%, purity: 77%) as a brown gum.
Step 5: Preparation of 1 -hy droxy -N-(5 -((5-methyl-8-(2-oxopy rrol i din-1 -y1)-5H-chromeno [4,3-c] py ri din-3-y0amino)py ri din-3-y1)-1,3 -dihy drobenzo [c]
[1,2] oxab orol e-6-carboxamide
217 N NHNHo [0511] To a mixture of 4-((5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c] py ri din-3-y0amino)py ri din-3 -yOcarb amoy1)-2-(4,4,5,5 -tetramethy1-1,3,2-di oxab orol an-2-yObenzyl acetate (120 mg, 0.174 mmol) in Me0H (8 mL) was added a solution of NaOH (14 mg, 0.35 mmol) in Me0H (2 mL), then the reaction mixture was stirred at 40 C
for 4 h to give a brown solution. LCMS (Rt = 0.717 min; MS Calcd: 547.2; MS Found: 548.1 [M+Hl+). The mixture was concentrated under reduced pressure. The residue was purified by prep-HPLC
(0.05% NH3.H20 as an additive) and lyophilized to give 1-hydroxy-N-(5-((5-methy1-8-(2-oxopy rroli din-l-y1)-5H-chromeno [4,3 -c] py ri din-3-yl)amino)py ri din-3-y1)-1,3 -dihydrobenzo[c][1,21oxaborole-6-carboxamide (16.8 mg, yield: 18%) as an off-white solid.
11-1NMR (400 MHz, DMSO-d6) 61.55 (3H, d, J= 6.8 Hz), 2.00-2.11 (2H, m), 2.49-2.52 (2H, m), 3.84 (2H, t, J= 7.6 Hz), 5.09 (2H, s), 5.27 (1H, q, J= 6.0 Hz), 6.77 (1H, s), 7.31 (1H, dd, J= 8.8, 2.4 Hz), 7.40 (1H, d, J= 2.0 Hz), 7.58 (1H, d, J= 7.6 Hz), 7.78 (1H, d, J= 8.8 Hz), 8.08 (1H, dd, J= 8.0, 1.6 Hz), 8.35 (1H, s), 8.49 (1H, d, J= 2.0 Hz), 8.62-8.71 (3H, m), 9.39 (1H, brs), 9.49 (1H, brs), 10.48 (1H, brs).
Example 118: 1-hydroxy-N-(5-05-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-y1)-1,3-dihydrobenzo[c][1,2]oxaborole-4-carboxamide I
N NHNH
Step 1: Preparation of 3-bromo-2-(hydroxymethyl)-N-(5-45-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno [4,3-c] py ridin-3 -yl)amino)py ri din-3-y Ob enzami de
for 4 h to give a brown solution. LCMS (Rt = 0.717 min; MS Calcd: 547.2; MS Found: 548.1 [M+Hl+). The mixture was concentrated under reduced pressure. The residue was purified by prep-HPLC
(0.05% NH3.H20 as an additive) and lyophilized to give 1-hydroxy-N-(5-((5-methy1-8-(2-oxopy rroli din-l-y1)-5H-chromeno [4,3 -c] py ri din-3-yl)amino)py ri din-3-y1)-1,3 -dihydrobenzo[c][1,21oxaborole-6-carboxamide (16.8 mg, yield: 18%) as an off-white solid.
11-1NMR (400 MHz, DMSO-d6) 61.55 (3H, d, J= 6.8 Hz), 2.00-2.11 (2H, m), 2.49-2.52 (2H, m), 3.84 (2H, t, J= 7.6 Hz), 5.09 (2H, s), 5.27 (1H, q, J= 6.0 Hz), 6.77 (1H, s), 7.31 (1H, dd, J= 8.8, 2.4 Hz), 7.40 (1H, d, J= 2.0 Hz), 7.58 (1H, d, J= 7.6 Hz), 7.78 (1H, d, J= 8.8 Hz), 8.08 (1H, dd, J= 8.0, 1.6 Hz), 8.35 (1H, s), 8.49 (1H, d, J= 2.0 Hz), 8.62-8.71 (3H, m), 9.39 (1H, brs), 9.49 (1H, brs), 10.48 (1H, brs).
Example 118: 1-hydroxy-N-(5-05-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-y1)-1,3-dihydrobenzo[c][1,2]oxaborole-4-carboxamide I
N NHNH
Step 1: Preparation of 3-bromo-2-(hydroxymethyl)-N-(5-45-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno [4,3-c] py ridin-3 -yl)amino)py ri din-3-y Ob enzami de
218 I
NN Br [0512] To a mixture of 1-(3-((5-aminopyridin-3-y0amino)-5-methyl-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (100 mg, 0.236 mmol, HC1 salt) and 4-bromoisobenzofuran-1(3H)-one (75 mg, 0.354 mmol) in toluene (5 mL) was added AlMe3 (2 M in toluene, 0.47 mL, 0.94 mmol) dropwise at 0 C, then warmed to 25 C and stirred for 0.5 hour.
The reaction mixture was heated at 50 C and stirred for 4.5 h to give a yellow suspension.
LCMS (Rt = 0.774 min; MS Calcd: 599.1; MS Found: 600.1 [M+Hl+). The mixture was quenched with saturated aqueous sodium potassium tartrate (25 mL), followed by Et0Ac (15 mL). The white precipitate was filtered and dried under high vacuum to give 3-bromo-2-(hydroxymethyl)-N-(5 -45-methy1-8-(2-oxopy rroli din-1-y 0-5H-chromeno [4,3-c] py ridin-3 -y Damino)py ridin-3 -yObenzamide (80 mg, yield: 50%) as an off-white solid.
Step 2: Preparation of 2-bromo-6-((5-((5-methyl-8-(2-oxopy rroli din-1 -y1)-5H-chromeno [4,3-c]pyridin-3-y0amino)pyridin-3-yOcarbamoyObenzyl acetate 0 OAc I Br NN
[0513] To a mixture of 3-bromo-2-(hydroxymethyl)-N-(5-45-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y1)amino)pyridin-3-y1)benzamide (80 mg, 0.133 mmol) in pyridine (5 mL) was added acetic anhydride (16 mg, 0.16 mmol), the reaction mixture was stirred at 25 C for 4 h to give a yellow solution. LCMS (Rt = 0.796 min; MS
Calcd: 643.1;
MS Found: 644.2 [M+Hl+). The mixture was concentrated under reduced pressure to give a residue. The residue was purified by washing with Me0H (10 mL x2) to give 2-bromo-6-((5-((5-methy1-8-(2-oxopy rrolidin-l-y1)-5H-chromeno [4,3 -c] py ridin-3-y0amino)py ridin-3 -yOcarbamoyObenzyl acetate (80 mg, yield: 93%) as an off-white solid.
11-1 NMR (400 MHz, DMSO-d6) (51.54 (3H, d, J= 6.4 Hz), 1.90 (3H, s), 2.00-2.12 (2H, m), 2.50-2.52 (2H, m), 3.84 (2H, t, J= 6.8 Hz), 5.22-5.35 (3H, m), 6.77 (1H, s), 7.33 (1H, dd, J =
NN Br [0512] To a mixture of 1-(3-((5-aminopyridin-3-y0amino)-5-methyl-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (100 mg, 0.236 mmol, HC1 salt) and 4-bromoisobenzofuran-1(3H)-one (75 mg, 0.354 mmol) in toluene (5 mL) was added AlMe3 (2 M in toluene, 0.47 mL, 0.94 mmol) dropwise at 0 C, then warmed to 25 C and stirred for 0.5 hour.
The reaction mixture was heated at 50 C and stirred for 4.5 h to give a yellow suspension.
LCMS (Rt = 0.774 min; MS Calcd: 599.1; MS Found: 600.1 [M+Hl+). The mixture was quenched with saturated aqueous sodium potassium tartrate (25 mL), followed by Et0Ac (15 mL). The white precipitate was filtered and dried under high vacuum to give 3-bromo-2-(hydroxymethyl)-N-(5 -45-methy1-8-(2-oxopy rroli din-1-y 0-5H-chromeno [4,3-c] py ridin-3 -y Damino)py ridin-3 -yObenzamide (80 mg, yield: 50%) as an off-white solid.
Step 2: Preparation of 2-bromo-6-((5-((5-methyl-8-(2-oxopy rroli din-1 -y1)-5H-chromeno [4,3-c]pyridin-3-y0amino)pyridin-3-yOcarbamoyObenzyl acetate 0 OAc I Br NN
[0513] To a mixture of 3-bromo-2-(hydroxymethyl)-N-(5-45-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y1)amino)pyridin-3-y1)benzamide (80 mg, 0.133 mmol) in pyridine (5 mL) was added acetic anhydride (16 mg, 0.16 mmol), the reaction mixture was stirred at 25 C for 4 h to give a yellow solution. LCMS (Rt = 0.796 min; MS
Calcd: 643.1;
MS Found: 644.2 [M+Hl+). The mixture was concentrated under reduced pressure to give a residue. The residue was purified by washing with Me0H (10 mL x2) to give 2-bromo-6-((5-((5-methy1-8-(2-oxopy rrolidin-l-y1)-5H-chromeno [4,3 -c] py ridin-3-y0amino)py ridin-3 -yOcarbamoyObenzyl acetate (80 mg, yield: 93%) as an off-white solid.
11-1 NMR (400 MHz, DMSO-d6) (51.54 (3H, d, J= 6.4 Hz), 1.90 (3H, s), 2.00-2.12 (2H, m), 2.50-2.52 (2H, m), 3.84 (2H, t, J= 6.8 Hz), 5.22-5.35 (3H, m), 6.77 (1H, s), 7.33 (1H, dd, J =
219 8.8, 1.6 Hz), 7.40 (1H, s), 7.47 (1H, t, J= 7.6 Hz), 7.63 (1H, d, J= 7.2 Hz), 7.81-7.92 (2H, m), 8.39 (1H, s), 8.60 (1H, s), 8.65 (1H, s), 8.73 (1H, d, J= 2.0 Hz), 9.52 (1H, brs), 10.68 (1H, brs).
Step 3: Preparation of 2-((5 -((5-methyl-8-(2-oxopyrroli din-1 -y1)-5H-chromeno [4,3-c] py ri din-3-y Damino)py ri din-3 -yOcarbamoy1)-6-(4,4,5 ,5 -tetramethy1-1,3,2-di oxaborol an-2-y Obenzyl acetate 0 Ac0 B
[0514] To a mixture of 2-bromo-6-((5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c1pyridin-3-y0amino)pyridin-3-yOcarbamoyObenzyl acetate (80 mg, 0.12 mmol), B2Pin2 (47 mg, 0.19 mmol), KOAc (49 mg, 0.50 mmol) in dioxane (5 mL) was added Pd(dppf)C12 (9 mg, 0.01 mmol) under N2 atmosphere, then the reaction mixture was stirred at 100 C under N2 atmosphere for 2 h to give a brown suspension. LCMS showed the reaction was completed. The mixture was diluted with water (10 mL) and then extracted with Et0Ac (20 mL x2). The combined extracts was washed with brine (25 mL x2), dried over Na2SO4, filtered and concentrated under reduced pressure to give 2-((5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno [4,3-c] py ri din-3 -yl)amino)py ri din-3-yl)carbamoy1)-6-(4,4,5 ,5-tetramethy1-1,3,2-dioxaborolan-2-yObenzyl acetate (80 mg, crude) as a brown solid.
Step 4: Preparation of 1-hy droxy -N-(5 -((5-methyl-8-(2-oxopyrroli din-1 -y1)-chromeno [4,3-c] py ri din-3-y0amino)py ri din-3-y1)-1,3 -dihy drobenzo [c]
[1,2] oxab orol e-4-carboxamide I I
N NHNH
[0515] To a mixture of 2-((5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c] py ri din-3-yl)amino)py ri din-3 -yl)carb amoy1)-6-(4,4,5,5 -tetramethy1-1,3,2-di oxab orol an-2-yl)benzyl acetate (60 mg, 0.087 mmol) in Me0H (20 mL) was added NaOH (7 mg, 0.2 mmol),
Step 3: Preparation of 2-((5 -((5-methyl-8-(2-oxopyrroli din-1 -y1)-5H-chromeno [4,3-c] py ri din-3-y Damino)py ri din-3 -yOcarbamoy1)-6-(4,4,5 ,5 -tetramethy1-1,3,2-di oxaborol an-2-y Obenzyl acetate 0 Ac0 B
[0514] To a mixture of 2-bromo-6-((5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c1pyridin-3-y0amino)pyridin-3-yOcarbamoyObenzyl acetate (80 mg, 0.12 mmol), B2Pin2 (47 mg, 0.19 mmol), KOAc (49 mg, 0.50 mmol) in dioxane (5 mL) was added Pd(dppf)C12 (9 mg, 0.01 mmol) under N2 atmosphere, then the reaction mixture was stirred at 100 C under N2 atmosphere for 2 h to give a brown suspension. LCMS showed the reaction was completed. The mixture was diluted with water (10 mL) and then extracted with Et0Ac (20 mL x2). The combined extracts was washed with brine (25 mL x2), dried over Na2SO4, filtered and concentrated under reduced pressure to give 2-((5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno [4,3-c] py ri din-3 -yl)amino)py ri din-3-yl)carbamoy1)-6-(4,4,5 ,5-tetramethy1-1,3,2-dioxaborolan-2-yObenzyl acetate (80 mg, crude) as a brown solid.
Step 4: Preparation of 1-hy droxy -N-(5 -((5-methyl-8-(2-oxopyrroli din-1 -y1)-chromeno [4,3-c] py ri din-3-y0amino)py ri din-3-y1)-1,3 -dihy drobenzo [c]
[1,2] oxab orol e-4-carboxamide I I
N NHNH
[0515] To a mixture of 2-((5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c] py ri din-3-yl)amino)py ri din-3 -yl)carb amoy1)-6-(4,4,5,5 -tetramethy1-1,3,2-di oxab orol an-2-yl)benzyl acetate (60 mg, 0.087 mmol) in Me0H (20 mL) was added NaOH (7 mg, 0.2 mmol),
220 the reaction mixture was stirred at 40 C for 2 h to give a brown solution.
LCMS (Rt = 0.747 min; MS Calcd: 547.2; MS Found: 548.2 [M+Hr). The mixture was concentrated and the residue was dissolved in Me0H (4 mL). The pH of the mixture was adjusted to 7 with formic acid and standing at 25 C for 16 h. The brown precipitate was filtered and purified by prep-HPLC (0.225% FA as an additive) purification to give 1-hydroxy-N-(5-((5-methy1-8-(2-oxopy rroli din-l-y1)-5H-chromeno [4,3 -c] py ri din-3-yl)amino)py ri din-3-y1)-1,3 -dihydrobenzo[c][1,2]oxaborole-4-carboxamide (2.26 mg, yield: 4% for 2 steps) as a yellow solid.
1FINMR (400 MHz, DMSO-d6) 61.55 (3H, d, J= 6.4 Hz), 2.00-2.12 (2H, m), 2.49-2.52 (2H, m), 3.84 (2H, t, J= 7.6 Hz), 5.25-5.32 (3H, m), 6.78 (1H, s), 7.32 (1H, dd, J=
8.4, 2.0 Hz), 7.40 (1H, d, J= 2.0 Hz), 7.58 (1H, t, J= 7.2 Hz), 7.88 (1H, d, J= 8.8 Hz), 7.97 (1H, d, J=
6.8 Hz), 8.11 (1H, d, J= 7.6 Hz), 8.48 (1H, s), 8.60-8.71 (2H, m), 8.75 (1H, s), 9.33 (1H, brs), 9.56 (1H, brs), 10.51 (1H, brs).
Example 119: 4-fluoro-N-(5-05-methyl-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-yl)benzamide I
NN
Step 1: Preparation of N-(5-bromopy ri din-3 -y1)-4-fluorobenzami de I
BrN
[0516] A
mixture of 4-fluorobenzoic acid (267 mg, 1.90 mmol), 5-bromopyridin-3-amine (300 mg, 1.73 mmol) and EDCI.HC1 (365 mg, 1.90 mmol) in pyridine (5 mL) was heated at 50 C for 1 hour. An orange solution was formed. The mixture was concentrated and the residue was poured into water (20 mL) and stirred for 2 minutes. The aqueous layer was extracted with ethyl acetate (20 mL x3). The combined organic layer was washed with water (20 mL x2) and brine (20 mL), dried over anhydrous Na2SO4, filtered and concentrated. The residue was
LCMS (Rt = 0.747 min; MS Calcd: 547.2; MS Found: 548.2 [M+Hr). The mixture was concentrated and the residue was dissolved in Me0H (4 mL). The pH of the mixture was adjusted to 7 with formic acid and standing at 25 C for 16 h. The brown precipitate was filtered and purified by prep-HPLC (0.225% FA as an additive) purification to give 1-hydroxy-N-(5-((5-methy1-8-(2-oxopy rroli din-l-y1)-5H-chromeno [4,3 -c] py ri din-3-yl)amino)py ri din-3-y1)-1,3 -dihydrobenzo[c][1,2]oxaborole-4-carboxamide (2.26 mg, yield: 4% for 2 steps) as a yellow solid.
1FINMR (400 MHz, DMSO-d6) 61.55 (3H, d, J= 6.4 Hz), 2.00-2.12 (2H, m), 2.49-2.52 (2H, m), 3.84 (2H, t, J= 7.6 Hz), 5.25-5.32 (3H, m), 6.78 (1H, s), 7.32 (1H, dd, J=
8.4, 2.0 Hz), 7.40 (1H, d, J= 2.0 Hz), 7.58 (1H, t, J= 7.2 Hz), 7.88 (1H, d, J= 8.8 Hz), 7.97 (1H, d, J=
6.8 Hz), 8.11 (1H, d, J= 7.6 Hz), 8.48 (1H, s), 8.60-8.71 (2H, m), 8.75 (1H, s), 9.33 (1H, brs), 9.56 (1H, brs), 10.51 (1H, brs).
Example 119: 4-fluoro-N-(5-05-methyl-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-yl)benzamide I
NN
Step 1: Preparation of N-(5-bromopy ri din-3 -y1)-4-fluorobenzami de I
BrN
[0516] A
mixture of 4-fluorobenzoic acid (267 mg, 1.90 mmol), 5-bromopyridin-3-amine (300 mg, 1.73 mmol) and EDCI.HC1 (365 mg, 1.90 mmol) in pyridine (5 mL) was heated at 50 C for 1 hour. An orange solution was formed. The mixture was concentrated and the residue was poured into water (20 mL) and stirred for 2 minutes. The aqueous layer was extracted with ethyl acetate (20 mL x3). The combined organic layer was washed with water (20 mL x2) and brine (20 mL), dried over anhydrous Na2SO4, filtered and concentrated. The residue was
221 triturated with pentane/EtOAC (3 mL, 3/1) to give N-(5-bromopyridin-3-y1)-4-fluorobenzamide (230 mg, yield: 44%) as a light yellow solid.
11-1 NMR (400 MHz DMSO-d6) (57.37-7.45 (2H, m), 8.04-8.09 (2H, m), 8.45 (1H, d, J= 2.0 Hz), 8.51 (1H, t, J= 2.1 Hz), 8.91 (1H, d, J= 2.0 Hz), 10.62 (1H, brs).
Step 2: Preparation of 4-fluoro-N-(5-((5 -methyl-8-(2-oxopy rroli din-1 -y1)-5H-chromeno [4,3 -clpyridin-3-y0amino)pyridin-3-y1)benzamide I I
N
[0517] A
mixture of 1-(3-amino-5-methy1-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (60 mg, 0.20 mmol), N-(5-bromopyridin-3-y1)-4-fluorobenzamide (66 mg, 0.22 mmol), Pd2(dba)3 (19 mg, 0.020 mmol), BrettPhos (22 mg, 0.041 mmol), Cs2CO3 (132 mg, 0.406 mmol) in dioxane (3 mL) was degassed and purged with N2 for 3 times.
Then the resulting reaction mixture was heated at 90 C for 15 h under N2 atmosphere. The reaction mixture turned into gray suspension from red suspension. LCMS (Rt = 0.735 min;
MS Calcd:
509.2; MS Found: 510.1 [M+Hl+). The mixture was diluted with water (20 mL) and extracted with Et0Ac/THF (20 mL x2, 1/1). The combined organic layer was washed with water (20 mL
x2), brine (20 mL x2), dried over anhydrous Na2SO4, filtered and concentrated.
The residue was purified by prep-HPLC (0.225% FA as an additive) and lyophilized to give 4-fluoro-N-(5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-y1)benzamide (35.9 mg, yield: 35%) as a yellow solid.
11-1NMR (400 MHz DMSO-d6) (5 1.55 (3H, d, J= 6.5 Hz), 2.01-2.10 (2H, m), 2.52-2.54 (2H, m, overlapped with the peak of DMSO), 3.84 (2H, t, J= 7.4 Hz), 5.28 (1H, q, J=
6.4 Hz), 6.78 (1H, s), 7.32 (1H, dd, J= 8.7, 2.1 Hz), 7.37-7.43 (3H, m), 7.88 (1H, d, J= 8.5 Hz), 8.05 (2H, dd, J= 8.8, 5.5 Hz), 8.49 (1H, s), 8.65-8.70 (3H, m), 9.55 (1H, brs), 10.47 (1H, brs).
Example 120: 3-fluoro-N-(5-05-methyl-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-yl)benzamide
11-1 NMR (400 MHz DMSO-d6) (57.37-7.45 (2H, m), 8.04-8.09 (2H, m), 8.45 (1H, d, J= 2.0 Hz), 8.51 (1H, t, J= 2.1 Hz), 8.91 (1H, d, J= 2.0 Hz), 10.62 (1H, brs).
Step 2: Preparation of 4-fluoro-N-(5-((5 -methyl-8-(2-oxopy rroli din-1 -y1)-5H-chromeno [4,3 -clpyridin-3-y0amino)pyridin-3-y1)benzamide I I
N
[0517] A
mixture of 1-(3-amino-5-methy1-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (60 mg, 0.20 mmol), N-(5-bromopyridin-3-y1)-4-fluorobenzamide (66 mg, 0.22 mmol), Pd2(dba)3 (19 mg, 0.020 mmol), BrettPhos (22 mg, 0.041 mmol), Cs2CO3 (132 mg, 0.406 mmol) in dioxane (3 mL) was degassed and purged with N2 for 3 times.
Then the resulting reaction mixture was heated at 90 C for 15 h under N2 atmosphere. The reaction mixture turned into gray suspension from red suspension. LCMS (Rt = 0.735 min;
MS Calcd:
509.2; MS Found: 510.1 [M+Hl+). The mixture was diluted with water (20 mL) and extracted with Et0Ac/THF (20 mL x2, 1/1). The combined organic layer was washed with water (20 mL
x2), brine (20 mL x2), dried over anhydrous Na2SO4, filtered and concentrated.
The residue was purified by prep-HPLC (0.225% FA as an additive) and lyophilized to give 4-fluoro-N-(5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-y1)benzamide (35.9 mg, yield: 35%) as a yellow solid.
11-1NMR (400 MHz DMSO-d6) (5 1.55 (3H, d, J= 6.5 Hz), 2.01-2.10 (2H, m), 2.52-2.54 (2H, m, overlapped with the peak of DMSO), 3.84 (2H, t, J= 7.4 Hz), 5.28 (1H, q, J=
6.4 Hz), 6.78 (1H, s), 7.32 (1H, dd, J= 8.7, 2.1 Hz), 7.37-7.43 (3H, m), 7.88 (1H, d, J= 8.5 Hz), 8.05 (2H, dd, J= 8.8, 5.5 Hz), 8.49 (1H, s), 8.65-8.70 (3H, m), 9.55 (1H, brs), 10.47 (1H, brs).
Example 120: 3-fluoro-N-(5-05-methyl-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-yl)benzamide
222 rN 0 F
N NN
Step 1: Preparation of N-(5-bromopyridin-3-y1)-3-fluorobenzamide I
BrN F
[0518] A
mixture of 3-fluorobenzoic acid (267 mg, 1.90 mmol), 5-bromopyridin-3-amine (300 mg, 1.73 mmol) and EDCI.HC1 (365 mg, 1.90 mmol) in pyridine (5 mL) was heated at 50 C for 1 hour. An orange solution was formed. The mixture was concentrated and the residue was poured into water (20 mL) and stirred for 2 minutes. The aqueous layer was extracted with ethyl acetate (20 mL x3). The combined organic layer was washed with water (20 mL x2) and brine (20 mL), dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by Combi Flash (30% to 50% Et0Ac in pentane) to give N-(5-bromopyridin-3-y1)-3-fluorobenzamide (400 mg, yield: 78%) as a light yellow solid.
1FINMR (400 MHz DMSO-d6) 67.50 (1H, td, J= 8.3, 2.3 Hz), 7.63 (1H, td, J= 8.0, 5.9 Hz), 7.77-7.86 (2H, m), 8.47 (1H, d, J = 2.0 Hz), 8.51 (1H, t, J= 2.1 Hz), 8.91 (1H, d, J= 2.0 Hz), 10.67 (1H, brs).
Step 2: Preparation of 3 -fluoro-N-(5-45 -methyl-8-(2-oxopy rroli din-l-y1)-5H-chromeno [4,3 -c] pyridin-3-y0amino)pyridin-3 -yl)benzamide I
NN
[0519] A
mixture of 1-(3-amino-5-methy1-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (60 mg, 0.20 mmol), N-(5-bromopyridin-3-y1)-3-fluorobenzamide (66 mg, 0.22 mmol), Pd2(dba)3 (19 mg, 0.020 mmol), BrettPhos (22 mg, 0.041 mmol), Cs2CO3 (132 mg, 0.406 mmol) in anhydrous dioxane (3 mL) was degassed and purged with N2 for 3 times. Then the resulting reaction mixture was heated at 90 C for 12 h under N2 atmosphere. The reaction
N NN
Step 1: Preparation of N-(5-bromopyridin-3-y1)-3-fluorobenzamide I
BrN F
[0518] A
mixture of 3-fluorobenzoic acid (267 mg, 1.90 mmol), 5-bromopyridin-3-amine (300 mg, 1.73 mmol) and EDCI.HC1 (365 mg, 1.90 mmol) in pyridine (5 mL) was heated at 50 C for 1 hour. An orange solution was formed. The mixture was concentrated and the residue was poured into water (20 mL) and stirred for 2 minutes. The aqueous layer was extracted with ethyl acetate (20 mL x3). The combined organic layer was washed with water (20 mL x2) and brine (20 mL), dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by Combi Flash (30% to 50% Et0Ac in pentane) to give N-(5-bromopyridin-3-y1)-3-fluorobenzamide (400 mg, yield: 78%) as a light yellow solid.
1FINMR (400 MHz DMSO-d6) 67.50 (1H, td, J= 8.3, 2.3 Hz), 7.63 (1H, td, J= 8.0, 5.9 Hz), 7.77-7.86 (2H, m), 8.47 (1H, d, J = 2.0 Hz), 8.51 (1H, t, J= 2.1 Hz), 8.91 (1H, d, J= 2.0 Hz), 10.67 (1H, brs).
Step 2: Preparation of 3 -fluoro-N-(5-45 -methyl-8-(2-oxopy rroli din-l-y1)-5H-chromeno [4,3 -c] pyridin-3-y0amino)pyridin-3 -yl)benzamide I
NN
[0519] A
mixture of 1-(3-amino-5-methy1-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (60 mg, 0.20 mmol), N-(5-bromopyridin-3-y1)-3-fluorobenzamide (66 mg, 0.22 mmol), Pd2(dba)3 (19 mg, 0.020 mmol), BrettPhos (22 mg, 0.041 mmol), Cs2CO3 (132 mg, 0.406 mmol) in anhydrous dioxane (3 mL) was degassed and purged with N2 for 3 times. Then the resulting reaction mixture was heated at 90 C for 12 h under N2 atmosphere. The reaction
223 mixture turned into gray suspension from red suspension. LCMS (Rt = 0.735 min;
MS Calcd:
509.2; MS Found: 510.1 [M+Hl+). The mixture was diluted with water (20 mL) and extracted with Et0Ac/THF (20 mL x2, 1/1). The combined organic layer was washed with water (20 mL
x2), brine (20 mL x2), dried over anhydrous Na2SO4, filtered and concentrated.
The residue was purified by prep-HPLC (0.225% FA as an additive) and lyophilized to give 3-fluoro-N-(5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno [4,3 -c] pyridin-3-yl)amino)pyridin-3 -yl)benzamide (28.1 mg, yield: 27%) as a yellow solid.
11-1NMR (400 MHz DMSO-d6) 1.55 (3H, d, J= 6.5 Hz), 2.01-2.10 (2H, m), 2.52-2.54 (2H, m, overlapped with the peak of DMSO), 3.84 (2H, t, J= 7.5 Hz), 5.28 (1H, q, J=
6.4 Hz), 6.78 (1H, s), 7.32 (1H, dd, J= 8.7, 2.1 Hz), 7.41 (1H, d, J= 2.3 Hz), 7.46-7.51 (1H, m), 7.59-7.66 (1H, m), 7.79-7.91 (3H, m), 8.49 (1H, s), 7.65-7.71 (3H, m), 9.53 (1H, brs), 10.50 (1H, brs).
Example 121: 3-methoxy-N-(5-05-methyl-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-yl)benzamide I I
N
Step 1: Preparation of N-(5-bromopyridin-3-y1)-3-methoxybenzamide I
BrN
[0520] A
mixture of 3-methoxybenzoic acid (290 mg, 1.90 mmol), 5-bromopyridin-3-amine (300 mg, 1.73 mmol) and EDCI.HC1 (365 mg, 1.90 mmol) in pyridine (5 mL) was heated at 50 C for 2 h. An orange solution was formed. The mixture was concentrated and the residue was poured into water (20 mL) and stirred for 2 minutes. The aqueous layer was extracted with ethyl acetate (20 mL x3). The combined organic layer was washed with water (20 mL x2) and brine (20 mL), dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by Combi Flash (30% to 50% Et0Ac in pentane) to give N-(5-bromopyridin-3-y1)-3-methoxybenzamide (500 mg, yield: 94%) as a light yellow solid.
MS Calcd:
509.2; MS Found: 510.1 [M+Hl+). The mixture was diluted with water (20 mL) and extracted with Et0Ac/THF (20 mL x2, 1/1). The combined organic layer was washed with water (20 mL
x2), brine (20 mL x2), dried over anhydrous Na2SO4, filtered and concentrated.
The residue was purified by prep-HPLC (0.225% FA as an additive) and lyophilized to give 3-fluoro-N-(5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno [4,3 -c] pyridin-3-yl)amino)pyridin-3 -yl)benzamide (28.1 mg, yield: 27%) as a yellow solid.
11-1NMR (400 MHz DMSO-d6) 1.55 (3H, d, J= 6.5 Hz), 2.01-2.10 (2H, m), 2.52-2.54 (2H, m, overlapped with the peak of DMSO), 3.84 (2H, t, J= 7.5 Hz), 5.28 (1H, q, J=
6.4 Hz), 6.78 (1H, s), 7.32 (1H, dd, J= 8.7, 2.1 Hz), 7.41 (1H, d, J= 2.3 Hz), 7.46-7.51 (1H, m), 7.59-7.66 (1H, m), 7.79-7.91 (3H, m), 8.49 (1H, s), 7.65-7.71 (3H, m), 9.53 (1H, brs), 10.50 (1H, brs).
Example 121: 3-methoxy-N-(5-05-methyl-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-yl)benzamide I I
N
Step 1: Preparation of N-(5-bromopyridin-3-y1)-3-methoxybenzamide I
BrN
[0520] A
mixture of 3-methoxybenzoic acid (290 mg, 1.90 mmol), 5-bromopyridin-3-amine (300 mg, 1.73 mmol) and EDCI.HC1 (365 mg, 1.90 mmol) in pyridine (5 mL) was heated at 50 C for 2 h. An orange solution was formed. The mixture was concentrated and the residue was poured into water (20 mL) and stirred for 2 minutes. The aqueous layer was extracted with ethyl acetate (20 mL x3). The combined organic layer was washed with water (20 mL x2) and brine (20 mL), dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by Combi Flash (30% to 50% Et0Ac in pentane) to give N-(5-bromopyridin-3-y1)-3-methoxybenzamide (500 mg, yield: 94%) as a light yellow solid.
224 11-1NMR (400 MHz DMSO-d6) (53.85 (3H, s), 7.20 (1H, d, J= 7.8 Hz), 7.44-7.58 (3H, m), 8.44 (1H, s), 8.51 (1H, d, J= 2.0 Hz), 8.93 (1H, s), 10.57 (1H, brs).
Step 2: Preparation of 3 -methoxy -N-(5 -((5-methyl-8-(2-oxopyrrolidin-1 -y1)-chromeno [4,3-c] pyridin-3 -yl)amino)pyridin-3-yl)benzamide rN 0 N NN (40 [0521] A
mixture of 1-(3-amino-5-methy1-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (60 mg, 0.20 mmol), N-(5-bromopyridin-3-y1)-3-methoxybenzamide (69 mg, 0.22 mmol), Pd2(dba)3 (19 mg, 0.020 mmol), BrettPhos (22 mg, 0.041 mmol), Cs2CO3 (132 mg, 0.406 mmol) in anhydrous dioxane (3 mL) was degassed and purged with N2 for 3 times.
Then the resulting reaction mixture was heated at 90 C for 14 h under N2 atmosphere. The reaction mixture turned into gray suspension from red suspension. LCMS (Rt = 0.757 min;
MS Calcd:
521.2; MS Found: 522.3 [M+H1+). The mixture was diluted with water (20 mL) and extracted with Et0Ac/THF (20 mL x2, 1/1). The combined organic layer was washed with water (20 mL
x2), brine (20 mL x2), dried over anhydrous Na2SO4, filtered and concentrated.
The residue was purified by prep-HPLC (0.225% FA as an additive) and lyophilized to give 3-methoxy-N-(5 -((5-methy1-8-(2-oxopy rroli din-1-y 0-5H-chromeno [4,3-c] py ridin-3 -y Damino)py ridin-3 -yObenzamide (26.1 mg, yield: 24%) as a yellow solid.
11-1 NMR (400 MHz DMSO-d6) (5 1.55 (3H, d, J= 6.5 Hz), 2.01-2.10 (2H, m), 2.52-2.54 (2H, m, overlapped with the peak of DMSO), 3.84 (2H, t, J= 7.4 Hz), 3.86 (3H, s), 5.29 (1H, q, J
= 6.7 Hz), 6.79 (1H, s), 7.20 (1H, dd, J= 8.2, 1.9 Hz), 7.32 (1H, dd, J= 8.5, 2.3 Hz), 7.41 (1H, d, J= 2.0 Hz), 7.49 (1H, t, J= 7.9 Hz), 7.52-7.54 (1H, m), 7.58 (1H, d, J= 8.0 Hz), 7.89 (1H, d, J= 8.8 Hz), 8.55(1H, d, J= 4.3 Hz), 8.69 (1H, s), 8.73(1H, t, J= 2.0 Hz), 8.76-8.79 (1H, m), 9.67 (1H, brs), 10.52 (1H, brs).
Example 122: 4-methoxy-N-(5-05-methyl-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-yl)benzamide
Step 2: Preparation of 3 -methoxy -N-(5 -((5-methyl-8-(2-oxopyrrolidin-1 -y1)-chromeno [4,3-c] pyridin-3 -yl)amino)pyridin-3-yl)benzamide rN 0 N NN (40 [0521] A
mixture of 1-(3-amino-5-methy1-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (60 mg, 0.20 mmol), N-(5-bromopyridin-3-y1)-3-methoxybenzamide (69 mg, 0.22 mmol), Pd2(dba)3 (19 mg, 0.020 mmol), BrettPhos (22 mg, 0.041 mmol), Cs2CO3 (132 mg, 0.406 mmol) in anhydrous dioxane (3 mL) was degassed and purged with N2 for 3 times.
Then the resulting reaction mixture was heated at 90 C for 14 h under N2 atmosphere. The reaction mixture turned into gray suspension from red suspension. LCMS (Rt = 0.757 min;
MS Calcd:
521.2; MS Found: 522.3 [M+H1+). The mixture was diluted with water (20 mL) and extracted with Et0Ac/THF (20 mL x2, 1/1). The combined organic layer was washed with water (20 mL
x2), brine (20 mL x2), dried over anhydrous Na2SO4, filtered and concentrated.
The residue was purified by prep-HPLC (0.225% FA as an additive) and lyophilized to give 3-methoxy-N-(5 -((5-methy1-8-(2-oxopy rroli din-1-y 0-5H-chromeno [4,3-c] py ridin-3 -y Damino)py ridin-3 -yObenzamide (26.1 mg, yield: 24%) as a yellow solid.
11-1 NMR (400 MHz DMSO-d6) (5 1.55 (3H, d, J= 6.5 Hz), 2.01-2.10 (2H, m), 2.52-2.54 (2H, m, overlapped with the peak of DMSO), 3.84 (2H, t, J= 7.4 Hz), 3.86 (3H, s), 5.29 (1H, q, J
= 6.7 Hz), 6.79 (1H, s), 7.20 (1H, dd, J= 8.2, 1.9 Hz), 7.32 (1H, dd, J= 8.5, 2.3 Hz), 7.41 (1H, d, J= 2.0 Hz), 7.49 (1H, t, J= 7.9 Hz), 7.52-7.54 (1H, m), 7.58 (1H, d, J= 8.0 Hz), 7.89 (1H, d, J= 8.8 Hz), 8.55(1H, d, J= 4.3 Hz), 8.69 (1H, s), 8.73(1H, t, J= 2.0 Hz), 8.76-8.79 (1H, m), 9.67 (1H, brs), 10.52 (1H, brs).
Example 122: 4-methoxy-N-(5-05-methyl-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-yl)benzamide
225 gN 0 =
Step 1: Preparation of N-(5-bromopyridin-3-y1)-4-methoxybenzamide I
BrN
[0522] A
mixture of 4-methoxybenzoic acid (290 mg, 1.90 mmol), 5-bromopyridin-3-amine (300 mg, 1.73 mmol) and EDCI.HC1 (365 mg, 1.90 mmol) in pyridine (5 mL) was heated at 50 C for 1 hour. An orange solution was formed. The mixture was concentrated and the residue was poured into water (20 mL) and stirred for 2 minutes. The aqueous layer was extracted with ethyl acetate (20 mL x3). The combined organic layer was washed with water (20 mL x2) and brine (20 mL), dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by Combi Flash (30% to 50% Et0Ac in pentane) to give N-(5-bromopyridin-3-y1)-4-methoxybenzamide (400 mg, yield: 74%) as a light yellow solid.
11-1 NMR (400 MHz DMSO-d6) 63.85 (3H, s), 7.09 (2H, d, J= 8.8 Hz), 7.98 (2H, d, J= 8.8 Hz), 8.42 (1H, d, J= 1.8 Hz), 8.51-8.53 (1H, m), 8.92 (1H, d, J= 1.8 Hz), 10.44 (1H, brs).
Step 2: Preparation of 4-methoxy-N-(5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno [4,3-c] py ri din-3 -yl)amino)py ri din-3-y Ob enzami de [0523] A
mixture of 1-(3-amino-5-methy1-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (60 mg, 0.20 mmol), N-(5-bromopyridin-3-y1)-4-methoxybenzamide (69 mg, 0.22 mmol), Pd2(dba)3 (19 mg, 0.020 mmol), BrettPhos (22 mg, 0.041 mmol), Cs2CO3 (132 mg, 0.406 mmol) in dioxane (3 mL) was degassed and purged with N2 for 3 times.
Then the resulting reaction mixture was heated at 90 C for 15 h under N2 atmosphere. The reaction
Step 1: Preparation of N-(5-bromopyridin-3-y1)-4-methoxybenzamide I
BrN
[0522] A
mixture of 4-methoxybenzoic acid (290 mg, 1.90 mmol), 5-bromopyridin-3-amine (300 mg, 1.73 mmol) and EDCI.HC1 (365 mg, 1.90 mmol) in pyridine (5 mL) was heated at 50 C for 1 hour. An orange solution was formed. The mixture was concentrated and the residue was poured into water (20 mL) and stirred for 2 minutes. The aqueous layer was extracted with ethyl acetate (20 mL x3). The combined organic layer was washed with water (20 mL x2) and brine (20 mL), dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by Combi Flash (30% to 50% Et0Ac in pentane) to give N-(5-bromopyridin-3-y1)-4-methoxybenzamide (400 mg, yield: 74%) as a light yellow solid.
11-1 NMR (400 MHz DMSO-d6) 63.85 (3H, s), 7.09 (2H, d, J= 8.8 Hz), 7.98 (2H, d, J= 8.8 Hz), 8.42 (1H, d, J= 1.8 Hz), 8.51-8.53 (1H, m), 8.92 (1H, d, J= 1.8 Hz), 10.44 (1H, brs).
Step 2: Preparation of 4-methoxy-N-(5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno [4,3-c] py ri din-3 -yl)amino)py ri din-3-y Ob enzami de [0523] A
mixture of 1-(3-amino-5-methy1-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (60 mg, 0.20 mmol), N-(5-bromopyridin-3-y1)-4-methoxybenzamide (69 mg, 0.22 mmol), Pd2(dba)3 (19 mg, 0.020 mmol), BrettPhos (22 mg, 0.041 mmol), Cs2CO3 (132 mg, 0.406 mmol) in dioxane (3 mL) was degassed and purged with N2 for 3 times.
Then the resulting reaction mixture was heated at 90 C for 15 h under N2 atmosphere. The reaction
226 mixture turned into gray suspension from red suspension. LCMS (Rt = 0.735 min;
MS Calcd:
521.2; MS Found: 521.9 [M+H1+). The mixture was diluted with water (20 mL) and extracted with Et0Ac/THF (20 mL x2, 1/1). The combined organic layer was washed with water (20 mL
x2), brine (20 mL x2), dried over anhydrous Na2SO4, filtered and concentrated.
The residue was purified by prep-HPLC (0.225% FA as an additive) and lyophilized to give 4-methoxy-N-(5 -((5-methy1-8-(2-oxopy rroli din-1-y 0-5H-chromeno [4,3-c] py ridin-3 -y Damino)py ridin-3 -yObenzamide (27.1 mg, yield: 25%) as a yellow solid.
NMR (400 MHz DMSO-d6) 61.55 (3H, d, J= 6.5 Hz), 2.01-2.10 (2H, m), 2.52-2.54 (2H, m, overlapped with the peak of DMSO), 3.84 (2H, t, J= 7.4 Hz), 3.86 (3H, s), 5.29 (1H, q, J
= 6.7 Hz), 6.80 (1H, s), 7.10 (2H, d, J= 8.8 Hz), 7.33 (1H, dd, J= 8.5, 2.3 Hz), 7.41 (1H, d, J
= 2.3 Hz), 7.90 (1H, d, J= 8.8 Hz), 8.01 (2H, d, J= 8.8 Hz), 8.56 (1H, s), 8.69-8.74 (2H, m), 8.77(1H,$), 9.68 (1H, brs), 10.41 (1H, brs).
Example 123: N-(5-05-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-yl)amino)pyridin-3-y1)-1H-indole-4-carboxamide ¨
I I NH
N NN
Step 1: Preparation of N-(5-bromopyridin-3-y1)-1H-indole-4-carboxamide I NH
BrN
[0524] A
mixture of 1H-indole-4-carboxylic acid (307 mg, 1.91 mmol), 5-bromopyridin-3-amine (300 mg, 1.73 mmol) and EDCI.HC1 (366 mg, 1.91 mmol) in pyridine (5 mL) was heated at 50 C for 1 hour. An orange solution was formed. The mixture was concentrated and the residue was poured into water (20 mL) and stirred for 2 minutes. The aqueous layer was extracted with ethyl acetate (20 mL x3).The combined organic layer was washed with water (20 mL x2) and brine (20 mL), dried over anhydrous Na2SO4, filtered and concentrated. The residue was triturated with pentane/EtOAC (3 mL, 3/1) to give N-(5-bromopyridin-3-y1)-1H-indole-4-carboxamide (470 mg, yield: 86%) as a yellow solid.
MS Calcd:
521.2; MS Found: 521.9 [M+H1+). The mixture was diluted with water (20 mL) and extracted with Et0Ac/THF (20 mL x2, 1/1). The combined organic layer was washed with water (20 mL
x2), brine (20 mL x2), dried over anhydrous Na2SO4, filtered and concentrated.
The residue was purified by prep-HPLC (0.225% FA as an additive) and lyophilized to give 4-methoxy-N-(5 -((5-methy1-8-(2-oxopy rroli din-1-y 0-5H-chromeno [4,3-c] py ridin-3 -y Damino)py ridin-3 -yObenzamide (27.1 mg, yield: 25%) as a yellow solid.
NMR (400 MHz DMSO-d6) 61.55 (3H, d, J= 6.5 Hz), 2.01-2.10 (2H, m), 2.52-2.54 (2H, m, overlapped with the peak of DMSO), 3.84 (2H, t, J= 7.4 Hz), 3.86 (3H, s), 5.29 (1H, q, J
= 6.7 Hz), 6.80 (1H, s), 7.10 (2H, d, J= 8.8 Hz), 7.33 (1H, dd, J= 8.5, 2.3 Hz), 7.41 (1H, d, J
= 2.3 Hz), 7.90 (1H, d, J= 8.8 Hz), 8.01 (2H, d, J= 8.8 Hz), 8.56 (1H, s), 8.69-8.74 (2H, m), 8.77(1H,$), 9.68 (1H, brs), 10.41 (1H, brs).
Example 123: N-(5-05-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-yl)amino)pyridin-3-y1)-1H-indole-4-carboxamide ¨
I I NH
N NN
Step 1: Preparation of N-(5-bromopyridin-3-y1)-1H-indole-4-carboxamide I NH
BrN
[0524] A
mixture of 1H-indole-4-carboxylic acid (307 mg, 1.91 mmol), 5-bromopyridin-3-amine (300 mg, 1.73 mmol) and EDCI.HC1 (366 mg, 1.91 mmol) in pyridine (5 mL) was heated at 50 C for 1 hour. An orange solution was formed. The mixture was concentrated and the residue was poured into water (20 mL) and stirred for 2 minutes. The aqueous layer was extracted with ethyl acetate (20 mL x3).The combined organic layer was washed with water (20 mL x2) and brine (20 mL), dried over anhydrous Na2SO4, filtered and concentrated. The residue was triturated with pentane/EtOAC (3 mL, 3/1) to give N-(5-bromopyridin-3-y1)-1H-indole-4-carboxamide (470 mg, yield: 86%) as a yellow solid.
227 1-1-1NMR (400 MHz DMSO-d6) (56.89 (1H, t, J= 2.0 Hz), 7.25 (1H, t, J= 7.7 Hz), 7.52 (1H, t, J= 2.8 Hz), 7.62 (1H, d, J= 6.8 Hz), 7.67 (1H, d, J= 8.3 Hz), 8.43 (1H, d, J= 2.0 Hz), 8.60 (1H, t, J= 2.1 Hz), 8.96 (1H, d, J= 2.3 Hz), 10.58 (1H, brs), 11.45 (1H, brs).
Step 2: Preparation of N-(5-((5 -methyl-8-(2-oxopy rroli din-l-y1)-5H-chromeno [4,3 -c] py ri din-3-y0amino)pyridin-3-y1)-1H-indole-4-carboxamide I N H
N N N
[0525] A
mixture of 1-(3-amino-5-methy1-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (60 mg, 0.20 mmol), N-(5-bromopyridin-3-y1)-1H-indole-4-carboxamide (64 mg, 0.20 mmol), Pd2(dba)3 (19 mg, 0.020 mmol), BrettPhos (22 mg, 0.041 mmol), Cs2CO3 (132 mg, 0.406 mmol) in anhydrous dioxane (3 mL) was degassed and purged with N2 for 3 times. Then the resulting reaction mixture was heated at 90 C for 12 h under N2 atmosphere. The reaction mixture turned into gray suspension from red suspension. LCMS (Rt = 0.721 min;
MS Calcd:
530.2; MS Found: 531.1 [M+H1+). The mixture was diluted with water (20 mL) and extracted with Et0Ac/THF (20 mL x2, 1/1). The combined organic layer was washed with water (20 mL
x2), brine (20 mL x2), dried over anhydrous Na2SO4, filtered and concentrated.
The residue was purified by prep-HPLC (0.225% FA as an additive) and lyophilized to give N-(5-((5-methy1-8-(2-oxopy rroli din-1 -y 0-5H-chromeno [4,3 -c] py ri din-3-y0amino)py ri din-3 -y1)-1H-indole-4-carboxamide (23.6 mg, yield: 22%) as a yellow solid.
1-1-1NMR (400 MHz DMSO-d6) (5 1.56 (3H, d, J= 6.5 Hz), 2.01-2.10 (2H, m), 2.52-2.54 (2H, m, overlapped with the peak of DMSO), 3.84 (2H, t, J= 7.9 Hz), 5.31 (1H, q, J=
6.4 Hz), 6.83 (1H, s), 6.89 (1H, t, J= 2.0 Hz), 7.26 (1H, t, J= 7.8 Hz), 7.33 (1H, dd, J= 8.5, 2.3 Hz), 7.41 (1H, d, J= 2.3 Hz), 7.52(1H, t, J= 2.8 Hz), 7.66(2H, dd, J= 11.7, 7.4 Hz), 7.90 (1H, d, J= 8.8 Hz), 8.64 (1H, s), 8.72 (1H, s), 8.79-8.83 (1H, m), 8.93(1H,$), 9.85 (1H, brs), 10.62 (1H, brs), 11.45 (1H, brs).
Example 124: N-(5-05-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-yl)amino)pyridin-3-y1)-1H-benzo[d]imidazole-4-carboxamide
Step 2: Preparation of N-(5-((5 -methyl-8-(2-oxopy rroli din-l-y1)-5H-chromeno [4,3 -c] py ri din-3-y0amino)pyridin-3-y1)-1H-indole-4-carboxamide I N H
N N N
[0525] A
mixture of 1-(3-amino-5-methy1-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (60 mg, 0.20 mmol), N-(5-bromopyridin-3-y1)-1H-indole-4-carboxamide (64 mg, 0.20 mmol), Pd2(dba)3 (19 mg, 0.020 mmol), BrettPhos (22 mg, 0.041 mmol), Cs2CO3 (132 mg, 0.406 mmol) in anhydrous dioxane (3 mL) was degassed and purged with N2 for 3 times. Then the resulting reaction mixture was heated at 90 C for 12 h under N2 atmosphere. The reaction mixture turned into gray suspension from red suspension. LCMS (Rt = 0.721 min;
MS Calcd:
530.2; MS Found: 531.1 [M+H1+). The mixture was diluted with water (20 mL) and extracted with Et0Ac/THF (20 mL x2, 1/1). The combined organic layer was washed with water (20 mL
x2), brine (20 mL x2), dried over anhydrous Na2SO4, filtered and concentrated.
The residue was purified by prep-HPLC (0.225% FA as an additive) and lyophilized to give N-(5-((5-methy1-8-(2-oxopy rroli din-1 -y 0-5H-chromeno [4,3 -c] py ri din-3-y0amino)py ri din-3 -y1)-1H-indole-4-carboxamide (23.6 mg, yield: 22%) as a yellow solid.
1-1-1NMR (400 MHz DMSO-d6) (5 1.56 (3H, d, J= 6.5 Hz), 2.01-2.10 (2H, m), 2.52-2.54 (2H, m, overlapped with the peak of DMSO), 3.84 (2H, t, J= 7.9 Hz), 5.31 (1H, q, J=
6.4 Hz), 6.83 (1H, s), 6.89 (1H, t, J= 2.0 Hz), 7.26 (1H, t, J= 7.8 Hz), 7.33 (1H, dd, J= 8.5, 2.3 Hz), 7.41 (1H, d, J= 2.3 Hz), 7.52(1H, t, J= 2.8 Hz), 7.66(2H, dd, J= 11.7, 7.4 Hz), 7.90 (1H, d, J= 8.8 Hz), 8.64 (1H, s), 8.72 (1H, s), 8.79-8.83 (1H, m), 8.93(1H,$), 9.85 (1H, brs), 10.62 (1H, brs), 11.45 (1H, brs).
Example 124: N-(5-05-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-yl)amino)pyridin-3-y1)-1H-benzo[d]imidazole-4-carboxamide
228 I NH
NN
[0526] A
mixture of 1-(3-((5 -aminopy ri din-3-yl)amino)-5 -methyl-5H-chromeno [4,3-c]pyridin-8-yl)pyrrolidin-2-one (60 mg, 0.14 mmol, HC1 salt), 1H-benzo[d]imidazole-4-carboxylic acid (57 mg, 0.35 mmol) and EDCI.HC1 (30 mg, 0.16 mmol) in pyridine (2 mL) was heated at 30 C for 12 h. A yellow suspension was formed. LCMS (Rt = 0.586 min; MS
Calcd: 531.2; MS Found: 532.2 [M+H1+). The mixture was concentrated and the residue was poured into water (20 mL) and stirred for 2 minutes. The aqueous layer was extracted with ethyl acetate (20 mL x3). The combined organic layer was washed with water (20 mL x2) and brine (20 mL), dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by prep-HPLC (0.225% FA as an additive) and lyophilized to give N-(5-((5-methyl-8-(2-oxopyrrolidin-1 -y1)-5H-chromeno [4,3 -c] pyridin-3 -yl)amino)pyridin-3-y1)-1H-benzo[d]imidazole-4-carboxamide (41.7 mg, yield: 55%) as a yellow solid.
1FINMR (400 MHz DMSO-d6) (51.56 (3H, d, J= 6.5 Hz), 2.01-2.10 (2H, m), 2.52-2.54 (2H, m, overlapped with the peak of DMSO), 3.84 (2H, t, J= 7.9 Hz), 5.30 (1H, q, J=
6.7 Hz), 6.79 (1H, s), 7.32 (1H, dd, J= 8.7, 2.1 Hz), 7.40 (1H, d, J= 2.3 Hz), 7.47 (1H, t, J= 7.8 Hz), 7.88-7.92 (2H, m), 8.03 (1H, d, J= 7.5 Hz), 8.62 (1H, d, J= 2.0 Hz), 8.66 (1H, s), 8.72 (1H, s), 8.75 (1H, t, J= 2.0 Hz), 8.81 (1H, d, J= 2.0 Hz), 9.72 (1H, brs), 12.06 (1H, brs).
Example 125: N-(5-05-methyl-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-yl)amino)pyridin-3-yl)pyridazine-4-carboxamide I I
N NNt, N
H I I
N
Step 1: Preparation of N-(5-bromopyridin-3-yl)pyridazine-4-carboxamide
NN
[0526] A
mixture of 1-(3-((5 -aminopy ri din-3-yl)amino)-5 -methyl-5H-chromeno [4,3-c]pyridin-8-yl)pyrrolidin-2-one (60 mg, 0.14 mmol, HC1 salt), 1H-benzo[d]imidazole-4-carboxylic acid (57 mg, 0.35 mmol) and EDCI.HC1 (30 mg, 0.16 mmol) in pyridine (2 mL) was heated at 30 C for 12 h. A yellow suspension was formed. LCMS (Rt = 0.586 min; MS
Calcd: 531.2; MS Found: 532.2 [M+H1+). The mixture was concentrated and the residue was poured into water (20 mL) and stirred for 2 minutes. The aqueous layer was extracted with ethyl acetate (20 mL x3). The combined organic layer was washed with water (20 mL x2) and brine (20 mL), dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by prep-HPLC (0.225% FA as an additive) and lyophilized to give N-(5-((5-methyl-8-(2-oxopyrrolidin-1 -y1)-5H-chromeno [4,3 -c] pyridin-3 -yl)amino)pyridin-3-y1)-1H-benzo[d]imidazole-4-carboxamide (41.7 mg, yield: 55%) as a yellow solid.
1FINMR (400 MHz DMSO-d6) (51.56 (3H, d, J= 6.5 Hz), 2.01-2.10 (2H, m), 2.52-2.54 (2H, m, overlapped with the peak of DMSO), 3.84 (2H, t, J= 7.9 Hz), 5.30 (1H, q, J=
6.7 Hz), 6.79 (1H, s), 7.32 (1H, dd, J= 8.7, 2.1 Hz), 7.40 (1H, d, J= 2.3 Hz), 7.47 (1H, t, J= 7.8 Hz), 7.88-7.92 (2H, m), 8.03 (1H, d, J= 7.5 Hz), 8.62 (1H, d, J= 2.0 Hz), 8.66 (1H, s), 8.72 (1H, s), 8.75 (1H, t, J= 2.0 Hz), 8.81 (1H, d, J= 2.0 Hz), 9.72 (1H, brs), 12.06 (1H, brs).
Example 125: N-(5-05-methyl-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-yl)amino)pyridin-3-yl)pyridazine-4-carboxamide I I
N NNt, N
H I I
N
Step 1: Preparation of N-(5-bromopyridin-3-yl)pyridazine-4-carboxamide
229 Br N N
I I
[0527] A
mixture of pyridazine-4-carboxylic acid (236 mg, 1.90 mmol), 5-bromopyridin-3-amine (300 mg, 1.73 mmol) and EDCI.HC1 (365 mg, 1.90 mmol) in pyridine (5 mL) was heated at 50 C for 1 hour. A brown solution was formed. The mixture was concentrated and the residue was poured into water (20 mL) and stirred for 2 minutes. The aqueous layer was extracted with Et0Ac (20 mL x3).The combined organic layer was washed with water (20 mL
x2) and brine (20 mL), dried over anhydrous Na2SO4, filtered and concentrated.
The residue was triturated with pentane/EtOAC (3 mL, 3/1) to give N-(5-bromopyridin-3-yl)pyridazine-4-carboxamide (400 mg, yield: 74%) as a yellow solid.
11-1 NMR (400 MHz DMSO-d6) (58.14 (1H, dd, J= 5.4, 2.4 Hz), 8.48-8.53 (2H, m), 8.89 (1H, d, J = 2.0 Hz), 9.55 (1H, dd, J = 5.4, 1.1 Hz), 9.66 (1H, dd, J= 2.3, 1.3 Hz), 11.08 (1H, brs).
Step 2: Preparation of N-(5-((5 -methyl-8-(2-oxopy rroli din-l-y1)-5H-chromeno [4,3 -c] py ri din-3 -yl)amino)pyridin-3-yl)pyridazine-4-carboxamide N N N N
H I I
[0528] A
mixture of 1-(3-amino-5-methy1-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (60 mg, 0.20 mmol), N-(5-bromopyridin-3-yl)pyridazine-4-carboxamide (113 mg, 0.406 mmol), Pd2(dba)3 (19 mg, 0.020 mmol), BrettPhos (22 mg, 0.041 mmol), Cs2CO3 (132 mg, 0.406 mmol) in anhydrous dioxane (3 mL) was degassed and purged with N2 for 3 times. Then the resulting reaction mixture was heated at 90 C for 14 h under N2 atmosphere. The reaction mixture turned into gray suspension from red suspension. LCMS (Rt = 0.579 min;
MS Calcd:
493.2; MS Found: 494.2 [M+H1+). The mixture was diluted with water (20 mL) and extracted with Et0Ac/THF (20 mL x2, 1/1). The combined organic layer was washed with water (20 mL
x2), brine (20 mL x2), dried over anhydrous Na2SO4, filtered and concentrated.
The residue was purified by prep-HPLC (0.225% FA as an additive) and lyophilized to give N-(5-((5-methy1-8-(2-oxopy rroli din-1 -y 0-5H-chromeno [4,3 -c] py ri din-3-yl)amino)py ri din-3 -yl)pyridazine-4-carboxamide (19.4 mg, yield: 19%) as a yellow solid.
I I
[0527] A
mixture of pyridazine-4-carboxylic acid (236 mg, 1.90 mmol), 5-bromopyridin-3-amine (300 mg, 1.73 mmol) and EDCI.HC1 (365 mg, 1.90 mmol) in pyridine (5 mL) was heated at 50 C for 1 hour. A brown solution was formed. The mixture was concentrated and the residue was poured into water (20 mL) and stirred for 2 minutes. The aqueous layer was extracted with Et0Ac (20 mL x3).The combined organic layer was washed with water (20 mL
x2) and brine (20 mL), dried over anhydrous Na2SO4, filtered and concentrated.
The residue was triturated with pentane/EtOAC (3 mL, 3/1) to give N-(5-bromopyridin-3-yl)pyridazine-4-carboxamide (400 mg, yield: 74%) as a yellow solid.
11-1 NMR (400 MHz DMSO-d6) (58.14 (1H, dd, J= 5.4, 2.4 Hz), 8.48-8.53 (2H, m), 8.89 (1H, d, J = 2.0 Hz), 9.55 (1H, dd, J = 5.4, 1.1 Hz), 9.66 (1H, dd, J= 2.3, 1.3 Hz), 11.08 (1H, brs).
Step 2: Preparation of N-(5-((5 -methyl-8-(2-oxopy rroli din-l-y1)-5H-chromeno [4,3 -c] py ri din-3 -yl)amino)pyridin-3-yl)pyridazine-4-carboxamide N N N N
H I I
[0528] A
mixture of 1-(3-amino-5-methy1-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (60 mg, 0.20 mmol), N-(5-bromopyridin-3-yl)pyridazine-4-carboxamide (113 mg, 0.406 mmol), Pd2(dba)3 (19 mg, 0.020 mmol), BrettPhos (22 mg, 0.041 mmol), Cs2CO3 (132 mg, 0.406 mmol) in anhydrous dioxane (3 mL) was degassed and purged with N2 for 3 times. Then the resulting reaction mixture was heated at 90 C for 14 h under N2 atmosphere. The reaction mixture turned into gray suspension from red suspension. LCMS (Rt = 0.579 min;
MS Calcd:
493.2; MS Found: 494.2 [M+H1+). The mixture was diluted with water (20 mL) and extracted with Et0Ac/THF (20 mL x2, 1/1). The combined organic layer was washed with water (20 mL
x2), brine (20 mL x2), dried over anhydrous Na2SO4, filtered and concentrated.
The residue was purified by prep-HPLC (0.225% FA as an additive) and lyophilized to give N-(5-((5-methy1-8-(2-oxopy rroli din-1 -y 0-5H-chromeno [4,3 -c] py ri din-3-yl)amino)py ri din-3 -yl)pyridazine-4-carboxamide (19.4 mg, yield: 19%) as a yellow solid.
230 1-1-1NMR (400 MHz DMSO-d6) (51.55 (3H, d, J= 6.8 Hz), 2.01-2.10 (2H, m), 2.52-2.54 (2H, m, overlapped with the peak of DMSO), 3.84 (2H, t, J= 7.5 Hz), 5.29 (1H, q, J=
6.4 Hz), 6.78 (1H, s), 7.33 (1H, dd, J= 8.5, 2.0 Hz), 7.41 (1H, d, J= 2.3 Hz), 7.89 (1H, d, J= 8.8 Hz), 8.16 (1H, dd, J= 5.3, 2.3 Hz), 8.51 (1H, s), 8.66-8.74 (3H, m), 9.53 (1H, d, J= 5.3 Hz), 9.61 (1H, s), 9.68 (1H, brs), 10.92 (1H, brs).
Example 126: 6-amino-N-(5-45-methyl-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-yl)pyrazine-2-carboxamide C, 0 [0529] A
mixture of 1-(3-((5 -aminopy ri din-3-y Damino)-5 -methyl-5H-chromeno [4,3-clpyridin-8-yOpyrrolidin-2-one (60 mg, 0.14 mmol, HC1 salt), 6-aminopyrazine-2-carboxylic acid (24 mg, 0.17 mmol) and EDCI.HC1 (30 mg, 0.16 mmol) in pyridine (2 mL) was heated at 50 C for 2 h. A black solution was formed. LCMS (Rt = 0.687 min; MS Calcd:
508.2; MS
Found: 509.1 [M+Hl+). The mixture was concentrated and the residue was poured into water (20 mL) and stirred for 2 minutes. The aqueous layer was extracted with ethyl acetate (20 mL
x3). The combined organic layer was washed with water (20 mL x2) and brine (20 mL), dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by prep-HPLC
(0.225% FA as an additive) and lyophilized to give 6-amino-N-(5-((5-methy1-8-(2-oxopy rroli din-l-y1)-5H-chromeno [4,3 -c] py ri din-3-yl)amino)py ri din-3-yl)py razine-2-carboxamide (23.5 mg, yield: 32%) as a yellow solid.
11-1NMR (400 MHz DMSO-d6) 61.55 (3H, d, J= 6.5 Hz), 2.01-2.10 (2H, m), 2.52-2.54 (2H, m, overlapped with the peak of DMSO), 3.84 (2H, t, J= 7.7 Hz), 5.30 (1H, q, J=
6.4 Hz), 6.80 (1H, s), 6.82 (2H, brs), 7.33 (1H, dd, J= 8.7, 2.1 Hz), 7.41 (1H, d, J=
2.3 Hz), 7.90(1H, d, J= 8.8 Hz), 8.15 (1H, s), 8.36 (1H, s), 8.55 (1H, s), 8.70 (1H, s), 8.76-8.83 (2H, m), 9.71 (1H, brs), 10.46 (1H, brs).
Example 127: 1-(5-methyl-3-(pyridazin-4-ylamino)-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one
6.4 Hz), 6.78 (1H, s), 7.33 (1H, dd, J= 8.5, 2.0 Hz), 7.41 (1H, d, J= 2.3 Hz), 7.89 (1H, d, J= 8.8 Hz), 8.16 (1H, dd, J= 5.3, 2.3 Hz), 8.51 (1H, s), 8.66-8.74 (3H, m), 9.53 (1H, d, J= 5.3 Hz), 9.61 (1H, s), 9.68 (1H, brs), 10.92 (1H, brs).
Example 126: 6-amino-N-(5-45-methyl-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-yl)pyrazine-2-carboxamide C, 0 [0529] A
mixture of 1-(3-((5 -aminopy ri din-3-y Damino)-5 -methyl-5H-chromeno [4,3-clpyridin-8-yOpyrrolidin-2-one (60 mg, 0.14 mmol, HC1 salt), 6-aminopyrazine-2-carboxylic acid (24 mg, 0.17 mmol) and EDCI.HC1 (30 mg, 0.16 mmol) in pyridine (2 mL) was heated at 50 C for 2 h. A black solution was formed. LCMS (Rt = 0.687 min; MS Calcd:
508.2; MS
Found: 509.1 [M+Hl+). The mixture was concentrated and the residue was poured into water (20 mL) and stirred for 2 minutes. The aqueous layer was extracted with ethyl acetate (20 mL
x3). The combined organic layer was washed with water (20 mL x2) and brine (20 mL), dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by prep-HPLC
(0.225% FA as an additive) and lyophilized to give 6-amino-N-(5-((5-methy1-8-(2-oxopy rroli din-l-y1)-5H-chromeno [4,3 -c] py ri din-3-yl)amino)py ri din-3-yl)py razine-2-carboxamide (23.5 mg, yield: 32%) as a yellow solid.
11-1NMR (400 MHz DMSO-d6) 61.55 (3H, d, J= 6.5 Hz), 2.01-2.10 (2H, m), 2.52-2.54 (2H, m, overlapped with the peak of DMSO), 3.84 (2H, t, J= 7.7 Hz), 5.30 (1H, q, J=
6.4 Hz), 6.80 (1H, s), 6.82 (2H, brs), 7.33 (1H, dd, J= 8.7, 2.1 Hz), 7.41 (1H, d, J=
2.3 Hz), 7.90(1H, d, J= 8.8 Hz), 8.15 (1H, s), 8.36 (1H, s), 8.55 (1H, s), 8.70 (1H, s), 8.76-8.83 (2H, m), 9.71 (1H, brs), 10.46 (1H, brs).
Example 127: 1-(5-methyl-3-(pyridazin-4-ylamino)-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one
231 N NH
[0530] A
mixture of 1-(3 -chloro-5 -methyl-5H-chromeno [4,3-c] py ri din-8-yl)py rroli din-2-one (80 mg, 0.25 mmol), pyridazin-4-amine (29 mg, 0.31 mmol), Pd2(dba)3 (23 mg, 0.025 mmol), BrettPhos (27 mg, 0.051 mmol), Cs2CO3 (166 mg, 0.508 mmol) in anhydrous dioxane (3 mL) was degassed and purged with N2 for 3 times. Then the resulting reaction mixture was heated at 90 C for 16 h under N2 atmosphere. The reaction mixture turned into gray suspension from red suspension. LCMS (Rt = 0.687 min; MS Calcd: 373.2; MS
Found: 374.1 [M+H]+). The mixture was diluted with water (20 mL) and extracted with Et0Ac (25 mL x2).
The combined organic layer was washed with brine (30 mL x2), dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by prep-HPLC (0.225% FA as an additive) and lyophilized to give 1-(5-methy1-3-(pyridazin-4-ylamino)-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (19.6 mg, yield: 21%) as a yellow solid.
11-1 NMR (400 MHz DMSO-d6) 61.55 (3H, d, J= 6.5 Hz), 2.01-2.10 (2H, m), 2.52-2.54 (2H, m, overlapped with the peak of DMSO), 3.85 (2H, t, J= 7.5 Hz), 5.33 (1H, q, J=
6.5 Hz), 6.86 (1H, s), 7.34 (1H, dd, J= 8.7, 2.2 Hz), 7.43 (1H, d, J= 2.2 Hz), 7.93 (1H, d, J= 8.6 Hz), 8.12-8.17 (1H, m), 8.79 (1H, s), 8.87 (1H, d, J= 6.1 Hz), 9.29 (1H, d, J= 2.2 Hz), 10.07 (1H, brs).
Example 128: 1-(5-methyl-3-(pyridazin-3-ylamino)-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one NN;
N NH
[0531] A
mixture of 1-(3 -chloro-5 -methyl-5H-chromeno [4,3-c] py ri din-8-yl)py rroli din-2-one (80 mg, 0.25 mmol), pyridazin-3-amine (29 mg, 0.31 mmol), Pd2(dba)3 (23 mg, 0.025 mmol), BrettPhos (27 mg, 0.051 mmol), Cs2CO3 (166 mg, 0.508 mmol) in anhydrous dioxane (3 mL) was degassed and purged with N2 for 3 times. Then the resulting reaction mixture was heated at 90 C for 16 h under N2 atmosphere. The reaction mixture turned into gray suspension from red suspension. LCMS (Rt = 0.666 min; MS Calcd: 373.2; MS
Found: 374.0
[0530] A
mixture of 1-(3 -chloro-5 -methyl-5H-chromeno [4,3-c] py ri din-8-yl)py rroli din-2-one (80 mg, 0.25 mmol), pyridazin-4-amine (29 mg, 0.31 mmol), Pd2(dba)3 (23 mg, 0.025 mmol), BrettPhos (27 mg, 0.051 mmol), Cs2CO3 (166 mg, 0.508 mmol) in anhydrous dioxane (3 mL) was degassed and purged with N2 for 3 times. Then the resulting reaction mixture was heated at 90 C for 16 h under N2 atmosphere. The reaction mixture turned into gray suspension from red suspension. LCMS (Rt = 0.687 min; MS Calcd: 373.2; MS
Found: 374.1 [M+H]+). The mixture was diluted with water (20 mL) and extracted with Et0Ac (25 mL x2).
The combined organic layer was washed with brine (30 mL x2), dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by prep-HPLC (0.225% FA as an additive) and lyophilized to give 1-(5-methy1-3-(pyridazin-4-ylamino)-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (19.6 mg, yield: 21%) as a yellow solid.
11-1 NMR (400 MHz DMSO-d6) 61.55 (3H, d, J= 6.5 Hz), 2.01-2.10 (2H, m), 2.52-2.54 (2H, m, overlapped with the peak of DMSO), 3.85 (2H, t, J= 7.5 Hz), 5.33 (1H, q, J=
6.5 Hz), 6.86 (1H, s), 7.34 (1H, dd, J= 8.7, 2.2 Hz), 7.43 (1H, d, J= 2.2 Hz), 7.93 (1H, d, J= 8.6 Hz), 8.12-8.17 (1H, m), 8.79 (1H, s), 8.87 (1H, d, J= 6.1 Hz), 9.29 (1H, d, J= 2.2 Hz), 10.07 (1H, brs).
Example 128: 1-(5-methyl-3-(pyridazin-3-ylamino)-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one NN;
N NH
[0531] A
mixture of 1-(3 -chloro-5 -methyl-5H-chromeno [4,3-c] py ri din-8-yl)py rroli din-2-one (80 mg, 0.25 mmol), pyridazin-3-amine (29 mg, 0.31 mmol), Pd2(dba)3 (23 mg, 0.025 mmol), BrettPhos (27 mg, 0.051 mmol), Cs2CO3 (166 mg, 0.508 mmol) in anhydrous dioxane (3 mL) was degassed and purged with N2 for 3 times. Then the resulting reaction mixture was heated at 90 C for 16 h under N2 atmosphere. The reaction mixture turned into gray suspension from red suspension. LCMS (Rt = 0.666 min; MS Calcd: 373.2; MS
Found: 374.0
232 [M+H1+). The mixture was diluted with water (20 mL) and extracted with Et0Ac (20 mL x2).
The combined organic layer was washed with brine (20 mL x2), dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by prep-HPLC (0.225% FA as an additive) and lyophilized to give 1-(5-methy1-3-(pyridazin-3-ylamino)-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (31.4 mg, yield: 33%) as a yellow solid.
11-1NMR (400 MHz DMSO-d6) 1.55 (3H, d, J= 6.5 Hz), 2.01-2.10 (2H, m), 2.52-2.54 (2H, m, overlapped with the peak of DMSO), 3.82-3.89 (2H, m), 5.38 (1H, q, J= 6.4 Hz), 7.36 (1H, dd, J= 8.7, 2.1 Hz), 7.42 (1H, d, J= 2.3 Hz), 7.61-7.68 (2H, m), 7.93 (1H, d, J= 8.5 Hz), 8.02-8.07 (1H, m), 8.76 (1H, s), 8.82 (1H, d, J= 4.3 Hz), 10.51 (1H, brs).
Example 129: N-(5-05-methyl-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-yl)amino)pyridazin-3-yl)acetamide 0 N, I
N N N
Step 1: Preparation of 5 -chloropyridazin-3 -amine N, [0532] A
mixture of 3,5-dichloropyridazine(1.00 g, 6.71 mmol) and liquid NH3 was stirred in a sealed tube for 12 h. A black residue was formed. The residue was purified by Combi Flash (50% to 100% Et0Ac in pentane) to give 5-chloropyridazin-3-amine (400 mg, yield: 44%) as a yellow solid.
11-1NMR (400 MHz DMSO-d6) (56.66 (1H, d, J= 2.3 Hz), 6.84 (2H, brs), 8.50 (1H, d, J= 2.3 Hz).
Step 2: Preparation of N-(5 -chloropy ridazin-3-yl)acetamide N, CI N
[0533] To a solution of 5-chloropyridazin-3-amine (100 mg, 0.772 mmol) and in pyridine (2 mL) was added acetyl chloride (91 mg, 1.2 mmol) dropwise at 30 C. The mixture was
The combined organic layer was washed with brine (20 mL x2), dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by prep-HPLC (0.225% FA as an additive) and lyophilized to give 1-(5-methy1-3-(pyridazin-3-ylamino)-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (31.4 mg, yield: 33%) as a yellow solid.
11-1NMR (400 MHz DMSO-d6) 1.55 (3H, d, J= 6.5 Hz), 2.01-2.10 (2H, m), 2.52-2.54 (2H, m, overlapped with the peak of DMSO), 3.82-3.89 (2H, m), 5.38 (1H, q, J= 6.4 Hz), 7.36 (1H, dd, J= 8.7, 2.1 Hz), 7.42 (1H, d, J= 2.3 Hz), 7.61-7.68 (2H, m), 7.93 (1H, d, J= 8.5 Hz), 8.02-8.07 (1H, m), 8.76 (1H, s), 8.82 (1H, d, J= 4.3 Hz), 10.51 (1H, brs).
Example 129: N-(5-05-methyl-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-yl)amino)pyridazin-3-yl)acetamide 0 N, I
N N N
Step 1: Preparation of 5 -chloropyridazin-3 -amine N, [0532] A
mixture of 3,5-dichloropyridazine(1.00 g, 6.71 mmol) and liquid NH3 was stirred in a sealed tube for 12 h. A black residue was formed. The residue was purified by Combi Flash (50% to 100% Et0Ac in pentane) to give 5-chloropyridazin-3-amine (400 mg, yield: 44%) as a yellow solid.
11-1NMR (400 MHz DMSO-d6) (56.66 (1H, d, J= 2.3 Hz), 6.84 (2H, brs), 8.50 (1H, d, J= 2.3 Hz).
Step 2: Preparation of N-(5 -chloropy ridazin-3-yl)acetamide N, CI N
[0533] To a solution of 5-chloropyridazin-3-amine (100 mg, 0.772 mmol) and in pyridine (2 mL) was added acetyl chloride (91 mg, 1.2 mmol) dropwise at 30 C. The mixture was
233 stirred at 30 C for 2 h, and a red solution was formed. The mixture was diluted with water (20 mL) and extracted with Et0Ac (20 mL x3). The combined organic layer was washed with water (20 mL x2), brine (20 mL), dried over anhydrous Na2SO4, filtered and concentrated.
The residue was purified by Combi Flash (50% to 100% Et0Ac in pentane) to give N-(5-chloropyridazin-3-yl)acetamide (30 mg, yield: 23%) as a white solid.
11-1NMR (400 MHz DMSO-d6) 62.15 (3H, s), 8.07 (1H, d, J= 2.3 Hz), 9.13 (1H, d, J= 2.0 Hz), Step 3: Preparation of N-(5-((5 -methyl-8-(2-oxopy rroli din-l-y1)-5H-chromeno [4,3 -c] py ri din-3-y Damino)py ri dazin-3 -y0acetami de 0 N, LNNHNHJL
[0534] A
mixture of 1-(3-amino-5-methy1-5H-chromeno [4,3-clpyridin-8-yOpyrrolidin-2-one (40 mg, 0.14 mmol), N-(5-chloropyridazin-3-yl)acetamide (26 mg, 0.15 mmol), Pd2(dba)3 (12 mg, 0.014 mmol), BrettPhos (15 mg, 0.027 mmol), Cs2CO3 (88 mg, 0.27 mmol) in anhydrous dioxane (3 mL) was degassed and purged with N2 for 3 times. Then the resulting reaction mixture was heated at 90 C for 14 h under N2 atmosphere. The reaction mixture turned into gray suspension from red suspension. LCMS (Rt = 0.674 min; MS
Calcd: 430.2;
MS Found: 431.1 [M+H1+). The mixture was diluted with water (20 mL) and extracted with Et0Ac/THF (20 mL x2, 1/1). The combined organic layer was washed with water (20 mL
x2), brine (20 mL x2), dried over anhydrous Na2SO4, filtered and concentrated.
The residue was purified by prep-HPLC (0.225% FA as an additive) and lyophilized to give N-(5-((5-methy1-8-(2-oxopy rroli din-1 -y 0-5H-chromeno [4,3 -c] py ri din-3-yl)amino)py ri dazin-3-yl)acetamide (14.4 mg, yield: 25%) as a yellow solid.
11-1NMR (400 MHz DMSO-d6) (5 1.55 (3H, d, J= 6.5 Hz), 2.01-2.09 (2H, m), 2.18 (3H, s), 2.52-2.54 (2H, m, overlapped with the peak of DMSO), 3.85 (2H, t, J= 7.9 Hz), 5.38 (1H, q, J= 6.4 Hz), 7.37 (1H, dd, J= 8.5, 2.0 Hz), 7.42 (1H, d, J= 1.8 Hz), 7.46 (1H, s), 7.93 (1H, d, J= 8.5 Hz), 8.37 (1H, d, J= 2.3 Hz), 8.76-8.81 (2H, m), 10.74-11.07 (2H, m).
Example 130: 1-(5-methyl-3-((5-(pyridin-2-ylamino)pyridin-3-yl)amino)-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one
The residue was purified by Combi Flash (50% to 100% Et0Ac in pentane) to give N-(5-chloropyridazin-3-yl)acetamide (30 mg, yield: 23%) as a white solid.
11-1NMR (400 MHz DMSO-d6) 62.15 (3H, s), 8.07 (1H, d, J= 2.3 Hz), 9.13 (1H, d, J= 2.0 Hz), Step 3: Preparation of N-(5-((5 -methyl-8-(2-oxopy rroli din-l-y1)-5H-chromeno [4,3 -c] py ri din-3-y Damino)py ri dazin-3 -y0acetami de 0 N, LNNHNHJL
[0534] A
mixture of 1-(3-amino-5-methy1-5H-chromeno [4,3-clpyridin-8-yOpyrrolidin-2-one (40 mg, 0.14 mmol), N-(5-chloropyridazin-3-yl)acetamide (26 mg, 0.15 mmol), Pd2(dba)3 (12 mg, 0.014 mmol), BrettPhos (15 mg, 0.027 mmol), Cs2CO3 (88 mg, 0.27 mmol) in anhydrous dioxane (3 mL) was degassed and purged with N2 for 3 times. Then the resulting reaction mixture was heated at 90 C for 14 h under N2 atmosphere. The reaction mixture turned into gray suspension from red suspension. LCMS (Rt = 0.674 min; MS
Calcd: 430.2;
MS Found: 431.1 [M+H1+). The mixture was diluted with water (20 mL) and extracted with Et0Ac/THF (20 mL x2, 1/1). The combined organic layer was washed with water (20 mL
x2), brine (20 mL x2), dried over anhydrous Na2SO4, filtered and concentrated.
The residue was purified by prep-HPLC (0.225% FA as an additive) and lyophilized to give N-(5-((5-methy1-8-(2-oxopy rroli din-1 -y 0-5H-chromeno [4,3 -c] py ri din-3-yl)amino)py ri dazin-3-yl)acetamide (14.4 mg, yield: 25%) as a yellow solid.
11-1NMR (400 MHz DMSO-d6) (5 1.55 (3H, d, J= 6.5 Hz), 2.01-2.09 (2H, m), 2.18 (3H, s), 2.52-2.54 (2H, m, overlapped with the peak of DMSO), 3.85 (2H, t, J= 7.9 Hz), 5.38 (1H, q, J= 6.4 Hz), 7.37 (1H, dd, J= 8.5, 2.0 Hz), 7.42 (1H, d, J= 1.8 Hz), 7.46 (1H, s), 7.93 (1H, d, J= 8.5 Hz), 8.37 (1H, d, J= 2.3 Hz), 8.76-8.81 (2H, m), 10.74-11.07 (2H, m).
Example 130: 1-(5-methyl-3-((5-(pyridin-2-ylamino)pyridin-3-yl)amino)-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one
234 ,N
I
N
Step 1: Preparation of tert-butyl (5-(pyridin-2-ylamino)pyridin-3-yl)carbamate !N
BocHNNN
[0535] A
mixture of tert-butyl (5-bromopyridin-3-yl)carbamate (300 mg, 1.10 mmol), pyridin-2-amine (124 mg, 1.32 mmol), Pd2(dba)3 (101 mg, 0.110 mmol), BrettPhos (118 mg, 0.220 mmol) and Cs2CO3 (716 mg, 2.20 mmol) in anhydrous dioxane (5 mL) was degassed and purged with N2 for 3 times. Then the resulting reaction mixture was stirred at 90 C for 16 h under N2 atmosphere. The reaction mixture turned into brown suspension from red. LCMS
(Rt = 0.656 min; MS Calcd: 286.1; MS Found: 287.1 [M+H1+). The reaction mixture was diluted with water (25 mL) and extracted with Et0Ac (25 mL x3). The combined organic layer was washed with brine (25 mL), dried over anhydrous Na2SO4 and concentrated.
The residue was purified by Combi Flash (40% to 100% Et0Ac in pentane) to give tert-butyl (5-(pyridin-2-ylamino)pyridin-3-yl)carbamate (163 mg, yield: 52%) as a yellow solid.
11-1NMR (400 MHz, CDC13) (51.53 (9H, s), 6.68(1H, brs), 6.71 (1H, brs), 6.80 (1H, dd, J =
6.8, 5.3 Hz), 6.84 (1H, d, J= 8.3 Hz), 7.54 (1H, ddd, J = 8.5, 7.1, 2.0 Hz), 8.14 (1H, d, J =
2.0 Hz), 8.20-8.26 (2H, m), 8.35 (1H, d, J= 2.0 Hz).
Step 2: Preparation of N3-(pyridin-2-yl)pyridine-3,5-diamine !N
[0536] To a suspension of tert-butyl (5-(pyridin-2-ylamino)pyridin-3-yl)carbamate (163 mg, 0.569 mmol) in Et0Ac (5 mL) was added HC1/Et0Ac (25 mL, 4N in Et0Ac) at 20-25 C.
Then the reaction mixture was stirred at 20-25 C for 2 h. The reaction mixture turned cloudy from yellow solution. The reaction mixture was concentrated and dried under vacuum to give N3-(pyridin-2-yl)pyridine-3,5-diamine (120 mg, yield: 95%, HC1 salt) as a yellow solid.
I
N
Step 1: Preparation of tert-butyl (5-(pyridin-2-ylamino)pyridin-3-yl)carbamate !N
BocHNNN
[0535] A
mixture of tert-butyl (5-bromopyridin-3-yl)carbamate (300 mg, 1.10 mmol), pyridin-2-amine (124 mg, 1.32 mmol), Pd2(dba)3 (101 mg, 0.110 mmol), BrettPhos (118 mg, 0.220 mmol) and Cs2CO3 (716 mg, 2.20 mmol) in anhydrous dioxane (5 mL) was degassed and purged with N2 for 3 times. Then the resulting reaction mixture was stirred at 90 C for 16 h under N2 atmosphere. The reaction mixture turned into brown suspension from red. LCMS
(Rt = 0.656 min; MS Calcd: 286.1; MS Found: 287.1 [M+H1+). The reaction mixture was diluted with water (25 mL) and extracted with Et0Ac (25 mL x3). The combined organic layer was washed with brine (25 mL), dried over anhydrous Na2SO4 and concentrated.
The residue was purified by Combi Flash (40% to 100% Et0Ac in pentane) to give tert-butyl (5-(pyridin-2-ylamino)pyridin-3-yl)carbamate (163 mg, yield: 52%) as a yellow solid.
11-1NMR (400 MHz, CDC13) (51.53 (9H, s), 6.68(1H, brs), 6.71 (1H, brs), 6.80 (1H, dd, J =
6.8, 5.3 Hz), 6.84 (1H, d, J= 8.3 Hz), 7.54 (1H, ddd, J = 8.5, 7.1, 2.0 Hz), 8.14 (1H, d, J =
2.0 Hz), 8.20-8.26 (2H, m), 8.35 (1H, d, J= 2.0 Hz).
Step 2: Preparation of N3-(pyridin-2-yl)pyridine-3,5-diamine !N
[0536] To a suspension of tert-butyl (5-(pyridin-2-ylamino)pyridin-3-yl)carbamate (163 mg, 0.569 mmol) in Et0Ac (5 mL) was added HC1/Et0Ac (25 mL, 4N in Et0Ac) at 20-25 C.
Then the reaction mixture was stirred at 20-25 C for 2 h. The reaction mixture turned cloudy from yellow solution. The reaction mixture was concentrated and dried under vacuum to give N3-(pyridin-2-yl)pyridine-3,5-diamine (120 mg, yield: 95%, HC1 salt) as a yellow solid.
235 1-1-1NMR (400 MHz, DMSO-d6) (56.95 (1H, td, J= 6.2, 0.8 Hz), 7.04 (1H, d, J=
8.5 Hz), 7.61 (1H, d, J= 1.8 Hz), 7.73 (1H, ddd, J= 8.5, 7.0, 1.8 Hz), 7.81 (1H, t, J=
2.1 Hz), 8.25 (1H, dd, J= 5.0, 1.3 Hz), 8.58 (1H, d, J= 1.5 Hz), 10.21 (1H, brs).
Step 3: Preparation of 1-(5 -methyl-3-45 -(py ri din-2-ylamino)py ri din-3-y0amino)-5H-chromeno[4,3-c]pyridin-8-yOpyrrolidin-2-one c 0 N
[0537] A
mixture of 1-(3 -chloro-5-methyl-5H-chromeno [4,3-c] py ri din-8-yl)py rroli din-2-one (60 mg, 0.19 mmol), N3-(pyridin-2-yl)pyridine-3,5-diamine (64 mg, 0.29 mmol, HC1 salt), Pd2(dba)3 (17 mg, 0.019 mmol), BrettPhos (20 mg, 0.038 mmol) and Cs2CO3 (186 mg, 0.572 mmol) in anhydrous dioxane (3 mL) was degassed and purged with N2 for 3 times.
Then the resulting reaction mixture was stirred at 90 C for 16 h under N2 atmosphere.
The reaction mixture turned into yellow suspension from red. LCMS (Rt = 0.718 min; MS
Calcd: 464.2;
MS Found: 465.6 [M+H1+). To the reaction mixture was added water (25 mL), then extracted with Et0Ac (25 mL x3). The combined organic layer was washed with brine (25 mL), dried over anhydrous Na2SO4 and concentrated. The residue was purified by prep-HPLC
(0.225%
FA as an additive). Most of the MeCN was removed under reduced pressure and the remaining part was lyophilized to give 1-(5-methy1-3-45-(pyridin-2-ylamino)pyridin-3-y0amino)-5H-chromeno[4,3-c]pyridin-8-yOpyrrolidin-2-one (24.8 mg, yield: 28%, FA salt) as a yellow solid.
1-1-1NMR (400 MHz, DMSO-d6) (5 1.55 (3H, d, J= 6.5 Hz), 2.01-2.10 (2H, m), 2.52-2.55 (2H, m), 3.84 (2H, t, J= 7.9 Hz), 5.28 (1H, q, J= 6.5 Hz), 6.79 (1H, s), 6.84 (1H, td, J= 6.1, 0.9 Hz), 6.92 (1H, d, J= 8.5 Hz), 7.33 (1H, dd, J= 8.7, 2.1 Hz), 7.40 (1H, d, J=
2.3 Hz), 7.64 (1H, ddd, J= 8.5, 7.0, 2.0 Hz), 7.89 (1H, d, J= 8.8 Hz), 8.14 (0.76H, s, FA
salt), 8.22 (1H, dd, J= 5.0, 1.3 Hz), 8.53 (1H, s), 8.58 (1H, s), 8.64 (1H, t, J= 2.1 Hz), 8.67 (1H, s), 9.38 (1H, brs), 9.54 (1H, brs).
Example 131: 1-(5-methyl-3-((5-(pyridazin-3-ylamino)pyridin-3-yl)amino)-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one
8.5 Hz), 7.61 (1H, d, J= 1.8 Hz), 7.73 (1H, ddd, J= 8.5, 7.0, 1.8 Hz), 7.81 (1H, t, J=
2.1 Hz), 8.25 (1H, dd, J= 5.0, 1.3 Hz), 8.58 (1H, d, J= 1.5 Hz), 10.21 (1H, brs).
Step 3: Preparation of 1-(5 -methyl-3-45 -(py ri din-2-ylamino)py ri din-3-y0amino)-5H-chromeno[4,3-c]pyridin-8-yOpyrrolidin-2-one c 0 N
[0537] A
mixture of 1-(3 -chloro-5-methyl-5H-chromeno [4,3-c] py ri din-8-yl)py rroli din-2-one (60 mg, 0.19 mmol), N3-(pyridin-2-yl)pyridine-3,5-diamine (64 mg, 0.29 mmol, HC1 salt), Pd2(dba)3 (17 mg, 0.019 mmol), BrettPhos (20 mg, 0.038 mmol) and Cs2CO3 (186 mg, 0.572 mmol) in anhydrous dioxane (3 mL) was degassed and purged with N2 for 3 times.
Then the resulting reaction mixture was stirred at 90 C for 16 h under N2 atmosphere.
The reaction mixture turned into yellow suspension from red. LCMS (Rt = 0.718 min; MS
Calcd: 464.2;
MS Found: 465.6 [M+H1+). To the reaction mixture was added water (25 mL), then extracted with Et0Ac (25 mL x3). The combined organic layer was washed with brine (25 mL), dried over anhydrous Na2SO4 and concentrated. The residue was purified by prep-HPLC
(0.225%
FA as an additive). Most of the MeCN was removed under reduced pressure and the remaining part was lyophilized to give 1-(5-methy1-3-45-(pyridin-2-ylamino)pyridin-3-y0amino)-5H-chromeno[4,3-c]pyridin-8-yOpyrrolidin-2-one (24.8 mg, yield: 28%, FA salt) as a yellow solid.
1-1-1NMR (400 MHz, DMSO-d6) (5 1.55 (3H, d, J= 6.5 Hz), 2.01-2.10 (2H, m), 2.52-2.55 (2H, m), 3.84 (2H, t, J= 7.9 Hz), 5.28 (1H, q, J= 6.5 Hz), 6.79 (1H, s), 6.84 (1H, td, J= 6.1, 0.9 Hz), 6.92 (1H, d, J= 8.5 Hz), 7.33 (1H, dd, J= 8.7, 2.1 Hz), 7.40 (1H, d, J=
2.3 Hz), 7.64 (1H, ddd, J= 8.5, 7.0, 2.0 Hz), 7.89 (1H, d, J= 8.8 Hz), 8.14 (0.76H, s, FA
salt), 8.22 (1H, dd, J= 5.0, 1.3 Hz), 8.53 (1H, s), 8.58 (1H, s), 8.64 (1H, t, J= 2.1 Hz), 8.67 (1H, s), 9.38 (1H, brs), 9.54 (1H, brs).
Example 131: 1-(5-methyl-3-((5-(pyridazin-3-ylamino)pyridin-3-yl)amino)-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one
236 N NNN
Step 1: Preparation of tert-butyl (5-(pyridazin-3-ylamino)pyridin-3-yl)carbamate f BocHNNN-N
[0538] A
mixture of tert-butyl (5-bromopyridin-3-yl)carbamate (300 mg, 1.10 mmol), pyridazin-3-amine (125 mg, 1.32 mmol), Pd2(dba)3 (101 mg, 0.110 mmol), BrettPhos (118 mg, 0.220 mmol) and Cs2CO3 (716 mg, 2.20 mmol) in anhydrous dioxane (5 mL) was degassed and purged with N2 for 3 times. Then the resulting reaction mixture was stirred at 90 C for 16 h under N2 atmosphere. The reaction mixture turned into brown suspension from red. The reaction mixture was diluted with water (25 mL) and Et0Ac (25 mL). The solid was filtered and washed with Et0Ac (5 mL x4), then dried under vacuum to give tert-butyl (5-(pyridazin-3-ylamino)pyridin-3-yl)carbamate (310 mg, yield: 98%) as a yellow solid.
11-1NMR (400 MHz, DMSO-d6) 61.50 (9H, s), 7.16 (1H, dd, J= 8.9, 1.4 Hz), 7.48 (1H, dd, J
= 9.0, 4.5 Hz), 8.22 (1H, d, J= 2.0 Hz), 8.43 (1H, t, J= 2.3 Hz), 8.63 (1H, d, J= 2.0 Hz), 8.71(1H, dd, J= 4.5, 1.3 Hz), 9.43 (1H, brs), 9.59 (1H, brs) Step 2: Preparation of N3-(pyridazin-3-yl)pyridine-3,5-diamine ,N
[0539] To a suspension of tert-butyl (5-(pyridazin-3-ylamino)pyridin-3-yl)carbamate (310 mg, 1.08 mmol) in Et0Ac (5 mL) was added 4N HC1/Et0Ac (25 mL) at 20-25 C.
Then the reaction mixture was stirred at 20-25 C for 2 h. The reaction mixture turned cloudy from solution. The reaction mixture was concentrated and dried under vacuum to give N3-(pyridazin-3-yl)pyridine-3,5-diamine (220 mg, yield: 91%, HC1 salt) as a yellow solid.
11-1NMR (400 MHz, DMSO-d6) (57.76 (1H, d, J = 1.8 Hz), 7.82-7.86 (1H, m), 7.90 (1H, t, J
= 2.0 Hz), 7.91-7.96 (1H, m), 8.57 (1H, d, J= 1.5 Hz), 9.02 (1H, dd, J= 4.6, 1.1 Hz), 11.34 (1H, brs).
Step 1: Preparation of tert-butyl (5-(pyridazin-3-ylamino)pyridin-3-yl)carbamate f BocHNNN-N
[0538] A
mixture of tert-butyl (5-bromopyridin-3-yl)carbamate (300 mg, 1.10 mmol), pyridazin-3-amine (125 mg, 1.32 mmol), Pd2(dba)3 (101 mg, 0.110 mmol), BrettPhos (118 mg, 0.220 mmol) and Cs2CO3 (716 mg, 2.20 mmol) in anhydrous dioxane (5 mL) was degassed and purged with N2 for 3 times. Then the resulting reaction mixture was stirred at 90 C for 16 h under N2 atmosphere. The reaction mixture turned into brown suspension from red. The reaction mixture was diluted with water (25 mL) and Et0Ac (25 mL). The solid was filtered and washed with Et0Ac (5 mL x4), then dried under vacuum to give tert-butyl (5-(pyridazin-3-ylamino)pyridin-3-yl)carbamate (310 mg, yield: 98%) as a yellow solid.
11-1NMR (400 MHz, DMSO-d6) 61.50 (9H, s), 7.16 (1H, dd, J= 8.9, 1.4 Hz), 7.48 (1H, dd, J
= 9.0, 4.5 Hz), 8.22 (1H, d, J= 2.0 Hz), 8.43 (1H, t, J= 2.3 Hz), 8.63 (1H, d, J= 2.0 Hz), 8.71(1H, dd, J= 4.5, 1.3 Hz), 9.43 (1H, brs), 9.59 (1H, brs) Step 2: Preparation of N3-(pyridazin-3-yl)pyridine-3,5-diamine ,N
[0539] To a suspension of tert-butyl (5-(pyridazin-3-ylamino)pyridin-3-yl)carbamate (310 mg, 1.08 mmol) in Et0Ac (5 mL) was added 4N HC1/Et0Ac (25 mL) at 20-25 C.
Then the reaction mixture was stirred at 20-25 C for 2 h. The reaction mixture turned cloudy from solution. The reaction mixture was concentrated and dried under vacuum to give N3-(pyridazin-3-yl)pyridine-3,5-diamine (220 mg, yield: 91%, HC1 salt) as a yellow solid.
11-1NMR (400 MHz, DMSO-d6) (57.76 (1H, d, J = 1.8 Hz), 7.82-7.86 (1H, m), 7.90 (1H, t, J
= 2.0 Hz), 7.91-7.96 (1H, m), 8.57 (1H, d, J= 1.5 Hz), 9.02 (1H, dd, J= 4.6, 1.1 Hz), 11.34 (1H, brs).
237 Step 3: Preparation of 1-(5 -methyl-3-45-(py ri dazin-3 -ylamino)py ri din-3-y Damino)-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one I
N
[0540] A
mixture of 1-(3 -chloro-5 -methyl-5H-chromeno [4,3-c] py ri din-8-yl)py rroli din-2-one (60 mg, 0.19 mmol), N3-(pyridazin-3-yl)pyridine-3,5-diamine (64 mg, 0.29 mmol, HC1 salt), Pd2(dba)3 (17 mg, 0.019 mmol), BrettPhos (20 mg, 0.038 mmol) and Cs2CO3 (186 mg, 0.572 mmol) in anhydrous dioxane (3 mL) was degassed and purged with N2 for 3 times. Then the resulting reaction mixture was stirred at 90 C for 16 h under N2 atmosphere. The reaction mixture turned into yellow suspension from red. LCMS (Rt = 0.689 min; MS
Calcd: 465.2;
MS Found: 466.2 [M+Hl+). To the reaction mixture was added water (20 mL) and Et0Ac (20 mL). Then the mixture was filtered and the solid was washed with Et0Ac (5 mL
x2). The crude product was purified by prep-HPLC (0.1% TFA as an additive) Most of the MeCN
was removed under reduced pressure and the remaining part was lyophilized to give 1-(5-methyl-3-45-(py ridazin-3 -ylamino)pyri din-3 -y0amino)-5H-chromeno [4,3 -c] pyri din-8-y Opyrroli din-2-one (3.06 mg, yield: 3.5%, TFA salt) as a yellow solid.
11-1 NMR (400 MHz, DMSO-d6) (51.56 (3H, d, J= 6.3 Hz), 2.02-2.11 (2H, m), 2.53-2.55 (2H, m), 3.85 (2H, t, J= 7.9 Hz), 5.33 (1H, q, J= 6.3 Hz), 6.87 (1H, s), 7.31-7.38 (2H, m), 7.42 (1H, d, J= 2.0 Hz), 7.63 (1H, dd, J= 8.9, 4.4 Hz), 7.93 (1H, d, J = 8.8 Hz), 8.75 (1H, s), 8.83-8.91 (3H, m), 9.02 (1H, brs), 10.23 (2H, brs).
Example 132: N-(5-05-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-yl)amino)pyridin-3-y1)-3-phenylbutanamide I
N
Step 1: Preparation of N-(5 -bromopyridin-3-y1)-3-phenylbutanami de
N
[0540] A
mixture of 1-(3 -chloro-5 -methyl-5H-chromeno [4,3-c] py ri din-8-yl)py rroli din-2-one (60 mg, 0.19 mmol), N3-(pyridazin-3-yl)pyridine-3,5-diamine (64 mg, 0.29 mmol, HC1 salt), Pd2(dba)3 (17 mg, 0.019 mmol), BrettPhos (20 mg, 0.038 mmol) and Cs2CO3 (186 mg, 0.572 mmol) in anhydrous dioxane (3 mL) was degassed and purged with N2 for 3 times. Then the resulting reaction mixture was stirred at 90 C for 16 h under N2 atmosphere. The reaction mixture turned into yellow suspension from red. LCMS (Rt = 0.689 min; MS
Calcd: 465.2;
MS Found: 466.2 [M+Hl+). To the reaction mixture was added water (20 mL) and Et0Ac (20 mL). Then the mixture was filtered and the solid was washed with Et0Ac (5 mL
x2). The crude product was purified by prep-HPLC (0.1% TFA as an additive) Most of the MeCN
was removed under reduced pressure and the remaining part was lyophilized to give 1-(5-methyl-3-45-(py ridazin-3 -ylamino)pyri din-3 -y0amino)-5H-chromeno [4,3 -c] pyri din-8-y Opyrroli din-2-one (3.06 mg, yield: 3.5%, TFA salt) as a yellow solid.
11-1 NMR (400 MHz, DMSO-d6) (51.56 (3H, d, J= 6.3 Hz), 2.02-2.11 (2H, m), 2.53-2.55 (2H, m), 3.85 (2H, t, J= 7.9 Hz), 5.33 (1H, q, J= 6.3 Hz), 6.87 (1H, s), 7.31-7.38 (2H, m), 7.42 (1H, d, J= 2.0 Hz), 7.63 (1H, dd, J= 8.9, 4.4 Hz), 7.93 (1H, d, J = 8.8 Hz), 8.75 (1H, s), 8.83-8.91 (3H, m), 9.02 (1H, brs), 10.23 (2H, brs).
Example 132: N-(5-05-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-yl)amino)pyridin-3-y1)-3-phenylbutanamide I
N
Step 1: Preparation of N-(5 -bromopyridin-3-y1)-3-phenylbutanami de
238 ; 0 I
BrN
[0541] A
mixture of 5-bromopyridin-3-amine (300 mg, 1.73 mmol), 3-phenylbutanoic acid (427 mg, 2.60 mmol) and EDCI.HC1 (499 mg, 2.60 mmol) in pyridine (4 mL) was stirred at 50 C for 2 h. The reaction mixture turned into brown solution from yellow. The reaction mixture was concentrated and the residue was diluted with water (25 mL), then extracted with Et0Ac (25 mL x3). The combined organic layer was washed with brine (25 mL), dried over anhydrous Na2SO4 and concentrated. The residue was purified by Combi Flash (30% to 50%
Et0Ac in pentane) to give N-(5-bromopyridin-3-y1)-3-phenylbutanamide (500 mg, yield:
90%) as a yellow solid.
1FINMR (400 MHz, CDC13) (51.38 (3H, d, J = 7.0 Hz), 2.64 (2H, d, J = 7.5 Hz), 3.30-3.41 (1H, m), 7.21-7.26(3H, m), 7.29-7.35 (2H, m), 7.37 (1H, brs), 8.15 (1H, d, J=
2.3 Hz), 8.29-8.32 (1H, m), 8.33 (1H, d, J= 2.0 Hz).
Step 2: Preparation of N-(5-((5 -methyl-8-(2-oxopy rroli din-l-y1)-5H-chromeno [4,3 -c] py ri din-3 -y Damino)py ri din-3-y1)-3 -pheny lbutanami de N; 0 I
NNJY
[0542] A
mixture of 1-(3-amino-5-methy1-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (60 mg, 0.20 mmol), N-(5-bromopyridin-3-y1)-3-phenylbutanamide (97 mg, 0.30 mmol), Pd2(dba)3 (19 mg, 0.020 mmol), BrettPhos (22 mg, 0.041 mmol) and Cs2CO3 (199 mg, 0.609 mmol) in anhydrous dioxane (3 mL) was degassed and purged with N2 for 3 times.
Then the resulting reaction mixture was stirred at 90 C for 16 h under N2 atmosphere.
The reaction mixture turned into yellow suspension from red. LCMS showed the purity of desired product (Rt = 0.763 min; MS Calcd: 533.2; MS Found: 534.4 [M+H1+). To the reaction mixture was added water (20 mL), then extracted with Et0Ac/THF (20 mL x3, 3/1). The combined organic layer was washed with brine (20 mL), dried over anhydrous Na2SO4 and concentrated. The residue was purified by prep-HPLC (0.225% FA as additive) purification. Most of the MeCN
was removed under reduced pressure and the remaining part was lyophilized to give N-(5-((5-
BrN
[0541] A
mixture of 5-bromopyridin-3-amine (300 mg, 1.73 mmol), 3-phenylbutanoic acid (427 mg, 2.60 mmol) and EDCI.HC1 (499 mg, 2.60 mmol) in pyridine (4 mL) was stirred at 50 C for 2 h. The reaction mixture turned into brown solution from yellow. The reaction mixture was concentrated and the residue was diluted with water (25 mL), then extracted with Et0Ac (25 mL x3). The combined organic layer was washed with brine (25 mL), dried over anhydrous Na2SO4 and concentrated. The residue was purified by Combi Flash (30% to 50%
Et0Ac in pentane) to give N-(5-bromopyridin-3-y1)-3-phenylbutanamide (500 mg, yield:
90%) as a yellow solid.
1FINMR (400 MHz, CDC13) (51.38 (3H, d, J = 7.0 Hz), 2.64 (2H, d, J = 7.5 Hz), 3.30-3.41 (1H, m), 7.21-7.26(3H, m), 7.29-7.35 (2H, m), 7.37 (1H, brs), 8.15 (1H, d, J=
2.3 Hz), 8.29-8.32 (1H, m), 8.33 (1H, d, J= 2.0 Hz).
Step 2: Preparation of N-(5-((5 -methyl-8-(2-oxopy rroli din-l-y1)-5H-chromeno [4,3 -c] py ri din-3 -y Damino)py ri din-3-y1)-3 -pheny lbutanami de N; 0 I
NNJY
[0542] A
mixture of 1-(3-amino-5-methy1-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (60 mg, 0.20 mmol), N-(5-bromopyridin-3-y1)-3-phenylbutanamide (97 mg, 0.30 mmol), Pd2(dba)3 (19 mg, 0.020 mmol), BrettPhos (22 mg, 0.041 mmol) and Cs2CO3 (199 mg, 0.609 mmol) in anhydrous dioxane (3 mL) was degassed and purged with N2 for 3 times.
Then the resulting reaction mixture was stirred at 90 C for 16 h under N2 atmosphere.
The reaction mixture turned into yellow suspension from red. LCMS showed the purity of desired product (Rt = 0.763 min; MS Calcd: 533.2; MS Found: 534.4 [M+H1+). To the reaction mixture was added water (20 mL), then extracted with Et0Ac/THF (20 mL x3, 3/1). The combined organic layer was washed with brine (20 mL), dried over anhydrous Na2SO4 and concentrated. The residue was purified by prep-HPLC (0.225% FA as additive) purification. Most of the MeCN
was removed under reduced pressure and the remaining part was lyophilized to give N-(5-((5-
239 methyl-8-(2-oxopy rroli din-1 -y 0-5H-chromeno [4,3 -c] py ri din-3-y0amino)py ri din-3 -y1)-3 -phenylbutanamide (50.7 mg, yield: 47%) as a yellow solid.
NMR (400 MHz, DMSO-d6) 1.26 (3H, d, J= 6.8 Hz), 1.54 (3H, d, J= 6.5 Hz), 2.01-2.11 (2H, m), 2.52-2.54 (2H, m), 2.60-2.70 (2H, m), 3.26-3.32 (1H, m), 3.84 (2H, t, J= 7.8 Hz), 5.27 (1H, q, J= 6.5 Hz), 6.74 (1H, s), 7.16-7.22 (1H, m), 7.27-7.35 (5H, m), 7.40 (1H, d, J= 2.0 Hz), 7.89 (1H, d, J= 8.5 Hz), 8.28 (1H, s), 8.45 (1H, t, J= 2.0 Hz), 8.62 (1H, d, J=
2.0 Hz), 8.65 (1H, s), 9.46 (1H, brs), 10.09 (1H, brs).
Example 133: 2-methyl-N-(5-05-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-y1)-3-phenylpropanamide I
NN
Step 1: Preparation of N-(5-bromopyridin-3-y1)-2-methyl-3-phenylpropanamide I
BrNflC
[0543] A
mixture of 5-bromopyridin-3-amine (300 mg, 1.73 mmol), 2-methy1-3-phenylpropanoic acid (426 mg, 2.60 mmol) and EDCI.HC1 (497 mg, 2.60 mmol) in pyridine (4 mL) was stirred at 50 C for 2 h. The reaction mixture turned into brown solution from yellow. The reaction mixture was concentrated and the residue was diluted with water (25 mL), and then extracted with Et0Ac (25 mL x3). The combined organic layer was washed with brine (25 mL), dried over anhydrous Na2SO4 and concentrated. The crude product was triturated with pentane/EtOAC (10 mL, 3/1) to give N-(5-bromopyridin-3-y1)-2-methy1-3-phenylpropanamide (480 mg, yield: 87%) as an off-white solid.
NMR (400 MHz, CDC13) (5 1.32 (3H, d, J= 6.8 Hz), 2.58-2.68 (1H, m), 2.79-2.85 (1H, m), 2.95-3.02 (1H, m), 6.91 (1H, brs), 7.16-7.20 (2H, m), 7.21-7.33 (3H, m), 8.12 (1H, d, J=
2.0 Hz), 8.32 (1H, t, J= 1.8 Hz), 8.35 (1H, d, J= 2.0 Hz).
Step 2: Preparation of 2-methyl-N-(5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-y1)-3-phenylpropanamide
NMR (400 MHz, DMSO-d6) 1.26 (3H, d, J= 6.8 Hz), 1.54 (3H, d, J= 6.5 Hz), 2.01-2.11 (2H, m), 2.52-2.54 (2H, m), 2.60-2.70 (2H, m), 3.26-3.32 (1H, m), 3.84 (2H, t, J= 7.8 Hz), 5.27 (1H, q, J= 6.5 Hz), 6.74 (1H, s), 7.16-7.22 (1H, m), 7.27-7.35 (5H, m), 7.40 (1H, d, J= 2.0 Hz), 7.89 (1H, d, J= 8.5 Hz), 8.28 (1H, s), 8.45 (1H, t, J= 2.0 Hz), 8.62 (1H, d, J=
2.0 Hz), 8.65 (1H, s), 9.46 (1H, brs), 10.09 (1H, brs).
Example 133: 2-methyl-N-(5-05-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-y1)-3-phenylpropanamide I
NN
Step 1: Preparation of N-(5-bromopyridin-3-y1)-2-methyl-3-phenylpropanamide I
BrNflC
[0543] A
mixture of 5-bromopyridin-3-amine (300 mg, 1.73 mmol), 2-methy1-3-phenylpropanoic acid (426 mg, 2.60 mmol) and EDCI.HC1 (497 mg, 2.60 mmol) in pyridine (4 mL) was stirred at 50 C for 2 h. The reaction mixture turned into brown solution from yellow. The reaction mixture was concentrated and the residue was diluted with water (25 mL), and then extracted with Et0Ac (25 mL x3). The combined organic layer was washed with brine (25 mL), dried over anhydrous Na2SO4 and concentrated. The crude product was triturated with pentane/EtOAC (10 mL, 3/1) to give N-(5-bromopyridin-3-y1)-2-methy1-3-phenylpropanamide (480 mg, yield: 87%) as an off-white solid.
NMR (400 MHz, CDC13) (5 1.32 (3H, d, J= 6.8 Hz), 2.58-2.68 (1H, m), 2.79-2.85 (1H, m), 2.95-3.02 (1H, m), 6.91 (1H, brs), 7.16-7.20 (2H, m), 7.21-7.33 (3H, m), 8.12 (1H, d, J=
2.0 Hz), 8.32 (1H, t, J= 1.8 Hz), 8.35 (1H, d, J= 2.0 Hz).
Step 2: Preparation of 2-methyl-N-(5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-y1)-3-phenylpropanamide
240 I I
N NN
[0544] A
mixture of 1-(3-amino-5-methy1-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (60 mg, 0.20 mmol), N-(5-bromopyridin-3-y1)-2-methyl-3-phenylpropanamide (97 mg, 0.30 mmol), Pd2(dba)3 (19 mg, 0.020 mmol), BrettPhos (22 mg, 0.041 mmol) and Cs2CO3 (199 mg, 0.609 mmol) in anhydrous dioxane (3 mL) was degassed and purged with N2 for 3 times.
Then the resulting reaction mixture was stirred at 90 C for 16 h under N2 atmosphere. The reaction mixture turned into yellow suspension from red. LCMS (Rt = 0.776 min;
MS Calcd:
533.2; MS Found: 534.1 [M+H1+). To the reaction mixture was added water (20 mL), then extracted with Et0Ac/THF (20 mL x3, 1/1). The combined organic layer was washed with brine (20 mL), dried over anhydrous Na2SO4 and concentrated. The residue was purified by prep-HPLC (0.225% FA as additive). Most of the MeCN was removed under reduced pressure and the remaining part was lyophilized to give 2-methyl-N-(5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-y1)-3-phenylpropanamide (39.1 mg, yield: 36%) as a yellow solid.
11-1NMR (400 MHz, DMSO-d6) (51.12 (3H, d, J= 6.8 Hz), 1.55 (3H, d, J= 6.5 Hz), 2.01-2.11 (2H, m), 2.52-2.54 (2H, m), 2.64 (1H, dd, J= 13.3, 6.8 Hz), 2.79-2.88 (1H, m), 2.99 (1H, dd, J= 13.1, 7.5 Hz), 3.85 (2H, t, J= 7.8 Hz), 5.28 (1H, q, J= 6.5 Hz), 6.75 (1H, s), 7.16-7.21 (1H, m), 7.22-7.31 (4H, m), 7.33 (1H, dd, J= 8.7, 2.1 Hz), 7.40 (1H, d, J= 2.3 Hz), 7.90 (1H, d, J= 8.8 Hz), 8.32 (1H, d, J= 2.0 Hz), 8.49 (1H, t, J= 2.3 Hz), 8.62 (1H, d, J
= 2.3 Hz), 8.67 (1H, s), 9.49 (1H, brs), 10.06 (1H, brs).
Example 134: 2-hydroxy-N-(5-05-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-y1)-3-phenylpropanamide c 0 I
NN
OH
Step 1: Preparation of 2-acetoxy-3-phenylpropanoic acid
N NN
[0544] A
mixture of 1-(3-amino-5-methy1-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (60 mg, 0.20 mmol), N-(5-bromopyridin-3-y1)-2-methyl-3-phenylpropanamide (97 mg, 0.30 mmol), Pd2(dba)3 (19 mg, 0.020 mmol), BrettPhos (22 mg, 0.041 mmol) and Cs2CO3 (199 mg, 0.609 mmol) in anhydrous dioxane (3 mL) was degassed and purged with N2 for 3 times.
Then the resulting reaction mixture was stirred at 90 C for 16 h under N2 atmosphere. The reaction mixture turned into yellow suspension from red. LCMS (Rt = 0.776 min;
MS Calcd:
533.2; MS Found: 534.1 [M+H1+). To the reaction mixture was added water (20 mL), then extracted with Et0Ac/THF (20 mL x3, 1/1). The combined organic layer was washed with brine (20 mL), dried over anhydrous Na2SO4 and concentrated. The residue was purified by prep-HPLC (0.225% FA as additive). Most of the MeCN was removed under reduced pressure and the remaining part was lyophilized to give 2-methyl-N-(5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-y1)-3-phenylpropanamide (39.1 mg, yield: 36%) as a yellow solid.
11-1NMR (400 MHz, DMSO-d6) (51.12 (3H, d, J= 6.8 Hz), 1.55 (3H, d, J= 6.5 Hz), 2.01-2.11 (2H, m), 2.52-2.54 (2H, m), 2.64 (1H, dd, J= 13.3, 6.8 Hz), 2.79-2.88 (1H, m), 2.99 (1H, dd, J= 13.1, 7.5 Hz), 3.85 (2H, t, J= 7.8 Hz), 5.28 (1H, q, J= 6.5 Hz), 6.75 (1H, s), 7.16-7.21 (1H, m), 7.22-7.31 (4H, m), 7.33 (1H, dd, J= 8.7, 2.1 Hz), 7.40 (1H, d, J= 2.3 Hz), 7.90 (1H, d, J= 8.8 Hz), 8.32 (1H, d, J= 2.0 Hz), 8.49 (1H, t, J= 2.3 Hz), 8.62 (1H, d, J
= 2.3 Hz), 8.67 (1H, s), 9.49 (1H, brs), 10.06 (1H, brs).
Example 134: 2-hydroxy-N-(5-05-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-y1)-3-phenylpropanamide c 0 I
NN
OH
Step 1: Preparation of 2-acetoxy-3-phenylpropanoic acid
241 HO
OAc LJ
[0545] To a solution of 2-hydroxy-3-phenylpropanoic acid (1.20 g, 7.22 mmol) in pyridine (25 mL) was added acetic anhydride (737 mg, 7.22 mmol) at 20-25 C. Then the reaction mixture was stirred at 20-25 C for 2 h. The reaction mixture turned into brown solution from yellow. The reaction mixture was concentrated and the residue was diluted with Et0Ac (100 mL), then washed with 2N aqueous HC1 (50 mL x2), brine (50 mL), dried over anhydrous Na2SO4 and concentrated and dried under vacuum to give 2-acetoxy-3-phenylpropanoic acid (1.20 g, yield: 80%) as yellow oil.
11-1 NMR (400 MHz, CDC13) (52.09 (3H, s), 3.08-3.16 (1H, m), 3.21-3.27 (1H, m), 5.25 (1H, dd, J= 9.0, 4.0 Hz), 6.85 (1H, brs), 7.23-7.35 (5H, m).
Step 2: Preparation of 1-((5 -((5-methyl-8-(2-oxopyrroli din-1 -y1)-5H-chromeno [4,3-c] py ri din-3-yl)amino)pyridin-3-yl)amino)-1-oxo-3-phenylpropan-2-y1 acetate I
NN
OAc [0546] A
mixture of 1-(3-((5-aminopyridin-3-yl)amino)-5-methy1-5H-chromeno[4,3-c]pyridin-8-y1)pyrrolidin-2-one (100 mg, 0.236 mmol, HC1 salt), 2-acetoxy-3-phenylpropanoic acid (74 mg, 0.35 mmol) and EDCI.HC1 (68 mg, 0.35 mmol) in pyridine (2 mL) was stirred at 50 C for 2 h. The reaction mixture turned into brown solution from yellow.
The reaction mixture was diluted with water (25 mL), then extracted with Et0Ac (25 mL x3).
The combined organic layer was washed with saturated aqueous NaHCO3 (25 mL), brine (25 mL), dried over anhydrous Na2SO4 and concentrated to give 1-((5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno [4,3-c] py ri din-3-yl)amino)py ri din-3 -yl)amino)-1 -oxo-3-pheny 1propan-2-y1 acetate (130 mg, yield: 73%) as yellow gum, which was directly used for the next step without further purification.
Step 3: Preparation of 2-hy droxy -N-(5 -((5-methyl-8-(2-oxopy rrol i din-1 -y1)-5H-chromeno[4,3-c]pyridin-3-y0amino)pyridin-3-y1)-3-phenylpropanamide
OAc LJ
[0545] To a solution of 2-hydroxy-3-phenylpropanoic acid (1.20 g, 7.22 mmol) in pyridine (25 mL) was added acetic anhydride (737 mg, 7.22 mmol) at 20-25 C. Then the reaction mixture was stirred at 20-25 C for 2 h. The reaction mixture turned into brown solution from yellow. The reaction mixture was concentrated and the residue was diluted with Et0Ac (100 mL), then washed with 2N aqueous HC1 (50 mL x2), brine (50 mL), dried over anhydrous Na2SO4 and concentrated and dried under vacuum to give 2-acetoxy-3-phenylpropanoic acid (1.20 g, yield: 80%) as yellow oil.
11-1 NMR (400 MHz, CDC13) (52.09 (3H, s), 3.08-3.16 (1H, m), 3.21-3.27 (1H, m), 5.25 (1H, dd, J= 9.0, 4.0 Hz), 6.85 (1H, brs), 7.23-7.35 (5H, m).
Step 2: Preparation of 1-((5 -((5-methyl-8-(2-oxopyrroli din-1 -y1)-5H-chromeno [4,3-c] py ri din-3-yl)amino)pyridin-3-yl)amino)-1-oxo-3-phenylpropan-2-y1 acetate I
NN
OAc [0546] A
mixture of 1-(3-((5-aminopyridin-3-yl)amino)-5-methy1-5H-chromeno[4,3-c]pyridin-8-y1)pyrrolidin-2-one (100 mg, 0.236 mmol, HC1 salt), 2-acetoxy-3-phenylpropanoic acid (74 mg, 0.35 mmol) and EDCI.HC1 (68 mg, 0.35 mmol) in pyridine (2 mL) was stirred at 50 C for 2 h. The reaction mixture turned into brown solution from yellow.
The reaction mixture was diluted with water (25 mL), then extracted with Et0Ac (25 mL x3).
The combined organic layer was washed with saturated aqueous NaHCO3 (25 mL), brine (25 mL), dried over anhydrous Na2SO4 and concentrated to give 1-((5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno [4,3-c] py ri din-3-yl)amino)py ri din-3 -yl)amino)-1 -oxo-3-pheny 1propan-2-y1 acetate (130 mg, yield: 73%) as yellow gum, which was directly used for the next step without further purification.
Step 3: Preparation of 2-hy droxy -N-(5 -((5-methyl-8-(2-oxopy rrol i din-1 -y1)-5H-chromeno[4,3-c]pyridin-3-y0amino)pyridin-3-y1)-3-phenylpropanamide
242 I I
N NN
OH
[0547] To a solution of 1-((5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-y1)amino)pyridin-3-y1)amino)-1-oxo-3-phenylpropan-2-y1 acetate(130 mg, 0.225 mmol) in THF (4 mL) and Me0H (2 mL) was added 2N aqueous NaOH (2 mL) at 20-25 C.
Then the resulting reaction mixture was stirred at 20-25 C for 2 h. The reaction mixture turned into yellow solution from suspension. LCMS (Rt = 0.624 min; MS Calcd: 535.2;
MS
Found: 536.1 [M+H1+). The reaction mixture was concentrated and the residue was diluted with water (25 mL), then extracted with Et0Ac/THF (25 mL x3, 1/1). The combined organic layer was washed with brine (25 mL), dried over anhydrous Na2SO4 and concentrated. The residue was purified by prep-HPLC (0.225% FA as an additive). Most of the MeCN
was removed under reduced pressure and the remaining part was lyophilized to give 2-hydroxy-N-(5 -((5-methy1-8-(2-oxopy rroli din-1-y 0-5H-chromeno [4,3-c] py ridin-3 -y Damino)py ridin-3 -y1)-3-phenylpropanamide (49.6 mg, yield: 41%) as a yellow solid.
11-1 NMR (400 MHz, DMSO-d6) 61.55 (3H, d, J= 6.5 Hz), 2.01-2.11 (2H, m), 2.52-2.54 (2H, m), 2.88 (1H, dd, J= 13.8, 8.3 Hz), 3.08 (1H, dd, J= 13.7, 4.1 Hz), 3.85 (2H, t, J= 7.8 Hz), 4.26-4.33 (1H, m), 5.28 (1H, q, J= 6.4 Hz), 5.89 (1H, d, J= 5.5 Hz), 6.76 (1H, s), 7.18-7.25 (1H, m), 7.27-7.30 (4H, m), 7.33 (1H, dd, J= 8.5, 2.3 Hz), 7.41 (1H, d, J= 2.0 Hz), 7.89 (1H, d, J= 8.8 Hz), 8.38 (1H, d, J= 2.0 Hz), 8.57 (1H, t, J= 2.1 Hz), 8.65 (1H, d, J= 2.3 Hz), 8.67 (1H, s), 9.48 (1H, brs), 9.90 (1H, brs).
Example 135: N-(5-05-methyl-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-yl)amino)pyridin-3-yl)tetrahydrofuran-2-carboxamide I
NN
)CO
Step 1: Preparation of N-(5-bromopyridin-3-yl)tetrahydrofuran-2-carboxamide
N NN
OH
[0547] To a solution of 1-((5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-y1)amino)pyridin-3-y1)amino)-1-oxo-3-phenylpropan-2-y1 acetate(130 mg, 0.225 mmol) in THF (4 mL) and Me0H (2 mL) was added 2N aqueous NaOH (2 mL) at 20-25 C.
Then the resulting reaction mixture was stirred at 20-25 C for 2 h. The reaction mixture turned into yellow solution from suspension. LCMS (Rt = 0.624 min; MS Calcd: 535.2;
MS
Found: 536.1 [M+H1+). The reaction mixture was concentrated and the residue was diluted with water (25 mL), then extracted with Et0Ac/THF (25 mL x3, 1/1). The combined organic layer was washed with brine (25 mL), dried over anhydrous Na2SO4 and concentrated. The residue was purified by prep-HPLC (0.225% FA as an additive). Most of the MeCN
was removed under reduced pressure and the remaining part was lyophilized to give 2-hydroxy-N-(5 -((5-methy1-8-(2-oxopy rroli din-1-y 0-5H-chromeno [4,3-c] py ridin-3 -y Damino)py ridin-3 -y1)-3-phenylpropanamide (49.6 mg, yield: 41%) as a yellow solid.
11-1 NMR (400 MHz, DMSO-d6) 61.55 (3H, d, J= 6.5 Hz), 2.01-2.11 (2H, m), 2.52-2.54 (2H, m), 2.88 (1H, dd, J= 13.8, 8.3 Hz), 3.08 (1H, dd, J= 13.7, 4.1 Hz), 3.85 (2H, t, J= 7.8 Hz), 4.26-4.33 (1H, m), 5.28 (1H, q, J= 6.4 Hz), 5.89 (1H, d, J= 5.5 Hz), 6.76 (1H, s), 7.18-7.25 (1H, m), 7.27-7.30 (4H, m), 7.33 (1H, dd, J= 8.5, 2.3 Hz), 7.41 (1H, d, J= 2.0 Hz), 7.89 (1H, d, J= 8.8 Hz), 8.38 (1H, d, J= 2.0 Hz), 8.57 (1H, t, J= 2.1 Hz), 8.65 (1H, d, J= 2.3 Hz), 8.67 (1H, s), 9.48 (1H, brs), 9.90 (1H, brs).
Example 135: N-(5-05-methyl-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-yl)amino)pyridin-3-yl)tetrahydrofuran-2-carboxamide I
NN
)CO
Step 1: Preparation of N-(5-bromopyridin-3-yl)tetrahydrofuran-2-carboxamide
243 BrN)10 [0548] A
mixture of 5-bromopyridin-3-amine (300 mg, 1.73 mmol), tetrahydrofuran-2-carboxylic acid (302 mg, 2.60 mmol) and EDCI.HC1 (497 mg, 2.60 mmol) in pyridine (4 mL) was stirred at 50 C for 2 h. The reaction mixture turned into brown solution from yellow. The reaction mixture was concentrated and the residue was diluted with water (25 mL), and then extracted with Et0Ac (25 mL x3). The combined organic layer was washed with brine (25 mL), dried over anhydrous Na2SO4 and concentrated. The residue was purified by Combi Flash (30% to 50% Et0Ac in pentane) to give N-(5-bromopyridin-3-yl)tetrahydrofuran-2-carboxamide (380 mg, yield: 65%) as a yellow solid.
1FINMR (400 MHz, CDC13) (51.88-2.04 (2H, m), 2.12-2.21 (1H, m), 2.34-2.44 (1H, m), 3.93-4.00 (1H, m), 4.02-4.09 (1H, m), 4.48 (1H, dd, J= 8.3, 6.0 Hz), 8.42 (1H, d, J= 2.0 Hz), 8.49-8.50 (1H, m), 8.51-8.53 (1H, m), 8.57 (1H, brs).
Step 2: Preparation of N-(5-((5 -methyl-8-(2-oxopy rroli din-l-y1)-5H-chromeno [4,3 -c] py ri din-3 -y Damino)py ri din-3-yOtetrahy drofuran-2-carb oxami de c 0 N N N
- -H H )0 [0549] A
mixture of 1-(3-amino-5-methy1-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (60 mg, 0.20 mmol), N-(5-bromopyridin-3-yl)tetrahydrofuran-2-carboxamide (83 mg, 0.30 mmol), Pd2(dba)3 (19 mg, 0.020 mmol), BrettPhos (22 mg, 0.041 mmol) and Cs2CO3 (199 mg, 0.609 mmol) in anhydrous dioxane (3 mL) was degassed and purged with N2 for 3 times.
Then the resulting reaction mixture was stirred at 90 C for 16 h under N2 atmosphere. The reaction mixture turned into yellow suspension from red. LCMS (Rt = 0.724 min;
MS Calcd:
485.2; MS Found: 486.2 [M+H1+). To the reaction mixture was added water (20 mL), then extracted with Et0Ac/THF (20 mL x3, 3/1). The combined organic layer was washed with brine (20 mL), dried over anhydrous Na2SO4 and concentrated. The residue was purified by prep-HPLC (0.225% FA as an additive). Most of the MeCN was removed under reduced pressure and the remaining part was lyophilized to give N-(5-((5-methy1-8-(2-oxopyrrolidin-
mixture of 5-bromopyridin-3-amine (300 mg, 1.73 mmol), tetrahydrofuran-2-carboxylic acid (302 mg, 2.60 mmol) and EDCI.HC1 (497 mg, 2.60 mmol) in pyridine (4 mL) was stirred at 50 C for 2 h. The reaction mixture turned into brown solution from yellow. The reaction mixture was concentrated and the residue was diluted with water (25 mL), and then extracted with Et0Ac (25 mL x3). The combined organic layer was washed with brine (25 mL), dried over anhydrous Na2SO4 and concentrated. The residue was purified by Combi Flash (30% to 50% Et0Ac in pentane) to give N-(5-bromopyridin-3-yl)tetrahydrofuran-2-carboxamide (380 mg, yield: 65%) as a yellow solid.
1FINMR (400 MHz, CDC13) (51.88-2.04 (2H, m), 2.12-2.21 (1H, m), 2.34-2.44 (1H, m), 3.93-4.00 (1H, m), 4.02-4.09 (1H, m), 4.48 (1H, dd, J= 8.3, 6.0 Hz), 8.42 (1H, d, J= 2.0 Hz), 8.49-8.50 (1H, m), 8.51-8.53 (1H, m), 8.57 (1H, brs).
Step 2: Preparation of N-(5-((5 -methyl-8-(2-oxopy rroli din-l-y1)-5H-chromeno [4,3 -c] py ri din-3 -y Damino)py ri din-3-yOtetrahy drofuran-2-carb oxami de c 0 N N N
- -H H )0 [0549] A
mixture of 1-(3-amino-5-methy1-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (60 mg, 0.20 mmol), N-(5-bromopyridin-3-yl)tetrahydrofuran-2-carboxamide (83 mg, 0.30 mmol), Pd2(dba)3 (19 mg, 0.020 mmol), BrettPhos (22 mg, 0.041 mmol) and Cs2CO3 (199 mg, 0.609 mmol) in anhydrous dioxane (3 mL) was degassed and purged with N2 for 3 times.
Then the resulting reaction mixture was stirred at 90 C for 16 h under N2 atmosphere. The reaction mixture turned into yellow suspension from red. LCMS (Rt = 0.724 min;
MS Calcd:
485.2; MS Found: 486.2 [M+H1+). To the reaction mixture was added water (20 mL), then extracted with Et0Ac/THF (20 mL x3, 3/1). The combined organic layer was washed with brine (20 mL), dried over anhydrous Na2SO4 and concentrated. The residue was purified by prep-HPLC (0.225% FA as an additive). Most of the MeCN was removed under reduced pressure and the remaining part was lyophilized to give N-(5-((5-methy1-8-(2-oxopyrrolidin-
244 1-y1)-5H-chromeno [4,3 -c] py ridin-3 -yl)amino)py ri din-3-yl)tetrahy drofuran-2-carb oxamide (11.7 mg, yield: 12%) as a yellow solid.
NMR (400 MHz, DMSO-d6) 1.54 (3H, d, J= 6.5 Hz), 1.84-1.93 (2H, m), 1.96-2.11 (3H, m), 2.17-2.27 (1H, m), 2.52-2.54 (2H, m), 3.81-3.88 (3H, m), 3.97-4.04 (1H, m), 4.44 (1H, dd, J= 8.2, 5.7 Hz), 5.27 (1H, q, J= 6.2 Hz), 6.76 (1H, s), 7.32 (1H, dd, J=
8.7, 2.1 Hz), 7.40 (1H, d, J= 2.0 Hz), 7.89 (1H, d, J= 8.5 Hz), 8.40 (1H, s), 8.56-8.59 (1H, m), 8.64-8.66 (1H, m), 8.67 (1H, s), 9.48 (1H, brs), 9.89 (1H, brs).
Example 136: N-(5-05-methyl-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-yl)amino)pyridin-3-yl)benzo[d][1,3]dioxole-5-carboxamide I I
N NN>
Step 1: Preparation of N-(5 -bromopy ri din-3-yl)b enzo [d] [1,3] di oxol e-5-carb oxami de BrN
0>
[0550] A
mixture of 5-bromopyridin-3-amine (300 mg, 1.73 mmol), benzo[d][1,3]dioxole-5-carboxylic acid (431 mg, 2.60 mmol) and EDCI.HC1 (497 mg, 2.60 mmol) in pyridine (4 mL) was stirred at 50 C for 2 h. The reaction mixture turned into brown solution from yellow. The reaction mixture was concentrated and the residue was diluted with water (25 mL), and then extracted with Et0Ac/THF (25 mL x3, 2/1). The combined organic layer was washed with brine (25 mL), dried over anhydrous Na2SO4 and concentrated. The crude product was triturated with pentane/EtOAC (10 mL, 1/1) to give N-(5-bromopyridin-3-yl)benzo[d][1,31dioxole-5-carboxamide (480 mg, yield: 86%) as a yellow solid.
NMR (400 MHz, CDC13) (56.08 (2H, s), 6.90 (1H, d, J= 8.0 Hz), 7.36 (1H, d, J=
1.5 Hz), 7.41 (1H, dd, J= 8.2, 1.6 Hz), 7.83 (1H, brs), 8.44 (1H, d, J= 2.0 Hz), 8.53-8.58 (2H, m).
Step 2: Preparation of N-(5-((5 -methyl-8-(2-oxopy rrolidin-l-y1)-5H-chromeno [4,3 -c] py ridin-3 -yl)amino)pyridin-3-yl)benzo [d] [1,3] dioxole-5-carboxamide
NMR (400 MHz, DMSO-d6) 1.54 (3H, d, J= 6.5 Hz), 1.84-1.93 (2H, m), 1.96-2.11 (3H, m), 2.17-2.27 (1H, m), 2.52-2.54 (2H, m), 3.81-3.88 (3H, m), 3.97-4.04 (1H, m), 4.44 (1H, dd, J= 8.2, 5.7 Hz), 5.27 (1H, q, J= 6.2 Hz), 6.76 (1H, s), 7.32 (1H, dd, J=
8.7, 2.1 Hz), 7.40 (1H, d, J= 2.0 Hz), 7.89 (1H, d, J= 8.5 Hz), 8.40 (1H, s), 8.56-8.59 (1H, m), 8.64-8.66 (1H, m), 8.67 (1H, s), 9.48 (1H, brs), 9.89 (1H, brs).
Example 136: N-(5-05-methyl-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-yl)amino)pyridin-3-yl)benzo[d][1,3]dioxole-5-carboxamide I I
N NN>
Step 1: Preparation of N-(5 -bromopy ri din-3-yl)b enzo [d] [1,3] di oxol e-5-carb oxami de BrN
0>
[0550] A
mixture of 5-bromopyridin-3-amine (300 mg, 1.73 mmol), benzo[d][1,3]dioxole-5-carboxylic acid (431 mg, 2.60 mmol) and EDCI.HC1 (497 mg, 2.60 mmol) in pyridine (4 mL) was stirred at 50 C for 2 h. The reaction mixture turned into brown solution from yellow. The reaction mixture was concentrated and the residue was diluted with water (25 mL), and then extracted with Et0Ac/THF (25 mL x3, 2/1). The combined organic layer was washed with brine (25 mL), dried over anhydrous Na2SO4 and concentrated. The crude product was triturated with pentane/EtOAC (10 mL, 1/1) to give N-(5-bromopyridin-3-yl)benzo[d][1,31dioxole-5-carboxamide (480 mg, yield: 86%) as a yellow solid.
NMR (400 MHz, CDC13) (56.08 (2H, s), 6.90 (1H, d, J= 8.0 Hz), 7.36 (1H, d, J=
1.5 Hz), 7.41 (1H, dd, J= 8.2, 1.6 Hz), 7.83 (1H, brs), 8.44 (1H, d, J= 2.0 Hz), 8.53-8.58 (2H, m).
Step 2: Preparation of N-(5-((5 -methyl-8-(2-oxopy rrolidin-l-y1)-5H-chromeno [4,3 -c] py ridin-3 -yl)amino)pyridin-3-yl)benzo [d] [1,3] dioxole-5-carboxamide
245 I
NN o>
[0551] A
mixture of 1-(3-amino-5-methy1-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (60 mg, 0.20 mmol), N-(5-bromopyridin-3-yObenzo[d][1,31dioxole-5-carboxamide (98 mg, 0.30 mmol), Pd2(dba)3 (19 mg, 0.020 mmol), BrettPhos (22 mg, 0.041 mmol) and Cs2CO3 (199 mg, 0.609 mmol) in anhydrous dioxane (3 mL) was degassed and purged with N2 for 3 times. Then the resulting reaction mixture was stirred at 90 C for 16 h under N2 atmosphere.
The reaction mixture turned into yellow suspension from red. LCMS (Rt = 0.735 min; MS
Calcd: 535.2; MS Found: 536.1 [M+Hl+). To the reaction mixture was added water (20 mL), then extracted with Et0Ac/THF (20 mL x3, 3/1). The combined organic layer was washed with brine (20 mL), dried over anhydrous Na2SO4 and concentrated. The residue was purified by prep-HPLC (0.225% FA as additive) purification. Most of the MeCN was removed under reduced pressure and the remaining part was lyophilized to give N-(5-((5-methy1-8-(2-oxopy rroli din-l-y1)-5H-chromeno [4,3 -c] py ri din-3-yl)amino)py ri din-3-yl)benzo[d][1,31dioxole-5-carboxamide (40.0 mg, yield: 37%) as a yellow solid.
11-1NMR (400 MHz, DMSO-d6) 61.55 (3H, d, J= 6.5 Hz), 2.01-2.11 (2H, m), 2.52-2.54 (2H, m), 3.84 (2H, t, J= 7.7 Hz), 5.29 (1H, q, J= 6.6 Hz), 6.16 (2H, s), 6.79 (1H, s), 7.09 (1H, d, J
= 8.0 Hz), 7.32 (1H, dd, J= 8.7, 2.1 Hz), 7.41 (1H, d, J= 2.0 Hz), 7.55 (1H, d, J= 1.5 Hz), 7.63 (1H, dd, J= 8.2, 1.6 Hz), 7.89 (1H, d, J= 8.8 Hz), 8.54 (1H, s), 8.68-8.73 (2H, m), 8.77 (1H, s), 9.67 (1H, brs), 10.37 (1H, brs).
Example 137: N-(5-05-methyl-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-yl)amino)pyridin-3-yl)benzo[d][1,3]dioxole-4-carboxamide 0 0---\
NN
Step 1: Preparation of N-(5 -bromopy ri din-3-yl)b enzo [d] [1,3] di oxol e-4-carb oxami de
NN o>
[0551] A
mixture of 1-(3-amino-5-methy1-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (60 mg, 0.20 mmol), N-(5-bromopyridin-3-yObenzo[d][1,31dioxole-5-carboxamide (98 mg, 0.30 mmol), Pd2(dba)3 (19 mg, 0.020 mmol), BrettPhos (22 mg, 0.041 mmol) and Cs2CO3 (199 mg, 0.609 mmol) in anhydrous dioxane (3 mL) was degassed and purged with N2 for 3 times. Then the resulting reaction mixture was stirred at 90 C for 16 h under N2 atmosphere.
The reaction mixture turned into yellow suspension from red. LCMS (Rt = 0.735 min; MS
Calcd: 535.2; MS Found: 536.1 [M+Hl+). To the reaction mixture was added water (20 mL), then extracted with Et0Ac/THF (20 mL x3, 3/1). The combined organic layer was washed with brine (20 mL), dried over anhydrous Na2SO4 and concentrated. The residue was purified by prep-HPLC (0.225% FA as additive) purification. Most of the MeCN was removed under reduced pressure and the remaining part was lyophilized to give N-(5-((5-methy1-8-(2-oxopy rroli din-l-y1)-5H-chromeno [4,3 -c] py ri din-3-yl)amino)py ri din-3-yl)benzo[d][1,31dioxole-5-carboxamide (40.0 mg, yield: 37%) as a yellow solid.
11-1NMR (400 MHz, DMSO-d6) 61.55 (3H, d, J= 6.5 Hz), 2.01-2.11 (2H, m), 2.52-2.54 (2H, m), 3.84 (2H, t, J= 7.7 Hz), 5.29 (1H, q, J= 6.6 Hz), 6.16 (2H, s), 6.79 (1H, s), 7.09 (1H, d, J
= 8.0 Hz), 7.32 (1H, dd, J= 8.7, 2.1 Hz), 7.41 (1H, d, J= 2.0 Hz), 7.55 (1H, d, J= 1.5 Hz), 7.63 (1H, dd, J= 8.2, 1.6 Hz), 7.89 (1H, d, J= 8.8 Hz), 8.54 (1H, s), 8.68-8.73 (2H, m), 8.77 (1H, s), 9.67 (1H, brs), 10.37 (1H, brs).
Example 137: N-(5-05-methyl-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-yl)amino)pyridin-3-yl)benzo[d][1,3]dioxole-4-carboxamide 0 0---\
NN
Step 1: Preparation of N-(5 -bromopy ri din-3-yl)b enzo [d] [1,3] di oxol e-4-carb oxami de
246 0 0--\
BrN
[0552] A
mixture of 5-bromopyridin-3-amine (300 mg, 1.73 mmol), benzo[d] [1,3]dioxole-4-carboxylic acid (431 mg, 2.60 mmol) and EDCI.HC1 (497 mg, 2.60 mmol) in pyridine (4 mL) was stirred at 50 C for 2 h. The reaction mixture turned into brown solution from yellow.
The reaction mixture was concentrated and the residue was diluted with water (25 mL), and then extracted with Et0Ac (25 mL x3). The combined organic layer was washed with brine (25 mL), dried over anhydrous Na2SO4 and concentrated. The crude product was triturated with pentane/EtOAC (10 mL, 1/1) to give N-(5-bromopyridin-3-yObenzo[d][1,31dioxo1e-carboxamide (385 mg, yield: 69%) as a yellow solid.
1FINMR (400 MHz, CDC13) 5 6.20 (2H, s), 6.99-7.07 (2H, m), 7.64 (1H, d, J=
7.5, 1.8 Hz), 8.44 (1H, d, J= 2.0 Hz), 8.57 (1H, d, J= 2.3 Hz), 8.60-8.63 (1H, m), 8.83 (1H, brs).
Step 2: Preparation of N-(5-((5 -methyl-8-(2-oxopy rroli din-l-y1)-5H-chromeno [4,3 -c] py ri din-3 -yl)amino)pyridin-3-yl)benzo [d] [1,3] dioxole-4-carboxamide 1\1 0 0¨\
NN
[0553] A
mixture of 1-(3-amino-5-methy1-5H-chromeno [4,3-clpyridin-8-yOpyrrolidin-2-one (60 mg, 0.20 mmol), N-(5-bromopyridin-3-yObenzo[d][1,31dioxole-4-carboxamide (98 mg, 0.30 mmol), Pd2(dba)3 (19 mg, 0.020 mmol), BrettPhos (22 mg, 0.041 mmol) and Cs2CO3 (199 mg, 0.609 mmol) in anhydrous dioxane (3 mL) was degassed and purged with N2 for 3 times. Then the resulting reaction mixture was stirred at 90 C for 16 h under N2 atmosphere.
The reaction mixture turned into yellow suspension from red. LCMS (Rt = 0.749 min; MS
Calcd: 535.2; MS Found: 536.1 [M+Hl+). To the reaction mixture was added water (20 mL) and Et0Ac (20 mL) and the reaction mixture was filtered and the solid was washed with Et0Ac (5 mL x2) and dried under vacuum. The crude product was purified by prep-HPLC
(0.225%
FA as additive). Most of the MeCN was removed under reduced pressure and the remaining part was lyophilized to give N-(5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-
BrN
[0552] A
mixture of 5-bromopyridin-3-amine (300 mg, 1.73 mmol), benzo[d] [1,3]dioxole-4-carboxylic acid (431 mg, 2.60 mmol) and EDCI.HC1 (497 mg, 2.60 mmol) in pyridine (4 mL) was stirred at 50 C for 2 h. The reaction mixture turned into brown solution from yellow.
The reaction mixture was concentrated and the residue was diluted with water (25 mL), and then extracted with Et0Ac (25 mL x3). The combined organic layer was washed with brine (25 mL), dried over anhydrous Na2SO4 and concentrated. The crude product was triturated with pentane/EtOAC (10 mL, 1/1) to give N-(5-bromopyridin-3-yObenzo[d][1,31dioxo1e-carboxamide (385 mg, yield: 69%) as a yellow solid.
1FINMR (400 MHz, CDC13) 5 6.20 (2H, s), 6.99-7.07 (2H, m), 7.64 (1H, d, J=
7.5, 1.8 Hz), 8.44 (1H, d, J= 2.0 Hz), 8.57 (1H, d, J= 2.3 Hz), 8.60-8.63 (1H, m), 8.83 (1H, brs).
Step 2: Preparation of N-(5-((5 -methyl-8-(2-oxopy rroli din-l-y1)-5H-chromeno [4,3 -c] py ri din-3 -yl)amino)pyridin-3-yl)benzo [d] [1,3] dioxole-4-carboxamide 1\1 0 0¨\
NN
[0553] A
mixture of 1-(3-amino-5-methy1-5H-chromeno [4,3-clpyridin-8-yOpyrrolidin-2-one (60 mg, 0.20 mmol), N-(5-bromopyridin-3-yObenzo[d][1,31dioxole-4-carboxamide (98 mg, 0.30 mmol), Pd2(dba)3 (19 mg, 0.020 mmol), BrettPhos (22 mg, 0.041 mmol) and Cs2CO3 (199 mg, 0.609 mmol) in anhydrous dioxane (3 mL) was degassed and purged with N2 for 3 times. Then the resulting reaction mixture was stirred at 90 C for 16 h under N2 atmosphere.
The reaction mixture turned into yellow suspension from red. LCMS (Rt = 0.749 min; MS
Calcd: 535.2; MS Found: 536.1 [M+Hl+). To the reaction mixture was added water (20 mL) and Et0Ac (20 mL) and the reaction mixture was filtered and the solid was washed with Et0Ac (5 mL x2) and dried under vacuum. The crude product was purified by prep-HPLC
(0.225%
FA as additive). Most of the MeCN was removed under reduced pressure and the remaining part was lyophilized to give N-(5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-
247 clpyridin-3-y0amino)pyridin-3-yObenzo[d][1,31dioxole-4-carboxamide (23.1 mg, yield: 21%) as a yellow solid.
NMR (400 MHz, DMSO-d6) (51.55 (3H, d, J= 6.5 Hz), 2.01-2.11 (2H, m), 2.52-2.54 (2H, m), 3.85 (2H, t, J= 7.8 Hz), 5.30 (1H, q, J= 6.5 Hz), 6.18 (2H, s), 6.79 (1H, s), 7.00 (1H, t, J
= 8.0 Hz), 7.16 (1H, d, J= 7.0 Hz), 7.27 (1H, d, J= 7.3 Hz), 7.33 (1H, dd, J=
8.7, 1.9 Hz), 7.41 (1H, d, J= 2.0 Hz), 7.90 (1H, d, J= 8.8 Hz), 8.48 (1H, d, J= 1.8 Hz), 8.68 (1H, t, J=
2.1 Hz), 8.70 (1H, s), 8.81 (1H, d, J= 1.5 Hz), 9.70 (1H, brs), 10.22 (1H, brs).
Example 138: N-(5-05-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-yl)amino)pyridin-3-y1)-2,3-dihydro-1H-indene-2-carboxamide gN 0 N
Step 1: Preparation of N-(5-bromopyri din-3-y1)-2,3 -dihy dro-1H-indene-2-carb oxami de BrN
HQ
[0554] A
mixture of 5-bromopyridin-3-amine (300 mg, 1.73 mmol), 2,3-dihydro-1H-indene-2-carboxylic acid (421 mg, 2.60 mmol) and EDCI.HC1 (497 mg, 2.60 mmol) in pyridine (4 mL) was stirred at 50 C for 2 h. The reaction mixture turned into brown solution from yellow. The reaction mixture was concentrated and the residue was diluted with water (25 mL), and then extracted with Et0Ac/THF (25 mL x3, 1/1). The combined organic layer was washed with brine (25 mL), dried over anhydrous Na2SO4 and concentrated. The crude product was triturated with pentane/EtOAC (10 mL, 1/1) to give N-(5-bromopyridin-3-y1)-2,3-dihydro-1H-indene-2-carboxamide (500 mg, yield: 91%) as a yellow solid.
NMR (400 MHz, CDC13) (53.23-3.41 (5H, m), 7.18-7.26 (4H, m), 7.39 (1H, brs), 8.41 (1H, d, J= 2.0 Hz), 8.43 (1H, d, J= 2.3 Hz), 8.48-8.51 (1H, m).
Step 2: Preparation of N-(5-((5 -methyl-8-(2-oxopy rroli din-l-y1)-5H-chromeno [4,3 -c] py ri din-3 -y Damino)py ri din-3-y 0-2,3-dihy dro-1H-indene-2-carboxami de
NMR (400 MHz, DMSO-d6) (51.55 (3H, d, J= 6.5 Hz), 2.01-2.11 (2H, m), 2.52-2.54 (2H, m), 3.85 (2H, t, J= 7.8 Hz), 5.30 (1H, q, J= 6.5 Hz), 6.18 (2H, s), 6.79 (1H, s), 7.00 (1H, t, J
= 8.0 Hz), 7.16 (1H, d, J= 7.0 Hz), 7.27 (1H, d, J= 7.3 Hz), 7.33 (1H, dd, J=
8.7, 1.9 Hz), 7.41 (1H, d, J= 2.0 Hz), 7.90 (1H, d, J= 8.8 Hz), 8.48 (1H, d, J= 1.8 Hz), 8.68 (1H, t, J=
2.1 Hz), 8.70 (1H, s), 8.81 (1H, d, J= 1.5 Hz), 9.70 (1H, brs), 10.22 (1H, brs).
Example 138: N-(5-05-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-yl)amino)pyridin-3-y1)-2,3-dihydro-1H-indene-2-carboxamide gN 0 N
Step 1: Preparation of N-(5-bromopyri din-3-y1)-2,3 -dihy dro-1H-indene-2-carb oxami de BrN
HQ
[0554] A
mixture of 5-bromopyridin-3-amine (300 mg, 1.73 mmol), 2,3-dihydro-1H-indene-2-carboxylic acid (421 mg, 2.60 mmol) and EDCI.HC1 (497 mg, 2.60 mmol) in pyridine (4 mL) was stirred at 50 C for 2 h. The reaction mixture turned into brown solution from yellow. The reaction mixture was concentrated and the residue was diluted with water (25 mL), and then extracted with Et0Ac/THF (25 mL x3, 1/1). The combined organic layer was washed with brine (25 mL), dried over anhydrous Na2SO4 and concentrated. The crude product was triturated with pentane/EtOAC (10 mL, 1/1) to give N-(5-bromopyridin-3-y1)-2,3-dihydro-1H-indene-2-carboxamide (500 mg, yield: 91%) as a yellow solid.
NMR (400 MHz, CDC13) (53.23-3.41 (5H, m), 7.18-7.26 (4H, m), 7.39 (1H, brs), 8.41 (1H, d, J= 2.0 Hz), 8.43 (1H, d, J= 2.3 Hz), 8.48-8.51 (1H, m).
Step 2: Preparation of N-(5-((5 -methyl-8-(2-oxopy rroli din-l-y1)-5H-chromeno [4,3 -c] py ri din-3 -y Damino)py ri din-3-y 0-2,3-dihy dro-1H-indene-2-carboxami de
248 I
N N
[0555] A
mixture of 1-(3-amino-5-methy1-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (60 mg, 0.20 mmol), N-(5-bromopyridin-3-y1)-2,3-dihydro-1H-indene-2-carboxamide (97 mg, 0.30 mmol), Pd2(dba)3 (19 mg, 0.020 mmol), BrettPhos (22 mg, 0.041 mmol) and Cs2CO3 (199 mg, 0.609 mmol) in anhydrous dioxane (3 mL) was degassed and purged with N2 for 3 times. Then the resulting reaction mixture was stirred at 90 C for 16 h under N2 atmosphere.
The reaction mixture turned into yellow suspension from red. LCMS (Rt = 0.922 min; MS
Calcd: 708.3; MS Found: 709.1 [M+H1+). To the reaction mixture was added water (20 mL), then extracted with Et0Ac/THF (20 mL x3, 1/1). The combined organic layer was washed with brine (20 mL), dried over anhydrous Na2SO4 and concentrated. The residue was purified by prep-HPLC (0.225% FA as additive). Most of the MeCN was removed under reduced pressure and the remaining part was lyophilized to give N-(5-45-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno [4,3-c] py ri din-3-y0amino)py ri din-3 -y1)-2,3 -dihy dro-1H-indene-2-carb oxami de (46.0 mg, yield: 43%) as a yellow solid.
11-1NMR (400 MHz, DMSO-d6) 5 1.55 (3H, d, J= 6.5 Hz), 2.01-2.11 (2H, m), 2.52-2.54 (2H, m), 3.14-3.27 (4H, m), 3.50-3.51 (1H, m), 3.84 (2H, t, J= 7.9 Hz), 5.28 (1H, q, J= 6.3 Hz), 6.78 (1H, s), 7.13-7.19 (2H, m), 7.22-7.27 (2H, m), 7.33 (1H, dd, J= 8.5, 2.0 Hz), 7.40(1H, d, J= 2.3 Hz), 7.90 (1H, d, J= 8.8 Hz), 8.46 (1H, s), 8.62 (1H, t, J= 2.0 Hz), 8.68 (1H, s), 8.72 (1H, d, J= 1.8 Hz), 9.67 (1H, brs), 10.41 (1H, brs).
Example 139: N-(5-05-methyl-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-yl)amino)pyridin-3-yl)imidazo[1,2-a]pyridine-2-carboxamide 0 )\1 0 )cN
N N N
H I /
\ -
N N
[0555] A
mixture of 1-(3-amino-5-methy1-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (60 mg, 0.20 mmol), N-(5-bromopyridin-3-y1)-2,3-dihydro-1H-indene-2-carboxamide (97 mg, 0.30 mmol), Pd2(dba)3 (19 mg, 0.020 mmol), BrettPhos (22 mg, 0.041 mmol) and Cs2CO3 (199 mg, 0.609 mmol) in anhydrous dioxane (3 mL) was degassed and purged with N2 for 3 times. Then the resulting reaction mixture was stirred at 90 C for 16 h under N2 atmosphere.
The reaction mixture turned into yellow suspension from red. LCMS (Rt = 0.922 min; MS
Calcd: 708.3; MS Found: 709.1 [M+H1+). To the reaction mixture was added water (20 mL), then extracted with Et0Ac/THF (20 mL x3, 1/1). The combined organic layer was washed with brine (20 mL), dried over anhydrous Na2SO4 and concentrated. The residue was purified by prep-HPLC (0.225% FA as additive). Most of the MeCN was removed under reduced pressure and the remaining part was lyophilized to give N-(5-45-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno [4,3-c] py ri din-3-y0amino)py ri din-3 -y1)-2,3 -dihy dro-1H-indene-2-carb oxami de (46.0 mg, yield: 43%) as a yellow solid.
11-1NMR (400 MHz, DMSO-d6) 5 1.55 (3H, d, J= 6.5 Hz), 2.01-2.11 (2H, m), 2.52-2.54 (2H, m), 3.14-3.27 (4H, m), 3.50-3.51 (1H, m), 3.84 (2H, t, J= 7.9 Hz), 5.28 (1H, q, J= 6.3 Hz), 6.78 (1H, s), 7.13-7.19 (2H, m), 7.22-7.27 (2H, m), 7.33 (1H, dd, J= 8.5, 2.0 Hz), 7.40(1H, d, J= 2.3 Hz), 7.90 (1H, d, J= 8.8 Hz), 8.46 (1H, s), 8.62 (1H, t, J= 2.0 Hz), 8.68 (1H, s), 8.72 (1H, d, J= 1.8 Hz), 9.67 (1H, brs), 10.41 (1H, brs).
Example 139: N-(5-05-methyl-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-yl)amino)pyridin-3-yl)imidazo[1,2-a]pyridine-2-carboxamide 0 )\1 0 )cN
N N N
H I /
\ -
249 [0556] A
mixture of 1-(3-((5-aminopyridin-3-yl)amino)-5-methy1-5H-chromeno[4,3-c]pyridin-8-y1)pyrrolidin-2-one (60 mg, 0.14 mmol, HC1 salt), imidazo[1,2-a]pyridine-2-carboxylic acid (34 mg, 0.21 mmol) and EDCI.HC1 (41 mg, 0.21 mmol) in pyridine (2 mL) was stirred at 50 C for 2 h. The reaction mixture turned into white suspension from yellow solution. LCMS (Rt = 0.750 min; MS Calcd: 531.2; MS Found: 532.1 [M+H]+). The reaction mixture was diluted with water (25 mL), and then extracted with Et0Ac/THF (25 mL x3, 1/1).
The combined organic layer was washed with saturated aqueous NaHCO3 (25 mL), brine (25 mL), dried over anhydrous Na2SO4 and concentrated. The residue was triturated with MeCN
(10 mL), then further purified by prep-HPLC (0.225% FA as an additive). Most of the MeCN
was removed under reduced pressure and the remaining part was lyophilized to give N-(5-((5-methy1-8-(2-oxopy rroli din-1 -y1)-5H-chromeno [4,3 -c] py ri din-3-yl)amino)py ri din-3 -yl)imidazo[1,2-a]pyridine-2-carboxamide (29.8 mg, yield: 40%) as a yellow solid.
11-1NMR (400 MHz, DMSO-d6) (51.56 (3H, d, J= 6.5 Hz), 2.01-2.11 (2H, m), 2.52-2.54 (2H, m), 3.85 (2H, t, J= 7.9 Hz), 5.29 (1H, q, J= 6.4 Hz), 6.79 (1H, s), 7.05 (1H, td, J= 6.8, 1.1 Hz), 7.33 (1H, dd, J= 8.7, 2.1 Hz), 7.39-7.44 (2H, m), 7.69 (1H, dd, J= 9.2, 0.9 Hz), 7.90 (1H, d, J= 8.8 Hz), 8.58 (1H, s), 8.59 (1H, t, J= 2.3 Hz), 8.65 (1H, td, J=
6.8, 1.1 Hz), 8.69 (1H, d, J= 2.3 Hz), 8.70 (1H, s), 8.78 (1H, t, J= 2.3 Hz), 9.52 (1H, brs), 10.51 (1H, brs).
Example 140: N-(5-05-methyl-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-yl)amino)pyridin-3-yl)pyrazolo[1,5-a]pyridine-2-carboxamide N N 11)n --N
\-Step 1: Preparation of N-(5 -bromopy ridin-3-yl)pyrazolo [1,5-a] py ridine-2-carb oxami de I
BrN).Y __________________________________ H
mixture of 5-bromopyridin-3-amine (300 mg, 1.73 mmol), pyrazolo[1,5-a]pyridine-2-carboxylic acid (421 mg, 2.60 mmol) and EDCI.HC1 (497 mg, 2.60 mmol) in
mixture of 1-(3-((5-aminopyridin-3-yl)amino)-5-methy1-5H-chromeno[4,3-c]pyridin-8-y1)pyrrolidin-2-one (60 mg, 0.14 mmol, HC1 salt), imidazo[1,2-a]pyridine-2-carboxylic acid (34 mg, 0.21 mmol) and EDCI.HC1 (41 mg, 0.21 mmol) in pyridine (2 mL) was stirred at 50 C for 2 h. The reaction mixture turned into white suspension from yellow solution. LCMS (Rt = 0.750 min; MS Calcd: 531.2; MS Found: 532.1 [M+H]+). The reaction mixture was diluted with water (25 mL), and then extracted with Et0Ac/THF (25 mL x3, 1/1).
The combined organic layer was washed with saturated aqueous NaHCO3 (25 mL), brine (25 mL), dried over anhydrous Na2SO4 and concentrated. The residue was triturated with MeCN
(10 mL), then further purified by prep-HPLC (0.225% FA as an additive). Most of the MeCN
was removed under reduced pressure and the remaining part was lyophilized to give N-(5-((5-methy1-8-(2-oxopy rroli din-1 -y1)-5H-chromeno [4,3 -c] py ri din-3-yl)amino)py ri din-3 -yl)imidazo[1,2-a]pyridine-2-carboxamide (29.8 mg, yield: 40%) as a yellow solid.
11-1NMR (400 MHz, DMSO-d6) (51.56 (3H, d, J= 6.5 Hz), 2.01-2.11 (2H, m), 2.52-2.54 (2H, m), 3.85 (2H, t, J= 7.9 Hz), 5.29 (1H, q, J= 6.4 Hz), 6.79 (1H, s), 7.05 (1H, td, J= 6.8, 1.1 Hz), 7.33 (1H, dd, J= 8.7, 2.1 Hz), 7.39-7.44 (2H, m), 7.69 (1H, dd, J= 9.2, 0.9 Hz), 7.90 (1H, d, J= 8.8 Hz), 8.58 (1H, s), 8.59 (1H, t, J= 2.3 Hz), 8.65 (1H, td, J=
6.8, 1.1 Hz), 8.69 (1H, d, J= 2.3 Hz), 8.70 (1H, s), 8.78 (1H, t, J= 2.3 Hz), 9.52 (1H, brs), 10.51 (1H, brs).
Example 140: N-(5-05-methyl-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-yl)amino)pyridin-3-yl)pyrazolo[1,5-a]pyridine-2-carboxamide N N 11)n --N
\-Step 1: Preparation of N-(5 -bromopy ridin-3-yl)pyrazolo [1,5-a] py ridine-2-carb oxami de I
BrN).Y __________________________________ H
mixture of 5-bromopyridin-3-amine (300 mg, 1.73 mmol), pyrazolo[1,5-a]pyridine-2-carboxylic acid (421 mg, 2.60 mmol) and EDCI.HC1 (497 mg, 2.60 mmol) in
250 pyridine (4 mL) was stirred at 50 C for 2 h. The reaction mixture turned into brown solution from yellow. The reaction mixture was concentrated and the residue was diluted with water (25 mL), and then extracted with Et0Ac/THF (25 mL x3, 3/1). The combined organic layer was washed with brine (25 mL), dried over anhydrous Na2SO4 and concentrated.
The crude product was triturated with pentane/EtOAC (10 mL, 1/1) to give N-(5-bromopyridin-3-yOpyrazolo[1,5-alpyridine-2-carboxamide (498 mg, yield: 91%) as a yellow solid.
11-1 NMR (400 MHz, DMSO-d6) 7.12 (1H, td, J= 6.9, 1.3 Hz), 7.19 (1H, s), 7.36 (1H, ddd, J= 9.0, 6.8, 1.0 Hz), 7.86 (1H, d, J= 8.8 Hz), 8.45 (1H, d, J= 2.0 Hz), 8.62 (1H, t, J= 2.1 Hz), 8.76 (1H, dd, J= 7.0, 1.0 Hz), 9.05 (1H, d, J= 2.3 Hz), 10.92 (1H, brs).
Step 2: Preparation of N-(5-((5 -methyl-8-(2-oxopy rroli din-l-y1)-5H-chromeno [4,3 -c] py ri din-3 -y0amino)pyridin-3-yOpyrazol o [1,5-a] pyridine-2-carboxami de N; 0 I I
N NN)Y
H
N-N
\ ¨
mixture of 1-(3-amino-5-methy1-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (60 mg, 0.20 mmol), N-(5-bromopyridin-3-yOpyrazolo[1,5-alpyridine-2-carboxamide (97 mg, 0.30 mmol), Pd2(dba)3 (19 mg, 0.020 mmol), BrettPhos (22 mg, 0.041 mmol) and Cs2CO3 (199 mg, 0.609 mmol) in anhydrous dioxane (3 mL) was degassed and purged with N2 for 3 times. Then the resulting reaction mixture was stirred at 90 C for 16 h under N2 atmosphere.
The reaction mixture turned into yellow suspension from red. LCMS indicated -50% of the starting material N-(5-bromopy ri din-3 -yl)pyrazol o [1,5 -a] py ri dine-2-carb oxami de was remained. To the reaction mixture was added another batch of Pd2(dba)3 (19 mg, 0.020 mmol), BrettPhos (22 mg, 0.041 mmol) and Cs2CO3 (199 mg, 0.609 mmol). Then the reaction mixture was degassed and purged with N2 for 3 times. Then the resulting reaction mixture was stirred at 90 C for another 8 h under N2 atmosphere. LCMS (Rt = 0.726 min; MS Calcd:
531.2; MS
Found: 532.1 [M+H1+). To the reaction mixture was added water (25 mL), then extracted with Et0Ac/THF (25 mL x3, 1/1). The combined organic layer was washed with brine (25 mL), dried over anhydrous Na2SO4 and concentrated. The residue was purified by prep-HPLC
(0.225% FA as additive). Most of the MeCN was removed under reduced pressure and the remaining part was lyophilized to give N-(5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-
The crude product was triturated with pentane/EtOAC (10 mL, 1/1) to give N-(5-bromopyridin-3-yOpyrazolo[1,5-alpyridine-2-carboxamide (498 mg, yield: 91%) as a yellow solid.
11-1 NMR (400 MHz, DMSO-d6) 7.12 (1H, td, J= 6.9, 1.3 Hz), 7.19 (1H, s), 7.36 (1H, ddd, J= 9.0, 6.8, 1.0 Hz), 7.86 (1H, d, J= 8.8 Hz), 8.45 (1H, d, J= 2.0 Hz), 8.62 (1H, t, J= 2.1 Hz), 8.76 (1H, dd, J= 7.0, 1.0 Hz), 9.05 (1H, d, J= 2.3 Hz), 10.92 (1H, brs).
Step 2: Preparation of N-(5-((5 -methyl-8-(2-oxopy rroli din-l-y1)-5H-chromeno [4,3 -c] py ri din-3 -y0amino)pyridin-3-yOpyrazol o [1,5-a] pyridine-2-carboxami de N; 0 I I
N NN)Y
H
N-N
\ ¨
mixture of 1-(3-amino-5-methy1-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (60 mg, 0.20 mmol), N-(5-bromopyridin-3-yOpyrazolo[1,5-alpyridine-2-carboxamide (97 mg, 0.30 mmol), Pd2(dba)3 (19 mg, 0.020 mmol), BrettPhos (22 mg, 0.041 mmol) and Cs2CO3 (199 mg, 0.609 mmol) in anhydrous dioxane (3 mL) was degassed and purged with N2 for 3 times. Then the resulting reaction mixture was stirred at 90 C for 16 h under N2 atmosphere.
The reaction mixture turned into yellow suspension from red. LCMS indicated -50% of the starting material N-(5-bromopy ri din-3 -yl)pyrazol o [1,5 -a] py ri dine-2-carb oxami de was remained. To the reaction mixture was added another batch of Pd2(dba)3 (19 mg, 0.020 mmol), BrettPhos (22 mg, 0.041 mmol) and Cs2CO3 (199 mg, 0.609 mmol). Then the reaction mixture was degassed and purged with N2 for 3 times. Then the resulting reaction mixture was stirred at 90 C for another 8 h under N2 atmosphere. LCMS (Rt = 0.726 min; MS Calcd:
531.2; MS
Found: 532.1 [M+H1+). To the reaction mixture was added water (25 mL), then extracted with Et0Ac/THF (25 mL x3, 1/1). The combined organic layer was washed with brine (25 mL), dried over anhydrous Na2SO4 and concentrated. The residue was purified by prep-HPLC
(0.225% FA as additive). Most of the MeCN was removed under reduced pressure and the remaining part was lyophilized to give N-(5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-
251 chromeno [4,3-c] pyridin-3-yl)amino)pyridin-3-yl)pyrazolo [1,5-a] pyri dine-2-carboxamide (12.8 mg, yield: 12%) as a yellow solid.
NMR (400 MHz, DMSO-d6) 1.56 (3H, d, J= 6.5 Hz), 2.01-2.11 (2H, m), 2.52-2.54 (2H, m), 3.85 (2H, t, J= 7.8 Hz), 5.31 (1H, q, J= 6.3 Hz), 6.82 (1H, s), 7.12 (1H, t, J= 6.9 Hz), 7.21 (1H, s), 7.31-7.39 (2H, m), 7.41 (1H, d, J= 2.3 Hz), 7.86 (1H, d, J= 9.0 Hz), 7.91 (1H, d, J= 8.5 Hz), 8.65-8.69 (1H, m), 8.72 (1H, s), 8.77 (1H, d, J= 7.0 Hz), 8.84-8.91 (2H, m), 9.83 (1H, brs), 10.87 (1H, brs).
Example 141: N-(5-05-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-yl)amino)pyridin-3-y1)-1H-indole-2-carboxamide N
H
[0559] A
mixture of 1-(3-((5-aminopyridin-3-yl)amino)-5-methy1-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one (60 mg, 0.14 mmol, HC1 salt), 1H-indole-2-carboxylic acid (34 mg, 0.21 mmol) and EDCI.HC1 (41 mg, 0.21 mmol) in pyridine (2 mL) was stirred at 50 C for 2 h. The reaction mixture turned into white suspension from yellow solution.
LCMS (Rt = 0.780 min; MS Calcd: 530.2; MS Found: 531.1 [M+H1+). The reaction mixture was diluted with water (25 mL), and then extracted with Et0Ac (25 mL x3). The combined organic layer was washed with saturated aqueous NaHCO3 (25 mL), brine (25 mL), dried over anhydrous Na2SO4 and concentrated. The residue was purified by prep-HPLC (0.225% FA as an additive).
Most of the MeCN was removed under reduced pressure and the remaining part was lyophilized to give N-(5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-y1)-1H-indole-2-carboxamide (32.8 mg, yield: 44%) as a yellow solid.
NMR (400 MHz, DMSO-d6) (5 1.56 (3H, d, J= 6.5 Hz), 2.01-2.11 (2H, m), 2.52-2.54 (2H, m), 3.84 (2H, t, J= 7.7 Hz), 5.30 (1H, q, J= 6.5 Hz), 6.81 (1H, s), 7.07-7.12 (1H, m), 7.26 (1H, t, J= 7.5 Hz), 7.33 (1H, dd, J= 8.5, 2.3 Hz), 7.41 (1H, d, J= 2.0 Hz), 7.47-7.52 (2H, m), 7.71 (1H, d, J= 7.8 Hz), 7.89 (1H, d, J= 8.5 Hz), 8.61 (1H, s), 8.69 (1H, s), 8.73-8.77 (2H, m), 9.67 (1H, brs), 10.51 (1H, brs), 11.83 (1H, brs).
NMR (400 MHz, DMSO-d6) 1.56 (3H, d, J= 6.5 Hz), 2.01-2.11 (2H, m), 2.52-2.54 (2H, m), 3.85 (2H, t, J= 7.8 Hz), 5.31 (1H, q, J= 6.3 Hz), 6.82 (1H, s), 7.12 (1H, t, J= 6.9 Hz), 7.21 (1H, s), 7.31-7.39 (2H, m), 7.41 (1H, d, J= 2.3 Hz), 7.86 (1H, d, J= 9.0 Hz), 7.91 (1H, d, J= 8.5 Hz), 8.65-8.69 (1H, m), 8.72 (1H, s), 8.77 (1H, d, J= 7.0 Hz), 8.84-8.91 (2H, m), 9.83 (1H, brs), 10.87 (1H, brs).
Example 141: N-(5-05-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-yl)amino)pyridin-3-y1)-1H-indole-2-carboxamide N
H
[0559] A
mixture of 1-(3-((5-aminopyridin-3-yl)amino)-5-methy1-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one (60 mg, 0.14 mmol, HC1 salt), 1H-indole-2-carboxylic acid (34 mg, 0.21 mmol) and EDCI.HC1 (41 mg, 0.21 mmol) in pyridine (2 mL) was stirred at 50 C for 2 h. The reaction mixture turned into white suspension from yellow solution.
LCMS (Rt = 0.780 min; MS Calcd: 530.2; MS Found: 531.1 [M+H1+). The reaction mixture was diluted with water (25 mL), and then extracted with Et0Ac (25 mL x3). The combined organic layer was washed with saturated aqueous NaHCO3 (25 mL), brine (25 mL), dried over anhydrous Na2SO4 and concentrated. The residue was purified by prep-HPLC (0.225% FA as an additive).
Most of the MeCN was removed under reduced pressure and the remaining part was lyophilized to give N-(5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-y1)-1H-indole-2-carboxamide (32.8 mg, yield: 44%) as a yellow solid.
NMR (400 MHz, DMSO-d6) (5 1.56 (3H, d, J= 6.5 Hz), 2.01-2.11 (2H, m), 2.52-2.54 (2H, m), 3.84 (2H, t, J= 7.7 Hz), 5.30 (1H, q, J= 6.5 Hz), 6.81 (1H, s), 7.07-7.12 (1H, m), 7.26 (1H, t, J= 7.5 Hz), 7.33 (1H, dd, J= 8.5, 2.3 Hz), 7.41 (1H, d, J= 2.0 Hz), 7.47-7.52 (2H, m), 7.71 (1H, d, J= 7.8 Hz), 7.89 (1H, d, J= 8.5 Hz), 8.61 (1H, s), 8.69 (1H, s), 8.73-8.77 (2H, m), 9.67 (1H, brs), 10.51 (1H, brs), 11.83 (1H, brs).
252 Example 142: N-(5-05-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno [4,3-c] pyri din-3-yl)amin o)pyrid in-3-y1)-2,3-dihyd rob enzofuran-2-carb oxamide I
HHQ
Step 1: Preparation of N-(5-bromopyri din-3-y1)-2,3 -dihy drob enzofuran-2-carboxami de BrN
HQ
[0560] A mixture of 5-bromopyridin-3-amine (300 mg, 1.73 mmol), 2,3-dihydrobenzofuran-2-carboxylic acid (426 mg, 2.60 mmol) and EDCI.HC1 (497 mg, 2.60 mmol) in pyridine (4 mL) was stirred at 50 C for 2 h. The reaction mixture turned into brown solution from yellow. The reaction mixture was concentrated and the residue was diluted with water (25 mL), and then extracted with Et0Ac (25 mL x3). The combined organic layer was washed with brine (25 mL), dried over anhydrous Na2SO4 and concentrated. The residue was purified by Combi Flash (20% to 50% Et0Ac in pentane) to give N-(5-bromopyridin-3-y1)-2,3-dihydrobenzofuran-2-carboxamide (500 mg, yield: 91%) as yellow gum.
1FINMR (400 MHz, CDC13) (53.49-3.57 (1H, m), 3.64-3.74 (1H, m), 5.28 (1H, dd, J= 10.8, 6.5 Hz), 6.94-7.01 (2H, m), 7.18-7.26 (2H, m), 8.39-8.49 (3H, m), 8.54 (1H, d, J = 2.3 Hz).
Step 2: Preparation of N-(5-((5 -methyl-8-(2-oxopy rroli din-l-y1)-5H-chromeno [4,3 -c] py ri din-3 -y Damino)py ri din-3-y 0-2,3-dihy drob enzofuran-2-carb oxami de I
HHQ
[0561] A
mixture of 1-(3-amino-5-methy1-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (60 mg, 0.20 mmol), N-(5-bromopyridin-3-y1)-2,3-dihydrobenzofuran-2-carboxamide (97
HHQ
Step 1: Preparation of N-(5-bromopyri din-3-y1)-2,3 -dihy drob enzofuran-2-carboxami de BrN
HQ
[0560] A mixture of 5-bromopyridin-3-amine (300 mg, 1.73 mmol), 2,3-dihydrobenzofuran-2-carboxylic acid (426 mg, 2.60 mmol) and EDCI.HC1 (497 mg, 2.60 mmol) in pyridine (4 mL) was stirred at 50 C for 2 h. The reaction mixture turned into brown solution from yellow. The reaction mixture was concentrated and the residue was diluted with water (25 mL), and then extracted with Et0Ac (25 mL x3). The combined organic layer was washed with brine (25 mL), dried over anhydrous Na2SO4 and concentrated. The residue was purified by Combi Flash (20% to 50% Et0Ac in pentane) to give N-(5-bromopyridin-3-y1)-2,3-dihydrobenzofuran-2-carboxamide (500 mg, yield: 91%) as yellow gum.
1FINMR (400 MHz, CDC13) (53.49-3.57 (1H, m), 3.64-3.74 (1H, m), 5.28 (1H, dd, J= 10.8, 6.5 Hz), 6.94-7.01 (2H, m), 7.18-7.26 (2H, m), 8.39-8.49 (3H, m), 8.54 (1H, d, J = 2.3 Hz).
Step 2: Preparation of N-(5-((5 -methyl-8-(2-oxopy rroli din-l-y1)-5H-chromeno [4,3 -c] py ri din-3 -y Damino)py ri din-3-y 0-2,3-dihy drob enzofuran-2-carb oxami de I
HHQ
[0561] A
mixture of 1-(3-amino-5-methy1-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (60 mg, 0.20 mmol), N-(5-bromopyridin-3-y1)-2,3-dihydrobenzofuran-2-carboxamide (97
253 mg, 0.30 mmol) Pd2(dba)3 (19 mg, 0.020 mmol), BrettPhos (22 mg, 0.041 mmol) and Cs2CO3 (199 mg, 0.609 mmol) in anhydrous dioxane (3 mL) was degassed and purged with N2 for 3 times. Then the resulting reaction mixture was stirred at 90 C for 16 h under N2 atmosphere.
The reaction mixture turned into yellow suspension from red. LCMS (Rt = 0.638 min; MS
Calcd: 533.2; MS Found: 534.1 [M+H1+). To the reaction mixture was added water (25 mL) and Et0Ac (20 mL), then extracted with Et0Ac/THF (25 mL x3, 3/1). The combined organic layer was washed with brine (25 mL), dried over anhydrous Na2SO4 and concentrated. The residue was purified by Combi Flash (2% to 10% Me0H in DCM), then triturated with MeCN
(10 mL) and dried under vacuum to give N-(5-45-methy1-8-(2-oxopyrrolidin-1-y1)-chromeno [4,3-c] py ri din-3-y0amino)py ri din-3-y1)-2,3 -dihy drobenzofuran-2-carb oxami de (51.7 mg, yield: 48%) as a yellow solid.
NMR (400 MHz, DMSO-d6) (51.54 (3H, d, J= 6.6 Hz), 2.01-2.11 (2H, m), 2.52-2.54 (2H, m), 3.40 (1H, dd, J= 15.8, 6.8 Hz), 3.52-3.60 (1H, m), 3.84 (2H, t, J = 7.8 Hz), 5.27 (1H, q, J
= 6.5 Hz), 5.37 (1H, dd, J= 10.2, 6.7 Hz), 6.75 (1H, s), 6.87-6.94 (2H, m), 7.13-7.19 (1H, m), 7.25-7.28 (1H, m), 7.32 (1H, dd, J = 8.6, 2.1 Hz), 7.40 (1H, d, J = 2.2 Hz), 7.89 (1H, d, J
= 8.7 Hz), 8.39 (1H, d, J= 1.3 Hz), 8.59-8.63 (2H, m), 8.67 (1H, s), 9.49 (1H, brs), 10.37 (1H, brs).
Example 143: N-(5-05-methyl-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-yl)amino)pyridin-3-yl)imidazo[1,2-a]pyridine-3-carboxamide gN 0 H
[0562] A
mixture of 1-(3-((5 -aminopy ri din-3-yl)amino)-5 -methyl-5H-chromeno [4,3-clpyridin-8-yOpyrrolidin-2-one (60 mg, 0.16 mmol, HC1 salt), imidazo[1,2-alpyridine-3-carboxylic acid (38 mg, 0.23 mmol) and EDCI.HC1 (45 mg, 0.23 mmol) in pyridine (2 mL) was heated at 30 C for 12 h. A yellow suspension was formed. LCMS (Rt = 0.689 min; MS
Calcd: 531.2; MS Found: 532.1 [M+H1+). The mixture was concentrated and the residue was poured into water (20 mL) and stirred for 2 minutes. The aqueous layer was extracted with ethyl acetate (20 mL x3). The combined organic layer was washed with water (20 mL x2) and brine (20 mL), dried over anhydrous Na2SO4, filtered and concentrated. The residue was
The reaction mixture turned into yellow suspension from red. LCMS (Rt = 0.638 min; MS
Calcd: 533.2; MS Found: 534.1 [M+H1+). To the reaction mixture was added water (25 mL) and Et0Ac (20 mL), then extracted with Et0Ac/THF (25 mL x3, 3/1). The combined organic layer was washed with brine (25 mL), dried over anhydrous Na2SO4 and concentrated. The residue was purified by Combi Flash (2% to 10% Me0H in DCM), then triturated with MeCN
(10 mL) and dried under vacuum to give N-(5-45-methy1-8-(2-oxopyrrolidin-1-y1)-chromeno [4,3-c] py ri din-3-y0amino)py ri din-3-y1)-2,3 -dihy drobenzofuran-2-carb oxami de (51.7 mg, yield: 48%) as a yellow solid.
NMR (400 MHz, DMSO-d6) (51.54 (3H, d, J= 6.6 Hz), 2.01-2.11 (2H, m), 2.52-2.54 (2H, m), 3.40 (1H, dd, J= 15.8, 6.8 Hz), 3.52-3.60 (1H, m), 3.84 (2H, t, J = 7.8 Hz), 5.27 (1H, q, J
= 6.5 Hz), 5.37 (1H, dd, J= 10.2, 6.7 Hz), 6.75 (1H, s), 6.87-6.94 (2H, m), 7.13-7.19 (1H, m), 7.25-7.28 (1H, m), 7.32 (1H, dd, J = 8.6, 2.1 Hz), 7.40 (1H, d, J = 2.2 Hz), 7.89 (1H, d, J
= 8.7 Hz), 8.39 (1H, d, J= 1.3 Hz), 8.59-8.63 (2H, m), 8.67 (1H, s), 9.49 (1H, brs), 10.37 (1H, brs).
Example 143: N-(5-05-methyl-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-yl)amino)pyridin-3-yl)imidazo[1,2-a]pyridine-3-carboxamide gN 0 H
[0562] A
mixture of 1-(3-((5 -aminopy ri din-3-yl)amino)-5 -methyl-5H-chromeno [4,3-clpyridin-8-yOpyrrolidin-2-one (60 mg, 0.16 mmol, HC1 salt), imidazo[1,2-alpyridine-3-carboxylic acid (38 mg, 0.23 mmol) and EDCI.HC1 (45 mg, 0.23 mmol) in pyridine (2 mL) was heated at 30 C for 12 h. A yellow suspension was formed. LCMS (Rt = 0.689 min; MS
Calcd: 531.2; MS Found: 532.1 [M+H1+). The mixture was concentrated and the residue was poured into water (20 mL) and stirred for 2 minutes. The aqueous layer was extracted with ethyl acetate (20 mL x3). The combined organic layer was washed with water (20 mL x2) and brine (20 mL), dried over anhydrous Na2SO4, filtered and concentrated. The residue was
254 purified by prep-HPLC (0.225% FA as an additive) and lyophilized to give N-(5-45-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-y0imidazo[1,2-alpyridine-3-carboxamide (48.6 mg, yield: 59%) as a yellow solid.
NMR (400 MHz DMSO-d6) 1.51-1.54 (3H, m), 2.04-2.16 (2H, m), 2.52-2.54 (2H, m, overlapped with the peak of DMSO), 3.72-4.56 (2H, m), 5.28-5.43 (1H, m), 6.82-7.00 (1H, m), 7.25-7.52 (3H, m), 7.58-7.73 (1H, m), 7.81-8.04 (2H, m), 8.68-9.08 (5H, m), 9.47-9.62 (1H, m), 10.07 (1H, brs), 10.88 (1H, brs).
Example 144: N-(5-05-methyl-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-yl)amino)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carboxamide c 0 rN 0 _ N NN
[0563] A
mixture of 1-(3-((5-aminopyridin-3-y0amino)-5-methyl-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (60 mg, 0.16 mmol, HC1 salt), pyrazolo[1,5-alpyridine-3-carboxylic acid(38 mg, 0.23 mmol) and EDCI.HC1 (45 mg, 0.23 mmol) in pyridine (2 mL) was heated at 30 C for 12 h. A yellow suspension was formed. LCMS (Rt = 0.720 min; MS Calcd:
531.2; MS Found: 532.1 [M+H]+). The mixture was concentrated and the residue was poured into water (20 mL) and stirred for 2 minutes. The aqueous layer was extracted with ethyl acetate (20 mL x3). The combined organic layer was washed with water (20 mL
x2) and brine (20 mL), dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by prep-HPLC (0.225% FA as an additive) and lyophilized to give N-(5-((5-methy1-8-(2-oxopy rroli din-l-y1)-5H-chromeno [4,3 -c] py ri din-3-yl)amino)py ri din-3-yl)pyrazol o [1,5-alpyridine-3-carboxamide (40.0 mg, yield: 48%) as a yellow solid.
NMR (400 MHz DMSO-d6) (5 1.56 (3H, d, J= 6.5 Hz), 2.02-2.10 (2H, m), 2.52-2.54 (2H, m, overlapped with the peak of DMSO), 3.85 (2H, t, J= 7.8 Hz), 5.29 (1H, q, J=
6.4 Hz), 6.79 (1H, s), 7.16 (1H, td, J= 6.9, 1.3 Hz), 7.32 (1H, dd, J= 8.5, 2.3 Hz), 7.41 (1H, d, J= 2.3 Hz), 7.57 (1H, t, J= 7.8 Hz), 7.90 (1H, d, J= 8.5 Hz), 8.30 (1H, d, J= 8.8 Hz), 8.52 (1H, s), 8.64-8.72 (3H, m), 8.84-8.89 (2H, m), 9.53 (1H, brs), 10.16 (1H, brs).
NMR (400 MHz DMSO-d6) 1.51-1.54 (3H, m), 2.04-2.16 (2H, m), 2.52-2.54 (2H, m, overlapped with the peak of DMSO), 3.72-4.56 (2H, m), 5.28-5.43 (1H, m), 6.82-7.00 (1H, m), 7.25-7.52 (3H, m), 7.58-7.73 (1H, m), 7.81-8.04 (2H, m), 8.68-9.08 (5H, m), 9.47-9.62 (1H, m), 10.07 (1H, brs), 10.88 (1H, brs).
Example 144: N-(5-05-methyl-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-yl)amino)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carboxamide c 0 rN 0 _ N NN
[0563] A
mixture of 1-(3-((5-aminopyridin-3-y0amino)-5-methyl-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (60 mg, 0.16 mmol, HC1 salt), pyrazolo[1,5-alpyridine-3-carboxylic acid(38 mg, 0.23 mmol) and EDCI.HC1 (45 mg, 0.23 mmol) in pyridine (2 mL) was heated at 30 C for 12 h. A yellow suspension was formed. LCMS (Rt = 0.720 min; MS Calcd:
531.2; MS Found: 532.1 [M+H]+). The mixture was concentrated and the residue was poured into water (20 mL) and stirred for 2 minutes. The aqueous layer was extracted with ethyl acetate (20 mL x3). The combined organic layer was washed with water (20 mL
x2) and brine (20 mL), dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by prep-HPLC (0.225% FA as an additive) and lyophilized to give N-(5-((5-methy1-8-(2-oxopy rroli din-l-y1)-5H-chromeno [4,3 -c] py ri din-3-yl)amino)py ri din-3-yl)pyrazol o [1,5-alpyridine-3-carboxamide (40.0 mg, yield: 48%) as a yellow solid.
NMR (400 MHz DMSO-d6) (5 1.56 (3H, d, J= 6.5 Hz), 2.02-2.10 (2H, m), 2.52-2.54 (2H, m, overlapped with the peak of DMSO), 3.85 (2H, t, J= 7.8 Hz), 5.29 (1H, q, J=
6.4 Hz), 6.79 (1H, s), 7.16 (1H, td, J= 6.9, 1.3 Hz), 7.32 (1H, dd, J= 8.5, 2.3 Hz), 7.41 (1H, d, J= 2.3 Hz), 7.57 (1H, t, J= 7.8 Hz), 7.90 (1H, d, J= 8.5 Hz), 8.30 (1H, d, J= 8.8 Hz), 8.52 (1H, s), 8.64-8.72 (3H, m), 8.84-8.89 (2H, m), 9.53 (1H, brs), 10.16 (1H, brs).
255 Example 145: 2-(imidazo[1,2-a]pyridin-3-y1)-N-(5-45-methyl-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-yl)acetamide I iNb Step 1: Preparation of 2-(imidazo [1,2-a] pyridin-3 -yl)aceti c acid iNL
HO
[0564] To a solution of pyridin-2-amine (1.00 g, 10.6 mmol) in de-mineralized water (13 mL) was added ethyl (E)-4-oxobut-2-enoate (1.40 g, 10.9 mmol) at 20-25 C.
Then the reaction mixture was stirred at 20-25 C for 1 hour. The reaction mixture turned into red solution from yellow. A solution of KOH (0.8 g) in de-mineralized water (1 mL) was added and the reaction mixture was stirred at 20-25 C for 1 hour. The pH of the reaction mixture was adjusted to 5-6 with 2N aqueous HC1 and the reaction mixture was stirred for further 1 hour at 20-25 C. The resulting product was filtered, washed successively with water (5 mL
x2), ethanol (5 mL) and dried under reduced pressure to give 2-(imidazo[1,2-a]pyridin-3-yl)acetic acid(720 mg, yield: 38%) as a yellow solid.
1FINMR (400 MHz, DMSO-d6) 64.05 (2H, s), 6.94 (1H, td, J= 6.8, 1.1 Hz), 7.25 (1H, ddd, J= 9.2, 6.7, 1.0 Hz), 7.49 (1H, s), 7.57 (1H, dt, J= 9.0, 1.0 Hz), 8.29-8.33 (1H, m).
Step 2: Preparation of 2-(imidazo[1,2-a]pyridin-3-y1)-N-(5-45-methyl-8-(2-oxopyrrolidin-1-y1)-5H-chromeno [4,3 -c] pyri din-3-yl)amino)py ridin-3 -yl)acetami de c 0 I iNbNN2N
[0565] A
mixture of 1-(3-((5-aminopyridin-3-yl)amino)-5-methy1-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one (60 mg, 0.14 mmol, HC1 salt), 2-(imidazo[1,2-a]pyridin-3-yl)acetic acid (37 mg, 0.21 mmol) and EDCI.HC1 (41 mg, 0.21 mmol) in pyridine (2 mL) was stirred at 50 C for 2 h. The reaction mixture turned into brown solution from yellow. LCMS
HO
[0564] To a solution of pyridin-2-amine (1.00 g, 10.6 mmol) in de-mineralized water (13 mL) was added ethyl (E)-4-oxobut-2-enoate (1.40 g, 10.9 mmol) at 20-25 C.
Then the reaction mixture was stirred at 20-25 C for 1 hour. The reaction mixture turned into red solution from yellow. A solution of KOH (0.8 g) in de-mineralized water (1 mL) was added and the reaction mixture was stirred at 20-25 C for 1 hour. The pH of the reaction mixture was adjusted to 5-6 with 2N aqueous HC1 and the reaction mixture was stirred for further 1 hour at 20-25 C. The resulting product was filtered, washed successively with water (5 mL
x2), ethanol (5 mL) and dried under reduced pressure to give 2-(imidazo[1,2-a]pyridin-3-yl)acetic acid(720 mg, yield: 38%) as a yellow solid.
1FINMR (400 MHz, DMSO-d6) 64.05 (2H, s), 6.94 (1H, td, J= 6.8, 1.1 Hz), 7.25 (1H, ddd, J= 9.2, 6.7, 1.0 Hz), 7.49 (1H, s), 7.57 (1H, dt, J= 9.0, 1.0 Hz), 8.29-8.33 (1H, m).
Step 2: Preparation of 2-(imidazo[1,2-a]pyridin-3-y1)-N-(5-45-methyl-8-(2-oxopyrrolidin-1-y1)-5H-chromeno [4,3 -c] pyri din-3-yl)amino)py ridin-3 -yl)acetami de c 0 I iNbNN2N
[0565] A
mixture of 1-(3-((5-aminopyridin-3-yl)amino)-5-methy1-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one (60 mg, 0.14 mmol, HC1 salt), 2-(imidazo[1,2-a]pyridin-3-yl)acetic acid (37 mg, 0.21 mmol) and EDCI.HC1 (41 mg, 0.21 mmol) in pyridine (2 mL) was stirred at 50 C for 2 h. The reaction mixture turned into brown solution from yellow. LCMS
256 (Rt = 0.700 min; MS Calcd: 545.2; MS Found: 546.1 [M+H]+). The reaction mixture was diluted with water (25 mL), and then extracted with Et0Ac/THF (25 mL x3, 1/1).
The combined organic layer was washed with saturated aqueous NaHCO3 (25 mL), brine (25 mL), dried over anhydrous Na2SO4 and concentrated. The residue was purified by prep-HPLC
(0.225% FA as an additive). Most of the MeCN was removed under reduced pressure and the remaining part was lyophilized to give 2-(imidazo[1,2-alpyridin-3-y1)-N-(5-45-methyl-8-(2-oxopy rroli din-l-y1)-5H-chromeno [4,3 -c] py ri din-3-yl)amino)py ri din-3-yl)acetami de (29.7 mg, yield: 38%) as a yellow solid.
1FINMR (400 MHz, DMSO-d6) 5 1.53 (3H, d, J= 6.5 Hz), 2.01-2.11 (2H, m), 2.52-2.54 (2H, m), 3.84 (2H, t, J= 7.7 Hz), 4.27 (2H, s), 5.26 (1H, q, J= 6.0 Hz), 6.74 (1H, s), 7.23 (1H, t, J
= 6.8 Hz), 7.32 (1H, dd, J= 8.5, 2.0 Hz), 7.39 (1H, d, J= 2.0 Hz), 7.56-7.62 (1H, m), 7.78 (1H, d, J= 8.8 Hz), 7.82 (1H, s), 7.88 (1H, d, J= 8.5 Hz), 8.35 (1H, d, J= 1.8 Hz), 8.54-8.56 (1H, m), 8.58 (1H, d, J= 2.0 Hz), 8.61-8.66 (2H, m), 9.49 (1H, brs), 10.56 (1H, brs).
Example 146: N-(5-05-methyl-8-(2-oxopyrrolidin-1-y1)-5H-chromeno14,3-c]
pyridin-3-yl)amino)pyridin-3-yl)imidazo [1,2-a] pyridine-5-carb oxami de gN 0 N
N NNN
H I
[0566] A
mixture of 1-(3-((5 -aminopy ri din-3-yl)amino)-5 -methyl-5H-chromeno [4,3-clpyridin-8-yOpyrrolidin-2-one (60 mg, 0.16 mmol, HC1 salt), imidazo[1,2-alpyridine-5-carboxylic acid (38 mg, 0.23 mmol) and EDCI.HC1 (45 mg, 0.23 mmol) in pyridine (2 mL) was heated at 30 C for 48 h. A brown suspension was formed. LCMS (Rt = 0.652 min; MS
Calcd: 531.2; MS Found: 532.1 [M+H]+). The mixture was concentrated and the residue was poured into water (20 mL) and stirred for 2 minutes. The aqueous layer was extracted with ethyl acetate (20 mL x3).The combined organic layer was washed with water (20 mL x2) and brine (20 mL), dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by prep-TLC (DCM/Me0H, 10/1) then further purified by prep-HPLC
(0.05%
NH3 .H20 as an additive) and lyophilized to give N-(5-45-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-y0imidazo[1,2-alpyridine-5-carboxamide (5.8 mg, yield: 7%) as a yellow solid.
The combined organic layer was washed with saturated aqueous NaHCO3 (25 mL), brine (25 mL), dried over anhydrous Na2SO4 and concentrated. The residue was purified by prep-HPLC
(0.225% FA as an additive). Most of the MeCN was removed under reduced pressure and the remaining part was lyophilized to give 2-(imidazo[1,2-alpyridin-3-y1)-N-(5-45-methyl-8-(2-oxopy rroli din-l-y1)-5H-chromeno [4,3 -c] py ri din-3-yl)amino)py ri din-3-yl)acetami de (29.7 mg, yield: 38%) as a yellow solid.
1FINMR (400 MHz, DMSO-d6) 5 1.53 (3H, d, J= 6.5 Hz), 2.01-2.11 (2H, m), 2.52-2.54 (2H, m), 3.84 (2H, t, J= 7.7 Hz), 4.27 (2H, s), 5.26 (1H, q, J= 6.0 Hz), 6.74 (1H, s), 7.23 (1H, t, J
= 6.8 Hz), 7.32 (1H, dd, J= 8.5, 2.0 Hz), 7.39 (1H, d, J= 2.0 Hz), 7.56-7.62 (1H, m), 7.78 (1H, d, J= 8.8 Hz), 7.82 (1H, s), 7.88 (1H, d, J= 8.5 Hz), 8.35 (1H, d, J= 1.8 Hz), 8.54-8.56 (1H, m), 8.58 (1H, d, J= 2.0 Hz), 8.61-8.66 (2H, m), 9.49 (1H, brs), 10.56 (1H, brs).
Example 146: N-(5-05-methyl-8-(2-oxopyrrolidin-1-y1)-5H-chromeno14,3-c]
pyridin-3-yl)amino)pyridin-3-yl)imidazo [1,2-a] pyridine-5-carb oxami de gN 0 N
N NNN
H I
[0566] A
mixture of 1-(3-((5 -aminopy ri din-3-yl)amino)-5 -methyl-5H-chromeno [4,3-clpyridin-8-yOpyrrolidin-2-one (60 mg, 0.16 mmol, HC1 salt), imidazo[1,2-alpyridine-5-carboxylic acid (38 mg, 0.23 mmol) and EDCI.HC1 (45 mg, 0.23 mmol) in pyridine (2 mL) was heated at 30 C for 48 h. A brown suspension was formed. LCMS (Rt = 0.652 min; MS
Calcd: 531.2; MS Found: 532.1 [M+H]+). The mixture was concentrated and the residue was poured into water (20 mL) and stirred for 2 minutes. The aqueous layer was extracted with ethyl acetate (20 mL x3).The combined organic layer was washed with water (20 mL x2) and brine (20 mL), dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by prep-TLC (DCM/Me0H, 10/1) then further purified by prep-HPLC
(0.05%
NH3 .H20 as an additive) and lyophilized to give N-(5-45-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-y0imidazo[1,2-alpyridine-5-carboxamide (5.8 mg, yield: 7%) as a yellow solid.
257 NMR (400 MHz DMSO-d6) (51.56 (3H, d, J= 6.5 Hz), 2.02-2.10 (2H, m), 2.52-2.54 (2H, m, overlapped with the peak of DMSO), 3.85 (2H, t, J= 7.8 Hz), 5.29 (1H, q, J=
6.5 Hz), 6.79 (1H, s), 7.33 (1H, dd, J= 8.5, 2.3 Hz), 7.40-7.47 (2H, m), 7.69 (1H, d, J= 7.3 Hz), 7.74 (1H, s), 7.86-7.91 (2H, m), 8.48-8.52 (2H, m), 8.67-8.75 (3H, m), 9.57 (1H, brs), 10.94 (1H, brs).
Example 147: N-(5-05-methyl-8-(2-oxo pyrrolidin-1-y1)-5H-chromeno[4,3-c]
pyridin-3-yl)amino)pyridin-3-yl)imidazo [1,2-a] pyridine-7-carb oxami de N NH NH\
[0567] A
mixture of 1-(3-((5 -aminopy ri din-3-y Damino)-5 -methyl-5H-chromeno [4,3-clpyridin-8-yOpyrrolidin-2-one (60 mg, 0.16 mmol, HC1 salt), imidazo[1,2-alpyridine-7-carboxylic acid (38 mg, 0.23 mmol) and EDCI.HC1 (45 mg, 0.23 mmol) in pyridine (2 mL) was heated at 30 C for 12 h. A yellow suspension was formed. LCMS (Rt = 0.652 min; MS
Calcd: 531.2; MS Found: 532.1 [M+H]+). The mixture was concentrated and the residue was poured into water (20 mL) and stirred for 2 minutes. The aqueous layer was extracted with ethyl acetate (20 mL x3). The combined organic layer was washed with water (20 mL x2) and brine (20 mL), dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by prep-HPLC (0.225% FA as an additive) and further triturated by DMF/DCM (4 mL, 1/1), and then lyophilized to give N-(5-45-methy1-8-(2-oxopyrrolidin-1-y1)-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-y0imidazo[1,2-alpyridine-7-carboxamide (20.1 mg, yield: 24%) as a yellow solid.
NMR (400 MHz DMSO-d6) (5 1.56 (3H, d, J= 6.5 Hz), 2.02-2.10 (2H, m), 2.52-2.54 (2H, m, overlapped with the peak of DMSO), 3.85 (2H, t, J= 7.8 Hz), 5.29 (1H, q, J=
6.4 Hz), 6.79 (1H, s), 7.32 (1H, dd, J= 8.5, 2.3 Hz), 7.41 (1H, d, J= 2.0 Hz), 7.44 (1H, dd, J= 7.0, 1.5 Hz), 7.79 (1H, s), 7.89 (1H, d, J= 8.8 Hz), 8.13 (1H, s), 8.40 (1H, s), 8.54 (1H, d, J= 2.0 Hz), 8.67-8.75 (4H, m), 9.52 (1H, brs), 10.56 (1H, brs).
6.5 Hz), 6.79 (1H, s), 7.33 (1H, dd, J= 8.5, 2.3 Hz), 7.40-7.47 (2H, m), 7.69 (1H, d, J= 7.3 Hz), 7.74 (1H, s), 7.86-7.91 (2H, m), 8.48-8.52 (2H, m), 8.67-8.75 (3H, m), 9.57 (1H, brs), 10.94 (1H, brs).
Example 147: N-(5-05-methyl-8-(2-oxo pyrrolidin-1-y1)-5H-chromeno[4,3-c]
pyridin-3-yl)amino)pyridin-3-yl)imidazo [1,2-a] pyridine-7-carb oxami de N NH NH\
[0567] A
mixture of 1-(3-((5 -aminopy ri din-3-y Damino)-5 -methyl-5H-chromeno [4,3-clpyridin-8-yOpyrrolidin-2-one (60 mg, 0.16 mmol, HC1 salt), imidazo[1,2-alpyridine-7-carboxylic acid (38 mg, 0.23 mmol) and EDCI.HC1 (45 mg, 0.23 mmol) in pyridine (2 mL) was heated at 30 C for 12 h. A yellow suspension was formed. LCMS (Rt = 0.652 min; MS
Calcd: 531.2; MS Found: 532.1 [M+H]+). The mixture was concentrated and the residue was poured into water (20 mL) and stirred for 2 minutes. The aqueous layer was extracted with ethyl acetate (20 mL x3). The combined organic layer was washed with water (20 mL x2) and brine (20 mL), dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by prep-HPLC (0.225% FA as an additive) and further triturated by DMF/DCM (4 mL, 1/1), and then lyophilized to give N-(5-45-methy1-8-(2-oxopyrrolidin-1-y1)-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-y0imidazo[1,2-alpyridine-7-carboxamide (20.1 mg, yield: 24%) as a yellow solid.
NMR (400 MHz DMSO-d6) (5 1.56 (3H, d, J= 6.5 Hz), 2.02-2.10 (2H, m), 2.52-2.54 (2H, m, overlapped with the peak of DMSO), 3.85 (2H, t, J= 7.8 Hz), 5.29 (1H, q, J=
6.4 Hz), 6.79 (1H, s), 7.32 (1H, dd, J= 8.5, 2.3 Hz), 7.41 (1H, d, J= 2.0 Hz), 7.44 (1H, dd, J= 7.0, 1.5 Hz), 7.79 (1H, s), 7.89 (1H, d, J= 8.8 Hz), 8.13 (1H, s), 8.40 (1H, s), 8.54 (1H, d, J= 2.0 Hz), 8.67-8.75 (4H, m), 9.52 (1H, brs), 10.56 (1H, brs).
258 Example 148: (S)-2-09-fluoro-5,5-dimethy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c] pyridin-3-yl)amino)-6,6a,7,8-tetrahydro-9H-pyrido [2,3-b] pyrrolo[1,2-d]
[1,4] oxazin-9-one gN 0 I H
N N
Step 1: Preparation of N-(4-bromo-2,5-difluoropheny1)-4-chlorobutanamide CI
H: ,F
Br [0568] To a solution of 4-bromo-2,5-difluoroaniline (2.85 g, 13.7 mmol) and Et3N (1.46 g, 14.4 mmol) in THF (40 mL) was added dropwise 4-chlorobutanoyl chloride (2.03 g, 14.4 mmol) at 0 C under Nz. And the mixture was stirred at 0 C for 1 hour. The yellow solution turned to suspension. TLC showed the starting material was consumed completely. The reaction suspension was used to next step directly.
Step 2: Preparation of 1-(4-bromo-2,5-difluorophenyl)pyrrolidin-2-one criV F
Br [0569] To a solution of N-(4-bromo-2,5-difluoropheny1)-4-chlorobutanamide (4.28 g, 13.7 mmol) in THF (50 mL) was added t-BuOK (3.69 g, 32.8 mmol) at 0 C and then the mixture was stirred at 20 C for 16 hours. A red suspension was formed. TLC showed N-(4-bromo-2,5-difluoropheny1)-4-chlorobutanamide was consumed nearly and a new spot was formed. The mixture was poured into sat.aq.NH4C1 (30 mL) and extracted with Et0Ac (30 mL
x3). The combined organic layer was washed with brine (20 mL), dried over Na2SO4 and concentrated to dryness. The residue was purified by Combi Flash (20% EA in PE) to give 1-(4-bromo-2,5-difluorophenyl)pyrrolidin-2-one (3.04 g, yield: 80%) as a yellow solid.
[1,4] oxazin-9-one gN 0 I H
N N
Step 1: Preparation of N-(4-bromo-2,5-difluoropheny1)-4-chlorobutanamide CI
H: ,F
Br [0568] To a solution of 4-bromo-2,5-difluoroaniline (2.85 g, 13.7 mmol) and Et3N (1.46 g, 14.4 mmol) in THF (40 mL) was added dropwise 4-chlorobutanoyl chloride (2.03 g, 14.4 mmol) at 0 C under Nz. And the mixture was stirred at 0 C for 1 hour. The yellow solution turned to suspension. TLC showed the starting material was consumed completely. The reaction suspension was used to next step directly.
Step 2: Preparation of 1-(4-bromo-2,5-difluorophenyl)pyrrolidin-2-one criV F
Br [0569] To a solution of N-(4-bromo-2,5-difluoropheny1)-4-chlorobutanamide (4.28 g, 13.7 mmol) in THF (50 mL) was added t-BuOK (3.69 g, 32.8 mmol) at 0 C and then the mixture was stirred at 20 C for 16 hours. A red suspension was formed. TLC showed N-(4-bromo-2,5-difluoropheny1)-4-chlorobutanamide was consumed nearly and a new spot was formed. The mixture was poured into sat.aq.NH4C1 (30 mL) and extracted with Et0Ac (30 mL
x3). The combined organic layer was washed with brine (20 mL), dried over Na2SO4 and concentrated to dryness. The residue was purified by Combi Flash (20% EA in PE) to give 1-(4-bromo-2,5-difluorophenyl)pyrrolidin-2-one (3.04 g, yield: 80%) as a yellow solid.
259 NMR (400 MHz, CDC13) 6 2.16-2.25 (2H, m), 2.56 (2H, t, J= 8.0 Hz), 3.84 (2H, t, J=
7.2 Hz), 7.30-7.38 (2H, m).
Step 3: Preparation of 1-(2,5-difluoro-4-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-yl)phenyl)pyrrolidin-2-one F
[0570] A
mixture of 1-(4-bromo-2,5-difluorophenyl)pyrrolidin-2-one (3.04 g, 11.0 mmol), Bispin (3.36 g, 13.2 mmol), KOAc (3.24 g, 33.0 mmol) and Pd(dppf)C12 (403 mg, 0.550 mmol) in toluene (60 mL) was stirred at 100 C for 16 hours under N2 atmosphere. The red solution turned to black gradually. LCMS showed the purity of product is 69% (Rt =
0.899 min; MS
Calcd: 323.2; MS Found: 354.9 [M+CH3OH]+). TLC indicated the 1-(4-bromo-2,5-difluorophenyl)pyrrolidin-2-one was consumed completely, and one major new spot with lower polarity was detected. The reaction mixture was cooled to 20 C and filtered through silica gel and washed with MTBE (1 L). The solvent was evaporated under reduced pressure to give 1-(2,5-difluoro-4-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-yl)phenyl)pyrrolidin-2-one (5.00 g, crude) as a yellow gum.
Step 4:
Preparation of methyl 2-chl oro-5-(2,5-difluoro-4-(2-oxopy rroli din-1-yl)phenyl)isonicotinate c11\1 0 OMe I
N CI
[0571] methyl 5-bromo-2-chloroisonicotinate (1.60 g, 6.39 mmol), 1-(2,5-difluoro-4-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-yOphenyOpyrrolidin-2-one (3.14 g, 6.71 mmol), K3PO4 (4.07 g, 19.2 mmol) and Pd(dppf)C12 (233 mg, 0.319 mmol) were taken up in dioxane (40 mL) and H20 (10 mL) and the resulting mixture was stirred at 80 C for 5 hours. A black solution was formed. LCMS showed the purity of the desired product is 45% (Rt = 0.655 min;
MS Calcd: 366.1; MS Found: 366.8 [M+H1+). TLC showed 1-(2,5-difluoro-4-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-yOphenyOpyrrolidin-2-one remained. The mixture was
7.2 Hz), 7.30-7.38 (2H, m).
Step 3: Preparation of 1-(2,5-difluoro-4-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-yl)phenyl)pyrrolidin-2-one F
[0570] A
mixture of 1-(4-bromo-2,5-difluorophenyl)pyrrolidin-2-one (3.04 g, 11.0 mmol), Bispin (3.36 g, 13.2 mmol), KOAc (3.24 g, 33.0 mmol) and Pd(dppf)C12 (403 mg, 0.550 mmol) in toluene (60 mL) was stirred at 100 C for 16 hours under N2 atmosphere. The red solution turned to black gradually. LCMS showed the purity of product is 69% (Rt =
0.899 min; MS
Calcd: 323.2; MS Found: 354.9 [M+CH3OH]+). TLC indicated the 1-(4-bromo-2,5-difluorophenyl)pyrrolidin-2-one was consumed completely, and one major new spot with lower polarity was detected. The reaction mixture was cooled to 20 C and filtered through silica gel and washed with MTBE (1 L). The solvent was evaporated under reduced pressure to give 1-(2,5-difluoro-4-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-yl)phenyl)pyrrolidin-2-one (5.00 g, crude) as a yellow gum.
Step 4:
Preparation of methyl 2-chl oro-5-(2,5-difluoro-4-(2-oxopy rroli din-1-yl)phenyl)isonicotinate c11\1 0 OMe I
N CI
[0571] methyl 5-bromo-2-chloroisonicotinate (1.60 g, 6.39 mmol), 1-(2,5-difluoro-4-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-yOphenyOpyrrolidin-2-one (3.14 g, 6.71 mmol), K3PO4 (4.07 g, 19.2 mmol) and Pd(dppf)C12 (233 mg, 0.319 mmol) were taken up in dioxane (40 mL) and H20 (10 mL) and the resulting mixture was stirred at 80 C for 5 hours. A black solution was formed. LCMS showed the purity of the desired product is 45% (Rt = 0.655 min;
MS Calcd: 366.1; MS Found: 366.8 [M+H1+). TLC showed 1-(2,5-difluoro-4-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-yOphenyOpyrrolidin-2-one remained. The mixture was
260 concentrated under reduced pressure. The residue was purified by Combi Flash (61% EA in PE) to give methyl 2-chloro-5-(2,5-difluoro-4-(2-oxopyrrolidin-1-yl)phenyl)isonicotinate (1.56 g, yield: 67%) as a yellow solid.
11-1NMR (400 MHz, CDC13) 6 2.18-2.26 (2H, m), 2.59 (2H, t, J= 8.0 Hz), 3.83 (3H, s), 3.92 (2H, t, J= 6.8 Hz), 7.11 (1H, dd, J= 10.8, 6.8 Hz), 7.38 (1H, dd, J= 10.8, 6.4 Hz), 7.84 (1H, s), 8.40 (1H, s).
Step 5:
Preparation of 1 -(4-(6-chl oro-4-(2-hy droxy prop an-2-y Opyri din-3-y1)-2,5 -difluorophenyOpyrrolidin-2-one c OH
I
N CI
[0572] MeMgC1 (3 M in Et20, 2.7 mL) was added slowly to a solution of methyl 2-chloro-5-(2,5-difluoro-4-(2-oxopyrrolidin-1-yl)phenyl)isonicotinate (1.00 g, 2.73 mmol) in THF (20 mL) at 0 C under a nitrogen atmosphere to give a suspension. The resulting mixture was stirred at 0 C for 2 hours. TLC (Petroleum ether/Ethyl acetate=1:3) showed the starting material was consumed completely. Sat. aq. NH4C1 (20 mL) was added followed by Et0Ac (20 mL). The organic layer was separated and the aqueous layer extracted with Et0Ac (20 mL
x2). The combined organics were dried over Na2SO4, filtered and concentrated. The residue was purified by Combi Flash (65% EA in PE) to give 1-(4-(6-chloro-4-(2-hydroxypropan-2-yl)pyridin-3-y1)-2,5-difluorophenyOpyrrolidin-2-one (690 mg, crude) as a yellow gum.
Step 6:
Preparation of 1-(3-chloro-9-fluoro-5,5-dimethy1-5H-chromeno[4,3-clpyridin-8-yl)pyrrolidin-2-one CI
[0573] NaH (150 mg, 3.76 mmol, 60% in mineral oil) was added to a solution of 14446-chloro-4-(2-hydroxypropan-2-yOpyridin-3-y1)-2,5-difluorophenyOpyrrolidin-2-one (690 mg, 1.88 mmol) in THF (20 mL) at 25 C and the resulting mixture was stirred at 25 C for 2 hours.
The yellow solution turned to red. TLC indicated one major new spot with lower polarity was
11-1NMR (400 MHz, CDC13) 6 2.18-2.26 (2H, m), 2.59 (2H, t, J= 8.0 Hz), 3.83 (3H, s), 3.92 (2H, t, J= 6.8 Hz), 7.11 (1H, dd, J= 10.8, 6.8 Hz), 7.38 (1H, dd, J= 10.8, 6.4 Hz), 7.84 (1H, s), 8.40 (1H, s).
Step 5:
Preparation of 1 -(4-(6-chl oro-4-(2-hy droxy prop an-2-y Opyri din-3-y1)-2,5 -difluorophenyOpyrrolidin-2-one c OH
I
N CI
[0572] MeMgC1 (3 M in Et20, 2.7 mL) was added slowly to a solution of methyl 2-chloro-5-(2,5-difluoro-4-(2-oxopyrrolidin-1-yl)phenyl)isonicotinate (1.00 g, 2.73 mmol) in THF (20 mL) at 0 C under a nitrogen atmosphere to give a suspension. The resulting mixture was stirred at 0 C for 2 hours. TLC (Petroleum ether/Ethyl acetate=1:3) showed the starting material was consumed completely. Sat. aq. NH4C1 (20 mL) was added followed by Et0Ac (20 mL). The organic layer was separated and the aqueous layer extracted with Et0Ac (20 mL
x2). The combined organics were dried over Na2SO4, filtered and concentrated. The residue was purified by Combi Flash (65% EA in PE) to give 1-(4-(6-chloro-4-(2-hydroxypropan-2-yl)pyridin-3-y1)-2,5-difluorophenyOpyrrolidin-2-one (690 mg, crude) as a yellow gum.
Step 6:
Preparation of 1-(3-chloro-9-fluoro-5,5-dimethy1-5H-chromeno[4,3-clpyridin-8-yl)pyrrolidin-2-one CI
[0573] NaH (150 mg, 3.76 mmol, 60% in mineral oil) was added to a solution of 14446-chloro-4-(2-hydroxypropan-2-yOpyridin-3-y1)-2,5-difluorophenyOpyrrolidin-2-one (690 mg, 1.88 mmol) in THF (20 mL) at 25 C and the resulting mixture was stirred at 25 C for 2 hours.
The yellow solution turned to red. TLC indicated one major new spot with lower polarity was
261 detected. LCMS showed the purity of the desired product is 56% (Rt = 0.784 min; MS Calcd:
346.1; MS Found: 346.9 [M+Hl+). The mixture was added sat. aq. NH4C1 (15 mL), extracted with Et0Ac (20 mL x3). The combined organic layer was dried over Na2SO4, filtered, concentrated. The residue was purified by Combi Flash (40% EA in PE) to give 1-(3-chloro-9-fluoro-5,5-dimethy1-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (220 mg, yield:
33%) as a white solid.
Step 7: Preparation of (S)-2-((9-fluoro-5,5-dimethy1-8-(2-oxopyrrolidin-1-y1)-chromeno [4,3-c] py ri din-3 -y0amino)-6,6a,7,8-tetrahy dro-9H-py ri do [2,3 -b] pyrrol o [1,2-d] [1,4] oxazin-9-one I H
N N
[0574] A
mixture of Pd2(dba)3 (16 mg, 0.017 mmol) and Brettphos (18 mg, 0.034 mmol) in 1,4-dioxane (1 mL) was stirred at 50 C for 10 min. 1-(3-chloro-9-fluoro-5,5-dimethy1-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (60 mg, 0.173 mmol), (S)-2-amino-6,6a,7,8-tetrahydro-9H-pyrido[2,3-blpyrrolo[1,2-d][1,41oxazin-9-one (43 mg, 0.21 mmol) in dioxane (6 mL) and Cs2CO3 (169 mg, 0.519 mmol) were added and the resulting mixture was stirred at 100 C for 16 hours. A black brown mixture was formed. LCMS showed that the purity of the desired product is 57% (Rt = 0.700 min; MS Calcd: 515.2; MS Found: 516.1 [M+Hl+). The reaction mixture was diluted with DCM (10 mL), filtered and concentrated. The residue was purified by prep-HPLC (0.05% NH31120 as an additive) and lyophilized to give (S)-2-((9-fluoro-5,5 -dimethy1-8-(2-oxopy rroli din-l-y1)-5H-chromeno [4,3 -c] py ri din-3-y0amino)-6,6a,7,8-tetrahy dro-9H-pyrido [2,3-b] pyrrolo [1,2-d] [1,4] oxazin-9-one (37.0 mg, yield: 41%) as a white solid.
NMR (400 MHz, DMSO-d6) 6 1.54 (6H, s), 1.64-1.75 (1H, m), 2.06-2.13 (2H, m), 2.18-2.26 (1H, m), 2.35-2.45 (3H, m), 2.62-2.72 (1H, m), 3.76 (2H, t, J= 7.2 Hz), 3.90 (1H, t, J=
10.8 Hz), 4.02-4.12(1H, m), 4.59 (1H, dd, J= 10.8, 3.2 Hz), 6.74(1H, s), 7.01 (1H, d, J=
6.8 Hz), 7.86 (1H, d, J= 12.0 Hz), 8.36 (1H, d, J= 2.8 Hz), 8.66 (1H, s), 8.95 (1H, d, J= 2.8 Hz), 9.37 (1H, brs).
346.1; MS Found: 346.9 [M+Hl+). The mixture was added sat. aq. NH4C1 (15 mL), extracted with Et0Ac (20 mL x3). The combined organic layer was dried over Na2SO4, filtered, concentrated. The residue was purified by Combi Flash (40% EA in PE) to give 1-(3-chloro-9-fluoro-5,5-dimethy1-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (220 mg, yield:
33%) as a white solid.
Step 7: Preparation of (S)-2-((9-fluoro-5,5-dimethy1-8-(2-oxopyrrolidin-1-y1)-chromeno [4,3-c] py ri din-3 -y0amino)-6,6a,7,8-tetrahy dro-9H-py ri do [2,3 -b] pyrrol o [1,2-d] [1,4] oxazin-9-one I H
N N
[0574] A
mixture of Pd2(dba)3 (16 mg, 0.017 mmol) and Brettphos (18 mg, 0.034 mmol) in 1,4-dioxane (1 mL) was stirred at 50 C for 10 min. 1-(3-chloro-9-fluoro-5,5-dimethy1-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (60 mg, 0.173 mmol), (S)-2-amino-6,6a,7,8-tetrahydro-9H-pyrido[2,3-blpyrrolo[1,2-d][1,41oxazin-9-one (43 mg, 0.21 mmol) in dioxane (6 mL) and Cs2CO3 (169 mg, 0.519 mmol) were added and the resulting mixture was stirred at 100 C for 16 hours. A black brown mixture was formed. LCMS showed that the purity of the desired product is 57% (Rt = 0.700 min; MS Calcd: 515.2; MS Found: 516.1 [M+Hl+). The reaction mixture was diluted with DCM (10 mL), filtered and concentrated. The residue was purified by prep-HPLC (0.05% NH31120 as an additive) and lyophilized to give (S)-2-((9-fluoro-5,5 -dimethy1-8-(2-oxopy rroli din-l-y1)-5H-chromeno [4,3 -c] py ri din-3-y0amino)-6,6a,7,8-tetrahy dro-9H-pyrido [2,3-b] pyrrolo [1,2-d] [1,4] oxazin-9-one (37.0 mg, yield: 41%) as a white solid.
NMR (400 MHz, DMSO-d6) 6 1.54 (6H, s), 1.64-1.75 (1H, m), 2.06-2.13 (2H, m), 2.18-2.26 (1H, m), 2.35-2.45 (3H, m), 2.62-2.72 (1H, m), 3.76 (2H, t, J= 7.2 Hz), 3.90 (1H, t, J=
10.8 Hz), 4.02-4.12(1H, m), 4.59 (1H, dd, J= 10.8, 3.2 Hz), 6.74(1H, s), 7.01 (1H, d, J=
6.8 Hz), 7.86 (1H, d, J= 12.0 Hz), 8.36 (1H, d, J= 2.8 Hz), 8.66 (1H, s), 8.95 (1H, d, J= 2.8 Hz), 9.37 (1H, brs).
262 Example 149: 1-(5-09-fluoro-5,5-dimethy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-yl)imidazolidin-2-one N NN
Step 1:
Preparation of 1-(3-amino-9-fluoro-5,5-dimethy1-5H-chromeno [4,3 -c] py ri din-yl)pyrrolidin-2-one I
[0575] A
mixture of Pd2(dba)3 (20 mg, 0.022 mmol) and Xantphos (25 mg, 0.043 mmol) in 1,4-dioxane (1 mL) was stirred at 50 C for 10 min. 1-(3-chloro-9-fluoro-5,5-dimethy1-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one (150 mg, 0.432 mmol), BocNH2 (66 mg, 0.56 mmol) in dioxane (8 mL) and Cs2CO3 (352 mg, 1.08 mmol) were added and the resulting mixture was stirred at 100 C for 16 hours. A black brown mixture was formed.
LCMS showed that the purity of the desired product 1-(3-amino-9-fluoro-5,5-dimethy1-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one is 36% (Rt = 0.633 min; MS Calcd: 327.1; MS
Found: 328.0 [M+H1+). LCMS showed that the purity of the desired product tert-butyl (9-fluoro-5,5-dimethy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno [4,3-c] py ri din-3-yl)carb amate is 21%
(Rt=0.826 min; MS Calcd: 427.2; MS Found: 450.1 [M+Na1+). TLC showed the starting material was consumed completely. The reaction mixture was diluted with DCM
(30 mL), filtered and concentrated. The residue was purified by Combi Flash (60% EA in PE) to give tert-butyl (9-fluoro-5,5-dimethy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno [4,3-c] py ri din-3 -yl)carbamate (37 mg, yield: 20%) as a white solid, purified by Combi Flash (EA) to give 1-(3-amino-9-fluoro-5,5-dimethy1-5H-chromeno [4,3 -c] py ri din-8-yl)py rroli din-2-one (71 mg, yield: 50%) as a yellow solid.
Step 1:
Preparation of 1-(3-amino-9-fluoro-5,5-dimethy1-5H-chromeno [4,3 -c] py ri din-yl)pyrrolidin-2-one I
[0575] A
mixture of Pd2(dba)3 (20 mg, 0.022 mmol) and Xantphos (25 mg, 0.043 mmol) in 1,4-dioxane (1 mL) was stirred at 50 C for 10 min. 1-(3-chloro-9-fluoro-5,5-dimethy1-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one (150 mg, 0.432 mmol), BocNH2 (66 mg, 0.56 mmol) in dioxane (8 mL) and Cs2CO3 (352 mg, 1.08 mmol) were added and the resulting mixture was stirred at 100 C for 16 hours. A black brown mixture was formed.
LCMS showed that the purity of the desired product 1-(3-amino-9-fluoro-5,5-dimethy1-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one is 36% (Rt = 0.633 min; MS Calcd: 327.1; MS
Found: 328.0 [M+H1+). LCMS showed that the purity of the desired product tert-butyl (9-fluoro-5,5-dimethy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno [4,3-c] py ri din-3-yl)carb amate is 21%
(Rt=0.826 min; MS Calcd: 427.2; MS Found: 450.1 [M+Na1+). TLC showed the starting material was consumed completely. The reaction mixture was diluted with DCM
(30 mL), filtered and concentrated. The residue was purified by Combi Flash (60% EA in PE) to give tert-butyl (9-fluoro-5,5-dimethy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno [4,3-c] py ri din-3 -yl)carbamate (37 mg, yield: 20%) as a white solid, purified by Combi Flash (EA) to give 1-(3-amino-9-fluoro-5,5-dimethy1-5H-chromeno [4,3 -c] py ri din-8-yl)py rroli din-2-one (71 mg, yield: 50%) as a yellow solid.
263 NMR (400 MHz, CDC13) 6 1.57 (6H, s), 2.16-2.24 (2H, m), 2.57 (2H, t, J= 8.0 Hz), 3.82 (2H, t, J= 6.8 Hz), 4.60 (2H, brs), 6.34 (1H, s), 6.97 (1H, d, J= 6.8 Hz), 7.41 (1H, d, J= 11.6 Hz), 8.34 (1H, s).
Step 2:
Preparation of 1-(5 -((9-fluoro-5,5-dimethy1-8-(2-oxopy rrolidin-1 -y1)-5H-chromeno [4,3-c] pyridin-3-y0amino)pyri din-3-y1)-3 -((2-(trimethylsilyl)ethoxy)methyl)imidazolidin-2-one I
'SEM
[0576] A
mixture of Pd2(dba)3 (20 mg, 0.021 mmol) and Brettphos (23 mg, 0.043 mmol) in 1,4-dioxane (1 mL) was stirred at 50 C for 10 min. 1-(3-amino-9-fluoro-5,5-dimethy1-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (70 mg, 0.214 mmol), 1-(5-bromopyridin-3-y1)-3-((2-(trimethylsilyl)ethoxy)methyl)imidazolidin-2-one (96 mg, 0.26 mmol) in dioxane (6 mL) and Cs2CO3 (139 mg, 0.428 mmol) were added and the resulting mixture was stirred at 100 C
for 16 hours. A black brown mixture was formed. TLC (Ethyl acetate) showed the starting material was consumed completely. LCMS showed the purity of the desired product is 51%
(Rt = 0.813 min; MS Calcd: 618.3; MS Found: 619.1 [M+H1+). The reaction mixture was diluted with dioxane (10 mL), filtered and concentrated. The residue was purified by Combi Flash (Et0Ac) to give 1-(5 -((9-fluoro-5,5-dimethy1-8-(2-oxopy rrolidin-1 -y1)-5H-chromeno [4,3-c] pyridin-3-y0amino)pyri din-3-y1)-3 -((2-(trimethylsilyl)ethoxy)methyl)imidazolidin-2-one (76 mg, yield: 57%) as a yellow solid.
Step 3:
Preparation of 1-(5 -((9-fluoro-5,5-dimethy1-8-(2-oxopy rrolidin-1 -y1)-5H-chromeno [4,3-c] py ri din-3-y0amino)py ri din-3 -y dazoli din-2-one
Step 2:
Preparation of 1-(5 -((9-fluoro-5,5-dimethy1-8-(2-oxopy rrolidin-1 -y1)-5H-chromeno [4,3-c] pyridin-3-y0amino)pyri din-3-y1)-3 -((2-(trimethylsilyl)ethoxy)methyl)imidazolidin-2-one I
'SEM
[0576] A
mixture of Pd2(dba)3 (20 mg, 0.021 mmol) and Brettphos (23 mg, 0.043 mmol) in 1,4-dioxane (1 mL) was stirred at 50 C for 10 min. 1-(3-amino-9-fluoro-5,5-dimethy1-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (70 mg, 0.214 mmol), 1-(5-bromopyridin-3-y1)-3-((2-(trimethylsilyl)ethoxy)methyl)imidazolidin-2-one (96 mg, 0.26 mmol) in dioxane (6 mL) and Cs2CO3 (139 mg, 0.428 mmol) were added and the resulting mixture was stirred at 100 C
for 16 hours. A black brown mixture was formed. TLC (Ethyl acetate) showed the starting material was consumed completely. LCMS showed the purity of the desired product is 51%
(Rt = 0.813 min; MS Calcd: 618.3; MS Found: 619.1 [M+H1+). The reaction mixture was diluted with dioxane (10 mL), filtered and concentrated. The residue was purified by Combi Flash (Et0Ac) to give 1-(5 -((9-fluoro-5,5-dimethy1-8-(2-oxopy rrolidin-1 -y1)-5H-chromeno [4,3-c] pyridin-3-y0amino)pyri din-3-y1)-3 -((2-(trimethylsilyl)ethoxy)methyl)imidazolidin-2-one (76 mg, yield: 57%) as a yellow solid.
Step 3:
Preparation of 1-(5 -((9-fluoro-5,5-dimethy1-8-(2-oxopy rrolidin-1 -y1)-5H-chromeno [4,3-c] py ri din-3-y0amino)py ri din-3 -y dazoli din-2-one
264 [0577] To a solution of 1-(5-49-fluoro-5,5-dimethy1-8-(2-oxopyrrolidin-1-y1)-chromeno[4,3-c] pyridin-3-y0amino)pyri din-3-y1)-3 (trimethylsilypethoxy)methypimidazolidin-2-one (76 mg, 0.12 mmol) in DCM (3 mL) was added TFA (1.9 mL, 25 mmol) at 25 C, and it was stirred at 25 C for 1 hour.
Then the mixture was concentrated under reduced pressure and the residue was diluted with Me0H
(3 mL), and then EDA (295 mg, 4.91 mmol) was added at 25 C. The residue was stirred at 25 C for 16 hours. A yellow solution was formed. Crude LCMS showed that the purity of product was 53%
(Rt = 0.577 min, MS Calcd.: 488.2; MS Found: 489.1 [M+H1+). The mixture was concentrated under reduced pressure. The residue was purified by prep-HPLC (0.05% NH31120 as an additive) and lyophilized to give 1-(5-((9-fluoro-5,5-dimethy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-y0imidazolidin-2-one (2.79 mg, yield: 5%) as a white solid.
11-1NMR (400 MHz, DMSO-d6) 6 1.55 (6H, s), 2.07-2.13 (2H, m), 2.42 (2H, t, J=
8.4 Hz), 3.46 (2H, overlap with H20), 3.77 (2H, t, J= 6.8 Hz), 3.89 (2H, t, J= 8.8 Hz), 6.83 (1H, s), 7.02 (1H, d, J= 6.8 Hz), 7.12 (1H, s), 7.88 (1H, d, J= 11.6 Hz), 8.25 (1H, d, J= 2.4 Hz), 8.42 (1H, t, J= 2.0 Hz), 8.62 (1H, d, J= 2.0 Hz), 8.72 (1H, brs), 9.52 (1H, brs).
Example 150: methyl 7-09-fluoro-5-methyl-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c] pyridin-3-yl)amino)-2,3-dihydro-1H-pyrido 12,3-b] [1,4] oxazine-1-carb oxylate I
NN
Step 1: Preparation of 1-(5 -bromo-2-chl oropy ri din-4-yl)ethan-1 -ol HO
Brn I
N CI
[0578] MeMgBr (3 M in Et20, 41 mL) was added slowly to a solution of 5-bromo-2-chloroisonicotinaldehyde (15.0 g, 68.0 mmol) in THF (400 mL) at 0 C under a nitrogen atmosphere. The resulting mixture was stirred at 0 C for 2 hours. The yellow solution turned
Then the mixture was concentrated under reduced pressure and the residue was diluted with Me0H
(3 mL), and then EDA (295 mg, 4.91 mmol) was added at 25 C. The residue was stirred at 25 C for 16 hours. A yellow solution was formed. Crude LCMS showed that the purity of product was 53%
(Rt = 0.577 min, MS Calcd.: 488.2; MS Found: 489.1 [M+H1+). The mixture was concentrated under reduced pressure. The residue was purified by prep-HPLC (0.05% NH31120 as an additive) and lyophilized to give 1-(5-((9-fluoro-5,5-dimethy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-y0imidazolidin-2-one (2.79 mg, yield: 5%) as a white solid.
11-1NMR (400 MHz, DMSO-d6) 6 1.55 (6H, s), 2.07-2.13 (2H, m), 2.42 (2H, t, J=
8.4 Hz), 3.46 (2H, overlap with H20), 3.77 (2H, t, J= 6.8 Hz), 3.89 (2H, t, J= 8.8 Hz), 6.83 (1H, s), 7.02 (1H, d, J= 6.8 Hz), 7.12 (1H, s), 7.88 (1H, d, J= 11.6 Hz), 8.25 (1H, d, J= 2.4 Hz), 8.42 (1H, t, J= 2.0 Hz), 8.62 (1H, d, J= 2.0 Hz), 8.72 (1H, brs), 9.52 (1H, brs).
Example 150: methyl 7-09-fluoro-5-methyl-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c] pyridin-3-yl)amino)-2,3-dihydro-1H-pyrido 12,3-b] [1,4] oxazine-1-carb oxylate I
NN
Step 1: Preparation of 1-(5 -bromo-2-chl oropy ri din-4-yl)ethan-1 -ol HO
Brn I
N CI
[0578] MeMgBr (3 M in Et20, 41 mL) was added slowly to a solution of 5-bromo-2-chloroisonicotinaldehyde (15.0 g, 68.0 mmol) in THF (400 mL) at 0 C under a nitrogen atmosphere. The resulting mixture was stirred at 0 C for 2 hours. The yellow solution turned
265 to black brown gradually. TLC indicated 5-bromo-2-chloroisonicotinaldehydewas consumed completely, and one new spot with larger polarity was detected. Sat. aq. NH4C1 (100 mL) was added followed by Et0Ac (100 mL). The organic layer was separated and the aqueous layer was extracted with Et0Ac (80 mL x2). The combined organics were dried over Na2SO4, filtered and concentrated to give 1-(5-bromo-2-chloropyridin-4-yl)ethan-1-ol (15.4 g, yield:
96%) as a yellow solid. Used for the next step without further purification.
NMR (400 MHz, DMSO-d6) 6 1.31 (3H, d, J= 6.4 Hz), 4.83-4.88 (1H, m), 5.80 (1H, d, J
= 4.0 Hz), 7.58 (1H, s), 8.52 (1H, s).
Step 2: Preparation of 1-(4-(6-chl oro-4-(1-hy droxy ethyl)py ri din-3 -y1)-2,5-difluorophenyl)pyrrolidin-2-one OH
I
N CI
105791 1-(5-bromo-2-chloropyridin-4-yl)ethan-1-ol (2.40 g, 10.1 mmol), 1-(2,5-difluoro-4-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-yl)phenyl)pyrrolidin-2-one (3.60 g, 11.1 mmol), K3PO4 (6.45 g, 30.4 mmol) and Pd(dppf)C12 (370 mg, 0.506 mmol) were taken up in dioxane (65 mL) and H20 (15 mL) and the resulting mixture was stirred at 80 C for 5 hours. A black solution was formed. LCMS showed the purity of the desired product is 25% (Rt = 0.746 min;
MS Calcd: 352.1; MS Found: 353.1 [M+H]+). The mixture was concentrated under reduced pressure. The residue was combined with last batch (es6012-362), purified by Combi Flash (62% EA in PE) to give 1-(4-(6-chloro-4-(1-hydroxyethyl)pyridin-3-y1)-2,5-difluorophenyl)pyrrolidin-2-one (3.33 g, yield: 55% for two steps) as a yellow solid.
Step 3: Preparation of 1-(3-chloro-9-fluoro-5-methy1-5H-chromeno [4,3-c] py ri din-8-yl)pyrrolidin-2-one N CI
96%) as a yellow solid. Used for the next step without further purification.
NMR (400 MHz, DMSO-d6) 6 1.31 (3H, d, J= 6.4 Hz), 4.83-4.88 (1H, m), 5.80 (1H, d, J
= 4.0 Hz), 7.58 (1H, s), 8.52 (1H, s).
Step 2: Preparation of 1-(4-(6-chl oro-4-(1-hy droxy ethyl)py ri din-3 -y1)-2,5-difluorophenyl)pyrrolidin-2-one OH
I
N CI
105791 1-(5-bromo-2-chloropyridin-4-yl)ethan-1-ol (2.40 g, 10.1 mmol), 1-(2,5-difluoro-4-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-yl)phenyl)pyrrolidin-2-one (3.60 g, 11.1 mmol), K3PO4 (6.45 g, 30.4 mmol) and Pd(dppf)C12 (370 mg, 0.506 mmol) were taken up in dioxane (65 mL) and H20 (15 mL) and the resulting mixture was stirred at 80 C for 5 hours. A black solution was formed. LCMS showed the purity of the desired product is 25% (Rt = 0.746 min;
MS Calcd: 352.1; MS Found: 353.1 [M+H]+). The mixture was concentrated under reduced pressure. The residue was combined with last batch (es6012-362), purified by Combi Flash (62% EA in PE) to give 1-(4-(6-chloro-4-(1-hydroxyethyl)pyridin-3-y1)-2,5-difluorophenyl)pyrrolidin-2-one (3.33 g, yield: 55% for two steps) as a yellow solid.
Step 3: Preparation of 1-(3-chloro-9-fluoro-5-methy1-5H-chromeno [4,3-c] py ri din-8-yl)pyrrolidin-2-one N CI
266 [0580] NaH (752 mg, 18.8 mmol, 60% purity in mineral oil) was added to a solution of 1-(4-(6-chl oro-4-(1-hy droxy ethyl)py ri din-3 -y1)-2,5 -difluorophenyl)pyrroli din-2-one (3.32 g, 9.41 mmol) in THF (100 mL) at 25 C and the resulting mixture was stirred at 25 C for 2 hours. The yellow solution turned to red. LCMS showed the purity of the desired product is 65% (Rt = 0.799 min; MS Calcd: 332.1; MS Found: 333.1 [M+Hl+). The mixture was added sat. aq. NH4C1 (70 mL), extracted with Et0Ac (60 mL x3). The combined organic layer was dried over Na2SO4, filtered, concentrated. The residue was purified by Combi Flash (50% EA
in DCM) to give 1-(3-chloro-9-fluoro-5-methy1-5H-chromeno[4,3-clpyridin-8-yl)pyrrolidin-2-one (2.75 g, yield: 88%) as a yellow solid.
11-1NMR (400 MHz, CDC13) 61.64 (3H, d, J= 6.8 Hz), 2.20-2.24 (2H, m), 2.57-2.60 (2H, m), 3.86-3.91 (2H, m), 5.19 (1H, q, J= 6.8 Hz), 7.12-7.15 (2H, m), 7.50 (1H, d, J=
11.2 Hz), 8.60 (1H, s).
Step 4: Preparation of 1 -(3-amino-9-fluoro-5-methy1-5H-chromeno [4,3 -c] py ri din-8-yl)pyrrolidin-2-one I
[0581] A
mixture of Pd2(dba)3 (68 mg, 0.075 mmol) and Xantphos (86 mg, 0.15 mmol) in 1,4-dioxane (1 mL) was stirred at 50 C for 10 min. 1-(3-chloro-9-fluoro-5-methy1-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (500 mg, 1.50 mmol), BocNH2 (228 mg, 1.95 mmol) in dioxane (20 mL) and Cs2CO3 (1.22 g, 3.76 mmol) were added, and the resulting mixture was stirred at 100 C for 16 hours. A black brown mixture was formed.
LCMS showed that the purity of 1-(3 -amino-9-fluoro-5 -methyl-5H-chromeno [4,3 -c] py ridin-8-y Opy rroli din-2-oneis 22% (Rt = 0.615 min; MS Calcd: 313.1; MS Found: 314.2 [M+Hl+). LCMS
showed that the purity of tert-butyl (9-fluoro-5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-yOcarbamateis 22% (Rt = 0.833 min; MS Calcd: 413.2; MS Found:
414.3 [M+Hl+). The reaction mixture was diluted with DCM (30 mL), filtered and concentrated. The residue was purified by Combi Flash (50% EA in PE) to give tert-butyl (9-fluoro-5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-yl)carbamate (220 mg, yield: 35%) as a yellow solid, purified by Combi Flash (EA) to give 1-(3-amino-9-fluoro-5-methy1-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (110 mg, yield: 23%) as a yellow solid.
in DCM) to give 1-(3-chloro-9-fluoro-5-methy1-5H-chromeno[4,3-clpyridin-8-yl)pyrrolidin-2-one (2.75 g, yield: 88%) as a yellow solid.
11-1NMR (400 MHz, CDC13) 61.64 (3H, d, J= 6.8 Hz), 2.20-2.24 (2H, m), 2.57-2.60 (2H, m), 3.86-3.91 (2H, m), 5.19 (1H, q, J= 6.8 Hz), 7.12-7.15 (2H, m), 7.50 (1H, d, J=
11.2 Hz), 8.60 (1H, s).
Step 4: Preparation of 1 -(3-amino-9-fluoro-5-methy1-5H-chromeno [4,3 -c] py ri din-8-yl)pyrrolidin-2-one I
[0581] A
mixture of Pd2(dba)3 (68 mg, 0.075 mmol) and Xantphos (86 mg, 0.15 mmol) in 1,4-dioxane (1 mL) was stirred at 50 C for 10 min. 1-(3-chloro-9-fluoro-5-methy1-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (500 mg, 1.50 mmol), BocNH2 (228 mg, 1.95 mmol) in dioxane (20 mL) and Cs2CO3 (1.22 g, 3.76 mmol) were added, and the resulting mixture was stirred at 100 C for 16 hours. A black brown mixture was formed.
LCMS showed that the purity of 1-(3 -amino-9-fluoro-5 -methyl-5H-chromeno [4,3 -c] py ridin-8-y Opy rroli din-2-oneis 22% (Rt = 0.615 min; MS Calcd: 313.1; MS Found: 314.2 [M+Hl+). LCMS
showed that the purity of tert-butyl (9-fluoro-5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-yOcarbamateis 22% (Rt = 0.833 min; MS Calcd: 413.2; MS Found:
414.3 [M+Hl+). The reaction mixture was diluted with DCM (30 mL), filtered and concentrated. The residue was purified by Combi Flash (50% EA in PE) to give tert-butyl (9-fluoro-5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-yl)carbamate (220 mg, yield: 35%) as a yellow solid, purified by Combi Flash (EA) to give 1-(3-amino-9-fluoro-5-methy1-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (110 mg, yield: 23%) as a yellow solid.
267 Step 5:
Preparation of methyl 7-((9-fluoro-5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno [4,3-c] py ri din-3 -yl)amino)-2,3 -dihy dro-1H-py ri do [2,3-b]
[1,4] oxazine-1-carboxylate gN 0 NN
[0582] A
mixture of Pd2(dba)3 (14 mg, 0.015 mmol) and Brettphos (17 mg, 0.031 mmol) in dioxane (1 mL) was stirred at 50 C for 10 min. 1-(3-amino-9-fluoro-5-methy1-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one (50 mg, 0.16 mmol), methyl 7-bromo-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazine-1-carboxylate (52 mg, 0.19 mmol) in dioxane (6 mL) and Cs2CO3 (155 mg, 0.478 mmol) were added and the resulting mixture was stirred at 100 C
for 14 hours. A black brown mixture was formed. LCMS showed that the purity of the desired product is 53% (Rt = 0.717 min; MS Calcd: 505.2; MS Found: 506.1 [M+H]+). The reaction mixture was diluted with DCM (10 mL), filtered and concentrated. The residue was purified by prep-HPLC (0.05% NH31120 as an additive) and lyophilized to give methyl 7-((9-fluoro-5-methy1-8-(2-oxopy rroli din-1 -y1)-5H-chromeno [4,3 -c] py ri din-3-yl)amino)-2,3-dihy dro-1H-pyrido[2,3-b][1,4]oxazine-1-carboxylate (37.1 mg, yield: 46%) as a white solid.
11-1NMR (400 MHz, DMSO-d6) 6 1.52 (3H, d, J= 6.4 Hz), 2.06-2.13 (2H, m), 2.42 (2H, t, J
= 8.0 Hz), 3.73-3.77 (2H, m), 3.78 (3H, s), 3.86 (2H, t, J= 4.8 Hz), 4.31 (2H, t, J= 4.8 Hz), 5.25 (1H, q, J= 6.4 Hz), 6.66 (1H, s), 7.04 (1H, d, J= 6.8 Hz), 7.86 (1H, d, J= 11.6 Hz), 8.24 (1H, d, J= 2.4 Hz), 8.64 (1H, s), 8.67 (1H, brs), 9.32 (1H, brs).
Example 151: 1-(5-09-fluoro-5-methyl-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-yl)imidazolidin-2-one I
N
0-="-NH
Preparation of methyl 7-((9-fluoro-5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno [4,3-c] py ri din-3 -yl)amino)-2,3 -dihy dro-1H-py ri do [2,3-b]
[1,4] oxazine-1-carboxylate gN 0 NN
[0582] A
mixture of Pd2(dba)3 (14 mg, 0.015 mmol) and Brettphos (17 mg, 0.031 mmol) in dioxane (1 mL) was stirred at 50 C for 10 min. 1-(3-amino-9-fluoro-5-methy1-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one (50 mg, 0.16 mmol), methyl 7-bromo-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazine-1-carboxylate (52 mg, 0.19 mmol) in dioxane (6 mL) and Cs2CO3 (155 mg, 0.478 mmol) were added and the resulting mixture was stirred at 100 C
for 14 hours. A black brown mixture was formed. LCMS showed that the purity of the desired product is 53% (Rt = 0.717 min; MS Calcd: 505.2; MS Found: 506.1 [M+H]+). The reaction mixture was diluted with DCM (10 mL), filtered and concentrated. The residue was purified by prep-HPLC (0.05% NH31120 as an additive) and lyophilized to give methyl 7-((9-fluoro-5-methy1-8-(2-oxopy rroli din-1 -y1)-5H-chromeno [4,3 -c] py ri din-3-yl)amino)-2,3-dihy dro-1H-pyrido[2,3-b][1,4]oxazine-1-carboxylate (37.1 mg, yield: 46%) as a white solid.
11-1NMR (400 MHz, DMSO-d6) 6 1.52 (3H, d, J= 6.4 Hz), 2.06-2.13 (2H, m), 2.42 (2H, t, J
= 8.0 Hz), 3.73-3.77 (2H, m), 3.78 (3H, s), 3.86 (2H, t, J= 4.8 Hz), 4.31 (2H, t, J= 4.8 Hz), 5.25 (1H, q, J= 6.4 Hz), 6.66 (1H, s), 7.04 (1H, d, J= 6.8 Hz), 7.86 (1H, d, J= 11.6 Hz), 8.24 (1H, d, J= 2.4 Hz), 8.64 (1H, s), 8.67 (1H, brs), 9.32 (1H, brs).
Example 151: 1-(5-09-fluoro-5-methyl-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-yl)imidazolidin-2-one I
N
0-="-NH
268 Step 1: Preparation of 1-(5-((9-fluoro-5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c] py ri din-3 -yl)amino)py ri din-3 -y1)-3-((2-(trimethyls ilyl)ethoxy)methyl)imi dazoli din-2-one N N
¨ 'SEM
mixture of Pd2(dba)3 (29 mg, 0.032 mmol) and Brettphos (34 mg, 0.064 mmol) in dioxane (1 mL) was stirred at 50 C for 10 min. 1-(3-amino-9-fluoro-5-methy1-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (100 mg, 0.319 mmol), 1-(5-bromopyridin-3-y1)-3-42-(trimethylsilypethoxy)methypimidazolidin-2-one (142 mg, 0.383 mmol) in dioxane (7 mL) and Cs2CO3 (260 mg, 0.798 mmol) were added and the resulting mixture was stirred at 100 C for 16 hours. A black brown mixture was formed. LCMS showed the purity of the desired product is 33% (Rt = 0.807 min; MS Calcd: 604.3; MS Found: 605.2 [M+H1+). The reaction mixture was diluted with dioxane (10 mL), filtered and concentrated.
The residue was purified by Combi Flash (Et0Ac) to give 1-(5-((9-fluoro-5-methy1-8-(2-oxopyrrolidin-l-y1)-5H-chromeno [4,3-c] py ridin-3 -yl)amino)py ri din-3-y1)-3 (trimethylsilypethoxy)methypimidazolidin-2-one (160 mg, yield: 83%) as a yellow solid.
Step 2: Preparation of 1-(5-((9-fluoro-5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c] pyridin-3-y0amino)pyridin-3-y1)imidazolidin-2-one , [0584] To a solution of 1-(5-((9-fluoro-5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno [4,3-c] pyridin-3-y0amino)pyridin-3-y1)-3-((2-(trimethylsily1)ethoxy)methyl)imidazolidin-2-one (60 mg, 0.099 mmol) in DCM (5 mL) was added TFA (5 mL) dropwise at 0 C over a period of 2 minutes under N2 atmosphere. The reaction mixture was stirred at 30 C for 2 hours, and it turned to a red solution. The reaction mixture was concentrated under reduced pressure to give a residue. The residue was dissolved
¨ 'SEM
mixture of Pd2(dba)3 (29 mg, 0.032 mmol) and Brettphos (34 mg, 0.064 mmol) in dioxane (1 mL) was stirred at 50 C for 10 min. 1-(3-amino-9-fluoro-5-methy1-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (100 mg, 0.319 mmol), 1-(5-bromopyridin-3-y1)-3-42-(trimethylsilypethoxy)methypimidazolidin-2-one (142 mg, 0.383 mmol) in dioxane (7 mL) and Cs2CO3 (260 mg, 0.798 mmol) were added and the resulting mixture was stirred at 100 C for 16 hours. A black brown mixture was formed. LCMS showed the purity of the desired product is 33% (Rt = 0.807 min; MS Calcd: 604.3; MS Found: 605.2 [M+H1+). The reaction mixture was diluted with dioxane (10 mL), filtered and concentrated.
The residue was purified by Combi Flash (Et0Ac) to give 1-(5-((9-fluoro-5-methy1-8-(2-oxopyrrolidin-l-y1)-5H-chromeno [4,3-c] py ridin-3 -yl)amino)py ri din-3-y1)-3 (trimethylsilypethoxy)methypimidazolidin-2-one (160 mg, yield: 83%) as a yellow solid.
Step 2: Preparation of 1-(5-((9-fluoro-5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c] pyridin-3-y0amino)pyridin-3-y1)imidazolidin-2-one , [0584] To a solution of 1-(5-((9-fluoro-5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno [4,3-c] pyridin-3-y0amino)pyridin-3-y1)-3-((2-(trimethylsily1)ethoxy)methyl)imidazolidin-2-one (60 mg, 0.099 mmol) in DCM (5 mL) was added TFA (5 mL) dropwise at 0 C over a period of 2 minutes under N2 atmosphere. The reaction mixture was stirred at 30 C for 2 hours, and it turned to a red solution. The reaction mixture was concentrated under reduced pressure to give a residue. The residue was dissolved
269 in dioxane (5 mL) and NH31120 (5 mL) at 30 C. The reaction mixture was stirred at 30 C for another 32 hours. After that, a brown solution was formed. LCMS showed the purity of the desired compound is 85% (Rt = 0.672 min; MS Calcd: 474.2; MS Found: 475.1 [M+H1+).
The reaction mixture was concentrated and diluted with saturated aqueous Na2CO3 (10 mL), then extracted with Et0Ac/THF (20 mL x3, 2/1). The combined organic layer was washed with saturated aqueous Na2CO3 (20 mL x2), brine (20 mL x2) and dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (0.05% NH31120 as an additive) and lyophilized to give 1-(5-((9-fluoro-5-methyl-8-(2-oxopyrroli din-1 -y 0-5H-chromeno [4,3 -c] py ri din-3 -y Damino)py ri din-3-y Di midazoli din-2-one (16.1 mg, yield: 34%) as a yellow solid.
11-1NMR (400 MHz DMSO-d6) (51.54 (3H, d, J= 6.4 Hz), 2.08-2.15 (2H, m), 2.43 (2H, t, J=
8.0 Hz), 3.44-3.73 (2H, m), 3.75-3.78 (2H, m), 3.80-3.92 (2H, m), 5.28 (1H, q, J= 6.5 Hz), 6.77 (1H, s), 7.06 (2H, m), 7.12 (1H, s), 7.88 (1H, d, J= 11.6 Hz), 8.28 (1H, d, J= 2.0 Hz), 8.42 (1H, t, J= 2.4 Hz), 8.66 (1H, d, J= 2.0 Hz), 8.71 (1H, s), 9.52 (1H, s).
Example 152: (6aS)-2-09-fluoro-5-methyl-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)-8-methyl-6,6a,7,8-tetrahydro-9H-pyrido[2,3-b]pyrrolo[1,2-d][1,4]oxazin-9-one gN 0 I I
N NN
10585] A
mixture of 1-(3-chl oro-9-fluoro-5 -methyl-5H-chromeno [4,3 -c] py ri din-8-yl)pyrrolidin-2-one (50 mg, 0.15 mmol), (6a5)-2-amino-8-methy1-6,6a,7,8-tetrahydro-9H-pyrido[2,3-blpyrrolo[1,2-d][1,41oxazin-9-one (36 mg, 0.16 mmol), Pd2(dba)3 (14 mg, 0.015 mmol), Brettphos (16 mg, 0.030 mmol), Cs2CO3 (98 mg, 0.30 mmol) in dioxane (3 mL) was degassed and purged with N2 for 3 times. Then the resulting reaction mixture was heated at 90 C for 15 hours under N2 atmosphere. The reaction mixture turned into brown suspension from red suspension. LCMS showed that the purity of the desired product is 40% (Rt = 0.673 min;
MS Calcd: 515.2; MS Found: 516.2 [M+H1+). The mixture was diluted with water (10 mL) and extracted with Et0Ac (20 mL x3). The combined organic layer was washed with water (20 mL
The reaction mixture was concentrated and diluted with saturated aqueous Na2CO3 (10 mL), then extracted with Et0Ac/THF (20 mL x3, 2/1). The combined organic layer was washed with saturated aqueous Na2CO3 (20 mL x2), brine (20 mL x2) and dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (0.05% NH31120 as an additive) and lyophilized to give 1-(5-((9-fluoro-5-methyl-8-(2-oxopyrroli din-1 -y 0-5H-chromeno [4,3 -c] py ri din-3 -y Damino)py ri din-3-y Di midazoli din-2-one (16.1 mg, yield: 34%) as a yellow solid.
11-1NMR (400 MHz DMSO-d6) (51.54 (3H, d, J= 6.4 Hz), 2.08-2.15 (2H, m), 2.43 (2H, t, J=
8.0 Hz), 3.44-3.73 (2H, m), 3.75-3.78 (2H, m), 3.80-3.92 (2H, m), 5.28 (1H, q, J= 6.5 Hz), 6.77 (1H, s), 7.06 (2H, m), 7.12 (1H, s), 7.88 (1H, d, J= 11.6 Hz), 8.28 (1H, d, J= 2.0 Hz), 8.42 (1H, t, J= 2.4 Hz), 8.66 (1H, d, J= 2.0 Hz), 8.71 (1H, s), 9.52 (1H, s).
Example 152: (6aS)-2-09-fluoro-5-methyl-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)-8-methyl-6,6a,7,8-tetrahydro-9H-pyrido[2,3-b]pyrrolo[1,2-d][1,4]oxazin-9-one gN 0 I I
N NN
10585] A
mixture of 1-(3-chl oro-9-fluoro-5 -methyl-5H-chromeno [4,3 -c] py ri din-8-yl)pyrrolidin-2-one (50 mg, 0.15 mmol), (6a5)-2-amino-8-methy1-6,6a,7,8-tetrahydro-9H-pyrido[2,3-blpyrrolo[1,2-d][1,41oxazin-9-one (36 mg, 0.16 mmol), Pd2(dba)3 (14 mg, 0.015 mmol), Brettphos (16 mg, 0.030 mmol), Cs2CO3 (98 mg, 0.30 mmol) in dioxane (3 mL) was degassed and purged with N2 for 3 times. Then the resulting reaction mixture was heated at 90 C for 15 hours under N2 atmosphere. The reaction mixture turned into brown suspension from red suspension. LCMS showed that the purity of the desired product is 40% (Rt = 0.673 min;
MS Calcd: 515.2; MS Found: 516.2 [M+H1+). The mixture was diluted with water (10 mL) and extracted with Et0Ac (20 mL x3). The combined organic layer was washed with water (20 mL
270 x2), brine (20 mL x2), dried over anhydrous Na2SO4, filtered and concentrated.
The residue was purified by prep-HPLC (0.225% FA as an additive) and lyophilized to give (6aS)-2-((9-fluoro-5 -methyl-8-(2-oxopy rroli din-l-y1)-5H-chromeno [4,3 -c] py ri din-3-y0amino)-8-methyl-6,6a,7,8-tetrahydro-9H-pyrido[2,3-blpyrrolo[1,2-d] [1,4]oxazin-9-one (24.7 mg, yield: 32%, dr =2.5:1) as a light yellow solid.
1-1-1NMR (400 MHz DMSO-d6) 1.16 (2.26H, d, J= 7.0 Hz), 1.23-1.27 (1.41H, m), 1.30-1.39 (0.87H, m), 1.53 (3H, dd, J= 6.4 Hz, 0.8 Hz), 1.91-2.00 (0.72H, m), 2.07-2.16 (2H, m), 2.40-2.48 (2.32H, m), 2.73-2.84 (1H, m), 3.73-3.81 (2H, m), 3.84-3.94 (1H, m), 3.96-4.17 (1H, m), 4.54-4.63 (1H, m), 5.26 (1H, q, J= 6.4 Hz), 6.68 (1H, s), 7.05 (1H, d, J= 6.8 Hz), 7.87 (1H, d, J= 11.8 Hz), 8.30-8.36 (1H, m), 8.64-8.68 (1H, m), 8.96 (0.27H, d, J= 4.0 Hz), 9.07 (0.69H, t, J= 4.0 Hz), 9.39 (1H, brs).
Example 153: (6aS)-2-09-fluoro-5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c] pyridin-3-yl)amino)-8,8-dimethyl-6,6a,7,8-tetrahydro-9H-pyrido [2,3-b]
pyrrolo [1,2-d][1,4]oxazin-9-one Fr NN
[0586] A
mixture of Pd2(dba)3 (14 mg, 0.015 mmol) and Brettphos (16 mg, 0.030 mmol) in dioxane (1 mL) was stirred at 50 C for 10 min. 1-(3-chloro-9-fluoro-5-methy1-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (50 mg, 0.15 mmol), (S)-2-amino-8,8-dimethy1-6,6a,7,8-tetrahydro-9H-pyrido[2,3-blpyrrolo[1,2-d][1,4]oxazin-9-one (39 mg, 0.17 mmol) in dioxane (3 mL) and Cs2CO3 (147 mg, 0.478 mmol) were added and the resulting mixture was stirred at 100 C for 15 hours. A black brown mixture was formed.
LCMS showed that the purity of the desired product is 49% (Rt = 0.647 min; MS Calcd:
529.2; MS Found:
530.1 [M+Hl+). The reaction mixture was diluted with DCM (10 mL), filtered and concentrated. The residue was purified by prep-HPLC (0.05% NH31120 as an additive) and lyophilized to give (6a5)-2-49-fluoro-5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c] pyridin-3-y0amino)-8,8-dimethyl-6,6a,7,8-tetrahy dro-9H-pyrido [2,3-blpyrrolo [1,2-d][1,41oxazin-9-one (23.6 mg, yield: 30%) as a yellow solid.
The residue was purified by prep-HPLC (0.225% FA as an additive) and lyophilized to give (6aS)-2-((9-fluoro-5 -methyl-8-(2-oxopy rroli din-l-y1)-5H-chromeno [4,3 -c] py ri din-3-y0amino)-8-methyl-6,6a,7,8-tetrahydro-9H-pyrido[2,3-blpyrrolo[1,2-d] [1,4]oxazin-9-one (24.7 mg, yield: 32%, dr =2.5:1) as a light yellow solid.
1-1-1NMR (400 MHz DMSO-d6) 1.16 (2.26H, d, J= 7.0 Hz), 1.23-1.27 (1.41H, m), 1.30-1.39 (0.87H, m), 1.53 (3H, dd, J= 6.4 Hz, 0.8 Hz), 1.91-2.00 (0.72H, m), 2.07-2.16 (2H, m), 2.40-2.48 (2.32H, m), 2.73-2.84 (1H, m), 3.73-3.81 (2H, m), 3.84-3.94 (1H, m), 3.96-4.17 (1H, m), 4.54-4.63 (1H, m), 5.26 (1H, q, J= 6.4 Hz), 6.68 (1H, s), 7.05 (1H, d, J= 6.8 Hz), 7.87 (1H, d, J= 11.8 Hz), 8.30-8.36 (1H, m), 8.64-8.68 (1H, m), 8.96 (0.27H, d, J= 4.0 Hz), 9.07 (0.69H, t, J= 4.0 Hz), 9.39 (1H, brs).
Example 153: (6aS)-2-09-fluoro-5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c] pyridin-3-yl)amino)-8,8-dimethyl-6,6a,7,8-tetrahydro-9H-pyrido [2,3-b]
pyrrolo [1,2-d][1,4]oxazin-9-one Fr NN
[0586] A
mixture of Pd2(dba)3 (14 mg, 0.015 mmol) and Brettphos (16 mg, 0.030 mmol) in dioxane (1 mL) was stirred at 50 C for 10 min. 1-(3-chloro-9-fluoro-5-methy1-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (50 mg, 0.15 mmol), (S)-2-amino-8,8-dimethy1-6,6a,7,8-tetrahydro-9H-pyrido[2,3-blpyrrolo[1,2-d][1,4]oxazin-9-one (39 mg, 0.17 mmol) in dioxane (3 mL) and Cs2CO3 (147 mg, 0.478 mmol) were added and the resulting mixture was stirred at 100 C for 15 hours. A black brown mixture was formed.
LCMS showed that the purity of the desired product is 49% (Rt = 0.647 min; MS Calcd:
529.2; MS Found:
530.1 [M+Hl+). The reaction mixture was diluted with DCM (10 mL), filtered and concentrated. The residue was purified by prep-HPLC (0.05% NH31120 as an additive) and lyophilized to give (6a5)-2-49-fluoro-5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c] pyridin-3-y0amino)-8,8-dimethyl-6,6a,7,8-tetrahy dro-9H-pyrido [2,3-blpyrrolo [1,2-d][1,41oxazin-9-one (23.6 mg, yield: 30%) as a yellow solid.
271 NMR (400 MHz, DMSO-d6) 6 1.17 (3H, s), 1.21 (3H, s), 1.52 (3H, d, J= 6.4 Hz), 1.59 (1H, dd, J= 12.4, 10.0 Hz), 2.07-2.14 (3H, m), 2.43 (2H, t, J= 7.6 Hz), 3.72-3.79 (2H, m), 3.88 (1H, t, J= 10.4 Hz), 4.06-4.14 (1H, m), 4.59 (1H, dd, J= 10.8, 3.2 Hz), 5.26 (1H, q, J=
6.8 Hz), 6.67 (1H, s), 7.04 (1H, d, J= 6.4 Hz), 7.87 (1H, d, J= 11.6 Hz), 8.28-8.31 (1H, m), 8.66 (1H, brs), 9.08-9.11 (1H, m), 9.38 (1H, d, J= 2.0 Hz).
Example 154: (6a'S)-2'4(9-fluoro-5-methyl-8-(2-oxopyrrolidin-1-y1)-5H-chromeno14,3-c]pyridin-3-yl)amino)-6a',7'-dihydro-6'H,9'H-spiro[cyclopropane-1,8'-pyrido12,3-b]pyrrolo[1,2-d111,4]oxazin]-9'-one I H
N
[0587] A mixture of 1-(3-chloro-9-fluoro-5-methy1-5H-chromeno[4,3-clpyridin-8-yl)pyrrolidin-2-one (50 mg, 0.15 mmol), (S)-2'-amino-6a',7'-dihydro-6'H,911-1-spiro[cyclopropane-1,8'-pyrido[2,3-blpyrrolo[1,2-d][1,410xazin1-9'-one (38 mg, 0.16 mmol), Pd2(dba)3 (14 mg, 0.015 mmol), Brettphos (16 mg, 0.030 mmol), Cs2CO3 (98 mg, 0.30 mmol) in dioxane (3 mL) was degassed and purged with N2 for 3 times. Then the resulting reaction mixture was heated at 90 C for 15 hours under N2 atmosphere. The reaction mixture turned into brown suspension from red suspension. LCMS showed that the purity of the desired product is 41% (Rt = 0.714 min; MS Calcd: 527.2; MS Found: 528.3 [M+H1+). The mixture was diluted with water (10 mL) and extracted with Et0Ac (20 mL x3). The combined organic layer was washed with water (20 mL x2), brine (20 mL x2), dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by prep-HPLC (0.225% FA as an additive) and lyophilized to give (6a'S)-2'4(9-fluoro-5-methy1-8-(2-oxopyrrolidin-1-y1)-chromeno [4,3-c] py ri din-3-yl)amino)-6a',7'-dihy dro-CH,911-1-spiro [cy clopropane-1,8'-pyrido[2,3-blpyrrolo[1,2-d][1,41oxazin1-9'-one (25.3 mg, yield: 32%) as a light yellow solid.
11-1NMR (400 MHz DMSO-d6) 5 0.84-0.88 (1H, m), 0.93-0.98 (1H, m), 1.00-1.06 (1H, m), 1.08-1.13 (1H, m), 1.52 (3H, d, J= 6.2 Hz), 1.98-2.05 (1H, m), 2.07-2.14 (2H, m), 2.16-2.23 (1H, m), 2.43 (2H, t, J= 7.8 Hz), 3.74-3.80 (2H, m), 3.97-4.04 (1H, m), 4.17-4.24 (1H, m),
6.8 Hz), 6.67 (1H, s), 7.04 (1H, d, J= 6.4 Hz), 7.87 (1H, d, J= 11.6 Hz), 8.28-8.31 (1H, m), 8.66 (1H, brs), 9.08-9.11 (1H, m), 9.38 (1H, d, J= 2.0 Hz).
Example 154: (6a'S)-2'4(9-fluoro-5-methyl-8-(2-oxopyrrolidin-1-y1)-5H-chromeno14,3-c]pyridin-3-yl)amino)-6a',7'-dihydro-6'H,9'H-spiro[cyclopropane-1,8'-pyrido12,3-b]pyrrolo[1,2-d111,4]oxazin]-9'-one I H
N
[0587] A mixture of 1-(3-chloro-9-fluoro-5-methy1-5H-chromeno[4,3-clpyridin-8-yl)pyrrolidin-2-one (50 mg, 0.15 mmol), (S)-2'-amino-6a',7'-dihydro-6'H,911-1-spiro[cyclopropane-1,8'-pyrido[2,3-blpyrrolo[1,2-d][1,410xazin1-9'-one (38 mg, 0.16 mmol), Pd2(dba)3 (14 mg, 0.015 mmol), Brettphos (16 mg, 0.030 mmol), Cs2CO3 (98 mg, 0.30 mmol) in dioxane (3 mL) was degassed and purged with N2 for 3 times. Then the resulting reaction mixture was heated at 90 C for 15 hours under N2 atmosphere. The reaction mixture turned into brown suspension from red suspension. LCMS showed that the purity of the desired product is 41% (Rt = 0.714 min; MS Calcd: 527.2; MS Found: 528.3 [M+H1+). The mixture was diluted with water (10 mL) and extracted with Et0Ac (20 mL x3). The combined organic layer was washed with water (20 mL x2), brine (20 mL x2), dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by prep-HPLC (0.225% FA as an additive) and lyophilized to give (6a'S)-2'4(9-fluoro-5-methy1-8-(2-oxopyrrolidin-1-y1)-chromeno [4,3-c] py ri din-3-yl)amino)-6a',7'-dihy dro-CH,911-1-spiro [cy clopropane-1,8'-pyrido[2,3-blpyrrolo[1,2-d][1,41oxazin1-9'-one (25.3 mg, yield: 32%) as a light yellow solid.
11-1NMR (400 MHz DMSO-d6) 5 0.84-0.88 (1H, m), 0.93-0.98 (1H, m), 1.00-1.06 (1H, m), 1.08-1.13 (1H, m), 1.52 (3H, d, J= 6.2 Hz), 1.98-2.05 (1H, m), 2.07-2.14 (2H, m), 2.16-2.23 (1H, m), 2.43 (2H, t, J= 7.8 Hz), 3.74-3.80 (2H, m), 3.97-4.04 (1H, m), 4.17-4.24 (1H, m),
272 4.60-4.65 (1H, m), 5.26 (1H, q, J= 6.4 Hz), 6.68 (1H, s), 7.05 (1H, d, J= 6.4 Hz), 7.87 (1H, d, J= 11.4 Hz), 8.31 (1H, s), 8.64 (1H, s), 8.99 (1H, s), 9.41 (1H, brs) Example 155: (6aS)-8-methyl-2-05-methyl-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)-6,6a,7,8-tetrahydro-9H-pyrido[2,3-b]pyrrolo[1,2-d]
11,41oxazin-9-one c 0 I I
N NN
[0588] A
mixture of 1-(3-chloro-5-methy1-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one (40 mg, 0.13 mmol), (6aS)-2-amino-8-methy1-6,6a,7,8-tetrahydro-9H-pyrido[2,3-blpyrrolo[1,2-d][1,41oxazin-9-one (31 mg, 0.14 mmol), Pd2(dba)3 (12 mg, 0.013 mmol), Brettphos (14 mg, 0.026 mmol), Cs2CO3 (83 mg, 0.26 mmol) in dioxane (3 mL) was degassed and purged with N2 for 3 times. Then the resulting reaction mixture was heated at 90 C for 15 hours under N2 atmosphere. The reaction mixture turned into brown suspension from red suspension. LCMS showed that the purity of the desired product is 50% (Rt = 0.664 min;
MS Calcd: 497.2; MS Found: 498.2 [M+Hl+). The mixture was diluted with water (10 mL) and extracted with Et0Ac (20 mL x3). The combined organic layer was washed with water (20 mL
x2), brine (20 mL x2), dried over anhydrous Na2SO4, filtered and concentrated.
The residue was purified by prep-HPLC (0.225% FA as an additive) and further purified by prep-TLC
(DCM/Me0H, 20/1), then lyophilized to give (6a5)-8-methy1-2-((5-methy1-8-(2-oxopy rroli din-l-y1)-5H-chromeno [4,3 -c] py ri din-3-yl)amino)-6,6 a,7, 8-tetrahy dro-9H-pyrido[2,3-b] pyrrolo[1,2-d] [1,41oxazin-9-one (16.3 mg, yield: 25%, dr =
1.9:1) as a white solid.
1-1-1NMR (400 Hz DMSO-d6) 6 1.16(2H, d, J= 7.0 Hz), 1.23-1.27 (1H, m), 1.30-1.39(1H, m), 1.53 (3H, d, J= 6.0 Hz), 1.91-2.12(3H, m), 2.40-2.48(2H, m), 2.73-2.84(1H, m), 3.81-3.95 (3H, m), 3.96-4.17 (1H, m), 4.54-4.63 (1H, m), 5.25 (1H, q, J= 6.4 Hz), 6.67 (1H, s), 7.31 (1H, d, J= 8.8 Hz), 7.39 (1H, d, J= 2.0 Hz), 7.87 (1H, d, J= 8.4 Hz), 8.30-8.37 (1H, m), 8.59-8.63 (1H, m), 8.96 (0.33H, d, J= 2.4 Hz), 9.08 (0.62H, t, J= 2.4 Hz), 9.28 (1H, brs).
11,41oxazin-9-one c 0 I I
N NN
[0588] A
mixture of 1-(3-chloro-5-methy1-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one (40 mg, 0.13 mmol), (6aS)-2-amino-8-methy1-6,6a,7,8-tetrahydro-9H-pyrido[2,3-blpyrrolo[1,2-d][1,41oxazin-9-one (31 mg, 0.14 mmol), Pd2(dba)3 (12 mg, 0.013 mmol), Brettphos (14 mg, 0.026 mmol), Cs2CO3 (83 mg, 0.26 mmol) in dioxane (3 mL) was degassed and purged with N2 for 3 times. Then the resulting reaction mixture was heated at 90 C for 15 hours under N2 atmosphere. The reaction mixture turned into brown suspension from red suspension. LCMS showed that the purity of the desired product is 50% (Rt = 0.664 min;
MS Calcd: 497.2; MS Found: 498.2 [M+Hl+). The mixture was diluted with water (10 mL) and extracted with Et0Ac (20 mL x3). The combined organic layer was washed with water (20 mL
x2), brine (20 mL x2), dried over anhydrous Na2SO4, filtered and concentrated.
The residue was purified by prep-HPLC (0.225% FA as an additive) and further purified by prep-TLC
(DCM/Me0H, 20/1), then lyophilized to give (6a5)-8-methy1-2-((5-methy1-8-(2-oxopy rroli din-l-y1)-5H-chromeno [4,3 -c] py ri din-3-yl)amino)-6,6 a,7, 8-tetrahy dro-9H-pyrido[2,3-b] pyrrolo[1,2-d] [1,41oxazin-9-one (16.3 mg, yield: 25%, dr =
1.9:1) as a white solid.
1-1-1NMR (400 Hz DMSO-d6) 6 1.16(2H, d, J= 7.0 Hz), 1.23-1.27 (1H, m), 1.30-1.39(1H, m), 1.53 (3H, d, J= 6.0 Hz), 1.91-2.12(3H, m), 2.40-2.48(2H, m), 2.73-2.84(1H, m), 3.81-3.95 (3H, m), 3.96-4.17 (1H, m), 4.54-4.63 (1H, m), 5.25 (1H, q, J= 6.4 Hz), 6.67 (1H, s), 7.31 (1H, d, J= 8.8 Hz), 7.39 (1H, d, J= 2.0 Hz), 7.87 (1H, d, J= 8.4 Hz), 8.30-8.37 (1H, m), 8.59-8.63 (1H, m), 8.96 (0.33H, d, J= 2.4 Hz), 9.08 (0.62H, t, J= 2.4 Hz), 9.28 (1H, brs).
273 Example 156: (6aS)-8,8-dimethy1-2-05-methyl-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)-6,6a,7,8-tetrahydro-9H-pyrido [2,3-b]pyrrolo [1,2-d] [1,4]oxazin-9-one c 0 I
NN
[0589] A
mixture of Pd2(dba)3 (14 mg, 0.015 mmol) and Brettphos (17 mg, 0.031 mmol) in dioxane (1 mL) was stirred at 50 C for 10 min. 1-(3-chloro-5-methy1-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (50 mg, 0.16 mmol), (S)-2-amino-8,8-dimethy1-6,6a,7,8-tetrahydro-9H-pyrido[2,3-blpyrrolo[1,2-d] [1,4]oxazin-9-one (41 mg, 0.17 mmol) in dioxane (6 mL) and Cs2CO3 (155 mg, 0.477 mmol) were added and the resulting mixture was stirred at 100 C for 15 hours. A black brown mixture was formed. LCMS showed that the purity of the desired product is 48% (Rt = 0.633 min; MS Calcd: 511.2; MS Found: 512.1 [M+Hl+). The reaction mixture was diluted with DCM (10 mL), filtered and concentrated. The residue was purified by prep-HPLC (0.05% NH31120 as an additive) and lyophilized to give (6a5)-8,8-dimethy1-2-45 -methyl-8-(2-oxopyrroli din-l-y1)-5H-chromeno [4,3 -c] py ri din-3 -yl)amino)-6,6a,7,8-tetrahydro-9H-pyrido[2,3-blpyrrolo[1,2-d] [1,4] oxazin-9-one (17.2 mg, yield: 21%) as a yellow solid.
11-1NMR (400 MHz, DMSO-d6) 6 1.15 (3H, s), 1.19 (3H, s), 1.50 (3H, d, J= 6.4 Hz), 1.57 (1H, dd, J= 12.4, 10.4 Hz), 2.02-2.12 (3H, m), 2.55 (2H, overlapped with DMSO), 3.60-3.89 (3H, m), 4.04-4.11 (1H, m), 4.56 (1H, dd, J= 10.8, 2.8 Hz), 5.23 (1H, q, J=
6.8 Hz), 6.64 (1H, brs), 7.28 (1H, dd, J= 8.4, 2.0 Hz), 7.37 (1H, d, J= 2.4 Hz), 7.86 (1H, d, J= 8.4 Hz), 8.27 (1H, d, J= 2.8 Hz), 8.58 (1H, s), 9.07 (1H, dd, J= 2.8, 1.2 Hz), 9.26 (1H, d, J= 2.0 Hz).
Example 157: (6a'S)-2'4(5-methyl-8-(2-oxopyrrolidin-1-y1)-5H-chromeno14,3-c]pyridin-3-yl)amino)-6a',7'-dihydro-6'H,9'H-spiro[cyclopropane-1,8'-pyrido12,3-b]pyrrolo11,2-d][1,4]oxazin]-9'-one
NN
[0589] A
mixture of Pd2(dba)3 (14 mg, 0.015 mmol) and Brettphos (17 mg, 0.031 mmol) in dioxane (1 mL) was stirred at 50 C for 10 min. 1-(3-chloro-5-methy1-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (50 mg, 0.16 mmol), (S)-2-amino-8,8-dimethy1-6,6a,7,8-tetrahydro-9H-pyrido[2,3-blpyrrolo[1,2-d] [1,4]oxazin-9-one (41 mg, 0.17 mmol) in dioxane (6 mL) and Cs2CO3 (155 mg, 0.477 mmol) were added and the resulting mixture was stirred at 100 C for 15 hours. A black brown mixture was formed. LCMS showed that the purity of the desired product is 48% (Rt = 0.633 min; MS Calcd: 511.2; MS Found: 512.1 [M+Hl+). The reaction mixture was diluted with DCM (10 mL), filtered and concentrated. The residue was purified by prep-HPLC (0.05% NH31120 as an additive) and lyophilized to give (6a5)-8,8-dimethy1-2-45 -methyl-8-(2-oxopyrroli din-l-y1)-5H-chromeno [4,3 -c] py ri din-3 -yl)amino)-6,6a,7,8-tetrahydro-9H-pyrido[2,3-blpyrrolo[1,2-d] [1,4] oxazin-9-one (17.2 mg, yield: 21%) as a yellow solid.
11-1NMR (400 MHz, DMSO-d6) 6 1.15 (3H, s), 1.19 (3H, s), 1.50 (3H, d, J= 6.4 Hz), 1.57 (1H, dd, J= 12.4, 10.4 Hz), 2.02-2.12 (3H, m), 2.55 (2H, overlapped with DMSO), 3.60-3.89 (3H, m), 4.04-4.11 (1H, m), 4.56 (1H, dd, J= 10.8, 2.8 Hz), 5.23 (1H, q, J=
6.8 Hz), 6.64 (1H, brs), 7.28 (1H, dd, J= 8.4, 2.0 Hz), 7.37 (1H, d, J= 2.4 Hz), 7.86 (1H, d, J= 8.4 Hz), 8.27 (1H, d, J= 2.8 Hz), 8.58 (1H, s), 9.07 (1H, dd, J= 2.8, 1.2 Hz), 9.26 (1H, d, J= 2.0 Hz).
Example 157: (6a'S)-2'4(5-methyl-8-(2-oxopyrrolidin-1-y1)-5H-chromeno14,3-c]pyridin-3-yl)amino)-6a',7'-dihydro-6'H,9'H-spiro[cyclopropane-1,8'-pyrido12,3-b]pyrrolo11,2-d][1,4]oxazin]-9'-one
274 çNo I H
NN
[0590] A
mixture of 1-(3-chloro-5-methy1-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one (40 mg, 0.13 mmol), (S)-2'-amino-6a',7'-dihydro-GH,911-1-spiro[cyclopropane-1,8'-pyrido[2,3-blpyrrolo[1,2-d][1,41oxazin1-9'-one (32 mg, 0.14 mmol), Pd2(dba)3 (12 mg, 0.013 mmol), Brettphos (14 mg, 0.026 mmol), Cs2CO3 (83 mg, 0.26 mmol) in dioxane (3 mL) was degassed and purged with N2 for 3 times. Then the resulting reaction mixture was heated at 90 C for 15 hours under N2 atmosphere. The reaction mixture turned into brown suspension from red suspension. LCMS showed that the purity of the desired product is 48% (Rt = 0.758 min;
MS Calcd: 509.2; MS Found: 510.3 [M+Hl+). The mixture was diluted with water (10 mL) and extracted with Et0Ac (20 mL x3). The combined organic layer was washed with water (20 mL
x2), brine (20 mL x2), dried over anhydrous Na2SO4, filtered and concentrated.
The residue was purified by prep-HPLC (0.225% FA as an additive), further purified by prep-TLC
(DCM/Me0H, 10/1) and triturated with MeCN (3 mL), then lyophilized to give (6a'S)-2'-((5-methy1-8-(2-oxopy rroli din-1 -y1)-5H-chromeno [4,3 -c] py ri din-3-yl)amino)-6a',7'-dihy dro-GH,911-1-spiro [cy clopropane-1,8'-pyrido[2,3-b] pyrrolo [1,2-d] [1,41oxazin1-91-one (24.7 mg, yield: 32%) as an off-white solid.
1-1-1NMR (400 MHz, DMSO-d6) 5 0.83-0.89 (1H, m), 0.93-0.99 (1H, m), 1.00-1.07 (1H, m), 1.08-1.14 (1H, m), 1.53 (3H, d, J= 6.4 Hz), 1.98-2.11 (3H, m), 2.16-2.23 (1H, m), 2.52-2.55 (2H, m, overlapped with DMSO), 3.85 (2H, t, J= 8.0 Hz), 4.00 (1H, t, J = 8.0 Hz), 4.16-4.25 (1H, m), 4.62 (1H, dd, J= 10.8 Hz, 3.0 Hz), 5.28 (1H, q, J= 6.4 Hz), 6.66 (1H, s), 7.31 (1H, dd, J= 8.4 Hz, 2.2 Hz), 7.39 (1H, d, J= 2.2 Hz), 7.87 (1H, d, J= 8.5 Hz), 8.31 (1H, d, J=
2.0 Hz), 8.60 (1H, s), 9.00 (1H, t, J = 4.0 Hz), 9.29 (1H, d, J= 2.2 Hz).
Example 158: (3aR)-8-05-methyl-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)-3a,4-dihydro-1H,3H-oxazolo[3,4-d]pyrido[2,3-b][1,4]0xazin-1-one
NN
[0590] A
mixture of 1-(3-chloro-5-methy1-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one (40 mg, 0.13 mmol), (S)-2'-amino-6a',7'-dihydro-GH,911-1-spiro[cyclopropane-1,8'-pyrido[2,3-blpyrrolo[1,2-d][1,41oxazin1-9'-one (32 mg, 0.14 mmol), Pd2(dba)3 (12 mg, 0.013 mmol), Brettphos (14 mg, 0.026 mmol), Cs2CO3 (83 mg, 0.26 mmol) in dioxane (3 mL) was degassed and purged with N2 for 3 times. Then the resulting reaction mixture was heated at 90 C for 15 hours under N2 atmosphere. The reaction mixture turned into brown suspension from red suspension. LCMS showed that the purity of the desired product is 48% (Rt = 0.758 min;
MS Calcd: 509.2; MS Found: 510.3 [M+Hl+). The mixture was diluted with water (10 mL) and extracted with Et0Ac (20 mL x3). The combined organic layer was washed with water (20 mL
x2), brine (20 mL x2), dried over anhydrous Na2SO4, filtered and concentrated.
The residue was purified by prep-HPLC (0.225% FA as an additive), further purified by prep-TLC
(DCM/Me0H, 10/1) and triturated with MeCN (3 mL), then lyophilized to give (6a'S)-2'-((5-methy1-8-(2-oxopy rroli din-1 -y1)-5H-chromeno [4,3 -c] py ri din-3-yl)amino)-6a',7'-dihy dro-GH,911-1-spiro [cy clopropane-1,8'-pyrido[2,3-b] pyrrolo [1,2-d] [1,41oxazin1-91-one (24.7 mg, yield: 32%) as an off-white solid.
1-1-1NMR (400 MHz, DMSO-d6) 5 0.83-0.89 (1H, m), 0.93-0.99 (1H, m), 1.00-1.07 (1H, m), 1.08-1.14 (1H, m), 1.53 (3H, d, J= 6.4 Hz), 1.98-2.11 (3H, m), 2.16-2.23 (1H, m), 2.52-2.55 (2H, m, overlapped with DMSO), 3.85 (2H, t, J= 8.0 Hz), 4.00 (1H, t, J = 8.0 Hz), 4.16-4.25 (1H, m), 4.62 (1H, dd, J= 10.8 Hz, 3.0 Hz), 5.28 (1H, q, J= 6.4 Hz), 6.66 (1H, s), 7.31 (1H, dd, J= 8.4 Hz, 2.2 Hz), 7.39 (1H, d, J= 2.2 Hz), 7.87 (1H, d, J= 8.5 Hz), 8.31 (1H, d, J=
2.0 Hz), 8.60 (1H, s), 9.00 (1H, t, J = 4.0 Hz), 9.29 (1H, d, J= 2.2 Hz).
Example 158: (3aR)-8-05-methyl-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)-3a,4-dihydro-1H,3H-oxazolo[3,4-d]pyrido[2,3-b][1,4]0xazin-1-one
275 N N
Step 1: Preparation of methyl 0-(tert-butyldimethylsily1)-L-serinate H2NµTh OTBS
[0591] To a mixture of methyl L-serinate (10.0 g, 64.0 mmol) and imidazole (8.75 g, 129 mmol) in MeCN (200 mL) was added TBSC1 (12.6 g, 83.6 mmol) drop wise at 10 C.
The mixture was stirred at 10 C for 16 hours. A white suspension was formed. TLC
showed that starting material was consumed and a less polar spot was formed. The mixture was concentrated and purified by Flash column (Et0Ac in PE from 50 to 100%) to give methyl 0-(tert-butyldimethylsily1)-L-serinate (14.0 g, yield: 93%) as colorless oil.
11-1NMR (400 MHz, DMSO-d6) (5 0.04 (3H, s), 0.05 (3H, s), 0.86 (9H, s), 3.53 (1H, t, J= 4.4 Hz), 3.73 (3H, s), 3.81 (1H, dd, J = 9.6, 3.6 Hz), 3.92 (1H, dd, J = 10.0, 4.0 Hz).
Note: two active protons were not observed.
Step 2: Preparation of methyl N-((benzyloxy)carbony1)-0-(tert-butyldimethylsily1)-L-serinate Cbz OTBS
[0592] To a mixture of methyl 0-(tert-butyldimethylsily1)-L-serinate (14.0 g, 60.0 mmol) NaHCO3 (10.1 g, 120 mmol) in THF (200 mL) was added CbzCl (13.3 g, 78.0 mmol) drop wise at 0 C. The mixture was warmed to 10 C and stirred for 16 hours. A
white suspension was formed. TLC showed that starting material was consumed and a less polar spot was formed. The mixture was added sat.NaHCO3 (200 mL), extracted with Et0Ac (200 mL x3), the combined layer was washed with brine (200 mL), dried over Na2SO4 and concentrated. The residue was purified by Flash column (Et0Ac in PE from 0 to 10%) to give methyl N-((benzyloxy)carbony1)-0-(tert-butyldimethylsily1)-L-serinate (18.0 g, yield:
82%) as colorless oil.
Step 1: Preparation of methyl 0-(tert-butyldimethylsily1)-L-serinate H2NµTh OTBS
[0591] To a mixture of methyl L-serinate (10.0 g, 64.0 mmol) and imidazole (8.75 g, 129 mmol) in MeCN (200 mL) was added TBSC1 (12.6 g, 83.6 mmol) drop wise at 10 C.
The mixture was stirred at 10 C for 16 hours. A white suspension was formed. TLC
showed that starting material was consumed and a less polar spot was formed. The mixture was concentrated and purified by Flash column (Et0Ac in PE from 50 to 100%) to give methyl 0-(tert-butyldimethylsily1)-L-serinate (14.0 g, yield: 93%) as colorless oil.
11-1NMR (400 MHz, DMSO-d6) (5 0.04 (3H, s), 0.05 (3H, s), 0.86 (9H, s), 3.53 (1H, t, J= 4.4 Hz), 3.73 (3H, s), 3.81 (1H, dd, J = 9.6, 3.6 Hz), 3.92 (1H, dd, J = 10.0, 4.0 Hz).
Note: two active protons were not observed.
Step 2: Preparation of methyl N-((benzyloxy)carbony1)-0-(tert-butyldimethylsily1)-L-serinate Cbz OTBS
[0592] To a mixture of methyl 0-(tert-butyldimethylsily1)-L-serinate (14.0 g, 60.0 mmol) NaHCO3 (10.1 g, 120 mmol) in THF (200 mL) was added CbzCl (13.3 g, 78.0 mmol) drop wise at 0 C. The mixture was warmed to 10 C and stirred for 16 hours. A
white suspension was formed. TLC showed that starting material was consumed and a less polar spot was formed. The mixture was added sat.NaHCO3 (200 mL), extracted with Et0Ac (200 mL x3), the combined layer was washed with brine (200 mL), dried over Na2SO4 and concentrated. The residue was purified by Flash column (Et0Ac in PE from 0 to 10%) to give methyl N-((benzyloxy)carbony1)-0-(tert-butyldimethylsily1)-L-serinate (18.0 g, yield:
82%) as colorless oil.
276 NMR (400 MHz, DMSO-d6) (5 0.01 (3H, s), 0.02 (3H, s), 0.85 (9H, s), 3.75 (3H, s), 3.84 (1H, dd, J= 10.0, 2.4 Hz), 4.07 (1H, dd, J= 10.0, 2.4 Hz), 4.43 (1H, dt, J=
8.8, 2.8 Hz), 5.13 (1H, d, J= 3.2 Hz), 5.60 (1H, d, J= 8.8 Hz), 7.30-7.38 (5H, m).
Step 3: Preparation of benzyl (R)-(1-((tert-butyldimethylsilyl)oxy)-3-hydroxypropan-2-yl)carbamate HO
HN"Th &)z OTBS
105931 To a mixture of methyl N-((benzyloxy)carbony1)-0-(tert-butyldimethylsily1)-L-serinate (18.0 g, 49.0 mmol) in Me0H (200 mL) was added NaBH4 (5.56 g, 147 mmol). The mixture was stirred at 0 C for 1 hour. The colorless solution was warmed to 20 C and stirred for another 15 hours. TLC showed that most of starting material was consumed and a more polar spot was formed. The mixture was added sat.NH4C1 (200 mL), extracted with Et0Ac (200 mL x3), the combined layer was washed with brine (200 mL), dried over Na2SO4 and concentrated. The residue was purified by Flash column (Et0Ac in PE from 0 to 30%) to give benzyl (R)-(1-((tert-butyldimethylsilyl)oxy)-3-hydroxypropan-2-yl)carbamate (15.0 g, yield:
90%) as colorless oil.
11-1NMR (400 MHz, DMSO-d6) (5 0.05 (3H, s), 0.06 (3H, s), 0.89 (9H, s), 2.55-2.57 (1H, m), 3.68-3.73 (1H, m), 3.79-3.82 (2H, m), 3.85-3.89 (1H, m), 5.12 (2H, m), 5.39 (1H, m), 7.33-7.38 (5H, m).
Note: one active proton was not observed.
Step 4: Preparation of compound OTBS
Br 105941 To a mixture of benzyl (R)-(1-((tert-butyldimethylsily0oxy)-3-hydroxypropan-2-yOcarbamate (15.0 g, 44.0 mmol) in dioxane (200 mL) was added K2CO3 (11.6 g, 84.2 mmol) and 3-bromo-2-chloro-5-nitropyridine (10.0 g, 42.1 mmol). The mixture was stirred at 80 C
for 16 hours. A red suspension was formed. TLC showed that starting material was remained and a more polar spot was formed. The mixture was stirred at 80 C for another 24 hours. TLC
showed that part of starting material was remained. The mixture was stirred at 80 C for
8.8, 2.8 Hz), 5.13 (1H, d, J= 3.2 Hz), 5.60 (1H, d, J= 8.8 Hz), 7.30-7.38 (5H, m).
Step 3: Preparation of benzyl (R)-(1-((tert-butyldimethylsilyl)oxy)-3-hydroxypropan-2-yl)carbamate HO
HN"Th &)z OTBS
105931 To a mixture of methyl N-((benzyloxy)carbony1)-0-(tert-butyldimethylsily1)-L-serinate (18.0 g, 49.0 mmol) in Me0H (200 mL) was added NaBH4 (5.56 g, 147 mmol). The mixture was stirred at 0 C for 1 hour. The colorless solution was warmed to 20 C and stirred for another 15 hours. TLC showed that most of starting material was consumed and a more polar spot was formed. The mixture was added sat.NH4C1 (200 mL), extracted with Et0Ac (200 mL x3), the combined layer was washed with brine (200 mL), dried over Na2SO4 and concentrated. The residue was purified by Flash column (Et0Ac in PE from 0 to 30%) to give benzyl (R)-(1-((tert-butyldimethylsilyl)oxy)-3-hydroxypropan-2-yl)carbamate (15.0 g, yield:
90%) as colorless oil.
11-1NMR (400 MHz, DMSO-d6) (5 0.05 (3H, s), 0.06 (3H, s), 0.89 (9H, s), 2.55-2.57 (1H, m), 3.68-3.73 (1H, m), 3.79-3.82 (2H, m), 3.85-3.89 (1H, m), 5.12 (2H, m), 5.39 (1H, m), 7.33-7.38 (5H, m).
Note: one active proton was not observed.
Step 4: Preparation of compound OTBS
Br 105941 To a mixture of benzyl (R)-(1-((tert-butyldimethylsily0oxy)-3-hydroxypropan-2-yOcarbamate (15.0 g, 44.0 mmol) in dioxane (200 mL) was added K2CO3 (11.6 g, 84.2 mmol) and 3-bromo-2-chloro-5-nitropyridine (10.0 g, 42.1 mmol). The mixture was stirred at 80 C
for 16 hours. A red suspension was formed. TLC showed that starting material was remained and a more polar spot was formed. The mixture was stirred at 80 C for another 24 hours. TLC
showed that part of starting material was remained. The mixture was stirred at 80 C for
277 another 72 hours. TLC showed that half starting material was consumed. The mixture was filtered and the solid was washed with Et0Ac (100 mL x3). The combined layer was concentrated the residue was purified by flash column (Et0Ac in PE from 0 to 10%) to give benzyl (R)-(1-((3-bromo-5-nitropyridin-2-yl)oxy)-3-((tert-butyldimethylsilyl)oxy)propan-2-yl)carbamate (6.00 g, yield: 26%) as light yellow oil.
NMR (400 MHz, DMSO-d6) (5 0.04 (6H, s), 0.87 (9H, s), 3.74-3.78-2.34 (1H, m), 3.90-3.92 (1H, m), 4.20-4.22 (1H, m), 4.49-4.53 (1H, m), 4.60-4.63 (1H, m), 5.12 (2H, d, J= 4.8 Hz), 5.19-5.21 (1H, m), 7.30-7.37 (5H, m), 8.82 (1H, s), 8.99 (1H, s).
Step 5: Preparation of (R)-2-(((tert-butyldimethylsily0oxy)methyl)-7-nitro-2,3-dihydro-1H-pyrido[2,3-b1 [1,41oxazine N
TBSO
[0595] To a mixture of benzyl (R)-(1-((3-bromo-5-nitropyridin-2-y0oxy)-3-((tert-butyldimethylsily0oxy)propan-2-yOcarbamate (5.00 g, 9.25 mmol) and Cs2CO3 (4.52 g, 13.9 mmol) in MeCN (200 mL) was added Pd2(dba)3 (424 mg, 0.463 mmol) and Xantphos (535 mg, 0.925 mmol). The mixture was stirred at 100 C for 16 hours. A black suspension was formed.
LCMS showed that starting material was consumed and the desired product was not formed.
TLC showed that more polar spots were formed. The mixture was concentrated and purified by flash column (EA in PE form 0 to 20%) to give (R)-2-(((tert-butyldimethylsily0oxy)methyl)-7-nitro-2,3-dihydro-lH-pyrido [2,3 -b] [1,4]
oxazine (300 mg, yield: 10%) as a yellow solid.
Step 6: Preparation of (R)-2-(((tert-butyldimethylsily0oxy)methyl)-2,3-dihydro-pyrido [2,3 -b] [1,4] oxazin-7-amine N
TBSO
[0596] To a solution of (R)-2-(((tert-butyldimethylsilypoxy)methyl)-7-nitro-2,3-dihydro-1H-pyrido[2,3-b1[1,41oxazine (300 mg, 0.922 mmol) in THF (5 mL) was added Pd/C
(100 mg, 10% purity in activated carbon). The mixture was degassed and purged with H2 for 3 times,
NMR (400 MHz, DMSO-d6) (5 0.04 (6H, s), 0.87 (9H, s), 3.74-3.78-2.34 (1H, m), 3.90-3.92 (1H, m), 4.20-4.22 (1H, m), 4.49-4.53 (1H, m), 4.60-4.63 (1H, m), 5.12 (2H, d, J= 4.8 Hz), 5.19-5.21 (1H, m), 7.30-7.37 (5H, m), 8.82 (1H, s), 8.99 (1H, s).
Step 5: Preparation of (R)-2-(((tert-butyldimethylsily0oxy)methyl)-7-nitro-2,3-dihydro-1H-pyrido[2,3-b1 [1,41oxazine N
TBSO
[0595] To a mixture of benzyl (R)-(1-((3-bromo-5-nitropyridin-2-y0oxy)-3-((tert-butyldimethylsily0oxy)propan-2-yOcarbamate (5.00 g, 9.25 mmol) and Cs2CO3 (4.52 g, 13.9 mmol) in MeCN (200 mL) was added Pd2(dba)3 (424 mg, 0.463 mmol) and Xantphos (535 mg, 0.925 mmol). The mixture was stirred at 100 C for 16 hours. A black suspension was formed.
LCMS showed that starting material was consumed and the desired product was not formed.
TLC showed that more polar spots were formed. The mixture was concentrated and purified by flash column (EA in PE form 0 to 20%) to give (R)-2-(((tert-butyldimethylsily0oxy)methyl)-7-nitro-2,3-dihydro-lH-pyrido [2,3 -b] [1,4]
oxazine (300 mg, yield: 10%) as a yellow solid.
Step 6: Preparation of (R)-2-(((tert-butyldimethylsily0oxy)methyl)-2,3-dihydro-pyrido [2,3 -b] [1,4] oxazin-7-amine N
TBSO
[0596] To a solution of (R)-2-(((tert-butyldimethylsilypoxy)methyl)-7-nitro-2,3-dihydro-1H-pyrido[2,3-b1[1,41oxazine (300 mg, 0.922 mmol) in THF (5 mL) was added Pd/C
(100 mg, 10% purity in activated carbon). The mixture was degassed and purged with H2 for 3 times,
278 stirred at 10 C for 16 hours under H2 (15 psi). A black suspension was formed. TLC showed that starting material remained and the desired product was formed. The mixture was filtered and concentrated the residue was purified by flash column (EA in PE
from 50 to 100%) to give (R)-2-(((tert-buty ldimethy ls ily Doxy)methyl)-2,3 -dihy dro-1H-py ri do [2,3 -b][1,410xazin-7-amine (200 mg, yield: 73%) as a yellow solid.
NMR (400 MHz, DMSO-d6) (5 0.05 (3H, s), 0.06 (3H, s), 0.88 (9H, s), 2.33-2.34 (1H, m), 3.48 (1H, dd, J= 10.0, 8.4 Hz), 3.56 (1H, dd, J= 10.4, 8.4 Hz), 3.99-4.04 (2H, m), 4.56 (2H, s), 5.87 (1H, d, J= 2.0 Hz), 6.24 (1H, d, J= 2.8 Hz), 6.75 (1H, d, J= 2.8 Hz).
Step 7: Preparation of 1-(3 -(((R)-2-(((tert-butyldimethyls ilyl)oxy)methyl)-2,3 -dihy dro-1H-py ri do [2,3 -b] [1,4] oxazin-7-yl)amino)-5-methyl-5H-chromeno [4,3 -c] py ri din-8-yl)py rroli din-2-one 0 1iLL1 N 0 N
H I
OTBS
[0597] To a mixture of (R)-2-(((tert-butyldimethylsilyl)oxy)methyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4loxazin-7-amine (100 mg, 0.32 mmol) and 1-(3-chloro-5-methy1-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (103 mg, 0.349 mmol) in dioxane (2 mL) was added Pd2(dba)3 (15 mg, 0.016 mmol), Brettphos (17 mg, 0.032 mmol) and Cs2CO3 (155 mg, 0.477 mmol). The mixture was degassed and purged with N2 and stirred at 100 C
for 16 hours.
A brown suspension was formed. LCMS showed the purity of product is 18% (Rt =
0.931 min;
MS Calcd: 573.8; MS Found: 574.2 [M+H]+). The mixture was concentrated and purified by Flash column (EA in PE from 50 to 100%) to give 1-(3-4(R)-2-(((tert-butyldimethylsily0oxy)methy 0-2,3-dihy dro-1H-py ri do [2,3-b] [1,4] oxazin-7-yl)amino)-5-methy1-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (150 mg, yield: 82%) as a yellow solid.
NMR (400 MHz, DMSO-d6) (5 0.07 (3H, s), 0.08 (3H, s), 0.89 (9H, s), 1.51 (3H, d, J= 6.8 Hz), 2.04-2.08 (2H, m), 2.55-2.57 (2H, m), 3.37-3.43 (2H, m), 3.53-3.60 (2H, m), 3.82-3.87 (2H, m), 4.11-4.14 (1H, m), 4.44-4.46 (1H, m), 5.24 (1H, q, J= 6.8 Hz), 6.21 (1H, s), 6.61 (1H, s), 7.30-7.33 (1H, m), 7.38 (1H, d, J= 2.4 Hz), 7.60 (1H, d, J= 2.0 Hz), 7.84 (1H, d, J=
8.8 Hz), 8.56 (1H, s), 8.96 (1H, s).
from 50 to 100%) to give (R)-2-(((tert-buty ldimethy ls ily Doxy)methyl)-2,3 -dihy dro-1H-py ri do [2,3 -b][1,410xazin-7-amine (200 mg, yield: 73%) as a yellow solid.
NMR (400 MHz, DMSO-d6) (5 0.05 (3H, s), 0.06 (3H, s), 0.88 (9H, s), 2.33-2.34 (1H, m), 3.48 (1H, dd, J= 10.0, 8.4 Hz), 3.56 (1H, dd, J= 10.4, 8.4 Hz), 3.99-4.04 (2H, m), 4.56 (2H, s), 5.87 (1H, d, J= 2.0 Hz), 6.24 (1H, d, J= 2.8 Hz), 6.75 (1H, d, J= 2.8 Hz).
Step 7: Preparation of 1-(3 -(((R)-2-(((tert-butyldimethyls ilyl)oxy)methyl)-2,3 -dihy dro-1H-py ri do [2,3 -b] [1,4] oxazin-7-yl)amino)-5-methyl-5H-chromeno [4,3 -c] py ri din-8-yl)py rroli din-2-one 0 1iLL1 N 0 N
H I
OTBS
[0597] To a mixture of (R)-2-(((tert-butyldimethylsilyl)oxy)methyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4loxazin-7-amine (100 mg, 0.32 mmol) and 1-(3-chloro-5-methy1-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (103 mg, 0.349 mmol) in dioxane (2 mL) was added Pd2(dba)3 (15 mg, 0.016 mmol), Brettphos (17 mg, 0.032 mmol) and Cs2CO3 (155 mg, 0.477 mmol). The mixture was degassed and purged with N2 and stirred at 100 C
for 16 hours.
A brown suspension was formed. LCMS showed the purity of product is 18% (Rt =
0.931 min;
MS Calcd: 573.8; MS Found: 574.2 [M+H]+). The mixture was concentrated and purified by Flash column (EA in PE from 50 to 100%) to give 1-(3-4(R)-2-(((tert-butyldimethylsily0oxy)methy 0-2,3-dihy dro-1H-py ri do [2,3-b] [1,4] oxazin-7-yl)amino)-5-methy1-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (150 mg, yield: 82%) as a yellow solid.
NMR (400 MHz, DMSO-d6) (5 0.07 (3H, s), 0.08 (3H, s), 0.89 (9H, s), 1.51 (3H, d, J= 6.8 Hz), 2.04-2.08 (2H, m), 2.55-2.57 (2H, m), 3.37-3.43 (2H, m), 3.53-3.60 (2H, m), 3.82-3.87 (2H, m), 4.11-4.14 (1H, m), 4.44-4.46 (1H, m), 5.24 (1H, q, J= 6.8 Hz), 6.21 (1H, s), 6.61 (1H, s), 7.30-7.33 (1H, m), 7.38 (1H, d, J= 2.4 Hz), 7.60 (1H, d, J= 2.0 Hz), 7.84 (1H, d, J=
8.8 Hz), 8.56 (1H, s), 8.96 (1H, s).
279 Step 8: Preparation of 1-(3-(((S)-2-(hy droxy methyl)-2,3-dihy dro-1H-py ri do [2,3-b] [1,41oxazin-7-y0amino)-5-methyl-5H-chromeno [4,3-c] py ridin-8-yl)py rroli din-2-one I
N N N
H
OH
[0598] To a solution of 1-(3-4(R)-2-(((tert-butyldimethylsily0oxy)methyl)-2,3-dihydro-1H-py ri do [2,3-b] [1,4] oxazin-7-yl)amino)-5-methyl-5H-chromeno [4,3 -c] py ri din-8-yl)pyrrolidin-2-one (15 mg, 0.26 mmol) in THF (5 mL) was added TBAF (137 mg, 0.523 mmol) at 0 C. The mixture was warmed to 20 C and stirred for 16 hours to give a red solution.
LCMS showed the purity of product is 35% (Rt = 0.747 min; MS Calcd: 485.5; MS
Found:
486.6 [M+Hl+). The mixture was concentrated and the residue was purified by prep.TLC
(DCM/Me0H, 10/1) to give 1-(3-4(S)-2-(hydroxymethyl)-2,3-dihydro-1H-pyrido[2,3-b] [1,4] oxazin-7-yl)amino)-5-methy1-5H-chromeno [4,3-c] py ridin-8-yl)py rroli din-2-one (100 mg, yield: 83%) as a yellow solid.
NMR (400 MHz, DMSO-d6) (51.51 (3H, d, J= 6.9 Hz), 2.09-2.15 (2H, m), 2.43 (2H, t, J
= 7.6 Hz), 3.15-3.19 (2H, m), 3.36-3.44 (2H, m), 3.74-3.79 (2H, m), 4.03-4.08 (1H, m), 4.18-4.21 (1H, m), 4.94 (1H, t, J= 5.6 Hz), 5.24 (1H, q, J= 6.8 Hz), 6.21 (1H, s), 6.63 (1H, s), 7.04 (1H, d, J= 6.8 Hz), 7.36 (1H, d, J= 2.4 Hz), 7.60 (1H, d, J= 2.4 Hz), 7.84 (1H, d, J=
11.6 Hz), 8.60 (1H, s), 9.06 (1H, s).
Step 9:
Preparation of (3aR)-8-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c] py ri din-3-yl)amino)-3a,4-dihy dro-1H,3H-oxazol o [3,4-d] pyri do [2,3 -b]
[1,4] oxazin-1 -one I
N N
[0599] To a solution of 1-(3-4(S)-2-(hydroxymethyl)-2,3-dihydro-1H-pyrido[2,3-b] [1,4] oxazin-7-yl)amino)-5-methy1-5H-chromeno [4,3-c] py ridin-8-y 1)py rrol i din-2-onein DCM (5 mL) was added TEA (33 mg, 0.33 mmol) and CDI (71 mg, 0.44 mmol). The mixture was stirred at 10 C for 16 hours. A white suspension was formed. LCMS showed the purity of
N N N
H
OH
[0598] To a solution of 1-(3-4(R)-2-(((tert-butyldimethylsily0oxy)methyl)-2,3-dihydro-1H-py ri do [2,3-b] [1,4] oxazin-7-yl)amino)-5-methyl-5H-chromeno [4,3 -c] py ri din-8-yl)pyrrolidin-2-one (15 mg, 0.26 mmol) in THF (5 mL) was added TBAF (137 mg, 0.523 mmol) at 0 C. The mixture was warmed to 20 C and stirred for 16 hours to give a red solution.
LCMS showed the purity of product is 35% (Rt = 0.747 min; MS Calcd: 485.5; MS
Found:
486.6 [M+Hl+). The mixture was concentrated and the residue was purified by prep.TLC
(DCM/Me0H, 10/1) to give 1-(3-4(S)-2-(hydroxymethyl)-2,3-dihydro-1H-pyrido[2,3-b] [1,4] oxazin-7-yl)amino)-5-methy1-5H-chromeno [4,3-c] py ridin-8-yl)py rroli din-2-one (100 mg, yield: 83%) as a yellow solid.
NMR (400 MHz, DMSO-d6) (51.51 (3H, d, J= 6.9 Hz), 2.09-2.15 (2H, m), 2.43 (2H, t, J
= 7.6 Hz), 3.15-3.19 (2H, m), 3.36-3.44 (2H, m), 3.74-3.79 (2H, m), 4.03-4.08 (1H, m), 4.18-4.21 (1H, m), 4.94 (1H, t, J= 5.6 Hz), 5.24 (1H, q, J= 6.8 Hz), 6.21 (1H, s), 6.63 (1H, s), 7.04 (1H, d, J= 6.8 Hz), 7.36 (1H, d, J= 2.4 Hz), 7.60 (1H, d, J= 2.4 Hz), 7.84 (1H, d, J=
11.6 Hz), 8.60 (1H, s), 9.06 (1H, s).
Step 9:
Preparation of (3aR)-8-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c] py ri din-3-yl)amino)-3a,4-dihy dro-1H,3H-oxazol o [3,4-d] pyri do [2,3 -b]
[1,4] oxazin-1 -one I
N N
[0599] To a solution of 1-(3-4(S)-2-(hydroxymethyl)-2,3-dihydro-1H-pyrido[2,3-b] [1,4] oxazin-7-yl)amino)-5-methy1-5H-chromeno [4,3-c] py ridin-8-y 1)py rrol i din-2-onein DCM (5 mL) was added TEA (33 mg, 0.33 mmol) and CDI (71 mg, 0.44 mmol). The mixture was stirred at 10 C for 16 hours. A white suspension was formed. LCMS showed the purity of
280 product is 59% (Rt = 0.783 min; MS Calcd: 485.5; MS Found: 486.6 [M+Hl+). The reaction mixture was purified by prep.TLC (DCM/Me0H, 20/1) to give a yellow solid, the residue was purified by prep-HPLC to give (3aR)-8-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c] pyridin-3-y0amino)-3a,4-dihy dro-1H,3H-oxazolo [3,4-d]
pyrido[2,3 -b][1,4loxazin-1-one (2.12 mg, yield: 4%) as a white solid.
11-1NMR (400 MHz, DMSO-d6) 1.53 (3H, d, J= 6.4 Hz), 2.04-2.08 (2H, m), 2.45-2.47 (2H, overlapped with DMSO), 3.85 (2H, t, J= 7.6 Hz), 4.12 (1H, t, J= 10.0 Hz), 4.19 (1H, t, J=
11.2 Hz), 4.33-4.41 (1H, m), 4.58-4.66 (2H, m), 5.26 (1H, q, J= 6.8 Hz), 6.67 (1H, s), 7.31 (1H, dd, J= 8.4 Hz, 2.0 Hz), 7.40 (1H, d, J= 2.0 Hz), 7.88 (1H, d, J= 8.8 Hz), 8.36 (1H, d, J
= 2.8 Hz), 8.58 (1H, dd, J= 6.0 Hz, 2.8 Hz), 8.62 (1H, s), 9.36 (1H, d, J= 2.0 Hz).
Example 159: (3aR)-8-09-fluoro-5-methyl-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c] pyridin-3-yl)amino)-3a,4-dihydro-1H,3H-oxazolo [3,4-d] pyrido [2,3-b] [1,4]
oxazin-1-one I H
N NS
Step 1: Preparation of 1-(3-4(R)-2-(((tert-butyldimethylsilypoxy)methyl)-2,3-dihydro-1H-py ri do [2,3-b] [1,4] oxazin-7-yl)amino)-9-fluoro-5-methyl-5H-chromeno [4,3-c] py ri din-8-yOpyrrolidin-2-one I I
H
OTBS
[0600] To a mixture of 1-(3-chloro-9-fluoro-5-methy1-5H-chromeno[4,3-clpyridin-8-yl)pyrrolidin-2-one (158 mg, 0.474 mmol) and (R)-2-(((tert-butyldimethylsily0oxy)methyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4loxazin-7-amine (140 mg, 0.474 mmol) in dioxane (2 mL) was added Pd2(dba)3 (21 mg, 0.023 mmol), Brettphos (25 mg, 0.047 mmol) and Cs2CO3 (232
pyrido[2,3 -b][1,4loxazin-1-one (2.12 mg, yield: 4%) as a white solid.
11-1NMR (400 MHz, DMSO-d6) 1.53 (3H, d, J= 6.4 Hz), 2.04-2.08 (2H, m), 2.45-2.47 (2H, overlapped with DMSO), 3.85 (2H, t, J= 7.6 Hz), 4.12 (1H, t, J= 10.0 Hz), 4.19 (1H, t, J=
11.2 Hz), 4.33-4.41 (1H, m), 4.58-4.66 (2H, m), 5.26 (1H, q, J= 6.8 Hz), 6.67 (1H, s), 7.31 (1H, dd, J= 8.4 Hz, 2.0 Hz), 7.40 (1H, d, J= 2.0 Hz), 7.88 (1H, d, J= 8.8 Hz), 8.36 (1H, d, J
= 2.8 Hz), 8.58 (1H, dd, J= 6.0 Hz, 2.8 Hz), 8.62 (1H, s), 9.36 (1H, d, J= 2.0 Hz).
Example 159: (3aR)-8-09-fluoro-5-methyl-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c] pyridin-3-yl)amino)-3a,4-dihydro-1H,3H-oxazolo [3,4-d] pyrido [2,3-b] [1,4]
oxazin-1-one I H
N NS
Step 1: Preparation of 1-(3-4(R)-2-(((tert-butyldimethylsilypoxy)methyl)-2,3-dihydro-1H-py ri do [2,3-b] [1,4] oxazin-7-yl)amino)-9-fluoro-5-methyl-5H-chromeno [4,3-c] py ri din-8-yOpyrrolidin-2-one I I
H
OTBS
[0600] To a mixture of 1-(3-chloro-9-fluoro-5-methy1-5H-chromeno[4,3-clpyridin-8-yl)pyrrolidin-2-one (158 mg, 0.474 mmol) and (R)-2-(((tert-butyldimethylsily0oxy)methyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4loxazin-7-amine (140 mg, 0.474 mmol) in dioxane (2 mL) was added Pd2(dba)3 (21 mg, 0.023 mmol), Brettphos (25 mg, 0.047 mmol) and Cs2CO3 (232
281 mg, 0.711 mmol). The mixture was degassed and purged with Nz. The mixture was stirred at 90 C for 16 hours. A brown suspension was formed. LCMS showed the purity of product is 55% (Rt = 0.944 min; MS Calcd: 591.8; MS Found: 592.2 [M+H]+). The mixture was concentrated and the residue was purified by Flash column (Me0H in DCM from 0 to 3%) to give 1-(3-4(R)-2-(((tert-butyldimethylsily0oxy)methyl)-2,3-dihy dro-1H-py rido [2,3 -b] [1,4] oxazin-7-yl)amino)-9-fluoro-5 -methyl-5H-chromeno [4,3-c] py ridin-8-yl)py rrol idin-2-one (200 mg, yield: 71%) as a yellow solid.
NMR (400 MHz, DMSO-d6) (5 0.07 (3H, s), 0.08 (3H, s), 0.89 (9H, s), 1.51 (3H, d, J= 6.4 Hz), 2.08-2.13 (2H, m), 2.41-2.45 (2H, m), 3.52-3.54 (1H, m), 3.57-3.61 (1H, m), 3.76-3.78 (3H, m), 4.11-4.14 (1H, m), 4.44-4.46 (1H, m), 5.24 (1H, q, J= 6.8 Hz), 6.23 (1H, s), 6.62 (1H, s), 7.04 (1H, d, J= 6.8 Hz), 7.37 (1H, d, J= 1.6 Hz), 7.60 (1H, d, J= 2.4 Hz), 7.84 (1H, d, J= 12.0 Hz), 8.60 (1H, s), 9.06 (1H, s).
Step 2: Preparation of 1 -(9-fluoro-3 -(((S)-2-(hy droxy methyl)-2,3-dihy dro-1H-py ri do [2,3 -b] [1,4] oxazin-7-y 1)amino)-5 -methyl-5H-chromeno [4,3-c] py ridin-8-yl)py rroli din-2-one I
N N N
H
OH
[0601] To a solution of 1-(3-4(R)-2-(((tert-butyldimethylsily0oxy)methyl)-2,3-dihydro-1H-py ri do [2,3-b] [1,4] oxazin-7-yl)amino)-9-fluoro-5 -methyl-5H-chromeno [4,3 -c] py ri din-8-yOpyrrolidin-2-one (200 mg, 0.338 mmol) in THF (5 mL) was added TBAF (176 mg, 0.676 mmol) at 0 C. The mixture was warmed to 20 C and stirred for 1 hour to give a red solution.
LCMS showed the purity of product is 67% (Rt = 0.698 min; MS Calcd: 477.5; MS
Found:
478.1 [M+Hl+). The mixture was added H20 (10 mL), extracted with Et0Ac (10 mL
x2) and DCM (10 mL x2). The combined organic layer was dried over Na2SO4 and concentrated. The residue was purified by Combi Flash (Me0H in DCM from 0 to 5%) to give 1-(9-fluoro-3-(((S)-2-(hy droxy methyl)-2,3-dihy dro-1H-py ri do [2,3 -b] [1,4] oxazin-7-y0amino)-5 -methyl-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (110 mg, yield: 68%) as a yellow solid.
NMR (400 MHz, DMSO-d6) (51.51 (3H, d, J= 6.8 Hz), 2.07-2.15 (2H, m), 2.43 (2H, t, J
= 7.6 Hz), 3.15-3.19 (2H, m), 3.37-3.46 (2H, m), 3.74-3.79 (2H, m), 4.02-4.08 (1H, m), 4.18-4.21 (1H, m), 4.94 (1H, t, J= 5.6 Hz), 5.24 (1H, q, J= 6.0 Hz), 6.21 (1H, s), 6.63 (1H, s),
NMR (400 MHz, DMSO-d6) (5 0.07 (3H, s), 0.08 (3H, s), 0.89 (9H, s), 1.51 (3H, d, J= 6.4 Hz), 2.08-2.13 (2H, m), 2.41-2.45 (2H, m), 3.52-3.54 (1H, m), 3.57-3.61 (1H, m), 3.76-3.78 (3H, m), 4.11-4.14 (1H, m), 4.44-4.46 (1H, m), 5.24 (1H, q, J= 6.8 Hz), 6.23 (1H, s), 6.62 (1H, s), 7.04 (1H, d, J= 6.8 Hz), 7.37 (1H, d, J= 1.6 Hz), 7.60 (1H, d, J= 2.4 Hz), 7.84 (1H, d, J= 12.0 Hz), 8.60 (1H, s), 9.06 (1H, s).
Step 2: Preparation of 1 -(9-fluoro-3 -(((S)-2-(hy droxy methyl)-2,3-dihy dro-1H-py ri do [2,3 -b] [1,4] oxazin-7-y 1)amino)-5 -methyl-5H-chromeno [4,3-c] py ridin-8-yl)py rroli din-2-one I
N N N
H
OH
[0601] To a solution of 1-(3-4(R)-2-(((tert-butyldimethylsily0oxy)methyl)-2,3-dihydro-1H-py ri do [2,3-b] [1,4] oxazin-7-yl)amino)-9-fluoro-5 -methyl-5H-chromeno [4,3 -c] py ri din-8-yOpyrrolidin-2-one (200 mg, 0.338 mmol) in THF (5 mL) was added TBAF (176 mg, 0.676 mmol) at 0 C. The mixture was warmed to 20 C and stirred for 1 hour to give a red solution.
LCMS showed the purity of product is 67% (Rt = 0.698 min; MS Calcd: 477.5; MS
Found:
478.1 [M+Hl+). The mixture was added H20 (10 mL), extracted with Et0Ac (10 mL
x2) and DCM (10 mL x2). The combined organic layer was dried over Na2SO4 and concentrated. The residue was purified by Combi Flash (Me0H in DCM from 0 to 5%) to give 1-(9-fluoro-3-(((S)-2-(hy droxy methyl)-2,3-dihy dro-1H-py ri do [2,3 -b] [1,4] oxazin-7-y0amino)-5 -methyl-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (110 mg, yield: 68%) as a yellow solid.
NMR (400 MHz, DMSO-d6) (51.51 (3H, d, J= 6.8 Hz), 2.07-2.15 (2H, m), 2.43 (2H, t, J
= 7.6 Hz), 3.15-3.19 (2H, m), 3.37-3.46 (2H, m), 3.74-3.79 (2H, m), 4.02-4.08 (1H, m), 4.18-4.21 (1H, m), 4.94 (1H, t, J= 5.6 Hz), 5.24 (1H, q, J= 6.0 Hz), 6.21 (1H, s), 6.63 (1H, s),
282 7.04 (1H, d, J= 6.8 Hz), 7.36 (1H, d, J= 2.4 Hz), 7.60 (1H, d, J= 2.4 Hz), 7.84 (1H, d, J=
11.6 Hz), 8.60 (1H, s), 9.06 (1H, s).
Step 3: Preparation of (3aR)-8-((9-fluoro-5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)-3a,4-dihy dro-1H,3H-oxazolo [3,4-d]
pyrido[2,3 -b] [1,4] oxazin-l-one gN 0 =====.
H
N N N
[0602] To a solution of 1-(9-fluoro-3-(((S)-2-(hydroxymethyl)-2,3-dihydro-1H-py ri do [2,3-b] [1,4] oxazin-7-yl)amino)-5-methyl-5H-chromeno [4,3 -c] py ri din-8-yl)py rroli din-2-one (110 mg, 0.230 mmol) in DCM (5 mL) was added TEA (69 mg, 0.69 mmol) and CDI
(149 mg, 0.921 mmol). The mixture was stirred at 20 C for 16 hours. A white suspension was formed. LCMS showed the purity of product is 72% (Rt = 0.698 min; MS Calcd:
503.5; MS
Found: 504.2 [M+Hl+). The residue was purified by prep-TLC (DCM/Me0H, 20/1) to give a yellow solid, and prep-HPLC to give (3aR)-8-09-fluoro-5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)-3a,4-dihydro-1H,3H-oxazolo[3,4-dlpyrido[2,3-b][1,41oxazin-1-one (28.6 mg, yield: 24%) as alight yellow solid.
NMR (400 MHz, DMSO-d6) (51.52 (3H, d, J= 6.4 Hz), 2.04-2.08 (2H, m), 2.43 (2H, t, J
= 8.0 Hz), 3.75-3.79 (2H, m), 4.12 (1H, t, J = 10.8 Hz), 4.19 (1H, t, J = 10.0 Hz), 4.33-4.41 (1H, m), 4.58-4.68 (2H, m), 5.27 (1H, q, J= 6.4 Hz), 6.68 (1H, s), 7.05 (1H, d, J= 6.8 Hz), 7.88 (1H, d, J= 11.6 Hz), 8.36 (1H, d, J= 2.0 Hz), 8.56-8.58 (1H, m), 8.67 (1H, s), 9.45 (1H, d, J = 2.0 Hz).
Example 160: 1-(5-08-(2-oxopyrrolidin-1-y1)-5H-chromeno14,3-c] pyrid in-3-yl)amino)pyridin-3-yl)imidazolidin-2-one
11.6 Hz), 8.60 (1H, s), 9.06 (1H, s).
Step 3: Preparation of (3aR)-8-((9-fluoro-5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)-3a,4-dihy dro-1H,3H-oxazolo [3,4-d]
pyrido[2,3 -b] [1,4] oxazin-l-one gN 0 =====.
H
N N N
[0602] To a solution of 1-(9-fluoro-3-(((S)-2-(hydroxymethyl)-2,3-dihydro-1H-py ri do [2,3-b] [1,4] oxazin-7-yl)amino)-5-methyl-5H-chromeno [4,3 -c] py ri din-8-yl)py rroli din-2-one (110 mg, 0.230 mmol) in DCM (5 mL) was added TEA (69 mg, 0.69 mmol) and CDI
(149 mg, 0.921 mmol). The mixture was stirred at 20 C for 16 hours. A white suspension was formed. LCMS showed the purity of product is 72% (Rt = 0.698 min; MS Calcd:
503.5; MS
Found: 504.2 [M+Hl+). The residue was purified by prep-TLC (DCM/Me0H, 20/1) to give a yellow solid, and prep-HPLC to give (3aR)-8-09-fluoro-5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)-3a,4-dihydro-1H,3H-oxazolo[3,4-dlpyrido[2,3-b][1,41oxazin-1-one (28.6 mg, yield: 24%) as alight yellow solid.
NMR (400 MHz, DMSO-d6) (51.52 (3H, d, J= 6.4 Hz), 2.04-2.08 (2H, m), 2.43 (2H, t, J
= 8.0 Hz), 3.75-3.79 (2H, m), 4.12 (1H, t, J = 10.8 Hz), 4.19 (1H, t, J = 10.0 Hz), 4.33-4.41 (1H, m), 4.58-4.68 (2H, m), 5.27 (1H, q, J= 6.4 Hz), 6.68 (1H, s), 7.05 (1H, d, J= 6.8 Hz), 7.88 (1H, d, J= 11.6 Hz), 8.36 (1H, d, J= 2.0 Hz), 8.56-8.58 (1H, m), 8.67 (1H, s), 9.45 (1H, d, J = 2.0 Hz).
Example 160: 1-(5-08-(2-oxopyrrolidin-1-y1)-5H-chromeno14,3-c] pyrid in-3-yl)amino)pyridin-3-yl)imidazolidin-2-one
283 I
Step 1: Preparation of 1-(5 -bromopyridin-3-y1)-3-((2-(trimethylsilyl)ethoxy)methyl)imidazolidin-2-one BrN
0 NsEm [0603] To a solution of 1-(5-bromopyridin-3-yl)imidazolidin-2-one (2.40 g, 9.91 mmol) in anhydrous DMF (25 mL) was added NaH (793 mg, 19.8 mmol, 60% dispersed in mineral oil) portions at 0 C. Then the reaction mixture was stirred at 0 C for 30 minutes. SEM-C1 (2.53 g, 14.9 mmol) was added dropwise to the reaction mixture at 0 C. After the completion of the addition, the reaction mixture was stirred at 30 C for 2.5 hours. A yellow suspension was formed. TLC showed the starting material was consumed completely. To the reaction mixture was added saturated aqueous NH4C1 (25 mL) and water (25 mL), then extracted with Et0Ac (50 mL x3). The combined organic layer was washed with water (50 mL x2), brine (50 mL), dried over anhydrous Na2SO4 and concentrated. The crude product was purified by Combi Flash (50% to 100% Et0Ac in PE) to afford 1-(5-bromopyridin-3-y1)-3-((2-(trimethylsilyl)ethoxy)methyl)imidazolidin-2-one (1.70 g, yield: 46%) as a white solid.
11-1NMR (400 MHz CDC13) (5 0.02 (9H, s), 0.90-0.99 (2H, m), 3.55-3.61 (2H, m), 3.66-3.72 (2H, m), 3.85-3.92 (2H, m), 4.78 (2H, s), 8.34-8.37 (1H, m), 8.42 (1H, t, J =
2.4 Hz), 8.52-8.55 (1H, m) Step 2:
Preparation of 1-(5 -((8-(2-oxopyrroli din-1 -y1)-5H-chromeno [4,3 -c] py ri din-3-yl)amino)pyridin-3-y1)-3-((2-(trimethylsilyl)ethoxy)methyl)imidazolidin-2-one gN 0 0---NµsErµi
Step 1: Preparation of 1-(5 -bromopyridin-3-y1)-3-((2-(trimethylsilyl)ethoxy)methyl)imidazolidin-2-one BrN
0 NsEm [0603] To a solution of 1-(5-bromopyridin-3-yl)imidazolidin-2-one (2.40 g, 9.91 mmol) in anhydrous DMF (25 mL) was added NaH (793 mg, 19.8 mmol, 60% dispersed in mineral oil) portions at 0 C. Then the reaction mixture was stirred at 0 C for 30 minutes. SEM-C1 (2.53 g, 14.9 mmol) was added dropwise to the reaction mixture at 0 C. After the completion of the addition, the reaction mixture was stirred at 30 C for 2.5 hours. A yellow suspension was formed. TLC showed the starting material was consumed completely. To the reaction mixture was added saturated aqueous NH4C1 (25 mL) and water (25 mL), then extracted with Et0Ac (50 mL x3). The combined organic layer was washed with water (50 mL x2), brine (50 mL), dried over anhydrous Na2SO4 and concentrated. The crude product was purified by Combi Flash (50% to 100% Et0Ac in PE) to afford 1-(5-bromopyridin-3-y1)-3-((2-(trimethylsilyl)ethoxy)methyl)imidazolidin-2-one (1.70 g, yield: 46%) as a white solid.
11-1NMR (400 MHz CDC13) (5 0.02 (9H, s), 0.90-0.99 (2H, m), 3.55-3.61 (2H, m), 3.66-3.72 (2H, m), 3.85-3.92 (2H, m), 4.78 (2H, s), 8.34-8.37 (1H, m), 8.42 (1H, t, J =
2.4 Hz), 8.52-8.55 (1H, m) Step 2:
Preparation of 1-(5 -((8-(2-oxopyrroli din-1 -y1)-5H-chromeno [4,3 -c] py ri din-3-yl)amino)pyridin-3-y1)-3-((2-(trimethylsilyl)ethoxy)methyl)imidazolidin-2-one gN 0 0---NµsErµi
284 [0604] A mixture of 1 -(5 -bromopyri din-3 -y1)-3 -((2-(trimethylsilyl)ethoxy)methyl)imidazolidin-2-one (66 mg, 0.18 mmol), 1-(3-amino-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (50 mg, 0.18 mmol), Pd2(dba)3 (16 mg, 0.018 mmol), Brettphos (19 mg, 0.036 mmol) and Cs2CO3 (116 mg, 0.116 mmol) in anhydrous dioxane (3 mL) was degassed and purged with N2 for 3 times. The resulting reaction mixture was stirred at 90 C for 14 hours under N2 atmosphere. A yellow suspension was formed.
LCMS showed the purity of the desired product is 40% (Rt = 0.692 min; MS
Calcd: 572.3; MS
Found: 573.1 [M+Hl+). The reaction mixture was diluted with water (20 mL) and extracted with Et0Ac (20 mL x2). The combined organic layer was washed with water (20 mL
x2), brine (20 mL x2), dried over anhydrous Na2SO4, filtered and concentrated to give 1-(5-((8-(2-oxopyrrolidin-1-y1)-5H-chromeno [4,3-c] py ri din-3-y0amino)py ri din-3 -y1)-3 (trimethylsilypethoxy)methypimidazolidin-2-one (90 mg, crude) as a yellow solid, which was used for the next step without further purification.
Step 3:
Preparation of 1-(5 -((8-(2-oxopyrroli din-1 -y1)-5H-chromeno [4,3 -c] py ri din-3-yl)amino)pyridin-3 -yl)imidazolidin-2-one I
[0605] To a suspension of 1-(5-48-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-y1)-3-42-(trimethylsilypethoxy)methypimidazolidin-2-one (90 mg, 0.16 mmol) in DCM (5 mL) was added TFA (5 mL) dropwise at 30 C. The resulting mixture was stirred at 30 C for 2 hours. A red solution was formed. After that, the reaction mixture was concentrated under reduced pressure to remove TFA. The residue was dissolved in dioxane (5 mL) and NH3.H20 (5 mL) and the reaction mixture was stirred at 30 C for 13 days. A yellow suspension was formed. LCMS showed the purity of the desired product is 60%
(Rt = 1.526 min; MS Calcd: 442.2; MS Found: 443.2 [M+Hl+). The reaction mixture was concentrated, then diluted with saturated aqueous Na2CO3 (10 mL) and extracted with Et0Ac (20 mL x3).
The combined organic layer was washed with saturated aqueous Na2CO3 (20 mL
x2), brine (20 nil x2), dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by prep-HPLC (0.225% FA as an additive) and lyophilized to give 1-(5-((8-(2-oxopyrrolidin-1-
LCMS showed the purity of the desired product is 40% (Rt = 0.692 min; MS
Calcd: 572.3; MS
Found: 573.1 [M+Hl+). The reaction mixture was diluted with water (20 mL) and extracted with Et0Ac (20 mL x2). The combined organic layer was washed with water (20 mL
x2), brine (20 mL x2), dried over anhydrous Na2SO4, filtered and concentrated to give 1-(5-((8-(2-oxopyrrolidin-1-y1)-5H-chromeno [4,3-c] py ri din-3-y0amino)py ri din-3 -y1)-3 (trimethylsilypethoxy)methypimidazolidin-2-one (90 mg, crude) as a yellow solid, which was used for the next step without further purification.
Step 3:
Preparation of 1-(5 -((8-(2-oxopyrroli din-1 -y1)-5H-chromeno [4,3 -c] py ri din-3-yl)amino)pyridin-3 -yl)imidazolidin-2-one I
[0605] To a suspension of 1-(5-48-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-y1)-3-42-(trimethylsilypethoxy)methypimidazolidin-2-one (90 mg, 0.16 mmol) in DCM (5 mL) was added TFA (5 mL) dropwise at 30 C. The resulting mixture was stirred at 30 C for 2 hours. A red solution was formed. After that, the reaction mixture was concentrated under reduced pressure to remove TFA. The residue was dissolved in dioxane (5 mL) and NH3.H20 (5 mL) and the reaction mixture was stirred at 30 C for 13 days. A yellow suspension was formed. LCMS showed the purity of the desired product is 60%
(Rt = 1.526 min; MS Calcd: 442.2; MS Found: 443.2 [M+Hl+). The reaction mixture was concentrated, then diluted with saturated aqueous Na2CO3 (10 mL) and extracted with Et0Ac (20 mL x3).
The combined organic layer was washed with saturated aqueous Na2CO3 (20 mL
x2), brine (20 nil x2), dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by prep-HPLC (0.225% FA as an additive) and lyophilized to give 1-(5-((8-(2-oxopyrrolidin-1-
285 y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-y0imidazolidin-2-one (10.6 mg, yield:
10% for two steps) as a yellow solid.
11-1NMR (400 MHz, DMSO-d6) 2.02-2.11 (2H, m), 2.50-2.55 (2H, m, overlapped with DMSO), 3.40-3.52 (2H, m, overlapped with water), 3.84 (2H, t, J= 7.0 Hz), 3.87-3.93 (2H, m), 5.11 (2H, s), 6.76(1H, s), 7.17 (1H, s), 7.34 (1H, dd, J= 8.6 Hz, 2.2 Hz), 7.38 (1H, d, J=
2.0 Hz), 7.88 (1H, d, J= 8.6 Hz), 8.35 (1H, d, J= 2.0 Hz), 8.42 (1H, t, J= 2.2 Hz), 8.66 (1H, brs), 8.75 (1H, d, J= 1.6 Hz), 9.56 (1H, brs).
Example 161: 1-(5-09-fluoro-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-yl)amino)pyridin-3-yl)imidazolidin-2-one I
Step 1: Preparation of 1-(5-bromopyridin-3-y1)-3-(4-methoxybenzyl)imidazoli din-2-one 0 NpmB
[0606] To a solution of 1-(5-bromopyridin-3-yl)imidazolidin-2-one (200 mg, 0.826 mmol) in anhydrous DMF (3 mL) was added NaH (66 mg, 1.6 mmol, 60% dispersed in mineral oil) at 0 C. Then the reaction mixture was stirred at 0 C for 30 minutes. PMB-C1 (168 mg, 1.07 mmol) was added to the reaction mixture at 0 C and the reaction mixture was stirred at 25 C
for 2.5 hours. A yellow suspension was formed. TLC showed the starting material was consumed completely. To the reaction mixture was added saturated aqueous NH4C1 (10 mL) and water (10 mL), then extracted with Et0Ac (20 mL x3). The combined organic layer was washed with water (20 mL x2), brine (20 mL), dried over anhydrous Na2SO4 and concentrated.
The residue was purified by Combi Flash (10% to 50% Et0Ac in PE) to afford 1-(5-bromopyridin-3-y1)-3-(4-methoxybenzyl)imidazolidin-2-one (330 mg, quantitative) as a yellow solid.
10% for two steps) as a yellow solid.
11-1NMR (400 MHz, DMSO-d6) 2.02-2.11 (2H, m), 2.50-2.55 (2H, m, overlapped with DMSO), 3.40-3.52 (2H, m, overlapped with water), 3.84 (2H, t, J= 7.0 Hz), 3.87-3.93 (2H, m), 5.11 (2H, s), 6.76(1H, s), 7.17 (1H, s), 7.34 (1H, dd, J= 8.6 Hz, 2.2 Hz), 7.38 (1H, d, J=
2.0 Hz), 7.88 (1H, d, J= 8.6 Hz), 8.35 (1H, d, J= 2.0 Hz), 8.42 (1H, t, J= 2.2 Hz), 8.66 (1H, brs), 8.75 (1H, d, J= 1.6 Hz), 9.56 (1H, brs).
Example 161: 1-(5-09-fluoro-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-yl)amino)pyridin-3-yl)imidazolidin-2-one I
Step 1: Preparation of 1-(5-bromopyridin-3-y1)-3-(4-methoxybenzyl)imidazoli din-2-one 0 NpmB
[0606] To a solution of 1-(5-bromopyridin-3-yl)imidazolidin-2-one (200 mg, 0.826 mmol) in anhydrous DMF (3 mL) was added NaH (66 mg, 1.6 mmol, 60% dispersed in mineral oil) at 0 C. Then the reaction mixture was stirred at 0 C for 30 minutes. PMB-C1 (168 mg, 1.07 mmol) was added to the reaction mixture at 0 C and the reaction mixture was stirred at 25 C
for 2.5 hours. A yellow suspension was formed. TLC showed the starting material was consumed completely. To the reaction mixture was added saturated aqueous NH4C1 (10 mL) and water (10 mL), then extracted with Et0Ac (20 mL x3). The combined organic layer was washed with water (20 mL x2), brine (20 mL), dried over anhydrous Na2SO4 and concentrated.
The residue was purified by Combi Flash (10% to 50% Et0Ac in PE) to afford 1-(5-bromopyridin-3-y1)-3-(4-methoxybenzyl)imidazolidin-2-one (330 mg, quantitative) as a yellow solid.
286 11-1 NMR (400 MHz CDC13) (53.37-3.43 (2H, m), 3.75-3.78 (2H, m), 3.79 (3H, s), 4.40 (2H, s), 6.87 (2H, d, J = 8.0 Hz), 7.22 (2H, d, J= 8.0 Hz), 8.31 (1H, d, J= 2.0 Hz), 8.45 (1H, dd, J
= 2.4 Hz, 2.0 Hz), 8.51 (1H, d, J = 2.4 Hz).
Step 2: Preparation of 1-(5-((9-fluoro-8-(2-oxopy rroli din-1 -y1)-5H-chromeno [4,3 -c] py ri din-3-y0amino)pyridin-3-y1)-3-(4-methoxybenzypimidazolidin-2-one PMB
N
[0607] A
mixture of 1-(5 -bromopyridin-3 -y1)-3 -(4-methoxybenzyl)imidazolidin-2-one (73 mg, 0.20 mmol), 1-(3-amino-9-fluoro-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one (60 mg, 0.20 mmol), Pd2(dba)3 (18 mg, 0.020 mmol), Brettphos (22 mg, 0.040 mmol) and Cs2CO3 (131 mg, 0.400 mmol) in anhydrous dioxane (3 mL) was degassed and purged with N2 for 3 times. Then the resulting reaction mixture was stirred at 90 C for 16 hours under N2 atmosphere. A brown suspension was formed. LCMS showed the purity of the desired product is 60% (Rt = 0.837 min; MS Calcd: 580.2; MS Found: 581.3 [M+Hl+). The reaction mixture was diluted with water (20 mL) and extracted with DCM/Me0H (20 mL x3, 5/1).
The combined organic layer was washed with water (20 mL x2), brine (20 mL x2), dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by Combi Flash (0% to 10% Me0H in DCM) to afford 1-(5-49-fluoro-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-y1)-3-(4-methoxybenzypimidazolidin-2-one (130 mg, yield:
95%) as a yellow solid.
Step 3: Preparation of 1-(5-((9-fluoro-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-yl)amino)pyridin-3-yl)imidazolidin-2-one I
N
0=-=-NH
= 2.4 Hz, 2.0 Hz), 8.51 (1H, d, J = 2.4 Hz).
Step 2: Preparation of 1-(5-((9-fluoro-8-(2-oxopy rroli din-1 -y1)-5H-chromeno [4,3 -c] py ri din-3-y0amino)pyridin-3-y1)-3-(4-methoxybenzypimidazolidin-2-one PMB
N
[0607] A
mixture of 1-(5 -bromopyridin-3 -y1)-3 -(4-methoxybenzyl)imidazolidin-2-one (73 mg, 0.20 mmol), 1-(3-amino-9-fluoro-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one (60 mg, 0.20 mmol), Pd2(dba)3 (18 mg, 0.020 mmol), Brettphos (22 mg, 0.040 mmol) and Cs2CO3 (131 mg, 0.400 mmol) in anhydrous dioxane (3 mL) was degassed and purged with N2 for 3 times. Then the resulting reaction mixture was stirred at 90 C for 16 hours under N2 atmosphere. A brown suspension was formed. LCMS showed the purity of the desired product is 60% (Rt = 0.837 min; MS Calcd: 580.2; MS Found: 581.3 [M+Hl+). The reaction mixture was diluted with water (20 mL) and extracted with DCM/Me0H (20 mL x3, 5/1).
The combined organic layer was washed with water (20 mL x2), brine (20 mL x2), dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by Combi Flash (0% to 10% Me0H in DCM) to afford 1-(5-49-fluoro-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-y1)-3-(4-methoxybenzypimidazolidin-2-one (130 mg, yield:
95%) as a yellow solid.
Step 3: Preparation of 1-(5-((9-fluoro-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-yl)amino)pyridin-3-yl)imidazolidin-2-one I
N
0=-=-NH
287 [0608] A solution of 1-(5 -((9-fluoro-8-(2-oxopyrroli din-l-y1)-5H-chromeno [4,3-c]pyridin-3-yl)amino)pyridin-3-y1)-3-(4-methoxybenzyl)imidazolidin-2-one (90 mg, 0.16 mmol) in TFA (5 mL) was stirred at 50 C for 16 hours. A red solution was formed. LCMS
showed the purity of the desired product is 63% (Rt = 0.738 min; MS Calcd:
460.2; MS Found:
461.1 [M+Hl+). The reaction mixture was concentrated and the residue was dissolved in DCM/Me0H (20 mL, 1/1), basified with 1 N aqueous NaOH to pH = 8. The precipitate was filtrated and washed with water (10 mL) and MeCN (10 mL), then lyophilizated to give 1-(5-((9-fluoro-8-(2-oxopy rroli din-l-y1)-5H-chromeno [4,3 -c] pyri din-3-yl)amino)pyri din-3 -yl)imidazolidin-2-one (53.6 mg, yield: 61%) as an off-white solid.
11-1 NMR (400 MHz, DMSO-d6) 5 2.07-2.18 (2H, m), 2.38-2.46 (2H, m, overlapped with DMSO), 3.40-3.52 (2H, m, overlapped with water), 3.72-3.81 (2H, m), 3.86-3.98 (2H, m), 5.12 (2H, s), 6.75 (1H, s), 7.02-7.15 (2H, m), 7.81-7.92 (1H, m), 8.30 (1H, s), 8.39 (1H, s), 8.62-8.78 (2H, m), 9.50 (1H, brs).
Example 162: 1-(5-05,5-d imethy1-8-(2-oxo pyrrolidin-1-y1)-5H-chromeno[4,3-c]
pyrid in-3-yl)amino)pyridin-3-yl)imidazolidin-2-one I
N
0-="-NH
Step 1: Preparation of tert-butyl (5-(3-(4-methoxybenzy1)-2-oxoimidazolidin-1-yl)pyridin-3-yl)carbamate BocHNN
0 µpmB
[0609] A
mixture of 1-(5-bromopyridin-3-y1)-3-(4-methoxybenzyl)imidazolidin-2-one (200 mg, 0.552 mmol), tert-butyl carbamate (97 mg, 0.20 mmol), Pd2(dba)3 (51 mg, 0.055 mmol), Xantphos (64 mg, 0.110 mmol) and Cs2CO3 (180 mg, 0.552 mmol) in anhydrous dioxane (5 mL) was degassed and purged with N2 for 3 times. And the resulting mixture was stirred at 90 C for 15 hours under N2 atmosphere. A yellow suspension was formed. LCMS
showed the purity of the desired product is 63% (Rt = 0.738 min; MS Calcd:
460.2; MS Found:
461.1 [M+Hl+). The reaction mixture was concentrated and the residue was dissolved in DCM/Me0H (20 mL, 1/1), basified with 1 N aqueous NaOH to pH = 8. The precipitate was filtrated and washed with water (10 mL) and MeCN (10 mL), then lyophilizated to give 1-(5-((9-fluoro-8-(2-oxopy rroli din-l-y1)-5H-chromeno [4,3 -c] pyri din-3-yl)amino)pyri din-3 -yl)imidazolidin-2-one (53.6 mg, yield: 61%) as an off-white solid.
11-1 NMR (400 MHz, DMSO-d6) 5 2.07-2.18 (2H, m), 2.38-2.46 (2H, m, overlapped with DMSO), 3.40-3.52 (2H, m, overlapped with water), 3.72-3.81 (2H, m), 3.86-3.98 (2H, m), 5.12 (2H, s), 6.75 (1H, s), 7.02-7.15 (2H, m), 7.81-7.92 (1H, m), 8.30 (1H, s), 8.39 (1H, s), 8.62-8.78 (2H, m), 9.50 (1H, brs).
Example 162: 1-(5-05,5-d imethy1-8-(2-oxo pyrrolidin-1-y1)-5H-chromeno[4,3-c]
pyrid in-3-yl)amino)pyridin-3-yl)imidazolidin-2-one I
N
0-="-NH
Step 1: Preparation of tert-butyl (5-(3-(4-methoxybenzy1)-2-oxoimidazolidin-1-yl)pyridin-3-yl)carbamate BocHNN
0 µpmB
[0609] A
mixture of 1-(5-bromopyridin-3-y1)-3-(4-methoxybenzyl)imidazolidin-2-one (200 mg, 0.552 mmol), tert-butyl carbamate (97 mg, 0.20 mmol), Pd2(dba)3 (51 mg, 0.055 mmol), Xantphos (64 mg, 0.110 mmol) and Cs2CO3 (180 mg, 0.552 mmol) in anhydrous dioxane (5 mL) was degassed and purged with N2 for 3 times. And the resulting mixture was stirred at 90 C for 15 hours under N2 atmosphere. A yellow suspension was formed. LCMS
288 showed the purity of the desired product is 37% (Rt = 0.813 min; MS Calcd:
398.2; MS Found:
399.1 [M+Hl+). The reaction mixture was diluted with water (20 mL) and extracted with Et0Ac (20 mL x2). The combined organic layer was washed with water (20 mL x2), brine (20 mL x2), and dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by Combi Flash (0% to 10% DCM in Et0Ac) to afford tert-butyl (5-(3-(4-methoxybenzy1)-2-oxoimidazolidin-1-yOpyridin-3-yOcarbamate (340 mg, yield: 74%) as a yellow solid.
Step 2: Preparation of 1-(5-aminopyridin-3-y1)-3-(4-methoxybenzyl)imidazolidin-2-one s's=N
0 ,pmB
[0610] A
solution of tert-butyl (5-(3-(4-methoxybenzy1)-2-oxoimidazolidin-1-yOpyridin-3-yOcarbamate (220 mg, 0.552 mmol) in DCM (3 mL) and TFA (3 mL) was stirred at for 1 hour. A red solution was formed. LCMS showed the purity of the desired product is 63%
(Rt = 0.591 min; MS Calcd: 298.1; MS Found: 298.9 [M+H]+). The reaction mixture was diluted with Et0Ac (20 mL) and basified with 1 N aqueous NaOH to pH = 8. The aqueous layer was extracted with Et0Ac (20 mL x2). The combined organic layer was washed with water (20 mL x2), brine (20 mL x2), and dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by Combi Flash (0% to 5% Me0H in DCM) to afford 1-(5-aminopyridin-3-y1)-3-(4-methoxybenzyl)imidazolidin-2-one (150 mg, yield:
87%) as a yellow solid.
Step 3:
Preparation of 1-(5-((5,5-dimethy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c] py ri din-3-yl)amino)pyri din-3-y1)-3-(4-methoxy benzyl)imi dazoli din-2-one 0---1\lµpi\AB
[0611] A
mixture of 1-(5-aminopyridin-3-y1)-3-(4-methoxybenzyl)imidazolidin-2-one (80 mg, 0.24 mmol), 1-(3-chloro-5,5-dimethy1-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one (73 mg, 0.24 mmol), Pd2(dba)3 (22 mg, 0.024 mmol), Brettphos (26 mg, 0.048 mmol) and Cs2CO3(158 mg, 0.486 mmol) in anhydrous dioxane (3 mL) was degassed and purged with N2
398.2; MS Found:
399.1 [M+Hl+). The reaction mixture was diluted with water (20 mL) and extracted with Et0Ac (20 mL x2). The combined organic layer was washed with water (20 mL x2), brine (20 mL x2), and dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by Combi Flash (0% to 10% DCM in Et0Ac) to afford tert-butyl (5-(3-(4-methoxybenzy1)-2-oxoimidazolidin-1-yOpyridin-3-yOcarbamate (340 mg, yield: 74%) as a yellow solid.
Step 2: Preparation of 1-(5-aminopyridin-3-y1)-3-(4-methoxybenzyl)imidazolidin-2-one s's=N
0 ,pmB
[0610] A
solution of tert-butyl (5-(3-(4-methoxybenzy1)-2-oxoimidazolidin-1-yOpyridin-3-yOcarbamate (220 mg, 0.552 mmol) in DCM (3 mL) and TFA (3 mL) was stirred at for 1 hour. A red solution was formed. LCMS showed the purity of the desired product is 63%
(Rt = 0.591 min; MS Calcd: 298.1; MS Found: 298.9 [M+H]+). The reaction mixture was diluted with Et0Ac (20 mL) and basified with 1 N aqueous NaOH to pH = 8. The aqueous layer was extracted with Et0Ac (20 mL x2). The combined organic layer was washed with water (20 mL x2), brine (20 mL x2), and dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by Combi Flash (0% to 5% Me0H in DCM) to afford 1-(5-aminopyridin-3-y1)-3-(4-methoxybenzyl)imidazolidin-2-one (150 mg, yield:
87%) as a yellow solid.
Step 3:
Preparation of 1-(5-((5,5-dimethy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c] py ri din-3-yl)amino)pyri din-3-y1)-3-(4-methoxy benzyl)imi dazoli din-2-one 0---1\lµpi\AB
[0611] A
mixture of 1-(5-aminopyridin-3-y1)-3-(4-methoxybenzyl)imidazolidin-2-one (80 mg, 0.24 mmol), 1-(3-chloro-5,5-dimethy1-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one (73 mg, 0.24 mmol), Pd2(dba)3 (22 mg, 0.024 mmol), Brettphos (26 mg, 0.048 mmol) and Cs2CO3(158 mg, 0.486 mmol) in anhydrous dioxane (3 mL) was degassed and purged with N2
289 for 3 times. Then the resulting mixture was stirred at 90 C for 16 hours under N2 atmosphere.
A yellow suspension was formed. LCMS showed the purity of the desired product is 26% (Rt = 0.840 min; MS Calcd: 590.3; MS Found: 591.2 [M+H]+). The reaction mixture was diluted with water (20 mL) and extracted with DCM/Me0H (20 mL x3, 5/1). The combined organic layer was washed with water (20 mL x2), brine (20 mL x2), dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by Combi Flash (0% to 10%
Me0H in DCM) to afford 1 -(5-((5,5 -dimethy1-8-(2-oxopy rroli din-l-y1)-5H-chromeno [4,3-c] pyri din-3-yl)amino)pyridin-3-y1)-3-(4-methoxybenzyl)imidazolidin-2-one (54 mg, yield:
38%) as a yellow solid.
Step 4:
Preparation of 1-(5-((5,5 -dimethy1-8-(2-oxopyrroli din-1 -y1)-5H-chromeno [4,3 -c] pyridin-3-y0amino)pyridin-3 -yl)imidazolidin-2-one fIN 0 I
[0612] A
solution of 1-(5 -((5,5 -dimethy1-8-(2-oxopy rroli din-1 -y 0-5H-chromeno [4,3 -clpyridin-3-yl)amino)pyridin-3-y1)-3-(4-methoxybenzyl)imidazolidin-2-one (54 mg, 0.091 mmol) in TFA (5 mL) was stirred at 50 C for 16 hours. A red solution was formed. LCMS
showed the purity of the desired product is 42% (Rt = 0.754 min; MS Calcd:
471.2; MS Found:
471.1 [M+Hl+). The reaction mixture was concentrated and the residue was dissolved in DCM/Me0H (20 mL, 1/1), basified with 1 N aqueous NaOH to pH = 8. The aqueous layer was extracted with DCM/Me0H (20 mL x2, 1/1). The combined organic layer was washed with water (20 mL x2), brine (20 mL), dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by Combi Flash (1% to 10% Me0H in DCM), then further purified by prep-HPLC (0.225% FA as an additive) and lyophilized to give 1-(5-45,5-dimethy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno [4,3-c] pyridin-3-y0amino)pyridin-3-y0imidazolidin-2-one (11.3 mg, yield: 27%) as a yellow solid.
11-1NMR (400 MHz, DMSO-d6) (51.57 (6H, s), 2.02-2.11 (2H, m), 2.50-2.55 (2H, m, overlapped with DMSO), 3.40-3.52 (2H, m, overlapped with water), 3.84 (2H, t, J= 7.0 Hz), 3.94 (2H, t, J = 8.0 Hz), 6.88 (1H, s), 7.31 (1H, dd, J = 8.6 Hz, 2.0 Hz), 7.40 (1H, d, J= 2.0
A yellow suspension was formed. LCMS showed the purity of the desired product is 26% (Rt = 0.840 min; MS Calcd: 590.3; MS Found: 591.2 [M+H]+). The reaction mixture was diluted with water (20 mL) and extracted with DCM/Me0H (20 mL x3, 5/1). The combined organic layer was washed with water (20 mL x2), brine (20 mL x2), dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by Combi Flash (0% to 10%
Me0H in DCM) to afford 1 -(5-((5,5 -dimethy1-8-(2-oxopy rroli din-l-y1)-5H-chromeno [4,3-c] pyri din-3-yl)amino)pyridin-3-y1)-3-(4-methoxybenzyl)imidazolidin-2-one (54 mg, yield:
38%) as a yellow solid.
Step 4:
Preparation of 1-(5-((5,5 -dimethy1-8-(2-oxopyrroli din-1 -y1)-5H-chromeno [4,3 -c] pyridin-3-y0amino)pyridin-3 -yl)imidazolidin-2-one fIN 0 I
[0612] A
solution of 1-(5 -((5,5 -dimethy1-8-(2-oxopy rroli din-1 -y 0-5H-chromeno [4,3 -clpyridin-3-yl)amino)pyridin-3-y1)-3-(4-methoxybenzyl)imidazolidin-2-one (54 mg, 0.091 mmol) in TFA (5 mL) was stirred at 50 C for 16 hours. A red solution was formed. LCMS
showed the purity of the desired product is 42% (Rt = 0.754 min; MS Calcd:
471.2; MS Found:
471.1 [M+Hl+). The reaction mixture was concentrated and the residue was dissolved in DCM/Me0H (20 mL, 1/1), basified with 1 N aqueous NaOH to pH = 8. The aqueous layer was extracted with DCM/Me0H (20 mL x2, 1/1). The combined organic layer was washed with water (20 mL x2), brine (20 mL), dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by Combi Flash (1% to 10% Me0H in DCM), then further purified by prep-HPLC (0.225% FA as an additive) and lyophilized to give 1-(5-45,5-dimethy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno [4,3-c] pyridin-3-y0amino)pyridin-3-y0imidazolidin-2-one (11.3 mg, yield: 27%) as a yellow solid.
11-1NMR (400 MHz, DMSO-d6) (51.57 (6H, s), 2.02-2.11 (2H, m), 2.50-2.55 (2H, m, overlapped with DMSO), 3.40-3.52 (2H, m, overlapped with water), 3.84 (2H, t, J= 7.0 Hz), 3.94 (2H, t, J = 8.0 Hz), 6.88 (1H, s), 7.31 (1H, dd, J = 8.6 Hz, 2.0 Hz), 7.40 (1H, d, J= 2.0
290 Hz), 7.48 (1H, s), 7.92 (1H, d, J= 8.6 Hz), 8.45-8.61 (2H, m), 8.74 (1H, s), 9.00 (1H, brs), 10.08 (1H, brs).
Example 163: 1-(3-((2,3-dihydro-11,41dioxino [2,3-b] pyridin-7-yl)amino)-5H-chromeno[4,3-c] pyridin-8-yl)pyrrolidin-2-one I
N
[0613] A
mixture of 1-(3-chloro-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one (50 mg, 0.17 mmol), 2,3-dihydro-[1,4]dioxino[2,3-blpyridin-7-amine (34 mg, 0.18 mmol, HC1 salt), Pd2(dba)3 (15 mg, 0.017 mmol), Brettphos (18 mg, 0.033 mmol), Cs2CO3 (108 mg, 0.332 mmol) in anhydrous dioxane (3 mL) was degassed and purged with N2 for 3 times.
Then the resulting reaction mixture was heated at 90 C for 14 hours under N2 atmosphere. The reaction mixture turned into yellow suspension from gray suspension. LCMS
showed that the purity of the desired product is 35% (Rt = 0.658 min; MS Calcd: 416.2; MS
Found: 417.1 [M+H]+). The mixture was diluted with water (20 mL) and extracted with Et0Ac/THF (20 mL
x3, 1/1). The combined organic layer was washed with water (20 mL x2), brine (20 mL x2), dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by prep-HPLC (0.225% FA as an additive) and lyophilized to give 1-(3-42,3-dihydro-[1,4]dioxino[2,3-blpyridin-7-y0amino)-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (14.1 mg, yield:
20%) as a yellow solid.
NMR (400 MHz DMSO-d6) 5 2.01-2.10 (2H, m), 2.55-2.59 (2H, m, overlapped with DMSO), 3.84 (2H, t, J= 7.0 Hz), 4.22-4.27 (2H, m), 4.33-4.40 (2H, m), 5.09 (2H, s), 6.65 (1H, s), 7.33 (1H, d, J= 8.4 Hz), 7.37 (1H, s), 7.77-7.88 (2H, m), 7.93 (1H, d, J= 2.0 Hz), 8.60 (1H, s), 9.24 (1H, brs).
Example 164: 1-(3-((2,3-dihydro-11,41dioxino12,3-b] pyridin-7-yl)amino)-5,5-dimethyl-5H-chromeno[4,3-c] pyridin-8-yl)pyrrolidin-2-one
Example 163: 1-(3-((2,3-dihydro-11,41dioxino [2,3-b] pyridin-7-yl)amino)-5H-chromeno[4,3-c] pyridin-8-yl)pyrrolidin-2-one I
N
[0613] A
mixture of 1-(3-chloro-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one (50 mg, 0.17 mmol), 2,3-dihydro-[1,4]dioxino[2,3-blpyridin-7-amine (34 mg, 0.18 mmol, HC1 salt), Pd2(dba)3 (15 mg, 0.017 mmol), Brettphos (18 mg, 0.033 mmol), Cs2CO3 (108 mg, 0.332 mmol) in anhydrous dioxane (3 mL) was degassed and purged with N2 for 3 times.
Then the resulting reaction mixture was heated at 90 C for 14 hours under N2 atmosphere. The reaction mixture turned into yellow suspension from gray suspension. LCMS
showed that the purity of the desired product is 35% (Rt = 0.658 min; MS Calcd: 416.2; MS
Found: 417.1 [M+H]+). The mixture was diluted with water (20 mL) and extracted with Et0Ac/THF (20 mL
x3, 1/1). The combined organic layer was washed with water (20 mL x2), brine (20 mL x2), dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by prep-HPLC (0.225% FA as an additive) and lyophilized to give 1-(3-42,3-dihydro-[1,4]dioxino[2,3-blpyridin-7-y0amino)-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (14.1 mg, yield:
20%) as a yellow solid.
NMR (400 MHz DMSO-d6) 5 2.01-2.10 (2H, m), 2.55-2.59 (2H, m, overlapped with DMSO), 3.84 (2H, t, J= 7.0 Hz), 4.22-4.27 (2H, m), 4.33-4.40 (2H, m), 5.09 (2H, s), 6.65 (1H, s), 7.33 (1H, d, J= 8.4 Hz), 7.37 (1H, s), 7.77-7.88 (2H, m), 7.93 (1H, d, J= 2.0 Hz), 8.60 (1H, s), 9.24 (1H, brs).
Example 164: 1-(3-((2,3-dihydro-11,41dioxino12,3-b] pyridin-7-yl)amino)-5,5-dimethyl-5H-chromeno[4,3-c] pyridin-8-yl)pyrrolidin-2-one
291 N
[0614] A mixture of 1 -(3-chl oro-5,5-dimethy1-5H-chromeno [4,3-c] py ri din-8-yl)pyrrolidin-2-one (25 mg, 0.076 mmol), 2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-7-amine (16 mg, 0.084 mmol, HC1 salt), Pd2(dba)3 (7 mg, 0.008 mmol), Brettphos (15 mg, 0.015 mmol), Cs2CO3 (50 mg, 0.152 mmol) in anhydrous dioxane (3 mL) was degassed and purged with N2 for 3 times. Then the resulting reaction mixture was heated at 90 C
for 14 hours under N2 atmosphere. The reaction mixture turned into yellow suspension from gray suspension.
LCMS showed that the purity of the desired product is 26% (Rt = 0.745 min; MS
Calcd: 444.2;
MS Found: 445.1 [M+H1+). The mixture was diluted with water (20 mL) and extracted with Et0Ac/THF (20 mL x3, 1/1). The combined organic layer was washed with water (20 mL
x2), brine (20 mL x2), dried over anhydrous Na2SO4, filtered and concentrated.
The residue was purified by prep-HPLC (0.225% FA as an additive) and lyophilized to give 1434(2,3-dihy dro- [1,4] di oxino [2,3 -b] py ri din-7-yl)amino)-5,5 -dimethy1-5H-chromeno [4,3-c] py ri din-8-yl)pyrrolidin-2-one (11.0 mg, yield: 33%) as a yellow solid.
11-1NMR (400 MHz DMSO-d6) 5 1.55 (6H, s), 2.01-2.10 (2H, m), 2.52-2.57 (2H, m, overlapped with DMSO), 3.84 (2H, t, J= 7.0 Hz), 4.22-4.27 (2H, m), 4.33-4.40 (2H, m), 6.71 (1H, s), 7.29 (1H, dd, J= 8.4 Hz, 2.2 Hz), 7.39 (1H, d, J= 2.0 Hz), 7.83 (1H, d, J = 2.2 Hz), 7.86 (1H, d, J = 8.8 Hz), 7.94 (1H, d, J = 2.4 Hz), 8.63 (1H, s), 9.25 (1H, brs).
Example 165: 1-(3-((2,3-dihydro-11,41dioxino12,3-b] pyridin-7-yl)amino)-9-fluoro-5H-chromeno[4,3-c] pyridin-8-yl)pyrrolidin-2-one N
[0615] A
mixture of 1-(3-chloro-9-fluoro-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one (50 mg, 0.16 mmol), 2,3-dihydro-[1,41dioxino[2,3-b]pyridin-7-amine (33 mg, 0.17 mmol, HC1 salt), Pd2(dba)3 (14 mg, 0.016 mmol), Brettphos (17 mg, 0.032 mmol), Cs2CO3 (102 mg,
[0614] A mixture of 1 -(3-chl oro-5,5-dimethy1-5H-chromeno [4,3-c] py ri din-8-yl)pyrrolidin-2-one (25 mg, 0.076 mmol), 2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-7-amine (16 mg, 0.084 mmol, HC1 salt), Pd2(dba)3 (7 mg, 0.008 mmol), Brettphos (15 mg, 0.015 mmol), Cs2CO3 (50 mg, 0.152 mmol) in anhydrous dioxane (3 mL) was degassed and purged with N2 for 3 times. Then the resulting reaction mixture was heated at 90 C
for 14 hours under N2 atmosphere. The reaction mixture turned into yellow suspension from gray suspension.
LCMS showed that the purity of the desired product is 26% (Rt = 0.745 min; MS
Calcd: 444.2;
MS Found: 445.1 [M+H1+). The mixture was diluted with water (20 mL) and extracted with Et0Ac/THF (20 mL x3, 1/1). The combined organic layer was washed with water (20 mL
x2), brine (20 mL x2), dried over anhydrous Na2SO4, filtered and concentrated.
The residue was purified by prep-HPLC (0.225% FA as an additive) and lyophilized to give 1434(2,3-dihy dro- [1,4] di oxino [2,3 -b] py ri din-7-yl)amino)-5,5 -dimethy1-5H-chromeno [4,3-c] py ri din-8-yl)pyrrolidin-2-one (11.0 mg, yield: 33%) as a yellow solid.
11-1NMR (400 MHz DMSO-d6) 5 1.55 (6H, s), 2.01-2.10 (2H, m), 2.52-2.57 (2H, m, overlapped with DMSO), 3.84 (2H, t, J= 7.0 Hz), 4.22-4.27 (2H, m), 4.33-4.40 (2H, m), 6.71 (1H, s), 7.29 (1H, dd, J= 8.4 Hz, 2.2 Hz), 7.39 (1H, d, J= 2.0 Hz), 7.83 (1H, d, J = 2.2 Hz), 7.86 (1H, d, J = 8.8 Hz), 7.94 (1H, d, J = 2.4 Hz), 8.63 (1H, s), 9.25 (1H, brs).
Example 165: 1-(3-((2,3-dihydro-11,41dioxino12,3-b] pyridin-7-yl)amino)-9-fluoro-5H-chromeno[4,3-c] pyridin-8-yl)pyrrolidin-2-one N
[0615] A
mixture of 1-(3-chloro-9-fluoro-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one (50 mg, 0.16 mmol), 2,3-dihydro-[1,41dioxino[2,3-b]pyridin-7-amine (33 mg, 0.17 mmol, HC1 salt), Pd2(dba)3 (14 mg, 0.016 mmol), Brettphos (17 mg, 0.032 mmol), Cs2CO3 (102 mg,
292 0.314 mmol) in anhydrous dioxane (3 mL) was degassed and purged with N2 for 3 times. Then the resulting reaction mixture was heated at 90 C for 14 hours under N2 atmosphere. The reaction mixture turned into yellow suspension from gray suspension. LCMS
showed that the purity of the desired product is 27% (Rt = 0.670 min; MS Calcd: 434.1; MS
Found: 435.1 [M+H1+). The mixture was diluted with water (20 mL) and extracted with Et0Ac/THF (20 mL
x3, 1/1). The combined organic layer was washed with water (20 mL x2), brine (20 mL x2), dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by prep-HPLC (0.225% FA as an additive) and lyophilized to give 1-(3-42,3-dihydro-[1,41dioxino[2,3-'Any ri din-7-yl)amino)-9-fluoro-5H-chromeno [4,3-c] py ri din-8-y Opy rroli din-2-one (16.4 mg, yield: 24%) as a yellow solid.
11-1 NMR (400 MHz DMSO-d6) 2.08-2.16 (2H, m), 2.43 (2H, t, J= 8.0 Hz), 3.76 (2H, t, J=
7.0 Hz), 4.22-4.27 (2H, m), 4.33-4.39 (2H, m), 5.09 (2H, s), 6.65 (1H, s), 7.05 (1H, d, J= 6.8 Hz), 7.79-7.86 (2H, m), 7.94 (1H, d, J= 2.4 Hz), 8.65 (1H, s), 9.30 (1H, brs).
Example 166: 1-(3-((2,3-dihydro-11,41dioxino[2,3-b]pyridin-7-yl)amino)-9-fluoro-5-methyl-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one NO
[0616] A
mixture of 1-(3-chl oro-9-fluoro-5 -methyl-5H-chromeno [4,3 -c] py ri din-8-yl)pyrrolidin-2-one (50 mg, 0.15 mmol), 2,3-dihydro-[1,41dioxino[2,3-blpyridin-7-amine (31 mg, 0.17 mmol, HC1 salt), Pd2(dba)3 (14 mg, 0.015 mmol), Brettphos (16 mg, 0.030 mmol), Cs2CO3 (98 mg, 0.300 mmol) in anhydrous dioxane (3 mL) was degassed and purged with N2 for 3 times. Then the resulting reaction mixture was heated at 90 C
for 14 hours under N2 atmosphere. The reaction mixture turned into yellow suspension from gray suspension.
LCMS showed that the purity of the desired product is 30% (Rt = 0.685 min; MS
Calcd: 448.2;
MS Found: 449.2 [M+H1+). The mixture was diluted with water (20 mL) and extracted with Et0Ac/THF (20 mL x3, 1/1). The combined organic layer was washed with water (20 mL
x2), brine (20 mL x2), dried over anhydrous Na2SO4, filtered and concentrated.
The residue
showed that the purity of the desired product is 27% (Rt = 0.670 min; MS Calcd: 434.1; MS
Found: 435.1 [M+H1+). The mixture was diluted with water (20 mL) and extracted with Et0Ac/THF (20 mL
x3, 1/1). The combined organic layer was washed with water (20 mL x2), brine (20 mL x2), dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by prep-HPLC (0.225% FA as an additive) and lyophilized to give 1-(3-42,3-dihydro-[1,41dioxino[2,3-'Any ri din-7-yl)amino)-9-fluoro-5H-chromeno [4,3-c] py ri din-8-y Opy rroli din-2-one (16.4 mg, yield: 24%) as a yellow solid.
11-1 NMR (400 MHz DMSO-d6) 2.08-2.16 (2H, m), 2.43 (2H, t, J= 8.0 Hz), 3.76 (2H, t, J=
7.0 Hz), 4.22-4.27 (2H, m), 4.33-4.39 (2H, m), 5.09 (2H, s), 6.65 (1H, s), 7.05 (1H, d, J= 6.8 Hz), 7.79-7.86 (2H, m), 7.94 (1H, d, J= 2.4 Hz), 8.65 (1H, s), 9.30 (1H, brs).
Example 166: 1-(3-((2,3-dihydro-11,41dioxino[2,3-b]pyridin-7-yl)amino)-9-fluoro-5-methyl-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one NO
[0616] A
mixture of 1-(3-chl oro-9-fluoro-5 -methyl-5H-chromeno [4,3 -c] py ri din-8-yl)pyrrolidin-2-one (50 mg, 0.15 mmol), 2,3-dihydro-[1,41dioxino[2,3-blpyridin-7-amine (31 mg, 0.17 mmol, HC1 salt), Pd2(dba)3 (14 mg, 0.015 mmol), Brettphos (16 mg, 0.030 mmol), Cs2CO3 (98 mg, 0.300 mmol) in anhydrous dioxane (3 mL) was degassed and purged with N2 for 3 times. Then the resulting reaction mixture was heated at 90 C
for 14 hours under N2 atmosphere. The reaction mixture turned into yellow suspension from gray suspension.
LCMS showed that the purity of the desired product is 30% (Rt = 0.685 min; MS
Calcd: 448.2;
MS Found: 449.2 [M+H1+). The mixture was diluted with water (20 mL) and extracted with Et0Ac/THF (20 mL x3, 1/1). The combined organic layer was washed with water (20 mL
x2), brine (20 mL x2), dried over anhydrous Na2SO4, filtered and concentrated.
The residue
293 was purified by prep-HPLC (0.225% FA as an additive) and lyophilized to give 1434(2,3-dihy dro- [1,4] di oxino [2,3 -b] py ri din-7-yl)amino)-9-fluoro-5-methy1-5H-chromeno [4,3-c]pyridin-8-yl)pyrrolidin-2-one (11.1 mg, yield: 16%) as a yellow solid.
NMR (400 MHz DMSO-d6) 1.52 (3H, d, J= 6.4 Hz), 2.06-2.16 (2H, m), 2.43 (2H, t, J=
8.0 Hz), 3.73-3.82 (2H, m), 4.22-4.27 (2H, m), 4.33-4.39 (2H, m), 5.26 (1H, q, J = 6.4 Hz), 6.65 (1H, s), 7.05 (1H, d, J= 6.8 Hz), 7.81-7.88 (2H, m), 7.94 (1H, d, J= 2.4 Hz), 8.66 (1H, s), 9.32 (1H, brs).
Example 167: 1-(3-((2,3-dihydro-11,41dioxino12,3-b]pyridin-7-yl)amino)-9-fluoro-5,5-dimethyl-5H-chromeno14,3-c] pyridin-8-yl)pyrrolidin-2-one 9, 0 N N
[0617] A
mixture of 1-(3-chloro-9-fluoro-5,5-dimethy1-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one (50 mg, 0.14 mmol), 2,3-dihydro-[1,41dioxino[2,3-b]pyridin-7-amine (30 mg, 0.16 mmol, HC1 salt), Pd2(dba)3 (13 mg, 0.014 mmol), Brettphos (15 mg, 0.028 mmol), Cs2CO3 (94 mg, 0.288 mmol) in anhydrous dioxane (3 mL) was degassed and purged with N2 for 3 times. Then the resulting reaction mixture was heated at 90 C
for 14 hours under N2 atmosphere. The reaction mixture turned into black suspension from gray suspension.
LCMS showed that the purity of the desired product is 32% (Rt = 0.749 min; MS
Calcd: 462.2;
MS Found: 463.1 [M+H1+). The mixture was diluted with water (20 mL) and extracted with Et0Ac/THF (20 mL x3, 1/1). The combined organic layer was washed with water (20 mL
x2), brine (20 mL x2), dried over anhydrous Na2SO4, filtered and concentrated.
The residue was purified by prep-HPLC (0.225% FA as an additive) and lyophilized to give 1434(2,3-dihy dro- [1,4] di oxino [2,3 -b] py ri din-7-yl)amino)-9-fluoro-5,5-dimethy1-5H-chromeno [4,3 -c]pyridin-8-yl)pyrrolidin-2-one (24.1 mg, yield: 36%) as a yellow solid.
NMR (400 MHz DMSO-d6) (5 1.56 (6H, s), 2.06-2.16 (2H, m), 2.43 (2H, t, J= 8.0 Hz), 3.78 (2H, t, J = 7.0 Hz), 4.22-4.27 (2H, m), 4.33-4.39 (2H, m), 6.71 (1H, s), 7.02 (1H, d, J=
6.8 Hz), 7.83 (1H, d, J= 2.2 Hz), 7.84-7.89 (1H, m), 7.95 (1H, d, J= 2.2 Hz), 8.68 (1H, s), 9.34 (1H, brs).
NMR (400 MHz DMSO-d6) 1.52 (3H, d, J= 6.4 Hz), 2.06-2.16 (2H, m), 2.43 (2H, t, J=
8.0 Hz), 3.73-3.82 (2H, m), 4.22-4.27 (2H, m), 4.33-4.39 (2H, m), 5.26 (1H, q, J = 6.4 Hz), 6.65 (1H, s), 7.05 (1H, d, J= 6.8 Hz), 7.81-7.88 (2H, m), 7.94 (1H, d, J= 2.4 Hz), 8.66 (1H, s), 9.32 (1H, brs).
Example 167: 1-(3-((2,3-dihydro-11,41dioxino12,3-b]pyridin-7-yl)amino)-9-fluoro-5,5-dimethyl-5H-chromeno14,3-c] pyridin-8-yl)pyrrolidin-2-one 9, 0 N N
[0617] A
mixture of 1-(3-chloro-9-fluoro-5,5-dimethy1-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one (50 mg, 0.14 mmol), 2,3-dihydro-[1,41dioxino[2,3-b]pyridin-7-amine (30 mg, 0.16 mmol, HC1 salt), Pd2(dba)3 (13 mg, 0.014 mmol), Brettphos (15 mg, 0.028 mmol), Cs2CO3 (94 mg, 0.288 mmol) in anhydrous dioxane (3 mL) was degassed and purged with N2 for 3 times. Then the resulting reaction mixture was heated at 90 C
for 14 hours under N2 atmosphere. The reaction mixture turned into black suspension from gray suspension.
LCMS showed that the purity of the desired product is 32% (Rt = 0.749 min; MS
Calcd: 462.2;
MS Found: 463.1 [M+H1+). The mixture was diluted with water (20 mL) and extracted with Et0Ac/THF (20 mL x3, 1/1). The combined organic layer was washed with water (20 mL
x2), brine (20 mL x2), dried over anhydrous Na2SO4, filtered and concentrated.
The residue was purified by prep-HPLC (0.225% FA as an additive) and lyophilized to give 1434(2,3-dihy dro- [1,4] di oxino [2,3 -b] py ri din-7-yl)amino)-9-fluoro-5,5-dimethy1-5H-chromeno [4,3 -c]pyridin-8-yl)pyrrolidin-2-one (24.1 mg, yield: 36%) as a yellow solid.
NMR (400 MHz DMSO-d6) (5 1.56 (6H, s), 2.06-2.16 (2H, m), 2.43 (2H, t, J= 8.0 Hz), 3.78 (2H, t, J = 7.0 Hz), 4.22-4.27 (2H, m), 4.33-4.39 (2H, m), 6.71 (1H, s), 7.02 (1H, d, J=
6.8 Hz), 7.83 (1H, d, J= 2.2 Hz), 7.84-7.89 (1H, m), 7.95 (1H, d, J= 2.2 Hz), 8.68 (1H, s), 9.34 (1H, brs).
294 Example 168: 1-(3-((5-(4-(3-methoxyp ro p an oyl)pip erazin-1-yl)pyridin-3-yl)amin o)-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one N
Step 1: Preparation of tert-butyl4-(3-methoxypropanoyDpiperazine-1-carboxylate Boc,N
NyO
[0618] To a solution of tert-butyl piperazine-l-carboxylate (10.0 g, 53.7 mmol), 3-methoxypropanoic acid (6.71 g, 64.4 mmol), EDCI (15.4 g, 80.5 mmol) and HOBt (14.5 g, 107 mmol) in anhydrous DMF (100 mL) was added Et3N (16.3 g, 161 mmol) at 20-25 C.
Then the reaction mixture was stirred at 20-25 C for 16 hours. The reaction mixture turned into white suspension from yellow solution. To the reaction mixture was added water (200 mL), then extracted with Et0Ac (200 mL x3). The combined organic layer was washed with water (100 mL x3), 1N aqueous HC1 (100 mL x2), saturated aqueous NaHCO3 (100 mL), brine (100 mL), dried over anhydrous Na2SO4 and concentrated to give tert-butyl 4-(3-methoxypropanoyl)piperazine-1-carboxylate (13.0 g, yield: 89%) as a white solid.
1FINMR (400 MHz, CDC13) (51.47 (9H, s), 2.61 (2H, t, J= 6.4 Hz), 3.35 (3H, s), 3.35-3.50 (6H, m), 3.55-3.65 (2H, m), 3.70 (2H, t, J= 6.8 Hz).
Step 2: Preparation of 3 -methoxy -1 -(piperazin-1-yl)propan-1 -one HN
[0619] To a solution of tert-butyl 4-(3-methoxypropanoyl)piperazine-1-carboxylate (13.0 g, 47.7 mmol) in Et0Ac (50 mL) was added 4N HC1/Et0Ac (100 mL) at 20-25 C.
Then the reaction mixture was stirred at 20-25 C for 2 hours. The reaction mixture turned into cloudy
Step 1: Preparation of tert-butyl4-(3-methoxypropanoyDpiperazine-1-carboxylate Boc,N
NyO
[0618] To a solution of tert-butyl piperazine-l-carboxylate (10.0 g, 53.7 mmol), 3-methoxypropanoic acid (6.71 g, 64.4 mmol), EDCI (15.4 g, 80.5 mmol) and HOBt (14.5 g, 107 mmol) in anhydrous DMF (100 mL) was added Et3N (16.3 g, 161 mmol) at 20-25 C.
Then the reaction mixture was stirred at 20-25 C for 16 hours. The reaction mixture turned into white suspension from yellow solution. To the reaction mixture was added water (200 mL), then extracted with Et0Ac (200 mL x3). The combined organic layer was washed with water (100 mL x3), 1N aqueous HC1 (100 mL x2), saturated aqueous NaHCO3 (100 mL), brine (100 mL), dried over anhydrous Na2SO4 and concentrated to give tert-butyl 4-(3-methoxypropanoyl)piperazine-1-carboxylate (13.0 g, yield: 89%) as a white solid.
1FINMR (400 MHz, CDC13) (51.47 (9H, s), 2.61 (2H, t, J= 6.4 Hz), 3.35 (3H, s), 3.35-3.50 (6H, m), 3.55-3.65 (2H, m), 3.70 (2H, t, J= 6.8 Hz).
Step 2: Preparation of 3 -methoxy -1 -(piperazin-1-yl)propan-1 -one HN
[0619] To a solution of tert-butyl 4-(3-methoxypropanoyl)piperazine-1-carboxylate (13.0 g, 47.7 mmol) in Et0Ac (50 mL) was added 4N HC1/Et0Ac (100 mL) at 20-25 C.
Then the reaction mixture was stirred at 20-25 C for 2 hours. The reaction mixture turned into cloudy
295 from solution. The reaction mixture was concentrated to give 3-methoxy-1-(piperazin-1-yl)propan-1-one (9.80 g, yield: 98%, HC1 salt) as a white solid.
11-1 NMR (400 MHz, DMSO-d6) (52.61 (2H, t, J= 6.8 Hz), 2.90-3.10 (4H, m), 3.22 (3H, s), 3.54 (2H, t, J = 6.4 Hz), 3.65-3.80 (4H, m), 9.66 (2H, s).
[0620] The product (9.80 g, 47.0 mmol) was dissolved in water (50 mL), then basified with 2N aqueous NaOH to pH = 9 and extracted with DCM/Me0H (25 mL x5, 4/1). The combined organic layer was dried over anhydrous Na2SO4 and concentrated to give 3-methoxy-1-(piperazin-1-yl)propan-1-one (1.90 g, free form) as yellow oil.
11-1 NMR (400 MHz, CDC13) (52.23 (1H, brs), 2.59 (2H, t, J = 6.4 Hz), 2.80-2.90 (4H, m), 3.35 (3H, s), 3.40-3.45 (2H, m), 3.55-3.60 (2H, m), 3.69 (2H, t, J= 6.4 Hz).
[0621] The aqueous layer was lyophilized and the solid was suspended in DCM/Me0H
(100 mL, 4/1) and stirred for 1 hour. The mixture was filtered and the filtrate was dried over anhydrous Na2SO4 and concentrated to give 3-methoxy-1-(piperazin-1-y0propan-1-one (1.50 g, free form) as yellow oil.
11-1 NMR (400 MHz, CDC13) (52.58 (2H, t, J= 6.4 Hz), 2.80-2.90 (4H, m), 3.15 (1H, brs), 3.34 (3H, s), 3.40-3.45 (2H, m), 3.55-3.60 (2H, m), 3.68 (2H, t, J= 6.4 Hz).
Step 3:
Preparation of tert-butyl (5-(4-(3-methoxypropanoyDpiperazin-1-y1)pyridin-3-y1)carbamate I
BocH N
[0622] A
mixture of tert-butyl (5-bromopyridin-3-yl)carbamate (3.50 g, 12.8 mmol), 3-methoxy-1-(piperazin-1-yl)propan-1-one (2.87 g, 16.7 mmol, free form), Pd2(dba)3 (1.17 g, 1.28 mmol), RuPhos (1.20 g, 2.56 mmol) and Cs2CO3 (8.35 g, 25.6 mmol) in anhydrous dioxane (50 mL) was degassed and purged with N2 for 3 times. Then the resulting reaction mixture was heated at 90 C for 16 hour under N2 atmosphere. The reaction mixture turned into yellow suspension from red. LCMS showed the purity of the desired product is 52% (Rt =
0.650 min; MS Calcd: 364.2; MS Found: 365.3 [M+H1+). To the reaction mixture was added water (100 mL), then extracted with Et0Ac (100 mL x3). The combined organic layer was washed with brine (100 mL), dried over anhydrous Na2SO4 and concentrated. The residue was
11-1 NMR (400 MHz, DMSO-d6) (52.61 (2H, t, J= 6.8 Hz), 2.90-3.10 (4H, m), 3.22 (3H, s), 3.54 (2H, t, J = 6.4 Hz), 3.65-3.80 (4H, m), 9.66 (2H, s).
[0620] The product (9.80 g, 47.0 mmol) was dissolved in water (50 mL), then basified with 2N aqueous NaOH to pH = 9 and extracted with DCM/Me0H (25 mL x5, 4/1). The combined organic layer was dried over anhydrous Na2SO4 and concentrated to give 3-methoxy-1-(piperazin-1-yl)propan-1-one (1.90 g, free form) as yellow oil.
11-1 NMR (400 MHz, CDC13) (52.23 (1H, brs), 2.59 (2H, t, J = 6.4 Hz), 2.80-2.90 (4H, m), 3.35 (3H, s), 3.40-3.45 (2H, m), 3.55-3.60 (2H, m), 3.69 (2H, t, J= 6.4 Hz).
[0621] The aqueous layer was lyophilized and the solid was suspended in DCM/Me0H
(100 mL, 4/1) and stirred for 1 hour. The mixture was filtered and the filtrate was dried over anhydrous Na2SO4 and concentrated to give 3-methoxy-1-(piperazin-1-y0propan-1-one (1.50 g, free form) as yellow oil.
11-1 NMR (400 MHz, CDC13) (52.58 (2H, t, J= 6.4 Hz), 2.80-2.90 (4H, m), 3.15 (1H, brs), 3.34 (3H, s), 3.40-3.45 (2H, m), 3.55-3.60 (2H, m), 3.68 (2H, t, J= 6.4 Hz).
Step 3:
Preparation of tert-butyl (5-(4-(3-methoxypropanoyDpiperazin-1-y1)pyridin-3-y1)carbamate I
BocH N
[0622] A
mixture of tert-butyl (5-bromopyridin-3-yl)carbamate (3.50 g, 12.8 mmol), 3-methoxy-1-(piperazin-1-yl)propan-1-one (2.87 g, 16.7 mmol, free form), Pd2(dba)3 (1.17 g, 1.28 mmol), RuPhos (1.20 g, 2.56 mmol) and Cs2CO3 (8.35 g, 25.6 mmol) in anhydrous dioxane (50 mL) was degassed and purged with N2 for 3 times. Then the resulting reaction mixture was heated at 90 C for 16 hour under N2 atmosphere. The reaction mixture turned into yellow suspension from red. LCMS showed the purity of the desired product is 52% (Rt =
0.650 min; MS Calcd: 364.2; MS Found: 365.3 [M+H1+). To the reaction mixture was added water (100 mL), then extracted with Et0Ac (100 mL x3). The combined organic layer was washed with brine (100 mL), dried over anhydrous Na2SO4 and concentrated. The residue was
296 purified by Combi Flash (50% to 100% Et0Ac in PE) to give tert-butyl (5-(4-(3-methoxypropanoyDpiperazin-1-yOpyridin-3-yl)carbamate (3.80 g, yield: 81%) as yellow gum.
11-1NMR (400 MHz, CDC13) (51.52 (9H, s), 2.65 (2H, t, J= 6.4 Hz), 3.15-3.25 (4H, m), 3.37 (3H, s), 3.60-3.65 (2H, m), 3.73 (2H, t, J= 6.4 Hz), 3.75-3.80 (2H, m), 6.55 (1H, brs), 7.74 (1H, s), 7.84 (1H, d, J= 2.0 Hz), 7.96 (1H, d, J= 2.8 Hz).
Step 4: Preparation of 1-(4-(5 -aminopy ri din-3 -yl)pip erazin-l-y1)-3 -methoxy propan-1-one I
N
[0623] To a solution of tert-butyl (5-(4-(3-methoxypropanoyl)piperazin-1-yl)pyridin-3-yl)carbamate (3.80 g, 10.4 mmol) in Et0Ac (20 mL) was added 4N HC1/Et0Ac (60 mL) at 20-25 C. Then the resulting reaction mixture was stirred at 20-25 C for 2 hours. The mixture turned into cloudy from yellow solution. LCMS showed the purity of the desired product is 99% (Rt = 0.320 min; MS Calcd: 264.2; MS Found: 265.0 [M+H]+). The reaction mixture was concentrated to give 1-(4-(5-aminopyridin-3-yl)piperazin-1-y1)-3-methoxypropan-1-one (3.40 g, yield: 87%, HC1 salt) as a yellow solid.
11-1NMR (400 MHz, DMSO-d6) (52.62 (2H, t, J= 6.4 Hz), 3.23(3H, s), 3.25-3.35 (4H, m), 3.50-3.70 (6H, m), 7.08 (1H, s), 7.46 (1H, d, J = 1.6 Hz), 7.72 (1H, d, J= 2.0 Hz).
Note: two active protons were not observed.
Step 5: Preparation of 1-(3 -((5 -(4-(3 -methoxyprop anoyl)piperazin-l-y Opyri din-3 -yl)amino)-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one ONN
I
[0624] A
mixture of 1-(3-chloro-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one (60 mg, 0.20 mmol), 1-(4-(5-aminopyridin-3-yl)piperazin-1-y1)-3-methoxypropan-1-one (89 mg, 0.24 mmol, HC1 salt), Pd2(dba)3 (18 mg, 0.020 mmol), Brettphos (21 mg, 0.040 mmol) and Cs2CO3 (325 mg, 0.998 mmol) in anhydrous dioxane (3 mL) was degassed and purged with N2
11-1NMR (400 MHz, CDC13) (51.52 (9H, s), 2.65 (2H, t, J= 6.4 Hz), 3.15-3.25 (4H, m), 3.37 (3H, s), 3.60-3.65 (2H, m), 3.73 (2H, t, J= 6.4 Hz), 3.75-3.80 (2H, m), 6.55 (1H, brs), 7.74 (1H, s), 7.84 (1H, d, J= 2.0 Hz), 7.96 (1H, d, J= 2.8 Hz).
Step 4: Preparation of 1-(4-(5 -aminopy ri din-3 -yl)pip erazin-l-y1)-3 -methoxy propan-1-one I
N
[0623] To a solution of tert-butyl (5-(4-(3-methoxypropanoyl)piperazin-1-yl)pyridin-3-yl)carbamate (3.80 g, 10.4 mmol) in Et0Ac (20 mL) was added 4N HC1/Et0Ac (60 mL) at 20-25 C. Then the resulting reaction mixture was stirred at 20-25 C for 2 hours. The mixture turned into cloudy from yellow solution. LCMS showed the purity of the desired product is 99% (Rt = 0.320 min; MS Calcd: 264.2; MS Found: 265.0 [M+H]+). The reaction mixture was concentrated to give 1-(4-(5-aminopyridin-3-yl)piperazin-1-y1)-3-methoxypropan-1-one (3.40 g, yield: 87%, HC1 salt) as a yellow solid.
11-1NMR (400 MHz, DMSO-d6) (52.62 (2H, t, J= 6.4 Hz), 3.23(3H, s), 3.25-3.35 (4H, m), 3.50-3.70 (6H, m), 7.08 (1H, s), 7.46 (1H, d, J = 1.6 Hz), 7.72 (1H, d, J= 2.0 Hz).
Note: two active protons were not observed.
Step 5: Preparation of 1-(3 -((5 -(4-(3 -methoxyprop anoyl)piperazin-l-y Opyri din-3 -yl)amino)-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one ONN
I
[0624] A
mixture of 1-(3-chloro-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one (60 mg, 0.20 mmol), 1-(4-(5-aminopyridin-3-yl)piperazin-1-y1)-3-methoxypropan-1-one (89 mg, 0.24 mmol, HC1 salt), Pd2(dba)3 (18 mg, 0.020 mmol), Brettphos (21 mg, 0.040 mmol) and Cs2CO3 (325 mg, 0.998 mmol) in anhydrous dioxane (3 mL) was degassed and purged with N2
297 for 3 times. Then the resulting reaction mixture was heated at 90 C for 16 hours under N2 atmosphere. The reaction mixture turned into brown from red. LCMS showed the purity of the desired product is 21% (Rt = 0.708 min; MS Calcd: 528.3; MS Found: 529.2 [M+Hl+). To the reaction mixture was added water (25 mL), then extracted with Et0Ac/THF (25 mL
x3, 1/1).
The combined organic layer was washed with brine (25 mL), dried over anhydrous Na2SO4 and concentrated. The residue was purified by prep-HPLC (0.225% FA as an additive). Most of CH3CN was removed under reduced pressure and the remaining part was lyophilized to give 1-(3 -(4-(3-methoxy prop anoy Opiperazin-1 -y 1)py ri din-3-yl)amino)-5H-chromeno [4,3-clpyridin-8-yOpyrrolidin-2-one (18.2 mg, yield: 17 %) as a yellow solid.
11-1NMR (400 MHz, DMSO-d6) 5 2.00-2.11 (2H, m), 2.52-2.54 (2H, m), 2.64 (2H, t, J= 6.4 Hz), 3.24 (3H, s), 3.25-3.32 (4H, m), 3.58 (2H, t, J= 6.4 Hz), 3.62-3.70 (4H, m), 3.84 (2H, t, J= 7.2 Hz), 5.12 (2H, s), 6.76 (1H, s), 7.34 (1H, dd, J= 8.4, 2.4 Hz), 7.38 (1H, d, J= 2.0 Hz), 7.86-7.91 (2H, m), 7.98 (1H, d, J= 2.4 Hz), 8.51 (1H, d, J= 1.6 Hz), 8.69 (1H, s), 9.61 (1H, brs).
Example 169: 1-(3-((5-(4-(3-methoxyprop anoyl)piperazin-1-yl)pyridin-3-yl)amino)-5-methyl-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one c 0 N
[0625] A
mixture of 1-(3 -chloro-5 -methyl-5H-chromeno [4,3-c] py ri din-8-yl)py rroli din-2-one (60 mg, 0.19 mmol), 1-(4-(5-aminopyridin-3-yl)piperazin-1-y1)-3-methoxypropan-1-one (85 mg, 0.23 mmol, HC1 salt), Pd2(dba)3 (17 mg, 0.019 mmol), Brettphos (20 mg, 0.038 mmol) and Cs2CO3 (311 mg, 0.953 mmol) in anhydrous dioxane (3 mL) was degassed and purged with N2 for 3 times. Then the resulting reaction mixture was heated at 90 C
for 16 hours under N2 atmosphere. The reaction mixture turned into brown from red. LCMS showed the purity of the desired product is 35% (Rt = 0.719 min; MS Calcd: 542.3; MS Found: 543.4 [M+H]+). To the reaction mixture was added water (25 mL), then extracted with Et0Ac/THF
(25 mL x3, 1/1). The combined organic layer was washed with brine (25 mL), dried over anhydrous
x3, 1/1).
The combined organic layer was washed with brine (25 mL), dried over anhydrous Na2SO4 and concentrated. The residue was purified by prep-HPLC (0.225% FA as an additive). Most of CH3CN was removed under reduced pressure and the remaining part was lyophilized to give 1-(3 -(4-(3-methoxy prop anoy Opiperazin-1 -y 1)py ri din-3-yl)amino)-5H-chromeno [4,3-clpyridin-8-yOpyrrolidin-2-one (18.2 mg, yield: 17 %) as a yellow solid.
11-1NMR (400 MHz, DMSO-d6) 5 2.00-2.11 (2H, m), 2.52-2.54 (2H, m), 2.64 (2H, t, J= 6.4 Hz), 3.24 (3H, s), 3.25-3.32 (4H, m), 3.58 (2H, t, J= 6.4 Hz), 3.62-3.70 (4H, m), 3.84 (2H, t, J= 7.2 Hz), 5.12 (2H, s), 6.76 (1H, s), 7.34 (1H, dd, J= 8.4, 2.4 Hz), 7.38 (1H, d, J= 2.0 Hz), 7.86-7.91 (2H, m), 7.98 (1H, d, J= 2.4 Hz), 8.51 (1H, d, J= 1.6 Hz), 8.69 (1H, s), 9.61 (1H, brs).
Example 169: 1-(3-((5-(4-(3-methoxyprop anoyl)piperazin-1-yl)pyridin-3-yl)amino)-5-methyl-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one c 0 N
[0625] A
mixture of 1-(3 -chloro-5 -methyl-5H-chromeno [4,3-c] py ri din-8-yl)py rroli din-2-one (60 mg, 0.19 mmol), 1-(4-(5-aminopyridin-3-yl)piperazin-1-y1)-3-methoxypropan-1-one (85 mg, 0.23 mmol, HC1 salt), Pd2(dba)3 (17 mg, 0.019 mmol), Brettphos (20 mg, 0.038 mmol) and Cs2CO3 (311 mg, 0.953 mmol) in anhydrous dioxane (3 mL) was degassed and purged with N2 for 3 times. Then the resulting reaction mixture was heated at 90 C
for 16 hours under N2 atmosphere. The reaction mixture turned into brown from red. LCMS showed the purity of the desired product is 35% (Rt = 0.719 min; MS Calcd: 542.3; MS Found: 543.4 [M+H]+). To the reaction mixture was added water (25 mL), then extracted with Et0Ac/THF
(25 mL x3, 1/1). The combined organic layer was washed with brine (25 mL), dried over anhydrous
298 Na2SO4 and concentrated. The residue was purified by prep-HPLC (0.225% FA as an additive).
Most of CH3CN was removed under reduced pressure and the remaining part was lyophilized to give 1-(3 -((5-(4-(3-methoxy prop anoyl)pip erazin-1 -y Opy ri din-3 -y0amino)-5-methyl-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (33.7 mg, yield: 33%) as a yellow solid.
11-1 NMR (400 MHz, DMSO-d6) 1.54 (3H, d, J= 6.4 Hz), 1.90-2.10 (2H, m), 2.52-2.54 (2H, m), 2.64 (2H, t, J= 6.4 Hz), 3.24 (3H, s), 3.25-3.32 (4H, m), 3.60 (2H, t, J=
6.4 Hz), 3.62-3.70 (4H, m), 3.84 (2H, t, J = 7.6 Hz), 5.29 (1H, q, J= 6.4 Hz), 6.75 (1H, s), 7.33 (1H, dd, J
= 8.4, 2.4 Hz), 7.40 (1H, d, J= 2.0 Hz), 7.80-7.90 (2H, m), 7.97 (1H, s), 8.48 (1H, s), 8.70 (1H, s), 9.60 (1H, brs).
Example 170: 1-(3-05-(4-(3-methoxypropanoyl)piperazin-1-yl)pyridin-3-yl)amino)-5,5-dimethyl-5H-chromeno[4,3-c]pyridin-8-y1)pyrrolidin-2-one [0626] A mixture of 1 -(3-chl oro-5,5-dimethy1-5H-chromeno [4,3-c] py ri din-8-yl)pyrrolidin-2-one (60 mg, 0.18 mmol), 1-(4-(5-aminopyridin-3-yOpiperazin-1-y1)-3-methoxypropan-1-one (82 mg, 0.22 mmol HC1 salt), Pd2(dba)3 (17 mg, 0.018 mmol), Brettphos (20 mg, 0.037 mmol) and Cs2CO3 (297 mg, 0.912 mmol) in anhydrous dioxane (3 mL) was degassed and purged with N2 for 3 times. Then the resulting reaction mixture was heated at 90 C for 16 hours under N2 atmosphere. The reaction mixture turned into brown from red. LCMS
showed the purity of the desired product is 32% (Rt = 0.733 min; MS Calcd:
556.3; MS Found:
557.2 [M+H]+). To the reaction mixture was added water (25 mL), then extracted with Et0Ac (25 mL x3). The combined organic layer was washed with brine (25 mL), dried over anhydrous Na2SO4 and concentrated. The residue was purified by prep-HPLC (0.225% FA as an additive).
Most of CH3CN was removed under reduced pressure and the remaining part was lyophilized, then further purified by prep-TLC (DCM/Me0H, 10/1) and lyophilized to give 1434(54443-methoxy propanoy Opip erazin-1 -y Opy ri din-3 -y Damino)-5,5-dimethy1-5H-chromeno [4,3-clpyridin-8-yOpyrrolidin-2-one (15.3 mg, yield: 15%) as an off-white solid.
Most of CH3CN was removed under reduced pressure and the remaining part was lyophilized to give 1-(3 -((5-(4-(3-methoxy prop anoyl)pip erazin-1 -y Opy ri din-3 -y0amino)-5-methyl-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (33.7 mg, yield: 33%) as a yellow solid.
11-1 NMR (400 MHz, DMSO-d6) 1.54 (3H, d, J= 6.4 Hz), 1.90-2.10 (2H, m), 2.52-2.54 (2H, m), 2.64 (2H, t, J= 6.4 Hz), 3.24 (3H, s), 3.25-3.32 (4H, m), 3.60 (2H, t, J=
6.4 Hz), 3.62-3.70 (4H, m), 3.84 (2H, t, J = 7.6 Hz), 5.29 (1H, q, J= 6.4 Hz), 6.75 (1H, s), 7.33 (1H, dd, J
= 8.4, 2.4 Hz), 7.40 (1H, d, J= 2.0 Hz), 7.80-7.90 (2H, m), 7.97 (1H, s), 8.48 (1H, s), 8.70 (1H, s), 9.60 (1H, brs).
Example 170: 1-(3-05-(4-(3-methoxypropanoyl)piperazin-1-yl)pyridin-3-yl)amino)-5,5-dimethyl-5H-chromeno[4,3-c]pyridin-8-y1)pyrrolidin-2-one [0626] A mixture of 1 -(3-chl oro-5,5-dimethy1-5H-chromeno [4,3-c] py ri din-8-yl)pyrrolidin-2-one (60 mg, 0.18 mmol), 1-(4-(5-aminopyridin-3-yOpiperazin-1-y1)-3-methoxypropan-1-one (82 mg, 0.22 mmol HC1 salt), Pd2(dba)3 (17 mg, 0.018 mmol), Brettphos (20 mg, 0.037 mmol) and Cs2CO3 (297 mg, 0.912 mmol) in anhydrous dioxane (3 mL) was degassed and purged with N2 for 3 times. Then the resulting reaction mixture was heated at 90 C for 16 hours under N2 atmosphere. The reaction mixture turned into brown from red. LCMS
showed the purity of the desired product is 32% (Rt = 0.733 min; MS Calcd:
556.3; MS Found:
557.2 [M+H]+). To the reaction mixture was added water (25 mL), then extracted with Et0Ac (25 mL x3). The combined organic layer was washed with brine (25 mL), dried over anhydrous Na2SO4 and concentrated. The residue was purified by prep-HPLC (0.225% FA as an additive).
Most of CH3CN was removed under reduced pressure and the remaining part was lyophilized, then further purified by prep-TLC (DCM/Me0H, 10/1) and lyophilized to give 1434(54443-methoxy propanoy Opip erazin-1 -y Opy ri din-3 -y Damino)-5,5-dimethy1-5H-chromeno [4,3-clpyridin-8-yOpyrrolidin-2-one (15.3 mg, yield: 15%) as an off-white solid.
299 NMR (400 MHz, DMSO-d6) (51.57 (6H, s), 2.00-2.10 (2H, m), 2.52-2.54 (2H, m), 2.63 (2H, t, J= 6.4 Hz), 3.10-3.20 (4H, m), 3.24 (3H, s), 3.58 (2H, t, J= 6.4 Hz), 3.60-3.70 (4H, m), 3.85 (2H, t, J= 7.2 Hz), 6.79 (1H, s), 7.30 (1H, dd, J= 8.4, 2.0 Hz), 7.40 (1H, d, J= 2.0 Hz), 7.85-7.92 (3H, m), 8.29 (1H, s), 8.70 (1H, s), 9.32 (1H, brs).
Example 171: 1-(9-fluoro-3-05-(4-(3-methoxypropanoyl)piperazin-1-yl)pyridin-3-yl)amino)-5H-chromeno14,3-c] pyridin-8-yl)pyrrolidin-2-one I
N N
N
[0627] A
mixture of 1-(3-chloro-9-fluoro-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one (60 mg, 0.19 mmol), 1-(4-(5-aminopyridin-3-yl)piperazin-1-y1)-3-methoxypropan-1-one (84 mg, 0.23 mmol, HC1 salt), Pd2(dba)3 (17 mg, 0.019 mmol), Brettphos (20 mg, 0.038 mmol) and Cs2CO3 (307 mg, 0.941 mmol) in anhydrous dioxane (3 mL) was degassed and purged with N2 for 3 times. Then the resulting reaction mixture was heated at 90 C
for 16 hours under N2 atmosphere. The reaction mixture turned into brown from red. LCMS showed the purity of the desired product is 13% (Rt = 0.700 min; MS Calcd: 546.2; MS Found: 547.3 [M+Hl+). To the reaction mixture was added water (25 mL), then extracted with Et0Ac/THF
(25 mL x3, 1/1). The combined organic layer was washed with brine (25 mL), dried over anhydrous Na2SO4 and concentrated. The residue was purified by prep-HPLC (0.225% FA as an additive).
Most of CH3CN was removed under reduced pressure and the remaining part was lyophilized, then further purified by prep-TLC (DCM/Me0H, 10/1) and lyophilized to give 1-(9-fluoro-3-((5-(4-(3-methoxypropanoyl)piperazin-1-yl)pyridin-3-yl)amino)-5H-chromeno[4,3-clpyridin-8-yl)pyrrolidin-2-one (8.8 mg, yield: 9%) as a yellow solid.
11-1NMR (400 MHz, DMSO-d6) (52.05-2.15 (2H, m), 2.43 (2H, t, J= 8.0 Hz), 2.63 (2H, t, J=
6.4 Hz), 3.10-3.25 (4+3H, m), 3.58 (2H, t, J= 6.4 Hz), 3.60-3.70 (4H, m), 3.77 (2H, t, J= 7.2 Hz), 5.11 (2H, s), 6.73 (1H, s), 7.06 (1H, d, J= 6.8 Hz), 7.82 (1H, s), 7.86 (1H, d, J= 11.6 Hz), 7.93 (1H, d, J= 2.4 Hz), 8.34 (1H, d, J= 2.0 Hz), 8.71 (1H, s), 9.40 (1H, brs).
Example 171: 1-(9-fluoro-3-05-(4-(3-methoxypropanoyl)piperazin-1-yl)pyridin-3-yl)amino)-5H-chromeno14,3-c] pyridin-8-yl)pyrrolidin-2-one I
N N
N
[0627] A
mixture of 1-(3-chloro-9-fluoro-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one (60 mg, 0.19 mmol), 1-(4-(5-aminopyridin-3-yl)piperazin-1-y1)-3-methoxypropan-1-one (84 mg, 0.23 mmol, HC1 salt), Pd2(dba)3 (17 mg, 0.019 mmol), Brettphos (20 mg, 0.038 mmol) and Cs2CO3 (307 mg, 0.941 mmol) in anhydrous dioxane (3 mL) was degassed and purged with N2 for 3 times. Then the resulting reaction mixture was heated at 90 C
for 16 hours under N2 atmosphere. The reaction mixture turned into brown from red. LCMS showed the purity of the desired product is 13% (Rt = 0.700 min; MS Calcd: 546.2; MS Found: 547.3 [M+Hl+). To the reaction mixture was added water (25 mL), then extracted with Et0Ac/THF
(25 mL x3, 1/1). The combined organic layer was washed with brine (25 mL), dried over anhydrous Na2SO4 and concentrated. The residue was purified by prep-HPLC (0.225% FA as an additive).
Most of CH3CN was removed under reduced pressure and the remaining part was lyophilized, then further purified by prep-TLC (DCM/Me0H, 10/1) and lyophilized to give 1-(9-fluoro-3-((5-(4-(3-methoxypropanoyl)piperazin-1-yl)pyridin-3-yl)amino)-5H-chromeno[4,3-clpyridin-8-yl)pyrrolidin-2-one (8.8 mg, yield: 9%) as a yellow solid.
11-1NMR (400 MHz, DMSO-d6) (52.05-2.15 (2H, m), 2.43 (2H, t, J= 8.0 Hz), 2.63 (2H, t, J=
6.4 Hz), 3.10-3.25 (4+3H, m), 3.58 (2H, t, J= 6.4 Hz), 3.60-3.70 (4H, m), 3.77 (2H, t, J= 7.2 Hz), 5.11 (2H, s), 6.73 (1H, s), 7.06 (1H, d, J= 6.8 Hz), 7.82 (1H, s), 7.86 (1H, d, J= 11.6 Hz), 7.93 (1H, d, J= 2.4 Hz), 8.34 (1H, d, J= 2.0 Hz), 8.71 (1H, s), 9.40 (1H, brs).
300 Example 172: 1-(9-fluoro-3-05-(4-(3-methoxypropanoyl)piperazin-1-yl)pyridin-3-yl)amino)-5-methyl-5H-chromeno14,3-c] pyridin-8-yl)pyrrolidin-2-one c 0 I
N
N
[0628] A
mixture of 1-(3-chl oro-9-fluoro-5 -methyl-5H-chromeno [4,3 -c] py ri din-8-yl)pyrrolidin-2-one (60 mg, 0.18 mmol), 1-(4-(5-aminopyridin-3-yOpiperazin-l-y1)-3-methoxypropan-1-one (81 mg, 0.22 mmol, HCl salt), Pd2(dba)3 (17 mg, 0.018 mmol), Brettphos (19 mg, 0.036 mmol) and Cs2CO3 (294 mg, 0.902 mmol) in anhydrous dioxane (3 mL) was degassed and purged with N2 for 3 times. Then the resulting reaction mixture was heated at 90 C for 16 hours under N2 atmosphere. The reaction mixture turned into brown from red. LCMS showed the purity of the desired product is 25% (Rt = 0.719 min; MS Calcd:
560.3; MS Found: 561.2 [M+H1+). To the reaction mixture was added water (25 mL), then extracted with Et0Ac/THF (25 mL x3, 1/1). The combined organic layer was washed with brine (25 mL), dried over anhydrous Na2SO4 and concentrated. The residue was purified by prep-HPLC (0.225% FA as an additive). Most of CH3CN was removed under reduced pressure and the remaining part was lyophilized to give 1-(9-fluoro-3-((5-(4-(3-methoxy propanoyl)pip erazin-1 -y Opy ri din-3 -y pamino)-5 -methyl-5H-chromeno [4,3-clpyridin-8-yOpyrrolidin-2-one (21.8 mg, yield: 22%) as a yellow solid.
11-1 NMR (400 MHz, DMSO-d6) 5 1.54 (3H, d, J= 6.8 Hz), 2.05-2.15 (2H, m), 2.44 (2H, t, J
= 8.4 Hz), 2.64 (2H, t, J= 6.8 Hz), 3.24 (3H, s), 3.30-3.40 (4H, m), 3.66 (2H, t, J= 6.4 Hz), 3.65-3.70 (4H, m), 3.75-3.80 (2H, m), 5.32 (1H, q, J= 6.4 Hz), 6.80 (1H, s), 7.08 (1H, d, J=
6.8 Hz), 7.90 (1H, d, J= 11.6 Hz), 7.95 (1H, s), 8.08 (1H, d, J= 2.4 Hz), 8.70 (1H, d, J= 1.6 Hz), 8.77 (1H, s), 10.04 (1H, brs).
Example 173: 1-(9-fluoro-3-05-(4-(3-methoxypropanoyl)piperazin-1-yl)pyridin-3-yl)amino)-5,5-dimethyl-5H-chromeno14,3-c] pyridin-8-yl)pyrrolidin-2-one
N
N
[0628] A
mixture of 1-(3-chl oro-9-fluoro-5 -methyl-5H-chromeno [4,3 -c] py ri din-8-yl)pyrrolidin-2-one (60 mg, 0.18 mmol), 1-(4-(5-aminopyridin-3-yOpiperazin-l-y1)-3-methoxypropan-1-one (81 mg, 0.22 mmol, HCl salt), Pd2(dba)3 (17 mg, 0.018 mmol), Brettphos (19 mg, 0.036 mmol) and Cs2CO3 (294 mg, 0.902 mmol) in anhydrous dioxane (3 mL) was degassed and purged with N2 for 3 times. Then the resulting reaction mixture was heated at 90 C for 16 hours under N2 atmosphere. The reaction mixture turned into brown from red. LCMS showed the purity of the desired product is 25% (Rt = 0.719 min; MS Calcd:
560.3; MS Found: 561.2 [M+H1+). To the reaction mixture was added water (25 mL), then extracted with Et0Ac/THF (25 mL x3, 1/1). The combined organic layer was washed with brine (25 mL), dried over anhydrous Na2SO4 and concentrated. The residue was purified by prep-HPLC (0.225% FA as an additive). Most of CH3CN was removed under reduced pressure and the remaining part was lyophilized to give 1-(9-fluoro-3-((5-(4-(3-methoxy propanoyl)pip erazin-1 -y Opy ri din-3 -y pamino)-5 -methyl-5H-chromeno [4,3-clpyridin-8-yOpyrrolidin-2-one (21.8 mg, yield: 22%) as a yellow solid.
11-1 NMR (400 MHz, DMSO-d6) 5 1.54 (3H, d, J= 6.8 Hz), 2.05-2.15 (2H, m), 2.44 (2H, t, J
= 8.4 Hz), 2.64 (2H, t, J= 6.8 Hz), 3.24 (3H, s), 3.30-3.40 (4H, m), 3.66 (2H, t, J= 6.4 Hz), 3.65-3.70 (4H, m), 3.75-3.80 (2H, m), 5.32 (1H, q, J= 6.4 Hz), 6.80 (1H, s), 7.08 (1H, d, J=
6.8 Hz), 7.90 (1H, d, J= 11.6 Hz), 7.95 (1H, s), 8.08 (1H, d, J= 2.4 Hz), 8.70 (1H, d, J= 1.6 Hz), 8.77 (1H, s), 10.04 (1H, brs).
Example 173: 1-(9-fluoro-3-05-(4-(3-methoxypropanoyl)piperazin-1-yl)pyridin-3-yl)amino)-5,5-dimethyl-5H-chromeno14,3-c] pyridin-8-yl)pyrrolidin-2-one
301 N NNTh N
[0629] A
mixture of 1-(3-chloro-9-fluoro-5,5-dimethy1-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one (60 mg, 0.17 mmol), 1-(4-(5-aminopyridin-3-yOpiperazin-l-y1)-3-methoxypropan-1-one (78 mg, 0.21 mmol, HCl salt), Pd2(dba)3 (16 mg, 0.017 mmol), Brettphos (19 mg, 0.035 mmol) and Cs2CO3 (282 mg, 0.865 mmol) in anhydrous dioxane (3 mL) was degassed and purged with N2 for 3 times. Then the resulting reaction mixture was heated at 90 C for 16 hours under N2 atmosphere. The reaction mixture turned into brown from red. LCMS showed the purity of the desired product is 20% (Rt = 0.742 min; MS Calcd:
574.3; MS Found: 575.3 [M+H]+). To the reaction mixture was added water (25 mL), then extracted with Et0Ac (25 mL x3). The combined organic layer was washed with brine (25 mL), dried over anhydrous Na2SO4 and concentrated. The residue was purified by prep-HPLC
(0.225% FA as an additive). Most of CH3CN was removed under reduced pressure and the remaining part was lyophilized to give 1-(9-fluoro-3-((5-(4-(3-methoxypropanoyl)piperazin-1-y Opy ri din-3-yl)amino)-5,5 -dimethy1-5H-chromeno [4,3 -c] py ri din-8-yl)pyrroli din-2-one (22.3 mg, yield: 22%) as a yellow solid.
11-1 NMR (400 MHz, DMSO-d6) 5 1.57 (6H, s), 2.05-2.15 (2H, m), 2.43 (2H, t, J=
8.0 Hz), 2.64 (2H, t, J= 6.8 Hz), 3.24 (3H, s), 3.30-3.40 (4H, m), 3.59 (2H, t, J = 6.4 Hz), 3.60-3.70 (4H, m), 3.78 (2H, d, J= 6.8 Hz), 6.83 (1H, s), 7.05 (1H, d, J= 6.8 Hz), 7.85-7.90 (2H, m), 8.02 (1H, d, J= 2.0 Hz), 8.53 (1H, s), 8.78 (1H, s), 9.77 (1H, brs).
Example 174: (E)-4-(4-(dimethylamino)but-2-enamido)-N-(5-((5-methyl-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-yl)benzamide N N
[0629] A
mixture of 1-(3-chloro-9-fluoro-5,5-dimethy1-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one (60 mg, 0.17 mmol), 1-(4-(5-aminopyridin-3-yOpiperazin-l-y1)-3-methoxypropan-1-one (78 mg, 0.21 mmol, HCl salt), Pd2(dba)3 (16 mg, 0.017 mmol), Brettphos (19 mg, 0.035 mmol) and Cs2CO3 (282 mg, 0.865 mmol) in anhydrous dioxane (3 mL) was degassed and purged with N2 for 3 times. Then the resulting reaction mixture was heated at 90 C for 16 hours under N2 atmosphere. The reaction mixture turned into brown from red. LCMS showed the purity of the desired product is 20% (Rt = 0.742 min; MS Calcd:
574.3; MS Found: 575.3 [M+H]+). To the reaction mixture was added water (25 mL), then extracted with Et0Ac (25 mL x3). The combined organic layer was washed with brine (25 mL), dried over anhydrous Na2SO4 and concentrated. The residue was purified by prep-HPLC
(0.225% FA as an additive). Most of CH3CN was removed under reduced pressure and the remaining part was lyophilized to give 1-(9-fluoro-3-((5-(4-(3-methoxypropanoyl)piperazin-1-y Opy ri din-3-yl)amino)-5,5 -dimethy1-5H-chromeno [4,3 -c] py ri din-8-yl)pyrroli din-2-one (22.3 mg, yield: 22%) as a yellow solid.
11-1 NMR (400 MHz, DMSO-d6) 5 1.57 (6H, s), 2.05-2.15 (2H, m), 2.43 (2H, t, J=
8.0 Hz), 2.64 (2H, t, J= 6.8 Hz), 3.24 (3H, s), 3.30-3.40 (4H, m), 3.59 (2H, t, J = 6.4 Hz), 3.60-3.70 (4H, m), 3.78 (2H, d, J= 6.8 Hz), 6.83 (1H, s), 7.05 (1H, d, J= 6.8 Hz), 7.85-7.90 (2H, m), 8.02 (1H, d, J= 2.0 Hz), 8.53 (1H, s), 8.78 (1H, s), 9.77 (1H, brs).
Example 174: (E)-4-(4-(dimethylamino)but-2-enamido)-N-(5-((5-methyl-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-yl)benzamide N N
302 Step 1:
Preparation of tert-butyl (4-((5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-yOcarbamoyl)phenyl)carbamate I I
N N 1\1 NHBoc [0630] To a mixture of 1-(3-((5-aminopyridin-3-y0amino)-5-methyl-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (400 mg, 0.944 mmol, HC1 salt) in pyridine (10 mL) was added 4-((tert-butoxycarbonyl)amino)benzoic acid (224 mg, 0.944 mmol) and EDC.HC1 (271 mg, 1.42 mmol), the reaction mixture was stirred at 50 C for 2 hours to give a brown solution. LCMS showed the purity of the desired product is 43% (Rt = 0.820 min; MS Calcd:
606.3; MS Found: 607.4 [M+H]+). The mixture was concentrated under reduced pressure to give a residue. The residue was purified by washing with DCM/Me0H (10 mL/5 mL) twice to give tert-butyl (4-((5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno [4,3-c]
py ri din-3-yl)amino)pyridin-3-yl)carbamoyl)phenyl)carbamate (300 mg, yield: 38%) as a brown solid.
11-1NMR (400 MHz, DMSO-d6) 6 1.51 (9H, s), 1.57 (3H, d, J= 6.4 Hz), 2.03-2.11 (2H, m), 2.49-2.51 (2H, m), 3.86 (2H, t, J= 8.0 Hz), 5.34 (1H, q, J= 6.8 Hz), 6.88 (1H, s), 7.35 (1H, dd, J = 8.8, 2.0 Hz), 7.42 (1H, d, J = 2.0 Hz), 7.65 (2H, d, J= 8.8 Hz), 7.93 (1H, d, J= 8.8 Hz), 7.98 (2H, d, J= 8.4 Hz), 8.75-8.82 (2H, m), 8.90 (1H, s), 9.10 (1H, s), 9.78 (1H, brs), 10.23 (1H, brs), 10.80 (1H, brs).
Step 2: Preparation of 4-amino-N-(5 -((5 -methyl-8-(2-oxopyrroli din-1 -y1)-5H-chromeno [4,3 -c] pyridin-3-yl)amino)pyridin-3-yl)benzamide gN 0 N N N
[0631] A mixture of tert-butyl (4-((5-((5-methyl-8-(2-oxopy rroli din-1 -y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-yOcarbamoyl)phenyl)carbamate (300 mg, 0.494 mmol) in Et0Ac (5 mL) was added HC1/Et0Ac (10 mL, 4 M in Et0Ac), the reaction mixture was stirred at 30 C for 2 hours to give a yellow suspension. LCMS
showed the purity
Preparation of tert-butyl (4-((5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-yOcarbamoyl)phenyl)carbamate I I
N N 1\1 NHBoc [0630] To a mixture of 1-(3-((5-aminopyridin-3-y0amino)-5-methyl-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (400 mg, 0.944 mmol, HC1 salt) in pyridine (10 mL) was added 4-((tert-butoxycarbonyl)amino)benzoic acid (224 mg, 0.944 mmol) and EDC.HC1 (271 mg, 1.42 mmol), the reaction mixture was stirred at 50 C for 2 hours to give a brown solution. LCMS showed the purity of the desired product is 43% (Rt = 0.820 min; MS Calcd:
606.3; MS Found: 607.4 [M+H]+). The mixture was concentrated under reduced pressure to give a residue. The residue was purified by washing with DCM/Me0H (10 mL/5 mL) twice to give tert-butyl (4-((5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno [4,3-c]
py ri din-3-yl)amino)pyridin-3-yl)carbamoyl)phenyl)carbamate (300 mg, yield: 38%) as a brown solid.
11-1NMR (400 MHz, DMSO-d6) 6 1.51 (9H, s), 1.57 (3H, d, J= 6.4 Hz), 2.03-2.11 (2H, m), 2.49-2.51 (2H, m), 3.86 (2H, t, J= 8.0 Hz), 5.34 (1H, q, J= 6.8 Hz), 6.88 (1H, s), 7.35 (1H, dd, J = 8.8, 2.0 Hz), 7.42 (1H, d, J = 2.0 Hz), 7.65 (2H, d, J= 8.8 Hz), 7.93 (1H, d, J= 8.8 Hz), 7.98 (2H, d, J= 8.4 Hz), 8.75-8.82 (2H, m), 8.90 (1H, s), 9.10 (1H, s), 9.78 (1H, brs), 10.23 (1H, brs), 10.80 (1H, brs).
Step 2: Preparation of 4-amino-N-(5 -((5 -methyl-8-(2-oxopyrroli din-1 -y1)-5H-chromeno [4,3 -c] pyridin-3-yl)amino)pyridin-3-yl)benzamide gN 0 N N N
[0631] A mixture of tert-butyl (4-((5-((5-methyl-8-(2-oxopy rroli din-1 -y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-yOcarbamoyl)phenyl)carbamate (300 mg, 0.494 mmol) in Et0Ac (5 mL) was added HC1/Et0Ac (10 mL, 4 M in Et0Ac), the reaction mixture was stirred at 30 C for 2 hours to give a yellow suspension. LCMS
showed the purity
303 of product is 73% (Rt = 0.737 min; MS Calcd: 506.2; MS Found: 507.5 [M+Hl+).
The mixture was concentrated under reduced pressure to give 4-amino-N-(5-((5-methy1-8-(2-oxopy rroli din-l-y1)-5H-chromeno [4,3 -c] py ri din-3-yl)amino)py ri din-3-yl)b enzami de (250 mg, crude, HC1 salt) as a yellow solid.
Step 3:
Preparation of (E)-4-(4-(dimethylamino)but-2-enamido)-N-(5-((5-methy1-8-(2-oxopy rroli din-l-y1)-5H-chromeno [4,3 -c] py ri din-3-yl)amino)py ri din-3-yl)b enzami de [0632] A mixture of 4-amino-N-(5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-yObenzamide (100 mg, 0.184 mmol, salt) in pyridine (5 mL) was added (E)-4-(dimethylamino)but-2-enoic acid (61 mg, 0.368 mmol, HC1 salt), EDCI (71 mg, 0.368 mmol) and 4 A molecular sieve (100 mg), the reaction mixture was stirred at 25 C for 4 hours to give a brown suspension. LCMS
showed the purity of product is 58% (Rt = 0.714 min; MS Calcd: 617.3; MS Found: 618.4 [M+Hl+).
The mixture was concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (0.05% NH3.H20 as an additive), 20 mg was obtained, but HNMR showed it is impure.
The impure product was further purified by prep-HPLC (0.225% FA as an additive) to give (E)-4-(4-(dimethylamino)but-2-enamido)-N-(5-((5-methy1-8-(2-oxopyrrolidin-l-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-yObenzamide (8.6 mg, yield for two steps:
8%) as a pale yellow solid.
NMR (400 MHz, DMSO-d6) 6 1.55 (3H, d, J= 6.4 Hz), 2.03-2.11 (2H, m), 2.49-2.51 (2H, m), 2.81 (6H, s), 3.85 (2H, t, J= 6.8 Hz), 3.98 (2H, d, J= 6.8 Hz), 5.28 (1H, q, J= 6.8 Hz), 6.52 (1H, d, J= 15.6 Hz), 6.71-6.86 (2H, m), 7.32 (1H, d, J= 8.8 Hz), 7.39 (1H, s), 7.74-7.89 (3H, m), 8.01 (2H, d, J= 8.0 Hz), 8.50 (1H, s), 8.62-8.73 (3H, m), 9.57 (1H, brs), 10.38 (1H, brs), 10.71 (1H, brs).
Example 175: 4-(4-(dimethylamino)butanamido)-N-(5-05-methyl-8-(2-oxopyrrolidin-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-yl)benzamide
The mixture was concentrated under reduced pressure to give 4-amino-N-(5-((5-methy1-8-(2-oxopy rroli din-l-y1)-5H-chromeno [4,3 -c] py ri din-3-yl)amino)py ri din-3-yl)b enzami de (250 mg, crude, HC1 salt) as a yellow solid.
Step 3:
Preparation of (E)-4-(4-(dimethylamino)but-2-enamido)-N-(5-((5-methy1-8-(2-oxopy rroli din-l-y1)-5H-chromeno [4,3 -c] py ri din-3-yl)amino)py ri din-3-yl)b enzami de [0632] A mixture of 4-amino-N-(5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-yObenzamide (100 mg, 0.184 mmol, salt) in pyridine (5 mL) was added (E)-4-(dimethylamino)but-2-enoic acid (61 mg, 0.368 mmol, HC1 salt), EDCI (71 mg, 0.368 mmol) and 4 A molecular sieve (100 mg), the reaction mixture was stirred at 25 C for 4 hours to give a brown suspension. LCMS
showed the purity of product is 58% (Rt = 0.714 min; MS Calcd: 617.3; MS Found: 618.4 [M+Hl+).
The mixture was concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (0.05% NH3.H20 as an additive), 20 mg was obtained, but HNMR showed it is impure.
The impure product was further purified by prep-HPLC (0.225% FA as an additive) to give (E)-4-(4-(dimethylamino)but-2-enamido)-N-(5-((5-methy1-8-(2-oxopyrrolidin-l-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-yObenzamide (8.6 mg, yield for two steps:
8%) as a pale yellow solid.
NMR (400 MHz, DMSO-d6) 6 1.55 (3H, d, J= 6.4 Hz), 2.03-2.11 (2H, m), 2.49-2.51 (2H, m), 2.81 (6H, s), 3.85 (2H, t, J= 6.8 Hz), 3.98 (2H, d, J= 6.8 Hz), 5.28 (1H, q, J= 6.8 Hz), 6.52 (1H, d, J= 15.6 Hz), 6.71-6.86 (2H, m), 7.32 (1H, d, J= 8.8 Hz), 7.39 (1H, s), 7.74-7.89 (3H, m), 8.01 (2H, d, J= 8.0 Hz), 8.50 (1H, s), 8.62-8.73 (3H, m), 9.57 (1H, brs), 10.38 (1H, brs), 10.71 (1H, brs).
Example 175: 4-(4-(dimethylamino)butanamido)-N-(5-05-methyl-8-(2-oxopyrrolidin-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-yl)benzamide
304 N- N,N 0 N)N
[0633] To a mixture of 1-(3-((5-aminopyridin-3-y0amino)-5-methyl-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (80 mg, 0.20 mmol, 0.13 HC1) and 4-(4-(dimethylamino)butanamido)benzoic acid (128 mg, 0.510 mmol) in pyridine (3 mL) was added EDCI (78 mg, 0.41 mmol) at 28 C. Then the reaction mixture was stirred at 28 C for 22 hours. A yellow solution was formed. LCMS showed that the purity of desired product is 95.8% (Rt = 0.600 min; MS Calcd: 619.2; MS Found: 620.1 [M+Hl+). The reaction mixture was concentrated to dryness. Then the residue was purified by prep-HPLC (0.1%
TFA as an additive) and lyophilized to give 4-(4-(dimethylamino)butanamido)-N-(5-45-methy1-8-(2-oxopy rroli din-l-y1)-5H-chromeno [4,3 -c] py ri din-3-yl)amino)py ri din-3-yl)b enzami de (23.6 mg, yield: 18%) as a yellow solid.
NMR (400 MHz, DMSO-d6) (51.56 (3H, d, J= 6.4 Hz), 1.91-2.01 (2H, m), 2.03-2.10 (2H, m), 2.47 (4H, m), 2.81 (6H, d, J= 3.6 Hz), 3.11 (2H, d, J= 4.8 Hz), 3.85 (2H, d, J= 7.2 Hz), 5.32 (1H, q, J = 6.4 Hz), 6.84 (1H, s), 7.35(1H, d, J= 8.4 Hz), 7.41 (1H, d, J= 2.0 Hz), 7.78 (2H, d, J= 8.8 Hz), 7.91 (1H, d, J= 3.6 Hz), 8.01 (2H, d, J= 8.8 Hz), 8.68 (1H, brs), 8.73 (1H, s), 8.85 (1H, s), 8.97 (1H, brs), 10.00 (1H, brs), 10.39 (1H, brs), 10.68 (1H, brs).
Example 176: (E)-4-(dimethylamino)-N-(3-(3-05-05-methyl-8-(2-oxopyrrolidin-l-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-yl)amino)-3-oxopropyl)phenyl)but-2-enamide I
NN
Step 1:
Preparation of tert-butyl (3-(3-((5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno [4,3-c] py ri din-3-y0amino)py ri din-3 -y Damino)-3 -oxopropy Opheny Ocarbamate
[0633] To a mixture of 1-(3-((5-aminopyridin-3-y0amino)-5-methyl-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (80 mg, 0.20 mmol, 0.13 HC1) and 4-(4-(dimethylamino)butanamido)benzoic acid (128 mg, 0.510 mmol) in pyridine (3 mL) was added EDCI (78 mg, 0.41 mmol) at 28 C. Then the reaction mixture was stirred at 28 C for 22 hours. A yellow solution was formed. LCMS showed that the purity of desired product is 95.8% (Rt = 0.600 min; MS Calcd: 619.2; MS Found: 620.1 [M+Hl+). The reaction mixture was concentrated to dryness. Then the residue was purified by prep-HPLC (0.1%
TFA as an additive) and lyophilized to give 4-(4-(dimethylamino)butanamido)-N-(5-45-methy1-8-(2-oxopy rroli din-l-y1)-5H-chromeno [4,3 -c] py ri din-3-yl)amino)py ri din-3-yl)b enzami de (23.6 mg, yield: 18%) as a yellow solid.
NMR (400 MHz, DMSO-d6) (51.56 (3H, d, J= 6.4 Hz), 1.91-2.01 (2H, m), 2.03-2.10 (2H, m), 2.47 (4H, m), 2.81 (6H, d, J= 3.6 Hz), 3.11 (2H, d, J= 4.8 Hz), 3.85 (2H, d, J= 7.2 Hz), 5.32 (1H, q, J = 6.4 Hz), 6.84 (1H, s), 7.35(1H, d, J= 8.4 Hz), 7.41 (1H, d, J= 2.0 Hz), 7.78 (2H, d, J= 8.8 Hz), 7.91 (1H, d, J= 3.6 Hz), 8.01 (2H, d, J= 8.8 Hz), 8.68 (1H, brs), 8.73 (1H, s), 8.85 (1H, s), 8.97 (1H, brs), 10.00 (1H, brs), 10.39 (1H, brs), 10.68 (1H, brs).
Example 176: (E)-4-(dimethylamino)-N-(3-(3-05-05-methyl-8-(2-oxopyrrolidin-l-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-yl)amino)-3-oxopropyl)phenyl)but-2-enamide I
NN
Step 1:
Preparation of tert-butyl (3-(3-((5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno [4,3-c] py ri din-3-y0amino)py ri din-3 -y Damino)-3 -oxopropy Opheny Ocarbamate
305 c 0 rN 0 N NN NHBoc [0634] To a mixture of 1-(3-((5-aminopyridin-3-y0amino)-5-methyl-5H-chromeno[4,3-c]pyridin-8-yOpyrrolidin-2-one (160 mg, 0.377 mmol, HC1 salt) in DMF (15 mL) was added 3-(3-((tert-butoxycarbonyl)amino)phenyl)propanoic acid (100 mg, 0.377 mmol), HOBt (102 mg, 0.754 mmol), EDCI (145 mg, 0.754 mmol) and TEA (114 mg, 1.13 mmol), the reaction mixture was stirred at 50 C for 2 hours to give a brown solution. LCMS showed the purity of the desired product is 48% (Rt = 0.769 min; MS Calcd: 634.3; MS Found:
635.2 [M+H1+). The mixture was diluted with water (15 mL), then extracted with Et0Ac (20 mL x2), the combined extracts was washed with brine (30 mL x2), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by Combi Flash (Et0Ac/Me0H = 100/1 to 95/5 to 10/1) to give tert-butyl (3-(3-((5-((5-methy1-8-(2-oxopy rroli din-l-y1)-5H-chromeno [4,3 -c] py ri din-3-yl)amino)py ri din-3 -yl)amino)-3-oxopropyl)phenyl)carbamate (100 mg, yield: 42%) as a yellow solid.
1FINMR (400 MHz, DMSO-d6) 6 1.47 (9H, s), 1.55 (3H, d, J= 6.8 Hz), 2.03-2.11 (2H, m), 2.49-2.51 (2H, m), 2.65-2.71 (2H, m), 2.89-2.93 (2H, m), 3.82-3.89 (2H, m), 5.31 (1H, q, J=
6.4 Hz), 6.82 (1H, s), 6.87 (1H, d, J= 7.2 Hz), 7.13-7.24 (2H, m), 7.35 (1H, dd, J= 8.4, 2.0 Hz), 7.41 (1H, d, J= 2.0 Hz), 7.46 (1H, s), 7.92 (1H, d, J= 8.8 Hz), 8.52 (1H, s), 8.60 (1H, d, J= 2.0 Hz), 8.71 (1H, s), 8.88 (1H, s), 9.30 (1H, brs), 9.95 (1H, brs), 10.54 (1H, brs).
Step 2: Preparation of 3-(3-aminopheny1)-N-(5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-y0amino)pyridin-3-y0propanamide ZIIIICYIIC1 ,N
I
[0635] A mixture of tert-butyl (3-(3-((5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-chromeno [4,3-c] py ri din-3-yl)amino)py ri din-3 -yl)amino)-3 -oxopropyl)phenyl)carbamate (100 mg, 0.158 mmol) in Et0Ac (5 mL) was added HC1/Et0Ac (5 mL, 4 M in Et0Ac), the reaction
635.2 [M+H1+). The mixture was diluted with water (15 mL), then extracted with Et0Ac (20 mL x2), the combined extracts was washed with brine (30 mL x2), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by Combi Flash (Et0Ac/Me0H = 100/1 to 95/5 to 10/1) to give tert-butyl (3-(3-((5-((5-methy1-8-(2-oxopy rroli din-l-y1)-5H-chromeno [4,3 -c] py ri din-3-yl)amino)py ri din-3 -yl)amino)-3-oxopropyl)phenyl)carbamate (100 mg, yield: 42%) as a yellow solid.
1FINMR (400 MHz, DMSO-d6) 6 1.47 (9H, s), 1.55 (3H, d, J= 6.8 Hz), 2.03-2.11 (2H, m), 2.49-2.51 (2H, m), 2.65-2.71 (2H, m), 2.89-2.93 (2H, m), 3.82-3.89 (2H, m), 5.31 (1H, q, J=
6.4 Hz), 6.82 (1H, s), 6.87 (1H, d, J= 7.2 Hz), 7.13-7.24 (2H, m), 7.35 (1H, dd, J= 8.4, 2.0 Hz), 7.41 (1H, d, J= 2.0 Hz), 7.46 (1H, s), 7.92 (1H, d, J= 8.8 Hz), 8.52 (1H, s), 8.60 (1H, d, J= 2.0 Hz), 8.71 (1H, s), 8.88 (1H, s), 9.30 (1H, brs), 9.95 (1H, brs), 10.54 (1H, brs).
Step 2: Preparation of 3-(3-aminopheny1)-N-(5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-y0amino)pyridin-3-y0propanamide ZIIIICYIIC1 ,N
I
[0635] A mixture of tert-butyl (3-(3-((5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-chromeno [4,3-c] py ri din-3-yl)amino)py ri din-3 -yl)amino)-3 -oxopropyl)phenyl)carbamate (100 mg, 0.158 mmol) in Et0Ac (5 mL) was added HC1/Et0Ac (5 mL, 4 M in Et0Ac), the reaction
306 mixture was stirred at 30 C for 2 hours to give a yellow suspension. LCMS
showed the purity of product is 88% (Rt = 0.682 min; MS Calcd: 534.2; MS Found: 535.0 [M+H1+).
The mixture was concentrated under reduced pressure to give 3-(3-aminopheny1)-N-(5-45-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno [4,3-c] pyridin-3-y0amino)pyridin-3-y0propanamide (90 mg, crude, HC1 salt) as a yellow solid.
Step 3: Preparation of (E)-4-(dimethy lamino)-N-(3 -(3-((5 -((5 -methyl-8-(2-oxopy rroli din-1-y 0-5H-chromeno [4,3 -c] pyri din-3-yl)amino)py ri din-3 -yl)amino)-3-oxopropyl)phenyl)but-2-enamide NN
[0636] A
mixture of 3 -(3 -aminopheny1)-N-(5 -((5-methyl-8-(2-oxopy rrolidin-1 -y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-y0propanamide (50 mg, 0.093 mmol) in pyridine (5 mL) was added (E)-4-(dimethylamino)but-2-enoic acid (31 mg, 0.19 mmol, HC1 salt), EDCI (36 mg, 0.19 mmol), the reaction mixture was stirred at 25 C for 1 hour to give a yellow suspension. LCMS showed the purity of product is 44% (Rt = 1.613 min;
MS Calcd:
645.3; MS Found: 646.3 [M+H1+). The mixture was concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (0.225% FA as an additive) to give (E)-4-(dimethylamino)-N-(3-(3 -methyl-8-(2-oxopy rroli din-l-y1)-5H-chromeno [4,3-clpyridin-3-yl)amino)pyridin-3-yl)amino)-3-oxopropyl)phenyl)but-2-enamide (11.4 mg, yield for two steps: 18%, FA salt) as a brown solid.
1-1-1NMR (400 MHz, DMSO-d6) 6 1.54(3H, d, J= 6.4 Hz), 2.03-2.11 (2H, m), 2.49-2.51 (2H, m), 2.68 (2H, t, J= 8.0 Hz), 2.75 (6H, s), 2.92 (2H, t, J= 8.0 Hz), 3.81-3.90 (4H, m), 5.27 (1H, q, J= 6.0 Hz), 6.45 (1H, d, J= 15.2 Hz), 6.67-6.75 (2H, m), 7.01 (1H, d, J= 7.2 Hz), 7.27 (1H, t, J= 8.0 Hz), 7.33 (1H, dd, J= 8.8, 2.0 Hz), 7.39 (1H, d, J= 2.4 Hz), 7.51 (1H, d, J= 8.8 Hz), 7.58 (1H, s), 7.89 (1H, d, J= 8.8 Hz), 8.33 (1H, s), 8.50 (1H, s), 8.58 (1H, s), 8.65 (1H, s), 9.46 (1H, brs), 10.11 (1H, brs), 10.27 (1H, brs).
showed the purity of product is 88% (Rt = 0.682 min; MS Calcd: 534.2; MS Found: 535.0 [M+H1+).
The mixture was concentrated under reduced pressure to give 3-(3-aminopheny1)-N-(5-45-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno [4,3-c] pyridin-3-y0amino)pyridin-3-y0propanamide (90 mg, crude, HC1 salt) as a yellow solid.
Step 3: Preparation of (E)-4-(dimethy lamino)-N-(3 -(3-((5 -((5 -methyl-8-(2-oxopy rroli din-1-y 0-5H-chromeno [4,3 -c] pyri din-3-yl)amino)py ri din-3 -yl)amino)-3-oxopropyl)phenyl)but-2-enamide NN
[0636] A
mixture of 3 -(3 -aminopheny1)-N-(5 -((5-methyl-8-(2-oxopy rrolidin-1 -y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-y0propanamide (50 mg, 0.093 mmol) in pyridine (5 mL) was added (E)-4-(dimethylamino)but-2-enoic acid (31 mg, 0.19 mmol, HC1 salt), EDCI (36 mg, 0.19 mmol), the reaction mixture was stirred at 25 C for 1 hour to give a yellow suspension. LCMS showed the purity of product is 44% (Rt = 1.613 min;
MS Calcd:
645.3; MS Found: 646.3 [M+H1+). The mixture was concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (0.225% FA as an additive) to give (E)-4-(dimethylamino)-N-(3-(3 -methyl-8-(2-oxopy rroli din-l-y1)-5H-chromeno [4,3-clpyridin-3-yl)amino)pyridin-3-yl)amino)-3-oxopropyl)phenyl)but-2-enamide (11.4 mg, yield for two steps: 18%, FA salt) as a brown solid.
1-1-1NMR (400 MHz, DMSO-d6) 6 1.54(3H, d, J= 6.4 Hz), 2.03-2.11 (2H, m), 2.49-2.51 (2H, m), 2.68 (2H, t, J= 8.0 Hz), 2.75 (6H, s), 2.92 (2H, t, J= 8.0 Hz), 3.81-3.90 (4H, m), 5.27 (1H, q, J= 6.0 Hz), 6.45 (1H, d, J= 15.2 Hz), 6.67-6.75 (2H, m), 7.01 (1H, d, J= 7.2 Hz), 7.27 (1H, t, J= 8.0 Hz), 7.33 (1H, dd, J= 8.8, 2.0 Hz), 7.39 (1H, d, J= 2.4 Hz), 7.51 (1H, d, J= 8.8 Hz), 7.58 (1H, s), 7.89 (1H, d, J= 8.8 Hz), 8.33 (1H, s), 8.50 (1H, s), 8.58 (1H, s), 8.65 (1H, s), 9.46 (1H, brs), 10.11 (1H, brs), 10.27 (1H, brs).
307 Example 177: 4-(dimethylamino)-N-(3-(3-05-05-methy1-8-(2-oxopyrrolidin-1-y1)-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-y1)amino)-3-oxopropyl)phenyl)butanamide NN
[0637] A
mixture of 3-(3-aminopheny1)-N-(5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-y1)amino)pyridin-3-y1)propanamide (130 mg, 0.243 mmol) in pyridine (5 mL) was added 4-(dimethylamino)butanoic acid (82 mg, 0.49 mmol, HC1 salt), EDCI (93 mg, 0.49 mmol), the reaction mixture was stirred at 25 C for 2 hours to give a yellow suspension. LCMS showed the purity of product is 55% (Rt = 1.590 min; MS
Calcd: 647.3;
MS Found: 648.3 [M+Hr). The mixture was concentrated under reduced pressure to give a crude product. Me0H (10 mL) was added. Some red solid was precipitated out and filtered.
The filtrate was concentrated under reduced pressure to give a residue. The residue was purified prep-HPLC (0.05% NH3.H20 as an additive) purification to give an impure product. The impure product was further purified by prep-HPLC (0.225% FA as an additive) to give 4-(dimethylamino)-N-(3 -(3-((5 -((5-methyl-8-(2-oxopy rroli din-1 -y1)-5H-chromeno [4,3 -c]pyridin-3-yl)amino)pyridin-3-yl)amino)-3-oxopropyl)phenyl)butanamide (14.0 mg, yield for two steps: 8%, 2 FA salt) as an orange solid.
1-1-1NMR (400 MHz, DMSO-d6) 6 1.54 (3H, d, J= 6.4 Hz), 1.65-1.74 (2H, m), 2.02-2.09 (2H, m), 2.14 (6H, s), 2.25 (2H, t, J= 7.2 Hz), 2.29-2.34 (2H, m), 2.49-2.51 (2H, m), 2.61-2.69 (2H, m), 2.88 (2H, t, J= 8.0 Hz), 3.84 (2H, t, J= 8.0 Hz), 5.27 (1H, q, J= 6.8 Hz), 6.75 (1H, s), 6.93 (1H, d, J= 6.8 Hz), 7.20 (1H, t, J= 8.0 Hz), 7.32 (1H, dd, J= 8.8, 2.0 Hz), 7.36-7.42 (2H, m), 7.54 (1H, s), 7.88 (1H, d, J= 8.8 Hz), 8.31 (1H, d, J= 2.4 Hz), 8.48 (1H, t, J= 2.0 Hz), 8.59 (1H, d, J= 2.0 Hz), 8.65 (1H, s), 9.44 (1H, brs), 9.86 (1H, brs), 10.09 (1H, brs).
Example 178: (E)-4-(dimethylamino)-N-(2-03-03-(5-05-methy1-8-(2-oxopyrrolidin-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-y1)-2-oxoimidazolidin-1-y1)methyl)phenyl)amino)-2-oxoethyl)but-2-enamide
[0637] A
mixture of 3-(3-aminopheny1)-N-(5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-y1)amino)pyridin-3-y1)propanamide (130 mg, 0.243 mmol) in pyridine (5 mL) was added 4-(dimethylamino)butanoic acid (82 mg, 0.49 mmol, HC1 salt), EDCI (93 mg, 0.49 mmol), the reaction mixture was stirred at 25 C for 2 hours to give a yellow suspension. LCMS showed the purity of product is 55% (Rt = 1.590 min; MS
Calcd: 647.3;
MS Found: 648.3 [M+Hr). The mixture was concentrated under reduced pressure to give a crude product. Me0H (10 mL) was added. Some red solid was precipitated out and filtered.
The filtrate was concentrated under reduced pressure to give a residue. The residue was purified prep-HPLC (0.05% NH3.H20 as an additive) purification to give an impure product. The impure product was further purified by prep-HPLC (0.225% FA as an additive) to give 4-(dimethylamino)-N-(3 -(3-((5 -((5-methyl-8-(2-oxopy rroli din-1 -y1)-5H-chromeno [4,3 -c]pyridin-3-yl)amino)pyridin-3-yl)amino)-3-oxopropyl)phenyl)butanamide (14.0 mg, yield for two steps: 8%, 2 FA salt) as an orange solid.
1-1-1NMR (400 MHz, DMSO-d6) 6 1.54 (3H, d, J= 6.4 Hz), 1.65-1.74 (2H, m), 2.02-2.09 (2H, m), 2.14 (6H, s), 2.25 (2H, t, J= 7.2 Hz), 2.29-2.34 (2H, m), 2.49-2.51 (2H, m), 2.61-2.69 (2H, m), 2.88 (2H, t, J= 8.0 Hz), 3.84 (2H, t, J= 8.0 Hz), 5.27 (1H, q, J= 6.8 Hz), 6.75 (1H, s), 6.93 (1H, d, J= 6.8 Hz), 7.20 (1H, t, J= 8.0 Hz), 7.32 (1H, dd, J= 8.8, 2.0 Hz), 7.36-7.42 (2H, m), 7.54 (1H, s), 7.88 (1H, d, J= 8.8 Hz), 8.31 (1H, d, J= 2.4 Hz), 8.48 (1H, t, J= 2.0 Hz), 8.59 (1H, d, J= 2.0 Hz), 8.65 (1H, s), 9.44 (1H, brs), 9.86 (1H, brs), 10.09 (1H, brs).
Example 178: (E)-4-(dimethylamino)-N-(2-03-03-(5-05-methy1-8-(2-oxopyrrolidin-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-y1)-2-oxoimidazolidin-1-y1)methyl)phenyl)amino)-2-oxoethyl)but-2-enamide
308 I I
N
NH-CH
1p 0 Step 1: Preparation of 1-(5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)py ridin-3-y1)-3-(3 -nitrobenzyl)imidazolidin-2-one NHN
I I
First batch:
[0638] To a mixture of 1-(3-amino-5 -methyl-5H-chromeno [4,3-c] pyri din-8-yl)py rroli din-2-one (80 mg, 0.24 mmol, HC1 salt) in dioxane (4 mL) was added 1-(5-bromopyridin-3-y1)-3-(3-nitrobenzyl)imidazolidin-2-one (109 mg, 0.289 mmol), Pd(dba)2 (14 mg, 0.024 mmol), Brettphos (13 mg, 0.024 mmol) and Cs2CO3 (196 mg, 0.603 mmol), the reaction mixture was purged in N2 atmosphere for 3 times and stirred at 50 C for 1 hour, then heated to 100 C
under N2 atmosphere and stirred for another 15 hours to give a yellow suspension. LCMS
showed the purity of the desired product is 70% (Rt = 0.762 min; MS Calcd:
591.2; MS
Found: 592.2 [M+H1+). The mixture was combined with next page.
Second batch:
[0639] To a mixture of 1-(3-amino-5 -methyl-5H-chromeno [4,3-c] pyri din-8-yl)py rroli din-2-one (400 mg, 1.21 mmol, HC1 salt) in dioxane (4 mL) was added 1-(5-bromopyridin-3-y1)-3-(3-nitrobenzyl)imidazolidin-2-one (546 mg, 1.45 mmol), Pd(dba)2 (69 mg, 0.12 mmol), Brettphos (65 mg, 0.12 mmol) and Cs2CO3 (786 mg, 2.41 mmol), the reaction mixture was purged in N2 atmosphere for 3 times and stirred at 50 C for 1 hour, then heated to 100 C
under N2 atmosphere and stirred for another 15 hours to give a yellow suspension. LCMS
showed the purity of the desired product is 84% (Rt = 0.762 min; MS Calcd:
591.2; MS
N
NH-CH
1p 0 Step 1: Preparation of 1-(5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)py ridin-3-y1)-3-(3 -nitrobenzyl)imidazolidin-2-one NHN
I I
First batch:
[0638] To a mixture of 1-(3-amino-5 -methyl-5H-chromeno [4,3-c] pyri din-8-yl)py rroli din-2-one (80 mg, 0.24 mmol, HC1 salt) in dioxane (4 mL) was added 1-(5-bromopyridin-3-y1)-3-(3-nitrobenzyl)imidazolidin-2-one (109 mg, 0.289 mmol), Pd(dba)2 (14 mg, 0.024 mmol), Brettphos (13 mg, 0.024 mmol) and Cs2CO3 (196 mg, 0.603 mmol), the reaction mixture was purged in N2 atmosphere for 3 times and stirred at 50 C for 1 hour, then heated to 100 C
under N2 atmosphere and stirred for another 15 hours to give a yellow suspension. LCMS
showed the purity of the desired product is 70% (Rt = 0.762 min; MS Calcd:
591.2; MS
Found: 592.2 [M+H1+). The mixture was combined with next page.
Second batch:
[0639] To a mixture of 1-(3-amino-5 -methyl-5H-chromeno [4,3-c] pyri din-8-yl)py rroli din-2-one (400 mg, 1.21 mmol, HC1 salt) in dioxane (4 mL) was added 1-(5-bromopyridin-3-y1)-3-(3-nitrobenzyl)imidazolidin-2-one (546 mg, 1.45 mmol), Pd(dba)2 (69 mg, 0.12 mmol), Brettphos (65 mg, 0.12 mmol) and Cs2CO3 (786 mg, 2.41 mmol), the reaction mixture was purged in N2 atmosphere for 3 times and stirred at 50 C for 1 hour, then heated to 100 C
under N2 atmosphere and stirred for another 15 hours to give a yellow suspension. LCMS
showed the purity of the desired product is 84% (Rt = 0.762 min; MS Calcd:
591.2; MS
309 Found: 592.2 [M+H1+). The mixture and the above batch were combined and filtered. The filter cake was washed with DCM (15 mL x2). The filtrate was concentrated under reduced pressure to give a residue. The residue was washed with Me0H/Et0Ac (1/2, 30 mL) to give 1-(5-((5-methy1-8-(2-oxopy rroli din-1 -y 0-5H-chromeno [4,3 -c] py ri din-3-y0amino)py ri din-3-y1)-3 -(3 -nitrobenzypimidazolidin-2-one (710 mg, average yield: 83%) as a yellow solid.
NMR (400 MHz, DMSO-d6) 6 1.54(3H, d, J= 6.4 Hz), 2.03-2.11 (2H, m), 2.49-2.51 (2H, m), 3.48 (2H, t, J= 8.0 Hz), 3.79-3.94 (4H, m), 4.58 (2H, s), 5.28 (1H, q, J=
6.8 Hz), 6.77 (1H, s), 7.32 (1H, dd, J= 8.8, 2.4 Hz), 7.40 (1H, d, J= 2.0 Hz), 7.70 (1H, t, J= 8.0 Hz), 7.82 (1H, d, J= 7.6 Hz), 7.89 (1H, d, J= 8.8 Hz), 8.14-8.20 (2H, m), 8.33 (1H, d, J= 2.4 Hz), 8.51 (1H, d, J= 2.0 Hz), 8.64 (1H, d, J= 2.0 Hz), 8.67 (1H, s), 9.47 (1H, brs).
Step 2:
Preparation of 1-(3-aminob enzy1)-3 -(5 -((5-methyl-8-(2-oxopy rroli din-1 -y1)-5H-chromeno [4,3-c] py ri din-3-y0amino)py ri din-3 -y dazoli din-2-one I I
NN N
[0640] A mixture of 1-(5-((5 -methyl-8-(2-oxopy rroli din-l-y1)-5H-chromeno [4,3 -clpyridin-3-y0amino)pyridin-3-y1)-3-(3-nitrobenzypimidazolidin-2-one (300 mg, 0.507 mmol) in THF (400 mL) was added Pd/C (100 mg, 10% purity, 50% wet), the resulting mixture was purged with H2 atmosphere for 3 times, then stirred at 25 C under H2 balloon (15 Psi) for 3 hours to give a black suspension. LCMS showed the purity of the desired product is 37%
(Rt = 0.715 min; MS Calcd: 561.3; MS Found: 562.5 [M+H1+). The mixture was filtered. The filtrate was concentrated under reduced pressure to give 1-(3-aminobenzy1)-3-(5-45-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-y0imidazolidin-2-one (220 mg, yield: 55%) as a yellow solid.
Step 3: Preparation of tert-butyl (2-((3 -((3 -(5 -((5-methyl-8-(2-oxopy rrolidin-1 -y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-y1)-2-oxoimidazolidin-1-yl)methyl)phenyl)amino)-2-oxoethyl)carbamate
NMR (400 MHz, DMSO-d6) 6 1.54(3H, d, J= 6.4 Hz), 2.03-2.11 (2H, m), 2.49-2.51 (2H, m), 3.48 (2H, t, J= 8.0 Hz), 3.79-3.94 (4H, m), 4.58 (2H, s), 5.28 (1H, q, J=
6.8 Hz), 6.77 (1H, s), 7.32 (1H, dd, J= 8.8, 2.4 Hz), 7.40 (1H, d, J= 2.0 Hz), 7.70 (1H, t, J= 8.0 Hz), 7.82 (1H, d, J= 7.6 Hz), 7.89 (1H, d, J= 8.8 Hz), 8.14-8.20 (2H, m), 8.33 (1H, d, J= 2.4 Hz), 8.51 (1H, d, J= 2.0 Hz), 8.64 (1H, d, J= 2.0 Hz), 8.67 (1H, s), 9.47 (1H, brs).
Step 2:
Preparation of 1-(3-aminob enzy1)-3 -(5 -((5-methyl-8-(2-oxopy rroli din-1 -y1)-5H-chromeno [4,3-c] py ri din-3-y0amino)py ri din-3 -y dazoli din-2-one I I
NN N
[0640] A mixture of 1-(5-((5 -methyl-8-(2-oxopy rroli din-l-y1)-5H-chromeno [4,3 -clpyridin-3-y0amino)pyridin-3-y1)-3-(3-nitrobenzypimidazolidin-2-one (300 mg, 0.507 mmol) in THF (400 mL) was added Pd/C (100 mg, 10% purity, 50% wet), the resulting mixture was purged with H2 atmosphere for 3 times, then stirred at 25 C under H2 balloon (15 Psi) for 3 hours to give a black suspension. LCMS showed the purity of the desired product is 37%
(Rt = 0.715 min; MS Calcd: 561.3; MS Found: 562.5 [M+H1+). The mixture was filtered. The filtrate was concentrated under reduced pressure to give 1-(3-aminobenzy1)-3-(5-45-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-y0imidazolidin-2-one (220 mg, yield: 55%) as a yellow solid.
Step 3: Preparation of tert-butyl (2-((3 -((3 -(5 -((5-methyl-8-(2-oxopy rrolidin-1 -y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-y1)-2-oxoimidazolidin-1-yl)methyl)phenyl)amino)-2-oxoethyl)carbamate
310 I
4¨NHBoc HN
1p 0 [0641] To a mixture of 1-(3-aminobenzy1)-3-(5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-y1)imidazolidin-2-one (220 mg, 0.392 mmol) in DMF (10 mL) was added Boc-gly-OH (343 mg, 1.96 mmol), TEA (159 mg, 1.57 mmol), EDCI
(225 mg, 1.18 mmol) and HOBt (159 mg, 1.18 mmol), the reaction mixture was stirred at 25 C for 2 hours to give a brown solution. LCMS showed the starting material was remained, then heated to 100 C and stirred for another 46 hours to give a brown solution. LCMS showed the purity of the desired product is 50% (Rt = 0.791 min; MS Calcd: 718.3; MS
Found: 719.4 [M+H1+). The mixture was extracted with Et0Ac (30 mL x2). The combined extracts was washed with brine (40 mL x2), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue and another batch E56958-291 were combined and purified by Combi Flash (DCM/Me0H = 100/1 to 95/5 to 10/1) to give tert-butyl (2-((3-((3-(5 -((5-methy1-8-(2-oxopy rroli din-1-y 0-5H-chromeno [4,3-c] py ridin-3 -y Damino)py ridin-3 -y1)-2-oxoimidazolidin-1-yl)methyl)phenyl)amino)-2-oxoethyl)carbamate (120 mg, average yield: 30%) as an off-white solid.
NMR (400 MHz, DMSO-d6) 6 1.38 (9H, s), 1.54 (3H, d, J= 6.4 Hz), 2.03-2.11 (2H, m), 2.49-2.51 (2H, m), 3.34-3.48 (2H, m), 3.71 (2H, d, J= 6.4 Hz), 3.80-3.94 (4H, m), 4.40 (2H, s), 5.28 (1H, q, J= 6.8 Hz), 6.41-6.52 (1H, m), 6.76 (1H, s), 6.95-7.09 (2H, m), 7.25-7.36 (2H, m), 7.40 (1H, d, J= 2.4 Hz), 7.51 (1H, s), 7.57 (1H, d, J= 8.4 Hz), 7.89 (1H, d, J= 8.8 Hz), 8.34 (1H, d, J= 2.0 Hz), 8.50 (1H, d, J= 2.0 Hz), 8.58-8.70 (1H, m), 9.45 (1H, brs), 9.96 (1H, brs).
Step 4:
Preparation of 2-amino-N-(3-((3-(5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-y1)-2-oxoimidazolidin-1-y1)methyl)phenyl)acetamide
4¨NHBoc HN
1p 0 [0641] To a mixture of 1-(3-aminobenzy1)-3-(5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-y1)imidazolidin-2-one (220 mg, 0.392 mmol) in DMF (10 mL) was added Boc-gly-OH (343 mg, 1.96 mmol), TEA (159 mg, 1.57 mmol), EDCI
(225 mg, 1.18 mmol) and HOBt (159 mg, 1.18 mmol), the reaction mixture was stirred at 25 C for 2 hours to give a brown solution. LCMS showed the starting material was remained, then heated to 100 C and stirred for another 46 hours to give a brown solution. LCMS showed the purity of the desired product is 50% (Rt = 0.791 min; MS Calcd: 718.3; MS
Found: 719.4 [M+H1+). The mixture was extracted with Et0Ac (30 mL x2). The combined extracts was washed with brine (40 mL x2), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue and another batch E56958-291 were combined and purified by Combi Flash (DCM/Me0H = 100/1 to 95/5 to 10/1) to give tert-butyl (2-((3-((3-(5 -((5-methy1-8-(2-oxopy rroli din-1-y 0-5H-chromeno [4,3-c] py ridin-3 -y Damino)py ridin-3 -y1)-2-oxoimidazolidin-1-yl)methyl)phenyl)amino)-2-oxoethyl)carbamate (120 mg, average yield: 30%) as an off-white solid.
NMR (400 MHz, DMSO-d6) 6 1.38 (9H, s), 1.54 (3H, d, J= 6.4 Hz), 2.03-2.11 (2H, m), 2.49-2.51 (2H, m), 3.34-3.48 (2H, m), 3.71 (2H, d, J= 6.4 Hz), 3.80-3.94 (4H, m), 4.40 (2H, s), 5.28 (1H, q, J= 6.8 Hz), 6.41-6.52 (1H, m), 6.76 (1H, s), 6.95-7.09 (2H, m), 7.25-7.36 (2H, m), 7.40 (1H, d, J= 2.4 Hz), 7.51 (1H, s), 7.57 (1H, d, J= 8.4 Hz), 7.89 (1H, d, J= 8.8 Hz), 8.34 (1H, d, J= 2.0 Hz), 8.50 (1H, d, J= 2.0 Hz), 8.58-8.70 (1H, m), 9.45 (1H, brs), 9.96 (1H, brs).
Step 4:
Preparation of 2-amino-N-(3-((3-(5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-y1)-2-oxoimidazolidin-1-y1)methyl)phenyl)acetamide
311 I I
N
HN
[0642] To a mixture of tert-butyl (2-((3-((3-(5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-y1)-2-oxoimidazolidin-1-y1)methyl)phenyl)amino)-2-oxoethyl)carbamate (120 mg, 0.167 mmol) in Et0Ac (10 mL) was added Et0Ac/HC1 (10 mL, 4 M in Et0Ac), the reaction was stirred at 25 C for 1 hour to give an off-white suspension. LCMS showed the purity of the desired product is 32%
(Rt = 1.565 min; MS Calcd: 618.3; MS Found: 619.2 [M+H1+). The mixture was concentrated under reduced pressure to give 2-amino-N-(3-((3 -(5 -((5-methyl-8-(2-oxopy rroli din-1 -y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-y1)-2-oxoimidazolidin-1-yl)methyl)phenyl)acetamide (100 mg, HC1 salt) as an off-white solid.
11-1NMR (400 MHz, DMSO-d6) 6 1.55 (3H, d, J= 6.4 Hz), 2.03-2.11 (2H, m), 2.49-2.51 (2H, m), 3.52-3.56 (2H, m), 3.74-3.80 (2H, m), 3.86 (2H, t, J= 7.6 Hz), 3.91-3.99 (2H, m), 4.46 (2H, s), 5.35 (1H, q, J= 6.4 Hz), 6.89 (1H, s), 7.08-7.12 (1H, m), 7.33-7.44 (3H, m), 7.55-7.61 (1H, m), 7.94 (1H, d, J= 8.8 Hz), 8.12-8.20 (1H, m), 8.65-8.72 (2H, m), 8.78 (1H, s), 9.14 (1H, s), 10.46 (1H, brs), 10.63 (1H, brs).
Note: Two active protons were not observed.
Step 5: Preparation of (E)-4-(dimethylamino)-N-(2-43-43-(5-45-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno [4,3-c] pyridin-3-y0amino)pyridin-3-y1)-2-oxoimidazolidin-1-yOmethyl)phenyl)amino)-2-oxoethyl)but-2-enamide 0 N¨
I
NN HN
N
NH H
11+ 0
N
HN
[0642] To a mixture of tert-butyl (2-((3-((3-(5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-y1)-2-oxoimidazolidin-1-y1)methyl)phenyl)amino)-2-oxoethyl)carbamate (120 mg, 0.167 mmol) in Et0Ac (10 mL) was added Et0Ac/HC1 (10 mL, 4 M in Et0Ac), the reaction was stirred at 25 C for 1 hour to give an off-white suspension. LCMS showed the purity of the desired product is 32%
(Rt = 1.565 min; MS Calcd: 618.3; MS Found: 619.2 [M+H1+). The mixture was concentrated under reduced pressure to give 2-amino-N-(3-((3 -(5 -((5-methyl-8-(2-oxopy rroli din-1 -y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-y1)-2-oxoimidazolidin-1-yl)methyl)phenyl)acetamide (100 mg, HC1 salt) as an off-white solid.
11-1NMR (400 MHz, DMSO-d6) 6 1.55 (3H, d, J= 6.4 Hz), 2.03-2.11 (2H, m), 2.49-2.51 (2H, m), 3.52-3.56 (2H, m), 3.74-3.80 (2H, m), 3.86 (2H, t, J= 7.6 Hz), 3.91-3.99 (2H, m), 4.46 (2H, s), 5.35 (1H, q, J= 6.4 Hz), 6.89 (1H, s), 7.08-7.12 (1H, m), 7.33-7.44 (3H, m), 7.55-7.61 (1H, m), 7.94 (1H, d, J= 8.8 Hz), 8.12-8.20 (1H, m), 8.65-8.72 (2H, m), 8.78 (1H, s), 9.14 (1H, s), 10.46 (1H, brs), 10.63 (1H, brs).
Note: Two active protons were not observed.
Step 5: Preparation of (E)-4-(dimethylamino)-N-(2-43-43-(5-45-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno [4,3-c] pyridin-3-y0amino)pyridin-3-y1)-2-oxoimidazolidin-1-yOmethyl)phenyl)amino)-2-oxoethyl)but-2-enamide 0 N¨
I
NN HN
N
NH H
11+ 0
312 [0643] To a mixture of 2-amino-N-(3-((3-(5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-y1)-2-oxoimidazolidin-1-y1)methyl)phenyl)acetamide (50 mg, 0.081 mmol) in pyridine (5 mL) was added (E)-4-(dimethylamino)but-2-enoic acid (54 mg, 0.32 mmol, HC1 salt), 4A molecular sieve (100 mg) and EDCI (31 mg, 0.161 mmol), the reaction mixture was stirred at 25 C
for 4 hours to give a red suspension. The reaction was repeated once. LCMS showed the purity of the desired product is 14% (Rt = 1.585 min; MS Calcd: 729.3; MS Found: 730.3 [M+H1+). The two batches were combined and filtered. The filter cake was washed with Me0H (10 mL x2). The filtrate was concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (0.1% TFA as an additive) to give (E)-4-(dimethylamino)-N-(2-((3-((3-(5-((5-methy1-8-(2-oxopy rroli din-1 -y 0-5H-chromeno [4,3 -c] py ri din-3-y0amino)py ri din-3 -y1)-2-oxoimidazolidin-1-yOmethyl)phenyl)amino)-2-oxoethyl)but-2-enamide (32.3 mg, yield for two steps: 21%, TFA salt) as an off-white solid.
11-1NMR (400 MHz, DMSO-d6) 6 1.54 (3H, d, J= 6.4 Hz), 2.02-2.13 (2H, m), 2.49-2.53 (2H, m), 2.78 (6H, s), 3.41-3.51 (2H, m), 3.84 (2H, t, J= 8.0 Hz), 3.90 (2H, t, J=
8.4 Hz), 3.97 (2H, d, J= 6.0 Hz), 4.31 (2H, s), 4.41 (2H, s), 5.31 (1H, q, J= 6.4 Hz), 6.11-6.20 (1H, m), 6.30 (1H, d, J= 11.6 Hz), 6.80 (1H, s), 7.03 (1H, d, J= 7.6 Hz), 7.30-7.36 (2H, m), 7.40 (1H, d, J= 2.0 Hz), 7.51-7.60 (2H, m), 7.91 (1H, d, J= 8.8 Hz), 8.54 (1H, d, J= 1.6 Hz), 8.58 (1H, d, J= 2.0 Hz), 8.70-8.76 (2H, m), 8.89 (1H, brs), 9.92 (1H, brs), 10.15 (1H, brs).
Example 179: (E)-4-(dimethylamino)-N-(2-04-03-(5-05-methy1-8-(2-oxopyrrolidin-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-y1)-2-oxoimidazolidin-1-yl)methyl)phenyl)amino)-2-oxoethyl)but-2-enamide NN N
o I I
1111 NC1)\--)1N\
Step 1: Preparation of tert-butyl (4-(hydroxymethyl)phenyl)carbamate NHBoc
for 4 hours to give a red suspension. The reaction was repeated once. LCMS showed the purity of the desired product is 14% (Rt = 1.585 min; MS Calcd: 729.3; MS Found: 730.3 [M+H1+). The two batches were combined and filtered. The filter cake was washed with Me0H (10 mL x2). The filtrate was concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (0.1% TFA as an additive) to give (E)-4-(dimethylamino)-N-(2-((3-((3-(5-((5-methy1-8-(2-oxopy rroli din-1 -y 0-5H-chromeno [4,3 -c] py ri din-3-y0amino)py ri din-3 -y1)-2-oxoimidazolidin-1-yOmethyl)phenyl)amino)-2-oxoethyl)but-2-enamide (32.3 mg, yield for two steps: 21%, TFA salt) as an off-white solid.
11-1NMR (400 MHz, DMSO-d6) 6 1.54 (3H, d, J= 6.4 Hz), 2.02-2.13 (2H, m), 2.49-2.53 (2H, m), 2.78 (6H, s), 3.41-3.51 (2H, m), 3.84 (2H, t, J= 8.0 Hz), 3.90 (2H, t, J=
8.4 Hz), 3.97 (2H, d, J= 6.0 Hz), 4.31 (2H, s), 4.41 (2H, s), 5.31 (1H, q, J= 6.4 Hz), 6.11-6.20 (1H, m), 6.30 (1H, d, J= 11.6 Hz), 6.80 (1H, s), 7.03 (1H, d, J= 7.6 Hz), 7.30-7.36 (2H, m), 7.40 (1H, d, J= 2.0 Hz), 7.51-7.60 (2H, m), 7.91 (1H, d, J= 8.8 Hz), 8.54 (1H, d, J= 1.6 Hz), 8.58 (1H, d, J= 2.0 Hz), 8.70-8.76 (2H, m), 8.89 (1H, brs), 9.92 (1H, brs), 10.15 (1H, brs).
Example 179: (E)-4-(dimethylamino)-N-(2-04-03-(5-05-methy1-8-(2-oxopyrrolidin-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-y1)-2-oxoimidazolidin-1-yl)methyl)phenyl)amino)-2-oxoethyl)but-2-enamide NN N
o I I
1111 NC1)\--)1N\
Step 1: Preparation of tert-butyl (4-(hydroxymethyl)phenyl)carbamate NHBoc
313 [0644] To a mixture of (4-aminophenyl)methanol (2.10 g, 17.1 mmol) in THF (30 mL) was added Boc20 (4.09 g, 18.8 mmol) and Na2CO3 (2.17 g, 20.5 mmol), the reaction mixture was stirred at 25 C for 12 hours to give a white suspension. TLC (PE/Et0Ac = 1/1) showed the reaction was completed. The mixture was filtered. The filter cake was washed with Et0Ac (10 mL x2). The filtrate was concentrated under reduced pressure to give a residue. The residue was purified by washing with PE (40 mL) to give tert-butyl (4-(hydroxymethyl)phenyl)carbamate (3.8 g, yield: 99 %) as a white solid.
11-1NMR (400 MHz, DMSO-d6) 6 1.48 (9H, s), 4.41 (2H, d, J= 4.8 Hz), 5.05 (1H, brs), 7.18 (2H, d, J= 8.4 Hz), 7.39 (2H, d, J= 8.4 Hz), 9.27 (1H, brs).
Step 2: Preparation of tert-butyl (4-(chloromethyl)phenyl)carbamate CI (00 NHBoc [0645] To a mixture of tert-butyl (4-(hydroxymethyl)phenyl)carbamate (2.00 g, 8.96 mmol), TEA (1.81 g, 17.9 mmol) in THF (30 mL) was added MsC1 (1.33 g, 11.6 mmol) dropwise at 0 C and stirred for 0.5 hour. Then warmed to 25 C and stirred for another 15.5 hours to give a yellow suspension. TLC (PE/Et0Ac = 5:1) showed the reaction was completed. The mixture was quenched with ice water (80 mL) slowly, then extracted with Et0Ac (60 mL x2), the combined extracts were washed with brine (80 mL
x2), dried over Na2SO4, filtered and concentrated under reduced pressure to give tert-butyl (4-(chloromethyl)phenyl)carbamate (2.16 g, crude) as a pale yellow gum.
Note: The product was instability in acid and silica gel. The product should be used directly without purification.
Step 3:
Preparation of tert-butyl (4-((3-(5-bromopyridin-3-y1)-2-oxoimidazolidin-1-yl)methyl)phenyl)carbamate Br 0 = NHBoc [0646] To a mixture of 1-(5-bromopyridin-3-yl)imidazolidin-2-one (800 mg, 3.30 mmol) in anhydrous DMF (15 mL) was added NaH (159 mg, 3.97 mmol, 60% dispersed in mineral oil) at 0 C in portions, the resulting mixture was stirred at 0 C
for 0.5 hours, then
11-1NMR (400 MHz, DMSO-d6) 6 1.48 (9H, s), 4.41 (2H, d, J= 4.8 Hz), 5.05 (1H, brs), 7.18 (2H, d, J= 8.4 Hz), 7.39 (2H, d, J= 8.4 Hz), 9.27 (1H, brs).
Step 2: Preparation of tert-butyl (4-(chloromethyl)phenyl)carbamate CI (00 NHBoc [0645] To a mixture of tert-butyl (4-(hydroxymethyl)phenyl)carbamate (2.00 g, 8.96 mmol), TEA (1.81 g, 17.9 mmol) in THF (30 mL) was added MsC1 (1.33 g, 11.6 mmol) dropwise at 0 C and stirred for 0.5 hour. Then warmed to 25 C and stirred for another 15.5 hours to give a yellow suspension. TLC (PE/Et0Ac = 5:1) showed the reaction was completed. The mixture was quenched with ice water (80 mL) slowly, then extracted with Et0Ac (60 mL x2), the combined extracts were washed with brine (80 mL
x2), dried over Na2SO4, filtered and concentrated under reduced pressure to give tert-butyl (4-(chloromethyl)phenyl)carbamate (2.16 g, crude) as a pale yellow gum.
Note: The product was instability in acid and silica gel. The product should be used directly without purification.
Step 3:
Preparation of tert-butyl (4-((3-(5-bromopyridin-3-y1)-2-oxoimidazolidin-1-yl)methyl)phenyl)carbamate Br 0 = NHBoc [0646] To a mixture of 1-(5-bromopyridin-3-yl)imidazolidin-2-one (800 mg, 3.30 mmol) in anhydrous DMF (15 mL) was added NaH (159 mg, 3.97 mmol, 60% dispersed in mineral oil) at 0 C in portions, the resulting mixture was stirred at 0 C
for 0.5 hours, then
314 added tert-butyl (4-(chloromethyl)phenyl)carbamate (1.08 g, 4.46 mmol) in anhydrous DMF
(5 mL) dropwise at 0 C and then warmed to 25 C and stirred for another 5.5 hours to give a pale yellow solution. The reaction was repeated once. LCMS showed the purity of product is 42% (Rt = 0.951 min; MS Calcd: 448.1; MS Found: 470.0[M+Nal+). The two batches were combined and poured into water (80 mL) slowly. Some white solid was precipitated out and filtered. The filter cake was dried in high vacuum to give a residue A. The filtrate was extracted with Et0Ac (50 mL x2), the combined extracts was washed with brine (80 mL x2), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue B.
The two residues were combined and purified by Combi Flash (PE/Et0Ac = 6/1 to 3/1 to 1/1) to give tert-butyl (4-((3-(5-bromopyridin-3-y1)-2-oxoimidazolidin-1-yl)methyl)phenyl)carbamate (2.18 g, yield for two steps: 58%) as a pale yellow gum.
Step 4:
Preparation of tert-butyl (4-((3-(5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-y1)-2-oxoimidazolidin-1-y1)methyl)phenyl)carbamate I r NHBoc [0647] To a mixture of 1-(3-amino-5 -methyl-5H-chromeno [4,3-c] pyri din-8-yl)py rroli din-2-one (99 mg, 0.34 mmol) in dioxane (4 mL) was added tert-butyl (4-((3-(5-bromopyridin-3-y1)-2-oxoimidazolidin-1-yl)methyl)phenyl)carbamate (150 mg, 0.34 mmol), Pd(dba)2 (19 mg, 0.034 mmol), Brettphos (18 mg, 0.034 mmol) and Cs2CO3 (219 mg, 0.671 mmol), the reaction mixture was purged in N2 atmosphere for 3 times and stirred at 50 C for 1 hour, then heated to 100 C under N2 atmosphere and stirred for another 15 hours to give a brown suspension. LCMS showed the purity of the desired product is 34% (Rt = 0.909 min; MS Calcd:
661.3; MS Found: 662.2 [M+Hl+). The mixture was filtered. The filter cake was washed with DCM (15 mL x2). The filtrate was concentrated under reduced pressure to give a residue. The residue was washed with Et0Ac/PE (30 mL, 2/1) twice to give tert-butyl (4-((3-(5-((5-methyl-8-(2-oxopyrroli din-1 -y 0-5H-chromeno [4,3 -c] py ri din-3 -yl)amino)py ri din-3 -y1)-2-oxoimidazolidin-1-yl)methyl)phenyl)carbamate (200 mg, yield: 90%) as a red solid.
(5 mL) dropwise at 0 C and then warmed to 25 C and stirred for another 5.5 hours to give a pale yellow solution. The reaction was repeated once. LCMS showed the purity of product is 42% (Rt = 0.951 min; MS Calcd: 448.1; MS Found: 470.0[M+Nal+). The two batches were combined and poured into water (80 mL) slowly. Some white solid was precipitated out and filtered. The filter cake was dried in high vacuum to give a residue A. The filtrate was extracted with Et0Ac (50 mL x2), the combined extracts was washed with brine (80 mL x2), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue B.
The two residues were combined and purified by Combi Flash (PE/Et0Ac = 6/1 to 3/1 to 1/1) to give tert-butyl (4-((3-(5-bromopyridin-3-y1)-2-oxoimidazolidin-1-yl)methyl)phenyl)carbamate (2.18 g, yield for two steps: 58%) as a pale yellow gum.
Step 4:
Preparation of tert-butyl (4-((3-(5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-y1)-2-oxoimidazolidin-1-y1)methyl)phenyl)carbamate I r NHBoc [0647] To a mixture of 1-(3-amino-5 -methyl-5H-chromeno [4,3-c] pyri din-8-yl)py rroli din-2-one (99 mg, 0.34 mmol) in dioxane (4 mL) was added tert-butyl (4-((3-(5-bromopyridin-3-y1)-2-oxoimidazolidin-1-yl)methyl)phenyl)carbamate (150 mg, 0.34 mmol), Pd(dba)2 (19 mg, 0.034 mmol), Brettphos (18 mg, 0.034 mmol) and Cs2CO3 (219 mg, 0.671 mmol), the reaction mixture was purged in N2 atmosphere for 3 times and stirred at 50 C for 1 hour, then heated to 100 C under N2 atmosphere and stirred for another 15 hours to give a brown suspension. LCMS showed the purity of the desired product is 34% (Rt = 0.909 min; MS Calcd:
661.3; MS Found: 662.2 [M+Hl+). The mixture was filtered. The filter cake was washed with DCM (15 mL x2). The filtrate was concentrated under reduced pressure to give a residue. The residue was washed with Et0Ac/PE (30 mL, 2/1) twice to give tert-butyl (4-((3-(5-((5-methyl-8-(2-oxopyrroli din-1 -y 0-5H-chromeno [4,3 -c] py ri din-3 -yl)amino)py ri din-3 -y1)-2-oxoimidazolidin-1-yl)methyl)phenyl)carbamate (200 mg, yield: 90%) as a red solid.
315 NMR (400 MHz, DMSO-d6) 6 1.47 (9H, s), 1.54 (3H, d, J= 6.4 Hz), 2.03-2.11 (2H, m), 2.49-2.51 (2H, m), 3.33-3.44 (2H, m), 3.79-3.90 (4H, m), 4.34 (2H, s), 5.27 (1H, q, J= 6.4 Hz), 6.76 (1H, s), 7.15-7.24 (2H, m), 7.29-7.34 (1H, m), 7.40 (1H, d, J= 2.0 Hz), 7.45 (2H, d, J= 8.4 Hz), 7.89 (1H, d, J= 8.8 Hz), 8.32 (1H, d, J= 2.0 Hz), 8.48 (1H, d, J= 2.0 Hz), 8.62 (1H, d, J= 2.0 Hz), 8.67 (1H, s), 9.35 (1H, brs), 9.45 (1H, brs).
Step 5:
Preparation of 1-(4-aminob enzy1)-3 -(5 -((5-methyl-8-(2-oxopy rroli din-1 -y1)-5H-chromeno [4,3-c] py ri din-3-y0amino)py ri din-3 -y dazoli din-2-one I
N NH
[0648] To a mixture of tert-butyl (4-((3-(5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-y1)-2-oxoimidazolidin-1-y1)methyl)phenyl)carbamate (200 mg, 0.302 mmol) in Et0Ac (5 mL) was added HC1/Et0Ac (20 mL, 4 M in Et0Ac), the reaction mixture was stirred at 25 C for 4 hours to give a yellow suspension. LCMS showed the purity of the desired product is 47% (Rt =1.658 min; MS Calcd:
561.3; MS Found: 562.2 [M+H1+). The mixture was concentrated under reduced pressure to give 1-(4-aminob enzy1)-3-(5-((5 -methyl-8-(2-oxopyrrol idin-1 -y1)-5H-chromeno [4,3-clpyridin-3-y0amino)pyridin-3-y0imidazolidin-2-one (200 mg, crude, HC1 salt) as a yellow solid.
NMR (400 MHz, DMSO-d6) 6 1.55 (3H, d, J= 6.4 Hz), 2.03-2.11 (2H, m), 2.49-2.51 (2H, m), 3.33-3.44 (2H, m), 3.83 (2H, t, J= 7.6 Hz), 3.94 (2H, t, J= 6.8 Hz), 4.48 (2H, s), 5.35 (1H, q, J= 6.4 Hz), 6.90 (1H, s), 7.31-7.41 (3H, m), 7.42-7.50 (4H, m), 7.94 (1H, d, J= 8.8 Hz), 8.64-8.71 (2H, m), 8.78 (1H, s), 9.19 (1H, brs).
Note: Two active protons were not observed.
Step 6:
Preparation of tert-butyl (2-44-43-(5-45-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-y1)-2-oxoimidazolidin-1-y1)methyl)phenyl)amino)-2-oxoethyl)carbamate
Step 5:
Preparation of 1-(4-aminob enzy1)-3 -(5 -((5-methyl-8-(2-oxopy rroli din-1 -y1)-5H-chromeno [4,3-c] py ri din-3-y0amino)py ri din-3 -y dazoli din-2-one I
N NH
[0648] To a mixture of tert-butyl (4-((3-(5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-y1)-2-oxoimidazolidin-1-y1)methyl)phenyl)carbamate (200 mg, 0.302 mmol) in Et0Ac (5 mL) was added HC1/Et0Ac (20 mL, 4 M in Et0Ac), the reaction mixture was stirred at 25 C for 4 hours to give a yellow suspension. LCMS showed the purity of the desired product is 47% (Rt =1.658 min; MS Calcd:
561.3; MS Found: 562.2 [M+H1+). The mixture was concentrated under reduced pressure to give 1-(4-aminob enzy1)-3-(5-((5 -methyl-8-(2-oxopyrrol idin-1 -y1)-5H-chromeno [4,3-clpyridin-3-y0amino)pyridin-3-y0imidazolidin-2-one (200 mg, crude, HC1 salt) as a yellow solid.
NMR (400 MHz, DMSO-d6) 6 1.55 (3H, d, J= 6.4 Hz), 2.03-2.11 (2H, m), 2.49-2.51 (2H, m), 3.33-3.44 (2H, m), 3.83 (2H, t, J= 7.6 Hz), 3.94 (2H, t, J= 6.8 Hz), 4.48 (2H, s), 5.35 (1H, q, J= 6.4 Hz), 6.90 (1H, s), 7.31-7.41 (3H, m), 7.42-7.50 (4H, m), 7.94 (1H, d, J= 8.8 Hz), 8.64-8.71 (2H, m), 8.78 (1H, s), 9.19 (1H, brs).
Note: Two active protons were not observed.
Step 6:
Preparation of tert-butyl (2-44-43-(5-45-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-y1)-2-oxoimidazolidin-1-y1)methyl)phenyl)amino)-2-oxoethyl)carbamate
316 I I
N
NHBoc [0649] To a mixture of 1-(4-aminobenzy1)-3-(5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-y0imidazolidin-2-one (200 mg, 0.334 mmol, HC1 salt) in DMF (10 mL) was added Boc-gly-OH (293 mg, 1.67 mmol), TEA (135 mg, 1.34 mmol), EDCI (192 mg, 1.00 mmol) and HOBt (136 mg, 1.00 mmol), the reaction mixture was stirred at 25 C for 1 hour to give a brown suspension. Then heated to 100 C
and stirred for another 15 hours to give a brown suspension. LCMS showed the purity of the desired product is 28% (Rt = 0.868 min; MS Calcd: 718.3; MS Found: 719.2 [M+H1+). The mixture was quenched with water (20 mL). Some brown solid was precipitated out and filtered. The filter cake was dried in high vacuum to give a residue. The residue was purified by washing with Et0Ac (15 mL) twice to give tert-butyl (2-((4-((3-(5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno [4,3-c] py ridin-3 -yl)amino)py ri din-3-y1)-2-oxoimi dazoli din-1-yl)methyl)phenyl)amino)-2-oxoethyl)carbamate (150 mg, yield for two steps:
69%) as a brown solid.
Step 7:
Preparation of 2-amino-N-(4-((3 -(5-((5-methyl-8-(2-oxopy rroli din-1 -y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-y1)-2-oxoimidazolidin-1-yl)methyl)phenyl)acetamide tNHN
I I
L' NH2 [0650] To a mixture of tert-butyl (2-((4-((3-(5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-y1)-2-oxoimidazolidin-1-
N
NHBoc [0649] To a mixture of 1-(4-aminobenzy1)-3-(5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-y0imidazolidin-2-one (200 mg, 0.334 mmol, HC1 salt) in DMF (10 mL) was added Boc-gly-OH (293 mg, 1.67 mmol), TEA (135 mg, 1.34 mmol), EDCI (192 mg, 1.00 mmol) and HOBt (136 mg, 1.00 mmol), the reaction mixture was stirred at 25 C for 1 hour to give a brown suspension. Then heated to 100 C
and stirred for another 15 hours to give a brown suspension. LCMS showed the purity of the desired product is 28% (Rt = 0.868 min; MS Calcd: 718.3; MS Found: 719.2 [M+H1+). The mixture was quenched with water (20 mL). Some brown solid was precipitated out and filtered. The filter cake was dried in high vacuum to give a residue. The residue was purified by washing with Et0Ac (15 mL) twice to give tert-butyl (2-((4-((3-(5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno [4,3-c] py ridin-3 -yl)amino)py ri din-3-y1)-2-oxoimi dazoli din-1-yl)methyl)phenyl)amino)-2-oxoethyl)carbamate (150 mg, yield for two steps:
69%) as a brown solid.
Step 7:
Preparation of 2-amino-N-(4-((3 -(5-((5-methyl-8-(2-oxopy rroli din-1 -y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-y1)-2-oxoimidazolidin-1-yl)methyl)phenyl)acetamide tNHN
I I
L' NH2 [0650] To a mixture of tert-butyl (2-((4-((3-(5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-y1)-2-oxoimidazolidin-1-
317 yl)methyl)phenyl)amino)-2-oxoethyl)carbamate (150 mg, 0.208 mmol) in Et0Ac (5 mL) was added HC1/Et0Ac (15 mL, 4 M in Et0Ac), the reaction mixture was stirred at 25 C for 4 hours to give a brown suspension. LCMS showed the purity of product is 47% (Rt = 0.824 min;
MS Calcd: 619.3; MS Found: 620.1 [M+H1+). The mixture was concentrated under reduced pressure to give a residue. The residue was washed with Et0Ac (10 mL) to give 2-amino-N-(4-((3-(5-((5-methy1-8-(2-oxopy rroli din-1-y 0-5H-chromeno [4,3 -c] py ri din-yl)amino)pyridin-3-y1)-2-oxoimidazolidin- 1-yl)methyl)phenyl)acetamide (120 mg, crude, HC1 salt) as a yellow solid.
Step 8: Preparation of (E)-4-(dimethylamino)-N-(2-44-43-(5-45-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno [4,3-c] pyridin-3-y0amino)pyridin-3-y1)-2-oxoimidazolidin-1-yOmethyl)phenyl)amino)-2-oxoethyl)but-2-enamide N
o N 3\3\1 [0651] To a mixture of 2-amino-N-(4-((3-(5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-y1)-2-oxoimidazolidin-1-y1)methyl)phenyl)acetamide (60 mg, 0.092 mmol, HC1 salt) in DMF (5 mL) was added (E)-4-(dimethylamino)but-2-enoic acid (30 mg, 0.18 mmol, HC1 salt), HOBt (25 mg, 0.18 mmol), TEA (28 mg, 0.27 mmol) and EDCI (35 mg, 0.18 mmol), the reaction mixture was stirred at 25 C for 2 hours to give a brown suspension. The reaction was repeated once.
LCMS showed the purity of product is 31% (Rt = 0.847 min; MS Calcd: 729.3; MS Found: 753.2 [M+Nal+). The two batches were combined and diluted with water (20 mL), then extracted with DCM (25 mL x2), the combined extracts was washed with brine (40 mL x2), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue.
The residue was purified by prep-HPLC (0.225% FA as an additive) to give (E)-4-(dimethylamino)-N-(2-((4-((3-(5-((5 -methy1-8-(2-oxopy rroli din-1 -y1)-5H-chromeno [4,3 -c] py ri din-3-y Damino)pyri din-3-y1)-2-oxoimidazolidin-1-yOmethyl)phenyl)amino)-2-oxoethyl)but-2-enamide (14.8 mg, yield for two steps: 10%) as a yellow solid.
MS Calcd: 619.3; MS Found: 620.1 [M+H1+). The mixture was concentrated under reduced pressure to give a residue. The residue was washed with Et0Ac (10 mL) to give 2-amino-N-(4-((3-(5-((5-methy1-8-(2-oxopy rroli din-1-y 0-5H-chromeno [4,3 -c] py ri din-yl)amino)pyridin-3-y1)-2-oxoimidazolidin- 1-yl)methyl)phenyl)acetamide (120 mg, crude, HC1 salt) as a yellow solid.
Step 8: Preparation of (E)-4-(dimethylamino)-N-(2-44-43-(5-45-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno [4,3-c] pyridin-3-y0amino)pyridin-3-y1)-2-oxoimidazolidin-1-yOmethyl)phenyl)amino)-2-oxoethyl)but-2-enamide N
o N 3\3\1 [0651] To a mixture of 2-amino-N-(4-((3-(5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-clpyridin-3-y0amino)pyridin-3-y1)-2-oxoimidazolidin-1-y1)methyl)phenyl)acetamide (60 mg, 0.092 mmol, HC1 salt) in DMF (5 mL) was added (E)-4-(dimethylamino)but-2-enoic acid (30 mg, 0.18 mmol, HC1 salt), HOBt (25 mg, 0.18 mmol), TEA (28 mg, 0.27 mmol) and EDCI (35 mg, 0.18 mmol), the reaction mixture was stirred at 25 C for 2 hours to give a brown suspension. The reaction was repeated once.
LCMS showed the purity of product is 31% (Rt = 0.847 min; MS Calcd: 729.3; MS Found: 753.2 [M+Nal+). The two batches were combined and diluted with water (20 mL), then extracted with DCM (25 mL x2), the combined extracts was washed with brine (40 mL x2), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue.
The residue was purified by prep-HPLC (0.225% FA as an additive) to give (E)-4-(dimethylamino)-N-(2-((4-((3-(5-((5 -methy1-8-(2-oxopy rroli din-1 -y1)-5H-chromeno [4,3 -c] py ri din-3-y Damino)pyri din-3-y1)-2-oxoimidazolidin-1-yOmethyl)phenyl)amino)-2-oxoethyl)but-2-enamide (14.8 mg, yield for two steps: 10%) as a yellow solid.
318 NMR (400 MHz, DMSO-d6) 6 1.53 (3H, d, J= 6.4 Hz), 2.02-2.13 (2H, m), 2.49-2.53 (2H, m), 2.71 (6H, s), 3.46-3.49 (2H, m), 3.81-3.91 (6H, m), 4.00 (2H, d, J= 5.6 Hz), 4.36 (2H, s), 5.27 (1H, q, J= 6.8 Hz), 6.36 (1H, d, J= 15.6 Hz), 6.55-6.64 (1H, m), 6.76 (1H, s), 7.26 (2H, d, J= 8.4 Hz), 7.31 (1H, dd, J= 8.0, 2.4 Hz), 7.39 (1H, d, J= 1.6 Hz), 7.58 (2H, d, J= 8.8 Hz), 7.88 (1H, d, J= 8.4 Hz), 8.32 (1H, d, J= 1.6 Hz), 8.49 (1H, s), 8.59-8.68 (3H, m), 9.46 (1H, brs), 10.11 (1H, brs).
Example 180: (6aR)-2-05-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)-6,6a,7,8-tetrahydro-9H-pyrido [2,3-b] pyrrolo [1,2-d] [1,4] oxazin-9-one ciN 0 0ii I N 0 I ol-1 N N N
Step 1: Preparation of (R)-5-(((3-bromo-5-nitropyridin-2-yl)oxy)methyl)pyrrolidin-2-one 'N+ Br O-[0652] To a suspension of (R)-5-(hydroxymethyl)pyrrolidin-2-one (5.00 g, 43.4 mmol), 3-bromo-2-chloro-5-nitropyridine (11.3 g, 47.8 mmol) and K2CO3(7.80 g, 56.4 mmol) in CH3CN
(100 mL) was heated at 100 C for 16 hours under N2 atmosphere. The reaction mixture turned into brown suspension from yellow. LCMS showed the purity of the desired product is 57%
(Rt = 0.609 min; MS Calcd: 316.1; MS Found: 316.7 [M+H1+). The reaction mixture was filtered and the solid was washed with CH3CN (50 mL x4). The filtrate was concentrated. The residue was purified by Combi Flash (20% to 100% Et0Ac in PE) to give (R)-5-(((3-bromo-5-nitropyridin-2-yl)oxy)methyl)pyrrolidin-2-one (10.8 g, yield: 79%) as a black brown solid.
1H NMR 1(400 MHz, CDC13) (51.96-2.04 (1H, m), 2.03-2.15 (2H, m), 2.42-2.57 (1H, m), 4.12 (1H, d, J= 3.6 Hz), 4.30 (1H, dd, J= 10.8, 7.6 Hz), 4.63 (1H, dd, J=
10.8, 3.6 Hz), 6.0 (1H, brs), 8.65 (1H, d, J= 2.4 Hz). 8.98 (1H, d, J= 2.4 Hz).
Example 180: (6aR)-2-05-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)-6,6a,7,8-tetrahydro-9H-pyrido [2,3-b] pyrrolo [1,2-d] [1,4] oxazin-9-one ciN 0 0ii I N 0 I ol-1 N N N
Step 1: Preparation of (R)-5-(((3-bromo-5-nitropyridin-2-yl)oxy)methyl)pyrrolidin-2-one 'N+ Br O-[0652] To a suspension of (R)-5-(hydroxymethyl)pyrrolidin-2-one (5.00 g, 43.4 mmol), 3-bromo-2-chloro-5-nitropyridine (11.3 g, 47.8 mmol) and K2CO3(7.80 g, 56.4 mmol) in CH3CN
(100 mL) was heated at 100 C for 16 hours under N2 atmosphere. The reaction mixture turned into brown suspension from yellow. LCMS showed the purity of the desired product is 57%
(Rt = 0.609 min; MS Calcd: 316.1; MS Found: 316.7 [M+H1+). The reaction mixture was filtered and the solid was washed with CH3CN (50 mL x4). The filtrate was concentrated. The residue was purified by Combi Flash (20% to 100% Et0Ac in PE) to give (R)-5-(((3-bromo-5-nitropyridin-2-yl)oxy)methyl)pyrrolidin-2-one (10.8 g, yield: 79%) as a black brown solid.
1H NMR 1(400 MHz, CDC13) (51.96-2.04 (1H, m), 2.03-2.15 (2H, m), 2.42-2.57 (1H, m), 4.12 (1H, d, J= 3.6 Hz), 4.30 (1H, dd, J= 10.8, 7.6 Hz), 4.63 (1H, dd, J=
10.8, 3.6 Hz), 6.0 (1H, brs), 8.65 (1H, d, J= 2.4 Hz). 8.98 (1H, d, J= 2.4 Hz).
319 Step 2:
Preparation of (R)-2-nitro-6,6a,7,8-tetrahydro-9H-pyrido[2,3-b]pyrrolo[1,2-d] [1,4] oxazin-9-one ,CCH
O.
N+ N
o-[0653] To a mixture of (R)-5-(((3-bromo-5-nitropyridin-2-yl)oxy)methyl)pyrrolidin-2-one (10.8 g, 34.2 mmol), CuI (1.95 g, 10.2 mmol) and Cs2CO3 (14.5 g, 44.4 mmol) in anhydrous dioxane (200 mL) was added N,N-dimethylethane-1,2-diamine (2.21 mL, 34.2 mmol).
Then the reaction mixture was degassed and purged with N2 for three times and stirred at 100 C for 20 hours under N2 atmosphere. A brown suspension was formed. LCMS showed the purity of the desired product is 78% (Rt = 0.521 min; MS Calcd: 235.2; MS
Found: 235.9 [M+Hl+). The reaction mixture was filtered through a pad of celite and washed with dioxane (50 mL x3). The filtrate was concentrated under reduced pressure. The residue was purified by Combi Flash (20% to 50% Et0Ac in DCM) to give (R)-2-nitro-6,6a,7,8-tetrahydro-9H-pyrido[2,3-blpyrrolo[1,2-d][1,41oxazin-9-one (4.30 g, yield: 54%) as a yellow solid.
1FINMR (400 MHz, CDC13) (51.77-1.86 (1H, m), 2.38-2.48 (1H, m), 2.59-2.69 (1H, m), 2.71-2.82 (1H, m), 3.97-4.06 (1H, m) 4.09-4.18 (1H, m), 4.81 (1H, dd, J= 3.2, 1.6 Hz), 8.86-8.90 (1H, m), 9.54-9.59 (1H, m).
Step 3:
Preparation of (R)-2-amino-6,6a,7,8-tetrahydro-9H-pyrido[2,3-b]pyrrolo[1,2-d] [1,4] oxazin-9-one N
[0654] A mixture of (R)-2-nitro-6,6a,7,8-tetrahy dro-9H-py ri do [2,3 -b] py rrol o [1,2-d] [1,41oxazin-9-one (4.30 g, 18.3 mmol) and Pd/C (800 mg, 10% purity in charcoal) in THF
(200 mL) was degassed and purged with H2 for 3 times. Then the reaction mixture was hydrogenated with a H2 balloon (15 psi) at 25 C for 3 hours. A black suspension was formed. LCMS showed the purity of the desired product is 54% (Rt = 0.325 min;
MS Calcd:
205.2; MS Found: 205.9 [M+Hl+). The reaction mixture was filtered and the solid was washed with DCM (25 mL x3). The filtrate was concentrated under reduced pressure. The residue was purified by Combi Flash (20% to 80% Et0Ac in DCM), then triturated with PE/Et0Ac (20
Preparation of (R)-2-nitro-6,6a,7,8-tetrahydro-9H-pyrido[2,3-b]pyrrolo[1,2-d] [1,4] oxazin-9-one ,CCH
O.
N+ N
o-[0653] To a mixture of (R)-5-(((3-bromo-5-nitropyridin-2-yl)oxy)methyl)pyrrolidin-2-one (10.8 g, 34.2 mmol), CuI (1.95 g, 10.2 mmol) and Cs2CO3 (14.5 g, 44.4 mmol) in anhydrous dioxane (200 mL) was added N,N-dimethylethane-1,2-diamine (2.21 mL, 34.2 mmol).
Then the reaction mixture was degassed and purged with N2 for three times and stirred at 100 C for 20 hours under N2 atmosphere. A brown suspension was formed. LCMS showed the purity of the desired product is 78% (Rt = 0.521 min; MS Calcd: 235.2; MS
Found: 235.9 [M+Hl+). The reaction mixture was filtered through a pad of celite and washed with dioxane (50 mL x3). The filtrate was concentrated under reduced pressure. The residue was purified by Combi Flash (20% to 50% Et0Ac in DCM) to give (R)-2-nitro-6,6a,7,8-tetrahydro-9H-pyrido[2,3-blpyrrolo[1,2-d][1,41oxazin-9-one (4.30 g, yield: 54%) as a yellow solid.
1FINMR (400 MHz, CDC13) (51.77-1.86 (1H, m), 2.38-2.48 (1H, m), 2.59-2.69 (1H, m), 2.71-2.82 (1H, m), 3.97-4.06 (1H, m) 4.09-4.18 (1H, m), 4.81 (1H, dd, J= 3.2, 1.6 Hz), 8.86-8.90 (1H, m), 9.54-9.59 (1H, m).
Step 3:
Preparation of (R)-2-amino-6,6a,7,8-tetrahydro-9H-pyrido[2,3-b]pyrrolo[1,2-d] [1,4] oxazin-9-one N
[0654] A mixture of (R)-2-nitro-6,6a,7,8-tetrahy dro-9H-py ri do [2,3 -b] py rrol o [1,2-d] [1,41oxazin-9-one (4.30 g, 18.3 mmol) and Pd/C (800 mg, 10% purity in charcoal) in THF
(200 mL) was degassed and purged with H2 for 3 times. Then the reaction mixture was hydrogenated with a H2 balloon (15 psi) at 25 C for 3 hours. A black suspension was formed. LCMS showed the purity of the desired product is 54% (Rt = 0.325 min;
MS Calcd:
205.2; MS Found: 205.9 [M+Hl+). The reaction mixture was filtered and the solid was washed with DCM (25 mL x3). The filtrate was concentrated under reduced pressure. The residue was purified by Combi Flash (20% to 80% Et0Ac in DCM), then triturated with PE/Et0Ac (20
320 mL, 1/1), to give (R)-2-amino-6,6a,7,8-tetrahydro-9H-pyrido[2,3-blpyrrolo[1,2-d] [1,41oxazin-9-one (2.08 g, yield: 55%) as a yellow solid.
NMR (400 MHz, DMSO-d6 ) (51.59-1.70 (1H, m), 2.15-2.19 (1H, m), 2.31-2.39 (1H, m), 2.58-2.68 (1H, m), 3.73-3.80 (1H, m), 3.98-4.02 (1H, m), 4.47 (1H, dd, J= 9.2, 3.2 Hz), 4.98 (2H, brs), 7.26 (1H, d, J= 2.8 Hz), 8.11 (1H, d, J= 2.8 Hz) Step 4:
Preparation of compound (6aR)-2-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno [4,3-c] py ri din-3 -y0amino)-6,6a,7,8-tetrahy dro-9H-py ri do [2,3 -b] pyrrol o [1,2-d] [1,4] oxazin-9-one ii I I ol-1 N N- -N
mixture of 1-(3 -chloro-5-methyl-5H-chromeno [4,3-c] py ri din-8-yl)py rroli din-2-one (60 mg, 0.19 mmol), (R)-2-amino-6,6a,7,8-tetrahydro-9H-pyrido[2,3-blpyrrolo[1,2-d][1,41oxazin-9-one (50 mg, 0.25 mmol), Pd2(dba)3 (17 mg, 0.019 mmol), Cs2CO3 (124 mg, 0.381 mmol), Brettphos (20 mg, 0.038 mmol) in anhydrous dioxane (3 mL) was degassed and purged with N2 for 3 times. Then the resulting reaction mixture was heated at 90 C for 16 hours under N2 atmosphere. The reaction mixture turned into yellow suspension from red. LCMS showed the purity of the desired product is 36% (Rt = 0.586 min; MS
Calcd: 483.2;
MS Found: 484.2 [M+Hl+). The reaction mixture was diluted with H20 (5 mL), EA
(5 mL) and extracted with THF (50 mL x4). The combined organic layers were dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to give a residue.
The residue was purified by HPLC (0.225% FA as an additive) and lyophlizated to give (6aR)-2-((5-methy1-8-(2-oxopy rroli din-l-y1)-5H-chromeno [4,3 -c] py ri din-3-y0amino)-6,6a,7,8-tetrahy dro-9H-pyrido[2,3-blpyrrolo[1,2-d][1,41oxazin-9-one (26.5 mg, yield: 29%) as a yellow solid.
NMR (400 MHz, DMSO-d6) (5 1.52 (3H, d, J= 6.4 Hz), 1.66-1.74 (1H, m), 2.02-2.08 (2H, m), 2.18-2.27 (1H, m), 2.35-2.41 (1H, m), 2.48 (2H, overlapped with DMSO), 2.65-2.70 (1H, m), 3.83 (2H, t, J= 7.2 Hz), 3.90 (1H, t, J=10.4 Hz), 4.03-4.11 (1H, m), 4.58 (1H, dd, J=
10.8, 2.8 Hz), 5.24 (1H, q, J= 6.4 Hz), 6.68 (1H, s), 7.29 (1H, dd, J= 7.6, 2.0 Hz), 7.38 (1H, d, J= 2.0 Hz), 7.85 (1H, d, J= 8.8 Hz), 8.36 (1H, t, J= 2.0 Hz), 8.58 (1H, s), 8.97 (1H, t, J=
2.8 Hz), 9.31 (1H, brs).
NMR (400 MHz, DMSO-d6 ) (51.59-1.70 (1H, m), 2.15-2.19 (1H, m), 2.31-2.39 (1H, m), 2.58-2.68 (1H, m), 3.73-3.80 (1H, m), 3.98-4.02 (1H, m), 4.47 (1H, dd, J= 9.2, 3.2 Hz), 4.98 (2H, brs), 7.26 (1H, d, J= 2.8 Hz), 8.11 (1H, d, J= 2.8 Hz) Step 4:
Preparation of compound (6aR)-2-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno [4,3-c] py ri din-3 -y0amino)-6,6a,7,8-tetrahy dro-9H-py ri do [2,3 -b] pyrrol o [1,2-d] [1,4] oxazin-9-one ii I I ol-1 N N- -N
mixture of 1-(3 -chloro-5-methyl-5H-chromeno [4,3-c] py ri din-8-yl)py rroli din-2-one (60 mg, 0.19 mmol), (R)-2-amino-6,6a,7,8-tetrahydro-9H-pyrido[2,3-blpyrrolo[1,2-d][1,41oxazin-9-one (50 mg, 0.25 mmol), Pd2(dba)3 (17 mg, 0.019 mmol), Cs2CO3 (124 mg, 0.381 mmol), Brettphos (20 mg, 0.038 mmol) in anhydrous dioxane (3 mL) was degassed and purged with N2 for 3 times. Then the resulting reaction mixture was heated at 90 C for 16 hours under N2 atmosphere. The reaction mixture turned into yellow suspension from red. LCMS showed the purity of the desired product is 36% (Rt = 0.586 min; MS
Calcd: 483.2;
MS Found: 484.2 [M+Hl+). The reaction mixture was diluted with H20 (5 mL), EA
(5 mL) and extracted with THF (50 mL x4). The combined organic layers were dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to give a residue.
The residue was purified by HPLC (0.225% FA as an additive) and lyophlizated to give (6aR)-2-((5-methy1-8-(2-oxopy rroli din-l-y1)-5H-chromeno [4,3 -c] py ri din-3-y0amino)-6,6a,7,8-tetrahy dro-9H-pyrido[2,3-blpyrrolo[1,2-d][1,41oxazin-9-one (26.5 mg, yield: 29%) as a yellow solid.
NMR (400 MHz, DMSO-d6) (5 1.52 (3H, d, J= 6.4 Hz), 1.66-1.74 (1H, m), 2.02-2.08 (2H, m), 2.18-2.27 (1H, m), 2.35-2.41 (1H, m), 2.48 (2H, overlapped with DMSO), 2.65-2.70 (1H, m), 3.83 (2H, t, J= 7.2 Hz), 3.90 (1H, t, J=10.4 Hz), 4.03-4.11 (1H, m), 4.58 (1H, dd, J=
10.8, 2.8 Hz), 5.24 (1H, q, J= 6.4 Hz), 6.68 (1H, s), 7.29 (1H, dd, J= 7.6, 2.0 Hz), 7.38 (1H, d, J= 2.0 Hz), 7.85 (1H, d, J= 8.8 Hz), 8.36 (1H, t, J= 2.0 Hz), 8.58 (1H, s), 8.97 (1H, t, J=
2.8 Hz), 9.31 (1H, brs).
321 Example 181: (6aR)-2-09-fluoro-5-methyl-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c] pyridin-3-yl)amino)-6,6a,7,8-tetrahydro-9H-pyrido [2,3-b] pyrrolo[1,2-d]
[1,4] oxazin-9-one ii I 0 N 0 N N
[0656] A mixture of 1-(3-chloro-9-fluoro-5-methy1-5H-chromeno[4,3-clpyridin-8-yl)pyrrolidin-2-one (60 mg, 0.18 mmol), (R)-2-amino-6,6a,7,8-tetrahydro-9H-pyrido[2,3-blpyrrolo[1,2-d][1,41oxazin-9-one (48 mg, 0.23 mmol), Pd2(dba)3 (16 mg, 0.018 mmol), Brettphos (19 mg, 0.036 mmol) and Cs2CO3 (117 mg, 0.360 mmol) in anhydrous dioxane (3 mL) was degassed and purged with N2 for 3 times. Then the resulting reaction mixture was heated at 90 C for 16 hours under N2 atmosphere. The reaction mixture turned into yellow suspension from red. Crude LCMS showed the purity of the desired product is 30% (Rt = 0.603 min; MS Calcd: 501.5; MS Found: 502.1 [M+Hl+). The reaction mixture was diluted with water (20 mL), Et0Ac (20 mL) and separated. The aqueous layer was extracted with Et0Ac/THF (20 mL x3, 1/1). The combined organic layer was washed with brine (25 mL), dried over anhydrous Na2SO4 and concentrated. The residue was purified by prep-HPLC (0.225% FA as an additive) and lyophlized to give a impure product further purified by pre-TLC (DCM/Me0H, 30/1) and lyophilized to give (6aR)-2-((9-fluoro-5-methy1-8-(2-oxopy rroli din-l-y1)-5H-chromeno [4,3 -c] py ri din-3-yl)amino)-6,6a,7,8-tetrahy dro-9H-pyrido[2,3-b] pyrrolo[1,2-d] [1,41oxazin-9-one (15.1 mg, yield: 17%) as an off-white solid.
NMR (400 MHz, DMSO-d6) 5 1.52 (3H, d, J= 6.8 Hz), 1.64-1.76 (1H, m), 2.07-2.15 (2H, m), 2.18-2.27 (1H, m), 2.35-2.46 (3H, m), 2.60-2.72 (1H, m), 3.71-3.81 (2H, m), 3.90 (1H, t, J= 10.4 Hz), 4.07 (1H, m), 4.58 (1H, dd, J= 10.8, 2.8 Hz), 5.25 (1H, q, J= 6.8 Hz), 6.67 (1H, s), 7.04 (1H, d, J= 6.8 Hz), 7.85 (1H, d, J= 11.6 Hz), 8.38 (1H, d, J=
2.8 Hz), 8.64 (1H, s), 8.96 (1H, t, J= 2.8 Hz), 9.37 (1H, d, J= 1.2 Hz), Example 182: (R)-2-08-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)-6,6a,7,8-tetrahydro-9H-pyrido[2,3-b]pyrrolo [1,2-d] [1,4] oxazin-9-one
[1,4] oxazin-9-one ii I 0 N 0 N N
[0656] A mixture of 1-(3-chloro-9-fluoro-5-methy1-5H-chromeno[4,3-clpyridin-8-yl)pyrrolidin-2-one (60 mg, 0.18 mmol), (R)-2-amino-6,6a,7,8-tetrahydro-9H-pyrido[2,3-blpyrrolo[1,2-d][1,41oxazin-9-one (48 mg, 0.23 mmol), Pd2(dba)3 (16 mg, 0.018 mmol), Brettphos (19 mg, 0.036 mmol) and Cs2CO3 (117 mg, 0.360 mmol) in anhydrous dioxane (3 mL) was degassed and purged with N2 for 3 times. Then the resulting reaction mixture was heated at 90 C for 16 hours under N2 atmosphere. The reaction mixture turned into yellow suspension from red. Crude LCMS showed the purity of the desired product is 30% (Rt = 0.603 min; MS Calcd: 501.5; MS Found: 502.1 [M+Hl+). The reaction mixture was diluted with water (20 mL), Et0Ac (20 mL) and separated. The aqueous layer was extracted with Et0Ac/THF (20 mL x3, 1/1). The combined organic layer was washed with brine (25 mL), dried over anhydrous Na2SO4 and concentrated. The residue was purified by prep-HPLC (0.225% FA as an additive) and lyophlized to give a impure product further purified by pre-TLC (DCM/Me0H, 30/1) and lyophilized to give (6aR)-2-((9-fluoro-5-methy1-8-(2-oxopy rroli din-l-y1)-5H-chromeno [4,3 -c] py ri din-3-yl)amino)-6,6a,7,8-tetrahy dro-9H-pyrido[2,3-b] pyrrolo[1,2-d] [1,41oxazin-9-one (15.1 mg, yield: 17%) as an off-white solid.
NMR (400 MHz, DMSO-d6) 5 1.52 (3H, d, J= 6.8 Hz), 1.64-1.76 (1H, m), 2.07-2.15 (2H, m), 2.18-2.27 (1H, m), 2.35-2.46 (3H, m), 2.60-2.72 (1H, m), 3.71-3.81 (2H, m), 3.90 (1H, t, J= 10.4 Hz), 4.07 (1H, m), 4.58 (1H, dd, J= 10.8, 2.8 Hz), 5.25 (1H, q, J= 6.8 Hz), 6.67 (1H, s), 7.04 (1H, d, J= 6.8 Hz), 7.85 (1H, d, J= 11.6 Hz), 8.38 (1H, d, J=
2.8 Hz), 8.64 (1H, s), 8.96 (1H, t, J= 2.8 Hz), 9.37 (1H, d, J= 1.2 Hz), Example 182: (R)-2-08-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)-6,6a,7,8-tetrahydro-9H-pyrido[2,3-b]pyrrolo [1,2-d] [1,4] oxazin-9-one
322 gN
ii I I
N N HI\n [0657] A
mixture of 1-(3-chloro-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one (60 mg, 0.20 mmol), (R)-2-amino-6,6a,7,8-tetrahydro-9H-pyrido[2,3-blpyrrolo[1,2-d][1,41oxazin-9-one (53 mg, 0.26 mmol), Bretiphos (21 mg, 0.040 mmol), Pd2(dba)3 (18 mg, 0.020 mmol) and Cs2CO3 (130 mg, 0.399 mmol) in anhydrous dioxane (3 mL) was degassed and purged with N2 for 3 times. Then the resulting reaction mixture was heated at 90 C
for 16 hours under N2 atmosphere. The reaction mixture turned into yellow suspension from red.
Crude LCMS showed the purity of the desired product is 15% (Rt = 0.583 min; MS
Calcd: 469.5; MS
Found: 470.1 [M+Hl+). The reaction mixture was diluted with water (20 mL) and Et0Ac (20 mL). The aqueous layer was extracted with Et0Ac/THF (20 mL x3, 1/1). The combined organic layer was washed with brine (25 mL), dried over anhydrous Na2SO4 and concentrated.
The residue was purified by prep-HPLC (0.225% FA as an additive) and lyophilized to give (R)-2-((8-(2-oxopyrrolidin-1 -y1)-5H-chromeno [4,3 -c] pyridin-3-y0amino)-6,6a,7,8-tetrahydro-9H-pyrido[2,3-blpyrrolo[1,2-d][1,41oxazin-9-one (10.1 mg, yield:
11%) as a yellow solid.
1-1-1NMR (400 MHz, DMSO-d6) 5 1.70 (1H, t, J= 10.8 Hz), 2.07 (2H, d, J= 7.2 Hz), 2.22 (1H, d, J= 10.0 Hz), 2.35 (3H, over lapped with DMSO), 2.68 (1H, s), 3.82-3.86 (3H, m), 4.07 (1H, d, J= 8.0 Hz), 4.69 (1H, d, J= 10.4 Hz), 5.08 (2H, s), 6.66 (1H, s), 7.33 (1H, d, J=
8.4 Hz), 7.37 (1H, s), 7.86 (1H, d, J= 8.4 Hz), 8.40 (1H, s), 8.58 (1H, s), 8.96 (1H, s), 9.30 (1H, brs), Example 183: (R)-2-05,5-dimethy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)-6,6a,7,8-tetrahydro-9H-pyrido[2,3-b]pyrrolo[1,2-d]
11,41oxazin-9-one
ii I I
N N HI\n [0657] A
mixture of 1-(3-chloro-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one (60 mg, 0.20 mmol), (R)-2-amino-6,6a,7,8-tetrahydro-9H-pyrido[2,3-blpyrrolo[1,2-d][1,41oxazin-9-one (53 mg, 0.26 mmol), Bretiphos (21 mg, 0.040 mmol), Pd2(dba)3 (18 mg, 0.020 mmol) and Cs2CO3 (130 mg, 0.399 mmol) in anhydrous dioxane (3 mL) was degassed and purged with N2 for 3 times. Then the resulting reaction mixture was heated at 90 C
for 16 hours under N2 atmosphere. The reaction mixture turned into yellow suspension from red.
Crude LCMS showed the purity of the desired product is 15% (Rt = 0.583 min; MS
Calcd: 469.5; MS
Found: 470.1 [M+Hl+). The reaction mixture was diluted with water (20 mL) and Et0Ac (20 mL). The aqueous layer was extracted with Et0Ac/THF (20 mL x3, 1/1). The combined organic layer was washed with brine (25 mL), dried over anhydrous Na2SO4 and concentrated.
The residue was purified by prep-HPLC (0.225% FA as an additive) and lyophilized to give (R)-2-((8-(2-oxopyrrolidin-1 -y1)-5H-chromeno [4,3 -c] pyridin-3-y0amino)-6,6a,7,8-tetrahydro-9H-pyrido[2,3-blpyrrolo[1,2-d][1,41oxazin-9-one (10.1 mg, yield:
11%) as a yellow solid.
1-1-1NMR (400 MHz, DMSO-d6) 5 1.70 (1H, t, J= 10.8 Hz), 2.07 (2H, d, J= 7.2 Hz), 2.22 (1H, d, J= 10.0 Hz), 2.35 (3H, over lapped with DMSO), 2.68 (1H, s), 3.82-3.86 (3H, m), 4.07 (1H, d, J= 8.0 Hz), 4.69 (1H, d, J= 10.4 Hz), 5.08 (2H, s), 6.66 (1H, s), 7.33 (1H, d, J=
8.4 Hz), 7.37 (1H, s), 7.86 (1H, d, J= 8.4 Hz), 8.40 (1H, s), 8.58 (1H, s), 8.96 (1H, s), 9.30 (1H, brs), Example 183: (R)-2-05,5-dimethy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)-6,6a,7,8-tetrahydro-9H-pyrido[2,3-b]pyrrolo[1,2-d]
11,41oxazin-9-one
323 =====, ii I
I .0H
[0658] A mixture of 1 -(3-chl oro-5,5-dimethy1-5H-chromeno [4,3-c] py ri din-8-yl)pyrrolidin-2-one (60 mg, 0.18 mmol), (R)-2-amino-6,6a,7,8-tetrahydro-9H-pyrido[2,3-blpyrrolo[1,2-d][1,4loxazin-9-one (48 mg, 0.24 mmol), Pd2(dba)3 (16 mg, 0.018 mmol), Brettphos (19 mg, 0.036 mmol) and Cs2CO3 (118 mg, 0.364 mmol) in anhydrous dioxane (3 mL) was degassed and purged with N2 for 3 times. Then the resulting reaction mixture was heated at 90 C for 16 hours under N2 atmosphere. The reaction mixture turned into yellow suspension from red. Crude LCMS showed the purity of the desired product is 47% (Rt = 0.610 min; MS Calcd: 497.5; MS Found: 498.1 [M+H]+). The reaction mixture was diluted with water (20 mL) and Et0Ac (20 mL). The aqueous layer was extracted with Et0Ac/THF (20 mL
x3, 1/1). The combined organic layer was washed with brine (25 mL), dried over anhydrous Na2SO4 and concentrated. The residue was purified by prep-HPLC (0.225% FA as an additive) and lyophilized to give a impure product. It was further purified by prep-TLC
(DCM/Me0H, 30/1) and lyophilized to give (R)-2-((5,5-dimethy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno [4,3-c] py ri din-3 -y0amino)-6,6a,7,8-tetrahy dro-9H-py ri do [2,3 -b] pyrrol o [1,2-d][1,4loxazin-9-one (23.5 mg, yield: 26%) as a yellow solid.
11-1NMR (400 MHz, DMSO-d6) 5 1.55 (6H, s), 1.70 (1H, t, J= 10.8 Hz), 2.06 (2H, t, J= 3.6 Hz), 2.22-2.25 (1H, m), 2.41(1H, t, J= 8.0 Hz), 2.49 (2H, over lapped with DMSO), 2.65-2.74 (1H, m), 3.86 (2H, t, J=10.8 Hz), 3.90 (1H, t, J= 10.4 Hz), 4.05-4.10 (1H, m), 4.58 (1H, dd, J= 10.8, 2.8 Hz), 6.75 (1H, s), 7.28 (1H, dd, J= 8.8, 2.4 Hz), 7.39 (1H, d, J=6.4 Hz), 7.87 (1H, d, J= 8.8 Hz), 8.37(1H, d, J=2.8 Hz), 8.60 (1H, s), 8.97(1H, d, J=2.8 Hz), 9.28 (1H, brs), Example 184: (R)-2-09-fluoro-5,5-dimethy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c] pyridin-3-yl)amino)-6,6a,7,8-tetrahydro-9H-pyrido [2,3-b] pyrrolo[1,2-d]
[1,4] oxazin-9-one
I .0H
[0658] A mixture of 1 -(3-chl oro-5,5-dimethy1-5H-chromeno [4,3-c] py ri din-8-yl)pyrrolidin-2-one (60 mg, 0.18 mmol), (R)-2-amino-6,6a,7,8-tetrahydro-9H-pyrido[2,3-blpyrrolo[1,2-d][1,4loxazin-9-one (48 mg, 0.24 mmol), Pd2(dba)3 (16 mg, 0.018 mmol), Brettphos (19 mg, 0.036 mmol) and Cs2CO3 (118 mg, 0.364 mmol) in anhydrous dioxane (3 mL) was degassed and purged with N2 for 3 times. Then the resulting reaction mixture was heated at 90 C for 16 hours under N2 atmosphere. The reaction mixture turned into yellow suspension from red. Crude LCMS showed the purity of the desired product is 47% (Rt = 0.610 min; MS Calcd: 497.5; MS Found: 498.1 [M+H]+). The reaction mixture was diluted with water (20 mL) and Et0Ac (20 mL). The aqueous layer was extracted with Et0Ac/THF (20 mL
x3, 1/1). The combined organic layer was washed with brine (25 mL), dried over anhydrous Na2SO4 and concentrated. The residue was purified by prep-HPLC (0.225% FA as an additive) and lyophilized to give a impure product. It was further purified by prep-TLC
(DCM/Me0H, 30/1) and lyophilized to give (R)-2-((5,5-dimethy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno [4,3-c] py ri din-3 -y0amino)-6,6a,7,8-tetrahy dro-9H-py ri do [2,3 -b] pyrrol o [1,2-d][1,4loxazin-9-one (23.5 mg, yield: 26%) as a yellow solid.
11-1NMR (400 MHz, DMSO-d6) 5 1.55 (6H, s), 1.70 (1H, t, J= 10.8 Hz), 2.06 (2H, t, J= 3.6 Hz), 2.22-2.25 (1H, m), 2.41(1H, t, J= 8.0 Hz), 2.49 (2H, over lapped with DMSO), 2.65-2.74 (1H, m), 3.86 (2H, t, J=10.8 Hz), 3.90 (1H, t, J= 10.4 Hz), 4.05-4.10 (1H, m), 4.58 (1H, dd, J= 10.8, 2.8 Hz), 6.75 (1H, s), 7.28 (1H, dd, J= 8.8, 2.4 Hz), 7.39 (1H, d, J=6.4 Hz), 7.87 (1H, d, J= 8.8 Hz), 8.37(1H, d, J=2.8 Hz), 8.60 (1H, s), 8.97(1H, d, J=2.8 Hz), 9.28 (1H, brs), Example 184: (R)-2-09-fluoro-5,5-dimethy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c] pyridin-3-yl)amino)-6,6a,7,8-tetrahydro-9H-pyrido [2,3-b] pyrrolo[1,2-d]
[1,4] oxazin-9-one
324 NNp [0659] A
mixture of 1-(3-chloro-9-fluoro-5,5-dimethy1-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one (60 mg, 0.17 mmol), (R)-2-amino-6,6a,7,8-tetrahydro-9H-pyrido[2,3-blpyrrolo[1,2-d][1,41oxazin-9-one (46 mg, 0.22 mmol), Pd2(dba)3 (16 mg, 0.017 mmol), Brettphos (19 mg, 0.034 mmol) and Cs2CO3 (113 mg, 0.0350 mmol) in anhydrous dioxane (3 mL)was degassed and purged with N2 for 3 times. Then the resulting reaction mixture was heated at 90 C for 15 hours under N2 atmosphere. The reaction mixture turned into yellow suspension from red. Crude LCMS showed the purity of the desired product is 24% (Rt = 0.618 min; MS Calcd: 515.5; MS Found: 516.1 [M+Hl+). The reaction mixture was diluted with water (20 mL), Et0Ac (20 mL) and separated. The aqueous layer was extracted with Et0Ac/THF (20 mL x3, 1/1). The combined organic layer was washed with brine (25 mL), dried over anhydrous Na2SO4 and concentrated. The residue was purified by prep-HPLC (0.225% FA as an additive) and lyophilized to give a impure product. It was further purified by prep-TLC (DCM/Me0H, 30/1) and lyophilized to give (R)-2-((9-fluoro-5,5-di methy1-8-(2-oxopy rroli din-l-y1)-5H-chromeno [4,3-c] py ri din-3-y Damino)-6,6 a,7,8-tetrahydro-9H-pyrido[2,3-blpyrrolo[1,2-d][1,41oxazin-9-one (19.8 mg, yield:
22%) as a yellow solid.
1-1-1NMR (400 MHz, DMSO-d6) 5 1.55 (6H, s), 1.65-1.74 (1H, m), 2.11 (2H, t, J=
7.2 Hz), 2.21-2.25 (1H, m), 2.39-2.48 (3H, m), 2.63-2.69 (1H, m), 3.77 (2H, t, J= 6.8 Hz), 3.91 (1H, t, J= 10.4 Hz), 4.06-4.09 (1H, m), 4.58 (1H, dd, J= 10.8,3.2 Hz), 6.75 (1H, s), 7.01(1H, d, J
= 6.8 Hz), 7.87(1H, d, J= 7.2 Hz), 8.37 (1H, d, J= 2.4 Hz), 8.67 (1H, s), 8.96 (1H, d, J= 2.4 Hz), 9.38 (1H, brs).
Example 185: 1-(5-methyl-3-((5-(5-methyl-1,1-dioxid o-1,2,5-thiadi azolidin-2-yl)pyrid in-3-yl)amino)-5H-ch romeno[4,3-c] pyrid in-8-yl)pyrroli din-2-one
mixture of 1-(3-chloro-9-fluoro-5,5-dimethy1-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one (60 mg, 0.17 mmol), (R)-2-amino-6,6a,7,8-tetrahydro-9H-pyrido[2,3-blpyrrolo[1,2-d][1,41oxazin-9-one (46 mg, 0.22 mmol), Pd2(dba)3 (16 mg, 0.017 mmol), Brettphos (19 mg, 0.034 mmol) and Cs2CO3 (113 mg, 0.0350 mmol) in anhydrous dioxane (3 mL)was degassed and purged with N2 for 3 times. Then the resulting reaction mixture was heated at 90 C for 15 hours under N2 atmosphere. The reaction mixture turned into yellow suspension from red. Crude LCMS showed the purity of the desired product is 24% (Rt = 0.618 min; MS Calcd: 515.5; MS Found: 516.1 [M+Hl+). The reaction mixture was diluted with water (20 mL), Et0Ac (20 mL) and separated. The aqueous layer was extracted with Et0Ac/THF (20 mL x3, 1/1). The combined organic layer was washed with brine (25 mL), dried over anhydrous Na2SO4 and concentrated. The residue was purified by prep-HPLC (0.225% FA as an additive) and lyophilized to give a impure product. It was further purified by prep-TLC (DCM/Me0H, 30/1) and lyophilized to give (R)-2-((9-fluoro-5,5-di methy1-8-(2-oxopy rroli din-l-y1)-5H-chromeno [4,3-c] py ri din-3-y Damino)-6,6 a,7,8-tetrahydro-9H-pyrido[2,3-blpyrrolo[1,2-d][1,41oxazin-9-one (19.8 mg, yield:
22%) as a yellow solid.
1-1-1NMR (400 MHz, DMSO-d6) 5 1.55 (6H, s), 1.65-1.74 (1H, m), 2.11 (2H, t, J=
7.2 Hz), 2.21-2.25 (1H, m), 2.39-2.48 (3H, m), 2.63-2.69 (1H, m), 3.77 (2H, t, J= 6.8 Hz), 3.91 (1H, t, J= 10.4 Hz), 4.06-4.09 (1H, m), 4.58 (1H, dd, J= 10.8,3.2 Hz), 6.75 (1H, s), 7.01(1H, d, J
= 6.8 Hz), 7.87(1H, d, J= 7.2 Hz), 8.37 (1H, d, J= 2.4 Hz), 8.67 (1H, s), 8.96 (1H, d, J= 2.4 Hz), 9.38 (1H, brs).
Example 185: 1-(5-methyl-3-((5-(5-methyl-1,1-dioxid o-1,2,5-thiadi azolidin-2-yl)pyrid in-3-yl)amino)-5H-ch romeno[4,3-c] pyrid in-8-yl)pyrroli din-2-one
325 I
N
0=1"---N
0 \
Step 1: Preparation of tert-butyl (N-(2-chloroethyl)-N-methylsulfamoyOcarbamate N, BocCI
0 1[1 [0660] To a solution of chlorosulfonyl isocyanate (2.50 g, 17.7 mmol) in anhydrous DCM
(25 mL) was added t-BuOH (1.69 mL, 17.7 mmol) dropwise at 0 C. After stirring at 0 C for 0.5 hour, the resulting N-Boc-sulfamoyl chloride and TEA (5.36 g, 53.0 mmol) solution was added dropwise to a solution of 2-chloro-N-methylethan-1-amine-HC1 (2.30 g, 17.7 mmol) in DCM (60 mL) at 0-5 C. After the completion of the addition, the reaction mixture was stirred at 0-5 C for 0.5 hour, then further stirred at 20-25 C for 2 hours. The reaction mixture turned into yellow suspension from solution. The reaction mixture was diluted with DCM (250 mL), then washed with 1N aqueous HC1 (100 mL), brine (100 mL), dried over anhydrous Na2SO4 and concentrated. The residue was purified by Combi Flash (10% to 25% Et0Ac in PE) to give tert-butyl (N-(2-chloroethyl)-N-methylsulfamoyl)carbamate (4.50 g, yield: 93%) as yellow oil.
11-1 NMR (400 MHz, CDC13) 61.50 (9H, s), 3.05 (3H, s), 3.68 (4H, s), 7.12 (1H, brs).
Step 2: Preparation of tert-butyl 5-methyl-1,2,5 -thiadiazolidine-2-carb oxy late 1,1-dioxide Boc, >
0 \
[0661] A
mixture of tert-butyl (N-(2-chloroethyl)-N-methylsulfamoyOcarbamate (4.00 g, 14.7 mmol) and K2CO3 (3.04 g, 22.0 mmol) in DMSO (40 mL) was stirred at 15-20 C for 16 hours. The reaction mixture turned into white suspension from colorless solution. To the reaction mixture was added water (100 mL), then extracted with Et0Ac (100 mL
x3). The combined organic layer was washed with water (100 mL x2), brine (100 mL), dried over anhydrous Na2SO4 and concentrated. The residue was purified by Combi Flash (10% to 25%
Et0Ac in PE) to give tert-butyl 5-methyl-1,2,5-thiadiazolidine-2-carboxylate 1,1-dioxide (2.80 g, yield: 81%) as a white solid.
N
0=1"---N
0 \
Step 1: Preparation of tert-butyl (N-(2-chloroethyl)-N-methylsulfamoyOcarbamate N, BocCI
0 1[1 [0660] To a solution of chlorosulfonyl isocyanate (2.50 g, 17.7 mmol) in anhydrous DCM
(25 mL) was added t-BuOH (1.69 mL, 17.7 mmol) dropwise at 0 C. After stirring at 0 C for 0.5 hour, the resulting N-Boc-sulfamoyl chloride and TEA (5.36 g, 53.0 mmol) solution was added dropwise to a solution of 2-chloro-N-methylethan-1-amine-HC1 (2.30 g, 17.7 mmol) in DCM (60 mL) at 0-5 C. After the completion of the addition, the reaction mixture was stirred at 0-5 C for 0.5 hour, then further stirred at 20-25 C for 2 hours. The reaction mixture turned into yellow suspension from solution. The reaction mixture was diluted with DCM (250 mL), then washed with 1N aqueous HC1 (100 mL), brine (100 mL), dried over anhydrous Na2SO4 and concentrated. The residue was purified by Combi Flash (10% to 25% Et0Ac in PE) to give tert-butyl (N-(2-chloroethyl)-N-methylsulfamoyl)carbamate (4.50 g, yield: 93%) as yellow oil.
11-1 NMR (400 MHz, CDC13) 61.50 (9H, s), 3.05 (3H, s), 3.68 (4H, s), 7.12 (1H, brs).
Step 2: Preparation of tert-butyl 5-methyl-1,2,5 -thiadiazolidine-2-carb oxy late 1,1-dioxide Boc, >
0 \
[0661] A
mixture of tert-butyl (N-(2-chloroethyl)-N-methylsulfamoyOcarbamate (4.00 g, 14.7 mmol) and K2CO3 (3.04 g, 22.0 mmol) in DMSO (40 mL) was stirred at 15-20 C for 16 hours. The reaction mixture turned into white suspension from colorless solution. To the reaction mixture was added water (100 mL), then extracted with Et0Ac (100 mL
x3). The combined organic layer was washed with water (100 mL x2), brine (100 mL), dried over anhydrous Na2SO4 and concentrated. The residue was purified by Combi Flash (10% to 25%
Et0Ac in PE) to give tert-butyl 5-methyl-1,2,5-thiadiazolidine-2-carboxylate 1,1-dioxide (2.80 g, yield: 81%) as a white solid.
326 NMR (400 MHz, CDC13) (51.55 (9H, s), 2.78 (3H, s), 3.31 (2H, t, J= 6.4 Hz), 3.81 (2H, t, J= 6.4 Hz).
Step 3: Preparation of 2-methyl-1,2,5-thiadiazolidine 1,1-dioxide HN
0 \
[0662] To a solution of tert-butyl 5-methyl-1,2,5-thiadiazolidine-2-carboxylate 1,1-dioxide (2.30 g, 9.73 mmol) in anhydrous DCM (25 mL) was added TFA (25 mL) at 15-20 C. Then the reaction mixture was stirred at 15-20 C for 1 hour. The reaction turned into pale yellow solution from colorless. The reaction mixture was concentrated and the residue was diluted with DCM (50 mL) and basified with DIPEA to pH = 8 and concentrated. The residue was purified by Combi Flash (10% to 50% Et0Ac in PE) to give 2-methyl-1,2,5-thiadiazolidine 1,1-dioxide (1.15 g, yield: 87%) as colorless oil.
1-1-1NMR (400 MHz, CDC13) (52.75 (3H, s), 3.36-341 (2H, m), 3.48-3.53 (2H, m), 4.47 (1H, brs).
Step 4: Preparation of 2-methyl-5 -(5-nitropy ri din-3 -y1)-1,2,5 -thi adi azoli dine 1,1-dioxide 0 \
[0663] A
mixture of 2-methyl-1,2,5-thiadiazolidine 1,1-dioxide (900 mg, 6.61 mmol), 3-bromo-5-nitro-pyridine (1.61 g, 7.93 mmol), Cut (378 mg, 1.98 mmol), Cs2CO3 (3.23 g, 9.91 mmol) and DMEDA (350 mg, 3.97 mmol) in anhydrous dioxane (80 mL) was degassed and purged with N2 for 3 times. Then the resulting reaction mixture was heated at 100 C for 16 hours under N2 atmosphere. The reaction mixture turned into brown suspension from blue.
LCMS showed the purity of the desired product is 91% (Rt = 0.693 min; MS
Calcd: 258.0; MS
Found: 258.8 [M+H1+). The reaction mixture was filtered and the solid was washed with Et0Ac (50 mL x3) and the filtrate was concentrated. The residue was purified by Combi Flash (1% to 5% Et0Ac in DCM) to give 2-methyl-5-(5-nitropyridin-3-y1)-1,2,5-thiadiazolidine 1,1-dioxide (1.57 g, yield: 92%) as a yellow solid.
11-1 NMR (400 MHz, CDC13) (52.91 (3H, s), 3.62 (2H, t, J= 6.4 Hz), 3.96 (2H, t, J= 6.4 Hz), 8.27 (1H, t, J= 2.4 Hz), 8.84 (1H, d, J= 2.4 Hz), 9.19 (1H, d, J= 2.0 Hz).
Step 5: Preparation of 2-(5-aminopyridin-3-y1)-5-methy1-1,2,5-thiadiazolidine 1,1-dioxide
Step 3: Preparation of 2-methyl-1,2,5-thiadiazolidine 1,1-dioxide HN
0 \
[0662] To a solution of tert-butyl 5-methyl-1,2,5-thiadiazolidine-2-carboxylate 1,1-dioxide (2.30 g, 9.73 mmol) in anhydrous DCM (25 mL) was added TFA (25 mL) at 15-20 C. Then the reaction mixture was stirred at 15-20 C for 1 hour. The reaction turned into pale yellow solution from colorless. The reaction mixture was concentrated and the residue was diluted with DCM (50 mL) and basified with DIPEA to pH = 8 and concentrated. The residue was purified by Combi Flash (10% to 50% Et0Ac in PE) to give 2-methyl-1,2,5-thiadiazolidine 1,1-dioxide (1.15 g, yield: 87%) as colorless oil.
1-1-1NMR (400 MHz, CDC13) (52.75 (3H, s), 3.36-341 (2H, m), 3.48-3.53 (2H, m), 4.47 (1H, brs).
Step 4: Preparation of 2-methyl-5 -(5-nitropy ri din-3 -y1)-1,2,5 -thi adi azoli dine 1,1-dioxide 0 \
[0663] A
mixture of 2-methyl-1,2,5-thiadiazolidine 1,1-dioxide (900 mg, 6.61 mmol), 3-bromo-5-nitro-pyridine (1.61 g, 7.93 mmol), Cut (378 mg, 1.98 mmol), Cs2CO3 (3.23 g, 9.91 mmol) and DMEDA (350 mg, 3.97 mmol) in anhydrous dioxane (80 mL) was degassed and purged with N2 for 3 times. Then the resulting reaction mixture was heated at 100 C for 16 hours under N2 atmosphere. The reaction mixture turned into brown suspension from blue.
LCMS showed the purity of the desired product is 91% (Rt = 0.693 min; MS
Calcd: 258.0; MS
Found: 258.8 [M+H1+). The reaction mixture was filtered and the solid was washed with Et0Ac (50 mL x3) and the filtrate was concentrated. The residue was purified by Combi Flash (1% to 5% Et0Ac in DCM) to give 2-methyl-5-(5-nitropyridin-3-y1)-1,2,5-thiadiazolidine 1,1-dioxide (1.57 g, yield: 92%) as a yellow solid.
11-1 NMR (400 MHz, CDC13) (52.91 (3H, s), 3.62 (2H, t, J= 6.4 Hz), 3.96 (2H, t, J= 6.4 Hz), 8.27 (1H, t, J= 2.4 Hz), 8.84 (1H, d, J= 2.4 Hz), 9.19 (1H, d, J= 2.0 Hz).
Step 5: Preparation of 2-(5-aminopyridin-3-y1)-5-methy1-1,2,5-thiadiazolidine 1,1-dioxide
327 O N
0 \
[0664] To a solution of 2-methyl-5-(5 -nitropyridin-3 -y1)-1,2,5 -thiadiazolidine 1,1-dioxide (1.57 g, 6.08 mmol) in Me0H (100 mL) was added 10% Pd/C (400 mg) under N2 atmosphere at 15-20 C. Then the reaction mixture was degassed and purged with H2 for 3 times and hydrogenated (30 psi) at 25 C for 16 hours. The reaction mixture turned into colorless solution from yellow. The reaction mixture was filtered and the solid was washed with Me0H
(20 mL x4). The residue was purified by Combi Flash (5% to 10% Me0H in DCM), then triturated with PE/Et0Ac (10 mL, 1/1) to give 2-(5-aminopyridin-3-y1)-5-methy1-1,2,5-thiadiazolidine 1,1-dioxide (1.34 g, yield: 97%) as a white solid.
11-1 NMR (400 MHz, DMSO-d6) (52.72 (3H, s), 3.47 (2H, t, J= 6.4 Hz), 3.81 (2H, t, J= 6.4 Hz), 5.54 (2H, brs), 6.83 (1H, t, J = 2.4 Hz), 7.60 (1H, d, J = 2.0 Hz), 7.72 (1H, d, J = 2.4 Hz).
Step 6:
Preparation of 1-(5 -methy1-3-45-(5-methy1-1,1 -di oxi do-1,2,5-thi adi azol i din-2-yl)py ri din-3-yl)amino)-5H-chromeno [4,3-c] py ri din-8-yl)py rroli din-2-one I
NN) 0 \
[0665] A
mixture of 2-(5-aminopyridin-3-y1)-5-methy1-1,2,5-thiadiazolidine 1,1-dioxide (65 mg, 0.28 mmol), 1-(3 -chl oro-5 -methyl-5H-chromeno [4,3-c] py ri din-8-yl)pyrroli din-2-one (108 mg, 0.342 mmol), Pd2(dba)3 (26 mg, 0.028 mmol), Brettphos (31 mg, 0.057 mmol) and Cs2CO3 (278 mg, 0.854 mmol) in anhydrous dioxane (4 mL) was degassed and purged with N2 for 3 times. Then the reaction mixture was heated at 90 C for 16 hours under N2 atmosphere.
The reaction mixture turned into brown suspension from red. LCMS showed the purity of the desired product is 52% (Rt = 0.744 min; MS Calcd: 506.2; MS Found: 507.1 [M+H]+). To the reaction mixture was added water (20 mL), then extracted with Et0Ac/THF (20 mL
x3, 1/1).
The combined organic layer was washed with brine (20 mL), dried over anhydrous Na2SO4 and concentrated. The residue was purified by Combi Flash (2% to 10% Me0H in DCM), then
0 \
[0664] To a solution of 2-methyl-5-(5 -nitropyridin-3 -y1)-1,2,5 -thiadiazolidine 1,1-dioxide (1.57 g, 6.08 mmol) in Me0H (100 mL) was added 10% Pd/C (400 mg) under N2 atmosphere at 15-20 C. Then the reaction mixture was degassed and purged with H2 for 3 times and hydrogenated (30 psi) at 25 C for 16 hours. The reaction mixture turned into colorless solution from yellow. The reaction mixture was filtered and the solid was washed with Me0H
(20 mL x4). The residue was purified by Combi Flash (5% to 10% Me0H in DCM), then triturated with PE/Et0Ac (10 mL, 1/1) to give 2-(5-aminopyridin-3-y1)-5-methy1-1,2,5-thiadiazolidine 1,1-dioxide (1.34 g, yield: 97%) as a white solid.
11-1 NMR (400 MHz, DMSO-d6) (52.72 (3H, s), 3.47 (2H, t, J= 6.4 Hz), 3.81 (2H, t, J= 6.4 Hz), 5.54 (2H, brs), 6.83 (1H, t, J = 2.4 Hz), 7.60 (1H, d, J = 2.0 Hz), 7.72 (1H, d, J = 2.4 Hz).
Step 6:
Preparation of 1-(5 -methy1-3-45-(5-methy1-1,1 -di oxi do-1,2,5-thi adi azol i din-2-yl)py ri din-3-yl)amino)-5H-chromeno [4,3-c] py ri din-8-yl)py rroli din-2-one I
NN) 0 \
[0665] A
mixture of 2-(5-aminopyridin-3-y1)-5-methy1-1,2,5-thiadiazolidine 1,1-dioxide (65 mg, 0.28 mmol), 1-(3 -chl oro-5 -methyl-5H-chromeno [4,3-c] py ri din-8-yl)pyrroli din-2-one (108 mg, 0.342 mmol), Pd2(dba)3 (26 mg, 0.028 mmol), Brettphos (31 mg, 0.057 mmol) and Cs2CO3 (278 mg, 0.854 mmol) in anhydrous dioxane (4 mL) was degassed and purged with N2 for 3 times. Then the reaction mixture was heated at 90 C for 16 hours under N2 atmosphere.
The reaction mixture turned into brown suspension from red. LCMS showed the purity of the desired product is 52% (Rt = 0.744 min; MS Calcd: 506.2; MS Found: 507.1 [M+H]+). To the reaction mixture was added water (20 mL), then extracted with Et0Ac/THF (20 mL
x3, 1/1).
The combined organic layer was washed with brine (20 mL), dried over anhydrous Na2SO4 and concentrated. The residue was purified by Combi Flash (2% to 10% Me0H in DCM), then
328 triturated with Et0Ac (5 mL), further purified by prep-HPLC (0.225% FA as an additive). Most of CH3CN was removed under reduced pressure and the remaining part was lyophilized to give 1-(5 -methy1-3 -((5-(5 -methyl-1,1 -di oxi do-1,2,5-thi adi azoli din-2-yl)py ri din-3-y0amino)-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (9.6 mg, yield: 7%) as a yellow solid.
NMR (400 MHz, DMSO-d6) 1.55 (3H, d, J= 6.8 Hz), 2.00-2.10 (2H, m), 2.55-2.60 (2H, m), 2.77 (3H, s), 3.55 (2H, t, J= 6.4 Hz), 3.85 (2H, t, J= 7.2 Hz), 3.93 (2H, t, J= 6.4 Hz), 5.29 (1H, q, J= 6.4 Hz), 6.77 (1H, s), 7.33 (1H, dd, J= 8.4, 2.0 Hz), 7.41 (1H, d, J= 2.4 Hz), 7.90 (1H, d, J= 8.4 Hz), 8.03 (1H, s), 8.20 (1H, s), 8.68 (1H, s), 8.75 (1H, s), 9.67 (1H, brs).
Example 186: 1-(5,5-dimethy1-3-05-(5-methyl-1,1-dioxido-1,2,5-thiadiazolidin-2-yl)pyridin-3-yl)amino)-5H-chromeno[4,3-c] pyri din-8-yl)pyrrolid in-2-one gN 0 N
NN) d [0666] A
mixture of 2-(5-aminopyridin-3-y1)-5-methy1-1,2,5-thiadiazolidine 1,1-dioxide (65 mg, 0.28 mmol), 1-(3-chloro-5,5-dimethy1-5H-chromeno [4,3-c]pyridin-8-yl)pyrrolidin-2-one (112 mg, 0.342 mmol), Pd2(dba)3 (26 mg, 0.028 mmol), Brettphos (31 mg, 0.057 mmol) and Cs2CO3 (278 mg, 0.854 mmol) in anhydrous dioxane (4 mL) was degassed and purged with N2 for 3 times. Then the reaction mixture was heated at 90 C for 16 hours under N2 atmosphere. The reaction mixture turned into brown suspension from red. LCMS
showed the purity of the desired product is 77% (Rt = 0.772 min; MS Calcd: 520.2; MS
Found: 521.1 [M+Hl+). To the reaction mixture was added water (20 mL), then extracted with Et0Ac/THF
(20 mL x3, 1/1). The combined organic layer was washed with brine (20 mL), dried over anhydrous Na2SO4 and concentrated. The residue was triturated with Et0Ac (5 mL) , then further purified by prep-HPLC (0.225% FA as an additive). Most of CH3CN
was removed under reduced pressure and the remaining part was lyophilized and the product was triturated with CH3CN (5 mL) and lyophilized to give 1-(5,5-dimethy1-3-((5-(5-methy1-1,1-dioxido-1,2,5-thiadiazolidin-2-yOpyridin-3-y0amino)-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (31.3 mg, yield: 21%) as a white solid.
NMR (400 MHz, DMSO-d6) 1.55 (3H, d, J= 6.8 Hz), 2.00-2.10 (2H, m), 2.55-2.60 (2H, m), 2.77 (3H, s), 3.55 (2H, t, J= 6.4 Hz), 3.85 (2H, t, J= 7.2 Hz), 3.93 (2H, t, J= 6.4 Hz), 5.29 (1H, q, J= 6.4 Hz), 6.77 (1H, s), 7.33 (1H, dd, J= 8.4, 2.0 Hz), 7.41 (1H, d, J= 2.4 Hz), 7.90 (1H, d, J= 8.4 Hz), 8.03 (1H, s), 8.20 (1H, s), 8.68 (1H, s), 8.75 (1H, s), 9.67 (1H, brs).
Example 186: 1-(5,5-dimethy1-3-05-(5-methyl-1,1-dioxido-1,2,5-thiadiazolidin-2-yl)pyridin-3-yl)amino)-5H-chromeno[4,3-c] pyri din-8-yl)pyrrolid in-2-one gN 0 N
NN) d [0666] A
mixture of 2-(5-aminopyridin-3-y1)-5-methy1-1,2,5-thiadiazolidine 1,1-dioxide (65 mg, 0.28 mmol), 1-(3-chloro-5,5-dimethy1-5H-chromeno [4,3-c]pyridin-8-yl)pyrrolidin-2-one (112 mg, 0.342 mmol), Pd2(dba)3 (26 mg, 0.028 mmol), Brettphos (31 mg, 0.057 mmol) and Cs2CO3 (278 mg, 0.854 mmol) in anhydrous dioxane (4 mL) was degassed and purged with N2 for 3 times. Then the reaction mixture was heated at 90 C for 16 hours under N2 atmosphere. The reaction mixture turned into brown suspension from red. LCMS
showed the purity of the desired product is 77% (Rt = 0.772 min; MS Calcd: 520.2; MS
Found: 521.1 [M+Hl+). To the reaction mixture was added water (20 mL), then extracted with Et0Ac/THF
(20 mL x3, 1/1). The combined organic layer was washed with brine (20 mL), dried over anhydrous Na2SO4 and concentrated. The residue was triturated with Et0Ac (5 mL) , then further purified by prep-HPLC (0.225% FA as an additive). Most of CH3CN
was removed under reduced pressure and the remaining part was lyophilized and the product was triturated with CH3CN (5 mL) and lyophilized to give 1-(5,5-dimethy1-3-((5-(5-methy1-1,1-dioxido-1,2,5-thiadiazolidin-2-yOpyridin-3-y0amino)-5H-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (31.3 mg, yield: 21%) as a white solid.
329 NMR (400 MHz, DMSO-d6) (51.57 (6H, s), 2.00-2.10 (2H, m), 2.55-2.60 (2H, m), 2.76 (3H, s), 3.54 (2H, t, J= 6.0 Hz), 3.84 (2H, t, J= 6.8 Hz), 3.92 (2H, t, J= 6.4 Hz), 6.83 (1H, s), 7.30 (1H, d, J= 8.4 Hz), 7.40 (1H, s), 7.91 (1H, d, J= 8.8 Hz), 8.00 (1H, s), 8.17 (1H, s), 8.65-8.70 (2H, m), 9.62 (1H, brs).
Example 187: 1-(5-methyl-3-(((S)-2-methyl-1,1-dioxido-2,3,3a,4-tetrahydropyrido12,3-b] [1,2,5] thiadiazolo [2,3-d] [1,4] oxazin-8-yl)amino)-5H-chromeno[4,3-c]
pyridin-8-yl)pyrrolidin-2-one I
N N N
0:---p¨N
0 \
Step 1: Preparation of (R)-1-(benzyloxy)-3-(methylamino)propan-2-ol OBn H z OH
[0667] A
solution of (S)-2-((benzyloxy)methypoxirane (6.00 g, 36.5 mmol) in DCM (25 mL) was added dropwise to MeNH2 (130 mL, 40% purity in Me0H) at 0 C. After the addition, the reaction mixture was stirred at 10-15 C for 16 hours. The reaction mixture turned into suspension from solution. The reaction mixture was concentrated and the remaining part was extracted with DCM (100 mL x3). The combined organic layer was washed with brine (50 mL), dried over anhydrous Na2SO4 and concentrated to give (R)-1-(benzyloxy)-3-(methylamino)propan-2-ol (6.10 g, yield: 86%) as yellow oil.
11-1 NMR (400 MHz, CDC13) (52.44 (3H, s), 2.65-2.70 (2H, m), 3.45-3.55 (2H, m), 3.90-3.95 (1H, m), 4.55 (2H, s), 7.25-7.40 (5H, m).
Step 2: Preparation of methyl (S)-3-((benzyloxy)methyl)-5-methy1-1,2,5-thiadiazolidine-2-carboxylate 1,1-dioxide OBn 0"Sec N 0 \
Example 187: 1-(5-methyl-3-(((S)-2-methyl-1,1-dioxido-2,3,3a,4-tetrahydropyrido12,3-b] [1,2,5] thiadiazolo [2,3-d] [1,4] oxazin-8-yl)amino)-5H-chromeno[4,3-c]
pyridin-8-yl)pyrrolidin-2-one I
N N N
0:---p¨N
0 \
Step 1: Preparation of (R)-1-(benzyloxy)-3-(methylamino)propan-2-ol OBn H z OH
[0667] A
solution of (S)-2-((benzyloxy)methypoxirane (6.00 g, 36.5 mmol) in DCM (25 mL) was added dropwise to MeNH2 (130 mL, 40% purity in Me0H) at 0 C. After the addition, the reaction mixture was stirred at 10-15 C for 16 hours. The reaction mixture turned into suspension from solution. The reaction mixture was concentrated and the remaining part was extracted with DCM (100 mL x3). The combined organic layer was washed with brine (50 mL), dried over anhydrous Na2SO4 and concentrated to give (R)-1-(benzyloxy)-3-(methylamino)propan-2-ol (6.10 g, yield: 86%) as yellow oil.
11-1 NMR (400 MHz, CDC13) (52.44 (3H, s), 2.65-2.70 (2H, m), 3.45-3.55 (2H, m), 3.90-3.95 (1H, m), 4.55 (2H, s), 7.25-7.40 (5H, m).
Step 2: Preparation of methyl (S)-3-((benzyloxy)methyl)-5-methy1-1,2,5-thiadiazolidine-2-carboxylate 1,1-dioxide OBn 0"Sec N 0 \
330 [0668] To a solution of (R)-1-(benzyloxy)-3-(methylamino)propan-2-ol (6.10 g, 31.2 mmol) in anhydrous THF (200 mL) was added Burgess reagent (18.6 g, 78.1 mmol) at 10-15 C. Then the reaction mixture was stirred at 75 C for 16 hours. The reaction mixture turned into yellow solution from colorless. To the reaction mixture was added saturated aqueous NH4C1 (100 mL), then extracted with Et0Ac (200 mL x2). The combined organic layer was washed with brine (100 mL), dried over anhydrous Na2SO4 and concentrated. The residue was purified by Combi Flash (10% to 30% Et0Ac in PE) to give methyl (S)-3-((benzyloxy)methyl)-5-methy1-1,2,5-thiadiazolidine-2-carboxylate 1,1-dioxide (5.92 g, yield: 60%) as yellow gum.
NMR (400 MHz, CDC13) (52.77 (3H, s), 3.33-3.39 (1H, m), 3.41-3.45 (1H, m), 3.64-3.69 (1H, m), 3.74-3.79 (1H, m), 3.90 (3H, s), 4.24-4.31 (1H, m), 4.52-4.60 (2H, m), 7.29-7.40 (5H, m).
Step 3: Preparation of methyl (S)-3-(hydroxymethyl)-5-methy1-1,2,5-thiadiazolidine-2-carboxylate 1,1-dioxide ,s¨NI, [0669] To a solution of methyl (S)-3-((benzyloxy)methyl)-5-methy1-1,2,5-thiadiazolidine-2-carboxylate 1,1-dioxide (5.92 g, 18.8 mmol) in absolute Me0H (200 mL) was added 10%
Pd(OH)2/C (1.00 g) under N2 atmosphere. The reaction mixture was degassed and purged with H2 for 3 times and the resulting reaction mixture was hydrogenated (50 psi) at 50 C for 24 hours. The reaction mixture turned into colorless from yellow solution. The reaction mixture was filtered and the solid was washed with Me0H (10 mL x3). The filtrate was concentrated and the residue was dissolved in Et0H (25 mL) and concentrated to give methyl (S)-3-(hydroxymethyl)-5-methy1-1,2,5-thiadiazolidine-2-carboxylate 1,1-dioxide (3.50 g, yield:
83%) as colorless gum.
NMR (400 MHz, CDC13) (52.80 (3H, s), 3.35-3.45 (2H, m), 3.75-3.85 (2H, m), 3.93 (3H, s), 4.20-4.30 (1H, m).
Step 4: Preparation of methyl (S)-3-(((3-bromo-5-nitropyridin-2-yl)oxy)methyl)-5-methyl-1,2,5 -thi adi azoli dine-2-carboxylate 1,1-dioxide
NMR (400 MHz, CDC13) (52.77 (3H, s), 3.33-3.39 (1H, m), 3.41-3.45 (1H, m), 3.64-3.69 (1H, m), 3.74-3.79 (1H, m), 3.90 (3H, s), 4.24-4.31 (1H, m), 4.52-4.60 (2H, m), 7.29-7.40 (5H, m).
Step 3: Preparation of methyl (S)-3-(hydroxymethyl)-5-methy1-1,2,5-thiadiazolidine-2-carboxylate 1,1-dioxide ,s¨NI, [0669] To a solution of methyl (S)-3-((benzyloxy)methyl)-5-methy1-1,2,5-thiadiazolidine-2-carboxylate 1,1-dioxide (5.92 g, 18.8 mmol) in absolute Me0H (200 mL) was added 10%
Pd(OH)2/C (1.00 g) under N2 atmosphere. The reaction mixture was degassed and purged with H2 for 3 times and the resulting reaction mixture was hydrogenated (50 psi) at 50 C for 24 hours. The reaction mixture turned into colorless from yellow solution. The reaction mixture was filtered and the solid was washed with Me0H (10 mL x3). The filtrate was concentrated and the residue was dissolved in Et0H (25 mL) and concentrated to give methyl (S)-3-(hydroxymethyl)-5-methy1-1,2,5-thiadiazolidine-2-carboxylate 1,1-dioxide (3.50 g, yield:
83%) as colorless gum.
NMR (400 MHz, CDC13) (52.80 (3H, s), 3.35-3.45 (2H, m), 3.75-3.85 (2H, m), 3.93 (3H, s), 4.20-4.30 (1H, m).
Step 4: Preparation of methyl (S)-3-(((3-bromo-5-nitropyridin-2-yl)oxy)methyl)-5-methyl-1,2,5 -thi adi azoli dine-2-carboxylate 1,1-dioxide
331 o ,0 N
[0670] A
mixture of methyl (S)-3-(hydroxymethyl)-5-methy1-1,2,5-thiadiazolidine-2-carboxylate 1,1-dioxide (3.30 g, 14.7 mmol), 3-bromo-2-chloro-5-nitro-pyridine (4.19 g, 17.7 mmol) and K2CO3 (4.07 g, 29.4 mmol) in CH3CN (60 mL) was heated at 90 C for 2 hours under N2 atmosphere. The reaction mixture turned into brown suspension from yellow. The reaction mixture was filtered and the solid was washed with Et0Ac (20 mL x3).
The filtrate was concentrated and the residue was purified by Combi Flash (20% to 40% Et0Ac in PE) to give methyl (S)-3-(((3-bromo-5-nitropyridin-2-y0oxy)methyl)-5-methyl-1,2,5-thiadiazolidine-2-carboxylate 1,1-dioxide (4.20 g, yield: 67%) as yellow gum.
Step 5: Preparation of methyl (S)-3-(((5-amino-3-bromopyridin-2-y0oxy)methyl)-5-methyl-1,2,5 -thi adi azoli dine-2-carboxylate 1,1-dioxide and (S)-3-(((5 -amino-3 -bromopy ri din-2-yl)oxy)methyl)-1,2,512-thiadiazolidine 1,1-dioxide \o..A c"-0 ON
H2N Br H2N Br [0671] A
mixture of methyl (S)-3 -(((3 -bromo-5-nitropy ri din-2-y0oxy)methyl)-5 -methyl-1,2,5-thiadiazolidine-2-carboxylate 1,1-dioxide (4.20 g, 9.88 mmol) and Fe powder (2.21 g, 39.5 mmol), NH4C1 (5.28 g, 98.8 mmol) in Et0H (45 mL) and H20 (15 mL) was heated at 90 C for 16 hours. The reaction mixture turned into black suspension from gray.
The reaction mixture was filtered through a pad of celite and the solid was washed with Et0H (20 mL x3).
The filtrate was concentrated and the residue was diluted with water (50 mL) and extracted with Et0Ac (50 mL x3). The combined organic layer was washed with brine (50 mL), dried over anhydrous Na2SO4 and concentrated. The residue was purified by Combi Flash (50% to 100% Et0Ac in PE) to give methyl (S)-3-(((5-amino-3-bromopyridin-2-y0oxy)methyl)-5-methyl-1,2,5-thiadiazolidine-2-carboxylate 1,1-dioxide (2.40 g, yield: 61 %) as a yellow solid and (S)-3-(((5 -amino-3 -bromopyridin-2-y0oxy)methyl)-1,2,512-thiadiazolidine 1,1-dioxide (860 mg, yield: 26%) as a gray solid.
Step 6: Preparation of methyl (S)-3-(43-bromo-5-((di-tert-butoxycarbonyl)amino)pyridin-2-
[0670] A
mixture of methyl (S)-3-(hydroxymethyl)-5-methy1-1,2,5-thiadiazolidine-2-carboxylate 1,1-dioxide (3.30 g, 14.7 mmol), 3-bromo-2-chloro-5-nitro-pyridine (4.19 g, 17.7 mmol) and K2CO3 (4.07 g, 29.4 mmol) in CH3CN (60 mL) was heated at 90 C for 2 hours under N2 atmosphere. The reaction mixture turned into brown suspension from yellow. The reaction mixture was filtered and the solid was washed with Et0Ac (20 mL x3).
The filtrate was concentrated and the residue was purified by Combi Flash (20% to 40% Et0Ac in PE) to give methyl (S)-3-(((3-bromo-5-nitropyridin-2-y0oxy)methyl)-5-methyl-1,2,5-thiadiazolidine-2-carboxylate 1,1-dioxide (4.20 g, yield: 67%) as yellow gum.
Step 5: Preparation of methyl (S)-3-(((5-amino-3-bromopyridin-2-y0oxy)methyl)-5-methyl-1,2,5 -thi adi azoli dine-2-carboxylate 1,1-dioxide and (S)-3-(((5 -amino-3 -bromopy ri din-2-yl)oxy)methyl)-1,2,512-thiadiazolidine 1,1-dioxide \o..A c"-0 ON
H2N Br H2N Br [0671] A
mixture of methyl (S)-3 -(((3 -bromo-5-nitropy ri din-2-y0oxy)methyl)-5 -methyl-1,2,5-thiadiazolidine-2-carboxylate 1,1-dioxide (4.20 g, 9.88 mmol) and Fe powder (2.21 g, 39.5 mmol), NH4C1 (5.28 g, 98.8 mmol) in Et0H (45 mL) and H20 (15 mL) was heated at 90 C for 16 hours. The reaction mixture turned into black suspension from gray.
The reaction mixture was filtered through a pad of celite and the solid was washed with Et0H (20 mL x3).
The filtrate was concentrated and the residue was diluted with water (50 mL) and extracted with Et0Ac (50 mL x3). The combined organic layer was washed with brine (50 mL), dried over anhydrous Na2SO4 and concentrated. The residue was purified by Combi Flash (50% to 100% Et0Ac in PE) to give methyl (S)-3-(((5-amino-3-bromopyridin-2-y0oxy)methyl)-5-methyl-1,2,5-thiadiazolidine-2-carboxylate 1,1-dioxide (2.40 g, yield: 61 %) as a yellow solid and (S)-3-(((5 -amino-3 -bromopyridin-2-y0oxy)methyl)-1,2,512-thiadiazolidine 1,1-dioxide (860 mg, yield: 26%) as a gray solid.
Step 6: Preparation of methyl (S)-3-(43-bromo-5-((di-tert-butoxycarbonyl)amino)pyridin-2-
332 yl)oxy)methy 0-5-methy1-1,2,5-thi adi azoli dine-2-carb oxylate-1,1 -di oxi de 0 rl N-S( N
(Boc)2NBr 106721 To a solution of methyl (S)-3-(((5-amino-3-bromopyridin-2-y0oxy)methyl)-5-methyl-1,2,5-thiadiazolidine-2-carboxylate 1,1-dioxide (3.20 g, 8.10 mmol), DIPEA (4.19 g, 32.4 mmol) and DMAP (198 mg, 1.62 mmol) in DCM (80 mL) was added Boc20 (7.07 g, 32.4 mmol) at 15-20 C. Then the reaction mixture was stirred at 15-20 C for 16 hours under N2 atmosphere. The reaction mixture turned into yellow solution from colorless.
The reaction mixture was concentrated and the residue was purified by Combi Flash (30% to 80% Et0Ac in PE) to give (S)-3-(43-bromo-5-((di-tert-butoxycarbonyl)amino)pyridin-2-y0oxy)methyl)-5-methyl-1,2,5-thiadiazolidine-2-carboxylate-1,1-dioxide (2.20 g, yield: 46%) as yellow gum.
NMR (400 MHz, CDC13) 61.45 (18H, s), 2.80 (3H, s), 3.15-3.25 (1H, m), 3.70-3.80 (4H, m), 4.25-4.35 (2H, m), 5.30-5.35 (1H, m), 7.84 (1H, d, J= 2.0 Hz), 8.21 (1H, d, J = 2.4 Hz).
Step 7: Preparation of tert-butyl (S)-3-(43-bromo-5-((di-tert-butoxycarbonyl)amino)pyridin-2-y Doxy)methyl)-5 -methyl-1,2,5-thi adiazoli dine-2-carb oxylate 1,1-dioxide Boc\ it õ0 N¨S, N
(Boc)2N Br 106731 To a solution of (S)-4-(((5-amino-3-bromopyridin-2-y0oxy)methyl)-2-methyl-1,2,5-thiadiazolidine 1,1-dioxide (860 mg, 2.55 mmol), DIPEA (1.32 g, 10.2 mmol) and DMAP (62 mg, 0.51 mmol) in DCM (25 mL) was added Boc20 (2.23 g, 10.2 mmol) at C. Then the reaction mixture was stirred at 15-20 C for 16 hours under N2 atmosphere. The reaction mixture turned into yellow solution from colorless. The reaction mixture was concentrated and the residue was purified by Combi Flash (20% to 50% Et0Ac in PE) to give tert-butyl (S)-3-(43-bromo-5-((di-tert-butoxy carb onyl)amino)pyri din-2-y Doxy)methyl)-5-methy1-1,2,5-thiadiazolidine-2-carboxylate 1,1-dioxide (1.50 g, yield: 92%) as colorless gum.
NMR (400 MHz, CDC13) 61.45 (27H, s), 2.79 (3H, s), 3.20-3.25 (1H, m), 3.75-3.80 (1H, m), 4.20-4.25 (2H, m), 5.25-5.30 (1H, m), 7.84 (1H, d, J= 2.4 Hz), 8.22 (1H, d, J = 2.0 Hz).
(Boc)2NBr 106721 To a solution of methyl (S)-3-(((5-amino-3-bromopyridin-2-y0oxy)methyl)-5-methyl-1,2,5-thiadiazolidine-2-carboxylate 1,1-dioxide (3.20 g, 8.10 mmol), DIPEA (4.19 g, 32.4 mmol) and DMAP (198 mg, 1.62 mmol) in DCM (80 mL) was added Boc20 (7.07 g, 32.4 mmol) at 15-20 C. Then the reaction mixture was stirred at 15-20 C for 16 hours under N2 atmosphere. The reaction mixture turned into yellow solution from colorless.
The reaction mixture was concentrated and the residue was purified by Combi Flash (30% to 80% Et0Ac in PE) to give (S)-3-(43-bromo-5-((di-tert-butoxycarbonyl)amino)pyridin-2-y0oxy)methyl)-5-methyl-1,2,5-thiadiazolidine-2-carboxylate-1,1-dioxide (2.20 g, yield: 46%) as yellow gum.
NMR (400 MHz, CDC13) 61.45 (18H, s), 2.80 (3H, s), 3.15-3.25 (1H, m), 3.70-3.80 (4H, m), 4.25-4.35 (2H, m), 5.30-5.35 (1H, m), 7.84 (1H, d, J= 2.0 Hz), 8.21 (1H, d, J = 2.4 Hz).
Step 7: Preparation of tert-butyl (S)-3-(43-bromo-5-((di-tert-butoxycarbonyl)amino)pyridin-2-y Doxy)methyl)-5 -methyl-1,2,5-thi adiazoli dine-2-carb oxylate 1,1-dioxide Boc\ it õ0 N¨S, N
(Boc)2N Br 106731 To a solution of (S)-4-(((5-amino-3-bromopyridin-2-y0oxy)methyl)-2-methyl-1,2,5-thiadiazolidine 1,1-dioxide (860 mg, 2.55 mmol), DIPEA (1.32 g, 10.2 mmol) and DMAP (62 mg, 0.51 mmol) in DCM (25 mL) was added Boc20 (2.23 g, 10.2 mmol) at C. Then the reaction mixture was stirred at 15-20 C for 16 hours under N2 atmosphere. The reaction mixture turned into yellow solution from colorless. The reaction mixture was concentrated and the residue was purified by Combi Flash (20% to 50% Et0Ac in PE) to give tert-butyl (S)-3-(43-bromo-5-((di-tert-butoxy carb onyl)amino)pyri din-2-y Doxy)methyl)-5-methy1-1,2,5-thiadiazolidine-2-carboxylate 1,1-dioxide (1.50 g, yield: 92%) as colorless gum.
NMR (400 MHz, CDC13) 61.45 (27H, s), 2.79 (3H, s), 3.20-3.25 (1H, m), 3.75-3.80 (1H, m), 4.20-4.25 (2H, m), 5.25-5.30 (1H, m), 7.84 (1H, d, J= 2.4 Hz), 8.22 (1H, d, J = 2.0 Hz).
333 Step 8: Preparation of tert-butyl (S)-(5-bromo-6-((5-methy1-1,1-dioxido-1,2,5-thiadiazolidin-3-yl)methoxy)pyridin-3 -yl)carbamate ?1, 0 N
BocHN Br [0674] To a solution of tert-butyl (S)-3-(43-bromo-5-((di-tert-butoxy carbonyl)amino)py ri din-2-yl)oxy)methyl)-5 -methyl-1,2,5 -thi adi azoli dine-2-carboxylate 1,1-dioxide (2.20 g, 3.69 mmol) in Me0H (40 mL) and H20 (20 mL) was added 10% aqueous NaOH (10 mL) at 15-20 C. Then the reaction mixture was stirred at C for 2 hours. The reaction mixture turned into yellow solution from colorless. The reaction mixture was concentrated. The residue was diluted with water (50 mL), then extracted with Et0Ac (50 mL x3). The combined organic layer was washed with brine (50 mL), dried over anhydrous Na2SO4 and concentrated. The residue was purified by Combi Flash (30% to 80%
Et0Ac in PE) to give tert-butyl (S)-(5-bromo-6-((5-methy1-1,1-dioxido-1,2,5-thiadiazolidin-3-yOmethoxy)pyridin-3-yOcarbamate (2.00 g) as colorless gum. The average yield was 46% for 3 steps.
NMR (400 MHz, CDC13) 61.55 (9H, s), 2.27 (1H, dd, J= 7.6, 5.6 Hz), 2.84 (3H, s), 3.34-3.40 (1H, m), 3.62-3.70 (3H, m), 4.82-4.90 (1H, m), 6.68 (1H, s), 8.29 (1H, d, J= 2.8 Hz), 8.44 (1H, s).
Step 9: Preparation of tert-butyl (S)-(2-methyl-1,1-di oxi do-2,3,3 a,4-tetrahy dropyrido [2,3-b] [1,2,51thiadiazolo [2,3-d] [1,4] oxazin-8-yOcarbamate BocHN N
d [0675] A mixture of tert-butyl (S)-(5-bromo-6-((5-methy1-1,1-dioxido-1,2,5-thiadiazolidin-3-yl)methoxy)pyridin-3-yl)carbamate (2.30 g, 5.26 mmol), CuI
(301 mg, 1.58 mmol), Cs2CO3 (3.43 g, 10.5 mmol) and DMEDA (278 mg, 3.16 mmol) in anhydrous dioxane (80 mL) was degassed and purged with N2 for 3 times. Then the resulting reaction mixture was heated at 90 C for 16 hours under N2 atmosphere. The reaction mixture turned into brown suspension from yellow. LCMS showed the purity of the desired product is 74%
(Rt = 0.754 min; MS Calcd: 356.1; MS Found: 379.2 [M+Nal+). The reaction mixture was filtered through
BocHN Br [0674] To a solution of tert-butyl (S)-3-(43-bromo-5-((di-tert-butoxy carbonyl)amino)py ri din-2-yl)oxy)methyl)-5 -methyl-1,2,5 -thi adi azoli dine-2-carboxylate 1,1-dioxide (2.20 g, 3.69 mmol) in Me0H (40 mL) and H20 (20 mL) was added 10% aqueous NaOH (10 mL) at 15-20 C. Then the reaction mixture was stirred at C for 2 hours. The reaction mixture turned into yellow solution from colorless. The reaction mixture was concentrated. The residue was diluted with water (50 mL), then extracted with Et0Ac (50 mL x3). The combined organic layer was washed with brine (50 mL), dried over anhydrous Na2SO4 and concentrated. The residue was purified by Combi Flash (30% to 80%
Et0Ac in PE) to give tert-butyl (S)-(5-bromo-6-((5-methy1-1,1-dioxido-1,2,5-thiadiazolidin-3-yOmethoxy)pyridin-3-yOcarbamate (2.00 g) as colorless gum. The average yield was 46% for 3 steps.
NMR (400 MHz, CDC13) 61.55 (9H, s), 2.27 (1H, dd, J= 7.6, 5.6 Hz), 2.84 (3H, s), 3.34-3.40 (1H, m), 3.62-3.70 (3H, m), 4.82-4.90 (1H, m), 6.68 (1H, s), 8.29 (1H, d, J= 2.8 Hz), 8.44 (1H, s).
Step 9: Preparation of tert-butyl (S)-(2-methyl-1,1-di oxi do-2,3,3 a,4-tetrahy dropyrido [2,3-b] [1,2,51thiadiazolo [2,3-d] [1,4] oxazin-8-yOcarbamate BocHN N
d [0675] A mixture of tert-butyl (S)-(5-bromo-6-((5-methy1-1,1-dioxido-1,2,5-thiadiazolidin-3-yl)methoxy)pyridin-3-yl)carbamate (2.30 g, 5.26 mmol), CuI
(301 mg, 1.58 mmol), Cs2CO3 (3.43 g, 10.5 mmol) and DMEDA (278 mg, 3.16 mmol) in anhydrous dioxane (80 mL) was degassed and purged with N2 for 3 times. Then the resulting reaction mixture was heated at 90 C for 16 hours under N2 atmosphere. The reaction mixture turned into brown suspension from yellow. LCMS showed the purity of the desired product is 74%
(Rt = 0.754 min; MS Calcd: 356.1; MS Found: 379.2 [M+Nal+). The reaction mixture was filtered through
334 a pad of celite and the solid was washed with Et0Ac (25 mL x4). The filtrate was concentrated and the residue was purified by Combi Flash (35% to 70% Et0Ac in PE), then further purified by YMC-Pack CN (0% to 80% Et0H in PE) to give tert-butyl (S)-(2-methy1-1,1-dioxido-2,3,3a,4-tetrahydropyrido[2,3-b1[1,2,51thiadiazolo[2,3-d][1,41oxazin-8-yl)carbamate (560 mg, yield: 30%) as a yellow solid.
NMR (400 MHz, CDC13) 1.51 (9H, s), 2.89 (3H, s), 3.24 (1H, dd, J= 10.4, 5.4 Hz), 3.60 (1H, dd, J= 10.0, 4.8 Hz), 3.85 (1H, t, J= 10.8 Hz), 4.15-4.23 (1H, m), 4.34 (1H, dd, J=
10.8, 3.2 Hz), 8.52 (1H, brs), 7.82-7.86 (2H, m).
Step 10: Preparation of (S)-8-amino-2-methy1-2,3,3a,4-tetrahy dropy ri do [2,3 -b] [1,2,5]thiadiazolo [2,3-d] [1,4] oxazine 1,1-dioxide N
)H
OzzS"--N
d [0676] To a solution of tert-butyl (S)-(2-methy1-1,1-dioxido-2,3,3a,4-tetrahy dropyri do [2,3-b] [1,2,5] thi adi azol o [2,3 -d] [1,4] oxazin-8-yl)carbamate (560 mg, 1.57 mmol) in anhydrous DCM (5 mL) was added TFA (5 mL) at 15-20 C. Then the reaction mixture was stirred at 15-20 C for 2 hours. The reaction mixture turned into yellow solution from colorless. The reaction mixture was concentrated and the residue was basified with saturated aqueous NaHCO3 to pH = 8, then extracted with DCM (15 mL x5). The combined organic layer was dried over anhydrous Na2SO4 and concentrated to give (S)-8-amino-2-methy1-2,3,3a,4-tetrahy dropy ri do [2,3 -b] [1,2,5] thi adi azol o [2,3-d]
[1,4] oxazine 1,1-dioxide (339 mg, yield: 84%) as a white solid.
NMR (400 MHz, CDC13) (52.80 (3H, s), 3.15 (1H, dd, J= 10.4, 4.8 Hz), 3.52 (1H, dd, J=
10.4, 7.2 Hz), 3.83 (1H, t, J= 10.8 Hz), 4.00-4.10 (1H, m), 4.18 (1H, dd, J=
10.8, 3.2 Hz), 6.56 (1H, d, J= 2.4 Hz), 7.60 (1H, d, J= 2.4 Hz).
Note: Two protons of NH2 were not observed.
Step 11:
Preparation of 1-(5-methy1-3-(((S)-2-methy1-1,1-dioxido-2,3,3a,4-tetrahy dropyri do [2,3-b] [1,2,5] thi adi azol o [2,3 -d] [1,4] oxazin-8-yl)amino)-5H-chromeno [4,3-clpyridin-8-yl)pyrrolidin-2-one
NMR (400 MHz, CDC13) 1.51 (9H, s), 2.89 (3H, s), 3.24 (1H, dd, J= 10.4, 5.4 Hz), 3.60 (1H, dd, J= 10.0, 4.8 Hz), 3.85 (1H, t, J= 10.8 Hz), 4.15-4.23 (1H, m), 4.34 (1H, dd, J=
10.8, 3.2 Hz), 8.52 (1H, brs), 7.82-7.86 (2H, m).
Step 10: Preparation of (S)-8-amino-2-methy1-2,3,3a,4-tetrahy dropy ri do [2,3 -b] [1,2,5]thiadiazolo [2,3-d] [1,4] oxazine 1,1-dioxide N
)H
OzzS"--N
d [0676] To a solution of tert-butyl (S)-(2-methy1-1,1-dioxido-2,3,3a,4-tetrahy dropyri do [2,3-b] [1,2,5] thi adi azol o [2,3 -d] [1,4] oxazin-8-yl)carbamate (560 mg, 1.57 mmol) in anhydrous DCM (5 mL) was added TFA (5 mL) at 15-20 C. Then the reaction mixture was stirred at 15-20 C for 2 hours. The reaction mixture turned into yellow solution from colorless. The reaction mixture was concentrated and the residue was basified with saturated aqueous NaHCO3 to pH = 8, then extracted with DCM (15 mL x5). The combined organic layer was dried over anhydrous Na2SO4 and concentrated to give (S)-8-amino-2-methy1-2,3,3a,4-tetrahy dropy ri do [2,3 -b] [1,2,5] thi adi azol o [2,3-d]
[1,4] oxazine 1,1-dioxide (339 mg, yield: 84%) as a white solid.
NMR (400 MHz, CDC13) (52.80 (3H, s), 3.15 (1H, dd, J= 10.4, 4.8 Hz), 3.52 (1H, dd, J=
10.4, 7.2 Hz), 3.83 (1H, t, J= 10.8 Hz), 4.00-4.10 (1H, m), 4.18 (1H, dd, J=
10.8, 3.2 Hz), 6.56 (1H, d, J= 2.4 Hz), 7.60 (1H, d, J= 2.4 Hz).
Note: Two protons of NH2 were not observed.
Step 11:
Preparation of 1-(5-methy1-3-(((S)-2-methy1-1,1-dioxido-2,3,3a,4-tetrahy dropyri do [2,3-b] [1,2,5] thi adi azol o [2,3 -d] [1,4] oxazin-8-yl)amino)-5H-chromeno [4,3-clpyridin-8-yl)pyrrolidin-2-one
335 N N NI
0-1¨N
0 \
[0677] A mixture of (S)-8-amino-2-methyl-2,3,3a,4-tetrahy dropyri do [2,3 -b][1,2,5]thiadiazolo[2,3-d][1,4]oxazine 1,1-dioxide (60 mg, 0.23 mmol), 1-(3-chloro-5-methy1-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one (88 mg, 0.28 mmol), Pd2(dba)3 (21 mg, 0.023 mmol), Brettphos (25 mg, 0.047 mmol) and Cs2CO3 (229 mg, 0.702 mmol) in anhydrous dioxane (3 mL) was degassed and purged with N2 for 3 times. Then the resulting reaction mixture was heated at 90 C for 16 hours. The reaction mixture turned into brown suspension from red. LCMS showed the purity of the desired product is 60% (Rt = 0.671 min;
MS Calcd: 534.2; MS Found: 535.1 [M+H]+). The mixture was filtered through a pad of celite and the solid was washed with DCM/Me0H (10 mL x4, 10/1) and the filtrate was concentrated.
The residue was purified by Combi Flash (2% to 10% Me0H in DCM), then triturated with CH3CN (5 mL) and lyophilized to give 1-(5-methy1-3-4(S)-2-methy1-1,1-dioxido-2,3,3a,4-tetrahy dropyri do [2,3-b] [1,2,5] thi adi azol o [2,3 -d] [1,4] oxazin-8-yl)amino)-5H-chromeno [4,3-c]pyridin-8-yl)pyrrolidin-2-one (30.0 mg, yield: 24%) as a yellow solid.
1-1-1NMR (400 MHz, DMSO-d6) 5 1.60 (3H, d, J= 6.4 Hz), 2.05-2.16 (2H, m), 2.55-2.60 (2H, m), 2.81 (3H, s), 3.35-3.40 (1H, m), 3.66 (1H, dd, J= 10.8, 7.2 Hz), 3.76 (1H, t, J= 10.8 Hz), 3.91 (2H, t, J= 7.6 Hz), 4.26-4.36 (1H, m), 4.56 (1H, dd, J= 11.2, 2.8 Hz), 5.34 (1H, q, J=
6.4 Hz), 6.77 (1H, s), 7.38 (1H, dd, J= 8.4, 1.6 Hz), 7.46 (1H, d, J= 2.0 Hz), 7.93 (1H, d, J=
8.4 Hz), 8.15-8.25 (2H, m), 8.72 (1H, s), 9.55 (1H, brs).
Example 188: (S)-1-(5,5-dimethy1-3-((2-methyl-1,1-dioxido-2,3,3a,4-tetrahydropyrido[2,3-b][1,2,5]thiadiazolo[2,3-d][1,4]oxazin-8-yl)amino)-5H-chromeno[4,3-c]pyridin-8-y1)pyrrolidin-2-one
0-1¨N
0 \
[0677] A mixture of (S)-8-amino-2-methyl-2,3,3a,4-tetrahy dropyri do [2,3 -b][1,2,5]thiadiazolo[2,3-d][1,4]oxazine 1,1-dioxide (60 mg, 0.23 mmol), 1-(3-chloro-5-methy1-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one (88 mg, 0.28 mmol), Pd2(dba)3 (21 mg, 0.023 mmol), Brettphos (25 mg, 0.047 mmol) and Cs2CO3 (229 mg, 0.702 mmol) in anhydrous dioxane (3 mL) was degassed and purged with N2 for 3 times. Then the resulting reaction mixture was heated at 90 C for 16 hours. The reaction mixture turned into brown suspension from red. LCMS showed the purity of the desired product is 60% (Rt = 0.671 min;
MS Calcd: 534.2; MS Found: 535.1 [M+H]+). The mixture was filtered through a pad of celite and the solid was washed with DCM/Me0H (10 mL x4, 10/1) and the filtrate was concentrated.
The residue was purified by Combi Flash (2% to 10% Me0H in DCM), then triturated with CH3CN (5 mL) and lyophilized to give 1-(5-methy1-3-4(S)-2-methy1-1,1-dioxido-2,3,3a,4-tetrahy dropyri do [2,3-b] [1,2,5] thi adi azol o [2,3 -d] [1,4] oxazin-8-yl)amino)-5H-chromeno [4,3-c]pyridin-8-yl)pyrrolidin-2-one (30.0 mg, yield: 24%) as a yellow solid.
1-1-1NMR (400 MHz, DMSO-d6) 5 1.60 (3H, d, J= 6.4 Hz), 2.05-2.16 (2H, m), 2.55-2.60 (2H, m), 2.81 (3H, s), 3.35-3.40 (1H, m), 3.66 (1H, dd, J= 10.8, 7.2 Hz), 3.76 (1H, t, J= 10.8 Hz), 3.91 (2H, t, J= 7.6 Hz), 4.26-4.36 (1H, m), 4.56 (1H, dd, J= 11.2, 2.8 Hz), 5.34 (1H, q, J=
6.4 Hz), 6.77 (1H, s), 7.38 (1H, dd, J= 8.4, 1.6 Hz), 7.46 (1H, d, J= 2.0 Hz), 7.93 (1H, d, J=
8.4 Hz), 8.15-8.25 (2H, m), 8.72 (1H, s), 9.55 (1H, brs).
Example 188: (S)-1-(5,5-dimethy1-3-((2-methyl-1,1-dioxido-2,3,3a,4-tetrahydropyrido[2,3-b][1,2,5]thiadiazolo[2,3-d][1,4]oxazin-8-yl)amino)-5H-chromeno[4,3-c]pyridin-8-y1)pyrrolidin-2-one
336 I N NN
0-1¨N
0 \
[0678] A mixture of (S)-8-amino-2-methyl-2,3,3a,4-tetrahy dropyri do [2,3 -b][1,2,51thiadiazolo[2,3-d][1,41oxazine 1,1-dioxide (60 mg, 0.23 mmol) (see Example 187, steps 1-10), 1-(3-chloro-5,5-dimethy1-5H-chromeno[4,3-clpyridin-8-yl)pyrrolidin-2-one (92 mg, 0.28 mmol), Pd2(dba)3 (21 mg, 0.023 mmol), Brettphos (25 mg, 0.047 mmol) and Cs2CO3 (229 mg, 0.702 mmol) in anhydrous dioxane (3 mL) was degassed and purged with N2 for 3 times. Then the resulting reaction mixture was heated at 90 C for 16 hours.
The reaction mixture turned into brown suspension from red. LCMS showed the purity of the desired product is 37% (Rt = 0.685 min; MS Calcd: 548.2; MS Found: 549.1 [M+Hl+). The mixture was filtered through a pad of celite and the solid was washed with DCM/Me0H
(10 mL x4, 10/1) and the filtrate was concentrated. The residue was purified by Combi Flash (2% to 10%
Me0H in DCM), then triturated with CH3CN (5 mL) twice and lyophilized to give (S)-1-(5,5-dimethy1-3-((2-methy1-1,1-di oxi do-2,3,3a,4-tetrahy dropy rido [2,3 -b]
[1,2,5] thi adi azol o [2,3-d][1,4]oxazin-8-yl)amino)-5H-chromeno[4,3-clpyridin-8-yl)pyrrolidin-2-one (29.8 mg, yield:
23%) as an off-white solid.
NMR (400 MHz, DMSO-d6) 5 1.56 (6H, s), 2.00-2.10 (2H, m), 2.55-2.60 (2H, m), 2.75 (3H, s), 3.25-3.30 (1H, m), 3.60 (1H, dd, J= 10.8, 6.8 Hz), 3.70 (1H, t, J=
10.8 Hz), 3.84 (2H, t, J= 6.8 Hz), 4.20-4.30 (1H, m), 4.49 (1H, dd, J= 11.2, 3.2 Hz), 6.76 (1H, s), 7.30 (1H, dd, J= 8.8, 2.0 Hz), 7.40 (1H, d, J= 1.6 Hz), 7.88 (1H, d, J= 8.8 Hz), 8.11(1H, d, J= 2.0 Hz), 8.15 (1H, d, J= 2.4 Hz), 8.68 (1H, s), 9.47 (1H, brs).
Example 189: (S)-2-05,5-dimethy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[3,4-d]pyrimidin-3-yl)amino)-6,6a,7,8-tetrahydro-9H-pyrido [2,3-b] pyrrolo [1,2-d]
[1,4] oxazin-9-one
0-1¨N
0 \
[0678] A mixture of (S)-8-amino-2-methyl-2,3,3a,4-tetrahy dropyri do [2,3 -b][1,2,51thiadiazolo[2,3-d][1,41oxazine 1,1-dioxide (60 mg, 0.23 mmol) (see Example 187, steps 1-10), 1-(3-chloro-5,5-dimethy1-5H-chromeno[4,3-clpyridin-8-yl)pyrrolidin-2-one (92 mg, 0.28 mmol), Pd2(dba)3 (21 mg, 0.023 mmol), Brettphos (25 mg, 0.047 mmol) and Cs2CO3 (229 mg, 0.702 mmol) in anhydrous dioxane (3 mL) was degassed and purged with N2 for 3 times. Then the resulting reaction mixture was heated at 90 C for 16 hours.
The reaction mixture turned into brown suspension from red. LCMS showed the purity of the desired product is 37% (Rt = 0.685 min; MS Calcd: 548.2; MS Found: 549.1 [M+Hl+). The mixture was filtered through a pad of celite and the solid was washed with DCM/Me0H
(10 mL x4, 10/1) and the filtrate was concentrated. The residue was purified by Combi Flash (2% to 10%
Me0H in DCM), then triturated with CH3CN (5 mL) twice and lyophilized to give (S)-1-(5,5-dimethy1-3-((2-methy1-1,1-di oxi do-2,3,3a,4-tetrahy dropy rido [2,3 -b]
[1,2,5] thi adi azol o [2,3-d][1,4]oxazin-8-yl)amino)-5H-chromeno[4,3-clpyridin-8-yl)pyrrolidin-2-one (29.8 mg, yield:
23%) as an off-white solid.
NMR (400 MHz, DMSO-d6) 5 1.56 (6H, s), 2.00-2.10 (2H, m), 2.55-2.60 (2H, m), 2.75 (3H, s), 3.25-3.30 (1H, m), 3.60 (1H, dd, J= 10.8, 6.8 Hz), 3.70 (1H, t, J=
10.8 Hz), 3.84 (2H, t, J= 6.8 Hz), 4.20-4.30 (1H, m), 4.49 (1H, dd, J= 11.2, 3.2 Hz), 6.76 (1H, s), 7.30 (1H, dd, J= 8.8, 2.0 Hz), 7.40 (1H, d, J= 1.6 Hz), 7.88 (1H, d, J= 8.8 Hz), 8.11(1H, d, J= 2.0 Hz), 8.15 (1H, d, J= 2.4 Hz), 8.68 (1H, s), 9.47 (1H, brs).
Example 189: (S)-2-05,5-dimethy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[3,4-d]pyrimidin-3-yl)amino)-6,6a,7,8-tetrahydro-9H-pyrido [2,3-b] pyrrolo [1,2-d]
[1,4] oxazin-9-one
337 N
N N N
Step 1:
Preparation of (S)-2-amino-6,6a,7, 8-tetrahy dro-9H-py ri do [2,3-b] pyrrol o [1,2-d] [1,4] oxazin-9-one Step 2: Preparation of methyl 5-chloro-2-(methylthio)pyrimidine-4-carboxylate 0,0Me tNS
106791 To a stirring mixture of 5-chloro-2-(methylthio)pyrimidine-4-carboxylic acid (2.00 g, 9.77 mmol) and DMF (143 mg, 1.95 mmol) in DCM (40 mL) was added oxalyl chloride (4.3 mL, 48 mmol). The reaction mixture was stirred at 20 C for 1 hour. A yellow solution was formed. The reaction was concentrated in vacuo. Me0H (20 mL) was slowly added under nitrogen atmosphere at 0 C. The reaction mixture was stirred at 20 C for 1 hour under N2 atmosphere. The yellow solution turned to brown gradually. LCMS showed the purity of product is 72% (Rt = 0.767 min; MS Calcd: 218.0; MS Found: 218.6 [M+H1+). TLC
indicated one new major spot was formed. The reaction mixture was concentrated under reduced pressure. The residue was purified by Combi Flash (5% EA in PE) to give methyl 5-chloro-2-(methylthio)pyrimidine-4-carboxylate (1.96 g, yield: 92%) as a light yellow solid.
11-1NMR (400 MHz, CDC13) (52.57 (3H, s), 4.00 (3H, s), 8.61 (1H, s).
Step 3:
Preparation of methyl 5-(2-fluoro-4-(2-oxopyrrolidin-1-yl)pheny1)-2-(methylthio)pyrimidine-4-carboxylate
N N N
Step 1:
Preparation of (S)-2-amino-6,6a,7, 8-tetrahy dro-9H-py ri do [2,3-b] pyrrol o [1,2-d] [1,4] oxazin-9-one Step 2: Preparation of methyl 5-chloro-2-(methylthio)pyrimidine-4-carboxylate 0,0Me tNS
106791 To a stirring mixture of 5-chloro-2-(methylthio)pyrimidine-4-carboxylic acid (2.00 g, 9.77 mmol) and DMF (143 mg, 1.95 mmol) in DCM (40 mL) was added oxalyl chloride (4.3 mL, 48 mmol). The reaction mixture was stirred at 20 C for 1 hour. A yellow solution was formed. The reaction was concentrated in vacuo. Me0H (20 mL) was slowly added under nitrogen atmosphere at 0 C. The reaction mixture was stirred at 20 C for 1 hour under N2 atmosphere. The yellow solution turned to brown gradually. LCMS showed the purity of product is 72% (Rt = 0.767 min; MS Calcd: 218.0; MS Found: 218.6 [M+H1+). TLC
indicated one new major spot was formed. The reaction mixture was concentrated under reduced pressure. The residue was purified by Combi Flash (5% EA in PE) to give methyl 5-chloro-2-(methylthio)pyrimidine-4-carboxylate (1.96 g, yield: 92%) as a light yellow solid.
11-1NMR (400 MHz, CDC13) (52.57 (3H, s), 4.00 (3H, s), 8.61 (1H, s).
Step 3:
Preparation of methyl 5-(2-fluoro-4-(2-oxopyrrolidin-1-yl)pheny1)-2-(methylthio)pyrimidine-4-carboxylate
338 N S
[0680] A mixture of 1-(3-fluoro-4-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-yl)phenyl)pyrrolidin-2-one (1.26 g, 4.12 mmol), methyl 5-chloro-2-(methylthio)pyrimidine-4-carboxylate (500 mg, 2.29 mmol), Cs2CO3 (1.49 g, 4.57 mmol) in H20 (4 mL) and Pd(t-Bu3P)2 (58 mg, 0.11 mmol) in dioxane (20 mL) was stirred at 100 C for 5 hours under N2 atmosphere.
A black mixture was formed. LCMS showed the purity of the desired product is 49% (Rt =
0.690 min; MS Calcd: 361.1; MS Found: 361.9 [M+Hl+). TLC showed the starting material was consumed completely. The mixture was concentrated under reduced pressure.
The residue was purified by Combi Flash (70% Et0Ac in PE) to give methyl 5-(2-fluoro-4-(2-oxopyrrolidin-1-yl)pheny1)-2-(methylthio)pyrimidine-4-carboxylate (331 mg, yield: 40%) as a yellow solid.
Step 4: Preparation of 1-(3-fluoro-4-(4-(2-hydroxypropan-2-y0-2-(methylthio)pyrimidin-5-yOphenyOpyrrolidin-2-one N S
[0681] MeMgBr (3 M in Et20, 1.1 mL) was added slowly to a solution of methyl 5-(2-fluoro-4-(2-oxopy rroli din-1 -yl)pheny1)-2-(methy lthi o)py rimi dine-4-carb oxylate (330 mg, 0.913 mmol) in THF (12 mL) and DCM (3 mL) at 10 C under a nitrogen atmosphere. The resulting mixture was stirred at 10 C for 2 hours. The yellow solution turned to suspension.
LCMS showed the purity of the desired product was 36% (Rt = 0.705 min; MS
Calcd: 361.1;
MS Found: 362.0 [M+1-11+). Sat. aq. NH4C1 (15 mL) was added followed by EA (20 mL). The organic layer was separated and the aqueous layer was extracted with EA (15 mL
x2). The combined organics were dried over Na2SO4, filtered and concentrated to give 1-(3-fluoro-4-(4-(2-hy droxy propan-2-y1)-2-(methy lthi o)pyrimi din-5 -yl)phenyl)py rroli din-2-one (330 mg, crude) as a yellow solid. Used for the next step without further purification.
[0680] A mixture of 1-(3-fluoro-4-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-yl)phenyl)pyrrolidin-2-one (1.26 g, 4.12 mmol), methyl 5-chloro-2-(methylthio)pyrimidine-4-carboxylate (500 mg, 2.29 mmol), Cs2CO3 (1.49 g, 4.57 mmol) in H20 (4 mL) and Pd(t-Bu3P)2 (58 mg, 0.11 mmol) in dioxane (20 mL) was stirred at 100 C for 5 hours under N2 atmosphere.
A black mixture was formed. LCMS showed the purity of the desired product is 49% (Rt =
0.690 min; MS Calcd: 361.1; MS Found: 361.9 [M+Hl+). TLC showed the starting material was consumed completely. The mixture was concentrated under reduced pressure.
The residue was purified by Combi Flash (70% Et0Ac in PE) to give methyl 5-(2-fluoro-4-(2-oxopyrrolidin-1-yl)pheny1)-2-(methylthio)pyrimidine-4-carboxylate (331 mg, yield: 40%) as a yellow solid.
Step 4: Preparation of 1-(3-fluoro-4-(4-(2-hydroxypropan-2-y0-2-(methylthio)pyrimidin-5-yOphenyOpyrrolidin-2-one N S
[0681] MeMgBr (3 M in Et20, 1.1 mL) was added slowly to a solution of methyl 5-(2-fluoro-4-(2-oxopy rroli din-1 -yl)pheny1)-2-(methy lthi o)py rimi dine-4-carb oxylate (330 mg, 0.913 mmol) in THF (12 mL) and DCM (3 mL) at 10 C under a nitrogen atmosphere. The resulting mixture was stirred at 10 C for 2 hours. The yellow solution turned to suspension.
LCMS showed the purity of the desired product was 36% (Rt = 0.705 min; MS
Calcd: 361.1;
MS Found: 362.0 [M+1-11+). Sat. aq. NH4C1 (15 mL) was added followed by EA (20 mL). The organic layer was separated and the aqueous layer was extracted with EA (15 mL
x2). The combined organics were dried over Na2SO4, filtered and concentrated to give 1-(3-fluoro-4-(4-(2-hy droxy propan-2-y1)-2-(methy lthi o)pyrimi din-5 -yl)phenyl)py rroli din-2-one (330 mg, crude) as a yellow solid. Used for the next step without further purification.
339 Step 5: Preparation of 1-(5,5-dimethy1-3 -(methy lthi o)-5H-chromeno [3,4-d]
pyrimi din-8-yl)pyrrolidin-2-one KN
I
N S
[0682] To a solution of 1-(3-fluoro-4-(4-(2-hy droxypropan-2-y1)-2-(methylthio)pyrimidin-5-yl)phenyl)pyrrolidin-2-one (330 mg, 0.913 mmol) in THF
(15 mL) was added NaH (109 mg, 2.74 mmol, 60% in minerial oil) at 15 C and the resulting mixture was stirred at 15 C for 1 hour. A yellow solution was formed. TLC showed the starting material was consumed completely. Sat. aq. NH4C1 (10 mL) was added and the mixture was extracted with Et0Ac (15 mL x3). The combined organic layer was dried over Na2SO4, filtered, concentrated. The residue was purified by Combi Flash (45% EA in PE) to give 1-(5,5-dimethy1-3 -(methy lthi o)-5H-chromeno [3,4-d] py rimidin-8-yl)py rrolidin-2-one (280 mg, yield:
90% for two steps) as a yellow solid.
Step 6: Preparation of 1-(5 ,5 -dimethy1-3 -(methylsulfony1)-5H-chromeno [3 ,4-d] pyrimi din-8-yl)pyrrolidin-2-one c 0 I
N
[0683] mCPBA
(252 mg, 1.46 mmol) was added to a solution of 1-(5,5-dimethy1-3-(methylthio)-5H-chromeno[3,4-d]pyrimidin-8-yl)pyrrolidin-2-one (100 mg, 0.292 mmol) in DCM (5 mL). The resulting mixture was stirred at 50 C for 20 hours. A yellow solution was formed. LCMS showed the purity of the desired product was 94% (Rt = 0.620 min;
MS Calcd:
373.1; MS Found: 374.0 [M+H]+). Sat. aq. Na2S03 (15 mL) was added followed by DCM (15 mL). The organic layer was separated and the aqueous layer was extracted with DCM (10 mL
x2). The combined organic phase was washed with Sat. aq. NaHCO3 (15 mL) and brine (10 mL), dried over Na2SO4, filtered and concentrated to give 1-(5,5-dimethy1-3-(methylsulfony1)-5H-chromeno[3,4-dlpyrimidin-8-yOpyrrolidin-2-one (100 mg, yield: 91%) as a yellow solid.
Used for the next step without further purification.
pyrimi din-8-yl)pyrrolidin-2-one KN
I
N S
[0682] To a solution of 1-(3-fluoro-4-(4-(2-hy droxypropan-2-y1)-2-(methylthio)pyrimidin-5-yl)phenyl)pyrrolidin-2-one (330 mg, 0.913 mmol) in THF
(15 mL) was added NaH (109 mg, 2.74 mmol, 60% in minerial oil) at 15 C and the resulting mixture was stirred at 15 C for 1 hour. A yellow solution was formed. TLC showed the starting material was consumed completely. Sat. aq. NH4C1 (10 mL) was added and the mixture was extracted with Et0Ac (15 mL x3). The combined organic layer was dried over Na2SO4, filtered, concentrated. The residue was purified by Combi Flash (45% EA in PE) to give 1-(5,5-dimethy1-3 -(methy lthi o)-5H-chromeno [3,4-d] py rimidin-8-yl)py rrolidin-2-one (280 mg, yield:
90% for two steps) as a yellow solid.
Step 6: Preparation of 1-(5 ,5 -dimethy1-3 -(methylsulfony1)-5H-chromeno [3 ,4-d] pyrimi din-8-yl)pyrrolidin-2-one c 0 I
N
[0683] mCPBA
(252 mg, 1.46 mmol) was added to a solution of 1-(5,5-dimethy1-3-(methylthio)-5H-chromeno[3,4-d]pyrimidin-8-yl)pyrrolidin-2-one (100 mg, 0.292 mmol) in DCM (5 mL). The resulting mixture was stirred at 50 C for 20 hours. A yellow solution was formed. LCMS showed the purity of the desired product was 94% (Rt = 0.620 min;
MS Calcd:
373.1; MS Found: 374.0 [M+H]+). Sat. aq. Na2S03 (15 mL) was added followed by DCM (15 mL). The organic layer was separated and the aqueous layer was extracted with DCM (10 mL
x2). The combined organic phase was washed with Sat. aq. NaHCO3 (15 mL) and brine (10 mL), dried over Na2SO4, filtered and concentrated to give 1-(5,5-dimethy1-3-(methylsulfony1)-5H-chromeno[3,4-dlpyrimidin-8-yOpyrrolidin-2-one (100 mg, yield: 91%) as a yellow solid.
Used for the next step without further purification.
340 Step 7:
Preparation of (S)-2-((5,5-dimethy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[3,4-d] py rimi din-3 -yl)amino)-6,6a,7,8-tetrahy dro-9H-py rido [2,3 -b] pyrrol o [1,2-d] [1,4] oxazin-9-one I
N
[0684] To a solution of 1-(5,5 -dimethy1-3 -(methylsulfony1)-5H-chromeno [3,4-d]pyrimidin-8-yl)pyrrolidin-2-one (130 mg, 0.348 mmol) and (S)-2-amino-6,6a,7,8-tetrahydro-9H-pyrido[2,3-b]pyrrolo[1,2-d][1,41oxazin-9-one (107 mg, 0.522 mmol) in DMF
(4 mL) was added NaH (20 mg, 0.52 mmol, 60% in minerial oil) at 20 C. The reaction mixture was stirred at 20 C for 12 hours under N2 atmosphere. A black solution was formed gradually.
LCMS showed the purity of the desired product is 40% (Rt = 0.665 min; MS
Calcd: 498.2; MS
Found: 499.1 [M+H1+). The mixture was filtered. The filtrate was purified by prep-HPLC
(0.05% N}{31120 as an additive) and lyophilized to give (S)-2-45,5-dimethy1-8-(2-oxopy rroli din-l-y1)-5H-chromeno [3,4-d] py rimi din-3-yl)amino)-6,6a,7,8-tetrahy dro-9H-pyrido[2,3-b] pyrrolo[1,2-d] [1,41oxazin-9-one (27.1 mg, yield: 16%) as a yellow solid.
NMR (400 MHz, DMSO-d6) 6 1.60 (3H, s), 1.61 (3H, s), 1.62-1.72 (1H, m), 2.01-2.10 (2H, m), 2.17-2.25 (1H, m), 2.43 (3H, overlapped with DMSO), 2.63-2.71 (1H, m), 3.84 (2H, t, J= 6.8 Hz), 3.90 (1H, t, J= 10.8 Hz), 4.01-4.09 (1H, m), 4.59 (1H, dd, J=
10.8, 2.8 Hz), 7.32 (1H, dd, J= 8.4, 1.6 Hz), 7.39 (1H, d, J= 2.0 Hz), 7.84 (1H, d, J= 8.4 Hz), 8.13 (1H, d, J= 2.0 Hz), 8.56 (1H, s), 9.38 (1H, brs), 9.90 (1H, s).
[0685] LCMS
showed the purity of byproduct 1-(3-hydroxy-5,5-dimethy1-5H-chromeno[3,4-d]pyrimidin-8-yl)pyrrolidin-2-one is 50% (Rt = 0.596 min; MS
Calcd: 311.1;
MS Found: 311.9 [M+H1+). The mixture was filtered. The filtrate was purified by prep-HPLC
(0.05% NH31120 as an additive) and lyophilized to give 1-(3-hydroxy-5,5-dimethy1-5H-chromeno[3,4-d]pyrimidin-8-yl)pyrrolidin-2-one (3.10 mg, yield: 9%) as a white solid.
NMR (400 MHz, DMSO-d6) 6 1.49 (6H, s), 2.02-2.09 (2H, m), 2.48 (2H, overlapped with DMSO), 3.82 (2H, t, J= 6.8 Hz), 7.29 (1H, dd, J= 8.8, 2.0 Hz), 7.38 (1H, d, J=
2.0 Hz), 7.72 (1H, d, J= 8.8 Hz), 8.49 (1H, s), 12.25 (1H, brs).
Preparation of (S)-2-((5,5-dimethy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[3,4-d] py rimi din-3 -yl)amino)-6,6a,7,8-tetrahy dro-9H-py rido [2,3 -b] pyrrol o [1,2-d] [1,4] oxazin-9-one I
N
[0684] To a solution of 1-(5,5 -dimethy1-3 -(methylsulfony1)-5H-chromeno [3,4-d]pyrimidin-8-yl)pyrrolidin-2-one (130 mg, 0.348 mmol) and (S)-2-amino-6,6a,7,8-tetrahydro-9H-pyrido[2,3-b]pyrrolo[1,2-d][1,41oxazin-9-one (107 mg, 0.522 mmol) in DMF
(4 mL) was added NaH (20 mg, 0.52 mmol, 60% in minerial oil) at 20 C. The reaction mixture was stirred at 20 C for 12 hours under N2 atmosphere. A black solution was formed gradually.
LCMS showed the purity of the desired product is 40% (Rt = 0.665 min; MS
Calcd: 498.2; MS
Found: 499.1 [M+H1+). The mixture was filtered. The filtrate was purified by prep-HPLC
(0.05% N}{31120 as an additive) and lyophilized to give (S)-2-45,5-dimethy1-8-(2-oxopy rroli din-l-y1)-5H-chromeno [3,4-d] py rimi din-3-yl)amino)-6,6a,7,8-tetrahy dro-9H-pyrido[2,3-b] pyrrolo[1,2-d] [1,41oxazin-9-one (27.1 mg, yield: 16%) as a yellow solid.
NMR (400 MHz, DMSO-d6) 6 1.60 (3H, s), 1.61 (3H, s), 1.62-1.72 (1H, m), 2.01-2.10 (2H, m), 2.17-2.25 (1H, m), 2.43 (3H, overlapped with DMSO), 2.63-2.71 (1H, m), 3.84 (2H, t, J= 6.8 Hz), 3.90 (1H, t, J= 10.8 Hz), 4.01-4.09 (1H, m), 4.59 (1H, dd, J=
10.8, 2.8 Hz), 7.32 (1H, dd, J= 8.4, 1.6 Hz), 7.39 (1H, d, J= 2.0 Hz), 7.84 (1H, d, J= 8.4 Hz), 8.13 (1H, d, J= 2.0 Hz), 8.56 (1H, s), 9.38 (1H, brs), 9.90 (1H, s).
[0685] LCMS
showed the purity of byproduct 1-(3-hydroxy-5,5-dimethy1-5H-chromeno[3,4-d]pyrimidin-8-yl)pyrrolidin-2-one is 50% (Rt = 0.596 min; MS
Calcd: 311.1;
MS Found: 311.9 [M+H1+). The mixture was filtered. The filtrate was purified by prep-HPLC
(0.05% NH31120 as an additive) and lyophilized to give 1-(3-hydroxy-5,5-dimethy1-5H-chromeno[3,4-d]pyrimidin-8-yl)pyrrolidin-2-one (3.10 mg, yield: 9%) as a white solid.
NMR (400 MHz, DMSO-d6) 6 1.49 (6H, s), 2.02-2.09 (2H, m), 2.48 (2H, overlapped with DMSO), 3.82 (2H, t, J= 6.8 Hz), 7.29 (1H, dd, J= 8.8, 2.0 Hz), 7.38 (1H, d, J=
2.0 Hz), 7.72 (1H, d, J= 8.8 Hz), 8.49 (1H, s), 12.25 (1H, brs).
341 Example 190: (S)-2-09-fluoro-5,5-dimethy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[3,4-d] pyrimidin-3-yl)amino)-6,6a,7,8-tetrahydro-9H-pyrido [2,3-b] pyrrolo[1,2-d]
[1,4] oxazin-9-one N
I
N N
Step 1:
Preparation of methyl 5-(2,5-difluoro-4-(2-oxopyrrolidin-1-yl)pheny1)-2-(methylthio)pyrimidine-4-carboxylate I
N S
[0686] A mixture of 1-(2,5-difluoro-4-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-yl)phenyl)pyrrolidin-2-one (962 mg, 2.98 mmol), methyl 5-chloro-2-(methylthio)pyrimidine-4-carboxylate (500 mg, 2.29 mmol), Cs2CO3 (1.49 g, 4.58 mmol) in H20 (4 mL) and Pd(t-Bu3P)2 (58 mg, 0.11 mmol) in dioxane (20 mL) was stirred at 100 C for 5 hours under N2 atmosphere. A black mixture was formed. LCMS showed the purity of the desired product is 36% (Rt = 0.686 min; MS Calcd: 379.1; MS Found: 380.0 [M+H1+). Sat. aq. NaHCO3 (15 mL) was added followed by EA (20 mL). The organic layer was separated and the aqueous layer extracted with EA (20 mL x2). The combined organics were dried over Na2SO4, filtered and concentrated. The residue was purified by Combi Flash (60% Et0Ac in PE) to give methyl 5-(2,5 -difluoro-4-(2-oxopy rroli din-1 -yl)pheny1)-2-(methy lthi o)py rimi dine-4-carboxy late (391 mg, yield: 45%) as a yellow gum.
Step 2: Preparation of 1-(2,5-difluoro-4-(4-(2-hydroxypropan-2-y1)-2-(methylthio)pyrimidin-5-yl)phenyl)pyrrolidin-2-one
[1,4] oxazin-9-one N
I
N N
Step 1:
Preparation of methyl 5-(2,5-difluoro-4-(2-oxopyrrolidin-1-yl)pheny1)-2-(methylthio)pyrimidine-4-carboxylate I
N S
[0686] A mixture of 1-(2,5-difluoro-4-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-yl)phenyl)pyrrolidin-2-one (962 mg, 2.98 mmol), methyl 5-chloro-2-(methylthio)pyrimidine-4-carboxylate (500 mg, 2.29 mmol), Cs2CO3 (1.49 g, 4.58 mmol) in H20 (4 mL) and Pd(t-Bu3P)2 (58 mg, 0.11 mmol) in dioxane (20 mL) was stirred at 100 C for 5 hours under N2 atmosphere. A black mixture was formed. LCMS showed the purity of the desired product is 36% (Rt = 0.686 min; MS Calcd: 379.1; MS Found: 380.0 [M+H1+). Sat. aq. NaHCO3 (15 mL) was added followed by EA (20 mL). The organic layer was separated and the aqueous layer extracted with EA (20 mL x2). The combined organics were dried over Na2SO4, filtered and concentrated. The residue was purified by Combi Flash (60% Et0Ac in PE) to give methyl 5-(2,5 -difluoro-4-(2-oxopy rroli din-1 -yl)pheny1)-2-(methy lthi o)py rimi dine-4-carboxy late (391 mg, yield: 45%) as a yellow gum.
Step 2: Preparation of 1-(2,5-difluoro-4-(4-(2-hydroxypropan-2-y1)-2-(methylthio)pyrimidin-5-yl)phenyl)pyrrolidin-2-one
342 OH
I
N S
[0687] MeMgBr (3 M in Et20, 1.2 mL) was added slowly to a solution of methyl 5-(2,5-difluoro-4-(2-oxopyrrolidin-1-yl)pheny1)-2-(methylthio)pyrimidine-4-carboxylate (390 mg, 1.03 mmol) in THF (12 mL) and DCM (3 mL) at 15 C under a nitrogen atmosphere.
The resulting mixture was stirred at 15 C for 2 hours. The yellow solution turned to suspension.
LCMS showed the purity of the desired product was 84% (Rt = 0.711 min; MS
Calcd: 379.1;
MS Found: 379.9 [M+141+). Sat. aq. NH4C1 (15 mL) was added followed by EA (20 mL). The organic layer was separated and the aqueous layer was extracted with EA (15 mL
x2). The combined organics were dried over Na2SO4, filtered and concentrated to give 1-(2,5-difluoro-4-(4-(2-hydroxypropan-2-y1)-2-(methylthio)pyrimidin-5-yOphenyOpyrrolidin-2-one (390 mg, crude) as a yellow gum. Used for the next step without further purification.
Step 3.
Preparation of 1-(9-fluoro-5,5-dimethy1-3-(methylthio)-5H-chromeno[3,4-d] pyrimidin-8-yOpyrrolidin-2-one N
I
N S
[0688] To a solution of 1-(2,5 -difluoro-4-(4-(2-hy droxy propan-2-y1)-2-(methylthio)py rimidin-5-yl)phenyl)pyrrolidin-2-one (390 mg, 1.03 mmol) in THF
(15 mL) was added NaH (123 mg, 3.08 mmol, 60% in minerial oil) at 15 C and the resulting mixture was stirred at 15 C for 1 hour. A yellow solution was formed. LCMS showed the purity of the desired product was 65% (Rt = 0.766 min; MS Calcd: 359.1; MS Found: 360.0 [M+H1+). TLC
showed the starting material was consumed completely. Sat. aq. NH4C1 (10 mL) was added and the mixture was extracted with Et0Ac (15 mL x3). The combined organic layer was dried over Na2SO4, filtered, concentrated. The residue was purified by Combi Flash (35% EA in PE) to give 1-(9-fluoro-5,5-dimethy1-3-(methylthio)-5H-chromeno [3 ,4-d1 pyrimi din-8-yOpyrrolidin-2-one (142 mg, yield: 38% for two steps) as a yellow solid.
I
N S
[0687] MeMgBr (3 M in Et20, 1.2 mL) was added slowly to a solution of methyl 5-(2,5-difluoro-4-(2-oxopyrrolidin-1-yl)pheny1)-2-(methylthio)pyrimidine-4-carboxylate (390 mg, 1.03 mmol) in THF (12 mL) and DCM (3 mL) at 15 C under a nitrogen atmosphere.
The resulting mixture was stirred at 15 C for 2 hours. The yellow solution turned to suspension.
LCMS showed the purity of the desired product was 84% (Rt = 0.711 min; MS
Calcd: 379.1;
MS Found: 379.9 [M+141+). Sat. aq. NH4C1 (15 mL) was added followed by EA (20 mL). The organic layer was separated and the aqueous layer was extracted with EA (15 mL
x2). The combined organics were dried over Na2SO4, filtered and concentrated to give 1-(2,5-difluoro-4-(4-(2-hydroxypropan-2-y1)-2-(methylthio)pyrimidin-5-yOphenyOpyrrolidin-2-one (390 mg, crude) as a yellow gum. Used for the next step without further purification.
Step 3.
Preparation of 1-(9-fluoro-5,5-dimethy1-3-(methylthio)-5H-chromeno[3,4-d] pyrimidin-8-yOpyrrolidin-2-one N
I
N S
[0688] To a solution of 1-(2,5 -difluoro-4-(4-(2-hy droxy propan-2-y1)-2-(methylthio)py rimidin-5-yl)phenyl)pyrrolidin-2-one (390 mg, 1.03 mmol) in THF
(15 mL) was added NaH (123 mg, 3.08 mmol, 60% in minerial oil) at 15 C and the resulting mixture was stirred at 15 C for 1 hour. A yellow solution was formed. LCMS showed the purity of the desired product was 65% (Rt = 0.766 min; MS Calcd: 359.1; MS Found: 360.0 [M+H1+). TLC
showed the starting material was consumed completely. Sat. aq. NH4C1 (10 mL) was added and the mixture was extracted with Et0Ac (15 mL x3). The combined organic layer was dried over Na2SO4, filtered, concentrated. The residue was purified by Combi Flash (35% EA in PE) to give 1-(9-fluoro-5,5-dimethy1-3-(methylthio)-5H-chromeno [3 ,4-d1 pyrimi din-8-yOpyrrolidin-2-one (142 mg, yield: 38% for two steps) as a yellow solid.
343 Step 4: Preparation of 1-(9-fluoro-5,5-dimethy1-3-(methylsulfiny1)-5H-chromeno[3,4-d] pyrimidin-8-yOpyrrolidin-2-one I N
N S
[0689] mCPBA
(336 mg, 1.95 mmol) was added to a solution of 1-(9-fluoro-5,5-dimethy1-3-(methylthio)-5H-chromeno[3,4-dlpyrimidin-8-yOpyrrolidin-2-one (140 mg, 0.389 mmol) in DCM (4 mL) at 25 C. The resulting mixture was stirred at 25 C for 10 hours.
Then the resulting mixture was stirred at 50 C for 5 hours. The suspension turned to a yellow solution. LCMS
showed the purity of the desired product was 96% (Rt = 0.642 min; MS Calcd:
391.1; MS
Found: 392.0 [M+H1+). Sat. aq. Na2S03 (15 mL) was added followed by DCM (15 mL). The organic layer was separated and the aqueous layer was extracted with DCM (10 mL x2). The combined organic phase was washed with Sat. aq. NaHCO3 (15 mL) and brine (10 mL), dried over Na2SO4, filtered and concentrated to give 1-(9-fluoro-5,5-dimethy1-3-(methylsulfiny1)-5H-chromeno[3,4-dlpyrimidin-8-yOpyrrolidin-2-one (150 mg, crude) as a yellow solid. Used for the next step without further purification.
Step 5:
Preparation of 1 -(9-fluoro-5,5 -dimethy1-3 -(methyls ulfony1)-5H-chromeno [3,4-d] pyrimidin-8-yOpyrrolidin-2-one N
I
N
[0690] mCPBA
(345 mg, 2.00 mmol) was added to a solution of 1-(9-fluoro-5,5-dimethy1-3-(methylsulfiny1)-5H-chromeno[3,4-dlpyrimidin-8-y1)pyrrolidin-2-one (150 mg, 0.399 mmol) in DCM (4 mL) at 25 C. The resulting mixture was stirred at 50 C for 12 hours. The suspension turned to a yellow solution. LCMS showed the purity of the desired product was 93% (Rt = 0.657 min; MS Calcd: 391.1; MS Found: 392.0 [M+H1+). Sat. aq. Na2S03 (15 mL) was added followed by DCM (15 mL). The organic layer was separated and the aqueous layer was extracted with DCM (10 mL x2). The combined organic phase was washed with Sat. aq.
NaHCO3 (15 mL) and brine (10 mL), dried over Na2SO4, filtered and concentrated to give 1-
N S
[0689] mCPBA
(336 mg, 1.95 mmol) was added to a solution of 1-(9-fluoro-5,5-dimethy1-3-(methylthio)-5H-chromeno[3,4-dlpyrimidin-8-yOpyrrolidin-2-one (140 mg, 0.389 mmol) in DCM (4 mL) at 25 C. The resulting mixture was stirred at 25 C for 10 hours.
Then the resulting mixture was stirred at 50 C for 5 hours. The suspension turned to a yellow solution. LCMS
showed the purity of the desired product was 96% (Rt = 0.642 min; MS Calcd:
391.1; MS
Found: 392.0 [M+H1+). Sat. aq. Na2S03 (15 mL) was added followed by DCM (15 mL). The organic layer was separated and the aqueous layer was extracted with DCM (10 mL x2). The combined organic phase was washed with Sat. aq. NaHCO3 (15 mL) and brine (10 mL), dried over Na2SO4, filtered and concentrated to give 1-(9-fluoro-5,5-dimethy1-3-(methylsulfiny1)-5H-chromeno[3,4-dlpyrimidin-8-yOpyrrolidin-2-one (150 mg, crude) as a yellow solid. Used for the next step without further purification.
Step 5:
Preparation of 1 -(9-fluoro-5,5 -dimethy1-3 -(methyls ulfony1)-5H-chromeno [3,4-d] pyrimidin-8-yOpyrrolidin-2-one N
I
N
[0690] mCPBA
(345 mg, 2.00 mmol) was added to a solution of 1-(9-fluoro-5,5-dimethy1-3-(methylsulfiny1)-5H-chromeno[3,4-dlpyrimidin-8-y1)pyrrolidin-2-one (150 mg, 0.399 mmol) in DCM (4 mL) at 25 C. The resulting mixture was stirred at 50 C for 12 hours. The suspension turned to a yellow solution. LCMS showed the purity of the desired product was 93% (Rt = 0.657 min; MS Calcd: 391.1; MS Found: 392.0 [M+H1+). Sat. aq. Na2S03 (15 mL) was added followed by DCM (15 mL). The organic layer was separated and the aqueous layer was extracted with DCM (10 mL x2). The combined organic phase was washed with Sat. aq.
NaHCO3 (15 mL) and brine (10 mL), dried over Na2SO4, filtered and concentrated to give 1-
344 (9-fluoro-5,5 -dimethy1-3 -(methylsulfony1)-5H-chromeno [3 ,4-d] py rimi din-8-yl)py rrolidin-2-one (150 mg, yield: 96% for two steps) as a yellow solid. Used for the next step without further purification.
Step 6:
Preparation of (S)-2-((9-fluoro-5,5-dimethy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno [3 ,4-d] py rimi din-3 -yl)amino)-6,6a,7,8-tetrahy dro-9H-py ri do [2,3 -b] py rrol o [1,2-d] [1,4] oxazin-9-one gN 0 N
I
N
[0691] To a solution of 1-(9-fluoro-5,5-dimethy1-3-(methylsulfony1)-5H-chromeno[3,4-dlpyrimidin-8-yOpyrrolidin-2-one (150 mg, 0.383 mmol) and (S)-2-amino-6,6a,7,8-tetrahydro-9H-pyrido[2,3-blpyrrolo[1,2-d][1,41oxazin-9-one (118 mg, 0.574 mmol) in DMF
(4 mL) was added NaH (23 mg, 0.58 mmol, 60% in mineral oil) at 20 C. The reaction mixture was stirred at 20 C for 12 hours under N2 atmosphere. A black solution was formed gradually.
LCMS showed the purity of the desired product is 23% (Rt = 0.697 min; MS
Calcd: 516.2; MS
Found: 517.1 [M+H]+). The mixture was filtered. The filtrate was purified by prep-HPLC
(0.05% NH31120 as an additive) and lyophilized to give (S)-2-((9-fluoro-5,5-dimethy1-8-(2-oxopy rroli din-l-y1)-5H-chromeno [3,4-d] py rimi din-3-yl)amino)-6,6a,7,8-tetrahy dro-9H-pyrido[2,3-b] pyrrolo[1,2-d] [1,4] oxazin-9-one (8.9 mg, yield: 5%) as an off-white solid.
NMR (400 MHz, DMSO-d6) 6 1.61 (3H, s), 1.62(3H, s), 1.67-1.73 (1H, m), 2.05-2.11 (2H, m), 2.20-2.25 (1H, m), 2.37-2.45 (3H, m), 2.65-2.72 (1H, m), 3.78 (2H, t, J= 7.2 Hz), 3.92 (1H, t, J= 10.8 Hz), 4.04-4.11 (1H, m), 4.60 (1H, dd, J= 11.2, 2.4 Hz), 7.06 (1H, d, J=
7.2 Hz), 7.87 (1H, d, J= 11.6 Hz), 7.14 (1H, d, J= 2.0 Hz), 9.01 (1H, s), 9.38 (1H, brs), 10.04 (1H, s).
Example 191: N-(5-05,5-dimethy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno14,3-c]pyridin-3-yl)amino)-2-methoxypyridin-3-yllacetamide
Step 6:
Preparation of (S)-2-((9-fluoro-5,5-dimethy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno [3 ,4-d] py rimi din-3 -yl)amino)-6,6a,7,8-tetrahy dro-9H-py ri do [2,3 -b] py rrol o [1,2-d] [1,4] oxazin-9-one gN 0 N
I
N
[0691] To a solution of 1-(9-fluoro-5,5-dimethy1-3-(methylsulfony1)-5H-chromeno[3,4-dlpyrimidin-8-yOpyrrolidin-2-one (150 mg, 0.383 mmol) and (S)-2-amino-6,6a,7,8-tetrahydro-9H-pyrido[2,3-blpyrrolo[1,2-d][1,41oxazin-9-one (118 mg, 0.574 mmol) in DMF
(4 mL) was added NaH (23 mg, 0.58 mmol, 60% in mineral oil) at 20 C. The reaction mixture was stirred at 20 C for 12 hours under N2 atmosphere. A black solution was formed gradually.
LCMS showed the purity of the desired product is 23% (Rt = 0.697 min; MS
Calcd: 516.2; MS
Found: 517.1 [M+H]+). The mixture was filtered. The filtrate was purified by prep-HPLC
(0.05% NH31120 as an additive) and lyophilized to give (S)-2-((9-fluoro-5,5-dimethy1-8-(2-oxopy rroli din-l-y1)-5H-chromeno [3,4-d] py rimi din-3-yl)amino)-6,6a,7,8-tetrahy dro-9H-pyrido[2,3-b] pyrrolo[1,2-d] [1,4] oxazin-9-one (8.9 mg, yield: 5%) as an off-white solid.
NMR (400 MHz, DMSO-d6) 6 1.61 (3H, s), 1.62(3H, s), 1.67-1.73 (1H, m), 2.05-2.11 (2H, m), 2.20-2.25 (1H, m), 2.37-2.45 (3H, m), 2.65-2.72 (1H, m), 3.78 (2H, t, J= 7.2 Hz), 3.92 (1H, t, J= 10.8 Hz), 4.04-4.11 (1H, m), 4.60 (1H, dd, J= 11.2, 2.4 Hz), 7.06 (1H, d, J=
7.2 Hz), 7.87 (1H, d, J= 11.6 Hz), 7.14 (1H, d, J= 2.0 Hz), 9.01 (1H, s), 9.38 (1H, brs), 10.04 (1H, s).
Example 191: N-(5-05,5-dimethy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno14,3-c]pyridin-3-yl)amino)-2-methoxypyridin-3-yllacetamide
345 9, 0 N N NH
[0692] A
mixture of Pd2(dba)3 (18 mg, 0.019 mmol) and Brettphos (21 mg, 0.038 mmol) in 1,4-dioxane (1 mL) was stirred at 50 C for 10 min. 1-(3-amino-5,5-dimethy1-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (75 mg, 0.24 mmol), N-(5-bromo-2-methoxypyridin-3-yl)acetamide (59 mg, 0.24 mmol) in dioxane (4 mL) and Cs2CO3 (197 mg, 0.606 mmol) were added and the resulting mixture was stirred at 100 C for 12 hours. A black brown mixture was formed. LCMS showed that the purity of the desired product is 50% (Rt =
0.613 min; MS Calcd: 473.2; MS Found: 474.2 [M+H1+). The reaction mixture was diluted with DCM (10 mL), filtered and concentrated. The residue was purified by prep-HPLC
(0.225% FA as an additive) and lyophilized to give N-(5-((5,5-dimethy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno [4,3 -c] pyri din-3 -y Damino)-2-methoxypyri din-3 -y0acetami de (19.9 mg, yield: 17%) as a yellow solid.
NMR (400 MHz, DMSO-d6) 6 1.54(6H, s), 2.02-2.11 (2H, m), 2.12(3H, s), 2.48 (2H, overlapped with DMSO), 3.84 (2H, t, J= 6.8 Hz), 3.91 (3H, s), 6.73 (1H, s), 7.28 (1H, dd, J
= 8.4, 2.0 Hz), 7.38 (1H, d, J= 2.4 Hz), 7.86 (1H, d, J= 8.8 Hz), 8.30 (1H, d, J= 2.4 Hz), 8.58 (1H, d, J= 2.4 Hz), 8.61 (1H, s), 9.15 (1H, brs), 9.34 (1H, brs).
[0693] The following compounds were prepared according to the general procedure described herein, as well as the individual procedure for any structurally related compounds.
The procedure utilized the appropriate reagents, solvents, and starting materials according to the final products. All reactions were carried out under suitable conditions, including but not limited to temperature, pressure, and time.
Table 1 illustrates compounds of the invention that were prepared in accordance with any of the synthetic method described above using suitable starting materials, reagents and appropriate and necessary conditions to these compounds.
[0692] A
mixture of Pd2(dba)3 (18 mg, 0.019 mmol) and Brettphos (21 mg, 0.038 mmol) in 1,4-dioxane (1 mL) was stirred at 50 C for 10 min. 1-(3-amino-5,5-dimethy1-chromeno[4,3-clpyridin-8-yOpyrrolidin-2-one (75 mg, 0.24 mmol), N-(5-bromo-2-methoxypyridin-3-yl)acetamide (59 mg, 0.24 mmol) in dioxane (4 mL) and Cs2CO3 (197 mg, 0.606 mmol) were added and the resulting mixture was stirred at 100 C for 12 hours. A black brown mixture was formed. LCMS showed that the purity of the desired product is 50% (Rt =
0.613 min; MS Calcd: 473.2; MS Found: 474.2 [M+H1+). The reaction mixture was diluted with DCM (10 mL), filtered and concentrated. The residue was purified by prep-HPLC
(0.225% FA as an additive) and lyophilized to give N-(5-((5,5-dimethy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno [4,3 -c] pyri din-3 -y Damino)-2-methoxypyri din-3 -y0acetami de (19.9 mg, yield: 17%) as a yellow solid.
NMR (400 MHz, DMSO-d6) 6 1.54(6H, s), 2.02-2.11 (2H, m), 2.12(3H, s), 2.48 (2H, overlapped with DMSO), 3.84 (2H, t, J= 6.8 Hz), 3.91 (3H, s), 6.73 (1H, s), 7.28 (1H, dd, J
= 8.4, 2.0 Hz), 7.38 (1H, d, J= 2.4 Hz), 7.86 (1H, d, J= 8.8 Hz), 8.30 (1H, d, J= 2.4 Hz), 8.58 (1H, d, J= 2.4 Hz), 8.61 (1H, s), 9.15 (1H, brs), 9.34 (1H, brs).
[0693] The following compounds were prepared according to the general procedure described herein, as well as the individual procedure for any structurally related compounds.
The procedure utilized the appropriate reagents, solvents, and starting materials according to the final products. All reactions were carried out under suitable conditions, including but not limited to temperature, pressure, and time.
Table 1 illustrates compounds of the invention that were prepared in accordance with any of the synthetic method described above using suitable starting materials, reagents and appropriate and necessary conditions to these compounds.
346 Example Compound Name Structure 192 (S)-2-(((R)-5-methy1-8-(2- 0 oxopyrrolidin-l-y1)-5H- H
chromeno [4,3-c] py ri din-3 - N
yl)amino)-6,6a,7,8-tetrahydro- I d 9H-py ri do [2,3-b] py rrol o [1,2- N
d] [1,4] oxazin-9-one CN,L1 0 193 (S)-2-(((S)-5-methy1-8-(2- 0 oxopyrrolidin-l-y1)-5H- H
chromeno [4,3-c] py ri din-3 - N N N
y1)amino)-6,6a,7,8-tetrahydro- I I
9H-py ri do [2,3-b] py rrol o [1,2- N o d] [1,4] oxazin-9-one 194 (S)-2-((8-(2-oxopyrrolidin-1- 0 yl)spiro [chromeno [4,3- H
c] py ri dine-5,3'-oxetan] -3 - N
yl)amino)-6,6a,7,8-tetrahydro- I LI
9H-py ri do [2,3-b] py rrol o [1,2- N 0 d] [1,4] oxazin-9-one CN.L1 0 0 195 (S)-2-((8-(2-oxopyrrolidin-1- o yl)spiro [chromeno [4,3- H
c] py ri dine-5,1'-cy cl obutan] -3- N N rx1\1-yl)amino)-6,6a,7,8-tetrahydro- I I
9H-py ri do [2,3-b] py rrol o [1,2- N o d] [1,4] oxazin-9-one Q o o 196 N-(5-((5-methy1-8-(2- /----.-- N
oxopyrrolidin-l-y1)-5H- HN
chromeno [4,3-c] py ri din-3 - H H
N N N
yl)amino)pyridin-3-y1)-1H-I I
N
benzo [d] imidazole-7-carboxami de CN.L1 0 o
chromeno [4,3-c] py ri din-3 - N
yl)amino)-6,6a,7,8-tetrahydro- I d 9H-py ri do [2,3-b] py rrol o [1,2- N
d] [1,4] oxazin-9-one CN,L1 0 193 (S)-2-(((S)-5-methy1-8-(2- 0 oxopyrrolidin-l-y1)-5H- H
chromeno [4,3-c] py ri din-3 - N N N
y1)amino)-6,6a,7,8-tetrahydro- I I
9H-py ri do [2,3-b] py rrol o [1,2- N o d] [1,4] oxazin-9-one 194 (S)-2-((8-(2-oxopyrrolidin-1- 0 yl)spiro [chromeno [4,3- H
c] py ri dine-5,3'-oxetan] -3 - N
yl)amino)-6,6a,7,8-tetrahydro- I LI
9H-py ri do [2,3-b] py rrol o [1,2- N 0 d] [1,4] oxazin-9-one CN.L1 0 0 195 (S)-2-((8-(2-oxopyrrolidin-1- o yl)spiro [chromeno [4,3- H
c] py ri dine-5,1'-cy cl obutan] -3- N N rx1\1-yl)amino)-6,6a,7,8-tetrahydro- I I
9H-py ri do [2,3-b] py rrol o [1,2- N o d] [1,4] oxazin-9-one Q o o 196 N-(5-((5-methy1-8-(2- /----.-- N
oxopyrrolidin-l-y1)-5H- HN
chromeno [4,3-c] py ri din-3 - H H
N N N
yl)amino)pyridin-3-y1)-1H-I I
N
benzo [d] imidazole-7-carboxami de CN.L1 0 o
347 Example Compound Name Structure 197 (S)-2'-((5-(3-fluoro-4-(2-oxopyrrolidin-1-yl)phenyl)pyridin-2-yl)amino)- H
Nrx 6a',7'-dihydro-6'H,9'H-I I
spiro[cyclopropane-1,8'- F õ..-N ...., pyrido[2,3-blpyrrolo[1,2-d][1,41oxazin1-9'-one CLI
o 198 (E)-N-(5-((5,5-dimethy1-8-(2- H
oxopyrrolidin-1-y1)-5H- N H H
N _ N
chromeno[4,3-clpyridin-3- I 0 yOamino)pyridin-3-y1)-4-(4- N
(dimethylamino)but-2-enamido)benzamide 0 199 (E)-N-(3-(3-((5-((5,5-dimethy1-8-(2-oxopyrrolidin-1-y1)-5H- N 111 Ill 0 H
N "
chromeno[4,3-clpyridin-3- N
yl)amino)pyridin-3-yl)amino)-3- n 0 oxopropyl)pheny1)-4- "--0 (dimethylamino)but-2-enamide 200 (E)-4-(4-(dimethylamino)but-2-H
enamido)-N-(5-((8-(2-oxopyrrolidin-1-y1)-5H- I U 0 chromeno[4,3-clpyridin-3- N
yl)amino)pyridin-3-yl)benzamide Q
201 (6aS)-2-((9-fluoro-5-methy1-8-(2-oxopyrrolidin-1-y1)-5H- 0 OH
chromeno[4,3-clpyridin-3- H
yl)amino)-8-hydroxy-6,6a,7,8-I I
tetrahydro-9H-pyrido[2,3- F
blpyrrolo[1,2-d][1,41oxazin-9-one Q o o 202 1-(4-(pyridin-4-y1)-5H-chromeno[4,3-clpyridin-8- N
yl)pyrrolidin-2-one I, ....,..-I
\ N
Nrx 6a',7'-dihydro-6'H,9'H-I I
spiro[cyclopropane-1,8'- F õ..-N ...., pyrido[2,3-blpyrrolo[1,2-d][1,41oxazin1-9'-one CLI
o 198 (E)-N-(5-((5,5-dimethy1-8-(2- H
oxopyrrolidin-1-y1)-5H- N H H
N _ N
chromeno[4,3-clpyridin-3- I 0 yOamino)pyridin-3-y1)-4-(4- N
(dimethylamino)but-2-enamido)benzamide 0 199 (E)-N-(3-(3-((5-((5,5-dimethy1-8-(2-oxopyrrolidin-1-y1)-5H- N 111 Ill 0 H
N "
chromeno[4,3-clpyridin-3- N
yl)amino)pyridin-3-yl)amino)-3- n 0 oxopropyl)pheny1)-4- "--0 (dimethylamino)but-2-enamide 200 (E)-4-(4-(dimethylamino)but-2-H
enamido)-N-(5-((8-(2-oxopyrrolidin-1-y1)-5H- I U 0 chromeno[4,3-clpyridin-3- N
yl)amino)pyridin-3-yl)benzamide Q
201 (6aS)-2-((9-fluoro-5-methy1-8-(2-oxopyrrolidin-1-y1)-5H- 0 OH
chromeno[4,3-clpyridin-3- H
yl)amino)-8-hydroxy-6,6a,7,8-I I
tetrahydro-9H-pyrido[2,3- F
blpyrrolo[1,2-d][1,41oxazin-9-one Q o o 202 1-(4-(pyridin-4-y1)-5H-chromeno[4,3-clpyridin-8- N
yl)pyrrolidin-2-one I, ....,..-I
\ N
348 Example Compound Name Structure 203 1-(5-methy1-4-(pyridin-4-ylamino)-5H-chromeno[4,3- N
clpyridin-8-yOpyrrolidin-2-one I I
/ /
N
jJ
H
204 (6aS,8R)-2-((9-fluoro-5-methy1-8-(2-oxopyrrolidin-1-y1)-5H- 9, 0 chromeno[4,3-c1pyridin-3- 0 N 0 yl)amino)-8-hydroxy-8-methyl- F
I N N
H
6,6a,7,8-tetrahydro-9H-N - ...
pyrido[2,3-blpyrrolo[1,2- H
d][1,4]oxazin-9-one 0._ HO
205 (6aS,8R)-8-hydroxy-8-methy1-2 cii -((5-methy1-8-(2-oxopyrrolidin-1- N 0 y1)-5H-chromeno[4,3-clpyridin- 0 TIIIIIII:IEIL 0 3-yl)amino)-6,6a,7,8-tetrahydro- I ._I-I
9H-pyrido[2,3-blpyrrolo[1,2-N NN
d][1,41oxazin-9-one H
206 (6aS)-8-hydroxy-2-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H- 9 0 chromeno[4,3-clpyridin-3- 0 N I :....
yl)amino)-6,6a,7,8-tetrahydro-I H
9H-pyrido[2,3-blpyrrolo[1,2-N NN
d][1,41oxazin-9-one H
207 1-(5-methy1-4-(pyridin-4-y1)-5H- N
i chromeno[4,3-clpyridin-8- I
yl)pyrrolidin-2-one I
N
Ct 0 208 1-(5,5-dimethy1-3-((1-methyl-2,3- H I
dihydro-1H-pyrido[2,3- NNN
b][1,41oxazin-7-y0amino)-5H- I I t I
chromeno[3,4-dlpyrimidin-8- N N 0 yl)pyrrolidin-2-one C.41 0
clpyridin-8-yOpyrrolidin-2-one I I
/ /
N
jJ
H
204 (6aS,8R)-2-((9-fluoro-5-methy1-8-(2-oxopyrrolidin-1-y1)-5H- 9, 0 chromeno[4,3-c1pyridin-3- 0 N 0 yl)amino)-8-hydroxy-8-methyl- F
I N N
H
6,6a,7,8-tetrahydro-9H-N - ...
pyrido[2,3-blpyrrolo[1,2- H
d][1,4]oxazin-9-one 0._ HO
205 (6aS,8R)-8-hydroxy-8-methy1-2 cii -((5-methy1-8-(2-oxopyrrolidin-1- N 0 y1)-5H-chromeno[4,3-clpyridin- 0 TIIIIIII:IEIL 0 3-yl)amino)-6,6a,7,8-tetrahydro- I ._I-I
9H-pyrido[2,3-blpyrrolo[1,2-N NN
d][1,41oxazin-9-one H
206 (6aS)-8-hydroxy-2-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H- 9 0 chromeno[4,3-clpyridin-3- 0 N I :....
yl)amino)-6,6a,7,8-tetrahydro-I H
9H-pyrido[2,3-blpyrrolo[1,2-N NN
d][1,41oxazin-9-one H
207 1-(5-methy1-4-(pyridin-4-y1)-5H- N
i chromeno[4,3-clpyridin-8- I
yl)pyrrolidin-2-one I
N
Ct 0 208 1-(5,5-dimethy1-3-((1-methyl-2,3- H I
dihydro-1H-pyrido[2,3- NNN
b][1,41oxazin-7-y0amino)-5H- I I t I
chromeno[3,4-dlpyrimidin-8- N N 0 yl)pyrrolidin-2-one C.41 0
349 Example Compound Name Structure 209 (S)-2-((5,5-dimethy1-8-(4- 0 methylisoxazol-3-y1)-5H- H
chromeno[4,3-c]pyridin-3- N NN
yl)amino)-6,6a,7,8-tetrahydro- I
9H-pyrido[2,3-b]pyrrolo[1,2-d][1,4]oxazin-9-one N 0 0' 210 (S)-2-((5,5-dimethy1-8-(4-methyl- 0 4H-1,2,4-triazol-3-y1)-5H- H
chromeno[3,4-d]pyrimidin-3- N NNI---yl)amino)-6,6a,7,8-tetrahydro- I I ( 9H-pyrido[2,3-b]pyrrolo[1,2-N
d][1,41oxazin-9-one ,N 0 N--N
\
211 (S)-2-((5,5-dimethy1-8-(4-methyl- 0 4H-1,2,4-triazol-3-y1)-5H- H
chromeno[4,3-c]pyridin-3- N Nr1\1-yl)amino)-6,6a,7,8-tetrahydro- I I
NO
9H-pyrido[2,3-b]pyrrolo[1,2-d][1,4]oxazin-9-one N,N,_ 0 t-N
\
212 N-(5-((5,5-dimethy1-8-(2- H H
N H H abh Nro00,-,N alb oxopyrrolidin-l-y1)-5H- 1 NUN 0 W 0 N VI
chromeno[4,3-c]pyridin-3- 0 ct 0 0 yl)amino)pyridin-3-y1)-4-(2-(2- c-NH
(2-(2-42-(2,6-dioxopiperidin-3-y1)-1,3-dioxoisoindolin-4-yl)amino)ethoxy)ethoxy)ethoxy)a cetamido)benzamide 213 N-(5-((5,5-dimethy1-8-(2- H 0 0 oxopyrrolidin-l-y1)-5H- H H
chromeno[4,3-c]pyridin-3- -, I '0- 0 N
yl)amino)pyridin-3-y1)-4-(4-(2- c _t 0 c 0 ((2-(2,6-dioxopiperidin-3-y1)-1,3- 0 \Cri-i dioxoisoindolin-4-yl)oxy)acetamido)butanamido)be nzamide 109A 4-formamido-3-hydroxy-N-(5- H
N .õ.0 ((5-methy1-8-(2-oxopyrrolidin-1- H H
N.s, N.õ...õ."...,,,./..N
y1)-5H-chromeno[4,3-c]pyridin- 1 441111'' OH
3-yl)amino)pyridin-3-yl)benzamide Qi 0 Biochemical Assays
chromeno[4,3-c]pyridin-3- N NN
yl)amino)-6,6a,7,8-tetrahydro- I
9H-pyrido[2,3-b]pyrrolo[1,2-d][1,4]oxazin-9-one N 0 0' 210 (S)-2-((5,5-dimethy1-8-(4-methyl- 0 4H-1,2,4-triazol-3-y1)-5H- H
chromeno[3,4-d]pyrimidin-3- N NNI---yl)amino)-6,6a,7,8-tetrahydro- I I ( 9H-pyrido[2,3-b]pyrrolo[1,2-N
d][1,41oxazin-9-one ,N 0 N--N
\
211 (S)-2-((5,5-dimethy1-8-(4-methyl- 0 4H-1,2,4-triazol-3-y1)-5H- H
chromeno[4,3-c]pyridin-3- N Nr1\1-yl)amino)-6,6a,7,8-tetrahydro- I I
NO
9H-pyrido[2,3-b]pyrrolo[1,2-d][1,4]oxazin-9-one N,N,_ 0 t-N
\
212 N-(5-((5,5-dimethy1-8-(2- H H
N H H abh Nro00,-,N alb oxopyrrolidin-l-y1)-5H- 1 NUN 0 W 0 N VI
chromeno[4,3-c]pyridin-3- 0 ct 0 0 yl)amino)pyridin-3-y1)-4-(2-(2- c-NH
(2-(2-42-(2,6-dioxopiperidin-3-y1)-1,3-dioxoisoindolin-4-yl)amino)ethoxy)ethoxy)ethoxy)a cetamido)benzamide 213 N-(5-((5,5-dimethy1-8-(2- H 0 0 oxopyrrolidin-l-y1)-5H- H H
chromeno[4,3-c]pyridin-3- -, I '0- 0 N
yl)amino)pyridin-3-y1)-4-(4-(2- c _t 0 c 0 ((2-(2,6-dioxopiperidin-3-y1)-1,3- 0 \Cri-i dioxoisoindolin-4-yl)oxy)acetamido)butanamido)be nzamide 109A 4-formamido-3-hydroxy-N-(5- H
N .õ.0 ((5-methy1-8-(2-oxopyrrolidin-1- H H
N.s, N.õ...õ."...,,,./..N
y1)-5H-chromeno[4,3-c]pyridin- 1 441111'' OH
3-yl)amino)pyridin-3-yl)benzamide Qi 0 Biochemical Assays
350 Example 214: ADP-Glo biochemical assay [0694] Dilution series of the compounds were prepared in DMSO at 100 times the final assay concentration (ni=n0/3 in 10 points). The compounds were further diluted to three times the assay concentration in assay buffer (20 mM MOPS pH 7.2, 25 mM magnesium chloride, 0.005% Tween 20). 6 pi of the diluted compounds were added to a 384 well assay plate followed by 9 pi of a mix consisting of 4 nM PIP4K2A (full length protein, SignalChem) and 100 [tM PI(5)P diC8 (Tebu-Bio). Enzyme and compounds were pre-incubated at room temperature for 15 minutes.
[0695] Then 3 pi of a solution containing 60 [tM ATP (Promega) in assay buffer was added to the wells containing compound and enzyme and mixing was performed by pipetting several times. The reaction was incubated at room temperature for 1 h. Then 18 pi of ADP-GloTM Reagent (Promega) was added to stop the kinase reaction and deplete the unconsumed ATP, mixing was performed by pipetting several times. The plate was incubated at room temperature for 40 minutes before addition of 36 1,it of Kinase Detection Reagent (Promega) to convert ADP to ATP and introduce luciferase and luciferin to detect ATP.
The reaction was incubated at room temperature for 40 minutes before the luminescence was measured in a in a Victor 3V 1420 multilabel counter (Perkin Elmer).
[0696] Percent inhibition of the compounds as compared to dimethyl sulfoxide treated control samples was calculated. Compound concentration versus percent inhibition were fitted to generate IC50 values. Results obtained with this assay are disclosed in Table 2-4 below.
Example 215: Assay protocol--PIP4KtypeIIA
[0697] GST
tagged PIP4KtypeIIA and B enzymes were overexpressed in E. Coli and purified to >80% homogeneity. Phosphatidyl inosito1-5-phosphate (PI5P, Cat. #
850152, Avanti Polar Lipids Inc.) was used as the lipid substrate and phosphatidyl ethanolamine (DOPE
18:1, Cat. # 850725, Avanti Polar Lipids Inc.) was used as the carrier lipid for assays.
Ultrapure ATP and GTP was purchased from Bellbrooke Labs. ADP Glo reagents were obtained from Promega. Transcreener FT reagent was obtained from Bellbrooke labs.
Buffers:
1. HEPES buffer mix: 200 mM HEPES pH 7.4, 50 mM MgCl2, 0.05% v/v triton X
2. FINE buffer: 20 mM HEPES, pH 7.4, 100 mM NaCl, 0.5 mM EGTA
[0695] Then 3 pi of a solution containing 60 [tM ATP (Promega) in assay buffer was added to the wells containing compound and enzyme and mixing was performed by pipetting several times. The reaction was incubated at room temperature for 1 h. Then 18 pi of ADP-GloTM Reagent (Promega) was added to stop the kinase reaction and deplete the unconsumed ATP, mixing was performed by pipetting several times. The plate was incubated at room temperature for 40 minutes before addition of 36 1,it of Kinase Detection Reagent (Promega) to convert ADP to ATP and introduce luciferase and luciferin to detect ATP.
The reaction was incubated at room temperature for 40 minutes before the luminescence was measured in a in a Victor 3V 1420 multilabel counter (Perkin Elmer).
[0696] Percent inhibition of the compounds as compared to dimethyl sulfoxide treated control samples was calculated. Compound concentration versus percent inhibition were fitted to generate IC50 values. Results obtained with this assay are disclosed in Table 2-4 below.
Example 215: Assay protocol--PIP4KtypeIIA
[0697] GST
tagged PIP4KtypeIIA and B enzymes were overexpressed in E. Coli and purified to >80% homogeneity. Phosphatidyl inosito1-5-phosphate (PI5P, Cat. #
850152, Avanti Polar Lipids Inc.) was used as the lipid substrate and phosphatidyl ethanolamine (DOPE
18:1, Cat. # 850725, Avanti Polar Lipids Inc.) was used as the carrier lipid for assays.
Ultrapure ATP and GTP was purchased from Bellbrooke Labs. ADP Glo reagents were obtained from Promega. Transcreener FT reagent was obtained from Bellbrooke labs.
Buffers:
1. HEPES buffer mix: 200 mM HEPES pH 7.4, 50 mM MgCl2, 0.05% v/v triton X
2. FINE buffer: 20 mM HEPES, pH 7.4, 100 mM NaCl, 0.5 mM EGTA
351 3. H:E buffer: 30 mM HEPES, pH 7.4, 1mM EGTA
[0698] Enzyme preparation: GST-tagged PIP4KtypeIIA (5uL, 1.43mg/mL) was diluted (1:10) to 50uL using HNE buffer. From the 1:10 diluted stock, a 6.4 uL aliquot was diluted further to 5 mL using HNE buffer to yield 5X enzyme stock (2.5 nM).
GST-tagged PIP4KtypeIIB (3.4 uL, 2.77 mg/mL) was diluted to 5 mL using HNE
buffer to yield 5X enzyme stock (25 nM) [0699] Lipid Preparation: In a 10 mL pyrex glass vial, lug of PI5P and lug of DOPE were suspended in 2.5 mL of HEPES buffer mix and 2.5 mL of H:E buffer. The contents were mixed and sonicated for 3 min to yield a translucent lipid stock.
[0700] Compound Preparation: Compounds were stored as 5mM stocks in neat DMSO as room temperature in glass vials. 5 mM stocks were diluted to 2mM and then serially diluted (3X) in neat DMSO in 96 well polypropylene plates. From the serially diluted stocks, 3 uL was delivered into 250 uL of 25% DMSO (in water) to generate 5X compound stocks.
Typically, the highest compound conc. was 24 uM.
Example 216: PIP4KtypellA Inhibition assay [0701] The assay volume was kept at 25 uL. To each well of the reaction plate, 10 uL of lipid stock (1:1 ratio PI5P: DOPE) was delivered. This was followed by the addition of 5 uL
of compound in 25% DMSO. Then, to each well, 5 uL of 2.5 nM (5X) typeIIA
enzyme was delivered. The contents were mixed well and incubated for 1 h at 27 C. After lh, reaction was initiated by adding 5 uL of 50 uM ATP and the contents were mixed well with a multi-channel pipetteman. The final concentration of the reagents are as follows: 50 mM
HEPES, pH 7.3, 10 mM MgCl2, 20 mM NaCl, 0.01% v/v triton-X100, 5 % DMSO, 10 uM ATP, 80 uM (2ug) PI5P, 2ug DOPE, and 0.5 nM PIP4KIIA. Typically, the highest conc. of compounds was 4.8 uM and the lowest conc. was 0.
[0702] After thr, the reaction was quenched by adding 25 uL of ADP Glo reagent. The contents were incubated for 1 hr. Afterwards, 50 uL of kinase detection reagent was delivered.
The contents were incubated for another hour. The luminescence was read using Molecular Devices Paradigm plate reader. Each plate had a "No inhibitor" control (max.
activity, 4 wells) and a blank (background noise, 4 wells). The blanks were averaged and subtracted from all other wells. Using a calibration curve, RLU was converted to uM ADP (product).
IC50 was
[0698] Enzyme preparation: GST-tagged PIP4KtypeIIA (5uL, 1.43mg/mL) was diluted (1:10) to 50uL using HNE buffer. From the 1:10 diluted stock, a 6.4 uL aliquot was diluted further to 5 mL using HNE buffer to yield 5X enzyme stock (2.5 nM).
GST-tagged PIP4KtypeIIB (3.4 uL, 2.77 mg/mL) was diluted to 5 mL using HNE
buffer to yield 5X enzyme stock (25 nM) [0699] Lipid Preparation: In a 10 mL pyrex glass vial, lug of PI5P and lug of DOPE were suspended in 2.5 mL of HEPES buffer mix and 2.5 mL of H:E buffer. The contents were mixed and sonicated for 3 min to yield a translucent lipid stock.
[0700] Compound Preparation: Compounds were stored as 5mM stocks in neat DMSO as room temperature in glass vials. 5 mM stocks were diluted to 2mM and then serially diluted (3X) in neat DMSO in 96 well polypropylene plates. From the serially diluted stocks, 3 uL was delivered into 250 uL of 25% DMSO (in water) to generate 5X compound stocks.
Typically, the highest compound conc. was 24 uM.
Example 216: PIP4KtypellA Inhibition assay [0701] The assay volume was kept at 25 uL. To each well of the reaction plate, 10 uL of lipid stock (1:1 ratio PI5P: DOPE) was delivered. This was followed by the addition of 5 uL
of compound in 25% DMSO. Then, to each well, 5 uL of 2.5 nM (5X) typeIIA
enzyme was delivered. The contents were mixed well and incubated for 1 h at 27 C. After lh, reaction was initiated by adding 5 uL of 50 uM ATP and the contents were mixed well with a multi-channel pipetteman. The final concentration of the reagents are as follows: 50 mM
HEPES, pH 7.3, 10 mM MgCl2, 20 mM NaCl, 0.01% v/v triton-X100, 5 % DMSO, 10 uM ATP, 80 uM (2ug) PI5P, 2ug DOPE, and 0.5 nM PIP4KIIA. Typically, the highest conc. of compounds was 4.8 uM and the lowest conc. was 0.
[0702] After thr, the reaction was quenched by adding 25 uL of ADP Glo reagent. The contents were incubated for 1 hr. Afterwards, 50 uL of kinase detection reagent was delivered.
The contents were incubated for another hour. The luminescence was read using Molecular Devices Paradigm plate reader. Each plate had a "No inhibitor" control (max.
activity, 4 wells) and a blank (background noise, 4 wells). The blanks were averaged and subtracted from all other wells. Using a calibration curve, RLU was converted to uM ADP (product).
IC50 was
352 calculated by plotting the residual activity (expressed as % No inhibitor control) vs. log [Inh.
conc.]
Example 217: PIP4KtypeIIB Inhibition assay [0703] The assay volume was kept at 25 uL. To each well of the reaction plate, 10 uL of lipid stock (1:1 ratio PI5P: DOPE) was delivered. This was followed by the addition of 5 uL
of compound in 25% DMSO. Then, to each well, 5 uL of 25 nM (5X) typeIIB enzyme was delivered. The contents were mixed well and incubated for 1 h at 27 C. After lh, reaction was initiated by adding 5 uL of 500 uM GTP and the contents were mixed well with a multi-channel pipetteman. The final concentration of the reagents are as follows: 50 mM
HEPES, pH 7.3, 10 mM MgCl2, 20 mM NaCl, 0.01% v/v triton-X100, 5 % DMSO, 100 uM GTP, 80 uM (2ug) PI5P, 2ug DOPE, and 5 nM PIP4KIIB Typically, the highest conc. of compounds was 4.8 uM
and the lowest conc. was 0.
[0704] After 2 h, the reaction was quenched by adding 25 uL of transcreener FT reagent.
The contents were incubated at RT for 1 h and the Fluorescence (Ex:584 Em:
623) was read using Molecular Devices Paradigm plate reader. Each plate had a "No inhibitor"
control (max.
activity, 4 wells) and a blank (background noise, 4 wells). The blanks were averaged and subtracted from all other wells. Using a calibration curve, RFU was converted to uM GDP
(product). IC50 was calculated by plotting the residual activity (expressed as % No inhibitor control) vs. log [Inh. conc.]
Table 2 represents PI5P4K activity of compounds (Examples No.:) of the invention arranged in accordance with the inhibition of PIP4K2 A kinase assay.
conc.]
Example 217: PIP4KtypeIIB Inhibition assay [0703] The assay volume was kept at 25 uL. To each well of the reaction plate, 10 uL of lipid stock (1:1 ratio PI5P: DOPE) was delivered. This was followed by the addition of 5 uL
of compound in 25% DMSO. Then, to each well, 5 uL of 25 nM (5X) typeIIB enzyme was delivered. The contents were mixed well and incubated for 1 h at 27 C. After lh, reaction was initiated by adding 5 uL of 500 uM GTP and the contents were mixed well with a multi-channel pipetteman. The final concentration of the reagents are as follows: 50 mM
HEPES, pH 7.3, 10 mM MgCl2, 20 mM NaCl, 0.01% v/v triton-X100, 5 % DMSO, 100 uM GTP, 80 uM (2ug) PI5P, 2ug DOPE, and 5 nM PIP4KIIB Typically, the highest conc. of compounds was 4.8 uM
and the lowest conc. was 0.
[0704] After 2 h, the reaction was quenched by adding 25 uL of transcreener FT reagent.
The contents were incubated at RT for 1 h and the Fluorescence (Ex:584 Em:
623) was read using Molecular Devices Paradigm plate reader. Each plate had a "No inhibitor"
control (max.
activity, 4 wells) and a blank (background noise, 4 wells). The blanks were averaged and subtracted from all other wells. Using a calibration curve, RFU was converted to uM GDP
(product). IC50 was calculated by plotting the residual activity (expressed as % No inhibitor control) vs. log [Inh. conc.]
Table 2 represents PI5P4K activity of compounds (Examples No.:) of the invention arranged in accordance with the inhibition of PIP4K2 A kinase assay.
353 Kinase Assay- PIP4K2 Kinase Assay- PIP4K2 Kinase Assay- PIP4K2 A IC50< 1 nM A IC50< 1 nM A 1 < IC5o< 10 nM
Kinase Assay- PIP4K2 82 170 A 10 <
IC5o< 100 nM
84 Kinase Assay- PIP4K2 187 73 A 1 < IC5o< 10 nM
Kinase Assay- PIP4K2 61 34 A 100 < IC5o< 1000 69 nM
Table 3 represents PI5P4K activity of compounds (Examples No.:) of the invention arranged in accordance with the inhibition of ADP-glo kinase assay PIP4K 2A.
Kinase Assay- PIP4K2 82 170 A 10 <
IC5o< 100 nM
84 Kinase Assay- PIP4K2 187 73 A 1 < IC5o< 10 nM
Kinase Assay- PIP4K2 61 34 A 100 < IC5o< 1000 69 nM
Table 3 represents PI5P4K activity of compounds (Examples No.:) of the invention arranged in accordance with the inhibition of ADP-glo kinase assay PIP4K 2A.
354 ADP-glo kinase assay ADP-glo kinase assay ADP-glo kinase assay PIP4K 2A 1 < IC5o< 10 PIP4K 2A IC50< 1 nM PIP4K 2A IC50< 1 nM
nM
69 ADP-glo kinase assay 112 PIP4K 2A 1< IC5o< 10 nM
nM
69 ADP-glo kinase assay 112 PIP4K 2A 1< IC5o< 10 nM
355 ADP-glo kinase assay ADP-glo kinase assay ADP-glo kinase assay PIP4K 2A 1< IC5o< 10 PIP4K 2A 1< IC5o< 10 PIP4K 2A 10< IC5o<
nM nM 100 nM
134 ADP-glo kinase assay 164 PIP4K 2A 100 < ICso <
166 ADP-glo kinase assay 1000 nM
101 PIP4K 2A 10 < ICso < 81 100 nM 89 102 80 ADP-glo kinase assay 117 65 PIP4K 2A IC50> 1000 169 nM
Table 4: represents PISP4K activity of compounds (Examples No.:) of the invention arranged in accordance with the inhibition of PIP4K2 B kinase assay.
nM nM 100 nM
134 ADP-glo kinase assay 164 PIP4K 2A 100 < ICso <
166 ADP-glo kinase assay 1000 nM
101 PIP4K 2A 10 < ICso < 81 100 nM 89 102 80 ADP-glo kinase assay 117 65 PIP4K 2A IC50> 1000 169 nM
Table 4: represents PISP4K activity of compounds (Examples No.:) of the invention arranged in accordance with the inhibition of PIP4K2 B kinase assay.
356 Trans-F! P kinase Trans-F! P kinase Trans-F! P kinase assays: PIP4K2B 1 < assays: PIP4K2B 1 < assays: PIP4K2B 10 <
IC50< 10 nM IC50< 10 nM IC50< 100 nM
58 Trans-Fl P kinase 135 60 assays: PIP4K2B 10 <
IC50< 100 nM
IC50< 10 nM IC50< 10 nM IC50< 100 nM
58 Trans-Fl P kinase 135 60 assays: PIP4K2B 10 <
IC50< 100 nM
357 Trans-F! P kinase Trans-F! P kinase Trans-F! P kinase assays: PIP4K2B 10 < assays: PIP4K2B 100 <
assays: PIP4K2B IC5o IC5o< 100 nM IC5o< 1000 nM > 1000 nM
assays: PIP4K2B IC5o IC5o< 100 nM IC5o< 1000 nM > 1000 nM
358 Equivalents [0705] Those skilled in the art will recognize, or be able to ascertain, using no more than routine experimentation, numerous equivalents to the specific embodiments described specifically herein. Such equivalents are intended to be encompassed in the scope of the following claims.
359
Claims (39)
1. A compound of Formula (1):
w R3 R2 Al G A2 (I) or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, isomer, or tautomer thereof, wherein:
Ring Al is 5- to 6-membered heteroaryl;
Ring A2 is heteroaryl optionally substituted with one or more Rs;
W is ¨0¨, ¨NH¨, ¨N(C1-6 alkyl)¨, ¨N(C3-8 cycloalkyl)¨, ¨N(ary1)¨, or ¨N(heteroary1)¨;
G is a bond, ¨0¨, ¨NH¨, or ¨N(C1-6 alkyl)¨;
Ri is ¨N(R5)C(0)R6, ¨C(0)N(Rs)(R6), ¨S(0)2N(Rs)(R6), -N(Rs)S(0)2R6, or heteroaryl, wherein the heteroaryl is optionally substituted with one or more R7;
R2 is H, halogen, ¨OH, ¨NH2, ¨NO2, ¨CN, ¨COOH, ¨C(0)NH2, C1-6 alkyl, C1-6 alkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, heterocyclyl, aryl, or heteroaryl;
R3 and R4 are each independently ¨H, halogen, C1-6 alkyl, C1-6 alkoxy, or C3-6 cycloalkyl, wherein the alkyl, alkoxy, or cycloalkyl is optionally substituted with one or more halogen, ¨OH, and ¨NH2; or R3 and R4 when taken together with the atom to which they are attached form a cycloalkyl or heterocyclyl;
Rs and R6 are independently, at each occurrence, ¨H, C1-6 alkyl, C2-6 alkenyl, or C2-6 alkynyl, wherein the alkyl, alkenyl, or alkynyl is optionally substituted with one or more R7; or Rs and R6 when taken together with the atom to which they are each attached form a heterocycle optionally substituted with one or more R7;
R7 is independently ¨H, halogen, ¨OH, ¨NH2, ¨NO2, ¨CN, C1-6 alkyl, C1-6 alkoxy, C3-8 cycloalkyl, heterocyclyl, aryl, or heteroaryl;
Rs is independently ¨N(R9)C(0)R1o, ¨N(R9)C(0)0R1o, ¨N(R9)C(0)N(R9)(R1o), ¨N(R9)C(0)N(R9)(R11), ¨N(R9)S(0)2R10, ¨N(R9)S(0)2N(R9)(R1o), ¨S(0)2R10 ¨N(R9)(R1o), ¨
ORio, ¨CF3, ¨CHF2, ¨Rio, ¨N(R9)C(0)R11, ¨N(R9)(R11) or halogen; or two Rs with the atoms they are attached form a C4-8 cycloalkyl or heterocyclyl, wherein the heterocyclyl or cycloalkyl is optionally substituted with one or more R12;
each R9 or Rio is independently, at each occurrence, ¨H, C1-6 alkyl, C3-8 cycloalkyl, or heterocyclyl, wherein the alkyl, cycloalkyl, or heterocyclyl is optionally substituted with one or more R13; or R9 and Rio when taken together with the atom to which they are each attached form a heterocycle ring optionally substituted with one or more R14 each Rii is aryl, C3-8 cycloalkyl, heterocyclyl, or heteroaryl, wherein the aryl or heteroaryl group is optionally substituted with one or more Ris and the cycloalkyl or heterocyclyl is optionally substituted with one or more R19;
each Ri2 is independently C1-6 alkyl, C3-6 cycloalkyl, ¨0R20, ¨C(0)R20, ¨C(0)0R20, ¨
S(0)2R20, or oxo; or two Ri2 taken together can form a C3-8 cycloalkyl or heterocyclyl, wherein the cycloalkyl or heterocyclyl are optionally substituted with one or more R14;
R13 is ¨H, halogen, ¨CN, oxo, C1-6 alkyl, ¨0R20, ¨C(0)2R20, C3-8 cycloalkyl, heterocyclyl, heteroaryl, aryl, or ¨C(0)N(R22)(R22), wherein the alkyl, aryl, or heteroaryl, is optionally substituted with one or more Ris;
R14 is independently ¨C(0)0R20; ¨C(0)R20, ¨0R20, oxo, C1-6 alkyl, heterocycle, cycloalkyl, or aryl, wherein the alkyl, heterocycle, cycloalkyl, or aryl is optionally substituted with one or more R16; or two R14 taken together can form a C3-6 cycloalkyl or heterocyclyl;
R15 is ¨H, C1-6 alkyl, C1-6 alkoxy, heteroaryl, aryl, ¨N(R22)(R22), ¨N(R22)C(0)0R22, or ¨
N(R22)C(0)¨U¨N(R22)¨Z;
U is ¨(CH2)p¨, ¨(CH2)p¨Ar¨,¨CH=CH(CH2)p¨, or heterocyclyl, Z is ¨R22 or ¨C(0)¨U¨N(R22)(R22);
R16 iS C3-8 cycloalkyl, heterocyclyl, heteroaryl, or aryl, wherein the heterocyclyl, cycloalkyl, heteroaryl or aryl is optionally substituted with one or more R17;
R17 is independently ¨0R22, ¨N(R22)(R22), or ¨N(R22)C(0)¨V¨N(R22)¨E;
V is ¨(CH2)o¨, ¨(CH2)o¨Ar¨, or ¨CH=CH(CH2)n¨;
E is ¨R22 or ¨C(0)¨V¨N(R22)(R22);
Ar is aryl;
R18 1S halogen, C1-6 alkyl, C3-6 cycloalkyl, ¨ORD), ¨N(R20)(R21), ¨C(0)R20, OXO, ¨N(R22)C(0)0R22, ¨N(R22)C(0)¨Q¨N(R22)¨F, or ¨N(R22)¨Q¨N(R22)¨F;
Q is ¨CH=CH(CH2)m¨, ¨(CH2)m¨, ¨(CH20)m¨, ¨(CH2)m¨Ar¨, or ¨(CH2CH20)0¨(CH2)m¨;
F is ¨H, C1-6 alkyl, aryl, heteroaryl, ¨C(0)¨Q¨R22, or ¨C(0)¨Q¨N(R22)(R22), wherein the alkyl, aryl, or heteroaryl is optionally substituted with one or more R22; or two R18 when on adjacent atoms may be taken together with the atoms to which they are each attached to form a C3-8 cycloalkyl or heterocyclic group optionally substituted with ¨0R21 or oxo;
R19 is independently ¨H, halogen, ¨OH, ¨NH2, oxo, ¨C(0)R20, ¨0R22, C3-6 cycloalkyl, or C1-6 alkyl; or two R19 when on adjacent atoms may be taken together with the atoms to which they are each attached to form an aryl or heteroaryl group optionally substituted with one or more R22;
R2o is ¨H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, heterocyclyl, aryl, or heteroaryl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, heteroaryl, or aryl is optionally substituted with one or more ¨H, halogen, ¨CN, ¨OH, C1-6 alkyl, C1-6 alkoxy, C3-8 cycloalkyl, heterocyclyl, heteroaryl, or aryl;
R21 is ¨H, C1-6 alkyl, or ¨C(0)R22;
each R22 is independently ¨H, C1-6 alkyl, C1-6 alkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, heterocyclyl, aryl, or heteroaryl;
each p is independently 1-4;
each n is independently 1-4;
each m is independently 1-4; and o is 1-3.
w R3 R2 Al G A2 (I) or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, isomer, or tautomer thereof, wherein:
Ring Al is 5- to 6-membered heteroaryl;
Ring A2 is heteroaryl optionally substituted with one or more Rs;
W is ¨0¨, ¨NH¨, ¨N(C1-6 alkyl)¨, ¨N(C3-8 cycloalkyl)¨, ¨N(ary1)¨, or ¨N(heteroary1)¨;
G is a bond, ¨0¨, ¨NH¨, or ¨N(C1-6 alkyl)¨;
Ri is ¨N(R5)C(0)R6, ¨C(0)N(Rs)(R6), ¨S(0)2N(Rs)(R6), -N(Rs)S(0)2R6, or heteroaryl, wherein the heteroaryl is optionally substituted with one or more R7;
R2 is H, halogen, ¨OH, ¨NH2, ¨NO2, ¨CN, ¨COOH, ¨C(0)NH2, C1-6 alkyl, C1-6 alkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, heterocyclyl, aryl, or heteroaryl;
R3 and R4 are each independently ¨H, halogen, C1-6 alkyl, C1-6 alkoxy, or C3-6 cycloalkyl, wherein the alkyl, alkoxy, or cycloalkyl is optionally substituted with one or more halogen, ¨OH, and ¨NH2; or R3 and R4 when taken together with the atom to which they are attached form a cycloalkyl or heterocyclyl;
Rs and R6 are independently, at each occurrence, ¨H, C1-6 alkyl, C2-6 alkenyl, or C2-6 alkynyl, wherein the alkyl, alkenyl, or alkynyl is optionally substituted with one or more R7; or Rs and R6 when taken together with the atom to which they are each attached form a heterocycle optionally substituted with one or more R7;
R7 is independently ¨H, halogen, ¨OH, ¨NH2, ¨NO2, ¨CN, C1-6 alkyl, C1-6 alkoxy, C3-8 cycloalkyl, heterocyclyl, aryl, or heteroaryl;
Rs is independently ¨N(R9)C(0)R1o, ¨N(R9)C(0)0R1o, ¨N(R9)C(0)N(R9)(R1o), ¨N(R9)C(0)N(R9)(R11), ¨N(R9)S(0)2R10, ¨N(R9)S(0)2N(R9)(R1o), ¨S(0)2R10 ¨N(R9)(R1o), ¨
ORio, ¨CF3, ¨CHF2, ¨Rio, ¨N(R9)C(0)R11, ¨N(R9)(R11) or halogen; or two Rs with the atoms they are attached form a C4-8 cycloalkyl or heterocyclyl, wherein the heterocyclyl or cycloalkyl is optionally substituted with one or more R12;
each R9 or Rio is independently, at each occurrence, ¨H, C1-6 alkyl, C3-8 cycloalkyl, or heterocyclyl, wherein the alkyl, cycloalkyl, or heterocyclyl is optionally substituted with one or more R13; or R9 and Rio when taken together with the atom to which they are each attached form a heterocycle ring optionally substituted with one or more R14 each Rii is aryl, C3-8 cycloalkyl, heterocyclyl, or heteroaryl, wherein the aryl or heteroaryl group is optionally substituted with one or more Ris and the cycloalkyl or heterocyclyl is optionally substituted with one or more R19;
each Ri2 is independently C1-6 alkyl, C3-6 cycloalkyl, ¨0R20, ¨C(0)R20, ¨C(0)0R20, ¨
S(0)2R20, or oxo; or two Ri2 taken together can form a C3-8 cycloalkyl or heterocyclyl, wherein the cycloalkyl or heterocyclyl are optionally substituted with one or more R14;
R13 is ¨H, halogen, ¨CN, oxo, C1-6 alkyl, ¨0R20, ¨C(0)2R20, C3-8 cycloalkyl, heterocyclyl, heteroaryl, aryl, or ¨C(0)N(R22)(R22), wherein the alkyl, aryl, or heteroaryl, is optionally substituted with one or more Ris;
R14 is independently ¨C(0)0R20; ¨C(0)R20, ¨0R20, oxo, C1-6 alkyl, heterocycle, cycloalkyl, or aryl, wherein the alkyl, heterocycle, cycloalkyl, or aryl is optionally substituted with one or more R16; or two R14 taken together can form a C3-6 cycloalkyl or heterocyclyl;
R15 is ¨H, C1-6 alkyl, C1-6 alkoxy, heteroaryl, aryl, ¨N(R22)(R22), ¨N(R22)C(0)0R22, or ¨
N(R22)C(0)¨U¨N(R22)¨Z;
U is ¨(CH2)p¨, ¨(CH2)p¨Ar¨,¨CH=CH(CH2)p¨, or heterocyclyl, Z is ¨R22 or ¨C(0)¨U¨N(R22)(R22);
R16 iS C3-8 cycloalkyl, heterocyclyl, heteroaryl, or aryl, wherein the heterocyclyl, cycloalkyl, heteroaryl or aryl is optionally substituted with one or more R17;
R17 is independently ¨0R22, ¨N(R22)(R22), or ¨N(R22)C(0)¨V¨N(R22)¨E;
V is ¨(CH2)o¨, ¨(CH2)o¨Ar¨, or ¨CH=CH(CH2)n¨;
E is ¨R22 or ¨C(0)¨V¨N(R22)(R22);
Ar is aryl;
R18 1S halogen, C1-6 alkyl, C3-6 cycloalkyl, ¨ORD), ¨N(R20)(R21), ¨C(0)R20, OXO, ¨N(R22)C(0)0R22, ¨N(R22)C(0)¨Q¨N(R22)¨F, or ¨N(R22)¨Q¨N(R22)¨F;
Q is ¨CH=CH(CH2)m¨, ¨(CH2)m¨, ¨(CH20)m¨, ¨(CH2)m¨Ar¨, or ¨(CH2CH20)0¨(CH2)m¨;
F is ¨H, C1-6 alkyl, aryl, heteroaryl, ¨C(0)¨Q¨R22, or ¨C(0)¨Q¨N(R22)(R22), wherein the alkyl, aryl, or heteroaryl is optionally substituted with one or more R22; or two R18 when on adjacent atoms may be taken together with the atoms to which they are each attached to form a C3-8 cycloalkyl or heterocyclic group optionally substituted with ¨0R21 or oxo;
R19 is independently ¨H, halogen, ¨OH, ¨NH2, oxo, ¨C(0)R20, ¨0R22, C3-6 cycloalkyl, or C1-6 alkyl; or two R19 when on adjacent atoms may be taken together with the atoms to which they are each attached to form an aryl or heteroaryl group optionally substituted with one or more R22;
R2o is ¨H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, heterocyclyl, aryl, or heteroaryl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, heteroaryl, or aryl is optionally substituted with one or more ¨H, halogen, ¨CN, ¨OH, C1-6 alkyl, C1-6 alkoxy, C3-8 cycloalkyl, heterocyclyl, heteroaryl, or aryl;
R21 is ¨H, C1-6 alkyl, or ¨C(0)R22;
each R22 is independently ¨H, C1-6 alkyl, C1-6 alkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, heterocyclyl, aryl, or heteroaryl;
each p is independently 1-4;
each n is independently 1-4;
each m is independently 1-4; and o is 1-3.
2. The compound of claim 1, represented by formula (Ia):
R6 yO
R5 N w R3 R8 (Ia), wherein Y1 is CH or N.
R6 yO
R5 N w R3 R8 (Ia), wherein Y1 is CH or N.
3. The compound of claim 1, represented by formula (Ib):
w R3 R6, G
R8 ob), wherein Y1 is CH or N.
w R3 R6, G
R8 ob), wherein Y1 is CH or N.
4. The compound of claim 1, represented by formula (lc):
oõ9 R8, N W R3 R
R2 I _\(1G A2 R8 (IC), wherein Y1 is CH or N.
oõ9 R8, N W R3 R
R2 I _\(1G A2 R8 (IC), wherein Y1 is CH or N.
5. The compound of claim 1, represented by formula (Id):
R8 (Id), wherein Y1 is CH or N.
R8 (Id), wherein Y1 is CH or N.
6. The compound of claim 1, represented by formula (Ie):
R2 I ' 1 R8 (Ie), wherein Y1 is CH or N.
R2 I ' 1 R8 (Ie), wherein Y1 is CH or N.
7. The compound of claim 1, represented by formula (Ih):
= = (Ih).
= = (Ih).
8. The compound of claim 1, represented by formula (Ii):
R1 w R3 a , e R2 Al if-(R8)p (E), wherein:
a, b, c, d, and e, are each independently C or N, wherein at least one of a, b, c, d, and e is N, and no more than two of a, b, c, d, and e, are N; and p is 1, 2, or 3.
R1 w R3 a , e R2 Al if-(R8)p (E), wherein:
a, b, c, d, and e, are each independently C or N, wherein at least one of a, b, c, d, and e is N, and no more than two of a, b, c, d, and e, are N; and p is 1, 2, or 3.
9. The compound of claim 1, represented by formula (Ij):
R1 w R3 a X3 R2 Al G¨H (R8)p c wherein:
a, b, c, and d, are each independently C or N, wherein at least one of a, b, c, and d is N, and no more than two of a, b, c, and d, are N;
X3 and Y3 are each independently ¨0¨, -CH2-, or ¨N(R8)¨;
p is 1, 2, or 3.
R1 w R3 a X3 R2 Al G¨H (R8)p c wherein:
a, b, c, and d, are each independently C or N, wherein at least one of a, b, c, and d is N, and no more than two of a, b, c, and d, are N;
X3 and Y3 are each independently ¨0¨, -CH2-, or ¨N(R8)¨;
p is 1, 2, or 3.
10. The compound of claim 1, represented by formula (Ik):
R1 w R3 b' R2 Al I .....,)c(R12)(0 d N
e 1 (Ik), wherein:
a, b, c, and d, are each independently C or N, wherein at least one of a, b, c, and d is N; and no more than two of a, b, c, d, and e, are N;
X4 and Zi are each independently ¨0¨, ¨N(R12)¨, or ¨C(R12)(R12)¨; and co is 1, 2, or 3.
R1 w R3 b' R2 Al I .....,)c(R12)(0 d N
e 1 (Ik), wherein:
a, b, c, and d, are each independently C or N, wherein at least one of a, b, c, and d is N; and no more than two of a, b, c, d, and e, are N;
X4 and Zi are each independently ¨0¨, ¨N(R12)¨, or ¨C(R12)(R12)¨; and co is 1, 2, or 3.
1 1. The compound of claim 1, represented by formula (I1):
R1 w R3 e R2 Al d N
R11 (R18)x.
(I1), wherein:
a, b, c, d, and e, are each independently C or N, wherein at least one of a, b, c, d, and e is N, and no more than two of a, b, c, d, and e, are N; and X, is 1, 2, or 3.
R1 w R3 e R2 Al d N
R11 (R18)x.
(I1), wherein:
a, b, c, d, and e, are each independently C or N, wherein at least one of a, b, c, d, and e is N, and no more than two of a, b, c, d, and e, are N; and X, is 1, 2, or 3.
12. The compound of claim 1, represented by formula (Im):
a , e 0 R2 Al C*dN
R11 (R19)x.
(Im), wherein:
a, b, c, d, and e, are each independently C or N, wherein at least one of a, b, c, d, and e is N, and no more than two of a, b, c, d, and e, are N; and X, is 1, 2, or 3.
a , e 0 R2 Al C*dN
R11 (R19)x.
(Im), wherein:
a, b, c, d, and e, are each independently C or N, wherein at least one of a, b, c, d, and e is N, and no more than two of a, b, c, d, and e, are N; and X, is 1, 2, or 3.
13. The compound of claim 1, represented by formula (In):
a, e R2 Al G 1R14 C(:1 -----Lf(14 (In), wherein:
a, b, c, d, and e, are each independently C or N, wherein at least one of a, b, c, d, and e is N, and no more than two of a, b, c, d, and e, are N;
Y4 is ¨0¨, ¨N(R14)¨, or ¨C(R14)(R14)¨; and 4:1) is 0, 1, or 2.
a, e R2 Al G 1R14 C(:1 -----Lf(14 (In), wherein:
a, b, c, d, and e, are each independently C or N, wherein at least one of a, b, c, d, and e is N, and no more than two of a, b, c, d, and e, are N;
Y4 is ¨0¨, ¨N(R14)¨, or ¨C(R14)(R14)¨; and 4:1) is 0, 1, or 2.
14. The compound of claim 1, represented by formula (Io):
a, e R2 Al G l 11 C
d N R11 (Io), wherein:
a, b, c, d, and e, are each independently C or N, wherein at least one of a, b, c, d, and e is N, and no more than two of a, b, c, d, and e, are N.
a, e R2 Al G l 11 C
d N R11 (Io), wherein:
a, b, c, d, and e, are each independently C or N, wherein at least one of a, b, c, d, and e is N, and no more than two of a, b, c, d, and e, are N.
15. The compound of claim 1, represented by formula (Ip):
R1 w R3 a R2 G, 1 Au d N N R11 R18 (Ip):
wherein:
a, b, c, d, and e, are each independently C or N, wherein at least one of a, b, c, d, and e is N, and no more than two of a, b, c, d, and e, are N.
R1 w R3 a R2 G, 1 Au d N N R11 R18 (Ip):
wherein:
a, b, c, d, and e, are each independently C or N, wherein at least one of a, b, c, d, and e is N, and no more than two of a, b, c, d, and e, are N.
16. The compound of claim 1, represented by formula (Iq):
* W 3 a, e R2 Al N
R11 N(R22)C(0)-Q-N(R22)-F
(Iq), wherein:
a, b, c, d, and e, are each independently C or N, wherein at least one of a, b, c, d, and e is N, and no more than two of a, b, c, d, and e, are N.
* W 3 a, e R2 Al N
R11 N(R22)C(0)-Q-N(R22)-F
(Iq), wherein:
a, b, c, d, and e, are each independently C or N, wherein at least one of a, b, c, d, and e is N, and no more than two of a, b, c, d, and e, are N.
17. The compound of claim 1, represented by formula (Ir):
R1 w R3 a e 0 R2 Al d N R10 R13 N(R22)C(0)-U-N(R22)-Z
(1r), wherein:
a, b, c, d, and e, are each independently C or N, wherein at least one of a, b, c, d, and e is N, and no more than two of a, b, c, d, and e, are N.
R1 w R3 a e 0 R2 Al d N R10 R13 N(R22)C(0)-U-N(R22)-Z
(1r), wherein:
a, b, c, d, and e, are each independently C or N, wherein at least one of a, b, c, d, and e is N, and no more than two of a, b, c, d, and e, are N.
18. The compound of claim 1 selected from the groups consisting of:
N,N,5-trimethy1-3-((5-(2-oxopyrrolidin-1-yl)pyridin-3-yl)amino)-5H-chromeno[4,3-c]pyridine-8-carboxamide;
N,N,5-trimethy1-3-(pyridin-3-ylamino)-5H-chromeno[4,3-c]pyridine-8-carboxamide;
1-(3-((1-acety1-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)amino)-5-methyl-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one;
5-cyclopropyl-N,N-dimethy1-3-((5-(2-oxopyrrolidin-1-y1)pyridin-3-y1)amino)-5H-chromeno[4,3-c]pyridine-8-carboxamide;
1-(3-((5-(difluoromethoxy)pyridin-3-yl)amino)-5-methy1-5H-chromeno[4,3-c]pyridin-8-y1)pyrrolidin-2-one;
N,N,5-trimethy1-3-(((S)-9-oxo-6a,7,8,9-tetrahydro-6H-pyrido[2,3-b]pyrrolo[1,2-d][1,4]oxazin-2-yl)amino)-5H-chromeno[4,3-c]pyridine-8-carboxamide;
(6aS)-2-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)-6,6a,7,8-tetrahydro-9H-pyrido[2,3-b]pyrrolo[1,2-d][1,4]oxazin-9-one;
5-cyclopropyl-N,N-dimethy1-3-(((S)-9-oxo-6a,7,8,9-tetrahydro-6H-pyrido[2,3-b]pyrrolo[1,2-d][1,4]oxazin-2-yl)amino)-5H-chromeno[4,3-c]pyridine-8-carboxamide;
1-(545-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-y1)cyclopropane-1-carbonitrile;
5-cyclopropyl-N,N-dimethy1-3-(pyridin-3-ylamino)-5H-chromeno[4,3-c]pyridine-8-carboxamide;
1-(5-methy1-3-(pyridin-3-ylamino)-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one;
1-methy1-3-(545-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-y1)amino)pyridin-3-y1)imidazolidin-2-one;
N,N,5,6-tetramethy1-3-(pyridin-3-ylamino)-5,6-dihydrobenzo[c][2,6]naphthyridine-8-carboxamide;
N-methyl-N-(5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-yl)methanesulfonamide;
1-(5-methy1-3-((1-(methylsulfony1)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)amino)-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one;
1-(345-fluoropyridin-3-yl)amino)-5-methyl-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one;
1-(3-((1-(cyclopropylsulfony1)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)amino)-5-methyl-5H-chromeno[4,3-c]pyridin-8-y1)pyrrolidin-2-one;
(S)-24(R)-5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)-6,6a,7,8-tetrahydro-9H-pyrido[2,3-b]pyrrolo[1,2-d][1,4]oxazin-9-one;
(S)-24(S)-5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)-6,6a,7,8-tetrahydro-9H-pyrido[2,3-b]pyrrolo[1,2-d][1,4]oxazin-9-one;
1-(5-methy1-345-(2-oxopyrrolidin-1-yl)pyridin-3-yl)amino)-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one;
1-(5-methy1-3-(pyrido[2,3-b]pyrazin-7-ylamino)-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one;
1-(34(1,5-naphthyridin-3-y1)amino)-5-methy1-5H-chromeno[4,3-c]pyridin-8-y1)pyrrolidin-2-one;
1-(5-methy1-3-(pyrimidin-5-ylamino)-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one ;
N-cyclopropyl-N-(5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-yl)methanesulfonamide;
1-(5-methy1-3-((1-(methylsulfony1)-1H-pyrrolo[3,2-b]pyridin-6-y1)amino)-5H-chromeno[4,3-c]pyridin-8-y1)pyrrolidin-2-one;
1-(5-methy1-3-((1-pivaloy1-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)amino)-chromeno[4,3-c]pyridin-8-y1)pyrrolidin-2-one;
1-(545-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-y1)imidazolidin-2-one;
1-(3-((2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-7-yl)amino)-5-methy1-5H-chromeno[4,3-c]pyridin-8-y1)pyrrolidin-2-one;
1-(5-methy1-3-(thiazolo[5,4-b]pyridin-6-ylamino)-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one;
1-(3-((1-(cyclopropanecarbony1)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)amino)-5-methyl-5H-chromeno[4,3-c]pyridin-8-y1)pyrrolidin-2-one;
3-((1-(cyclopropylsulfony1)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)amino)-N,N,5-trimethyl-5H-chromeno[4,3-c]pyridine-8-carboxamide;
N,N,5-trimethy1-341-pivaloy1-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)amino)-5H-chromeno[4,3-c]pyridine-8-carboxamide;
341-(cyclopropanecarbony1)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)amino)-N,N,5-trimethyl-5H-chromeno[4,3-c]pyridine-8-carboxamide;
341-acety1-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)amino)-N,N,5-trimethyl-chromeno[4,3-c]pyridine-8-carboxamide;
N,N,5-trimethy1-341-(methylsulfony1)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-y1)amino)-5H-chromeno[4,3-c]pyridine-8-carboxamide;
1-(5-methy1-345-(trifluoromethyl)pyridin-3-yl)amino)-5H-chromeno[4,3-c]pyridin-yl)pyrrolidin-2-one;
N-(2-methoxy-5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-y1)amino)pyridin-3-y1)acetamide;
N-(2-methoxy-5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-y1)amino)pyridin-3-y1)methanesulfonamide;
1-(341-isobutyry1-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)amino)-5-methy1-chromeno[4,3-c]pyridin-8-y1)pyrrolidin-2-one;
(S)-245,5-dimethy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)-6,6a,7,8-tetrahydro-9H-pyrido[2,3-b]pyrrolo[1,2-d][1,4]oxazin-9-one;
N-(2-methoxy-5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-y1)amino)pyridin-3-y1)-N-methylmethanesulfonamide;
1-(545-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-y1)-3-(thiazol-4-ylmethyl)imidazolidin-2-one;
methyl 745-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazine-1-carboxylate;
1-(5-methy1-3-((5-(methylsulfonyl)pyridin-3-yl)amino)-5H-chromeno[4,3-c]pyridin-8-y1)pyrrolidin-2-one;
1-(3-((1-(2-hydroxyacety1)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)amino)-5-methyl-5H-chromeno[4,3-c]pyridin-8-y1)pyrrolidin-2-one;
methyl 7-((8-(dimethylcarbamoy1)-5-methy1-5H-chromeno[4,3-c]pyridin-3-yl)amino)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazine-1-carboxylate;
N-(2-methoxy-5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-y1)amino)pyridin-3-y1)-N-methylacetamide;
1-(5,6-dimethy1-3-(pyridin-3-ylamino)-5,6-dihydrobenzo[c][2,6]naphthyridin-8-yl)pyrrolidin-2-one;
1-(9-fluoro-5-methy1-3-(pyridin-3-ylamino)-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one;
(6aS)-2-((5,6-dimethy1-8-(2-oxopyrrolidin-1-y1)-5,6-dihydrobenzo[c][2,6]naphthyridin-3-yl)amino)-6,6a,7,8-tetrahydro-9H-pyrido[2,3-b]pyrrolo[1,2-d][1,4]oxazin-9-one;
methyl 7-((8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazine-1-carboxylate;
(S)-2-((8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)-6,6a,7,8-tetrahydro-9H-pyrido[2,3-b]pyrrolo[1,2-d][1,4]oxazin-9-one;
1-(5-methy1-345-morpholinopyridin-3-yl)amino)-5H-chromeno[4,3-c]pyridin-8-y1)pyrrolidin-2-one;
1-(3-((1-(2-hydroxy-2-methylpropanoy1)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)amino)-5-methyl-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one;
1-(3-((1-(cyclopropanecarbony1)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)amino)-5H-chromeno[4,3-c]pyridin-8-y1)pyrrolidin-2-one;
1-(3-((1-(methylsulfony1)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)amino)-chromeno[4,3-c]pyridin-8-y1)pyrrolidin-2-one;
(S)-2-((8-(2-oxopyrrolidin-1-yl)spiro[chromeno[4,3-c]pyridine-5,3'-oxetan]-3-y1)amino)-6,6a,7,8-tetrahydro-9H-pyrido[2,3-b]pyrrolo[1,2-d][1,4]oxazin-9-one;
(S)-2-((8-(2-oxopyrrolidin-1-yl)spiro[chromeno[4,3-c]pyridine-5,1'-cyclobutan]-3-y1)amino)-6,6a,7,8-tetrahydro-9H-pyrido[2,3-b]pyrrolo[1,2-d][1,4]oxazin-9-one;
745-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)-1H-pyrido[2,3-b][1,4]oxazin-2(3H)-one;
1-(3-((2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)amino)-5-methy1-5H-chromeno[4,3-c]pyridin-8-y1)pyrrolidin-2-one;
1-(5-methy1-345-methylpyridin-3-yl)amino)-5H-chromeno[4,3-c]pyridin-8-y1)pyrrolidin-2-one;
(6a5)-249-fluoro-5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)-6,6a,7,8-tetrahydro-9H-pyrido[2,3-b]pyrrolo[1,2-d][1,4]oxazin-9-one;
1-(3-((2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-7-yl)amino)-5,6-dimethy1-5,6-dihydrobenzo[c][2,6]naphthyridin-8-y1)pyrrolidin-2-one;
1-(3-((1-(cyclopropylsulfony1)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)amino)-5H-chromeno[4,3-c]pyridin-8-y1)pyrrolidin-2-one;
1-(3-((1-(isopropylsulfony1)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)amino)-5H-chromeno[4,3-c]pyridin-8-y1)pyrrolidin-2-one;
4-(545-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-y1)morpholin-3-one;
1-(3-((1-(1-hydroxycyclopropane-1-carbony1)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)amino)-5-methyl-5H-chromeno[4,3-c]pyridin-8-y1)pyrrolidin-2-one;
1-(3-((1-(2-hydroxypropanoy1)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)amino)-5-methyl-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one;
1-(3-((1-(isopropylsulfony1)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)amino)-5-methyl-5H-chromeno[4,3-c]pyridin-8-y1)pyrrolidin-2-one;
(S)-249-fluoro-5,5-dimethy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)-6,6a,7,8-tetrahydro-9H-pyrido[2,3-b]pyrrolo[1,2-d][1,4]oxazin-9-one;
N-(545-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-y1)acetamide;
1-benzy1-3-(545-methyl-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-yl)urea;
3-amino-N-(545-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-y1)benzamide;
1-(5-methy1-3-(pyridazin-4-ylamino)-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one;
1-(5-methy1-3-(pyridazin-3-ylamino)-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one;
1-(549-fluoro-5,5-dimethy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-yl)amino)pyridin-3-y1)imidazolidin-2-one;
1-methy1-3-(545-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-y1)amino)pyridin-3-y1)urea;
N-(5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-y1)-3-phenylpropanamide;
N-(545-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-y1)-2-phenylacetamide;
(1S,2S)-N-(545-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-y1)-2-phenylcyclopropane-1-carboxamide;
N-(545-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-y1)picolinamide;
N-(545-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-y1)nicotinamide;
N-(545-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-y1)isonicotinamide;
4-fluoro-N-(545-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-y1)benzamide;
3-fluoro-N-(545-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-y1)benzamide;
3-methoxy-N-(5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-y1)amino)pyridin-3-y1)benzamide;
4-methoxy-N-(5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-y1)amino)pyridin-3-y1)benzamide;
1-(5-methy1-345-(pyridin-2-ylamino)pyridin-3-yl)amino)-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one;
1-(5-methy1-345-(pyridazin-3-ylamino)pyridin-3-yl)amino)-5H-chromeno[4,3-c]pyridin-8-y1)pyrrolidin-2-one;
N-(545-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-y1)-3-phenylbutanamide;
2-methyl-N-(5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-y1)-3-phenylpropanamide;
N-(545-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-y1)tetrahydrofuran-2-carboxamide;
N-(545-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-y1)benzo[d][1,3]dioxole-5-carboxamide;
N-(545-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-y1)benzo[d][1,3]dioxole-4-carboxamide;
1-(5-methy1-345-(methylsulfonyl)quinolin-3-yl)amino)-5H-chromeno[4,3-c]pyridin-y1)pyrrolidin-2-one;
methyl 749-fluoro-5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazine-1-carboxylate;
N-(545-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-y1)-2-oxopyrrolidine-3-carboxamide;
N-(545-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-y1)-2,3-dihydro-1H-indene-2-carboxamide;
N-(545-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-y1)pyrazolo[1,5-a]pyridine-2-carboxamide;
N-(545-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-y1)-2,3-dihydrobenzofuran-2-carboxamide;
methyl (54(5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-y1)carbamate;
445-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-y1)amino)-4-oxobutanoic acid;
N-(545-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-y1)-1H-indole-6-carboxamide;
N-(5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-y1)-1H-indole-4-carboxamide;
N-(545-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-y1)-1H-benzo[d]imidazole-7-carboxamide;
N-(545-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-y1)imidazo[1,2-a]pyridine-2-carboxamide;
N-(545-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-y1)-1H-indole-2-carboxamide;
2-(imidazo[1,2-a]pyridin-3-y1)-N-(545-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-y1)acetamide;
1-(549-fluoro-5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-y1)imidazolidin-2-one;
4-formamido-3-hydroxy-N-(5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-yl)benzamide;
N-(545-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-y1)pyridazine-4-carboxamide;
6-amino-N-(545-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-y1)pyrazine-2-carboxamide;
2-hydroxy-N-(5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-y1)amino)pyridin-3-y1)-3-phenylpropanamide;
N-(545-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-y1)imidazo[1,2-a]pyridine-3-carboxamide;
N-(545-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-y1)pyrazolo[1,5-a]pyridine-3-carboxamide;
1-(3-((2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-7-yl)amino)-5,5-dimethy1-5H-chromeno[4,3-c]pyridin-8-y1)pyrrolidin-2-one;
1-(3-((2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-7-yl)amino)-9-fluoro-5-methy1-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one;
1-(34(2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-7-yl)amino)-9-fluoro-5,5-dimethy1-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one;
2-hydroxy-N-(5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-y1)amino)pyridin-3-y1)acetamide;
N-(545-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-y1)benzo[d]oxazole-6-carboxamide;
1-hydroxy-N-(5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-y1)amino)pyridin-3-y1)-1,3-dihydrobenzo[c][1,2]oxaborole-5-carboxamide;
N-(545-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridazin-3-y1)acetamide;
N-(545-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-y1)imidazo[1,2-a]pyridine-7-carboxamide;
1-(3-((2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-7-yl)amino)-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one;
1-(545-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-y1)-3-(pyridin-2-yOurea;
1-hydroxy-N-(5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-y1)amino)pyridin-3-y1)-1,3-dihydrobenzo[c][1,2]oxaborole-6-carboxamide;
N-(545-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-y1)imidazo[1,2-a]pyridine-5-carboxamide;
1-(342,3-dihydro-[1,4]dioxino[2,3-b]pyridin-7-yl)amino)-9-fluoro-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one;
1-(5-methy1-4-(pyridin-4-y1)-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one;
1-(3-((5-(4-(3-methoxypropanoyl)piperazin-1-yl)pyridin-3-yl)amino)-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one;
1-(3-((5-(4-(3-methoxypropanoyl)piperazin-1-yl)pyridin-3-yl)amino)-5-methyl-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one;
1-(3-((5-(4-(3-methoxypropanoyl)piperazin-1-yl)pyridin-3-yl)amino)-5,5-dimethyl-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one;
(E)-4-(dimethylamino)-N-(3-(34(54(5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-y1)amino)-3-oxopropyl)phenyl)but-2-enamide;
2-amino-N-(54(5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-y1)isonicotinamide;
1-(9-fluoro-3-((5-(4-(3-methoxypropanoyl)piperazin-1-yl)pyridin-3-yl)amino)-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one;
1-(9-fluoro-3-((5-(4-(3-methoxypropanoyl)piperazin-1-yl)pyridin-3-yl)amino)-5-methyl-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one;
1-(9-fluoro-3-((5-(4-(3-methoxypropanoyl)piperazin-1-yl)pyridin-3-yl)amino)-5,5-dimethyl-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one;
1-(54(8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-yl)imidazolidin-2-one;
(E)-4-(4-(dimethylamino)but-2-enamido)-N-(5-((5-methy1-8-(2-oxopyrrolidin-l-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-yl)benzamide;
(6aS)-8,8-dimethy1-24(5-methyl-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)-6,6a,7,8-tetrahydro-9H-pyrido[2,3-b]pyrrolo[1,2-d][1,4]oxazin-9-one;
(6aS)-2-((9-fluoro-5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)-8,8-dimethyl-6,6a,7,8-tetrahydro-9H-pyrido[2,3-b]pyrrolo[1,2-d][1,4]oxazin-9-one;
1-hydroxy-N-(5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-y1)amino)pyridin-3-y1)-1,3-dihydrobenzo[c][1,2]oxaborole-4-carboxamide;
(6aR)-2-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)-6,6a,7,8-tetrahydro-9H-pyrido[2,3-b]pyrrolo[1,2-d][1,4]oxazin-9-one;
(6aS)-2-((9-fluoro-5-methyl-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)-8-methyl-6,6a,7,8-tetrahydro-9H-pyrido[2,3-b]pyrrolo[1,2-d][1,4]oxazin-9-one;
(6aR)-2-((9-fluoro-5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)-6,6a,7,8-tetrahydro-9H-pyrido[2,3-b]pyrrolo[1,2-d][1,4]oxazin-9-one;
(R)-2-((8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)-6,6a,7,8-tetrahydro-9H-pyrido[2,3-b]pyrrolo[1,2-d][1,4]oxazin-9-one;
(R)-24(5,5-dimethy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)-6,6a,7,8-tetrahydro-9H-pyrido[2,3-b]pyrrolo[1,2-d][1,4]oxazin-9-one;
(R)-24(9-fluoro-5,5-dimethyl-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)-6,6a,7,8-tetrahydro-9H-pyrido[2,3-b]pyrrolo[1,2-d][1,4]oxazin-9-one;
(6aS)-8-methy1-245-methyl-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)-6,6a,7,8-tetrahydro-9H-pyrido[2,3-b]pyrrolo[1,2-d][1,4]oxazin-9-one;
4-(dimethylamino)-N-(3-(34(54(5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-y1)amino)-3-oxopropyl)phenyl)butanamide;
(E)-4-(dimethylamino)-N-(2-((3-((3-(5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-y1)-2-oxoimidazolidin-1-y1)methyl)phenyl)amino)-oxoethyl)but-2-enamide;
(6a'S)-2'4(5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)-6a',7'-dihydro-6'H,9'H-spiro[cyclopropane-1,8'-pyrido[2,3-b]pyrrolo[1,2-d][1,4]oxazin]-9'-one;
(S)-2'-((5-(3-fluoro-4-(2-oxopyrrolidin-1-yl)phenyl)pyridin-2-yl)amino)-6a',7'-dihydro-6'H,9'H-spiro[cyclopropane-1,8'-pyrido[2,3-b]pyrrolo[1,2-d][1,4]oxazin]-9'-one;
(6a'S)-2'-((9-fluoro-5-methyl-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)-6a',7'-dihydro-6'H,9'H-spiro[cyclopropane-1,8'-pyrido[2,3-b]pyrrolo[1,2-d][1,4]oxazin]-9'-one;
(E)-N-(5-((5,5-dimethy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-y1)amino)pyridin-3-y1)-4-(4-(dimethylamino)but-2-enamido)benzamide;
(E)-N-(3-(3-((5-((5,5-dimethy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-y1)amino)pyridin-3-y1)amino)-3-oxopropyl)pheny1)-4-(dimethylamino)but-2-enamide;
(E)-4-(4-(dimethylamino)but-2-enamido)-N-(5-((8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-y1)benzamide;
1-(5-((9-fluoro-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-yl)imidazolidin-2-one;
1-(54(5,5-dimethy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-y1)imidazolidin-2-one;
(6aS)-2-((9-fluoro-5-methyl-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)-8-hydroxy-6,6a,7,8-tetrahydro-9H-pyrido[2,3-b]pyrrolo[1,2-d][1,4]oxazin-9-one;
(E)-4-(dimethylamino)-N-(2-((4-((3-(5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-y1)amino)pyridin-3-y1)-2-oxoimidazolidin-1-y1)methyl)phenyl)amino)-oxoethyl)but-2-enamide;
1-(4-(pyridin-4-y1)-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one;
1-(5-methy1-4-(pyridin-4-ylamino)-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one;
(S)-249-fluoro-5,5-dimethy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[3,4-d]pyrimidin-3-yl)amino)-6,6a,7,8-tetrahydro-9H-pyrido[2,3-b]pyrrolo[1,2-d][1,4]oxazin-9-one;
(S)-2-((5,5-dimethy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[3,4-d]pyrimidin-3-yl)amino)-6,6a,7,8-tetrahydro-9H-pyrido[2,3-b]pyrrolo[1,2-d][1,4]oxazin-9-one;
(3aR)-8-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)-3a,4-dihydro-1H,3H-oxazolo[3,4-d]pyrido[2,3-b][1,4]oxazin-1-one;
N-(54(9-fluoro-5,5-dimethyl-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)-2-methoxypyridin-3-yl)acetamide;
N-(54(5,5-dimethy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)-2-methoxypyridin-3-y1)acetamide;
1-(5-methy1-3-((5-(5-methy1-1,1-dioxido-1,2,5-thiadiazolidin-2-yl)pyridin-3-yl)amino)-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one;
(6aS,8R)-2-((9-fluoro-5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)-8-hydroxy-8-methy1-6,6a,7,8-tetrahydro-9H-pyrido[2,3-b]pyrrolo[1,2-d][1,4]oxazin-9-one;
(6aS,8R)-8-hydroxy-8-methy1-2-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-y1)amino)-6,6a,7,8-tetrahydro-9H-pyrido[2,3-b]pyrrolo[1,2-d][1,4]oxazin-9-one;
1-(5,5-dimethy1-3-((5-(5-methy1-1,1-dioxido-1,2,5-thiadiazolidin-2-yl)pyridin-3-yl)amino)-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one;
N-(545-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-y1)-1H-benzo[d]imidazole-4-carboxamide;
(3aR)-84(9-fluoro-5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)-3a,4-dihydro-1H,3H-oxazolo[3,4-d]pyrido[2,3-b][1,4]oxazin-1-one;
4-(4-(dimethylamino)butanamido)-N-(545-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-y1)amino)pyridin-3-y1)benzamide;
1-(5-methy1-3-(((S)-2-methy1-1,1-dioxido-2,3,3a,4-tetrahydropyrido[2,3-b][1,2,5]thiadiazolo[2,3-d][1,4]oxazin-8-yl)amino)-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one;
(S)-1-(5,5-dimethy1-3-((2-methy1-1,1-dioxido-2,3,3a,4-tetrahydropyrido[2,3-b][1,2,5]thiadiazolo[2,3-d][1,4]oxazin-8-yl)amino)-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one;
(6aS)-8-hydroxy-2-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-y1)amino)-6,6a,7,8-tetrahydro-9H-pyrido[2,3-b]pyrrolo[1,2-d][1,4]oxazin-9-one;
1-(5-methy1-3-(oxazolo[4,5-b]pyridin-6-ylamino)-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one;
1-(5,5-dimethy1-3-((1-methyl-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)amino)-5H-chromeno[3,4-d]pyrimidin-8-yl)pyrrolidin-2-one;
(S)-2-((5,5-dimethy1-8-(4-methylisoxazol-3-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)-6,6a,7,8-tetrahydro-9H-pyrido[2,3-b]pyrrolo[1,2-d][1,4]oxazin-9-one;
(S)-2-((5,5-dimethy1-8-(4-methyl-4H-1,2,4-triazol-3-y1)-5H-chromeno[3,4-d]pyrimidin-3-yl)amino)-6,6a,7,8-tetrahydro-9H-pyrido[2,3-b]pyrrolo[1,2-d] [1,4]oxazin-9-one;
(S)-2-((5,5-dimethy1-8-(4-methyl-4H-1,2,4-triazol-3-y1)-51-1-chromeno[4,3-c]pyridin-3-yl)amino)-6,6a,7,8-tetrahydro-9H-pyrido[2,3-b]pyrrolo[1,2-d] [1,4]oxazin-9-one;
N-(54(5,5-dimethy1-8-(2-oxopyrrolidin-1-y1)-51-1-chromeno[4,3 -c]pyridin-3 -yl)amino)pyridin-3 -y1)-4-(2-(2-(2-(24(2-(2,6-di oxopiperidin-3 -y1)-1,3 -di oxoi soindolin-4-yl)amino)ethoxy)ethoxy)ethoxy)acetami do)b enzami de;
and N-(54(5,5-dimethy1-8-(2-oxopyrrolidin-1-y1)-51-1-chromeno[4,3 -c]pyridin-3 -yl)amino)pyridin-3 -y1)-4-(4-(2-((2-(2,6-di oxopiperidin-3 -y1)-1,3 -di oxoi soindolin-4-yl)oxy)ac etami do)butanami do)b enzami de.
N,N,5-trimethy1-3-((5-(2-oxopyrrolidin-1-yl)pyridin-3-yl)amino)-5H-chromeno[4,3-c]pyridine-8-carboxamide;
N,N,5-trimethy1-3-(pyridin-3-ylamino)-5H-chromeno[4,3-c]pyridine-8-carboxamide;
1-(3-((1-acety1-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)amino)-5-methyl-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one;
5-cyclopropyl-N,N-dimethy1-3-((5-(2-oxopyrrolidin-1-y1)pyridin-3-y1)amino)-5H-chromeno[4,3-c]pyridine-8-carboxamide;
1-(3-((5-(difluoromethoxy)pyridin-3-yl)amino)-5-methy1-5H-chromeno[4,3-c]pyridin-8-y1)pyrrolidin-2-one;
N,N,5-trimethy1-3-(((S)-9-oxo-6a,7,8,9-tetrahydro-6H-pyrido[2,3-b]pyrrolo[1,2-d][1,4]oxazin-2-yl)amino)-5H-chromeno[4,3-c]pyridine-8-carboxamide;
(6aS)-2-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)-6,6a,7,8-tetrahydro-9H-pyrido[2,3-b]pyrrolo[1,2-d][1,4]oxazin-9-one;
5-cyclopropyl-N,N-dimethy1-3-(((S)-9-oxo-6a,7,8,9-tetrahydro-6H-pyrido[2,3-b]pyrrolo[1,2-d][1,4]oxazin-2-yl)amino)-5H-chromeno[4,3-c]pyridine-8-carboxamide;
1-(545-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-y1)cyclopropane-1-carbonitrile;
5-cyclopropyl-N,N-dimethy1-3-(pyridin-3-ylamino)-5H-chromeno[4,3-c]pyridine-8-carboxamide;
1-(5-methy1-3-(pyridin-3-ylamino)-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one;
1-methy1-3-(545-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-y1)amino)pyridin-3-y1)imidazolidin-2-one;
N,N,5,6-tetramethy1-3-(pyridin-3-ylamino)-5,6-dihydrobenzo[c][2,6]naphthyridine-8-carboxamide;
N-methyl-N-(5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-yl)methanesulfonamide;
1-(5-methy1-3-((1-(methylsulfony1)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)amino)-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one;
1-(345-fluoropyridin-3-yl)amino)-5-methyl-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one;
1-(3-((1-(cyclopropylsulfony1)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)amino)-5-methyl-5H-chromeno[4,3-c]pyridin-8-y1)pyrrolidin-2-one;
(S)-24(R)-5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)-6,6a,7,8-tetrahydro-9H-pyrido[2,3-b]pyrrolo[1,2-d][1,4]oxazin-9-one;
(S)-24(S)-5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)-6,6a,7,8-tetrahydro-9H-pyrido[2,3-b]pyrrolo[1,2-d][1,4]oxazin-9-one;
1-(5-methy1-345-(2-oxopyrrolidin-1-yl)pyridin-3-yl)amino)-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one;
1-(5-methy1-3-(pyrido[2,3-b]pyrazin-7-ylamino)-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one;
1-(34(1,5-naphthyridin-3-y1)amino)-5-methy1-5H-chromeno[4,3-c]pyridin-8-y1)pyrrolidin-2-one;
1-(5-methy1-3-(pyrimidin-5-ylamino)-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one ;
N-cyclopropyl-N-(5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-yl)methanesulfonamide;
1-(5-methy1-3-((1-(methylsulfony1)-1H-pyrrolo[3,2-b]pyridin-6-y1)amino)-5H-chromeno[4,3-c]pyridin-8-y1)pyrrolidin-2-one;
1-(5-methy1-3-((1-pivaloy1-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)amino)-chromeno[4,3-c]pyridin-8-y1)pyrrolidin-2-one;
1-(545-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-y1)imidazolidin-2-one;
1-(3-((2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-7-yl)amino)-5-methy1-5H-chromeno[4,3-c]pyridin-8-y1)pyrrolidin-2-one;
1-(5-methy1-3-(thiazolo[5,4-b]pyridin-6-ylamino)-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one;
1-(3-((1-(cyclopropanecarbony1)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)amino)-5-methyl-5H-chromeno[4,3-c]pyridin-8-y1)pyrrolidin-2-one;
3-((1-(cyclopropylsulfony1)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)amino)-N,N,5-trimethyl-5H-chromeno[4,3-c]pyridine-8-carboxamide;
N,N,5-trimethy1-341-pivaloy1-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)amino)-5H-chromeno[4,3-c]pyridine-8-carboxamide;
341-(cyclopropanecarbony1)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)amino)-N,N,5-trimethyl-5H-chromeno[4,3-c]pyridine-8-carboxamide;
341-acety1-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)amino)-N,N,5-trimethyl-chromeno[4,3-c]pyridine-8-carboxamide;
N,N,5-trimethy1-341-(methylsulfony1)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-y1)amino)-5H-chromeno[4,3-c]pyridine-8-carboxamide;
1-(5-methy1-345-(trifluoromethyl)pyridin-3-yl)amino)-5H-chromeno[4,3-c]pyridin-yl)pyrrolidin-2-one;
N-(2-methoxy-5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-y1)amino)pyridin-3-y1)acetamide;
N-(2-methoxy-5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-y1)amino)pyridin-3-y1)methanesulfonamide;
1-(341-isobutyry1-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)amino)-5-methy1-chromeno[4,3-c]pyridin-8-y1)pyrrolidin-2-one;
(S)-245,5-dimethy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)-6,6a,7,8-tetrahydro-9H-pyrido[2,3-b]pyrrolo[1,2-d][1,4]oxazin-9-one;
N-(2-methoxy-5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-y1)amino)pyridin-3-y1)-N-methylmethanesulfonamide;
1-(545-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-y1)-3-(thiazol-4-ylmethyl)imidazolidin-2-one;
methyl 745-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazine-1-carboxylate;
1-(5-methy1-3-((5-(methylsulfonyl)pyridin-3-yl)amino)-5H-chromeno[4,3-c]pyridin-8-y1)pyrrolidin-2-one;
1-(3-((1-(2-hydroxyacety1)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)amino)-5-methyl-5H-chromeno[4,3-c]pyridin-8-y1)pyrrolidin-2-one;
methyl 7-((8-(dimethylcarbamoy1)-5-methy1-5H-chromeno[4,3-c]pyridin-3-yl)amino)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazine-1-carboxylate;
N-(2-methoxy-5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-y1)amino)pyridin-3-y1)-N-methylacetamide;
1-(5,6-dimethy1-3-(pyridin-3-ylamino)-5,6-dihydrobenzo[c][2,6]naphthyridin-8-yl)pyrrolidin-2-one;
1-(9-fluoro-5-methy1-3-(pyridin-3-ylamino)-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one;
(6aS)-2-((5,6-dimethy1-8-(2-oxopyrrolidin-1-y1)-5,6-dihydrobenzo[c][2,6]naphthyridin-3-yl)amino)-6,6a,7,8-tetrahydro-9H-pyrido[2,3-b]pyrrolo[1,2-d][1,4]oxazin-9-one;
methyl 7-((8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazine-1-carboxylate;
(S)-2-((8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)-6,6a,7,8-tetrahydro-9H-pyrido[2,3-b]pyrrolo[1,2-d][1,4]oxazin-9-one;
1-(5-methy1-345-morpholinopyridin-3-yl)amino)-5H-chromeno[4,3-c]pyridin-8-y1)pyrrolidin-2-one;
1-(3-((1-(2-hydroxy-2-methylpropanoy1)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)amino)-5-methyl-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one;
1-(3-((1-(cyclopropanecarbony1)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)amino)-5H-chromeno[4,3-c]pyridin-8-y1)pyrrolidin-2-one;
1-(3-((1-(methylsulfony1)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)amino)-chromeno[4,3-c]pyridin-8-y1)pyrrolidin-2-one;
(S)-2-((8-(2-oxopyrrolidin-1-yl)spiro[chromeno[4,3-c]pyridine-5,3'-oxetan]-3-y1)amino)-6,6a,7,8-tetrahydro-9H-pyrido[2,3-b]pyrrolo[1,2-d][1,4]oxazin-9-one;
(S)-2-((8-(2-oxopyrrolidin-1-yl)spiro[chromeno[4,3-c]pyridine-5,1'-cyclobutan]-3-y1)amino)-6,6a,7,8-tetrahydro-9H-pyrido[2,3-b]pyrrolo[1,2-d][1,4]oxazin-9-one;
745-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)-1H-pyrido[2,3-b][1,4]oxazin-2(3H)-one;
1-(3-((2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)amino)-5-methy1-5H-chromeno[4,3-c]pyridin-8-y1)pyrrolidin-2-one;
1-(5-methy1-345-methylpyridin-3-yl)amino)-5H-chromeno[4,3-c]pyridin-8-y1)pyrrolidin-2-one;
(6a5)-249-fluoro-5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)-6,6a,7,8-tetrahydro-9H-pyrido[2,3-b]pyrrolo[1,2-d][1,4]oxazin-9-one;
1-(3-((2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-7-yl)amino)-5,6-dimethy1-5,6-dihydrobenzo[c][2,6]naphthyridin-8-y1)pyrrolidin-2-one;
1-(3-((1-(cyclopropylsulfony1)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)amino)-5H-chromeno[4,3-c]pyridin-8-y1)pyrrolidin-2-one;
1-(3-((1-(isopropylsulfony1)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)amino)-5H-chromeno[4,3-c]pyridin-8-y1)pyrrolidin-2-one;
4-(545-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-y1)morpholin-3-one;
1-(3-((1-(1-hydroxycyclopropane-1-carbony1)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)amino)-5-methyl-5H-chromeno[4,3-c]pyridin-8-y1)pyrrolidin-2-one;
1-(3-((1-(2-hydroxypropanoy1)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)amino)-5-methyl-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one;
1-(3-((1-(isopropylsulfony1)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)amino)-5-methyl-5H-chromeno[4,3-c]pyridin-8-y1)pyrrolidin-2-one;
(S)-249-fluoro-5,5-dimethy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)-6,6a,7,8-tetrahydro-9H-pyrido[2,3-b]pyrrolo[1,2-d][1,4]oxazin-9-one;
N-(545-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-y1)acetamide;
1-benzy1-3-(545-methyl-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-yl)urea;
3-amino-N-(545-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-y1)benzamide;
1-(5-methy1-3-(pyridazin-4-ylamino)-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one;
1-(5-methy1-3-(pyridazin-3-ylamino)-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one;
1-(549-fluoro-5,5-dimethy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-yl)amino)pyridin-3-y1)imidazolidin-2-one;
1-methy1-3-(545-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-y1)amino)pyridin-3-y1)urea;
N-(5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-y1)-3-phenylpropanamide;
N-(545-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-y1)-2-phenylacetamide;
(1S,2S)-N-(545-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-y1)-2-phenylcyclopropane-1-carboxamide;
N-(545-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-y1)picolinamide;
N-(545-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-y1)nicotinamide;
N-(545-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-y1)isonicotinamide;
4-fluoro-N-(545-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-y1)benzamide;
3-fluoro-N-(545-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-y1)benzamide;
3-methoxy-N-(5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-y1)amino)pyridin-3-y1)benzamide;
4-methoxy-N-(5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-y1)amino)pyridin-3-y1)benzamide;
1-(5-methy1-345-(pyridin-2-ylamino)pyridin-3-yl)amino)-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one;
1-(5-methy1-345-(pyridazin-3-ylamino)pyridin-3-yl)amino)-5H-chromeno[4,3-c]pyridin-8-y1)pyrrolidin-2-one;
N-(545-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-y1)-3-phenylbutanamide;
2-methyl-N-(5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-y1)-3-phenylpropanamide;
N-(545-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-y1)tetrahydrofuran-2-carboxamide;
N-(545-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-y1)benzo[d][1,3]dioxole-5-carboxamide;
N-(545-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-y1)benzo[d][1,3]dioxole-4-carboxamide;
1-(5-methy1-345-(methylsulfonyl)quinolin-3-yl)amino)-5H-chromeno[4,3-c]pyridin-y1)pyrrolidin-2-one;
methyl 749-fluoro-5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazine-1-carboxylate;
N-(545-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-y1)-2-oxopyrrolidine-3-carboxamide;
N-(545-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-y1)-2,3-dihydro-1H-indene-2-carboxamide;
N-(545-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-y1)pyrazolo[1,5-a]pyridine-2-carboxamide;
N-(545-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-y1)-2,3-dihydrobenzofuran-2-carboxamide;
methyl (54(5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-y1)carbamate;
445-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-y1)amino)-4-oxobutanoic acid;
N-(545-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-y1)-1H-indole-6-carboxamide;
N-(5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-y1)-1H-indole-4-carboxamide;
N-(545-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-y1)-1H-benzo[d]imidazole-7-carboxamide;
N-(545-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-y1)imidazo[1,2-a]pyridine-2-carboxamide;
N-(545-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-y1)-1H-indole-2-carboxamide;
2-(imidazo[1,2-a]pyridin-3-y1)-N-(545-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-y1)acetamide;
1-(549-fluoro-5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-y1)imidazolidin-2-one;
4-formamido-3-hydroxy-N-(5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-yl)benzamide;
N-(545-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-y1)pyridazine-4-carboxamide;
6-amino-N-(545-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-y1)pyrazine-2-carboxamide;
2-hydroxy-N-(5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-y1)amino)pyridin-3-y1)-3-phenylpropanamide;
N-(545-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-y1)imidazo[1,2-a]pyridine-3-carboxamide;
N-(545-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-y1)pyrazolo[1,5-a]pyridine-3-carboxamide;
1-(3-((2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-7-yl)amino)-5,5-dimethy1-5H-chromeno[4,3-c]pyridin-8-y1)pyrrolidin-2-one;
1-(3-((2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-7-yl)amino)-9-fluoro-5-methy1-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one;
1-(34(2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-7-yl)amino)-9-fluoro-5,5-dimethy1-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one;
2-hydroxy-N-(5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-y1)amino)pyridin-3-y1)acetamide;
N-(545-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-y1)benzo[d]oxazole-6-carboxamide;
1-hydroxy-N-(5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-y1)amino)pyridin-3-y1)-1,3-dihydrobenzo[c][1,2]oxaborole-5-carboxamide;
N-(545-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridazin-3-y1)acetamide;
N-(545-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-y1)imidazo[1,2-a]pyridine-7-carboxamide;
1-(3-((2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-7-yl)amino)-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one;
1-(545-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-y1)-3-(pyridin-2-yOurea;
1-hydroxy-N-(5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-y1)amino)pyridin-3-y1)-1,3-dihydrobenzo[c][1,2]oxaborole-6-carboxamide;
N-(545-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-y1)imidazo[1,2-a]pyridine-5-carboxamide;
1-(342,3-dihydro-[1,4]dioxino[2,3-b]pyridin-7-yl)amino)-9-fluoro-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one;
1-(5-methy1-4-(pyridin-4-y1)-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one;
1-(3-((5-(4-(3-methoxypropanoyl)piperazin-1-yl)pyridin-3-yl)amino)-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one;
1-(3-((5-(4-(3-methoxypropanoyl)piperazin-1-yl)pyridin-3-yl)amino)-5-methyl-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one;
1-(3-((5-(4-(3-methoxypropanoyl)piperazin-1-yl)pyridin-3-yl)amino)-5,5-dimethyl-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one;
(E)-4-(dimethylamino)-N-(3-(34(54(5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-y1)amino)-3-oxopropyl)phenyl)but-2-enamide;
2-amino-N-(54(5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-y1)isonicotinamide;
1-(9-fluoro-3-((5-(4-(3-methoxypropanoyl)piperazin-1-yl)pyridin-3-yl)amino)-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one;
1-(9-fluoro-3-((5-(4-(3-methoxypropanoyl)piperazin-1-yl)pyridin-3-yl)amino)-5-methyl-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one;
1-(9-fluoro-3-((5-(4-(3-methoxypropanoyl)piperazin-1-yl)pyridin-3-yl)amino)-5,5-dimethyl-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one;
1-(54(8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-yl)imidazolidin-2-one;
(E)-4-(4-(dimethylamino)but-2-enamido)-N-(5-((5-methy1-8-(2-oxopyrrolidin-l-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-yl)benzamide;
(6aS)-8,8-dimethy1-24(5-methyl-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)-6,6a,7,8-tetrahydro-9H-pyrido[2,3-b]pyrrolo[1,2-d][1,4]oxazin-9-one;
(6aS)-2-((9-fluoro-5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)-8,8-dimethyl-6,6a,7,8-tetrahydro-9H-pyrido[2,3-b]pyrrolo[1,2-d][1,4]oxazin-9-one;
1-hydroxy-N-(5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-y1)amino)pyridin-3-y1)-1,3-dihydrobenzo[c][1,2]oxaborole-4-carboxamide;
(6aR)-2-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)-6,6a,7,8-tetrahydro-9H-pyrido[2,3-b]pyrrolo[1,2-d][1,4]oxazin-9-one;
(6aS)-2-((9-fluoro-5-methyl-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)-8-methyl-6,6a,7,8-tetrahydro-9H-pyrido[2,3-b]pyrrolo[1,2-d][1,4]oxazin-9-one;
(6aR)-2-((9-fluoro-5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)-6,6a,7,8-tetrahydro-9H-pyrido[2,3-b]pyrrolo[1,2-d][1,4]oxazin-9-one;
(R)-2-((8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)-6,6a,7,8-tetrahydro-9H-pyrido[2,3-b]pyrrolo[1,2-d][1,4]oxazin-9-one;
(R)-24(5,5-dimethy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)-6,6a,7,8-tetrahydro-9H-pyrido[2,3-b]pyrrolo[1,2-d][1,4]oxazin-9-one;
(R)-24(9-fluoro-5,5-dimethyl-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)-6,6a,7,8-tetrahydro-9H-pyrido[2,3-b]pyrrolo[1,2-d][1,4]oxazin-9-one;
(6aS)-8-methy1-245-methyl-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)-6,6a,7,8-tetrahydro-9H-pyrido[2,3-b]pyrrolo[1,2-d][1,4]oxazin-9-one;
4-(dimethylamino)-N-(3-(34(54(5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-y1)amino)-3-oxopropyl)phenyl)butanamide;
(E)-4-(dimethylamino)-N-(2-((3-((3-(5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-y1)-2-oxoimidazolidin-1-y1)methyl)phenyl)amino)-oxoethyl)but-2-enamide;
(6a'S)-2'4(5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)-6a',7'-dihydro-6'H,9'H-spiro[cyclopropane-1,8'-pyrido[2,3-b]pyrrolo[1,2-d][1,4]oxazin]-9'-one;
(S)-2'-((5-(3-fluoro-4-(2-oxopyrrolidin-1-yl)phenyl)pyridin-2-yl)amino)-6a',7'-dihydro-6'H,9'H-spiro[cyclopropane-1,8'-pyrido[2,3-b]pyrrolo[1,2-d][1,4]oxazin]-9'-one;
(6a'S)-2'-((9-fluoro-5-methyl-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)-6a',7'-dihydro-6'H,9'H-spiro[cyclopropane-1,8'-pyrido[2,3-b]pyrrolo[1,2-d][1,4]oxazin]-9'-one;
(E)-N-(5-((5,5-dimethy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-y1)amino)pyridin-3-y1)-4-(4-(dimethylamino)but-2-enamido)benzamide;
(E)-N-(3-(3-((5-((5,5-dimethy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-y1)amino)pyridin-3-y1)amino)-3-oxopropyl)pheny1)-4-(dimethylamino)but-2-enamide;
(E)-4-(4-(dimethylamino)but-2-enamido)-N-(5-((8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-y1)benzamide;
1-(5-((9-fluoro-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-yl)imidazolidin-2-one;
1-(54(5,5-dimethy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-y1)imidazolidin-2-one;
(6aS)-2-((9-fluoro-5-methyl-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)-8-hydroxy-6,6a,7,8-tetrahydro-9H-pyrido[2,3-b]pyrrolo[1,2-d][1,4]oxazin-9-one;
(E)-4-(dimethylamino)-N-(2-((4-((3-(5-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-y1)amino)pyridin-3-y1)-2-oxoimidazolidin-1-y1)methyl)phenyl)amino)-oxoethyl)but-2-enamide;
1-(4-(pyridin-4-y1)-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one;
1-(5-methy1-4-(pyridin-4-ylamino)-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one;
(S)-249-fluoro-5,5-dimethy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[3,4-d]pyrimidin-3-yl)amino)-6,6a,7,8-tetrahydro-9H-pyrido[2,3-b]pyrrolo[1,2-d][1,4]oxazin-9-one;
(S)-2-((5,5-dimethy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[3,4-d]pyrimidin-3-yl)amino)-6,6a,7,8-tetrahydro-9H-pyrido[2,3-b]pyrrolo[1,2-d][1,4]oxazin-9-one;
(3aR)-8-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)-3a,4-dihydro-1H,3H-oxazolo[3,4-d]pyrido[2,3-b][1,4]oxazin-1-one;
N-(54(9-fluoro-5,5-dimethyl-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)-2-methoxypyridin-3-yl)acetamide;
N-(54(5,5-dimethy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)-2-methoxypyridin-3-y1)acetamide;
1-(5-methy1-3-((5-(5-methy1-1,1-dioxido-1,2,5-thiadiazolidin-2-yl)pyridin-3-yl)amino)-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one;
(6aS,8R)-2-((9-fluoro-5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)-8-hydroxy-8-methy1-6,6a,7,8-tetrahydro-9H-pyrido[2,3-b]pyrrolo[1,2-d][1,4]oxazin-9-one;
(6aS,8R)-8-hydroxy-8-methy1-2-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-y1)amino)-6,6a,7,8-tetrahydro-9H-pyrido[2,3-b]pyrrolo[1,2-d][1,4]oxazin-9-one;
1-(5,5-dimethy1-3-((5-(5-methy1-1,1-dioxido-1,2,5-thiadiazolidin-2-yl)pyridin-3-yl)amino)-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one;
N-(545-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)pyridin-3-y1)-1H-benzo[d]imidazole-4-carboxamide;
(3aR)-84(9-fluoro-5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)-3a,4-dihydro-1H,3H-oxazolo[3,4-d]pyrido[2,3-b][1,4]oxazin-1-one;
4-(4-(dimethylamino)butanamido)-N-(545-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-y1)amino)pyridin-3-y1)benzamide;
1-(5-methy1-3-(((S)-2-methy1-1,1-dioxido-2,3,3a,4-tetrahydropyrido[2,3-b][1,2,5]thiadiazolo[2,3-d][1,4]oxazin-8-yl)amino)-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one;
(S)-1-(5,5-dimethy1-3-((2-methy1-1,1-dioxido-2,3,3a,4-tetrahydropyrido[2,3-b][1,2,5]thiadiazolo[2,3-d][1,4]oxazin-8-yl)amino)-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one;
(6aS)-8-hydroxy-2-((5-methy1-8-(2-oxopyrrolidin-1-y1)-5H-chromeno[4,3-c]pyridin-3-y1)amino)-6,6a,7,8-tetrahydro-9H-pyrido[2,3-b]pyrrolo[1,2-d][1,4]oxazin-9-one;
1-(5-methy1-3-(oxazolo[4,5-b]pyridin-6-ylamino)-5H-chromeno[4,3-c]pyridin-8-yl)pyrrolidin-2-one;
1-(5,5-dimethy1-3-((1-methyl-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)amino)-5H-chromeno[3,4-d]pyrimidin-8-yl)pyrrolidin-2-one;
(S)-2-((5,5-dimethy1-8-(4-methylisoxazol-3-y1)-5H-chromeno[4,3-c]pyridin-3-yl)amino)-6,6a,7,8-tetrahydro-9H-pyrido[2,3-b]pyrrolo[1,2-d][1,4]oxazin-9-one;
(S)-2-((5,5-dimethy1-8-(4-methyl-4H-1,2,4-triazol-3-y1)-5H-chromeno[3,4-d]pyrimidin-3-yl)amino)-6,6a,7,8-tetrahydro-9H-pyrido[2,3-b]pyrrolo[1,2-d] [1,4]oxazin-9-one;
(S)-2-((5,5-dimethy1-8-(4-methyl-4H-1,2,4-triazol-3-y1)-51-1-chromeno[4,3-c]pyridin-3-yl)amino)-6,6a,7,8-tetrahydro-9H-pyrido[2,3-b]pyrrolo[1,2-d] [1,4]oxazin-9-one;
N-(54(5,5-dimethy1-8-(2-oxopyrrolidin-1-y1)-51-1-chromeno[4,3 -c]pyridin-3 -yl)amino)pyridin-3 -y1)-4-(2-(2-(2-(24(2-(2,6-di oxopiperidin-3 -y1)-1,3 -di oxoi soindolin-4-yl)amino)ethoxy)ethoxy)ethoxy)acetami do)b enzami de;
and N-(54(5,5-dimethy1-8-(2-oxopyrrolidin-1-y1)-51-1-chromeno[4,3 -c]pyridin-3 -yl)amino)pyridin-3 -y1)-4-(4-(2-((2-(2,6-di oxopiperidin-3 -y1)-1,3 -di oxoi soindolin-4-yl)oxy)ac etami do)butanami do)b enzami de.
19. A pharmaceutical composition comprising, a compound of any one of claims 1 to 18, and a pharmaceutically acceptable carrier.
20. A method of treating a disease or disorder associated with modulation of phosphatidylinosito1-5-phosphate-4-kinase (PISP4K) comprising, administering to a patient in need thereof an effective amount of a compound of anyone of claims 1 to 18.
21. The method of claim 20, wherein the disease or disorder associated with modulation of (PISP4K) is a cancer or cell proliferative disorder, a metabolic disorder, neurodegenerative disease, and an inflammatory disease.
22. A method of inhibiting PISP4K comprising, administering to a patient in need thereof an effective amount of a compound of any one of claims 1 to 18.
23. A method of treating cancer or a cell proliferative disorder, the method comprising administering, to a patient in need thereof an effective amount of a compound of anyone of claims 1 to 18.
24. The method of claim 23, wherein the cancer or cell proliferative disorder is leukemias (e.g., acute leukemia, acute lymphocytic leukemia, acute my el ocytic leukemia, acute my el oblasti c leukemia, acute promyelocytic leukemia, acute myelomonocytic leukemia, acute monocytic leukemia, acute erythrol eukemi a, chronic leukemia, chronic my el ocyti c leukemia, chronic lymphocytic leukemia), polycythemia vera, lymphoma (Hodgkin's disease, non-Hodgkin's disease), Waldenstrom's macroglobulinemia, heavy chain disease, and solid tumors such as sarcomas and carcinomas (e.g., fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilm's tumor, cervical cancer, uterine cancer, testicular cancer, lung carcinoma, small cell lung carcinoma, bladder carcinoma, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodenroglioma, schwannoma, meningioma, melanoma, neuroblastoma, and retinoblastoma).
25. A method of treating a neurodegenerative disease, comprising administering to a patient in need thereof an effective amount of a compound of anyone of claims 1 to 18.
26. The method of claim 25, wherein the neurodegenerative disease is brain trauma, spinal cord trauma, trauma to the peripheral nervous system, Alzheimer's disease, Pick's disease, diffuse Lewy body disease, progressive supranuclear palsy (Steel-Richardson syndrome), multisy stem degeneration (Shy-Drager syndrome), motor neuron diseases including amyotrophic lateral sclerosis, degenerative ataxias, cortical basal degeneration, ALS-Parkinson's-Dementia complex of Guam, subacute sclerosing panencephalitis, Huntington's disease, Parkinson's disease, synucleinopathies, primary progressive aphasia, striatonigral degeneration, Machado-Joseph disease/spinocerebellar ataxia type 3 and olivopontocerebellar degenerations, Gilles De La Tourette's disease, bulbar and pseudobulbar palsy, spinal and spinobulbar muscular atrophy (Kennedy's disease), primary lateral sclerosis, familial spastic paraplegia, Werdnig-Hoffman disease, Kugelberg-Welander disease, Tay-Sach's disease, Sandhoff disease, familial spastic disease, Wohlfart-Kugelberg-Welander disease, spastic paraparesis, progressive multifocal leukoencephalopathy, and prion diseases (including Creutzfeldt-Jakob, Gerstmann-Straussler-Scheinker disease, Kuru and fatal familial insomnia, age-related dementia, vascular dementia, diffuse white matter disease (Binswanger's disease), dementia of endocrine or metabolic origin, dementia of head trauma and diffuse brain damage, dementia pugilistica or frontal lobe dementia, neurodegenerative disorders resulting from cerebral ischemia or infaction including embolic occlusion and thrombotic occlusion as well as intracranial hemorrhage of any type, intracranial and intravertebral lesions, hereditary cerebral angiopathy, normeuropathic hereditary amyloid, Down's syndrome, macroglobulinemia, secondary familial Mediterranean fever, Muckle-Wells syndrome, multiple myeloma, pancreatic- and cardiac-related amyloidosis, chronic hemodialysis arthropathy, or Finnish and Iowa amyloidosis.
27. A method of treating an inflammatory disease, the method comprising administering to a patient in need thereof an effective amount of a compound of anyone of claims 1 to 18.
28. The method of claim 27, wherein the inflammatory disease is associated with a metabolic disorder.
29. The method of any one of claims 28, wherein the metabolic disease is Type II diabetes, insulin resistance cardiovascular disease, arrhythmia, atherosclerosis, coronary artery disease, hypertriglyceridemia, dyslipidemia, retinopathy, nephropathy, neuropathy, or macular edema.
30. The method of Claim 27, wherein the inflammatory disease or condition is associated with an inflammatory bowel disease.
31. The method of Claim 30, wherein the inflammatory bowel disease is ileitis, ulcerative colitis, Barrett's syndrome, or Crohn's disease.
32. The method of any one of claims 20 to 31, wherein administering is performed orally, parentally, subcutaneously, by injection, or by infusion.
33. The method of any one of claims 20 to 32, wherein the patient is selected for treatment based on gene amplification and/or elevated tumor expression of PI5P4K.
34. The method of claim 33, wherein the gene amplified and/or expressed is PI5P4Ka gene, PI5P4K0 gene, or PI5P4Ky gene.
35. The method of any one of claims 20 to 32, wherein the patient is selected for the treatment based on tumor expression of p53 mutations.
36. The method of any one of claims 20 to 32, wherein administration of the compound induces a change in the cell cycle or cell viability.
37. A method of inducing cell cycle arrest, apoptosis in tumor cells, and/or enhanced tumor specific T-cell immunity, comprising contacting the cells with an effective amount of a compound of anyone of claims 1 to 18.
38. A compound of anyone of claims 1 to 18 for use in the manufacture of a medicament for treating a disease associated with inhibiting PI5P4K.
39. Use of a compound of anyone of claims 1 to 18 in the treatment of a disease associated with inhibiting PI5P4K.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762609578P | 2017-12-22 | 2017-12-22 | |
US62/609,578 | 2017-12-22 | ||
PCT/US2018/067261 WO2019126730A1 (en) | 2017-12-22 | 2018-12-21 | Chromenopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
CA3085147A1 true CA3085147A1 (en) | 2019-06-27 |
Family
ID=65244604
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA3085147A Pending CA3085147A1 (en) | 2017-12-22 | 2018-12-21 | Chromenopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors |
Country Status (11)
Country | Link |
---|---|
US (1) | US11584763B2 (en) |
EP (2) | EP3728217B1 (en) |
JP (1) | JP7335893B2 (en) |
CN (1) | CN111936484A (en) |
AU (1) | AU2018392816B2 (en) |
BR (1) | BR112020012644A2 (en) |
CA (1) | CA3085147A1 (en) |
IL (1) | IL275489B1 (en) |
MX (1) | MX2020006614A (en) |
RU (1) | RU2020124136A (en) |
WO (1) | WO2019126730A1 (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019126731A1 (en) | 2017-12-22 | 2019-06-27 | Petra Pharma Corporation | Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors |
JP7335893B2 (en) | 2017-12-22 | 2023-08-30 | ラヴェンナ ファーマシューティカルズ,インコーポレイテッド | Chromenopyridine Derivatives as Phosphatidylinositol Phosphate Kinase Inhibitors |
EP3728230A1 (en) | 2017-12-22 | 2020-10-28 | Ravenna Pharmaceuticals, Inc. | Aryl-bipyridine amine derivatives as phosphatidylinositol phosphate kinase inhibitors |
MX2021003158A (en) | 2018-09-18 | 2021-07-16 | Nikang Therapeutics Inc | Fused tricyclic ring derivatives as src homology-2 phosphatase inhibitors. |
TW202112784A (en) | 2019-06-17 | 2021-04-01 | 美商佩特拉製藥公司 | Chromenopyrimidine derivatives as phosphatidylinositol phosphate kinase inhibitors |
KR20220090443A (en) * | 2020-12-21 | 2022-06-29 | 주식회사 비투에스바이오 | Heteroaryl derivative compounds, and uses thereof |
KR20230098422A (en) * | 2021-12-24 | 2023-07-04 | 이화여자대학교 산학협력단 | Novel compound as a leukotriene B4 receptor inhibitor and use thereof |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4111942A (en) | 1977-03-28 | 1978-09-05 | Abbott Laboratories | 10-Amino-5H-[1]benzopyrano[4,3-c]pyridines |
US5262564A (en) | 1992-10-30 | 1993-11-16 | Octamer, Inc. | Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents |
EP0876375A1 (en) | 1995-11-17 | 1998-11-11 | E.I. Du Pont De Nemours And Company | Tricyclic herbicidal heterocycles |
DE19653009A1 (en) | 1996-12-19 | 1998-06-25 | Hoechst Ag | 6-fluorophenanthridine derivatives and their use in liquid-crystalline mixtures |
TW200619300A (en) * | 2004-08-31 | 2006-06-16 | Sumitomo Chemical Co | Luminescent-polymer composition and luminescent -polymer device |
WO2008028168A2 (en) | 2006-09-01 | 2008-03-06 | Cylene Pharmaceuticals, Inc. | Serine-threonine protein kinase and parp modulators |
CN101878031A (en) * | 2007-04-20 | 2010-11-03 | 迪赛孚尔制药有限公司 | The inhibitors of kinases that is used for the treatment of myeloproliferative disease and other proliferative diseases |
US7910600B2 (en) | 2007-08-31 | 2011-03-22 | Cylene Pharmaceuticals, Inc. | Therapeutic kinase modulators |
AU2008300026A1 (en) | 2007-09-11 | 2009-03-19 | Merck Sharp & Dohme Corp. | Inhibitors of Janus kinases |
MX2010009445A (en) | 2008-02-29 | 2011-05-25 | Cylene Pharmaceuticals Inc | Protein kinase modulators. |
US20110212053A1 (en) | 2008-06-19 | 2011-09-01 | Dapeng Qian | Phosphatidylinositol 3 kinase inhibitors |
US9040508B2 (en) | 2008-12-08 | 2015-05-26 | Vm Pharma Llc | Compositions of protein receptor tyrosine kinase inhibitors |
CN102481289A (en) | 2009-04-17 | 2012-05-30 | 赛林药物股份有限公司 | Method of treating disorders associated with protein kinase ck2 activity |
KR101690358B1 (en) * | 2009-10-29 | 2017-01-09 | 제노스코 | Kinase inhibitors |
TW201206936A (en) | 2010-07-19 | 2012-02-16 | Alcon Res Ltd | Methods and compositions for the treatment of allergy |
US20120129849A1 (en) | 2010-10-22 | 2012-05-24 | Cylene Pharmaceuticals, Inc. | Deuterated serine-threonine protein kinase modulators |
WO2012112245A1 (en) * | 2011-02-14 | 2012-08-23 | Beth Israel Deaconess Medical Center, Inc. | Modulation of phosphatidylinositol-5-phosphate-4-kinase activity |
WO2012110860A1 (en) * | 2011-02-17 | 2012-08-23 | Glenmark Pharmaceuticals S.A. | TRICYCLIC COMPOUNDS AS mPGES-1 INHIBITORS |
EP2766723A4 (en) | 2011-10-12 | 2015-06-10 | Univ North Carolina | Multiplexed kinase inhibitor beads and uses thereof |
PL2794600T3 (en) * | 2011-12-22 | 2018-06-29 | Novartis Ag | 2,3-Dihydro-benzo[1,4]oxazine derivatives and related compounds as phosphoinositide-3 kinase (PI3K) inhibitors for the treatment of e.g. rheumatoid arthritis |
MX2014008706A (en) | 2012-01-18 | 2015-03-05 | Zafgen Inc | Tricyclic sulfonamide compounds and methods of making and using same. |
WO2013180376A1 (en) | 2012-05-30 | 2013-12-05 | Alpha Chem Co., Ltd. | New electron transport material and organic electroluminescent device using the same |
TW201441197A (en) | 2013-01-31 | 2014-11-01 | Shionogi & Co | HIV replication inhibitor |
KR102169446B1 (en) | 2013-07-16 | 2020-10-23 | 에스에프씨 주식회사 | An organoelectroluminescent compounds and organoelectroluminescent device using the same |
WO2015147247A1 (en) | 2014-03-28 | 2015-10-01 | 塩野義製薬株式会社 | Tricyclic derivative having hiv replication inhibitory activity |
WO2015196335A1 (en) * | 2014-06-23 | 2015-12-30 | Tocopherx, Inc. | Pyrazole compounds as modulators of fshr and uses thereof |
KR101825544B1 (en) | 2014-10-29 | 2018-02-05 | 삼성에스디아이 주식회사 | Compound, organic optoelectric device and display device |
JPWO2016129694A1 (en) | 2015-02-13 | 2017-11-24 | 出光興産株式会社 | COMPOUND, MATERIAL FOR ORGANIC ELECTROLUMINESCENT DEVICE, INK COMPOSITION, ORGANIC ELECTROLUMINESCENT DEVICE, AND ELECTRONIC DEVICE |
KR102429882B1 (en) | 2015-03-25 | 2022-08-05 | 엘지디스플레이 주식회사 | Organic light emitting device |
EP3313530B1 (en) * | 2015-06-26 | 2022-10-05 | Dana Farber Cancer Institute, Inc. | 4,6-pyrimidinylene derivatives and uses thereof |
JP2018522867A (en) * | 2015-06-26 | 2018-08-16 | ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド | Fused bicyclic pyrimidine derivatives and their use |
KR102656918B1 (en) | 2015-12-03 | 2024-04-16 | 솔루스첨단소재 주식회사 | Organic compounds and organic electro luminescence device comprising the same |
US20190350964A1 (en) * | 2016-12-08 | 2019-11-21 | National University Of Singapore | Anti-cancer compounds and uses thereof |
EP3728230A1 (en) | 2017-12-22 | 2020-10-28 | Ravenna Pharmaceuticals, Inc. | Aryl-bipyridine amine derivatives as phosphatidylinositol phosphate kinase inhibitors |
JP7335893B2 (en) | 2017-12-22 | 2023-08-30 | ラヴェンナ ファーマシューティカルズ,インコーポレイテッド | Chromenopyridine Derivatives as Phosphatidylinositol Phosphate Kinase Inhibitors |
WO2019126731A1 (en) | 2017-12-22 | 2019-06-27 | Petra Pharma Corporation | Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors |
TW202112767A (en) | 2019-06-17 | 2021-04-01 | 美商佩特拉製藥公司 | Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors |
TW202112784A (en) | 2019-06-17 | 2021-04-01 | 美商佩特拉製藥公司 | Chromenopyrimidine derivatives as phosphatidylinositol phosphate kinase inhibitors |
-
2018
- 2018-12-21 JP JP2020554060A patent/JP7335893B2/en active Active
- 2018-12-21 BR BR112020012644-6A patent/BR112020012644A2/en not_active Application Discontinuation
- 2018-12-21 EP EP18842619.1A patent/EP3728217B1/en active Active
- 2018-12-21 IL IL275489A patent/IL275489B1/en unknown
- 2018-12-21 CN CN201880089930.5A patent/CN111936484A/en active Pending
- 2018-12-21 MX MX2020006614A patent/MX2020006614A/en unknown
- 2018-12-21 EP EP23209010.0A patent/EP4335512A2/en active Pending
- 2018-12-21 CA CA3085147A patent/CA3085147A1/en active Pending
- 2018-12-21 RU RU2020124136A patent/RU2020124136A/en unknown
- 2018-12-21 US US16/956,981 patent/US11584763B2/en active Active
- 2018-12-21 AU AU2018392816A patent/AU2018392816B2/en active Active
- 2018-12-21 WO PCT/US2018/067261 patent/WO2019126730A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
JP2021506977A (en) | 2021-02-22 |
JP7335893B2 (en) | 2023-08-30 |
BR112020012644A2 (en) | 2020-12-01 |
IL275489A (en) | 2020-08-31 |
AU2018392816B2 (en) | 2023-04-20 |
IL275489B1 (en) | 2024-02-01 |
EP3728217C0 (en) | 2023-11-15 |
EP3728217B1 (en) | 2023-11-15 |
EP3728217A1 (en) | 2020-10-28 |
MX2020006614A (en) | 2020-11-06 |
US11584763B2 (en) | 2023-02-21 |
CN111936484A (en) | 2020-11-13 |
EP4335512A2 (en) | 2024-03-13 |
AU2018392816A1 (en) | 2020-06-18 |
US20210253600A1 (en) | 2021-08-19 |
RU2020124136A (en) | 2022-01-25 |
WO2019126730A1 (en) | 2019-06-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2018388404B2 (en) | Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors | |
AU2018392816B2 (en) | Chromenopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors | |
AU2018388406B2 (en) | Aryl-bipyridine amine derivatives as phosphatidylinositol phosphate kinase inhibitors | |
CA2821712C (en) | Substituted n-(1h-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type iii receptor tyrosine kinase inhibitors | |
WO2020257253A1 (en) | Chromenopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors | |
WO2020257271A1 (en) | Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors | |
WO2023283372A1 (en) | Compounds for targeting degradation of irak4 proteins | |
US10961238B2 (en) | Modulators of hedgehog (Hh) signaling pathway | |
US20240158415A1 (en) | Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors | |
AU2022308734A1 (en) | Compounds for targeting degradation of irak4 proteins | |
EP4251149A1 (en) | Modified isoindolinones as glucosylceramide synthase inhibitors |